{ "metadata": { "generated_at": "2026-05-13T08:26:35+00:00", "domain_filter": "cross_domain", "quality_filter": [ "high", "mid" ], "total_count": 2123, "domains": [ "als", "alzheimer", "depression", "epilepsy", "glioblastoma", "heart_failure", "inflammatory_bowel_disease", "multiple_sclerosis", "pancreatic_cancer", "rheumatoid_arthritis", "type_2_diabetes" ], "evidence_papers": 6574, "quality_breakdown": { "high": 295, "mid": 1828, "low": 11568, "excluded": 17770 }, "duplicate_count": 279, "validation_breakdown": { "clinical_trials": { "unknown": 505, "active": 117, "none": 1345, "completed": 134, "preclinical_only": 22 }, "literature": { "unknown": 15, "partial_evidence": 320, "novel_signal": 887, "reproduces_known": 396 } }, "schema_version": "1.3" }, "hypotheses": [ { "id": 3772, "drug": "curcumin", "drug_type": "drug", "drug_domain": "alzheimer", "predicate_ab": "binds_to", "mediator": "TDP-43", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "ALS", "outcome_type": "disease", "outcome_domain": "als", "score": 0.40943445622221003, "filtered_score": 0.614151684333315, "filter_reason": "boosted_repurposing", "outreach_score": 0.614151684333315, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "completed", "clinical_trial_nct_ids": [ "NCT04654689", "NCT04499963" ], "literature_status": "reproduces_known", "drug_canonical": "curcumin", "mediator_canonical": "TDP-43", "outcome_canonical": "amyotrophic lateral sclerosis", "ab_count": 1, "bc_count": 29, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "30092839", "title": "Different curcumin forms selectively bind fibrillar amyloid beta in post mortem Alzheimer’s disease brains: Implications for in-vivo diagnostics", "doi": "10.1186/s40478-018-0577-2", "year": 2018 } ], "bc": [ { "pmid": "41570741", "title": "ALS-related proteinopathies: From TDP-43 to mitochondrial proteinopathies", "doi": "10.1016/j.conb.2025.103163", "year": 2026 }, { "pmid": "42013476", "title": "Cryptic Splicing in ALS: From Driving Disease Progression to Unlocking Novel Therapeutics", "doi": "10.1146/annurev-genom-022024-011307", "year": 2026 }, { "pmid": "41851044", "title": "Reduced nuclear TDP-43 and cytoplasmic DLK1 as markers of motor neuron degeneration in amyotrophic lateral sclerosis", "doi": "10.1093/jnen/nlag017", "year": 2026 } ] } }, { "id": 37636, "drug": "Auranofin", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "inhibits", "mediator": "TDP-43", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "ALS", "outcome_type": "disease", "outcome_domain": "als", "score": 0.40943445622221003, "filtered_score": 0.614151684333315, "filter_reason": "boosted_repurposing", "outreach_score": 0.614151684333315, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "auranofin", "mediator_canonical": "TDP-43", "outcome_canonical": "amyotrophic lateral sclerosis", "ab_count": 1, "bc_count": 29, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "29396541", "title": "TDP-43 self-interaction is modulated by redox-active compounds Auranofin, Chelerythrine and Riluzole", "doi": "10.1038/s41598-018-20565-0", "year": 2018 } ], "bc": [ { "pmid": "41570741", "title": "ALS-related proteinopathies: From TDP-43 to mitochondrial proteinopathies", "doi": "10.1016/j.conb.2025.103163", "year": 2026 }, { "pmid": "42013476", "title": "Cryptic Splicing in ALS: From Driving Disease Progression to Unlocking Novel Therapeutics", "doi": "10.1146/annurev-genom-022024-011307", "year": 2026 }, { "pmid": "41851044", "title": "Reduced nuclear TDP-43 and cytoplasmic DLK1 as markers of motor neuron degeneration in amyotrophic lateral sclerosis", "doi": "10.1093/jnen/nlag017", "year": 2026 } ] } }, { "id": 60968, "drug": "metformin", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "activates", "mediator": "AMPK", "mediator_type": "protein", "predicate_bc": "prevents", "outcome": "metabolic dysfunction", "outcome_type": "disease", "outcome_domain": "heart_failure", "score": 0.3401197381662156, "filtered_score": 0.5101796072493234, "filter_reason": "boosted_repurposing", "outreach_score": 0.5101796072493234, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 9, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41222548", "title": "Insulin resistance and metabolic dysfunction in thyroid nodules and differentiated thyroid cancer", "doi": "10.1097/cco.0000000000001202", "year": 2025 }, { "pmid": "35605453", "title": "Metformin modulates mitochondrial function and mitophagy in peripheral blood mononuclear cells from type 2 diabetic patients", "doi": "10.1016/j.redox.2022.102342", "year": 2022 }, { "pmid": "36417940", "title": "Metformin suppresses SARS-CoV-2 in cell culture", "doi": "10.1016/j.virusres.2022.199010", "year": 2022 } ], "bc": [ { "pmid": "37194385", "title": "Adenosine monophosphate‐activated protein kinase is elevated in human cachectic muscle and prevents cancer‐induced metabolic dysfunction in mice", "doi": "10.1002/jcsm.13238", "year": 2023 } ] } }, { "id": 4387, "drug": "erlotinib", "drug_type": "drug", "drug_domain": "pancreatic_cancer", "predicate_ab": "inhibits", "mediator": "EGFR", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "glioblastoma", "outcome_type": "disease", "outcome_domain": "glioblastoma", "score": 0.3044522437723423, "filtered_score": 0.4566783656585135, "filter_reason": "boosted_repurposing", "outreach_score": 0.4566783656585135, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "completed", "clinical_trial_nct_ids": [ "NCT01257594", "NCT00509431", "NCT00720356" ], "literature_status": "reproduces_known", "drug_canonical": "erlotinib", "mediator_canonical": "EGFR", "outcome_canonical": "glioblastoma", "ab_count": 6, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37847995", "title": "Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group", "doi": "10.1200/jco.22.02770", "year": 2023 }, { "pmid": "36092320", "title": "A phase II trial of gemcitabine and erlotinib followed by ChemoProton therapy plus capecitabine and oxaliplatin for locally advanced pancreatic cancer", "doi": "10.21037/jgo-22-327", "year": 2022 }, { "pmid": "33862582", "title": "A genetically defined signature of responsiveness to erlotinib in early-stage pancreatic cancer patients: Results from the CONKO-005 trial", "doi": "10.1016/j.ebiom.2021.103327", "year": 2021 } ], "bc": [ { "pmid": "41473440", "title": "A PET-CT study of the uptake of labeled aptamers [18F]FB-Gol1 and [18F]FB-GR20 in rat 101.8 glioblastoma model", "doi": "10.3389/fonc.2025.1713181", "year": 2025 }, { "pmid": "38396993", "title": "Epidermal Growth Factor Receptor Inhibitors in Glioblastoma: Current Status and Future Possibilities", "doi": "10.3390/ijms25042316", "year": 2024 } ] } }, { "id": 60982, "drug": "metformin", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "activates", "mediator": "AMPK", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "cardiovascular aging", "outcome_type": "phenotype", "outcome_domain": "heart_failure", "score": 0.29957322735539915, "filtered_score": 0.44935984103309873, "filter_reason": "boosted_repurposing", "outreach_score": 0.44935984103309873, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 9, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41222548", "title": "Insulin resistance and metabolic dysfunction in thyroid nodules and differentiated thyroid cancer", "doi": "10.1097/cco.0000000000001202", "year": 2025 }, { "pmid": "35605453", "title": "Metformin modulates mitochondrial function and mitophagy in peripheral blood mononuclear cells from type 2 diabetic patients", "doi": "10.1016/j.redox.2022.102342", "year": 2022 }, { "pmid": "36417940", "title": "Metformin suppresses SARS-CoV-2 in cell culture", "doi": "10.1016/j.virusres.2022.199010", "year": 2022 } ], "bc": [ { "pmid": "41194190", "title": "Cellular senescence and cell therapy in cardiovascular diseases", "doi": "10.1186/s13287-025-04731-6", "year": 2025 } ] } }, { "id": 60975, "drug": "metformin", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "activates", "mediator": "AMPK", "mediator_type": "protein", "predicate_bc": "increases", "outcome": "glycogen storage", "outcome_type": "phenotype", "outcome_domain": "heart_failure", "score": 0.29957322735539915, "filtered_score": 0.44935984103309873, "filter_reason": "boosted_repurposing", "outreach_score": 0.44935984103309873, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 9, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41222548", "title": "Insulin resistance and metabolic dysfunction in thyroid nodules and differentiated thyroid cancer", "doi": "10.1097/cco.0000000000001202", "year": 2025 }, { "pmid": "35605453", "title": "Metformin modulates mitochondrial function and mitophagy in peripheral blood mononuclear cells from type 2 diabetic patients", "doi": "10.1016/j.redox.2022.102342", "year": 2022 }, { "pmid": "36417940", "title": "Metformin suppresses SARS-CoV-2 in cell culture", "doi": "10.1016/j.virusres.2022.199010", "year": 2022 } ], "bc": [ { "pmid": "28009297", "title": "Integrative Analysis of PRKAG2 Cardiomyopathy iPS and Microtissue Models Identifies AMPK as a Regulator of Metabolism, Survival, and Fibrosis", "doi": "10.1016/j.celrep.2016.11.066", "year": 2016 } ] } }, { "id": 60972, "drug": "metformin", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "activates", "mediator": "AMPK", "mediator_type": "protein", "predicate_bc": "causes", "outcome": "dilated cardiomyopathy", "outcome_type": "disease", "outcome_domain": "heart_failure", "score": 0.29957322735539915, "filtered_score": 0.44935984103309873, "filter_reason": "boosted_repurposing", "outreach_score": 0.44935984103309873, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 9, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41222548", "title": "Insulin resistance and metabolic dysfunction in thyroid nodules and differentiated thyroid cancer", "doi": "10.1097/cco.0000000000001202", "year": 2025 }, { "pmid": "35605453", "title": "Metformin modulates mitochondrial function and mitophagy in peripheral blood mononuclear cells from type 2 diabetic patients", "doi": "10.1016/j.redox.2022.102342", "year": 2022 }, { "pmid": "36417940", "title": "Metformin suppresses SARS-CoV-2 in cell culture", "doi": "10.1016/j.virusres.2022.199010", "year": 2022 } ], "bc": [ { "pmid": "26023060", "title": "AMPK deficiency in cardiac muscle results in dilated cardiomyopathy in the absence of changes in energy metabolism", "doi": "10.1093/cvr/cvv166", "year": 2015 } ] } }, { "id": 40769, "drug": "metformin", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "activates", "mediator": "AMPK", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "pancreatic cancer progression", "outcome_type": "disease", "outcome_domain": "pancreatic_cancer", "score": 0.29957322735539915, "filtered_score": 0.44935984103309873, "filter_reason": "boosted_repurposing", "outreach_score": 0.44935984103309873, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "active", "clinical_trial_nct_ids": [ "NCT04207944", "NCT05261997", "NCT02978547" ], "literature_status": "partial_evidence", "drug_canonical": "metformin", "mediator_canonical": "AMPK", "outcome_canonical": "pancreatic cancer progression", "ab_count": 9, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41222548", "title": "Insulin resistance and metabolic dysfunction in thyroid nodules and differentiated thyroid cancer", "doi": "10.1097/cco.0000000000001202", "year": 2025 }, { "pmid": "35605453", "title": "Metformin modulates mitochondrial function and mitophagy in peripheral blood mononuclear cells from type 2 diabetic patients", "doi": "10.1016/j.redox.2022.102342", "year": 2022 }, { "pmid": "36417940", "title": "Metformin suppresses SARS-CoV-2 in cell culture", "doi": "10.1016/j.virusres.2022.199010", "year": 2022 } ], "bc": [ { "pmid": "31205544", "title": "AMPK Inhibition Suppresses the Malignant Phenotype of Pancreatic Cancer Cells in Part by Attenuating Aerobic Glycolysis", "doi": "10.7150/jca.28299", "year": 2019 } ] } }, { "id": 39394, "drug": "metformin", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "activates", "mediator": "AMPK", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "amyotrophic lateral sclerosis", "outcome_type": "disease", "outcome_domain": "als", "score": 0.29957322735539915, "filtered_score": 0.44935984103309873, "filter_reason": "boosted_repurposing", "outreach_score": 0.44935984103309873, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "active", "clinical_trial_nct_ids": [ "NCT04220021" ], "literature_status": "reproduces_known", "drug_canonical": "metformin", "mediator_canonical": "AMPK", "outcome_canonical": "amyotrophic lateral sclerosis", "ab_count": 9, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41222548", "title": "Insulin resistance and metabolic dysfunction in thyroid nodules and differentiated thyroid cancer", "doi": "10.1097/cco.0000000000001202", "year": 2025 }, { "pmid": "35605453", "title": "Metformin modulates mitochondrial function and mitophagy in peripheral blood mononuclear cells from type 2 diabetic patients", "doi": "10.1016/j.redox.2022.102342", "year": 2022 }, { "pmid": "36417940", "title": "Metformin suppresses SARS-CoV-2 in cell culture", "doi": "10.1016/j.virusres.2022.199010", "year": 2022 } ], "bc": [ { "pmid": "34393724", "title": "Contribution of Energy Dysfunction to Impaired Protein Translation in Neurodegenerative Diseases", "doi": "10.3389/fncel.2021.668500", "year": 2021 } ] } }, { "id": 40366, "drug": "metformin", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "activates", "mediator": "AMPK", "mediator_type": "protein", "predicate_bc": "treats", "outcome": "intestinal inflammation", "outcome_type": "disease", "outcome_domain": "inflammatory_bowel_disease", "score": 0.29957322735539915, "filtered_score": 0.44935984103309873, "filter_reason": "boosted_repurposing", "outreach_score": 0.44935984103309873, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "completed", "clinical_trial_nct_ids": [ "NCT04979130", "NCT01827280", "NCT04502303" ], "literature_status": "reproduces_known", "drug_canonical": "metformin", "mediator_canonical": "AMPK", "outcome_canonical": "intestinal inflammation", "ab_count": 9, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41222548", "title": "Insulin resistance and metabolic dysfunction in thyroid nodules and differentiated thyroid cancer", "doi": "10.1097/cco.0000000000001202", "year": 2025 }, { "pmid": "35605453", "title": "Metformin modulates mitochondrial function and mitophagy in peripheral blood mononuclear cells from type 2 diabetic patients", "doi": "10.1016/j.redox.2022.102342", "year": 2022 }, { "pmid": "36417940", "title": "Metformin suppresses SARS-CoV-2 in cell culture", "doi": "10.1016/j.virusres.2022.199010", "year": 2022 } ], "bc": [ { "pmid": "33252129", "title": "Salicylates Ameliorate Intestinal Inflammation by Activating Macrophage AMPK", "doi": "10.1093/ibd/izaa305", "year": 2020 } ] } }, { "id": 40368, "drug": "metformin", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "activates", "mediator": "AMPK", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "intestinal epithelial repair", "outcome_type": "phenotype", "outcome_domain": "inflammatory_bowel_disease", "score": 0.29957322735539915, "filtered_score": 0.44935984103309873, "filter_reason": "boosted_repurposing", "outreach_score": 0.44935984103309873, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "metformin", "mediator_canonical": "AMPK", "outcome_canonical": "intestinal epithelial repair", "ab_count": 9, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41222548", "title": "Insulin resistance and metabolic dysfunction in thyroid nodules and differentiated thyroid cancer", "doi": "10.1097/cco.0000000000001202", "year": 2025 }, { "pmid": "35605453", "title": "Metformin modulates mitochondrial function and mitophagy in peripheral blood mononuclear cells from type 2 diabetic patients", "doi": "10.1016/j.redox.2022.102342", "year": 2022 }, { "pmid": "36417940", "title": "Metformin suppresses SARS-CoV-2 in cell culture", "doi": "10.1016/j.virusres.2022.199010", "year": 2022 } ], "bc": [ { "pmid": "35203241", "title": "Intestinal Epithelial AMPK Deficiency Causes Delayed Colonic Epithelial Repair in DSS-Induced Colitis", "doi": "10.3390/cells11040590", "year": 2022 } ] } }, { "id": 39979, "drug": "metformin", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "activates", "mediator": "AMPK", "mediator_type": "protein", "predicate_bc": "increases", "outcome": "epileptiform network activity", "outcome_type": "phenotype", "outcome_domain": "epilepsy", "score": 0.29957322735539915, "filtered_score": 0.44935984103309873, "filter_reason": "boosted_repurposing", "outreach_score": 0.44935984103309873, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "metformin", "mediator_canonical": "AMPK", "outcome_canonical": "epileptiform network activity", "ab_count": 9, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41222548", "title": "Insulin resistance and metabolic dysfunction in thyroid nodules and differentiated thyroid cancer", "doi": "10.1097/cco.0000000000001202", "year": 2025 }, { "pmid": "35605453", "title": "Metformin modulates mitochondrial function and mitophagy in peripheral blood mononuclear cells from type 2 diabetic patients", "doi": "10.1016/j.redox.2022.102342", "year": 2022 }, { "pmid": "36417940", "title": "Metformin suppresses SARS-CoV-2 in cell culture", "doi": "10.1016/j.virusres.2022.199010", "year": 2022 } ], "bc": [ { "pmid": "35134125", "title": "AMPK-mediated potentiation of GABAergic signalling drives hypoglycaemia-provoked spike-wave seizures", "doi": "10.1093/brain/awac037", "year": 2022 } ] } }, { "id": 60983, "drug": "metformin", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "activates", "mediator": "AMPK", "mediator_type": "protein", "predicate_bc": "prevents", "outcome": "myocardial ischemia-reperfusion injury", "outcome_type": "disease", "outcome_domain": "heart_failure", "score": 0.29957322735539915, "filtered_score": 0.44935984103309873, "filter_reason": "boosted_repurposing", "outreach_score": 0.44935984103309873, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 9, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41222548", "title": "Insulin resistance and metabolic dysfunction in thyroid nodules and differentiated thyroid cancer", "doi": "10.1097/cco.0000000000001202", "year": 2025 }, { "pmid": "35605453", "title": "Metformin modulates mitochondrial function and mitophagy in peripheral blood mononuclear cells from type 2 diabetic patients", "doi": "10.1016/j.redox.2022.102342", "year": 2022 }, { "pmid": "36417940", "title": "Metformin suppresses SARS-CoV-2 in cell culture", "doi": "10.1016/j.virusres.2022.199010", "year": 2022 } ], "bc": [ { "pmid": "29689567", "title": "AMPK Contributes to Cardioprotective Effects of Pterostilbene Against Myocardial Ischemia- Reperfusion Injury in Diabetic Rats by Suppressing Cardiac Oxidative Stress and Apoptosis", "doi": "10.1159/000489154", "year": 2018 } ] } }, { "id": 60978, "drug": "metformin", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "activates", "mediator": "AMPK", "mediator_type": "protein", "predicate_bc": "increases", "outcome": "ventricular cell shortening", "outcome_type": "phenotype", "outcome_domain": "heart_failure", "score": 0.29957322735539915, "filtered_score": 0.44935984103309873, "filter_reason": "boosted_repurposing", "outreach_score": 0.44935984103309873, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 9, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41222548", "title": "Insulin resistance and metabolic dysfunction in thyroid nodules and differentiated thyroid cancer", "doi": "10.1097/cco.0000000000001202", "year": 2025 }, { "pmid": "35605453", "title": "Metformin modulates mitochondrial function and mitophagy in peripheral blood mononuclear cells from type 2 diabetic patients", "doi": "10.1016/j.redox.2022.102342", "year": 2022 }, { "pmid": "36417940", "title": "Metformin suppresses SARS-CoV-2 in cell culture", "doi": "10.1016/j.virusres.2022.199010", "year": 2022 } ], "bc": [ { "pmid": "26023060", "title": "AMPK deficiency in cardiac muscle results in dilated cardiomyopathy in the absence of changes in energy metabolism", "doi": "10.1093/cvr/cvv166", "year": 2015 } ] } }, { "id": 51556, "drug": "resveratrol", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "activates", "mediator": "SIRT1", "mediator_type": "protein", "predicate_bc": "increases", "outcome": "proliferation", "outcome_type": "phenotype", "outcome_domain": "pancreatic_cancer", "score": 0.28903717578961646, "filtered_score": 0.4335557636844247, "filter_reason": "boosted_repurposing", "outreach_score": 0.4335557636844247, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 5, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37487007", "title": "Resveratrol inhibits ferroptosis and decelerates heart failure progression via Sirt1/p53 pathway activation", "doi": "10.1111/jcmm.17874", "year": 2023 }, { "pmid": "36926277", "title": "Resveratrol alleviates high glucose-induced oxidative stress and apoptosis in rat cardiac microvascular endothelial cell through AMPK/Sirt1 activation", "doi": "10.1016/j.bbrep.2023.101444", "year": 2023 }, { "pmid": "35791579", "title": "Resveratrol, novel application by preconditioning to attenuate myocardial ischemia/reperfusion injury in mice through regulate AMPK pathway and autophagy level", "doi": "10.1111/jcmm.17431", "year": 2022 } ], "bc": [ { "pmid": "34163012", "title": "SIRT1 coordinates with the CRL4B complex to regulate pancreatic cancer stem cells to promote tumorigenesis", "doi": "10.1038/s41418-021-00821-z", "year": 2021 }, { "pmid": "27494892", "title": "Sirtuin 1 stimulates the proliferation and the expression of glycolysis genes in pancreatic neoplastic lesions", "doi": "10.18632/oncotarget.11013", "year": 2016 } ] } }, { "id": 33750, "drug": "Curcumin", "drug_type": "drug", "drug_domain": "inflammatory_bowel_disease", "predicate_ab": "upregulates", "mediator": "STAT3", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "prurigo nodularis", "outcome_type": "disease", "outcome_domain": "rheumatoid_arthritis", "score": 0.2772588722239781, "filtered_score": 0.4158883083359671, "filter_reason": "boosted_repurposing", "outreach_score": 0.4158883083359671, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "curcumin", "mediator_canonical": "STAT3", "outcome_canonical": "prurigo nodularis", "ab_count": 3, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "34931590", "title": "Curcumin Inhibits T Follicular Helper Cell Differentiation in Mice with Dextran Sulfate Sodium (DSS)-Induced Colitis", "doi": "10.1142/s0192415x22500100", "year": 2021 }, { "pmid": "29629345", "title": "Comparative Effects of Curcumin and Tetrahydrocurcumin on Dextran Sulfate Sodium-induced Colitis and Inflammatory Signaling in Mice", "doi": "10.15430/jcp.2018.23.1.18", "year": 2018 }, { "pmid": "27932984", "title": "Curcumin Suppressed Activation of Dendritic Cells via JAK/STAT/SOCS Signal in Mice with Experimental Colitis", "doi": "10.3389/fphar.2016.00455", "year": 2016 } ], "bc": [ { "pmid": "39912139", "title": "Translating tissue expression of STAT 1, 3 and 6 in prurigo nodularis to clinical efficacy of oral tofacitinib – A prospective single-arm investigational study", "doi": "10.25259/ijdvl_1017_2024", "year": 2025 }, { "pmid": "40162359", "title": "Successful Use of Tofacitinib in Paediatric Prurigo Nodularis: A Report of Four Cases", "doi": "10.4103/ijd.ijd_842_24", "year": 2025 }, { "pmid": "37521237", "title": "A case of recalcitrant prurigo nodularis with heightened expression of STAT 3 and STAT 6 and its dramatic response to tofacitinib", "doi": "10.4103/idoj.idoj_508_22", "year": 2023 } ] } }, { "id": 576, "drug": "auraptene", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "downregulates", "mediator": "MMP-9", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "epilepsy", "outcome_type": "disease", "outcome_domain": "epilepsy", "score": 0.2772588722239781, "filtered_score": 0.4158883083359671, "filter_reason": "boosted_repurposing", "outreach_score": 0.4158883083359671, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "auraptene", "mediator_canonical": "MMP9", "outcome_canonical": "epilepsy", "ab_count": 1, "bc_count": 7, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "39086858", "title": "Auraptene inhibits migration, invasion and metastatic behavior of human malignant glioblastoma cells: An in vitro and in silico study.", "doi": "10.22038/ajp.2023.23586", "year": 2024 } ], "bc": [ { "pmid": "38449733", "title": "Meta-analysis of MMP-9 levels in the serum of patients with epilepsy", "doi": "10.3389/fnins.2024.1296876", "year": 2024 }, { "pmid": "36766708", "title": "Blood-Brain Barrier-Associated Proteins Are Elevated in Serum of Epilepsy Patients", "doi": "10.3390/cells12030368", "year": 2023 }, { "pmid": "32538745", "title": "Correlation of MMP-9 and HMGB1 expression with the cognitive function in patients with epilepsy and factors affecting the prognosis", "doi": "10.14715/cmb/2020.66.3.6", "year": 2020 } ] } }, { "id": 1558, "drug": "osimertinib", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "inhibits", "mediator": "EGFR", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "pancreatic ductal adenocarcinoma", "outcome_type": "disease", "outcome_domain": "pancreatic_cancer", "score": 0.2772588722239781, "filtered_score": 0.4158883083359671, "filter_reason": "boosted_repurposing", "outreach_score": 0.4158883083359671, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "osimertinib", "mediator_canonical": "EGFR", "outcome_canonical": "pancreatic ductal adenocarcinoma", "ab_count": 3, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40719865", "title": "Resistance of recurrent epidermal growth factor receptor-altered glioblastoma to anti-epidermal growth factor receptor targeted therapy with osimertinib", "doi": "10.1093/oncolo/oyaf146", "year": 2025 }, { "pmid": "40051661", "title": "A comparative study of preclinical and clinical molecular imaging response to EGFR inhibition using osimertinib in glioblastoma", "doi": "10.1093/noajnl/vdaf022", "year": 2025 }, { "pmid": "41120287", "title": "GSCs differentiation model-informed nanotherapy: dual-functional brain-targeting liposomes with iRGD modification for co-delivery of osimertinib and bortezomib to combat radioresistant glioblastoma", "doi": "10.1038/s41419-025-08083-0", "year": 2025 } ], "bc": [ { "pmid": "40130819", "title": "Identification of Tumor‐Specific Surface Proteins Enables Quantification of Extracellular Vesicle Subtypes for Early Detection of Pancreatic Ductal Adenocarcinoma", "doi": "10.1002/advs.202414982", "year": 2025 }, { "pmid": "31584260", "title": "Design and Evaluation of PEGylated Liposomal Formulation of a Novel Multikinase Inhibitor for Enhanced Chemosensitivity and Inhibition of Metastatic Pancreatic Ductal Adenocarcinoma", "doi": "10.1021/acs.bioconjchem.9b00632", "year": 2019 }, { "pmid": "26339400", "title": "EGFR expression in pancreatic intraepithelial neoplasia and ductal adenocarcinoma.", "doi": null, "year": 2015 } ] } }, { "id": 6867, "drug": "metformin", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "upregulates", "mediator": "α-synuclein", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "Parkinson's disease", "outcome_type": "disease", "outcome_domain": "alzheimer", "score": 0.2772588722239781, "filtered_score": 0.4158883083359671, "filter_reason": "boosted_repurposing", "outreach_score": 0.4158883083359671, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "active", "clinical_trial_nct_ids": [ "NCT07055958", "NCT05781711", "NCT03685357" ], "literature_status": "reproduces_known", "drug_canonical": "metformin", "mediator_canonical": "SNCA", "outcome_canonical": "Parkinson disease", "ab_count": 1, "bc_count": 7, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "30308130", "title": "Effects of metformin on apoptosis and α-synuclein in a rat model of pentylenetetrazole-induced epilepsy", "doi": "10.1139/cjpp-2018-0266", "year": 2018 } ], "bc": [ { "pmid": "38338966", "title": "Retinal Alterations Predict Early Prodromal Signs of Neurodegenerative Disease", "doi": "10.3390/ijms25031689", "year": 2024 }, { "pmid": "38899873", "title": "Thioflavin T─a Reporter of Microviscosity in Protein Aggregation Process: The Study Case of α-Synuclein", "doi": "10.1021/acs.jpclett.4c00699", "year": 2024 }, { "pmid": "37956285", "title": "In pursuit of degenerative brain disease diagnosis: Dementia biomarkers detected by DNA aptamer-attached portable graphene biosensor", "doi": "10.1073/pnas.2311565120", "year": 2023 } ] } }, { "id": 7645, "drug": "Riluzole", "drug_type": "drug", "drug_domain": "als", "predicate_ab": "downregulates", "mediator": "MMP-9", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "epilepsy", "outcome_type": "disease", "outcome_domain": "epilepsy", "score": 0.2772588722239781, "filtered_score": 0.4158883083359671, "filter_reason": "boosted_repurposing", "outreach_score": 0.4158883083359671, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "riluzole", "mediator_canonical": "MMP9", "outcome_canonical": "epilepsy", "ab_count": 1, "bc_count": 7, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40012807", "title": "Investigation of the Neuroprotective Effect of Riluzole on Matrix Metalloproteinases in an Experimental Model of Glaucoma", "doi": "10.4103/joco.joco_290_23", "year": 2024 } ], "bc": [ { "pmid": "38449733", "title": "Meta-analysis of MMP-9 levels in the serum of patients with epilepsy", "doi": "10.3389/fnins.2024.1296876", "year": 2024 }, { "pmid": "36766708", "title": "Blood-Brain Barrier-Associated Proteins Are Elevated in Serum of Epilepsy Patients", "doi": "10.3390/cells12030368", "year": 2023 }, { "pmid": "32538745", "title": "Correlation of MMP-9 and HMGB1 expression with the cognitive function in patients with epilepsy and factors affecting the prognosis", "doi": "10.14715/cmb/2020.66.3.6", "year": 2020 } ] } }, { "id": 35461, "drug": "Dimethyl fumarate", "drug_type": "drug", "drug_domain": "multiple_sclerosis", "predicate_ab": "activates", "mediator": "Nrf2", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "rheumatoid arthritis", "outcome_type": "disease", "outcome_domain": "rheumatoid_arthritis", "score": 0.40943445622221003, "filtered_score": 0.40943445622221003, "filter_reason": null, "outreach_score": 0.40943445622221003, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "completed", "clinical_trial_nct_ids": [ "NCT00810836" ], "literature_status": "reproduces_known", "drug_canonical": "dimethyl fumarate", "mediator_canonical": "NRF2", "outcome_canonical": "rheumatoid arthritis", "ab_count": 19, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "38368281", "title": "Identification of key neuronal mechanisms triggered by dimethyl fumarate in SH-SY5Y human neuroblastoma cells through a metabolomic approach", "doi": "10.1007/s00204-024-03683-9", "year": 2024 }, { "pmid": "37751291", "title": "Dimethyl fumarate modulates the dystrophic disease program following short-term treatment", "doi": "10.1172/jci.insight.165974", "year": 2023 }, { "pmid": "36065971", "title": "Dimethyl fumarate attenuates pain behaviors in osteoarthritis rats via induction of Nrf2-mediated mitochondrial biogenesis", "doi": "10.1177/17448069221124920", "year": 2022 } ], "bc": [ { "pmid": "40247798", "title": "Emerging Therapeutic Targets in Rheumatoid Arthritis: Focusing on HIF-1α, Nrf2, STATs, and RORγt", "doi": "10.2174/0113894501372670250408074908", "year": 2025 }, { "pmid": "36574898", "title": "Expression of Nrf2 protein in serum of patients with rheumatoid arthritis: A novel indicator for disease activity and disease prognosis", "doi": "10.1016/j.clinbiochem.2022.12.011", "year": 2022 } ] } }, { "id": 37635, "drug": "chelerythrine", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "inhibits", "mediator": "TDP-43", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "ALS", "outcome_type": "disease", "outcome_domain": "als", "score": 0.40943445622221003, "filtered_score": 0.40943445622221003, "filter_reason": null, "outreach_score": 0.40943445622221003, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "chelerythrine", "mediator_canonical": "TDP-43", "outcome_canonical": "amyotrophic lateral sclerosis", "ab_count": 1, "bc_count": 29, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "29396541", "title": "TDP-43 self-interaction is modulated by redox-active compounds Auranofin, Chelerythrine and Riluzole", "doi": "10.1038/s41598-018-20565-0", "year": 2018 } ], "bc": [ { "pmid": "41570741", "title": "ALS-related proteinopathies: From TDP-43 to mitochondrial proteinopathies", "doi": "10.1016/j.conb.2025.103163", "year": 2026 }, { "pmid": "42013476", "title": "Cryptic Splicing in ALS: From Driving Disease Progression to Unlocking Novel Therapeutics", "doi": "10.1146/annurev-genom-022024-011307", "year": 2026 }, { "pmid": "41851044", "title": "Reduced nuclear TDP-43 and cytoplasmic DLK1 as markers of motor neuron degeneration in amyotrophic lateral sclerosis", "doi": "10.1093/jnen/nlag017", "year": 2026 } ] } }, { "id": 35266, "drug": "Dimethyl fumarate", "drug_type": "drug", "drug_domain": "multiple_sclerosis", "predicate_ab": "activates", "mediator": "Nrf2", "mediator_type": "protein", "predicate_bc": "causes", "outcome": "chemoresistance", "outcome_type": "phenotype", "outcome_domain": "pancreatic_cancer", "score": 0.40943445622221003, "filtered_score": 0.40943445622221003, "filter_reason": null, "outreach_score": 0.40943445622221003, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "dimethyl fumarate", "mediator_canonical": "NRF2", "outcome_canonical": null, "ab_count": 19, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "38368281", "title": "Identification of key neuronal mechanisms triggered by dimethyl fumarate in SH-SY5Y human neuroblastoma cells through a metabolomic approach", "doi": "10.1007/s00204-024-03683-9", "year": 2024 }, { "pmid": "37751291", "title": "Dimethyl fumarate modulates the dystrophic disease program following short-term treatment", "doi": "10.1172/jci.insight.165974", "year": 2023 }, { "pmid": "36065971", "title": "Dimethyl fumarate attenuates pain behaviors in osteoarthritis rats via induction of Nrf2-mediated mitochondrial biogenesis", "doi": "10.1177/17448069221124920", "year": 2022 } ], "bc": [ { "pmid": "31911550", "title": "Undermining Glutaminolysis Bolsters Chemotherapy While NRF2 Promotes Chemoresistance in KRAS-Driven Pancreatic Cancers", "doi": "10.1158/0008-5472.can-19-1363", "year": 2020 }, { "pmid": "30735911", "title": "Digoxin sensitizes gemcitabine-resistant pancreatic cancer cells to gemcitabine via inhibiting Nrf2 signaling pathway", "doi": "10.1016/j.redox.2019.101131", "year": 2019 } ] } }, { "id": 23805, "drug": "Dimethyl fumarate", "drug_type": "drug", "drug_domain": "multiple_sclerosis", "predicate_ab": "activates", "mediator": "NRF2", "mediator_type": "protein", "predicate_bc": "causes", "outcome": "chemoresistance", "outcome_type": "phenotype", "outcome_domain": "pancreatic_cancer", "score": 0.40943445622221003, "filtered_score": 0.40943445622221003, "filter_reason": null, "outreach_score": 0.40943445622221003, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "dimethyl fumarate", "mediator_canonical": "NRF2", "outcome_canonical": null, "ab_count": 19, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "38368281", "title": "Identification of key neuronal mechanisms triggered by dimethyl fumarate in SH-SY5Y human neuroblastoma cells through a metabolomic approach", "doi": "10.1007/s00204-024-03683-9", "year": 2024 }, { "pmid": "37751291", "title": "Dimethyl fumarate modulates the dystrophic disease program following short-term treatment", "doi": "10.1172/jci.insight.165974", "year": 2023 }, { "pmid": "36065971", "title": "Dimethyl fumarate attenuates pain behaviors in osteoarthritis rats via induction of Nrf2-mediated mitochondrial biogenesis", "doi": "10.1177/17448069221124920", "year": 2022 } ], "bc": [ { "pmid": "31911550", "title": "Undermining Glutaminolysis Bolsters Chemotherapy While NRF2 Promotes Chemoresistance in KRAS-Driven Pancreatic Cancers", "doi": "10.1158/0008-5472.can-19-1363", "year": 2020 }, { "pmid": "30735911", "title": "Digoxin sensitizes gemcitabine-resistant pancreatic cancer cells to gemcitabine via inhibiting Nrf2 signaling pathway", "doi": "10.1016/j.redox.2019.101131", "year": 2019 } ] } }, { "id": 39004, "drug": "Auranofin", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "activates", "mediator": "Nrf2", "mediator_type": "protein", "predicate_bc": "causes", "outcome": "chemoresistance", "outcome_type": "phenotype", "outcome_domain": "pancreatic_cancer", "score": 0.270805020110221, "filtered_score": 0.4062075301653315, "filter_reason": "boosted_repurposing", "outreach_score": 0.4062075301653315, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "auranofin", "mediator_canonical": "NRF2", "outcome_canonical": null, "ab_count": 4, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37760943", "title": "Auranofin Modulates Thioredoxin Reductase/Nrf2 Signaling in Peripheral Immune Cells and the CNS in a Mouse Model of Relapsing–Remitting EAE", "doi": "10.3390/biomedicines11092502", "year": 2023 }, { "pmid": "35738800", "title": "Targeting of Nrf2 improves antitumoral responses by human NK cells, TIL and CAR T cells during oxidative stress", "doi": "10.1136/jitc-2021-004458", "year": 2022 }, { "pmid": "34788728", "title": "Comprehensive chemical proteomics analyses reveal that the new TRi-1 and TRi-2 compounds are more specific thioredoxin reductase 1 inhibitors than auranofin", "doi": "10.1016/j.redox.2021.102184", "year": 2021 } ], "bc": [ { "pmid": "31911550", "title": "Undermining Glutaminolysis Bolsters Chemotherapy While NRF2 Promotes Chemoresistance in KRAS-Driven Pancreatic Cancers", "doi": "10.1158/0008-5472.can-19-1363", "year": 2020 }, { "pmid": "30735911", "title": "Digoxin sensitizes gemcitabine-resistant pancreatic cancer cells to gemcitabine via inhibiting Nrf2 signaling pathway", "doi": "10.1016/j.redox.2019.101131", "year": 2019 } ] } }, { "id": 4982, "drug": "erlotinib", "drug_type": "drug", "drug_domain": "pancreatic_cancer", "predicate_ab": "inhibits", "mediator": "EGFR", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "Alzheimer's disease", "outcome_type": "disease", "outcome_domain": "alzheimer", "score": 0.26390573296152586, "filtered_score": 0.3958585994422888, "filter_reason": "boosted_repurposing", "outreach_score": 0.3958585994422888, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "erlotinib", "mediator_canonical": "EGFR", "outcome_canonical": "Alzheimer disease", "ab_count": 6, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37847995", "title": "Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group", "doi": "10.1200/jco.22.02770", "year": 2023 }, { "pmid": "36092320", "title": "A phase II trial of gemcitabine and erlotinib followed by ChemoProton therapy plus capecitabine and oxaliplatin for locally advanced pancreatic cancer", "doi": "10.21037/jgo-22-327", "year": 2022 }, { "pmid": "33862582", "title": "A genetically defined signature of responsiveness to erlotinib in early-stage pancreatic cancer patients: Results from the CONKO-005 trial", "doi": "10.1016/j.ebiom.2021.103327", "year": 2021 } ], "bc": [ { "pmid": "39252463", "title": "Plasma proteomics for risk prediction of Alzheimer's disease in the general population", "doi": "10.1111/acel.14330", "year": 2024 } ] } }, { "id": 4395, "drug": "erlotinib", "drug_type": "drug", "drug_domain": "pancreatic_cancer", "predicate_ab": "inhibits", "mediator": "EGFR", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "worse survival", "outcome_type": "phenotype", "outcome_domain": "glioblastoma", "score": 0.26390573296152586, "filtered_score": 0.3958585994422888, "filter_reason": "boosted_repurposing", "outreach_score": 0.3958585994422888, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "erlotinib", "mediator_canonical": "EGFR", "outcome_canonical": null, "ab_count": 6, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37847995", "title": "Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group", "doi": "10.1200/jco.22.02770", "year": 2023 }, { "pmid": "36092320", "title": "A phase II trial of gemcitabine and erlotinib followed by ChemoProton therapy plus capecitabine and oxaliplatin for locally advanced pancreatic cancer", "doi": "10.21037/jgo-22-327", "year": 2022 }, { "pmid": "33862582", "title": "A genetically defined signature of responsiveness to erlotinib in early-stage pancreatic cancer patients: Results from the CONKO-005 trial", "doi": "10.1016/j.ebiom.2021.103327", "year": 2021 } ], "bc": [ { "pmid": "36035640", "title": "Immunohistochemical Detection and Prognostic Significance of p53, Epidermal Growth Factor Receptor, Murine Double Minute 2, and Isocitrate Dehydrogenase 1 in Glioblastoma Multiforme Patients of Pakistan", "doi": "10.1177/11795549221119107", "year": 2022 } ] } }, { "id": 50184, "drug": "metformin", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "activates", "mediator": "AMPK", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "amyotrophic lateral sclerosis", "outcome_type": "disease", "outcome_domain": "als", "score": 0.26390573296152586, "filtered_score": 0.3958585994422888, "filter_reason": "boosted_repurposing", "outreach_score": 0.3958585994422888, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 6, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37750221", "title": "Metformin inhibits mitochondrial dysfunction and apoptosis in cardiomyocytes induced by high glucose via upregulating AMPK activity", "doi": "10.1177/15353702231191178", "year": 2023 }, { "pmid": "36481406", "title": "The combination of exercise and metformin inhibits TGF-β1/Smad pathway to attenuate myocardial fibrosis in db/db mice by reducing NF-κB–mediated inflammatory response", "doi": "10.1016/j.biopha.2022.114080", "year": 2022 }, { "pmid": "32248762", "title": "Metformin Improves Cardiac Metabolism and Function, and Prevents Left Ventricular Hypertrophy in Spontaneously Hypertensive Rats", "doi": "10.1161/jaha.119.015154", "year": 2020 } ], "bc": [ { "pmid": "34393724", "title": "Contribution of Energy Dysfunction to Impaired Protein Translation in Neurodegenerative Diseases", "doi": "10.3389/fncel.2021.668500", "year": 2021 } ] } }, { "id": 51166, "drug": "metformin", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "activates", "mediator": "AMPK", "mediator_type": "protein", "predicate_bc": "treats", "outcome": "intestinal inflammation", "outcome_type": "disease", "outcome_domain": "inflammatory_bowel_disease", "score": 0.26390573296152586, "filtered_score": 0.3958585994422888, "filter_reason": "boosted_repurposing", "outreach_score": 0.3958585994422888, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 6, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37750221", "title": "Metformin inhibits mitochondrial dysfunction and apoptosis in cardiomyocytes induced by high glucose via upregulating AMPK activity", "doi": "10.1177/15353702231191178", "year": 2023 }, { "pmid": "36481406", "title": "The combination of exercise and metformin inhibits TGF-β1/Smad pathway to attenuate myocardial fibrosis in db/db mice by reducing NF-κB–mediated inflammatory response", "doi": "10.1016/j.biopha.2022.114080", "year": 2022 }, { "pmid": "32248762", "title": "Metformin Improves Cardiac Metabolism and Function, and Prevents Left Ventricular Hypertrophy in Spontaneously Hypertensive Rats", "doi": "10.1161/jaha.119.015154", "year": 2020 } ], "bc": [ { "pmid": "33252129", "title": "Salicylates Ameliorate Intestinal Inflammation by Activating Macrophage AMPK", "doi": "10.1093/ibd/izaa305", "year": 2020 } ] } }, { "id": 4388, "drug": "erlotinib", "drug_type": "drug", "drug_domain": "pancreatic_cancer", "predicate_ab": "inhibits", "mediator": "EGFR", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "glioblastoma aggressiveness", "outcome_type": "phenotype", "outcome_domain": "glioblastoma", "score": 0.26390573296152586, "filtered_score": 0.3958585994422888, "filter_reason": "boosted_repurposing", "outreach_score": 0.3958585994422888, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "erlotinib", "mediator_canonical": "EGFR", "outcome_canonical": "glioblastoma aggressiveness", "ab_count": 6, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37847995", "title": "Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group", "doi": "10.1200/jco.22.02770", "year": 2023 }, { "pmid": "36092320", "title": "A phase II trial of gemcitabine and erlotinib followed by ChemoProton therapy plus capecitabine and oxaliplatin for locally advanced pancreatic cancer", "doi": "10.21037/jgo-22-327", "year": 2022 }, { "pmid": "33862582", "title": "A genetically defined signature of responsiveness to erlotinib in early-stage pancreatic cancer patients: Results from the CONKO-005 trial", "doi": "10.1016/j.ebiom.2021.103327", "year": 2021 } ], "bc": [ { "pmid": "36297416", "title": "Bioimaging Nucleic-Acid Aptamers with Different Specificities in Human Glioblastoma Tissues Highlights Tumoral Heterogeneity", "doi": "10.3390/pharmaceutics14101980", "year": 2022 } ] } }, { "id": 51165, "drug": "metformin", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "activates", "mediator": "AMPK", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "intestinal epithelial repair", "outcome_type": "phenotype", "outcome_domain": "inflammatory_bowel_disease", "score": 0.26390573296152586, "filtered_score": 0.3958585994422888, "filter_reason": "boosted_repurposing", "outreach_score": 0.3958585994422888, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 6, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37750221", "title": "Metformin inhibits mitochondrial dysfunction and apoptosis in cardiomyocytes induced by high glucose via upregulating AMPK activity", "doi": "10.1177/15353702231191178", "year": 2023 }, { "pmid": "36481406", "title": "The combination of exercise and metformin inhibits TGF-β1/Smad pathway to attenuate myocardial fibrosis in db/db mice by reducing NF-κB–mediated inflammatory response", "doi": "10.1016/j.biopha.2022.114080", "year": 2022 }, { "pmid": "32248762", "title": "Metformin Improves Cardiac Metabolism and Function, and Prevents Left Ventricular Hypertrophy in Spontaneously Hypertensive Rats", "doi": "10.1161/jaha.119.015154", "year": 2020 } ], "bc": [ { "pmid": "35203241", "title": "Intestinal Epithelial AMPK Deficiency Causes Delayed Colonic Epithelial Repair in DSS-Induced Colitis", "doi": "10.3390/cells11040590", "year": 2022 } ] } }, { "id": 50774, "drug": "metformin", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "activates", "mediator": "AMPK", "mediator_type": "protein", "predicate_bc": "increases", "outcome": "epileptiform network activity", "outcome_type": "phenotype", "outcome_domain": "epilepsy", "score": 0.26390573296152586, "filtered_score": 0.3958585994422888, "filter_reason": "boosted_repurposing", "outreach_score": 0.3958585994422888, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 6, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37750221", "title": "Metformin inhibits mitochondrial dysfunction and apoptosis in cardiomyocytes induced by high glucose via upregulating AMPK activity", "doi": "10.1177/15353702231191178", "year": 2023 }, { "pmid": "36481406", "title": "The combination of exercise and metformin inhibits TGF-β1/Smad pathway to attenuate myocardial fibrosis in db/db mice by reducing NF-κB–mediated inflammatory response", "doi": "10.1016/j.biopha.2022.114080", "year": 2022 }, { "pmid": "32248762", "title": "Metformin Improves Cardiac Metabolism and Function, and Prevents Left Ventricular Hypertrophy in Spontaneously Hypertensive Rats", "doi": "10.1161/jaha.119.015154", "year": 2020 } ], "bc": [ { "pmid": "35134125", "title": "AMPK-mediated potentiation of GABAergic signalling drives hypoglycaemia-provoked spike-wave seizures", "doi": "10.1093/brain/awac037", "year": 2022 } ] } }, { "id": 51557, "drug": "metformin", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "activates", "mediator": "AMPK", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "pancreatic cancer progression", "outcome_type": "disease", "outcome_domain": "pancreatic_cancer", "score": 0.26390573296152586, "filtered_score": 0.3958585994422888, "filter_reason": "boosted_repurposing", "outreach_score": 0.3958585994422888, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 6, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37750221", "title": "Metformin inhibits mitochondrial dysfunction and apoptosis in cardiomyocytes induced by high glucose via upregulating AMPK activity", "doi": "10.1177/15353702231191178", "year": 2023 }, { "pmid": "36481406", "title": "The combination of exercise and metformin inhibits TGF-β1/Smad pathway to attenuate myocardial fibrosis in db/db mice by reducing NF-κB–mediated inflammatory response", "doi": "10.1016/j.biopha.2022.114080", "year": 2022 }, { "pmid": "32248762", "title": "Metformin Improves Cardiac Metabolism and Function, and Prevents Left Ventricular Hypertrophy in Spontaneously Hypertensive Rats", "doi": "10.1161/jaha.119.015154", "year": 2020 } ], "bc": [ { "pmid": "31205544", "title": "AMPK Inhibition Suppresses the Malignant Phenotype of Pancreatic Cancer Cells in Part by Attenuating Aerobic Glycolysis", "doi": "10.7150/jca.28299", "year": 2019 } ] } }, { "id": 39388, "drug": "saxagliptin", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "upregulates", "mediator": "SOD1", "mediator_type": "gene", "predicate_bc": "associated_with", "outcome": "ALS", "outcome_type": "disease", "outcome_domain": "als", "score": 0.38286413964890953, "filtered_score": 0.38286413964890953, "filter_reason": null, "outreach_score": 0.38286413964890953, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "saxagliptin", "mediator_canonical": "SOD1", "outcome_canonical": "amyotrophic lateral sclerosis", "ab_count": 1, "bc_count": 22, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "29724198", "title": "The synergistic effects of saxagliptin and metformin on CD34+ endothelial progenitor cells in early type 2 diabetes patients: a randomized clinical trial", "doi": "10.1186/s12933-018-0709-9", "year": 2018 } ], "bc": [ { "pmid": "41852184", "title": "High Prevalence of SOD1 Pathogenic Variants in the UK Biobank: Implications for Early Intervention in Amyotrophic Lateral Sclerosis", "doi": "10.1002/ana.78195", "year": 2026 }, { "pmid": "41513843", "title": "Demographic, clinical and genetic characteristics of patients with amyotrophic lateral sclerosis from two specialised centres in Austria", "doi": "10.1007/s00415-025-13614-y", "year": 2026 }, { "pmid": "40957416", "title": "Landscapes of missense variant impact for human superoxide dismutase 1", "doi": "10.1016/j.ajhg.2025.08.019", "year": 2025 } ] } }, { "id": 32317, "drug": "LWE", "drug_type": "drug", "drug_domain": "inflammatory_bowel_disease", "predicate_ab": "upregulates", "mediator": "SOD1", "mediator_type": "gene", "predicate_bc": "associated_with", "outcome": "ALS", "outcome_type": "disease", "outcome_domain": "als", "score": 0.38286413964890953, "filtered_score": 0.38286413964890953, "filter_reason": null, "outreach_score": 0.38286413964890953, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "lwe", "mediator_canonical": "SOD1", "outcome_canonical": "amyotrophic lateral sclerosis", "ab_count": 1, "bc_count": 22, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "39061864", "title": "Hydroethanolic Extract of Lepidium apetalum Willdenow Alleviates Dextran Sulfate Sodium-Induced Colitis by Enhancing Intestinal Barrier Integrity and Inhibiting Oxidative Stress and Inflammasome Activation", "doi": "10.3390/antiox13070795", "year": 2024 } ], "bc": [ { "pmid": "41852184", "title": "High Prevalence of SOD1 Pathogenic Variants in the UK Biobank: Implications for Early Intervention in Amyotrophic Lateral Sclerosis", "doi": "10.1002/ana.78195", "year": 2026 }, { "pmid": "41513843", "title": "Demographic, clinical and genetic characteristics of patients with amyotrophic lateral sclerosis from two specialised centres in Austria", "doi": "10.1007/s00415-025-13614-y", "year": 2026 }, { "pmid": "40957416", "title": "Landscapes of missense variant impact for human superoxide dismutase 1", "doi": "10.1016/j.ajhg.2025.08.019", "year": 2025 } ] } }, { "id": 3773, "drug": "sodium butyrate", "drug_type": "drug", "drug_domain": "alzheimer", "predicate_ab": "upregulates", "mediator": "Sod1", "mediator_type": "gene", "predicate_bc": "associated_with", "outcome": "ALS", "outcome_type": "disease", "outcome_domain": "als", "score": 0.38286413964890953, "filtered_score": 0.38286413964890953, "filter_reason": null, "outreach_score": 0.38286413964890953, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "sodium butyrate", "mediator_canonical": "SOD1", "outcome_canonical": "amyotrophic lateral sclerosis", "ab_count": 1, "bc_count": 22, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "32555166", "title": "Sodium butyrate inhibits high cholesterol-induced neuronal amyloidogenesis by modulating NRF2 stabilization-mediated ROS levels: involvement of NOX2 and SOD1", "doi": "10.1038/s41419-020-2663-1", "year": 2020 } ], "bc": [ { "pmid": "41852184", "title": "High Prevalence of SOD1 Pathogenic Variants in the UK Biobank: Implications for Early Intervention in Amyotrophic Lateral Sclerosis", "doi": "10.1002/ana.78195", "year": 2026 }, { "pmid": "41513843", "title": "Demographic, clinical and genetic characteristics of patients with amyotrophic lateral sclerosis from two specialised centres in Austria", "doi": "10.1007/s00415-025-13614-y", "year": 2026 }, { "pmid": "40957416", "title": "Landscapes of missense variant impact for human superoxide dismutase 1", "doi": "10.1016/j.ajhg.2025.08.019", "year": 2025 } ] } }, { "id": 2091, "drug": "Ketogenic diet", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "upregulates", "mediator": "Sod1", "mediator_type": "gene", "predicate_bc": "associated_with", "outcome": "ALS", "outcome_type": "disease", "outcome_domain": "als", "score": 0.38286413964890953, "filtered_score": 0.38286413964890953, "filter_reason": null, "outreach_score": 0.38286413964890953, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "active", "clinical_trial_nct_ids": [ "NCT07233148", "NCT04204889", "NCT01016522" ], "literature_status": "reproduces_known", "drug_canonical": "ketogenic diet", "mediator_canonical": "SOD1", "outcome_canonical": "amyotrophic lateral sclerosis", "ab_count": 1, "bc_count": 22, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "31873138", "title": "Ketogenic diet induces skeletal muscle atrophy via reducing muscle protein synthesis and possibly activating proteolysis in mice", "doi": "10.1038/s41598-019-56166-8", "year": 2019 } ], "bc": [ { "pmid": "41852184", "title": "High Prevalence of SOD1 Pathogenic Variants in the UK Biobank: Implications for Early Intervention in Amyotrophic Lateral Sclerosis", "doi": "10.1002/ana.78195", "year": 2026 }, { "pmid": "41513843", "title": "Demographic, clinical and genetic characteristics of patients with amyotrophic lateral sclerosis from two specialised centres in Austria", "doi": "10.1007/s00415-025-13614-y", "year": 2026 }, { "pmid": "40957416", "title": "Landscapes of missense variant impact for human superoxide dismutase 1", "doi": "10.1016/j.ajhg.2025.08.019", "year": 2025 } ] } }, { "id": 50186, "drug": "resveratrol", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "activates", "mediator": "SIRT1", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "overexpression", "outcome_type": "phenotype", "outcome_domain": "als", "score": 0.24849066497880004, "filtered_score": 0.3727359974682001, "filter_reason": "boosted_repurposing", "outreach_score": 0.3727359974682001, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 5, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37487007", "title": "Resveratrol inhibits ferroptosis and decelerates heart failure progression via Sirt1/p53 pathway activation", "doi": "10.1111/jcmm.17874", "year": 2023 }, { "pmid": "36926277", "title": "Resveratrol alleviates high glucose-induced oxidative stress and apoptosis in rat cardiac microvascular endothelial cell through AMPK/Sirt1 activation", "doi": "10.1016/j.bbrep.2023.101444", "year": 2023 }, { "pmid": "35791579", "title": "Resveratrol, novel application by preconditioning to attenuate myocardial ischemia/reperfusion injury in mice through regulate AMPK pathway and autophagy level", "doi": "10.1111/jcmm.17431", "year": 2022 } ], "bc": [ { "pmid": "35448021", "title": "SIRT1 Interacts with Prepro-Orexin in the Hypothalamus in SOD1G93A Mice", "doi": "10.3390/brainsci12040490", "year": 2022 } ] } }, { "id": 1567, "drug": "erlotinib", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "inhibits", "mediator": "EGFR", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "pancreatic ductal adenocarcinoma", "outcome_type": "disease", "outcome_domain": "pancreatic_cancer", "score": 0.24849066497880004, "filtered_score": 0.3727359974682001, "filter_reason": "boosted_repurposing", "outreach_score": 0.3727359974682001, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "active", "clinical_trial_nct_ids": [ "NCT00878163", "NCT01013649", "NCT01600807" ], "literature_status": "reproduces_known", "drug_canonical": "erlotinib", "mediator_canonical": "EGFR", "outcome_canonical": "pancreatic ductal adenocarcinoma", "ab_count": 2, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40945534", "title": "Biodegradable nanofibrous scaffolds enhance standard of care for glioblastoma via localized targeted therapy", "doi": "10.1016/j.jconrel.2025.114225", "year": 2025 }, { "pmid": "30410775", "title": "The role of erlotinib and the Optune device in a patient with an epidermal growth factor receptor viii amplified glioblastoma", "doi": "10.1093/omcr/omy095", "year": 2018 } ], "bc": [ { "pmid": "40130819", "title": "Identification of Tumor‐Specific Surface Proteins Enables Quantification of Extracellular Vesicle Subtypes for Early Detection of Pancreatic Ductal Adenocarcinoma", "doi": "10.1002/advs.202414982", "year": 2025 }, { "pmid": "31584260", "title": "Design and Evaluation of PEGylated Liposomal Formulation of a Novel Multikinase Inhibitor for Enhanced Chemosensitivity and Inhibition of Metastatic Pancreatic Ductal Adenocarcinoma", "doi": "10.1021/acs.bioconjchem.9b00632", "year": 2019 }, { "pmid": "26339400", "title": "EGFR expression in pancreatic intraepithelial neoplasia and ductal adenocarcinoma.", "doi": null, "year": 2015 } ] } }, { "id": 50383, "drug": "resveratrol", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "activates", "mediator": "SIRT1", "mediator_type": "protein", "predicate_bc": "prevents", "outcome": "Aβ-induced neurotoxicity", "outcome_type": "phenotype", "outcome_domain": "alzheimer", "score": 0.24849066497880004, "filtered_score": 0.3727359974682001, "filter_reason": "boosted_repurposing", "outreach_score": 0.3727359974682001, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 5, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37487007", "title": "Resveratrol inhibits ferroptosis and decelerates heart failure progression via Sirt1/p53 pathway activation", "doi": "10.1111/jcmm.17874", "year": 2023 }, { "pmid": "36926277", "title": "Resveratrol alleviates high glucose-induced oxidative stress and apoptosis in rat cardiac microvascular endothelial cell through AMPK/Sirt1 activation", "doi": "10.1016/j.bbrep.2023.101444", "year": 2023 }, { "pmid": "35791579", "title": "Resveratrol, novel application by preconditioning to attenuate myocardial ischemia/reperfusion injury in mice through regulate AMPK pathway and autophagy level", "doi": "10.1111/jcmm.17431", "year": 2022 } ], "bc": [ { "pmid": "37602729", "title": "Cooperative effects of SIRT1 and SIRT2 on APP acetylation", "doi": "10.1111/acel.13967", "year": 2023 } ] } }, { "id": 50384, "drug": "resveratrol", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "activates", "mediator": "SIRT1", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "Braak stage", "outcome_type": "phenotype", "outcome_domain": "alzheimer", "score": 0.24849066497880004, "filtered_score": 0.3727359974682001, "filter_reason": "boosted_repurposing", "outreach_score": 0.3727359974682001, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 5, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37487007", "title": "Resveratrol inhibits ferroptosis and decelerates heart failure progression via Sirt1/p53 pathway activation", "doi": "10.1111/jcmm.17874", "year": 2023 }, { "pmid": "36926277", "title": "Resveratrol alleviates high glucose-induced oxidative stress and apoptosis in rat cardiac microvascular endothelial cell through AMPK/Sirt1 activation", "doi": "10.1016/j.bbrep.2023.101444", "year": 2023 }, { "pmid": "35791579", "title": "Resveratrol, novel application by preconditioning to attenuate myocardial ischemia/reperfusion injury in mice through regulate AMPK pathway and autophagy level", "doi": "10.1111/jcmm.17431", "year": 2022 } ], "bc": [ { "pmid": "30185534", "title": "Reduced expression of SIRT1 and SOD-1 and the correlation between these levels in various regions of the brains of patients with Alzheimer's disease", "doi": "10.1136/jclinpath-2018-205320", "year": 2018 } ] } }, { "id": 2486, "drug": "valproic acid", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "downregulates", "mediator": "PKM2", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "poor overall survival", "outcome_type": "phenotype", "outcome_domain": "pancreatic_cancer", "score": 0.24849066497880004, "filtered_score": 0.3727359974682001, "filter_reason": "boosted_repurposing", "outreach_score": 0.3727359974682001, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "valproic acid", "mediator_canonical": "PKM", "outcome_canonical": "poor overall survival", "ab_count": 1, "bc_count": 5, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "34263655", "title": "Valproic acid Suppresses Breast Cancer Cell Growth Through Triggering Pyruvate Kinase M2 Isoform Mediated Warburg Effect", "doi": "10.1177/09636897211027524", "year": 2021 } ], "bc": [ { "pmid": "27478385", "title": "Pyruvate kinase M2 overexpression and poor prognosis in solid tumors of digestive system: evidence from 16 cohort studies", "doi": "10.2147/ott.s106508", "year": 2016 } ] } }, { "id": 51941, "drug": "resveratrol", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "activates", "mediator": "SIRT1", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "T2D onset", "outcome_type": "disease", "outcome_domain": "type_2_diabetes", "score": 0.24849066497880004, "filtered_score": 0.3727359974682001, "filter_reason": "boosted_repurposing", "outreach_score": 0.3727359974682001, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 5, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37487007", "title": "Resveratrol inhibits ferroptosis and decelerates heart failure progression via Sirt1/p53 pathway activation", "doi": "10.1111/jcmm.17874", "year": 2023 }, { "pmid": "36926277", "title": "Resveratrol alleviates high glucose-induced oxidative stress and apoptosis in rat cardiac microvascular endothelial cell through AMPK/Sirt1 activation", "doi": "10.1016/j.bbrep.2023.101444", "year": 2023 }, { "pmid": "35791579", "title": "Resveratrol, novel application by preconditioning to attenuate myocardial ischemia/reperfusion injury in mice through regulate AMPK pathway and autophagy level", "doi": "10.1111/jcmm.17431", "year": 2022 } ], "bc": [ { "pmid": "35879296", "title": "Phenylalanine impairs insulin signaling and inhibits glucose uptake through modification of IRβ", "doi": "10.1038/s41467-022-32000-0", "year": 2022 } ] } }, { "id": 50385, "drug": "resveratrol", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "activates", "mediator": "SIRT1", "mediator_type": "protein", "predicate_bc": "prevents", "outcome": "tau accumulation", "outcome_type": "phenotype", "outcome_domain": "alzheimer", "score": 0.24849066497880004, "filtered_score": 0.3727359974682001, "filter_reason": "boosted_repurposing", "outreach_score": 0.3727359974682001, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 5, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37487007", "title": "Resveratrol inhibits ferroptosis and decelerates heart failure progression via Sirt1/p53 pathway activation", "doi": "10.1111/jcmm.17874", "year": 2023 }, { "pmid": "36926277", "title": "Resveratrol alleviates high glucose-induced oxidative stress and apoptosis in rat cardiac microvascular endothelial cell through AMPK/Sirt1 activation", "doi": "10.1016/j.bbrep.2023.101444", "year": 2023 }, { "pmid": "35791579", "title": "Resveratrol, novel application by preconditioning to attenuate myocardial ischemia/reperfusion injury in mice through regulate AMPK pathway and autophagy level", "doi": "10.1111/jcmm.17431", "year": 2022 } ], "bc": [ { "pmid": "29883958", "title": "A silver lining for 24-hydroxycholesterol in Alzheimer's disease: The involvement of the neuroprotective enzyme sirtuin 1", "doi": "10.1016/j.redox.2018.05.009", "year": 2018 } ] } }, { "id": 51940, "drug": "resveratrol", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "activates", "mediator": "SIRT1", "mediator_type": "protein", "predicate_bc": "decreases", "outcome": "metabolic dysfunction", "outcome_type": "disease", "outcome_domain": "type_2_diabetes", "score": 0.24849066497880004, "filtered_score": 0.3727359974682001, "filter_reason": "boosted_repurposing", "outreach_score": 0.3727359974682001, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 5, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37487007", "title": "Resveratrol inhibits ferroptosis and decelerates heart failure progression via Sirt1/p53 pathway activation", "doi": "10.1111/jcmm.17874", "year": 2023 }, { "pmid": "36926277", "title": "Resveratrol alleviates high glucose-induced oxidative stress and apoptosis in rat cardiac microvascular endothelial cell through AMPK/Sirt1 activation", "doi": "10.1016/j.bbrep.2023.101444", "year": 2023 }, { "pmid": "35791579", "title": "Resveratrol, novel application by preconditioning to attenuate myocardial ischemia/reperfusion injury in mice through regulate AMPK pathway and autophagy level", "doi": "10.1111/jcmm.17431", "year": 2022 } ], "bc": [ { "pmid": "30988688", "title": "Exercise training upregulates SIRT1 to attenuate inflammation and metabolic dysfunction in kidney and liver of diabetic db/db mice", "doi": "10.1186/s12986-019-0349-4", "year": 2019 } ] } }, { "id": 51360, "drug": "resveratrol", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "activates", "mediator": "SIRT1", "mediator_type": "protein", "predicate_bc": "treats", "outcome": "rheumatoid arthritis", "outcome_type": "disease", "outcome_domain": "multiple_sclerosis", "score": 0.24849066497880004, "filtered_score": 0.3727359974682001, "filter_reason": "boosted_repurposing", "outreach_score": 0.3727359974682001, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 5, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37487007", "title": "Resveratrol inhibits ferroptosis and decelerates heart failure progression via Sirt1/p53 pathway activation", "doi": "10.1111/jcmm.17874", "year": 2023 }, { "pmid": "36926277", "title": "Resveratrol alleviates high glucose-induced oxidative stress and apoptosis in rat cardiac microvascular endothelial cell through AMPK/Sirt1 activation", "doi": "10.1016/j.bbrep.2023.101444", "year": 2023 }, { "pmid": "35791579", "title": "Resveratrol, novel application by preconditioning to attenuate myocardial ischemia/reperfusion injury in mice through regulate AMPK pathway and autophagy level", "doi": "10.1111/jcmm.17431", "year": 2022 } ], "bc": [ { "pmid": "38305342", "title": "Targeting Pathways and Integrated Approaches to Treat Rheumatoid Arthritis", "doi": "10.1615/critrevtherdrugcarriersyst.2023044719", "year": 2023 } ] } }, { "id": 51359, "drug": "resveratrol", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "activates", "mediator": "SIRT1", "mediator_type": "protein", "predicate_bc": "decreases", "outcome": "axon demyelination", "outcome_type": "phenotype", "outcome_domain": "multiple_sclerosis", "score": 0.24849066497880004, "filtered_score": 0.3727359974682001, "filter_reason": "boosted_repurposing", "outreach_score": 0.3727359974682001, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 5, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37487007", "title": "Resveratrol inhibits ferroptosis and decelerates heart failure progression via Sirt1/p53 pathway activation", "doi": "10.1111/jcmm.17874", "year": 2023 }, { "pmid": "36926277", "title": "Resveratrol alleviates high glucose-induced oxidative stress and apoptosis in rat cardiac microvascular endothelial cell through AMPK/Sirt1 activation", "doi": "10.1016/j.bbrep.2023.101444", "year": 2023 }, { "pmid": "35791579", "title": "Resveratrol, novel application by preconditioning to attenuate myocardial ischemia/reperfusion injury in mice through regulate AMPK pathway and autophagy level", "doi": "10.1111/jcmm.17431", "year": 2022 } ], "bc": [ { "pmid": "35740955", "title": "Selective Upregulation of SIRT1 Expression in Retinal Ganglion Cells by AAV-Mediated Gene Delivery Increases Neuronal Cell Survival and Alleviates Axon Demyelination Associated with Optic Neuritis", "doi": "10.3390/biom12060830", "year": 2022 } ] } }, { "id": 50386, "drug": "resveratrol", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "activates", "mediator": "SIRT1", "mediator_type": "protein", "predicate_bc": "increases", "outcome": "APP recycling", "outcome_type": "phenotype", "outcome_domain": "alzheimer", "score": 0.24849066497880004, "filtered_score": 0.3727359974682001, "filter_reason": "boosted_repurposing", "outreach_score": 0.3727359974682001, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 5, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37487007", "title": "Resveratrol inhibits ferroptosis and decelerates heart failure progression via Sirt1/p53 pathway activation", "doi": "10.1111/jcmm.17874", "year": 2023 }, { "pmid": "36926277", "title": "Resveratrol alleviates high glucose-induced oxidative stress and apoptosis in rat cardiac microvascular endothelial cell through AMPK/Sirt1 activation", "doi": "10.1016/j.bbrep.2023.101444", "year": 2023 }, { "pmid": "35791579", "title": "Resveratrol, novel application by preconditioning to attenuate myocardial ischemia/reperfusion injury in mice through regulate AMPK pathway and autophagy level", "doi": "10.1111/jcmm.17431", "year": 2022 } ], "bc": [ { "pmid": "37602729", "title": "Cooperative effects of SIRT1 and SIRT2 on APP acetylation", "doi": "10.1111/acel.13967", "year": 2023 } ] } }, { "id": 51944, "drug": "resveratrol", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "activates", "mediator": "SIRT1", "mediator_type": "protein", "predicate_bc": "treats", "outcome": "Type 2 Diabetes Mellitus", "outcome_type": "disease", "outcome_domain": "type_2_diabetes", "score": 0.24849066497880004, "filtered_score": 0.3727359974682001, "filter_reason": "boosted_repurposing", "outreach_score": 0.3727359974682001, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 5, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37487007", "title": "Resveratrol inhibits ferroptosis and decelerates heart failure progression via Sirt1/p53 pathway activation", "doi": "10.1111/jcmm.17874", "year": 2023 }, { "pmid": "36926277", "title": "Resveratrol alleviates high glucose-induced oxidative stress and apoptosis in rat cardiac microvascular endothelial cell through AMPK/Sirt1 activation", "doi": "10.1016/j.bbrep.2023.101444", "year": 2023 }, { "pmid": "35791579", "title": "Resveratrol, novel application by preconditioning to attenuate myocardial ischemia/reperfusion injury in mice through regulate AMPK pathway and autophagy level", "doi": "10.1111/jcmm.17431", "year": 2022 } ], "bc": [ { "pmid": "34379994", "title": "SIRT1: a promising therapeutic target in type 2 diabetes mellitus", "doi": "10.1080/13813455.2021.1956976", "year": 2021 } ] } }, { "id": 51942, "drug": "resveratrol", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "activates", "mediator": "SIRT1", "mediator_type": "protein", "predicate_bc": "decreases", "outcome": "inflammation", "outcome_type": "disease", "outcome_domain": "type_2_diabetes", "score": 0.24849066497880004, "filtered_score": 0.3727359974682001, "filter_reason": "boosted_repurposing", "outreach_score": 0.3727359974682001, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 5, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37487007", "title": "Resveratrol inhibits ferroptosis and decelerates heart failure progression via Sirt1/p53 pathway activation", "doi": "10.1111/jcmm.17874", "year": 2023 }, { "pmid": "36926277", "title": "Resveratrol alleviates high glucose-induced oxidative stress and apoptosis in rat cardiac microvascular endothelial cell through AMPK/Sirt1 activation", "doi": "10.1016/j.bbrep.2023.101444", "year": 2023 }, { "pmid": "35791579", "title": "Resveratrol, novel application by preconditioning to attenuate myocardial ischemia/reperfusion injury in mice through regulate AMPK pathway and autophagy level", "doi": "10.1111/jcmm.17431", "year": 2022 } ], "bc": [ { "pmid": "30988688", "title": "Exercise training upregulates SIRT1 to attenuate inflammation and metabolic dysfunction in kidney and liver of diabetic db/db mice", "doi": "10.1186/s12986-019-0349-4", "year": 2019 } ] } }, { "id": 51561, "drug": "resveratrol", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "activates", "mediator": "SIRT1", "mediator_type": "protein", "predicate_bc": "increases", "outcome": "tumor-initiating capacity", "outcome_type": "phenotype", "outcome_domain": "pancreatic_cancer", "score": 0.24849066497880004, "filtered_score": 0.3727359974682001, "filter_reason": "boosted_repurposing", "outreach_score": 0.3727359974682001, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 5, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37487007", "title": "Resveratrol inhibits ferroptosis and decelerates heart failure progression via Sirt1/p53 pathway activation", "doi": "10.1111/jcmm.17874", "year": 2023 }, { "pmid": "36926277", "title": "Resveratrol alleviates high glucose-induced oxidative stress and apoptosis in rat cardiac microvascular endothelial cell through AMPK/Sirt1 activation", "doi": "10.1016/j.bbrep.2023.101444", "year": 2023 }, { "pmid": "35791579", "title": "Resveratrol, novel application by preconditioning to attenuate myocardial ischemia/reperfusion injury in mice through regulate AMPK pathway and autophagy level", "doi": "10.1111/jcmm.17431", "year": 2022 } ], "bc": [ { "pmid": "34163012", "title": "SIRT1 coordinates with the CRL4B complex to regulate pancreatic cancer stem cells to promote tumorigenesis", "doi": "10.1038/s41418-021-00821-z", "year": 2021 } ] } }, { "id": 50387, "drug": "resveratrol", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "activates", "mediator": "SIRT1", "mediator_type": "protein", "predicate_bc": "decreases", "outcome": "tau acetylation", "outcome_type": "phenotype", "outcome_domain": "alzheimer", "score": 0.24849066497880004, "filtered_score": 0.3727359974682001, "filter_reason": "boosted_repurposing", "outreach_score": 0.3727359974682001, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 5, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37487007", "title": "Resveratrol inhibits ferroptosis and decelerates heart failure progression via Sirt1/p53 pathway activation", "doi": "10.1111/jcmm.17874", "year": 2023 }, { "pmid": "36926277", "title": "Resveratrol alleviates high glucose-induced oxidative stress and apoptosis in rat cardiac microvascular endothelial cell through AMPK/Sirt1 activation", "doi": "10.1016/j.bbrep.2023.101444", "year": 2023 }, { "pmid": "35791579", "title": "Resveratrol, novel application by preconditioning to attenuate myocardial ischemia/reperfusion injury in mice through regulate AMPK pathway and autophagy level", "doi": "10.1111/jcmm.17431", "year": 2022 } ], "bc": [ { "pmid": "29540553", "title": "SIRT1 Deacetylates Tau and Reduces Pathogenic Tau Spread in a Mouse Model of Tauopathy", "doi": "10.1523/jneurosci.2369-17.2018", "year": 2018 } ] } }, { "id": 50388, "drug": "resveratrol", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "activates", "mediator": "SIRT1", "mediator_type": "protein", "predicate_bc": "decreases", "outcome": "APP transit to endosome", "outcome_type": "phenotype", "outcome_domain": "alzheimer", "score": 0.24849066497880004, "filtered_score": 0.3727359974682001, "filter_reason": "boosted_repurposing", "outreach_score": 0.3727359974682001, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 5, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37487007", "title": "Resveratrol inhibits ferroptosis and decelerates heart failure progression via Sirt1/p53 pathway activation", "doi": "10.1111/jcmm.17874", "year": 2023 }, { "pmid": "36926277", "title": "Resveratrol alleviates high glucose-induced oxidative stress and apoptosis in rat cardiac microvascular endothelial cell through AMPK/Sirt1 activation", "doi": "10.1016/j.bbrep.2023.101444", "year": 2023 }, { "pmid": "35791579", "title": "Resveratrol, novel application by preconditioning to attenuate myocardial ischemia/reperfusion injury in mice through regulate AMPK pathway and autophagy level", "doi": "10.1111/jcmm.17431", "year": 2022 } ], "bc": [ { "pmid": "37602729", "title": "Cooperative effects of SIRT1 and SIRT2 on APP acetylation", "doi": "10.1111/acel.13967", "year": 2023 } ] } }, { "id": 51559, "drug": "resveratrol", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "activates", "mediator": "SIRT1", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "patient survival", "outcome_type": "phenotype", "outcome_domain": "pancreatic_cancer", "score": 0.24849066497880004, "filtered_score": 0.3727359974682001, "filter_reason": "boosted_repurposing", "outreach_score": 0.3727359974682001, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 5, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37487007", "title": "Resveratrol inhibits ferroptosis and decelerates heart failure progression via Sirt1/p53 pathway activation", "doi": "10.1111/jcmm.17874", "year": 2023 }, { "pmid": "36926277", "title": "Resveratrol alleviates high glucose-induced oxidative stress and apoptosis in rat cardiac microvascular endothelial cell through AMPK/Sirt1 activation", "doi": "10.1016/j.bbrep.2023.101444", "year": 2023 }, { "pmid": "35791579", "title": "Resveratrol, novel application by preconditioning to attenuate myocardial ischemia/reperfusion injury in mice through regulate AMPK pathway and autophagy level", "doi": "10.1111/jcmm.17431", "year": 2022 } ], "bc": [ { "pmid": "27494892", "title": "Sirtuin 1 stimulates the proliferation and the expression of glycolysis genes in pancreatic neoplastic lesions", "doi": "10.18632/oncotarget.11013", "year": 2016 } ] } }, { "id": 50776, "drug": "resveratrol", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "activates", "mediator": "SIRT1", "mediator_type": "protein", "predicate_bc": "prevents", "outcome": "neuronal cell death", "outcome_type": "phenotype", "outcome_domain": "epilepsy", "score": 0.24849066497880004, "filtered_score": 0.3727359974682001, "filter_reason": "boosted_repurposing", "outreach_score": 0.3727359974682001, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 5, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37487007", "title": "Resveratrol inhibits ferroptosis and decelerates heart failure progression via Sirt1/p53 pathway activation", "doi": "10.1111/jcmm.17874", "year": 2023 }, { "pmid": "36926277", "title": "Resveratrol alleviates high glucose-induced oxidative stress and apoptosis in rat cardiac microvascular endothelial cell through AMPK/Sirt1 activation", "doi": "10.1016/j.bbrep.2023.101444", "year": 2023 }, { "pmid": "35791579", "title": "Resveratrol, novel application by preconditioning to attenuate myocardial ischemia/reperfusion injury in mice through regulate AMPK pathway and autophagy level", "doi": "10.1111/jcmm.17431", "year": 2022 } ], "bc": [ { "pmid": "31340436", "title": "Sirtuin 1 Regulates Mitochondrial Biogenesis and Provides an Endogenous Neuroprotective Mechanism Against Seizure-Induced Neuronal Cell Death in the Hippocampus Following Status Epilepticus", "doi": "10.3390/ijms20143588", "year": 2019 } ] } }, { "id": 1568, "drug": "osimertinib", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "inhibits", "mediator": "EGFR", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "pancreatic adenocarcinoma", "outcome_type": "disease", "outcome_domain": "pancreatic_cancer", "score": 0.24849066497880004, "filtered_score": 0.3727359974682001, "filter_reason": "boosted_repurposing", "outreach_score": 0.3727359974682001, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "active", "clinical_trial_nct_ids": [ "NCT02465060" ], "literature_status": "partial_evidence", "drug_canonical": "osimertinib", "mediator_canonical": "EGFR", "outcome_canonical": "pancreatic adenocarcinoma", "ab_count": 3, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40719865", "title": "Resistance of recurrent epidermal growth factor receptor-altered glioblastoma to anti-epidermal growth factor receptor targeted therapy with osimertinib", "doi": "10.1093/oncolo/oyaf146", "year": 2025 }, { "pmid": "40051661", "title": "A comparative study of preclinical and clinical molecular imaging response to EGFR inhibition using osimertinib in glioblastoma", "doi": "10.1093/noajnl/vdaf022", "year": 2025 }, { "pmid": "41120287", "title": "GSCs differentiation model-informed nanotherapy: dual-functional brain-targeting liposomes with iRGD modification for co-delivery of osimertinib and bortezomib to combat radioresistant glioblastoma", "doi": "10.1038/s41419-025-08083-0", "year": 2025 } ], "bc": [ { "pmid": "37370756", "title": "Anoikis-Related Gene Signature for Prognostication of Pancreatic Adenocarcinoma: A Multi-Omics Exploration and Verification Study", "doi": "10.3390/cancers15123146", "year": 2023 }, { "pmid": "27130234", "title": "Selecting Tumor-Specific Molecular Targets in Pancreatic Adenocarcinoma: Paving the Way for Image-Guided Pancreatic Surgery", "doi": "10.1007/s11307-016-0959-4", "year": 2016 } ] } }, { "id": 51943, "drug": "resveratrol", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "activates", "mediator": "SIRT1", "mediator_type": "protein", "predicate_bc": "treats", "outcome": "diabetic nephropathy", "outcome_type": "disease", "outcome_domain": "type_2_diabetes", "score": 0.24849066497880004, "filtered_score": 0.3727359974682001, "filter_reason": "boosted_repurposing", "outreach_score": 0.3727359974682001, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 5, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37487007", "title": "Resveratrol inhibits ferroptosis and decelerates heart failure progression via Sirt1/p53 pathway activation", "doi": "10.1111/jcmm.17874", "year": 2023 }, { "pmid": "36926277", "title": "Resveratrol alleviates high glucose-induced oxidative stress and apoptosis in rat cardiac microvascular endothelial cell through AMPK/Sirt1 activation", "doi": "10.1016/j.bbrep.2023.101444", "year": 2023 }, { "pmid": "35791579", "title": "Resveratrol, novel application by preconditioning to attenuate myocardial ischemia/reperfusion injury in mice through regulate AMPK pathway and autophagy level", "doi": "10.1111/jcmm.17431", "year": 2022 } ], "bc": [ { "pmid": "30988688", "title": "Exercise training upregulates SIRT1 to attenuate inflammation and metabolic dysfunction in kidney and liver of diabetic db/db mice", "doi": "10.1186/s12986-019-0349-4", "year": 2019 } ] } }, { "id": 50967, "drug": "metformin", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "inhibits", "mediator": "mTOR", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "glioblastoma", "outcome_type": "disease", "outcome_domain": "glioblastoma", "score": 0.24849066497880004, "filtered_score": 0.3727359974682001, "filter_reason": "boosted_repurposing", "outreach_score": 0.3727359974682001, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 2, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "32248762", "title": "Metformin Improves Cardiac Metabolism and Function, and Prevents Left Ventricular Hypertrophy in Spontaneously Hypertensive Rats", "doi": "10.1161/jaha.119.015154", "year": 2020 }, { "pmid": "30922066", "title": "Metformin Enhances Autophagy and Provides Cardioprotection in δ-Sarcoglycan Deficiency-Induced Dilated Cardiomyopathy", "doi": "10.1161/circheartfailure.118.005418", "year": 2019 } ], "bc": [ { "pmid": "39622049", "title": "A Dual-Target and Dual-Mechanism Design Strategy by Combining Inhibition and Degradation Together", "doi": "10.1021/jacs.4c11930", "year": 2024 }, { "pmid": "33162811", "title": "Mitochondrial dysfunction contributes to Rapamycin-induced apoptosis of Human Glioblastoma Cells - A synergistic effect with Temozolomide", "doi": "10.7150/ijms.40159", "year": 2020 }, { "pmid": "30793789", "title": "The effect of the mTOR inhibitor rapamycin on glucoCEST signal in a preclinical model of glioblastoma", "doi": "10.1002/mrm.27683", "year": 2019 } ] } }, { "id": 40795, "drug": "resveratrol", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "activates", "mediator": "SIRT1", "mediator_type": "protein", "predicate_bc": "increases", "outcome": "proliferation", "outcome_type": "phenotype", "outcome_domain": "pancreatic_cancer", "score": 0.24849066497880004, "filtered_score": 0.3727359974682001, "filter_reason": "boosted_repurposing", "outreach_score": 0.3727359974682001, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "preclinical_only", "clinical_trial_nct_ids": [ "NCT00455416" ], "literature_status": "reproduces_known", "drug_canonical": "resveratrol", "mediator_canonical": "SIRT1", "outcome_canonical": null, "ab_count": 3, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "32808479", "title": "Resveratrol improves sperm DNA quality and reproductive capacity in type 1 diabetes", "doi": "10.1111/andr.12891", "year": 2020 }, { "pmid": "31486447", "title": "The effects of resveratrol on metabolic status in patients with type 2 diabetes mellitus and coronary heart disease", "doi": "10.1039/c9fo01075k", "year": 2019 }, { "pmid": "30621358", "title": "Protective Effect of Resveratrol against Ischemia-Reperfusion Injury via Enhanced High Energy Compounds and eNOS-SIRT1 Expression in Type 2 Diabetic Female Rat Heart", "doi": "10.3390/nu11010105", "year": 2019 } ], "bc": [ { "pmid": "34163012", "title": "SIRT1 coordinates with the CRL4B complex to regulate pancreatic cancer stem cells to promote tumorigenesis", "doi": "10.1038/s41418-021-00821-z", "year": 2021 }, { "pmid": "27494892", "title": "Sirtuin 1 stimulates the proliferation and the expression of glycolysis genes in pancreatic neoplastic lesions", "doi": "10.18632/oncotarget.11013", "year": 2016 } ] } }, { "id": 51558, "drug": "resveratrol", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "activates", "mediator": "SIRT1", "mediator_type": "protein", "predicate_bc": "increases", "outcome": "stemness marker expression", "outcome_type": "phenotype", "outcome_domain": "pancreatic_cancer", "score": 0.24849066497880004, "filtered_score": 0.3727359974682001, "filter_reason": "boosted_repurposing", "outreach_score": 0.3727359974682001, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 5, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37487007", "title": "Resveratrol inhibits ferroptosis and decelerates heart failure progression via Sirt1/p53 pathway activation", "doi": "10.1111/jcmm.17874", "year": 2023 }, { "pmid": "36926277", "title": "Resveratrol alleviates high glucose-induced oxidative stress and apoptosis in rat cardiac microvascular endothelial cell through AMPK/Sirt1 activation", "doi": "10.1016/j.bbrep.2023.101444", "year": 2023 }, { "pmid": "35791579", "title": "Resveratrol, novel application by preconditioning to attenuate myocardial ischemia/reperfusion injury in mice through regulate AMPK pathway and autophagy level", "doi": "10.1111/jcmm.17431", "year": 2022 } ], "bc": [ { "pmid": "34163012", "title": "SIRT1 coordinates with the CRL4B complex to regulate pancreatic cancer stem cells to promote tumorigenesis", "doi": "10.1038/s41418-021-00821-z", "year": 2021 } ] } }, { "id": 51751, "drug": "resveratrol", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "activates", "mediator": "SIRT1", "mediator_type": "protein", "predicate_bc": "decreases", "outcome": "TNF-alpha secretion", "outcome_type": "phenotype", "outcome_domain": "rheumatoid_arthritis", "score": 0.24849066497880004, "filtered_score": 0.3727359974682001, "filter_reason": "boosted_repurposing", "outreach_score": 0.3727359974682001, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 5, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37487007", "title": "Resveratrol inhibits ferroptosis and decelerates heart failure progression via Sirt1/p53 pathway activation", "doi": "10.1111/jcmm.17874", "year": 2023 }, { "pmid": "36926277", "title": "Resveratrol alleviates high glucose-induced oxidative stress and apoptosis in rat cardiac microvascular endothelial cell through AMPK/Sirt1 activation", "doi": "10.1016/j.bbrep.2023.101444", "year": 2023 }, { "pmid": "35791579", "title": "Resveratrol, novel application by preconditioning to attenuate myocardial ischemia/reperfusion injury in mice through regulate AMPK pathway and autophagy level", "doi": "10.1111/jcmm.17431", "year": 2022 } ], "bc": [ { "pmid": "29784872", "title": "SIRT1 inhibits rheumatoid arthritis fibroblast-like synoviocyte aggressiveness and inflammatory response via suppressing NF-κB pathway", "doi": "10.1042/bsr20180541", "year": 2018 } ] } }, { "id": 55087, "drug": "Dimethyl fumarate", "drug_type": "drug", "drug_domain": "multiple_sclerosis", "predicate_ab": "activates", "mediator": "Nrf2", "mediator_type": "protein", "predicate_bc": "increases", "outcome": "antioxidant status", "outcome_type": "phenotype", "outcome_domain": "heart_failure", "score": 0.36888794541139364, "filtered_score": 0.36888794541139364, "filter_reason": null, "outreach_score": 0.36888794541139364, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 19, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "38368281", "title": "Identification of key neuronal mechanisms triggered by dimethyl fumarate in SH-SY5Y human neuroblastoma cells through a metabolomic approach", "doi": "10.1007/s00204-024-03683-9", "year": 2024 }, { "pmid": "37751291", "title": "Dimethyl fumarate modulates the dystrophic disease program following short-term treatment", "doi": "10.1172/jci.insight.165974", "year": 2023 }, { "pmid": "36065971", "title": "Dimethyl fumarate attenuates pain behaviors in osteoarthritis rats via induction of Nrf2-mediated mitochondrial biogenesis", "doi": "10.1177/17448069221124920", "year": 2022 } ], "bc": [ { "pmid": "31155513", "title": "Enhanced Keap1-Nrf2 signaling protects the myocardium from isoproterenol-induced pathological remodeling in mice", "doi": "10.1016/j.redox.2019.101212", "year": 2019 } ] } }, { "id": 35462, "drug": "Dimethyl fumarate", "drug_type": "drug", "drug_domain": "multiple_sclerosis", "predicate_ab": "activates", "mediator": "Nrf2", "mediator_type": "protein", "predicate_bc": "decreases", "outcome": "efficacy of synthetic anti-rheumatic drugs", "outcome_type": "phenotype", "outcome_domain": "rheumatoid_arthritis", "score": 0.36888794541139364, "filtered_score": 0.36888794541139364, "filter_reason": null, "outreach_score": 0.36888794541139364, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "dimethyl fumarate", "mediator_canonical": "NRF2", "outcome_canonical": "efficacy of synthetic anti-rheumatic drugs", "ab_count": 19, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "38368281", "title": "Identification of key neuronal mechanisms triggered by dimethyl fumarate in SH-SY5Y human neuroblastoma cells through a metabolomic approach", "doi": "10.1007/s00204-024-03683-9", "year": 2024 }, { "pmid": "37751291", "title": "Dimethyl fumarate modulates the dystrophic disease program following short-term treatment", "doi": "10.1172/jci.insight.165974", "year": 2023 }, { "pmid": "36065971", "title": "Dimethyl fumarate attenuates pain behaviors in osteoarthritis rats via induction of Nrf2-mediated mitochondrial biogenesis", "doi": "10.1177/17448069221124920", "year": 2022 } ], "bc": [ { "pmid": "35964840", "title": "Pros and cons of NRF2 activation as adjunctive therapy in rheumatoid arthritis", "doi": "10.1016/j.freeradbiomed.2022.08.012", "year": 2022 } ] } }, { "id": 35656, "drug": "Dimethyl fumarate", "drug_type": "drug", "drug_domain": "multiple_sclerosis", "predicate_ab": "activates", "mediator": "Nrf2", "mediator_type": "protein", "predicate_bc": "prevents", "outcome": "type 1 diabetes", "outcome_type": "disease", "outcome_domain": "type_2_diabetes", "score": 0.36888794541139364, "filtered_score": 0.36888794541139364, "filter_reason": null, "outreach_score": 0.36888794541139364, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "active", "clinical_trial_nct_ids": [ "NCT07548996", "NCT07258394" ], "literature_status": "reproduces_known", "drug_canonical": "dimethyl fumarate", "mediator_canonical": "NRF2", "outcome_canonical": "type 1 diabetes", "ab_count": 19, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "38368281", "title": "Identification of key neuronal mechanisms triggered by dimethyl fumarate in SH-SY5Y human neuroblastoma cells through a metabolomic approach", "doi": "10.1007/s00204-024-03683-9", "year": 2024 }, { "pmid": "37751291", "title": "Dimethyl fumarate modulates the dystrophic disease program following short-term treatment", "doi": "10.1172/jci.insight.165974", "year": 2023 }, { "pmid": "36065971", "title": "Dimethyl fumarate attenuates pain behaviors in osteoarthritis rats via induction of Nrf2-mediated mitochondrial biogenesis", "doi": "10.1177/17448069221124920", "year": 2022 } ], "bc": [ { "pmid": "30625116", "title": "Nrf2 represses the onset of type 1 diabetes in non-obese diabetic mice", "doi": "10.1530/joe-18-0355", "year": 2019 } ] } }, { "id": 35463, "drug": "Dimethyl fumarate", "drug_type": "drug", "drug_domain": "multiple_sclerosis", "predicate_ab": "activates", "mediator": "Nrf2", "mediator_type": "protein", "predicate_bc": "increases", "outcome": "drug efflux", "outcome_type": "phenotype", "outcome_domain": "rheumatoid_arthritis", "score": 0.36888794541139364, "filtered_score": 0.36888794541139364, "filter_reason": null, "outreach_score": 0.36888794541139364, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "dimethyl fumarate", "mediator_canonical": "NRF2", "outcome_canonical": "drug efflux", "ab_count": 19, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "38368281", "title": "Identification of key neuronal mechanisms triggered by dimethyl fumarate in SH-SY5Y human neuroblastoma cells through a metabolomic approach", "doi": "10.1007/s00204-024-03683-9", "year": 2024 }, { "pmid": "37751291", "title": "Dimethyl fumarate modulates the dystrophic disease program following short-term treatment", "doi": "10.1172/jci.insight.165974", "year": 2023 }, { "pmid": "36065971", "title": "Dimethyl fumarate attenuates pain behaviors in osteoarthritis rats via induction of Nrf2-mediated mitochondrial biogenesis", "doi": "10.1177/17448069221124920", "year": 2022 } ], "bc": [ { "pmid": "35964840", "title": "Pros and cons of NRF2 activation as adjunctive therapy in rheumatoid arthritis", "doi": "10.1016/j.freeradbiomed.2022.08.012", "year": 2022 } ] } }, { "id": 35464, "drug": "Dimethyl fumarate", "drug_type": "drug", "drug_domain": "multiple_sclerosis", "predicate_ab": "activates", "mediator": "Nrf2", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "interstitial lung disease", "outcome_type": "disease", "outcome_domain": "rheumatoid_arthritis", "score": 0.36888794541139364, "filtered_score": 0.36888794541139364, "filter_reason": null, "outreach_score": 0.36888794541139364, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "dimethyl fumarate", "mediator_canonical": "NRF2", "outcome_canonical": "interstitial lung disease", "ab_count": 19, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "38368281", "title": "Identification of key neuronal mechanisms triggered by dimethyl fumarate in SH-SY5Y human neuroblastoma cells through a metabolomic approach", "doi": "10.1007/s00204-024-03683-9", "year": 2024 }, { "pmid": "37751291", "title": "Dimethyl fumarate modulates the dystrophic disease program following short-term treatment", "doi": "10.1172/jci.insight.165974", "year": 2023 }, { "pmid": "36065971", "title": "Dimethyl fumarate attenuates pain behaviors in osteoarthritis rats via induction of Nrf2-mediated mitochondrial biogenesis", "doi": "10.1177/17448069221124920", "year": 2022 } ], "bc": [ { "pmid": "36574898", "title": "Expression of Nrf2 protein in serum of patients with rheumatoid arthritis: A novel indicator for disease activity and disease prognosis", "doi": "10.1016/j.clinbiochem.2022.12.011", "year": 2022 } ] } }, { "id": 35465, "drug": "Dimethyl fumarate", "drug_type": "drug", "drug_domain": "multiple_sclerosis", "predicate_ab": "activates", "mediator": "Nrf2", "mediator_type": "protein", "predicate_bc": "decreases", "outcome": "toxicity of conventional anti-rheumatic therapies", "outcome_type": "phenotype", "outcome_domain": "rheumatoid_arthritis", "score": 0.36888794541139364, "filtered_score": 0.36888794541139364, "filter_reason": null, "outreach_score": 0.36888794541139364, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "dimethyl fumarate", "mediator_canonical": "NRF2", "outcome_canonical": "toxicity of conventional anti-rheumatic therapies", "ab_count": 19, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "38368281", "title": "Identification of key neuronal mechanisms triggered by dimethyl fumarate in SH-SY5Y human neuroblastoma cells through a metabolomic approach", "doi": "10.1007/s00204-024-03683-9", "year": 2024 }, { "pmid": "37751291", "title": "Dimethyl fumarate modulates the dystrophic disease program following short-term treatment", "doi": "10.1172/jci.insight.165974", "year": 2023 }, { "pmid": "36065971", "title": "Dimethyl fumarate attenuates pain behaviors in osteoarthritis rats via induction of Nrf2-mediated mitochondrial biogenesis", "doi": "10.1177/17448069221124920", "year": 2022 } ], "bc": [ { "pmid": "35964840", "title": "Pros and cons of NRF2 activation as adjunctive therapy in rheumatoid arthritis", "doi": "10.1016/j.freeradbiomed.2022.08.012", "year": 2022 } ] } }, { "id": 35267, "drug": "Dimethyl fumarate", "drug_type": "drug", "drug_domain": "multiple_sclerosis", "predicate_ab": "activates", "mediator": "Nrf2", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "poor prognosis", "outcome_type": "phenotype", "outcome_domain": "pancreatic_cancer", "score": 0.36888794541139364, "filtered_score": 0.36888794541139364, "filter_reason": null, "outreach_score": 0.36888794541139364, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "dimethyl fumarate", "mediator_canonical": "NRF2", "outcome_canonical": null, "ab_count": 19, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "38368281", "title": "Identification of key neuronal mechanisms triggered by dimethyl fumarate in SH-SY5Y human neuroblastoma cells through a metabolomic approach", "doi": "10.1007/s00204-024-03683-9", "year": 2024 }, { "pmid": "37751291", "title": "Dimethyl fumarate modulates the dystrophic disease program following short-term treatment", "doi": "10.1172/jci.insight.165974", "year": 2023 }, { "pmid": "36065971", "title": "Dimethyl fumarate attenuates pain behaviors in osteoarthritis rats via induction of Nrf2-mediated mitochondrial biogenesis", "doi": "10.1177/17448069221124920", "year": 2022 } ], "bc": [ { "pmid": "31911550", "title": "Undermining Glutaminolysis Bolsters Chemotherapy While NRF2 Promotes Chemoresistance in KRAS-Driven Pancreatic Cancers", "doi": "10.1158/0008-5472.can-19-1363", "year": 2020 } ] } }, { "id": 55089, "drug": "Dimethyl fumarate", "drug_type": "drug", "drug_domain": "multiple_sclerosis", "predicate_ab": "activates", "mediator": "Nrf2", "mediator_type": "protein", "predicate_bc": "prevents", "outcome": "myocardial necrosis", "outcome_type": "phenotype", "outcome_domain": "heart_failure", "score": 0.36888794541139364, "filtered_score": 0.36888794541139364, "filter_reason": null, "outreach_score": 0.36888794541139364, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 19, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "38368281", "title": "Identification of key neuronal mechanisms triggered by dimethyl fumarate in SH-SY5Y human neuroblastoma cells through a metabolomic approach", "doi": "10.1007/s00204-024-03683-9", "year": 2024 }, { "pmid": "37751291", "title": "Dimethyl fumarate modulates the dystrophic disease program following short-term treatment", "doi": "10.1172/jci.insight.165974", "year": 2023 }, { "pmid": "36065971", "title": "Dimethyl fumarate attenuates pain behaviors in osteoarthritis rats via induction of Nrf2-mediated mitochondrial biogenesis", "doi": "10.1177/17448069221124920", "year": 2022 } ], "bc": [ { "pmid": "26573705", "title": "Nrf2-Mediated Cardiac Maladaptive Remodeling and Dysfunction in a Setting of Autophagy Insufficiency", "doi": "10.1161/hypertensionaha.115.06062", "year": 2015 } ] } }, { "id": 55088, "drug": "Dimethyl fumarate", "drug_type": "drug", "drug_domain": "multiple_sclerosis", "predicate_ab": "activates", "mediator": "Nrf2", "mediator_type": "protein", "predicate_bc": "prevents", "outcome": "DNA damage", "outcome_type": "phenotype", "outcome_domain": "heart_failure", "score": 0.36888794541139364, "filtered_score": 0.36888794541139364, "filter_reason": null, "outreach_score": 0.36888794541139364, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 19, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "38368281", "title": "Identification of key neuronal mechanisms triggered by dimethyl fumarate in SH-SY5Y human neuroblastoma cells through a metabolomic approach", "doi": "10.1007/s00204-024-03683-9", "year": 2024 }, { "pmid": "37751291", "title": "Dimethyl fumarate modulates the dystrophic disease program following short-term treatment", "doi": "10.1172/jci.insight.165974", "year": 2023 }, { "pmid": "36065971", "title": "Dimethyl fumarate attenuates pain behaviors in osteoarthritis rats via induction of Nrf2-mediated mitochondrial biogenesis", "doi": "10.1177/17448069221124920", "year": 2022 } ], "bc": [ { "pmid": "39657243", "title": "NRF2 activation in the heart induces glucose metabolic reprogramming and reduces cardiac dysfunction via upregulation of the pentose phosphate pathway", "doi": "10.1093/cvr/cvae250", "year": 2024 } ] } }, { "id": 55086, "drug": "Dimethyl fumarate", "drug_type": "drug", "drug_domain": "multiple_sclerosis", "predicate_ab": "activates", "mediator": "Nrf2", "mediator_type": "protein", "predicate_bc": "increases", "outcome": "exercise capacity", "outcome_type": "phenotype", "outcome_domain": "heart_failure", "score": 0.36888794541139364, "filtered_score": 0.36888794541139364, "filter_reason": null, "outreach_score": 0.36888794541139364, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 19, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "38368281", "title": "Identification of key neuronal mechanisms triggered by dimethyl fumarate in SH-SY5Y human neuroblastoma cells through a metabolomic approach", "doi": "10.1007/s00204-024-03683-9", "year": 2024 }, { "pmid": "37751291", "title": "Dimethyl fumarate modulates the dystrophic disease program following short-term treatment", "doi": "10.1172/jci.insight.165974", "year": 2023 }, { "pmid": "36065971", "title": "Dimethyl fumarate attenuates pain behaviors in osteoarthritis rats via induction of Nrf2-mediated mitochondrial biogenesis", "doi": "10.1177/17448069221124920", "year": 2022 } ], "bc": [ { "pmid": "30589411", "title": "Myocardial NADPH oxidase-4 regulates the physiological response to acute exercise", "doi": "10.7554/elife.41044", "year": 2018 } ] } }, { "id": 55085, "drug": "Dimethyl fumarate", "drug_type": "drug", "drug_domain": "multiple_sclerosis", "predicate_ab": "activates", "mediator": "Nrf2", "mediator_type": "protein", "predicate_bc": "prevents", "outcome": "angiotensin II-induced cardiomyopathy", "outcome_type": "disease", "outcome_domain": "heart_failure", "score": 0.36888794541139364, "filtered_score": 0.36888794541139364, "filter_reason": null, "outreach_score": 0.36888794541139364, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 19, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "38368281", "title": "Identification of key neuronal mechanisms triggered by dimethyl fumarate in SH-SY5Y human neuroblastoma cells through a metabolomic approach", "doi": "10.1007/s00204-024-03683-9", "year": 2024 }, { "pmid": "37751291", "title": "Dimethyl fumarate modulates the dystrophic disease program following short-term treatment", "doi": "10.1172/jci.insight.165974", "year": 2023 }, { "pmid": "36065971", "title": "Dimethyl fumarate attenuates pain behaviors in osteoarthritis rats via induction of Nrf2-mediated mitochondrial biogenesis", "doi": "10.1177/17448069221124920", "year": 2022 } ], "bc": [ { "pmid": "29353218", "title": "Sulforaphane prevents angiotensin II-induced cardiomyopathy by activation of Nrf2 via stimulating the Akt/GSK-3ß/Fyn pathway", "doi": "10.1016/j.redox.2017.12.016", "year": 2018 } ] } }, { "id": 23806, "drug": "Dimethyl fumarate", "drug_type": "drug", "drug_domain": "multiple_sclerosis", "predicate_ab": "activates", "mediator": "NRF2", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "poor prognosis", "outcome_type": "phenotype", "outcome_domain": "pancreatic_cancer", "score": 0.36888794541139364, "filtered_score": 0.36888794541139364, "filter_reason": null, "outreach_score": 0.36888794541139364, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "dimethyl fumarate", "mediator_canonical": "NRF2", "outcome_canonical": null, "ab_count": 19, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "38368281", "title": "Identification of key neuronal mechanisms triggered by dimethyl fumarate in SH-SY5Y human neuroblastoma cells through a metabolomic approach", "doi": "10.1007/s00204-024-03683-9", "year": 2024 }, { "pmid": "37751291", "title": "Dimethyl fumarate modulates the dystrophic disease program following short-term treatment", "doi": "10.1172/jci.insight.165974", "year": 2023 }, { "pmid": "36065971", "title": "Dimethyl fumarate attenuates pain behaviors in osteoarthritis rats via induction of Nrf2-mediated mitochondrial biogenesis", "doi": "10.1177/17448069221124920", "year": 2022 } ], "bc": [ { "pmid": "31911550", "title": "Undermining Glutaminolysis Bolsters Chemotherapy While NRF2 Promotes Chemoresistance in KRAS-Driven Pancreatic Cancers", "doi": "10.1158/0008-5472.can-19-1363", "year": 2020 } ] } }, { "id": 23410, "drug": "Dimethyl fumarate", "drug_type": "drug", "drug_domain": "multiple_sclerosis", "predicate_ab": "activates", "mediator": "NRF2", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "antioxidant defense", "outcome_type": "phenotype", "outcome_domain": "als", "score": 0.36888794541139364, "filtered_score": 0.36888794541139364, "filter_reason": null, "outreach_score": 0.36888794541139364, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "dimethyl fumarate", "mediator_canonical": "NRF2", "outcome_canonical": "antioxidant defense", "ab_count": 19, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "38368281", "title": "Identification of key neuronal mechanisms triggered by dimethyl fumarate in SH-SY5Y human neuroblastoma cells through a metabolomic approach", "doi": "10.1007/s00204-024-03683-9", "year": 2024 }, { "pmid": "37751291", "title": "Dimethyl fumarate modulates the dystrophic disease program following short-term treatment", "doi": "10.1172/jci.insight.165974", "year": 2023 }, { "pmid": "36065971", "title": "Dimethyl fumarate attenuates pain behaviors in osteoarthritis rats via induction of Nrf2-mediated mitochondrial biogenesis", "doi": "10.1177/17448069221124920", "year": 2022 } ], "bc": [ { "pmid": "37862202", "title": "NRF2 signaling cascade in amyotrophic lateral sclerosis: bridging the gap between promise and reality", "doi": "10.4103/1673-5374.385283", "year": 2023 } ] } }, { "id": 40756, "drug": "dapagliflozin", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "inhibits", "mediator": "SGLT2", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "pancreatic adenocarcinoma", "outcome_type": "disease", "outcome_domain": "pancreatic_cancer", "score": 0.3637586159726386, "filtered_score": 0.3637586159726386, "filter_reason": null, "outreach_score": 0.3637586159726386, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "dapagliflozin", "mediator_canonical": "sglt2", "outcome_canonical": "pancreatic adenocarcinoma", "ab_count": 18, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37479045", "title": "RNA-Seq transcriptome analysis of renal tissue from spontaneously hypertensive rats revealed renal protective effects of dapagliflozin, an inhibitor of sodium-glucose cotransporter 2", "doi": "10.1016/j.ejps.2023.106531", "year": 2023 }, { "pmid": "36213291", "title": "An integrated RNA sequencing and network pharmacology approach reveals the molecular mechanism of dapagliflozin in the treatment of diabetic nephropathy", "doi": "10.3389/fendo.2022.967822", "year": 2022 }, { "pmid": "33660982", "title": "Fluorophore-Dapagliflozin Dyad for Detecting Diabetic Liver/Kidney Damages via Fluorescent Imaging and Treating Diabetes via Inhibiting SGLT2", "doi": "10.1021/acs.analchem.1c00223", "year": 2021 } ], "bc": [ { "pmid": "26170283", "title": "Functional expression of sodium-glucose transporters in cancer", "doi": "10.1073/pnas.1511698112", "year": 2015 } ] } }, { "id": 60966, "drug": "dapagliflozin", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "inhibits", "mediator": "SGLT2", "mediator_type": "protein", "predicate_bc": "causes", "outcome": "eNOS-NO/ROS imbalance", "outcome_type": "phenotype", "outcome_domain": "heart_failure", "score": 0.3637586159726386, "filtered_score": 0.3637586159726386, "filter_reason": null, "outreach_score": 0.3637586159726386, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 18, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37479045", "title": "RNA-Seq transcriptome analysis of renal tissue from spontaneously hypertensive rats revealed renal protective effects of dapagliflozin, an inhibitor of sodium-glucose cotransporter 2", "doi": "10.1016/j.ejps.2023.106531", "year": 2023 }, { "pmid": "36213291", "title": "An integrated RNA sequencing and network pharmacology approach reveals the molecular mechanism of dapagliflozin in the treatment of diabetic nephropathy", "doi": "10.3389/fendo.2022.967822", "year": 2022 }, { "pmid": "33660982", "title": "Fluorophore-Dapagliflozin Dyad for Detecting Diabetic Liver/Kidney Damages via Fluorescent Imaging and Treating Diabetes via Inhibiting SGLT2", "doi": "10.1021/acs.analchem.1c00223", "year": 2021 } ], "bc": [ { "pmid": "39739876", "title": "SGLT2 expression in human vasculature and heart correlates with low-grade inflammation and causes eNOS-NO/ROS imbalance", "doi": "10.1093/cvr/cvae257", "year": 2024 } ] } }, { "id": 40757, "drug": "dapagliflozin", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "inhibits", "mediator": "SGLT2", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "prostate adenocarcinoma", "outcome_type": "disease", "outcome_domain": "pancreatic_cancer", "score": 0.3637586159726386, "filtered_score": 0.3637586159726386, "filter_reason": null, "outreach_score": 0.3637586159726386, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "dapagliflozin", "mediator_canonical": "sglt2", "outcome_canonical": "prostate adenocarcinoma", "ab_count": 18, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37479045", "title": "RNA-Seq transcriptome analysis of renal tissue from spontaneously hypertensive rats revealed renal protective effects of dapagliflozin, an inhibitor of sodium-glucose cotransporter 2", "doi": "10.1016/j.ejps.2023.106531", "year": 2023 }, { "pmid": "36213291", "title": "An integrated RNA sequencing and network pharmacology approach reveals the molecular mechanism of dapagliflozin in the treatment of diabetic nephropathy", "doi": "10.3389/fendo.2022.967822", "year": 2022 }, { "pmid": "33660982", "title": "Fluorophore-Dapagliflozin Dyad for Detecting Diabetic Liver/Kidney Damages via Fluorescent Imaging and Treating Diabetes via Inhibiting SGLT2", "doi": "10.1021/acs.analchem.1c00223", "year": 2021 } ], "bc": [ { "pmid": "26170283", "title": "Functional expression of sodium-glucose transporters in cancer", "doi": "10.1073/pnas.1511698112", "year": 2015 } ] } }, { "id": 40363, "drug": "linagliptin", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "inhibits", "mediator": "DPP-4", "mediator_type": "protein", "predicate_bc": "predicts", "outcome": "disease activity", "outcome_type": "phenotype", "outcome_domain": "inflammatory_bowel_disease", "score": 0.358351893845611, "filtered_score": 0.358351893845611, "filter_reason": null, "outreach_score": 0.358351893845611, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "completed", "clinical_trial_nct_ids": [ "NCT03429543", "NCT04564872", "NCT02197078" ], "literature_status": "partial_evidence", "drug_canonical": "linagliptin", "mediator_canonical": "dpp-4", "outcome_canonical": "disease activity", "ab_count": 11, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "39724680", "title": "Dipeptidyl peptidase-4 inhibitor linagliptin reduces inflammatory response, ameliorates tissue edema formation, and improves survival in severe sepsis", "doi": "10.1016/j.biopha.2024.117778", "year": 2024 }, { "pmid": "30632692", "title": "Urinary Proteomics as a Tool to Identify Kidney Responders to Dipeptidyl Peptidase‐4 Inhibition: A Hypothesis‐Generating Analysis from the MARLINA‐T2D Trial", "doi": "10.1002/prca.201800144", "year": 2019 }, { "pmid": "30418475", "title": "Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk", "doi": "10.1001/jama.2018.18269", "year": 2018 } ], "bc": [ { "pmid": "31912883", "title": "Serum Dipeptidyl Peptidase 4: A Predictor of Disease Activity and Prognosis in Inflammatory Bowel Disease", "doi": "10.1093/ibd/izz319", "year": 2020 } ] } }, { "id": 38993, "drug": "baricitinib", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "inhibits", "mediator": "JAK2", "mediator_type": "protein", "predicate_bc": "predicts", "outcome": "poor prognosis", "outcome_type": "phenotype", "outcome_domain": "pancreatic_cancer", "score": 0.35263605246161617, "filtered_score": 0.35263605246161617, "filter_reason": null, "outreach_score": 0.35263605246161617, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "baricitinib", "mediator_canonical": "jak2", "outcome_canonical": null, "ab_count": 16, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "36793118", "title": "A multi-center, open-label, randomized study to explore efficacy and safety of baricitinib in active primary Sjogren’s syndrome patients", "doi": "10.1186/s13063-023-07087-5", "year": 2023 }, { "pmid": "37752637", "title": "A Novel LC-MS/MS Method for Therapeutic Drug Monitoring of Baricitinib in Plasma of Pediatric Patients", "doi": "10.1097/ftd.0000000000001128", "year": 2023 }, { "pmid": "37249471", "title": "A case in which baricitinib was effective for both rheumatoid arthritis and essential thrombocythemia", "doi": "10.1093/mrcr/rxad012", "year": 2023 } ], "bc": [ { "pmid": "33029256", "title": "High JAK2 Protein Expression Predicts a Poor Prognosis in Patients with Resectable Pancreatic Ductal Adenocarcinoma", "doi": "10.1155/2020/7656031", "year": 2020 } ] } }, { "id": 59086, "drug": "Auranofin", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "activates", "mediator": "Nrf2", "mediator_type": "protein", "predicate_bc": "prevents", "outcome": "DNA damage", "outcome_type": "phenotype", "outcome_domain": "heart_failure", "score": 0.23025850929940456, "filtered_score": 0.34538776394910686, "filter_reason": "boosted_repurposing", "outreach_score": 0.34538776394910686, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 4, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37760943", "title": "Auranofin Modulates Thioredoxin Reductase/Nrf2 Signaling in Peripheral Immune Cells and the CNS in a Mouse Model of Relapsing–Remitting EAE", "doi": "10.3390/biomedicines11092502", "year": 2023 }, { "pmid": "35738800", "title": "Targeting of Nrf2 improves antitumoral responses by human NK cells, TIL and CAR T cells during oxidative stress", "doi": "10.1136/jitc-2021-004458", "year": 2022 }, { "pmid": "34788728", "title": "Comprehensive chemical proteomics analyses reveal that the new TRi-1 and TRi-2 compounds are more specific thioredoxin reductase 1 inhibitors than auranofin", "doi": "10.1016/j.redox.2021.102184", "year": 2021 } ], "bc": [ { "pmid": "39657243", "title": "NRF2 activation in the heart induces glucose metabolic reprogramming and reduces cardiac dysfunction via upregulation of the pentose phosphate pathway", "doi": "10.1093/cvr/cvae250", "year": 2024 } ] } }, { "id": 37662, "drug": "Auranofin", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "activates", "mediator": "Nrf2", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "antioxidant defense", "outcome_type": "phenotype", "outcome_domain": "als", "score": 0.23025850929940456, "filtered_score": 0.34538776394910686, "filter_reason": "boosted_repurposing", "outreach_score": 0.34538776394910686, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "auranofin", "mediator_canonical": "NRF2", "outcome_canonical": "antioxidant defense", "ab_count": 4, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37760943", "title": "Auranofin Modulates Thioredoxin Reductase/Nrf2 Signaling in Peripheral Immune Cells and the CNS in a Mouse Model of Relapsing–Remitting EAE", "doi": "10.3390/biomedicines11092502", "year": 2023 }, { "pmid": "35738800", "title": "Targeting of Nrf2 improves antitumoral responses by human NK cells, TIL and CAR T cells during oxidative stress", "doi": "10.1136/jitc-2021-004458", "year": 2022 }, { "pmid": "34788728", "title": "Comprehensive chemical proteomics analyses reveal that the new TRi-1 and TRi-2 compounds are more specific thioredoxin reductase 1 inhibitors than auranofin", "doi": "10.1016/j.redox.2021.102184", "year": 2021 } ], "bc": [ { "pmid": "37862202", "title": "NRF2 signaling cascade in amyotrophic lateral sclerosis: bridging the gap between promise and reality", "doi": "10.4103/1673-5374.385283", "year": 2023 } ] } }, { "id": 37870, "drug": "Auranofin", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "activates", "mediator": "Nrf2", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "Alzheimer's disease", "outcome_type": "disease", "outcome_domain": "alzheimer", "score": 0.23025850929940456, "filtered_score": 0.34538776394910686, "filter_reason": "boosted_repurposing", "outreach_score": 0.34538776394910686, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "auranofin", "mediator_canonical": "NRF2", "outcome_canonical": "Alzheimer disease", "ab_count": 4, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37760943", "title": "Auranofin Modulates Thioredoxin Reductase/Nrf2 Signaling in Peripheral Immune Cells and the CNS in a Mouse Model of Relapsing–Remitting EAE", "doi": "10.3390/biomedicines11092502", "year": 2023 }, { "pmid": "35738800", "title": "Targeting of Nrf2 improves antitumoral responses by human NK cells, TIL and CAR T cells during oxidative stress", "doi": "10.1136/jitc-2021-004458", "year": 2022 }, { "pmid": "34788728", "title": "Comprehensive chemical proteomics analyses reveal that the new TRi-1 and TRi-2 compounds are more specific thioredoxin reductase 1 inhibitors than auranofin", "doi": "10.1016/j.redox.2021.102184", "year": 2021 } ], "bc": [ { "pmid": "40867848", "title": "Exploring the Impact of Bioactive Compounds Found in Extra Virgin Olive Oil on NRF2 Modulation in Alzheimer’s Disease", "doi": "10.3390/antiox14080952", "year": 2025 } ] } }, { "id": 39231, "drug": "Auranofin", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "activates", "mediator": "Nrf2", "mediator_type": "protein", "predicate_bc": "prevents", "outcome": "type 1 diabetes", "outcome_type": "disease", "outcome_domain": "type_2_diabetes", "score": 0.23025850929940456, "filtered_score": 0.34538776394910686, "filter_reason": "boosted_repurposing", "outreach_score": 0.34538776394910686, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "auranofin", "mediator_canonical": "NRF2", "outcome_canonical": "type 1 diabetes", "ab_count": 4, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37760943", "title": "Auranofin Modulates Thioredoxin Reductase/Nrf2 Signaling in Peripheral Immune Cells and the CNS in a Mouse Model of Relapsing–Remitting EAE", "doi": "10.3390/biomedicines11092502", "year": 2023 }, { "pmid": "35738800", "title": "Targeting of Nrf2 improves antitumoral responses by human NK cells, TIL and CAR T cells during oxidative stress", "doi": "10.1136/jitc-2021-004458", "year": 2022 }, { "pmid": "34788728", "title": "Comprehensive chemical proteomics analyses reveal that the new TRi-1 and TRi-2 compounds are more specific thioredoxin reductase 1 inhibitors than auranofin", "doi": "10.1016/j.redox.2021.102184", "year": 2021 } ], "bc": [ { "pmid": "30625116", "title": "Nrf2 represses the onset of type 1 diabetes in non-obese diabetic mice", "doi": "10.1530/joe-18-0355", "year": 2019 } ] } }, { "id": 59090, "drug": "Auranofin", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "activates", "mediator": "Nrf2", "mediator_type": "protein", "predicate_bc": "prevents", "outcome": "angiotensin II-induced cardiomyopathy", "outcome_type": "disease", "outcome_domain": "heart_failure", "score": 0.23025850929940456, "filtered_score": 0.34538776394910686, "filter_reason": "boosted_repurposing", "outreach_score": 0.34538776394910686, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 4, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37760943", "title": "Auranofin Modulates Thioredoxin Reductase/Nrf2 Signaling in Peripheral Immune Cells and the CNS in a Mouse Model of Relapsing–Remitting EAE", "doi": "10.3390/biomedicines11092502", "year": 2023 }, { "pmid": "35738800", "title": "Targeting of Nrf2 improves antitumoral responses by human NK cells, TIL and CAR T cells during oxidative stress", "doi": "10.1136/jitc-2021-004458", "year": 2022 }, { "pmid": "34788728", "title": "Comprehensive chemical proteomics analyses reveal that the new TRi-1 and TRi-2 compounds are more specific thioredoxin reductase 1 inhibitors than auranofin", "doi": "10.1016/j.redox.2021.102184", "year": 2021 } ], "bc": [ { "pmid": "29353218", "title": "Sulforaphane prevents angiotensin II-induced cardiomyopathy by activation of Nrf2 via stimulating the Akt/GSK-3ß/Fyn pathway", "doi": "10.1016/j.redox.2017.12.016", "year": 2018 } ] } }, { "id": 59091, "drug": "Auranofin", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "activates", "mediator": "Nrf2", "mediator_type": "protein", "predicate_bc": "increases", "outcome": "exercise capacity", "outcome_type": "phenotype", "outcome_domain": "heart_failure", "score": 0.23025850929940456, "filtered_score": 0.34538776394910686, "filter_reason": "boosted_repurposing", "outreach_score": 0.34538776394910686, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 4, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37760943", "title": "Auranofin Modulates Thioredoxin Reductase/Nrf2 Signaling in Peripheral Immune Cells and the CNS in a Mouse Model of Relapsing–Remitting EAE", "doi": "10.3390/biomedicines11092502", "year": 2023 }, { "pmid": "35738800", "title": "Targeting of Nrf2 improves antitumoral responses by human NK cells, TIL and CAR T cells during oxidative stress", "doi": "10.1136/jitc-2021-004458", "year": 2022 }, { "pmid": "34788728", "title": "Comprehensive chemical proteomics analyses reveal that the new TRi-1 and TRi-2 compounds are more specific thioredoxin reductase 1 inhibitors than auranofin", "doi": "10.1016/j.redox.2021.102184", "year": 2021 } ], "bc": [ { "pmid": "30589411", "title": "Myocardial NADPH oxidase-4 regulates the physiological response to acute exercise", "doi": "10.7554/elife.41044", "year": 2018 } ] } }, { "id": 59084, "drug": "Auranofin", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "activates", "mediator": "Nrf2", "mediator_type": "protein", "predicate_bc": "prevents", "outcome": "myocardial necrosis", "outcome_type": "phenotype", "outcome_domain": "heart_failure", "score": 0.23025850929940456, "filtered_score": 0.34538776394910686, "filter_reason": "boosted_repurposing", "outreach_score": 0.34538776394910686, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 4, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37760943", "title": "Auranofin Modulates Thioredoxin Reductase/Nrf2 Signaling in Peripheral Immune Cells and the CNS in a Mouse Model of Relapsing–Remitting EAE", "doi": "10.3390/biomedicines11092502", "year": 2023 }, { "pmid": "35738800", "title": "Targeting of Nrf2 improves antitumoral responses by human NK cells, TIL and CAR T cells during oxidative stress", "doi": "10.1136/jitc-2021-004458", "year": 2022 }, { "pmid": "34788728", "title": "Comprehensive chemical proteomics analyses reveal that the new TRi-1 and TRi-2 compounds are more specific thioredoxin reductase 1 inhibitors than auranofin", "doi": "10.1016/j.redox.2021.102184", "year": 2021 } ], "bc": [ { "pmid": "26573705", "title": "Nrf2-Mediated Cardiac Maladaptive Remodeling and Dysfunction in a Setting of Autophagy Insufficiency", "doi": "10.1161/hypertensionaha.115.06062", "year": 2015 } ] } }, { "id": 6681, "drug": "valproic acid", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "inhibits", "mediator": "histone deacetylase", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "amyotrophic lateral sclerosis", "outcome_type": "disease", "outcome_domain": "als", "score": 0.23025850929940456, "filtered_score": 0.34538776394910686, "filter_reason": "boosted_repurposing", "outreach_score": 0.34538776394910686, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "completed", "clinical_trial_nct_ids": [ "NCT03204500", "NCT00136110" ], "literature_status": "reproduces_known", "drug_canonical": "valproic acid", "mediator_canonical": "histone deacetylase", "outcome_canonical": "amyotrophic lateral sclerosis", "ab_count": 4, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "34621499", "title": "https://researchopenworld.com/the-addition-of-valproic-acid-to-concurrent-radiation-therapy-and-temozolomide-improves-patient-outcome-a-correlative-analysis-of-rtog-0525-seer-and-a-phase-ii-nci-trial/#", "doi": "10.31038/cst.2020511", "year": 2020 }, { "pmid": "31092106", "title": "Metabolomics reveals the effect of valproic acid on MCF-7 and MDA-MB-231 cells", "doi": "10.1080/00498254.2019.1618510", "year": 2019 }, { "pmid": "32642660", "title": "Effects of valproic acid on histone deacetylase inhibition in vitro and in glioblastoma patient samples", "doi": "10.1093/noajnl/vdz025", "year": 2019 } ], "bc": [ { "pmid": "31241177", "title": "Class I and II histone deacetylase expression is not altered in human amyotrophic lateral sclerosis: Neuropathological and positron emission tomography molecular neuroimaging evidence", "doi": "10.1002/mus.26620", "year": 2019 } ] } }, { "id": 59085, "drug": "Auranofin", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "activates", "mediator": "Nrf2", "mediator_type": "protein", "predicate_bc": "increases", "outcome": "antioxidant status", "outcome_type": "phenotype", "outcome_domain": "heart_failure", "score": 0.23025850929940456, "filtered_score": 0.34538776394910686, "filter_reason": "boosted_repurposing", "outreach_score": 0.34538776394910686, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 4, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37760943", "title": "Auranofin Modulates Thioredoxin Reductase/Nrf2 Signaling in Peripheral Immune Cells and the CNS in a Mouse Model of Relapsing–Remitting EAE", "doi": "10.3390/biomedicines11092502", "year": 2023 }, { "pmid": "35738800", "title": "Targeting of Nrf2 improves antitumoral responses by human NK cells, TIL and CAR T cells during oxidative stress", "doi": "10.1136/jitc-2021-004458", "year": 2022 }, { "pmid": "34788728", "title": "Comprehensive chemical proteomics analyses reveal that the new TRi-1 and TRi-2 compounds are more specific thioredoxin reductase 1 inhibitors than auranofin", "doi": "10.1016/j.redox.2021.102184", "year": 2021 } ], "bc": [ { "pmid": "31155513", "title": "Enhanced Keap1-Nrf2 signaling protects the myocardium from isoproterenol-induced pathological remodeling in mice", "doi": "10.1016/j.redox.2019.101212", "year": 2019 } ] } }, { "id": 39032, "drug": "Auranofin", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "activates", "mediator": "Nrf2", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "poor prognosis", "outcome_type": "phenotype", "outcome_domain": "pancreatic_cancer", "score": 0.23025850929940456, "filtered_score": 0.34538776394910686, "filter_reason": "boosted_repurposing", "outreach_score": 0.34538776394910686, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "auranofin", "mediator_canonical": "NRF2", "outcome_canonical": null, "ab_count": 4, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37760943", "title": "Auranofin Modulates Thioredoxin Reductase/Nrf2 Signaling in Peripheral Immune Cells and the CNS in a Mouse Model of Relapsing–Remitting EAE", "doi": "10.3390/biomedicines11092502", "year": 2023 }, { "pmid": "35738800", "title": "Targeting of Nrf2 improves antitumoral responses by human NK cells, TIL and CAR T cells during oxidative stress", "doi": "10.1136/jitc-2021-004458", "year": 2022 }, { "pmid": "34788728", "title": "Comprehensive chemical proteomics analyses reveal that the new TRi-1 and TRi-2 compounds are more specific thioredoxin reductase 1 inhibitors than auranofin", "doi": "10.1016/j.redox.2021.102184", "year": 2021 } ], "bc": [ { "pmid": "31911550", "title": "Undermining Glutaminolysis Bolsters Chemotherapy While NRF2 Promotes Chemoresistance in KRAS-Driven Pancreatic Cancers", "doi": "10.1158/0008-5472.can-19-1363", "year": 2020 } ] } }, { "id": 37665, "drug": "Auranofin", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "activates", "mediator": "Nrf2", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "ALS", "outcome_type": "disease", "outcome_domain": "als", "score": 0.23025850929940456, "filtered_score": 0.34538776394910686, "filter_reason": "boosted_repurposing", "outreach_score": 0.34538776394910686, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "auranofin", "mediator_canonical": "NRF2", "outcome_canonical": "amyotrophic lateral sclerosis", "ab_count": 4, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37760943", "title": "Auranofin Modulates Thioredoxin Reductase/Nrf2 Signaling in Peripheral Immune Cells and the CNS in a Mouse Model of Relapsing–Remitting EAE", "doi": "10.3390/biomedicines11092502", "year": 2023 }, { "pmid": "35738800", "title": "Targeting of Nrf2 improves antitumoral responses by human NK cells, TIL and CAR T cells during oxidative stress", "doi": "10.1136/jitc-2021-004458", "year": 2022 }, { "pmid": "34788728", "title": "Comprehensive chemical proteomics analyses reveal that the new TRi-1 and TRi-2 compounds are more specific thioredoxin reductase 1 inhibitors than auranofin", "doi": "10.1016/j.redox.2021.102184", "year": 2021 } ], "bc": [ { "pmid": "40581791", "title": "Identification of disease-associated molecular signatures in the Prp-TDP-43A315T mouse model of ALS: Toward preclinical biomarker development", "doi": "10.1093/jnen/nlaf071", "year": 2025 } ] } }, { "id": 38829, "drug": "Auranofin", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "activates", "mediator": "Nrf2", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "disease progression", "outcome_type": "phenotype", "outcome_domain": "multiple_sclerosis", "score": 0.23025850929940456, "filtered_score": 0.34538776394910686, "filter_reason": "boosted_repurposing", "outreach_score": 0.34538776394910686, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "auranofin", "mediator_canonical": "NRF2", "outcome_canonical": "disease progression", "ab_count": 4, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37760943", "title": "Auranofin Modulates Thioredoxin Reductase/Nrf2 Signaling in Peripheral Immune Cells and the CNS in a Mouse Model of Relapsing–Remitting EAE", "doi": "10.3390/biomedicines11092502", "year": 2023 }, { "pmid": "35738800", "title": "Targeting of Nrf2 improves antitumoral responses by human NK cells, TIL and CAR T cells during oxidative stress", "doi": "10.1136/jitc-2021-004458", "year": 2022 }, { "pmid": "34788728", "title": "Comprehensive chemical proteomics analyses reveal that the new TRi-1 and TRi-2 compounds are more specific thioredoxin reductase 1 inhibitors than auranofin", "doi": "10.1016/j.redox.2021.102184", "year": 2021 } ], "bc": [ { "pmid": "33396641", "title": "Peripheral Blood NRF2 Expression as a Biomarker in Human Health and Disease", "doi": "10.3390/antiox10010028", "year": 2020 } ] } }, { "id": 60967, "drug": "Canagliflozin", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "activates", "mediator": "AMPK", "mediator_type": "protein", "predicate_bc": "prevents", "outcome": "metabolic dysfunction", "outcome_type": "disease", "outcome_domain": "heart_failure", "score": 0.3401197381662156, "filtered_score": 0.3401197381662156, "filter_reason": null, "outreach_score": 0.3401197381662156, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 9, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37584455", "title": "Canagliflozin mediates tumor suppression alone and in combination with radiotherapy in non‐small cell lung cancer (NSCLC) through inhibition of HIF‐1α", "doi": "10.1002/1878-0261.13508", "year": 2023 }, { "pmid": "37247463", "title": "Canagliflozin mitigates carfilzomib-induced endothelial apoptosis via an AMPK-dependent pathway", "doi": "10.1016/j.biopha.2023.114907", "year": 2023 }, { "pmid": "36583437", "title": "Canagliflozin Improves Myocardial Perfusion, Fibrosis, and Function in a Swine Model of Chronic Myocardial Ischemia", "doi": "10.1161/jaha.122.028623", "year": 2022 } ], "bc": [ { "pmid": "37194385", "title": "Adenosine monophosphate‐activated protein kinase is elevated in human cachectic muscle and prevents cancer‐induced metabolic dysfunction in mice", "doi": "10.1002/jcsm.13238", "year": 2023 } ] } }, { "id": 37832, "drug": "tofacitinib", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "inhibits", "mediator": "JAK-STAT pathway", "mediator_type": "pathway", "predicate_bc": "correlates_with", "outcome": "Alzheimer's disease", "outcome_type": "disease", "outcome_domain": "alzheimer", "score": 0.3332204510175204, "filtered_score": 0.3332204510175204, "filter_reason": null, "outreach_score": 0.3332204510175204, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "completed", "clinical_trial_nct_ids": [ "NCT04529876" ], "literature_status": "reproduces_known", "drug_canonical": "tofacitinib", "mediator_canonical": "jak-stat pathway", "outcome_canonical": "Alzheimer disease", "ab_count": 13, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40162359", "title": "Successful Use of Tofacitinib in Paediatric Prurigo Nodularis: A Report of Four Cases", "doi": "10.4103/ijd.ijd_842_24", "year": 2025 }, { "pmid": "39210332", "title": "Tofacitinib for the treatment of immune-related adverse events in cancer immunotherapy: a multi-center observational study", "doi": "10.1186/s12967-024-05617-6", "year": 2024 }, { "pmid": "39439798", "title": "Tofacitinib for child-onset systemic lupus erythematosus", "doi": "10.3389/fimmu.2024.1457821", "year": 2024 } ], "bc": [ { "pmid": "31072055", "title": "Genetic and Real-World Clinical Data, Combined with Empirical Validation, Nominate Jak-Stat Signaling as a Target for Alzheimer’s Disease Therapeutic Development", "doi": "10.3390/cells8050425", "year": 2019 } ] } }, { "id": 35466, "drug": "ocrelizumab", "drug_type": "drug", "drug_domain": "multiple_sclerosis", "predicate_ab": "binds_to", "mediator": "CD20", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "CDAI", "outcome_type": "phenotype", "outcome_domain": "rheumatoid_arthritis", "score": 0.3332204510175204, "filtered_score": 0.3332204510175204, "filter_reason": null, "outreach_score": 0.3332204510175204, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "ocrelizumab", "mediator_canonical": "cd20", "outcome_canonical": "cdai", "ab_count": 13, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41357832", "title": "Late-onset severe neutropenia in patients with relapsing remitting multiple sclerosis treated with ocrelizumab: case report and literature review", "doi": "10.3389/fnins.2025.1685209", "year": 2025 }, { "pmid": "38604001", "title": "Efficacy and safety of ocrelizumab in patients with relapsing multiple sclerosis: Real-world experience of two Swiss multiple sclerosis centers", "doi": "10.1016/j.msard.2024.105570", "year": 2024 }, { "pmid": "38912173", "title": "Planned dose reduction of ocrelizumab in relapsing-remitting multiple sclerosis: a single-centre observational study", "doi": "10.1136/bmjno-2024-000672", "year": 2024 } ], "bc": [ { "pmid": "31186464", "title": "General synovitis score and immunologic synovitis score reflect clinical disease activity in patients with advanced stage rheumatoid arthritis", "doi": "10.1038/s41598-019-44895-9", "year": 2019 } ] } }, { "id": 37873, "drug": "Auranofin", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "inhibits", "mediator": "GSK-3β", "mediator_type": "protein", "predicate_bc": "increases", "outcome": "tau hyperphosphorylation", "outcome_type": "phenotype", "outcome_domain": "alzheimer", "score": 0.21972245773362195, "filtered_score": 0.3295836866004329, "filter_reason": "boosted_repurposing", "outreach_score": 0.3295836866004329, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "auranofin", "mediator_canonical": "GSK3B", "outcome_canonical": "tau hyperphosphorylation", "ab_count": 2, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40842183", "title": "Gold‐Containing Compound Auranofin Ameliorates 6‐OHDA Induced Neurotoxicity in Rats: Via Targeting PI3K/Akt/GSK‐3β Signalling", "doi": "10.1111/1440-1681.70070", "year": 2025 } ], "bc": [ { "pmid": "41459736", "title": "Type 3 Diabetes: A Molecular Link Between Cerebral Insulin Resistance and Neurodegeneration via AGE–RAGE Signaling", "doi": "10.1111/ejn.70364", "year": 2025 }, { "pmid": "33554064", "title": "Isoform-selective decrease of glycogen synthase kinase-3-beta (GSK-3β) reduces synaptic tau phosphorylation, transcellular spreading, and aggregation", "doi": "10.1016/j.isci.2021.102058", "year": 2021 } ] } }, { "id": 51566, "drug": "Curcumin", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "activates", "mediator": "Nrf2", "mediator_type": "protein", "predicate_bc": "causes", "outcome": "chemoresistance", "outcome_type": "phenotype", "outcome_domain": "pancreatic_cancer", "score": 0.21972245773362195, "filtered_score": 0.3295836866004329, "filter_reason": "boosted_repurposing", "outreach_score": 0.3295836866004329, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 2, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37101595", "title": "Curcumin Improves Diabetic Cardiomyopathy by Inhibiting Pyroptosis through AKT/Nrf2/ARE Pathway", "doi": "10.1155/2023/3906043", "year": 2023 }, { "pmid": "35909950", "title": "Curcumin Attenuates Ferroptosis-Induced Myocardial Injury in Diabetic Cardiomyopathy through the Nrf2 Pathway", "doi": "10.1155/2022/3159717", "year": 2022 } ], "bc": [ { "pmid": "31911550", "title": "Undermining Glutaminolysis Bolsters Chemotherapy While NRF2 Promotes Chemoresistance in KRAS-Driven Pancreatic Cancers", "doi": "10.1158/0008-5472.can-19-1363", "year": 2020 }, { "pmid": "30735911", "title": "Digoxin sensitizes gemcitabine-resistant pancreatic cancer cells to gemcitabine via inhibiting Nrf2 signaling pathway", "doi": "10.1016/j.redox.2019.101131", "year": 2019 } ] } }, { "id": 51568, "drug": "resveratrol", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "upregulates", "mediator": "SIRT1", "mediator_type": "gene", "predicate_bc": "increases", "outcome": "cell migration", "outcome_type": "phenotype", "outcome_domain": "pancreatic_cancer", "score": 0.21972245773362195, "filtered_score": 0.3295836866004329, "filter_reason": "boosted_repurposing", "outreach_score": 0.3295836866004329, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 2, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "35081907", "title": "Resveratrol ameliorates myocardial fibrosis by regulating Sirt1/Smad3 deacetylation pathway in rat model with dilated cardiomyopathy", "doi": "10.1186/s12872-021-02401-y", "year": 2022 }, { "pmid": "26638758", "title": "Iron-overload injury and cardiomyopathy in acquired and genetic models is attenuated by resveratrol therapy", "doi": "10.1038/srep18132", "year": 2015 } ], "bc": [ { "pmid": "27170223", "title": "SIRT 1 Overexpression is Associated with Metastasis of Pancreatic Ductal Adenocarcinoma (PDAC) and Promotes Migration and Growth of PDAC Cells", "doi": "10.12659/msm.896697", "year": 2016 } ] } }, { "id": 47022, "drug": "valproic acid", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "downregulates", "mediator": "Nrf2", "mediator_type": "gene", "predicate_bc": "increases", "outcome": "diabetic cardiomyopathy", "outcome_type": "disease", "outcome_domain": "heart_failure", "score": 0.21972245773362195, "filtered_score": 0.3295836866004329, "filter_reason": "boosted_repurposing", "outreach_score": 0.3295836866004329, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 2, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "34050116", "title": "Chronic valproic acid administration enhances oxidative stress, upregulates IL6 and downregulates Nrf2, Glut1 and Glut4 in rat’s liver and brain", "doi": "10.1097/wnr.0000000000001663", "year": 2021 }, { "pmid": "34686779", "title": "Valproic acid disables the Nrf2 anti-oxidant response in acute myeloid leukaemia cells enhancing reactive oxygen species-mediated killing", "doi": "10.1038/s41416-021-01570-z", "year": 2021 } ], "bc": [ { "pmid": "38308838", "title": "Nrf2 prevents diabetic cardiomyopathy via antioxidant effect and normalization of glucose and lipid metabolism in the heart", "doi": "10.1002/jcp.31149", "year": 2024 }, { "pmid": "32948607", "title": "Autophagy Inhibition Enables Nrf2 to Exaggerate the Progression of Diabetic Cardiomyopathy in Mice", "doi": "10.2337/db19-1176", "year": 2020 } ] } }, { "id": 53139, "drug": "metformin", "drug_type": "drug", "drug_domain": "inflammatory_bowel_disease", "predicate_ab": "activates", "mediator": "AMPK", "mediator_type": "protein", "predicate_bc": "prevents", "outcome": "metabolic dysfunction", "outcome_type": "disease", "outcome_domain": "heart_failure", "score": 0.21972245773362195, "filtered_score": 0.3295836866004329, "filter_reason": "boosted_repurposing", "outreach_score": 0.3295836866004329, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 2, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "35064693", "title": "Metformin ameliorates chronic colitis in a mouse model by regulating interferon‐γ‐producing lamina propria CD4 + T cells through AMPK activation", "doi": "10.1096/fj.202100831rr", "year": 2022 }, { "pmid": "30061832", "title": "Activating AMPK to Restore Tight Junction Assembly in Intestinal Epithelium and to Attenuate Experimental Colitis by Metformin", "doi": "10.3389/fphar.2018.00761", "year": 2018 } ], "bc": [ { "pmid": "37194385", "title": "Adenosine monophosphate‐activated protein kinase is elevated in human cachectic muscle and prevents cancer‐induced metabolic dysfunction in mice", "doi": "10.1002/jcsm.13238", "year": 2023 } ] } }, { "id": 53141, "drug": "Apigenin", "drug_type": "drug", "drug_domain": "inflammatory_bowel_disease", "predicate_ab": "activates", "mediator": "AMPK", "mediator_type": "protein", "predicate_bc": "prevents", "outcome": "metabolic dysfunction", "outcome_type": "disease", "outcome_domain": "heart_failure", "score": 0.21972245773362195, "filtered_score": 0.3295836866004329, "filter_reason": "boosted_repurposing", "outreach_score": 0.3295836866004329, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 2, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41428381", "title": "Natural Dietary Flavonoid Apigenin Mitigates Ulcerative Colitis via Modulating the AMPK/NF-κB/NLRP3 Signaling Axis", "doi": "10.1021/acs.jafc.5c15405", "year": 2025 } ], "bc": [ { "pmid": "37194385", "title": "Adenosine monophosphate‐activated protein kinase is elevated in human cachectic muscle and prevents cancer‐induced metabolic dysfunction in mice", "doi": "10.1002/jcsm.13238", "year": 2023 } ] } }, { "id": 58279, "drug": "Auranofin", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "inhibits", "mediator": "GSK-3β", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "Alzheimer's disease", "outcome_type": "disease", "outcome_domain": "alzheimer", "score": 0.21972245773362195, "filtered_score": 0.3295836866004329, "filter_reason": "boosted_repurposing", "outreach_score": 0.3295836866004329, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 2, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40842183", "title": "Gold‐Containing Compound Auranofin Ameliorates 6‐OHDA Induced Neurotoxicity in Rats: Via Targeting PI3K/Akt/GSK‐3β Signalling", "doi": "10.1111/1440-1681.70070", "year": 2025 } ], "bc": [ { "pmid": "40414897", "title": "Mapping the hippocampal spatial proteomic signature in male and female mice of an early Alzheimer’s disease model", "doi": "10.1186/s13293-025-00697-5", "year": 2025 }, { "pmid": "33945025", "title": "High-throughput screening of natural compounds and inhibition of a major therapeutic target HsGSK-3β for Alzheimer’s disease using computational approaches", "doi": "10.1186/s43141-021-00163-w", "year": 2021 } ] } }, { "id": 57064, "drug": "metformin", "drug_type": "drug", "drug_domain": "pancreatic_cancer", "predicate_ab": "activates", "mediator": "AMPK", "mediator_type": "protein", "predicate_bc": "prevents", "outcome": "metabolic dysfunction", "outcome_type": "disease", "outcome_domain": "heart_failure", "score": 0.21972245773362195, "filtered_score": 0.3295836866004329, "filter_reason": "boosted_repurposing", "outreach_score": 0.3295836866004329, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 2, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "26760500", "title": "Metformin Treatment Does Not Inhibit Growth of Pancreatic Cancer Patient-Derived Xenografts", "doi": "10.1371/journal.pone.0147113", "year": 2016 }, { "pmid": "25688512", "title": "Rationale and protocol of the MetNET-1 trial, a prospective, single center, phase II study to evaluate the activity and safety of everolimus in combination with octreotide LAR and metformin in patients with advanced pancreatic neuroendocrine tumors.", "doi": "10.1700/1778.19298", "year": 2015 } ], "bc": [ { "pmid": "37194385", "title": "Adenosine monophosphate‐activated protein kinase is elevated in human cachectic muscle and prevents cancer‐induced metabolic dysfunction in mice", "doi": "10.1002/jcsm.13238", "year": 2023 } ] } }, { "id": 1630, "drug": "erlotinib", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "inhibits", "mediator": "EGFR", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "pancreatic adenocarcinoma", "outcome_type": "disease", "outcome_domain": "pancreatic_cancer", "score": 0.21972245773362195, "filtered_score": 0.3295836866004329, "filter_reason": "boosted_repurposing", "outreach_score": 0.3295836866004329, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "active", "clinical_trial_nct_ids": [ "NCT01389440", "NCT06483555", "NCT00878163" ], "literature_status": "reproduces_known", "drug_canonical": "erlotinib", "mediator_canonical": "EGFR", "outcome_canonical": "pancreatic adenocarcinoma", "ab_count": 2, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40945534", "title": "Biodegradable nanofibrous scaffolds enhance standard of care for glioblastoma via localized targeted therapy", "doi": "10.1016/j.jconrel.2025.114225", "year": 2025 }, { "pmid": "30410775", "title": "The role of erlotinib and the Optune device in a patient with an epidermal growth factor receptor viii amplified glioblastoma", "doi": "10.1093/omcr/omy095", "year": 2018 } ], "bc": [ { "pmid": "37370756", "title": "Anoikis-Related Gene Signature for Prognostication of Pancreatic Adenocarcinoma: A Multi-Omics Exploration and Verification Study", "doi": "10.3390/cancers15123146", "year": 2023 }, { "pmid": "27130234", "title": "Selecting Tumor-Specific Molecular Targets in Pancreatic Adenocarcinoma: Paving the Way for Image-Guided Pancreatic Surgery", "doi": "10.1007/s11307-016-0959-4", "year": 2016 } ] } }, { "id": 51764, "drug": "Curcumin", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "activates", "mediator": "Nrf2", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "disease activity", "outcome_type": "phenotype", "outcome_domain": "rheumatoid_arthritis", "score": 0.21972245773362195, "filtered_score": 0.3295836866004329, "filter_reason": "boosted_repurposing", "outreach_score": 0.3295836866004329, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 2, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37101595", "title": "Curcumin Improves Diabetic Cardiomyopathy by Inhibiting Pyroptosis through AKT/Nrf2/ARE Pathway", "doi": "10.1155/2023/3906043", "year": 2023 }, { "pmid": "35909950", "title": "Curcumin Attenuates Ferroptosis-Induced Myocardial Injury in Diabetic Cardiomyopathy through the Nrf2 Pathway", "doi": "10.1155/2022/3159717", "year": 2022 } ], "bc": [ { "pmid": "36574898", "title": "Expression of Nrf2 protein in serum of patients with rheumatoid arthritis: A novel indicator for disease activity and disease prognosis", "doi": "10.1016/j.clinbiochem.2022.12.011", "year": 2022 } ] } }, { "id": 50971, "drug": "haloperidol", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "downregulates", "mediator": "Sigma-1 receptor", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "glioblastoma", "outcome_type": "disease", "outcome_domain": "glioblastoma", "score": 0.21972245773362195, "filtered_score": 0.3295836866004329, "filter_reason": "boosted_repurposing", "outreach_score": 0.3295836866004329, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 2, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "27435383", "title": "Haloperidol aggravates transverse aortic constriction-induced heart failure via mitochondrial dysfunction", "doi": "10.1016/j.jphs.2016.05.012", "year": 2016 } ], "bc": [ { "pmid": "32384802", "title": "Sigma-1 Receptor Positron Emission Tomography: A New Molecular Imaging Approach Using (S)-(−)-[18F]Fluspidine in Glioblastoma", "doi": "10.3390/molecules25092170", "year": 2020 } ] } }, { "id": 60969, "drug": "Empagliflozin", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "inhibits", "mediator": "SGLT2", "mediator_type": "protein", "predicate_bc": "causes", "outcome": "eNOS-NO/ROS imbalance", "outcome_type": "phenotype", "outcome_domain": "heart_failure", "score": 0.3258096538021482, "filtered_score": 0.3258096538021482, "filter_reason": null, "outreach_score": 0.3258096538021482, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 12, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40065073", "title": "Single cell transcriptomic analysis of SGLT2 expression supports an indirect or off-target role for the cardioprotective benefits of empagliflozin in heart failure", "doi": "10.1038/s41598-025-93144-9", "year": 2025 }, { "pmid": "38061371", "title": "Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial", "doi": "10.1016/s2213-8587(23)00321-2", "year": 2023 }, { "pmid": "37428955", "title": "Finerenone Added to RAS/SGLT2 Blockade for CKD in Alport Syndrome. Results of a Randomized Controlled Trial with Col4a3 −/− Mice", "doi": "10.1681/asn.0000000000000186", "year": 2023 } ], "bc": [ { "pmid": "39739876", "title": "SGLT2 expression in human vasculature and heart correlates with low-grade inflammation and causes eNOS-NO/ROS imbalance", "doi": "10.1093/cvr/cvae257", "year": 2024 } ] } }, { "id": 40759, "drug": "Empagliflozin", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "inhibits", "mediator": "SGLT2", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "pancreatic adenocarcinoma", "outcome_type": "disease", "outcome_domain": "pancreatic_cancer", "score": 0.3258096538021482, "filtered_score": 0.3258096538021482, "filter_reason": null, "outreach_score": 0.3258096538021482, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "empagliflozin", "mediator_canonical": "sglt2", "outcome_canonical": "pancreatic adenocarcinoma", "ab_count": 12, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40065073", "title": "Single cell transcriptomic analysis of SGLT2 expression supports an indirect or off-target role for the cardioprotective benefits of empagliflozin in heart failure", "doi": "10.1038/s41598-025-93144-9", "year": 2025 }, { "pmid": "38061371", "title": "Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial", "doi": "10.1016/s2213-8587(23)00321-2", "year": 2023 }, { "pmid": "37428955", "title": "Finerenone Added to RAS/SGLT2 Blockade for CKD in Alport Syndrome. Results of a Randomized Controlled Trial with Col4a3 −/− Mice", "doi": "10.1681/asn.0000000000000186", "year": 2023 } ], "bc": [ { "pmid": "26170283", "title": "Functional expression of sodium-glucose transporters in cancer", "doi": "10.1073/pnas.1511698112", "year": 2015 } ] } }, { "id": 40758, "drug": "Empagliflozin", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "inhibits", "mediator": "SGLT2", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "prostate adenocarcinoma", "outcome_type": "disease", "outcome_domain": "pancreatic_cancer", "score": 0.3258096538021482, "filtered_score": 0.3258096538021482, "filter_reason": null, "outreach_score": 0.3258096538021482, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "empagliflozin", "mediator_canonical": "sglt2", "outcome_canonical": "prostate adenocarcinoma", "ab_count": 12, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40065073", "title": "Single cell transcriptomic analysis of SGLT2 expression supports an indirect or off-target role for the cardioprotective benefits of empagliflozin in heart failure", "doi": "10.1038/s41598-025-93144-9", "year": 2025 }, { "pmid": "38061371", "title": "Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial", "doi": "10.1016/s2213-8587(23)00321-2", "year": 2023 }, { "pmid": "37428955", "title": "Finerenone Added to RAS/SGLT2 Blockade for CKD in Alport Syndrome. Results of a Randomized Controlled Trial with Col4a3 −/− Mice", "doi": "10.1681/asn.0000000000000186", "year": 2023 } ], "bc": [ { "pmid": "26170283", "title": "Functional expression of sodium-glucose transporters in cancer", "doi": "10.1073/pnas.1511698112", "year": 2015 } ] } }, { "id": 40364, "drug": "linagliptin", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "inhibits", "mediator": "DPP-4", "mediator_type": "protein", "predicate_bc": "predicts", "outcome": "biological treatment response", "outcome_type": "phenotype", "outcome_domain": "inflammatory_bowel_disease", "score": 0.31780538303479455, "filtered_score": 0.31780538303479455, "filter_reason": null, "outreach_score": 0.31780538303479455, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "linagliptin", "mediator_canonical": "dpp-4", "outcome_canonical": "biological treatment response", "ab_count": 11, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "39724680", "title": "Dipeptidyl peptidase-4 inhibitor linagliptin reduces inflammatory response, ameliorates tissue edema formation, and improves survival in severe sepsis", "doi": "10.1016/j.biopha.2024.117778", "year": 2024 }, { "pmid": "30632692", "title": "Urinary Proteomics as a Tool to Identify Kidney Responders to Dipeptidyl Peptidase‐4 Inhibition: A Hypothesis‐Generating Analysis from the MARLINA‐T2D Trial", "doi": "10.1002/prca.201800144", "year": 2019 }, { "pmid": "30418475", "title": "Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk", "doi": "10.1001/jama.2018.18269", "year": 2018 } ], "bc": [ { "pmid": "31912883", "title": "Serum Dipeptidyl Peptidase 4: A Predictor of Disease Activity and Prognosis in Inflammatory Bowel Disease", "doi": "10.1093/ibd/izz319", "year": 2020 } ] } }, { "id": 40760, "drug": "liraglutide", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "upregulates", "mediator": "GLP-1R", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "pancreatic ductal adenocarcinoma", "outcome_type": "disease", "outcome_domain": "pancreatic_cancer", "score": 0.31780538303479455, "filtered_score": 0.31780538303479455, "filter_reason": null, "outreach_score": 0.31780538303479455, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "liraglutide", "mediator_canonical": "glp-1r", "outcome_canonical": "pancreatic ductal adenocarcinoma", "ab_count": 11, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "38877189", "title": "Liraglutide exhibits potential anti-tumor effects on the progression of intrahepatic cholangiocarcinoma, in vitro and in vivo", "doi": "10.1038/s41598-024-64774-2", "year": 2024 }, { "pmid": "38548245", "title": "Liraglutide attenuates angiotensin II-induced aortic dissection and aortic aneurysm via inhibiting M1 macrophage polarization in APOE -/- mice", "doi": "10.1016/j.bcp.2024.116170", "year": 2024 }, { "pmid": "38279433", "title": "GLP-1 receptor agonist liraglutide inhibits the proliferation and migration of thyroid cancer cells", "doi": "10.14715/cmb/2023.69.14.37", "year": 2023 } ], "bc": [ { "pmid": "26495786", "title": "Glucagon-Like Peptide-1 Receptor Expression in Normal and Neoplastic Human Pancreatic Tissues", "doi": "10.1097/mpa.0000000000000521", "year": 2015 } ] } }, { "id": 38624, "drug": "bimekizumab", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "inhibits", "mediator": "IL-17A", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "inflammatory bowel disease", "outcome_type": "disease", "outcome_domain": "inflammatory_bowel_disease", "score": 0.31780538303479455, "filtered_score": 0.31780538303479455, "filter_reason": null, "outreach_score": 0.31780538303479455, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "preclinical_only", "clinical_trial_nct_ids": [ "NCT07138898" ], "literature_status": "reproduces_known", "drug_canonical": "bimekizumab", "mediator_canonical": "il-17a", "outcome_canonical": "inflammatory bowel disease", "ab_count": 5, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "39215949", "title": "Safety and Efficacy of Bimekizumab in Patients with Psoriatic Arthritis: 2-Year Results from Two Phase 3 Studies", "doi": "10.1007/s40744-024-00708-8", "year": 2024 }, { "pmid": "39620046", "title": "Impact of bimekizumab and certolizumab pegol on efficacy, safety and osteoblastic activity in radiographic axial spondyloarthritis: results from a phase IIa, multicentre, randomised, double-blind, exploratory study with PET-CT imaging", "doi": "10.1177/1759720x241293944", "year": 2024 }, { "pmid": "37808274", "title": "Safe and Effective Subcutaneous Self-Injection of Bimekizumab with Safety Syringe and Auto-Injector Devices: Results from a Multicenter, Randomized, Open-Label Study in Patients with Psoriatic Arthritis", "doi": "10.2147/ppa.s427809", "year": 2023 } ], "bc": [ { "pmid": "32724117", "title": "Serum interleukin 17A and interleukin 17F in children with inflammatory bowel disease", "doi": "10.1038/s41598-020-69567-x", "year": 2020 }, { "pmid": "27049090", "title": "Relationship between serum interleukin-17 level and inflammatory bowel disease.", "doi": null, "year": 2016 } ] } }, { "id": 60970, "drug": "Empagliflozin", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "activates", "mediator": "AMPK", "mediator_type": "protein", "predicate_bc": "prevents", "outcome": "metabolic dysfunction", "outcome_type": "disease", "outcome_domain": "heart_failure", "score": 0.31780538303479455, "filtered_score": 0.31780538303479455, "filter_reason": null, "outreach_score": 0.31780538303479455, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 7, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40767292", "title": "Sodium Glucose Transporter 2 Inhibitor Protects Against Heart Failure With Preserved Ejection Fraction: Preclinical “2‐Hit” Model Reveals Autophagy Enhancement Via AMP‐Activated Protein Kinase/Mammalian Target of Rapamycin Complex 1 Pathway", "doi": "10.1161/jaha.124.040093", "year": 2025 }, { "pmid": "37373164", "title": "Empagliflozin Attenuates Vascular Calcification in Mice with Chronic Kidney Disease by Regulating the NFR2/HO-1 Anti-Inflammatory Pathway through AMPK Activation", "doi": "10.3390/ijms241210016", "year": 2023 }, { "pmid": "36358524", "title": "Effect of Empagliflozin on Thioacetamide-Induced Liver Injury in Rats: Role of AMPK/SIRT-1/HIF-1α Pathway in Halting Liver Fibrosis", "doi": "10.3390/antiox11112152", "year": 2022 } ], "bc": [ { "pmid": "37194385", "title": "Adenosine monophosphate‐activated protein kinase is elevated in human cachectic muscle and prevents cancer‐induced metabolic dysfunction in mice", "doi": "10.1002/jcsm.13238", "year": 2023 } ] } }, { "id": 40365, "drug": "linagliptin", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "inhibits", "mediator": "DPP-4", "mediator_type": "protein", "predicate_bc": "predicts", "outcome": "treatment escalation", "outcome_type": "phenotype", "outcome_domain": "inflammatory_bowel_disease", "score": 0.31780538303479455, "filtered_score": 0.31780538303479455, "filter_reason": null, "outreach_score": 0.31780538303479455, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "linagliptin", "mediator_canonical": "dpp-4", "outcome_canonical": "treatment escalation", "ab_count": 11, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "39724680", "title": "Dipeptidyl peptidase-4 inhibitor linagliptin reduces inflammatory response, ameliorates tissue edema formation, and improves survival in severe sepsis", "doi": "10.1016/j.biopha.2024.117778", "year": 2024 }, { "pmid": "30632692", "title": "Urinary Proteomics as a Tool to Identify Kidney Responders to Dipeptidyl Peptidase‐4 Inhibition: A Hypothesis‐Generating Analysis from the MARLINA‐T2D Trial", "doi": "10.1002/prca.201800144", "year": 2019 }, { "pmid": "30418475", "title": "Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk", "doi": "10.1001/jama.2018.18269", "year": 2018 } ], "bc": [ { "pmid": "31912883", "title": "Serum Dipeptidyl Peptidase 4: A Predictor of Disease Activity and Prognosis in Inflammatory Bowel Disease", "doi": "10.1093/ibd/izz319", "year": 2020 } ] } }, { "id": 2324, "drug": "valproic acid", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "binds_to", "mediator": "HDAC2", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "cholinergic nbM neuronal dysfunction", "outcome_type": "phenotype", "outcome_domain": "alzheimer", "score": 0.20794415416798356, "filtered_score": 0.3119162312519753, "filter_reason": "boosted_repurposing", "outreach_score": 0.3119162312519753, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "valproic acid", "mediator_canonical": "hdac2", "outcome_canonical": "cholinergic nbm neuronal dysfunction", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "35715448", "title": "Histone deacetylase 2 inhibitor valproic acid attenuates bisphenol A-induced liver pathology in male mice", "doi": "10.1038/s41598-022-12937-4", "year": 2022 }, { "pmid": "30909413", "title": "HDAC2 Inhibitor Valproic Acid Increases Radiation Sensitivity of Drug-Resistant Melanoma Cells", "doi": "10.3390/medsci7030051", "year": 2019 } ], "bc": [ { "pmid": "30252960", "title": "HDAC2 dysregulation in the nucleus basalis of Meynert during the progression of Alzheimer's disease", "doi": "10.1111/nan.12518", "year": 2018 } ] } }, { "id": 25542, "drug": "sunitinib", "drug_type": "drug", "drug_domain": "als", "predicate_ab": "inhibits", "mediator": "STAT3", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "prurigo nodularis", "outcome_type": "disease", "outcome_domain": "rheumatoid_arthritis", "score": 0.20794415416798356, "filtered_score": 0.3119162312519753, "filter_reason": "boosted_repurposing", "outreach_score": 0.3119162312519753, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "sunitinib", "mediator_canonical": "STAT3", "outcome_canonical": "prurigo nodularis", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "38914173", "title": "Sunitinib-mediated inhibition of STAT3 in skeletal muscle and spinal cord does not affect the disease in a mouse model of ALS", "doi": "10.1016/j.nbd.2024.106576", "year": 2024 } ], "bc": [ { "pmid": "39912139", "title": "Translating tissue expression of STAT 1, 3 and 6 in prurigo nodularis to clinical efficacy of oral tofacitinib – A prospective single-arm investigational study", "doi": "10.25259/ijdvl_1017_2024", "year": 2025 }, { "pmid": "40162359", "title": "Successful Use of Tofacitinib in Paediatric Prurigo Nodularis: A Report of Four Cases", "doi": "10.4103/ijd.ijd_842_24", "year": 2025 }, { "pmid": "37521237", "title": "A case of recalcitrant prurigo nodularis with heightened expression of STAT 3 and STAT 6 and its dramatic response to tofacitinib", "doi": "10.4103/idoj.idoj_508_22", "year": 2023 } ] } }, { "id": 2696, "drug": "valproic acid", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "downregulates", "mediator": "BDNF", "mediator_type": "protein", "predicate_bc": "decreases", "outcome": "schizophrenia", "outcome_type": "disease", "outcome_domain": "depression", "score": 0.20794415416798356, "filtered_score": 0.3119162312519753, "filter_reason": "boosted_repurposing", "outreach_score": 0.3119162312519753, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "active", "clinical_trial_nct_ids": [ "NCT01094249", "NCT05603104", "NCT06729541" ], "literature_status": "reproduces_known", "drug_canonical": "valproic acid", "mediator_canonical": "BDNF", "outcome_canonical": "schizophrenia", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "35465089", "title": "Excitatory and Inhibitory Synaptic Imbalance Caused by Brain-Derived Neurotrophic Factor Deficits During Development in a Valproic Acid Mouse Model of Autism", "doi": "10.3389/fnmol.2022.860275", "year": 2022 } ], "bc": [ { "pmid": "34280516", "title": "Associations of immunological proteins/traits with schizophrenia, major depression and bipolar disorder: A bi-directional two-sample mendelian randomization study", "doi": "10.1016/j.bbi.2021.07.009", "year": 2021 }, { "pmid": "30794585", "title": "Accuracy of brain-derived neurotrophic factor levels for differentiating between Taiwanese patients with major depressive disorder or schizophrenia and healthy controls", "doi": "10.1371/journal.pone.0212373", "year": 2019 } ] } }, { "id": 51593, "drug": "resveratrol", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "activates", "mediator": "AMPK", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "pancreatic cancer progression", "outcome_type": "disease", "outcome_domain": "pancreatic_cancer", "score": 0.20794415416798356, "filtered_score": 0.3119162312519753, "filter_reason": "boosted_repurposing", "outreach_score": 0.3119162312519753, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "36926277", "title": "Resveratrol alleviates high glucose-induced oxidative stress and apoptosis in rat cardiac microvascular endothelial cell through AMPK/Sirt1 activation", "doi": "10.1016/j.bbrep.2023.101444", "year": 2023 }, { "pmid": "35791579", "title": "Resveratrol, novel application by preconditioning to attenuate myocardial ischemia/reperfusion injury in mice through regulate AMPK pathway and autophagy level", "doi": "10.1111/jcmm.17431", "year": 2022 }, { "pmid": "27398147", "title": "Resveratrol attenuated estrogen-deficient-induced cardiac dysfunction: role of AMPK, SIRT1, and mitochondrial function.", "doi": null, "year": 2016 } ], "bc": [ { "pmid": "31205544", "title": "AMPK Inhibition Suppresses the Malignant Phenotype of Pancreatic Cancer Cells in Part by Attenuating Aerobic Glycolysis", "doi": "10.7150/jca.28299", "year": 2019 } ] } }, { "id": 51584, "drug": "erlotinib", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "inhibits", "mediator": "EGFR", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "pancreatic ductal adenocarcinoma", "outcome_type": "disease", "outcome_domain": "pancreatic_cancer", "score": 0.20794415416798356, "filtered_score": 0.3119162312519753, "filter_reason": "boosted_repurposing", "outreach_score": 0.3119162312519753, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "31277074", "title": "Inhibition of EGFR-STAT3 attenuates cardiomyopathy in streptozotocin-induced type 1 diabetes", "doi": "10.1530/joe-19-0058", "year": 2019 } ], "bc": [ { "pmid": "40130819", "title": "Identification of Tumor‐Specific Surface Proteins Enables Quantification of Extracellular Vesicle Subtypes for Early Detection of Pancreatic Ductal Adenocarcinoma", "doi": "10.1002/advs.202414982", "year": 2025 }, { "pmid": "31584260", "title": "Design and Evaluation of PEGylated Liposomal Formulation of a Novel Multikinase Inhibitor for Enhanced Chemosensitivity and Inhibition of Metastatic Pancreatic Ductal Adenocarcinoma", "doi": "10.1021/acs.bioconjchem.9b00632", "year": 2019 }, { "pmid": "26339400", "title": "EGFR expression in pancreatic intraepithelial neoplasia and ductal adenocarcinoma.", "doi": null, "year": 2015 } ] } }, { "id": 57077, "drug": "hydroxychloroquine", "drug_type": "drug", "drug_domain": "pancreatic_cancer", "predicate_ab": "inhibits", "mediator": "myeloperoxidase", "mediator_type": "protein", "predicate_bc": "causes", "outcome": "interstitial fibrosis", "outcome_type": "phenotype", "outcome_domain": "heart_failure", "score": 0.20794415416798356, "filtered_score": 0.3119162312519753, "filter_reason": "boosted_repurposing", "outreach_score": 0.3119162312519753, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40797324", "title": "Hydroxychloroquine reduces metastatic tumor burden in pancreatic adenocarcinoma through myeloperoxidase inhibition", "doi": "10.1186/s12950-025-00456-8", "year": 2025 } ], "bc": [ { "pmid": "37470101", "title": "Rationale and Design of ENDEAVOR: A Sequential Phase 2b–3 Randomized Clinical Trial to Evaluate the Effect of Myeloperoxidase Inhibition on Symptoms and Exercise Capacity in Heart Failure with Preserved or Mildly Reduced Ejection Fraction", "doi": "10.1002/ejhf.2977", "year": 2023 } ] } }, { "id": 24953, "drug": "riluzole", "drug_type": "drug", "drug_domain": "als", "predicate_ab": "downregulates", "mediator": "MMP-9", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "ulcerative colitis", "outcome_type": "disease", "outcome_domain": "inflammatory_bowel_disease", "score": 0.20794415416798356, "filtered_score": 0.3119162312519753, "filter_reason": "boosted_repurposing", "outreach_score": 0.3119162312519753, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "riluzole", "mediator_canonical": "MMP9", "outcome_canonical": "ulcerative colitis", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40012807", "title": "Investigation of the Neuroprotective Effect of Riluzole on Matrix Metalloproteinases in an Experimental Model of Glaucoma", "doi": "10.4103/joco.joco_290_23", "year": 2024 } ], "bc": [ { "pmid": "35566780", "title": "Are Matrix Metalloproteinase-9 and Tissue Inhibitor of Metalloproteinase-1 Useful as Markers in Diagnostic Management of Children with Newly Diagnosed Ulcerative Colitis?", "doi": "10.3390/jcm11092655", "year": 2022 }, { "pmid": "27034654", "title": "Expressions of Matrix Metalloproteinases (MMP-2, MMP-7, and MMP-9) and Their Inhibitors (TIMP-1, TIMP-2) in Inflammatory Bowel Diseases", "doi": "10.1155/2016/2456179", "year": 2016 }, { "pmid": "26514773", "title": "Matrix metalloproteinase 9-induced increase in intestinal epithelial tight junction permeability contributes to the severity of experimental DSS colitis", "doi": "10.1152/ajpgi.00256.2015", "year": 2015 } ] } }, { "id": 32924, "drug": "Curcumin", "drug_type": "drug", "drug_domain": "inflammatory_bowel_disease", "predicate_ab": "upregulates", "mediator": "STAT3", "mediator_type": "protein", "predicate_bc": "prevents", "outcome": "general cell loss", "outcome_type": "phenotype", "outcome_domain": "epilepsy", "score": 0.20794415416798356, "filtered_score": 0.3119162312519753, "filter_reason": "boosted_repurposing", "outreach_score": 0.3119162312519753, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "curcumin", "mediator_canonical": "STAT3", "outcome_canonical": "general cell loss", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "34931590", "title": "Curcumin Inhibits T Follicular Helper Cell Differentiation in Mice with Dextran Sulfate Sodium (DSS)-Induced Colitis", "doi": "10.1142/s0192415x22500100", "year": 2021 }, { "pmid": "29629345", "title": "Comparative Effects of Curcumin and Tetrahydrocurcumin on Dextran Sulfate Sodium-induced Colitis and Inflammatory Signaling in Mice", "doi": "10.15430/jcp.2018.23.1.18", "year": 2018 }, { "pmid": "27932984", "title": "Curcumin Suppressed Activation of Dendritic Cells via JAK/STAT/SOCS Signal in Mice with Experimental Colitis", "doi": "10.3389/fphar.2016.00455", "year": 2016 } ], "bc": [ { "pmid": "36825472", "title": "Blockage of STAT3 during epileptogenesis prevents GABAergic loss and imprinting of the epileptic state", "doi": "10.1093/brain/awad055", "year": 2023 } ] } }, { "id": 33521, "drug": "Curcumin", "drug_type": "drug", "drug_domain": "inflammatory_bowel_disease", "predicate_ab": "upregulates", "mediator": "STAT3", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "drug resistance", "outcome_type": "phenotype", "outcome_domain": "pancreatic_cancer", "score": 0.20794415416798356, "filtered_score": 0.3119162312519753, "filter_reason": "boosted_repurposing", "outreach_score": 0.3119162312519753, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "curcumin", "mediator_canonical": "STAT3", "outcome_canonical": null, "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "34931590", "title": "Curcumin Inhibits T Follicular Helper Cell Differentiation in Mice with Dextran Sulfate Sodium (DSS)-Induced Colitis", "doi": "10.1142/s0192415x22500100", "year": 2021 }, { "pmid": "29629345", "title": "Comparative Effects of Curcumin and Tetrahydrocurcumin on Dextran Sulfate Sodium-induced Colitis and Inflammatory Signaling in Mice", "doi": "10.15430/jcp.2018.23.1.18", "year": 2018 }, { "pmid": "27932984", "title": "Curcumin Suppressed Activation of Dendritic Cells via JAK/STAT/SOCS Signal in Mice with Experimental Colitis", "doi": "10.3389/fphar.2016.00455", "year": 2016 } ], "bc": [ { "pmid": "38464736", "title": "Role of STAT3 in pancreatic cancer", "doi": "10.37349/etat.2024.00202", "year": 2024 } ] } }, { "id": 6153, "drug": "osimertinib", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "inhibits", "mediator": "EGFR", "mediator_type": "protein", "predicate_bc": "decreases", "outcome": "survival", "outcome_type": "phenotype", "outcome_domain": "pancreatic_cancer", "score": 0.20794415416798356, "filtered_score": 0.3119162312519753, "filter_reason": "boosted_repurposing", "outreach_score": 0.3119162312519753, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "active", "clinical_trial_nct_ids": [ "NCT04324164", "NCT04322890", "NCT02959749" ], "literature_status": "reproduces_known", "drug_canonical": "osimertinib", "mediator_canonical": "EGFR", "outcome_canonical": null, "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40719865", "title": "Resistance of recurrent epidermal growth factor receptor-altered glioblastoma to anti-epidermal growth factor receptor targeted therapy with osimertinib", "doi": "10.1093/oncolo/oyaf146", "year": 2025 }, { "pmid": "40051661", "title": "A comparative study of preclinical and clinical molecular imaging response to EGFR inhibition using osimertinib in glioblastoma", "doi": "10.1093/noajnl/vdaf022", "year": 2025 }, { "pmid": "41120287", "title": "GSCs differentiation model-informed nanotherapy: dual-functional brain-targeting liposomes with iRGD modification for co-delivery of osimertinib and bortezomib to combat radioresistant glioblastoma", "doi": "10.1038/s41419-025-08083-0", "year": 2025 } ], "bc": [ { "pmid": "32335999", "title": "Unraveling ERBB network dynamics upon betacellulin signaling in pancreatic ductal adenocarcinoma in mice", "doi": "10.1002/1878-0261.12699", "year": 2020 } ] } }, { "id": 52468, "drug": "Curcumin", "drug_type": "drug", "drug_domain": "inflammatory_bowel_disease", "predicate_ab": "upregulates", "mediator": "STAT3", "mediator_type": "protein", "predicate_bc": "treats", "outcome": "tau-N368-induced protein pathology", "outcome_type": "disease", "outcome_domain": "alzheimer", "score": 0.20794415416798356, "filtered_score": 0.3119162312519753, "filter_reason": "boosted_repurposing", "outreach_score": 0.3119162312519753, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "34931590", "title": "Curcumin Inhibits T Follicular Helper Cell Differentiation in Mice with Dextran Sulfate Sodium (DSS)-Induced Colitis", "doi": "10.1142/s0192415x22500100", "year": 2021 }, { "pmid": "29629345", "title": "Comparative Effects of Curcumin and Tetrahydrocurcumin on Dextran Sulfate Sodium-induced Colitis and Inflammatory Signaling in Mice", "doi": "10.15430/jcp.2018.23.1.18", "year": 2018 }, { "pmid": "27932984", "title": "Curcumin Suppressed Activation of Dendritic Cells via JAK/STAT/SOCS Signal in Mice with Experimental Colitis", "doi": "10.3389/fphar.2016.00455", "year": 2016 } ], "bc": [ { "pmid": "37843229", "title": "STAT3 ameliorates truncated tau-induced cognitive deficits", "doi": "10.4103/1673-5374.382253", "year": 2023 } ] } }, { "id": 51579, "drug": "resveratrol", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "activates", "mediator": "AMPK", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "pancreatic ductal adenocarcinoma", "outcome_type": "disease", "outcome_domain": "pancreatic_cancer", "score": 0.20794415416798356, "filtered_score": 0.3119162312519753, "filter_reason": "boosted_repurposing", "outreach_score": 0.3119162312519753, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "36926277", "title": "Resveratrol alleviates high glucose-induced oxidative stress and apoptosis in rat cardiac microvascular endothelial cell through AMPK/Sirt1 activation", "doi": "10.1016/j.bbrep.2023.101444", "year": 2023 }, { "pmid": "35791579", "title": "Resveratrol, novel application by preconditioning to attenuate myocardial ischemia/reperfusion injury in mice through regulate AMPK pathway and autophagy level", "doi": "10.1111/jcmm.17431", "year": 2022 }, { "pmid": "27398147", "title": "Resveratrol attenuated estrogen-deficient-induced cardiac dysfunction: role of AMPK, SIRT1, and mitochondrial function.", "doi": null, "year": 2016 } ], "bc": [ { "pmid": "38885414", "title": "A Novel AMPK Inhibitor Sensitizes Pancreatic Cancer Cells to Ferroptosis Induction", "doi": "10.1002/advs.202307695", "year": 2024 } ] } }, { "id": 39629, "drug": "resveratrol", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "activates", "mediator": "SIRT1", "mediator_type": "protein", "predicate_bc": "prevents", "outcome": "tau accumulation", "outcome_type": "phenotype", "outcome_domain": "alzheimer", "score": 0.20794415416798356, "filtered_score": 0.3119162312519753, "filter_reason": "boosted_repurposing", "outreach_score": 0.3119162312519753, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "resveratrol", "mediator_canonical": "SIRT1", "outcome_canonical": "tau accumulation", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "32808479", "title": "Resveratrol improves sperm DNA quality and reproductive capacity in type 1 diabetes", "doi": "10.1111/andr.12891", "year": 2020 }, { "pmid": "31486447", "title": "The effects of resveratrol on metabolic status in patients with type 2 diabetes mellitus and coronary heart disease", "doi": "10.1039/c9fo01075k", "year": 2019 }, { "pmid": "30621358", "title": "Protective Effect of Resveratrol against Ischemia-Reperfusion Injury via Enhanced High Energy Compounds and eNOS-SIRT1 Expression in Type 2 Diabetic Female Rat Heart", "doi": "10.3390/nu11010105", "year": 2019 } ], "bc": [ { "pmid": "29883958", "title": "A silver lining for 24-hydroxycholesterol in Alzheimer's disease: The involvement of the neuroprotective enzyme sirtuin 1", "doi": "10.1016/j.redox.2018.05.009", "year": 2018 } ] } }, { "id": 53151, "drug": "metformin", "drug_type": "drug", "drug_domain": "inflammatory_bowel_disease", "predicate_ab": "downregulates", "mediator": "IL-18", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "adverse clinical events", "outcome_type": "disease", "outcome_domain": "heart_failure", "score": 0.20794415416798356, "filtered_score": 0.3119162312519753, "filter_reason": "boosted_repurposing", "outreach_score": 0.3119162312519753, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "31501716", "title": "Downregulation of IL-18 Expression in the Gut by Metformin-induced Gut Microbiota Modulation", "doi": "10.4110/in.2019.19.e28", "year": 2019 } ], "bc": [ { "pmid": "38402570", "title": "Prognostic significance of IL‐18 in acute coronary syndrome patients", "doi": "10.1002/clc.24229", "year": 2024 } ] } }, { "id": 51571, "drug": "resveratrol", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "activates", "mediator": "AMPK", "mediator_type": "protein", "predicate_bc": "decreases", "outcome": "invasion", "outcome_type": "phenotype", "outcome_domain": "pancreatic_cancer", "score": 0.20794415416798356, "filtered_score": 0.3119162312519753, "filter_reason": "boosted_repurposing", "outreach_score": 0.3119162312519753, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "36926277", "title": "Resveratrol alleviates high glucose-induced oxidative stress and apoptosis in rat cardiac microvascular endothelial cell through AMPK/Sirt1 activation", "doi": "10.1016/j.bbrep.2023.101444", "year": 2023 }, { "pmid": "35791579", "title": "Resveratrol, novel application by preconditioning to attenuate myocardial ischemia/reperfusion injury in mice through regulate AMPK pathway and autophagy level", "doi": "10.1111/jcmm.17431", "year": 2022 }, { "pmid": "27398147", "title": "Resveratrol attenuated estrogen-deficient-induced cardiac dysfunction: role of AMPK, SIRT1, and mitochondrial function.", "doi": null, "year": 2016 } ], "bc": [ { "pmid": "28783244", "title": "Loss of AMPK activation promotes the invasion and metastasis of pancreatic cancer through an HSF1‐dependent pathway", "doi": "10.1002/1878-0261.12116", "year": 2017 } ] } }, { "id": 32596, "drug": "Curcumin", "drug_type": "drug", "drug_domain": "inflammatory_bowel_disease", "predicate_ab": "upregulates", "mediator": "STAT3", "mediator_type": "protein", "predicate_bc": "treats", "outcome": "cognitive deficits", "outcome_type": "phenotype", "outcome_domain": "alzheimer", "score": 0.20794415416798356, "filtered_score": 0.3119162312519753, "filter_reason": "boosted_repurposing", "outreach_score": 0.3119162312519753, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "active", "clinical_trial_nct_ids": [ "NCT03935958", "NCT06470061", "NCT04705220" ], "literature_status": "reproduces_known", "drug_canonical": "curcumin", "mediator_canonical": "STAT3", "outcome_canonical": "cognitive deficits", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "34931590", "title": "Curcumin Inhibits T Follicular Helper Cell Differentiation in Mice with Dextran Sulfate Sodium (DSS)-Induced Colitis", "doi": "10.1142/s0192415x22500100", "year": 2021 }, { "pmid": "29629345", "title": "Comparative Effects of Curcumin and Tetrahydrocurcumin on Dextran Sulfate Sodium-induced Colitis and Inflammatory Signaling in Mice", "doi": "10.15430/jcp.2018.23.1.18", "year": 2018 }, { "pmid": "27932984", "title": "Curcumin Suppressed Activation of Dendritic Cells via JAK/STAT/SOCS Signal in Mice with Experimental Colitis", "doi": "10.3389/fphar.2016.00455", "year": 2016 } ], "bc": [ { "pmid": "33859760", "title": "STAT3 ameliorates cognitive deficits via regulation of NMDAR expression in an Alzheimer's disease animal model", "doi": "10.7150/thno.56541", "year": 2021 } ] } }, { "id": 37692, "drug": "riluzole", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "inhibits", "mediator": "TDP-43", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "FTLD", "outcome_type": "disease", "outcome_domain": "als", "score": 0.20794415416798356, "filtered_score": 0.3119162312519753, "filter_reason": "boosted_repurposing", "outreach_score": 0.3119162312519753, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "riluzole", "mediator_canonical": "TDP-43", "outcome_canonical": "ftld", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "29396541", "title": "TDP-43 self-interaction is modulated by redox-active compounds Auranofin, Chelerythrine and Riluzole", "doi": "10.1038/s41598-018-20565-0", "year": 2018 } ], "bc": [ { "pmid": "40619651", "title": "TDP-43 Proteinopathies in ALS and FTLD: Mechanistic Insights andTherapeutic Approaches", "doi": "10.2174/0118715273374466250617085832", "year": 2025 }, { "pmid": "31529970", "title": "Using Tetracysteine-Tagged TDP-43 with a Biarsenical Dye To Monitor Real-Time Trafficking in a Cell Model of Amyotrophic Lateral Sclerosis", "doi": "10.1021/acs.biochem.9b00592", "year": 2019 }, { "pmid": "26689008", "title": "[RNA processing TDP-43 protein has a main pathological role in FTLD and ALS].", "doi": null, "year": 2015 } ] } }, { "id": 37736, "drug": "Auranofin", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "inhibits", "mediator": "TDP-43", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "FTLD", "outcome_type": "disease", "outcome_domain": "als", "score": 0.20794415416798356, "filtered_score": 0.3119162312519753, "filter_reason": "boosted_repurposing", "outreach_score": 0.3119162312519753, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "auranofin", "mediator_canonical": "TDP-43", "outcome_canonical": "ftld", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "29396541", "title": "TDP-43 self-interaction is modulated by redox-active compounds Auranofin, Chelerythrine and Riluzole", "doi": "10.1038/s41598-018-20565-0", "year": 2018 } ], "bc": [ { "pmid": "40619651", "title": "TDP-43 Proteinopathies in ALS and FTLD: Mechanistic Insights andTherapeutic Approaches", "doi": "10.2174/0118715273374466250617085832", "year": 2025 }, { "pmid": "31529970", "title": "Using Tetracysteine-Tagged TDP-43 with a Biarsenical Dye To Monitor Real-Time Trafficking in a Cell Model of Amyotrophic Lateral Sclerosis", "doi": "10.1021/acs.biochem.9b00592", "year": 2019 }, { "pmid": "26689008", "title": "[RNA processing TDP-43 protein has a main pathological role in FTLD and ALS].", "doi": null, "year": 2015 } ] } }, { "id": 1374, "drug": "apigenin", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "upregulates", "mediator": "GFAP", "mediator_type": "protein", "predicate_bc": "predicts", "outcome": "Alzheimer's disease", "outcome_type": "disease", "outcome_domain": "alzheimer", "score": 0.20794415416798356, "filtered_score": 0.3119162312519753, "filter_reason": "boosted_repurposing", "outreach_score": 0.3119162312519753, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "apigenin", "mediator_canonical": "GFAP", "outcome_canonical": "Alzheimer disease", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41090780", "title": "Apigenin Induces Autophagy and Apoptosis in Chemoresistant Glioblastoma Cells and Inhibits Tumorigenicity Associated with Regulation of Immunomodulatory Proteins and Glial Cells Response", "doi": "10.3390/cells14191552", "year": 2025 } ], "bc": [ { "pmid": "39252463", "title": "Plasma proteomics for risk prediction of Alzheimer's disease in the general population", "doi": "10.1111/acel.14330", "year": 2024 }, { "pmid": "35890250", "title": "Glial Fibrillary Acidic Protein: A Biomarker and Drug Target for Alzheimer’s Disease", "doi": "10.3390/pharmaceutics14071354", "year": 2022 }, { "pmid": "34828359", "title": "Investigating Markers of the NLRP3 Inflammasome Pathway in Alzheimer’s Disease: A Human Post-Mortem Study", "doi": "10.3390/genes12111753", "year": 2021 } ] } }, { "id": 1383, "drug": "apigenin", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "upregulates", "mediator": "GFAP", "mediator_type": "protein", "predicate_bc": "predicts", "outcome": "cognitive decline", "outcome_type": "phenotype", "outcome_domain": "alzheimer", "score": 0.20794415416798356, "filtered_score": 0.3119162312519753, "filter_reason": "boosted_repurposing", "outreach_score": 0.3119162312519753, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "apigenin", "mediator_canonical": "GFAP", "outcome_canonical": "cognitive decline", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41090780", "title": "Apigenin Induces Autophagy and Apoptosis in Chemoresistant Glioblastoma Cells and Inhibits Tumorigenicity Associated with Regulation of Immunomodulatory Proteins and Glial Cells Response", "doi": "10.3390/cells14191552", "year": 2025 } ], "bc": [ { "pmid": "40110647", "title": "Exploratory analysis of the proteomic profile in plasma in adults with Down syndrome in the context of Alzheimer's disease", "doi": "10.1002/alz.70040", "year": 2025 }, { "pmid": "37787146", "title": "Longitudinal associations of serum biomarkers with early cognitive, amyloid and grey matter changes", "doi": "10.1093/brain/awad330", "year": 2023 }, { "pmid": "36446595", "title": "Longitudinal Changes in Blood Biomarkers of Clinical Alzheimer Disease in a Biracial Population Sample", "doi": "10.1212/wnl.0000000000201289", "year": 2022 } ] } }, { "id": 31340, "drug": "auraptene", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "downregulates", "mediator": "MMP-9", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "ulcerative colitis", "outcome_type": "disease", "outcome_domain": "inflammatory_bowel_disease", "score": 0.20794415416798356, "filtered_score": 0.3119162312519753, "filter_reason": "boosted_repurposing", "outreach_score": 0.3119162312519753, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "auraptene", "mediator_canonical": "MMP9", "outcome_canonical": "ulcerative colitis", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "39086858", "title": "Auraptene inhibits migration, invasion and metastatic behavior of human malignant glioblastoma cells: An in vitro and in silico study.", "doi": "10.22038/ajp.2023.23586", "year": 2024 } ], "bc": [ { "pmid": "35566780", "title": "Are Matrix Metalloproteinase-9 and Tissue Inhibitor of Metalloproteinase-1 Useful as Markers in Diagnostic Management of Children with Newly Diagnosed Ulcerative Colitis?", "doi": "10.3390/jcm11092655", "year": 2022 }, { "pmid": "27034654", "title": "Expressions of Matrix Metalloproteinases (MMP-2, MMP-7, and MMP-9) and Their Inhibitors (TIMP-1, TIMP-2) in Inflammatory Bowel Diseases", "doi": "10.1155/2016/2456179", "year": 2016 }, { "pmid": "26514773", "title": "Matrix metalloproteinase 9-induced increase in intestinal epithelial tight junction permeability contributes to the severity of experimental DSS colitis", "doi": "10.1152/ajpgi.00256.2015", "year": 2015 } ] } }, { "id": 49014, "drug": "staurosporine", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "binds_to", "mediator": "FLNC", "mediator_type": "gene", "predicate_bc": "associated_with", "outcome": "restrictive cardiomyopathy", "outcome_type": "disease", "outcome_domain": "heart_failure", "score": 0.20794415416798356, "filtered_score": 0.3119162312519753, "filter_reason": "boosted_repurposing", "outreach_score": 0.3119162312519753, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "39946771", "title": "Identification of therapeutic targets and immune landscape in glioblastoma through crosstalk with glioma-associated mesenchymal stem cells", "doi": "10.1016/j.intimp.2025.114228", "year": 2025 } ], "bc": [ { "pmid": "29858533", "title": "De novo mutations in FLNC leading to early-onset restrictive cardiomyopathy and congenital myopathy", "doi": "10.1002/humu.23559", "year": 2018 }, { "pmid": "29212899", "title": "Novel Mutation in FLNC (Filamin C) Causes Familial Restrictive Cardiomyopathy", "doi": "10.1161/circgenetics.117.001780", "year": 2017 }, { "pmid": "26666891", "title": "Mutations inFLNCare Associated with Familial Restrictive Cardiomyopathy", "doi": "10.1002/humu.22942", "year": 2015 } ] } }, { "id": 40568, "drug": "resveratrol", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "activates", "mediator": "SIRT1", "mediator_type": "protein", "predicate_bc": "increases", "outcome": "optokinetic response", "outcome_type": "phenotype", "outcome_domain": "multiple_sclerosis", "score": 0.20794415416798356, "filtered_score": 0.3119162312519753, "filter_reason": "boosted_repurposing", "outreach_score": 0.3119162312519753, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "resveratrol", "mediator_canonical": "SIRT1", "outcome_canonical": "optokinetic response", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "32808479", "title": "Resveratrol improves sperm DNA quality and reproductive capacity in type 1 diabetes", "doi": "10.1111/andr.12891", "year": 2020 }, { "pmid": "31486447", "title": "The effects of resveratrol on metabolic status in patients with type 2 diabetes mellitus and coronary heart disease", "doi": "10.1039/c9fo01075k", "year": 2019 }, { "pmid": "30621358", "title": "Protective Effect of Resveratrol against Ischemia-Reperfusion Injury via Enhanced High Energy Compounds and eNOS-SIRT1 Expression in Type 2 Diabetic Female Rat Heart", "doi": "10.3390/nu11010105", "year": 2019 } ], "bc": [ { "pmid": "35740955", "title": "Selective Upregulation of SIRT1 Expression in Retinal Ganglion Cells by AAV-Mediated Gene Delivery Increases Neuronal Cell Survival and Alleviates Axon Demyelination Associated with Optic Neuritis", "doi": "10.3390/biom12060830", "year": 2022 } ] } }, { "id": 1411, "drug": "apigenin", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "upregulates", "mediator": "GFAP", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "cognitive impairment", "outcome_type": "phenotype", "outcome_domain": "alzheimer", "score": 0.20794415416798356, "filtered_score": 0.3119162312519753, "filter_reason": "boosted_repurposing", "outreach_score": 0.3119162312519753, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "apigenin", "mediator_canonical": "GFAP", "outcome_canonical": "cognitive impairment", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41090780", "title": "Apigenin Induces Autophagy and Apoptosis in Chemoresistant Glioblastoma Cells and Inhibits Tumorigenicity Associated with Regulation of Immunomodulatory Proteins and Glial Cells Response", "doi": "10.3390/cells14191552", "year": 2025 } ], "bc": [ { "pmid": "36576155", "title": "Plasma glial fibrillary acidic protein in autosomal dominant Alzheimer's disease: Associations with Aβ‐PET, neurodegeneration, and cognition", "doi": "10.1002/alz.12879", "year": 2022 }, { "pmid": "32514860", "title": "Synaptic Loss, ER Stress and Neuro-Inflammation Emerge Late in the Lateral Temporal Cortex and Associate with Progressive Tau Pathology in Alzheimer’s Disease", "doi": "10.1007/s12035-020-01950-1", "year": 2020 }, { "pmid": "30594925", "title": "Glial Fibrillary Acidic Protein in Serum is Increased in Alzheimer’s Disease and Correlates with Cognitive Impairment", "doi": "10.3233/jad-180325", "year": 2018 } ] } }, { "id": 40565, "drug": "resveratrol", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "activates", "mediator": "SIRT1", "mediator_type": "protein", "predicate_bc": "decreases", "outcome": "axon demyelination", "outcome_type": "phenotype", "outcome_domain": "multiple_sclerosis", "score": 0.20794415416798356, "filtered_score": 0.3119162312519753, "filter_reason": "boosted_repurposing", "outreach_score": 0.3119162312519753, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "resveratrol", "mediator_canonical": "SIRT1", "outcome_canonical": "axon demyelination", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "32808479", "title": "Resveratrol improves sperm DNA quality and reproductive capacity in type 1 diabetes", "doi": "10.1111/andr.12891", "year": 2020 }, { "pmid": "31486447", "title": "The effects of resveratrol on metabolic status in patients with type 2 diabetes mellitus and coronary heart disease", "doi": "10.1039/c9fo01075k", "year": 2019 }, { "pmid": "30621358", "title": "Protective Effect of Resveratrol against Ischemia-Reperfusion Injury via Enhanced High Energy Compounds and eNOS-SIRT1 Expression in Type 2 Diabetic Female Rat Heart", "doi": "10.3390/nu11010105", "year": 2019 } ], "bc": [ { "pmid": "35740955", "title": "Selective Upregulation of SIRT1 Expression in Retinal Ganglion Cells by AAV-Mediated Gene Delivery Increases Neuronal Cell Survival and Alleviates Axon Demyelination Associated with Optic Neuritis", "doi": "10.3390/biom12060830", "year": 2022 } ] } }, { "id": 40809, "drug": "resveratrol", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "activates", "mediator": "SIRT1", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "patient survival", "outcome_type": "phenotype", "outcome_domain": "pancreatic_cancer", "score": 0.20794415416798356, "filtered_score": 0.3119162312519753, "filter_reason": "boosted_repurposing", "outreach_score": 0.3119162312519753, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "resveratrol", "mediator_canonical": "SIRT1", "outcome_canonical": "patient survival", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "32808479", "title": "Resveratrol improves sperm DNA quality and reproductive capacity in type 1 diabetes", "doi": "10.1111/andr.12891", "year": 2020 }, { "pmid": "31486447", "title": "The effects of resveratrol on metabolic status in patients with type 2 diabetes mellitus and coronary heart disease", "doi": "10.1039/c9fo01075k", "year": 2019 }, { "pmid": "30621358", "title": "Protective Effect of Resveratrol against Ischemia-Reperfusion Injury via Enhanced High Energy Compounds and eNOS-SIRT1 Expression in Type 2 Diabetic Female Rat Heart", "doi": "10.3390/nu11010105", "year": 2019 } ], "bc": [ { "pmid": "27494892", "title": "Sirtuin 1 stimulates the proliferation and the expression of glycolysis genes in pancreatic neoplastic lesions", "doi": "10.18632/oncotarget.11013", "year": 2016 } ] } }, { "id": 39636, "drug": "resveratrol", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "activates", "mediator": "SIRT1", "mediator_type": "protein", "predicate_bc": "prevents", "outcome": "Aβ-induced neurotoxicity", "outcome_type": "phenotype", "outcome_domain": "alzheimer", "score": 0.20794415416798356, "filtered_score": 0.3119162312519753, "filter_reason": "boosted_repurposing", "outreach_score": 0.3119162312519753, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "resveratrol", "mediator_canonical": "SIRT1", "outcome_canonical": "aβ-induced neurotoxicity", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "32808479", "title": "Resveratrol improves sperm DNA quality and reproductive capacity in type 1 diabetes", "doi": "10.1111/andr.12891", "year": 2020 }, { "pmid": "31486447", "title": "The effects of resveratrol on metabolic status in patients with type 2 diabetes mellitus and coronary heart disease", "doi": "10.1039/c9fo01075k", "year": 2019 }, { "pmid": "30621358", "title": "Protective Effect of Resveratrol against Ischemia-Reperfusion Injury via Enhanced High Energy Compounds and eNOS-SIRT1 Expression in Type 2 Diabetic Female Rat Heart", "doi": "10.3390/nu11010105", "year": 2019 } ], "bc": [ { "pmid": "37602729", "title": "Cooperative effects of SIRT1 and SIRT2 on APP acetylation", "doi": "10.1111/acel.13967", "year": 2023 } ] } }, { "id": 30334, "drug": "valproic acid", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "downregulates", "mediator": "DNA methylation", "mediator_type": "biomarker", "predicate_bc": "associated_with", "outcome": "type 2 diabetes", "outcome_type": "disease", "outcome_domain": "type_2_diabetes", "score": 0.20794415416798356, "filtered_score": 0.3119162312519753, "filter_reason": "boosted_repurposing", "outreach_score": 0.3119162312519753, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "valproic acid", "mediator_canonical": "dna methylation", "outcome_canonical": "type 2 diabetes", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "35312054", "title": "Developmental administration of valproic acid alters DNA methylation and maternal behavior", "doi": "10.1002/dev.22231", "year": 2022 } ], "bc": [ { "pmid": "32033992", "title": "Epigenetic Link Between Statin Therapy and Type 2 Diabetes", "doi": "10.2337/dc19-1828", "year": 2020 }, { "pmid": "29466957", "title": "Altered DNA methylation in liver and adipose tissues derived from individuals with obesity and type 2 diabetes", "doi": "10.1186/s12881-018-0542-8", "year": 2018 }, { "pmid": "26101197", "title": "Novel epigenetic determinants of type 2 diabetes in Mexican-American families", "doi": "10.1093/hmg/ddv232", "year": 2015 } ] } }, { "id": 30139, "drug": "valproic acid", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "downregulates", "mediator": "HDAC3", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "RA-ILD", "outcome_type": "disease", "outcome_domain": "rheumatoid_arthritis", "score": 0.20794415416798356, "filtered_score": 0.3119162312519753, "filter_reason": "boosted_repurposing", "outreach_score": 0.3119162312519753, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "valproic acid", "mediator_canonical": "hdac3", "outcome_canonical": "ra-ild", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "29776446", "title": "Valproic acid attenuates traumatic spinal cord injury-induced inflammation via STAT1 and NF-κB pathway dependent of HDAC3", "doi": "10.1186/s12974-018-1193-6", "year": 2018 }, { "pmid": "29719500", "title": "Valproic Acid Attenuates Traumatic Brain Injury-Induced Inflammation in Vivo: Involvement of Autophagy and the Nrf2/ARE Signaling Pathway", "doi": "10.3389/fnmol.2018.00117", "year": 2018 }, { "pmid": "30127218", "title": "Disruption of Planar Cell Polarity Pathway Attributable to Valproic Acid-Induced Congenital Heart Disease through Hdac3 Participation in Mice", "doi": "10.4103/0366-6999.239311", "year": 2018 } ], "bc": [ { "pmid": "33343379", "title": "Histone Deacetylase 3-Mediated Inhibition of microRNA-19a-3p Facilitates the Development of Rheumatoid Arthritis-Associated Interstitial Lung Disease", "doi": "10.3389/fphys.2020.549656", "year": 2020 } ] } }, { "id": 39610, "drug": "resveratrol", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "activates", "mediator": "SIRT1", "mediator_type": "protein", "predicate_bc": "increases", "outcome": "APP recycling", "outcome_type": "phenotype", "outcome_domain": "alzheimer", "score": 0.20794415416798356, "filtered_score": 0.3119162312519753, "filter_reason": "boosted_repurposing", "outreach_score": 0.3119162312519753, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "resveratrol", "mediator_canonical": "SIRT1", "outcome_canonical": "app recycling", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "32808479", "title": "Resveratrol improves sperm DNA quality and reproductive capacity in type 1 diabetes", "doi": "10.1111/andr.12891", "year": 2020 }, { "pmid": "31486447", "title": "The effects of resveratrol on metabolic status in patients with type 2 diabetes mellitus and coronary heart disease", "doi": "10.1039/c9fo01075k", "year": 2019 }, { "pmid": "30621358", "title": "Protective Effect of Resveratrol against Ischemia-Reperfusion Injury via Enhanced High Energy Compounds and eNOS-SIRT1 Expression in Type 2 Diabetic Female Rat Heart", "doi": "10.3390/nu11010105", "year": 2019 } ], "bc": [ { "pmid": "37602729", "title": "Cooperative effects of SIRT1 and SIRT2 on APP acetylation", "doi": "10.1111/acel.13967", "year": 2023 } ] } }, { "id": 39611, "drug": "resveratrol", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "activates", "mediator": "SIRT1", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "Braak stage", "outcome_type": "phenotype", "outcome_domain": "alzheimer", "score": 0.20794415416798356, "filtered_score": 0.3119162312519753, "filter_reason": "boosted_repurposing", "outreach_score": 0.3119162312519753, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "resveratrol", "mediator_canonical": "SIRT1", "outcome_canonical": "braak stage", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "32808479", "title": "Resveratrol improves sperm DNA quality and reproductive capacity in type 1 diabetes", "doi": "10.1111/andr.12891", "year": 2020 }, { "pmid": "31486447", "title": "The effects of resveratrol on metabolic status in patients with type 2 diabetes mellitus and coronary heart disease", "doi": "10.1039/c9fo01075k", "year": 2019 }, { "pmid": "30621358", "title": "Protective Effect of Resveratrol against Ischemia-Reperfusion Injury via Enhanced High Energy Compounds and eNOS-SIRT1 Expression in Type 2 Diabetic Female Rat Heart", "doi": "10.3390/nu11010105", "year": 2019 } ], "bc": [ { "pmid": "30185534", "title": "Reduced expression of SIRT1 and SOD-1 and the correlation between these levels in various regions of the brains of patients with Alzheimer's disease", "doi": "10.1136/jclinpath-2018-205320", "year": 2018 } ] } }, { "id": 1571, "drug": "osimertinib", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "inhibits", "mediator": "EGFR", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "pancreatic intraepithelial neoplasia", "outcome_type": "phenotype", "outcome_domain": "pancreatic_cancer", "score": 0.20794415416798356, "filtered_score": 0.3119162312519753, "filter_reason": "boosted_repurposing", "outreach_score": 0.3119162312519753, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "osimertinib", "mediator_canonical": "EGFR", "outcome_canonical": "pancreatic intraepithelial neoplasia", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40719865", "title": "Resistance of recurrent epidermal growth factor receptor-altered glioblastoma to anti-epidermal growth factor receptor targeted therapy with osimertinib", "doi": "10.1093/oncolo/oyaf146", "year": 2025 }, { "pmid": "40051661", "title": "A comparative study of preclinical and clinical molecular imaging response to EGFR inhibition using osimertinib in glioblastoma", "doi": "10.1093/noajnl/vdaf022", "year": 2025 }, { "pmid": "41120287", "title": "GSCs differentiation model-informed nanotherapy: dual-functional brain-targeting liposomes with iRGD modification for co-delivery of osimertinib and bortezomib to combat radioresistant glioblastoma", "doi": "10.1038/s41419-025-08083-0", "year": 2025 } ], "bc": [ { "pmid": "26339400", "title": "EGFR expression in pancreatic intraepithelial neoplasia and ductal adenocarcinoma.", "doi": null, "year": 2015 } ] } }, { "id": 39622, "drug": "resveratrol", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "activates", "mediator": "SIRT1", "mediator_type": "protein", "predicate_bc": "decreases", "outcome": "APP transit to endosome", "outcome_type": "phenotype", "outcome_domain": "alzheimer", "score": 0.20794415416798356, "filtered_score": 0.3119162312519753, "filter_reason": "boosted_repurposing", "outreach_score": 0.3119162312519753, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "resveratrol", "mediator_canonical": "SIRT1", "outcome_canonical": "app transit to endosome", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "32808479", "title": "Resveratrol improves sperm DNA quality and reproductive capacity in type 1 diabetes", "doi": "10.1111/andr.12891", "year": 2020 }, { "pmid": "31486447", "title": "The effects of resveratrol on metabolic status in patients with type 2 diabetes mellitus and coronary heart disease", "doi": "10.1039/c9fo01075k", "year": 2019 }, { "pmid": "30621358", "title": "Protective Effect of Resveratrol against Ischemia-Reperfusion Injury via Enhanced High Energy Compounds and eNOS-SIRT1 Expression in Type 2 Diabetic Female Rat Heart", "doi": "10.3390/nu11010105", "year": 2019 } ], "bc": [ { "pmid": "37602729", "title": "Cooperative effects of SIRT1 and SIRT2 on APP acetylation", "doi": "10.1111/acel.13967", "year": 2023 } ] } }, { "id": 1570, "drug": "osimertinib", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "inhibits", "mediator": "EGFR", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "AGR2-dependent oncogenic phenotypes", "outcome_type": "phenotype", "outcome_domain": "pancreatic_cancer", "score": 0.20794415416798356, "filtered_score": 0.3119162312519753, "filter_reason": "boosted_repurposing", "outreach_score": 0.3119162312519753, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "osimertinib", "mediator_canonical": "EGFR", "outcome_canonical": "agr2-dependent oncogenic phenotypes", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40719865", "title": "Resistance of recurrent epidermal growth factor receptor-altered glioblastoma to anti-epidermal growth factor receptor targeted therapy with osimertinib", "doi": "10.1093/oncolo/oyaf146", "year": 2025 }, { "pmid": "40051661", "title": "A comparative study of preclinical and clinical molecular imaging response to EGFR inhibition using osimertinib in glioblastoma", "doi": "10.1093/noajnl/vdaf022", "year": 2025 }, { "pmid": "41120287", "title": "GSCs differentiation model-informed nanotherapy: dual-functional brain-targeting liposomes with iRGD modification for co-delivery of osimertinib and bortezomib to combat radioresistant glioblastoma", "doi": "10.1038/s41419-025-08083-0", "year": 2025 } ], "bc": [ { "pmid": "33413231", "title": "Effects of ER-resident and secreted AGR2 on cell proliferation, migration, invasion, and survival in PANC-1 pancreatic cancer cells", "doi": "10.1186/s12885-020-07743-y", "year": 2021 } ] } }, { "id": 6143, "drug": "osimertinib", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "inhibits", "mediator": "EGFR", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "pancreatic cancer", "outcome_type": "disease", "outcome_domain": "pancreatic_cancer", "score": 0.20794415416798356, "filtered_score": 0.3119162312519753, "filter_reason": "boosted_repurposing", "outreach_score": 0.3119162312519753, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "active", "clinical_trial_nct_ids": [ "NCT02465060", "NCT03989115", "NCT06630325" ], "literature_status": "reproduces_known", "drug_canonical": "osimertinib", "mediator_canonical": "EGFR", "outcome_canonical": "pancreatic cancer", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40719865", "title": "Resistance of recurrent epidermal growth factor receptor-altered glioblastoma to anti-epidermal growth factor receptor targeted therapy with osimertinib", "doi": "10.1093/oncolo/oyaf146", "year": 2025 }, { "pmid": "40051661", "title": "A comparative study of preclinical and clinical molecular imaging response to EGFR inhibition using osimertinib in glioblastoma", "doi": "10.1093/noajnl/vdaf022", "year": 2025 }, { "pmid": "41120287", "title": "GSCs differentiation model-informed nanotherapy: dual-functional brain-targeting liposomes with iRGD modification for co-delivery of osimertinib and bortezomib to combat radioresistant glioblastoma", "doi": "10.1038/s41419-025-08083-0", "year": 2025 } ], "bc": [ { "pmid": "36092320", "title": "A phase II trial of gemcitabine and erlotinib followed by ChemoProton therapy plus capecitabine and oxaliplatin for locally advanced pancreatic cancer", "doi": "10.21037/jgo-22-327", "year": 2022 } ] } }, { "id": 4173, "drug": "curcumin", "drug_type": "drug", "drug_domain": "alzheimer", "predicate_ab": "upregulates", "mediator": "BDNF", "mediator_type": "protein", "predicate_bc": "decreases", "outcome": "schizophrenia", "outcome_type": "disease", "outcome_domain": "depression", "score": 0.20794415416798356, "filtered_score": 0.3119162312519753, "filter_reason": "boosted_repurposing", "outreach_score": 0.3119162312519753, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "completed", "clinical_trial_nct_ids": [ "NCT07523256", "NCT02104752", "NCT02298985" ], "literature_status": "reproduces_known", "drug_canonical": "curcumin", "mediator_canonical": "BDNF", "outcome_canonical": "schizophrenia", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "38791161", "title": "Curcumin Improves Neurogenesis in Alzheimer’s Disease Mice via the Upregulation of Wnt/β-Catenin and BDNF", "doi": "10.3390/ijms25105123", "year": 2024 } ], "bc": [ { "pmid": "34280516", "title": "Associations of immunological proteins/traits with schizophrenia, major depression and bipolar disorder: A bi-directional two-sample mendelian randomization study", "doi": "10.1016/j.bbi.2021.07.009", "year": 2021 }, { "pmid": "30794585", "title": "Accuracy of brain-derived neurotrophic factor levels for differentiating between Taiwanese patients with major depressive disorder or schizophrenia and healthy controls", "doi": "10.1371/journal.pone.0212373", "year": 2019 } ] } }, { "id": 32926, "drug": "Curcumin", "drug_type": "drug", "drug_domain": "inflammatory_bowel_disease", "predicate_ab": "upregulates", "mediator": "STAT3", "mediator_type": "protein", "predicate_bc": "prevents", "outcome": "GABAergic neuron loss", "outcome_type": "phenotype", "outcome_domain": "epilepsy", "score": 0.20794415416798356, "filtered_score": 0.3119162312519753, "filter_reason": "boosted_repurposing", "outreach_score": 0.3119162312519753, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "curcumin", "mediator_canonical": "STAT3", "outcome_canonical": "gabaergic neuron loss", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "34931590", "title": "Curcumin Inhibits T Follicular Helper Cell Differentiation in Mice with Dextran Sulfate Sodium (DSS)-Induced Colitis", "doi": "10.1142/s0192415x22500100", "year": 2021 }, { "pmid": "29629345", "title": "Comparative Effects of Curcumin and Tetrahydrocurcumin on Dextran Sulfate Sodium-induced Colitis and Inflammatory Signaling in Mice", "doi": "10.15430/jcp.2018.23.1.18", "year": 2018 }, { "pmid": "27932984", "title": "Curcumin Suppressed Activation of Dendritic Cells via JAK/STAT/SOCS Signal in Mice with Experimental Colitis", "doi": "10.3389/fphar.2016.00455", "year": 2016 } ], "bc": [ { "pmid": "36825472", "title": "Blockage of STAT3 during epileptogenesis prevents GABAergic loss and imprinting of the epileptic state", "doi": "10.1093/brain/awad055", "year": 2023 } ] } }, { "id": 39996, "drug": "resveratrol", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "activates", "mediator": "SIRT1", "mediator_type": "protein", "predicate_bc": "prevents", "outcome": "neuronal cell death", "outcome_type": "phenotype", "outcome_domain": "epilepsy", "score": 0.20794415416798356, "filtered_score": 0.3119162312519753, "filter_reason": "boosted_repurposing", "outreach_score": 0.3119162312519753, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "resveratrol", "mediator_canonical": "SIRT1", "outcome_canonical": "neuronal cell death", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "32808479", "title": "Resveratrol improves sperm DNA quality and reproductive capacity in type 1 diabetes", "doi": "10.1111/andr.12891", "year": 2020 }, { "pmid": "31486447", "title": "The effects of resveratrol on metabolic status in patients with type 2 diabetes mellitus and coronary heart disease", "doi": "10.1039/c9fo01075k", "year": 2019 }, { "pmid": "30621358", "title": "Protective Effect of Resveratrol against Ischemia-Reperfusion Injury via Enhanced High Energy Compounds and eNOS-SIRT1 Expression in Type 2 Diabetic Female Rat Heart", "doi": "10.3390/nu11010105", "year": 2019 } ], "bc": [ { "pmid": "31340436", "title": "Sirtuin 1 Regulates Mitochondrial Biogenesis and Provides an Endogenous Neuroprotective Mechanism Against Seizure-Induced Neuronal Cell Death in the Hippocampus Following Status Epilepticus", "doi": "10.3390/ijms20143588", "year": 2019 } ] } }, { "id": 36870, "drug": "hydroxychloroquine", "drug_type": "drug", "drug_domain": "pancreatic_cancer", "predicate_ab": "inhibits", "mediator": "myeloperoxidase", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "hepatic inflammation", "outcome_type": "phenotype", "outcome_domain": "inflammatory_bowel_disease", "score": 0.20794415416798356, "filtered_score": 0.3119162312519753, "filter_reason": "boosted_repurposing", "outreach_score": 0.3119162312519753, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "hydroxychloroquine", "mediator_canonical": "myeloperoxidase", "outcome_canonical": "hepatic inflammation", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40797324", "title": "Hydroxychloroquine reduces metastatic tumor burden in pancreatic adenocarcinoma through myeloperoxidase inhibition", "doi": "10.1186/s12950-025-00456-8", "year": 2025 } ], "bc": [ { "pmid": "33169705", "title": "Myeloperoxidase and calprotectin; Any role as non-invasive markers for the prediction of ınflammation and fibrosis in non-alcoholic steatohepatitis?", "doi": "10.5152/tjg.2020.19403", "year": 2020 } ] } }, { "id": 40847, "drug": "resveratrol", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "activates", "mediator": "SIRT1", "mediator_type": "protein", "predicate_bc": "increases", "outcome": "tumor-initiating capacity", "outcome_type": "phenotype", "outcome_domain": "pancreatic_cancer", "score": 0.20794415416798356, "filtered_score": 0.3119162312519753, "filter_reason": "boosted_repurposing", "outreach_score": 0.3119162312519753, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "resveratrol", "mediator_canonical": "SIRT1", "outcome_canonical": "tumor-initiating capacity", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "32808479", "title": "Resveratrol improves sperm DNA quality and reproductive capacity in type 1 diabetes", "doi": "10.1111/andr.12891", "year": 2020 }, { "pmid": "31486447", "title": "The effects of resveratrol on metabolic status in patients with type 2 diabetes mellitus and coronary heart disease", "doi": "10.1039/c9fo01075k", "year": 2019 }, { "pmid": "30621358", "title": "Protective Effect of Resveratrol against Ischemia-Reperfusion Injury via Enhanced High Energy Compounds and eNOS-SIRT1 Expression in Type 2 Diabetic Female Rat Heart", "doi": "10.3390/nu11010105", "year": 2019 } ], "bc": [ { "pmid": "34163012", "title": "SIRT1 coordinates with the CRL4B complex to regulate pancreatic cancer stem cells to promote tumorigenesis", "doi": "10.1038/s41418-021-00821-z", "year": 2021 } ] } }, { "id": 8816, "drug": "curcumin", "drug_type": "drug", "drug_domain": "alzheimer", "predicate_ab": "binds_to", "mediator": "TDP-43", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "FTLD", "outcome_type": "disease", "outcome_domain": "als", "score": 0.20794415416798356, "filtered_score": 0.3119162312519753, "filter_reason": "boosted_repurposing", "outreach_score": 0.3119162312519753, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "curcumin", "mediator_canonical": "TDP-43", "outcome_canonical": "ftld", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "30092839", "title": "Different curcumin forms selectively bind fibrillar amyloid beta in post mortem Alzheimer’s disease brains: Implications for in-vivo diagnostics", "doi": "10.1186/s40478-018-0577-2", "year": 2018 } ], "bc": [ { "pmid": "40619651", "title": "TDP-43 Proteinopathies in ALS and FTLD: Mechanistic Insights andTherapeutic Approaches", "doi": "10.2174/0118715273374466250617085832", "year": 2025 }, { "pmid": "31529970", "title": "Using Tetracysteine-Tagged TDP-43 with a Biarsenical Dye To Monitor Real-Time Trafficking in a Cell Model of Amyotrophic Lateral Sclerosis", "doi": "10.1021/acs.biochem.9b00592", "year": 2019 }, { "pmid": "26689008", "title": "[RNA processing TDP-43 protein has a main pathological role in FTLD and ALS].", "doi": null, "year": 2015 } ] } }, { "id": 40996, "drug": "resveratrol", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "activates", "mediator": "SIRT1", "mediator_type": "protein", "predicate_bc": "decreases", "outcome": "TNF-alpha secretion", "outcome_type": "phenotype", "outcome_domain": "rheumatoid_arthritis", "score": 0.20794415416798356, "filtered_score": 0.3119162312519753, "filter_reason": "boosted_repurposing", "outreach_score": 0.3119162312519753, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "resveratrol", "mediator_canonical": "SIRT1", "outcome_canonical": "tnf-alpha secretion", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "32808479", "title": "Resveratrol improves sperm DNA quality and reproductive capacity in type 1 diabetes", "doi": "10.1111/andr.12891", "year": 2020 }, { "pmid": "31486447", "title": "The effects of resveratrol on metabolic status in patients with type 2 diabetes mellitus and coronary heart disease", "doi": "10.1039/c9fo01075k", "year": 2019 }, { "pmid": "30621358", "title": "Protective Effect of Resveratrol against Ischemia-Reperfusion Injury via Enhanced High Energy Compounds and eNOS-SIRT1 Expression in Type 2 Diabetic Female Rat Heart", "doi": "10.3390/nu11010105", "year": 2019 } ], "bc": [ { "pmid": "29784872", "title": "SIRT1 inhibits rheumatoid arthritis fibroblast-like synoviocyte aggressiveness and inflammatory response via suppressing NF-κB pathway", "doi": "10.1042/bsr20180541", "year": 2018 } ] } }, { "id": 33530, "drug": "Curcumin", "drug_type": "drug", "drug_domain": "inflammatory_bowel_disease", "predicate_ab": "upregulates", "mediator": "STAT3", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "pancreatic ductal adenocarcinoma", "outcome_type": "disease", "outcome_domain": "pancreatic_cancer", "score": 0.20794415416798356, "filtered_score": 0.3119162312519753, "filter_reason": "boosted_repurposing", "outreach_score": 0.3119162312519753, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "curcumin", "mediator_canonical": "STAT3", "outcome_canonical": "pancreatic ductal adenocarcinoma", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "34931590", "title": "Curcumin Inhibits T Follicular Helper Cell Differentiation in Mice with Dextran Sulfate Sodium (DSS)-Induced Colitis", "doi": "10.1142/s0192415x22500100", "year": 2021 }, { "pmid": "29629345", "title": "Comparative Effects of Curcumin and Tetrahydrocurcumin on Dextran Sulfate Sodium-induced Colitis and Inflammatory Signaling in Mice", "doi": "10.15430/jcp.2018.23.1.18", "year": 2018 }, { "pmid": "27932984", "title": "Curcumin Suppressed Activation of Dendritic Cells via JAK/STAT/SOCS Signal in Mice with Experimental Colitis", "doi": "10.3389/fphar.2016.00455", "year": 2016 } ], "bc": [ { "pmid": "38464736", "title": "Role of STAT3 in pancreatic cancer", "doi": "10.37349/etat.2024.00202", "year": 2024 } ] } }, { "id": 33113, "drug": "Curcumin", "drug_type": "drug", "drug_domain": "inflammatory_bowel_disease", "predicate_ab": "upregulates", "mediator": "STAT3", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "glioblastoma progression", "outcome_type": "disease", "outcome_domain": "glioblastoma", "score": 0.20794415416798356, "filtered_score": 0.3119162312519753, "filter_reason": "boosted_repurposing", "outreach_score": 0.3119162312519753, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "curcumin", "mediator_canonical": "STAT3", "outcome_canonical": "glioblastoma progression", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "34931590", "title": "Curcumin Inhibits T Follicular Helper Cell Differentiation in Mice with Dextran Sulfate Sodium (DSS)-Induced Colitis", "doi": "10.1142/s0192415x22500100", "year": 2021 }, { "pmid": "29629345", "title": "Comparative Effects of Curcumin and Tetrahydrocurcumin on Dextran Sulfate Sodium-induced Colitis and Inflammatory Signaling in Mice", "doi": "10.15430/jcp.2018.23.1.18", "year": 2018 }, { "pmid": "27932984", "title": "Curcumin Suppressed Activation of Dendritic Cells via JAK/STAT/SOCS Signal in Mice with Experimental Colitis", "doi": "10.3389/fphar.2016.00455", "year": 2016 } ], "bc": [ { "pmid": "41747967", "title": "STAT3 signaling as an adaptive hub in glioblastoma: Network rewiring, non-coding RNA circuits, and therapeutic vulnerabilities", "doi": "10.1016/j.nbd.2026.107330", "year": 2026 } ] } }, { "id": 7054, "drug": "valproic acid", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "downregulates", "mediator": "HDAC3", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "lymph node metastasis", "outcome_type": "disease", "outcome_domain": "pancreatic_cancer", "score": 0.20794415416798356, "filtered_score": 0.3119162312519753, "filter_reason": "boosted_repurposing", "outreach_score": 0.3119162312519753, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "valproic acid", "mediator_canonical": "hdac3", "outcome_canonical": "lymph node metastasis", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "29776446", "title": "Valproic acid attenuates traumatic spinal cord injury-induced inflammation via STAT1 and NF-κB pathway dependent of HDAC3", "doi": "10.1186/s12974-018-1193-6", "year": 2018 }, { "pmid": "29719500", "title": "Valproic Acid Attenuates Traumatic Brain Injury-Induced Inflammation in Vivo: Involvement of Autophagy and the Nrf2/ARE Signaling Pathway", "doi": "10.3389/fnmol.2018.00117", "year": 2018 }, { "pmid": "30127218", "title": "Disruption of Planar Cell Polarity Pathway Attributable to Valproic Acid-Induced Congenital Heart Disease through Hdac3 Participation in Mice", "doi": "10.4103/0366-6999.239311", "year": 2018 } ], "bc": [ { "pmid": "26918727", "title": "Aberrant expression of nuclear HDAC3 and cytoplasmic CDH1 predict a poor prognosis for patients with pancreatic cancer", "doi": "10.18632/oncotarget.7663", "year": 2016 } ] } }, { "id": 40572, "drug": "resveratrol", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "activates", "mediator": "SIRT1", "mediator_type": "protein", "predicate_bc": "treats", "outcome": "rheumatoid arthritis", "outcome_type": "disease", "outcome_domain": "multiple_sclerosis", "score": 0.20794415416798356, "filtered_score": 0.3119162312519753, "filter_reason": "boosted_repurposing", "outreach_score": 0.3119162312519753, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "active", "clinical_trial_nct_ids": [ "NCT07089381" ], "literature_status": "reproduces_known", "drug_canonical": "resveratrol", "mediator_canonical": "SIRT1", "outcome_canonical": "rheumatoid arthritis", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "32808479", "title": "Resveratrol improves sperm DNA quality and reproductive capacity in type 1 diabetes", "doi": "10.1111/andr.12891", "year": 2020 }, { "pmid": "31486447", "title": "The effects of resveratrol on metabolic status in patients with type 2 diabetes mellitus and coronary heart disease", "doi": "10.1039/c9fo01075k", "year": 2019 }, { "pmid": "30621358", "title": "Protective Effect of Resveratrol against Ischemia-Reperfusion Injury via Enhanced High Energy Compounds and eNOS-SIRT1 Expression in Type 2 Diabetic Female Rat Heart", "doi": "10.3390/nu11010105", "year": 2019 } ], "bc": [ { "pmid": "38305342", "title": "Targeting Pathways and Integrated Approaches to Treat Rheumatoid Arthritis", "doi": "10.1615/critrevtherdrugcarriersyst.2023044719", "year": 2023 } ] } }, { "id": 40822, "drug": "resveratrol", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "activates", "mediator": "SIRT1", "mediator_type": "protein", "predicate_bc": "increases", "outcome": "stemness marker expression", "outcome_type": "phenotype", "outcome_domain": "pancreatic_cancer", "score": 0.20794415416798356, "filtered_score": 0.3119162312519753, "filter_reason": "boosted_repurposing", "outreach_score": 0.3119162312519753, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "resveratrol", "mediator_canonical": "SIRT1", "outcome_canonical": "stemness marker expression", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "32808479", "title": "Resveratrol improves sperm DNA quality and reproductive capacity in type 1 diabetes", "doi": "10.1111/andr.12891", "year": 2020 }, { "pmid": "31486447", "title": "The effects of resveratrol on metabolic status in patients with type 2 diabetes mellitus and coronary heart disease", "doi": "10.1039/c9fo01075k", "year": 2019 }, { "pmid": "30621358", "title": "Protective Effect of Resveratrol against Ischemia-Reperfusion Injury via Enhanced High Energy Compounds and eNOS-SIRT1 Expression in Type 2 Diabetic Female Rat Heart", "doi": "10.3390/nu11010105", "year": 2019 } ], "bc": [ { "pmid": "34163012", "title": "SIRT1 coordinates with the CRL4B complex to regulate pancreatic cancer stem cells to promote tumorigenesis", "doi": "10.1038/s41418-021-00821-z", "year": 2021 } ] } }, { "id": 27338, "drug": "hydroxychloroquine", "drug_type": "drug", "drug_domain": "alzheimer", "predicate_ab": "inhibits", "mediator": "STAT3", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "prurigo nodularis", "outcome_type": "disease", "outcome_domain": "rheumatoid_arthritis", "score": 0.20794415416798356, "filtered_score": 0.3119162312519753, "filter_reason": "boosted_repurposing", "outreach_score": 0.3119162312519753, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "hydroxychloroquine", "mediator_canonical": "STAT3", "outcome_canonical": "prurigo nodularis", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "36577843", "title": "Hydroxychloroquine lowers Alzheimer’s disease and related dementias risk and rescues molecular phenotypes related to Alzheimer’s disease", "doi": "10.1038/s41380-022-01912-0", "year": 2022 } ], "bc": [ { "pmid": "39912139", "title": "Translating tissue expression of STAT 1, 3 and 6 in prurigo nodularis to clinical efficacy of oral tofacitinib – A prospective single-arm investigational study", "doi": "10.25259/ijdvl_1017_2024", "year": 2025 }, { "pmid": "40162359", "title": "Successful Use of Tofacitinib in Paediatric Prurigo Nodularis: A Report of Four Cases", "doi": "10.4103/ijd.ijd_842_24", "year": 2025 }, { "pmid": "37521237", "title": "A case of recalcitrant prurigo nodularis with heightened expression of STAT 3 and STAT 6 and its dramatic response to tofacitinib", "doi": "10.4103/idoj.idoj_508_22", "year": 2023 } ] } }, { "id": 50195, "drug": "resveratrol", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "activates", "mediator": "AMPK", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "amyotrophic lateral sclerosis", "outcome_type": "disease", "outcome_domain": "als", "score": 0.20794415416798356, "filtered_score": 0.3119162312519753, "filter_reason": "boosted_repurposing", "outreach_score": 0.3119162312519753, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "36926277", "title": "Resveratrol alleviates high glucose-induced oxidative stress and apoptosis in rat cardiac microvascular endothelial cell through AMPK/Sirt1 activation", "doi": "10.1016/j.bbrep.2023.101444", "year": 2023 }, { "pmid": "35791579", "title": "Resveratrol, novel application by preconditioning to attenuate myocardial ischemia/reperfusion injury in mice through regulate AMPK pathway and autophagy level", "doi": "10.1111/jcmm.17431", "year": 2022 }, { "pmid": "27398147", "title": "Resveratrol attenuated estrogen-deficient-induced cardiac dysfunction: role of AMPK, SIRT1, and mitochondrial function.", "doi": null, "year": 2016 } ], "bc": [ { "pmid": "34393724", "title": "Contribution of Energy Dysfunction to Impaired Protein Translation in Neurodegenerative Diseases", "doi": "10.3389/fncel.2021.668500", "year": 2021 } ] } }, { "id": 31943, "drug": "Flubendazole", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "inhibits", "mediator": "STAT3", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "prurigo nodularis", "outcome_type": "disease", "outcome_domain": "rheumatoid_arthritis", "score": 0.20794415416798356, "filtered_score": 0.3119162312519753, "filter_reason": "boosted_repurposing", "outreach_score": 0.3119162312519753, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "flubendazole", "mediator_canonical": "STAT3", "outcome_canonical": "prurigo nodularis", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37045903", "title": "Flubendazole exhibits anti-glioblastoma effect by inhibiting STAT3 and promoting cell cycle arrest", "doi": "10.1038/s41598-023-33047-9", "year": 2023 } ], "bc": [ { "pmid": "39912139", "title": "Translating tissue expression of STAT 1, 3 and 6 in prurigo nodularis to clinical efficacy of oral tofacitinib – A prospective single-arm investigational study", "doi": "10.25259/ijdvl_1017_2024", "year": 2025 }, { "pmid": "40162359", "title": "Successful Use of Tofacitinib in Paediatric Prurigo Nodularis: A Report of Four Cases", "doi": "10.4103/ijd.ijd_842_24", "year": 2025 }, { "pmid": "37521237", "title": "A case of recalcitrant prurigo nodularis with heightened expression of STAT 3 and STAT 6 and its dramatic response to tofacitinib", "doi": "10.4103/idoj.idoj_508_22", "year": 2023 } ] } }, { "id": 25544, "drug": "niclosamide", "drug_type": "drug", "drug_domain": "als", "predicate_ab": "inhibits", "mediator": "STAT3", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "prurigo nodularis", "outcome_type": "disease", "outcome_domain": "rheumatoid_arthritis", "score": 0.20794415416798356, "filtered_score": 0.3119162312519753, "filter_reason": "boosted_repurposing", "outreach_score": 0.3119162312519753, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "niclosamide", "mediator_canonical": "STAT3", "outcome_canonical": "prurigo nodularis", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "38493058", "title": "Neuroprotective effects of niclosamide on disease progression via inflammatory pathways modulation in SOD1-G93A and FUS-associated amyotrophic lateral sclerosis models", "doi": "10.1016/j.neurot.2024.e00346", "year": 2024 } ], "bc": [ { "pmid": "39912139", "title": "Translating tissue expression of STAT 1, 3 and 6 in prurigo nodularis to clinical efficacy of oral tofacitinib – A prospective single-arm investigational study", "doi": "10.25259/ijdvl_1017_2024", "year": 2025 }, { "pmid": "40162359", "title": "Successful Use of Tofacitinib in Paediatric Prurigo Nodularis: A Report of Four Cases", "doi": "10.4103/ijd.ijd_842_24", "year": 2025 }, { "pmid": "37521237", "title": "A case of recalcitrant prurigo nodularis with heightened expression of STAT 3 and STAT 6 and its dramatic response to tofacitinib", "doi": "10.4103/idoj.idoj_508_22", "year": 2023 } ] } }, { "id": 7053, "drug": "valproic acid", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "downregulates", "mediator": "HDAC3", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "clinical stage", "outcome_type": "disease", "outcome_domain": "pancreatic_cancer", "score": 0.20794415416798356, "filtered_score": 0.3119162312519753, "filter_reason": "boosted_repurposing", "outreach_score": 0.3119162312519753, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "completed", "clinical_trial_nct_ids": [ "NCT02600507", "NCT00395694", "NCT00439673" ], "literature_status": "partial_evidence", "drug_canonical": "valproic acid", "mediator_canonical": "hdac3", "outcome_canonical": "clinical stage", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "29776446", "title": "Valproic acid attenuates traumatic spinal cord injury-induced inflammation via STAT1 and NF-κB pathway dependent of HDAC3", "doi": "10.1186/s12974-018-1193-6", "year": 2018 }, { "pmid": "29719500", "title": "Valproic Acid Attenuates Traumatic Brain Injury-Induced Inflammation in Vivo: Involvement of Autophagy and the Nrf2/ARE Signaling Pathway", "doi": "10.3389/fnmol.2018.00117", "year": 2018 }, { "pmid": "30127218", "title": "Disruption of Planar Cell Polarity Pathway Attributable to Valproic Acid-Induced Congenital Heart Disease through Hdac3 Participation in Mice", "doi": "10.4103/0366-6999.239311", "year": 2018 } ], "bc": [ { "pmid": "26918727", "title": "Aberrant expression of nuclear HDAC3 and cytoplasmic CDH1 predict a poor prognosis for patients with pancreatic cancer", "doi": "10.18632/oncotarget.7663", "year": 2016 } ] } }, { "id": 32925, "drug": "Curcumin", "drug_type": "drug", "drug_domain": "inflammatory_bowel_disease", "predicate_ab": "upregulates", "mediator": "STAT3", "mediator_type": "protein", "predicate_bc": "prevents", "outcome": "imprinting of epileptic activity patterns", "outcome_type": "phenotype", "outcome_domain": "epilepsy", "score": 0.20794415416798356, "filtered_score": 0.3119162312519753, "filter_reason": "boosted_repurposing", "outreach_score": 0.3119162312519753, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "curcumin", "mediator_canonical": "STAT3", "outcome_canonical": "imprinting of epileptic activity patterns", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "34931590", "title": "Curcumin Inhibits T Follicular Helper Cell Differentiation in Mice with Dextran Sulfate Sodium (DSS)-Induced Colitis", "doi": "10.1142/s0192415x22500100", "year": 2021 }, { "pmid": "29629345", "title": "Comparative Effects of Curcumin and Tetrahydrocurcumin on Dextran Sulfate Sodium-induced Colitis and Inflammatory Signaling in Mice", "doi": "10.15430/jcp.2018.23.1.18", "year": 2018 }, { "pmid": "27932984", "title": "Curcumin Suppressed Activation of Dendritic Cells via JAK/STAT/SOCS Signal in Mice with Experimental Colitis", "doi": "10.3389/fphar.2016.00455", "year": 2016 } ], "bc": [ { "pmid": "36825472", "title": "Blockage of STAT3 during epileptogenesis prevents GABAergic loss and imprinting of the epileptic state", "doi": "10.1093/brain/awad055", "year": 2023 } ] } }, { "id": 50981, "drug": "verapamil", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "inhibits", "mediator": "P-glycoprotein", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "multidrug resistance", "outcome_type": "phenotype", "outcome_domain": "glioblastoma", "score": 0.20794415416798356, "filtered_score": 0.3119162312519753, "filter_reason": "boosted_repurposing", "outreach_score": 0.3119162312519753, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "32504272", "title": "Validation of a Drug Transporter Probe Cocktail Using the Prototypical Inhibitors Rifampin, Probenecid, Verapamil, and Cimetidine", "doi": "10.1007/s40262-020-00907-w", "year": 2020 }, { "pmid": "26823559", "title": "Unravelling the complex drug–drug interactions of the cardiovascular drugs, verapamil and digoxin, with P-glycoprotein", "doi": "10.1042/bsr20150317", "year": 2016 } ], "bc": [ { "pmid": "35093870", "title": "Ko143 Reverses MDR in Glioblastoma via Deactivating P-Glycoprotein, Sensitizing a Resistant Phenotype to TMZ Treatment", "doi": "10.21873/anticanres.15530", "year": 2022 } ] } }, { "id": 50984, "drug": "verapamil", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "inhibits", "mediator": "P-glycoprotein", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "temozolomide resistance", "outcome_type": "phenotype", "outcome_domain": "glioblastoma", "score": 0.20794415416798356, "filtered_score": 0.3119162312519753, "filter_reason": "boosted_repurposing", "outreach_score": 0.3119162312519753, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "32504272", "title": "Validation of a Drug Transporter Probe Cocktail Using the Prototypical Inhibitors Rifampin, Probenecid, Verapamil, and Cimetidine", "doi": "10.1007/s40262-020-00907-w", "year": 2020 }, { "pmid": "26823559", "title": "Unravelling the complex drug–drug interactions of the cardiovascular drugs, verapamil and digoxin, with P-glycoprotein", "doi": "10.1042/bsr20150317", "year": 2016 } ], "bc": [ { "pmid": "35093870", "title": "Ko143 Reverses MDR in Glioblastoma via Deactivating P-Glycoprotein, Sensitizing a Resistant Phenotype to TMZ Treatment", "doi": "10.21873/anticanres.15530", "year": 2022 } ] } }, { "id": 51182, "drug": "resveratrol", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "activates", "mediator": "AMPK", "mediator_type": "protein", "predicate_bc": "treats", "outcome": "intestinal inflammation", "outcome_type": "disease", "outcome_domain": "inflammatory_bowel_disease", "score": 0.20794415416798356, "filtered_score": 0.3119162312519753, "filter_reason": "boosted_repurposing", "outreach_score": 0.3119162312519753, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "36926277", "title": "Resveratrol alleviates high glucose-induced oxidative stress and apoptosis in rat cardiac microvascular endothelial cell through AMPK/Sirt1 activation", "doi": "10.1016/j.bbrep.2023.101444", "year": 2023 }, { "pmid": "35791579", "title": "Resveratrol, novel application by preconditioning to attenuate myocardial ischemia/reperfusion injury in mice through regulate AMPK pathway and autophagy level", "doi": "10.1111/jcmm.17431", "year": 2022 }, { "pmid": "27398147", "title": "Resveratrol attenuated estrogen-deficient-induced cardiac dysfunction: role of AMPK, SIRT1, and mitochondrial function.", "doi": null, "year": 2016 } ], "bc": [ { "pmid": "33252129", "title": "Salicylates Ameliorate Intestinal Inflammation by Activating Macrophage AMPK", "doi": "10.1093/ibd/izaa305", "year": 2020 } ] } }, { "id": 36869, "drug": "hydroxychloroquine", "drug_type": "drug", "drug_domain": "pancreatic_cancer", "predicate_ab": "inhibits", "mediator": "myeloperoxidase", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "tissue damage", "outcome_type": "phenotype", "outcome_domain": "inflammatory_bowel_disease", "score": 0.20794415416798356, "filtered_score": 0.3119162312519753, "filter_reason": "boosted_repurposing", "outreach_score": 0.3119162312519753, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "active", "clinical_trial_nct_ids": [ "NCT06887517", "NCT06519617" ], "literature_status": "reproduces_known", "drug_canonical": "hydroxychloroquine", "mediator_canonical": "myeloperoxidase", "outcome_canonical": "tissue damage", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40797324", "title": "Hydroxychloroquine reduces metastatic tumor burden in pancreatic adenocarcinoma through myeloperoxidase inhibition", "doi": "10.1186/s12950-025-00456-8", "year": 2025 } ], "bc": [ { "pmid": "40411448", "title": "Myeloperoxidase Enzyme Activity in Feces Reflects Endoscopic Severity in Inflammatory Bowel Disease", "doi": "10.1093/ibd/izaf109", "year": 2025 } ] } }, { "id": 32923, "drug": "Curcumin", "drug_type": "drug", "drug_domain": "inflammatory_bowel_disease", "predicate_ab": "upregulates", "mediator": "STAT3", "mediator_type": "protein", "predicate_bc": "prevents", "outcome": "persistence of reactive glial states", "outcome_type": "phenotype", "outcome_domain": "epilepsy", "score": 0.20794415416798356, "filtered_score": 0.3119162312519753, "filter_reason": "boosted_repurposing", "outreach_score": 0.3119162312519753, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "curcumin", "mediator_canonical": "STAT3", "outcome_canonical": "persistence of reactive glial states", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "34931590", "title": "Curcumin Inhibits T Follicular Helper Cell Differentiation in Mice with Dextran Sulfate Sodium (DSS)-Induced Colitis", "doi": "10.1142/s0192415x22500100", "year": 2021 }, { "pmid": "29629345", "title": "Comparative Effects of Curcumin and Tetrahydrocurcumin on Dextran Sulfate Sodium-induced Colitis and Inflammatory Signaling in Mice", "doi": "10.15430/jcp.2018.23.1.18", "year": 2018 }, { "pmid": "27932984", "title": "Curcumin Suppressed Activation of Dendritic Cells via JAK/STAT/SOCS Signal in Mice with Experimental Colitis", "doi": "10.3389/fphar.2016.00455", "year": 2016 } ], "bc": [ { "pmid": "36825472", "title": "Blockage of STAT3 during epileptogenesis prevents GABAergic loss and imprinting of the epileptic state", "doi": "10.1093/brain/awad055", "year": 2023 } ] } }, { "id": 57074, "drug": "hydroxychloroquine", "drug_type": "drug", "drug_domain": "pancreatic_cancer", "predicate_ab": "inhibits", "mediator": "myeloperoxidase", "mediator_type": "protein", "predicate_bc": "causes", "outcome": "reperfusion injury", "outcome_type": "disease", "outcome_domain": "heart_failure", "score": 0.20794415416798356, "filtered_score": 0.3119162312519753, "filter_reason": "boosted_repurposing", "outreach_score": 0.3119162312519753, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40797324", "title": "Hydroxychloroquine reduces metastatic tumor burden in pancreatic adenocarcinoma through myeloperoxidase inhibition", "doi": "10.1186/s12950-025-00456-8", "year": 2025 } ], "bc": [ { "pmid": "32517486", "title": "Neutrophil-Mediated Cardiac Damage After Acute Myocardial Infarction: Significance of Defining a New Target Cell Type for Developing Cardioprotective Drugs", "doi": "10.1089/ars.2019.7928", "year": 2020 } ] } }, { "id": 57071, "drug": "hydroxychloroquine", "drug_type": "drug", "drug_domain": "pancreatic_cancer", "predicate_ab": "inhibits", "mediator": "myeloperoxidase", "mediator_type": "protein", "predicate_bc": "causes", "outcome": "atrial fibrillation", "outcome_type": "disease", "outcome_domain": "heart_failure", "score": 0.20794415416798356, "filtered_score": 0.3119162312519753, "filter_reason": "boosted_repurposing", "outreach_score": 0.3119162312519753, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40797324", "title": "Hydroxychloroquine reduces metastatic tumor burden in pancreatic adenocarcinoma through myeloperoxidase inhibition", "doi": "10.1186/s12950-025-00456-8", "year": 2025 } ], "bc": [ { "pmid": "32517486", "title": "Neutrophil-Mediated Cardiac Damage After Acute Myocardial Infarction: Significance of Defining a New Target Cell Type for Developing Cardioprotective Drugs", "doi": "10.1089/ars.2019.7928", "year": 2020 } ] } }, { "id": 57070, "drug": "hydroxychloroquine", "drug_type": "drug", "drug_domain": "pancreatic_cancer", "predicate_ab": "inhibits", "mediator": "myeloperoxidase", "mediator_type": "protein", "predicate_bc": "causes", "outcome": "vascular dysfunction", "outcome_type": "phenotype", "outcome_domain": "heart_failure", "score": 0.20794415416798356, "filtered_score": 0.3119162312519753, "filter_reason": "boosted_repurposing", "outreach_score": 0.3119162312519753, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40797324", "title": "Hydroxychloroquine reduces metastatic tumor burden in pancreatic adenocarcinoma through myeloperoxidase inhibition", "doi": "10.1186/s12950-025-00456-8", "year": 2025 } ], "bc": [ { "pmid": "32517486", "title": "Neutrophil-Mediated Cardiac Damage After Acute Myocardial Infarction: Significance of Defining a New Target Cell Type for Developing Cardioprotective Drugs", "doi": "10.1089/ars.2019.7928", "year": 2020 } ] } }, { "id": 57069, "drug": "hydroxychloroquine", "drug_type": "drug", "drug_domain": "pancreatic_cancer", "predicate_ab": "inhibits", "mediator": "myeloperoxidase", "mediator_type": "protein", "predicate_bc": "causes", "outcome": "adverse ventricular remodeling", "outcome_type": "phenotype", "outcome_domain": "heart_failure", "score": 0.20794415416798356, "filtered_score": 0.3119162312519753, "filter_reason": "boosted_repurposing", "outreach_score": 0.3119162312519753, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40797324", "title": "Hydroxychloroquine reduces metastatic tumor burden in pancreatic adenocarcinoma through myeloperoxidase inhibition", "doi": "10.1186/s12950-025-00456-8", "year": 2025 } ], "bc": [ { "pmid": "32517486", "title": "Neutrophil-Mediated Cardiac Damage After Acute Myocardial Infarction: Significance of Defining a New Target Cell Type for Developing Cardioprotective Drugs", "doi": "10.1089/ars.2019.7928", "year": 2020 } ] } }, { "id": 7262, "drug": "Baicalin", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "upregulates", "mediator": "BDNF", "mediator_type": "protein", "predicate_bc": "decreases", "outcome": "schizophrenia", "outcome_type": "disease", "outcome_domain": "depression", "score": 0.20794415416798356, "filtered_score": 0.3119162312519753, "filter_reason": "boosted_repurposing", "outreach_score": 0.3119162312519753, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "baicalin", "mediator_canonical": "BDNF", "outcome_canonical": "schizophrenia", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "38778616", "title": "Exploring the Therapeutic Potential of Baicalin: Mitigating Anxiety and Depression in Epileptic Rats", "doi": "10.2174/0113862073316021240520110301", "year": 2024 } ], "bc": [ { "pmid": "34280516", "title": "Associations of immunological proteins/traits with schizophrenia, major depression and bipolar disorder: A bi-directional two-sample mendelian randomization study", "doi": "10.1016/j.bbi.2021.07.009", "year": 2021 }, { "pmid": "30794585", "title": "Accuracy of brain-derived neurotrophic factor levels for differentiating between Taiwanese patients with major depressive disorder or schizophrenia and healthy controls", "doi": "10.1371/journal.pone.0212373", "year": 2019 } ] } }, { "id": 57068, "drug": "hydroxychloroquine", "drug_type": "drug", "drug_domain": "pancreatic_cancer", "predicate_ab": "inhibits", "mediator": "myeloperoxidase", "mediator_type": "protein", "predicate_bc": "causes", "outcome": "microvascular endothelial dysfunction", "outcome_type": "phenotype", "outcome_domain": "heart_failure", "score": 0.20794415416798356, "filtered_score": 0.3119162312519753, "filter_reason": "boosted_repurposing", "outreach_score": 0.3119162312519753, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40797324", "title": "Hydroxychloroquine reduces metastatic tumor burden in pancreatic adenocarcinoma through myeloperoxidase inhibition", "doi": "10.1186/s12950-025-00456-8", "year": 2025 } ], "bc": [ { "pmid": "37470101", "title": "Rationale and Design of ENDEAVOR: A Sequential Phase 2b–3 Randomized Clinical Trial to Evaluate the Effect of Myeloperoxidase Inhibition on Symptoms and Exercise Capacity in Heart Failure with Preserved or Mildly Reduced Ejection Fraction", "doi": "10.1002/ejhf.2977", "year": 2023 } ] } }, { "id": 33524, "drug": "Curcumin", "drug_type": "drug", "drug_domain": "inflammatory_bowel_disease", "predicate_ab": "upregulates", "mediator": "STAT3", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "immune escape", "outcome_type": "phenotype", "outcome_domain": "pancreatic_cancer", "score": 0.20794415416798356, "filtered_score": 0.3119162312519753, "filter_reason": "boosted_repurposing", "outreach_score": 0.3119162312519753, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "curcumin", "mediator_canonical": "STAT3", "outcome_canonical": "immune escape", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "34931590", "title": "Curcumin Inhibits T Follicular Helper Cell Differentiation in Mice with Dextran Sulfate Sodium (DSS)-Induced Colitis", "doi": "10.1142/s0192415x22500100", "year": 2021 }, { "pmid": "29629345", "title": "Comparative Effects of Curcumin and Tetrahydrocurcumin on Dextran Sulfate Sodium-induced Colitis and Inflammatory Signaling in Mice", "doi": "10.15430/jcp.2018.23.1.18", "year": 2018 }, { "pmid": "27932984", "title": "Curcumin Suppressed Activation of Dendritic Cells via JAK/STAT/SOCS Signal in Mice with Experimental Colitis", "doi": "10.3389/fphar.2016.00455", "year": 2016 } ], "bc": [ { "pmid": "38464736", "title": "Role of STAT3 in pancreatic cancer", "doi": "10.37349/etat.2024.00202", "year": 2024 } ] } }, { "id": 57067, "drug": "hydroxychloroquine", "drug_type": "drug", "drug_domain": "pancreatic_cancer", "predicate_ab": "inhibits", "mediator": "myeloperoxidase", "mediator_type": "protein", "predicate_bc": "causes", "outcome": "cardiomyocyte remodelling", "outcome_type": "phenotype", "outcome_domain": "heart_failure", "score": 0.20794415416798356, "filtered_score": 0.3119162312519753, "filter_reason": "boosted_repurposing", "outreach_score": 0.3119162312519753, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40797324", "title": "Hydroxychloroquine reduces metastatic tumor burden in pancreatic adenocarcinoma through myeloperoxidase inhibition", "doi": "10.1186/s12950-025-00456-8", "year": 2025 } ], "bc": [ { "pmid": "37470101", "title": "Rationale and Design of ENDEAVOR: A Sequential Phase 2b–3 Randomized Clinical Trial to Evaluate the Effect of Myeloperoxidase Inhibition on Symptoms and Exercise Capacity in Heart Failure with Preserved or Mildly Reduced Ejection Fraction", "doi": "10.1002/ejhf.2977", "year": 2023 } ] } }, { "id": 8395, "drug": "metformin", "drug_type": "drug", "drug_domain": "alzheimer", "predicate_ab": "inhibits", "mediator": "mTOR", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "glioblastoma", "outcome_type": "disease", "outcome_domain": "glioblastoma", "score": 0.20794415416798356, "filtered_score": 0.3119162312519753, "filter_reason": "boosted_repurposing", "outreach_score": 0.3119162312519753, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "active", "clinical_trial_nct_ids": [ "NCT03243851", "NCT04945148", "NCT05929495" ], "literature_status": "reproduces_known", "drug_canonical": "metformin", "mediator_canonical": "mTOR", "outcome_canonical": "glioblastoma", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "34432352", "title": "Pretreatment with metformin prevents microcystin‐LR‐induced tau hyperphosphorylation via mTOR‐dependent PP2A and GSK‐3β activation", "doi": "10.1002/tox.23354", "year": 2021 } ], "bc": [ { "pmid": "39622049", "title": "A Dual-Target and Dual-Mechanism Design Strategy by Combining Inhibition and Degradation Together", "doi": "10.1021/jacs.4c11930", "year": 2024 }, { "pmid": "33162811", "title": "Mitochondrial dysfunction contributes to Rapamycin-induced apoptosis of Human Glioblastoma Cells - A synergistic effect with Temozolomide", "doi": "10.7150/ijms.40159", "year": 2020 }, { "pmid": "30793789", "title": "The effect of the mTOR inhibitor rapamycin on glucoCEST signal in a preclinical model of glioblastoma", "doi": "10.1002/mrm.27683", "year": 2019 } ] } }, { "id": 39045, "drug": "resveratrol", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "binds_to", "mediator": "EGFR", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "pancreatic ductal adenocarcinoma", "outcome_type": "disease", "outcome_domain": "pancreatic_cancer", "score": 0.20794415416798356, "filtered_score": 0.3119162312519753, "filter_reason": "boosted_repurposing", "outreach_score": 0.3119162312519753, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "resveratrol", "mediator_canonical": "EGFR", "outcome_canonical": "pancreatic ductal adenocarcinoma", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40993911", "title": "Therapeutic Targeting of Apoptosis‐Driven Inflammation in Rheumatoid Arthritis: A Biochemical and Molecular Modeling Approach Using Plant‐Derived Compounds", "doi": "10.1111/1756-185x.70423", "year": 2025 } ], "bc": [ { "pmid": "40130819", "title": "Identification of Tumor‐Specific Surface Proteins Enables Quantification of Extracellular Vesicle Subtypes for Early Detection of Pancreatic Ductal Adenocarcinoma", "doi": "10.1002/advs.202414982", "year": 2025 }, { "pmid": "31584260", "title": "Design and Evaluation of PEGylated Liposomal Formulation of a Novel Multikinase Inhibitor for Enhanced Chemosensitivity and Inhibition of Metastatic Pancreatic Ductal Adenocarcinoma", "doi": "10.1021/acs.bioconjchem.9b00632", "year": 2019 }, { "pmid": "26339400", "title": "EGFR expression in pancreatic intraepithelial neoplasia and ductal adenocarcinoma.", "doi": null, "year": 2015 } ] } }, { "id": 2903, "drug": "niclosamide", "drug_type": "drug", "drug_domain": "als", "predicate_ab": "inhibits", "mediator": "mTOR", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "glioblastoma", "outcome_type": "disease", "outcome_domain": "glioblastoma", "score": 0.20794415416798356, "filtered_score": 0.3119162312519753, "filter_reason": "boosted_repurposing", "outreach_score": 0.3119162312519753, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "niclosamide", "mediator_canonical": "mTOR", "outcome_canonical": "glioblastoma", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "38493058", "title": "Neuroprotective effects of niclosamide on disease progression via inflammatory pathways modulation in SOD1-G93A and FUS-associated amyotrophic lateral sclerosis models", "doi": "10.1016/j.neurot.2024.e00346", "year": 2024 } ], "bc": [ { "pmid": "39622049", "title": "A Dual-Target and Dual-Mechanism Design Strategy by Combining Inhibition and Degradation Together", "doi": "10.1021/jacs.4c11930", "year": 2024 }, { "pmid": "33162811", "title": "Mitochondrial dysfunction contributes to Rapamycin-induced apoptosis of Human Glioblastoma Cells - A synergistic effect with Temozolomide", "doi": "10.7150/ijms.40159", "year": 2020 }, { "pmid": "30793789", "title": "The effect of the mTOR inhibitor rapamycin on glucoCEST signal in a preclinical model of glioblastoma", "doi": "10.1002/mrm.27683", "year": 2019 } ] } }, { "id": 50781, "drug": "verapamil", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "inhibits", "mediator": "P-glycoprotein", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "drug-resistant epilepsy", "outcome_type": "disease", "outcome_domain": "epilepsy", "score": 0.20794415416798356, "filtered_score": 0.3119162312519753, "filter_reason": "boosted_repurposing", "outreach_score": 0.3119162312519753, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "32504272", "title": "Validation of a Drug Transporter Probe Cocktail Using the Prototypical Inhibitors Rifampin, Probenecid, Verapamil, and Cimetidine", "doi": "10.1007/s40262-020-00907-w", "year": 2020 }, { "pmid": "26823559", "title": "Unravelling the complex drug–drug interactions of the cardiovascular drugs, verapamil and digoxin, with P-glycoprotein", "doi": "10.1042/bsr20150317", "year": 2016 } ], "bc": [ { "pmid": "32627849", "title": "P‐glycoprotein overactivity in epileptogenic developmental lesions measured in vivo using (R)‐[11C]verapamil PET", "doi": "10.1111/epi.16581", "year": 2020 } ] } }, { "id": 51176, "drug": "resveratrol", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "activates", "mediator": "AMPK", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "intestinal epithelial repair", "outcome_type": "phenotype", "outcome_domain": "inflammatory_bowel_disease", "score": 0.20794415416798356, "filtered_score": 0.3119162312519753, "filter_reason": "boosted_repurposing", "outreach_score": 0.3119162312519753, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "36926277", "title": "Resveratrol alleviates high glucose-induced oxidative stress and apoptosis in rat cardiac microvascular endothelial cell through AMPK/Sirt1 activation", "doi": "10.1016/j.bbrep.2023.101444", "year": 2023 }, { "pmid": "35791579", "title": "Resveratrol, novel application by preconditioning to attenuate myocardial ischemia/reperfusion injury in mice through regulate AMPK pathway and autophagy level", "doi": "10.1111/jcmm.17431", "year": 2022 }, { "pmid": "27398147", "title": "Resveratrol attenuated estrogen-deficient-induced cardiac dysfunction: role of AMPK, SIRT1, and mitochondrial function.", "doi": null, "year": 2016 } ], "bc": [ { "pmid": "35203241", "title": "Intestinal Epithelial AMPK Deficiency Causes Delayed Colonic Epithelial Repair in DSS-Induced Colitis", "doi": "10.3390/cells11040590", "year": 2022 } ] } }, { "id": 57065, "drug": "hydroxychloroquine", "drug_type": "drug", "drug_domain": "pancreatic_cancer", "predicate_ab": "inhibits", "mediator": "myeloperoxidase", "mediator_type": "protein", "predicate_bc": "causes", "outcome": "oxidative stress", "outcome_type": "phenotype", "outcome_domain": "heart_failure", "score": 0.20794415416798356, "filtered_score": 0.3119162312519753, "filter_reason": "boosted_repurposing", "outreach_score": 0.3119162312519753, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40797324", "title": "Hydroxychloroquine reduces metastatic tumor burden in pancreatic adenocarcinoma through myeloperoxidase inhibition", "doi": "10.1186/s12950-025-00456-8", "year": 2025 } ], "bc": [ { "pmid": "37470101", "title": "Rationale and Design of ENDEAVOR: A Sequential Phase 2b–3 Randomized Clinical Trial to Evaluate the Effect of Myeloperoxidase Inhibition on Symptoms and Exercise Capacity in Heart Failure with Preserved or Mildly Reduced Ejection Fraction", "doi": "10.1002/ejhf.2977", "year": 2023 } ] } }, { "id": 36864, "drug": "hydroxychloroquine", "drug_type": "drug", "drug_domain": "pancreatic_cancer", "predicate_ab": "inhibits", "mediator": "myeloperoxidase", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "fibrosis", "outcome_type": "disease", "outcome_domain": "inflammatory_bowel_disease", "score": 0.20794415416798356, "filtered_score": 0.3119162312519753, "filter_reason": "boosted_repurposing", "outreach_score": 0.3119162312519753, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "completed", "clinical_trial_nct_ids": [ "NCT01495403", "NCT00311883" ], "literature_status": "reproduces_known", "drug_canonical": "hydroxychloroquine", "mediator_canonical": "myeloperoxidase", "outcome_canonical": "fibrosis", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40797324", "title": "Hydroxychloroquine reduces metastatic tumor burden in pancreatic adenocarcinoma through myeloperoxidase inhibition", "doi": "10.1186/s12950-025-00456-8", "year": 2025 } ], "bc": [ { "pmid": "33169705", "title": "Myeloperoxidase and calprotectin; Any role as non-invasive markers for the prediction of ınflammation and fibrosis in non-alcoholic steatohepatitis?", "doi": "10.5152/tjg.2020.19403", "year": 2020 } ] } }, { "id": 36873, "drug": "hydroxychloroquine", "drug_type": "drug", "drug_domain": "pancreatic_cancer", "predicate_ab": "inhibits", "mediator": "myeloperoxidase", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "NASH", "outcome_type": "disease", "outcome_domain": "inflammatory_bowel_disease", "score": 0.20794415416798356, "filtered_score": 0.3119162312519753, "filter_reason": "boosted_repurposing", "outreach_score": 0.3119162312519753, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "active", "clinical_trial_nct_ids": [ "NCT07265297", "NCT05733897" ], "literature_status": "partial_evidence", "drug_canonical": "hydroxychloroquine", "mediator_canonical": "myeloperoxidase", "outcome_canonical": "nash", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40797324", "title": "Hydroxychloroquine reduces metastatic tumor burden in pancreatic adenocarcinoma through myeloperoxidase inhibition", "doi": "10.1186/s12950-025-00456-8", "year": 2025 } ], "bc": [ { "pmid": "33169705", "title": "Myeloperoxidase and calprotectin; Any role as non-invasive markers for the prediction of ınflammation and fibrosis in non-alcoholic steatohepatitis?", "doi": "10.5152/tjg.2020.19403", "year": 2020 } ] } }, { "id": 50783, "drug": "resveratrol", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "activates", "mediator": "AMPK", "mediator_type": "protein", "predicate_bc": "increases", "outcome": "spike-wave seizures", "outcome_type": "phenotype", "outcome_domain": "epilepsy", "score": 0.20794415416798356, "filtered_score": 0.3119162312519753, "filter_reason": "boosted_repurposing", "outreach_score": 0.3119162312519753, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "36926277", "title": "Resveratrol alleviates high glucose-induced oxidative stress and apoptosis in rat cardiac microvascular endothelial cell through AMPK/Sirt1 activation", "doi": "10.1016/j.bbrep.2023.101444", "year": 2023 }, { "pmid": "35791579", "title": "Resveratrol, novel application by preconditioning to attenuate myocardial ischemia/reperfusion injury in mice through regulate AMPK pathway and autophagy level", "doi": "10.1111/jcmm.17431", "year": 2022 }, { "pmid": "27398147", "title": "Resveratrol attenuated estrogen-deficient-induced cardiac dysfunction: role of AMPK, SIRT1, and mitochondrial function.", "doi": null, "year": 2016 } ], "bc": [ { "pmid": "35134125", "title": "AMPK-mediated potentiation of GABAergic signalling drives hypoglycaemia-provoked spike-wave seizures", "doi": "10.1093/brain/awac037", "year": 2022 } ] } }, { "id": 50785, "drug": "resveratrol", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "activates", "mediator": "AMPK", "mediator_type": "protein", "predicate_bc": "increases", "outcome": "epileptiform network activity", "outcome_type": "phenotype", "outcome_domain": "epilepsy", "score": 0.20794415416798356, "filtered_score": 0.3119162312519753, "filter_reason": "boosted_repurposing", "outreach_score": 0.3119162312519753, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "36926277", "title": "Resveratrol alleviates high glucose-induced oxidative stress and apoptosis in rat cardiac microvascular endothelial cell through AMPK/Sirt1 activation", "doi": "10.1016/j.bbrep.2023.101444", "year": 2023 }, { "pmid": "35791579", "title": "Resveratrol, novel application by preconditioning to attenuate myocardial ischemia/reperfusion injury in mice through regulate AMPK pathway and autophagy level", "doi": "10.1111/jcmm.17431", "year": 2022 }, { "pmid": "27398147", "title": "Resveratrol attenuated estrogen-deficient-induced cardiac dysfunction: role of AMPK, SIRT1, and mitochondrial function.", "doi": null, "year": 2016 } ], "bc": [ { "pmid": "35134125", "title": "AMPK-mediated potentiation of GABAergic signalling drives hypoglycaemia-provoked spike-wave seizures", "doi": "10.1093/brain/awac037", "year": 2022 } ] } }, { "id": 50787, "drug": "verapamil", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "inhibits", "mediator": "P-glycoprotein", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "SUDEP", "outcome_type": "disease", "outcome_domain": "epilepsy", "score": 0.20794415416798356, "filtered_score": 0.3119162312519753, "filter_reason": "boosted_repurposing", "outreach_score": 0.3119162312519753, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "32504272", "title": "Validation of a Drug Transporter Probe Cocktail Using the Prototypical Inhibitors Rifampin, Probenecid, Verapamil, and Cimetidine", "doi": "10.1007/s40262-020-00907-w", "year": 2020 }, { "pmid": "26823559", "title": "Unravelling the complex drug–drug interactions of the cardiovascular drugs, verapamil and digoxin, with P-glycoprotein", "doi": "10.1042/bsr20150317", "year": 2016 } ], "bc": [ { "pmid": "29462915", "title": "Pilocarpine-Induced Status Epilepticus Is Associated with P-Glycoprotein Induction in Cardiomyocytes, Electrocardiographic Changes, and Sudden Death", "doi": "10.3390/ph11010021", "year": 2018 } ] } }, { "id": 50789, "drug": "verapamil", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "inhibits", "mediator": "P-glycoprotein", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "QT interval prolongation", "outcome_type": "phenotype", "outcome_domain": "epilepsy", "score": 0.20794415416798356, "filtered_score": 0.3119162312519753, "filter_reason": "boosted_repurposing", "outreach_score": 0.3119162312519753, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "32504272", "title": "Validation of a Drug Transporter Probe Cocktail Using the Prototypical Inhibitors Rifampin, Probenecid, Verapamil, and Cimetidine", "doi": "10.1007/s40262-020-00907-w", "year": 2020 }, { "pmid": "26823559", "title": "Unravelling the complex drug–drug interactions of the cardiovascular drugs, verapamil and digoxin, with P-glycoprotein", "doi": "10.1042/bsr20150317", "year": 2016 } ], "bc": [ { "pmid": "29462915", "title": "Pilocarpine-Induced Status Epilepticus Is Associated with P-Glycoprotein Induction in Cardiomyocytes, Electrocardiographic Changes, and Sudden Death", "doi": "10.3390/ph11010021", "year": 2018 } ] } }, { "id": 53878, "drug": "Curcumin", "drug_type": "drug", "drug_domain": "inflammatory_bowel_disease", "predicate_ab": "upregulates", "mediator": "STAT3", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "arthritis", "outcome_type": "disease", "outcome_domain": "rheumatoid_arthritis", "score": 0.20794415416798356, "filtered_score": 0.3119162312519753, "filter_reason": "boosted_repurposing", "outreach_score": 0.3119162312519753, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "34931590", "title": "Curcumin Inhibits T Follicular Helper Cell Differentiation in Mice with Dextran Sulfate Sodium (DSS)-Induced Colitis", "doi": "10.1142/s0192415x22500100", "year": 2021 }, { "pmid": "29629345", "title": "Comparative Effects of Curcumin and Tetrahydrocurcumin on Dextran Sulfate Sodium-induced Colitis and Inflammatory Signaling in Mice", "doi": "10.15430/jcp.2018.23.1.18", "year": 2018 }, { "pmid": "27932984", "title": "Curcumin Suppressed Activation of Dendritic Cells via JAK/STAT/SOCS Signal in Mice with Experimental Colitis", "doi": "10.3389/fphar.2016.00455", "year": 2016 } ], "bc": [ { "pmid": "36368156", "title": "The Stat3 inhibitor F0648-0027 is a potential therapeutic against rheumatoid arthritis", "doi": "10.1016/j.bbrc.2022.10.106", "year": 2022 } ] } }, { "id": 33539, "drug": "Curcumin", "drug_type": "drug", "drug_domain": "inflammatory_bowel_disease", "predicate_ab": "upregulates", "mediator": "STAT3", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "pancreatic cancer", "outcome_type": "disease", "outcome_domain": "pancreatic_cancer", "score": 0.20794415416798356, "filtered_score": 0.3119162312519753, "filter_reason": "boosted_repurposing", "outreach_score": 0.3119162312519753, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "completed", "clinical_trial_nct_ids": [ "NCT00094445", "NCT00192842", "NCT00486460" ], "literature_status": "reproduces_known", "drug_canonical": "curcumin", "mediator_canonical": "STAT3", "outcome_canonical": "pancreatic cancer", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "34931590", "title": "Curcumin Inhibits T Follicular Helper Cell Differentiation in Mice with Dextran Sulfate Sodium (DSS)-Induced Colitis", "doi": "10.1142/s0192415x22500100", "year": 2021 }, { "pmid": "29629345", "title": "Comparative Effects of Curcumin and Tetrahydrocurcumin on Dextran Sulfate Sodium-induced Colitis and Inflammatory Signaling in Mice", "doi": "10.15430/jcp.2018.23.1.18", "year": 2018 }, { "pmid": "27932984", "title": "Curcumin Suppressed Activation of Dendritic Cells via JAK/STAT/SOCS Signal in Mice with Experimental Colitis", "doi": "10.3389/fphar.2016.00455", "year": 2016 } ], "bc": [ { "pmid": "26873728", "title": "Applying Small Molecule Signal Transducer and Activator of Transcription-3 (STAT3) Protein Inhibitors as Pancreatic Cancer Therapeutics", "doi": "10.1158/1535-7163.mct-15-0003", "year": 2016 } ] } }, { "id": 1380, "drug": "osimertinib", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "inhibits", "mediator": "EGFR", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "Alzheimer's disease", "outcome_type": "disease", "outcome_domain": "alzheimer", "score": 0.20794415416798356, "filtered_score": 0.3119162312519753, "filter_reason": "boosted_repurposing", "outreach_score": 0.3119162312519753, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "osimertinib", "mediator_canonical": "EGFR", "outcome_canonical": "Alzheimer disease", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40719865", "title": "Resistance of recurrent epidermal growth factor receptor-altered glioblastoma to anti-epidermal growth factor receptor targeted therapy with osimertinib", "doi": "10.1093/oncolo/oyaf146", "year": 2025 }, { "pmid": "40051661", "title": "A comparative study of preclinical and clinical molecular imaging response to EGFR inhibition using osimertinib in glioblastoma", "doi": "10.1093/noajnl/vdaf022", "year": 2025 }, { "pmid": "41120287", "title": "GSCs differentiation model-informed nanotherapy: dual-functional brain-targeting liposomes with iRGD modification for co-delivery of osimertinib and bortezomib to combat radioresistant glioblastoma", "doi": "10.1038/s41419-025-08083-0", "year": 2025 } ], "bc": [ { "pmid": "39252463", "title": "Plasma proteomics for risk prediction of Alzheimer's disease in the general population", "doi": "10.1111/acel.14330", "year": 2024 } ] } }, { "id": 39418, "drug": "resveratrol", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "activates", "mediator": "SIRT1", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "overexpression", "outcome_type": "phenotype", "outcome_domain": "als", "score": 0.20794415416798356, "filtered_score": 0.3119162312519753, "filter_reason": "boosted_repurposing", "outreach_score": 0.3119162312519753, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "resveratrol", "mediator_canonical": "SIRT1", "outcome_canonical": "overexpression", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "32808479", "title": "Resveratrol improves sperm DNA quality and reproductive capacity in type 1 diabetes", "doi": "10.1111/andr.12891", "year": 2020 }, { "pmid": "31486447", "title": "The effects of resveratrol on metabolic status in patients with type 2 diabetes mellitus and coronary heart disease", "doi": "10.1039/c9fo01075k", "year": 2019 }, { "pmid": "30621358", "title": "Protective Effect of Resveratrol against Ischemia-Reperfusion Injury via Enhanced High Energy Compounds and eNOS-SIRT1 Expression in Type 2 Diabetic Female Rat Heart", "doi": "10.3390/nu11010105", "year": 2019 } ], "bc": [ { "pmid": "35448021", "title": "SIRT1 Interacts with Prepro-Orexin in the Hypothalamus in SOD1G93A Mice", "doi": "10.3390/brainsci12040490", "year": 2022 } ] } }, { "id": 39628, "drug": "resveratrol", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "activates", "mediator": "SIRT1", "mediator_type": "protein", "predicate_bc": "decreases", "outcome": "tau acetylation", "outcome_type": "phenotype", "outcome_domain": "alzheimer", "score": 0.20794415416798356, "filtered_score": 0.3119162312519753, "filter_reason": "boosted_repurposing", "outreach_score": 0.3119162312519753, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "resveratrol", "mediator_canonical": "SIRT1", "outcome_canonical": "tau acetylation", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "32808479", "title": "Resveratrol improves sperm DNA quality and reproductive capacity in type 1 diabetes", "doi": "10.1111/andr.12891", "year": 2020 }, { "pmid": "31486447", "title": "The effects of resveratrol on metabolic status in patients with type 2 diabetes mellitus and coronary heart disease", "doi": "10.1039/c9fo01075k", "year": 2019 }, { "pmid": "30621358", "title": "Protective Effect of Resveratrol against Ischemia-Reperfusion Injury via Enhanced High Energy Compounds and eNOS-SIRT1 Expression in Type 2 Diabetic Female Rat Heart", "doi": "10.3390/nu11010105", "year": 2019 } ], "bc": [ { "pmid": "29540553", "title": "SIRT1 Deacetylates Tau and Reduces Pathogenic Tau Spread in a Mouse Model of Tauopathy", "doi": "10.1523/jneurosci.2369-17.2018", "year": 2018 } ] } }, { "id": 60971, "drug": "pioglitazone", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "activates", "mediator": "PPARγ", "mediator_type": "protein", "predicate_bc": "decreases", "outcome": "interstitial fibrosis", "outcome_type": "disease", "outcome_domain": "heart_failure", "score": 0.3091042453358316, "filtered_score": 0.3091042453358316, "filter_reason": null, "outreach_score": 0.3091042453358316, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 10, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40320521", "title": "The anti-diabetic PPARγ agonist Pioglitazone inhibits cell proliferation and induces metabolic reprogramming in prostate cancer", "doi": "10.1186/s12943-025-02320-y", "year": 2025 }, { "pmid": "32215295", "title": "Pioglitazone ameliorates neuronal damage after traumatic brain injury via the PPARγ/NF-κB/IL-6 signaling pathway", "doi": "10.1016/j.gendis.2019.05.002", "year": 2019 }, { "pmid": "31548602", "title": "Pioglitazone attenuates kidney injury in an experimental model of gentamicin-induced nephrotoxicity in rats", "doi": "10.1038/s41598-019-49835-1", "year": 2019 } ], "bc": [ { "pmid": "25633415", "title": "Activation of Peroxisome Proliferator-Activated Receptor γ (PPARγ) Through NF-κB/Brg1 and TGF-ß1 Pathways Attenuates Cardiac Remodeling in Pressure-Overloaded Rat Hearts", "doi": "10.1159/000369747", "year": 2015 } ] } }, { "id": 40765, "drug": "Canagliflozin", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "activates", "mediator": "AMPK", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "pancreatic cancer progression", "outcome_type": "disease", "outcome_domain": "pancreatic_cancer", "score": 0.29957322735539915, "filtered_score": 0.29957322735539915, "filter_reason": null, "outreach_score": 0.29957322735539915, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "canagliflozin", "mediator_canonical": "AMPK", "outcome_canonical": "pancreatic cancer progression", "ab_count": 9, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37584455", "title": "Canagliflozin mediates tumor suppression alone and in combination with radiotherapy in non‐small cell lung cancer (NSCLC) through inhibition of HIF‐1α", "doi": "10.1002/1878-0261.13508", "year": 2023 }, { "pmid": "37247463", "title": "Canagliflozin mitigates carfilzomib-induced endothelial apoptosis via an AMPK-dependent pathway", "doi": "10.1016/j.biopha.2023.114907", "year": 2023 }, { "pmid": "36583437", "title": "Canagliflozin Improves Myocardial Perfusion, Fibrosis, and Function in a Swine Model of Chronic Myocardial Ischemia", "doi": "10.1161/jaha.122.028623", "year": 2022 } ], "bc": [ { "pmid": "31205544", "title": "AMPK Inhibition Suppresses the Malignant Phenotype of Pancreatic Cancer Cells in Part by Attenuating Aerobic Glycolysis", "doi": "10.7150/jca.28299", "year": 2019 } ] } }, { "id": 40772, "drug": "Canagliflozin", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "activates", "mediator": "AMPK", "mediator_type": "protein", "predicate_bc": "decreases", "outcome": "invasion", "outcome_type": "phenotype", "outcome_domain": "pancreatic_cancer", "score": 0.29957322735539915, "filtered_score": 0.29957322735539915, "filter_reason": null, "outreach_score": 0.29957322735539915, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "canagliflozin", "mediator_canonical": "AMPK", "outcome_canonical": "invasion", "ab_count": 9, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37584455", "title": "Canagliflozin mediates tumor suppression alone and in combination with radiotherapy in non‐small cell lung cancer (NSCLC) through inhibition of HIF‐1α", "doi": "10.1002/1878-0261.13508", "year": 2023 }, { "pmid": "37247463", "title": "Canagliflozin mitigates carfilzomib-induced endothelial apoptosis via an AMPK-dependent pathway", "doi": "10.1016/j.biopha.2023.114907", "year": 2023 }, { "pmid": "36583437", "title": "Canagliflozin Improves Myocardial Perfusion, Fibrosis, and Function in a Swine Model of Chronic Myocardial Ischemia", "doi": "10.1161/jaha.122.028623", "year": 2022 } ], "bc": [ { "pmid": "28783244", "title": "Loss of AMPK activation promotes the invasion and metastasis of pancreatic cancer through an HSF1‐dependent pathway", "doi": "10.1002/1878-0261.12116", "year": 2017 } ] } }, { "id": 7049, "drug": "carbamazepine", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "binds_to", "mediator": "KRAS", "mediator_type": "gene", "predicate_bc": "associated_with", "outcome": "pancreatic ductal adenocarcinoma", "outcome_type": "disease", "outcome_domain": "pancreatic_cancer", "score": 0.29957322735539915, "filtered_score": 0.29957322735539915, "filter_reason": null, "outreach_score": 0.29957322735539915, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "carbamazepine", "mediator_canonical": "kras", "outcome_canonical": "pancreatic ductal adenocarcinoma", "ab_count": 1, "bc_count": 9, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "38446332", "title": "Impact of carbamazepine on SMARCA4 (BRG1) expression in colorectal cancer: modulation by KRAS mutation status", "doi": "10.1007/s10637-024-01418-2", "year": 2024 } ], "bc": [ { "pmid": "39999309", "title": "Somatic Genomic Profiling of Pancreatic Ductal Adenocarcinomas From a Diverse Cohort of Patients", "doi": "10.1097/mpa.0000000000002408", "year": 2025 }, { "pmid": "39279379", "title": "Hope on the Horizon: A Revolution in KRAS Inhibition Is Creating a New Treatment Paradigm for Patients with Pancreatic Cancer", "doi": "10.1158/0008-5472.can-24-1926", "year": 2024 }, { "pmid": "35511415", "title": "Comprehensive molecular profiling of pancreatic ductal adenocarcinoma in FNA, biopsy, and resection specimens", "doi": "10.1002/cncy.22589", "year": 2022 } ] } }, { "id": 40762, "drug": "Canagliflozin", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "inhibits", "mediator": "SGLT2", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "pancreatic adenocarcinoma", "outcome_type": "disease", "outcome_domain": "pancreatic_cancer", "score": 0.29957322735539915, "filtered_score": 0.29957322735539915, "filter_reason": null, "outreach_score": 0.29957322735539915, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "canagliflozin", "mediator_canonical": "sglt2", "outcome_canonical": "pancreatic adenocarcinoma", "ab_count": 9, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "33480065", "title": "Inhibition of the sodium–glucose co‐transporter SGLT2 by canagliflozin ameliorates diet‐induced obesity by increasing intra‐adipose sympathetic innervation", "doi": "10.1111/bph.15381", "year": 2021 }, { "pmid": "32387022", "title": "Osmotic Nephrosis and Acute Kidney Injury Associated With SGLT2 Inhibitor Use: A Case Report", "doi": "10.1053/j.ajkd.2020.01.015", "year": 2020 }, { "pmid": "31143117", "title": "Cost-Effectiveness of Canagliflozin Versus Dapagliflozin Added to Metformin in Patients With Type 2 Diabetes in China", "doi": "10.3389/fphar.2019.00480", "year": 2019 } ], "bc": [ { "pmid": "26170283", "title": "Functional expression of sodium-glucose transporters in cancer", "doi": "10.1073/pnas.1511698112", "year": 2015 } ] } }, { "id": 40763, "drug": "Canagliflozin", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "activates", "mediator": "AMPK", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "pancreatic ductal adenocarcinoma", "outcome_type": "disease", "outcome_domain": "pancreatic_cancer", "score": 0.29957322735539915, "filtered_score": 0.29957322735539915, "filter_reason": null, "outreach_score": 0.29957322735539915, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "canagliflozin", "mediator_canonical": "AMPK", "outcome_canonical": "pancreatic ductal adenocarcinoma", "ab_count": 9, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37584455", "title": "Canagliflozin mediates tumor suppression alone and in combination with radiotherapy in non‐small cell lung cancer (NSCLC) through inhibition of HIF‐1α", "doi": "10.1002/1878-0261.13508", "year": 2023 }, { "pmid": "37247463", "title": "Canagliflozin mitigates carfilzomib-induced endothelial apoptosis via an AMPK-dependent pathway", "doi": "10.1016/j.biopha.2023.114907", "year": 2023 }, { "pmid": "36583437", "title": "Canagliflozin Improves Myocardial Perfusion, Fibrosis, and Function in a Swine Model of Chronic Myocardial Ischemia", "doi": "10.1161/jaha.122.028623", "year": 2022 } ], "bc": [ { "pmid": "38885414", "title": "A Novel AMPK Inhibitor Sensitizes Pancreatic Cancer Cells to Ferroptosis Induction", "doi": "10.1002/advs.202307695", "year": 2024 } ] } }, { "id": 60976, "drug": "Canagliflozin", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "inhibits", "mediator": "SGLT2", "mediator_type": "protein", "predicate_bc": "causes", "outcome": "eNOS-NO/ROS imbalance", "outcome_type": "phenotype", "outcome_domain": "heart_failure", "score": 0.29957322735539915, "filtered_score": 0.29957322735539915, "filter_reason": null, "outreach_score": 0.29957322735539915, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 9, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "33480065", "title": "Inhibition of the sodium–glucose co‐transporter SGLT2 by canagliflozin ameliorates diet‐induced obesity by increasing intra‐adipose sympathetic innervation", "doi": "10.1111/bph.15381", "year": 2021 }, { "pmid": "32387022", "title": "Osmotic Nephrosis and Acute Kidney Injury Associated With SGLT2 Inhibitor Use: A Case Report", "doi": "10.1053/j.ajkd.2020.01.015", "year": 2020 }, { "pmid": "31143117", "title": "Cost-Effectiveness of Canagliflozin Versus Dapagliflozin Added to Metformin in Patients With Type 2 Diabetes in China", "doi": "10.3389/fphar.2019.00480", "year": 2019 } ], "bc": [ { "pmid": "39739876", "title": "SGLT2 expression in human vasculature and heart correlates with low-grade inflammation and causes eNOS-NO/ROS imbalance", "doi": "10.1093/cvr/cvae257", "year": 2024 } ] } }, { "id": 39977, "drug": "Canagliflozin", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "activates", "mediator": "AMPK", "mediator_type": "protein", "predicate_bc": "increases", "outcome": "spike-wave seizures", "outcome_type": "phenotype", "outcome_domain": "epilepsy", "score": 0.29957322735539915, "filtered_score": 0.29957322735539915, "filter_reason": null, "outreach_score": 0.29957322735539915, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "canagliflozin", "mediator_canonical": "AMPK", "outcome_canonical": "spike-wave seizures", "ab_count": 9, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37584455", "title": "Canagliflozin mediates tumor suppression alone and in combination with radiotherapy in non‐small cell lung cancer (NSCLC) through inhibition of HIF‐1α", "doi": "10.1002/1878-0261.13508", "year": 2023 }, { "pmid": "37247463", "title": "Canagliflozin mitigates carfilzomib-induced endothelial apoptosis via an AMPK-dependent pathway", "doi": "10.1016/j.biopha.2023.114907", "year": 2023 }, { "pmid": "36583437", "title": "Canagliflozin Improves Myocardial Perfusion, Fibrosis, and Function in a Swine Model of Chronic Myocardial Ischemia", "doi": "10.1161/jaha.122.028623", "year": 2022 } ], "bc": [ { "pmid": "35134125", "title": "AMPK-mediated potentiation of GABAergic signalling drives hypoglycaemia-provoked spike-wave seizures", "doi": "10.1093/brain/awac037", "year": 2022 } ] } }, { "id": 60974, "drug": "Canagliflozin", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "activates", "mediator": "AMPK", "mediator_type": "protein", "predicate_bc": "increases", "outcome": "ventricular cell shortening", "outcome_type": "phenotype", "outcome_domain": "heart_failure", "score": 0.29957322735539915, "filtered_score": 0.29957322735539915, "filter_reason": null, "outreach_score": 0.29957322735539915, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 9, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37584455", "title": "Canagliflozin mediates tumor suppression alone and in combination with radiotherapy in non‐small cell lung cancer (NSCLC) through inhibition of HIF‐1α", "doi": "10.1002/1878-0261.13508", "year": 2023 }, { "pmid": "37247463", "title": "Canagliflozin mitigates carfilzomib-induced endothelial apoptosis via an AMPK-dependent pathway", "doi": "10.1016/j.biopha.2023.114907", "year": 2023 }, { "pmid": "36583437", "title": "Canagliflozin Improves Myocardial Perfusion, Fibrosis, and Function in a Swine Model of Chronic Myocardial Ischemia", "doi": "10.1161/jaha.122.028623", "year": 2022 } ], "bc": [ { "pmid": "26023060", "title": "AMPK deficiency in cardiac muscle results in dilated cardiomyopathy in the absence of changes in energy metabolism", "doi": "10.1093/cvr/cvv166", "year": 2015 } ] } }, { "id": 60973, "drug": "Canagliflozin", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "activates", "mediator": "AMPK", "mediator_type": "protein", "predicate_bc": "increases", "outcome": "glycogen storage", "outcome_type": "phenotype", "outcome_domain": "heart_failure", "score": 0.29957322735539915, "filtered_score": 0.29957322735539915, "filter_reason": null, "outreach_score": 0.29957322735539915, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 9, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37584455", "title": "Canagliflozin mediates tumor suppression alone and in combination with radiotherapy in non‐small cell lung cancer (NSCLC) through inhibition of HIF‐1α", "doi": "10.1002/1878-0261.13508", "year": 2023 }, { "pmid": "37247463", "title": "Canagliflozin mitigates carfilzomib-induced endothelial apoptosis via an AMPK-dependent pathway", "doi": "10.1016/j.biopha.2023.114907", "year": 2023 }, { "pmid": "36583437", "title": "Canagliflozin Improves Myocardial Perfusion, Fibrosis, and Function in a Swine Model of Chronic Myocardial Ischemia", "doi": "10.1161/jaha.122.028623", "year": 2022 } ], "bc": [ { "pmid": "28009297", "title": "Integrative Analysis of PRKAG2 Cardiomyopathy iPS and Microtissue Models Identifies AMPK as a Regulator of Metabolism, Survival, and Fibrosis", "doi": "10.1016/j.celrep.2016.11.066", "year": 2016 } ] } }, { "id": 2289, "drug": "ERK inhibitor", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "downregulates", "mediator": "Aβ", "mediator_type": "protein", "predicate_bc": "causes", "outcome": "Alzheimer's disease", "outcome_type": "disease", "outcome_domain": "alzheimer", "score": 0.29957322735539915, "filtered_score": 0.29957322735539915, "filter_reason": null, "outreach_score": 0.29957322735539915, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "completed", "clinical_trial_nct_ids": [ "NCT03402659", "NCT02423122", "NCT02423200" ], "literature_status": "reproduces_known", "drug_canonical": "erk inhibitor", "mediator_canonical": "aβ", "outcome_canonical": "Alzheimer disease", "ab_count": 1, "bc_count": 9, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "39545066", "title": "Epileptic seizures induced by pentylenetetrazole kindling accelerate Alzheimer-like neuropathology in 5×FAD mice", "doi": "10.3389/fphar.2024.1500105", "year": 2024 } ], "bc": [ { "pmid": "40423635", "title": "Layer-Specific Colocalization of Microglia with Amyloid Plaques in the Middle Temporal Gyrus Predicts Cognitive Decline in Alzheimer's Disease", "doi": "10.14336/ad.2025.0409", "year": 2025 }, { "pmid": "38405339", "title": "Novel Development and Prospects in Pathogenesis, Diagnosis, and Therapy of Alzheimer’s Disease", "doi": "10.3233/adr-230130", "year": 2024 }, { "pmid": "38223341", "title": "Sequence-based identification of amyloidogenic β-hairpins reveals a prostatic acid phosphatase fragment promoting semen amyloid formation", "doi": "10.1016/j.csbj.2023.12.023", "year": 2023 } ] } }, { "id": 60981, "drug": "Canagliflozin", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "activates", "mediator": "AMPK", "mediator_type": "protein", "predicate_bc": "prevents", "outcome": "myocardial ischemia-reperfusion injury", "outcome_type": "disease", "outcome_domain": "heart_failure", "score": 0.29957322735539915, "filtered_score": 0.29957322735539915, "filter_reason": null, "outreach_score": 0.29957322735539915, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 9, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37584455", "title": "Canagliflozin mediates tumor suppression alone and in combination with radiotherapy in non‐small cell lung cancer (NSCLC) through inhibition of HIF‐1α", "doi": "10.1002/1878-0261.13508", "year": 2023 }, { "pmid": "37247463", "title": "Canagliflozin mitigates carfilzomib-induced endothelial apoptosis via an AMPK-dependent pathway", "doi": "10.1016/j.biopha.2023.114907", "year": 2023 }, { "pmid": "36583437", "title": "Canagliflozin Improves Myocardial Perfusion, Fibrosis, and Function in a Swine Model of Chronic Myocardial Ischemia", "doi": "10.1161/jaha.122.028623", "year": 2022 } ], "bc": [ { "pmid": "29689567", "title": "AMPK Contributes to Cardioprotective Effects of Pterostilbene Against Myocardial Ischemia- Reperfusion Injury in Diabetic Rats by Suppressing Cardiac Oxidative Stress and Apoptosis", "doi": "10.1159/000489154", "year": 2018 } ] } }, { "id": 39978, "drug": "Canagliflozin", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "activates", "mediator": "AMPK", "mediator_type": "protein", "predicate_bc": "increases", "outcome": "epileptiform network activity", "outcome_type": "phenotype", "outcome_domain": "epilepsy", "score": 0.29957322735539915, "filtered_score": 0.29957322735539915, "filter_reason": null, "outreach_score": 0.29957322735539915, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "canagliflozin", "mediator_canonical": "AMPK", "outcome_canonical": "epileptiform network activity", "ab_count": 9, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37584455", "title": "Canagliflozin mediates tumor suppression alone and in combination with radiotherapy in non‐small cell lung cancer (NSCLC) through inhibition of HIF‐1α", "doi": "10.1002/1878-0261.13508", "year": 2023 }, { "pmid": "37247463", "title": "Canagliflozin mitigates carfilzomib-induced endothelial apoptosis via an AMPK-dependent pathway", "doi": "10.1016/j.biopha.2023.114907", "year": 2023 }, { "pmid": "36583437", "title": "Canagliflozin Improves Myocardial Perfusion, Fibrosis, and Function in a Swine Model of Chronic Myocardial Ischemia", "doi": "10.1161/jaha.122.028623", "year": 2022 } ], "bc": [ { "pmid": "35134125", "title": "AMPK-mediated potentiation of GABAergic signalling drives hypoglycaemia-provoked spike-wave seizures", "doi": "10.1093/brain/awac037", "year": 2022 } ] } }, { "id": 40776, "drug": "Canagliflozin", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "inhibits", "mediator": "SGLT2", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "prostate adenocarcinoma", "outcome_type": "disease", "outcome_domain": "pancreatic_cancer", "score": 0.29957322735539915, "filtered_score": 0.29957322735539915, "filter_reason": null, "outreach_score": 0.29957322735539915, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "canagliflozin", "mediator_canonical": "sglt2", "outcome_canonical": "prostate adenocarcinoma", "ab_count": 9, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "33480065", "title": "Inhibition of the sodium–glucose co‐transporter SGLT2 by canagliflozin ameliorates diet‐induced obesity by increasing intra‐adipose sympathetic innervation", "doi": "10.1111/bph.15381", "year": 2021 }, { "pmid": "32387022", "title": "Osmotic Nephrosis and Acute Kidney Injury Associated With SGLT2 Inhibitor Use: A Case Report", "doi": "10.1053/j.ajkd.2020.01.015", "year": 2020 }, { "pmid": "31143117", "title": "Cost-Effectiveness of Canagliflozin Versus Dapagliflozin Added to Metformin in Patients With Type 2 Diabetes in China", "doi": "10.3389/fphar.2019.00480", "year": 2019 } ], "bc": [ { "pmid": "26170283", "title": "Functional expression of sodium-glucose transporters in cancer", "doi": "10.1073/pnas.1511698112", "year": 2015 } ] } }, { "id": 39398, "drug": "Canagliflozin", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "activates", "mediator": "AMPK", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "amyotrophic lateral sclerosis", "outcome_type": "disease", "outcome_domain": "als", "score": 0.29957322735539915, "filtered_score": 0.29957322735539915, "filter_reason": null, "outreach_score": 0.29957322735539915, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "canagliflozin", "mediator_canonical": "AMPK", "outcome_canonical": "amyotrophic lateral sclerosis", "ab_count": 9, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37584455", "title": "Canagliflozin mediates tumor suppression alone and in combination with radiotherapy in non‐small cell lung cancer (NSCLC) through inhibition of HIF‐1α", "doi": "10.1002/1878-0261.13508", "year": 2023 }, { "pmid": "37247463", "title": "Canagliflozin mitigates carfilzomib-induced endothelial apoptosis via an AMPK-dependent pathway", "doi": "10.1016/j.biopha.2023.114907", "year": 2023 }, { "pmid": "36583437", "title": "Canagliflozin Improves Myocardial Perfusion, Fibrosis, and Function in a Swine Model of Chronic Myocardial Ischemia", "doi": "10.1161/jaha.122.028623", "year": 2022 } ], "bc": [ { "pmid": "34393724", "title": "Contribution of Energy Dysfunction to Impaired Protein Translation in Neurodegenerative Diseases", "doi": "10.3389/fncel.2021.668500", "year": 2021 } ] } }, { "id": 60980, "drug": "Canagliflozin", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "activates", "mediator": "AMPK", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "cardiovascular aging", "outcome_type": "phenotype", "outcome_domain": "heart_failure", "score": 0.29957322735539915, "filtered_score": 0.29957322735539915, "filter_reason": null, "outreach_score": 0.29957322735539915, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 9, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37584455", "title": "Canagliflozin mediates tumor suppression alone and in combination with radiotherapy in non‐small cell lung cancer (NSCLC) through inhibition of HIF‐1α", "doi": "10.1002/1878-0261.13508", "year": 2023 }, { "pmid": "37247463", "title": "Canagliflozin mitigates carfilzomib-induced endothelial apoptosis via an AMPK-dependent pathway", "doi": "10.1016/j.biopha.2023.114907", "year": 2023 }, { "pmid": "36583437", "title": "Canagliflozin Improves Myocardial Perfusion, Fibrosis, and Function in a Swine Model of Chronic Myocardial Ischemia", "doi": "10.1161/jaha.122.028623", "year": 2022 } ], "bc": [ { "pmid": "41194190", "title": "Cellular senescence and cell therapy in cardiovascular diseases", "doi": "10.1186/s13287-025-04731-6", "year": 2025 } ] } }, { "id": 60977, "drug": "Canagliflozin", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "activates", "mediator": "AMPK", "mediator_type": "protein", "predicate_bc": "causes", "outcome": "dilated cardiomyopathy", "outcome_type": "disease", "outcome_domain": "heart_failure", "score": 0.29957322735539915, "filtered_score": 0.29957322735539915, "filter_reason": null, "outreach_score": 0.29957322735539915, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 9, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37584455", "title": "Canagliflozin mediates tumor suppression alone and in combination with radiotherapy in non‐small cell lung cancer (NSCLC) through inhibition of HIF‐1α", "doi": "10.1002/1878-0261.13508", "year": 2023 }, { "pmid": "37247463", "title": "Canagliflozin mitigates carfilzomib-induced endothelial apoptosis via an AMPK-dependent pathway", "doi": "10.1016/j.biopha.2023.114907", "year": 2023 }, { "pmid": "36583437", "title": "Canagliflozin Improves Myocardial Perfusion, Fibrosis, and Function in a Swine Model of Chronic Myocardial Ischemia", "doi": "10.1161/jaha.122.028623", "year": 2022 } ], "bc": [ { "pmid": "26023060", "title": "AMPK deficiency in cardiac muscle results in dilated cardiomyopathy in the absence of changes in energy metabolism", "doi": "10.1093/cvr/cvv166", "year": 2015 } ] } }, { "id": 40373, "drug": "Canagliflozin", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "activates", "mediator": "AMPK", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "intestinal epithelial repair", "outcome_type": "phenotype", "outcome_domain": "inflammatory_bowel_disease", "score": 0.29957322735539915, "filtered_score": 0.29957322735539915, "filter_reason": null, "outreach_score": 0.29957322735539915, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "canagliflozin", "mediator_canonical": "AMPK", "outcome_canonical": "intestinal epithelial repair", "ab_count": 9, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37584455", "title": "Canagliflozin mediates tumor suppression alone and in combination with radiotherapy in non‐small cell lung cancer (NSCLC) through inhibition of HIF‐1α", "doi": "10.1002/1878-0261.13508", "year": 2023 }, { "pmid": "37247463", "title": "Canagliflozin mitigates carfilzomib-induced endothelial apoptosis via an AMPK-dependent pathway", "doi": "10.1016/j.biopha.2023.114907", "year": 2023 }, { "pmid": "36583437", "title": "Canagliflozin Improves Myocardial Perfusion, Fibrosis, and Function in a Swine Model of Chronic Myocardial Ischemia", "doi": "10.1161/jaha.122.028623", "year": 2022 } ], "bc": [ { "pmid": "35203241", "title": "Intestinal Epithelial AMPK Deficiency Causes Delayed Colonic Epithelial Repair in DSS-Induced Colitis", "doi": "10.3390/cells11040590", "year": 2022 } ] } }, { "id": 40367, "drug": "Canagliflozin", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "activates", "mediator": "AMPK", "mediator_type": "protein", "predicate_bc": "treats", "outcome": "intestinal inflammation", "outcome_type": "disease", "outcome_domain": "inflammatory_bowel_disease", "score": 0.29957322735539915, "filtered_score": 0.29957322735539915, "filter_reason": null, "outreach_score": 0.29957322735539915, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "canagliflozin", "mediator_canonical": "AMPK", "outcome_canonical": "intestinal inflammation", "ab_count": 9, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37584455", "title": "Canagliflozin mediates tumor suppression alone and in combination with radiotherapy in non‐small cell lung cancer (NSCLC) through inhibition of HIF‐1α", "doi": "10.1002/1878-0261.13508", "year": 2023 }, { "pmid": "37247463", "title": "Canagliflozin mitigates carfilzomib-induced endothelial apoptosis via an AMPK-dependent pathway", "doi": "10.1016/j.biopha.2023.114907", "year": 2023 }, { "pmid": "36583437", "title": "Canagliflozin Improves Myocardial Perfusion, Fibrosis, and Function in a Swine Model of Chronic Myocardial Ischemia", "doi": "10.1161/jaha.122.028623", "year": 2022 } ], "bc": [ { "pmid": "33252129", "title": "Salicylates Ameliorate Intestinal Inflammation by Activating Macrophage AMPK", "doi": "10.1093/ibd/izaa305", "year": 2020 } ] } }, { "id": 39399, "drug": "amlexanox", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "inhibits", "mediator": "TBK1", "mediator_type": "gene", "predicate_bc": "associated_with", "outcome": "ALS", "outcome_type": "disease", "outcome_domain": "als", "score": 0.2890371757896165, "filtered_score": 0.2890371757896165, "filter_reason": null, "outreach_score": 0.2890371757896165, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "amlexanox", "mediator_canonical": "tbk1", "outcome_canonical": "amyotrophic lateral sclerosis", "ab_count": 1, "bc_count": 8, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "29935921", "title": "Loss of Tbk1 kinase activity protects mice from diet-induced metabolic dysfunction", "doi": "10.1016/j.molmet.2018.06.007", "year": 2018 } ], "bc": [ { "pmid": "38443977", "title": "TBK1, a prioritized drug repurposing target for amyotrophic lateral sclerosis: evidence from druggable genome Mendelian randomization and pharmacological verification in vitro", "doi": "10.1186/s12916-024-03314-1", "year": 2024 }, { "pmid": "31498468", "title": "Neuropathological characterization of a novel TANK binding kinase (TBK1) gene loss of function mutation associated with amyotrophic lateral sclerosis", "doi": "10.1111/nan.12578", "year": 2019 }, { "pmid": "29149916", "title": "Whole-exome sequencing in amyotrophic lateral sclerosis suggests NEK1 is a risk gene in Chinese", "doi": "10.1186/s13073-017-0487-0", "year": 2017 } ] } }, { "id": 22873, "drug": "ketamine", "drug_type": "drug", "drug_domain": "depression", "predicate_ab": "inhibits", "mediator": "NMDA receptor", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "neuronal degeneration", "outcome_type": "phenotype", "outcome_domain": "multiple_sclerosis", "score": 0.2890371757896165, "filtered_score": 0.2890371757896165, "filter_reason": null, "outreach_score": 0.2890371757896165, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "ketamine", "mediator_canonical": "nmda receptor", "outcome_canonical": "neuronal degeneration", "ab_count": 8, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41765199", "title": "Ketamine pharmacotherapy for major depressive disorder: A narrative review", "doi": "10.1016/j.pnpbp.2026.111651", "year": 2026 }, { "pmid": "41690063", "title": "Ketamine combined with psychotherapy for treatment-resistant depression: Real-world outcomes and the role of subjective experience", "doi": "10.1016/j.genhosppsych.2026.02.001", "year": 2026 }, { "pmid": "41656677", "title": "Comparative Efficacy and Safety of Ketamine Versus Midazolam for Suicidality: A GRADE‐Assessed Systematic Review and Meta‐Analysis of Randomized Controlled Trials", "doi": "10.1002/brb3.71255", "year": 2026 } ], "bc": [ { "pmid": "31412103", "title": "MicroRNA-223 protects neurons from degeneration in experimental autoimmune encephalomyelitis", "doi": "10.1093/brain/awz245", "year": 2019 } ] } }, { "id": 22878, "drug": "Esketamine", "drug_type": "drug", "drug_domain": "depression", "predicate_ab": "inhibits", "mediator": "NMDA receptor", "mediator_type": "protein", "predicate_bc": "causes", "outcome": "calcium accumulation", "outcome_type": "phenotype", "outcome_domain": "multiple_sclerosis", "score": 0.2890371757896165, "filtered_score": 0.2890371757896165, "filter_reason": null, "outreach_score": 0.2890371757896165, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "esketamine", "mediator_canonical": "nmda receptor", "outcome_canonical": "calcium accumulation", "ab_count": 8, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41835037", "title": "Evaluation of Current Evidence on the Efficacy of Esketamine in Treating Substance-Use Disorders in Patients With Treatment-Resistant Depression (TRD): A Narrative Review", "doi": "10.7759/cureus.105219", "year": 2026 }, { "pmid": "41923438", "title": "Esketamine Nasal Spray: Mechanism of Action, Clinical, and Translational Science", "doi": "10.1111/cts.70527", "year": 2026 }, { "pmid": "40865291", "title": "Effectiveness of repeated Esketamine nasal spray administration on anhedonic symptoms in treatment-resistant bipolar and unipolar depression: A secondary analysis from the REAL-ESK study group", "doi": "10.1016/j.psychres.2025.116655", "year": 2025 } ], "bc": [ { "pmid": "32031240", "title": "Influence of retinal NMDA receptor activity during autoimmune optic neuritis", "doi": "10.1111/jnc.14980", "year": 2020 } ] } }, { "id": 5346, "drug": "Esketamine", "drug_type": "drug", "drug_domain": "depression", "predicate_ab": "inhibits", "mediator": "NMDA receptor", "mediator_type": "protein", "predicate_bc": "causes", "outcome": "neuronal death", "outcome_type": "phenotype", "outcome_domain": "epilepsy", "score": 0.2890371757896165, "filtered_score": 0.2890371757896165, "filter_reason": null, "outreach_score": 0.2890371757896165, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "esketamine", "mediator_canonical": "nmda receptor", "outcome_canonical": "neuronal death", "ab_count": 8, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41835037", "title": "Evaluation of Current Evidence on the Efficacy of Esketamine in Treating Substance-Use Disorders in Patients With Treatment-Resistant Depression (TRD): A Narrative Review", "doi": "10.7759/cureus.105219", "year": 2026 }, { "pmid": "41923438", "title": "Esketamine Nasal Spray: Mechanism of Action, Clinical, and Translational Science", "doi": "10.1111/cts.70527", "year": 2026 }, { "pmid": "40865291", "title": "Effectiveness of repeated Esketamine nasal spray administration on anhedonic symptoms in treatment-resistant bipolar and unipolar depression: A secondary analysis from the REAL-ESK study group", "doi": "10.1016/j.psychres.2025.116655", "year": 2025 } ], "bc": [ { "pmid": "36648377", "title": "Reactive oxygen species in status epilepticus", "doi": "10.1002/epi4.12691", "year": 2023 } ] } }, { "id": 10442, "drug": "ketamine", "drug_type": "drug", "drug_domain": "depression", "predicate_ab": "inhibits", "mediator": "NMDA receptor", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "neurodevelopmental disorders", "outcome_type": "disease", "outcome_domain": "epilepsy", "score": 0.2890371757896165, "filtered_score": 0.2890371757896165, "filter_reason": null, "outreach_score": 0.2890371757896165, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "active", "clinical_trial_nct_ids": [ "NCT02611921", "NCT07324057", "NCT01246765" ], "literature_status": "reproduces_known", "drug_canonical": "ketamine", "mediator_canonical": "nmda receptor", "outcome_canonical": "neurodevelopmental disorders", "ab_count": 8, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41765199", "title": "Ketamine pharmacotherapy for major depressive disorder: A narrative review", "doi": "10.1016/j.pnpbp.2026.111651", "year": 2026 }, { "pmid": "41690063", "title": "Ketamine combined with psychotherapy for treatment-resistant depression: Real-world outcomes and the role of subjective experience", "doi": "10.1016/j.genhosppsych.2026.02.001", "year": 2026 }, { "pmid": "41656677", "title": "Comparative Efficacy and Safety of Ketamine Versus Midazolam for Suicidality: A GRADE‐Assessed Systematic Review and Meta‐Analysis of Randomized Controlled Trials", "doi": "10.1002/brb3.71255", "year": 2026 } ], "bc": [ { "pmid": "30280376", "title": "GRIN2D variants in three cases of developmental and epileptic encephalopathy", "doi": "10.1111/cge.13454", "year": 2018 } ] } }, { "id": 5315, "drug": "ketamine", "drug_type": "drug", "drug_domain": "depression", "predicate_ab": "inhibits", "mediator": "NMDA receptor", "mediator_type": "protein", "predicate_bc": "causes", "outcome": "neuronal death", "outcome_type": "phenotype", "outcome_domain": "epilepsy", "score": 0.2890371757896165, "filtered_score": 0.2890371757896165, "filter_reason": null, "outreach_score": 0.2890371757896165, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "ketamine", "mediator_canonical": "nmda receptor", "outcome_canonical": "neuronal death", "ab_count": 8, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41765199", "title": "Ketamine pharmacotherapy for major depressive disorder: A narrative review", "doi": "10.1016/j.pnpbp.2026.111651", "year": 2026 }, { "pmid": "41690063", "title": "Ketamine combined with psychotherapy for treatment-resistant depression: Real-world outcomes and the role of subjective experience", "doi": "10.1016/j.genhosppsych.2026.02.001", "year": 2026 }, { "pmid": "41656677", "title": "Comparative Efficacy and Safety of Ketamine Versus Midazolam for Suicidality: A GRADE‐Assessed Systematic Review and Meta‐Analysis of Randomized Controlled Trials", "doi": "10.1002/brb3.71255", "year": 2026 } ], "bc": [ { "pmid": "36648377", "title": "Reactive oxygen species in status epilepticus", "doi": "10.1002/epi4.12691", "year": 2023 } ] } }, { "id": 22877, "drug": "Esketamine", "drug_type": "drug", "drug_domain": "depression", "predicate_ab": "inhibits", "mediator": "NMDA receptor", "mediator_type": "protein", "predicate_bc": "causes", "outcome": "deterioration of visual acuity", "outcome_type": "phenotype", "outcome_domain": "multiple_sclerosis", "score": 0.2890371757896165, "filtered_score": 0.2890371757896165, "filter_reason": null, "outreach_score": 0.2890371757896165, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "esketamine", "mediator_canonical": "nmda receptor", "outcome_canonical": "deterioration of visual acuity", "ab_count": 8, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41835037", "title": "Evaluation of Current Evidence on the Efficacy of Esketamine in Treating Substance-Use Disorders in Patients With Treatment-Resistant Depression (TRD): A Narrative Review", "doi": "10.7759/cureus.105219", "year": 2026 }, { "pmid": "41923438", "title": "Esketamine Nasal Spray: Mechanism of Action, Clinical, and Translational Science", "doi": "10.1111/cts.70527", "year": 2026 }, { "pmid": "40865291", "title": "Effectiveness of repeated Esketamine nasal spray administration on anhedonic symptoms in treatment-resistant bipolar and unipolar depression: A secondary analysis from the REAL-ESK study group", "doi": "10.1016/j.psychres.2025.116655", "year": 2025 } ], "bc": [ { "pmid": "32031240", "title": "Influence of retinal NMDA receptor activity during autoimmune optic neuritis", "doi": "10.1111/jnc.14980", "year": 2020 } ] } }, { "id": 5386, "drug": "ketamine", "drug_type": "drug", "drug_domain": "depression", "predicate_ab": "inhibits", "mediator": "NMDA receptor", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "cell-autonomous excitotoxicity", "outcome_type": "phenotype", "outcome_domain": "als", "score": 0.2890371757896165, "filtered_score": 0.2890371757896165, "filter_reason": null, "outreach_score": 0.2890371757896165, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "ketamine", "mediator_canonical": "nmda receptor", "outcome_canonical": "cell-autonomous excitotoxicity", "ab_count": 8, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41765199", "title": "Ketamine pharmacotherapy for major depressive disorder: A narrative review", "doi": "10.1016/j.pnpbp.2026.111651", "year": 2026 }, { "pmid": "41690063", "title": "Ketamine combined with psychotherapy for treatment-resistant depression: Real-world outcomes and the role of subjective experience", "doi": "10.1016/j.genhosppsych.2026.02.001", "year": 2026 }, { "pmid": "41656677", "title": "Comparative Efficacy and Safety of Ketamine Versus Midazolam for Suicidality: A GRADE‐Assessed Systematic Review and Meta‐Analysis of Randomized Controlled Trials", "doi": "10.1002/brb3.71255", "year": 2026 } ], "bc": [ { "pmid": "30037833", "title": "C9orf72 Dipeptide Repeats Cause Selective Neurodegeneration and Cell-Autonomous Excitotoxicity in Drosophila Glutamatergic Neurons", "doi": "10.1523/jneurosci.0908-18.2018", "year": 2018 } ] } }, { "id": 5393, "drug": "Esketamine", "drug_type": "drug", "drug_domain": "depression", "predicate_ab": "inhibits", "mediator": "NMDA receptor", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "cell-autonomous excitotoxicity", "outcome_type": "phenotype", "outcome_domain": "als", "score": 0.2890371757896165, "filtered_score": 0.2890371757896165, "filter_reason": null, "outreach_score": 0.2890371757896165, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "esketamine", "mediator_canonical": "nmda receptor", "outcome_canonical": "cell-autonomous excitotoxicity", "ab_count": 8, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41835037", "title": "Evaluation of Current Evidence on the Efficacy of Esketamine in Treating Substance-Use Disorders in Patients With Treatment-Resistant Depression (TRD): A Narrative Review", "doi": "10.7759/cureus.105219", "year": 2026 }, { "pmid": "41923438", "title": "Esketamine Nasal Spray: Mechanism of Action, Clinical, and Translational Science", "doi": "10.1111/cts.70527", "year": 2026 }, { "pmid": "40865291", "title": "Effectiveness of repeated Esketamine nasal spray administration on anhedonic symptoms in treatment-resistant bipolar and unipolar depression: A secondary analysis from the REAL-ESK study group", "doi": "10.1016/j.psychres.2025.116655", "year": 2025 } ], "bc": [ { "pmid": "30037833", "title": "C9orf72 Dipeptide Repeats Cause Selective Neurodegeneration and Cell-Autonomous Excitotoxicity in Drosophila Glutamatergic Neurons", "doi": "10.1523/jneurosci.0908-18.2018", "year": 2018 } ] } }, { "id": 10441, "drug": "Esketamine", "drug_type": "drug", "drug_domain": "depression", "predicate_ab": "inhibits", "mediator": "NMDA receptor", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "neurodevelopmental disorders", "outcome_type": "disease", "outcome_domain": "epilepsy", "score": 0.2890371757896165, "filtered_score": 0.2890371757896165, "filter_reason": null, "outreach_score": 0.2890371757896165, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "active", "clinical_trial_nct_ids": [ "NCT07324057", "NCT01246765", "NCT06633315" ], "literature_status": "partial_evidence", "drug_canonical": "esketamine", "mediator_canonical": "nmda receptor", "outcome_canonical": "neurodevelopmental disorders", "ab_count": 8, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41835037", "title": "Evaluation of Current Evidence on the Efficacy of Esketamine in Treating Substance-Use Disorders in Patients With Treatment-Resistant Depression (TRD): A Narrative Review", "doi": "10.7759/cureus.105219", "year": 2026 }, { "pmid": "41923438", "title": "Esketamine Nasal Spray: Mechanism of Action, Clinical, and Translational Science", "doi": "10.1111/cts.70527", "year": 2026 }, { "pmid": "40865291", "title": "Effectiveness of repeated Esketamine nasal spray administration on anhedonic symptoms in treatment-resistant bipolar and unipolar depression: A secondary analysis from the REAL-ESK study group", "doi": "10.1016/j.psychres.2025.116655", "year": 2025 } ], "bc": [ { "pmid": "30280376", "title": "GRIN2D variants in three cases of developmental and epileptic encephalopathy", "doi": "10.1111/cge.13454", "year": 2018 } ] } }, { "id": 22871, "drug": "Esketamine", "drug_type": "drug", "drug_domain": "depression", "predicate_ab": "inhibits", "mediator": "NMDA receptor", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "neuronal degeneration", "outcome_type": "phenotype", "outcome_domain": "multiple_sclerosis", "score": 0.2890371757896165, "filtered_score": 0.2890371757896165, "filter_reason": null, "outreach_score": 0.2890371757896165, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "esketamine", "mediator_canonical": "nmda receptor", "outcome_canonical": "neuronal degeneration", "ab_count": 8, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41835037", "title": "Evaluation of Current Evidence on the Efficacy of Esketamine in Treating Substance-Use Disorders in Patients With Treatment-Resistant Depression (TRD): A Narrative Review", "doi": "10.7759/cureus.105219", "year": 2026 }, { "pmid": "41923438", "title": "Esketamine Nasal Spray: Mechanism of Action, Clinical, and Translational Science", "doi": "10.1111/cts.70527", "year": 2026 }, { "pmid": "40865291", "title": "Effectiveness of repeated Esketamine nasal spray administration on anhedonic symptoms in treatment-resistant bipolar and unipolar depression: A secondary analysis from the REAL-ESK study group", "doi": "10.1016/j.psychres.2025.116655", "year": 2025 } ], "bc": [ { "pmid": "31412103", "title": "MicroRNA-223 protects neurons from degeneration in experimental autoimmune encephalomyelitis", "doi": "10.1093/brain/awz245", "year": 2019 } ] } }, { "id": 22875, "drug": "ketamine", "drug_type": "drug", "drug_domain": "depression", "predicate_ab": "inhibits", "mediator": "NMDA receptor", "mediator_type": "protein", "predicate_bc": "causes", "outcome": "calcium accumulation", "outcome_type": "phenotype", "outcome_domain": "multiple_sclerosis", "score": 0.2890371757896165, "filtered_score": 0.2890371757896165, "filter_reason": null, "outreach_score": 0.2890371757896165, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "ketamine", "mediator_canonical": "nmda receptor", "outcome_canonical": "calcium accumulation", "ab_count": 8, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41765199", "title": "Ketamine pharmacotherapy for major depressive disorder: A narrative review", "doi": "10.1016/j.pnpbp.2026.111651", "year": 2026 }, { "pmid": "41690063", "title": "Ketamine combined with psychotherapy for treatment-resistant depression: Real-world outcomes and the role of subjective experience", "doi": "10.1016/j.genhosppsych.2026.02.001", "year": 2026 }, { "pmid": "41656677", "title": "Comparative Efficacy and Safety of Ketamine Versus Midazolam for Suicidality: A GRADE‐Assessed Systematic Review and Meta‐Analysis of Randomized Controlled Trials", "doi": "10.1002/brb3.71255", "year": 2026 } ], "bc": [ { "pmid": "32031240", "title": "Influence of retinal NMDA receptor activity during autoimmune optic neuritis", "doi": "10.1111/jnc.14980", "year": 2020 } ] } }, { "id": 22876, "drug": "ketamine", "drug_type": "drug", "drug_domain": "depression", "predicate_ab": "inhibits", "mediator": "NMDA receptor", "mediator_type": "protein", "predicate_bc": "causes", "outcome": "deterioration of visual acuity", "outcome_type": "phenotype", "outcome_domain": "multiple_sclerosis", "score": 0.2890371757896165, "filtered_score": 0.2890371757896165, "filter_reason": null, "outreach_score": 0.2890371757896165, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "ketamine", "mediator_canonical": "nmda receptor", "outcome_canonical": "deterioration of visual acuity", "ab_count": 8, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41765199", "title": "Ketamine pharmacotherapy for major depressive disorder: A narrative review", "doi": "10.1016/j.pnpbp.2026.111651", "year": 2026 }, { "pmid": "41690063", "title": "Ketamine combined with psychotherapy for treatment-resistant depression: Real-world outcomes and the role of subjective experience", "doi": "10.1016/j.genhosppsych.2026.02.001", "year": 2026 }, { "pmid": "41656677", "title": "Comparative Efficacy and Safety of Ketamine Versus Midazolam for Suicidality: A GRADE‐Assessed Systematic Review and Meta‐Analysis of Randomized Controlled Trials", "doi": "10.1002/brb3.71255", "year": 2026 } ], "bc": [ { "pmid": "32031240", "title": "Influence of retinal NMDA receptor activity during autoimmune optic neuritis", "doi": "10.1111/jnc.14980", "year": 2020 } ] } }, { "id": 22874, "drug": "Esketamine", "drug_type": "drug", "drug_domain": "depression", "predicate_ab": "inhibits", "mediator": "NMDA receptor", "mediator_type": "protein", "predicate_bc": "causes", "outcome": "actin destabilization", "outcome_type": "phenotype", "outcome_domain": "multiple_sclerosis", "score": 0.2890371757896165, "filtered_score": 0.2890371757896165, "filter_reason": null, "outreach_score": 0.2890371757896165, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "esketamine", "mediator_canonical": "nmda receptor", "outcome_canonical": "actin destabilization", "ab_count": 8, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41835037", "title": "Evaluation of Current Evidence on the Efficacy of Esketamine in Treating Substance-Use Disorders in Patients With Treatment-Resistant Depression (TRD): A Narrative Review", "doi": "10.7759/cureus.105219", "year": 2026 }, { "pmid": "41923438", "title": "Esketamine Nasal Spray: Mechanism of Action, Clinical, and Translational Science", "doi": "10.1111/cts.70527", "year": 2026 }, { "pmid": "40865291", "title": "Effectiveness of repeated Esketamine nasal spray administration on anhedonic symptoms in treatment-resistant bipolar and unipolar depression: A secondary analysis from the REAL-ESK study group", "doi": "10.1016/j.psychres.2025.116655", "year": 2025 } ], "bc": [ { "pmid": "32031240", "title": "Influence of retinal NMDA receptor activity during autoimmune optic neuritis", "doi": "10.1111/jnc.14980", "year": 2020 } ] } }, { "id": 22872, "drug": "ketamine", "drug_type": "drug", "drug_domain": "depression", "predicate_ab": "inhibits", "mediator": "NMDA receptor", "mediator_type": "protein", "predicate_bc": "causes", "outcome": "actin destabilization", "outcome_type": "phenotype", "outcome_domain": "multiple_sclerosis", "score": 0.2890371757896165, "filtered_score": 0.2890371757896165, "filter_reason": null, "outreach_score": 0.2890371757896165, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "ketamine", "mediator_canonical": "nmda receptor", "outcome_canonical": "actin destabilization", "ab_count": 8, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41765199", "title": "Ketamine pharmacotherapy for major depressive disorder: A narrative review", "doi": "10.1016/j.pnpbp.2026.111651", "year": 2026 }, { "pmid": "41690063", "title": "Ketamine combined with psychotherapy for treatment-resistant depression: Real-world outcomes and the role of subjective experience", "doi": "10.1016/j.genhosppsych.2026.02.001", "year": 2026 }, { "pmid": "41656677", "title": "Comparative Efficacy and Safety of Ketamine Versus Midazolam for Suicidality: A GRADE‐Assessed Systematic Review and Meta‐Analysis of Randomized Controlled Trials", "doi": "10.1002/brb3.71255", "year": 2026 } ], "bc": [ { "pmid": "32031240", "title": "Influence of retinal NMDA receptor activity during autoimmune optic neuritis", "doi": "10.1111/jnc.14980", "year": 2020 } ] } }, { "id": 35070, "drug": "Dimethyl fumarate", "drug_type": "drug", "drug_domain": "multiple_sclerosis", "predicate_ab": "activates", "mediator": "Nrf2 pathway", "mediator_type": "pathway", "predicate_bc": "decreases", "outcome": "tau clearance", "outcome_type": "phenotype", "outcome_domain": "inflammatory_bowel_disease", "score": 0.2890371757896165, "filtered_score": 0.2890371757896165, "filter_reason": null, "outreach_score": 0.2890371757896165, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "dimethyl fumarate", "mediator_canonical": "nrf2 pathway", "outcome_canonical": "tau clearance", "ab_count": 8, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41627610", "title": "Dimethyl fumarate as a versatile therapeutic agent: molecular mechanisms and potential clinical applications", "doi": "10.1007/s11033-026-11478-7", "year": 2026 }, { "pmid": "41146249", "title": "Fumarate-based drugs protect against neuroinflammation via upregulation of anti-ferroptotic pathways", "doi": "10.1186/s12974-025-03592-3", "year": 2025 }, { "pmid": "38494482", "title": "Disrupting pro-survival and inflammatory pathways with dimethyl fumarate sensitizes chronic lymphocytic leukemia to cell death", "doi": "10.1038/s41419-024-06602-z", "year": 2024 } ], "bc": [ { "pmid": "32436623", "title": "Tau accumulates in Crohn's disease gut", "doi": "10.1096/fj.202000414r", "year": 2020 } ] } }, { "id": 38803, "drug": "bimekizumab", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "inhibits", "mediator": "IL-17A", "mediator_type": "protein", "predicate_bc": "predicts", "outcome": "cognitive impairment", "outcome_type": "phenotype", "outcome_domain": "multiple_sclerosis", "score": 0.28903717578961646, "filtered_score": 0.28903717578961646, "filter_reason": null, "outreach_score": 0.28903717578961646, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "bimekizumab", "mediator_canonical": "il-17a", "outcome_canonical": "cognitive impairment", "ab_count": 5, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "39215949", "title": "Safety and Efficacy of Bimekizumab in Patients with Psoriatic Arthritis: 2-Year Results from Two Phase 3 Studies", "doi": "10.1007/s40744-024-00708-8", "year": 2024 }, { "pmid": "39620046", "title": "Impact of bimekizumab and certolizumab pegol on efficacy, safety and osteoblastic activity in radiographic axial spondyloarthritis: results from a phase IIa, multicentre, randomised, double-blind, exploratory study with PET-CT imaging", "doi": "10.1177/1759720x241293944", "year": 2024 }, { "pmid": "37808274", "title": "Safe and Effective Subcutaneous Self-Injection of Bimekizumab with Safety Syringe and Auto-Injector Devices: Results from a Multicenter, Randomized, Open-Label Study in Patients with Psoriatic Arthritis", "doi": "10.2147/ppa.s427809", "year": 2023 } ], "bc": [ { "pmid": "29297273", "title": "Circulating levels of interleukin-17A, tumor necrosis factor-alpha, interleukin-18, interleukin-10, and cognitive performance of patients with relapsing-remitting multiple sclerosis", "doi": "10.1080/01616412.2017.1420522", "year": 2018 } ] } }, { "id": 60984, "drug": "dapagliflozin", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "upregulates", "mediator": "AMPK", "mediator_type": "protein", "predicate_bc": "prevents", "outcome": "metabolic dysfunction", "outcome_type": "disease", "outcome_domain": "heart_failure", "score": 0.28903717578961646, "filtered_score": 0.28903717578961646, "filter_reason": null, "outreach_score": 0.28903717578961646, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 5, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40264429", "title": "Dapagliflozin ameliorates kidney injury following limb ischemia-reperfusion via the AMPK/SIRT1/NLRP3 pathway", "doi": "10.1080/0886022x.2025.2495111", "year": 2025 }, { "pmid": "36809274", "title": "Mapping the metabolic reprogramming induced by sodium-glucose cotransporter 2 inhibition", "doi": "10.1172/jci.insight.164296", "year": 2023 }, { "pmid": "35274762", "title": "Dapagliflozin attenuates high glucose‐induced endothelial cell apoptosis and inflammation through AMPK/SIRT1 activation", "doi": "10.1111/1440-1681.13638", "year": 2022 } ], "bc": [ { "pmid": "37194385", "title": "Adenosine monophosphate‐activated protein kinase is elevated in human cachectic muscle and prevents cancer‐induced metabolic dysfunction in mice", "doi": "10.1002/jcsm.13238", "year": 2023 } ] } }, { "id": 51749, "drug": "sulforaphane", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "activates", "mediator": "Nrf2", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "disease activity", "outcome_type": "phenotype", "outcome_domain": "rheumatoid_arthritis", "score": 0.28903717578961646, "filtered_score": 0.28903717578961646, "filter_reason": null, "outreach_score": 0.28903717578961646, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 5, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "33067900", "title": "Sulforaphane prevents age‐associated cardiac and muscular dysfunction through Nrf2 signaling", "doi": "10.1111/acel.13261", "year": 2020 }, { "pmid": "31270951", "title": "Protection against diabetic cardiomyopathy is achieved using a combination of sulforaphane and zinc in type 1 diabetic OVE26 mice", "doi": "10.1111/jcmm.14520", "year": 2019 }, { "pmid": "29353218", "title": "Sulforaphane prevents angiotensin II-induced cardiomyopathy by activation of Nrf2 via stimulating the Akt/GSK-3ß/Fyn pathway", "doi": "10.1016/j.redox.2017.12.016", "year": 2018 } ], "bc": [ { "pmid": "36574898", "title": "Expression of Nrf2 protein in serum of patients with rheumatoid arthritis: A novel indicator for disease activity and disease prognosis", "doi": "10.1016/j.clinbiochem.2022.12.011", "year": 2022 } ] } }, { "id": 38627, "drug": "bimekizumab", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "inhibits", "mediator": "IL-17A", "mediator_type": "protein", "predicate_bc": "predicts", "outcome": "IBD", "outcome_type": "disease", "outcome_domain": "inflammatory_bowel_disease", "score": 0.28903717578961646, "filtered_score": 0.28903717578961646, "filter_reason": null, "outreach_score": 0.28903717578961646, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "preclinical_only", "clinical_trial_nct_ids": [ "NCT07138898" ], "literature_status": "partial_evidence", "drug_canonical": "bimekizumab", "mediator_canonical": "il-17a", "outcome_canonical": "ibd", "ab_count": 5, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "39215949", "title": "Safety and Efficacy of Bimekizumab in Patients with Psoriatic Arthritis: 2-Year Results from Two Phase 3 Studies", "doi": "10.1007/s40744-024-00708-8", "year": 2024 }, { "pmid": "39620046", "title": "Impact of bimekizumab and certolizumab pegol on efficacy, safety and osteoblastic activity in radiographic axial spondyloarthritis: results from a phase IIa, multicentre, randomised, double-blind, exploratory study with PET-CT imaging", "doi": "10.1177/1759720x241293944", "year": 2024 }, { "pmid": "37808274", "title": "Safe and Effective Subcutaneous Self-Injection of Bimekizumab with Safety Syringe and Auto-Injector Devices: Results from a Multicenter, Randomized, Open-Label Study in Patients with Psoriatic Arthritis", "doi": "10.2147/ppa.s427809", "year": 2023 } ], "bc": [ { "pmid": "40481885", "title": "Serum proteins and faecal microbiota as potential biomarkers in newly diagnosed, treatment-naïve inflammatory bowel disease and irritable bowel syndrome patients", "doi": "10.1007/s00109-025-02558-5", "year": 2025 }, { "pmid": "26650150", "title": "Are sTWEAK and IL-17A Levels in Inflammatory Bowel Disease Associated with Disease Activity and Etiopathogenesis?", "doi": "10.1097/mib.0000000000000632", "year": 2015 } ] } }, { "id": 38626, "drug": "bimekizumab", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "inhibits", "mediator": "IL-17A", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "ulcerative colitis", "outcome_type": "disease", "outcome_domain": "inflammatory_bowel_disease", "score": 0.28903717578961646, "filtered_score": 0.28903717578961646, "filter_reason": null, "outreach_score": 0.28903717578961646, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "bimekizumab", "mediator_canonical": "il-17a", "outcome_canonical": "ulcerative colitis", "ab_count": 5, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "39215949", "title": "Safety and Efficacy of Bimekizumab in Patients with Psoriatic Arthritis: 2-Year Results from Two Phase 3 Studies", "doi": "10.1007/s40744-024-00708-8", "year": 2024 }, { "pmid": "39620046", "title": "Impact of bimekizumab and certolizumab pegol on efficacy, safety and osteoblastic activity in radiographic axial spondyloarthritis: results from a phase IIa, multicentre, randomised, double-blind, exploratory study with PET-CT imaging", "doi": "10.1177/1759720x241293944", "year": 2024 }, { "pmid": "37808274", "title": "Safe and Effective Subcutaneous Self-Injection of Bimekizumab with Safety Syringe and Auto-Injector Devices: Results from a Multicenter, Randomized, Open-Label Study in Patients with Psoriatic Arthritis", "doi": "10.2147/ppa.s427809", "year": 2023 } ], "bc": [ { "pmid": "37798683", "title": "Molecular analyses of ADAMTS-1, -4, -5, and IL-17 a cytokine relationship in patients with ulcerative colitis", "doi": "10.1186/s12876-023-02985-z", "year": 2023 }, { "pmid": "32724117", "title": "Serum interleukin 17A and interleukin 17F in children with inflammatory bowel disease", "doi": "10.1038/s41598-020-69567-x", "year": 2020 } ] } }, { "id": 7644, "drug": "glycyrrhizin", "drug_type": "drug", "drug_domain": "als", "predicate_ab": "binds_to", "mediator": "HMGB1", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "epilepsy", "outcome_type": "disease", "outcome_domain": "epilepsy", "score": 0.28903717578961646, "filtered_score": 0.28903717578961646, "filter_reason": null, "outreach_score": 0.28903717578961646, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "glycyrrhizin", "mediator_canonical": "HMGB1", "outcome_canonical": "epilepsy", "ab_count": 2, "bc_count": 5, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41139682", "title": "Therapeutic potential of glycyrrhizin in nervous system diseases", "doi": "10.1097/cm9.0000000000003806", "year": 2025 } ], "bc": [ { "pmid": "39466324", "title": "Clinical and biochemical assessments of circulating High Mobility Group Box Protein1 in children with epilepsy: relation to cognitive function and drug responsiveness", "doi": "10.1007/s10072-024-07795-z", "year": 2024 }, { "pmid": "32538745", "title": "Correlation of MMP-9 and HMGB1 expression with the cognitive function in patients with epilepsy and factors affecting the prognosis", "doi": "10.14715/cmb/2020.66.3.6", "year": 2020 }, { "pmid": "33150666", "title": "Evaluation of serum high-mobility group box 1 concentration in dogs with epilepsy: A case-control study", "doi": "10.1111/jvim.15940", "year": 2020 } ] } }, { "id": 40778, "drug": "dapagliflozin", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "upregulates", "mediator": "SIRT1", "mediator_type": "protein", "predicate_bc": "increases", "outcome": "proliferation", "outcome_type": "phenotype", "outcome_domain": "pancreatic_cancer", "score": 0.28903717578961646, "filtered_score": 0.28903717578961646, "filter_reason": null, "outreach_score": 0.28903717578961646, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "dapagliflozin", "mediator_canonical": "SIRT1", "outcome_canonical": null, "ab_count": 5, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37517289", "title": "Dapagliflozin prevents oxidative stress-induced endothelial dysfunction via sirtuin 1 activation", "doi": "10.1016/j.biopha.2023.115213", "year": 2023 }, { "pmid": "38017499", "title": "SIRT1 mediates the inhibitory effect of Dapagliflozin on EndMT by inhibiting the acetylation of endothelium Notch1", "doi": "10.1186/s12933-023-02040-x", "year": 2023 }, { "pmid": "37664712", "title": "Dapagliflozin impedes endothelial cell senescence by activating the SIRT1 signaling pathway in type 2 diabetes", "doi": "10.1016/j.heliyon.2023.e19152", "year": 2023 } ], "bc": [ { "pmid": "34163012", "title": "SIRT1 coordinates with the CRL4B complex to regulate pancreatic cancer stem cells to promote tumorigenesis", "doi": "10.1038/s41418-021-00821-z", "year": 2021 }, { "pmid": "27494892", "title": "Sirtuin 1 stimulates the proliferation and the expression of glycolysis genes in pancreatic neoplastic lesions", "doi": "10.18632/oncotarget.11013", "year": 2016 } ] } }, { "id": 51555, "drug": "sulforaphane", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "activates", "mediator": "Nrf2", "mediator_type": "protein", "predicate_bc": "causes", "outcome": "chemoresistance", "outcome_type": "phenotype", "outcome_domain": "pancreatic_cancer", "score": 0.28903717578961646, "filtered_score": 0.28903717578961646, "filter_reason": null, "outreach_score": 0.28903717578961646, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 5, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "33067900", "title": "Sulforaphane prevents age‐associated cardiac and muscular dysfunction through Nrf2 signaling", "doi": "10.1111/acel.13261", "year": 2020 }, { "pmid": "31270951", "title": "Protection against diabetic cardiomyopathy is achieved using a combination of sulforaphane and zinc in type 1 diabetic OVE26 mice", "doi": "10.1111/jcmm.14520", "year": 2019 }, { "pmid": "29353218", "title": "Sulforaphane prevents angiotensin II-induced cardiomyopathy by activation of Nrf2 via stimulating the Akt/GSK-3ß/Fyn pathway", "doi": "10.1016/j.redox.2017.12.016", "year": 2018 } ], "bc": [ { "pmid": "31911550", "title": "Undermining Glutaminolysis Bolsters Chemotherapy While NRF2 Promotes Chemoresistance in KRAS-Driven Pancreatic Cancers", "doi": "10.1158/0008-5472.can-19-1363", "year": 2020 }, { "pmid": "30735911", "title": "Digoxin sensitizes gemcitabine-resistant pancreatic cancer cells to gemcitabine via inhibiting Nrf2 signaling pathway", "doi": "10.1016/j.redox.2019.101131", "year": 2019 } ] } }, { "id": 40777, "drug": "dapagliflozin", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "upregulates", "mediator": "SIRT1", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "pancreatic cancer", "outcome_type": "disease", "outcome_domain": "pancreatic_cancer", "score": 0.28903717578961646, "filtered_score": 0.28903717578961646, "filter_reason": null, "outreach_score": 0.28903717578961646, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "completed", "clinical_trial_nct_ids": [ "NCT04542291" ], "literature_status": "partial_evidence", "drug_canonical": "dapagliflozin", "mediator_canonical": "SIRT1", "outcome_canonical": "pancreatic cancer", "ab_count": 5, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37517289", "title": "Dapagliflozin prevents oxidative stress-induced endothelial dysfunction via sirtuin 1 activation", "doi": "10.1016/j.biopha.2023.115213", "year": 2023 }, { "pmid": "38017499", "title": "SIRT1 mediates the inhibitory effect of Dapagliflozin on EndMT by inhibiting the acetylation of endothelium Notch1", "doi": "10.1186/s12933-023-02040-x", "year": 2023 }, { "pmid": "37664712", "title": "Dapagliflozin impedes endothelial cell senescence by activating the SIRT1 signaling pathway in type 2 diabetes", "doi": "10.1016/j.heliyon.2023.e19152", "year": 2023 } ], "bc": [ { "pmid": "34163012", "title": "SIRT1 coordinates with the CRL4B complex to regulate pancreatic cancer stem cells to promote tumorigenesis", "doi": "10.1038/s41418-021-00821-z", "year": 2021 }, { "pmid": "28351313", "title": "SIRT1 promotes the proliferation and metastasis of human pancreatic cancer cells", "doi": "10.1177/1010428317691180", "year": 2017 } ] } }, { "id": 1359, "drug": "Bevacizumab", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "binds_to", "mediator": "VEGF", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "Alzheimer's disease", "outcome_type": "disease", "outcome_domain": "alzheimer", "score": 0.28903717578961646, "filtered_score": 0.28903717578961646, "filter_reason": null, "outreach_score": 0.28903717578961646, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "bevacizumab", "mediator_canonical": "VEGF", "outcome_canonical": "Alzheimer disease", "ab_count": 5, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41951573", "title": "L-RNA aptamer-based CXCL12 inhibition combined with radiotherapy and bevacizumab in newly-diagnosed glioblastoma: expansion of the phase I/II GLORIA trial", "doi": "10.1038/s41467-026-71362-7", "year": 2026 }, { "pmid": "40757003", "title": "Developing Immunoniosomes (INs): Antibody and Fab conjugations of niosomal nanoparticles via UV-NBS and EDC/NHS chemistry for treating glioblastoma cells", "doi": "10.1016/j.ijpx.2025.100367", "year": 2025 }, { "pmid": "41431343", "title": "Incidence of Bevacizumab‐Associated Toxicity in Children With Low‐Grade Glioma With and Without Neurofibromatosis Type 1", "doi": "10.1002/1545-5017.70059", "year": 2025 } ], "bc": [ { "pmid": "39872450", "title": "Blood levels of cytokines highlight the role of inflammation in Alzheimer's disease", "doi": "10.1016/j.heliyon.2025.e41725", "year": 2025 }, { "pmid": "29933741", "title": "Vascular Endothelial Growth Factor remains unchanged in cerebrospinal fluid of patients with Alzheimer’s disease and vascular dementia", "doi": "10.1186/s13195-018-0385-8", "year": 2018 } ] } }, { "id": 51750, "drug": "sulforaphane", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "activates", "mediator": "Nrf2", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "rheumatoid arthritis", "outcome_type": "disease", "outcome_domain": "rheumatoid_arthritis", "score": 0.28903717578961646, "filtered_score": 0.28903717578961646, "filter_reason": null, "outreach_score": 0.28903717578961646, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 5, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "33067900", "title": "Sulforaphane prevents age‐associated cardiac and muscular dysfunction through Nrf2 signaling", "doi": "10.1111/acel.13261", "year": 2020 }, { "pmid": "31270951", "title": "Protection against diabetic cardiomyopathy is achieved using a combination of sulforaphane and zinc in type 1 diabetic OVE26 mice", "doi": "10.1111/jcmm.14520", "year": 2019 }, { "pmid": "29353218", "title": "Sulforaphane prevents angiotensin II-induced cardiomyopathy by activation of Nrf2 via stimulating the Akt/GSK-3ß/Fyn pathway", "doi": "10.1016/j.redox.2017.12.016", "year": 2018 } ], "bc": [ { "pmid": "40247798", "title": "Emerging Therapeutic Targets in Rheumatoid Arthritis: Focusing on HIF-1α, Nrf2, STATs, and RORγt", "doi": "10.2174/0113894501372670250408074908", "year": 2025 }, { "pmid": "36574898", "title": "Expression of Nrf2 protein in serum of patients with rheumatoid arthritis: A novel indicator for disease activity and disease prognosis", "doi": "10.1016/j.clinbiochem.2022.12.011", "year": 2022 } ] } }, { "id": 39402, "drug": "Empagliflozin", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "activates", "mediator": "AMPK", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "Alzheimer's disease", "outcome_type": "disease", "outcome_domain": "als", "score": 0.2772588722239781, "filtered_score": 0.2772588722239781, "filter_reason": null, "outreach_score": 0.2772588722239781, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "completed", "clinical_trial_nct_ids": [ "NCT05081219", "NCT03852901" ], "literature_status": "reproduces_known", "drug_canonical": "empagliflozin", "mediator_canonical": "AMPK", "outcome_canonical": "Alzheimer disease", "ab_count": 7, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40767292", "title": "Sodium Glucose Transporter 2 Inhibitor Protects Against Heart Failure With Preserved Ejection Fraction: Preclinical “2‐Hit” Model Reveals Autophagy Enhancement Via AMP‐Activated Protein Kinase/Mammalian Target of Rapamycin Complex 1 Pathway", "doi": "10.1161/jaha.124.040093", "year": 2025 }, { "pmid": "37373164", "title": "Empagliflozin Attenuates Vascular Calcification in Mice with Chronic Kidney Disease by Regulating the NFR2/HO-1 Anti-Inflammatory Pathway through AMPK Activation", "doi": "10.3390/ijms241210016", "year": 2023 }, { "pmid": "36358524", "title": "Effect of Empagliflozin on Thioacetamide-Induced Liver Injury in Rats: Role of AMPK/SIRT-1/HIF-1α Pathway in Halting Liver Fibrosis", "doi": "10.3390/antiox11112152", "year": 2022 } ], "bc": [ { "pmid": "34393724", "title": "Contribution of Energy Dysfunction to Impaired Protein Translation in Neurodegenerative Diseases", "doi": "10.3389/fncel.2021.668500", "year": 2021 } ] } }, { "id": 6868, "drug": "pentylenetetrazole", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "upregulates", "mediator": "α-synuclein", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "Parkinson's disease", "outcome_type": "disease", "outcome_domain": "alzheimer", "score": 0.2772588722239781, "filtered_score": 0.2772588722239781, "filter_reason": null, "outreach_score": 0.2772588722239781, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "pentylenetetrazole", "mediator_canonical": "SNCA", "outcome_canonical": "Parkinson disease", "ab_count": 1, "bc_count": 7, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "30308130", "title": "Effects of metformin on apoptosis and α-synuclein in a rat model of pentylenetetrazole-induced epilepsy", "doi": "10.1139/cjpp-2018-0266", "year": 2018 } ], "bc": [ { "pmid": "38338966", "title": "Retinal Alterations Predict Early Prodromal Signs of Neurodegenerative Disease", "doi": "10.3390/ijms25031689", "year": 2024 }, { "pmid": "38899873", "title": "Thioflavin T─a Reporter of Microviscosity in Protein Aggregation Process: The Study Case of α-Synuclein", "doi": "10.1021/acs.jpclett.4c00699", "year": 2024 }, { "pmid": "37956285", "title": "In pursuit of degenerative brain disease diagnosis: Dementia biomarkers detected by DNA aptamer-attached portable graphene biosensor", "doi": "10.1073/pnas.2311565120", "year": 2023 } ] } }, { "id": 5489, "drug": "paroxetine", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "downregulates", "mediator": "MMP-9", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "epilepsy", "outcome_type": "disease", "outcome_domain": "epilepsy", "score": 0.2772588722239781, "filtered_score": 0.2772588722239781, "filter_reason": null, "outreach_score": 0.2772588722239781, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "paroxetine", "mediator_canonical": "MMP9", "outcome_canonical": "epilepsy", "ab_count": 1, "bc_count": 7, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41698807", "title": "Targeting of HSP27 and MMP-2/9 Crosstalk by High-Throughput Drug Repurposing Strategies Identifies Paroxetine as a Potential Candidate in Glioblastoma", "doi": "10.1021/acs.jmedchem.5c03278", "year": 2026 } ], "bc": [ { "pmid": "38449733", "title": "Meta-analysis of MMP-9 levels in the serum of patients with epilepsy", "doi": "10.3389/fnins.2024.1296876", "year": 2024 }, { "pmid": "36766708", "title": "Blood-Brain Barrier-Associated Proteins Are Elevated in Serum of Epilepsy Patients", "doi": "10.3390/cells12030368", "year": 2023 }, { "pmid": "32538745", "title": "Correlation of MMP-9 and HMGB1 expression with the cognitive function in patients with epilepsy and factors affecting the prognosis", "doi": "10.14715/cmb/2020.66.3.6", "year": 2020 } ] } }, { "id": 38228, "drug": "infliximab", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "downregulates", "mediator": "MMP-9", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "epilepsy", "outcome_type": "disease", "outcome_domain": "epilepsy", "score": 0.2772588722239781, "filtered_score": 0.2772588722239781, "filter_reason": null, "outreach_score": 0.2772588722239781, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "infliximab", "mediator_canonical": "MMP9", "outcome_canonical": "epilepsy", "ab_count": 1, "bc_count": 7, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "36912319", "title": "Synovial monocytes from psoriatic and rheumatoid arthritis patients are modulated differently by TNF inhibitors and glucocorticoids: an ex-vivo study", "doi": "10.55563/clinexprheumatol/d3mfat", "year": 2022 } ], "bc": [ { "pmid": "38449733", "title": "Meta-analysis of MMP-9 levels in the serum of patients with epilepsy", "doi": "10.3389/fnins.2024.1296876", "year": 2024 }, { "pmid": "36766708", "title": "Blood-Brain Barrier-Associated Proteins Are Elevated in Serum of Epilepsy Patients", "doi": "10.3390/cells12030368", "year": 2023 }, { "pmid": "32538745", "title": "Correlation of MMP-9 and HMGB1 expression with the cognitive function in patients with epilepsy and factors affecting the prognosis", "doi": "10.14715/cmb/2020.66.3.6", "year": 2020 } ] } }, { "id": 50773, "drug": "Anti-CCL21 antibody", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "suppresses", "mediator": "MMP-9", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "epilepsy", "outcome_type": "disease", "outcome_domain": "epilepsy", "score": 0.2772588722239781, "filtered_score": 0.2772588722239781, "filter_reason": null, "outreach_score": 0.2772588722239781, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 7, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "26393504", "title": "Anti-CCL21 Antibody Attenuates Infarct Size and Improves Cardiac Remodeling After Myocardial Infarction", "doi": "10.1159/000430224", "year": 2015 } ], "bc": [ { "pmid": "38449733", "title": "Meta-analysis of MMP-9 levels in the serum of patients with epilepsy", "doi": "10.3389/fnins.2024.1296876", "year": 2024 }, { "pmid": "36766708", "title": "Blood-Brain Barrier-Associated Proteins Are Elevated in Serum of Epilepsy Patients", "doi": "10.3390/cells12030368", "year": 2023 }, { "pmid": "32538745", "title": "Correlation of MMP-9 and HMGB1 expression with the cognitive function in patients with epilepsy and factors affecting the prognosis", "doi": "10.14715/cmb/2020.66.3.6", "year": 2020 } ] } }, { "id": 578, "drug": "Astaxanthin", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "downregulates", "mediator": "MMP-9", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "epilepsy", "outcome_type": "disease", "outcome_domain": "epilepsy", "score": 0.2772588722239781, "filtered_score": 0.2772588722239781, "filter_reason": null, "outreach_score": 0.2772588722239781, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "astaxanthin", "mediator_canonical": "MMP9", "outcome_canonical": "epilepsy", "ab_count": 1, "bc_count": 7, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "32711429", "title": "Anti-Migration and Invasion Effects of Astaxanthin against A172 Human Glioblastoma Cell Line", "doi": "10.31557/apjcp.2020.21.7.2029", "year": 2020 } ], "bc": [ { "pmid": "38449733", "title": "Meta-analysis of MMP-9 levels in the serum of patients with epilepsy", "doi": "10.3389/fnins.2024.1296876", "year": 2024 }, { "pmid": "36766708", "title": "Blood-Brain Barrier-Associated Proteins Are Elevated in Serum of Epilepsy Patients", "doi": "10.3390/cells12030368", "year": 2023 }, { "pmid": "32538745", "title": "Correlation of MMP-9 and HMGB1 expression with the cognitive function in patients with epilepsy and factors affecting the prognosis", "doi": "10.14715/cmb/2020.66.3.6", "year": 2020 } ] } }, { "id": 9585, "drug": "Indox", "drug_type": "drug", "drug_domain": "pancreatic_cancer", "predicate_ab": "downregulates", "mediator": "MMP-9", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "epilepsy", "outcome_type": "disease", "outcome_domain": "epilepsy", "score": 0.2772588722239781, "filtered_score": 0.2772588722239781, "filter_reason": null, "outreach_score": 0.2772588722239781, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "indox", "mediator_canonical": "MMP9", "outcome_canonical": "epilepsy", "ab_count": 1, "bc_count": 7, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "31671317", "title": "Indirubin 3′-Oxime Inhibits Migration, Invasion, and Metastasis in Mice Bearing Spontaneously Occurring Pancreatic Cancer via Blocking the RAF/ERK, AKT, and SAPK/JNK Pathways", "doi": "10.1016/j.tranon.2019.08.010", "year": 2019 } ], "bc": [ { "pmid": "38449733", "title": "Meta-analysis of MMP-9 levels in the serum of patients with epilepsy", "doi": "10.3389/fnins.2024.1296876", "year": 2024 }, { "pmid": "36766708", "title": "Blood-Brain Barrier-Associated Proteins Are Elevated in Serum of Epilepsy Patients", "doi": "10.3390/cells12030368", "year": 2023 }, { "pmid": "32538745", "title": "Correlation of MMP-9 and HMGB1 expression with the cognitive function in patients with epilepsy and factors affecting the prognosis", "doi": "10.14715/cmb/2020.66.3.6", "year": 2020 } ] } }, { "id": 38235, "drug": "gp130 monoclonal antibody", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "downregulates", "mediator": "MMP-9", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "epilepsy", "outcome_type": "disease", "outcome_domain": "epilepsy", "score": 0.2772588722239781, "filtered_score": 0.2772588722239781, "filter_reason": null, "outreach_score": 0.2772588722239781, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "gp130 monoclonal antibody", "mediator_canonical": "MMP9", "outcome_canonical": "epilepsy", "ab_count": 1, "bc_count": 7, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "33604457", "title": "The study of gp130/the inflammatory factors regulating osteoclast differentiation in rheumatoid arthritis", "doi": "10.1016/j.bbrep.2021.100934", "year": 2021 } ], "bc": [ { "pmid": "38449733", "title": "Meta-analysis of MMP-9 levels in the serum of patients with epilepsy", "doi": "10.3389/fnins.2024.1296876", "year": 2024 }, { "pmid": "36766708", "title": "Blood-Brain Barrier-Associated Proteins Are Elevated in Serum of Epilepsy Patients", "doi": "10.3390/cells12030368", "year": 2023 }, { "pmid": "32538745", "title": "Correlation of MMP-9 and HMGB1 expression with the cognitive function in patients with epilepsy and factors affecting the prognosis", "doi": "10.14715/cmb/2020.66.3.6", "year": 2020 } ] } }, { "id": 39401, "drug": "Sitagliptin", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "inhibits", "mediator": "DPP4", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "microglial dysregulation", "outcome_type": "phenotype", "outcome_domain": "als", "score": 0.2772588722239781, "filtered_score": 0.2772588722239781, "filter_reason": null, "outreach_score": 0.2772588722239781, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "sitagliptin", "mediator_canonical": "dpp4", "outcome_canonical": "microglial dysregulation", "ab_count": 7, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "34493714", "title": "Dipeptidyl peptidase-4 (DPP4) inhibitor sitagliptin alleviates liver inflammation of diabetic mice by acting as a ROS scavenger and inhibiting the NFκB pathway", "doi": "10.1038/s41420-021-00625-7", "year": 2021 }, { "pmid": "32724076", "title": "Plasma levels of DPP4 activity and sDPP4 are dissociated from inflammation in mice and humans", "doi": "10.1038/s41467-020-17556-z", "year": 2020 }, { "pmid": "33151168", "title": "Sitagliptin: a potential drug for the treatment of COVID-19?", "doi": "10.2478/acph-2021-0013", "year": 2020 } ], "bc": [ { "pmid": "37736756", "title": "C9orf72-ALS human iPSC microglia are pro-inflammatory and toxic to co-cultured motor neurons via MMP9", "doi": "10.1038/s41467-023-41603-0", "year": 2023 } ] } }, { "id": 39400, "drug": "Empagliflozin", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "activates", "mediator": "AMPK", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "amyotrophic lateral sclerosis", "outcome_type": "disease", "outcome_domain": "als", "score": 0.2772588722239781, "filtered_score": 0.2772588722239781, "filter_reason": null, "outreach_score": 0.2772588722239781, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "empagliflozin", "mediator_canonical": "AMPK", "outcome_canonical": "amyotrophic lateral sclerosis", "ab_count": 7, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40767292", "title": "Sodium Glucose Transporter 2 Inhibitor Protects Against Heart Failure With Preserved Ejection Fraction: Preclinical “2‐Hit” Model Reveals Autophagy Enhancement Via AMP‐Activated Protein Kinase/Mammalian Target of Rapamycin Complex 1 Pathway", "doi": "10.1161/jaha.124.040093", "year": 2025 }, { "pmid": "37373164", "title": "Empagliflozin Attenuates Vascular Calcification in Mice with Chronic Kidney Disease by Regulating the NFR2/HO-1 Anti-Inflammatory Pathway through AMPK Activation", "doi": "10.3390/ijms241210016", "year": 2023 }, { "pmid": "36358524", "title": "Effect of Empagliflozin on Thioacetamide-Induced Liver Injury in Rats: Role of AMPK/SIRT-1/HIF-1α Pathway in Halting Liver Fibrosis", "doi": "10.3390/antiox11112152", "year": 2022 } ], "bc": [ { "pmid": "34393724", "title": "Contribution of Energy Dysfunction to Impaired Protein Translation in Neurodegenerative Diseases", "doi": "10.3389/fncel.2021.668500", "year": 2021 } ] } }, { "id": 40169, "drug": "Canagliflozin", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "inhibits", "mediator": "mTOR", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "glioblastoma", "outcome_type": "disease", "outcome_domain": "glioblastoma", "score": 0.2772588722239781, "filtered_score": 0.2772588722239781, "filter_reason": null, "outreach_score": 0.2772588722239781, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "canagliflozin", "mediator_canonical": "mTOR", "outcome_canonical": "glioblastoma", "ab_count": 3, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37584455", "title": "Canagliflozin mediates tumor suppression alone and in combination with radiotherapy in non‐small cell lung cancer (NSCLC) through inhibition of HIF‐1α", "doi": "10.1002/1878-0261.13508", "year": 2023 }, { "pmid": "34142035", "title": "Canagliflozin attenuates lipotoxicity in cardiomyocytes and protects diabetic mouse hearts by inhibiting the mTOR/HIF-1α pathway", "doi": "10.1016/j.isci.2021.102521", "year": 2021 } ], "bc": [ { "pmid": "39622049", "title": "A Dual-Target and Dual-Mechanism Design Strategy by Combining Inhibition and Degradation Together", "doi": "10.1021/jacs.4c11930", "year": 2024 }, { "pmid": "33162811", "title": "Mitochondrial dysfunction contributes to Rapamycin-induced apoptosis of Human Glioblastoma Cells - A synergistic effect with Temozolomide", "doi": "10.7150/ijms.40159", "year": 2020 }, { "pmid": "30793789", "title": "The effect of the mTOR inhibitor rapamycin on glucoCEST signal in a preclinical model of glioblastoma", "doi": "10.1002/mrm.27683", "year": 2019 } ] } }, { "id": 60985, "drug": "Empagliflozin", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "activates", "mediator": "AMPK", "mediator_type": "protein", "predicate_bc": "increases", "outcome": "glycogen storage", "outcome_type": "phenotype", "outcome_domain": "heart_failure", "score": 0.2772588722239781, "filtered_score": 0.2772588722239781, "filter_reason": null, "outreach_score": 0.2772588722239781, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 7, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40767292", "title": "Sodium Glucose Transporter 2 Inhibitor Protects Against Heart Failure With Preserved Ejection Fraction: Preclinical “2‐Hit” Model Reveals Autophagy Enhancement Via AMP‐Activated Protein Kinase/Mammalian Target of Rapamycin Complex 1 Pathway", "doi": "10.1161/jaha.124.040093", "year": 2025 }, { "pmid": "37373164", "title": "Empagliflozin Attenuates Vascular Calcification in Mice with Chronic Kidney Disease by Regulating the NFR2/HO-1 Anti-Inflammatory Pathway through AMPK Activation", "doi": "10.3390/ijms241210016", "year": 2023 }, { "pmid": "36358524", "title": "Effect of Empagliflozin on Thioacetamide-Induced Liver Injury in Rats: Role of AMPK/SIRT-1/HIF-1α Pathway in Halting Liver Fibrosis", "doi": "10.3390/antiox11112152", "year": 2022 } ], "bc": [ { "pmid": "28009297", "title": "Integrative Analysis of PRKAG2 Cardiomyopathy iPS and Microtissue Models Identifies AMPK as a Regulator of Metabolism, Survival, and Fibrosis", "doi": "10.1016/j.celrep.2016.11.066", "year": 2016 } ] } }, { "id": 4588, "drug": "LXA4", "drug_type": "drug", "drug_domain": "pancreatic_cancer", "predicate_ab": "inhibits", "mediator": "MMP-9", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "epilepsy", "outcome_type": "disease", "outcome_domain": "epilepsy", "score": 0.2772588722239781, "filtered_score": 0.2772588722239781, "filter_reason": null, "outreach_score": 0.2772588722239781, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "lxa4", "mediator_canonical": "MMP9", "outcome_canonical": "epilepsy", "ab_count": 1, "bc_count": 7, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "26649143", "title": "Lipoxin A4 Attenuates Cell Invasion by Inhibiting ROS/ERK/MMP Pathway in Pancreatic Cancer", "doi": "10.1155/2016/6815727", "year": 2015 } ], "bc": [ { "pmid": "38449733", "title": "Meta-analysis of MMP-9 levels in the serum of patients with epilepsy", "doi": "10.3389/fnins.2024.1296876", "year": 2024 }, { "pmid": "36766708", "title": "Blood-Brain Barrier-Associated Proteins Are Elevated in Serum of Epilepsy Patients", "doi": "10.3390/cells12030368", "year": 2023 }, { "pmid": "32538745", "title": "Correlation of MMP-9 and HMGB1 expression with the cognitive function in patients with epilepsy and factors affecting the prognosis", "doi": "10.14715/cmb/2020.66.3.6", "year": 2020 } ] } }, { "id": 39981, "drug": "Empagliflozin", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "activates", "mediator": "AMPK", "mediator_type": "protein", "predicate_bc": "increases", "outcome": "spike-wave seizures", "outcome_type": "phenotype", "outcome_domain": "epilepsy", "score": 0.2772588722239781, "filtered_score": 0.2772588722239781, "filter_reason": null, "outreach_score": 0.2772588722239781, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "empagliflozin", "mediator_canonical": "AMPK", "outcome_canonical": "spike-wave seizures", "ab_count": 7, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40767292", "title": "Sodium Glucose Transporter 2 Inhibitor Protects Against Heart Failure With Preserved Ejection Fraction: Preclinical “2‐Hit” Model Reveals Autophagy Enhancement Via AMP‐Activated Protein Kinase/Mammalian Target of Rapamycin Complex 1 Pathway", "doi": "10.1161/jaha.124.040093", "year": 2025 }, { "pmid": "37373164", "title": "Empagliflozin Attenuates Vascular Calcification in Mice with Chronic Kidney Disease by Regulating the NFR2/HO-1 Anti-Inflammatory Pathway through AMPK Activation", "doi": "10.3390/ijms241210016", "year": 2023 }, { "pmid": "36358524", "title": "Effect of Empagliflozin on Thioacetamide-Induced Liver Injury in Rats: Role of AMPK/SIRT-1/HIF-1α Pathway in Halting Liver Fibrosis", "doi": "10.3390/antiox11112152", "year": 2022 } ], "bc": [ { "pmid": "35134125", "title": "AMPK-mediated potentiation of GABAergic signalling drives hypoglycaemia-provoked spike-wave seizures", "doi": "10.1093/brain/awac037", "year": 2022 } ] } }, { "id": 39980, "drug": "Empagliflozin", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "activates", "mediator": "AMPK", "mediator_type": "protein", "predicate_bc": "increases", "outcome": "epileptiform network activity", "outcome_type": "phenotype", "outcome_domain": "epilepsy", "score": 0.2772588722239781, "filtered_score": 0.2772588722239781, "filter_reason": null, "outreach_score": 0.2772588722239781, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "empagliflozin", "mediator_canonical": "AMPK", "outcome_canonical": "epileptiform network activity", "ab_count": 7, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40767292", "title": "Sodium Glucose Transporter 2 Inhibitor Protects Against Heart Failure With Preserved Ejection Fraction: Preclinical “2‐Hit” Model Reveals Autophagy Enhancement Via AMP‐Activated Protein Kinase/Mammalian Target of Rapamycin Complex 1 Pathway", "doi": "10.1161/jaha.124.040093", "year": 2025 }, { "pmid": "37373164", "title": "Empagliflozin Attenuates Vascular Calcification in Mice with Chronic Kidney Disease by Regulating the NFR2/HO-1 Anti-Inflammatory Pathway through AMPK Activation", "doi": "10.3390/ijms241210016", "year": 2023 }, { "pmid": "36358524", "title": "Effect of Empagliflozin on Thioacetamide-Induced Liver Injury in Rats: Role of AMPK/SIRT-1/HIF-1α Pathway in Halting Liver Fibrosis", "doi": "10.3390/antiox11112152", "year": 2022 } ], "bc": [ { "pmid": "35134125", "title": "AMPK-mediated potentiation of GABAergic signalling drives hypoglycaemia-provoked spike-wave seizures", "doi": "10.1093/brain/awac037", "year": 2022 } ] } }, { "id": 30333, "drug": "long-term ketogenic diet", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "activates", "mediator": "TCF7L2", "mediator_type": "gene", "predicate_bc": "associated_with", "outcome": "type 2 diabetes", "outcome_type": "disease", "outcome_domain": "type_2_diabetes", "score": 0.2772588722239781, "filtered_score": 0.2772588722239781, "filter_reason": null, "outreach_score": 0.2772588722239781, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "long-term ketogenic diet", "mediator_canonical": "tcf7l2", "outcome_canonical": "type 2 diabetes", "ab_count": 1, "bc_count": 7, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "39662156", "title": "Differential effects of short-term and long-term ketogenic diet on gene expression in the aging mouse brain", "doi": "10.1016/j.jnha.2024.100427", "year": 2024 } ], "bc": [ { "pmid": "31049640", "title": "Genome-wide association study of type 2 diabetes in Africa", "doi": "10.1007/s00125-019-4880-7", "year": 2019 }, { "pmid": "31123324", "title": "ATAC-seq reveals alterations in open chromatin in pancreatic islets from subjects with type 2 diabetes", "doi": "10.1038/s41598-019-44076-8", "year": 2019 }, { "pmid": "29871606", "title": "Impact of KCNQ1, CDKN2A/2B, CDKAL1, HHEX, MTNR1B, SLC30A8, TCF7L2, and UBE2E2 on risk of developing type 2 diabetes in Thai population", "doi": "10.1186/s12881-018-0614-9", "year": 2018 } ] } }, { "id": 38233, "drug": "doxycycline", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "inhibits", "mediator": "MMP-9", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "epilepsy", "outcome_type": "disease", "outcome_domain": "epilepsy", "score": 0.2772588722239781, "filtered_score": 0.2772588722239781, "filter_reason": null, "outreach_score": 0.2772588722239781, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "doxycycline", "mediator_canonical": "MMP9", "outcome_canonical": "epilepsy", "ab_count": 1, "bc_count": 7, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "33185166", "title": "Predictors of Cardiovascular Affection in Patients with Active Rheumatoid Arthritis: Secondary Analysis of a Randomized Controlled Trial", "doi": "10.2174/1573397116666201113090145", "year": 2020 } ], "bc": [ { "pmid": "38449733", "title": "Meta-analysis of MMP-9 levels in the serum of patients with epilepsy", "doi": "10.3389/fnins.2024.1296876", "year": 2024 }, { "pmid": "36766708", "title": "Blood-Brain Barrier-Associated Proteins Are Elevated in Serum of Epilepsy Patients", "doi": "10.3390/cells12030368", "year": 2023 }, { "pmid": "32538745", "title": "Correlation of MMP-9 and HMGB1 expression with the cognitive function in patients with epilepsy and factors affecting the prognosis", "doi": "10.14715/cmb/2020.66.3.6", "year": 2020 } ] } }, { "id": 4379, "drug": "Monensin", "drug_type": "drug", "drug_domain": "pancreatic_cancer", "predicate_ab": "downregulates", "mediator": "EGFR", "mediator_type": "gene", "predicate_bc": "associated_with", "outcome": "glioblastoma", "outcome_type": "disease", "outcome_domain": "glioblastoma", "score": 0.2772588722239781, "filtered_score": 0.2772588722239781, "filter_reason": null, "outreach_score": 0.2772588722239781, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "monensin", "mediator_canonical": "EGFR", "outcome_canonical": "glioblastoma", "ab_count": 1, "bc_count": 7, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "30559409", "title": "Monensin inhibits cell proliferation and tumor growth of chemo-resistant pancreatic cancer cells by targeting the EGFR signaling pathway", "doi": "10.1038/s41598-018-36214-5", "year": 2018 } ], "bc": [ { "pmid": "40638267", "title": "Integrative multi-omics analysis reveal novel therapeutic targets for glioblastoma", "doi": "10.1097/js9.0000000000002941", "year": 2025 }, { "pmid": "41003641", "title": "Molecular Characterization of a Rare Glioblastoma Case With Atypical Histopathologic Features", "doi": "10.46883/2025.25921050", "year": 2025 }, { "pmid": "38553638", "title": "Generation of glioblastoma in mice engrafted with human cytomegalovirus-infected astrocytes", "doi": "10.1038/s41417-024-00767-7", "year": 2024 } ] } }, { "id": 4375, "drug": "cetuximab", "drug_type": "drug", "drug_domain": "pancreatic_cancer", "predicate_ab": "binds_to", "mediator": "EGFR", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "worse survival", "outcome_type": "phenotype", "outcome_domain": "glioblastoma", "score": 0.2772588722239781, "filtered_score": 0.2772588722239781, "filter_reason": null, "outreach_score": 0.2772588722239781, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "cetuximab", "mediator_canonical": "EGFR", "outcome_canonical": null, "ab_count": 7, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37772552", "title": "Cetuximab Enhances the Efficacy of MRTX1133, a Novel KRASG12DInhibitor, in Colorectal Cancer Treatment", "doi": "10.21873/anticanres.16629", "year": 2023 }, { "pmid": "35300246", "title": "Cetuximab, gemcitabine and radiotherapy in locally advanced pancreatic cancer: Long-term results of the randomized controlled phase II PARC trial", "doi": "10.1016/j.ctro.2022.03.003", "year": 2022 }, { "pmid": "32103952", "title": "<p>Targeting Pancreatic Cancer Cells and Stellate Cells Using Designer Nanotherapeutics in vitro</p>", "doi": "10.2147/ijn.s234112", "year": 2020 } ], "bc": [ { "pmid": "36035640", "title": "Immunohistochemical Detection and Prognostic Significance of p53, Epidermal Growth Factor Receptor, Murine Double Minute 2, and Isocitrate Dehydrogenase 1 in Glioblastoma Multiforme Patients of Pakistan", "doi": "10.1177/11795549221119107", "year": 2022 } ] } }, { "id": 40375, "drug": "Empagliflozin", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "activates", "mediator": "AMPK", "mediator_type": "protein", "predicate_bc": "treats", "outcome": "intestinal inflammation", "outcome_type": "disease", "outcome_domain": "inflammatory_bowel_disease", "score": 0.2772588722239781, "filtered_score": 0.2772588722239781, "filter_reason": null, "outreach_score": 0.2772588722239781, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "empagliflozin", "mediator_canonical": "AMPK", "outcome_canonical": "intestinal inflammation", "ab_count": 7, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40767292", "title": "Sodium Glucose Transporter 2 Inhibitor Protects Against Heart Failure With Preserved Ejection Fraction: Preclinical “2‐Hit” Model Reveals Autophagy Enhancement Via AMP‐Activated Protein Kinase/Mammalian Target of Rapamycin Complex 1 Pathway", "doi": "10.1161/jaha.124.040093", "year": 2025 }, { "pmid": "37373164", "title": "Empagliflozin Attenuates Vascular Calcification in Mice with Chronic Kidney Disease by Regulating the NFR2/HO-1 Anti-Inflammatory Pathway through AMPK Activation", "doi": "10.3390/ijms241210016", "year": 2023 }, { "pmid": "36358524", "title": "Effect of Empagliflozin on Thioacetamide-Induced Liver Injury in Rats: Role of AMPK/SIRT-1/HIF-1α Pathway in Halting Liver Fibrosis", "doi": "10.3390/antiox11112152", "year": 2022 } ], "bc": [ { "pmid": "33252129", "title": "Salicylates Ameliorate Intestinal Inflammation by Activating Macrophage AMPK", "doi": "10.1093/ibd/izaa305", "year": 2020 } ] } }, { "id": 23411, "drug": "pentamidine", "drug_type": "drug", "drug_domain": "multiple_sclerosis", "predicate_ab": "inhibits", "mediator": "S100B", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "ALS", "outcome_type": "disease", "outcome_domain": "als", "score": 0.2772588722239781, "filtered_score": 0.2772588722239781, "filter_reason": null, "outreach_score": 0.2772588722239781, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "pentamidine", "mediator_canonical": "s100b", "outcome_canonical": "amyotrophic lateral sclerosis", "ab_count": 3, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40649727", "title": "Effect on Different Glial Cell Types of S100B Modulation in Multiple Sclerosis Experimental Models", "doi": "10.3390/ijms26135948", "year": 2025 }, { "pmid": "35620168", "title": "S100B inhibition protects from chronic experimental autoimmune encephalomyelitis", "doi": "10.1093/braincomms/fcac076", "year": 2022 }, { "pmid": "32197530", "title": "The S100B Inhibitor Pentamidine Ameliorates Clinical Score and Neuropathology of Relapsing—Remitting Multiple Sclerosis Mouse Model", "doi": "10.3390/cells9030748", "year": 2020 } ], "bc": [ { "pmid": "35216298", "title": "The Involvement of RAGE and Its Ligands during Progression of ALS in SOD1 G93A Transgenic Mice", "doi": "10.3390/ijms23042184", "year": 2022 }, { "pmid": "28713206", "title": "The Astrocytic S100B Protein with Its Receptor RAGE Is Aberrantly Expressed in SOD1G93A Models, and Its Inhibition Decreases the Expression of Proinflammatory Genes", "doi": "10.1155/2017/1626204", "year": 2017 }, { "pmid": "26733811", "title": "Receptor for Advanced Glycation End Products and its Inflammatory Ligands are Upregulated in Amyotrophic Lateral Sclerosis", "doi": "10.3389/fncel.2015.00485", "year": 2015 } ] } }, { "id": 40376, "drug": "Empagliflozin", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "activates", "mediator": "AMPK", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "intestinal epithelial repair", "outcome_type": "phenotype", "outcome_domain": "inflammatory_bowel_disease", "score": 0.2772588722239781, "filtered_score": 0.2772588722239781, "filter_reason": null, "outreach_score": 0.2772588722239781, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "empagliflozin", "mediator_canonical": "AMPK", "outcome_canonical": "intestinal epithelial repair", "ab_count": 7, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40767292", "title": "Sodium Glucose Transporter 2 Inhibitor Protects Against Heart Failure With Preserved Ejection Fraction: Preclinical “2‐Hit” Model Reveals Autophagy Enhancement Via AMP‐Activated Protein Kinase/Mammalian Target of Rapamycin Complex 1 Pathway", "doi": "10.1161/jaha.124.040093", "year": 2025 }, { "pmid": "37373164", "title": "Empagliflozin Attenuates Vascular Calcification in Mice with Chronic Kidney Disease by Regulating the NFR2/HO-1 Anti-Inflammatory Pathway through AMPK Activation", "doi": "10.3390/ijms241210016", "year": 2023 }, { "pmid": "36358524", "title": "Effect of Empagliflozin on Thioacetamide-Induced Liver Injury in Rats: Role of AMPK/SIRT-1/HIF-1α Pathway in Halting Liver Fibrosis", "doi": "10.3390/antiox11112152", "year": 2022 } ], "bc": [ { "pmid": "35203241", "title": "Intestinal Epithelial AMPK Deficiency Causes Delayed Colonic Epithelial Repair in DSS-Induced Colitis", "doi": "10.3390/cells11040590", "year": 2022 } ] } }, { "id": 40780, "drug": "Empagliflozin", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "activates", "mediator": "AMPK", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "pancreatic ductal adenocarcinoma", "outcome_type": "disease", "outcome_domain": "pancreatic_cancer", "score": 0.2772588722239781, "filtered_score": 0.2772588722239781, "filter_reason": null, "outreach_score": 0.2772588722239781, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "empagliflozin", "mediator_canonical": "AMPK", "outcome_canonical": "pancreatic ductal adenocarcinoma", "ab_count": 7, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40767292", "title": "Sodium Glucose Transporter 2 Inhibitor Protects Against Heart Failure With Preserved Ejection Fraction: Preclinical “2‐Hit” Model Reveals Autophagy Enhancement Via AMP‐Activated Protein Kinase/Mammalian Target of Rapamycin Complex 1 Pathway", "doi": "10.1161/jaha.124.040093", "year": 2025 }, { "pmid": "37373164", "title": "Empagliflozin Attenuates Vascular Calcification in Mice with Chronic Kidney Disease by Regulating the NFR2/HO-1 Anti-Inflammatory Pathway through AMPK Activation", "doi": "10.3390/ijms241210016", "year": 2023 }, { "pmid": "36358524", "title": "Effect of Empagliflozin on Thioacetamide-Induced Liver Injury in Rats: Role of AMPK/SIRT-1/HIF-1α Pathway in Halting Liver Fibrosis", "doi": "10.3390/antiox11112152", "year": 2022 } ], "bc": [ { "pmid": "38885414", "title": "A Novel AMPK Inhibitor Sensitizes Pancreatic Cancer Cells to Ferroptosis Induction", "doi": "10.1002/advs.202307695", "year": 2024 } ] } }, { "id": 38427, "drug": "tofacitinib", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "inhibits", "mediator": "JAK/STAT pathway", "mediator_type": "pathway", "predicate_bc": "associated_with", "outcome": "anti-inflammatory environment", "outcome_type": "phenotype", "outcome_domain": "glioblastoma", "score": 0.2772588722239781, "filtered_score": 0.2772588722239781, "filter_reason": null, "outreach_score": 0.2772588722239781, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "tofacitinib", "mediator_canonical": "jak/stat pathway", "outcome_canonical": "anti-inflammatory environment", "ab_count": 7, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41834310", "title": "De novo Generalized Pustular Psoriasis: A Tofacitinib-Induced Paradoxical Adverse Event", "doi": "10.4103/idoj.idoj_328_25", "year": 2026 }, { "pmid": "40614601", "title": "Old drugs with new applications: Tofacitinib-mediated inhibition of M1-like macrophage polarization in acute pancreatitis by the JAK/STAT and emerging NOD-like receptor pathways", "doi": "10.1016/j.intimp.2025.115135", "year": 2025 }, { "pmid": "39220289", "title": "Tofacitinib for Pityriasis Rubra Pilaris: A Case Report", "doi": "10.2147/ccid.s470170", "year": 2024 } ], "bc": [ { "pmid": "31186414", "title": "Tumor-associated reactive astrocytes aid the evolution of immunosuppressive environment in glioblastoma", "doi": "10.1038/s41467-019-10493-6", "year": 2019 } ] } }, { "id": 38225, "drug": "tomatidine", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "downregulates", "mediator": "MMP-9", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "epilepsy", "outcome_type": "disease", "outcome_domain": "epilepsy", "score": 0.2772588722239781, "filtered_score": 0.2772588722239781, "filter_reason": null, "outreach_score": 0.2772588722239781, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "tomatidine", "mediator_canonical": "MMP9", "outcome_canonical": "epilepsy", "ab_count": 1, "bc_count": 7, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "34512321", "title": "Tomatidine Suppresses the Destructive Behaviors of Fibroblast-Like Synoviocytes and Ameliorates Type II Collagen-Induced Arthritis in Rats", "doi": "10.3389/fphar.2021.670707", "year": 2021 } ], "bc": [ { "pmid": "38449733", "title": "Meta-analysis of MMP-9 levels in the serum of patients with epilepsy", "doi": "10.3389/fnins.2024.1296876", "year": 2024 }, { "pmid": "36766708", "title": "Blood-Brain Barrier-Associated Proteins Are Elevated in Serum of Epilepsy Patients", "doi": "10.3390/cells12030368", "year": 2023 }, { "pmid": "32538745", "title": "Correlation of MMP-9 and HMGB1 expression with the cognitive function in patients with epilepsy and factors affecting the prognosis", "doi": "10.14715/cmb/2020.66.3.6", "year": 2020 } ] } }, { "id": 40779, "drug": "Empagliflozin", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "activates", "mediator": "AMPK", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "pancreatic cancer progression", "outcome_type": "disease", "outcome_domain": "pancreatic_cancer", "score": 0.2772588722239781, "filtered_score": 0.2772588722239781, "filter_reason": null, "outreach_score": 0.2772588722239781, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "empagliflozin", "mediator_canonical": "AMPK", "outcome_canonical": "pancreatic cancer progression", "ab_count": 7, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40767292", "title": "Sodium Glucose Transporter 2 Inhibitor Protects Against Heart Failure With Preserved Ejection Fraction: Preclinical “2‐Hit” Model Reveals Autophagy Enhancement Via AMP‐Activated Protein Kinase/Mammalian Target of Rapamycin Complex 1 Pathway", "doi": "10.1161/jaha.124.040093", "year": 2025 }, { "pmid": "37373164", "title": "Empagliflozin Attenuates Vascular Calcification in Mice with Chronic Kidney Disease by Regulating the NFR2/HO-1 Anti-Inflammatory Pathway through AMPK Activation", "doi": "10.3390/ijms241210016", "year": 2023 }, { "pmid": "36358524", "title": "Effect of Empagliflozin on Thioacetamide-Induced Liver Injury in Rats: Role of AMPK/SIRT-1/HIF-1α Pathway in Halting Liver Fibrosis", "doi": "10.3390/antiox11112152", "year": 2022 } ], "bc": [ { "pmid": "31205544", "title": "AMPK Inhibition Suppresses the Malignant Phenotype of Pancreatic Cancer Cells in Part by Attenuating Aerobic Glycolysis", "doi": "10.7150/jca.28299", "year": 2019 } ] } }, { "id": 40781, "drug": "Empagliflozin", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "activates", "mediator": "AMPK", "mediator_type": "protein", "predicate_bc": "decreases", "outcome": "invasion", "outcome_type": "phenotype", "outcome_domain": "pancreatic_cancer", "score": 0.2772588722239781, "filtered_score": 0.2772588722239781, "filter_reason": null, "outreach_score": 0.2772588722239781, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "empagliflozin", "mediator_canonical": "AMPK", "outcome_canonical": "invasion", "ab_count": 7, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40767292", "title": "Sodium Glucose Transporter 2 Inhibitor Protects Against Heart Failure With Preserved Ejection Fraction: Preclinical “2‐Hit” Model Reveals Autophagy Enhancement Via AMP‐Activated Protein Kinase/Mammalian Target of Rapamycin Complex 1 Pathway", "doi": "10.1161/jaha.124.040093", "year": 2025 }, { "pmid": "37373164", "title": "Empagliflozin Attenuates Vascular Calcification in Mice with Chronic Kidney Disease by Regulating the NFR2/HO-1 Anti-Inflammatory Pathway through AMPK Activation", "doi": "10.3390/ijms241210016", "year": 2023 }, { "pmid": "36358524", "title": "Effect of Empagliflozin on Thioacetamide-Induced Liver Injury in Rats: Role of AMPK/SIRT-1/HIF-1α Pathway in Halting Liver Fibrosis", "doi": "10.3390/antiox11112152", "year": 2022 } ], "bc": [ { "pmid": "28783244", "title": "Loss of AMPK activation promotes the invasion and metastasis of pancreatic cancer through an HSF1‐dependent pathway", "doi": "10.1002/1878-0261.12116", "year": 2017 } ] } }, { "id": 60989, "drug": "Empagliflozin", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "activates", "mediator": "AMPK", "mediator_type": "protein", "predicate_bc": "causes", "outcome": "dilated cardiomyopathy", "outcome_type": "disease", "outcome_domain": "heart_failure", "score": 0.2772588722239781, "filtered_score": 0.2772588722239781, "filter_reason": null, "outreach_score": 0.2772588722239781, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 7, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40767292", "title": "Sodium Glucose Transporter 2 Inhibitor Protects Against Heart Failure With Preserved Ejection Fraction: Preclinical “2‐Hit” Model Reveals Autophagy Enhancement Via AMP‐Activated Protein Kinase/Mammalian Target of Rapamycin Complex 1 Pathway", "doi": "10.1161/jaha.124.040093", "year": 2025 }, { "pmid": "37373164", "title": "Empagliflozin Attenuates Vascular Calcification in Mice with Chronic Kidney Disease by Regulating the NFR2/HO-1 Anti-Inflammatory Pathway through AMPK Activation", "doi": "10.3390/ijms241210016", "year": 2023 }, { "pmid": "36358524", "title": "Effect of Empagliflozin on Thioacetamide-Induced Liver Injury in Rats: Role of AMPK/SIRT-1/HIF-1α Pathway in Halting Liver Fibrosis", "doi": "10.3390/antiox11112152", "year": 2022 } ], "bc": [ { "pmid": "26023060", "title": "AMPK deficiency in cardiac muscle results in dilated cardiomyopathy in the absence of changes in energy metabolism", "doi": "10.1093/cvr/cvv166", "year": 2015 } ] } }, { "id": 2092, "drug": "zonisamide", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "downregulates", "mediator": "Cx43", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "ALS", "outcome_type": "disease", "outcome_domain": "als", "score": 0.2772588722239781, "filtered_score": 0.2772588722239781, "filter_reason": null, "outreach_score": 0.2772588722239781, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "zonisamide", "mediator_canonical": "GJA1", "outcome_canonical": "amyotrophic lateral sclerosis", "ab_count": 3, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "32516974", "title": "Effects of Carbamazepine, Lacosamide and Zonisamide on Gliotransmitter Release Associated with Activated Astroglial Hemichannels", "doi": "10.3390/ph13060117", "year": 2020 }, { "pmid": "32443400", "title": "Upregulated and Hyperactivated Thalamic Connexin 43 Plays Important Roles in Pathomechanisms of Cognitive Impairment and Seizure of Autosomal Dominant Sleep-Related Hypermotor Epilepsy with S284L-Mutant α4 Subunit of Nicotinic ACh Receptor", "doi": "10.3390/ph13050099", "year": 2020 } ], "bc": [ { "pmid": "35312356", "title": "Cx43 hemichannels contribute to astrocyte-mediated toxicity in sporadic and familial ALS", "doi": "10.1073/pnas.2107391119", "year": 2022 }, { "pmid": "27083773", "title": "Connexin 43 in astrocytes contributes to motor neuron toxicity in amyotrophic lateral sclerosis", "doi": "10.1002/glia.22989", "year": 2016 } ] } }, { "id": 32909, "drug": "scopoletin", "drug_type": "drug", "drug_domain": "inflammatory_bowel_disease", "predicate_ab": "suppresses", "mediator": "MMP-9", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "epilepsy", "outcome_type": "disease", "outcome_domain": "epilepsy", "score": 0.2772588722239781, "filtered_score": 0.2772588722239781, "filter_reason": null, "outreach_score": 0.2772588722239781, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "scopoletin", "mediator_canonical": "MMP9", "outcome_canonical": "epilepsy", "ab_count": 1, "bc_count": 7, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40995618", "title": "Scopoletin Mitigates DSS‐Induced Ulcerative Colitis by Attenuating NF‐κB/MMP‐9 Mediated Inflammation and Activating the Nrf2 Pathway to Preserve Colonic Barrier Integrity", "doi": "10.1002/ddr.70165", "year": 2025 } ], "bc": [ { "pmid": "38449733", "title": "Meta-analysis of MMP-9 levels in the serum of patients with epilepsy", "doi": "10.3389/fnins.2024.1296876", "year": 2024 }, { "pmid": "36766708", "title": "Blood-Brain Barrier-Associated Proteins Are Elevated in Serum of Epilepsy Patients", "doi": "10.3390/cells12030368", "year": 2023 }, { "pmid": "32538745", "title": "Correlation of MMP-9 and HMGB1 expression with the cognitive function in patients with epilepsy and factors affecting the prognosis", "doi": "10.14715/cmb/2020.66.3.6", "year": 2020 } ] } }, { "id": 4376, "drug": "licofelone+gefitinib", "drug_type": "drug", "drug_domain": "pancreatic_cancer", "predicate_ab": "downregulates", "mediator": "EGFR", "mediator_type": "gene", "predicate_bc": "associated_with", "outcome": "glioblastoma", "outcome_type": "disease", "outcome_domain": "glioblastoma", "score": 0.2772588722239781, "filtered_score": 0.2772588722239781, "filter_reason": null, "outreach_score": 0.2772588722239781, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "unknown", "drug_canonical": "licofelone+gefitinib", "mediator_canonical": "EGFR", "outcome_canonical": "glioblastoma", "ab_count": 1, "bc_count": 7, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "26429877", "title": "Simultaneous targeting of 5-LOX-COX and EGFR blocks progression of pancreatic ductal adenocarcinoma", "doi": "10.18632/oncotarget.5396", "year": 2015 } ], "bc": [ { "pmid": "40638267", "title": "Integrative multi-omics analysis reveal novel therapeutic targets for glioblastoma", "doi": "10.1097/js9.0000000000002941", "year": 2025 }, { "pmid": "41003641", "title": "Molecular Characterization of a Rare Glioblastoma Case With Atypical Histopathologic Features", "doi": "10.46883/2025.25921050", "year": 2025 }, { "pmid": "38553638", "title": "Generation of glioblastoma in mice engrafted with human cytomegalovirus-infected astrocytes", "doi": "10.1038/s41417-024-00767-7", "year": 2024 } ] } }, { "id": 4573, "drug": "APS", "drug_type": "drug", "drug_domain": "pancreatic_cancer", "predicate_ab": "downregulates", "mediator": "MMP-9", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "epilepsy", "outcome_type": "disease", "outcome_domain": "epilepsy", "score": 0.2772588722239781, "filtered_score": 0.2772588722239781, "filter_reason": null, "outreach_score": 0.2772588722239781, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "aps", "mediator_canonical": "MMP9", "outcome_canonical": "epilepsy", "ab_count": 1, "bc_count": 7, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "29785118", "title": "Traditional Chinese medicine <em>Astragalus </em>polysaccharide enhanced antitumor effects of the angiogenesis inhibitor apatinib in pancreatic cancer cells on proliferation, invasiveness, and apoptosis", "doi": "10.2147/ott.s157129", "year": 2018 } ], "bc": [ { "pmid": "38449733", "title": "Meta-analysis of MMP-9 levels in the serum of patients with epilepsy", "doi": "10.3389/fnins.2024.1296876", "year": 2024 }, { "pmid": "36766708", "title": "Blood-Brain Barrier-Associated Proteins Are Elevated in Serum of Epilepsy Patients", "doi": "10.3390/cells12030368", "year": 2023 }, { "pmid": "32538745", "title": "Correlation of MMP-9 and HMGB1 expression with the cognitive function in patients with epilepsy and factors affecting the prognosis", "doi": "10.14715/cmb/2020.66.3.6", "year": 2020 } ] } }, { "id": 38641, "drug": "tofacitinib", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "inhibits", "mediator": "JAK/STAT pathway", "mediator_type": "pathway", "predicate_bc": "predicts", "outcome": "post-operative recurrence", "outcome_type": "disease", "outcome_domain": "inflammatory_bowel_disease", "score": 0.2772588722239781, "filtered_score": 0.2772588722239781, "filter_reason": null, "outreach_score": 0.2772588722239781, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "tofacitinib", "mediator_canonical": "jak/stat pathway", "outcome_canonical": "post-operative recurrence", "ab_count": 7, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41834310", "title": "De novo Generalized Pustular Psoriasis: A Tofacitinib-Induced Paradoxical Adverse Event", "doi": "10.4103/idoj.idoj_328_25", "year": 2026 }, { "pmid": "40614601", "title": "Old drugs with new applications: Tofacitinib-mediated inhibition of M1-like macrophage polarization in acute pancreatitis by the JAK/STAT and emerging NOD-like receptor pathways", "doi": "10.1016/j.intimp.2025.115135", "year": 2025 }, { "pmid": "39220289", "title": "Tofacitinib for Pityriasis Rubra Pilaris: A Case Report", "doi": "10.2147/ccid.s470170", "year": 2024 } ], "bc": [ { "pmid": "35143619", "title": "Identification of Gene Expression Profiles Associated with an Increased Risk of Post-Operative Recurrence in Crohn’s Disease", "doi": "10.1093/ecco-jcc/jjac021", "year": 2022 } ] } }, { "id": 4381, "drug": "cetuximab", "drug_type": "drug", "drug_domain": "pancreatic_cancer", "predicate_ab": "binds_to", "mediator": "EGFR", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "glioblastoma aggressiveness", "outcome_type": "phenotype", "outcome_domain": "glioblastoma", "score": 0.2772588722239781, "filtered_score": 0.2772588722239781, "filter_reason": null, "outreach_score": 0.2772588722239781, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "cetuximab", "mediator_canonical": "EGFR", "outcome_canonical": "glioblastoma aggressiveness", "ab_count": 7, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37772552", "title": "Cetuximab Enhances the Efficacy of MRTX1133, a Novel KRASG12DInhibitor, in Colorectal Cancer Treatment", "doi": "10.21873/anticanres.16629", "year": 2023 }, { "pmid": "35300246", "title": "Cetuximab, gemcitabine and radiotherapy in locally advanced pancreatic cancer: Long-term results of the randomized controlled phase II PARC trial", "doi": "10.1016/j.ctro.2022.03.003", "year": 2022 }, { "pmid": "32103952", "title": "<p>Targeting Pancreatic Cancer Cells and Stellate Cells Using Designer Nanotherapeutics in vitro</p>", "doi": "10.2147/ijn.s234112", "year": 2020 } ], "bc": [ { "pmid": "36297416", "title": "Bioimaging Nucleic-Acid Aptamers with Different Specificities in Human Glioblastoma Tissues Highlights Tumoral Heterogeneity", "doi": "10.3390/pharmaceutics14101980", "year": 2022 } ] } }, { "id": 9584, "drug": "Deguelin", "drug_type": "drug", "drug_domain": "pancreatic_cancer", "predicate_ab": "suppresses", "mediator": "MMP-9", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "epilepsy", "outcome_type": "disease", "outcome_domain": "epilepsy", "score": 0.2772588722239781, "filtered_score": 0.2772588722239781, "filter_reason": null, "outreach_score": 0.2772588722239781, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "deguelin", "mediator_canonical": "MMP9", "outcome_canonical": "epilepsy", "ab_count": 1, "bc_count": 7, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "27698853", "title": "Deguelin inhibits proliferation and migration of human pancreatic cancer cells in vitro targeting hedgehog pathway", "doi": "10.3892/ol.2016.4928", "year": 2016 } ], "bc": [ { "pmid": "38449733", "title": "Meta-analysis of MMP-9 levels in the serum of patients with epilepsy", "doi": "10.3389/fnins.2024.1296876", "year": 2024 }, { "pmid": "36766708", "title": "Blood-Brain Barrier-Associated Proteins Are Elevated in Serum of Epilepsy Patients", "doi": "10.3390/cells12030368", "year": 2023 }, { "pmid": "32538745", "title": "Correlation of MMP-9 and HMGB1 expression with the cognitive function in patients with epilepsy and factors affecting the prognosis", "doi": "10.14715/cmb/2020.66.3.6", "year": 2020 } ] } }, { "id": 567, "drug": "Hesperetin", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "downregulates", "mediator": "MMP-9", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "epilepsy", "outcome_type": "disease", "outcome_domain": "epilepsy", "score": 0.2772588722239781, "filtered_score": 0.2772588722239781, "filter_reason": null, "outreach_score": 0.2772588722239781, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "hesperetin", "mediator_canonical": "MMP9", "outcome_canonical": "epilepsy", "ab_count": 1, "bc_count": 7, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "35836521", "title": "Hesperetin ameliorates glioblastoma by inhibiting proliferation, inducing apoptosis, and suppressing metastasis", "doi": "10.21037/tcr-22-1497", "year": 2022 } ], "bc": [ { "pmid": "38449733", "title": "Meta-analysis of MMP-9 levels in the serum of patients with epilepsy", "doi": "10.3389/fnins.2024.1296876", "year": 2024 }, { "pmid": "36766708", "title": "Blood-Brain Barrier-Associated Proteins Are Elevated in Serum of Epilepsy Patients", "doi": "10.3390/cells12030368", "year": 2023 }, { "pmid": "32538745", "title": "Correlation of MMP-9 and HMGB1 expression with the cognitive function in patients with epilepsy and factors affecting the prognosis", "doi": "10.14715/cmb/2020.66.3.6", "year": 2020 } ] } }, { "id": 9587, "drug": "paeoniflorin", "drug_type": "drug", "drug_domain": "pancreatic_cancer", "predicate_ab": "downregulates", "mediator": "MMP-9", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "epilepsy", "outcome_type": "disease", "outcome_domain": "epilepsy", "score": 0.2772588722239781, "filtered_score": 0.2772588722239781, "filter_reason": null, "outreach_score": 0.2772588722239781, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "paeoniflorin", "mediator_canonical": "MMP9", "outcome_canonical": "epilepsy", "ab_count": 1, "bc_count": 7, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "27446455", "title": "Paeoniflorin inhibits human pancreatic cancer cell apoptosis via suppression of MMP-9 and ERK signaling", "doi": "10.3892/ol.2016.4761", "year": 2016 } ], "bc": [ { "pmid": "38449733", "title": "Meta-analysis of MMP-9 levels in the serum of patients with epilepsy", "doi": "10.3389/fnins.2024.1296876", "year": 2024 }, { "pmid": "36766708", "title": "Blood-Brain Barrier-Associated Proteins Are Elevated in Serum of Epilepsy Patients", "doi": "10.3390/cells12030368", "year": 2023 }, { "pmid": "32538745", "title": "Correlation of MMP-9 and HMGB1 expression with the cognitive function in patients with epilepsy and factors affecting the prognosis", "doi": "10.14715/cmb/2020.66.3.6", "year": 2020 } ] } }, { "id": 60986, "drug": "Empagliflozin", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "activates", "mediator": "AMPK", "mediator_type": "protein", "predicate_bc": "increases", "outcome": "ventricular cell shortening", "outcome_type": "phenotype", "outcome_domain": "heart_failure", "score": 0.2772588722239781, "filtered_score": 0.2772588722239781, "filter_reason": null, "outreach_score": 0.2772588722239781, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 7, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40767292", "title": "Sodium Glucose Transporter 2 Inhibitor Protects Against Heart Failure With Preserved Ejection Fraction: Preclinical “2‐Hit” Model Reveals Autophagy Enhancement Via AMP‐Activated Protein Kinase/Mammalian Target of Rapamycin Complex 1 Pathway", "doi": "10.1161/jaha.124.040093", "year": 2025 }, { "pmid": "37373164", "title": "Empagliflozin Attenuates Vascular Calcification in Mice with Chronic Kidney Disease by Regulating the NFR2/HO-1 Anti-Inflammatory Pathway through AMPK Activation", "doi": "10.3390/ijms241210016", "year": 2023 }, { "pmid": "36358524", "title": "Effect of Empagliflozin on Thioacetamide-Induced Liver Injury in Rats: Role of AMPK/SIRT-1/HIF-1α Pathway in Halting Liver Fibrosis", "doi": "10.3390/antiox11112152", "year": 2022 } ], "bc": [ { "pmid": "26023060", "title": "AMPK deficiency in cardiac muscle results in dilated cardiomyopathy in the absence of changes in energy metabolism", "doi": "10.1093/cvr/cvv166", "year": 2015 } ] } }, { "id": 10376, "drug": "olanzapine", "drug_type": "drug", "drug_domain": "depression", "predicate_ab": "binds_to", "mediator": "EGFR", "mediator_type": "gene", "predicate_bc": "associated_with", "outcome": "glioblastoma", "outcome_type": "disease", "outcome_domain": "glioblastoma", "score": 0.2772588722239781, "filtered_score": 0.2772588722239781, "filter_reason": null, "outreach_score": 0.2772588722239781, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "active", "clinical_trial_nct_ids": [ "NCT04216329" ], "literature_status": "reproduces_known", "drug_canonical": "olanzapine", "mediator_canonical": "EGFR", "outcome_canonical": "glioblastoma", "ab_count": 1, "bc_count": 7, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41318403", "title": "Dual-target mechanisms of olanzapine in bipolar disorder: a network pharmacology and molecular docking study revealing phase-specific regulation of longevity and PI3K-Akt pathways", "doi": "10.1186/s12888-025-07661-y", "year": 2025 } ], "bc": [ { "pmid": "40638267", "title": "Integrative multi-omics analysis reveal novel therapeutic targets for glioblastoma", "doi": "10.1097/js9.0000000000002941", "year": 2025 }, { "pmid": "41003641", "title": "Molecular Characterization of a Rare Glioblastoma Case With Atypical Histopathologic Features", "doi": "10.46883/2025.25921050", "year": 2025 }, { "pmid": "38553638", "title": "Generation of glioblastoma in mice engrafted with human cytomegalovirus-infected astrocytes", "doi": "10.1038/s41417-024-00767-7", "year": 2024 } ] } }, { "id": 60987, "drug": "Empagliflozin", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "activates", "mediator": "AMPK", "mediator_type": "protein", "predicate_bc": "prevents", "outcome": "myocardial ischemia-reperfusion injury", "outcome_type": "disease", "outcome_domain": "heart_failure", "score": 0.2772588722239781, "filtered_score": 0.2772588722239781, "filter_reason": null, "outreach_score": 0.2772588722239781, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 7, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40767292", "title": "Sodium Glucose Transporter 2 Inhibitor Protects Against Heart Failure With Preserved Ejection Fraction: Preclinical “2‐Hit” Model Reveals Autophagy Enhancement Via AMP‐Activated Protein Kinase/Mammalian Target of Rapamycin Complex 1 Pathway", "doi": "10.1161/jaha.124.040093", "year": 2025 }, { "pmid": "37373164", "title": "Empagliflozin Attenuates Vascular Calcification in Mice with Chronic Kidney Disease by Regulating the NFR2/HO-1 Anti-Inflammatory Pathway through AMPK Activation", "doi": "10.3390/ijms241210016", "year": 2023 }, { "pmid": "36358524", "title": "Effect of Empagliflozin on Thioacetamide-Induced Liver Injury in Rats: Role of AMPK/SIRT-1/HIF-1α Pathway in Halting Liver Fibrosis", "doi": "10.3390/antiox11112152", "year": 2022 } ], "bc": [ { "pmid": "29689567", "title": "AMPK Contributes to Cardioprotective Effects of Pterostilbene Against Myocardial Ischemia- Reperfusion Injury in Diabetic Rats by Suppressing Cardiac Oxidative Stress and Apoptosis", "doi": "10.1159/000489154", "year": 2018 } ] } }, { "id": 60988, "drug": "Empagliflozin", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "activates", "mediator": "AMPK", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "cardiovascular aging", "outcome_type": "phenotype", "outcome_domain": "heart_failure", "score": 0.2772588722239781, "filtered_score": 0.2772588722239781, "filter_reason": null, "outreach_score": 0.2772588722239781, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 7, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40767292", "title": "Sodium Glucose Transporter 2 Inhibitor Protects Against Heart Failure With Preserved Ejection Fraction: Preclinical “2‐Hit” Model Reveals Autophagy Enhancement Via AMP‐Activated Protein Kinase/Mammalian Target of Rapamycin Complex 1 Pathway", "doi": "10.1161/jaha.124.040093", "year": 2025 }, { "pmid": "37373164", "title": "Empagliflozin Attenuates Vascular Calcification in Mice with Chronic Kidney Disease by Regulating the NFR2/HO-1 Anti-Inflammatory Pathway through AMPK Activation", "doi": "10.3390/ijms241210016", "year": 2023 }, { "pmid": "36358524", "title": "Effect of Empagliflozin on Thioacetamide-Induced Liver Injury in Rats: Role of AMPK/SIRT-1/HIF-1α Pathway in Halting Liver Fibrosis", "doi": "10.3390/antiox11112152", "year": 2022 } ], "bc": [ { "pmid": "41194190", "title": "Cellular senescence and cell therapy in cardiovascular diseases", "doi": "10.1186/s13287-025-04731-6", "year": 2025 } ] } }, { "id": 38236, "drug": "CLHE", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "downregulates", "mediator": "MMP-9", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "epilepsy", "outcome_type": "disease", "outcome_domain": "epilepsy", "score": 0.2772588722239781, "filtered_score": 0.2772588722239781, "filter_reason": null, "outreach_score": 0.2772588722239781, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "clhe", "mediator_canonical": "MMP9", "outcome_canonical": "epilepsy", "ab_count": 1, "bc_count": 7, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "39683414", "title": "Phytochemical, Cytoprotective Profiling, and Anti-Inflammatory Potential of Colchicum luteum in Rheumatoid Arthritis: An Experimental and Simulation Study", "doi": "10.3390/nu16234020", "year": 2024 } ], "bc": [ { "pmid": "38449733", "title": "Meta-analysis of MMP-9 levels in the serum of patients with epilepsy", "doi": "10.3389/fnins.2024.1296876", "year": 2024 }, { "pmid": "36766708", "title": "Blood-Brain Barrier-Associated Proteins Are Elevated in Serum of Epilepsy Patients", "doi": "10.3390/cells12030368", "year": 2023 }, { "pmid": "32538745", "title": "Correlation of MMP-9 and HMGB1 expression with the cognitive function in patients with epilepsy and factors affecting the prognosis", "doi": "10.14715/cmb/2020.66.3.6", "year": 2020 } ] } }, { "id": 4974, "drug": "cetuximab", "drug_type": "drug", "drug_domain": "pancreatic_cancer", "predicate_ab": "binds_to", "mediator": "EGFR", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "Alzheimer's disease", "outcome_type": "disease", "outcome_domain": "alzheimer", "score": 0.2772588722239781, "filtered_score": 0.2772588722239781, "filter_reason": null, "outreach_score": 0.2772588722239781, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "cetuximab", "mediator_canonical": "EGFR", "outcome_canonical": "Alzheimer disease", "ab_count": 7, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37772552", "title": "Cetuximab Enhances the Efficacy of MRTX1133, a Novel KRASG12DInhibitor, in Colorectal Cancer Treatment", "doi": "10.21873/anticanres.16629", "year": 2023 }, { "pmid": "35300246", "title": "Cetuximab, gemcitabine and radiotherapy in locally advanced pancreatic cancer: Long-term results of the randomized controlled phase II PARC trial", "doi": "10.1016/j.ctro.2022.03.003", "year": 2022 }, { "pmid": "32103952", "title": "<p>Targeting Pancreatic Cancer Cells and Stellate Cells Using Designer Nanotherapeutics in vitro</p>", "doi": "10.2147/ijn.s234112", "year": 2020 } ], "bc": [ { "pmid": "39252463", "title": "Plasma proteomics for risk prediction of Alzheimer's disease in the general population", "doi": "10.1111/acel.14330", "year": 2024 } ] } }, { "id": 40953, "drug": "Sitagliptin", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "inhibits", "mediator": "DPP4", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "autoimmune diseases", "outcome_type": "disease", "outcome_domain": "rheumatoid_arthritis", "score": 0.2772588722239781, "filtered_score": 0.2772588722239781, "filter_reason": null, "outreach_score": 0.2772588722239781, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "completed", "clinical_trial_nct_ids": [ "NCT05219409", "NCT04409795", "NCT06115460" ], "literature_status": "reproduces_known", "drug_canonical": "sitagliptin", "mediator_canonical": "dpp4", "outcome_canonical": "autoimmune diseases", "ab_count": 7, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "34493714", "title": "Dipeptidyl peptidase-4 (DPP4) inhibitor sitagliptin alleviates liver inflammation of diabetic mice by acting as a ROS scavenger and inhibiting the NFκB pathway", "doi": "10.1038/s41420-021-00625-7", "year": 2021 }, { "pmid": "32724076", "title": "Plasma levels of DPP4 activity and sDPP4 are dissociated from inflammation in mice and humans", "doi": "10.1038/s41467-020-17556-z", "year": 2020 }, { "pmid": "33151168", "title": "Sitagliptin: a potential drug for the treatment of COVID-19?", "doi": "10.2478/acph-2021-0013", "year": 2020 } ], "bc": [ { "pmid": "38544813", "title": "Revolutionizing Treatment Strategies for Autoimmune and Inflammatory Disorders: The Impact of Dipeptidyl-Peptidase 4 Inhibitors", "doi": "10.2147/jir.s442106", "year": 2024 } ] } }, { "id": 38808, "drug": "secukinumab", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "inhibits", "mediator": "IL-17A", "mediator_type": "protein", "predicate_bc": "predicts", "outcome": "cognitive impairment", "outcome_type": "phenotype", "outcome_domain": "multiple_sclerosis", "score": 0.270805020110221, "filtered_score": 0.270805020110221, "filter_reason": null, "outreach_score": 0.270805020110221, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "secukinumab", "mediator_canonical": "il-17a", "outcome_canonical": "cognitive impairment", "ab_count": 4, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "33913511", "title": "Efficacy of secukinumab and adalimumab in patients with psoriatic arthritis and concomitant moderate‐to‐severe plaque psoriasis: results from EXCEED, a randomized, double‐blind head‐to‐head monotherapy study", "doi": "10.1111/bjd.20413", "year": 2021 }, { "pmid": "34919658", "title": "Secukinumab-induced systemic lupus erythematosus occurring in a patient with ankylosing spondylitis", "doi": "10.1093/rheumatology/keab918", "year": 2021 }, { "pmid": "33120695", "title": "Role of secukinumab in ankylosing spondylitis with tubercular uveitis", "doi": "10.4103/ijo.ijo_1081_20", "year": 2020 } ], "bc": [ { "pmid": "29297273", "title": "Circulating levels of interleukin-17A, tumor necrosis factor-alpha, interleukin-18, interleukin-10, and cognitive performance of patients with relapsing-remitting multiple sclerosis", "doi": "10.1080/01616412.2017.1420522", "year": 2018 } ] } }, { "id": 35268, "drug": "DMF", "drug_type": "drug", "drug_domain": "multiple_sclerosis", "predicate_ab": "activates", "mediator": "Nrf2", "mediator_type": "protein", "predicate_bc": "causes", "outcome": "chemoresistance", "outcome_type": "phenotype", "outcome_domain": "pancreatic_cancer", "score": 0.270805020110221, "filtered_score": 0.270805020110221, "filter_reason": null, "outreach_score": 0.270805020110221, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "dmf", "mediator_canonical": "NRF2", "outcome_canonical": null, "ab_count": 4, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "35743211", "title": "Mechanisms of Sensitivity and Resistance of Primary Effusion Lymphoma to Dimethyl Fumarate (DMF)", "doi": "10.3390/ijms23126773", "year": 2022 }, { "pmid": "32672401", "title": "Structural insights into the multiple binding modes of Dimethyl Fumarate (DMF) and its analogs to the Kelch domain of Keap1", "doi": "10.1111/febs.15485", "year": 2020 }, { "pmid": "32394330", "title": "Characterization of More Selective Central Nervous System Nrf2-Activating Novel Vinyl Sulfoximine Compounds Compared to Dimethyl Fumarate", "doi": "10.1007/s13311-020-00855-0", "year": 2020 } ], "bc": [ { "pmid": "31911550", "title": "Undermining Glutaminolysis Bolsters Chemotherapy While NRF2 Promotes Chemoresistance in KRAS-Driven Pancreatic Cancers", "doi": "10.1158/0008-5472.can-19-1363", "year": 2020 }, { "pmid": "30735911", "title": "Digoxin sensitizes gemcitabine-resistant pancreatic cancer cells to gemcitabine via inhibiting Nrf2 signaling pathway", "doi": "10.1016/j.redox.2019.101131", "year": 2019 } ] } }, { "id": 35474, "drug": "DMF", "drug_type": "drug", "drug_domain": "multiple_sclerosis", "predicate_ab": "activates", "mediator": "Nrf2", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "rheumatoid arthritis", "outcome_type": "disease", "outcome_domain": "rheumatoid_arthritis", "score": 0.270805020110221, "filtered_score": 0.270805020110221, "filter_reason": null, "outreach_score": 0.270805020110221, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "completed", "clinical_trial_nct_ids": [ "NCT00810836" ], "literature_status": "reproduces_known", "drug_canonical": "dmf", "mediator_canonical": "NRF2", "outcome_canonical": "rheumatoid arthritis", "ab_count": 4, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "35743211", "title": "Mechanisms of Sensitivity and Resistance of Primary Effusion Lymphoma to Dimethyl Fumarate (DMF)", "doi": "10.3390/ijms23126773", "year": 2022 }, { "pmid": "32672401", "title": "Structural insights into the multiple binding modes of Dimethyl Fumarate (DMF) and its analogs to the Kelch domain of Keap1", "doi": "10.1111/febs.15485", "year": 2020 }, { "pmid": "32394330", "title": "Characterization of More Selective Central Nervous System Nrf2-Activating Novel Vinyl Sulfoximine Compounds Compared to Dimethyl Fumarate", "doi": "10.1007/s13311-020-00855-0", "year": 2020 } ], "bc": [ { "pmid": "40247798", "title": "Emerging Therapeutic Targets in Rheumatoid Arthritis: Focusing on HIF-1α, Nrf2, STATs, and RORγt", "doi": "10.2174/0113894501372670250408074908", "year": 2025 }, { "pmid": "36574898", "title": "Expression of Nrf2 protein in serum of patients with rheumatoid arthritis: A novel indicator for disease activity and disease prognosis", "doi": "10.1016/j.clinbiochem.2022.12.011", "year": 2022 } ] } }, { "id": 5168, "drug": "gemcitabine", "drug_type": "drug", "drug_domain": "pancreatic_cancer", "predicate_ab": "upregulates", "mediator": "IL-8", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "major depressive disorder", "outcome_type": "disease", "outcome_domain": "depression", "score": 0.270805020110221, "filtered_score": 0.270805020110221, "filter_reason": null, "outreach_score": 0.270805020110221, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "gemcitabine", "mediator_canonical": "IL8", "outcome_canonical": "major depressive disorder", "ab_count": 2, "bc_count": 4, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "30097594", "title": "Gemcitabine treatment promotes immunosuppressive microenvironment in pancreatic tumors by supporting the infiltration, growth, and polarization of macrophages", "doi": "10.1038/s41598-018-30437-2", "year": 2018 }, { "pmid": "25970774", "title": "Gemcitabine triggers angiogenesis-promoting molecular signals in pancreatic cancer cells: Therapeutic implications", "doi": "10.18632/oncotarget.3784", "year": 2015 } ], "bc": [ { "pmid": "41876463", "title": "Prediction of depressive episodes based on clinical features, cognitive characteristics, inflammation-related proteins, and EEG data", "doi": "10.1038/s41398-026-03960-4", "year": 2026 }, { "pmid": "34294614", "title": "White Matter Alterations Associated with Pro-inflammatory Cytokines in Patients with Major Depressive Disorder", "doi": "10.9758/cpn.2021.19.3.449", "year": 2021 }, { "pmid": "32874955", "title": "Serum levels of chemokines in adolescents with major depression treated with fluoxetine", "doi": "10.5498/wjp.v10.i8.175", "year": 2020 } ] } }, { "id": 39005, "drug": "HA-AKBA-LCNP", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "downregulates", "mediator": "CD44", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "poor prognosis", "outcome_type": "phenotype", "outcome_domain": "pancreatic_cancer", "score": 0.270805020110221, "filtered_score": 0.270805020110221, "filter_reason": null, "outreach_score": 0.270805020110221, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "ha-akba-lcnp", "mediator_canonical": "cd44", "outcome_canonical": null, "ab_count": 2, "bc_count": 4, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41267073", "title": "Surface-engineered hyaluronic acid-coated lyotropic liquid crystalline nanoparticles for CD44-targeting of 3-Acetyl-11-keto-β-boswellic acid in rheumatoid arthritis treatment", "doi": "10.1186/s12951-025-03846-5", "year": 2025 } ], "bc": [ { "pmid": "35931675", "title": "Gemcitabine resistance of pancreatic cancer cells is mediated by IGF1R dependent upregulation of CD44 expression and isoform switching", "doi": "10.1038/s41419-022-05103-1", "year": 2022 }, { "pmid": "28659655", "title": "Expression and Clinical Significance of Cancer Stem Cell Markers CD24, CD44, and CD133 in Pancreatic Ductal Adenocarcinoma and Chronic Pancreatitis", "doi": "10.1155/2017/3276806", "year": 2017 }, { "pmid": "26261555", "title": "Expression of CD44 in pancreatic cancer and its significance.", "doi": null, "year": 2015 } ] } }, { "id": 35475, "drug": "DMF", "drug_type": "drug", "drug_domain": "multiple_sclerosis", "predicate_ab": "activates", "mediator": "Nrf2", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "disease activity", "outcome_type": "phenotype", "outcome_domain": "rheumatoid_arthritis", "score": 0.270805020110221, "filtered_score": 0.270805020110221, "filter_reason": null, "outreach_score": 0.270805020110221, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "active", "clinical_trial_nct_ids": [ "NCT06551519", "NCT06850597", "NCT04788615" ], "literature_status": "reproduces_known", "drug_canonical": "dmf", "mediator_canonical": "NRF2", "outcome_canonical": "disease activity", "ab_count": 4, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "35743211", "title": "Mechanisms of Sensitivity and Resistance of Primary Effusion Lymphoma to Dimethyl Fumarate (DMF)", "doi": "10.3390/ijms23126773", "year": 2022 }, { "pmid": "32672401", "title": "Structural insights into the multiple binding modes of Dimethyl Fumarate (DMF) and its analogs to the Kelch domain of Keap1", "doi": "10.1111/febs.15485", "year": 2020 }, { "pmid": "32394330", "title": "Characterization of More Selective Central Nervous System Nrf2-Activating Novel Vinyl Sulfoximine Compounds Compared to Dimethyl Fumarate", "doi": "10.1007/s13311-020-00855-0", "year": 2020 } ], "bc": [ { "pmid": "36574898", "title": "Expression of Nrf2 protein in serum of patients with rheumatoid arthritis: A novel indicator for disease activity and disease prognosis", "doi": "10.1016/j.clinbiochem.2022.12.011", "year": 2022 } ] } }, { "id": 23807, "drug": "DMF", "drug_type": "drug", "drug_domain": "multiple_sclerosis", "predicate_ab": "activates", "mediator": "NRF2", "mediator_type": "protein", "predicate_bc": "causes", "outcome": "chemoresistance", "outcome_type": "phenotype", "outcome_domain": "pancreatic_cancer", "score": 0.270805020110221, "filtered_score": 0.270805020110221, "filter_reason": null, "outreach_score": 0.270805020110221, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "dmf", "mediator_canonical": "NRF2", "outcome_canonical": null, "ab_count": 4, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "35743211", "title": "Mechanisms of Sensitivity and Resistance of Primary Effusion Lymphoma to Dimethyl Fumarate (DMF)", "doi": "10.3390/ijms23126773", "year": 2022 }, { "pmid": "32672401", "title": "Structural insights into the multiple binding modes of Dimethyl Fumarate (DMF) and its analogs to the Kelch domain of Keap1", "doi": "10.1111/febs.15485", "year": 2020 }, { "pmid": "32394330", "title": "Characterization of More Selective Central Nervous System Nrf2-Activating Novel Vinyl Sulfoximine Compounds Compared to Dimethyl Fumarate", "doi": "10.1007/s13311-020-00855-0", "year": 2020 } ], "bc": [ { "pmid": "31911550", "title": "Undermining Glutaminolysis Bolsters Chemotherapy While NRF2 Promotes Chemoresistance in KRAS-Driven Pancreatic Cancers", "doi": "10.1158/0008-5472.can-19-1363", "year": 2020 }, { "pmid": "30735911", "title": "Digoxin sensitizes gemcitabine-resistant pancreatic cancer cells to gemcitabine via inhibiting Nrf2 signaling pathway", "doi": "10.1016/j.redox.2019.101131", "year": 2019 } ] } }, { "id": 40377, "drug": "Sitagliptin", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "inhibits", "mediator": "DPP-4", "mediator_type": "protein", "predicate_bc": "predicts", "outcome": "disease activity", "outcome_type": "phenotype", "outcome_domain": "inflammatory_bowel_disease", "score": 0.270805020110221, "filtered_score": 0.270805020110221, "filter_reason": null, "outreach_score": 0.270805020110221, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "active", "clinical_trial_nct_ids": [ "NCT06972732", "NCT07365358", "NCT02512523" ], "literature_status": "partial_evidence", "drug_canonical": "sitagliptin", "mediator_canonical": "dpp-4", "outcome_canonical": "disease activity", "ab_count": 4, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "38556837", "title": "Selective targeting of dipeptidyl‐peptidase 4 (DPP‐4) positive senescent chondrocyte ameliorates osteoarthritis progression", "doi": "10.1111/acel.14161", "year": 2024 }, { "pmid": "33406328", "title": "Dipeptidyl Peptidase 4 Inhibition for Prophylaxis of Acute Graft-versus-Host Disease", "doi": "10.1056/nejmoa2027372", "year": 2021 }, { "pmid": "34779087", "title": "A randomized clinical trial of the efficacy and safety of sitagliptin as initial oral therapy in youth with type 2 diabetes", "doi": "10.1111/pedi.13279", "year": 2021 } ], "bc": [ { "pmid": "31912883", "title": "Serum Dipeptidyl Peptidase 4: A Predictor of Disease Activity and Prognosis in Inflammatory Bowel Disease", "doi": "10.1093/ibd/izz319", "year": 2020 } ] } }, { "id": 38645, "drug": "secukinumab", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "inhibits", "mediator": "IL-17A", "mediator_type": "protein", "predicate_bc": "predicts", "outcome": "IBD", "outcome_type": "disease", "outcome_domain": "inflammatory_bowel_disease", "score": 0.270805020110221, "filtered_score": 0.270805020110221, "filter_reason": null, "outreach_score": 0.270805020110221, "outreach_quality": "high", "outreach_reason": null, "clinical_trial_status": "completed", "clinical_trial_nct_ids": [ "NCT01009281", "NCT07138898", "NCT00584740" ], "literature_status": "reproduces_known", "drug_canonical": "secukinumab", "mediator_canonical": "il-17a", "outcome_canonical": "ibd", "ab_count": 4, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "33913511", "title": "Efficacy of secukinumab and adalimumab in patients with psoriatic arthritis and concomitant moderate‐to‐severe plaque psoriasis: results from EXCEED, a randomized, double‐blind head‐to‐head monotherapy study", "doi": "10.1111/bjd.20413", "year": 2021 }, { "pmid": "34919658", "title": "Secukinumab-induced systemic lupus erythematosus occurring in a patient with ankylosing spondylitis", "doi": "10.1093/rheumatology/keab918", "year": 2021 }, { "pmid": "33120695", "title": "Role of secukinumab in ankylosing spondylitis with tubercular uveitis", "doi": "10.4103/ijo.ijo_1081_20", "year": 2020 } ], "bc": [ { "pmid": "40481885", "title": "Serum proteins and faecal microbiota as potential biomarkers in newly diagnosed, treatment-naïve inflammatory bowel disease and irritable bowel syndrome patients", "doi": "10.1007/s00109-025-02558-5", "year": 2025 }, { "pmid": "26650150", "title": "Are sTWEAK and IL-17A Levels in Inflammatory Bowel Disease Associated with Disease Activity and Etiopathogenesis?", "doi": "10.1097/mib.0000000000000632", "year": 2015 } ] } }, { "id": 6521, "drug": "curcumin", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "inhibits", "mediator": "MAPK pathway", "mediator_type": "pathway", "predicate_bc": "associated_with", "outcome": "pediatric diffuse low-grade glioma", "outcome_type": "disease", "outcome_domain": "glioblastoma", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "curcumin", "mediator_canonical": "mapk pathway", "outcome_canonical": "pediatric diffuse low-grade glioma", "ab_count": 2, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "35180639", "title": "No persistent effects of intracerebral curcumin administration on seizure progression and neuropathology in the kindling rat model for temporal lobe epilepsy", "doi": "10.1016/j.eplepsyres.2022.106873", "year": 2022 }, { "pmid": "30037344", "title": "Effects of rapamycin and curcumin on inflammation and oxidative stress in vitro and in vivo — in search of potential anti-epileptogenic strategies for temporal lobe epilepsy", "doi": "10.1186/s12974-018-1247-9", "year": 2018 } ], "bc": [ { "pmid": "41089195", "title": "Pediatric diffuse low‑grade glioma with oligodendroglioma‑like features: A case report", "doi": "10.3892/etm.2025.12985", "year": 2025 } ] } }, { "id": 38459, "drug": "resveratrol", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "binds_to", "mediator": "EGFR", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "glioblastoma", "outcome_type": "disease", "outcome_domain": "glioblastoma", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "resveratrol", "mediator_canonical": "EGFR", "outcome_canonical": "glioblastoma", "ab_count": 1, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40993911", "title": "Therapeutic Targeting of Apoptosis‐Driven Inflammation in Rheumatoid Arthritis: A Biochemical and Molecular Modeling Approach Using Plant‐Derived Compounds", "doi": "10.1111/1756-185x.70423", "year": 2025 } ], "bc": [ { "pmid": "41473440", "title": "A PET-CT study of the uptake of labeled aptamers [18F]FB-Gol1 and [18F]FB-GR20 in rat 101.8 glioblastoma model", "doi": "10.3389/fonc.2025.1713181", "year": 2025 }, { "pmid": "38396993", "title": "Epidermal Growth Factor Receptor Inhibitors in Glioblastoma: Current Status and Future Possibilities", "doi": "10.3390/ijms25042316", "year": 2024 } ] } }, { "id": 51984, "drug": "Curcumin", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "downregulates", "mediator": "ET-1", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "hypertension", "outcome_type": "disease", "outcome_domain": "type_2_diabetes", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "30020318", "title": "Curcumin exerts anti-inflammatory and vasoprotective effects through amelioration of NFAT-dependent endothelin-1 production in mice with acute Chagas cardiomyopathy", "doi": "10.1590/0074-02760180171", "year": 2018 } ], "bc": [ { "pmid": "27490532", "title": "Serum Concentrations of Endothelin-1 and Matrix Metalloproteinases-2, -9 in Pre-Hypertensive and Hypertensive Patients with Type 2 Diabetes", "doi": "10.3390/ijms17081182", "year": 2016 } ] } }, { "id": 52015, "drug": "Curcumin", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "activates", "mediator": "Nrf2", "mediator_type": "protein", "predicate_bc": "prevents", "outcome": "type 1 diabetes", "outcome_type": "disease", "outcome_domain": "type_2_diabetes", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 2, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37101595", "title": "Curcumin Improves Diabetic Cardiomyopathy by Inhibiting Pyroptosis through AKT/Nrf2/ARE Pathway", "doi": "10.1155/2023/3906043", "year": 2023 }, { "pmid": "35909950", "title": "Curcumin Attenuates Ferroptosis-Induced Myocardial Injury in Diabetic Cardiomyopathy through the Nrf2 Pathway", "doi": "10.1155/2022/3159717", "year": 2022 } ], "bc": [ { "pmid": "30625116", "title": "Nrf2 represses the onset of type 1 diabetes in non-obese diabetic mice", "doi": "10.1530/joe-18-0355", "year": 2019 } ] } }, { "id": 52081, "drug": "simvastatin", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "activates", "mediator": "AMPK pathway", "mediator_type": "pathway", "predicate_bc": "increases", "outcome": "memory dysfunction", "outcome_type": "phenotype", "outcome_domain": "type_2_diabetes", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "31955524", "title": "Simvastatin alleviated diabetes mellitus‐induced erectile dysfunction in rats by enhancing AMPK pathway‐induced autophagy", "doi": "10.1111/andr.12758", "year": 2020 } ], "bc": [ { "pmid": "25190626", "title": "Metformin Treatment Alters Memory Function in a Mouse Model of Alzheimer's Disease", "doi": "10.3233/jad-141332", "year": 2015 } ] } }, { "id": 58799, "drug": "Auranofin", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "inhibits", "mediator": "GSK-3β", "mediator_type": "protein", "predicate_bc": "increases", "outcome": "neurodegeneration", "outcome_type": "phenotype", "outcome_domain": "epilepsy", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 2, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40842183", "title": "Gold‐Containing Compound Auranofin Ameliorates 6‐OHDA Induced Neurotoxicity in Rats: Via Targeting PI3K/Akt/GSK‐3β Signalling", "doi": "10.1111/1440-1681.70070", "year": 2025 } ], "bc": [ { "pmid": "30237424", "title": "Bi-directional genetic modulation of GSK-3β exacerbates hippocampal neuropathology in experimental status epilepticus", "doi": "10.1038/s41419-018-0963-5", "year": 2018 } ] } }, { "id": 32432, "drug": "Apigenin", "drug_type": "drug", "drug_domain": "inflammatory_bowel_disease", "predicate_ab": "activates", "mediator": "AMPK", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "amyotrophic lateral sclerosis", "outcome_type": "disease", "outcome_domain": "als", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "apigenin", "mediator_canonical": "AMPK", "outcome_canonical": "amyotrophic lateral sclerosis", "ab_count": 2, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41428381", "title": "Natural Dietary Flavonoid Apigenin Mitigates Ulcerative Colitis via Modulating the AMPK/NF-κB/NLRP3 Signaling Axis", "doi": "10.1021/acs.jafc.5c15405", "year": 2025 } ], "bc": [ { "pmid": "34393724", "title": "Contribution of Energy Dysfunction to Impaired Protein Translation in Neurodegenerative Diseases", "doi": "10.3389/fncel.2021.668500", "year": 2021 } ] } }, { "id": 32439, "drug": "Apigenin", "drug_type": "drug", "drug_domain": "inflammatory_bowel_disease", "predicate_ab": "activates", "mediator": "AMPK", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "Alzheimer's disease", "outcome_type": "disease", "outcome_domain": "als", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "apigenin", "mediator_canonical": "AMPK", "outcome_canonical": "Alzheimer disease", "ab_count": 2, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41428381", "title": "Natural Dietary Flavonoid Apigenin Mitigates Ulcerative Colitis via Modulating the AMPK/NF-κB/NLRP3 Signaling Axis", "doi": "10.1021/acs.jafc.5c15405", "year": 2025 } ], "bc": [ { "pmid": "34393724", "title": "Contribution of Energy Dysfunction to Impaired Protein Translation in Neurodegenerative Diseases", "doi": "10.3389/fncel.2021.668500", "year": 2021 } ] } }, { "id": 58744, "drug": "imatinib", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "downregulates", "mediator": "CSF1R", "mediator_type": "protein", "predicate_bc": "treats", "outcome": "epilepsy", "outcome_type": "disease", "outcome_domain": "epilepsy", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 2, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "30281780", "title": "Imatinib inhibits CSF1R that stimulates proliferation of rheumatoid arthritis fibroblast-like synoviocytes", "doi": "10.1111/cei.13220", "year": 2018 } ], "bc": [ { "pmid": "30177815", "title": "A systems-level framework for drug discovery identifies Csf1R as an anti-epileptic drug target", "doi": "10.1038/s41467-018-06008-4", "year": 2018 } ] } }, { "id": 57174, "drug": "metformin", "drug_type": "drug", "drug_domain": "pancreatic_cancer", "predicate_ab": "activates", "mediator": "AMPK", "mediator_type": "protein", "predicate_bc": "prevents", "outcome": "myocardial ischemia-reperfusion injury", "outcome_type": "disease", "outcome_domain": "heart_failure", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 2, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "26760500", "title": "Metformin Treatment Does Not Inhibit Growth of Pancreatic Cancer Patient-Derived Xenografts", "doi": "10.1371/journal.pone.0147113", "year": 2016 }, { "pmid": "25688512", "title": "Rationale and protocol of the MetNET-1 trial, a prospective, single center, phase II study to evaluate the activity and safety of everolimus in combination with octreotide LAR and metformin in patients with advanced pancreatic neuroendocrine tumors.", "doi": "10.1700/1778.19298", "year": 2015 } ], "bc": [ { "pmid": "29689567", "title": "AMPK Contributes to Cardioprotective Effects of Pterostilbene Against Myocardial Ischemia- Reperfusion Injury in Diabetic Rats by Suppressing Cardiac Oxidative Stress and Apoptosis", "doi": "10.1159/000489154", "year": 2018 } ] } }, { "id": 33056, "drug": "Apigenin", "drug_type": "drug", "drug_domain": "inflammatory_bowel_disease", "predicate_ab": "activates", "mediator": "AMPK", "mediator_type": "protein", "predicate_bc": "increases", "outcome": "epileptiform network activity", "outcome_type": "phenotype", "outcome_domain": "epilepsy", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "apigenin", "mediator_canonical": "AMPK", "outcome_canonical": "epileptiform network activity", "ab_count": 2, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41428381", "title": "Natural Dietary Flavonoid Apigenin Mitigates Ulcerative Colitis via Modulating the AMPK/NF-κB/NLRP3 Signaling Axis", "doi": "10.1021/acs.jafc.5c15405", "year": 2025 } ], "bc": [ { "pmid": "35134125", "title": "AMPK-mediated potentiation of GABAergic signalling drives hypoglycaemia-provoked spike-wave seizures", "doi": "10.1093/brain/awac037", "year": 2022 } ] } }, { "id": 53230, "drug": "metformin", "drug_type": "drug", "drug_domain": "inflammatory_bowel_disease", "predicate_ab": "activates", "mediator": "AMPK", "mediator_type": "protein", "predicate_bc": "increases", "outcome": "glycogen storage", "outcome_type": "phenotype", "outcome_domain": "heart_failure", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 2, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "35064693", "title": "Metformin ameliorates chronic colitis in a mouse model by regulating interferon‐γ‐producing lamina propria CD4 + T cells through AMPK activation", "doi": "10.1096/fj.202100831rr", "year": 2022 }, { "pmid": "30061832", "title": "Activating AMPK to Restore Tight Junction Assembly in Intestinal Epithelium and to Attenuate Experimental Colitis by Metformin", "doi": "10.3389/fphar.2018.00761", "year": 2018 } ], "bc": [ { "pmid": "28009297", "title": "Integrative Analysis of PRKAG2 Cardiomyopathy iPS and Microtissue Models Identifies AMPK as a Regulator of Metabolism, Survival, and Fibrosis", "doi": "10.1016/j.celrep.2016.11.066", "year": 2016 } ] } }, { "id": 53231, "drug": "metformin", "drug_type": "drug", "drug_domain": "inflammatory_bowel_disease", "predicate_ab": "activates", "mediator": "AMPK", "mediator_type": "protein", "predicate_bc": "prevents", "outcome": "myocardial ischemia-reperfusion injury", "outcome_type": "disease", "outcome_domain": "heart_failure", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 2, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "35064693", "title": "Metformin ameliorates chronic colitis in a mouse model by regulating interferon‐γ‐producing lamina propria CD4 + T cells through AMPK activation", "doi": "10.1096/fj.202100831rr", "year": 2022 }, { "pmid": "30061832", "title": "Activating AMPK to Restore Tight Junction Assembly in Intestinal Epithelium and to Attenuate Experimental Colitis by Metformin", "doi": "10.3389/fphar.2018.00761", "year": 2018 } ], "bc": [ { "pmid": "29689567", "title": "AMPK Contributes to Cardioprotective Effects of Pterostilbene Against Myocardial Ischemia- Reperfusion Injury in Diabetic Rats by Suppressing Cardiac Oxidative Stress and Apoptosis", "doi": "10.1159/000489154", "year": 2018 } ] } }, { "id": 2709, "drug": "valproic acid", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "downregulates", "mediator": "BDNF", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "major depressive disorder", "outcome_type": "disease", "outcome_domain": "depression", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "active", "clinical_trial_nct_ids": [ "NCT05603104", "NCT06729541", "NCT00581009" ], "literature_status": "reproduces_known", "drug_canonical": "valproic acid", "mediator_canonical": "BDNF", "outcome_canonical": "major depressive disorder", "ab_count": 1, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "35465089", "title": "Excitatory and Inhibitory Synaptic Imbalance Caused by Brain-Derived Neurotrophic Factor Deficits During Development in a Valproic Acid Mouse Model of Autism", "doi": "10.3389/fnmol.2022.860275", "year": 2022 } ], "bc": [ { "pmid": "30794585", "title": "Accuracy of brain-derived neurotrophic factor levels for differentiating between Taiwanese patients with major depressive disorder or schizophrenia and healthy controls", "doi": "10.1371/journal.pone.0212373", "year": 2019 } ] } }, { "id": 53311, "drug": "metformin", "drug_type": "drug", "drug_domain": "inflammatory_bowel_disease", "predicate_ab": "downregulates", "mediator": "IL-17", "mediator_type": "protein", "predicate_bc": "increases", "outcome": "cardiac fibrosis", "outcome_type": "disease", "outcome_domain": "heart_failure", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 2, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "32654569", "title": "Metformin alleviates experimental colitis in mice by up-regulating TGF-β signaling", "doi": "10.1080/10520295.2020.1776896", "year": 2020 }, { "pmid": "26360050", "title": "Metformin Ameliorates Inflammatory Bowel Disease by Suppression of the STAT3 Signaling Pathway and Regulation of the between Th17/Treg Balance", "doi": "10.1371/journal.pone.0135858", "year": 2015 } ], "bc": [ { "pmid": "32351959", "title": "LncRNA-MIAT-Mediated miR-214-3p Silencing Is Responsible for IL-17 Production and Cardiac Fibrosis in Diabetic Cardiomyopathy", "doi": "10.3389/fcell.2020.00243", "year": 2020 } ] } }, { "id": 53312, "drug": "metformin", "drug_type": "drug", "drug_domain": "inflammatory_bowel_disease", "predicate_ab": "activates", "mediator": "AMPK", "mediator_type": "protein", "predicate_bc": "increases", "outcome": "ventricular cell shortening", "outcome_type": "phenotype", "outcome_domain": "heart_failure", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 2, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "35064693", "title": "Metformin ameliorates chronic colitis in a mouse model by regulating interferon‐γ‐producing lamina propria CD4 + T cells through AMPK activation", "doi": "10.1096/fj.202100831rr", "year": 2022 }, { "pmid": "30061832", "title": "Activating AMPK to Restore Tight Junction Assembly in Intestinal Epithelium and to Attenuate Experimental Colitis by Metformin", "doi": "10.3389/fphar.2018.00761", "year": 2018 } ], "bc": [ { "pmid": "26023060", "title": "AMPK deficiency in cardiac muscle results in dilated cardiomyopathy in the absence of changes in energy metabolism", "doi": "10.1093/cvr/cvv166", "year": 2015 } ] } }, { "id": 53313, "drug": "metformin", "drug_type": "drug", "drug_domain": "inflammatory_bowel_disease", "predicate_ab": "activates", "mediator": "AMPK", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "cardiovascular aging", "outcome_type": "phenotype", "outcome_domain": "heart_failure", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 2, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "35064693", "title": "Metformin ameliorates chronic colitis in a mouse model by regulating interferon‐γ‐producing lamina propria CD4 + T cells through AMPK activation", "doi": "10.1096/fj.202100831rr", "year": 2022 }, { "pmid": "30061832", "title": "Activating AMPK to Restore Tight Junction Assembly in Intestinal Epithelium and to Attenuate Experimental Colitis by Metformin", "doi": "10.3389/fphar.2018.00761", "year": 2018 } ], "bc": [ { "pmid": "41194190", "title": "Cellular senescence and cell therapy in cardiovascular diseases", "doi": "10.1186/s13287-025-04731-6", "year": 2025 } ] } }, { "id": 53315, "drug": "luteolin", "drug_type": "drug", "drug_domain": "inflammatory_bowel_disease", "predicate_ab": "binds_to", "mediator": "AMPK", "mediator_type": "protein", "predicate_bc": "prevents", "outcome": "metabolic dysfunction", "outcome_type": "disease", "outcome_domain": "heart_failure", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41077623", "title": "Luteolin Inhibits NLRP3 Inflammasome Activation to Ameliorate DSS ‐Induced Colitis by Regulating AMPK Signalling", "doi": "10.1111/cpr.70134", "year": 2025 } ], "bc": [ { "pmid": "37194385", "title": "Adenosine monophosphate‐activated protein kinase is elevated in human cachectic muscle and prevents cancer‐induced metabolic dysfunction in mice", "doi": "10.1002/jcsm.13238", "year": 2023 } ] } }, { "id": 53318, "drug": "Apigenin", "drug_type": "drug", "drug_domain": "inflammatory_bowel_disease", "predicate_ab": "activates", "mediator": "AMPK", "mediator_type": "protein", "predicate_bc": "increases", "outcome": "ventricular cell shortening", "outcome_type": "phenotype", "outcome_domain": "heart_failure", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 2, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41428381", "title": "Natural Dietary Flavonoid Apigenin Mitigates Ulcerative Colitis via Modulating the AMPK/NF-κB/NLRP3 Signaling Axis", "doi": "10.1021/acs.jafc.5c15405", "year": 2025 } ], "bc": [ { "pmid": "26023060", "title": "AMPK deficiency in cardiac muscle results in dilated cardiomyopathy in the absence of changes in energy metabolism", "doi": "10.1093/cvr/cvv166", "year": 2015 } ] } }, { "id": 33358, "drug": "metformin", "drug_type": "drug", "drug_domain": "inflammatory_bowel_disease", "predicate_ab": "downregulates", "mediator": "IL-17", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "social-cognitive functioning", "outcome_type": "phenotype", "outcome_domain": "multiple_sclerosis", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "metformin", "mediator_canonical": "il-17", "outcome_canonical": "social-cognitive functioning", "ab_count": 2, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "32654569", "title": "Metformin alleviates experimental colitis in mice by up-regulating TGF-β signaling", "doi": "10.1080/10520295.2020.1776896", "year": 2020 }, { "pmid": "26360050", "title": "Metformin Ameliorates Inflammatory Bowel Disease by Suppression of the STAT3 Signaling Pathway and Regulation of the between Th17/Treg Balance", "doi": "10.1371/journal.pone.0135858", "year": 2015 } ], "bc": [ { "pmid": "34589763", "title": "Innate immunity impacts social-cognitive functioning in people with multiple sclerosis and healthy individuals: Implications for IL-1ra and urinary immune markers", "doi": "10.1016/j.bbih.2021.100254", "year": 2021 } ] } }, { "id": 33416, "drug": "metformin", "drug_type": "drug", "drug_domain": "inflammatory_bowel_disease", "predicate_ab": "downregulates", "mediator": "IL-17", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "disease activity", "outcome_type": "phenotype", "outcome_domain": "multiple_sclerosis", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "completed", "clinical_trial_nct_ids": [ "NCT07365358", "NCT07272109", "NCT01071850" ], "literature_status": "reproduces_known", "drug_canonical": "metformin", "mediator_canonical": "il-17", "outcome_canonical": "disease activity", "ab_count": 2, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "32654569", "title": "Metformin alleviates experimental colitis in mice by up-regulating TGF-β signaling", "doi": "10.1080/10520295.2020.1776896", "year": 2020 }, { "pmid": "26360050", "title": "Metformin Ameliorates Inflammatory Bowel Disease by Suppression of the STAT3 Signaling Pathway and Regulation of the between Th17/Treg Balance", "doi": "10.1371/journal.pone.0135858", "year": 2015 } ], "bc": [ { "pmid": "33879167", "title": "STEAP4 expression in CNS resident cells promotes Th17 cell-induced autoimmune encephalomyelitis", "doi": "10.1186/s12974-021-02146-7", "year": 2021 } ] } }, { "id": 33484, "drug": "metformin", "drug_type": "drug", "drug_domain": "inflammatory_bowel_disease", "predicate_ab": "downregulates", "mediator": "IL-17", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "MS relapse", "outcome_type": "disease", "outcome_domain": "multiple_sclerosis", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "completed", "clinical_trial_nct_ids": [ "NCT06812585" ], "literature_status": "novel_signal", "drug_canonical": "metformin", "mediator_canonical": "il-17", "outcome_canonical": "ms relapse", "ab_count": 2, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "32654569", "title": "Metformin alleviates experimental colitis in mice by up-regulating TGF-β signaling", "doi": "10.1080/10520295.2020.1776896", "year": 2020 }, { "pmid": "26360050", "title": "Metformin Ameliorates Inflammatory Bowel Disease by Suppression of the STAT3 Signaling Pathway and Regulation of the between Th17/Treg Balance", "doi": "10.1371/journal.pone.0135858", "year": 2015 } ], "bc": [ { "pmid": "35126353", "title": "Long-Term Suppression of Circulating Proinflammatory Cytokines in Multiple Sclerosis Patients Following Autologous Haematopoietic Stem Cell Transplantation", "doi": "10.3389/fimmu.2021.782935", "year": 2022 } ] } }, { "id": 33558, "drug": "Apigenin", "drug_type": "drug", "drug_domain": "inflammatory_bowel_disease", "predicate_ab": "activates", "mediator": "AMPK", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "pancreatic ductal adenocarcinoma", "outcome_type": "disease", "outcome_domain": "pancreatic_cancer", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "apigenin", "mediator_canonical": "AMPK", "outcome_canonical": "pancreatic ductal adenocarcinoma", "ab_count": 2, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41428381", "title": "Natural Dietary Flavonoid Apigenin Mitigates Ulcerative Colitis via Modulating the AMPK/NF-κB/NLRP3 Signaling Axis", "doi": "10.1021/acs.jafc.5c15405", "year": 2025 } ], "bc": [ { "pmid": "38885414", "title": "A Novel AMPK Inhibitor Sensitizes Pancreatic Cancer Cells to Ferroptosis Induction", "doi": "10.1002/advs.202307695", "year": 2024 } ] } }, { "id": 9218, "drug": "curcumin", "drug_type": "drug", "drug_domain": "alzheimer", "predicate_ab": "upregulates", "mediator": "BDNF", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "depression severity", "outcome_type": "phenotype", "outcome_domain": "depression", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "curcumin", "mediator_canonical": "BDNF", "outcome_canonical": "depression severity", "ab_count": 1, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "38791161", "title": "Curcumin Improves Neurogenesis in Alzheimer’s Disease Mice via the Upregulation of Wnt/β-Catenin and BDNF", "doi": "10.3390/ijms25105123", "year": 2024 } ], "bc": [ { "pmid": "34841285", "title": "The ratio and interaction between neurotrophin and immune signaling during electroconvulsive therapy in late-life depression", "doi": "10.1016/j.bbih.2021.100389", "year": 2021 }, { "pmid": "29614706", "title": "Yoga- and meditation-based lifestyle intervention increases neuroplasticity and reduces severity of major depressive disorder: A randomized controlled trial", "doi": "10.3233/rnn-170810", "year": 2018 } ] } }, { "id": 23446, "drug": "amantadine", "drug_type": "drug", "drug_domain": "multiple_sclerosis", "predicate_ab": "activates", "mediator": "NMDA receptor", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "cell-autonomous excitotoxicity", "outcome_type": "phenotype", "outcome_domain": "als", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "amantadine", "mediator_canonical": "nmda receptor", "outcome_canonical": "cell-autonomous excitotoxicity", "ab_count": 2, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37419676", "title": "Amantadine toxicity causing visual hallucinations", "doi": "10.1136/pn-2023-003723", "year": 2023 }, { "pmid": "33350472", "title": "Amantadine for COVID‐19", "doi": "10.1002/jcph.1802", "year": 2020 } ], "bc": [ { "pmid": "30037833", "title": "C9orf72 Dipeptide Repeats Cause Selective Neurodegeneration and Cell-Autonomous Excitotoxicity in Drosophila Glutamatergic Neurons", "doi": "10.1523/jneurosci.0908-18.2018", "year": 2018 } ] } }, { "id": 23439, "drug": "amantadine", "drug_type": "drug", "drug_domain": "multiple_sclerosis", "predicate_ab": "activates", "mediator": "NMDA receptor", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "pain", "outcome_type": "phenotype", "outcome_domain": "als", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "active", "clinical_trial_nct_ids": [ "NCT07421427", "NCT01602185", "NCT06833203" ], "literature_status": "reproduces_known", "drug_canonical": "amantadine", "mediator_canonical": "nmda receptor", "outcome_canonical": "pain", "ab_count": 2, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37419676", "title": "Amantadine toxicity causing visual hallucinations", "doi": "10.1136/pn-2023-003723", "year": 2023 }, { "pmid": "33350472", "title": "Amantadine for COVID‐19", "doi": "10.1002/jcph.1802", "year": 2020 } ], "bc": [ { "pmid": "33467407", "title": "Delayed Onset Muscle Soreness (DOMS): The Repeated Bout Effect and Chemotherapy-Induced Axonopathy May Help Explain the Dying-Back Mechanism in Amyotrophic Lateral Sclerosis and Other Neurodegenerative Diseases", "doi": "10.3390/brainsci11010108", "year": 2021 } ] } }, { "id": 4422, "drug": "niclosamide", "drug_type": "drug", "drug_domain": "pancreatic_cancer", "predicate_ab": "downregulates", "mediator": "PD-L1", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "overall survival", "outcome_type": "phenotype", "outcome_domain": "glioblastoma", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "niclosamide", "mediator_canonical": "PD-L1", "outcome_canonical": null, "ab_count": 1, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "35115509", "title": "The anthelmintic drug niclosamide induces GSK-β-mediated β-catenin degradation to potentiate gemcitabine activity, reduce immune evasion ability and suppress pancreatic cancer progression", "doi": "10.1038/s41419-022-04573-7", "year": 2022 } ], "bc": [ { "pmid": "40002543", "title": "Prognostic Biomarkers in Isocitrate Dehydrogenase Wild-Type Glioblastoma: A Focus on B7-H3", "doi": "10.3390/brainsci15020212", "year": 2025 }, { "pmid": "37529045", "title": "Plasma PD-L1 as a biomarker in the clinical management of glioblastoma multiforme—a retrospective cohort study", "doi": "10.3389/fimmu.2023.1202098", "year": 2023 } ] } }, { "id": 4438, "drug": "resveratrol", "drug_type": "drug", "drug_domain": "pancreatic_cancer", "predicate_ab": "upregulates", "mediator": "PTEN", "mediator_type": "gene", "predicate_bc": "associated_with", "outcome": "glioblastoma", "outcome_type": "disease", "outcome_domain": "glioblastoma", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "resveratrol", "mediator_canonical": "PTEN", "outcome_canonical": "glioblastoma", "ab_count": 1, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "29854071", "title": "Resveratrol Inhibits ROS‐Promoted Activation and Glycolysis of Pancreatic Stellate Cells via Suppression of miR‐21", "doi": "10.1155/2018/1346958", "year": 2018 } ], "bc": [ { "pmid": "38217295", "title": "Diagnostic utility of genetic alterations in distinguishing IDH‐wildtype glioblastoma from lower‐grade gliomas: Insight from next‐generation sequencing analysis of 479 cases", "doi": "10.1111/bpa.13234", "year": 2024 }, { "pmid": "37140883", "title": "Genome-wide profiling of patient-derived glioblastoma stem-like cells reveals recurrent genetic and transcriptomic signatures associated with brain tumors", "doi": "10.1007/s11060-023-04287-6", "year": 2023 } ] } }, { "id": 36878, "drug": "resveratrol", "drug_type": "drug", "drug_domain": "pancreatic_cancer", "predicate_ab": "downregulates", "mediator": "miR-21", "mediator_type": "gene", "predicate_bc": "associated_with", "outcome": "ulcerative colitis", "outcome_type": "disease", "outcome_domain": "inflammatory_bowel_disease", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "completed", "clinical_trial_nct_ids": [ "NCT05761327" ], "literature_status": "reproduces_known", "drug_canonical": "resveratrol", "mediator_canonical": "mir-21", "outcome_canonical": "ulcerative colitis", "ab_count": 1, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "29854071", "title": "Resveratrol Inhibits ROS‐Promoted Activation and Glycolysis of Pancreatic Stellate Cells via Suppression of miR‐21", "doi": "10.1155/2018/1346958", "year": 2018 } ], "bc": [ { "pmid": "32332611", "title": "Aberrant expression of miR-21 in patients with inflammatory bowel disease", "doi": "10.1097/md.0000000000019693", "year": 2020 }, { "pmid": "25886994", "title": "MicroRNA signatures differentiate Crohn’s disease from ulcerative colitis", "doi": "10.1186/s12865-015-0069-0", "year": 2015 } ] } }, { "id": 36961, "drug": "Auranofin", "drug_type": "drug", "drug_domain": "pancreatic_cancer", "predicate_ab": "inhibits", "mediator": "HIF-1α", "mediator_type": "protein", "predicate_bc": "prevents", "outcome": "ulcerative colitis", "outcome_type": "disease", "outcome_domain": "inflammatory_bowel_disease", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "auranofin", "mediator_canonical": "hif-1α", "outcome_canonical": "ulcerative colitis", "ab_count": 1, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "33981979", "title": "Antineoplastic effects of auranofin in human pancreatic adenocarcinoma preclinical models", "doi": "10.1016/j.sopen.2019.05.004", "year": 2019 } ], "bc": [ { "pmid": "38137357", "title": "Interrelation of Hypoxia-Inducible Factor-1 Alpha (HIF-1 α) and the Ratio between the Mean Corpuscular Volume/Lymphocytes (MCVL) and the Cumulative Inflammatory Index (IIC) in Ulcerative Colitis", "doi": "10.3390/biomedicines11123137", "year": 2023 }, { "pmid": "31944416", "title": "Mucosal inflammation downregulates PHD1 expression promoting a barrier‐protective HIF‐1α response in ulcerative colitis patients", "doi": "10.1096/fj.201902103r", "year": 2020 } ] } }, { "id": 55155, "drug": "metformin", "drug_type": "drug", "drug_domain": "multiple_sclerosis", "predicate_ab": "activates", "mediator": "AMPK", "mediator_type": "protein", "predicate_bc": "prevents", "outcome": "metabolic dysfunction", "outcome_type": "disease", "outcome_domain": "heart_failure", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37904733", "title": "The AMPK activator metformin improves recovery from demyelination by shifting oligodendrocyte bioenergetics and accelerating OPC differentiation", "doi": "10.3389/fncel.2023.1254303", "year": 2023 } ], "bc": [ { "pmid": "37194385", "title": "Adenosine monophosphate‐activated protein kinase is elevated in human cachectic muscle and prevents cancer‐induced metabolic dysfunction in mice", "doi": "10.1002/jcsm.13238", "year": 2023 } ] } }, { "id": 8046, "drug": "resveratrol", "drug_type": "drug", "drug_domain": "als", "predicate_ab": "activates", "mediator": "SIRT1", "mediator_type": "protein", "predicate_bc": "increases", "outcome": "proliferation", "outcome_type": "phenotype", "outcome_domain": "pancreatic_cancer", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "preclinical_only", "clinical_trial_nct_ids": [ "NCT00455416" ], "literature_status": "reproduces_known", "drug_canonical": "resveratrol", "mediator_canonical": "SIRT1", "outcome_canonical": null, "ab_count": 1, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "26981091", "title": "How does resveratrol influence the genesis of some neurodegenerative diseases?", "doi": "10.4103/1673-5374.175047", "year": 2016 } ], "bc": [ { "pmid": "34163012", "title": "SIRT1 coordinates with the CRL4B complex to regulate pancreatic cancer stem cells to promote tumorigenesis", "doi": "10.1038/s41418-021-00821-z", "year": 2021 }, { "pmid": "27494892", "title": "Sirtuin 1 stimulates the proliferation and the expression of glycolysis genes in pancreatic neoplastic lesions", "doi": "10.18632/oncotarget.11013", "year": 2016 } ] } }, { "id": 209, "drug": "valproic acid", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "upregulates", "mediator": "mTOR signaling", "mediator_type": "pathway", "predicate_bc": "causes", "outcome": "U87mg electrotaxis", "outcome_type": "phenotype", "outcome_domain": "glioblastoma", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "valproic acid", "mediator_canonical": "mtor signaling", "outcome_canonical": "u87mg electrotaxis", "ab_count": 2, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "33809910", "title": "Alterations in Tau Protein Level and Phosphorylation State in the Brain of the Autistic-Like Rats Induced by Prenatal Exposure to Valproic Acid", "doi": "10.3390/ijms22063209", "year": 2021 }, { "pmid": "31551670", "title": "Valproic Acid Enhances Reprogramming Efficiency and Neuronal Differentiation on Small Molecules Staged-Induction Neural Stem Cells: Suggested Role of mTOR Signaling", "doi": "10.3389/fnins.2019.00867", "year": 2019 } ], "bc": [ { "pmid": "30926929", "title": "Electrotaxis of Glioblastoma and Medulloblastoma Spheroidal Aggregates", "doi": "10.1038/s41598-019-41505-6", "year": 2019 } ] } }, { "id": 23870, "drug": "valproic acid", "drug_type": "drug", "drug_domain": "multiple_sclerosis", "predicate_ab": "upregulates", "mediator": "β-catenin", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "cell invasiveness", "outcome_type": "phenotype", "outcome_domain": "pancreatic_cancer", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "valproic acid", "mediator_canonical": "β-catenin", "outcome_canonical": "cell invasiveness", "ab_count": 1, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37937413", "title": "Valproic acid effects on human adipose-derived stem cell differentiation into oligodendrocytes and improved remyelination in a mouse model of Multiple Sclerosis", "doi": "10.1387/ijdb.230154ng", "year": 2023 } ], "bc": [ { "pmid": "30360026", "title": "β-Catenin expression is associated with cell invasiveness in pancreatic cancer", "doi": "10.3904/kjim.2017.155", "year": 2018 } ] } }, { "id": 8061, "drug": "niclosamide", "drug_type": "drug", "drug_domain": "als", "predicate_ab": "inhibits", "mediator": "S100A4", "mediator_type": "gene", "predicate_bc": "associated_with", "outcome": "pancreatic adenocarcinoma", "outcome_type": "disease", "outcome_domain": "pancreatic_cancer", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "niclosamide", "mediator_canonical": "s100a4", "outcome_canonical": "pancreatic adenocarcinoma", "ab_count": 2, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "34118929", "title": "Targeting S100A4 with niclosamide attenuates inflammatory and profibrotic pathways in models of amyotrophic lateral sclerosis", "doi": "10.1186/s12974-021-02184-1", "year": 2021 }, { "pmid": "31623154", "title": "The S100A4 Transcriptional Inhibitor Niclosamide Reduces Pro-Inflammatory and Migratory Phenotypes of Microglia: Implications for Amyotrophic Lateral Sclerosis", "doi": "10.3390/cells8101261", "year": 2019 } ], "bc": [ { "pmid": "38463521", "title": "Comprehensive analysis based on the disulfidptosis-related genes identifies hub genes and immune infiltration for pancreatic adenocarcinoma", "doi": "10.1515/med-2024-0906", "year": 2024 } ] } }, { "id": 37793, "drug": "Auranofin", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "activates", "mediator": "Caspase-3", "mediator_type": "protein", "predicate_bc": "causes", "outcome": "neuronal apoptosis", "outcome_type": "phenotype", "outcome_domain": "als", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "auranofin", "mediator_canonical": "CASP3", "outcome_canonical": "neuronal apoptosis", "ab_count": 2, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "36014444", "title": "Anti-Cancer Effects of Auranofin in Human Lung Cancer Cells by Increasing Intracellular ROS Levels and Depleting GSH Levels", "doi": "10.3390/molecules27165207", "year": 2022 }, { "pmid": "33125149", "title": "Auranofin inhibits the proliferation of lung cancer cells via necrosis and caspase‑dependent apoptosis", "doi": "10.3892/or.2020.7818", "year": 2020 } ], "bc": [ { "pmid": "26064904", "title": "Implication of Caspase-3 as a Common Therapeutic Target for Multineurodegenerative Disorders and Its Inhibition Using Nonpeptidyl Natural Compounds", "doi": "10.1155/2015/379817", "year": 2015 } ] } }, { "id": 37791, "drug": "riluzole", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "inhibits", "mediator": "TDP-43", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "neurodegeneration", "outcome_type": "phenotype", "outcome_domain": "als", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "completed", "clinical_trial_nct_ids": [ "NCT00818389" ], "literature_status": "reproduces_known", "drug_canonical": "riluzole", "mediator_canonical": "TDP-43", "outcome_canonical": null, "ab_count": 1, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "29396541", "title": "TDP-43 self-interaction is modulated by redox-active compounds Auranofin, Chelerythrine and Riluzole", "doi": "10.1038/s41598-018-20565-0", "year": 2018 } ], "bc": [ { "pmid": "39810199", "title": "Alternative 3′ UTR polyadenylation is disrupted in the rNLS8 mouse model of ALS/FTLD", "doi": "10.1186/s13041-025-01174-1", "year": 2025 }, { "pmid": "30922385", "title": "Transcriptomopathies of pre- and post-symptomatic frontotemporal dementia-like mice with TDP-43 depletion in forebrain neurons", "doi": "10.1186/s40478-019-0674-x", "year": 2019 } ] } }, { "id": 37790, "drug": "Auranofin", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "inhibits", "mediator": "TDP-43", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "frontotemporal dementia", "outcome_type": "disease", "outcome_domain": "als", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "auranofin", "mediator_canonical": "TDP-43", "outcome_canonical": "frontotemporal dementia", "ab_count": 1, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "29396541", "title": "TDP-43 self-interaction is modulated by redox-active compounds Auranofin, Chelerythrine and Riluzole", "doi": "10.1038/s41598-018-20565-0", "year": 2018 } ], "bc": [ { "pmid": "37841575", "title": "Uncovering Critical Roles for RNA in Neurodegeneration.", "doi": null, "year": 2023 }, { "pmid": "33065281", "title": "TDP-43 and Tau Oligomers in Alzheimer's Disease, Amyotrophic Lateral Sclerosis, and Frontotemporal Dementia", "doi": "10.1016/j.nbd.2020.105130", "year": 2020 } ] } }, { "id": 3886, "drug": "curcumin", "drug_type": "drug", "drug_domain": "alzheimer", "predicate_ab": "binds_to", "mediator": "TDP-43", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "Frontotemporal dementia", "outcome_type": "disease", "outcome_domain": "als", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "curcumin", "mediator_canonical": "TDP-43", "outcome_canonical": "frontotemporal dementia", "ab_count": 1, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "30092839", "title": "Different curcumin forms selectively bind fibrillar amyloid beta in post mortem Alzheimer’s disease brains: Implications for in-vivo diagnostics", "doi": "10.1186/s40478-018-0577-2", "year": 2018 } ], "bc": [ { "pmid": "37841575", "title": "Uncovering Critical Roles for RNA in Neurodegeneration.", "doi": null, "year": 2023 }, { "pmid": "33065281", "title": "TDP-43 and Tau Oligomers in Alzheimer's Disease, Amyotrophic Lateral Sclerosis, and Frontotemporal Dementia", "doi": "10.1016/j.nbd.2020.105130", "year": 2020 } ] } }, { "id": 565, "drug": "auraptene", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "downregulates", "mediator": "MMP-9", "mediator_type": "protein", "predicate_bc": "increases", "outcome": "seizures", "outcome_type": "phenotype", "outcome_domain": "epilepsy", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "auraptene", "mediator_canonical": "MMP9", "outcome_canonical": "seizures", "ab_count": 1, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "39086858", "title": "Auraptene inhibits migration, invasion and metastatic behavior of human malignant glioblastoma cells: An in vitro and in silico study.", "doi": "10.22038/ajp.2023.23586", "year": 2024 } ], "bc": [ { "pmid": "29667129", "title": "Elevation of MMP-9 Levels Promotes Epileptogenesis After Traumatic Brain Injury", "doi": "10.1007/s12035-018-1061-5", "year": 2018 } ] } }, { "id": 37810, "drug": "riluzole", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "inhibits", "mediator": "TDP-43", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "neurodegenerative diseases", "outcome_type": "disease", "outcome_domain": "als", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "active", "clinical_trial_nct_ids": [ "NCT00690118", "NCT07142291", "NCT07414212" ], "literature_status": "reproduces_known", "drug_canonical": "riluzole", "mediator_canonical": "TDP-43", "outcome_canonical": null, "ab_count": 1, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "29396541", "title": "TDP-43 self-interaction is modulated by redox-active compounds Auranofin, Chelerythrine and Riluzole", "doi": "10.1038/s41598-018-20565-0", "year": 2018 } ], "bc": [ { "pmid": "41900026", "title": "Chemical and Molecular Strategies in Restoring Autophagic Flux in TDP-43 Proteinopathy", "doi": "10.3390/molecules31060924", "year": 2026 }, { "pmid": "40960157", "title": "Protein aggregation in neurodegenerative diseases", "doi": "10.1097/cm9.0000000000003802", "year": 2025 } ] } }, { "id": 37308, "drug": "valproic acid", "drug_type": "drug", "drug_domain": "pancreatic_cancer", "predicate_ab": "downregulates", "mediator": "EGFR", "mediator_type": "gene", "predicate_bc": "associated_with", "outcome": "rheumatoid arthritis", "outcome_type": "disease", "outcome_domain": "rheumatoid_arthritis", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "valproic acid", "mediator_canonical": "EGFR", "outcome_canonical": "rheumatoid arthritis", "ab_count": 1, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "30961642", "title": "Valproic acid exhibits anti-tumor activity selectively against EGFR/ErbB2/ErbB3-coexpressing pancreatic cancer via induction of ErbB family members-targeting microRNAs", "doi": "10.1186/s13046-019-1160-9", "year": 2019 } ], "bc": [ { "pmid": "40964982", "title": "Selection of Common Genes Associated with Rheumatoid Arthritis and Cardiovascular Disease via a Network- and Pathway-Based Approach", "doi": "10.14744/anatoljcardiol.2025.5375", "year": 2025 }, { "pmid": "36247278", "title": "Identification and validation of potential hub genes in rheumatoid arthritis by bioinformatics analysis.", "doi": null, "year": 2022 } ] } }, { "id": 37742, "drug": "Auranofin", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "inhibits", "mediator": "TDP-43", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "neurodegenerative diseases", "outcome_type": "disease", "outcome_domain": "als", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "auranofin", "mediator_canonical": "TDP-43", "outcome_canonical": null, "ab_count": 1, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "29396541", "title": "TDP-43 self-interaction is modulated by redox-active compounds Auranofin, Chelerythrine and Riluzole", "doi": "10.1038/s41598-018-20565-0", "year": 2018 } ], "bc": [ { "pmid": "41900026", "title": "Chemical and Molecular Strategies in Restoring Autophagic Flux in TDP-43 Proteinopathy", "doi": "10.3390/molecules31060924", "year": 2026 }, { "pmid": "40960157", "title": "Protein aggregation in neurodegenerative diseases", "doi": "10.1097/cm9.0000000000003802", "year": 2025 } ] } }, { "id": 37744, "drug": "Auranofin", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "activates", "mediator": "Caspase-3", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "Alzheimer's disease", "outcome_type": "disease", "outcome_domain": "als", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "auranofin", "mediator_canonical": "CASP3", "outcome_canonical": "Alzheimer disease", "ab_count": 2, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "36014444", "title": "Anti-Cancer Effects of Auranofin in Human Lung Cancer Cells by Increasing Intracellular ROS Levels and Depleting GSH Levels", "doi": "10.3390/molecules27165207", "year": 2022 }, { "pmid": "33125149", "title": "Auranofin inhibits the proliferation of lung cancer cells via necrosis and caspase‑dependent apoptosis", "doi": "10.3892/or.2020.7818", "year": 2020 } ], "bc": [ { "pmid": "26064904", "title": "Implication of Caspase-3 as a Common Therapeutic Target for Multineurodegenerative Disorders and Its Inhibition Using Nonpeptidyl Natural Compounds", "doi": "10.1155/2015/379817", "year": 2015 } ] } }, { "id": 37809, "drug": "riluzole", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "inhibits", "mediator": "TDP-43", "mediator_type": "protein", "predicate_bc": "causes", "outcome": "neuronal dysfunction", "outcome_type": "phenotype", "outcome_domain": "als", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "riluzole", "mediator_canonical": "TDP-43", "outcome_canonical": "neuronal dysfunction", "ab_count": 1, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "29396541", "title": "TDP-43 self-interaction is modulated by redox-active compounds Auranofin, Chelerythrine and Riluzole", "doi": "10.1038/s41598-018-20565-0", "year": 2018 } ], "bc": [ { "pmid": "41571758", "title": "Cytoplasmic TDP-43 leads to early behavioral impairments without neurodegeneration in a serotonergic neuron-specific C. elegans model", "doi": "10.1038/s41598-026-36138-5", "year": 2026 }, { "pmid": "42013476", "title": "Cryptic Splicing in ALS: From Driving Disease Progression to Unlocking Novel Therapeutics", "doi": "10.1146/annurev-genom-022024-011307", "year": 2026 } ] } }, { "id": 37773, "drug": "Auranofin", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "inhibits", "mediator": "TDP-43", "mediator_type": "protein", "predicate_bc": "causes", "outcome": "neuronal dysfunction", "outcome_type": "phenotype", "outcome_domain": "als", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "auranofin", "mediator_canonical": "TDP-43", "outcome_canonical": "neuronal dysfunction", "ab_count": 1, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "29396541", "title": "TDP-43 self-interaction is modulated by redox-active compounds Auranofin, Chelerythrine and Riluzole", "doi": "10.1038/s41598-018-20565-0", "year": 2018 } ], "bc": [ { "pmid": "41571758", "title": "Cytoplasmic TDP-43 leads to early behavioral impairments without neurodegeneration in a serotonergic neuron-specific C. elegans model", "doi": "10.1038/s41598-026-36138-5", "year": 2026 }, { "pmid": "42013476", "title": "Cryptic Splicing in ALS: From Driving Disease Progression to Unlocking Novel Therapeutics", "doi": "10.1146/annurev-genom-022024-011307", "year": 2026 } ] } }, { "id": 38417, "drug": "imatinib", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "downregulates", "mediator": "CSF1R", "mediator_type": "protein", "predicate_bc": "decreases", "outcome": "seizure", "outcome_type": "phenotype", "outcome_domain": "epilepsy", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "imatinib", "mediator_canonical": "csf1r", "outcome_canonical": "seizure", "ab_count": 2, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "30281780", "title": "Imatinib inhibits CSF1R that stimulates proliferation of rheumatoid arthritis fibroblast-like synoviocytes", "doi": "10.1111/cei.13220", "year": 2018 } ], "bc": [ { "pmid": "30177815", "title": "A systems-level framework for drug discovery identifies Csf1R as an anti-epileptic drug target", "doi": "10.1038/s41467-018-06008-4", "year": 2018 } ] } }, { "id": 38289, "drug": "Auranofin", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "inhibits", "mediator": "TDP-43", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "Hippocampal sclerosis", "outcome_type": "disease", "outcome_domain": "epilepsy", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "auranofin", "mediator_canonical": "TDP-43", "outcome_canonical": "hippocampal sclerosis", "ab_count": 1, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "29396541", "title": "TDP-43 self-interaction is modulated by redox-active compounds Auranofin, Chelerythrine and Riluzole", "doi": "10.1038/s41598-018-20565-0", "year": 2018 } ], "bc": [ { "pmid": "30452409", "title": "TDP-43 Neuropathologic Associations in the Nun Study and the Honolulu-Asia Aging Study", "doi": "10.3233/jad-180162", "year": 2018 } ] } }, { "id": 38288, "drug": "riluzole", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "inhibits", "mediator": "TDP-43", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "Hippocampal sclerosis", "outcome_type": "disease", "outcome_domain": "epilepsy", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "riluzole", "mediator_canonical": "TDP-43", "outcome_canonical": "hippocampal sclerosis", "ab_count": 1, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "29396541", "title": "TDP-43 self-interaction is modulated by redox-active compounds Auranofin, Chelerythrine and Riluzole", "doi": "10.1038/s41598-018-20565-0", "year": 2018 } ], "bc": [ { "pmid": "30452409", "title": "TDP-43 Neuropathologic Associations in the Nun Study and the Honolulu-Asia Aging Study", "doi": "10.3233/jad-180162", "year": 2018 } ] } }, { "id": 38483, "drug": "sunitinib", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "inhibits", "mediator": "angiogenesis", "mediator_type": "pathway", "predicate_bc": "associated_with", "outcome": "glioblastoma", "outcome_type": "disease", "outcome_domain": "glioblastoma", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "completed", "clinical_trial_nct_ids": [ "NCT00864864", "NCT00499473", "NCT00611728" ], "literature_status": "reproduces_known", "drug_canonical": "sunitinib", "mediator_canonical": "angiogenesis", "outcome_canonical": "glioblastoma", "ab_count": 1, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "39851530", "title": "Unveiling the Anti-Angiogenic Potential of Small-Molecule (Kinase) Inhibitors for Application in Rheumatoid Arthritis", "doi": "10.3390/cells14020102", "year": 2025 } ], "bc": [ { "pmid": "36259473", "title": "Angiogenesis and Its Targeting in Glioblastoma with Focus on Clinical Approaches.", "doi": "10.22074/cellj.2022.8154", "year": 2022 }, { "pmid": "32924014", "title": "Glioblastoma: Targeting Angiogenesis and Tyrosine Kinase Pathways", "doi": "10.31031/nacs.2020.04.000596", "year": 2020 } ] } }, { "id": 4194, "drug": "curcumin", "drug_type": "drug", "drug_domain": "alzheimer", "predicate_ab": "upregulates", "mediator": "BDNF", "mediator_type": "protein", "predicate_bc": "decreases", "outcome": "bipolar disorder", "outcome_type": "disease", "outcome_domain": "depression", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "completed", "clinical_trial_nct_ids": [ "NCT01928043" ], "literature_status": "reproduces_known", "drug_canonical": "curcumin", "mediator_canonical": "BDNF", "outcome_canonical": "bipolar disorder", "ab_count": 1, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "38791161", "title": "Curcumin Improves Neurogenesis in Alzheimer’s Disease Mice via the Upregulation of Wnt/β-Catenin and BDNF", "doi": "10.3390/ijms25105123", "year": 2024 } ], "bc": [ { "pmid": "36700317", "title": "Brain-derived Neurotrophic Factor and High Sensitive C-reactive Protein in Bipolar Depression and Unipolar Depression: The Practical Usage as a Discriminatory Tool", "doi": "10.9758/cpn.2023.21.1.108", "year": 2023 } ] } }, { "id": 37741, "drug": "Auranofin", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "inhibits", "mediator": "TDP-43", "mediator_type": "protein", "predicate_bc": "prevents", "outcome": "motor deficits", "outcome_type": "phenotype", "outcome_domain": "als", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "auranofin", "mediator_canonical": "TDP-43", "outcome_canonical": "motor deficits", "ab_count": 1, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "29396541", "title": "TDP-43 self-interaction is modulated by redox-active compounds Auranofin, Chelerythrine and Riluzole", "doi": "10.1038/s41598-018-20565-0", "year": 2018 } ], "bc": [ { "pmid": "33127758", "title": "Loss of TDP-43 in astrocytes leads to motor deficits by triggering A1-like reactive phenotype and triglial dysfunction", "doi": "10.1073/pnas.2007806117", "year": 2020 }, { "pmid": "29787578", "title": "mTh1 driven expression of hTDP-43 results in typical ALS/FTLD neuropathological symptoms", "doi": "10.1371/journal.pone.0197674", "year": 2018 } ] } }, { "id": 37769, "drug": "riluzole", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "inhibits", "mediator": "TDP-43", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "Alzheimer's disease", "outcome_type": "disease", "outcome_domain": "als", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "completed", "clinical_trial_nct_ids": [ "NCT01703117" ], "literature_status": "reproduces_known", "drug_canonical": "riluzole", "mediator_canonical": "TDP-43", "outcome_canonical": "Alzheimer disease", "ab_count": 1, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "29396541", "title": "TDP-43 self-interaction is modulated by redox-active compounds Auranofin, Chelerythrine and Riluzole", "doi": "10.1038/s41598-018-20565-0", "year": 2018 } ], "bc": [ { "pmid": "38175301", "title": "Cryptic splicing of stathmin-2 and UNC13A mRNAs is a pathological hallmark of TDP-43-associated Alzheimer’s disease", "doi": "10.1007/s00401-023-02655-0", "year": 2024 }, { "pmid": "26231953", "title": "TDP-43 proteinopathies: pathological identification of brain regions differentiating clinical phenotypes", "doi": "10.1093/brain/awv220", "year": 2015 } ] } }, { "id": 37768, "drug": "Auranofin", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "inhibits", "mediator": "TDP-43", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "Alzheimer's disease", "outcome_type": "disease", "outcome_domain": "als", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "auranofin", "mediator_canonical": "TDP-43", "outcome_canonical": "Alzheimer disease", "ab_count": 1, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "29396541", "title": "TDP-43 self-interaction is modulated by redox-active compounds Auranofin, Chelerythrine and Riluzole", "doi": "10.1038/s41598-018-20565-0", "year": 2018 } ], "bc": [ { "pmid": "38175301", "title": "Cryptic splicing of stathmin-2 and UNC13A mRNAs is a pathological hallmark of TDP-43-associated Alzheimer’s disease", "doi": "10.1007/s00401-023-02655-0", "year": 2024 }, { "pmid": "26231953", "title": "TDP-43 proteinopathies: pathological identification of brain regions differentiating clinical phenotypes", "doi": "10.1093/brain/awv220", "year": 2015 } ] } }, { "id": 37802, "drug": "riluzole", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "inhibits", "mediator": "TDP-43", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "frontotemporal dementia", "outcome_type": "disease", "outcome_domain": "als", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "riluzole", "mediator_canonical": "TDP-43", "outcome_canonical": "frontotemporal dementia", "ab_count": 1, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "29396541", "title": "TDP-43 self-interaction is modulated by redox-active compounds Auranofin, Chelerythrine and Riluzole", "doi": "10.1038/s41598-018-20565-0", "year": 2018 } ], "bc": [ { "pmid": "37841575", "title": "Uncovering Critical Roles for RNA in Neurodegeneration.", "doi": null, "year": 2023 }, { "pmid": "33065281", "title": "TDP-43 and Tau Oligomers in Alzheimer's Disease, Amyotrophic Lateral Sclerosis, and Frontotemporal Dementia", "doi": "10.1016/j.nbd.2020.105130", "year": 2020 } ] } }, { "id": 1389, "drug": "apigenin", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "upregulates", "mediator": "GFAP", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "cognitive performance", "outcome_type": "phenotype", "outcome_domain": "alzheimer", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "apigenin", "mediator_canonical": "GFAP", "outcome_canonical": "cognitive performance", "ab_count": 1, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41090780", "title": "Apigenin Induces Autophagy and Apoptosis in Chemoresistant Glioblastoma Cells and Inhibits Tumorigenicity Associated with Regulation of Immunomodulatory Proteins and Glial Cells Response", "doi": "10.3390/cells14191552", "year": 2025 } ], "bc": [ { "pmid": "38623387", "title": "Relationship of plasma biomarkers to digital cognitive tests in Alzheimer's disease", "doi": "10.1002/dad2.12590", "year": 2024 }, { "pmid": "37268240", "title": "Head-to-head comparison of plasma p-tau181, p-tau231 and glial fibrillary acidic protein in clinically unimpaired elderly with three levels of APOE4-related risk for Alzheimer's disease", "doi": "10.1016/j.nbd.2023.106175", "year": 2023 } ] } }, { "id": 1406, "drug": "apigenin", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "upregulates", "mediator": "GFAP", "mediator_type": "protein", "predicate_bc": "predicts", "outcome": "dementia with Lewy bodies", "outcome_type": "disease", "outcome_domain": "alzheimer", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "apigenin", "mediator_canonical": "GFAP", "outcome_canonical": "dementia with lewy bodies", "ab_count": 1, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41090780", "title": "Apigenin Induces Autophagy and Apoptosis in Chemoresistant Glioblastoma Cells and Inhibits Tumorigenicity Associated with Regulation of Immunomodulatory Proteins and Glial Cells Response", "doi": "10.3390/cells14191552", "year": 2025 } ], "bc": [ { "pmid": "40551285", "title": "Diagnostic performance of plasma Aβ42/40 ratio, p‐tau181, GFAP, and NfL along the continuum of Alzheimer's disease and non‐AD dementias: An international multi‐center study", "doi": "10.1002/alz.14573", "year": 2025 }, { "pmid": "29755340", "title": "Glutamate Transporter GLT1 Expression in Alzheimer Disease and Dementia With Lewy Bodies", "doi": "10.3389/fnagi.2018.00122", "year": 2018 } ] } }, { "id": 39495, "drug": "Curcumin", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "downregulates", "mediator": "total cholesterol", "mediator_type": "biomarker", "predicate_bc": "associated_with", "outcome": "ALS", "outcome_type": "disease", "outcome_domain": "als", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "completed", "clinical_trial_nct_ids": [ "NCT04654689", "NCT04499963" ], "literature_status": "reproduces_known", "drug_canonical": "curcumin", "mediator_canonical": "total cholesterol", "outcome_canonical": "amyotrophic lateral sclerosis", "ab_count": 1, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "31645652", "title": "Histological evidence of chitosan-encapsulated curcumin suppresses heart and kidney damages on streptozotocin-induced type-1 diabetes in mice model", "doi": "10.1038/s41598-019-51821-6", "year": 2019 } ], "bc": [ { "pmid": "36853389", "title": "Association of blood lipids with onset and prognosis of amyotrophic lateral sclerosis: results from the ALS Swabia registry", "doi": "10.1007/s00415-023-11630-4", "year": 2023 }, { "pmid": "38117120", "title": "Premorbid lipid levels and long-term risk of ALS—a population-based cohort study", "doi": "10.1080/21678421.2023.2295455", "year": 2023 } ] } }, { "id": 37337, "drug": "resveratrol", "drug_type": "drug", "drug_domain": "pancreatic_cancer", "predicate_ab": "downregulates", "mediator": "miR-21", "mediator_type": "gene", "predicate_bc": "correlates_with", "outcome": "rheumatoid arthritis", "outcome_type": "disease", "outcome_domain": "rheumatoid_arthritis", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "active", "clinical_trial_nct_ids": [ "NCT07089381" ], "literature_status": "reproduces_known", "drug_canonical": "resveratrol", "mediator_canonical": "mir-21", "outcome_canonical": "rheumatoid arthritis", "ab_count": 1, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "29854071", "title": "Resveratrol Inhibits ROS‐Promoted Activation and Glycolysis of Pancreatic Stellate Cells via Suppression of miR‐21", "doi": "10.1155/2018/1346958", "year": 2018 } ], "bc": [ { "pmid": "40256764", "title": "Expression of lncRNA NEAT1, miR-21, and IL17 in Rheumatoid Arthritis Patients", "doi": "10.2147/btt.s519558", "year": 2025 }, { "pmid": "34708894", "title": "Long non‐coding RNA NEAT1 and its targets (microRNA‐21 and microRNA‐125a) in rheumatoid arthritis: Altered expression and potential to monitor disease activity and treatment outcome", "doi": "10.1002/jcla.24076", "year": 2021 } ] } }, { "id": 8980, "drug": "verteporfin", "drug_type": "drug", "drug_domain": "alzheimer", "predicate_ab": "inhibits", "mediator": "APP", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "amyotrophic lateral sclerosis", "outcome_type": "disease", "outcome_domain": "als", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "verteporfin", "mediator_canonical": "app", "outcome_canonical": "amyotrophic lateral sclerosis", "ab_count": 2, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "35247387", "title": "Verteporfin is a substrate-selective γ-secretase inhibitor that binds the amyloid precursor protein transmembrane domain", "doi": "10.1016/j.jbc.2022.101792", "year": 2022 } ], "bc": [ { "pmid": "37238921", "title": "Discovery of Biomarkers for Amyotrophic Lateral Sclerosis from Human Cerebrospinal Fluid Using Mass-Spectrometry-Based Proteomics", "doi": "10.3390/biomedicines11051250", "year": 2023 } ] } }, { "id": 7946, "drug": "Riluzole", "drug_type": "drug", "drug_domain": "als", "predicate_ab": "downregulates", "mediator": "MMP-9", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "Alzheimer's disease", "outcome_type": "disease", "outcome_domain": "alzheimer", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "completed", "clinical_trial_nct_ids": [ "NCT01703117" ], "literature_status": "reproduces_known", "drug_canonical": "riluzole", "mediator_canonical": "MMP9", "outcome_canonical": "Alzheimer disease", "ab_count": 1, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40012807", "title": "Investigation of the Neuroprotective Effect of Riluzole on Matrix Metalloproteinases in an Experimental Model of Glaucoma", "doi": "10.4103/joco.joco_290_23", "year": 2024 } ], "bc": [ { "pmid": "37695608", "title": "Plasma MMP-9/TIMP-1 ratio serves as a novel potential biomarker in Alzheimer’s disease", "doi": "10.1097/wnr.0000000000001952", "year": 2023 }, { "pmid": "32790155", "title": "Elevated matrix metalloproteinase‐9 levels in neuronal extracellular vesicles in Alzheimer’s disease", "doi": "10.1002/acn3.51155", "year": 2020 } ] } }, { "id": 39126, "drug": "Auranofin", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "upregulates", "mediator": "PD-L1", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "poor differentiation", "outcome_type": "phenotype", "outcome_domain": "pancreatic_cancer", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "auranofin", "mediator_canonical": "PD-L1", "outcome_canonical": null, "ab_count": 1, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "31090219", "title": "Therapeutic cooperation between auranofin, a thioredoxin reductase inhibitor and anti‐PD‐L1 antibody for treatment of triple‐negative breast cancer", "doi": "10.1002/ijc.32410", "year": 2019 } ], "bc": [ { "pmid": "35624419", "title": "Clinical significance and correlation of PD-L1, B7-H3, B7-H4, and TILs in pancreatic cancer", "doi": "10.1186/s12885-022-09639-5", "year": 2022 }, { "pmid": "28030840", "title": "Prognostic value and clinicopathological features of PD-1/PD-L1 expression with mismatch repair status and desmoplastic stroma in Chinese patients with pancreatic cancer", "doi": "10.18632/oncotarget.14069", "year": 2016 } ] } }, { "id": 1597, "drug": "erlotinib", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "inhibits", "mediator": "EGFR", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "pancreatic intraepithelial neoplasia", "outcome_type": "phenotype", "outcome_domain": "pancreatic_cancer", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "erlotinib", "mediator_canonical": "EGFR", "outcome_canonical": "pancreatic intraepithelial neoplasia", "ab_count": 2, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40945534", "title": "Biodegradable nanofibrous scaffolds enhance standard of care for glioblastoma via localized targeted therapy", "doi": "10.1016/j.jconrel.2025.114225", "year": 2025 }, { "pmid": "30410775", "title": "The role of erlotinib and the Optune device in a patient with an epidermal growth factor receptor viii amplified glioblastoma", "doi": "10.1093/omcr/omy095", "year": 2018 } ], "bc": [ { "pmid": "26339400", "title": "EGFR expression in pancreatic intraepithelial neoplasia and ductal adenocarcinoma.", "doi": null, "year": 2015 } ] } }, { "id": 8852, "drug": "curcumin", "drug_type": "drug", "drug_domain": "alzheimer", "predicate_ab": "binds_to", "mediator": "TDP-43", "mediator_type": "protein", "predicate_bc": "causes", "outcome": "neuronal dysfunction", "outcome_type": "phenotype", "outcome_domain": "als", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "curcumin", "mediator_canonical": "TDP-43", "outcome_canonical": "neuronal dysfunction", "ab_count": 1, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "30092839", "title": "Different curcumin forms selectively bind fibrillar amyloid beta in post mortem Alzheimer’s disease brains: Implications for in-vivo diagnostics", "doi": "10.1186/s40478-018-0577-2", "year": 2018 } ], "bc": [ { "pmid": "41571758", "title": "Cytoplasmic TDP-43 leads to early behavioral impairments without neurodegeneration in a serotonergic neuron-specific C. elegans model", "doi": "10.1038/s41598-026-36138-5", "year": 2026 }, { "pmid": "42013476", "title": "Cryptic Splicing in ALS: From Driving Disease Progression to Unlocking Novel Therapeutics", "doi": "10.1146/annurev-genom-022024-011307", "year": 2026 } ] } }, { "id": 35153, "drug": "chloroquine", "drug_type": "drug", "drug_domain": "multiple_sclerosis", "predicate_ab": "upregulates", "mediator": "IL-10", "mediator_type": "protein", "predicate_bc": "prevents", "outcome": "colitis", "outcome_type": "disease", "outcome_domain": "inflammatory_bowel_disease", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "active", "clinical_trial_nct_ids": [ "NCT05119140" ], "literature_status": "reproduces_known", "drug_canonical": "chloroquine", "mediator_canonical": "il-10", "outcome_canonical": "colitis", "ab_count": 1, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "32516999", "title": "Comprehensive Analysis of the Immune and Stromal Compartments of the CNS in EAE Mice Reveal Pathways by Which Chloroquine Suppresses Neuroinflammation", "doi": "10.3390/brainsci10060348", "year": 2020 } ], "bc": [ { "pmid": "29545807", "title": "The Dynamics of Interleukin-10-Afforded Protection during Dextran Sulfate Sodium-Induced Colitis", "doi": "10.3389/fimmu.2018.00400", "year": 2018 } ] } }, { "id": 2891, "drug": "niclosamide", "drug_type": "drug", "drug_domain": "als", "predicate_ab": "inhibits", "mediator": "S100A4", "mediator_type": "gene", "predicate_bc": "associated_with", "outcome": "overall survival", "outcome_type": "phenotype", "outcome_domain": "glioblastoma", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "niclosamide", "mediator_canonical": "s100a4", "outcome_canonical": null, "ab_count": 2, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "34118929", "title": "Targeting S100A4 with niclosamide attenuates inflammatory and profibrotic pathways in models of amyotrophic lateral sclerosis", "doi": "10.1186/s12974-021-02184-1", "year": 2021 }, { "pmid": "31623154", "title": "The S100A4 Transcriptional Inhibitor Niclosamide Reduces Pro-Inflammatory and Migratory Phenotypes of Microglia: Implications for Amyotrophic Lateral Sclerosis", "doi": "10.3390/cells8101261", "year": 2019 } ], "bc": [ { "pmid": "35069135", "title": "Integrated Analysis to Obtain Potential Prognostic Signature in Glioblastoma", "doi": "10.3389/fnint.2021.717629", "year": 2022 } ] } }, { "id": 25563, "drug": "riluzole", "drug_type": "drug", "drug_domain": "als", "predicate_ab": "downregulates", "mediator": "MMP-9", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "rheumatoid arthritis", "outcome_type": "disease", "outcome_domain": "rheumatoid_arthritis", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "riluzole", "mediator_canonical": "MMP9", "outcome_canonical": "rheumatoid arthritis", "ab_count": 1, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40012807", "title": "Investigation of the Neuroprotective Effect of Riluzole on Matrix Metalloproteinases in an Experimental Model of Glaucoma", "doi": "10.4103/joco.joco_290_23", "year": 2024 } ], "bc": [ { "pmid": "38419379", "title": "A Novel Activatable Nanoradiosensitizer for Second Near‐Infrared Fluorescence Imaging‐Guided Safe‐Dose Synergetic Chemo‐Radiotherapy of Rheumatoid Arthritis", "doi": "10.1002/advs.202308905", "year": 2024 }, { "pmid": "34912337", "title": "Proteoform Analysis of Matrix Metalloproteinase-9/Gelatinase B and Discovery of Its Citrullination in Rheumatoid Arthritis Synovial Fluids", "doi": "10.3389/fimmu.2021.763832", "year": 2021 } ] } }, { "id": 2593, "drug": "valproic acid", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "suppresses", "mediator": "NRF2", "mediator_type": "gene", "predicate_bc": "associated_with", "outcome": "5-FU resistance", "outcome_type": "phenotype", "outcome_domain": "pancreatic_cancer", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "valproic acid", "mediator_canonical": "NRF2", "outcome_canonical": "5-fu resistance", "ab_count": 2, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "34050116", "title": "Chronic valproic acid administration enhances oxidative stress, upregulates IL6 and downregulates Nrf2, Glut1 and Glut4 in rat’s liver and brain", "doi": "10.1097/wnr.0000000000001663", "year": 2021 }, { "pmid": "34686779", "title": "Valproic acid disables the Nrf2 anti-oxidant response in acute myeloid leukaemia cells enhancing reactive oxygen species-mediated killing", "doi": "10.1038/s41416-021-01570-z", "year": 2021 } ], "bc": [ { "pmid": "32629871", "title": "NRF2 Knockdown Resensitizes 5-Fluorouracil-Resistant Pancreatic Cancer Cells by Suppressing HO-1 and ABCG2 Expression", "doi": "10.3390/ijms21134646", "year": 2020 } ] } }, { "id": 23256, "drug": "amantadine", "drug_type": "drug", "drug_domain": "multiple_sclerosis", "predicate_ab": "activates", "mediator": "NMDA receptor", "mediator_type": "protein", "predicate_bc": "causes", "outcome": "neuronal death", "outcome_type": "phenotype", "outcome_domain": "epilepsy", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "amantadine", "mediator_canonical": "nmda receptor", "outcome_canonical": "neuronal death", "ab_count": 2, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37419676", "title": "Amantadine toxicity causing visual hallucinations", "doi": "10.1136/pn-2023-003723", "year": 2023 }, { "pmid": "33350472", "title": "Amantadine for COVID‐19", "doi": "10.1002/jcph.1802", "year": 2020 } ], "bc": [ { "pmid": "36648377", "title": "Reactive oxygen species in status epilepticus", "doi": "10.1002/epi4.12691", "year": 2023 } ] } }, { "id": 61091, "drug": "Curcumin", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "downregulates", "mediator": "blood glucose", "mediator_type": "biomarker", "predicate_bc": "associated_with", "outcome": "all-cause death", "outcome_type": "phenotype", "outcome_domain": "heart_failure", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "31645652", "title": "Histological evidence of chitosan-encapsulated curcumin suppresses heart and kidney damages on streptozotocin-induced type-1 diabetes in mice model", "doi": "10.1038/s41598-019-51821-6", "year": 2019 } ], "bc": [ { "pmid": "25572328", "title": "Presentation blood glucose and death, hospitalization, and future diabetes risk in patients with acute heart failure syndromes", "doi": "10.1093/eurheartj/ehu462", "year": 2015 } ] } }, { "id": 36905, "drug": "resveratrol", "drug_type": "drug", "drug_domain": "pancreatic_cancer", "predicate_ab": "downregulates", "mediator": "miR-21", "mediator_type": "gene", "predicate_bc": "correlates_with", "outcome": "disease activity", "outcome_type": "phenotype", "outcome_domain": "inflammatory_bowel_disease", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "completed", "clinical_trial_nct_ids": [ "NCT00920556" ], "literature_status": "reproduces_known", "drug_canonical": "resveratrol", "mediator_canonical": "mir-21", "outcome_canonical": "disease activity", "ab_count": 1, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "29854071", "title": "Resveratrol Inhibits ROS‐Promoted Activation and Glycolysis of Pancreatic Stellate Cells via Suppression of miR‐21", "doi": "10.1155/2018/1346958", "year": 2018 } ], "bc": [ { "pmid": "32332611", "title": "Aberrant expression of miR-21 in patients with inflammatory bowel disease", "doi": "10.1097/md.0000000000019693", "year": 2020 } ] } }, { "id": 36898, "drug": "niclosamide", "drug_type": "drug", "drug_domain": "pancreatic_cancer", "predicate_ab": "downregulates", "mediator": "PD-L1", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "colitis", "outcome_type": "disease", "outcome_domain": "inflammatory_bowel_disease", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "completed", "clinical_trial_nct_ids": [ "NCT03521232" ], "literature_status": "partial_evidence", "drug_canonical": "niclosamide", "mediator_canonical": "PD-L1", "outcome_canonical": "colitis", "ab_count": 1, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "35115509", "title": "The anthelmintic drug niclosamide induces GSK-β-mediated β-catenin degradation to potentiate gemcitabine activity, reduce immune evasion ability and suppress pancreatic cancer progression", "doi": "10.1038/s41419-022-04573-7", "year": 2022 } ], "bc": [ { "pmid": "40661950", "title": "PD-L1 deficiency exacerbates colitis severity by remodeling gut microbiota in inflammatory bowel disease", "doi": "10.3389/fimmu.2025.1622744", "year": 2025 }, { "pmid": "37435072", "title": "Case Report: A severe case of immunosuppressant-refractory immune checkpoint inhibitor-mediated colitis rescued by tofacitinib", "doi": "10.3389/fimmu.2023.1212432", "year": 2023 } ] } }, { "id": 2869, "drug": "valproic acid", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "downregulates", "mediator": "BDNF", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "depression severity", "outcome_type": "phenotype", "outcome_domain": "depression", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "valproic acid", "mediator_canonical": "BDNF", "outcome_canonical": "depression severity", "ab_count": 1, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "35465089", "title": "Excitatory and Inhibitory Synaptic Imbalance Caused by Brain-Derived Neurotrophic Factor Deficits During Development in a Valproic Acid Mouse Model of Autism", "doi": "10.3389/fnmol.2022.860275", "year": 2022 } ], "bc": [ { "pmid": "34841285", "title": "The ratio and interaction between neurotrophin and immune signaling during electroconvulsive therapy in late-life depression", "doi": "10.1016/j.bbih.2021.100389", "year": 2021 }, { "pmid": "29614706", "title": "Yoga- and meditation-based lifestyle intervention increases neuroplasticity and reduces severity of major depressive disorder: A randomized controlled trial", "doi": "10.3233/rnn-170810", "year": 2018 } ] } }, { "id": 8877, "drug": "curcumin", "drug_type": "drug", "drug_domain": "alzheimer", "predicate_ab": "binds_to", "mediator": "TDP-43", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "neurodegenerative diseases", "outcome_type": "disease", "outcome_domain": "als", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "active", "clinical_trial_nct_ids": [ "NCT04499963", "NCT05363267", "NCT06470061" ], "literature_status": "reproduces_known", "drug_canonical": "curcumin", "mediator_canonical": "TDP-43", "outcome_canonical": null, "ab_count": 1, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "30092839", "title": "Different curcumin forms selectively bind fibrillar amyloid beta in post mortem Alzheimer’s disease brains: Implications for in-vivo diagnostics", "doi": "10.1186/s40478-018-0577-2", "year": 2018 } ], "bc": [ { "pmid": "41900026", "title": "Chemical and Molecular Strategies in Restoring Autophagic Flux in TDP-43 Proteinopathy", "doi": "10.3390/molecules31060924", "year": 2026 }, { "pmid": "40960157", "title": "Protein aggregation in neurodegenerative diseases", "doi": "10.1097/cm9.0000000000003802", "year": 2025 } ] } }, { "id": 37820, "drug": "Auranofin", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "inhibits", "mediator": "GSK-3β", "mediator_type": "protein", "predicate_bc": "prevents", "outcome": "FUS-induced neurotoxicity", "outcome_type": "phenotype", "outcome_domain": "als", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "auranofin", "mediator_canonical": "GSK3B", "outcome_canonical": "fus-induced neurotoxicity", "ab_count": 2, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40842183", "title": "Gold‐Containing Compound Auranofin Ameliorates 6‐OHDA Induced Neurotoxicity in Rats: Via Targeting PI3K/Akt/GSK‐3β Signalling", "doi": "10.1111/1440-1681.70070", "year": 2025 } ], "bc": [ { "pmid": "34605896", "title": "FUS-induced neurotoxicity is prevented by inhibiting GSK-3β in aDrosophilamodel of amyotrophic lateral sclerosis", "doi": "10.1093/hmg/ddab290", "year": 2021 } ] } }, { "id": 35555, "drug": "chloroquine", "drug_type": "drug", "drug_domain": "multiple_sclerosis", "predicate_ab": "upregulates", "mediator": "IL-10", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "depressive symptoms", "outcome_type": "phenotype", "outcome_domain": "rheumatoid_arthritis", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "chloroquine", "mediator_canonical": "il-10", "outcome_canonical": "depressive symptoms", "ab_count": 1, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "32516999", "title": "Comprehensive Analysis of the Immune and Stromal Compartments of the CNS in EAE Mice Reveal Pathways by Which Chloroquine Suppresses Neuroinflammation", "doi": "10.3390/brainsci10060348", "year": 2020 } ], "bc": [ { "pmid": "30148175", "title": "Influence of Biological Therapeutics, Cytokines, and Disease Activity on Depression in Rheumatoid Arthritis", "doi": "10.1155/2018/5954897", "year": 2018 } ] } }, { "id": 25352, "drug": "riluzole", "drug_type": "drug", "drug_domain": "als", "predicate_ab": "activates", "mediator": "ATM", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "recurrence", "outcome_type": "phenotype", "outcome_domain": "pancreatic_cancer", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "active", "clinical_trial_nct_ids": [ "NCT06552260", "NCT01303341", "NCT00866840" ], "literature_status": "partial_evidence", "drug_canonical": "riluzole", "mediator_canonical": "atm", "outcome_canonical": null, "ab_count": 1, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "32231713", "title": "Riluzole Enhances the Response of Human Nasopharyngeal Carcinoma Cells to Ionizing Radiation via ATM/P53 Signalling Pathway", "doi": "10.7150/jca.41217", "year": 2020 } ], "bc": [ { "pmid": "32209898", "title": "Expression Patterns and Prognostic Value of DNA Damage Repair Proteins in Resected Pancreatic Neuroendocrine Neoplasms", "doi": "10.1097/sla.0000000000003884", "year": 2020 } ] } }, { "id": 33645, "drug": "resveratrol", "drug_type": "drug", "drug_domain": "inflammatory_bowel_disease", "predicate_ab": "inhibits", "mediator": "β-catenin", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "cell invasiveness", "outcome_type": "phenotype", "outcome_domain": "pancreatic_cancer", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "resveratrol", "mediator_canonical": "β-catenin", "outcome_canonical": "cell invasiveness", "ab_count": 1, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "32115503", "title": "Resveratrol Attenuates Inflammatory Bowel Disease in Mice by Regulating SUMO1", "doi": "10.1248/bpb.b19-00786", "year": 2020 } ], "bc": [ { "pmid": "30360026", "title": "β-Catenin expression is associated with cell invasiveness in pancreatic cancer", "doi": "10.3904/kjim.2017.155", "year": 2018 } ] } }, { "id": 33581, "drug": "resveratrol", "drug_type": "drug", "drug_domain": "inflammatory_bowel_disease", "predicate_ab": "binds_to", "mediator": "Nrf2", "mediator_type": "protein", "predicate_bc": "causes", "outcome": "chemoresistance", "outcome_type": "phenotype", "outcome_domain": "pancreatic_cancer", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "completed", "clinical_trial_nct_ids": [ "NCT04266353" ], "literature_status": "reproduces_known", "drug_canonical": "resveratrol", "mediator_canonical": "NRF2", "outcome_canonical": null, "ab_count": 1, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "38488031", "title": "Resveratrol ameliorates ulcerative colitis by upregulating Nrf2/HO‑1 pathway activity: Integrating animal experiments and network pharmacology", "doi": "10.3892/mmr.2024.13201", "year": 2024 } ], "bc": [ { "pmid": "31911550", "title": "Undermining Glutaminolysis Bolsters Chemotherapy While NRF2 Promotes Chemoresistance in KRAS-Driven Pancreatic Cancers", "doi": "10.1158/0008-5472.can-19-1363", "year": 2020 }, { "pmid": "30735911", "title": "Digoxin sensitizes gemcitabine-resistant pancreatic cancer cells to gemcitabine via inhibiting Nrf2 signaling pathway", "doi": "10.1016/j.redox.2019.101131", "year": 2019 } ] } }, { "id": 3786, "drug": "curcumin", "drug_type": "drug", "drug_domain": "alzheimer", "predicate_ab": "binds_to", "mediator": "TDP-43", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "neurodegeneration", "outcome_type": "phenotype", "outcome_domain": "als", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "curcumin", "mediator_canonical": "TDP-43", "outcome_canonical": null, "ab_count": 1, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "30092839", "title": "Different curcumin forms selectively bind fibrillar amyloid beta in post mortem Alzheimer’s disease brains: Implications for in-vivo diagnostics", "doi": "10.1186/s40478-018-0577-2", "year": 2018 } ], "bc": [ { "pmid": "39810199", "title": "Alternative 3′ UTR polyadenylation is disrupted in the rNLS8 mouse model of ALS/FTLD", "doi": "10.1186/s13041-025-01174-1", "year": 2025 }, { "pmid": "30922385", "title": "Transcriptomopathies of pre- and post-symptomatic frontotemporal dementia-like mice with TDP-43 depletion in forebrain neurons", "doi": "10.1186/s40478-019-0674-x", "year": 2019 } ] } }, { "id": 33601, "drug": "Apigenin", "drug_type": "drug", "drug_domain": "inflammatory_bowel_disease", "predicate_ab": "activates", "mediator": "AMPK", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "pancreatic cancer progression", "outcome_type": "disease", "outcome_domain": "pancreatic_cancer", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "apigenin", "mediator_canonical": "AMPK", "outcome_canonical": "pancreatic cancer progression", "ab_count": 2, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41428381", "title": "Natural Dietary Flavonoid Apigenin Mitigates Ulcerative Colitis via Modulating the AMPK/NF-κB/NLRP3 Signaling Axis", "doi": "10.1021/acs.jafc.5c15405", "year": 2025 } ], "bc": [ { "pmid": "31205544", "title": "AMPK Inhibition Suppresses the Malignant Phenotype of Pancreatic Cancer Cells in Part by Attenuating Aerobic Glycolysis", "doi": "10.7150/jca.28299", "year": 2019 } ] } }, { "id": 33541, "drug": "resveratrol", "drug_type": "drug", "drug_domain": "inflammatory_bowel_disease", "predicate_ab": "activates", "mediator": "SIRT1", "mediator_type": "protein", "predicate_bc": "increases", "outcome": "proliferation", "outcome_type": "phenotype", "outcome_domain": "pancreatic_cancer", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "preclinical_only", "clinical_trial_nct_ids": [ "NCT00455416" ], "literature_status": "reproduces_known", "drug_canonical": "resveratrol", "mediator_canonical": "SIRT1", "outcome_canonical": null, "ab_count": 1, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "32636719", "title": "The Protection Effect of Resveratrol Against Radiation-Induced Inflammatory Bowel Disease via NLRP-3 Inflammasome Repression in Mice", "doi": "10.1177/1559325820931292", "year": 2020 } ], "bc": [ { "pmid": "34163012", "title": "SIRT1 coordinates with the CRL4B complex to regulate pancreatic cancer stem cells to promote tumorigenesis", "doi": "10.1038/s41418-021-00821-z", "year": 2021 }, { "pmid": "27494892", "title": "Sirtuin 1 stimulates the proliferation and the expression of glycolysis genes in pancreatic neoplastic lesions", "doi": "10.18632/oncotarget.11013", "year": 2016 } ] } }, { "id": 33439, "drug": "metformin", "drug_type": "drug", "drug_domain": "inflammatory_bowel_disease", "predicate_ab": "downregulates", "mediator": "IL-17", "mediator_type": "protein", "predicate_bc": "increases", "outcome": "cGVHD severity", "outcome_type": "phenotype", "outcome_domain": "multiple_sclerosis", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "metformin", "mediator_canonical": "il-17", "outcome_canonical": "cgvhd severity", "ab_count": 2, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "32654569", "title": "Metformin alleviates experimental colitis in mice by up-regulating TGF-β signaling", "doi": "10.1080/10520295.2020.1776896", "year": 2020 }, { "pmid": "26360050", "title": "Metformin Ameliorates Inflammatory Bowel Disease by Suppression of the STAT3 Signaling Pathway and Regulation of the between Th17/Treg Balance", "doi": "10.1371/journal.pone.0135858", "year": 2015 } ], "bc": [ { "pmid": "30042768", "title": "IL-1-IL-17 Signaling Axis Contributes to Fibrosis and Inflammation in Two Different Murine Models of Systemic Sclerosis", "doi": "10.3389/fimmu.2018.01611", "year": 2018 } ] } }, { "id": 33342, "drug": "metformin", "drug_type": "drug", "drug_domain": "inflammatory_bowel_disease", "predicate_ab": "downregulates", "mediator": "IL-17", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "new enhancing MRI lesions", "outcome_type": "phenotype", "outcome_domain": "multiple_sclerosis", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "metformin", "mediator_canonical": "il-17", "outcome_canonical": "new enhancing mri lesions", "ab_count": 2, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "32654569", "title": "Metformin alleviates experimental colitis in mice by up-regulating TGF-β signaling", "doi": "10.1080/10520295.2020.1776896", "year": 2020 }, { "pmid": "26360050", "title": "Metformin Ameliorates Inflammatory Bowel Disease by Suppression of the STAT3 Signaling Pathway and Regulation of the between Th17/Treg Balance", "doi": "10.1371/journal.pone.0135858", "year": 2015 } ], "bc": [ { "pmid": "38137391", "title": "New Enhancing MRI Lesions Associate with IL-17, Neutrophil Degranulation and Integrin Microparticles: Multi-Omics Combined with Frequent MRI in Multiple Sclerosis", "doi": "10.3390/biomedicines11123170", "year": 2023 } ] } }, { "id": 53279, "drug": "metformin", "drug_type": "drug", "drug_domain": "inflammatory_bowel_disease", "predicate_ab": "activates", "mediator": "AMPK", "mediator_type": "protein", "predicate_bc": "causes", "outcome": "dilated cardiomyopathy", "outcome_type": "disease", "outcome_domain": "heart_failure", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 2, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "35064693", "title": "Metformin ameliorates chronic colitis in a mouse model by regulating interferon‐γ‐producing lamina propria CD4 + T cells through AMPK activation", "doi": "10.1096/fj.202100831rr", "year": 2022 }, { "pmid": "30061832", "title": "Activating AMPK to Restore Tight Junction Assembly in Intestinal Epithelium and to Attenuate Experimental Colitis by Metformin", "doi": "10.3389/fphar.2018.00761", "year": 2018 } ], "bc": [ { "pmid": "26023060", "title": "AMPK deficiency in cardiac muscle results in dilated cardiomyopathy in the absence of changes in energy metabolism", "doi": "10.1093/cvr/cvv166", "year": 2015 } ] } }, { "id": 33057, "drug": "Apigenin", "drug_type": "drug", "drug_domain": "inflammatory_bowel_disease", "predicate_ab": "activates", "mediator": "AMPK", "mediator_type": "protein", "predicate_bc": "increases", "outcome": "spike-wave seizures", "outcome_type": "phenotype", "outcome_domain": "epilepsy", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "apigenin", "mediator_canonical": "AMPK", "outcome_canonical": "spike-wave seizures", "ab_count": 2, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41428381", "title": "Natural Dietary Flavonoid Apigenin Mitigates Ulcerative Colitis via Modulating the AMPK/NF-κB/NLRP3 Signaling Axis", "doi": "10.1021/acs.jafc.5c15405", "year": 2025 } ], "bc": [ { "pmid": "35134125", "title": "AMPK-mediated potentiation of GABAergic signalling drives hypoglycaemia-provoked spike-wave seizures", "doi": "10.1093/brain/awac037", "year": 2022 } ] } }, { "id": 3888, "drug": "curcumin", "drug_type": "drug", "drug_domain": "alzheimer", "predicate_ab": "binds_to", "mediator": "TDP-43", "mediator_type": "protein", "predicate_bc": "prevents", "outcome": "motor deficits", "outcome_type": "phenotype", "outcome_domain": "als", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "curcumin", "mediator_canonical": "TDP-43", "outcome_canonical": "motor deficits", "ab_count": 1, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "30092839", "title": "Different curcumin forms selectively bind fibrillar amyloid beta in post mortem Alzheimer’s disease brains: Implications for in-vivo diagnostics", "doi": "10.1186/s40478-018-0577-2", "year": 2018 } ], "bc": [ { "pmid": "33127758", "title": "Loss of TDP-43 in astrocytes leads to motor deficits by triggering A1-like reactive phenotype and triglial dysfunction", "doi": "10.1073/pnas.2007806117", "year": 2020 }, { "pmid": "29787578", "title": "mTh1 driven expression of hTDP-43 results in typical ALS/FTLD neuropathological symptoms", "doi": "10.1371/journal.pone.0197674", "year": 2018 } ] } }, { "id": 57169, "drug": "metformin", "drug_type": "drug", "drug_domain": "pancreatic_cancer", "predicate_ab": "activates", "mediator": "AMPK", "mediator_type": "protein", "predicate_bc": "causes", "outcome": "dilated cardiomyopathy", "outcome_type": "disease", "outcome_domain": "heart_failure", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 2, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "26760500", "title": "Metformin Treatment Does Not Inhibit Growth of Pancreatic Cancer Patient-Derived Xenografts", "doi": "10.1371/journal.pone.0147113", "year": 2016 }, { "pmid": "25688512", "title": "Rationale and protocol of the MetNET-1 trial, a prospective, single center, phase II study to evaluate the activity and safety of everolimus in combination with octreotide LAR and metformin in patients with advanced pancreatic neuroendocrine tumors.", "doi": "10.1700/1778.19298", "year": 2015 } ], "bc": [ { "pmid": "26023060", "title": "AMPK deficiency in cardiac muscle results in dilated cardiomyopathy in the absence of changes in energy metabolism", "doi": "10.1093/cvr/cvv166", "year": 2015 } ] } }, { "id": 57139, "drug": "resveratrol", "drug_type": "drug", "drug_domain": "pancreatic_cancer", "predicate_ab": "activates", "mediator": "AMPK", "mediator_type": "protein", "predicate_bc": "prevents", "outcome": "metabolic dysfunction", "outcome_type": "disease", "outcome_domain": "heart_failure", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "27669292", "title": "YAP Inhibition by Resveratrol via Activation of AMPK Enhances the Sensitivity of Pancreatic Cancer Cells to Gemcitabine", "doi": "10.3390/nu8100546", "year": 2016 } ], "bc": [ { "pmid": "37194385", "title": "Adenosine monophosphate‐activated protein kinase is elevated in human cachectic muscle and prevents cancer‐induced metabolic dysfunction in mice", "doi": "10.1002/jcsm.13238", "year": 2023 } ] } }, { "id": 57130, "drug": "metformin", "drug_type": "drug", "drug_domain": "pancreatic_cancer", "predicate_ab": "activates", "mediator": "AMPK", "mediator_type": "protein", "predicate_bc": "increases", "outcome": "ventricular cell shortening", "outcome_type": "phenotype", "outcome_domain": "heart_failure", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 2, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "26760500", "title": "Metformin Treatment Does Not Inhibit Growth of Pancreatic Cancer Patient-Derived Xenografts", "doi": "10.1371/journal.pone.0147113", "year": 2016 }, { "pmid": "25688512", "title": "Rationale and protocol of the MetNET-1 trial, a prospective, single center, phase II study to evaluate the activity and safety of everolimus in combination with octreotide LAR and metformin in patients with advanced pancreatic neuroendocrine tumors.", "doi": "10.1700/1778.19298", "year": 2015 } ], "bc": [ { "pmid": "26023060", "title": "AMPK deficiency in cardiac muscle results in dilated cardiomyopathy in the absence of changes in energy metabolism", "doi": "10.1093/cvr/cvv166", "year": 2015 } ] } }, { "id": 57125, "drug": "metformin", "drug_type": "drug", "drug_domain": "pancreatic_cancer", "predicate_ab": "activates", "mediator": "AMPK", "mediator_type": "protein", "predicate_bc": "increases", "outcome": "glycogen storage", "outcome_type": "phenotype", "outcome_domain": "heart_failure", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 2, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "26760500", "title": "Metformin Treatment Does Not Inhibit Growth of Pancreatic Cancer Patient-Derived Xenografts", "doi": "10.1371/journal.pone.0147113", "year": 2016 }, { "pmid": "25688512", "title": "Rationale and protocol of the MetNET-1 trial, a prospective, single center, phase II study to evaluate the activity and safety of everolimus in combination with octreotide LAR and metformin in patients with advanced pancreatic neuroendocrine tumors.", "doi": "10.1700/1778.19298", "year": 2015 } ], "bc": [ { "pmid": "28009297", "title": "Integrative Analysis of PRKAG2 Cardiomyopathy iPS and Microtissue Models Identifies AMPK as a Regulator of Metabolism, Survival, and Fibrosis", "doi": "10.1016/j.celrep.2016.11.066", "year": 2016 } ] } }, { "id": 51877, "drug": "resveratrol", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "inhibits", "mediator": "mitophagy", "mediator_type": "pathway", "predicate_bc": "associated_with", "outcome": "rheumatoid arthritis", "outcome_type": "disease", "outcome_domain": "rheumatoid_arthritis", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "29578301", "title": "Resveratrol Improves Muscle Atrophy by Modulating Mitochondrial Quality Control in STZ‐Induced Diabetic Mice", "doi": "10.1002/mnfr.201700941", "year": 2018 } ], "bc": [ { "pmid": "40671345", "title": "Identification of mitophagy-related biomarkers in human rheumatoid arthritis using machine learning models", "doi": "10.1080/21691401.2025.2533361", "year": 2025 }, { "pmid": "39544132", "title": "Mitophagy drives maldifferentiation of tissue-resident memory T cells in patients with rheumatoid arthritis", "doi": "10.1080/03009742.2024.2420432", "year": 2024 } ] } }, { "id": 51826, "drug": "resveratrol", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "upregulates", "mediator": "SIRT1", "mediator_type": "gene", "predicate_bc": "associated_with", "outcome": "rheumatoid arthritis", "outcome_type": "disease", "outcome_domain": "rheumatoid_arthritis", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 2, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "35081907", "title": "Resveratrol ameliorates myocardial fibrosis by regulating Sirt1/Smad3 deacetylation pathway in rat model with dilated cardiomyopathy", "doi": "10.1186/s12872-021-02401-y", "year": 2022 }, { "pmid": "26638758", "title": "Iron-overload injury and cardiomyopathy in acquired and genetic models is attenuated by resveratrol therapy", "doi": "10.1038/srep18132", "year": 2015 } ], "bc": [ { "pmid": "35821263", "title": "Multi-omics profiling of collagen-induced arthritis mouse model reveals early metabolic dysregulation via SIRT1 axis", "doi": "10.1038/s41598-022-16005-9", "year": 2022 } ] } }, { "id": 51813, "drug": "luteolin", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "upregulates", "mediator": "Nrf2", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "disease activity", "outcome_type": "phenotype", "outcome_domain": "rheumatoid_arthritis", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "31089405", "title": "Luteolin Attenuates Cardiac Ischemia/Reperfusion Injury in Diabetic Rats by Modulating Nrf2 Antioxidative Function", "doi": "10.1155/2019/2719252", "year": 2019 } ], "bc": [ { "pmid": "36574898", "title": "Expression of Nrf2 protein in serum of patients with rheumatoid arthritis: A novel indicator for disease activity and disease prognosis", "doi": "10.1016/j.clinbiochem.2022.12.011", "year": 2022 } ] } }, { "id": 51725, "drug": "Curcumin", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "activates", "mediator": "Nrf2", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "poor prognosis", "outcome_type": "phenotype", "outcome_domain": "pancreatic_cancer", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 2, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37101595", "title": "Curcumin Improves Diabetic Cardiomyopathy by Inhibiting Pyroptosis through AKT/Nrf2/ARE Pathway", "doi": "10.1155/2023/3906043", "year": 2023 }, { "pmid": "35909950", "title": "Curcumin Attenuates Ferroptosis-Induced Myocardial Injury in Diabetic Cardiomyopathy through the Nrf2 Pathway", "doi": "10.1155/2022/3159717", "year": 2022 } ], "bc": [ { "pmid": "31911550", "title": "Undermining Glutaminolysis Bolsters Chemotherapy While NRF2 Promotes Chemoresistance in KRAS-Driven Pancreatic Cancers", "doi": "10.1158/0008-5472.can-19-1363", "year": 2020 } ] } }, { "id": 51710, "drug": "resveratrol", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "upregulates", "mediator": "SIRT1", "mediator_type": "gene", "predicate_bc": "associated_with", "outcome": "metastasis", "outcome_type": "phenotype", "outcome_domain": "pancreatic_cancer", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 2, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "35081907", "title": "Resveratrol ameliorates myocardial fibrosis by regulating Sirt1/Smad3 deacetylation pathway in rat model with dilated cardiomyopathy", "doi": "10.1186/s12872-021-02401-y", "year": 2022 }, { "pmid": "26638758", "title": "Iron-overload injury and cardiomyopathy in acquired and genetic models is attenuated by resveratrol therapy", "doi": "10.1038/srep18132", "year": 2015 } ], "bc": [ { "pmid": "27170223", "title": "SIRT 1 Overexpression is Associated with Metastasis of Pancreatic Ductal Adenocarcinoma (PDAC) and Promotes Migration and Growth of PDAC Cells", "doi": "10.12659/msm.896697", "year": 2016 } ] } }, { "id": 51620, "drug": "Curcumin", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "activates", "mediator": "SIRT1", "mediator_type": "protein", "predicate_bc": "increases", "outcome": "proliferation", "outcome_type": "phenotype", "outcome_domain": "pancreatic_cancer", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "38586339", "title": "Curcumin simultaneously improves mitochondrial dynamics and myocardial cell bioenergy after sepsis via the SIRT1-DRP1/PGC-1α pathway", "doi": "10.1016/j.heliyon.2024.e28501", "year": 2024 } ], "bc": [ { "pmid": "34163012", "title": "SIRT1 coordinates with the CRL4B complex to regulate pancreatic cancer stem cells to promote tumorigenesis", "doi": "10.1038/s41418-021-00821-z", "year": 2021 }, { "pmid": "27494892", "title": "Sirtuin 1 stimulates the proliferation and the expression of glycolysis genes in pancreatic neoplastic lesions", "doi": "10.18632/oncotarget.11013", "year": 2016 } ] } }, { "id": 51619, "drug": "Curcumin", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "activates", "mediator": "SIRT1", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "pancreatic cancer", "outcome_type": "disease", "outcome_domain": "pancreatic_cancer", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "38586339", "title": "Curcumin simultaneously improves mitochondrial dynamics and myocardial cell bioenergy after sepsis via the SIRT1-DRP1/PGC-1α pathway", "doi": "10.1016/j.heliyon.2024.e28501", "year": 2024 } ], "bc": [ { "pmid": "34163012", "title": "SIRT1 coordinates with the CRL4B complex to regulate pancreatic cancer stem cells to promote tumorigenesis", "doi": "10.1038/s41418-021-00821-z", "year": 2021 }, { "pmid": "28351313", "title": "SIRT1 promotes the proliferation and metastasis of human pancreatic cancer cells", "doi": "10.1177/1010428317691180", "year": 2017 } ] } }, { "id": 51597, "drug": "resveratrol", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "inhibits", "mediator": "Akt", "mediator_type": "protein", "predicate_bc": "increases", "outcome": "spheroid growth", "outcome_type": "phenotype", "outcome_domain": "pancreatic_cancer", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 2, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "31655498", "title": "Resveratrol Attenuates Pressure Overload‐Induced Cardiac Fibrosis and Diastolic Dysfunction via PTEN/AKT/Smad2/3 and NF‐κB Signaling Pathways", "doi": "10.1002/mnfr.201900418", "year": 2019 }, { "pmid": "28678055", "title": "Resveratrol Ameliorates Cardiac Dysfunction by Inhibiting Apoptosis via the PI3K/Akt/FoxO3a Pathway in a Rat Model of Diabetic Cardiomyopathy", "doi": "10.1097/fjc.0000000000000504", "year": 2017 } ], "bc": [ { "pmid": "36408933", "title": "Crosstalk between tumor acidosis, p53 and extracellular matrix regulates pancreatic cancer aggressiveness", "doi": "10.1002/ijc.34367", "year": 2022 } ] } }, { "id": 14120, "drug": "curcumin", "drug_type": "drug", "drug_domain": "alzheimer", "predicate_ab": "binds_to", "mediator": "TDP-43", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "hippocampal sclerosis", "outcome_type": "disease", "outcome_domain": "epilepsy", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "curcumin", "mediator_canonical": "TDP-43", "outcome_canonical": "hippocampal sclerosis", "ab_count": 1, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "30092839", "title": "Different curcumin forms selectively bind fibrillar amyloid beta in post mortem Alzheimer’s disease brains: Implications for in-vivo diagnostics", "doi": "10.1186/s40478-018-0577-2", "year": 2018 } ], "bc": [ { "pmid": "30452409", "title": "TDP-43 Neuropathologic Associations in the Nun Study and the Honolulu-Asia Aging Study", "doi": "10.3233/jad-180162", "year": 2018 } ] } }, { "id": 35536, "drug": "chloroquine", "drug_type": "drug", "drug_domain": "multiple_sclerosis", "predicate_ab": "upregulates", "mediator": "IL-10", "mediator_type": "protein", "predicate_bc": "increases", "outcome": "rheumatoid arthritis", "outcome_type": "disease", "outcome_domain": "rheumatoid_arthritis", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "active", "clinical_trial_nct_ids": [ "NCT02374021", "NCT03414502", "NCT04981145" ], "literature_status": "reproduces_known", "drug_canonical": "chloroquine", "mediator_canonical": "il-10", "outcome_canonical": "rheumatoid arthritis", "ab_count": 1, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "32516999", "title": "Comprehensive Analysis of the Immune and Stromal Compartments of the CNS in EAE Mice Reveal Pathways by Which Chloroquine Suppresses Neuroinflammation", "doi": "10.3390/brainsci10060348", "year": 2020 } ], "bc": [ { "pmid": "39475124", "title": "Inflammatory cytokines, metabolites, and rheumatoid arthritis", "doi": "10.1093/postmj/qgae146", "year": 2024 }, { "pmid": "30915732", "title": "Diagnostic values of serum IL-10 and IL-17 in rheumatoid arthritis and their correlation with serum 14-3-3η protein.", "doi": "10.26355/eurrev_201903_17227", "year": 2019 } ] } }, { "id": 6266, "drug": "erlotinib", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "inhibits", "mediator": "EGFR", "mediator_type": "protein", "predicate_bc": "decreases", "outcome": "survival", "outcome_type": "phenotype", "outcome_domain": "pancreatic_cancer", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "active", "clinical_trial_nct_ids": [ "NCT04322890", "NCT03192501", "NCT05934461" ], "literature_status": "reproduces_known", "drug_canonical": "erlotinib", "mediator_canonical": "EGFR", "outcome_canonical": null, "ab_count": 2, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40945534", "title": "Biodegradable nanofibrous scaffolds enhance standard of care for glioblastoma via localized targeted therapy", "doi": "10.1016/j.jconrel.2025.114225", "year": 2025 }, { "pmid": "30410775", "title": "The role of erlotinib and the Optune device in a patient with an epidermal growth factor receptor viii amplified glioblastoma", "doi": "10.1093/omcr/omy095", "year": 2018 } ], "bc": [ { "pmid": "32335999", "title": "Unraveling ERBB network dynamics upon betacellulin signaling in pancreatic ductal adenocarcinoma in mice", "doi": "10.1002/1878-0261.12699", "year": 2020 } ] } }, { "id": 7295, "drug": "Baicalin", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "upregulates", "mediator": "BDNF", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "major depressive disorder", "outcome_type": "disease", "outcome_domain": "depression", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "baicalin", "mediator_canonical": "BDNF", "outcome_canonical": "major depressive disorder", "ab_count": 1, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "38778616", "title": "Exploring the Therapeutic Potential of Baicalin: Mitigating Anxiety and Depression in Epileptic Rats", "doi": "10.2174/0113862073316021240520110301", "year": 2024 } ], "bc": [ { "pmid": "30794585", "title": "Accuracy of brain-derived neurotrophic factor levels for differentiating between Taiwanese patients with major depressive disorder or schizophrenia and healthy controls", "doi": "10.1371/journal.pone.0212373", "year": 2019 } ] } }, { "id": 7066, "drug": "valproic acid", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "suppresses", "mediator": "galectin-3", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "pancreatic cancer-associated diabetes", "outcome_type": "disease", "outcome_domain": "pancreatic_cancer", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "valproic acid", "mediator_canonical": "LGALS3", "outcome_canonical": "pancreatic cancer-associated diabetes", "ab_count": 1, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "34122007", "title": "Post-stroke Delivery of Valproic Acid Promotes Functional Recovery and Differentially Modifies Responses of Peri-Infarct Microglia", "doi": "10.3389/fnmol.2021.639145", "year": 2021 } ], "bc": [ { "pmid": "31262951", "title": "Galectin-3 and S100A9: Novel Diabetogenic Factors Mediating Pancreatic Cancer–Associated Diabetes", "doi": "10.2337/dc19-0217", "year": 2019 } ] } }, { "id": 51417, "drug": "losartan", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "downregulates", "mediator": "TGF-β1", "mediator_type": "protein", "predicate_bc": "increases", "outcome": "remyelination", "outcome_type": "phenotype", "outcome_domain": "multiple_sclerosis", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "25755735", "title": "Losartan reduces myocardial interstitial fibrosis in diabetic cardiomyopathy rats by inhibiting JAK/STAT signaling pathway.", "doi": null, "year": 2015 } ], "bc": [ { "pmid": "32985478", "title": "Glial-derived transforming growth factor β1 (TGF-β1): a key factor in multiple sclerosis neuroinflammation", "doi": "10.4103/1673-5374.293147", "year": 2020 }, { "pmid": "31071011", "title": "Circulating transforming growth factor-β1 facilitates remyelination in the adult central nervous system", "doi": "10.7554/elife.41869", "year": 2019 } ] } }, { "id": 51413, "drug": "Curcumin", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "activates", "mediator": "Nrf2", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "disease progression", "outcome_type": "phenotype", "outcome_domain": "multiple_sclerosis", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 2, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37101595", "title": "Curcumin Improves Diabetic Cardiomyopathy by Inhibiting Pyroptosis through AKT/Nrf2/ARE Pathway", "doi": "10.1155/2023/3906043", "year": 2023 }, { "pmid": "35909950", "title": "Curcumin Attenuates Ferroptosis-Induced Myocardial Injury in Diabetic Cardiomyopathy through the Nrf2 Pathway", "doi": "10.1155/2022/3159717", "year": 2022 } ], "bc": [ { "pmid": "33396641", "title": "Peripheral Blood NRF2 Expression as a Biomarker in Human Health and Disease", "doi": "10.3390/antiox10010028", "year": 2020 } ] } }, { "id": 7661, "drug": "Riluzole", "drug_type": "drug", "drug_domain": "als", "predicate_ab": "downregulates", "mediator": "MMP-9", "mediator_type": "protein", "predicate_bc": "increases", "outcome": "seizures", "outcome_type": "phenotype", "outcome_domain": "epilepsy", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "riluzole", "mediator_canonical": "MMP9", "outcome_canonical": "seizures", "ab_count": 1, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40012807", "title": "Investigation of the Neuroprotective Effect of Riluzole on Matrix Metalloproteinases in an Experimental Model of Glaucoma", "doi": "10.4103/joco.joco_290_23", "year": 2024 } ], "bc": [ { "pmid": "29667129", "title": "Elevation of MMP-9 Levels Promotes Epileptogenesis After Traumatic Brain Injury", "doi": "10.1007/s12035-018-1061-5", "year": 2018 } ] } }, { "id": 51390, "drug": "spironolactone", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "downregulates", "mediator": "TGF-β1", "mediator_type": "protein", "predicate_bc": "increases", "outcome": "remyelination", "outcome_type": "phenotype", "outcome_domain": "multiple_sclerosis", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "27097055", "title": "Spironolactone Attenuates Doxorubicin‐induced Cardiotoxicity in Rats", "doi": "10.1111/1755-5922.12189", "year": 2016 } ], "bc": [ { "pmid": "32985478", "title": "Glial-derived transforming growth factor β1 (TGF-β1): a key factor in multiple sclerosis neuroinflammation", "doi": "10.4103/1673-5374.293147", "year": 2020 }, { "pmid": "31071011", "title": "Circulating transforming growth factor-β1 facilitates remyelination in the adult central nervous system", "doi": "10.7554/elife.41869", "year": 2019 } ] } }, { "id": 51361, "drug": "resveratrol", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "activates", "mediator": "SIRT1", "mediator_type": "protein", "predicate_bc": "increases", "outcome": "optokinetic response", "outcome_type": "phenotype", "outcome_domain": "multiple_sclerosis", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 2, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "35081907", "title": "Resveratrol ameliorates myocardial fibrosis by regulating Sirt1/Smad3 deacetylation pathway in rat model with dilated cardiomyopathy", "doi": "10.1186/s12872-021-02401-y", "year": 2022 }, { "pmid": "26638758", "title": "Iron-overload injury and cardiomyopathy in acquired and genetic models is attenuated by resveratrol therapy", "doi": "10.1038/srep18132", "year": 2015 } ], "bc": [ { "pmid": "29494741", "title": "SIRT1 and NRF2 Gene Transfer Mediate Distinct Neuroprotective Effects Upon Retinal Ganglion Cell Survival and Function in Experimental Optic Neuritis", "doi": "10.1167/iovs.17-22972", "year": 2018 } ] } }, { "id": 51384, "drug": "atorvastatin", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "downregulates", "mediator": "TGF-β1", "mediator_type": "protein", "predicate_bc": "increases", "outcome": "remyelination", "outcome_type": "phenotype", "outcome_domain": "multiple_sclerosis", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "26579943", "title": "Atorvastatin Ameliorates Radiation-Induced Cardiac Fibrosis in Rats", "doi": "10.1667/rr14075.1", "year": 2015 } ], "bc": [ { "pmid": "32985478", "title": "Glial-derived transforming growth factor β1 (TGF-β1): a key factor in multiple sclerosis neuroinflammation", "doi": "10.4103/1673-5374.293147", "year": 2020 }, { "pmid": "31071011", "title": "Circulating transforming growth factor-β1 facilitates remyelination in the adult central nervous system", "doi": "10.7554/elife.41869", "year": 2019 } ] } }, { "id": 8048, "drug": "Riluzole", "drug_type": "drug", "drug_domain": "als", "predicate_ab": "inhibits", "mediator": "CK1δ", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "bladder cancer", "outcome_type": "disease", "outcome_domain": "pancreatic_cancer", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "riluzole", "mediator_canonical": "ck1δ", "outcome_canonical": "bladder cancer", "ab_count": 2, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "31397342", "title": "Rethinking to riluzole mechanism of action: the molecular link among protein kinase CK1δ activity, TDP-43 phosphorylation, and amyotrophic lateral sclerosis pharmacological treatment", "doi": "10.4103/1673-5374.262578", "year": 2019 }, { "pmid": "30359484", "title": "Targeting Protein Kinase CK1δ with Riluzole: Could It Be One of the Possible Missing Bricks to Interpret Its Effect in the Treatment of ALS from a Molecular Point of View?", "doi": "10.1002/cmdc.201800632", "year": 2018 } ], "bc": [ { "pmid": "32430484", "title": "Targeting Casein Kinase 1 Delta Sensitizes Pancreatic and Bladder Cancer Cells to Gemcitabine Treatment by Upregulating Deoxycytidine Kinase", "doi": "10.1158/1535-7163.mct-19-0997", "year": 2020 } ] } }, { "id": 8914, "drug": "verteporfin", "drug_type": "drug", "drug_domain": "alzheimer", "predicate_ab": "inhibits", "mediator": "APP", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "MND", "outcome_type": "disease", "outcome_domain": "als", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "verteporfin", "mediator_canonical": "app", "outcome_canonical": "mnd", "ab_count": 2, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "35247387", "title": "Verteporfin is a substrate-selective γ-secretase inhibitor that binds the amyloid precursor protein transmembrane domain", "doi": "10.1016/j.jbc.2022.101792", "year": 2022 } ], "bc": [ { "pmid": "27877154", "title": "Immununochemical Markers of the Amyloid Cascade in the Hippocampus in Motor Neuron Diseases", "doi": "10.3389/fneur.2016.00195", "year": 2016 } ] } }, { "id": 9014, "drug": "resveratrol", "drug_type": "drug", "drug_domain": "alzheimer", "predicate_ab": "upregulates", "mediator": "Sirt1", "mediator_type": "gene", "predicate_bc": "increases", "outcome": "cell migration", "outcome_type": "phenotype", "outcome_domain": "pancreatic_cancer", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "resveratrol", "mediator_canonical": "SIRT1", "outcome_canonical": "cell migration", "ab_count": 1, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "33381265", "title": "Resveratrol Mitigates Hippocampal Tau Acetylation and Cognitive Deficit by Activation SIRT1 in Aged Rats following Anesthesia and Surgery", "doi": "10.1155/2020/4635163", "year": 2020 } ], "bc": [ { "pmid": "27170223", "title": "SIRT 1 Overexpression is Associated with Metastasis of Pancreatic Ductal Adenocarcinoma (PDAC) and Promotes Migration and Growth of PDAC Cells", "doi": "10.12659/msm.896697", "year": 2016 } ] } }, { "id": 26061, "drug": "Curcumin", "drug_type": "drug", "drug_domain": "alzheimer", "predicate_ab": "binds_to", "mediator": "TDP-43", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "neurodegeneration", "outcome_type": "phenotype", "outcome_domain": "als", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "curcumin", "mediator_canonical": "TDP-43", "outcome_canonical": null, "ab_count": 1, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "30092839", "title": "Different curcumin forms selectively bind fibrillar amyloid beta in post mortem Alzheimer’s disease brains: Implications for in-vivo diagnostics", "doi": "10.1186/s40478-018-0577-2", "year": 2018 } ], "bc": [ { "pmid": "39810199", "title": "Alternative 3′ UTR polyadenylation is disrupted in the rNLS8 mouse model of ALS/FTLD", "doi": "10.1186/s13041-025-01174-1", "year": 2025 }, { "pmid": "30922385", "title": "Transcriptomopathies of pre- and post-symptomatic frontotemporal dementia-like mice with TDP-43 depletion in forebrain neurons", "doi": "10.1186/s40478-019-0674-x", "year": 2019 } ] } }, { "id": 8991, "drug": "resveratrol", "drug_type": "drug", "drug_domain": "alzheimer", "predicate_ab": "activates", "mediator": "SIRT1", "mediator_type": "protein", "predicate_bc": "increases", "outcome": "proliferation", "outcome_type": "phenotype", "outcome_domain": "pancreatic_cancer", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "preclinical_only", "clinical_trial_nct_ids": [ "NCT00455416" ], "literature_status": "reproduces_known", "drug_canonical": "resveratrol", "mediator_canonical": "SIRT1", "outcome_canonical": null, "ab_count": 1, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "30243024", "title": "Sirt1 enhances tau exon 10 inclusion and improves spatial memory of Htau mice", "doi": "10.18632/aging.101564", "year": 2018 } ], "bc": [ { "pmid": "34163012", "title": "SIRT1 coordinates with the CRL4B complex to regulate pancreatic cancer stem cells to promote tumorigenesis", "doi": "10.1038/s41418-021-00821-z", "year": 2021 }, { "pmid": "27494892", "title": "Sirtuin 1 stimulates the proliferation and the expression of glycolysis genes in pancreatic neoplastic lesions", "doi": "10.18632/oncotarget.11013", "year": 2016 } ] } }, { "id": 51265, "drug": "imatinib", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "suppresses", "mediator": "hepcidin", "mediator_type": "protein", "predicate_bc": "predicts", "outcome": "iron deficiency", "outcome_type": "disease", "outcome_domain": "inflammatory_bowel_disease", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "28385785", "title": "Imatinib and spironolactone suppress hepcidin expression", "doi": "10.3324/haematol.2016.162917", "year": 2017 } ], "bc": [ { "pmid": "36748574", "title": "Hepcidin and Iron Status in Patients With Inflammatory Bowel Disease Undergoing Induction Therapy With Vedolizumab or Infliximab", "doi": "10.1093/ibd/izad010", "year": 2023 } ] } }, { "id": 51261, "drug": "spironolactone", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "suppresses", "mediator": "hepcidin", "mediator_type": "protein", "predicate_bc": "predicts", "outcome": "iron deficiency", "outcome_type": "disease", "outcome_domain": "inflammatory_bowel_disease", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "28385785", "title": "Imatinib and spironolactone suppress hepcidin expression", "doi": "10.3324/haematol.2016.162917", "year": 2017 } ], "bc": [ { "pmid": "36748574", "title": "Hepcidin and Iron Status in Patients With Inflammatory Bowel Disease Undergoing Induction Therapy With Vedolizumab or Infliximab", "doi": "10.1093/ibd/izad010", "year": 2023 } ] } }, { "id": 51260, "drug": "resveratrol", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "inhibits", "mediator": "Akt", "mediator_type": "protein", "predicate_bc": "causes", "outcome": "microfilament depolymerization", "outcome_type": "phenotype", "outcome_domain": "inflammatory_bowel_disease", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 2, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "31655498", "title": "Resveratrol Attenuates Pressure Overload‐Induced Cardiac Fibrosis and Diastolic Dysfunction via PTEN/AKT/Smad2/3 and NF‐κB Signaling Pathways", "doi": "10.1002/mnfr.201900418", "year": 2019 }, { "pmid": "28678055", "title": "Resveratrol Ameliorates Cardiac Dysfunction by Inhibiting Apoptosis via the PI3K/Akt/FoxO3a Pathway in a Rat Model of Diabetic Cardiomyopathy", "doi": "10.1097/fjc.0000000000000504", "year": 2017 } ], "bc": [ { "pmid": "33075564", "title": "Fibrinogen/AKT/Microfilament Axis Promotes Colitis by Enhancing Vascular Permeability", "doi": "10.1016/j.jcmgh.2020.10.007", "year": 2020 } ] } }, { "id": 51227, "drug": "imatinib", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "suppresses", "mediator": "hepcidin", "mediator_type": "protein", "predicate_bc": "causes", "outcome": "iron malabsorption", "outcome_type": "phenotype", "outcome_domain": "inflammatory_bowel_disease", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "28385785", "title": "Imatinib and spironolactone suppress hepcidin expression", "doi": "10.3324/haematol.2016.162917", "year": 2017 } ], "bc": [ { "pmid": "30868856", "title": "Serum Hepcidin Levels Predict Intestinal Iron Absorption in Patients with Inflammatory Bowel Disease", "doi": "10.7754/clin.lab.2019.190106", "year": 2019 }, { "pmid": "26733407", "title": "Serum Hepcidin and Iron Absorption in Paediatric Inflammatory Bowel Disease", "doi": "10.1093/ecco-jcc/jjv242", "year": 2016 } ] } }, { "id": 43504, "drug": "Curcumin", "drug_type": "drug", "drug_domain": "alzheimer", "predicate_ab": "binds_to", "mediator": "amyloid beta", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "cerebral amyloid angiopathy-related inflammation", "outcome_type": "disease", "outcome_domain": "epilepsy", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 2, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "31736502", "title": "Labeling and Imaging of Amyloid Plaques in Brain Tissue Using the Natural Polyphenol Curcumin", "doi": "10.3791/60377", "year": 2019 } ], "bc": [ { "pmid": "33480610", "title": "Cerebral Amyloid Angiopathy-related Inflammation Presenting With a Cystic Lesion in Young-onset Alzheimer Disease", "doi": "10.1097/wad.0000000000000432", "year": 2021 } ] } }, { "id": 11654, "drug": "cisplatin", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "upregulates", "mediator": "PD-L1", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "type 2 autoimmune pancreatitis", "outcome_type": "disease", "outcome_domain": "pancreatic_cancer", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "cisplatin", "mediator_canonical": "PD-L1", "outcome_canonical": "type 2 autoimmune pancreatitis", "ab_count": 1, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "39810130", "title": "Engineered biomimetic cisplatin-polyphenol nanocomplex for chemo-immunotherapy of glioblastoma by inducing pyroptosis", "doi": "10.1186/s12951-025-03091-w", "year": 2025 } ], "bc": [ { "pmid": "31135488", "title": "Autoimmune Pancreatitis Type 2", "doi": "10.1097/pas.0000000000001282", "year": 2019 } ] } }, { "id": 51212, "drug": "spironolactone", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "suppresses", "mediator": "hepcidin", "mediator_type": "protein", "predicate_bc": "causes", "outcome": "iron malabsorption", "outcome_type": "phenotype", "outcome_domain": "inflammatory_bowel_disease", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "28385785", "title": "Imatinib and spironolactone suppress hepcidin expression", "doi": "10.3324/haematol.2016.162917", "year": 2017 } ], "bc": [ { "pmid": "30868856", "title": "Serum Hepcidin Levels Predict Intestinal Iron Absorption in Patients with Inflammatory Bowel Disease", "doi": "10.7754/clin.lab.2019.190106", "year": 2019 }, { "pmid": "26733407", "title": "Serum Hepcidin and Iron Absorption in Paediatric Inflammatory Bowel Disease", "doi": "10.1093/ecco-jcc/jjv242", "year": 2016 } ] } }, { "id": 51199, "drug": "luteolin", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "inhibits", "mediator": "Mst1", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "IBD", "outcome_type": "disease", "outcome_domain": "inflammatory_bowel_disease", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "26538370", "title": "Luteolin alleviates post‐infarction cardiac dysfunction by up‐regulating autophagy through Mst1 inhibition", "doi": "10.1111/jcmm.12714", "year": 2015 } ], "bc": [ { "pmid": "39414629", "title": "Identification of potential novel targets for treating inflammatory bowel disease using Mendelian randomization analysis", "doi": "10.1007/s00384-024-04744-2", "year": 2024 }, { "pmid": "36857861", "title": "Therapeutic targets for inflammatory bowel disease: proteome-wide Mendelian randomization and colocalization analyses", "doi": "10.1016/j.ebiom.2023.104494", "year": 2023 } ] } }, { "id": 51004, "drug": "metformin", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "downregulates", "mediator": "P-glycoprotein", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "temozolomide resistance", "outcome_type": "phenotype", "outcome_domain": "glioblastoma", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 2, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "27499787", "title": "Inhibition of P-glycoprotein expression and function by anti-diabetic drugs gliclazide, metformin, and pioglitazone in vitro and in situ.", "doi": null, "year": 2016 } ], "bc": [ { "pmid": "35093870", "title": "Ko143 Reverses MDR in Glioblastoma via Deactivating P-Glycoprotein, Sensitizing a Resistant Phenotype to TMZ Treatment", "doi": "10.21873/anticanres.15530", "year": 2022 } ] } }, { "id": 51000, "drug": "erlotinib", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "inhibits", "mediator": "EGFR", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "glioblastoma", "outcome_type": "disease", "outcome_domain": "glioblastoma", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "31277074", "title": "Inhibition of EGFR-STAT3 attenuates cardiomyopathy in streptozotocin-induced type 1 diabetes", "doi": "10.1530/joe-19-0058", "year": 2019 } ], "bc": [ { "pmid": "41473440", "title": "A PET-CT study of the uptake of labeled aptamers [18F]FB-Gol1 and [18F]FB-GR20 in rat 101.8 glioblastoma model", "doi": "10.3389/fonc.2025.1713181", "year": 2025 }, { "pmid": "38396993", "title": "Epidermal Growth Factor Receptor Inhibitors in Glioblastoma: Current Status and Future Possibilities", "doi": "10.3390/ijms25042316", "year": 2024 } ] } }, { "id": 50999, "drug": "metformin", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "downregulates", "mediator": "P-glycoprotein", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "multidrug resistance", "outcome_type": "phenotype", "outcome_domain": "glioblastoma", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 2, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "27499787", "title": "Inhibition of P-glycoprotein expression and function by anti-diabetic drugs gliclazide, metformin, and pioglitazone in vitro and in situ.", "doi": null, "year": 2016 } ], "bc": [ { "pmid": "35093870", "title": "Ko143 Reverses MDR in Glioblastoma via Deactivating P-Glycoprotein, Sensitizing a Resistant Phenotype to TMZ Treatment", "doi": "10.21873/anticanres.15530", "year": 2022 } ] } }, { "id": 50997, "drug": "resveratrol", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "inhibits", "mediator": "Akt", "mediator_type": "protein", "predicate_bc": "causes", "outcome": "subclonal progression", "outcome_type": "phenotype", "outcome_domain": "glioblastoma", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 2, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "31655498", "title": "Resveratrol Attenuates Pressure Overload‐Induced Cardiac Fibrosis and Diastolic Dysfunction via PTEN/AKT/Smad2/3 and NF‐κB Signaling Pathways", "doi": "10.1002/mnfr.201900418", "year": 2019 }, { "pmid": "28678055", "title": "Resveratrol Ameliorates Cardiac Dysfunction by Inhibiting Apoptosis via the PI3K/Akt/FoxO3a Pathway in a Rat Model of Diabetic Cardiomyopathy", "doi": "10.1097/fjc.0000000000000504", "year": 2017 } ], "bc": [ { "pmid": "36239995", "title": "A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma", "doi": "10.1158/1078-0432.ccr-22-0611", "year": 2022 } ] } }, { "id": 17142, "drug": "linalool", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "downregulates", "mediator": "PD-L1", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "type 2 autoimmune pancreatitis", "outcome_type": "disease", "outcome_domain": "pancreatic_cancer", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "linalool", "mediator_canonical": "PD-L1", "outcome_canonical": "type 2 autoimmune pancreatitis", "ab_count": 1, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40504869", "title": "Linalool-based silver nanoconjugates as potential therapeutics for glioblastoma: in silico and in vitro insights", "doi": "10.1371/journal.pone.0325281", "year": 2025 } ], "bc": [ { "pmid": "31135488", "title": "Autoimmune Pancreatitis Type 2", "doi": "10.1097/pas.0000000000001282", "year": 2019 } ] } }, { "id": 17429, "drug": "apigenin", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "upregulates", "mediator": "GFAP", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "NMOSD attacks", "outcome_type": "disease", "outcome_domain": "multiple_sclerosis", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "apigenin", "mediator_canonical": "GFAP", "outcome_canonical": "nmosd attacks", "ab_count": 1, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41090780", "title": "Apigenin Induces Autophagy and Apoptosis in Chemoresistant Glioblastoma Cells and Inhibits Tumorigenicity Associated with Regulation of Immunomodulatory Proteins and Glial Cells Response", "doi": "10.3390/cells14191552", "year": 2025 } ], "bc": [ { "pmid": "34212756", "title": "Longitudinal follow-up of serum biomarkers in patients with neuromyelitis optica spectrum disorder", "doi": "10.1177/13524585211024978", "year": 2021 } ] } }, { "id": 17439, "drug": "apigenin", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "upregulates", "mediator": "GFAP", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "AQP4-NMOSD", "outcome_type": "disease", "outcome_domain": "multiple_sclerosis", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "apigenin", "mediator_canonical": "GFAP", "outcome_canonical": "aqp4-nmosd", "ab_count": 1, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41090780", "title": "Apigenin Induces Autophagy and Apoptosis in Chemoresistant Glioblastoma Cells and Inhibits Tumorigenicity Associated with Regulation of Immunomodulatory Proteins and Glial Cells Response", "doi": "10.3390/cells14191552", "year": 2025 } ], "bc": [ { "pmid": "39893752", "title": "The value of CSF diagnostic and prognostic biomarkers in NMOSD and MOGAD in real-life use", "doi": "10.1016/j.msard.2025.106302", "year": 2025 } ] } }, { "id": 17453, "drug": "apigenin", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "upregulates", "mediator": "GFAP", "mediator_type": "protein", "predicate_bc": "predicts", "outcome": "confirmed disability worsening", "outcome_type": "phenotype", "outcome_domain": "multiple_sclerosis", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "apigenin", "mediator_canonical": "GFAP", "outcome_canonical": "confirmed disability worsening", "ab_count": 1, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41090780", "title": "Apigenin Induces Autophagy and Apoptosis in Chemoresistant Glioblastoma Cells and Inhibits Tumorigenicity Associated with Regulation of Immunomodulatory Proteins and Glial Cells Response", "doi": "10.3390/cells14191552", "year": 2025 } ], "bc": [ { "pmid": "40506119", "title": "Blood biomarkers for predicting disability worsening in progressive multiple sclerosis: a multinational, individual participant-level analysis", "doi": "10.1136/jnnp-2025-335831", "year": 2025 } ] } }, { "id": 2527, "drug": "valproic acid", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "suppresses", "mediator": "NRF2", "mediator_type": "gene", "predicate_bc": "correlates_with", "outcome": "poor survival", "outcome_type": "phenotype", "outcome_domain": "pancreatic_cancer", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "valproic acid", "mediator_canonical": "NRF2", "outcome_canonical": "poor survival", "ab_count": 2, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "34050116", "title": "Chronic valproic acid administration enhances oxidative stress, upregulates IL6 and downregulates Nrf2, Glut1 and Glut4 in rat’s liver and brain", "doi": "10.1097/wnr.0000000000001663", "year": 2021 }, { "pmid": "34686779", "title": "Valproic acid disables the Nrf2 anti-oxidant response in acute myeloid leukaemia cells enhancing reactive oxygen species-mediated killing", "doi": "10.1038/s41416-021-01570-z", "year": 2021 } ], "bc": [ { "pmid": "32629871", "title": "NRF2 Knockdown Resensitizes 5-Fluorouracil-Resistant Pancreatic Cancer Cells by Suppressing HO-1 and ABCG2 Expression", "doi": "10.3390/ijms21134646", "year": 2020 } ] } }, { "id": 50833, "drug": "metformin", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "downregulates", "mediator": "P-glycoprotein", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "drug-resistant epilepsy", "outcome_type": "disease", "outcome_domain": "epilepsy", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 2, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "27499787", "title": "Inhibition of P-glycoprotein expression and function by anti-diabetic drugs gliclazide, metformin, and pioglitazone in vitro and in situ.", "doi": null, "year": 2016 } ], "bc": [ { "pmid": "32627849", "title": "P‐glycoprotein overactivity in epileptogenic developmental lesions measured in vivo using (R)‐[11C]verapamil PET", "doi": "10.1111/epi.16581", "year": 2020 } ] } }, { "id": 18597, "drug": "valproic acid", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "downregulates", "mediator": "NRF2", "mediator_type": "gene", "predicate_bc": "associated_with", "outcome": "Hashimoto's thyroiditis", "outcome_type": "disease", "outcome_domain": "multiple_sclerosis", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "valproic acid", "mediator_canonical": "NRF2", "outcome_canonical": "hashimoto's thyroiditis", "ab_count": 2, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "34050116", "title": "Chronic valproic acid administration enhances oxidative stress, upregulates IL6 and downregulates Nrf2, Glut1 and Glut4 in rat’s liver and brain", "doi": "10.1097/wnr.0000000000001663", "year": 2021 }, { "pmid": "34686779", "title": "Valproic acid disables the Nrf2 anti-oxidant response in acute myeloid leukaemia cells enhancing reactive oxygen species-mediated killing", "doi": "10.1038/s41416-021-01570-z", "year": 2021 } ], "bc": [ { "pmid": "35624879", "title": "Thyroid Disorders in Patients Treated with Dimethyl Fumarate for Multiple Sclerosis: A Retrospective Observational Study", "doi": "10.3390/antiox11051015", "year": 2022 } ] } }, { "id": 18608, "drug": "valproic acid", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "downregulates", "mediator": "NRF2", "mediator_type": "gene", "predicate_bc": "increases", "outcome": "visual function", "outcome_type": "phenotype", "outcome_domain": "multiple_sclerosis", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "completed", "clinical_trial_nct_ids": [ "NCT07226141", "NCT03717909", "NCT00385710" ], "literature_status": "reproduces_known", "drug_canonical": "valproic acid", "mediator_canonical": "NRF2", "outcome_canonical": "visual function", "ab_count": 2, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "34050116", "title": "Chronic valproic acid administration enhances oxidative stress, upregulates IL6 and downregulates Nrf2, Glut1 and Glut4 in rat’s liver and brain", "doi": "10.1097/wnr.0000000000001663", "year": 2021 }, { "pmid": "34686779", "title": "Valproic acid disables the Nrf2 anti-oxidant response in acute myeloid leukaemia cells enhancing reactive oxygen species-mediated killing", "doi": "10.1038/s41416-021-01570-z", "year": 2021 } ], "bc": [ { "pmid": "29494741", "title": "SIRT1 and NRF2 Gene Transfer Mediate Distinct Neuroprotective Effects Upon Retinal Ganglion Cell Survival and Function in Experimental Optic Neuritis", "doi": "10.1167/iovs.17-22972", "year": 2018 } ] } }, { "id": 50830, "drug": "haloperidol", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "downregulates", "mediator": "Sigma-1 receptor", "mediator_type": "protein", "predicate_bc": "decreases", "outcome": "seizure susceptibility", "outcome_type": "phenotype", "outcome_domain": "epilepsy", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 2, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "27435383", "title": "Haloperidol aggravates transverse aortic constriction-induced heart failure via mitochondrial dysfunction", "doi": "10.1016/j.jphs.2016.05.012", "year": 2016 } ], "bc": [ { "pmid": "33385516", "title": "Genetic inactivation of the sigma-1 chaperone protein results in decreased expression of the R2 subunit of the GABA-B receptor and increased susceptibility to seizures", "doi": "10.1016/j.nbd.2020.105244", "year": 2020 } ] } }, { "id": 19724, "drug": "Riluzole", "drug_type": "drug", "drug_domain": "als", "predicate_ab": "upregulates", "mediator": "EAAT2", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "multiple sclerosis relapse", "outcome_type": "disease", "outcome_domain": "multiple_sclerosis", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "riluzole", "mediator_canonical": "eaat2", "outcome_canonical": "multiple sclerosis relapse", "ab_count": 1, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "39806490", "title": "CEST imaging combined with 1H-MRS reveal the neuroprotective effects of riluzole by improving neurotransmitter imbalances in Alzheimer’s disease mice", "doi": "10.1186/s13195-025-01672-3", "year": 2025 } ], "bc": [ { "pmid": "39223661", "title": "Proteomic profile of extracellular vesicles from plasma and CSF of multiple sclerosis patients reveals disease activity-associated EAAT2", "doi": "10.1186/s12974-024-03148-x", "year": 2024 } ] } }, { "id": 50827, "drug": "metformin", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "inhibits", "mediator": "mTOR", "mediator_type": "protein", "predicate_bc": "increases", "outcome": "neuronal spiking activity", "outcome_type": "phenotype", "outcome_domain": "epilepsy", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 2, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "32248762", "title": "Metformin Improves Cardiac Metabolism and Function, and Prevents Left Ventricular Hypertrophy in Spontaneously Hypertensive Rats", "doi": "10.1161/jaha.119.015154", "year": 2020 }, { "pmid": "30922066", "title": "Metformin Enhances Autophagy and Provides Cardioprotection in δ-Sarcoglycan Deficiency-Induced Dilated Cardiomyopathy", "doi": "10.1161/circheartfailure.118.005418", "year": 2019 } ], "bc": [ { "pmid": "34994387", "title": "IDH-mutated gliomas promote epileptogenesis through d-2-hydroxyglutarate-dependent mTOR hyperactivation", "doi": "10.1093/neuonc/noac003", "year": 2022 } ] } }, { "id": 50820, "drug": "metformin", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "inhibits", "mediator": "mTOR", "mediator_type": "protein", "predicate_bc": "causes", "outcome": "mTOR-opathies", "outcome_type": "disease", "outcome_domain": "epilepsy", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 2, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "32248762", "title": "Metformin Improves Cardiac Metabolism and Function, and Prevents Left Ventricular Hypertrophy in Spontaneously Hypertensive Rats", "doi": "10.1161/jaha.119.015154", "year": 2020 }, { "pmid": "30922066", "title": "Metformin Enhances Autophagy and Provides Cardioprotection in δ-Sarcoglycan Deficiency-Induced Dilated Cardiomyopathy", "doi": "10.1161/circheartfailure.118.005418", "year": 2019 } ], "bc": [ { "pmid": "29447953", "title": "Dendrite growth and the effect of ectopic Rheb expression on cortical neurons", "doi": "10.1016/j.neulet.2018.02.021", "year": 2018 } ] } }, { "id": 50817, "drug": "metformin", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "downregulates", "mediator": "P-glycoprotein", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "QT interval prolongation", "outcome_type": "phenotype", "outcome_domain": "epilepsy", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 2, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "27499787", "title": "Inhibition of P-glycoprotein expression and function by anti-diabetic drugs gliclazide, metformin, and pioglitazone in vitro and in situ.", "doi": null, "year": 2016 } ], "bc": [ { "pmid": "29462915", "title": "Pilocarpine-Induced Status Epilepticus Is Associated with P-Glycoprotein Induction in Cardiomyocytes, Electrocardiographic Changes, and Sudden Death", "doi": "10.3390/ph11010021", "year": 2018 } ] } }, { "id": 50801, "drug": "metformin", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "downregulates", "mediator": "P-glycoprotein", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "SUDEP", "outcome_type": "disease", "outcome_domain": "epilepsy", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 2, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "27499787", "title": "Inhibition of P-glycoprotein expression and function by anti-diabetic drugs gliclazide, metformin, and pioglitazone in vitro and in situ.", "doi": null, "year": 2016 } ], "bc": [ { "pmid": "29462915", "title": "Pilocarpine-Induced Status Epilepticus Is Associated with P-Glycoprotein Induction in Cardiomyocytes, Electrocardiographic Changes, and Sudden Death", "doi": "10.3390/ph11010021", "year": 2018 } ] } }, { "id": 50793, "drug": "resveratrol", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "upregulates", "mediator": "SIRT1", "mediator_type": "gene", "predicate_bc": "increases", "outcome": "proliferation", "outcome_type": "phenotype", "outcome_domain": "epilepsy", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 2, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "35081907", "title": "Resveratrol ameliorates myocardial fibrosis by regulating Sirt1/Smad3 deacetylation pathway in rat model with dilated cardiomyopathy", "doi": "10.1186/s12872-021-02401-y", "year": 2022 }, { "pmid": "26638758", "title": "Iron-overload injury and cardiomyopathy in acquired and genetic models is attenuated by resveratrol therapy", "doi": "10.1038/srep18132", "year": 2015 } ], "bc": [ { "pmid": "33747170", "title": "miR‑135a‑5p inhibitor protects glial cells against apoptosis via targeting SIRT1 in epilepsy", "doi": "10.3892/etm.2021.9848", "year": 2021 } ] } }, { "id": 50792, "drug": "resveratrol", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "upregulates", "mediator": "SIRT1", "mediator_type": "gene", "predicate_bc": "correlates_with", "outcome": "circadian rhythm disruption", "outcome_type": "phenotype", "outcome_domain": "epilepsy", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 2, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "35081907", "title": "Resveratrol ameliorates myocardial fibrosis by regulating Sirt1/Smad3 deacetylation pathway in rat model with dilated cardiomyopathy", "doi": "10.1186/s12872-021-02401-y", "year": 2022 }, { "pmid": "26638758", "title": "Iron-overload injury and cardiomyopathy in acquired and genetic models is attenuated by resveratrol therapy", "doi": "10.1038/srep18132", "year": 2015 } ], "bc": [ { "pmid": "30009381", "title": "Altered circadian rhythms and oscillation of clock genes and sirtuin 1 in a model of sudden unexpected death in epilepsy", "doi": "10.1111/epi.14513", "year": 2018 } ] } }, { "id": 59789, "drug": "Auranofin", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "inhibits", "mediator": "GSK-3β", "mediator_type": "protein", "predicate_bc": "increases", "outcome": "PanIN progression", "outcome_type": "disease", "outcome_domain": "pancreatic_cancer", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 2, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40842183", "title": "Gold‐Containing Compound Auranofin Ameliorates 6‐OHDA Induced Neurotoxicity in Rats: Via Targeting PI3K/Akt/GSK‐3β Signalling", "doi": "10.1111/1440-1681.70070", "year": 2025 } ], "bc": [ { "pmid": "28639695", "title": "Glycogen synthase kinase‐3β ablation limits pancreatitis‐induced acinar‐to‐ductal metaplasia", "doi": "10.1002/path.4928", "year": 2017 } ] } }, { "id": 39123, "drug": "Auranofin", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "activates", "mediator": "Caspase-3", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "inflammatory peritumoral infiltration", "outcome_type": "phenotype", "outcome_domain": "pancreatic_cancer", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "auranofin", "mediator_canonical": "CASP3", "outcome_canonical": "inflammatory peritumoral infiltration", "ab_count": 2, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "36014444", "title": "Anti-Cancer Effects of Auranofin in Human Lung Cancer Cells by Increasing Intracellular ROS Levels and Depleting GSH Levels", "doi": "10.3390/molecules27165207", "year": 2022 }, { "pmid": "33125149", "title": "Auranofin inhibits the proliferation of lung cancer cells via necrosis and caspase‑dependent apoptosis", "doi": "10.3892/or.2020.7818", "year": 2020 } ], "bc": [ { "pmid": "26998093", "title": "Reduced expression of caspase-8 and cleaved caspase-3 in pancreatic ductal adenocarcinoma cells", "doi": "10.3892/ol.2016.4125", "year": 2016 } ] } }, { "id": 39077, "drug": "Auranofin", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "inhibits", "mediator": "TXNRD1", "mediator_type": "protein", "predicate_bc": "predicts", "outcome": "resistance", "outcome_type": "phenotype", "outcome_domain": "pancreatic_cancer", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "auranofin", "mediator_canonical": "txnrd1", "outcome_canonical": "resistance", "ab_count": 2, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "39434427", "title": "Thioredoxin reductase inhibition and glutathione depletion mediated by glaucocalyxin A promote intracellular disulfide stress in gastric cancer cells", "doi": "10.1111/febs.17301", "year": 2024 }, { "pmid": "32199331", "title": "Comprehensive chemical proteomics for target deconvolution of the redox active drug auranofin", "doi": "10.1016/j.redox.2020.101491", "year": 2020 } ], "bc": [ { "pmid": "33981979", "title": "Antineoplastic effects of auranofin in human pancreatic adenocarcinoma preclinical models", "doi": "10.1016/j.sopen.2019.05.004", "year": 2019 } ] } }, { "id": 39100, "drug": "Auranofin", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "inhibits", "mediator": "GSK-3β", "mediator_type": "protein", "predicate_bc": "increases", "outcome": "acinar-to-ductal metaplasia", "outcome_type": "disease", "outcome_domain": "pancreatic_cancer", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "auranofin", "mediator_canonical": "GSK3B", "outcome_canonical": "acinar-to-ductal metaplasia", "ab_count": 2, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40842183", "title": "Gold‐Containing Compound Auranofin Ameliorates 6‐OHDA Induced Neurotoxicity in Rats: Via Targeting PI3K/Akt/GSK‐3β Signalling", "doi": "10.1111/1440-1681.70070", "year": 2025 } ], "bc": [ { "pmid": "28639695", "title": "Glycogen synthase kinase‐3β ablation limits pancreatitis‐induced acinar‐to‐ductal metaplasia", "doi": "10.1002/path.4928", "year": 2017 } ] } }, { "id": 39078, "drug": "resveratrol", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "binds_to", "mediator": "EGFR", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "pancreatic adenocarcinoma", "outcome_type": "disease", "outcome_domain": "pancreatic_cancer", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "resveratrol", "mediator_canonical": "EGFR", "outcome_canonical": "pancreatic adenocarcinoma", "ab_count": 1, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40993911", "title": "Therapeutic Targeting of Apoptosis‐Driven Inflammation in Rheumatoid Arthritis: A Biochemical and Molecular Modeling Approach Using Plant‐Derived Compounds", "doi": "10.1111/1756-185x.70423", "year": 2025 } ], "bc": [ { "pmid": "37370756", "title": "Anoikis-Related Gene Signature for Prognostication of Pancreatic Adenocarcinoma: A Multi-Omics Exploration and Verification Study", "doi": "10.3390/cancers15123146", "year": 2023 }, { "pmid": "27130234", "title": "Selecting Tumor-Specific Molecular Targets in Pancreatic Adenocarcinoma: Paving the Way for Image-Guided Pancreatic Surgery", "doi": "10.1007/s11307-016-0959-4", "year": 2016 } ] } }, { "id": 8078, "drug": "Riluzole", "drug_type": "drug", "drug_domain": "als", "predicate_ab": "activates", "mediator": "ATM", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "recurrence", "outcome_type": "phenotype", "outcome_domain": "pancreatic_cancer", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "active", "clinical_trial_nct_ids": [ "NCT06552260", "NCT01303341", "NCT00866840" ], "literature_status": "partial_evidence", "drug_canonical": "riluzole", "mediator_canonical": "atm", "outcome_canonical": null, "ab_count": 1, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "32231713", "title": "Riluzole Enhances the Response of Human Nasopharyngeal Carcinoma Cells to Ionizing Radiation via ATM/P53 Signalling Pathway", "doi": "10.7150/jca.41217", "year": 2020 } ], "bc": [ { "pmid": "32209898", "title": "Expression Patterns and Prognostic Value of DNA Damage Repair Proteins in Resected Pancreatic Neuroendocrine Neoplasms", "doi": "10.1097/sla.0000000000003884", "year": 2020 } ] } }, { "id": 38917, "drug": "imatinib", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "downregulates", "mediator": "CSF1R", "mediator_type": "protein", "predicate_bc": "prevents", "outcome": "neurological impairments", "outcome_type": "phenotype", "outcome_domain": "multiple_sclerosis", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "imatinib", "mediator_canonical": "csf1r", "outcome_canonical": "neurological impairments", "ab_count": 2, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "30281780", "title": "Imatinib inhibits CSF1R that stimulates proliferation of rheumatoid arthritis fibroblast-like synoviocytes", "doi": "10.1111/cei.13220", "year": 2018 } ], "bc": [ { "pmid": "33097690", "title": "CSF1R signaling is a regulator of pathogenesis in progressive MS", "doi": "10.1038/s41419-020-03084-7", "year": 2020 } ] } }, { "id": 50505, "drug": "luteolin", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "suppresses", "mediator": "JNK", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "tau pathology", "outcome_type": "disease", "outcome_domain": "alzheimer", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 2, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "36852907", "title": "The protection of luteolin against diabetic cardiomyopathy in rats is related to reversing JNK-suppressed autophagy", "doi": "10.1039/d2fo03871d", "year": 2023 }, { "pmid": "26327560", "title": "A Food-Derived Flavonoid Luteolin Protects against Angiotensin II-Induced Cardiac Remodeling", "doi": "10.1371/journal.pone.0137106", "year": 2015 } ], "bc": [ { "pmid": "36976903", "title": "JNK Activation in Alzheimer’s Disease Is Driven by Amyloid β and Is Associated with Tau Pathology", "doi": "10.1021/acschemneuro.3c00093", "year": 2023 } ] } }, { "id": 23242, "drug": "amantadine", "drug_type": "drug", "drug_domain": "multiple_sclerosis", "predicate_ab": "activates", "mediator": "NMDA receptor", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "neurodevelopmental disorders", "outcome_type": "disease", "outcome_domain": "epilepsy", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "completed", "clinical_trial_nct_ids": [ "NCT07531940", "NCT01972074", "NCT01333865" ], "literature_status": "partial_evidence", "drug_canonical": "amantadine", "mediator_canonical": "nmda receptor", "outcome_canonical": "neurodevelopmental disorders", "ab_count": 2, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37419676", "title": "Amantadine toxicity causing visual hallucinations", "doi": "10.1136/pn-2023-003723", "year": 2023 }, { "pmid": "33350472", "title": "Amantadine for COVID‐19", "doi": "10.1002/jcph.1802", "year": 2020 } ], "bc": [ { "pmid": "30280376", "title": "GRIN2D variants in three cases of developmental and epileptic encephalopathy", "doi": "10.1111/cge.13454", "year": 2018 } ] } }, { "id": 18593, "drug": "valproic acid", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "downregulates", "mediator": "NRF2", "mediator_type": "gene", "predicate_bc": "increases", "outcome": "retinal ganglion cell survival", "outcome_type": "phenotype", "outcome_domain": "multiple_sclerosis", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "valproic acid", "mediator_canonical": "NRF2", "outcome_canonical": "retinal ganglion cell survival", "ab_count": 2, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "34050116", "title": "Chronic valproic acid administration enhances oxidative stress, upregulates IL6 and downregulates Nrf2, Glut1 and Glut4 in rat’s liver and brain", "doi": "10.1097/wnr.0000000000001663", "year": 2021 }, { "pmid": "34686779", "title": "Valproic acid disables the Nrf2 anti-oxidant response in acute myeloid leukaemia cells enhancing reactive oxygen species-mediated killing", "doi": "10.1038/s41416-021-01570-z", "year": 2021 } ], "bc": [ { "pmid": "29494741", "title": "SIRT1 and NRF2 Gene Transfer Mediate Distinct Neuroprotective Effects Upon Retinal Ganglion Cell Survival and Function in Experimental Optic Neuritis", "doi": "10.1167/iovs.17-22972", "year": 2018 } ] } }, { "id": 37794, "drug": "Auranofin", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "inhibits", "mediator": "TDP-43", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "neurodegeneration", "outcome_type": "phenotype", "outcome_domain": "als", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "auranofin", "mediator_canonical": "TDP-43", "outcome_canonical": null, "ab_count": 1, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "29396541", "title": "TDP-43 self-interaction is modulated by redox-active compounds Auranofin, Chelerythrine and Riluzole", "doi": "10.1038/s41598-018-20565-0", "year": 2018 } ], "bc": [ { "pmid": "39810199", "title": "Alternative 3′ UTR polyadenylation is disrupted in the rNLS8 mouse model of ALS/FTLD", "doi": "10.1186/s13041-025-01174-1", "year": 2025 }, { "pmid": "30922385", "title": "Transcriptomopathies of pre- and post-symptomatic frontotemporal dementia-like mice with TDP-43 depletion in forebrain neurons", "doi": "10.1186/s40478-019-0674-x", "year": 2019 } ] } }, { "id": 38391, "drug": "Auranofin", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "inhibits", "mediator": "GSK-3β", "mediator_type": "protein", "predicate_bc": "increases", "outcome": "hippocampal damage", "outcome_type": "phenotype", "outcome_domain": "epilepsy", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "auranofin", "mediator_canonical": "GSK3B", "outcome_canonical": "hippocampal damage", "ab_count": 2, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40842183", "title": "Gold‐Containing Compound Auranofin Ameliorates 6‐OHDA Induced Neurotoxicity in Rats: Via Targeting PI3K/Akt/GSK‐3β Signalling", "doi": "10.1111/1440-1681.70070", "year": 2025 } ], "bc": [ { "pmid": "30237424", "title": "Bi-directional genetic modulation of GSK-3β exacerbates hippocampal neuropathology in experimental status epilepticus", "doi": "10.1038/s41419-018-0963-5", "year": 2018 } ] } }, { "id": 8055, "drug": "Riluzole", "drug_type": "drug", "drug_domain": "als", "predicate_ab": "inhibits", "mediator": "CK1δ", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "pancreatic cancer", "outcome_type": "disease", "outcome_domain": "pancreatic_cancer", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "riluzole", "mediator_canonical": "ck1δ", "outcome_canonical": "pancreatic cancer", "ab_count": 2, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "31397342", "title": "Rethinking to riluzole mechanism of action: the molecular link among protein kinase CK1δ activity, TDP-43 phosphorylation, and amyotrophic lateral sclerosis pharmacological treatment", "doi": "10.4103/1673-5374.262578", "year": 2019 }, { "pmid": "30359484", "title": "Targeting Protein Kinase CK1δ with Riluzole: Could It Be One of the Possible Missing Bricks to Interpret Its Effect in the Treatment of ALS from a Molecular Point of View?", "doi": "10.1002/cmdc.201800632", "year": 2018 } ], "bc": [ { "pmid": "32430484", "title": "Targeting Casein Kinase 1 Delta Sensitizes Pancreatic and Bladder Cancer Cells to Gemcitabine Treatment by Upregulating Deoxycytidine Kinase", "doi": "10.1158/1535-7163.mct-19-0997", "year": 2020 } ] } }, { "id": 59557, "drug": "resveratrol", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "suppresses", "mediator": "TGF-β1", "mediator_type": "protein", "predicate_bc": "increases", "outcome": "remyelination", "outcome_type": "phenotype", "outcome_domain": "multiple_sclerosis", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "38745204", "title": "Resveratrol attenuates inflammation and fibrosis in rheumatoid arthritis-associated interstitial lung disease via the AKT/TMEM175 pathway", "doi": "10.1186/s12967-024-05228-1", "year": 2024 } ], "bc": [ { "pmid": "32985478", "title": "Glial-derived transforming growth factor β1 (TGF-β1): a key factor in multiple sclerosis neuroinflammation", "doi": "10.4103/1673-5374.293147", "year": 2020 }, { "pmid": "31071011", "title": "Circulating transforming growth factor-β1 facilitates remyelination in the adult central nervous system", "doi": "10.7554/elife.41869", "year": 2019 } ] } }, { "id": 20154, "drug": "curcumin", "drug_type": "drug", "drug_domain": "alzheimer", "predicate_ab": "binds_to", "mediator": "amyloid beta", "mediator_type": "protein", "predicate_bc": "increases", "outcome": "seizure susceptibility", "outcome_type": "phenotype", "outcome_domain": "epilepsy", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "curcumin", "mediator_canonical": "amyloid beta", "outcome_canonical": "seizure susceptibility", "ab_count": 2, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "31736502", "title": "Labeling and Imaging of Amyloid Plaques in Brain Tissue Using the Natural Polyphenol Curcumin", "doi": "10.3791/60377", "year": 2019 } ], "bc": [ { "pmid": "35775150", "title": "Higher susceptibility to 6 Hz corneal kindling and lower responsiveness to antiseizure drugs in mouse models of Alzheimer's disease", "doi": "10.1111/epi.17355", "year": 2022 } ] } }, { "id": 50254, "drug": "Curcumin", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "activates", "mediator": "Nrf2", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "antioxidant defense", "outcome_type": "phenotype", "outcome_domain": "als", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 2, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37101595", "title": "Curcumin Improves Diabetic Cardiomyopathy by Inhibiting Pyroptosis through AKT/Nrf2/ARE Pathway", "doi": "10.1155/2023/3906043", "year": 2023 }, { "pmid": "35909950", "title": "Curcumin Attenuates Ferroptosis-Induced Myocardial Injury in Diabetic Cardiomyopathy through the Nrf2 Pathway", "doi": "10.1155/2022/3159717", "year": 2022 } ], "bc": [ { "pmid": "37862202", "title": "NRF2 signaling cascade in amyotrophic lateral sclerosis: bridging the gap between promise and reality", "doi": "10.4103/1673-5374.385283", "year": 2023 } ] } }, { "id": 26106, "drug": "Curcumin", "drug_type": "drug", "drug_domain": "alzheimer", "predicate_ab": "binds_to", "mediator": "TDP-43", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "neurodegenerative diseases", "outcome_type": "disease", "outcome_domain": "als", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "active", "clinical_trial_nct_ids": [ "NCT05363267", "NCT06470061", "NCT03431896" ], "literature_status": "reproduces_known", "drug_canonical": "curcumin", "mediator_canonical": "TDP-43", "outcome_canonical": null, "ab_count": 1, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "30092839", "title": "Different curcumin forms selectively bind fibrillar amyloid beta in post mortem Alzheimer’s disease brains: Implications for in-vivo diagnostics", "doi": "10.1186/s40478-018-0577-2", "year": 2018 } ], "bc": [ { "pmid": "41900026", "title": "Chemical and Molecular Strategies in Restoring Autophagic Flux in TDP-43 Proteinopathy", "doi": "10.3390/molecules31060924", "year": 2026 }, { "pmid": "40960157", "title": "Protein aggregation in neurodegenerative diseases", "doi": "10.1097/cm9.0000000000003802", "year": 2025 } ] } }, { "id": 50240, "drug": "Curcumin", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "activates", "mediator": "Nrf2", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "ALS", "outcome_type": "disease", "outcome_domain": "als", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 2, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37101595", "title": "Curcumin Improves Diabetic Cardiomyopathy by Inhibiting Pyroptosis through AKT/Nrf2/ARE Pathway", "doi": "10.1155/2023/3906043", "year": 2023 }, { "pmid": "35909950", "title": "Curcumin Attenuates Ferroptosis-Induced Myocardial Injury in Diabetic Cardiomyopathy through the Nrf2 Pathway", "doi": "10.1155/2022/3159717", "year": 2022 } ], "bc": [ { "pmid": "40581791", "title": "Identification of disease-associated molecular signatures in the Prp-TDP-43A315T mouse model of ALS: Toward preclinical biomarker development", "doi": "10.1093/jnen/nlaf071", "year": 2025 } ] } }, { "id": 8773, "drug": "curcumin", "drug_type": "drug", "drug_domain": "alzheimer", "predicate_ab": "binds_to", "mediator": "amyloid beta", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "cerebral amyloid angiopathy-related inflammation", "outcome_type": "disease", "outcome_domain": "epilepsy", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "curcumin", "mediator_canonical": "amyloid beta", "outcome_canonical": "cerebral amyloid angiopathy-related inflammation", "ab_count": 2, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "31736502", "title": "Labeling and Imaging of Amyloid Plaques in Brain Tissue Using the Natural Polyphenol Curcumin", "doi": "10.3791/60377", "year": 2019 } ], "bc": [ { "pmid": "33480610", "title": "Cerebral Amyloid Angiopathy-related Inflammation Presenting With a Cystic Lesion in Young-onset Alzheimer Disease", "doi": "10.1097/wad.0000000000000432", "year": 2021 } ] } }, { "id": 25755, "drug": "metformin", "drug_type": "drug", "drug_domain": "als", "predicate_ab": "activates", "mediator": "AMPK pathway", "mediator_type": "pathway", "predicate_bc": "increases", "outcome": "memory dysfunction", "outcome_type": "phenotype", "outcome_domain": "type_2_diabetes", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "active", "clinical_trial_nct_ids": [ "NCT05230758" ], "literature_status": "reproduces_known", "drug_canonical": "metformin", "mediator_canonical": "ampk pathway", "outcome_canonical": "memory dysfunction", "ab_count": 1, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41930282", "title": "Metformin Repurposing in Neurological Disorders: A Clinical Trial Landscape", "doi": "10.1177/09727531261421807", "year": 2026 } ], "bc": [ { "pmid": "25190626", "title": "Metformin Treatment Alters Memory Function in a Mouse Model of Alzheimer's Disease", "doi": "10.3233/jad-141332", "year": 2015 } ] } }, { "id": 31993, "drug": "auraptene", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "downregulates", "mediator": "MMP-9", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "rheumatoid arthritis", "outcome_type": "disease", "outcome_domain": "rheumatoid_arthritis", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "auraptene", "mediator_canonical": "MMP9", "outcome_canonical": "rheumatoid arthritis", "ab_count": 1, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "39086858", "title": "Auraptene inhibits migration, invasion and metastatic behavior of human malignant glioblastoma cells: An in vitro and in silico study.", "doi": "10.22038/ajp.2023.23586", "year": 2024 } ], "bc": [ { "pmid": "38419379", "title": "A Novel Activatable Nanoradiosensitizer for Second Near‐Infrared Fluorescence Imaging‐Guided Safe‐Dose Synergetic Chemo‐Radiotherapy of Rheumatoid Arthritis", "doi": "10.1002/advs.202308905", "year": 2024 }, { "pmid": "34912337", "title": "Proteoform Analysis of Matrix Metalloproteinase-9/Gelatinase B and Discovery of Its Citrullination in Rheumatoid Arthritis Synovial Fluids", "doi": "10.3389/fimmu.2021.763832", "year": 2021 } ] } }, { "id": 31991, "drug": "erlotinib", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "inhibits", "mediator": "EGFR", "mediator_type": "gene", "predicate_bc": "associated_with", "outcome": "rheumatoid arthritis", "outcome_type": "disease", "outcome_domain": "rheumatoid_arthritis", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "erlotinib", "mediator_canonical": "EGFR", "outcome_canonical": "rheumatoid arthritis", "ab_count": 1, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "30240496", "title": "Design of a Multicompartment Hydrogel that Facilitates Time‐Resolved Delivery of Combination Therapy and Synergized Killing of Glioblastoma", "doi": "10.1002/anie.201806483", "year": 2018 } ], "bc": [ { "pmid": "40964982", "title": "Selection of Common Genes Associated with Rheumatoid Arthritis and Cardiovascular Disease via a Network- and Pathway-Based Approach", "doi": "10.14744/anatoljcardiol.2025.5375", "year": 2025 }, { "pmid": "36247278", "title": "Identification and validation of potential hub genes in rheumatoid arthritis by bioinformatics analysis.", "doi": null, "year": 2022 } ] } }, { "id": 32008, "drug": "osimertinib", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "inhibits", "mediator": "EGFR", "mediator_type": "gene", "predicate_bc": "associated_with", "outcome": "rheumatoid arthritis", "outcome_type": "disease", "outcome_domain": "rheumatoid_arthritis", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "osimertinib", "mediator_canonical": "EGFR", "outcome_canonical": "rheumatoid arthritis", "ab_count": 1, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "31678994", "title": "Betacellulin drives therapy resistance in glioblastoma", "doi": "10.1093/neuonc/noz206", "year": 2019 } ], "bc": [ { "pmid": "40964982", "title": "Selection of Common Genes Associated with Rheumatoid Arthritis and Cardiovascular Disease via a Network- and Pathway-Based Approach", "doi": "10.14744/anatoljcardiol.2025.5375", "year": 2025 }, { "pmid": "36247278", "title": "Identification and validation of potential hub genes in rheumatoid arthritis by bioinformatics analysis.", "doi": null, "year": 2022 } ] } }, { "id": 31986, "drug": "Verteporfin", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "downregulates", "mediator": "EGFR", "mediator_type": "gene", "predicate_bc": "associated_with", "outcome": "rheumatoid arthritis", "outcome_type": "disease", "outcome_domain": "rheumatoid_arthritis", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "verteporfin", "mediator_canonical": "EGFR", "outcome_canonical": "rheumatoid arthritis", "ab_count": 1, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "33172899", "title": "YAP/TAZ Transcriptional Coactivators Create Therapeutic Vulnerability to Verteporfin in EGFR-mutant Glioblastoma", "doi": "10.1158/1078-0432.ccr-20-0018", "year": 2020 } ], "bc": [ { "pmid": "40964982", "title": "Selection of Common Genes Associated with Rheumatoid Arthritis and Cardiovascular Disease via a Network- and Pathway-Based Approach", "doi": "10.14744/anatoljcardiol.2025.5375", "year": 2025 }, { "pmid": "36247278", "title": "Identification and validation of potential hub genes in rheumatoid arthritis by bioinformatics analysis.", "doi": null, "year": 2022 } ] } }, { "id": 39170, "drug": "Auranofin", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "upregulates", "mediator": "PD-L1", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "type 2 autoimmune pancreatitis", "outcome_type": "disease", "outcome_domain": "pancreatic_cancer", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "auranofin", "mediator_canonical": "PD-L1", "outcome_canonical": "type 2 autoimmune pancreatitis", "ab_count": 1, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "31090219", "title": "Therapeutic cooperation between auranofin, a thioredoxin reductase inhibitor and anti‐PD‐L1 antibody for treatment of triple‐negative breast cancer", "doi": "10.1002/ijc.32410", "year": 2019 } ], "bc": [ { "pmid": "31135488", "title": "Autoimmune Pancreatitis Type 2", "doi": "10.1097/pas.0000000000001282", "year": 2019 } ] } }, { "id": 6171, "drug": "linalool", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "downregulates", "mediator": "PD-L1", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "poor differentiation", "outcome_type": "phenotype", "outcome_domain": "pancreatic_cancer", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "linalool", "mediator_canonical": "PD-L1", "outcome_canonical": null, "ab_count": 1, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40504869", "title": "Linalool-based silver nanoconjugates as potential therapeutics for glioblastoma: in silico and in vitro insights", "doi": "10.1371/journal.pone.0325281", "year": 2025 } ], "bc": [ { "pmid": "35624419", "title": "Clinical significance and correlation of PD-L1, B7-H3, B7-H4, and TILs in pancreatic cancer", "doi": "10.1186/s12885-022-09639-5", "year": 2022 }, { "pmid": "28030840", "title": "Prognostic value and clinicopathological features of PD-1/PD-L1 expression with mismatch repair status and desmoplastic stroma in Chinese patients with pancreatic cancer", "doi": "10.18632/oncotarget.14069", "year": 2016 } ] } }, { "id": 39877, "drug": "resveratrol", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "upregulates", "mediator": "adiponectin", "mediator_type": "protein", "predicate_bc": "predicts", "outcome": "MDD", "outcome_type": "disease", "outcome_domain": "depression", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "resveratrol", "mediator_canonical": "adiponectin", "outcome_canonical": "major depressive disorder", "ab_count": 1, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "36991247", "title": "Resveratrol and Dulaglutide ameliorate adiposity and liver dysfunction in rats with diet-induced metabolic syndrome: Role of SIRT-1 / adipokines / PPARγ and IGF-1", "doi": "10.1007/s40199-023-00458-y", "year": 2023 } ], "bc": [ { "pmid": "36409748", "title": "Altered serum adiponectin and interleukin-8 levels are associated in the pathophysiology of major depressive disorder: A case-control study", "doi": "10.1371/journal.pone.0276619", "year": 2022 } ] } }, { "id": 3078, "drug": "Riluzole", "drug_type": "drug", "drug_domain": "als", "predicate_ab": "inhibits", "mediator": "CK1δ", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "tau aggregation", "outcome_type": "phenotype", "outcome_domain": "alzheimer", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "riluzole", "mediator_canonical": "ck1δ", "outcome_canonical": "tau aggregation", "ab_count": 2, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "31397342", "title": "Rethinking to riluzole mechanism of action: the molecular link among protein kinase CK1δ activity, TDP-43 phosphorylation, and amyotrophic lateral sclerosis pharmacological treatment", "doi": "10.4103/1673-5374.262578", "year": 2019 }, { "pmid": "30359484", "title": "Targeting Protein Kinase CK1δ with Riluzole: Could It Be One of the Possible Missing Bricks to Interpret Its Effect in the Treatment of ALS from a Molecular Point of View?", "doi": "10.1002/cmdc.201800632", "year": 2018 } ], "bc": [ { "pmid": "36203870", "title": "Comprehensive Characterization of CK1δ-Mediated Tau Phosphorylation in Alzheimer’s Disease", "doi": "10.3389/fmolb.2022.872171", "year": 2022 } ] } }, { "id": 7976, "drug": "resveratrol", "drug_type": "drug", "drug_domain": "als", "predicate_ab": "downregulates", "mediator": "GSK-3β", "mediator_type": "protein", "predicate_bc": "increases", "outcome": "tau hyperphosphorylation", "outcome_type": "phenotype", "outcome_domain": "alzheimer", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "resveratrol", "mediator_canonical": "GSK3B", "outcome_canonical": "tau hyperphosphorylation", "ab_count": 1, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "26981091", "title": "How does resveratrol influence the genesis of some neurodegenerative diseases?", "doi": "10.4103/1673-5374.175047", "year": 2016 } ], "bc": [ { "pmid": "41459736", "title": "Type 3 Diabetes: A Molecular Link Between Cerebral Insulin Resistance and Neurodegeneration via AGE–RAGE Signaling", "doi": "10.1111/ejn.70364", "year": 2025 }, { "pmid": "33554064", "title": "Isoform-selective decrease of glycogen synthase kinase-3-beta (GSK-3β) reduces synaptic tau phosphorylation, transcellular spreading, and aggregation", "doi": "10.1016/j.isci.2021.102058", "year": 2021 } ] } }, { "id": 30145, "drug": "valproate", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "downregulates", "mediator": "COX-2", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "disease activity", "outcome_type": "phenotype", "outcome_domain": "rheumatoid_arthritis", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "completed", "clinical_trial_nct_ids": [ "NCT00211757", "NCT00211796", "NCT02593643" ], "literature_status": "novel_signal", "drug_canonical": "valproic acid", "mediator_canonical": "cox-2", "outcome_canonical": "disease activity", "ab_count": 1, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "32054883", "title": "Downregulation of peripheral PTGS2/COX-2 in response to valproate treatment in patients with epilepsy", "doi": "10.1038/s41598-020-59259-x", "year": 2020 } ], "bc": [ { "pmid": "32742333", "title": "Serum COX‑2 and FOXO3a in patients with rheumatoid arthritis and correlation with disease activity", "doi": "10.3892/etm.2020.8779", "year": 2020 } ] } }, { "id": 30350, "drug": "valproic acid", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "downregulates", "mediator": "Nrf2", "mediator_type": "gene", "predicate_bc": "prevents", "outcome": "diabetic cardiomyopathy", "outcome_type": "disease", "outcome_domain": "type_2_diabetes", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "valproic acid", "mediator_canonical": "NRF2", "outcome_canonical": "diabetic cardiomyopathy", "ab_count": 2, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "34050116", "title": "Chronic valproic acid administration enhances oxidative stress, upregulates IL6 and downregulates Nrf2, Glut1 and Glut4 in rat’s liver and brain", "doi": "10.1097/wnr.0000000000001663", "year": 2021 }, { "pmid": "34686779", "title": "Valproic acid disables the Nrf2 anti-oxidant response in acute myeloid leukaemia cells enhancing reactive oxygen species-mediated killing", "doi": "10.1038/s41416-021-01570-z", "year": 2021 } ], "bc": [ { "pmid": "27903744", "title": "Metallothionein Is Downstream of Nrf2 and Partially Mediates Sulforaphane Prevention of Diabetic Cardiomyopathy", "doi": "10.2337/db15-1274", "year": 2016 } ] } }, { "id": 30355, "drug": "valproic acid", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "downregulates", "mediator": "FASN", "mediator_type": "gene", "predicate_bc": "treats", "outcome": "NAFLD", "outcome_type": "disease", "outcome_domain": "type_2_diabetes", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "valproic acid", "mediator_canonical": "fasn", "outcome_canonical": "nafld", "ab_count": 1, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "36544904", "title": "Metabolomic profiling of triple negative breast cancer cells suggests that valproic acid can enhance the anticancer effect of cisplatin", "doi": "10.3389/fcell.2022.1014798", "year": 2022 } ], "bc": [ { "pmid": "37681411", "title": "Hepatic FASN deficiency differentially affects nonalcoholic fatty liver disease and diabetes in mouse obesity models", "doi": "10.1172/jci.insight.161282", "year": 2023 } ] } }, { "id": 30335, "drug": "valproic acid", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "downregulates", "mediator": "DNA methylation", "mediator_type": "biomarker", "predicate_bc": "associated_with", "outcome": "insulin resistance", "outcome_type": "phenotype", "outcome_domain": "type_2_diabetes", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "completed", "clinical_trial_nct_ids": [ "NCT00552500", "NCT00665444" ], "literature_status": "reproduces_known", "drug_canonical": "valproic acid", "mediator_canonical": "dna methylation", "outcome_canonical": "insulin resistance", "ab_count": 1, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "35312054", "title": "Developmental administration of valproic acid alters DNA methylation and maternal behavior", "doi": "10.1002/dev.22231", "year": 2022 } ], "bc": [ { "pmid": "32033992", "title": "Epigenetic Link Between Statin Therapy and Type 2 Diabetes", "doi": "10.2337/dc19-1828", "year": 2020 }, { "pmid": "27535281", "title": "The epigenetic signature of systemic insulin resistance in obese women", "doi": "10.1007/s00125-016-4074-5", "year": 2016 } ] } }, { "id": 1603, "drug": "erlotinib", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "inhibits", "mediator": "EGFR", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "AGR2-dependent oncogenic phenotypes", "outcome_type": "phenotype", "outcome_domain": "pancreatic_cancer", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "erlotinib", "mediator_canonical": "EGFR", "outcome_canonical": "agr2-dependent oncogenic phenotypes", "ab_count": 2, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40945534", "title": "Biodegradable nanofibrous scaffolds enhance standard of care for glioblastoma via localized targeted therapy", "doi": "10.1016/j.jconrel.2025.114225", "year": 2025 }, { "pmid": "30410775", "title": "The role of erlotinib and the Optune device in a patient with an epidermal growth factor receptor viii amplified glioblastoma", "doi": "10.1093/omcr/omy095", "year": 2018 } ], "bc": [ { "pmid": "33413231", "title": "Effects of ER-resident and secreted AGR2 on cell proliferation, migration, invasion, and survival in PANC-1 pancreatic cancer cells", "doi": "10.1186/s12885-020-07743-y", "year": 2021 } ] } }, { "id": 31397, "drug": "acriflavine", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "inhibits", "mediator": "HIF-1α", "mediator_type": "protein", "predicate_bc": "prevents", "outcome": "ulcerative colitis", "outcome_type": "disease", "outcome_domain": "inflammatory_bowel_disease", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "acriflavine", "mediator_canonical": "hif-1α", "outcome_canonical": "ulcerative colitis", "ab_count": 1, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40405165", "title": "Photo-controlled co-delivery of verteporfin and acriflavine via platelets achieves potentiated glioblastoma-targeted photodynamic therapy", "doi": "10.1186/s12951-025-03395-x", "year": 2025 } ], "bc": [ { "pmid": "38137357", "title": "Interrelation of Hypoxia-Inducible Factor-1 Alpha (HIF-1 α) and the Ratio between the Mean Corpuscular Volume/Lymphocytes (MCVL) and the Cumulative Inflammatory Index (IIC) in Ulcerative Colitis", "doi": "10.3390/biomedicines11123137", "year": 2023 }, { "pmid": "31944416", "title": "Mucosal inflammation downregulates PHD1 expression promoting a barrier‐protective HIF‐1α response in ulcerative colitis patients", "doi": "10.1096/fj.201902103r", "year": 2020 } ] } }, { "id": 31376, "drug": "cisplatin", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "upregulates", "mediator": "PD-L1", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "colitis", "outcome_type": "disease", "outcome_domain": "inflammatory_bowel_disease", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "cisplatin", "mediator_canonical": "PD-L1", "outcome_canonical": "colitis", "ab_count": 1, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "39810130", "title": "Engineered biomimetic cisplatin-polyphenol nanocomplex for chemo-immunotherapy of glioblastoma by inducing pyroptosis", "doi": "10.1186/s12951-025-03091-w", "year": 2025 } ], "bc": [ { "pmid": "40661950", "title": "PD-L1 deficiency exacerbates colitis severity by remodeling gut microbiota in inflammatory bowel disease", "doi": "10.3389/fimmu.2025.1622744", "year": 2025 }, { "pmid": "37435072", "title": "Case Report: A severe case of immunosuppressant-refractory immune checkpoint inhibitor-mediated colitis rescued by tofacitinib", "doi": "10.3389/fimmu.2023.1212432", "year": 2023 } ] } }, { "id": 31377, "drug": "linalool", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "downregulates", "mediator": "PD-L1", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "colitis", "outcome_type": "disease", "outcome_domain": "inflammatory_bowel_disease", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "linalool", "mediator_canonical": "PD-L1", "outcome_canonical": "colitis", "ab_count": 1, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40504869", "title": "Linalool-based silver nanoconjugates as potential therapeutics for glioblastoma: in silico and in vitro insights", "doi": "10.1371/journal.pone.0325281", "year": 2025 } ], "bc": [ { "pmid": "40661950", "title": "PD-L1 deficiency exacerbates colitis severity by remodeling gut microbiota in inflammatory bowel disease", "doi": "10.3389/fimmu.2025.1622744", "year": 2025 }, { "pmid": "37435072", "title": "Case Report: A severe case of immunosuppressant-refractory immune checkpoint inhibitor-mediated colitis rescued by tofacitinib", "doi": "10.3389/fimmu.2023.1212432", "year": 2023 } ] } }, { "id": 49051, "drug": "Curcumin", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "upregulates", "mediator": "Nrf2", "mediator_type": "gene", "predicate_bc": "increases", "outcome": "diabetic cardiomyopathy", "outcome_type": "disease", "outcome_domain": "heart_failure", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40081725", "title": "Matrix metallopeptidase 2-responsive curcumin-loaded nanoparticles-induced signal transducer and activator of transcription 3 inhibition suppresses glioblastoma multiforme growth via enhancing nuclear factor erythroid 2-related factor 2 activity", "doi": "10.1016/j.ijbiomac.2025.141998", "year": 2025 } ], "bc": [ { "pmid": "38308838", "title": "Nrf2 prevents diabetic cardiomyopathy via antioxidant effect and normalization of glucose and lipid metabolism in the heart", "doi": "10.1002/jcp.31149", "year": 2024 }, { "pmid": "32948607", "title": "Autophagy Inhibition Enables Nrf2 to Exaggerate the Progression of Diabetic Cardiomyopathy in Mice", "doi": "10.2337/db19-1176", "year": 2020 } ] } }, { "id": 6980, "drug": "Baicalin", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "upregulates", "mediator": "BDNF", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "Alzheimer's disease", "outcome_type": "disease", "outcome_domain": "alzheimer", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "baicalin", "mediator_canonical": "BDNF", "outcome_canonical": "Alzheimer disease", "ab_count": 1, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "38778616", "title": "Exploring the Therapeutic Potential of Baicalin: Mitigating Anxiety and Depression in Epileptic Rats", "doi": "10.2174/0113862073316021240520110301", "year": 2024 } ], "bc": [ { "pmid": "37262102", "title": "Exercise training and BDNF injections alter amyloid precursor protein (APP) processing enzymes and improve cognition", "doi": "10.1152/japplphysiol.00114.2023", "year": 2023 }, { "pmid": "36979505", "title": "Relationship between Brain-Derived Neurotrophic Factor and Cognitive Decline in Patients with Mild Cognitive Impairment and Dementia", "doi": "10.3390/biom13030570", "year": 2023 } ] } }, { "id": 32941, "drug": "metformin", "drug_type": "drug", "drug_domain": "inflammatory_bowel_disease", "predicate_ab": "downregulates", "mediator": "IL-17", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "suspected autoimmune epilepsy", "outcome_type": "disease", "outcome_domain": "epilepsy", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "metformin", "mediator_canonical": "il-17", "outcome_canonical": "suspected autoimmune epilepsy", "ab_count": 2, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "32654569", "title": "Metformin alleviates experimental colitis in mice by up-regulating TGF-β signaling", "doi": "10.1080/10520295.2020.1776896", "year": 2020 }, { "pmid": "26360050", "title": "Metformin Ameliorates Inflammatory Bowel Disease by Suppression of the STAT3 Signaling Pathway and Regulation of the between Th17/Treg Balance", "doi": "10.1371/journal.pone.0135858", "year": 2015 } ], "bc": [ { "pmid": "32547032", "title": "<p>HMGB1/CXCL12-Mediated Immunity and Th17 Cells Might Underlie Highly Suspected Autoimmune Epilepsy in Elderly Individuals</p>", "doi": "10.2147/ndt.s242766", "year": 2020 } ] } }, { "id": 33690, "drug": "Apigenin", "drug_type": "drug", "drug_domain": "inflammatory_bowel_disease", "predicate_ab": "activates", "mediator": "AMPK", "mediator_type": "protein", "predicate_bc": "decreases", "outcome": "invasion", "outcome_type": "phenotype", "outcome_domain": "pancreatic_cancer", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "apigenin", "mediator_canonical": "AMPK", "outcome_canonical": "invasion", "ab_count": 2, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41428381", "title": "Natural Dietary Flavonoid Apigenin Mitigates Ulcerative Colitis via Modulating the AMPK/NF-κB/NLRP3 Signaling Axis", "doi": "10.1021/acs.jafc.5c15405", "year": 2025 } ], "bc": [ { "pmid": "28783244", "title": "Loss of AMPK activation promotes the invasion and metastasis of pancreatic cancer through an HSF1‐dependent pathway", "doi": "10.1002/1878-0261.12116", "year": 2017 } ] } }, { "id": 7920, "drug": "lithium", "drug_type": "drug", "drug_domain": "als", "predicate_ab": "inhibits", "mediator": "GSK-3β", "mediator_type": "protein", "predicate_bc": "increases", "outcome": "tau hyperphosphorylation", "outcome_type": "phenotype", "outcome_domain": "alzheimer", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "lithium", "mediator_canonical": "GSK3B", "outcome_canonical": "tau hyperphosphorylation", "ab_count": 1, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "39363657", "title": "Lithium alleviates paralysis in experimental autoimmune neuritis in Lewis rats by modulating glycogen synthase kinase-3β activity", "doi": "10.4142/jvs.24212", "year": 2024 } ], "bc": [ { "pmid": "41459736", "title": "Type 3 Diabetes: A Molecular Link Between Cerebral Insulin Resistance and Neurodegeneration via AGE–RAGE Signaling", "doi": "10.1111/ejn.70364", "year": 2025 }, { "pmid": "33554064", "title": "Isoform-selective decrease of glycogen synthase kinase-3-beta (GSK-3β) reduces synaptic tau phosphorylation, transcellular spreading, and aggregation", "doi": "10.1016/j.isci.2021.102058", "year": 2021 } ] } }, { "id": 7928, "drug": "lithium", "drug_type": "drug", "drug_domain": "als", "predicate_ab": "inhibits", "mediator": "GSK-3β", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "Alzheimer's disease", "outcome_type": "disease", "outcome_domain": "alzheimer", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "completed", "clinical_trial_nct_ids": [ "NCT07459959", "NCT03185208", "NCT05363293" ], "literature_status": "reproduces_known", "drug_canonical": "lithium", "mediator_canonical": "GSK3B", "outcome_canonical": "Alzheimer disease", "ab_count": 1, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "39363657", "title": "Lithium alleviates paralysis in experimental autoimmune neuritis in Lewis rats by modulating glycogen synthase kinase-3β activity", "doi": "10.4142/jvs.24212", "year": 2024 } ], "bc": [ { "pmid": "40414897", "title": "Mapping the hippocampal spatial proteomic signature in male and female mice of an early Alzheimer’s disease model", "doi": "10.1186/s13293-025-00697-5", "year": 2025 }, { "pmid": "33945025", "title": "High-throughput screening of natural compounds and inhibition of a major therapeutic target HsGSK-3β for Alzheimer’s disease using computational approaches", "doi": "10.1186/s43141-021-00163-w", "year": 2021 } ] } }, { "id": 1446, "drug": "auraptene", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "downregulates", "mediator": "MMP-9", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "Alzheimer's disease", "outcome_type": "disease", "outcome_domain": "alzheimer", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "auraptene", "mediator_canonical": "MMP9", "outcome_canonical": "Alzheimer disease", "ab_count": 1, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "39086858", "title": "Auraptene inhibits migration, invasion and metastatic behavior of human malignant glioblastoma cells: An in vitro and in silico study.", "doi": "10.22038/ajp.2023.23586", "year": 2024 } ], "bc": [ { "pmid": "37695608", "title": "Plasma MMP-9/TIMP-1 ratio serves as a novel potential biomarker in Alzheimer’s disease", "doi": "10.1097/wnr.0000000000001952", "year": 2023 }, { "pmid": "32790155", "title": "Elevated matrix metalloproteinase‐9 levels in neuronal extracellular vesicles in Alzheimer’s disease", "doi": "10.1002/acn3.51155", "year": 2020 } ] } }, { "id": 40626, "drug": "resveratrol", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "upregulates", "mediator": "adiponectin", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "multiple sclerosis", "outcome_type": "disease", "outcome_domain": "multiple_sclerosis", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "resveratrol", "mediator_canonical": "adiponectin", "outcome_canonical": "multiple sclerosis", "ab_count": 1, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "36991247", "title": "Resveratrol and Dulaglutide ameliorate adiposity and liver dysfunction in rats with diet-induced metabolic syndrome: Role of SIRT-1 / adipokines / PPARγ and IGF-1", "doi": "10.1007/s40199-023-00458-y", "year": 2023 } ], "bc": [ { "pmid": "33486671", "title": "Adiponectin in Cerebrospinal Fluid from Patients Affected by Multiple Sclerosis Is Correlated with the Progression and Severity of Disease", "doi": "10.1007/s12035-021-02287-z", "year": 2021 }, { "pmid": "30300462", "title": "Adiponectin profile at baseline is correlated to progression and severity of multiple sclerosis", "doi": "10.1111/ene.13822", "year": 2018 } ] } }, { "id": 47054, "drug": "valproic acid", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "upregulates", "mediator": "mTOR signaling", "mediator_type": "pathway", "predicate_bc": "causes", "outcome": "cardiac hypertrophy", "outcome_type": "phenotype", "outcome_domain": "heart_failure", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 2, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "33809910", "title": "Alterations in Tau Protein Level and Phosphorylation State in the Brain of the Autistic-Like Rats Induced by Prenatal Exposure to Valproic Acid", "doi": "10.3390/ijms22063209", "year": 2021 }, { "pmid": "31551670", "title": "Valproic Acid Enhances Reprogramming Efficiency and Neuronal Differentiation on Small Molecules Staged-Induction Neural Stem Cells: Suggested Role of mTOR Signaling", "doi": "10.3389/fnins.2019.00867", "year": 2019 } ], "bc": [ { "pmid": "35971771", "title": "MKK6 deficiency promotes cardiac dysfunction through MKK3-p38γ/δ-mTOR hyperactivation", "doi": "10.7554/elife.75250", "year": 2022 } ] } }, { "id": 47057, "drug": "valproic acid", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "downregulates", "mediator": "Nrf2", "mediator_type": "gene", "predicate_bc": "decreases", "outcome": "myocardial fibrosis", "outcome_type": "phenotype", "outcome_domain": "heart_failure", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 2, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "34050116", "title": "Chronic valproic acid administration enhances oxidative stress, upregulates IL6 and downregulates Nrf2, Glut1 and Glut4 in rat’s liver and brain", "doi": "10.1097/wnr.0000000000001663", "year": 2021 }, { "pmid": "34686779", "title": "Valproic acid disables the Nrf2 anti-oxidant response in acute myeloid leukaemia cells enhancing reactive oxygen species-mediated killing", "doi": "10.1038/s41416-021-01570-z", "year": 2021 } ], "bc": [ { "pmid": "38308838", "title": "Nrf2 prevents diabetic cardiomyopathy via antioxidant effect and normalization of glucose and lipid metabolism in the heart", "doi": "10.1002/jcp.31149", "year": 2024 } ] } }, { "id": 47077, "drug": "valproic acid", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "downregulates", "mediator": "Nrf2", "mediator_type": "gene", "predicate_bc": "associated_with", "outcome": "sympathetic nerve activity", "outcome_type": "phenotype", "outcome_domain": "heart_failure", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 2, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "34050116", "title": "Chronic valproic acid administration enhances oxidative stress, upregulates IL6 and downregulates Nrf2, Glut1 and Glut4 in rat’s liver and brain", "doi": "10.1097/wnr.0000000000001663", "year": 2021 }, { "pmid": "34686779", "title": "Valproic acid disables the Nrf2 anti-oxidant response in acute myeloid leukaemia cells enhancing reactive oxygen species-mediated killing", "doi": "10.1038/s41416-021-01570-z", "year": 2021 } ], "bc": [ { "pmid": "36098045", "title": "Extracellular Vesicles Regulate Sympatho-Excitation by Nrf2 in Heart Failure", "doi": "10.1161/circresaha.122.320916", "year": 2022 } ] } }, { "id": 47088, "drug": "valproic acid", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "downregulates", "mediator": "Nrf2", "mediator_type": "gene", "predicate_bc": "decreases", "outcome": "cardiac inflammation", "outcome_type": "phenotype", "outcome_domain": "heart_failure", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 2, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "34050116", "title": "Chronic valproic acid administration enhances oxidative stress, upregulates IL6 and downregulates Nrf2, Glut1 and Glut4 in rat’s liver and brain", "doi": "10.1097/wnr.0000000000001663", "year": 2021 }, { "pmid": "34686779", "title": "Valproic acid disables the Nrf2 anti-oxidant response in acute myeloid leukaemia cells enhancing reactive oxygen species-mediated killing", "doi": "10.1038/s41416-021-01570-z", "year": 2021 } ], "bc": [ { "pmid": "38308838", "title": "Nrf2 prevents diabetic cardiomyopathy via antioxidant effect and normalization of glucose and lipid metabolism in the heart", "doi": "10.1002/jcp.31149", "year": 2024 } ] } }, { "id": 29579, "drug": "valproic acid", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "upregulates", "mediator": "mTOR signaling", "mediator_type": "pathway", "predicate_bc": "increases", "outcome": "colitis", "outcome_type": "disease", "outcome_domain": "inflammatory_bowel_disease", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "valproic acid", "mediator_canonical": "mtor signaling", "outcome_canonical": "colitis", "ab_count": 2, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "33809910", "title": "Alterations in Tau Protein Level and Phosphorylation State in the Brain of the Autistic-Like Rats Induced by Prenatal Exposure to Valproic Acid", "doi": "10.3390/ijms22063209", "year": 2021 }, { "pmid": "31551670", "title": "Valproic Acid Enhances Reprogramming Efficiency and Neuronal Differentiation on Small Molecules Staged-Induction Neural Stem Cells: Suggested Role of mTOR Signaling", "doi": "10.3389/fnins.2019.00867", "year": 2019 } ], "bc": [ { "pmid": "32290362", "title": "Glucocorticoids Promote the Onset of Acute Experimental Colitis and Cancer by Upregulating mTOR Signaling in Intestinal Epithelial Cells", "doi": "10.3390/cancers12040945", "year": 2020 } ] } }, { "id": 6709, "drug": "valproic acid", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "downregulates", "mediator": "NRF2", "mediator_type": "gene", "predicate_bc": "associated_with", "outcome": "neurodegenerative processes", "outcome_type": "disease", "outcome_domain": "als", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "active", "clinical_trial_nct_ids": [ "NCT01552434" ], "literature_status": "novel_signal", "drug_canonical": "valproic acid", "mediator_canonical": "NRF2", "outcome_canonical": "neurodegenerative processes", "ab_count": 2, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "34050116", "title": "Chronic valproic acid administration enhances oxidative stress, upregulates IL6 and downregulates Nrf2, Glut1 and Glut4 in rat’s liver and brain", "doi": "10.1097/wnr.0000000000001663", "year": 2021 }, { "pmid": "34686779", "title": "Valproic acid disables the Nrf2 anti-oxidant response in acute myeloid leukaemia cells enhancing reactive oxygen species-mediated killing", "doi": "10.1038/s41416-021-01570-z", "year": 2021 } ], "bc": [ { "pmid": "41684011", "title": "Nrf2-Activating Natural Compounds in Neurodegenerative Diseases: Targeting Oxidative Stress and Protein Aggregation", "doi": "10.3390/ijms27031592", "year": 2026 } ] } }, { "id": 3075, "drug": "Riluzole", "drug_type": "drug", "drug_domain": "als", "predicate_ab": "upregulates", "mediator": "EAAT2", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "Alzheimer's disease", "outcome_type": "disease", "outcome_domain": "alzheimer", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "completed", "clinical_trial_nct_ids": [ "NCT01703117" ], "literature_status": "reproduces_known", "drug_canonical": "riluzole", "mediator_canonical": "eaat2", "outcome_canonical": "Alzheimer disease", "ab_count": 1, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "39806490", "title": "CEST imaging combined with 1H-MRS reveal the neuroprotective effects of riluzole by improving neurotransmitter imbalances in Alzheimer’s disease mice", "doi": "10.1186/s13195-025-01672-3", "year": 2025 } ], "bc": [ { "pmid": "34588956", "title": "EAAT2 Expression in the Hippocampus, Subiculum, Entorhinal Cortex and Superior Temporal Gyrus in Alzheimer’s Disease", "doi": "10.3389/fncel.2021.702824", "year": 2021 } ] } }, { "id": 29592, "drug": "valproic acid", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "suppresses", "mediator": "galectin-3", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "inflammatory bowel diseases", "outcome_type": "disease", "outcome_domain": "inflammatory_bowel_disease", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "valproic acid", "mediator_canonical": "LGALS3", "outcome_canonical": "inflammatory bowel diseases", "ab_count": 1, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "34122007", "title": "Post-stroke Delivery of Valproic Acid Promotes Functional Recovery and Differentially Modifies Responses of Peri-Infarct Microglia", "doi": "10.3389/fnmol.2021.639145", "year": 2021 } ], "bc": [ { "pmid": "31929564", "title": "Serum galectins as potential biomarkers of inflammatory bowel diseases", "doi": "10.1371/journal.pone.0227306", "year": 2020 } ] } }, { "id": 29553, "drug": "valproate", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "downregulates", "mediator": "COX-2", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "inflammatory bowel disease and low grade alimentary lymphoma", "outcome_type": "disease", "outcome_domain": "inflammatory_bowel_disease", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "valproic acid", "mediator_canonical": "cox-2", "outcome_canonical": "inflammatory bowel disease and low grade alimentary lymphoma", "ab_count": 1, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "32054883", "title": "Downregulation of peripheral PTGS2/COX-2 in response to valproate treatment in patients with epilepsy", "doi": "10.1038/s41598-020-59259-x", "year": 2020 } ], "bc": [ { "pmid": "29764431", "title": "Cyclooxygenase-2 immunoexpression in intestinal epithelium and lamina propria of cats with inflammatory bowel disease and low grade alimentary lymphoma", "doi": "10.1186/s12917-018-1486-0", "year": 2018 } ] } }, { "id": 7276, "drug": "Baicalin", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "upregulates", "mediator": "BDNF", "mediator_type": "protein", "predicate_bc": "decreases", "outcome": "bipolar disorder", "outcome_type": "disease", "outcome_domain": "depression", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "baicalin", "mediator_canonical": "BDNF", "outcome_canonical": "bipolar disorder", "ab_count": 1, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "38778616", "title": "Exploring the Therapeutic Potential of Baicalin: Mitigating Anxiety and Depression in Epileptic Rats", "doi": "10.2174/0113862073316021240520110301", "year": 2024 } ], "bc": [ { "pmid": "36700317", "title": "Brain-derived Neurotrophic Factor and High Sensitive C-reactive Protein in Bipolar Depression and Unipolar Depression: The Practical Usage as a Discriminatory Tool", "doi": "10.9758/cpn.2023.21.1.108", "year": 2023 } ] } }, { "id": 33008, "drug": "metformin", "drug_type": "drug", "drug_domain": "inflammatory_bowel_disease", "predicate_ab": "downregulates", "mediator": "IL-17", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "idiopathic epilepsy", "outcome_type": "disease", "outcome_domain": "epilepsy", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "metformin", "mediator_canonical": "il-17", "outcome_canonical": "idiopathic epilepsy", "ab_count": 2, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "32654569", "title": "Metformin alleviates experimental colitis in mice by up-regulating TGF-β signaling", "doi": "10.1080/10520295.2020.1776896", "year": 2020 }, { "pmid": "26360050", "title": "Metformin Ameliorates Inflammatory Bowel Disease by Suppression of the STAT3 Signaling Pathway and Regulation of the between Th17/Treg Balance", "doi": "10.1371/journal.pone.0135858", "year": 2015 } ], "bc": [ { "pmid": "35025939", "title": "Th17 cell-mediated immune response in a subpopulation of dogs with idiopathic epilepsy", "doi": "10.1371/journal.pone.0262285", "year": 2022 } ] } }, { "id": 30185, "drug": "valproic acid", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "upregulates", "mediator": "NF-κB signaling pathway", "mediator_type": "pathway", "predicate_bc": "associated_with", "outcome": "rheumatoid arthritis", "outcome_type": "disease", "outcome_domain": "rheumatoid_arthritis", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "valproic acid", "mediator_canonical": "nf-κb signaling pathway", "outcome_canonical": "rheumatoid arthritis", "ab_count": 1, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "39622390", "title": "Lipopolysaccharide induces neuroinflammation in a valproic acid male model of autism", "doi": "10.1016/j.brainresbull.2024.111154", "year": 2024 } ], "bc": [ { "pmid": "37012872", "title": "Inhibition of NEMO alleviates arthritis by blocking the M1 macrophage polarization", "doi": "10.1016/j.intimp.2023.109983", "year": 2023 }, { "pmid": "36687056", "title": "Core Constituents of Caragana sinica Root for Rheumatoid Arthritis Treatment and the Potential Mechanism", "doi": "10.1021/acsomega.2c07094", "year": 2023 } ] } }, { "id": 7284, "drug": "Baicalin", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "upregulates", "mediator": "BDNF", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "depression severity", "outcome_type": "phenotype", "outcome_domain": "depression", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "baicalin", "mediator_canonical": "BDNF", "outcome_canonical": "depression severity", "ab_count": 1, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "38778616", "title": "Exploring the Therapeutic Potential of Baicalin: Mitigating Anxiety and Depression in Epileptic Rats", "doi": "10.2174/0113862073316021240520110301", "year": 2024 } ], "bc": [ { "pmid": "34841285", "title": "The ratio and interaction between neurotrophin and immune signaling during electroconvulsive therapy in late-life depression", "doi": "10.1016/j.bbih.2021.100389", "year": 2021 }, { "pmid": "29614706", "title": "Yoga- and meditation-based lifestyle intervention increases neuroplasticity and reduces severity of major depressive disorder: A randomized controlled trial", "doi": "10.3233/rnn-170810", "year": 2018 } ] } }, { "id": 30379, "drug": "valproic acid", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "suppresses", "mediator": "galectin-3", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "cardiovascular events", "outcome_type": "disease", "outcome_domain": "type_2_diabetes", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "valproic acid", "mediator_canonical": "LGALS3", "outcome_canonical": "cardiovascular events", "ab_count": 1, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "34122007", "title": "Post-stroke Delivery of Valproic Acid Promotes Functional Recovery and Differentially Modifies Responses of Peri-Infarct Microglia", "doi": "10.3389/fnmol.2021.639145", "year": 2021 } ], "bc": [ { "pmid": "30378236", "title": "Galectin‐3 and risk of cardiovascular events and all‐cause mortality in type 2 diabetes", "doi": "10.1002/dmrr.3093", "year": 2018 } ] } }, { "id": 30344, "drug": "valproic acid", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "suppresses", "mediator": "galectin-3", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "all-cause mortality", "outcome_type": "phenotype", "outcome_domain": "type_2_diabetes", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "valproic acid", "mediator_canonical": "LGALS3", "outcome_canonical": "all-cause mortality", "ab_count": 1, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "34122007", "title": "Post-stroke Delivery of Valproic Acid Promotes Functional Recovery and Differentially Modifies Responses of Peri-Infarct Microglia", "doi": "10.3389/fnmol.2021.639145", "year": 2021 } ], "bc": [ { "pmid": "30378236", "title": "Galectin‐3 and risk of cardiovascular events and all‐cause mortality in type 2 diabetes", "doi": "10.1002/dmrr.3093", "year": 2018 } ] } }, { "id": 38390, "drug": "Auranofin", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "activates", "mediator": "Caspase-3", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "drug-resistant epilepsy", "outcome_type": "disease", "outcome_domain": "epilepsy", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "auranofin", "mediator_canonical": "CASP3", "outcome_canonical": "drug-resistant epilepsy", "ab_count": 2, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "36014444", "title": "Anti-Cancer Effects of Auranofin in Human Lung Cancer Cells by Increasing Intracellular ROS Levels and Depleting GSH Levels", "doi": "10.3390/molecules27165207", "year": 2022 }, { "pmid": "33125149", "title": "Auranofin inhibits the proliferation of lung cancer cells via necrosis and caspase‑dependent apoptosis", "doi": "10.3892/or.2020.7818", "year": 2020 } ], "bc": [ { "pmid": "37833937", "title": "Expression of Cytoskeletal Proteins (GFAP, Vimentin), Proapoptotic Protein (Caspase-3) and Protective Protein (S100) in the Epileptic Focus in Adults and Children with Drug-Resistant Temporal Lobe Epilepsy Associated with Focal Cortical Dysplasia", "doi": "10.3390/ijms241914490", "year": 2023 } ] } }, { "id": 346, "drug": "valproic acid", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "suppresses", "mediator": "NRF2", "mediator_type": "gene", "predicate_bc": "correlates_with", "outcome": "patient survival", "outcome_type": "phenotype", "outcome_domain": "glioblastoma", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "completed", "clinical_trial_nct_ids": [ "NCT02446652" ], "literature_status": "reproduces_known", "drug_canonical": "valproic acid", "mediator_canonical": "NRF2", "outcome_canonical": "patient survival", "ab_count": 2, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "34050116", "title": "Chronic valproic acid administration enhances oxidative stress, upregulates IL6 and downregulates Nrf2, Glut1 and Glut4 in rat’s liver and brain", "doi": "10.1097/wnr.0000000000001663", "year": 2021 }, { "pmid": "34686779", "title": "Valproic acid disables the Nrf2 anti-oxidant response in acute myeloid leukaemia cells enhancing reactive oxygen species-mediated killing", "doi": "10.1038/s41416-021-01570-z", "year": 2021 } ], "bc": [ { "pmid": "33271924", "title": "Revealing Temozolomide Resistance Mechanisms via Genome-Wide CRISPR Libraries", "doi": "10.3390/cells9122573", "year": 2020 } ] } }, { "id": 8781, "drug": "curcumin", "drug_type": "drug", "drug_domain": "alzheimer", "predicate_ab": "upregulates", "mediator": "BDNF", "mediator_type": "protein", "predicate_bc": "decreases", "outcome": "seizure frequency", "outcome_type": "phenotype", "outcome_domain": "epilepsy", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "curcumin", "mediator_canonical": "BDNF", "outcome_canonical": "seizure frequency", "ab_count": 1, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "38791161", "title": "Curcumin Improves Neurogenesis in Alzheimer’s Disease Mice via the Upregulation of Wnt/β-Catenin and BDNF", "doi": "10.3390/ijms25105123", "year": 2024 } ], "bc": [ { "pmid": "38203674", "title": "Concordance between the In Vivo Content of Neurospecific Proteins (BDNF, NSE, VILIP-1, S100B) in the Hippocampus and Blood in Patients with Epilepsy", "doi": "10.3390/ijms25010502", "year": 2023 }, { "pmid": "29766029", "title": "Seizure-Suppressant and Neuroprotective Effects of Encapsulated BDNF-Producing Cells in a Rat Model of Temporal Lobe Epilepsy", "doi": "10.1016/j.omtm.2018.03.001", "year": 2018 } ] } }, { "id": 17448, "drug": "apigenin", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "upregulates", "mediator": "GFAP", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "EDSS", "outcome_type": "phenotype", "outcome_domain": "multiple_sclerosis", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "apigenin", "mediator_canonical": "GFAP", "outcome_canonical": "edss", "ab_count": 1, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41090780", "title": "Apigenin Induces Autophagy and Apoptosis in Chemoresistant Glioblastoma Cells and Inhibits Tumorigenicity Associated with Regulation of Immunomodulatory Proteins and Glial Cells Response", "doi": "10.3390/cells14191552", "year": 2025 } ], "bc": [ { "pmid": "32495489", "title": "Clinical implication of serum biomarkers and patient age in inflammatory demyelinating diseases", "doi": "10.1002/acn3.51070", "year": 2020 } ] } }, { "id": 6738, "drug": "metformin", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "upregulates", "mediator": "α-synuclein", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "neurodegenerative diseases", "outcome_type": "disease", "outcome_domain": "als", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "active", "clinical_trial_nct_ids": [ "NCT03757910", "NCT05768139", "NCT05532813" ], "literature_status": "reproduces_known", "drug_canonical": "metformin", "mediator_canonical": "SNCA", "outcome_canonical": null, "ab_count": 1, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "30308130", "title": "Effects of metformin on apoptosis and α-synuclein in a rat model of pentylenetetrazole-induced epilepsy", "doi": "10.1139/cjpp-2018-0266", "year": 2018 } ], "bc": [ { "pmid": "40960157", "title": "Protein aggregation in neurodegenerative diseases", "doi": "10.1097/cm9.0000000000003802", "year": 2025 }, { "pmid": "38382884", "title": "The potential roles of salivary biomarkers in neurodegenerative diseases", "doi": "10.1016/j.nbd.2024.106442", "year": 2024 } ] } }, { "id": 6737, "drug": "metformin", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "upregulates", "mediator": "α-synuclein", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "multiple system atrophy", "outcome_type": "disease", "outcome_domain": "als", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "metformin", "mediator_canonical": "SNCA", "outcome_canonical": "multiple system atrophy", "ab_count": 1, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "30308130", "title": "Effects of metformin on apoptosis and α-synuclein in a rat model of pentylenetetrazole-induced epilepsy", "doi": "10.1139/cjpp-2018-0266", "year": 2018 } ], "bc": [ { "pmid": "35746899", "title": "A pathologically confirmed case of combined amyotrophic lateral sclerosis with C9orf72 mutation and multiple system atrophy", "doi": "10.1111/neup.12808", "year": 2022 }, { "pmid": "26705184", "title": "[Histopathological and immunohistochemical study of spinal cord tissues in neurodegenerative diseases].", "doi": null, "year": 2015 } ] } }, { "id": 2107, "drug": "valproic acid", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "upregulates", "mediator": "mTOR signaling", "mediator_type": "pathway", "predicate_bc": "decreases", "outcome": "VAP(P58S) aggregation", "outcome_type": "phenotype", "outcome_domain": "als", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "valproic acid", "mediator_canonical": "mtor signaling", "outcome_canonical": "vap(p58s) aggregation", "ab_count": 2, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "33809910", "title": "Alterations in Tau Protein Level and Phosphorylation State in the Brain of the Autistic-Like Rats Induced by Prenatal Exposure to Valproic Acid", "doi": "10.3390/ijms22063209", "year": 2021 }, { "pmid": "31551670", "title": "Valproic Acid Enhances Reprogramming Efficiency and Neuronal Differentiation on Small Molecules Staged-Induction Neural Stem Cells: Suggested Role of mTOR Signaling", "doi": "10.3389/fnins.2019.00867", "year": 2019 } ], "bc": [ { "pmid": "30635270", "title": "SOD1 activity threshold and TOR signalling modulate VAP(P58S) aggregation via ROS-induced proteasomal degradation in a Drosophila model of Amyotrophic Lateral Sclerosis", "doi": "10.1242/dmm.033803", "year": 2019 } ] } }, { "id": 6255, "drug": "cisplatin", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "upregulates", "mediator": "PD-L1", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "poor differentiation", "outcome_type": "phenotype", "outcome_domain": "pancreatic_cancer", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "cisplatin", "mediator_canonical": "PD-L1", "outcome_canonical": null, "ab_count": 1, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "39810130", "title": "Engineered biomimetic cisplatin-polyphenol nanocomplex for chemo-immunotherapy of glioblastoma by inducing pyroptosis", "doi": "10.1186/s12951-025-03091-w", "year": 2025 } ], "bc": [ { "pmid": "35624419", "title": "Clinical significance and correlation of PD-L1, B7-H3, B7-H4, and TILs in pancreatic cancer", "doi": "10.1186/s12885-022-09639-5", "year": 2022 }, { "pmid": "28030840", "title": "Prognostic value and clinicopathological features of PD-1/PD-L1 expression with mismatch repair status and desmoplastic stroma in Chinese patients with pancreatic cancer", "doi": "10.18632/oncotarget.14069", "year": 2016 } ] } }, { "id": 50514, "drug": "resveratrol", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "upregulates", "mediator": "SIRT1", "mediator_type": "gene", "predicate_bc": "associated_with", "outcome": "Parkinson's disease", "outcome_type": "disease", "outcome_domain": "alzheimer", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 2, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "35081907", "title": "Resveratrol ameliorates myocardial fibrosis by regulating Sirt1/Smad3 deacetylation pathway in rat model with dilated cardiomyopathy", "doi": "10.1186/s12872-021-02401-y", "year": 2022 }, { "pmid": "26638758", "title": "Iron-overload injury and cardiomyopathy in acquired and genetic models is attenuated by resveratrol therapy", "doi": "10.1038/srep18132", "year": 2015 } ], "bc": [ { "pmid": "31366155", "title": "Evaluation of the Common Molecular Basis in Alzheimer’s and Parkinson’s Diseases", "doi": "10.3390/ijms20153730", "year": 2019 } ] } }, { "id": 50523, "drug": "haloperidol", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "downregulates", "mediator": "Sigma-1 receptor", "mediator_type": "protein", "predicate_bc": "treats", "outcome": "Alzheimer's disease", "outcome_type": "disease", "outcome_domain": "alzheimer", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 2, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "27435383", "title": "Haloperidol aggravates transverse aortic constriction-induced heart failure via mitochondrial dysfunction", "doi": "10.1016/j.jphs.2016.05.012", "year": 2016 } ], "bc": [ { "pmid": "41488323", "title": "Sigma receptors and mitochondria-associated ER membranes are converging therapeutic targets for Alzheimer’s disease", "doi": "10.3389/fnins.2025.1733659", "year": 2025 } ] } }, { "id": 50595, "drug": "resveratrol", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "upregulates", "mediator": "SIRT1", "mediator_type": "gene", "predicate_bc": "increases", "outcome": "depressive symptoms", "outcome_type": "phenotype", "outcome_domain": "depression", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 2, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "35081907", "title": "Resveratrol ameliorates myocardial fibrosis by regulating Sirt1/Smad3 deacetylation pathway in rat model with dilated cardiomyopathy", "doi": "10.1186/s12872-021-02401-y", "year": 2022 }, { "pmid": "26638758", "title": "Iron-overload injury and cardiomyopathy in acquired and genetic models is attenuated by resveratrol therapy", "doi": "10.1038/srep18132", "year": 2015 } ], "bc": [ { "pmid": "32849821", "title": "A Comprehensive Analysis of the Effect of SIRT1 Variation on the Risk of Schizophrenia and Depressive Symptoms", "doi": "10.3389/fgene.2020.00832", "year": 2020 } ] } }, { "id": 50597, "drug": "luteolin", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "suppresses", "mediator": "JNK", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "social cognition performance", "outcome_type": "phenotype", "outcome_domain": "depression", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 2, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "36852907", "title": "The protection of luteolin against diabetic cardiomyopathy in rats is related to reversing JNK-suppressed autophagy", "doi": "10.1039/d2fo03871d", "year": 2023 }, { "pmid": "26327560", "title": "A Food-Derived Flavonoid Luteolin Protects against Angiotensin II-Induced Cardiac Remodeling", "doi": "10.1371/journal.pone.0137106", "year": 2015 } ], "bc": [ { "pmid": "41786038", "title": "Associations between social cognition and inflammatory markers in eating disorders and borderline personality disorder", "doi": "10.1016/j.sjpmh.2026.02.003", "year": 2026 } ] } }, { "id": 51626, "drug": "resveratrol", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "upregulates", "mediator": "SIRT1", "mediator_type": "gene", "predicate_bc": "increases", "outcome": "cell growth", "outcome_type": "phenotype", "outcome_domain": "pancreatic_cancer", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 2, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "35081907", "title": "Resveratrol ameliorates myocardial fibrosis by regulating Sirt1/Smad3 deacetylation pathway in rat model with dilated cardiomyopathy", "doi": "10.1186/s12872-021-02401-y", "year": 2022 }, { "pmid": "26638758", "title": "Iron-overload injury and cardiomyopathy in acquired and genetic models is attenuated by resveratrol therapy", "doi": "10.1038/srep18132", "year": 2015 } ], "bc": [ { "pmid": "27170223", "title": "SIRT 1 Overexpression is Associated with Metastasis of Pancreatic Ductal Adenocarcinoma (PDAC) and Promotes Migration and Growth of PDAC Cells", "doi": "10.12659/msm.896697", "year": 2016 } ] } }, { "id": 51649, "drug": "luteolin", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "upregulates", "mediator": "Nrf2", "mediator_type": "protein", "predicate_bc": "causes", "outcome": "chemoresistance", "outcome_type": "phenotype", "outcome_domain": "pancreatic_cancer", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "31089405", "title": "Luteolin Attenuates Cardiac Ischemia/Reperfusion Injury in Diabetic Rats by Modulating Nrf2 Antioxidative Function", "doi": "10.1155/2019/2719252", "year": 2019 } ], "bc": [ { "pmid": "31911550", "title": "Undermining Glutaminolysis Bolsters Chemotherapy While NRF2 Promotes Chemoresistance in KRAS-Driven Pancreatic Cancers", "doi": "10.1158/0008-5472.can-19-1363", "year": 2020 }, { "pmid": "30735911", "title": "Digoxin sensitizes gemcitabine-resistant pancreatic cancer cells to gemcitabine via inhibiting Nrf2 signaling pathway", "doi": "10.1016/j.redox.2019.101131", "year": 2019 } ] } }, { "id": 51664, "drug": "resveratrol", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "inhibits", "mediator": "Akt", "mediator_type": "protein", "predicate_bc": "decreases", "outcome": "spheroid formation", "outcome_type": "phenotype", "outcome_domain": "pancreatic_cancer", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 2, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "31655498", "title": "Resveratrol Attenuates Pressure Overload‐Induced Cardiac Fibrosis and Diastolic Dysfunction via PTEN/AKT/Smad2/3 and NF‐κB Signaling Pathways", "doi": "10.1002/mnfr.201900418", "year": 2019 }, { "pmid": "28678055", "title": "Resveratrol Ameliorates Cardiac Dysfunction by Inhibiting Apoptosis via the PI3K/Akt/FoxO3a Pathway in a Rat Model of Diabetic Cardiomyopathy", "doi": "10.1097/fjc.0000000000000504", "year": 2017 } ], "bc": [ { "pmid": "32457900", "title": "An FGFR/AKT/SOX2 Signaling Axis Controls Pancreatic Cancer Stemness", "doi": "10.3389/fcell.2020.00287", "year": 2020 } ] } }, { "id": 51673, "drug": "erlotinib", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "inhibits", "mediator": "EGFR", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "pancreatic adenocarcinoma", "outcome_type": "disease", "outcome_domain": "pancreatic_cancer", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "31277074", "title": "Inhibition of EGFR-STAT3 attenuates cardiomyopathy in streptozotocin-induced type 1 diabetes", "doi": "10.1530/joe-19-0058", "year": 2019 } ], "bc": [ { "pmid": "37370756", "title": "Anoikis-Related Gene Signature for Prognostication of Pancreatic Adenocarcinoma: A Multi-Omics Exploration and Verification Study", "doi": "10.3390/cancers15123146", "year": 2023 }, { "pmid": "27130234", "title": "Selecting Tumor-Specific Molecular Targets in Pancreatic Adenocarcinoma: Paving the Way for Image-Guided Pancreatic Surgery", "doi": "10.1007/s11307-016-0959-4", "year": 2016 } ] } }, { "id": 51678, "drug": "luteolin", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "suppresses", "mediator": "JNK", "mediator_type": "protein", "predicate_bc": "causes", "outcome": "pancreatic tumor development", "outcome_type": "disease", "outcome_domain": "pancreatic_cancer", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 2, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "36852907", "title": "The protection of luteolin against diabetic cardiomyopathy in rats is related to reversing JNK-suppressed autophagy", "doi": "10.1039/d2fo03871d", "year": 2023 }, { "pmid": "26327560", "title": "A Food-Derived Flavonoid Luteolin Protects against Angiotensin II-Induced Cardiac Remodeling", "doi": "10.1371/journal.pone.0137106", "year": 2015 } ], "bc": [ { "pmid": "28837246", "title": "c‐Jun N‐terminal kinase in pancreatic tumor stroma augments tumor development in mice", "doi": "10.1111/cas.13382", "year": 2017 } ] } }, { "id": 51688, "drug": "luteolin", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "suppresses", "mediator": "JNK", "mediator_type": "protein", "predicate_bc": "increases", "outcome": "tumor cell invasion", "outcome_type": "phenotype", "outcome_domain": "pancreatic_cancer", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 2, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "36852907", "title": "The protection of luteolin against diabetic cardiomyopathy in rats is related to reversing JNK-suppressed autophagy", "doi": "10.1039/d2fo03871d", "year": 2023 }, { "pmid": "26327560", "title": "A Food-Derived Flavonoid Luteolin Protects against Angiotensin II-Induced Cardiac Remodeling", "doi": "10.1371/journal.pone.0137106", "year": 2015 } ], "bc": [ { "pmid": "28837246", "title": "c‐Jun N‐terminal kinase in pancreatic tumor stroma augments tumor development in mice", "doi": "10.1111/cas.13382", "year": 2017 } ] } }, { "id": 51692, "drug": "luteolin", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "suppresses", "mediator": "TGFβ1", "mediator_type": "gene", "predicate_bc": "associated_with", "outcome": "improved survival", "outcome_type": "phenotype", "outcome_domain": "pancreatic_cancer", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 2, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "26327560", "title": "A Food-Derived Flavonoid Luteolin Protects against Angiotensin II-Induced Cardiac Remodeling", "doi": "10.1371/journal.pone.0137106", "year": 2015 } ], "bc": [ { "pmid": "27895310", "title": "TGFβ1 overexpression is associated with improved survival and low tumor cell proliferation in patients with early-stage pancreatic ductal adenocarcinoma", "doi": "10.18632/oncotarget.13533", "year": 2016 } ] } }, { "id": 2894, "drug": "niclosamide", "drug_type": "drug", "drug_domain": "als", "predicate_ab": "inhibits", "mediator": "S100A4", "mediator_type": "gene", "predicate_bc": "predicts", "outcome": "GBM prognosis", "outcome_type": "phenotype", "outcome_domain": "glioblastoma", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "niclosamide", "mediator_canonical": "s100a4", "outcome_canonical": "gbm prognosis", "ab_count": 2, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "34118929", "title": "Targeting S100A4 with niclosamide attenuates inflammatory and profibrotic pathways in models of amyotrophic lateral sclerosis", "doi": "10.1186/s12974-021-02184-1", "year": 2021 }, { "pmid": "31623154", "title": "The S100A4 Transcriptional Inhibitor Niclosamide Reduces Pro-Inflammatory and Migratory Phenotypes of Microglia: Implications for Amyotrophic Lateral Sclerosis", "doi": "10.3390/cells8101261", "year": 2019 } ], "bc": [ { "pmid": "35069135", "title": "Integrated Analysis to Obtain Potential Prognostic Signature in Glioblastoma", "doi": "10.3389/fnint.2021.717629", "year": 2022 } ] } }, { "id": 2900, "drug": "niclosamide", "drug_type": "drug", "drug_domain": "als", "predicate_ab": "inhibits", "mediator": "S100A4", "mediator_type": "gene", "predicate_bc": "predicts", "outcome": "glioblastoma", "outcome_type": "disease", "outcome_domain": "glioblastoma", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "niclosamide", "mediator_canonical": "s100a4", "outcome_canonical": "glioblastoma", "ab_count": 2, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "34118929", "title": "Targeting S100A4 with niclosamide attenuates inflammatory and profibrotic pathways in models of amyotrophic lateral sclerosis", "doi": "10.1186/s12974-021-02184-1", "year": 2021 }, { "pmid": "31623154", "title": "The S100A4 Transcriptional Inhibitor Niclosamide Reduces Pro-Inflammatory and Migratory Phenotypes of Microglia: Implications for Amyotrophic Lateral Sclerosis", "doi": "10.3390/cells8101261", "year": 2019 } ], "bc": [ { "pmid": "32510239", "title": "DNA Methylation-based Diagnostic and Prognostic Biomarkers for Glioblastoma", "doi": "10.1177/0963689720933241", "year": 2020 } ] } }, { "id": 51873, "drug": "Curcumin", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "activates", "mediator": "Nrf2", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "interstitial lung disease", "outcome_type": "disease", "outcome_domain": "rheumatoid_arthritis", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 2, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37101595", "title": "Curcumin Improves Diabetic Cardiomyopathy by Inhibiting Pyroptosis through AKT/Nrf2/ARE Pathway", "doi": "10.1155/2023/3906043", "year": 2023 }, { "pmid": "35909950", "title": "Curcumin Attenuates Ferroptosis-Induced Myocardial Injury in Diabetic Cardiomyopathy through the Nrf2 Pathway", "doi": "10.1155/2022/3159717", "year": 2022 } ], "bc": [ { "pmid": "36574898", "title": "Expression of Nrf2 protein in serum of patients with rheumatoid arthritis: A novel indicator for disease activity and disease prognosis", "doi": "10.1016/j.clinbiochem.2022.12.011", "year": 2022 } ] } }, { "id": 51893, "drug": "Curcumin", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "activates", "mediator": "Nrf2", "mediator_type": "protein", "predicate_bc": "decreases", "outcome": "efficacy of synthetic anti-rheumatic drugs", "outcome_type": "phenotype", "outcome_domain": "rheumatoid_arthritis", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 2, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37101595", "title": "Curcumin Improves Diabetic Cardiomyopathy by Inhibiting Pyroptosis through AKT/Nrf2/ARE Pathway", "doi": "10.1155/2023/3906043", "year": 2023 }, { "pmid": "35909950", "title": "Curcumin Attenuates Ferroptosis-Induced Myocardial Injury in Diabetic Cardiomyopathy through the Nrf2 Pathway", "doi": "10.1155/2022/3159717", "year": 2022 } ], "bc": [ { "pmid": "35964840", "title": "Pros and cons of NRF2 activation as adjunctive therapy in rheumatoid arthritis", "doi": "10.1016/j.freeradbiomed.2022.08.012", "year": 2022 } ] } }, { "id": 51894, "drug": "Curcumin", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "activates", "mediator": "Nrf2", "mediator_type": "protein", "predicate_bc": "decreases", "outcome": "toxicity of conventional anti-rheumatic therapies", "outcome_type": "phenotype", "outcome_domain": "rheumatoid_arthritis", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 2, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37101595", "title": "Curcumin Improves Diabetic Cardiomyopathy by Inhibiting Pyroptosis through AKT/Nrf2/ARE Pathway", "doi": "10.1155/2023/3906043", "year": 2023 }, { "pmid": "35909950", "title": "Curcumin Attenuates Ferroptosis-Induced Myocardial Injury in Diabetic Cardiomyopathy through the Nrf2 Pathway", "doi": "10.1155/2022/3159717", "year": 2022 } ], "bc": [ { "pmid": "35964840", "title": "Pros and cons of NRF2 activation as adjunctive therapy in rheumatoid arthritis", "doi": "10.1016/j.freeradbiomed.2022.08.012", "year": 2022 } ] } }, { "id": 51914, "drug": "Curcumin", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "activates", "mediator": "Nrf2", "mediator_type": "protein", "predicate_bc": "increases", "outcome": "drug efflux", "outcome_type": "phenotype", "outcome_domain": "rheumatoid_arthritis", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 2, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37101595", "title": "Curcumin Improves Diabetic Cardiomyopathy by Inhibiting Pyroptosis through AKT/Nrf2/ARE Pathway", "doi": "10.1155/2023/3906043", "year": 2023 }, { "pmid": "35909950", "title": "Curcumin Attenuates Ferroptosis-Induced Myocardial Injury in Diabetic Cardiomyopathy through the Nrf2 Pathway", "doi": "10.1155/2022/3159717", "year": 2022 } ], "bc": [ { "pmid": "35964840", "title": "Pros and cons of NRF2 activation as adjunctive therapy in rheumatoid arthritis", "doi": "10.1016/j.freeradbiomed.2022.08.012", "year": 2022 } ] } }, { "id": 51922, "drug": "resveratrol", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "suppresses", "mediator": "FOXO3a", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "disease activity", "outcome_type": "phenotype", "outcome_domain": "rheumatoid_arthritis", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "28678055", "title": "Resveratrol Ameliorates Cardiac Dysfunction by Inhibiting Apoptosis via the PI3K/Akt/FoxO3a Pathway in a Rat Model of Diabetic Cardiomyopathy", "doi": "10.1097/fjc.0000000000000504", "year": 2017 } ], "bc": [ { "pmid": "32742333", "title": "Serum COX‑2 and FOXO3a in patients with rheumatoid arthritis and correlation with disease activity", "doi": "10.3892/etm.2020.8779", "year": 2020 } ] } }, { "id": 57104, "drug": "metformin", "drug_type": "drug", "drug_domain": "pancreatic_cancer", "predicate_ab": "activates", "mediator": "AMPK", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "cardiovascular aging", "outcome_type": "phenotype", "outcome_domain": "heart_failure", "score": 0.1791759469228055, "filtered_score": 0.26876392038420827, "filter_reason": "boosted_repurposing", "outreach_score": 0.26876392038420827, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 2, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "26760500", "title": "Metformin Treatment Does Not Inhibit Growth of Pancreatic Cancer Patient-Derived Xenografts", "doi": "10.1371/journal.pone.0147113", "year": 2016 }, { "pmid": "25688512", "title": "Rationale and protocol of the MetNET-1 trial, a prospective, single center, phase II study to evaluate the activity and safety of everolimus in combination with octreotide LAR and metformin in patients with advanced pancreatic neuroendocrine tumors.", "doi": "10.1700/1778.19298", "year": 2015 } ], "bc": [ { "pmid": "41194190", "title": "Cellular senescence and cell therapy in cardiovascular diseases", "doi": "10.1186/s13287-025-04731-6", "year": 2025 } ] } }, { "id": 32320, "drug": "6-TG", "drug_type": "drug", "drug_domain": "inflammatory_bowel_disease", "predicate_ab": "downregulates", "mediator": "SOD1", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "ALS", "outcome_type": "disease", "outcome_domain": "als", "score": 0.26390573296152586, "filtered_score": 0.26390573296152586, "filter_reason": null, "outreach_score": 0.26390573296152586, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "6-tg", "mediator_canonical": "SOD1", "outcome_canonical": "amyotrophic lateral sclerosis", "ab_count": 1, "bc_count": 6, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "25873760", "title": "Thiopurines Induce Oxidative Stress in T‐Lymphocytes: A Proteomic Approach", "doi": "10.1155/2015/434825", "year": 2015 } ], "bc": [ { "pmid": "41570741", "title": "ALS-related proteinopathies: From TDP-43 to mitochondrial proteinopathies", "doi": "10.1016/j.conb.2025.103163", "year": 2026 }, { "pmid": "33825682", "title": "The metal cofactor zinc and interacting membranes modulate SOD1 conformation-aggregation landscape in an in vitro ALS model", "doi": "10.7554/elife.61453", "year": 2021 }, { "pmid": "30872628", "title": "Combined Tissue-Fluid Proteomics to Unravel Phenotypic Variability in Amyotrophic Lateral Sclerosis", "doi": "10.1038/s41598-019-40632-4", "year": 2019 } ] } }, { "id": 32321, "drug": "HFE", "drug_type": "drug", "drug_domain": "inflammatory_bowel_disease", "predicate_ab": "upregulates", "mediator": "SOD1", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "ALS", "outcome_type": "disease", "outcome_domain": "als", "score": 0.26390573296152586, "filtered_score": 0.26390573296152586, "filter_reason": null, "outreach_score": 0.26390573296152586, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "hfe", "mediator_canonical": "SOD1", "outcome_canonical": "amyotrophic lateral sclerosis", "ab_count": 1, "bc_count": 6, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "33413490", "title": "Hawthorn fruit extract reduced trimethylamine-N-oxide (TMAO)-exacerbated atherogenesis in mice via anti-inflammation and anti-oxidation", "doi": "10.1186/s12986-020-00535-y", "year": 2021 } ], "bc": [ { "pmid": "41570741", "title": "ALS-related proteinopathies: From TDP-43 to mitochondrial proteinopathies", "doi": "10.1016/j.conb.2025.103163", "year": 2026 }, { "pmid": "33825682", "title": "The metal cofactor zinc and interacting membranes modulate SOD1 conformation-aggregation landscape in an in vitro ALS model", "doi": "10.7554/elife.61453", "year": 2021 }, { "pmid": "30872628", "title": "Combined Tissue-Fluid Proteomics to Unravel Phenotypic Variability in Amyotrophic Lateral Sclerosis", "doi": "10.1038/s41598-019-40632-4", "year": 2019 } ] } }, { "id": 32117, "drug": "Arsenicum album", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "downregulates", "mediator": "branched-chain amino acids", "mediator_type": "biomarker", "predicate_bc": "associated_with", "outcome": "type 2 diabetes", "outcome_type": "disease", "outcome_domain": "type_2_diabetes", "score": 0.26390573296152586, "filtered_score": 0.26390573296152586, "filter_reason": null, "outreach_score": 0.26390573296152586, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "arsenicum album", "mediator_canonical": "branched-chain amino acids", "outcome_canonical": "type 2 diabetes", "ab_count": 1, "bc_count": 6, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41660917", "title": "Arsenic-Based Homeopathic Preparations Induce Metabolic Disruption and Reactive Oxygen Species-Mediated Cell Death in Glioblastoma Multiforme", "doi": "10.31557/apjcp.2026.27.2.589", "year": 2026 } ], "bc": [ { "pmid": "35998626", "title": "Amino acids, microbiota-related metabolites, and the risk of incident diabetes among normoglycemic Chinese adults: Findings from the 4C study", "doi": "10.1016/j.xcrm.2022.100727", "year": 2022 }, { "pmid": "34848488", "title": "Circulating Metabolites and the Development of Type 2 Diabetes in Chinese Adults", "doi": "10.2337/dc21-1415", "year": 2021 }, { "pmid": "33395372", "title": "Metabolic features of adiposity and glucose homoeostasis among school-aged inuit children from Nunavik (Northern Quebec, Canada)", "doi": "10.1080/22423982.2020.1858605", "year": 2021 } ] } }, { "id": 40784, "drug": "SGLT2 inhibitors", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "inhibits", "mediator": "SGLT2", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "prostate adenocarcinoma", "outcome_type": "disease", "outcome_domain": "pancreatic_cancer", "score": 0.26390573296152586, "filtered_score": 0.26390573296152586, "filter_reason": null, "outreach_score": 0.26390573296152586, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "sglt2 inhibitors", "mediator_canonical": "sglt2", "outcome_canonical": "prostate adenocarcinoma", "ab_count": 6, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "38262151", "title": "Safety assessment of the SGLT2 inhibitors empagliflozin, dapagliflozin and canagliflozin during pregnancy: An ex vivo human placenta perfusion and in vitro study", "doi": "10.1016/j.biopha.2024.116177", "year": 2024 }, { "pmid": "35419546", "title": "SGLT2 Inhibitors: Physiology and Pharmacology", "doi": "10.34067/kid.0002772021", "year": 2021 }, { "pmid": "31110116", "title": "SGLT Inhibitors for Type 1 Diabetes: Proceed With Extreme Caution", "doi": "10.2337/dci19-0008", "year": 2019 } ], "bc": [ { "pmid": "26170283", "title": "Functional expression of sodium-glucose transporters in cancer", "doi": "10.1073/pnas.1511698112", "year": 2015 } ] } }, { "id": 60990, "drug": "SGLT2 inhibitors", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "inhibits", "mediator": "SGLT2", "mediator_type": "protein", "predicate_bc": "causes", "outcome": "eNOS-NO/ROS imbalance", "outcome_type": "phenotype", "outcome_domain": "heart_failure", "score": 0.26390573296152586, "filtered_score": 0.26390573296152586, "filter_reason": null, "outreach_score": 0.26390573296152586, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 6, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "38262151", "title": "Safety assessment of the SGLT2 inhibitors empagliflozin, dapagliflozin and canagliflozin during pregnancy: An ex vivo human placenta perfusion and in vitro study", "doi": "10.1016/j.biopha.2024.116177", "year": 2024 }, { "pmid": "35419546", "title": "SGLT2 Inhibitors: Physiology and Pharmacology", "doi": "10.34067/kid.0002772021", "year": 2021 }, { "pmid": "31110116", "title": "SGLT Inhibitors for Type 1 Diabetes: Proceed With Extreme Caution", "doi": "10.2337/dci19-0008", "year": 2019 } ], "bc": [ { "pmid": "39739876", "title": "SGLT2 expression in human vasculature and heart correlates with low-grade inflammation and causes eNOS-NO/ROS imbalance", "doi": "10.1093/cvr/cvae257", "year": 2024 } ] } }, { "id": 40783, "drug": "liraglutide", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "activates", "mediator": "Akt", "mediator_type": "protein", "predicate_bc": "increases", "outcome": "spheroid growth", "outcome_type": "phenotype", "outcome_domain": "pancreatic_cancer", "score": 0.26390573296152586, "filtered_score": 0.26390573296152586, "filter_reason": null, "outreach_score": 0.26390573296152586, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "liraglutide", "mediator_canonical": "akt", "outcome_canonical": "spheroid growth", "ab_count": 6, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "38279433", "title": "GLP-1 receptor agonist liraglutide inhibits the proliferation and migration of thyroid cancer cells", "doi": "10.14715/cmb/2023.69.14.37", "year": 2023 }, { "pmid": "35397526", "title": "Liraglutide preserves CD34+ stem cells from dysfunction Induced by high glucose exposure", "doi": "10.1186/s12933-022-01486-9", "year": 2022 }, { "pmid": "29524296", "title": "Liraglutide, a human glucagon‐like peptide‐1 analogue, stimulates AKT‐dependent survival signalling and inhibits pancreatic β‐cell apoptosis", "doi": "10.1111/jcmm.13259", "year": 2018 } ], "bc": [ { "pmid": "36408933", "title": "Crosstalk between tumor acidosis, p53 and extracellular matrix regulates pancreatic cancer aggressiveness", "doi": "10.1002/ijc.34367", "year": 2022 } ] } }, { "id": 40785, "drug": "SGLT2 inhibitors", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "inhibits", "mediator": "SGLT2", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "pancreatic adenocarcinoma", "outcome_type": "disease", "outcome_domain": "pancreatic_cancer", "score": 0.26390573296152586, "filtered_score": 0.26390573296152586, "filter_reason": null, "outreach_score": 0.26390573296152586, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "sglt2 inhibitors", "mediator_canonical": "sglt2", "outcome_canonical": "pancreatic adenocarcinoma", "ab_count": 6, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "38262151", "title": "Safety assessment of the SGLT2 inhibitors empagliflozin, dapagliflozin and canagliflozin during pregnancy: An ex vivo human placenta perfusion and in vitro study", "doi": "10.1016/j.biopha.2024.116177", "year": 2024 }, { "pmid": "35419546", "title": "SGLT2 Inhibitors: Physiology and Pharmacology", "doi": "10.34067/kid.0002772021", "year": 2021 }, { "pmid": "31110116", "title": "SGLT Inhibitors for Type 1 Diabetes: Proceed With Extreme Caution", "doi": "10.2337/dci19-0008", "year": 2019 } ], "bc": [ { "pmid": "26170283", "title": "Functional expression of sodium-glucose transporters in cancer", "doi": "10.1073/pnas.1511698112", "year": 2015 } ] } }, { "id": 40786, "drug": "liraglutide", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "activates", "mediator": "Akt", "mediator_type": "protein", "predicate_bc": "decreases", "outcome": "spheroid formation", "outcome_type": "phenotype", "outcome_domain": "pancreatic_cancer", "score": 0.26390573296152586, "filtered_score": 0.26390573296152586, "filter_reason": null, "outreach_score": 0.26390573296152586, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "liraglutide", "mediator_canonical": "akt", "outcome_canonical": "spheroid formation", "ab_count": 6, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "38279433", "title": "GLP-1 receptor agonist liraglutide inhibits the proliferation and migration of thyroid cancer cells", "doi": "10.14715/cmb/2023.69.14.37", "year": 2023 }, { "pmid": "35397526", "title": "Liraglutide preserves CD34+ stem cells from dysfunction Induced by high glucose exposure", "doi": "10.1186/s12933-022-01486-9", "year": 2022 }, { "pmid": "29524296", "title": "Liraglutide, a human glucagon‐like peptide‐1 analogue, stimulates AKT‐dependent survival signalling and inhibits pancreatic β‐cell apoptosis", "doi": "10.1111/jcmm.13259", "year": 2018 } ], "bc": [ { "pmid": "32457900", "title": "An FGFR/AKT/SOX2 Signaling Axis Controls Pancreatic Cancer Stemness", "doi": "10.3389/fcell.2020.00287", "year": 2020 } ] } }, { "id": 60991, "drug": "liraglutide", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "activates", "mediator": "Akt", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "cardiovascular aging", "outcome_type": "phenotype", "outcome_domain": "heart_failure", "score": 0.26390573296152586, "filtered_score": 0.26390573296152586, "filter_reason": null, "outreach_score": 0.26390573296152586, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 6, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "38279433", "title": "GLP-1 receptor agonist liraglutide inhibits the proliferation and migration of thyroid cancer cells", "doi": "10.14715/cmb/2023.69.14.37", "year": 2023 }, { "pmid": "35397526", "title": "Liraglutide preserves CD34+ stem cells from dysfunction Induced by high glucose exposure", "doi": "10.1186/s12933-022-01486-9", "year": 2022 }, { "pmid": "29524296", "title": "Liraglutide, a human glucagon‐like peptide‐1 analogue, stimulates AKT‐dependent survival signalling and inhibits pancreatic β‐cell apoptosis", "doi": "10.1111/jcmm.13259", "year": 2018 } ], "bc": [ { "pmid": "41194190", "title": "Cellular senescence and cell therapy in cardiovascular diseases", "doi": "10.1186/s13287-025-04731-6", "year": 2025 } ] } }, { "id": 7050, "drug": "carbamazepine", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "binds_to", "mediator": "KRAS", "mediator_type": "gene", "predicate_bc": "associated_with", "outcome": "pancreatic cancer", "outcome_type": "disease", "outcome_domain": "pancreatic_cancer", "score": 0.26390573296152586, "filtered_score": 0.26390573296152586, "filter_reason": null, "outreach_score": 0.26390573296152586, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "carbamazepine", "mediator_canonical": "kras", "outcome_canonical": "pancreatic cancer", "ab_count": 1, "bc_count": 6, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "38446332", "title": "Impact of carbamazepine on SMARCA4 (BRG1) expression in colorectal cancer: modulation by KRAS mutation status", "doi": "10.1007/s10637-024-01418-2", "year": 2024 } ], "bc": [ { "pmid": "41477820", "title": "Machine learning–powered single-molecule cancer diagnosis using DNA origami tags", "doi": "10.1126/sciadv.adz8174", "year": 2026 }, { "pmid": "41386881", "title": "Transcriptomics analysis unveils the complex interplay between diabetes and hypertension in regulating renal cell carcinoma pathway followed by pancreatic metastasis", "doi": "10.1016/j.jgeb.2025.100616", "year": 2025 }, { "pmid": "41511487", "title": "Six-Color Multiplex Digital PCR Assays for Comprehensive Screening and Identification of Multiple Driver Mutations Associated with Pancreatic Carcinogenesis", "doi": "10.1093/clinchem/hvaf181", "year": 2025 } ] } }, { "id": 40379, "drug": "liraglutide", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "activates", "mediator": "Akt", "mediator_type": "protein", "predicate_bc": "causes", "outcome": "microfilament depolymerization", "outcome_type": "phenotype", "outcome_domain": "inflammatory_bowel_disease", "score": 0.26390573296152586, "filtered_score": 0.26390573296152586, "filter_reason": null, "outreach_score": 0.26390573296152586, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "liraglutide", "mediator_canonical": "akt", "outcome_canonical": "microfilament depolymerization", "ab_count": 6, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "38279433", "title": "GLP-1 receptor agonist liraglutide inhibits the proliferation and migration of thyroid cancer cells", "doi": "10.14715/cmb/2023.69.14.37", "year": 2023 }, { "pmid": "35397526", "title": "Liraglutide preserves CD34+ stem cells from dysfunction Induced by high glucose exposure", "doi": "10.1186/s12933-022-01486-9", "year": 2022 }, { "pmid": "29524296", "title": "Liraglutide, a human glucagon‐like peptide‐1 analogue, stimulates AKT‐dependent survival signalling and inhibits pancreatic β‐cell apoptosis", "doi": "10.1111/jcmm.13259", "year": 2018 } ], "bc": [ { "pmid": "33075564", "title": "Fibrinogen/AKT/Microfilament Axis Promotes Colitis by Enhancing Vascular Permeability", "doi": "10.1016/j.jcmgh.2020.10.007", "year": 2020 } ] } }, { "id": 40782, "drug": "liraglutide", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "activates", "mediator": "Akt", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "pancreatic cancer", "outcome_type": "disease", "outcome_domain": "pancreatic_cancer", "score": 0.26390573296152586, "filtered_score": 0.26390573296152586, "filter_reason": null, "outreach_score": 0.26390573296152586, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "completed", "clinical_trial_nct_ids": [ "NCT02475499" ], "literature_status": "reproduces_known", "drug_canonical": "liraglutide", "mediator_canonical": "akt", "outcome_canonical": "pancreatic cancer", "ab_count": 6, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "38279433", "title": "GLP-1 receptor agonist liraglutide inhibits the proliferation and migration of thyroid cancer cells", "doi": "10.14715/cmb/2023.69.14.37", "year": 2023 }, { "pmid": "35397526", "title": "Liraglutide preserves CD34+ stem cells from dysfunction Induced by high glucose exposure", "doi": "10.1186/s12933-022-01486-9", "year": 2022 }, { "pmid": "29524296", "title": "Liraglutide, a human glucagon‐like peptide‐1 analogue, stimulates AKT‐dependent survival signalling and inhibits pancreatic β‐cell apoptosis", "doi": "10.1111/jcmm.13259", "year": 2018 } ], "bc": [ { "pmid": "39556934", "title": "Synthesis and biological evaluation of a new class of azole urea compounds as Akt inhibitors with promising anticancer activity in pancreatic cancer models", "doi": "10.1016/j.bioorg.2024.107959", "year": 2024 } ] } }, { "id": 40378, "drug": "pioglitazone", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "upregulates", "mediator": "PPAR-γ", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "disease activity of ulcerative colitis", "outcome_type": "phenotype", "outcome_domain": "inflammatory_bowel_disease", "score": 0.26390573296152586, "filtered_score": 0.26390573296152586, "filter_reason": null, "outreach_score": 0.26390573296152586, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "pioglitazone", "mediator_canonical": "ppar-γ", "outcome_canonical": "disease activity of ulcerative colitis", "ab_count": 6, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "39738433", "title": "PPAR-γ agonist mitigates intestinal barrier dysfunction and inflammation induced by Clostridioides difficile SlpA in vitro", "doi": "10.1038/s41598-024-83815-4", "year": 2024 }, { "pmid": "34022606", "title": "Pioglitazone rescues high-fat diet-induced depression-like phenotypes and hippocampal astrocytic deficits in mice", "doi": "10.1016/j.biopha.2021.111734", "year": 2021 }, { "pmid": "34349671", "title": "Pioglitazone Ameliorates Renal Ischemia-Reperfusion Injury via Inhibition of NF-κB Activation and Inflammation in Rats", "doi": "10.3389/fphys.2021.707344", "year": 2021 } ], "bc": [ { "pmid": "26622660", "title": "Peroxisome proliferator-activated receptor-γ is downregulated in ulcerative colitis and is involved in experimental colitis-associated neoplasia", "doi": "10.3892/ol.2015.3397", "year": 2015 } ] } }, { "id": 23609, "drug": "clemastine fumarate", "drug_type": "drug", "drug_domain": "multiple_sclerosis", "predicate_ab": "inhibits", "mediator": "tau protein", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "Alzheimer's disease", "outcome_type": "disease", "outcome_domain": "alzheimer", "score": 0.26390573296152586, "filtered_score": 0.26390573296152586, "filter_reason": null, "outreach_score": 0.26390573296152586, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "clemastine fumarate", "mediator_canonical": "MAPT", "outcome_canonical": "Alzheimer disease", "ab_count": 1, "bc_count": 6, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37494840", "title": "Clemastine fumarate attenuates tauopathy and meliorates cognition in hTau mice via autophagy enhancement", "doi": "10.1016/j.intimp.2023.110649", "year": 2023 } ], "bc": [ { "pmid": "40908526", "title": "Key Elements Involved in Alzheimer's Disease Progression", "doi": "10.2174/0118715249388578250827072156", "year": 2025 }, { "pmid": "37800234", "title": "Aging Brain, Dementia and Impaired Glymphatic Pathway: Causal Relationships.", "doi": null, "year": 2023 }, { "pmid": "36168682", "title": "Potential biomarkers of early diagnosis of Alzheimer’s disease", "doi": "10.17116/jnevro20221220917", "year": 2022 } ] } }, { "id": 20903, "drug": "Polyphenols", "drug_type": "drug", "drug_domain": "alzheimer", "predicate_ab": "inhibits", "mediator": "homocysteine", "mediator_type": "biomarker", "predicate_bc": "associated_with", "outcome": "Multiple Sclerosis", "outcome_type": "disease", "outcome_domain": "multiple_sclerosis", "score": 0.26390573296152586, "filtered_score": 0.26390573296152586, "filter_reason": null, "outreach_score": 0.26390573296152586, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "polyphenols", "mediator_canonical": "homocysteine", "outcome_canonical": "multiple sclerosis", "ab_count": 1, "bc_count": 6, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "34099562", "title": "Homocysteine fibrillar assemblies display cross-talk with Alzheimer’s disease β-amyloid polypeptide", "doi": "10.1073/pnas.2017575118", "year": 2021 } ], "bc": [ { "pmid": "38648773", "title": "Association of Increased Homocysteine Levels with Impaired Folate Metabolism and Vitamin B Deficiency in Early-Onset Multiple Sclerosis", "doi": "10.1134/s0006297924030143", "year": 2024 }, { "pmid": "34816003", "title": "Homocysteine as a Predictor Tool in Multiple Sclerosis", "doi": "10.15190/d.2021.14", "year": 2021 }, { "pmid": "34387453", "title": "Homocysteine and markers of endothelial dysfunction in multiple sclerosis", "doi": "10.17116/jnevro202112107290", "year": 2021 } ] } }, { "id": 32516, "drug": "OPAHs", "drug_type": "drug", "drug_domain": "inflammatory_bowel_disease", "predicate_ab": "binds_to", "mediator": "APP", "mediator_type": "protein", "predicate_bc": "predicts", "outcome": "Alzheimer's disease", "outcome_type": "disease", "outcome_domain": "alzheimer", "score": 0.26390573296152586, "filtered_score": 0.26390573296152586, "filter_reason": null, "outreach_score": 0.26390573296152586, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "opahs", "mediator_canonical": "app", "outcome_canonical": "Alzheimer disease", "ab_count": 1, "bc_count": 6, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41038021", "title": "Exploring the mechanisms underlying effects of oxygenated polycyclic aromatic hydrocarbons exposure on inflammatory bowel disease", "doi": "10.1016/j.ecoenv.2025.119153", "year": 2025 } ], "bc": [ { "pmid": "36776048", "title": "Machine Learning Selection of Most Predictive Brain Proteins Suggests Role of Sugar Metabolism in Alzheimer’s Disease", "doi": "10.3233/jad-220683", "year": 2023 }, { "pmid": "34997052", "title": "Regulation of gene expression by the APP family in the adult cerebral cortex", "doi": "10.1038/s41598-021-04027-8", "year": 2022 }, { "pmid": "34140878", "title": "Sunday Driver Mediates Multi-Compartment Golgi Outposts Defects Induced by Amyloid Precursor Protein", "doi": "10.3389/fnins.2021.673684", "year": 2021 } ] } }, { "id": 23412, "drug": "TOL", "drug_type": "drug", "drug_domain": "multiple_sclerosis", "predicate_ab": "upregulates", "mediator": "SOD1", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "ALS", "outcome_type": "disease", "outcome_domain": "als", "score": 0.26390573296152586, "filtered_score": 0.26390573296152586, "filter_reason": null, "outreach_score": 0.26390573296152586, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "tol", "mediator_canonical": "SOD1", "outcome_canonical": "amyotrophic lateral sclerosis", "ab_count": 1, "bc_count": 6, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "32802267", "title": "Olive Leaf Polyphenols Attenuate the Clinical Course of Experimental Autoimmune Encephalomyelitis and Provide Neuroprotection by Reducing Oxidative Stress, Regulating Microglia and SIRT1, and Preserving Myelin Integrity", "doi": "10.1155/2020/6125638", "year": 2020 } ], "bc": [ { "pmid": "41570741", "title": "ALS-related proteinopathies: From TDP-43 to mitochondrial proteinopathies", "doi": "10.1016/j.conb.2025.103163", "year": 2026 }, { "pmid": "33825682", "title": "The metal cofactor zinc and interacting membranes modulate SOD1 conformation-aggregation landscape in an in vitro ALS model", "doi": "10.7554/elife.61453", "year": 2021 }, { "pmid": "30872628", "title": "Combined Tissue-Fluid Proteomics to Unravel Phenotypic Variability in Amyotrophic Lateral Sclerosis", "doi": "10.1038/s41598-019-40632-4", "year": 2019 } ] } }, { "id": 5453, "drug": "Glyphosate", "drug_type": "drug", "drug_domain": "depression", "predicate_ab": "binds_to", "mediator": "TP53", "mediator_type": "gene", "predicate_bc": "associated_with", "outcome": "pancreatic ductal adenocarcinoma", "outcome_type": "disease", "outcome_domain": "pancreatic_cancer", "score": 0.26390573296152586, "filtered_score": 0.26390573296152586, "filter_reason": null, "outreach_score": 0.26390573296152586, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "glyphosate", "mediator_canonical": "TP53", "outcome_canonical": "pancreatic ductal adenocarcinoma", "ab_count": 1, "bc_count": 6, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "38297317", "title": "Clarification of the molecular mechanisms underlying glyphosate-induced major depressive disorder: a network toxicology approach", "doi": "10.1186/s12991-024-00491-4", "year": 2024 } ], "bc": [ { "pmid": "39999309", "title": "Somatic Genomic Profiling of Pancreatic Ductal Adenocarcinomas From a Diverse Cohort of Patients", "doi": "10.1097/mpa.0000000000002408", "year": 2025 }, { "pmid": "35511415", "title": "Comprehensive molecular profiling of pancreatic ductal adenocarcinoma in FNA, biopsy, and resection specimens", "doi": "10.1002/cncy.22589", "year": 2022 }, { "pmid": "34905283", "title": "Adequacy evaluation and use of pancreatic adenocarcinoma specimens for next‐generation sequencing acquired by endoscopic ultrasound–guided FNA and FNB", "doi": "10.1002/cncy.22533", "year": 2021 } ] } }, { "id": 40170, "drug": "liraglutide", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "activates", "mediator": "Akt", "mediator_type": "protein", "predicate_bc": "causes", "outcome": "subclonal progression", "outcome_type": "phenotype", "outcome_domain": "glioblastoma", "score": 0.26390573296152586, "filtered_score": 0.26390573296152586, "filter_reason": null, "outreach_score": 0.26390573296152586, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "liraglutide", "mediator_canonical": "akt", "outcome_canonical": "subclonal progression", "ab_count": 6, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "38279433", "title": "GLP-1 receptor agonist liraglutide inhibits the proliferation and migration of thyroid cancer cells", "doi": "10.14715/cmb/2023.69.14.37", "year": 2023 }, { "pmid": "35397526", "title": "Liraglutide preserves CD34+ stem cells from dysfunction Induced by high glucose exposure", "doi": "10.1186/s12933-022-01486-9", "year": 2022 }, { "pmid": "29524296", "title": "Liraglutide, a human glucagon‐like peptide‐1 analogue, stimulates AKT‐dependent survival signalling and inhibits pancreatic β‐cell apoptosis", "doi": "10.1111/jcmm.13259", "year": 2018 } ], "bc": [ { "pmid": "36239995", "title": "A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma", "doi": "10.1158/1078-0432.ccr-22-0611", "year": 2022 } ] } }, { "id": 35476, "drug": "ofatumumab", "drug_type": "drug", "drug_domain": "multiple_sclerosis", "predicate_ab": "binds_to", "mediator": "CD20", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "CDAI", "outcome_type": "phenotype", "outcome_domain": "rheumatoid_arthritis", "score": 0.26390573296152586, "filtered_score": 0.26390573296152586, "filter_reason": null, "outreach_score": 0.26390573296152586, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "ofatumumab", "mediator_canonical": "cd20", "outcome_canonical": "cdai", "ab_count": 6, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "39917326", "title": "Real-world pharmacovigilance of ofatumumab in multiple sclerosis: a comprehensive FAERS data analysis", "doi": "10.3389/fphar.2024.1521726", "year": 2025 }, { "pmid": "40130187", "title": "Cost-Effectiveness Analysis of Ofatumumab versus Teriflunomide for Relapsing-Remitting Multiple Sclerosis: A 10-Year Markov Model", "doi": "10.2147/ceor.s503842", "year": 2025 }, { "pmid": "35233753", "title": "Population Pharmacokinetic–B Cell Modeling for Ofatumumab in Patients with Relapsing Multiple Sclerosis", "doi": "10.1007/s40263-021-00895-w", "year": 2022 } ], "bc": [ { "pmid": "31186464", "title": "General synovitis score and immunologic synovitis score reflect clinical disease activity in patients with advanced stage rheumatoid arthritis", "doi": "10.1038/s41598-019-44895-9", "year": 2019 } ] } }, { "id": 6082, "drug": "AEV01", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "upregulates", "mediator": "TP53", "mediator_type": "gene", "predicate_bc": "associated_with", "outcome": "pancreatic ductal adenocarcinoma", "outcome_type": "disease", "outcome_domain": "pancreatic_cancer", "score": 0.26390573296152586, "filtered_score": 0.26390573296152586, "filter_reason": null, "outreach_score": 0.26390573296152586, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "aev01", "mediator_canonical": "TP53", "outcome_canonical": "pancreatic ductal adenocarcinoma", "ab_count": 1, "bc_count": 6, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40011495", "title": "Anti-tumor efficacy and safety of AEV01 in preclinical glioblastoma and hepatocellular carcinoma models", "doi": "10.1038/s41598-025-89594-w", "year": 2025 } ], "bc": [ { "pmid": "39999309", "title": "Somatic Genomic Profiling of Pancreatic Ductal Adenocarcinomas From a Diverse Cohort of Patients", "doi": "10.1097/mpa.0000000000002408", "year": 2025 }, { "pmid": "35511415", "title": "Comprehensive molecular profiling of pancreatic ductal adenocarcinoma in FNA, biopsy, and resection specimens", "doi": "10.1002/cncy.22589", "year": 2022 }, { "pmid": "34905283", "title": "Adequacy evaluation and use of pancreatic adenocarcinoma specimens for next‐generation sequencing acquired by endoscopic ultrasound–guided FNA and FNB", "doi": "10.1002/cncy.22533", "year": 2021 } ] } }, { "id": 31925, "drug": "Bevacizumab", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "inhibits", "mediator": "VEGF", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "swollen joint count", "outcome_type": "phenotype", "outcome_domain": "rheumatoid_arthritis", "score": 0.24849066497880004, "filtered_score": 0.24849066497880004, "filter_reason": null, "outreach_score": 0.24849066497880004, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "bevacizumab", "mediator_canonical": "VEGF", "outcome_canonical": "swollen joint count", "ab_count": 5, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41951573", "title": "L-RNA aptamer-based CXCL12 inhibition combined with radiotherapy and bevacizumab in newly-diagnosed glioblastoma: expansion of the phase I/II GLORIA trial", "doi": "10.1038/s41467-026-71362-7", "year": 2026 }, { "pmid": "40757003", "title": "Developing Immunoniosomes (INs): Antibody and Fab conjugations of niosomal nanoparticles via UV-NBS and EDC/NHS chemistry for treating glioblastoma cells", "doi": "10.1016/j.ijpx.2025.100367", "year": 2025 }, { "pmid": "41431343", "title": "Incidence of Bevacizumab‐Associated Toxicity in Children With Low‐Grade Glioma With and Without Neurofibromatosis Type 1", "doi": "10.1002/1545-5017.70059", "year": 2025 } ], "bc": [ { "pmid": "35744097", "title": "VEGF Profile in Early Undifferentiated Arthritis Cohort", "doi": "10.3390/medicina58060833", "year": 2022 } ] } }, { "id": 40793, "drug": "dapagliflozin", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "upregulates", "mediator": "SIRT1", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "patient survival", "outcome_type": "phenotype", "outcome_domain": "pancreatic_cancer", "score": 0.24849066497880004, "filtered_score": 0.24849066497880004, "filter_reason": null, "outreach_score": 0.24849066497880004, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "preclinical_only", "clinical_trial_nct_ids": [ "NCT07272057" ], "literature_status": "partial_evidence", "drug_canonical": "dapagliflozin", "mediator_canonical": "SIRT1", "outcome_canonical": "patient survival", "ab_count": 5, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37517289", "title": "Dapagliflozin prevents oxidative stress-induced endothelial dysfunction via sirtuin 1 activation", "doi": "10.1016/j.biopha.2023.115213", "year": 2023 }, { "pmid": "38017499", "title": "SIRT1 mediates the inhibitory effect of Dapagliflozin on EndMT by inhibiting the acetylation of endothelium Notch1", "doi": "10.1186/s12933-023-02040-x", "year": 2023 }, { "pmid": "37664712", "title": "Dapagliflozin impedes endothelial cell senescence by activating the SIRT1 signaling pathway in type 2 diabetes", "doi": "10.1016/j.heliyon.2023.e19152", "year": 2023 } ], "bc": [ { "pmid": "27494892", "title": "Sirtuin 1 stimulates the proliferation and the expression of glycolysis genes in pancreatic neoplastic lesions", "doi": "10.18632/oncotarget.11013", "year": 2016 } ] } }, { "id": 33757, "drug": "Rosmarinic acid", "drug_type": "drug", "drug_domain": "inflammatory_bowel_disease", "predicate_ab": "suppresses", "mediator": "STAT3", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "prurigo nodularis", "outcome_type": "disease", "outcome_domain": "rheumatoid_arthritis", "score": 0.24849066497880004, "filtered_score": 0.24849066497880004, "filter_reason": null, "outreach_score": 0.24849066497880004, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "rosmarinic acid", "mediator_canonical": "STAT3", "outcome_canonical": "prurigo nodularis", "ab_count": 2, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "34077834", "title": "Rosmarinic acid represses colitis-associated colon cancer: A pivotal involvement of the TLR4-mediated NF-κB-STAT3 axis", "doi": "10.1016/j.neo.2021.05.002", "year": 2021 }, { "pmid": "28383063", "title": "Rosmarinic acid suppresses colonic inflammation in dextran sulphate sodium (DSS)-induced mice via dual inhibition of NF-κB and STAT3 activation", "doi": "10.1038/srep46252", "year": 2017 } ], "bc": [ { "pmid": "39912139", "title": "Translating tissue expression of STAT 1, 3 and 6 in prurigo nodularis to clinical efficacy of oral tofacitinib – A prospective single-arm investigational study", "doi": "10.25259/ijdvl_1017_2024", "year": 2025 }, { "pmid": "40162359", "title": "Successful Use of Tofacitinib in Paediatric Prurigo Nodularis: A Report of Four Cases", "doi": "10.4103/ijd.ijd_842_24", "year": 2025 }, { "pmid": "37521237", "title": "A case of recalcitrant prurigo nodularis with heightened expression of STAT 3 and STAT 6 and its dramatic response to tofacitinib", "doi": "10.4103/idoj.idoj_508_22", "year": 2023 } ] } }, { "id": 2093, "drug": "carbamazepine", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "downregulates", "mediator": "Cx43", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "ALS", "outcome_type": "disease", "outcome_domain": "als", "score": 0.24849066497880004, "filtered_score": 0.24849066497880004, "filter_reason": null, "outreach_score": 0.24849066497880004, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "carbamazepine", "mediator_canonical": "GJA1", "outcome_canonical": "amyotrophic lateral sclerosis", "ab_count": 2, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "32516974", "title": "Effects of Carbamazepine, Lacosamide and Zonisamide on Gliotransmitter Release Associated with Activated Astroglial Hemichannels", "doi": "10.3390/ph13060117", "year": 2020 }, { "pmid": "32443400", "title": "Upregulated and Hyperactivated Thalamic Connexin 43 Plays Important Roles in Pathomechanisms of Cognitive Impairment and Seizure of Autosomal Dominant Sleep-Related Hypermotor Epilepsy with S284L-Mutant α4 Subunit of Nicotinic ACh Receptor", "doi": "10.3390/ph13050099", "year": 2020 } ], "bc": [ { "pmid": "35312356", "title": "Cx43 hemichannels contribute to astrocyte-mediated toxicity in sporadic and familial ALS", "doi": "10.1073/pnas.2107391119", "year": 2022 }, { "pmid": "27083773", "title": "Connexin 43 in astrocytes contributes to motor neuron toxicity in amyotrophic lateral sclerosis", "doi": "10.1002/glia.22989", "year": 2016 } ] } }, { "id": 2094, "drug": "lacosamide", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "downregulates", "mediator": "Cx43", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "ALS", "outcome_type": "disease", "outcome_domain": "als", "score": 0.24849066497880004, "filtered_score": 0.24849066497880004, "filter_reason": null, "outreach_score": 0.24849066497880004, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "completed", "clinical_trial_nct_ids": [ "NCT03186040" ], "literature_status": "novel_signal", "drug_canonical": "lacosamide", "mediator_canonical": "GJA1", "outcome_canonical": "amyotrophic lateral sclerosis", "ab_count": 2, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "32516974", "title": "Effects of Carbamazepine, Lacosamide and Zonisamide on Gliotransmitter Release Associated with Activated Astroglial Hemichannels", "doi": "10.3390/ph13060117", "year": 2020 } ], "bc": [ { "pmid": "35312356", "title": "Cx43 hemichannels contribute to astrocyte-mediated toxicity in sporadic and familial ALS", "doi": "10.1073/pnas.2107391119", "year": 2022 }, { "pmid": "27083773", "title": "Connexin 43 in astrocytes contributes to motor neuron toxicity in amyotrophic lateral sclerosis", "doi": "10.1002/glia.22989", "year": 2016 } ] } }, { "id": 40792, "drug": "dapagliflozin", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "upregulates", "mediator": "AMPK", "mediator_type": "protein", "predicate_bc": "decreases", "outcome": "invasion", "outcome_type": "phenotype", "outcome_domain": "pancreatic_cancer", "score": 0.24849066497880004, "filtered_score": 0.24849066497880004, "filter_reason": null, "outreach_score": 0.24849066497880004, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "dapagliflozin", "mediator_canonical": "AMPK", "outcome_canonical": "invasion", "ab_count": 5, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40264429", "title": "Dapagliflozin ameliorates kidney injury following limb ischemia-reperfusion via the AMPK/SIRT1/NLRP3 pathway", "doi": "10.1080/0886022x.2025.2495111", "year": 2025 }, { "pmid": "36809274", "title": "Mapping the metabolic reprogramming induced by sodium-glucose cotransporter 2 inhibition", "doi": "10.1172/jci.insight.164296", "year": 2023 }, { "pmid": "35274762", "title": "Dapagliflozin attenuates high glucose‐induced endothelial cell apoptosis and inflammation through AMPK/SIRT1 activation", "doi": "10.1111/1440-1681.13638", "year": 2022 } ], "bc": [ { "pmid": "28783244", "title": "Loss of AMPK activation promotes the invasion and metastasis of pancreatic cancer through an HSF1‐dependent pathway", "doi": "10.1002/1878-0261.12116", "year": 2017 } ] } }, { "id": 40794, "drug": "dapagliflozin", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "upregulates", "mediator": "SIRT1", "mediator_type": "protein", "predicate_bc": "increases", "outcome": "stemness marker expression", "outcome_type": "phenotype", "outcome_domain": "pancreatic_cancer", "score": 0.24849066497880004, "filtered_score": 0.24849066497880004, "filter_reason": null, "outreach_score": 0.24849066497880004, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "dapagliflozin", "mediator_canonical": "SIRT1", "outcome_canonical": "stemness marker expression", "ab_count": 5, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37517289", "title": "Dapagliflozin prevents oxidative stress-induced endothelial dysfunction via sirtuin 1 activation", "doi": "10.1016/j.biopha.2023.115213", "year": 2023 }, { "pmid": "38017499", "title": "SIRT1 mediates the inhibitory effect of Dapagliflozin on EndMT by inhibiting the acetylation of endothelium Notch1", "doi": "10.1186/s12933-023-02040-x", "year": 2023 }, { "pmid": "37664712", "title": "Dapagliflozin impedes endothelial cell senescence by activating the SIRT1 signaling pathway in type 2 diabetes", "doi": "10.1016/j.heliyon.2023.e19152", "year": 2023 } ], "bc": [ { "pmid": "34163012", "title": "SIRT1 coordinates with the CRL4B complex to regulate pancreatic cancer stem cells to promote tumorigenesis", "doi": "10.1038/s41418-021-00821-z", "year": 2021 } ] } }, { "id": 40789, "drug": "dapagliflozin", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "upregulates", "mediator": "AMPK", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "pancreatic ductal adenocarcinoma", "outcome_type": "disease", "outcome_domain": "pancreatic_cancer", "score": 0.24849066497880004, "filtered_score": 0.24849066497880004, "filter_reason": null, "outreach_score": 0.24849066497880004, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "dapagliflozin", "mediator_canonical": "AMPK", "outcome_canonical": "pancreatic ductal adenocarcinoma", "ab_count": 5, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40264429", "title": "Dapagliflozin ameliorates kidney injury following limb ischemia-reperfusion via the AMPK/SIRT1/NLRP3 pathway", "doi": "10.1080/0886022x.2025.2495111", "year": 2025 }, { "pmid": "36809274", "title": "Mapping the metabolic reprogramming induced by sodium-glucose cotransporter 2 inhibition", "doi": "10.1172/jci.insight.164296", "year": 2023 }, { "pmid": "35274762", "title": "Dapagliflozin attenuates high glucose‐induced endothelial cell apoptosis and inflammation through AMPK/SIRT1 activation", "doi": "10.1111/1440-1681.13638", "year": 2022 } ], "bc": [ { "pmid": "38885414", "title": "A Novel AMPK Inhibitor Sensitizes Pancreatic Cancer Cells to Ferroptosis Induction", "doi": "10.1002/advs.202307695", "year": 2024 } ] } }, { "id": 211, "drug": "rapamycin", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "inhibits", "mediator": "mTOR", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "glioblastoma", "outcome_type": "disease", "outcome_domain": "glioblastoma", "score": 0.24849066497880004, "filtered_score": 0.24849066497880004, "filter_reason": null, "outreach_score": 0.24849066497880004, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "active", "clinical_trial_nct_ids": [ "NCT00800917", "NCT05773326", "NCT03522298" ], "literature_status": "reproduces_known", "drug_canonical": "sirolimus", "mediator_canonical": "mTOR", "outcome_canonical": "glioblastoma", "ab_count": 2, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "34877936", "title": "Identifying the temporal electrophysiological and molecular changes that contribute to TSC-associated epileptogenesis", "doi": "10.1172/jci.insight.150120", "year": 2021 }, { "pmid": "30816216", "title": "Suppression of Akt-mTOR pathway rescued the social behavior in Cntnap2-deficient mice", "doi": "10.1038/s41598-019-39434-5", "year": 2019 } ], "bc": [ { "pmid": "39622049", "title": "A Dual-Target and Dual-Mechanism Design Strategy by Combining Inhibition and Degradation Together", "doi": "10.1021/jacs.4c11930", "year": 2024 }, { "pmid": "33162811", "title": "Mitochondrial dysfunction contributes to Rapamycin-induced apoptosis of Human Glioblastoma Cells - A synergistic effect with Temozolomide", "doi": "10.7150/ijms.40159", "year": 2020 }, { "pmid": "30793789", "title": "The effect of the mTOR inhibitor rapamycin on glucoCEST signal in a preclinical model of glioblastoma", "doi": "10.1002/mrm.27683", "year": 2019 } ] } }, { "id": 38206, "drug": "bimekizumab", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "inhibits", "mediator": "IL-17A", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "antidepressant treatment resistance", "outcome_type": "phenotype", "outcome_domain": "depression", "score": 0.24849066497880004, "filtered_score": 0.24849066497880004, "filter_reason": null, "outreach_score": 0.24849066497880004, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "bimekizumab", "mediator_canonical": "il-17a", "outcome_canonical": "antidepressant treatment resistance", "ab_count": 5, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "39215949", "title": "Safety and Efficacy of Bimekizumab in Patients with Psoriatic Arthritis: 2-Year Results from Two Phase 3 Studies", "doi": "10.1007/s40744-024-00708-8", "year": 2024 }, { "pmid": "39620046", "title": "Impact of bimekizumab and certolizumab pegol on efficacy, safety and osteoblastic activity in radiographic axial spondyloarthritis: results from a phase IIa, multicentre, randomised, double-blind, exploratory study with PET-CT imaging", "doi": "10.1177/1759720x241293944", "year": 2024 }, { "pmid": "37808274", "title": "Safe and Effective Subcutaneous Self-Injection of Bimekizumab with Safety Syringe and Auto-Injector Devices: Results from a Multicenter, Randomized, Open-Label Study in Patients with Psoriatic Arthritis", "doi": "10.2147/ppa.s427809", "year": 2023 } ], "bc": [ { "pmid": "31793127", "title": "The cytokine IL‐17A as a marker of treatment resistance in major depressive disorder?", "doi": "10.1111/ejn.14636", "year": 2019 } ] } }, { "id": 40787, "drug": "Semaglutide", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "activates", "mediator": "GLP-1R", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "pancreatic ductal adenocarcinoma", "outcome_type": "disease", "outcome_domain": "pancreatic_cancer", "score": 0.24849066497880004, "filtered_score": 0.24849066497880004, "filter_reason": null, "outreach_score": 0.24849066497880004, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "semaglutide", "mediator_canonical": "glp-1r", "outcome_canonical": "pancreatic ductal adenocarcinoma", "ab_count": 5, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "39908200", "title": "Semaglutide Reprograms Macrophages via the GLP-1R/PPARG/ACSL1 Pathway to Suppress Papillary Thyroid Carcinoma Growth", "doi": "10.1210/clinem/dgaf053", "year": 2025 }, { "pmid": "39693407", "title": "The pharmacological basis for nonpeptide agonism of the GLP-1 receptor by orforglipron", "doi": "10.1126/scitranslmed.adp5765", "year": 2024 }, { "pmid": "36706596", "title": "Semaglutide inhibits ischemia/reperfusion-induced cardiomyocyte apoptosis through activating PKG/PKCε/ERK1/2 pathway", "doi": "10.1016/j.bbrc.2023.01.049", "year": 2023 } ], "bc": [ { "pmid": "26495786", "title": "Glucagon-Like Peptide-1 Receptor Expression in Normal and Neoplastic Human Pancreatic Tissues", "doi": "10.1097/mpa.0000000000000521", "year": 2015 } ] } }, { "id": 59053, "drug": "bimekizumab", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "inhibits", "mediator": "IL-17A", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "atrial fibrillation", "outcome_type": "disease", "outcome_domain": "heart_failure", "score": 0.24849066497880004, "filtered_score": 0.24849066497880004, "filter_reason": null, "outreach_score": 0.24849066497880004, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 5, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "39215949", "title": "Safety and Efficacy of Bimekizumab in Patients with Psoriatic Arthritis: 2-Year Results from Two Phase 3 Studies", "doi": "10.1007/s40744-024-00708-8", "year": 2024 }, { "pmid": "39620046", "title": "Impact of bimekizumab and certolizumab pegol on efficacy, safety and osteoblastic activity in radiographic axial spondyloarthritis: results from a phase IIa, multicentre, randomised, double-blind, exploratory study with PET-CT imaging", "doi": "10.1177/1759720x241293944", "year": 2024 }, { "pmid": "37808274", "title": "Safe and Effective Subcutaneous Self-Injection of Bimekizumab with Safety Syringe and Auto-Injector Devices: Results from a Multicenter, Randomized, Open-Label Study in Patients with Psoriatic Arthritis", "doi": "10.2147/ppa.s427809", "year": 2023 } ], "bc": [ { "pmid": "27198976", "title": "Elevated plasma levels of Th17-related cytokines are associated with increased risk of atrial fibrillation", "doi": "10.1038/srep26543", "year": 2016 } ] } }, { "id": 40788, "drug": "Empagliflozin", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "downregulates", "mediator": "PKM2", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "poor overall survival", "outcome_type": "phenotype", "outcome_domain": "pancreatic_cancer", "score": 0.24849066497880004, "filtered_score": 0.24849066497880004, "filter_reason": null, "outreach_score": 0.24849066497880004, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "empagliflozin", "mediator_canonical": "PKM", "outcome_canonical": "poor overall survival", "ab_count": 1, "bc_count": 5, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40237854", "title": "SGLT2 inhibitor empagliflozin ameliorates tubulointerstitial fibrosis in DKD by downregulating renal tubular PKM2", "doi": "10.1007/s00018-025-05688-8", "year": 2025 } ], "bc": [ { "pmid": "27478385", "title": "Pyruvate kinase M2 overexpression and poor prognosis in solid tumors of digestive system: evidence from 16 cohort studies", "doi": "10.2147/ott.s106508", "year": 2016 } ] } }, { "id": 38816, "drug": "bimekizumab", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "inhibits", "mediator": "IL-17A", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "intestinal homeostasis", "outcome_type": "phenotype", "outcome_domain": "multiple_sclerosis", "score": 0.24849066497880004, "filtered_score": 0.24849066497880004, "filter_reason": null, "outreach_score": 0.24849066497880004, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "bimekizumab", "mediator_canonical": "il-17a", "outcome_canonical": "intestinal homeostasis", "ab_count": 5, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "39215949", "title": "Safety and Efficacy of Bimekizumab in Patients with Psoriatic Arthritis: 2-Year Results from Two Phase 3 Studies", "doi": "10.1007/s40744-024-00708-8", "year": 2024 }, { "pmid": "39620046", "title": "Impact of bimekizumab and certolizumab pegol on efficacy, safety and osteoblastic activity in radiographic axial spondyloarthritis: results from a phase IIa, multicentre, randomised, double-blind, exploratory study with PET-CT imaging", "doi": "10.1177/1759720x241293944", "year": 2024 }, { "pmid": "37808274", "title": "Safe and Effective Subcutaneous Self-Injection of Bimekizumab with Safety Syringe and Auto-Injector Devices: Results from a Multicenter, Randomized, Open-Label Study in Patients with Psoriatic Arthritis", "doi": "10.2147/ppa.s427809", "year": 2023 } ], "bc": [ { "pmid": "33547052", "title": "IL-17 controls central nervous system autoimmunity through the intestinal microbiome", "doi": "10.1126/sciimmunol.aaz6563", "year": 2021 } ] } }, { "id": 23216, "drug": "pentamidine", "drug_type": "drug", "drug_domain": "multiple_sclerosis", "predicate_ab": "inhibits", "mediator": "S100B", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "epilepsy", "outcome_type": "disease", "outcome_domain": "epilepsy", "score": 0.24849066497880004, "filtered_score": 0.24849066497880004, "filter_reason": null, "outreach_score": 0.24849066497880004, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "pentamidine", "mediator_canonical": "s100b", "outcome_canonical": "epilepsy", "ab_count": 3, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40649727", "title": "Effect on Different Glial Cell Types of S100B Modulation in Multiple Sclerosis Experimental Models", "doi": "10.3390/ijms26135948", "year": 2025 }, { "pmid": "35620168", "title": "S100B inhibition protects from chronic experimental autoimmune encephalomyelitis", "doi": "10.1093/braincomms/fcac076", "year": 2022 }, { "pmid": "32197530", "title": "The S100B Inhibitor Pentamidine Ameliorates Clinical Score and Neuropathology of Relapsing—Remitting Multiple Sclerosis Mouse Model", "doi": "10.3390/cells9030748", "year": 2020 } ], "bc": [ { "pmid": "36766708", "title": "Blood-Brain Barrier-Associated Proteins Are Elevated in Serum of Epilepsy Patients", "doi": "10.3390/cells12030368", "year": 2023 }, { "pmid": "32857458", "title": "Blood biomarkers predictive of epilepsy after an acute stroke event", "doi": "10.1111/epi.16648", "year": 2020 } ] } }, { "id": 51752, "drug": "sulforaphane", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "activates", "mediator": "Nrf2", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "interstitial lung disease", "outcome_type": "disease", "outcome_domain": "rheumatoid_arthritis", "score": 0.24849066497880004, "filtered_score": 0.24849066497880004, "filter_reason": null, "outreach_score": 0.24849066497880004, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 5, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "33067900", "title": "Sulforaphane prevents age‐associated cardiac and muscular dysfunction through Nrf2 signaling", "doi": "10.1111/acel.13261", "year": 2020 }, { "pmid": "31270951", "title": "Protection against diabetic cardiomyopathy is achieved using a combination of sulforaphane and zinc in type 1 diabetic OVE26 mice", "doi": "10.1111/jcmm.14520", "year": 2019 }, { "pmid": "29353218", "title": "Sulforaphane prevents angiotensin II-induced cardiomyopathy by activation of Nrf2 via stimulating the Akt/GSK-3ß/Fyn pathway", "doi": "10.1016/j.redox.2017.12.016", "year": 2018 } ], "bc": [ { "pmid": "36574898", "title": "Expression of Nrf2 protein in serum of patients with rheumatoid arthritis: A novel indicator for disease activity and disease prognosis", "doi": "10.1016/j.clinbiochem.2022.12.011", "year": 2022 } ] } }, { "id": 51753, "drug": "sulforaphane", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "activates", "mediator": "Nrf2", "mediator_type": "protein", "predicate_bc": "decreases", "outcome": "efficacy of synthetic anti-rheumatic drugs", "outcome_type": "phenotype", "outcome_domain": "rheumatoid_arthritis", "score": 0.24849066497880004, "filtered_score": 0.24849066497880004, "filter_reason": null, "outreach_score": 0.24849066497880004, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 5, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "33067900", "title": "Sulforaphane prevents age‐associated cardiac and muscular dysfunction through Nrf2 signaling", "doi": "10.1111/acel.13261", "year": 2020 }, { "pmid": "31270951", "title": "Protection against diabetic cardiomyopathy is achieved using a combination of sulforaphane and zinc in type 1 diabetic OVE26 mice", "doi": "10.1111/jcmm.14520", "year": 2019 }, { "pmid": "29353218", "title": "Sulforaphane prevents angiotensin II-induced cardiomyopathy by activation of Nrf2 via stimulating the Akt/GSK-3ß/Fyn pathway", "doi": "10.1016/j.redox.2017.12.016", "year": 2018 } ], "bc": [ { "pmid": "35964840", "title": "Pros and cons of NRF2 activation as adjunctive therapy in rheumatoid arthritis", "doi": "10.1016/j.freeradbiomed.2022.08.012", "year": 2022 } ] } }, { "id": 50780, "drug": "H3 relaxin", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "activates", "mediator": "P2X7R", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "temporal lobe epilepsy", "outcome_type": "disease", "outcome_domain": "epilepsy", "score": 0.24849066497880004, "filtered_score": 0.24849066497880004, "filter_reason": null, "outreach_score": 0.24849066497880004, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 2, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "33584279", "title": "H3 Relaxin Alleviates Migration, Apoptosis and Pyroptosis Through P2X7R-Mediated Nucleotide Binding Oligomerization Domain-Like Receptor Protein 3 Inflammasome Activation in Retinopathy Induced by Hyperglycemia", "doi": "10.3389/fphar.2020.603689", "year": 2020 }, { "pmid": "29314607", "title": "H3 relaxin inhibits the collagen synthesis via ROS‐ and P2X7R‐mediated NLRP3 inflammasome activation in cardiac fibroblasts under high glucose", "doi": "10.1111/jcmm.13464", "year": 2018 } ], "bc": [ { "pmid": "36507708", "title": "Increased uptake of the P2X7 receptor radiotracer 18F‐JNJ‐64413739 in the brain and peripheral organs according to the severity of status epilepticus in male mice", "doi": "10.1111/epi.17484", "year": 2022 }, { "pmid": "34572093", "title": "Circulating P2X7 Receptor Signaling Components as Diagnostic Biomarkers for Temporal Lobe Epilepsy", "doi": "10.3390/cells10092444", "year": 2021 }, { "pmid": "31059094", "title": "Increased expression of the P2X7 receptor in temporal lobe epilepsy: Animal models and clinical evidence", "doi": "10.3892/mmr.2019.10202", "year": 2019 } ] } }, { "id": 50779, "drug": "H3 relaxin", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "activates", "mediator": "P2X7R", "mediator_type": "protein", "predicate_bc": "increases", "outcome": "seizure severity", "outcome_type": "phenotype", "outcome_domain": "epilepsy", "score": 0.24849066497880004, "filtered_score": 0.24849066497880004, "filter_reason": null, "outreach_score": 0.24849066497880004, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 2, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "33584279", "title": "H3 Relaxin Alleviates Migration, Apoptosis and Pyroptosis Through P2X7R-Mediated Nucleotide Binding Oligomerization Domain-Like Receptor Protein 3 Inflammasome Activation in Retinopathy Induced by Hyperglycemia", "doi": "10.3389/fphar.2020.603689", "year": 2020 }, { "pmid": "29314607", "title": "H3 relaxin inhibits the collagen synthesis via ROS‐ and P2X7R‐mediated NLRP3 inflammasome activation in cardiac fibroblasts under high glucose", "doi": "10.1111/jcmm.13464", "year": 2018 } ], "bc": [ { "pmid": "36637008", "title": "The P2X7 receptor contributes to seizures and inflammation‐driven long‐lasting brain hyperexcitability following hypoxia in neonatal mice", "doi": "10.1111/bph.16033", "year": 2023 }, { "pmid": "36507708", "title": "Increased uptake of the P2X7 receptor radiotracer 18F‐JNJ‐64413739 in the brain and peripheral organs according to the severity of status epilepticus in male mice", "doi": "10.1111/epi.17484", "year": 2022 } ] } }, { "id": 50778, "drug": "Empagliflozin", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "downregulates", "mediator": "HMGB1", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "epilepsy", "outcome_type": "disease", "outcome_domain": "epilepsy", "score": 0.24849066497880004, "filtered_score": 0.24849066497880004, "filter_reason": null, "outreach_score": 0.24849066497880004, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 5, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "35156391", "title": "HMGB1‐Promoted Neutrophil Extracellular Traps Contribute to Cardiac Diastolic Dysfunction in Mice", "doi": "10.1161/jaha.121.023800", "year": 2022 } ], "bc": [ { "pmid": "39466324", "title": "Clinical and biochemical assessments of circulating High Mobility Group Box Protein1 in children with epilepsy: relation to cognitive function and drug responsiveness", "doi": "10.1007/s10072-024-07795-z", "year": 2024 }, { "pmid": "32538745", "title": "Correlation of MMP-9 and HMGB1 expression with the cognitive function in patients with epilepsy and factors affecting the prognosis", "doi": "10.14715/cmb/2020.66.3.6", "year": 2020 }, { "pmid": "33150666", "title": "Evaluation of serum high-mobility group box 1 concentration in dogs with epilepsy: A case-control study", "doi": "10.1111/jvim.15940", "year": 2020 } ] } }, { "id": 50777, "drug": "DEX", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "inhibits", "mediator": "HMGB1", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "epilepsy", "outcome_type": "disease", "outcome_domain": "epilepsy", "score": 0.24849066497880004, "filtered_score": 0.24849066497880004, "filter_reason": null, "outreach_score": 0.24849066497880004, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 5, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "31344138", "title": "Dexmedetomidine-induced cardioprotection is mediated by inhibition of high mobility group box-1 and the cholinergic anti-inflammatory pathway in myocardial ischemia-reperfusion injury", "doi": "10.1371/journal.pone.0218726", "year": 2019 } ], "bc": [ { "pmid": "39466324", "title": "Clinical and biochemical assessments of circulating High Mobility Group Box Protein1 in children with epilepsy: relation to cognitive function and drug responsiveness", "doi": "10.1007/s10072-024-07795-z", "year": 2024 }, { "pmid": "32538745", "title": "Correlation of MMP-9 and HMGB1 expression with the cognitive function in patients with epilepsy and factors affecting the prognosis", "doi": "10.14715/cmb/2020.66.3.6", "year": 2020 }, { "pmid": "33150666", "title": "Evaluation of serum high-mobility group box 1 concentration in dogs with epilepsy: A case-control study", "doi": "10.1111/jvim.15940", "year": 2020 } ] } }, { "id": 50775, "drug": "salvianolic acid B", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "inhibits", "mediator": "HMGB1", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "epilepsy", "outcome_type": "disease", "outcome_domain": "epilepsy", "score": 0.24849066497880004, "filtered_score": 0.24849066497880004, "filter_reason": null, "outreach_score": 0.24849066497880004, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 5, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "31853618", "title": "Salvianolic acid B protects against myocardial ischaemia-reperfusion injury in rats via inhibiting high mobility group box 1 protein expression through the PI3K/Akt signalling pathway", "doi": "10.1007/s00210-019-01755-7", "year": 2019 } ], "bc": [ { "pmid": "39466324", "title": "Clinical and biochemical assessments of circulating High Mobility Group Box Protein1 in children with epilepsy: relation to cognitive function and drug responsiveness", "doi": "10.1007/s10072-024-07795-z", "year": 2024 }, { "pmid": "32538745", "title": "Correlation of MMP-9 and HMGB1 expression with the cognitive function in patients with epilepsy and factors affecting the prognosis", "doi": "10.14715/cmb/2020.66.3.6", "year": 2020 }, { "pmid": "33150666", "title": "Evaluation of serum high-mobility group box 1 concentration in dogs with epilepsy: A case-control study", "doi": "10.1111/jvim.15940", "year": 2020 } ] } }, { "id": 37246, "drug": "curcuminoids", "drug_type": "drug", "drug_domain": "pancreatic_cancer", "predicate_ab": "binds_to", "mediator": "STAT3", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "prurigo nodularis", "outcome_type": "disease", "outcome_domain": "rheumatoid_arthritis", "score": 0.24849066497880004, "filtered_score": 0.24849066497880004, "filter_reason": null, "outreach_score": 0.24849066497880004, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "curcuminoids", "mediator_canonical": "STAT3", "outcome_canonical": "prurigo nodularis", "ab_count": 2, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37514107", "title": "Fluorinated and N-Acryloyl-Modified 3,5-Di[(E)-benzylidene]piperidin-4-one Curcuminoids for the Treatment of Pancreatic Carcinoma", "doi": "10.3390/pharmaceutics15071921", "year": 2023 } ], "bc": [ { "pmid": "39912139", "title": "Translating tissue expression of STAT 1, 3 and 6 in prurigo nodularis to clinical efficacy of oral tofacitinib – A prospective single-arm investigational study", "doi": "10.25259/ijdvl_1017_2024", "year": 2025 }, { "pmid": "40162359", "title": "Successful Use of Tofacitinib in Paediatric Prurigo Nodularis: A Report of Four Cases", "doi": "10.4103/ijd.ijd_842_24", "year": 2025 }, { "pmid": "37521237", "title": "A case of recalcitrant prurigo nodularis with heightened expression of STAT 3 and STAT 6 and its dramatic response to tofacitinib", "doi": "10.4103/idoj.idoj_508_22", "year": 2023 } ] } }, { "id": 39010, "drug": "bimekizumab", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "inhibits", "mediator": "IL-17A", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "acinar-ductal metaplasia", "outcome_type": "phenotype", "outcome_domain": "pancreatic_cancer", "score": 0.24849066497880004, "filtered_score": 0.24849066497880004, "filter_reason": null, "outreach_score": 0.24849066497880004, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "bimekizumab", "mediator_canonical": "il-17a", "outcome_canonical": "acinar-ductal metaplasia", "ab_count": 5, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "39215949", "title": "Safety and Efficacy of Bimekizumab in Patients with Psoriatic Arthritis: 2-Year Results from Two Phase 3 Studies", "doi": "10.1007/s40744-024-00708-8", "year": 2024 }, { "pmid": "39620046", "title": "Impact of bimekizumab and certolizumab pegol on efficacy, safety and osteoblastic activity in radiographic axial spondyloarthritis: results from a phase IIa, multicentre, randomised, double-blind, exploratory study with PET-CT imaging", "doi": "10.1177/1759720x241293944", "year": 2024 }, { "pmid": "37808274", "title": "Safe and Effective Subcutaneous Self-Injection of Bimekizumab with Safety Syringe and Auto-Injector Devices: Results from a Multicenter, Randomized, Open-Label Study in Patients with Psoriatic Arthritis", "doi": "10.2147/ppa.s427809", "year": 2023 } ], "bc": [ { "pmid": "33294254", "title": "IL-17 in pancreatic disease: pathogenesis and pharmacotherapy.", "doi": null, "year": 2020 } ] } }, { "id": 39019, "drug": "bimekizumab", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "inhibits", "mediator": "IL-17A", "mediator_type": "protein", "predicate_bc": "causes", "outcome": "islet β-cell apoptosis", "outcome_type": "phenotype", "outcome_domain": "pancreatic_cancer", "score": 0.24849066497880004, "filtered_score": 0.24849066497880004, "filter_reason": null, "outreach_score": 0.24849066497880004, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "bimekizumab", "mediator_canonical": "il-17a", "outcome_canonical": "islet β-cell apoptosis", "ab_count": 5, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "39215949", "title": "Safety and Efficacy of Bimekizumab in Patients with Psoriatic Arthritis: 2-Year Results from Two Phase 3 Studies", "doi": "10.1007/s40744-024-00708-8", "year": 2024 }, { "pmid": "39620046", "title": "Impact of bimekizumab and certolizumab pegol on efficacy, safety and osteoblastic activity in radiographic axial spondyloarthritis: results from a phase IIa, multicentre, randomised, double-blind, exploratory study with PET-CT imaging", "doi": "10.1177/1759720x241293944", "year": 2024 }, { "pmid": "37808274", "title": "Safe and Effective Subcutaneous Self-Injection of Bimekizumab with Safety Syringe and Auto-Injector Devices: Results from a Multicenter, Randomized, Open-Label Study in Patients with Psoriatic Arthritis", "doi": "10.2147/ppa.s427809", "year": 2023 } ], "bc": [ { "pmid": "33294254", "title": "IL-17 in pancreatic disease: pathogenesis and pharmacotherapy.", "doi": null, "year": 2020 } ] } }, { "id": 40384, "drug": "DPP-4 inhibitors", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "binds_to", "mediator": "DPP-4", "mediator_type": "protein", "predicate_bc": "predicts", "outcome": "disease activity", "outcome_type": "phenotype", "outcome_domain": "inflammatory_bowel_disease", "score": 0.24849066497880004, "filtered_score": 0.24849066497880004, "filter_reason": null, "outreach_score": 0.24849066497880004, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "active", "clinical_trial_nct_ids": [ "NCT06827002", "NCT04161430", "NCT02043054" ], "literature_status": "novel_signal", "drug_canonical": "dpp-4 inhibitors", "mediator_canonical": "dpp-4", "outcome_canonical": "disease activity", "ab_count": 3, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "28794822", "title": "Overview of Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Patients with Type 2 Diabetes.", "doi": null, "year": 2017 }, { "pmid": "30815539", "title": "A comparative study of the binding properties, dipeptidyl peptidase‐4 (DPP‐4) inhibitory activity and glucose‐lowering efficacy of the DPP‐4 inhibitors alogliptin, linagliptin, saxagliptin, sitagliptin and vildagliptin in mice", "doi": "10.1002/edm2.2", "year": 2017 } ], "bc": [ { "pmid": "31912883", "title": "Serum Dipeptidyl Peptidase 4: A Predictor of Disease Activity and Prognosis in Inflammatory Bowel Disease", "doi": "10.1093/ibd/izz319", "year": 2020 } ] } }, { "id": 38257, "drug": "bimekizumab", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "inhibits", "mediator": "IL-17A", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "anxiety", "outcome_type": "phenotype", "outcome_domain": "epilepsy", "score": 0.24849066497880004, "filtered_score": 0.24849066497880004, "filter_reason": null, "outreach_score": 0.24849066497880004, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "bimekizumab", "mediator_canonical": "il-17a", "outcome_canonical": "anxiety", "ab_count": 5, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "39215949", "title": "Safety and Efficacy of Bimekizumab in Patients with Psoriatic Arthritis: 2-Year Results from Two Phase 3 Studies", "doi": "10.1007/s40744-024-00708-8", "year": 2024 }, { "pmid": "39620046", "title": "Impact of bimekizumab and certolizumab pegol on efficacy, safety and osteoblastic activity in radiographic axial spondyloarthritis: results from a phase IIa, multicentre, randomised, double-blind, exploratory study with PET-CT imaging", "doi": "10.1177/1759720x241293944", "year": 2024 }, { "pmid": "37808274", "title": "Safe and Effective Subcutaneous Self-Injection of Bimekizumab with Safety Syringe and Auto-Injector Devices: Results from a Multicenter, Randomized, Open-Label Study in Patients with Psoriatic Arthritis", "doi": "10.2147/ppa.s427809", "year": 2023 } ], "bc": [ { "pmid": "35875667", "title": "Interleukin-17A Mediates Hippocampal Damage and Aberrant Neurogenesis Contributing to Epilepsy-Associated Anxiety", "doi": "10.3389/fnmol.2022.917598", "year": 2022 } ] } }, { "id": 38253, "drug": "bimekizumab", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "inhibits", "mediator": "IL-17A", "mediator_type": "protein", "predicate_bc": "increases", "outcome": "hippocampal neuronal death", "outcome_type": "phenotype", "outcome_domain": "epilepsy", "score": 0.24849066497880004, "filtered_score": 0.24849066497880004, "filter_reason": null, "outreach_score": 0.24849066497880004, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "bimekizumab", "mediator_canonical": "il-17a", "outcome_canonical": "hippocampal neuronal death", "ab_count": 5, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "39215949", "title": "Safety and Efficacy of Bimekizumab in Patients with Psoriatic Arthritis: 2-Year Results from Two Phase 3 Studies", "doi": "10.1007/s40744-024-00708-8", "year": 2024 }, { "pmid": "39620046", "title": "Impact of bimekizumab and certolizumab pegol on efficacy, safety and osteoblastic activity in radiographic axial spondyloarthritis: results from a phase IIa, multicentre, randomised, double-blind, exploratory study with PET-CT imaging", "doi": "10.1177/1759720x241293944", "year": 2024 }, { "pmid": "37808274", "title": "Safe and Effective Subcutaneous Self-Injection of Bimekizumab with Safety Syringe and Auto-Injector Devices: Results from a Multicenter, Randomized, Open-Label Study in Patients with Psoriatic Arthritis", "doi": "10.2147/ppa.s427809", "year": 2023 } ], "bc": [ { "pmid": "35875667", "title": "Interleukin-17A Mediates Hippocampal Damage and Aberrant Neurogenesis Contributing to Epilepsy-Associated Anxiety", "doi": "10.3389/fnmol.2022.917598", "year": 2022 } ] } }, { "id": 38252, "drug": "bimekizumab", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "inhibits", "mediator": "IL-17A", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "LTP dysfunction", "outcome_type": "phenotype", "outcome_domain": "epilepsy", "score": 0.24849066497880004, "filtered_score": 0.24849066497880004, "filter_reason": null, "outreach_score": 0.24849066497880004, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "bimekizumab", "mediator_canonical": "il-17a", "outcome_canonical": "ltp dysfunction", "ab_count": 5, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "39215949", "title": "Safety and Efficacy of Bimekizumab in Patients with Psoriatic Arthritis: 2-Year Results from Two Phase 3 Studies", "doi": "10.1007/s40744-024-00708-8", "year": 2024 }, { "pmid": "39620046", "title": "Impact of bimekizumab and certolizumab pegol on efficacy, safety and osteoblastic activity in radiographic axial spondyloarthritis: results from a phase IIa, multicentre, randomised, double-blind, exploratory study with PET-CT imaging", "doi": "10.1177/1759720x241293944", "year": 2024 }, { "pmid": "37808274", "title": "Safe and Effective Subcutaneous Self-Injection of Bimekizumab with Safety Syringe and Auto-Injector Devices: Results from a Multicenter, Randomized, Open-Label Study in Patients with Psoriatic Arthritis", "doi": "10.2147/ppa.s427809", "year": 2023 } ], "bc": [ { "pmid": "34879272", "title": "Interleukin-17 affects synaptic plasticity and cognition in an experimental model of multiple sclerosis", "doi": "10.1016/j.celrep.2021.110094", "year": 2021 } ] } }, { "id": 40383, "drug": "Canagliflozin", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "suppresses", "mediator": "HIF-1α", "mediator_type": "protein", "predicate_bc": "prevents", "outcome": "ulcerative colitis", "outcome_type": "disease", "outcome_domain": "inflammatory_bowel_disease", "score": 0.24849066497880004, "filtered_score": 0.24849066497880004, "filter_reason": null, "outreach_score": 0.24849066497880004, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "canagliflozin", "mediator_canonical": "hif-1α", "outcome_canonical": "ulcerative colitis", "ab_count": 3, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37684337", "title": "The SGLT2 inhibitor canagliflozin suppresses growth and enhances prostate cancer response to radiotherapy", "doi": "10.1038/s42003-023-05289-w", "year": 2023 }, { "pmid": "37584455", "title": "Canagliflozin mediates tumor suppression alone and in combination with radiotherapy in non‐small cell lung cancer (NSCLC) through inhibition of HIF‐1α", "doi": "10.1002/1878-0261.13508", "year": 2023 }, { "pmid": "34142035", "title": "Canagliflozin attenuates lipotoxicity in cardiomyocytes and protects diabetic mouse hearts by inhibiting the mTOR/HIF-1α pathway", "doi": "10.1016/j.isci.2021.102521", "year": 2021 } ], "bc": [ { "pmid": "38137357", "title": "Interrelation of Hypoxia-Inducible Factor-1 Alpha (HIF-1 α) and the Ratio between the Mean Corpuscular Volume/Lymphocytes (MCVL) and the Cumulative Inflammatory Index (IIC) in Ulcerative Colitis", "doi": "10.3390/biomedicines11123137", "year": 2023 }, { "pmid": "31944416", "title": "Mucosal inflammation downregulates PHD1 expression promoting a barrier‐protective HIF‐1α response in ulcerative colitis patients", "doi": "10.1096/fj.201902103r", "year": 2020 } ] } }, { "id": 50391, "drug": "Phloretin", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "upregulates", "mediator": "SIRT1", "mediator_type": "protein", "predicate_bc": "predicts", "outcome": "Alzheimer's disease", "outcome_type": "disease", "outcome_domain": "alzheimer", "score": 0.24849066497880004, "filtered_score": 0.24849066497880004, "filter_reason": null, "outreach_score": 0.24849066497880004, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 2, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "31076562", "title": "Phloretin protects against cardiac damage and remodeling via restoring SIRT1 and anti-inflammatory effects in the streptozotocin-induced diabetic mouse model", "doi": "10.18632/aging.101954", "year": 2019 } ], "bc": [ { "pmid": "37742223", "title": "Serum sirtuin1: a potential blood biomarker for early diagnosis of Alzheimer’s disease", "doi": "10.18632/aging.205015", "year": 2023 }, { "pmid": "30243024", "title": "Sirt1 enhances tau exon 10 inclusion and improves spatial memory of Htau mice", "doi": "10.18632/aging.101564", "year": 2018 } ] } }, { "id": 40382, "drug": "dapagliflozin", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "upregulates", "mediator": "AMPK", "mediator_type": "protein", "predicate_bc": "treats", "outcome": "intestinal inflammation", "outcome_type": "disease", "outcome_domain": "inflammatory_bowel_disease", "score": 0.24849066497880004, "filtered_score": 0.24849066497880004, "filter_reason": null, "outreach_score": 0.24849066497880004, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "dapagliflozin", "mediator_canonical": "AMPK", "outcome_canonical": "intestinal inflammation", "ab_count": 5, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40264429", "title": "Dapagliflozin ameliorates kidney injury following limb ischemia-reperfusion via the AMPK/SIRT1/NLRP3 pathway", "doi": "10.1080/0886022x.2025.2495111", "year": 2025 }, { "pmid": "36809274", "title": "Mapping the metabolic reprogramming induced by sodium-glucose cotransporter 2 inhibition", "doi": "10.1172/jci.insight.164296", "year": 2023 }, { "pmid": "35274762", "title": "Dapagliflozin attenuates high glucose‐induced endothelial cell apoptosis and inflammation through AMPK/SIRT1 activation", "doi": "10.1111/1440-1681.13638", "year": 2022 } ], "bc": [ { "pmid": "33252129", "title": "Salicylates Ameliorate Intestinal Inflammation by Activating Macrophage AMPK", "doi": "10.1093/ibd/izaa305", "year": 2020 } ] } }, { "id": 40381, "drug": "dapagliflozin", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "upregulates", "mediator": "AMPK", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "intestinal epithelial repair", "outcome_type": "phenotype", "outcome_domain": "inflammatory_bowel_disease", "score": 0.24849066497880004, "filtered_score": 0.24849066497880004, "filter_reason": null, "outreach_score": 0.24849066497880004, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "dapagliflozin", "mediator_canonical": "AMPK", "outcome_canonical": "intestinal epithelial repair", "ab_count": 5, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40264429", "title": "Dapagliflozin ameliorates kidney injury following limb ischemia-reperfusion via the AMPK/SIRT1/NLRP3 pathway", "doi": "10.1080/0886022x.2025.2495111", "year": 2025 }, { "pmid": "36809274", "title": "Mapping the metabolic reprogramming induced by sodium-glucose cotransporter 2 inhibition", "doi": "10.1172/jci.insight.164296", "year": 2023 }, { "pmid": "35274762", "title": "Dapagliflozin attenuates high glucose‐induced endothelial cell apoptosis and inflammation through AMPK/SIRT1 activation", "doi": "10.1111/1440-1681.13638", "year": 2022 } ], "bc": [ { "pmid": "35203241", "title": "Intestinal Epithelial AMPK Deficiency Causes Delayed Colonic Epithelial Repair in DSS-Induced Colitis", "doi": "10.3390/cells11040590", "year": 2022 } ] } }, { "id": 40380, "drug": "dapagliflozin", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "upregulates", "mediator": "SIRT1", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "radiation-induced inflammatory bowel disease", "outcome_type": "disease", "outcome_domain": "inflammatory_bowel_disease", "score": 0.24849066497880004, "filtered_score": 0.24849066497880004, "filter_reason": null, "outreach_score": 0.24849066497880004, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "dapagliflozin", "mediator_canonical": "SIRT1", "outcome_canonical": "radiation-induced inflammatory bowel disease", "ab_count": 5, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37517289", "title": "Dapagliflozin prevents oxidative stress-induced endothelial dysfunction via sirtuin 1 activation", "doi": "10.1016/j.biopha.2023.115213", "year": 2023 }, { "pmid": "38017499", "title": "SIRT1 mediates the inhibitory effect of Dapagliflozin on EndMT by inhibiting the acetylation of endothelium Notch1", "doi": "10.1186/s12933-023-02040-x", "year": 2023 }, { "pmid": "37664712", "title": "Dapagliflozin impedes endothelial cell senescence by activating the SIRT1 signaling pathway in type 2 diabetes", "doi": "10.1016/j.heliyon.2023.e19152", "year": 2023 } ], "bc": [ { "pmid": "32636719", "title": "The Protection Effect of Resveratrol Against Radiation-Induced Inflammatory Bowel Disease via NLRP-3 Inflammasome Repression in Mice", "doi": "10.1177/1559325820931292", "year": 2020 } ] } }, { "id": 37645, "drug": "bimekizumab", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "inhibits", "mediator": "IL-17A", "mediator_type": "protein", "predicate_bc": "decreases", "outcome": "neurite length", "outcome_type": "phenotype", "outcome_domain": "als", "score": 0.24849066497880004, "filtered_score": 0.24849066497880004, "filter_reason": null, "outreach_score": 0.24849066497880004, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "bimekizumab", "mediator_canonical": "il-17a", "outcome_canonical": "neurite length", "ab_count": 5, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "39215949", "title": "Safety and Efficacy of Bimekizumab in Patients with Psoriatic Arthritis: 2-Year Results from Two Phase 3 Studies", "doi": "10.1007/s40744-024-00708-8", "year": 2024 }, { "pmid": "39620046", "title": "Impact of bimekizumab and certolizumab pegol on efficacy, safety and osteoblastic activity in radiographic axial spondyloarthritis: results from a phase IIa, multicentre, randomised, double-blind, exploratory study with PET-CT imaging", "doi": "10.1177/1759720x241293944", "year": 2024 }, { "pmid": "37808274", "title": "Safe and Effective Subcutaneous Self-Injection of Bimekizumab with Safety Syringe and Auto-Injector Devices: Results from a Multicenter, Randomized, Open-Label Study in Patients with Psoriatic Arthritis", "doi": "10.2147/ppa.s427809", "year": 2023 } ], "bc": [ { "pmid": "34360808", "title": "Interleukin-17 and Th17 Lymphocytes Directly Impair Motoneuron Survival of Wildtype and FUS-ALS Mutant Human iPSCs", "doi": "10.3390/ijms22158042", "year": 2021 } ] } }, { "id": 37652, "drug": "bimekizumab", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "inhibits", "mediator": "IL-17F", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "motor neuron survival", "outcome_type": "phenotype", "outcome_domain": "als", "score": 0.24849066497880004, "filtered_score": 0.24849066497880004, "filter_reason": null, "outreach_score": 0.24849066497880004, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "bimekizumab", "mediator_canonical": "il-17f", "outcome_canonical": "motor neuron survival", "ab_count": 5, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "39215949", "title": "Safety and Efficacy of Bimekizumab in Patients with Psoriatic Arthritis: 2-Year Results from Two Phase 3 Studies", "doi": "10.1007/s40744-024-00708-8", "year": 2024 }, { "pmid": "39620046", "title": "Impact of bimekizumab and certolizumab pegol on efficacy, safety and osteoblastic activity in radiographic axial spondyloarthritis: results from a phase IIa, multicentre, randomised, double-blind, exploratory study with PET-CT imaging", "doi": "10.1177/1759720x241293944", "year": 2024 }, { "pmid": "37808274", "title": "Safe and Effective Subcutaneous Self-Injection of Bimekizumab with Safety Syringe and Auto-Injector Devices: Results from a Multicenter, Randomized, Open-Label Study in Patients with Psoriatic Arthritis", "doi": "10.2147/ppa.s427809", "year": 2023 } ], "bc": [ { "pmid": "34360808", "title": "Interleukin-17 and Th17 Lymphocytes Directly Impair Motoneuron Survival of Wildtype and FUS-ALS Mutant Human iPSCs", "doi": "10.3390/ijms22158042", "year": 2021 } ] } }, { "id": 5681, "drug": "Bevacizumab", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "inhibits", "mediator": "VEGF", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "susceptibility to neurodegeneration", "outcome_type": "phenotype", "outcome_domain": "als", "score": 0.24849066497880004, "filtered_score": 0.24849066497880004, "filter_reason": null, "outreach_score": 0.24849066497880004, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "bevacizumab", "mediator_canonical": "VEGF", "outcome_canonical": "susceptibility to neurodegeneration", "ab_count": 5, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41951573", "title": "L-RNA aptamer-based CXCL12 inhibition combined with radiotherapy and bevacizumab in newly-diagnosed glioblastoma: expansion of the phase I/II GLORIA trial", "doi": "10.1038/s41467-026-71362-7", "year": 2026 }, { "pmid": "40757003", "title": "Developing Immunoniosomes (INs): Antibody and Fab conjugations of niosomal nanoparticles via UV-NBS and EDC/NHS chemistry for treating glioblastoma cells", "doi": "10.1016/j.ijpx.2025.100367", "year": 2025 }, { "pmid": "41431343", "title": "Incidence of Bevacizumab‐Associated Toxicity in Children With Low‐Grade Glioma With and Without Neurofibromatosis Type 1", "doi": "10.1002/1545-5017.70059", "year": 2025 } ], "bc": [ { "pmid": "28570669", "title": "Extraocular motoneurons of the adult rat show higher levels of vascular endothelial growth factor and its receptor Flk-1 than other cranial motoneurons", "doi": "10.1371/journal.pone.0178616", "year": 2017 } ] } }, { "id": 38240, "drug": "bimekizumab", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "inhibits", "mediator": "IL-17A", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "neural progenitor proliferation", "outcome_type": "phenotype", "outcome_domain": "epilepsy", "score": 0.24849066497880004, "filtered_score": 0.24849066497880004, "filter_reason": null, "outreach_score": 0.24849066497880004, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "bimekizumab", "mediator_canonical": "il-17a", "outcome_canonical": "neural progenitor proliferation", "ab_count": 5, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "39215949", "title": "Safety and Efficacy of Bimekizumab in Patients with Psoriatic Arthritis: 2-Year Results from Two Phase 3 Studies", "doi": "10.1007/s40744-024-00708-8", "year": 2024 }, { "pmid": "39620046", "title": "Impact of bimekizumab and certolizumab pegol on efficacy, safety and osteoblastic activity in radiographic axial spondyloarthritis: results from a phase IIa, multicentre, randomised, double-blind, exploratory study with PET-CT imaging", "doi": "10.1177/1759720x241293944", "year": 2024 }, { "pmid": "37808274", "title": "Safe and Effective Subcutaneous Self-Injection of Bimekizumab with Safety Syringe and Auto-Injector Devices: Results from a Multicenter, Randomized, Open-Label Study in Patients with Psoriatic Arthritis", "doi": "10.2147/ppa.s427809", "year": 2023 } ], "bc": [ { "pmid": "35875667", "title": "Interleukin-17A Mediates Hippocampal Damage and Aberrant Neurogenesis Contributing to Epilepsy-Associated Anxiety", "doi": "10.3389/fnmol.2022.917598", "year": 2022 } ] } }, { "id": 38245, "drug": "EMO", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "inhibits", "mediator": "HMGB1", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "epilepsy", "outcome_type": "disease", "outcome_domain": "epilepsy", "score": 0.24849066497880004, "filtered_score": 0.24849066497880004, "filter_reason": null, "outreach_score": 0.24849066497880004, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "emo", "mediator_canonical": "HMGB1", "outcome_canonical": "epilepsy", "ab_count": 1, "bc_count": 5, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37324499", "title": "The elucidation of the anti-inflammatory mechanism of EMO in rheumatoid arthritis through an integrative approach combining bioinformatics and experimental verification", "doi": "10.3389/fphar.2023.1195567", "year": 2023 } ], "bc": [ { "pmid": "39466324", "title": "Clinical and biochemical assessments of circulating High Mobility Group Box Protein1 in children with epilepsy: relation to cognitive function and drug responsiveness", "doi": "10.1007/s10072-024-07795-z", "year": 2024 }, { "pmid": "32538745", "title": "Correlation of MMP-9 and HMGB1 expression with the cognitive function in patients with epilepsy and factors affecting the prognosis", "doi": "10.14715/cmb/2020.66.3.6", "year": 2020 }, { "pmid": "33150666", "title": "Evaluation of serum high-mobility group box 1 concentration in dogs with epilepsy: A case-control study", "doi": "10.1111/jvim.15940", "year": 2020 } ] } }, { "id": 38246, "drug": "P2-1", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "binds_to", "mediator": "HMGB1", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "epilepsy", "outcome_type": "disease", "outcome_domain": "epilepsy", "score": 0.24849066497880004, "filtered_score": 0.24849066497880004, "filter_reason": null, "outreach_score": 0.24849066497880004, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "p2-1", "mediator_canonical": "HMGB1", "outcome_canonical": "epilepsy", "ab_count": 1, "bc_count": 5, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41810149", "title": "Repurposing a detrimental antibody epitope as targeted therapeutics for sepsis and rheumatoid arthritis", "doi": "10.1186/s40779-026-00686-8", "year": 2026 } ], "bc": [ { "pmid": "39466324", "title": "Clinical and biochemical assessments of circulating High Mobility Group Box Protein1 in children with epilepsy: relation to cognitive function and drug responsiveness", "doi": "10.1007/s10072-024-07795-z", "year": 2024 }, { "pmid": "32538745", "title": "Correlation of MMP-9 and HMGB1 expression with the cognitive function in patients with epilepsy and factors affecting the prognosis", "doi": "10.14715/cmb/2020.66.3.6", "year": 2020 }, { "pmid": "33150666", "title": "Evaluation of serum high-mobility group box 1 concentration in dogs with epilepsy: A case-control study", "doi": "10.1111/jvim.15940", "year": 2020 } ] } }, { "id": 5684, "drug": "Bevacizumab", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "inhibits", "mediator": "VEGF", "mediator_type": "protein", "predicate_bc": "prevents", "outcome": "motoneuron cell death", "outcome_type": "phenotype", "outcome_domain": "als", "score": 0.24849066497880004, "filtered_score": 0.24849066497880004, "filter_reason": null, "outreach_score": 0.24849066497880004, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "bevacizumab", "mediator_canonical": "VEGF", "outcome_canonical": "motoneuron cell death", "ab_count": 5, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41951573", "title": "L-RNA aptamer-based CXCL12 inhibition combined with radiotherapy and bevacizumab in newly-diagnosed glioblastoma: expansion of the phase I/II GLORIA trial", "doi": "10.1038/s41467-026-71362-7", "year": 2026 }, { "pmid": "40757003", "title": "Developing Immunoniosomes (INs): Antibody and Fab conjugations of niosomal nanoparticles via UV-NBS and EDC/NHS chemistry for treating glioblastoma cells", "doi": "10.1016/j.ijpx.2025.100367", "year": 2025 }, { "pmid": "41431343", "title": "Incidence of Bevacizumab‐Associated Toxicity in Children With Low‐Grade Glioma With and Without Neurofibromatosis Type 1", "doi": "10.1002/1545-5017.70059", "year": 2025 } ], "bc": [ { "pmid": "28570669", "title": "Extraocular motoneurons of the adult rat show higher levels of vascular endothelial growth factor and its receptor Flk-1 than other cranial motoneurons", "doi": "10.1371/journal.pone.0178616", "year": 2017 } ] } }, { "id": 55090, "drug": "DMF", "drug_type": "drug", "drug_domain": "multiple_sclerosis", "predicate_ab": "upregulates", "mediator": "Nrf2", "mediator_type": "gene", "predicate_bc": "increases", "outcome": "diabetic cardiomyopathy", "outcome_type": "disease", "outcome_domain": "heart_failure", "score": 0.24849066497880004, "filtered_score": 0.24849066497880004, "filter_reason": null, "outreach_score": 0.24849066497880004, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 3, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "35326142", "title": "Lung-Targeted Delivery of Dimethyl Fumarate Promotes the Reversal of Age-Dependent Established Lung Fibrosis", "doi": "10.3390/antiox11030492", "year": 2022 }, { "pmid": "36670906", "title": "Dimethyl Fumarate Protects Retinal Pigment Epithelium from Blue Light-Induced Oxidative Damage via the Nrf2 Pathway", "doi": "10.3390/antiox12010045", "year": 2022 } ], "bc": [ { "pmid": "38308838", "title": "Nrf2 prevents diabetic cardiomyopathy via antioxidant effect and normalization of glucose and lipid metabolism in the heart", "doi": "10.1002/jcp.31149", "year": 2024 }, { "pmid": "32948607", "title": "Autophagy Inhibition Enables Nrf2 to Exaggerate the Progression of Diabetic Cardiomyopathy in Mice", "doi": "10.2337/db19-1176", "year": 2020 } ] } }, { "id": 37248, "drug": "WB436B", "drug_type": "drug", "drug_domain": "pancreatic_cancer", "predicate_ab": "inhibits", "mediator": "STAT3", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "prurigo nodularis", "outcome_type": "disease", "outcome_domain": "rheumatoid_arthritis", "score": 0.24849066497880004, "filtered_score": 0.24849066497880004, "filter_reason": null, "outreach_score": 0.24849066497880004, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "wb436b", "mediator_canonical": "STAT3", "outcome_canonical": "prurigo nodularis", "ab_count": 2, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "36374556", "title": "Selectively Targeting STAT3 Using a Small Molecule Inhibitor is a Potential Therapeutic Strategy for Pancreatic Cancer", "doi": "10.1158/1078-0432.ccr-22-0997", "year": 2022 } ], "bc": [ { "pmid": "39912139", "title": "Translating tissue expression of STAT 1, 3 and 6 in prurigo nodularis to clinical efficacy of oral tofacitinib – A prospective single-arm investigational study", "doi": "10.25259/ijdvl_1017_2024", "year": 2025 }, { "pmid": "40162359", "title": "Successful Use of Tofacitinib in Paediatric Prurigo Nodularis: A Report of Four Cases", "doi": "10.4103/ijd.ijd_842_24", "year": 2025 }, { "pmid": "37521237", "title": "A case of recalcitrant prurigo nodularis with heightened expression of STAT 3 and STAT 6 and its dramatic response to tofacitinib", "doi": "10.4103/idoj.idoj_508_22", "year": 2023 } ] } }, { "id": 38654, "drug": "bimekizumab", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "inhibits", "mediator": "IL-17A", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "endoscopic severity", "outcome_type": "phenotype", "outcome_domain": "inflammatory_bowel_disease", "score": 0.24849066497880004, "filtered_score": 0.24849066497880004, "filter_reason": null, "outreach_score": 0.24849066497880004, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "bimekizumab", "mediator_canonical": "il-17a", "outcome_canonical": "endoscopic severity", "ab_count": 5, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "39215949", "title": "Safety and Efficacy of Bimekizumab in Patients with Psoriatic Arthritis: 2-Year Results from Two Phase 3 Studies", "doi": "10.1007/s40744-024-00708-8", "year": 2024 }, { "pmid": "39620046", "title": "Impact of bimekizumab and certolizumab pegol on efficacy, safety and osteoblastic activity in radiographic axial spondyloarthritis: results from a phase IIa, multicentre, randomised, double-blind, exploratory study with PET-CT imaging", "doi": "10.1177/1759720x241293944", "year": 2024 }, { "pmid": "37808274", "title": "Safe and Effective Subcutaneous Self-Injection of Bimekizumab with Safety Syringe and Auto-Injector Devices: Results from a Multicenter, Randomized, Open-Label Study in Patients with Psoriatic Arthritis", "doi": "10.2147/ppa.s427809", "year": 2023 } ], "bc": [ { "pmid": "39412247", "title": "Mucosal Cytokine Expression Associated With Deep Endoscopic Mucosal Healing in Ulcerative Colitis", "doi": "10.1093/ecco-jcc/jjae158", "year": 2024 } ] } }, { "id": 2105, "drug": "Ketogenic diet", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "upregulates", "mediator": "Sod1", "mediator_type": "gene", "predicate_bc": "associated_with", "outcome": "familial amyotrophic lateral sclerosis", "outcome_type": "disease", "outcome_domain": "als", "score": 0.24849066497880004, "filtered_score": 0.24849066497880004, "filter_reason": null, "outreach_score": 0.24849066497880004, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "ketogenic diet", "mediator_canonical": "SOD1", "outcome_canonical": "familial amyotrophic lateral sclerosis", "ab_count": 1, "bc_count": 5, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "31873138", "title": "Ketogenic diet induces skeletal muscle atrophy via reducing muscle protein synthesis and possibly activating proteolysis in mice", "doi": "10.1038/s41598-019-56166-8", "year": 2019 } ], "bc": [ { "pmid": "35576897", "title": "Genetic Epidemiology of Amyotrophic Lateral Sclerosis in Norway: A 2-Year Population-Based Study", "doi": "10.1159/000525091", "year": 2022 }, { "pmid": "31134679", "title": "SOD1 in amyotrophic lateral sclerosis development – in silico analysis and molecular dynamics of A4F and A4V variants", "doi": "10.1002/jcb.29048", "year": 2019 }, { "pmid": "29609497", "title": "A novel D90_K91insN mutation in exon 4 of the SOD1 gene caused familial amyotrophic lateral sclerosis in a Chinese pedigree", "doi": "10.1080/21678421.2018.1457057", "year": 2018 } ] } }, { "id": 51754, "drug": "sulforaphane", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "activates", "mediator": "Nrf2", "mediator_type": "protein", "predicate_bc": "increases", "outcome": "drug efflux", "outcome_type": "phenotype", "outcome_domain": "rheumatoid_arthritis", "score": 0.24849066497880004, "filtered_score": 0.24849066497880004, "filter_reason": null, "outreach_score": 0.24849066497880004, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 5, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "33067900", "title": "Sulforaphane prevents age‐associated cardiac and muscular dysfunction through Nrf2 signaling", "doi": "10.1111/acel.13261", "year": 2020 }, { "pmid": "31270951", "title": "Protection against diabetic cardiomyopathy is achieved using a combination of sulforaphane and zinc in type 1 diabetic OVE26 mice", "doi": "10.1111/jcmm.14520", "year": 2019 }, { "pmid": "29353218", "title": "Sulforaphane prevents angiotensin II-induced cardiomyopathy by activation of Nrf2 via stimulating the Akt/GSK-3ß/Fyn pathway", "doi": "10.1016/j.redox.2017.12.016", "year": 2018 } ], "bc": [ { "pmid": "35964840", "title": "Pros and cons of NRF2 activation as adjunctive therapy in rheumatoid arthritis", "doi": "10.1016/j.freeradbiomed.2022.08.012", "year": 2022 } ] } }, { "id": 51755, "drug": "sulforaphane", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "activates", "mediator": "Nrf2", "mediator_type": "protein", "predicate_bc": "decreases", "outcome": "toxicity of conventional anti-rheumatic therapies", "outcome_type": "phenotype", "outcome_domain": "rheumatoid_arthritis", "score": 0.24849066497880004, "filtered_score": 0.24849066497880004, "filter_reason": null, "outreach_score": 0.24849066497880004, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 5, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "33067900", "title": "Sulforaphane prevents age‐associated cardiac and muscular dysfunction through Nrf2 signaling", "doi": "10.1111/acel.13261", "year": 2020 }, { "pmid": "31270951", "title": "Protection against diabetic cardiomyopathy is achieved using a combination of sulforaphane and zinc in type 1 diabetic OVE26 mice", "doi": "10.1111/jcmm.14520", "year": 2019 }, { "pmid": "29353218", "title": "Sulforaphane prevents angiotensin II-induced cardiomyopathy by activation of Nrf2 via stimulating the Akt/GSK-3ß/Fyn pathway", "doi": "10.1016/j.redox.2017.12.016", "year": 2018 } ], "bc": [ { "pmid": "35964840", "title": "Pros and cons of NRF2 activation as adjunctive therapy in rheumatoid arthritis", "doi": "10.1016/j.freeradbiomed.2022.08.012", "year": 2022 } ] } }, { "id": 38814, "drug": "bimekizumab", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "inhibits", "mediator": "IL-17A", "mediator_type": "protein", "predicate_bc": "increases", "outcome": "EAE", "outcome_type": "disease", "outcome_domain": "multiple_sclerosis", "score": 0.24849066497880004, "filtered_score": 0.24849066497880004, "filter_reason": null, "outreach_score": 0.24849066497880004, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "bimekizumab", "mediator_canonical": "il-17a", "outcome_canonical": "eae", "ab_count": 5, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "39215949", "title": "Safety and Efficacy of Bimekizumab in Patients with Psoriatic Arthritis: 2-Year Results from Two Phase 3 Studies", "doi": "10.1007/s40744-024-00708-8", "year": 2024 }, { "pmid": "39620046", "title": "Impact of bimekizumab and certolizumab pegol on efficacy, safety and osteoblastic activity in radiographic axial spondyloarthritis: results from a phase IIa, multicentre, randomised, double-blind, exploratory study with PET-CT imaging", "doi": "10.1177/1759720x241293944", "year": 2024 }, { "pmid": "37808274", "title": "Safe and Effective Subcutaneous Self-Injection of Bimekizumab with Safety Syringe and Auto-Injector Devices: Results from a Multicenter, Randomized, Open-Label Study in Patients with Psoriatic Arthritis", "doi": "10.2147/ppa.s427809", "year": 2023 } ], "bc": [ { "pmid": "31034962", "title": "IL-17A is associated with the breakdown of the blood-brain barrier in relapsing-remitting multiple sclerosis", "doi": "10.1016/j.jneuroim.2019.04.011", "year": 2019 } ] } }, { "id": 38815, "drug": "bimekizumab", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "inhibits", "mediator": "IL-17A", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "response to interferon-beta therapy", "outcome_type": "phenotype", "outcome_domain": "multiple_sclerosis", "score": 0.24849066497880004, "filtered_score": 0.24849066497880004, "filter_reason": null, "outreach_score": 0.24849066497880004, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "bimekizumab", "mediator_canonical": "il-17a", "outcome_canonical": "response to interferon-beta therapy", "ab_count": 5, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "39215949", "title": "Safety and Efficacy of Bimekizumab in Patients with Psoriatic Arthritis: 2-Year Results from Two Phase 3 Studies", "doi": "10.1007/s40744-024-00708-8", "year": 2024 }, { "pmid": "39620046", "title": "Impact of bimekizumab and certolizumab pegol on efficacy, safety and osteoblastic activity in radiographic axial spondyloarthritis: results from a phase IIa, multicentre, randomised, double-blind, exploratory study with PET-CT imaging", "doi": "10.1177/1759720x241293944", "year": 2024 }, { "pmid": "37808274", "title": "Safe and Effective Subcutaneous Self-Injection of Bimekizumab with Safety Syringe and Auto-Injector Devices: Results from a Multicenter, Randomized, Open-Label Study in Patients with Psoriatic Arthritis", "doi": "10.2147/ppa.s427809", "year": 2023 } ], "bc": [ { "pmid": "33463108", "title": "Comparison of Expression Levels of miR-29b-3p and miR-326 in T Helper-1 and T Helper-17 Cells Isolated from Responsive and Non-responsive Relapsing-remitting Multiple Sclerosis Patients Treated with Interferon-beta", "doi": "10.18502/ijaai.v19i4.4116", "year": 2020 } ] } }, { "id": 17408, "drug": "Bevacizumab", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "inhibits", "mediator": "VEGF", "mediator_type": "protein", "predicate_bc": "causes", "outcome": "Multiple Sclerosis", "outcome_type": "disease", "outcome_domain": "multiple_sclerosis", "score": 0.24849066497880004, "filtered_score": 0.24849066497880004, "filter_reason": null, "outreach_score": 0.24849066497880004, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "bevacizumab", "mediator_canonical": "VEGF", "outcome_canonical": "multiple sclerosis", "ab_count": 5, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41951573", "title": "L-RNA aptamer-based CXCL12 inhibition combined with radiotherapy and bevacizumab in newly-diagnosed glioblastoma: expansion of the phase I/II GLORIA trial", "doi": "10.1038/s41467-026-71362-7", "year": 2026 }, { "pmid": "40757003", "title": "Developing Immunoniosomes (INs): Antibody and Fab conjugations of niosomal nanoparticles via UV-NBS and EDC/NHS chemistry for treating glioblastoma cells", "doi": "10.1016/j.ijpx.2025.100367", "year": 2025 }, { "pmid": "41431343", "title": "Incidence of Bevacizumab‐Associated Toxicity in Children With Low‐Grade Glioma With and Without Neurofibromatosis Type 1", "doi": "10.1002/1545-5017.70059", "year": 2025 } ], "bc": [ { "pmid": "34745143", "title": "Growth Factors and Their Roles in Multiple Sclerosis Risk", "doi": "10.3389/fimmu.2021.768682", "year": 2021 } ] } }, { "id": 61002, "drug": "liraglutide", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "activates", "mediator": "AMPK", "mediator_type": "protein", "predicate_bc": "prevents", "outcome": "metabolic dysfunction", "outcome_type": "disease", "outcome_domain": "heart_failure", "score": 0.24849066497880004, "filtered_score": 0.24849066497880004, "filter_reason": null, "outreach_score": 0.24849066497880004, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 3, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "39779525", "title": "The protective effects of liraglutide in reducing lipid droplets accumulation and myocardial fibrosis in diabetic cardiomyopathy", "doi": "10.1007/s00018-024-05558-9", "year": 2025 }, { "pmid": "34357376", "title": "Glucagon-like peptide-1 attenuates cardiac hypertrophy via the AngII/AT1R/ACE2 and AMPK/mTOR/p70S6K pathways", "doi": "10.1093/abbs/gmab099", "year": 2021 }, { "pmid": "27473212", "title": "The GLP-1 receptor agonists exenatide and liraglutide activate Glucose transport by an AMPK-dependent mechanism", "doi": "10.1186/s12967-016-0985-7", "year": 2016 } ], "bc": [ { "pmid": "37194385", "title": "Adenosine monophosphate‐activated protein kinase is elevated in human cachectic muscle and prevents cancer‐induced metabolic dysfunction in mice", "doi": "10.1002/jcsm.13238", "year": 2023 } ] } }, { "id": 61001, "drug": "exenatide", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "activates", "mediator": "AMPK", "mediator_type": "protein", "predicate_bc": "prevents", "outcome": "metabolic dysfunction", "outcome_type": "disease", "outcome_domain": "heart_failure", "score": 0.24849066497880004, "filtered_score": 0.24849066497880004, "filter_reason": null, "outreach_score": 0.24849066497880004, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 3, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "33044023", "title": "Exenatide improves random‐pattern skin flap survival via TFE3 mediated autophagy augment", "doi": "10.1002/jcp.30102", "year": 2020 }, { "pmid": "27473212", "title": "The GLP-1 receptor agonists exenatide and liraglutide activate Glucose transport by an AMPK-dependent mechanism", "doi": "10.1186/s12967-016-0985-7", "year": 2016 }, { "pmid": "25720388", "title": "Exenatide Protects Against Glucose- and Lipid-Induced Endothelial Dysfunction: Evidence for Direct Vasodilation Effect of GLP-1 Receptor Agonists in Humans", "doi": "10.2337/db14-0976", "year": 2015 } ], "bc": [ { "pmid": "37194385", "title": "Adenosine monophosphate‐activated protein kinase is elevated in human cachectic muscle and prevents cancer‐induced metabolic dysfunction in mice", "doi": "10.1002/jcsm.13238", "year": 2023 } ] } }, { "id": 61000, "drug": "dapagliflozin", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "upregulates", "mediator": "AMPK", "mediator_type": "protein", "predicate_bc": "prevents", "outcome": "myocardial ischemia-reperfusion injury", "outcome_type": "disease", "outcome_domain": "heart_failure", "score": 0.24849066497880004, "filtered_score": 0.24849066497880004, "filter_reason": null, "outreach_score": 0.24849066497880004, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 5, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40264429", "title": "Dapagliflozin ameliorates kidney injury following limb ischemia-reperfusion via the AMPK/SIRT1/NLRP3 pathway", "doi": "10.1080/0886022x.2025.2495111", "year": 2025 }, { "pmid": "36809274", "title": "Mapping the metabolic reprogramming induced by sodium-glucose cotransporter 2 inhibition", "doi": "10.1172/jci.insight.164296", "year": 2023 }, { "pmid": "35274762", "title": "Dapagliflozin attenuates high glucose‐induced endothelial cell apoptosis and inflammation through AMPK/SIRT1 activation", "doi": "10.1111/1440-1681.13638", "year": 2022 } ], "bc": [ { "pmid": "29689567", "title": "AMPK Contributes to Cardioprotective Effects of Pterostilbene Against Myocardial Ischemia- Reperfusion Injury in Diabetic Rats by Suppressing Cardiac Oxidative Stress and Apoptosis", "doi": "10.1159/000489154", "year": 2018 } ] } }, { "id": 60999, "drug": "dapagliflozin", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "upregulates", "mediator": "AMPK", "mediator_type": "protein", "predicate_bc": "causes", "outcome": "dilated cardiomyopathy", "outcome_type": "disease", "outcome_domain": "heart_failure", "score": 0.24849066497880004, "filtered_score": 0.24849066497880004, "filter_reason": null, "outreach_score": 0.24849066497880004, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 5, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40264429", "title": "Dapagliflozin ameliorates kidney injury following limb ischemia-reperfusion via the AMPK/SIRT1/NLRP3 pathway", "doi": "10.1080/0886022x.2025.2495111", "year": 2025 }, { "pmid": "36809274", "title": "Mapping the metabolic reprogramming induced by sodium-glucose cotransporter 2 inhibition", "doi": "10.1172/jci.insight.164296", "year": 2023 }, { "pmid": "35274762", "title": "Dapagliflozin attenuates high glucose‐induced endothelial cell apoptosis and inflammation through AMPK/SIRT1 activation", "doi": "10.1111/1440-1681.13638", "year": 2022 } ], "bc": [ { "pmid": "26023060", "title": "AMPK deficiency in cardiac muscle results in dilated cardiomyopathy in the absence of changes in energy metabolism", "doi": "10.1093/cvr/cvv166", "year": 2015 } ] } }, { "id": 39009, "drug": "Shikonin", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "inhibits", "mediator": "PKM2", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "poor overall survival", "outcome_type": "phenotype", "outcome_domain": "pancreatic_cancer", "score": 0.24849066497880004, "filtered_score": 0.24849066497880004, "filter_reason": null, "outreach_score": 0.24849066497880004, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "shikonin", "mediator_canonical": "PKM", "outcome_canonical": "poor overall survival", "ab_count": 1, "bc_count": 5, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "34521930", "title": "Shikonin induces programmed death of fibroblast synovial cells in rheumatoid arthritis by inhibiting energy pathways", "doi": "10.1038/s41598-021-97713-6", "year": 2021 } ], "bc": [ { "pmid": "27478385", "title": "Pyruvate kinase M2 overexpression and poor prognosis in solid tumors of digestive system: evidence from 16 cohort studies", "doi": "10.2147/ott.s106508", "year": 2016 } ] } }, { "id": 50187, "drug": "sulforaphane", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "activates", "mediator": "Nrf2", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "antioxidant defense", "outcome_type": "phenotype", "outcome_domain": "als", "score": 0.24849066497880004, "filtered_score": 0.24849066497880004, "filter_reason": null, "outreach_score": 0.24849066497880004, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 5, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "33067900", "title": "Sulforaphane prevents age‐associated cardiac and muscular dysfunction through Nrf2 signaling", "doi": "10.1111/acel.13261", "year": 2020 }, { "pmid": "31270951", "title": "Protection against diabetic cardiomyopathy is achieved using a combination of sulforaphane and zinc in type 1 diabetic OVE26 mice", "doi": "10.1111/jcmm.14520", "year": 2019 }, { "pmid": "29353218", "title": "Sulforaphane prevents angiotensin II-induced cardiomyopathy by activation of Nrf2 via stimulating the Akt/GSK-3ß/Fyn pathway", "doi": "10.1016/j.redox.2017.12.016", "year": 2018 } ], "bc": [ { "pmid": "37862202", "title": "NRF2 signaling cascade in amyotrophic lateral sclerosis: bridging the gap between promise and reality", "doi": "10.4103/1673-5374.385283", "year": 2023 } ] } }, { "id": 60998, "drug": "dapagliflozin", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "upregulates", "mediator": "AMPK", "mediator_type": "protein", "predicate_bc": "increases", "outcome": "ventricular cell shortening", "outcome_type": "phenotype", "outcome_domain": "heart_failure", "score": 0.24849066497880004, "filtered_score": 0.24849066497880004, "filter_reason": null, "outreach_score": 0.24849066497880004, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 5, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40264429", "title": "Dapagliflozin ameliorates kidney injury following limb ischemia-reperfusion via the AMPK/SIRT1/NLRP3 pathway", "doi": "10.1080/0886022x.2025.2495111", "year": 2025 }, { "pmid": "36809274", "title": "Mapping the metabolic reprogramming induced by sodium-glucose cotransporter 2 inhibition", "doi": "10.1172/jci.insight.164296", "year": 2023 }, { "pmid": "35274762", "title": "Dapagliflozin attenuates high glucose‐induced endothelial cell apoptosis and inflammation through AMPK/SIRT1 activation", "doi": "10.1111/1440-1681.13638", "year": 2022 } ], "bc": [ { "pmid": "26023060", "title": "AMPK deficiency in cardiac muscle results in dilated cardiomyopathy in the absence of changes in energy metabolism", "doi": "10.1093/cvr/cvv166", "year": 2015 } ] } }, { "id": 50185, "drug": "sulforaphane", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "activates", "mediator": "Nrf2", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "ALS", "outcome_type": "disease", "outcome_domain": "als", "score": 0.24849066497880004, "filtered_score": 0.24849066497880004, "filter_reason": null, "outreach_score": 0.24849066497880004, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 5, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "33067900", "title": "Sulforaphane prevents age‐associated cardiac and muscular dysfunction through Nrf2 signaling", "doi": "10.1111/acel.13261", "year": 2020 }, { "pmid": "31270951", "title": "Protection against diabetic cardiomyopathy is achieved using a combination of sulforaphane and zinc in type 1 diabetic OVE26 mice", "doi": "10.1111/jcmm.14520", "year": 2019 }, { "pmid": "29353218", "title": "Sulforaphane prevents angiotensin II-induced cardiomyopathy by activation of Nrf2 via stimulating the Akt/GSK-3ß/Fyn pathway", "doi": "10.1016/j.redox.2017.12.016", "year": 2018 } ], "bc": [ { "pmid": "40581791", "title": "Identification of disease-associated molecular signatures in the Prp-TDP-43A315T mouse model of ALS: Toward preclinical biomarker development", "doi": "10.1093/jnen/nlaf071", "year": 2025 } ] } }, { "id": 60997, "drug": "Canagliflozin", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "inhibits", "mediator": "SGLT1", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "LVEDD", "outcome_type": "phenotype", "outcome_domain": "heart_failure", "score": 0.24849066497880004, "filtered_score": 0.24849066497880004, "filter_reason": null, "outreach_score": 0.24849066497880004, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 5, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "38744404", "title": "Sodium-glucose exchanger 2 inhibitor canagliflozin promotes mitochondrial metabolism and alleviates salt-induced cardiac hypertrophy via preserving SIRT3 expression", "doi": "10.1016/j.jare.2024.04.030", "year": 2024 }, { "pmid": "32064793", "title": "Differentiating the Sodium‐Glucose Cotransporter 1 Inhibition Capacity of Canagliflozin vs. Dapagliflozin and Empagliflozin Using Quantitative Systems Pharmacology Modeling", "doi": "10.1002/psp4.12498", "year": 2020 }, { "pmid": "30416006", "title": "SGLT1 in pancreatic α cells regulates glucagon secretion in mice, possibly explaining the distinct effects of SGLT2 inhibitors on plasma glucagon levels", "doi": "10.1016/j.molmet.2018.10.009", "year": 2018 } ], "bc": [ { "pmid": "32998746", "title": "Characterization of left ventricular myocardial sodium-glucose cotransporter 1 expression in patients with end-stage heart failure", "doi": "10.1186/s12933-020-01141-1", "year": 2020 } ] } }, { "id": 60996, "drug": "dapagliflozin", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "upregulates", "mediator": "AMPK", "mediator_type": "protein", "predicate_bc": "increases", "outcome": "glycogen storage", "outcome_type": "phenotype", "outcome_domain": "heart_failure", "score": 0.24849066497880004, "filtered_score": 0.24849066497880004, "filter_reason": null, "outreach_score": 0.24849066497880004, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 5, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40264429", "title": "Dapagliflozin ameliorates kidney injury following limb ischemia-reperfusion via the AMPK/SIRT1/NLRP3 pathway", "doi": "10.1080/0886022x.2025.2495111", "year": 2025 }, { "pmid": "36809274", "title": "Mapping the metabolic reprogramming induced by sodium-glucose cotransporter 2 inhibition", "doi": "10.1172/jci.insight.164296", "year": 2023 }, { "pmid": "35274762", "title": "Dapagliflozin attenuates high glucose‐induced endothelial cell apoptosis and inflammation through AMPK/SIRT1 activation", "doi": "10.1111/1440-1681.13638", "year": 2022 } ], "bc": [ { "pmid": "28009297", "title": "Integrative Analysis of PRKAG2 Cardiomyopathy iPS and Microtissue Models Identifies AMPK as a Regulator of Metabolism, Survival, and Fibrosis", "doi": "10.1016/j.celrep.2016.11.066", "year": 2016 } ] } }, { "id": 60993, "drug": "dapagliflozin", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "upregulates", "mediator": "AMPK", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "cardiovascular aging", "outcome_type": "phenotype", "outcome_domain": "heart_failure", "score": 0.24849066497880004, "filtered_score": 0.24849066497880004, "filter_reason": null, "outreach_score": 0.24849066497880004, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 5, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40264429", "title": "Dapagliflozin ameliorates kidney injury following limb ischemia-reperfusion via the AMPK/SIRT1/NLRP3 pathway", "doi": "10.1080/0886022x.2025.2495111", "year": 2025 }, { "pmid": "36809274", "title": "Mapping the metabolic reprogramming induced by sodium-glucose cotransporter 2 inhibition", "doi": "10.1172/jci.insight.164296", "year": 2023 }, { "pmid": "35274762", "title": "Dapagliflozin attenuates high glucose‐induced endothelial cell apoptosis and inflammation through AMPK/SIRT1 activation", "doi": "10.1111/1440-1681.13638", "year": 2022 } ], "bc": [ { "pmid": "41194190", "title": "Cellular senescence and cell therapy in cardiovascular diseases", "doi": "10.1186/s13287-025-04731-6", "year": 2025 } ] } }, { "id": 60992, "drug": "sotagliflozin", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "inhibits", "mediator": "SGLT1", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "LVEDD", "outcome_type": "phenotype", "outcome_domain": "heart_failure", "score": 0.24849066497880004, "filtered_score": 0.24849066497880004, "filter_reason": null, "outreach_score": 0.24849066497880004, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 5, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "35817022", "title": "Metabolic, Intestinal, and Cardiovascular Effects of Sotagliflozin Compared With Empagliflozin in Patients With Type 2 Diabetes: A Randomized, Double-Blind Study", "doi": "10.2337/dc21-2166", "year": 2022 }, { "pmid": "34152828", "title": "Effect of Sotagliflozin on Total Hospitalizations in Patients With Type 2 Diabetes and Worsening Heart Failure", "doi": "10.7326/m21-0651", "year": 2021 }, { "pmid": "31837264", "title": "Sotagliflozin Decreases Postprandial Glucose and Insulin Concentrations by Delaying Intestinal Glucose Absorption", "doi": "10.1210/clinem/dgz258", "year": 2019 } ], "bc": [ { "pmid": "32998746", "title": "Characterization of left ventricular myocardial sodium-glucose cotransporter 1 expression in patients with end-stage heart failure", "doi": "10.1186/s12933-020-01141-1", "year": 2020 } ] } }, { "id": 39589, "drug": "dapagliflozin", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "upregulates", "mediator": "SIRT1", "mediator_type": "protein", "predicate_bc": "decreases", "outcome": "tau acetylation", "outcome_type": "phenotype", "outcome_domain": "alzheimer", "score": 0.24849066497880004, "filtered_score": 0.24849066497880004, "filter_reason": null, "outreach_score": 0.24849066497880004, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "dapagliflozin", "mediator_canonical": "SIRT1", "outcome_canonical": "tau acetylation", "ab_count": 5, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37517289", "title": "Dapagliflozin prevents oxidative stress-induced endothelial dysfunction via sirtuin 1 activation", "doi": "10.1016/j.biopha.2023.115213", "year": 2023 }, { "pmid": "38017499", "title": "SIRT1 mediates the inhibitory effect of Dapagliflozin on EndMT by inhibiting the acetylation of endothelium Notch1", "doi": "10.1186/s12933-023-02040-x", "year": 2023 }, { "pmid": "37664712", "title": "Dapagliflozin impedes endothelial cell senescence by activating the SIRT1 signaling pathway in type 2 diabetes", "doi": "10.1016/j.heliyon.2023.e19152", "year": 2023 } ], "bc": [ { "pmid": "29540553", "title": "SIRT1 Deacetylates Tau and Reduces Pathogenic Tau Spread in a Mouse Model of Tauopathy", "doi": "10.1523/jneurosci.2369-17.2018", "year": 2018 } ] } }, { "id": 39591, "drug": "dapagliflozin", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "upregulates", "mediator": "SIRT1", "mediator_type": "protein", "predicate_bc": "decreases", "outcome": "APP transit to endosome", "outcome_type": "phenotype", "outcome_domain": "alzheimer", "score": 0.24849066497880004, "filtered_score": 0.24849066497880004, "filter_reason": null, "outreach_score": 0.24849066497880004, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "dapagliflozin", "mediator_canonical": "SIRT1", "outcome_canonical": "app transit to endosome", "ab_count": 5, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37517289", "title": "Dapagliflozin prevents oxidative stress-induced endothelial dysfunction via sirtuin 1 activation", "doi": "10.1016/j.biopha.2023.115213", "year": 2023 }, { "pmid": "38017499", "title": "SIRT1 mediates the inhibitory effect of Dapagliflozin on EndMT by inhibiting the acetylation of endothelium Notch1", "doi": "10.1186/s12933-023-02040-x", "year": 2023 }, { "pmid": "37664712", "title": "Dapagliflozin impedes endothelial cell senescence by activating the SIRT1 signaling pathway in type 2 diabetes", "doi": "10.1016/j.heliyon.2023.e19152", "year": 2023 } ], "bc": [ { "pmid": "37602729", "title": "Cooperative effects of SIRT1 and SIRT2 on APP acetylation", "doi": "10.1111/acel.13967", "year": 2023 } ] } }, { "id": 39592, "drug": "dapagliflozin", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "upregulates", "mediator": "SIRT1", "mediator_type": "protein", "predicate_bc": "increases", "outcome": "APP recycling", "outcome_type": "phenotype", "outcome_domain": "alzheimer", "score": 0.24849066497880004, "filtered_score": 0.24849066497880004, "filter_reason": null, "outreach_score": 0.24849066497880004, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "dapagliflozin", "mediator_canonical": "SIRT1", "outcome_canonical": "app recycling", "ab_count": 5, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37517289", "title": "Dapagliflozin prevents oxidative stress-induced endothelial dysfunction via sirtuin 1 activation", "doi": "10.1016/j.biopha.2023.115213", "year": 2023 }, { "pmid": "38017499", "title": "SIRT1 mediates the inhibitory effect of Dapagliflozin on EndMT by inhibiting the acetylation of endothelium Notch1", "doi": "10.1186/s12933-023-02040-x", "year": 2023 }, { "pmid": "37664712", "title": "Dapagliflozin impedes endothelial cell senescence by activating the SIRT1 signaling pathway in type 2 diabetes", "doi": "10.1016/j.heliyon.2023.e19152", "year": 2023 } ], "bc": [ { "pmid": "37602729", "title": "Cooperative effects of SIRT1 and SIRT2 on APP acetylation", "doi": "10.1111/acel.13967", "year": 2023 } ] } }, { "id": 39593, "drug": "dapagliflozin", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "upregulates", "mediator": "SIRT1", "mediator_type": "protein", "predicate_bc": "prevents", "outcome": "Aβ-induced neurotoxicity", "outcome_type": "phenotype", "outcome_domain": "alzheimer", "score": 0.24849066497880004, "filtered_score": 0.24849066497880004, "filter_reason": null, "outreach_score": 0.24849066497880004, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "dapagliflozin", "mediator_canonical": "SIRT1", "outcome_canonical": "aβ-induced neurotoxicity", "ab_count": 5, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37517289", "title": "Dapagliflozin prevents oxidative stress-induced endothelial dysfunction via sirtuin 1 activation", "doi": "10.1016/j.biopha.2023.115213", "year": 2023 }, { "pmid": "38017499", "title": "SIRT1 mediates the inhibitory effect of Dapagliflozin on EndMT by inhibiting the acetylation of endothelium Notch1", "doi": "10.1186/s12933-023-02040-x", "year": 2023 }, { "pmid": "37664712", "title": "Dapagliflozin impedes endothelial cell senescence by activating the SIRT1 signaling pathway in type 2 diabetes", "doi": "10.1016/j.heliyon.2023.e19152", "year": 2023 } ], "bc": [ { "pmid": "37602729", "title": "Cooperative effects of SIRT1 and SIRT2 on APP acetylation", "doi": "10.1111/acel.13967", "year": 2023 } ] } }, { "id": 39595, "drug": "alirocumab", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "inhibits", "mediator": "PCSK9", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "Alzheimer's disease", "outcome_type": "disease", "outcome_domain": "alzheimer", "score": 0.24849066497880004, "filtered_score": 0.24849066497880004, "filter_reason": null, "outreach_score": 0.24849066497880004, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "alirocumab", "mediator_canonical": "pcsk9", "outcome_canonical": "Alzheimer disease", "ab_count": 3, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "32035487", "title": "Effect of alirocumab on individuals with type 2 diabetes, high triglycerides, and low high-density lipoprotein cholesterol", "doi": "10.1186/s12933-020-0991-1", "year": 2020 }, { "pmid": "28799203", "title": "Efficacy and safety of alirocumab in people with prediabetes vs those with normoglycaemia at baseline: a pooled analysis of 10 phase III ODYSSEY clinical trials", "doi": "10.1111/dme.13450", "year": 2017 }, { "pmid": "28545518", "title": "Design and rationale of the ODYSSEY DM-DYSLIPIDEMIA trial: lipid-lowering efficacy and safety of alirocumab in individuals with type 2 diabetes and mixed dyslipidaemia at high cardiovascular risk", "doi": "10.1186/s12933-017-0552-4", "year": 2017 } ], "bc": [ { "pmid": "41465790", "title": "The Roles of PCSK9 in Alzheimer’s Disease: A Systematic Review of Clinical, Genetic, and Preclinical Evidence", "doi": "10.3390/life15121851", "year": 2025 }, { "pmid": "31178716", "title": "Proprotein Convertase Subtilisin/Kexin Type 9, Brain Cholesterol Homeostasis and Potential Implication for Alzheimer’s Disease", "doi": "10.3389/fnagi.2019.00120", "year": 2019 } ] } }, { "id": 39597, "drug": "alirocumab", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "inhibits", "mediator": "PCSK9", "mediator_type": "protein", "predicate_bc": "increases", "outcome": "Aβ accumulation", "outcome_type": "phenotype", "outcome_domain": "alzheimer", "score": 0.24849066497880004, "filtered_score": 0.24849066497880004, "filter_reason": null, "outreach_score": 0.24849066497880004, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "alirocumab", "mediator_canonical": "pcsk9", "outcome_canonical": "aβ accumulation", "ab_count": 3, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "32035487", "title": "Effect of alirocumab on individuals with type 2 diabetes, high triglycerides, and low high-density lipoprotein cholesterol", "doi": "10.1186/s12933-020-0991-1", "year": 2020 }, { "pmid": "28799203", "title": "Efficacy and safety of alirocumab in people with prediabetes vs those with normoglycaemia at baseline: a pooled analysis of 10 phase III ODYSSEY clinical trials", "doi": "10.1111/dme.13450", "year": 2017 }, { "pmid": "28545518", "title": "Design and rationale of the ODYSSEY DM-DYSLIPIDEMIA trial: lipid-lowering efficacy and safety of alirocumab in individuals with type 2 diabetes and mixed dyslipidaemia at high cardiovascular risk", "doi": "10.1186/s12933-017-0552-4", "year": 2017 } ], "bc": [ { "pmid": "41465790", "title": "The Roles of PCSK9 in Alzheimer’s Disease: A Systematic Review of Clinical, Genetic, and Preclinical Evidence", "doi": "10.3390/life15121851", "year": 2025 } ] } }, { "id": 39599, "drug": "pioglitazone", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "activates", "mediator": "SIRT1", "mediator_type": "protein", "predicate_bc": "predicts", "outcome": "Alzheimer's disease", "outcome_type": "disease", "outcome_domain": "alzheimer", "score": 0.24849066497880004, "filtered_score": 0.24849066497880004, "filter_reason": null, "outreach_score": 0.24849066497880004, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "completed", "clinical_trial_nct_ids": [ "NCT00982202", "NCT01931566", "NCT02284906" ], "literature_status": "reproduces_known", "drug_canonical": "pioglitazone", "mediator_canonical": "SIRT1", "outcome_canonical": "Alzheimer disease", "ab_count": 2, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37934372", "title": "Pioglitazone attenuates tamoxifen-induced liver damage in rats via modulating Keap1/Nrf2/HO-1 and SIRT1/Notch1 signaling pathways: In-vivo investigations, and molecular docking analysis", "doi": "10.1007/s11033-023-08847-x", "year": 2023 }, { "pmid": "32881246", "title": "Pioglitazone alleviates cisplatin nephrotoxicity by suppressing mitochondria‐mediated apoptosis via SIRT1/p53 signalling", "doi": "10.1111/jcmm.15782", "year": 2020 } ], "bc": [ { "pmid": "37742223", "title": "Serum sirtuin1: a potential blood biomarker for early diagnosis of Alzheimer’s disease", "doi": "10.18632/aging.205015", "year": 2023 }, { "pmid": "30243024", "title": "Sirt1 enhances tau exon 10 inclusion and improves spatial memory of Htau mice", "doi": "10.18632/aging.101564", "year": 2018 } ] } }, { "id": 38662, "drug": "bimekizumab", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "inhibits", "mediator": "IL-17A", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "fibrosis", "outcome_type": "disease", "outcome_domain": "inflammatory_bowel_disease", "score": 0.24849066497880004, "filtered_score": 0.24849066497880004, "filter_reason": null, "outreach_score": 0.24849066497880004, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "bimekizumab", "mediator_canonical": "il-17a", "outcome_canonical": "fibrosis", "ab_count": 5, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "39215949", "title": "Safety and Efficacy of Bimekizumab in Patients with Psoriatic Arthritis: 2-Year Results from Two Phase 3 Studies", "doi": "10.1007/s40744-024-00708-8", "year": 2024 }, { "pmid": "39620046", "title": "Impact of bimekizumab and certolizumab pegol on efficacy, safety and osteoblastic activity in radiographic axial spondyloarthritis: results from a phase IIa, multicentre, randomised, double-blind, exploratory study with PET-CT imaging", "doi": "10.1177/1759720x241293944", "year": 2024 }, { "pmid": "37808274", "title": "Safe and Effective Subcutaneous Self-Injection of Bimekizumab with Safety Syringe and Auto-Injector Devices: Results from a Multicenter, Randomized, Open-Label Study in Patients with Psoriatic Arthritis", "doi": "10.2147/ppa.s427809", "year": 2023 } ], "bc": [ { "pmid": "31296924", "title": "Fibrogenesis in Chronic DSS Colitis is Not Influenced by Neutralisation of Regulatory T Cells, of Major T Helper Cytokines or Absence of IL-13", "doi": "10.1038/s41598-019-46472-6", "year": 2019 } ] } }, { "id": 59073, "drug": "bimekizumab", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "inhibits", "mediator": "IL-17A", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "left ventricular function", "outcome_type": "phenotype", "outcome_domain": "heart_failure", "score": 0.24849066497880004, "filtered_score": 0.24849066497880004, "filter_reason": null, "outreach_score": 0.24849066497880004, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 5, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "39215949", "title": "Safety and Efficacy of Bimekizumab in Patients with Psoriatic Arthritis: 2-Year Results from Two Phase 3 Studies", "doi": "10.1007/s40744-024-00708-8", "year": 2024 }, { "pmid": "39620046", "title": "Impact of bimekizumab and certolizumab pegol on efficacy, safety and osteoblastic activity in radiographic axial spondyloarthritis: results from a phase IIa, multicentre, randomised, double-blind, exploratory study with PET-CT imaging", "doi": "10.1177/1759720x241293944", "year": 2024 }, { "pmid": "37808274", "title": "Safe and Effective Subcutaneous Self-Injection of Bimekizumab with Safety Syringe and Auto-Injector Devices: Results from a Multicenter, Randomized, Open-Label Study in Patients with Psoriatic Arthritis", "doi": "10.2147/ppa.s427809", "year": 2023 } ], "bc": [ { "pmid": "28278264", "title": "The role of interleukin 17-mediated immune response in Chagas disease: High level is correlated with better left ventricular function", "doi": "10.1371/journal.pone.0172833", "year": 2017 } ] } }, { "id": 39983, "drug": "dapagliflozin", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "upregulates", "mediator": "AMPK", "mediator_type": "protein", "predicate_bc": "increases", "outcome": "spike-wave seizures", "outcome_type": "phenotype", "outcome_domain": "epilepsy", "score": 0.24849066497880004, "filtered_score": 0.24849066497880004, "filter_reason": null, "outreach_score": 0.24849066497880004, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "dapagliflozin", "mediator_canonical": "AMPK", "outcome_canonical": "spike-wave seizures", "ab_count": 5, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40264429", "title": "Dapagliflozin ameliorates kidney injury following limb ischemia-reperfusion via the AMPK/SIRT1/NLRP3 pathway", "doi": "10.1080/0886022x.2025.2495111", "year": 2025 }, { "pmid": "36809274", "title": "Mapping the metabolic reprogramming induced by sodium-glucose cotransporter 2 inhibition", "doi": "10.1172/jci.insight.164296", "year": 2023 }, { "pmid": "35274762", "title": "Dapagliflozin attenuates high glucose‐induced endothelial cell apoptosis and inflammation through AMPK/SIRT1 activation", "doi": "10.1111/1440-1681.13638", "year": 2022 } ], "bc": [ { "pmid": "35134125", "title": "AMPK-mediated potentiation of GABAergic signalling drives hypoglycaemia-provoked spike-wave seizures", "doi": "10.1093/brain/awac037", "year": 2022 } ] } }, { "id": 39985, "drug": "dapagliflozin", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "upregulates", "mediator": "SIRT1", "mediator_type": "protein", "predicate_bc": "prevents", "outcome": "neuronal cell death", "outcome_type": "phenotype", "outcome_domain": "epilepsy", "score": 0.24849066497880004, "filtered_score": 0.24849066497880004, "filter_reason": null, "outreach_score": 0.24849066497880004, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "dapagliflozin", "mediator_canonical": "SIRT1", "outcome_canonical": "neuronal cell death", "ab_count": 5, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37517289", "title": "Dapagliflozin prevents oxidative stress-induced endothelial dysfunction via sirtuin 1 activation", "doi": "10.1016/j.biopha.2023.115213", "year": 2023 }, { "pmid": "38017499", "title": "SIRT1 mediates the inhibitory effect of Dapagliflozin on EndMT by inhibiting the acetylation of endothelium Notch1", "doi": "10.1186/s12933-023-02040-x", "year": 2023 }, { "pmid": "37664712", "title": "Dapagliflozin impedes endothelial cell senescence by activating the SIRT1 signaling pathway in type 2 diabetes", "doi": "10.1016/j.heliyon.2023.e19152", "year": 2023 } ], "bc": [ { "pmid": "31340436", "title": "Sirtuin 1 Regulates Mitochondrial Biogenesis and Provides an Endogenous Neuroprotective Mechanism Against Seizure-Induced Neuronal Cell Death in the Hippocampus Following Status Epilepticus", "doi": "10.3390/ijms20143588", "year": 2019 } ] } }, { "id": 39984, "drug": "dapagliflozin", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "upregulates", "mediator": "AMPK", "mediator_type": "protein", "predicate_bc": "increases", "outcome": "epileptiform network activity", "outcome_type": "phenotype", "outcome_domain": "epilepsy", "score": 0.24849066497880004, "filtered_score": 0.24849066497880004, "filter_reason": null, "outreach_score": 0.24849066497880004, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "dapagliflozin", "mediator_canonical": "AMPK", "outcome_canonical": "epileptiform network activity", "ab_count": 5, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40264429", "title": "Dapagliflozin ameliorates kidney injury following limb ischemia-reperfusion via the AMPK/SIRT1/NLRP3 pathway", "doi": "10.1080/0886022x.2025.2495111", "year": 2025 }, { "pmid": "36809274", "title": "Mapping the metabolic reprogramming induced by sodium-glucose cotransporter 2 inhibition", "doi": "10.1172/jci.insight.164296", "year": 2023 }, { "pmid": "35274762", "title": "Dapagliflozin attenuates high glucose‐induced endothelial cell apoptosis and inflammation through AMPK/SIRT1 activation", "doi": "10.1111/1440-1681.13638", "year": 2022 } ], "bc": [ { "pmid": "35134125", "title": "AMPK-mediated potentiation of GABAergic signalling drives hypoglycaemia-provoked spike-wave seizures", "doi": "10.1093/brain/awac037", "year": 2022 } ] } }, { "id": 561, "drug": "Bevacizumab", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "binds_to", "mediator": "VEGF", "mediator_type": "protein", "predicate_bc": "causes", "outcome": "cerebral vascular abnormalities", "outcome_type": "phenotype", "outcome_domain": "epilepsy", "score": 0.24849066497880004, "filtered_score": 0.24849066497880004, "filter_reason": null, "outreach_score": 0.24849066497880004, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "active", "clinical_trial_nct_ids": [ "NCT06264531", "NCT07075757", "NCT02819479" ], "literature_status": "novel_signal", "drug_canonical": "bevacizumab", "mediator_canonical": "VEGF", "outcome_canonical": "cerebral vascular abnormalities", "ab_count": 5, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41951573", "title": "L-RNA aptamer-based CXCL12 inhibition combined with radiotherapy and bevacizumab in newly-diagnosed glioblastoma: expansion of the phase I/II GLORIA trial", "doi": "10.1038/s41467-026-71362-7", "year": 2026 }, { "pmid": "40757003", "title": "Developing Immunoniosomes (INs): Antibody and Fab conjugations of niosomal nanoparticles via UV-NBS and EDC/NHS chemistry for treating glioblastoma cells", "doi": "10.1016/j.ijpx.2025.100367", "year": 2025 }, { "pmid": "41431343", "title": "Incidence of Bevacizumab‐Associated Toxicity in Children With Low‐Grade Glioma With and Without Neurofibromatosis Type 1", "doi": "10.1002/1545-5017.70059", "year": 2025 } ], "bc": [ { "pmid": "38049961", "title": "Cerebral vascular and blood brain–barrier abnormalities in a mouse model of epilepsy and tuberous sclerosis complex", "doi": "10.1111/epi.17848", "year": 2023 } ] } }, { "id": 39406, "drug": "saxagliptin", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "upregulates", "mediator": "SOD1", "mediator_type": "gene", "predicate_bc": "associated_with", "outcome": "familial amyotrophic lateral sclerosis", "outcome_type": "disease", "outcome_domain": "als", "score": 0.24849066497880004, "filtered_score": 0.24849066497880004, "filter_reason": null, "outreach_score": 0.24849066497880004, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "saxagliptin", "mediator_canonical": "SOD1", "outcome_canonical": "familial amyotrophic lateral sclerosis", "ab_count": 1, "bc_count": 5, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "29724198", "title": "The synergistic effects of saxagliptin and metformin on CD34+ endothelial progenitor cells in early type 2 diabetes patients: a randomized clinical trial", "doi": "10.1186/s12933-018-0709-9", "year": 2018 } ], "bc": [ { "pmid": "35576897", "title": "Genetic Epidemiology of Amyotrophic Lateral Sclerosis in Norway: A 2-Year Population-Based Study", "doi": "10.1159/000525091", "year": 2022 }, { "pmid": "31134679", "title": "SOD1 in amyotrophic lateral sclerosis development – in silico analysis and molecular dynamics of A4F and A4V variants", "doi": "10.1002/jcb.29048", "year": 2019 }, { "pmid": "29609497", "title": "A novel D90_K91insN mutation in exon 4 of the SOD1 gene caused familial amyotrophic lateral sclerosis in a Chinese pedigree", "doi": "10.1080/21678421.2018.1457057", "year": 2018 } ] } }, { "id": 39590, "drug": "dapagliflozin", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "upregulates", "mediator": "SIRT1", "mediator_type": "protein", "predicate_bc": "prevents", "outcome": "tau accumulation", "outcome_type": "phenotype", "outcome_domain": "alzheimer", "score": 0.24849066497880004, "filtered_score": 0.24849066497880004, "filter_reason": null, "outreach_score": 0.24849066497880004, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "dapagliflozin", "mediator_canonical": "SIRT1", "outcome_canonical": "tau accumulation", "ab_count": 5, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37517289", "title": "Dapagliflozin prevents oxidative stress-induced endothelial dysfunction via sirtuin 1 activation", "doi": "10.1016/j.biopha.2023.115213", "year": 2023 }, { "pmid": "38017499", "title": "SIRT1 mediates the inhibitory effect of Dapagliflozin on EndMT by inhibiting the acetylation of endothelium Notch1", "doi": "10.1186/s12933-023-02040-x", "year": 2023 }, { "pmid": "37664712", "title": "Dapagliflozin impedes endothelial cell senescence by activating the SIRT1 signaling pathway in type 2 diabetes", "doi": "10.1016/j.heliyon.2023.e19152", "year": 2023 } ], "bc": [ { "pmid": "29883958", "title": "A silver lining for 24-hydroxycholesterol in Alzheimer's disease: The involvement of the neuroprotective enzyme sirtuin 1", "doi": "10.1016/j.redox.2018.05.009", "year": 2018 } ] } }, { "id": 1557, "drug": "TTFields", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "downregulates", "mediator": "PKM2", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "poor overall survival", "outcome_type": "phenotype", "outcome_domain": "pancreatic_cancer", "score": 0.24849066497880004, "filtered_score": 0.24849066497880004, "filter_reason": null, "outreach_score": 0.24849066497880004, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "ttfields", "mediator_canonical": "PKM", "outcome_canonical": "poor overall survival", "ab_count": 1, "bc_count": 5, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "33221711", "title": "Tumor treating fields (TTFields) impairs aberrant glycolysis in glioblastoma as evaluated by [18F]DASA-23, a non-invasive probe of pyruvate kinase M2 (PKM2) expression", "doi": "10.1016/j.neo.2020.11.003", "year": 2020 } ], "bc": [ { "pmid": "27478385", "title": "Pyruvate kinase M2 overexpression and poor prognosis in solid tumors of digestive system: evidence from 16 cohort studies", "doi": "10.2147/ott.s106508", "year": 2016 } ] } }, { "id": 60204, "drug": "Alirocumab", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "inhibits", "mediator": "PCSK9", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "Alzheimer's disease", "outcome_type": "disease", "outcome_domain": "alzheimer", "score": 0.24849066497880004, "filtered_score": 0.24849066497880004, "filter_reason": null, "outreach_score": 0.24849066497880004, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 3, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "32035487", "title": "Effect of alirocumab on individuals with type 2 diabetes, high triglycerides, and low high-density lipoprotein cholesterol", "doi": "10.1186/s12933-020-0991-1", "year": 2020 }, { "pmid": "28799203", "title": "Efficacy and safety of alirocumab in people with prediabetes vs those with normoglycaemia at baseline: a pooled analysis of 10 phase III ODYSSEY clinical trials", "doi": "10.1111/dme.13450", "year": 2017 }, { "pmid": "28545518", "title": "Design and rationale of the ODYSSEY DM-DYSLIPIDEMIA trial: lipid-lowering efficacy and safety of alirocumab in individuals with type 2 diabetes and mixed dyslipidaemia at high cardiovascular risk", "doi": "10.1186/s12933-017-0552-4", "year": 2017 } ], "bc": [ { "pmid": "41465790", "title": "The Roles of PCSK9 in Alzheimer’s Disease: A Systematic Review of Clinical, Genetic, and Preclinical Evidence", "doi": "10.3390/life15121851", "year": 2025 }, { "pmid": "31178716", "title": "Proprotein Convertase Subtilisin/Kexin Type 9, Brain Cholesterol Homeostasis and Potential Implication for Alzheimer’s Disease", "doi": "10.3389/fnagi.2019.00120", "year": 2019 } ] } }, { "id": 60202, "drug": "Alirocumab", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "inhibits", "mediator": "PCSK9", "mediator_type": "protein", "predicate_bc": "increases", "outcome": "Aβ accumulation", "outcome_type": "phenotype", "outcome_domain": "alzheimer", "score": 0.24849066497880004, "filtered_score": 0.24849066497880004, "filter_reason": null, "outreach_score": 0.24849066497880004, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 3, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "32035487", "title": "Effect of alirocumab on individuals with type 2 diabetes, high triglycerides, and low high-density lipoprotein cholesterol", "doi": "10.1186/s12933-020-0991-1", "year": 2020 }, { "pmid": "28799203", "title": "Efficacy and safety of alirocumab in people with prediabetes vs those with normoglycaemia at baseline: a pooled analysis of 10 phase III ODYSSEY clinical trials", "doi": "10.1111/dme.13450", "year": 2017 }, { "pmid": "28545518", "title": "Design and rationale of the ODYSSEY DM-DYSLIPIDEMIA trial: lipid-lowering efficacy and safety of alirocumab in individuals with type 2 diabetes and mixed dyslipidaemia at high cardiovascular risk", "doi": "10.1186/s12933-017-0552-4", "year": 2017 } ], "bc": [ { "pmid": "41465790", "title": "The Roles of PCSK9 in Alzheimer’s Disease: A Systematic Review of Clinical, Genetic, and Preclinical Evidence", "doi": "10.3390/life15121851", "year": 2025 } ] } }, { "id": 39594, "drug": "dapagliflozin", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "upregulates", "mediator": "SIRT1", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "Braak stage", "outcome_type": "phenotype", "outcome_domain": "alzheimer", "score": 0.24849066497880004, "filtered_score": 0.24849066497880004, "filter_reason": null, "outreach_score": 0.24849066497880004, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "dapagliflozin", "mediator_canonical": "SIRT1", "outcome_canonical": "braak stage", "ab_count": 5, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37517289", "title": "Dapagliflozin prevents oxidative stress-induced endothelial dysfunction via sirtuin 1 activation", "doi": "10.1016/j.biopha.2023.115213", "year": 2023 }, { "pmid": "38017499", "title": "SIRT1 mediates the inhibitory effect of Dapagliflozin on EndMT by inhibiting the acetylation of endothelium Notch1", "doi": "10.1186/s12933-023-02040-x", "year": 2023 }, { "pmid": "37664712", "title": "Dapagliflozin impedes endothelial cell senescence by activating the SIRT1 signaling pathway in type 2 diabetes", "doi": "10.1016/j.heliyon.2023.e19152", "year": 2023 } ], "bc": [ { "pmid": "30185534", "title": "Reduced expression of SIRT1 and SOD-1 and the correlation between these levels in various regions of the brains of patients with Alzheimer's disease", "doi": "10.1136/jclinpath-2018-205320", "year": 2018 } ] } }, { "id": 59057, "drug": "bimekizumab", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "inhibits", "mediator": "IL-17A", "mediator_type": "protein", "predicate_bc": "prevents", "outcome": "myocardial damage", "outcome_type": "phenotype", "outcome_domain": "heart_failure", "score": 0.24849066497880004, "filtered_score": 0.24849066497880004, "filter_reason": null, "outreach_score": 0.24849066497880004, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 5, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "39215949", "title": "Safety and Efficacy of Bimekizumab in Patients with Psoriatic Arthritis: 2-Year Results from Two Phase 3 Studies", "doi": "10.1007/s40744-024-00708-8", "year": 2024 }, { "pmid": "39620046", "title": "Impact of bimekizumab and certolizumab pegol on efficacy, safety and osteoblastic activity in radiographic axial spondyloarthritis: results from a phase IIa, multicentre, randomised, double-blind, exploratory study with PET-CT imaging", "doi": "10.1177/1759720x241293944", "year": 2024 }, { "pmid": "37808274", "title": "Safe and Effective Subcutaneous Self-Injection of Bimekizumab with Safety Syringe and Auto-Injector Devices: Results from a Multicenter, Randomized, Open-Label Study in Patients with Psoriatic Arthritis", "doi": "10.2147/ppa.s427809", "year": 2023 } ], "bc": [ { "pmid": "28278264", "title": "The role of interleukin 17-mediated immune response in Chagas disease: High level is correlated with better left ventricular function", "doi": "10.1371/journal.pone.0172833", "year": 2017 } ] } }, { "id": 31927, "drug": "Bevacizumab", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "inhibits", "mediator": "VEGF", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "RA disease activity", "outcome_type": "phenotype", "outcome_domain": "rheumatoid_arthritis", "score": 0.24849066497880004, "filtered_score": 0.24849066497880004, "filter_reason": null, "outreach_score": 0.24849066497880004, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "bevacizumab", "mediator_canonical": "VEGF", "outcome_canonical": "ra disease activity", "ab_count": 5, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41951573", "title": "L-RNA aptamer-based CXCL12 inhibition combined with radiotherapy and bevacizumab in newly-diagnosed glioblastoma: expansion of the phase I/II GLORIA trial", "doi": "10.1038/s41467-026-71362-7", "year": 2026 }, { "pmid": "40757003", "title": "Developing Immunoniosomes (INs): Antibody and Fab conjugations of niosomal nanoparticles via UV-NBS and EDC/NHS chemistry for treating glioblastoma cells", "doi": "10.1016/j.ijpx.2025.100367", "year": 2025 }, { "pmid": "41431343", "title": "Incidence of Bevacizumab‐Associated Toxicity in Children With Low‐Grade Glioma With and Without Neurofibromatosis Type 1", "doi": "10.1002/1545-5017.70059", "year": 2025 } ], "bc": [ { "pmid": "41134171", "title": "A Study on the Serum Levels of POSTN and VEGF in Rheumatoid Arthritis Patients and Their Correlations", "doi": "10.12968/hmed.2025.0293", "year": 2025 } ] } }, { "id": 31928, "drug": "Bevacizumab", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "inhibits", "mediator": "VEGF", "mediator_type": "protein", "predicate_bc": "increases", "outcome": "psoriatic arthritis", "outcome_type": "disease", "outcome_domain": "rheumatoid_arthritis", "score": 0.24849066497880004, "filtered_score": 0.24849066497880004, "filter_reason": null, "outreach_score": 0.24849066497880004, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "bevacizumab", "mediator_canonical": "VEGF", "outcome_canonical": "psoriatic arthritis", "ab_count": 5, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41951573", "title": "L-RNA aptamer-based CXCL12 inhibition combined with radiotherapy and bevacizumab in newly-diagnosed glioblastoma: expansion of the phase I/II GLORIA trial", "doi": "10.1038/s41467-026-71362-7", "year": 2026 }, { "pmid": "40757003", "title": "Developing Immunoniosomes (INs): Antibody and Fab conjugations of niosomal nanoparticles via UV-NBS and EDC/NHS chemistry for treating glioblastoma cells", "doi": "10.1016/j.ijpx.2025.100367", "year": 2025 }, { "pmid": "41431343", "title": "Incidence of Bevacizumab‐Associated Toxicity in Children With Low‐Grade Glioma With and Without Neurofibromatosis Type 1", "doi": "10.1002/1545-5017.70059", "year": 2025 } ], "bc": [ { "pmid": "37979213", "title": "Exploring the causal relationship between inflammatory cytokines and inflammatory arthritis: A Mendelian randomization study", "doi": "10.1016/j.cyto.2023.156446", "year": 2023 } ] } }, { "id": 23215, "drug": "Fingolimod", "drug_type": "drug", "drug_domain": "multiple_sclerosis", "predicate_ab": "downregulates", "mediator": "HMGB1", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "epilepsy", "outcome_type": "disease", "outcome_domain": "epilepsy", "score": 0.24849066497880004, "filtered_score": 0.24849066497880004, "filter_reason": null, "outreach_score": 0.24849066497880004, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "fingolimod", "mediator_canonical": "HMGB1", "outcome_canonical": "epilepsy", "ab_count": 1, "bc_count": 5, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "39207074", "title": "Fingolimod Alleviates Inflammation after Cerebral Ischemia via HMGB1/TLR4/NF-κB Signaling Pathway", "doi": "10.31083/j.jin2308142", "year": 2024 } ], "bc": [ { "pmid": "39466324", "title": "Clinical and biochemical assessments of circulating High Mobility Group Box Protein1 in children with epilepsy: relation to cognitive function and drug responsiveness", "doi": "10.1007/s10072-024-07795-z", "year": 2024 }, { "pmid": "32538745", "title": "Correlation of MMP-9 and HMGB1 expression with the cognitive function in patients with epilepsy and factors affecting the prognosis", "doi": "10.14715/cmb/2020.66.3.6", "year": 2020 }, { "pmid": "33150666", "title": "Evaluation of serum high-mobility group box 1 concentration in dogs with epilepsy: A case-control study", "doi": "10.1111/jvim.15940", "year": 2020 } ] } }, { "id": 40560, "drug": "dapagliflozin", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "upregulates", "mediator": "SIRT1", "mediator_type": "protein", "predicate_bc": "treats", "outcome": "rheumatoid arthritis", "outcome_type": "disease", "outcome_domain": "multiple_sclerosis", "score": 0.24849066497880004, "filtered_score": 0.24849066497880004, "filter_reason": null, "outreach_score": 0.24849066497880004, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "dapagliflozin", "mediator_canonical": "SIRT1", "outcome_canonical": "rheumatoid arthritis", "ab_count": 5, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37517289", "title": "Dapagliflozin prevents oxidative stress-induced endothelial dysfunction via sirtuin 1 activation", "doi": "10.1016/j.biopha.2023.115213", "year": 2023 }, { "pmid": "38017499", "title": "SIRT1 mediates the inhibitory effect of Dapagliflozin on EndMT by inhibiting the acetylation of endothelium Notch1", "doi": "10.1186/s12933-023-02040-x", "year": 2023 }, { "pmid": "37664712", "title": "Dapagliflozin impedes endothelial cell senescence by activating the SIRT1 signaling pathway in type 2 diabetes", "doi": "10.1016/j.heliyon.2023.e19152", "year": 2023 } ], "bc": [ { "pmid": "38305342", "title": "Targeting Pathways and Integrated Approaches to Treat Rheumatoid Arthritis", "doi": "10.1615/critrevtherdrugcarriersyst.2023044719", "year": 2023 } ] } }, { "id": 40561, "drug": "dapagliflozin", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "upregulates", "mediator": "SIRT1", "mediator_type": "protein", "predicate_bc": "decreases", "outcome": "axon demyelination", "outcome_type": "phenotype", "outcome_domain": "multiple_sclerosis", "score": 0.24849066497880004, "filtered_score": 0.24849066497880004, "filter_reason": null, "outreach_score": 0.24849066497880004, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "dapagliflozin", "mediator_canonical": "SIRT1", "outcome_canonical": "axon demyelination", "ab_count": 5, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37517289", "title": "Dapagliflozin prevents oxidative stress-induced endothelial dysfunction via sirtuin 1 activation", "doi": "10.1016/j.biopha.2023.115213", "year": 2023 }, { "pmid": "38017499", "title": "SIRT1 mediates the inhibitory effect of Dapagliflozin on EndMT by inhibiting the acetylation of endothelium Notch1", "doi": "10.1186/s12933-023-02040-x", "year": 2023 }, { "pmid": "37664712", "title": "Dapagliflozin impedes endothelial cell senescence by activating the SIRT1 signaling pathway in type 2 diabetes", "doi": "10.1016/j.heliyon.2023.e19152", "year": 2023 } ], "bc": [ { "pmid": "35740955", "title": "Selective Upregulation of SIRT1 Expression in Retinal Ganglion Cells by AAV-Mediated Gene Delivery Increases Neuronal Cell Survival and Alleviates Axon Demyelination Associated with Optic Neuritis", "doi": "10.3390/biom12060830", "year": 2022 } ] } }, { "id": 40562, "drug": "dapagliflozin", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "upregulates", "mediator": "SIRT1", "mediator_type": "protein", "predicate_bc": "increases", "outcome": "optokinetic response", "outcome_type": "phenotype", "outcome_domain": "multiple_sclerosis", "score": 0.24849066497880004, "filtered_score": 0.24849066497880004, "filter_reason": null, "outreach_score": 0.24849066497880004, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "dapagliflozin", "mediator_canonical": "SIRT1", "outcome_canonical": "optokinetic response", "ab_count": 5, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37517289", "title": "Dapagliflozin prevents oxidative stress-induced endothelial dysfunction via sirtuin 1 activation", "doi": "10.1016/j.biopha.2023.115213", "year": 2023 }, { "pmid": "38017499", "title": "SIRT1 mediates the inhibitory effect of Dapagliflozin on EndMT by inhibiting the acetylation of endothelium Notch1", "doi": "10.1186/s12933-023-02040-x", "year": 2023 }, { "pmid": "37664712", "title": "Dapagliflozin impedes endothelial cell senescence by activating the SIRT1 signaling pathway in type 2 diabetes", "doi": "10.1016/j.heliyon.2023.e19152", "year": 2023 } ], "bc": [ { "pmid": "35740955", "title": "Selective Upregulation of SIRT1 Expression in Retinal Ganglion Cells by AAV-Mediated Gene Delivery Increases Neuronal Cell Survival and Alleviates Axon Demyelination Associated with Optic Neuritis", "doi": "10.3390/biom12060830", "year": 2022 } ] } }, { "id": 2290, "drug": "VPA", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "downregulates", "mediator": "TREM2", "mediator_type": "gene", "predicate_bc": "associated_with", "outcome": "Alzheimer's disease", "outcome_type": "disease", "outcome_domain": "alzheimer", "score": 0.24849066497880004, "filtered_score": 0.24849066497880004, "filter_reason": null, "outreach_score": 0.24849066497880004, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "completed", "clinical_trial_nct_ids": [ "NCT01729598", "NCT00071721", "NCT00208819" ], "literature_status": "reproduces_known", "drug_canonical": "valproic acid", "mediator_canonical": "trem2", "outcome_canonical": "Alzheimer disease", "ab_count": 1, "bc_count": 5, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "36870407", "title": "Prenatally VPA exposure is likely to cause autistic-like behavior in the rats offspring via TREM2 down-regulation to affect the microglial activation and synapse alterations", "doi": "10.1016/j.etap.2023.104090", "year": 2023 } ], "bc": [ { "pmid": "36966244", "title": "TREM2 gene expression associations with Alzheimer’s disease neuropathology are region-specific: implications for cortical versus subcortical microglia", "doi": "10.1007/s00401-023-02564-2", "year": 2023 }, { "pmid": "36411364", "title": "Exome sequencing identifies rare damaging variants in ATP8B4 and ABCA1 as risk factors for Alzheimer’s disease", "doi": "10.1038/s41588-022-01208-7", "year": 2022 }, { "pmid": "36219197", "title": "Chronic TREM2 activation exacerbates Aβ-associated tau seeding and spreading", "doi": "10.1084/jem.20220654", "year": 2022 } ] } }, { "id": 31326, "drug": "Bevacizumab", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "inhibits", "mediator": "VEGF", "mediator_type": "protein", "predicate_bc": "predicts", "outcome": "glucocorticoid-free remission", "outcome_type": "phenotype", "outcome_domain": "inflammatory_bowel_disease", "score": 0.24849066497880004, "filtered_score": 0.24849066497880004, "filter_reason": null, "outreach_score": 0.24849066497880004, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "bevacizumab", "mediator_canonical": "VEGF", "outcome_canonical": "glucocorticoid-free remission", "ab_count": 5, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41951573", "title": "L-RNA aptamer-based CXCL12 inhibition combined with radiotherapy and bevacizumab in newly-diagnosed glioblastoma: expansion of the phase I/II GLORIA trial", "doi": "10.1038/s41467-026-71362-7", "year": 2026 }, { "pmid": "40757003", "title": "Developing Immunoniosomes (INs): Antibody and Fab conjugations of niosomal nanoparticles via UV-NBS and EDC/NHS chemistry for treating glioblastoma cells", "doi": "10.1016/j.ijpx.2025.100367", "year": 2025 }, { "pmid": "41431343", "title": "Incidence of Bevacizumab‐Associated Toxicity in Children With Low‐Grade Glioma With and Without Neurofibromatosis Type 1", "doi": "10.1002/1545-5017.70059", "year": 2025 } ], "bc": [ { "pmid": "30805622", "title": "Markers of angiogenesis and macrophage products for predicting disease course and monitoring vascular inflammation in giant cell arteritis", "doi": "10.1093/rheumatology/kez034", "year": 2019 } ] } }, { "id": 49003, "drug": "Bevacizumab", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "inhibits", "mediator": "VEGF", "mediator_type": "protein", "predicate_bc": "causes", "outcome": "atrial conduction slowing", "outcome_type": "phenotype", "outcome_domain": "heart_failure", "score": 0.24849066497880004, "filtered_score": 0.24849066497880004, "filter_reason": null, "outreach_score": 0.24849066497880004, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 5, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41951573", "title": "L-RNA aptamer-based CXCL12 inhibition combined with radiotherapy and bevacizumab in newly-diagnosed glioblastoma: expansion of the phase I/II GLORIA trial", "doi": "10.1038/s41467-026-71362-7", "year": 2026 }, { "pmid": "40757003", "title": "Developing Immunoniosomes (INs): Antibody and Fab conjugations of niosomal nanoparticles via UV-NBS and EDC/NHS chemistry for treating glioblastoma cells", "doi": "10.1016/j.ijpx.2025.100367", "year": 2025 }, { "pmid": "41431343", "title": "Incidence of Bevacizumab‐Associated Toxicity in Children With Low‐Grade Glioma With and Without Neurofibromatosis Type 1", "doi": "10.1002/1545-5017.70059", "year": 2025 } ], "bc": [ { "pmid": "33235263", "title": "Vascular endothelial growth factor promotes atrial arrhythmias by inducing acute intercalated disk remodeling", "doi": "10.1038/s41598-020-77562-5", "year": 2020 } ] } }, { "id": 49002, "drug": "Bevacizumab", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "inhibits", "mediator": "VEGF", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "ICU survival", "outcome_type": "phenotype", "outcome_domain": "heart_failure", "score": 0.24849066497880004, "filtered_score": 0.24849066497880004, "filter_reason": null, "outreach_score": 0.24849066497880004, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 5, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41951573", "title": "L-RNA aptamer-based CXCL12 inhibition combined with radiotherapy and bevacizumab in newly-diagnosed glioblastoma: expansion of the phase I/II GLORIA trial", "doi": "10.1038/s41467-026-71362-7", "year": 2026 }, { "pmid": "40757003", "title": "Developing Immunoniosomes (INs): Antibody and Fab conjugations of niosomal nanoparticles via UV-NBS and EDC/NHS chemistry for treating glioblastoma cells", "doi": "10.1016/j.ijpx.2025.100367", "year": 2025 }, { "pmid": "41431343", "title": "Incidence of Bevacizumab‐Associated Toxicity in Children With Low‐Grade Glioma With and Without Neurofibromatosis Type 1", "doi": "10.1002/1545-5017.70059", "year": 2025 } ], "bc": [ { "pmid": "31165286", "title": "A multiplex analysis of sepsis mediators during human septic shock: a preliminary study on myocardial depression and organ failures", "doi": "10.1186/s13613-019-0538-3", "year": 2019 } ] } }, { "id": 31921, "drug": "Bevacizumab", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "inhibits", "mediator": "VEGF", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "SDAI", "outcome_type": "phenotype", "outcome_domain": "rheumatoid_arthritis", "score": 0.24849066497880004, "filtered_score": 0.24849066497880004, "filter_reason": null, "outreach_score": 0.24849066497880004, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "bevacizumab", "mediator_canonical": "VEGF", "outcome_canonical": "sdai", "ab_count": 5, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41951573", "title": "L-RNA aptamer-based CXCL12 inhibition combined with radiotherapy and bevacizumab in newly-diagnosed glioblastoma: expansion of the phase I/II GLORIA trial", "doi": "10.1038/s41467-026-71362-7", "year": 2026 }, { "pmid": "40757003", "title": "Developing Immunoniosomes (INs): Antibody and Fab conjugations of niosomal nanoparticles via UV-NBS and EDC/NHS chemistry for treating glioblastoma cells", "doi": "10.1016/j.ijpx.2025.100367", "year": 2025 }, { "pmid": "41431343", "title": "Incidence of Bevacizumab‐Associated Toxicity in Children With Low‐Grade Glioma With and Without Neurofibromatosis Type 1", "doi": "10.1002/1545-5017.70059", "year": 2025 } ], "bc": [ { "pmid": "31820713", "title": "Expression of Galectin-9 and correlation with disease activity and vascular endothelial growth factor in rheumatoid arthritis.", "doi": null, "year": 2020 } ] } }, { "id": 40955, "drug": "dapagliflozin", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "upregulates", "mediator": "SIRT1", "mediator_type": "protein", "predicate_bc": "decreases", "outcome": "TNF-alpha secretion", "outcome_type": "phenotype", "outcome_domain": "rheumatoid_arthritis", "score": 0.24849066497880004, "filtered_score": 0.24849066497880004, "filter_reason": null, "outreach_score": 0.24849066497880004, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "dapagliflozin", "mediator_canonical": "SIRT1", "outcome_canonical": "tnf-alpha secretion", "ab_count": 5, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37517289", "title": "Dapagliflozin prevents oxidative stress-induced endothelial dysfunction via sirtuin 1 activation", "doi": "10.1016/j.biopha.2023.115213", "year": 2023 }, { "pmid": "38017499", "title": "SIRT1 mediates the inhibitory effect of Dapagliflozin on EndMT by inhibiting the acetylation of endothelium Notch1", "doi": "10.1186/s12933-023-02040-x", "year": 2023 }, { "pmid": "37664712", "title": "Dapagliflozin impedes endothelial cell senescence by activating the SIRT1 signaling pathway in type 2 diabetes", "doi": "10.1016/j.heliyon.2023.e19152", "year": 2023 } ], "bc": [ { "pmid": "29784872", "title": "SIRT1 inhibits rheumatoid arthritis fibroblast-like synoviocyte aggressiveness and inflammatory response via suppressing NF-κB pathway", "doi": "10.1042/bsr20180541", "year": 2018 } ] } }, { "id": 48999, "drug": "Bevacizumab", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "inhibits", "mediator": "VEGF", "mediator_type": "protein", "predicate_bc": "causes", "outcome": "atrial arrhythmias", "outcome_type": "disease", "outcome_domain": "heart_failure", "score": 0.24849066497880004, "filtered_score": 0.24849066497880004, "filter_reason": null, "outreach_score": 0.24849066497880004, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 5, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41951573", "title": "L-RNA aptamer-based CXCL12 inhibition combined with radiotherapy and bevacizumab in newly-diagnosed glioblastoma: expansion of the phase I/II GLORIA trial", "doi": "10.1038/s41467-026-71362-7", "year": 2026 }, { "pmid": "40757003", "title": "Developing Immunoniosomes (INs): Antibody and Fab conjugations of niosomal nanoparticles via UV-NBS and EDC/NHS chemistry for treating glioblastoma cells", "doi": "10.1016/j.ijpx.2025.100367", "year": 2025 }, { "pmid": "41431343", "title": "Incidence of Bevacizumab‐Associated Toxicity in Children With Low‐Grade Glioma With and Without Neurofibromatosis Type 1", "doi": "10.1002/1545-5017.70059", "year": 2025 } ], "bc": [ { "pmid": "33235263", "title": "Vascular endothelial growth factor promotes atrial arrhythmias by inducing acute intercalated disk remodeling", "doi": "10.1038/s41598-020-77562-5", "year": 2020 } ] } }, { "id": 48998, "drug": "Bevacizumab", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "inhibits", "mediator": "VEGF", "mediator_type": "protein", "predicate_bc": "increases", "outcome": "long-term vascularization", "outcome_type": "phenotype", "outcome_domain": "heart_failure", "score": 0.24849066497880004, "filtered_score": 0.24849066497880004, "filter_reason": null, "outreach_score": 0.24849066497880004, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 5, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41951573", "title": "L-RNA aptamer-based CXCL12 inhibition combined with radiotherapy and bevacizumab in newly-diagnosed glioblastoma: expansion of the phase I/II GLORIA trial", "doi": "10.1038/s41467-026-71362-7", "year": 2026 }, { "pmid": "40757003", "title": "Developing Immunoniosomes (INs): Antibody and Fab conjugations of niosomal nanoparticles via UV-NBS and EDC/NHS chemistry for treating glioblastoma cells", "doi": "10.1016/j.ijpx.2025.100367", "year": 2025 }, { "pmid": "41431343", "title": "Incidence of Bevacizumab‐Associated Toxicity in Children With Low‐Grade Glioma With and Without Neurofibromatosis Type 1", "doi": "10.1002/1545-5017.70059", "year": 2025 } ], "bc": [ { "pmid": "35950643", "title": "Sulfonated Thermoresponsive Injectable Gel for Sequential Release of Therapeutic Proteins to Protect Cardiac Function after Myocardial Infarction", "doi": "10.1021/acsbiomaterials.2c00616", "year": 2022 } ] } }, { "id": 6871, "drug": "Sinapic Acid", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "binds_to", "mediator": "ASC", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "MCI", "outcome_type": "disease", "outcome_domain": "alzheimer", "score": 0.24849066497880004, "filtered_score": 0.24849066497880004, "filter_reason": null, "outreach_score": 0.24849066497880004, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "sinapic acid", "mediator_canonical": "asc", "outcome_canonical": "mci", "ab_count": 2, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "38662166", "title": "Sinapic Acid Mitigates Pentylenetetrazol-induced Acute Seizures By Modulating the NLRP3 Inflammasome and Regulating Calcium/calcineurin Signaling: In Vivo and In Silico Approaches", "doi": "10.1007/s10753-024-02019-0", "year": 2024 } ], "bc": [ { "pmid": "32630059", "title": "The Inflammasome Adaptor Protein ASC in Mild Cognitive Impairment and Alzheimer’s Disease", "doi": "10.3390/ijms21134674", "year": 2020 } ] } }, { "id": 4374, "drug": "durvalumab", "drug_type": "drug", "drug_domain": "pancreatic_cancer", "predicate_ab": "inhibits", "mediator": "PD-L1", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "overall survival", "outcome_type": "phenotype", "outcome_domain": "glioblastoma", "score": 0.24849066497880004, "filtered_score": 0.24849066497880004, "filter_reason": null, "outreach_score": 0.24849066497880004, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "active", "clinical_trial_nct_ids": [ "NCT03164616", "NCT01993810", "NCT04078152" ], "literature_status": "reproduces_known", "drug_canonical": "durvalumab", "mediator_canonical": "PD-L1", "outcome_canonical": null, "ab_count": 3, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37452505", "title": "Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: An early exploratory analysis of real‐world data", "doi": "10.1111/liv.15641", "year": 2023 }, { "pmid": "33688022", "title": "Safety and activity of the TGFβ receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer", "doi": "10.1136/jitc-2020-002068", "year": 2021 }, { "pmid": "31230047", "title": "A Phase 1b/2 Study of the Bruton Tyrosine Kinase Inhibitor Ibrutinib and the PD-L1 Inhibitor Durvalumab in Patients with Pretreated Solid Tumors", "doi": "10.1159/000500571", "year": 2019 } ], "bc": [ { "pmid": "40002543", "title": "Prognostic Biomarkers in Isocitrate Dehydrogenase Wild-Type Glioblastoma: A Focus on B7-H3", "doi": "10.3390/brainsci15020212", "year": 2025 }, { "pmid": "37529045", "title": "Plasma PD-L1 as a biomarker in the clinical management of glioblastoma multiforme—a retrospective cohort study", "doi": "10.3389/fimmu.2023.1202098", "year": 2023 } ] } }, { "id": 31926, "drug": "Bevacizumab", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "inhibits", "mediator": "VEGF", "mediator_type": "protein", "predicate_bc": "predicts", "outcome": "rheumatoid arthritis", "outcome_type": "disease", "outcome_domain": "rheumatoid_arthritis", "score": 0.24849066497880004, "filtered_score": 0.24849066497880004, "filter_reason": null, "outreach_score": 0.24849066497880004, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "bevacizumab", "mediator_canonical": "VEGF", "outcome_canonical": "rheumatoid arthritis", "ab_count": 5, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41951573", "title": "L-RNA aptamer-based CXCL12 inhibition combined with radiotherapy and bevacizumab in newly-diagnosed glioblastoma: expansion of the phase I/II GLORIA trial", "doi": "10.1038/s41467-026-71362-7", "year": 2026 }, { "pmid": "40757003", "title": "Developing Immunoniosomes (INs): Antibody and Fab conjugations of niosomal nanoparticles via UV-NBS and EDC/NHS chemistry for treating glioblastoma cells", "doi": "10.1016/j.ijpx.2025.100367", "year": 2025 }, { "pmid": "41431343", "title": "Incidence of Bevacizumab‐Associated Toxicity in Children With Low‐Grade Glioma With and Without Neurofibromatosis Type 1", "doi": "10.1002/1545-5017.70059", "year": 2025 } ], "bc": [ { "pmid": "35744097", "title": "VEGF Profile in Early Undifferentiated Arthritis Cohort", "doi": "10.3390/medicina58060833", "year": 2022 } ] } }, { "id": 31924, "drug": "Bevacizumab", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "inhibits", "mediator": "VEGF", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "active infection", "outcome_type": "disease", "outcome_domain": "rheumatoid_arthritis", "score": 0.24849066497880004, "filtered_score": 0.24849066497880004, "filter_reason": null, "outreach_score": 0.24849066497880004, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "bevacizumab", "mediator_canonical": "VEGF", "outcome_canonical": "active infection", "ab_count": 5, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41951573", "title": "L-RNA aptamer-based CXCL12 inhibition combined with radiotherapy and bevacizumab in newly-diagnosed glioblastoma: expansion of the phase I/II GLORIA trial", "doi": "10.1038/s41467-026-71362-7", "year": 2026 }, { "pmid": "40757003", "title": "Developing Immunoniosomes (INs): Antibody and Fab conjugations of niosomal nanoparticles via UV-NBS and EDC/NHS chemistry for treating glioblastoma cells", "doi": "10.1016/j.ijpx.2025.100367", "year": 2025 }, { "pmid": "41431343", "title": "Incidence of Bevacizumab‐Associated Toxicity in Children With Low‐Grade Glioma With and Without Neurofibromatosis Type 1", "doi": "10.1002/1545-5017.70059", "year": 2025 } ], "bc": [ { "pmid": "35744097", "title": "VEGF Profile in Early Undifferentiated Arthritis Cohort", "doi": "10.3390/medicina58060833", "year": 2022 } ] } }, { "id": 4384, "drug": "everolimus", "drug_type": "drug", "drug_domain": "pancreatic_cancer", "predicate_ab": "inhibits", "mediator": "mTOR", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "glioblastoma", "outcome_type": "disease", "outcome_domain": "glioblastoma", "score": 0.24849066497880004, "filtered_score": 0.24849066497880004, "filter_reason": null, "outreach_score": 0.24849066497880004, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "active", "clinical_trial_nct_ids": [ "NCT00805961", "NCT05843253", "NCT04135807" ], "literature_status": "reproduces_known", "drug_canonical": "everolimus", "mediator_canonical": "mTOR", "outcome_canonical": "glioblastoma", "ab_count": 2, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "33849427", "title": "Everolimus regulates the activity of gemcitabine-resistant pancreatic cancer cells by targeting the Warburg effect via PI3K/AKT/mTOR signaling", "doi": "10.1186/s10020-021-00300-8", "year": 2021 }, { "pmid": "25822310", "title": "Phase II study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced pancreatic cancer", "doi": "10.1007/s00280-015-2730-y", "year": 2015 } ], "bc": [ { "pmid": "39622049", "title": "A Dual-Target and Dual-Mechanism Design Strategy by Combining Inhibition and Degradation Together", "doi": "10.1021/jacs.4c11930", "year": 2024 }, { "pmid": "33162811", "title": "Mitochondrial dysfunction contributes to Rapamycin-induced apoptosis of Human Glioblastoma Cells - A synergistic effect with Temozolomide", "doi": "10.7150/ijms.40159", "year": 2020 }, { "pmid": "30793789", "title": "The effect of the mTOR inhibitor rapamycin on glucoCEST signal in a preclinical model of glioblastoma", "doi": "10.1002/mrm.27683", "year": 2019 } ] } }, { "id": 32121, "drug": "Bevacizumab", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "inhibits", "mediator": "VEGF", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "diabetic retinopathy", "outcome_type": "disease", "outcome_domain": "type_2_diabetes", "score": 0.24849066497880004, "filtered_score": 0.24849066497880004, "filter_reason": null, "outreach_score": 0.24849066497880004, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "active", "clinical_trial_nct_ids": [ "NCT07550777", "NCT06899529", "NCT07481500" ], "literature_status": "reproduces_known", "drug_canonical": "bevacizumab", "mediator_canonical": "VEGF", "outcome_canonical": "diabetic retinopathy", "ab_count": 5, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41951573", "title": "L-RNA aptamer-based CXCL12 inhibition combined with radiotherapy and bevacizumab in newly-diagnosed glioblastoma: expansion of the phase I/II GLORIA trial", "doi": "10.1038/s41467-026-71362-7", "year": 2026 }, { "pmid": "40757003", "title": "Developing Immunoniosomes (INs): Antibody and Fab conjugations of niosomal nanoparticles via UV-NBS and EDC/NHS chemistry for treating glioblastoma cells", "doi": "10.1016/j.ijpx.2025.100367", "year": 2025 }, { "pmid": "41431343", "title": "Incidence of Bevacizumab‐Associated Toxicity in Children With Low‐Grade Glioma With and Without Neurofibromatosis Type 1", "doi": "10.1002/1545-5017.70059", "year": 2025 } ], "bc": [ { "pmid": "29582815", "title": "Biochemical scenario behind initiation of diabetic retinopathy in type 2 diabetes mellitus", "doi": "10.4103/ijo.ijo_1121_17", "year": 2018 } ] } }, { "id": 32122, "drug": "Bevacizumab", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "inhibits", "mediator": "VEGF", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "enlarged foveal avascular zone", "outcome_type": "phenotype", "outcome_domain": "type_2_diabetes", "score": 0.24849066497880004, "filtered_score": 0.24849066497880004, "filter_reason": null, "outreach_score": 0.24849066497880004, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "bevacizumab", "mediator_canonical": "VEGF", "outcome_canonical": "enlarged foveal avascular zone", "ab_count": 5, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41951573", "title": "L-RNA aptamer-based CXCL12 inhibition combined with radiotherapy and bevacizumab in newly-diagnosed glioblastoma: expansion of the phase I/II GLORIA trial", "doi": "10.1038/s41467-026-71362-7", "year": 2026 }, { "pmid": "40757003", "title": "Developing Immunoniosomes (INs): Antibody and Fab conjugations of niosomal nanoparticles via UV-NBS and EDC/NHS chemistry for treating glioblastoma cells", "doi": "10.1016/j.ijpx.2025.100367", "year": 2025 }, { "pmid": "41431343", "title": "Incidence of Bevacizumab‐Associated Toxicity in Children With Low‐Grade Glioma With and Without Neurofibromatosis Type 1", "doi": "10.1002/1545-5017.70059", "year": 2025 } ], "bc": [ { "pmid": "28328965", "title": "Peripheral blood metabolic and inflammatory factors as biomarkers to ocular findings in diabetic macular edema", "doi": "10.1371/journal.pone.0173865", "year": 2017 } ] } }, { "id": 38811, "drug": "bimekizumab", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "inhibits", "mediator": "IL-17A", "mediator_type": "protein", "predicate_bc": "increases", "outcome": "EAE susceptibility", "outcome_type": "disease", "outcome_domain": "multiple_sclerosis", "score": 0.24849066497880004, "filtered_score": 0.24849066497880004, "filter_reason": null, "outreach_score": 0.24849066497880004, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "bimekizumab", "mediator_canonical": "il-17a", "outcome_canonical": "eae susceptibility", "ab_count": 5, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "39215949", "title": "Safety and Efficacy of Bimekizumab in Patients with Psoriatic Arthritis: 2-Year Results from Two Phase 3 Studies", "doi": "10.1007/s40744-024-00708-8", "year": 2024 }, { "pmid": "39620046", "title": "Impact of bimekizumab and certolizumab pegol on efficacy, safety and osteoblastic activity in radiographic axial spondyloarthritis: results from a phase IIa, multicentre, randomised, double-blind, exploratory study with PET-CT imaging", "doi": "10.1177/1759720x241293944", "year": 2024 }, { "pmid": "37808274", "title": "Safe and Effective Subcutaneous Self-Injection of Bimekizumab with Safety Syringe and Auto-Injector Devices: Results from a Multicenter, Randomized, Open-Label Study in Patients with Psoriatic Arthritis", "doi": "10.2147/ppa.s427809", "year": 2023 } ], "bc": [ { "pmid": "33547052", "title": "IL-17 controls central nervous system autoimmunity through the intestinal microbiome", "doi": "10.1126/sciimmunol.aaz6563", "year": 2021 } ] } }, { "id": 32914, "drug": "Ethyl pyruvate", "drug_type": "drug", "drug_domain": "inflammatory_bowel_disease", "predicate_ab": "inhibits", "mediator": "HMGB1", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "epilepsy", "outcome_type": "disease", "outcome_domain": "epilepsy", "score": 0.24849066497880004, "filtered_score": 0.24849066497880004, "filter_reason": null, "outreach_score": 0.24849066497880004, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "ethyl pyruvate", "mediator_canonical": "HMGB1", "outcome_canonical": "epilepsy", "ab_count": 1, "bc_count": 5, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "31082723", "title": "Melatonin alleviates circadian rhythm disruption exacerbating DSS-induced colitis by inhibiting the distribution of HMGB1 in intestinal tissues", "doi": "10.1016/j.intimp.2019.05.005", "year": 2019 } ], "bc": [ { "pmid": "39466324", "title": "Clinical and biochemical assessments of circulating High Mobility Group Box Protein1 in children with epilepsy: relation to cognitive function and drug responsiveness", "doi": "10.1007/s10072-024-07795-z", "year": 2024 }, { "pmid": "32538745", "title": "Correlation of MMP-9 and HMGB1 expression with the cognitive function in patients with epilepsy and factors affecting the prognosis", "doi": "10.14715/cmb/2020.66.3.6", "year": 2020 }, { "pmid": "33150666", "title": "Evaluation of serum high-mobility group box 1 concentration in dogs with epilepsy: A case-control study", "doi": "10.1111/jvim.15940", "year": 2020 } ] } }, { "id": 38820, "drug": "bimekizumab", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "inhibits", "mediator": "IL-17A", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "BBB dysfunction", "outcome_type": "phenotype", "outcome_domain": "multiple_sclerosis", "score": 0.24849066497880004, "filtered_score": 0.24849066497880004, "filter_reason": null, "outreach_score": 0.24849066497880004, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "bimekizumab", "mediator_canonical": "il-17a", "outcome_canonical": "bbb dysfunction", "ab_count": 5, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "39215949", "title": "Safety and Efficacy of Bimekizumab in Patients with Psoriatic Arthritis: 2-Year Results from Two Phase 3 Studies", "doi": "10.1007/s40744-024-00708-8", "year": 2024 }, { "pmid": "39620046", "title": "Impact of bimekizumab and certolizumab pegol on efficacy, safety and osteoblastic activity in radiographic axial spondyloarthritis: results from a phase IIa, multicentre, randomised, double-blind, exploratory study with PET-CT imaging", "doi": "10.1177/1759720x241293944", "year": 2024 }, { "pmid": "37808274", "title": "Safe and Effective Subcutaneous Self-Injection of Bimekizumab with Safety Syringe and Auto-Injector Devices: Results from a Multicenter, Randomized, Open-Label Study in Patients with Psoriatic Arthritis", "doi": "10.2147/ppa.s427809", "year": 2023 } ], "bc": [ { "pmid": "31034962", "title": "IL-17A is associated with the breakdown of the blood-brain barrier in relapsing-remitting multiple sclerosis", "doi": "10.1016/j.jneuroim.2019.04.011", "year": 2019 } ] } }, { "id": 33504, "drug": "Chlorogenic acid", "drug_type": "drug", "drug_domain": "inflammatory_bowel_disease", "predicate_ab": "inhibits", "mediator": "PKM2", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "poor overall survival", "outcome_type": "phenotype", "outcome_domain": "pancreatic_cancer", "score": 0.24849066497880004, "filtered_score": 0.24849066497880004, "filter_reason": null, "outreach_score": 0.24849066497880004, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "chlorogenic acid", "mediator_canonical": "PKM", "outcome_canonical": "poor overall survival", "ab_count": 1, "bc_count": 5, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37813835", "title": "Polyphenol-rich diet mediates interplay between macrophage-neutrophil and gut microbiota to alleviate intestinal inflammation", "doi": "10.1038/s41419-023-06190-4", "year": 2023 } ], "bc": [ { "pmid": "27478385", "title": "Pyruvate kinase M2 overexpression and poor prognosis in solid tumors of digestive system: evidence from 16 cohort studies", "doi": "10.2147/ott.s106508", "year": 2016 } ] } }, { "id": 1378, "drug": "Bevacizumab", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "binds_to", "mediator": "VEGF", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "Vascular dementia", "outcome_type": "disease", "outcome_domain": "alzheimer", "score": 0.24849066497880004, "filtered_score": 0.24849066497880004, "filter_reason": null, "outreach_score": 0.24849066497880004, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "bevacizumab", "mediator_canonical": "VEGF", "outcome_canonical": "Vascular dementia", "ab_count": 5, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41951573", "title": "L-RNA aptamer-based CXCL12 inhibition combined with radiotherapy and bevacizumab in newly-diagnosed glioblastoma: expansion of the phase I/II GLORIA trial", "doi": "10.1038/s41467-026-71362-7", "year": 2026 }, { "pmid": "40757003", "title": "Developing Immunoniosomes (INs): Antibody and Fab conjugations of niosomal nanoparticles via UV-NBS and EDC/NHS chemistry for treating glioblastoma cells", "doi": "10.1016/j.ijpx.2025.100367", "year": 2025 }, { "pmid": "41431343", "title": "Incidence of Bevacizumab‐Associated Toxicity in Children With Low‐Grade Glioma With and Without Neurofibromatosis Type 1", "doi": "10.1002/1545-5017.70059", "year": 2025 } ], "bc": [ { "pmid": "29933741", "title": "Vascular Endothelial Growth Factor remains unchanged in cerebrospinal fluid of patients with Alzheimer’s disease and vascular dementia", "doi": "10.1186/s13195-018-0385-8", "year": 2018 } ] } }, { "id": 6279, "drug": "Bevacizumab", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "inhibits", "mediator": "VEGF", "mediator_type": "protein", "predicate_bc": "predicts", "outcome": "antidepressant response to ketamine", "outcome_type": "phenotype", "outcome_domain": "depression", "score": 0.24849066497880004, "filtered_score": 0.24849066497880004, "filter_reason": null, "outreach_score": 0.24849066497880004, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "bevacizumab", "mediator_canonical": "VEGF", "outcome_canonical": "antidepressant response to ketamine", "ab_count": 5, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41951573", "title": "L-RNA aptamer-based CXCL12 inhibition combined with radiotherapy and bevacizumab in newly-diagnosed glioblastoma: expansion of the phase I/II GLORIA trial", "doi": "10.1038/s41467-026-71362-7", "year": 2026 }, { "pmid": "40757003", "title": "Developing Immunoniosomes (INs): Antibody and Fab conjugations of niosomal nanoparticles via UV-NBS and EDC/NHS chemistry for treating glioblastoma cells", "doi": "10.1016/j.ijpx.2025.100367", "year": 2025 }, { "pmid": "41431343", "title": "Incidence of Bevacizumab‐Associated Toxicity in Children With Low‐Grade Glioma With and Without Neurofibromatosis Type 1", "doi": "10.1002/1545-5017.70059", "year": 2025 } ], "bc": [ { "pmid": "34035893", "title": "Association of plasma VEGF levels and the antidepressant effects of ketamine in patients with depression", "doi": "10.1177/20451253211014320", "year": 2021 } ] } }, { "id": 1760, "drug": "Bevacizumab", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "binds_to", "mediator": "VEGF", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "depressive symptom severity", "outcome_type": "phenotype", "outcome_domain": "depression", "score": 0.24849066497880004, "filtered_score": 0.24849066497880004, "filter_reason": null, "outreach_score": 0.24849066497880004, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "bevacizumab", "mediator_canonical": "VEGF", "outcome_canonical": "depressive symptom severity", "ab_count": 5, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41951573", "title": "L-RNA aptamer-based CXCL12 inhibition combined with radiotherapy and bevacizumab in newly-diagnosed glioblastoma: expansion of the phase I/II GLORIA trial", "doi": "10.1038/s41467-026-71362-7", "year": 2026 }, { "pmid": "40757003", "title": "Developing Immunoniosomes (INs): Antibody and Fab conjugations of niosomal nanoparticles via UV-NBS and EDC/NHS chemistry for treating glioblastoma cells", "doi": "10.1016/j.ijpx.2025.100367", "year": 2025 }, { "pmid": "41431343", "title": "Incidence of Bevacizumab‐Associated Toxicity in Children With Low‐Grade Glioma With and Without Neurofibromatosis Type 1", "doi": "10.1002/1545-5017.70059", "year": 2025 } ], "bc": [ { "pmid": "32956213", "title": "Peripheral vascular endothelial growth factor changes after transcranial magnetic stimulation in treatment-resistant depression", "doi": "10.1097/wnr.0000000000001523", "year": 2020 } ] } }, { "id": 2300, "drug": "chrysophanol", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "suppresses", "mediator": "cortisol", "mediator_type": "biomarker", "predicate_bc": "correlates_with", "outcome": "Alzheimer's disease", "outcome_type": "disease", "outcome_domain": "alzheimer", "score": 0.24849066497880004, "filtered_score": 0.24849066497880004, "filter_reason": null, "outreach_score": 0.24849066497880004, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "chrysophanol", "mediator_canonical": "cortisol", "outcome_canonical": "Alzheimer disease", "ab_count": 1, "bc_count": 5, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "39650161", "title": "Chrysophanol attenuates cognitive impairment, neuroinflammation, and oxidative stress by TLR4/NFκB-Nrf2/HO-1 and BDNF/VEGF signaling in stress-intensified PTZ induced epilepsy in mice", "doi": "10.3389/fphar.2024.1446304", "year": 2024 } ], "bc": [ { "pmid": "37251803", "title": "Serum cortisol is negatively related to hippocampal volume, brain structure, and memory performance in healthy aging and Alzheimer’s disease", "doi": "10.3389/fnagi.2023.1154112", "year": 2023 }, { "pmid": "37583892", "title": "The effect of plasma cortisol on hippocampal atrophy and clinical progression in mild cognitive impairment", "doi": "10.1002/dad2.12463", "year": 2023 }, { "pmid": "31256117", "title": "Cortisol, Amyloid-β, and Reserve Predicts Alzheimer’s Disease Progression for Cognitively Normal Older Adults", "doi": "10.3233/jad-181030", "year": 2019 } ] } }, { "id": 38653, "drug": "bimekizumab", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "inhibits", "mediator": "IL-17A", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "Behcet's uveitis", "outcome_type": "disease", "outcome_domain": "inflammatory_bowel_disease", "score": 0.24849066497880004, "filtered_score": 0.24849066497880004, "filter_reason": null, "outreach_score": 0.24849066497880004, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "bimekizumab", "mediator_canonical": "il-17a", "outcome_canonical": "behcet's uveitis", "ab_count": 5, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "39215949", "title": "Safety and Efficacy of Bimekizumab in Patients with Psoriatic Arthritis: 2-Year Results from Two Phase 3 Studies", "doi": "10.1007/s40744-024-00708-8", "year": 2024 }, { "pmid": "39620046", "title": "Impact of bimekizumab and certolizumab pegol on efficacy, safety and osteoblastic activity in radiographic axial spondyloarthritis: results from a phase IIa, multicentre, randomised, double-blind, exploratory study with PET-CT imaging", "doi": "10.1177/1759720x241293944", "year": 2024 }, { "pmid": "37808274", "title": "Safe and Effective Subcutaneous Self-Injection of Bimekizumab with Safety Syringe and Auto-Injector Devices: Results from a Multicenter, Randomized, Open-Label Study in Patients with Psoriatic Arthritis", "doi": "10.2147/ppa.s427809", "year": 2023 } ], "bc": [ { "pmid": "37553722", "title": "Potential gastrointestinal Behcet’s disease flare after treatment with anti-interleukin 17a therapy", "doi": "10.1186/s41927-023-00344-9", "year": 2023 } ] } }, { "id": 38656, "drug": "bimekizumab", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "inhibits", "mediator": "IL-17A", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "Crohn's disease", "outcome_type": "disease", "outcome_domain": "inflammatory_bowel_disease", "score": 0.24849066497880004, "filtered_score": 0.24849066497880004, "filter_reason": null, "outreach_score": 0.24849066497880004, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "bimekizumab", "mediator_canonical": "il-17a", "outcome_canonical": "crohn's disease", "ab_count": 5, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "39215949", "title": "Safety and Efficacy of Bimekizumab in Patients with Psoriatic Arthritis: 2-Year Results from Two Phase 3 Studies", "doi": "10.1007/s40744-024-00708-8", "year": 2024 }, { "pmid": "39620046", "title": "Impact of bimekizumab and certolizumab pegol on efficacy, safety and osteoblastic activity in radiographic axial spondyloarthritis: results from a phase IIa, multicentre, randomised, double-blind, exploratory study with PET-CT imaging", "doi": "10.1177/1759720x241293944", "year": 2024 }, { "pmid": "37808274", "title": "Safe and Effective Subcutaneous Self-Injection of Bimekizumab with Safety Syringe and Auto-Injector Devices: Results from a Multicenter, Randomized, Open-Label Study in Patients with Psoriatic Arthritis", "doi": "10.2147/ppa.s427809", "year": 2023 } ], "bc": [ { "pmid": "32724117", "title": "Serum interleukin 17A and interleukin 17F in children with inflammatory bowel disease", "doi": "10.1038/s41598-020-69567-x", "year": 2020 } ] } }, { "id": 38650, "drug": "bimekizumab", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "inhibits", "mediator": "IL-17F", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "inflammatory bowel disease", "outcome_type": "disease", "outcome_domain": "inflammatory_bowel_disease", "score": 0.24849066497880004, "filtered_score": 0.24849066497880004, "filter_reason": null, "outreach_score": 0.24849066497880004, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "preclinical_only", "clinical_trial_nct_ids": [ "NCT07138898" ], "literature_status": "reproduces_known", "drug_canonical": "bimekizumab", "mediator_canonical": "il-17f", "outcome_canonical": "inflammatory bowel disease", "ab_count": 5, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "39215949", "title": "Safety and Efficacy of Bimekizumab in Patients with Psoriatic Arthritis: 2-Year Results from Two Phase 3 Studies", "doi": "10.1007/s40744-024-00708-8", "year": 2024 }, { "pmid": "39620046", "title": "Impact of bimekizumab and certolizumab pegol on efficacy, safety and osteoblastic activity in radiographic axial spondyloarthritis: results from a phase IIa, multicentre, randomised, double-blind, exploratory study with PET-CT imaging", "doi": "10.1177/1759720x241293944", "year": 2024 }, { "pmid": "37808274", "title": "Safe and Effective Subcutaneous Self-Injection of Bimekizumab with Safety Syringe and Auto-Injector Devices: Results from a Multicenter, Randomized, Open-Label Study in Patients with Psoriatic Arthritis", "doi": "10.2147/ppa.s427809", "year": 2023 } ], "bc": [ { "pmid": "32724117", "title": "Serum interleukin 17A and interleukin 17F in children with inflammatory bowel disease", "doi": "10.1038/s41598-020-69567-x", "year": 2020 } ] } }, { "id": 51945, "drug": "sulforaphane", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "activates", "mediator": "Nrf2", "mediator_type": "protein", "predicate_bc": "prevents", "outcome": "type 1 diabetes", "outcome_type": "disease", "outcome_domain": "type_2_diabetes", "score": 0.24849066497880004, "filtered_score": 0.24849066497880004, "filter_reason": null, "outreach_score": 0.24849066497880004, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 5, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "33067900", "title": "Sulforaphane prevents age‐associated cardiac and muscular dysfunction through Nrf2 signaling", "doi": "10.1111/acel.13261", "year": 2020 }, { "pmid": "31270951", "title": "Protection against diabetic cardiomyopathy is achieved using a combination of sulforaphane and zinc in type 1 diabetic OVE26 mice", "doi": "10.1111/jcmm.14520", "year": 2019 }, { "pmid": "29353218", "title": "Sulforaphane prevents angiotensin II-induced cardiomyopathy by activation of Nrf2 via stimulating the Akt/GSK-3ß/Fyn pathway", "doi": "10.1016/j.redox.2017.12.016", "year": 2018 } ], "bc": [ { "pmid": "30625116", "title": "Nrf2 represses the onset of type 1 diabetes in non-obese diabetic mice", "doi": "10.1530/joe-18-0355", "year": 2019 } ] } }, { "id": 2100, "drug": "carbenoxolone", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "downregulates", "mediator": "Cx43", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "ALS", "outcome_type": "disease", "outcome_domain": "als", "score": 0.24849066497880004, "filtered_score": 0.24849066497880004, "filter_reason": null, "outreach_score": 0.24849066497880004, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "carbenoxolone", "mediator_canonical": "GJA1", "outcome_canonical": "amyotrophic lateral sclerosis", "ab_count": 2, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "35615064", "title": "Anticonvulsant Effect of Carbenoxolone on Chronic Epileptic Rats and Its Mechanism Related to Connexin and High-Frequency Oscillations", "doi": "10.3389/fnmol.2022.870947", "year": 2022 }, { "pmid": "31930025", "title": "The protective effect of carbenoxolone on gap junction damage in the hippocampal CA1 area of a temporal lobe epilepsy rat model", "doi": "10.21037/atm.2019.11.04", "year": 2019 } ], "bc": [ { "pmid": "35312356", "title": "Cx43 hemichannels contribute to astrocyte-mediated toxicity in sporadic and familial ALS", "doi": "10.1073/pnas.2107391119", "year": 2022 }, { "pmid": "27083773", "title": "Connexin 43 in astrocytes contributes to motor neuron toxicity in amyotrophic lateral sclerosis", "doi": "10.1002/glia.22989", "year": 2016 } ] } }, { "id": 5884, "drug": "Bevacizumab", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "inhibits", "mediator": "VEGF", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "tau burden", "outcome_type": "phenotype", "outcome_domain": "alzheimer", "score": 0.24849066497880004, "filtered_score": 0.24849066497880004, "filter_reason": null, "outreach_score": 0.24849066497880004, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "bevacizumab", "mediator_canonical": "VEGF", "outcome_canonical": "tau burden", "ab_count": 5, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41951573", "title": "L-RNA aptamer-based CXCL12 inhibition combined with radiotherapy and bevacizumab in newly-diagnosed glioblastoma: expansion of the phase I/II GLORIA trial", "doi": "10.1038/s41467-026-71362-7", "year": 2026 }, { "pmid": "40757003", "title": "Developing Immunoniosomes (INs): Antibody and Fab conjugations of niosomal nanoparticles via UV-NBS and EDC/NHS chemistry for treating glioblastoma cells", "doi": "10.1016/j.ijpx.2025.100367", "year": 2025 }, { "pmid": "41431343", "title": "Incidence of Bevacizumab‐Associated Toxicity in Children With Low‐Grade Glioma With and Without Neurofibromatosis Type 1", "doi": "10.1002/1545-5017.70059", "year": 2025 } ], "bc": [ { "pmid": "38471064", "title": "Association of Neurotrophic Factors at Midlife With In Vivo Measures of β-Amyloid and Tau Burden 15 Years Later in Dementia-Free Adults", "doi": "10.1212/wnl.0000000000209198", "year": 2024 } ] } }, { "id": 51562, "drug": "DQP", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "upregulates", "mediator": "PKM2", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "poor overall survival", "outcome_type": "phenotype", "outcome_domain": "pancreatic_cancer", "score": 0.24849066497880004, "filtered_score": 0.24849066497880004, "filter_reason": null, "outreach_score": 0.24849066497880004, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 5, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "32372956", "title": "Danqi Pill Protects Against Heart Failure Post-Acute Myocardial Infarction via HIF-1α/PGC-1α Mediated Glucose Metabolism Pathway", "doi": "10.3389/fphar.2020.00458", "year": 2020 } ], "bc": [ { "pmid": "27478385", "title": "Pyruvate kinase M2 overexpression and poor prognosis in solid tumors of digestive system: evidence from 16 cohort studies", "doi": "10.2147/ott.s106508", "year": 2016 } ] } }, { "id": 6096, "drug": "THQPMP", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "inhibits", "mediator": "EGFR", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "pancreatic ductal adenocarcinoma", "outcome_type": "disease", "outcome_domain": "pancreatic_cancer", "score": 0.24849066497880004, "filtered_score": 0.24849066497880004, "filter_reason": null, "outreach_score": 0.24849066497880004, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "thqpmp", "mediator_canonical": "EGFR", "outcome_canonical": "pancreatic ductal adenocarcinoma", "ab_count": 2, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41839309", "title": "Preclinical validation of tetrahydroquinoline derivatives as EGFR inhibitor inducing glioblastoma cell death", "doi": "10.1016/j.ejps.2026.107503", "year": 2026 } ], "bc": [ { "pmid": "40130819", "title": "Identification of Tumor‐Specific Surface Proteins Enables Quantification of Extracellular Vesicle Subtypes for Early Detection of Pancreatic Ductal Adenocarcinoma", "doi": "10.1002/advs.202414982", "year": 2025 }, { "pmid": "31584260", "title": "Design and Evaluation of PEGylated Liposomal Formulation of a Novel Multikinase Inhibitor for Enhanced Chemosensitivity and Inhibition of Metastatic Pancreatic Ductal Adenocarcinoma", "doi": "10.1021/acs.bioconjchem.9b00632", "year": 2019 }, { "pmid": "26339400", "title": "EGFR expression in pancreatic intraepithelial neoplasia and ductal adenocarcinoma.", "doi": null, "year": 2015 } ] } }, { "id": 5885, "drug": "Bevacizumab", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "inhibits", "mediator": "VEGF", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "amyloid-β burden", "outcome_type": "phenotype", "outcome_domain": "alzheimer", "score": 0.24849066497880004, "filtered_score": 0.24849066497880004, "filter_reason": null, "outreach_score": 0.24849066497880004, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "bevacizumab", "mediator_canonical": "VEGF", "outcome_canonical": "amyloid-β burden", "ab_count": 5, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41951573", "title": "L-RNA aptamer-based CXCL12 inhibition combined with radiotherapy and bevacizumab in newly-diagnosed glioblastoma: expansion of the phase I/II GLORIA trial", "doi": "10.1038/s41467-026-71362-7", "year": 2026 }, { "pmid": "40757003", "title": "Developing Immunoniosomes (INs): Antibody and Fab conjugations of niosomal nanoparticles via UV-NBS and EDC/NHS chemistry for treating glioblastoma cells", "doi": "10.1016/j.ijpx.2025.100367", "year": 2025 }, { "pmid": "41431343", "title": "Incidence of Bevacizumab‐Associated Toxicity in Children With Low‐Grade Glioma With and Without Neurofibromatosis Type 1", "doi": "10.1002/1545-5017.70059", "year": 2025 } ], "bc": [ { "pmid": "38471064", "title": "Association of Neurotrophic Factors at Midlife With In Vivo Measures of β-Amyloid and Tau Burden 15 Years Later in Dementia-Free Adults", "doi": "10.1212/wnl.0000000000209198", "year": 2024 } ] } }, { "id": 6280, "drug": "Bevacizumab", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "inhibits", "mediator": "VEGF", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "antisuicidal effects of ketamine", "outcome_type": "phenotype", "outcome_domain": "depression", "score": 0.24849066497880004, "filtered_score": 0.24849066497880004, "filter_reason": null, "outreach_score": 0.24849066497880004, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "bevacizumab", "mediator_canonical": "VEGF", "outcome_canonical": "antisuicidal effects of ketamine", "ab_count": 5, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41951573", "title": "L-RNA aptamer-based CXCL12 inhibition combined with radiotherapy and bevacizumab in newly-diagnosed glioblastoma: expansion of the phase I/II GLORIA trial", "doi": "10.1038/s41467-026-71362-7", "year": 2026 }, { "pmid": "40757003", "title": "Developing Immunoniosomes (INs): Antibody and Fab conjugations of niosomal nanoparticles via UV-NBS and EDC/NHS chemistry for treating glioblastoma cells", "doi": "10.1016/j.ijpx.2025.100367", "year": 2025 }, { "pmid": "41431343", "title": "Incidence of Bevacizumab‐Associated Toxicity in Children With Low‐Grade Glioma With and Without Neurofibromatosis Type 1", "doi": "10.1002/1545-5017.70059", "year": 2025 } ], "bc": [ { "pmid": "35546941", "title": "Plasma VEGF Concentrations and Ketamine's Effects on Suicidal Ideation in Depression With Suicidal Ideation", "doi": "10.3389/fpsyt.2022.855995", "year": 2022 } ] } }, { "id": 5491, "drug": "DOX", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "suppresses", "mediator": "HMGB1", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "epilepsy", "outcome_type": "disease", "outcome_domain": "epilepsy", "score": 0.24849066497880004, "filtered_score": 0.24849066497880004, "filter_reason": null, "outreach_score": 0.24849066497880004, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "dox", "mediator_canonical": "HMGB1", "outcome_canonical": "epilepsy", "ab_count": 1, "bc_count": 5, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "30676239", "title": "Doxorubicin Conjugated With Nanodiamonds and in Free Form Commit Glioblastoma Cells to Heterodromous Fates", "doi": "10.2217/nnm-2018-0330", "year": 2019 } ], "bc": [ { "pmid": "39466324", "title": "Clinical and biochemical assessments of circulating High Mobility Group Box Protein1 in children with epilepsy: relation to cognitive function and drug responsiveness", "doi": "10.1007/s10072-024-07795-z", "year": 2024 }, { "pmid": "32538745", "title": "Correlation of MMP-9 and HMGB1 expression with the cognitive function in patients with epilepsy and factors affecting the prognosis", "doi": "10.14715/cmb/2020.66.3.6", "year": 2020 }, { "pmid": "33150666", "title": "Evaluation of serum high-mobility group box 1 concentration in dogs with epilepsy: A case-control study", "doi": "10.1111/jvim.15940", "year": 2020 } ] } }, { "id": 51560, "drug": "LPS", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "upregulates", "mediator": "PKM2", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "poor overall survival", "outcome_type": "phenotype", "outcome_domain": "pancreatic_cancer", "score": 0.24849066497880004, "filtered_score": 0.24849066497880004, "filter_reason": null, "outreach_score": 0.24849066497880004, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 5, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "36564378", "title": "PKM2 deficiency exacerbates gram-negative sepsis-induced cardiomyopathy via disrupting cardiac calcium homeostasis", "doi": "10.1038/s41420-022-01287-9", "year": 2022 } ], "bc": [ { "pmid": "27478385", "title": "Pyruvate kinase M2 overexpression and poor prognosis in solid tumors of digestive system: evidence from 16 cohort studies", "doi": "10.2147/ott.s106508", "year": 2016 } ] } }, { "id": 51757, "drug": "Celastrol", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "inhibits", "mediator": "STAT3", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "prurigo nodularis", "outcome_type": "disease", "outcome_domain": "rheumatoid_arthritis", "score": 0.24849066497880004, "filtered_score": 0.24849066497880004, "filter_reason": null, "outreach_score": 0.24849066497880004, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 2, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "32098592", "title": "Celastrol Attenuates Angiotensin II–Induced Cardiac Remodeling by Targeting STAT3", "doi": "10.1161/circresaha.119.315861", "year": 2020 } ], "bc": [ { "pmid": "39912139", "title": "Translating tissue expression of STAT 1, 3 and 6 in prurigo nodularis to clinical efficacy of oral tofacitinib – A prospective single-arm investigational study", "doi": "10.25259/ijdvl_1017_2024", "year": 2025 }, { "pmid": "40162359", "title": "Successful Use of Tofacitinib in Paediatric Prurigo Nodularis: A Report of Four Cases", "doi": "10.4103/ijd.ijd_842_24", "year": 2025 }, { "pmid": "37521237", "title": "A case of recalcitrant prurigo nodularis with heightened expression of STAT 3 and STAT 6 and its dramatic response to tofacitinib", "doi": "10.4103/idoj.idoj_508_22", "year": 2023 } ] } }, { "id": 39404, "drug": "dapagliflozin", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "upregulates", "mediator": "SIRT1", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "overexpression", "outcome_type": "phenotype", "outcome_domain": "als", "score": 0.24849066497880004, "filtered_score": 0.24849066497880004, "filter_reason": null, "outreach_score": 0.24849066497880004, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "dapagliflozin", "mediator_canonical": "SIRT1", "outcome_canonical": "overexpression", "ab_count": 5, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37517289", "title": "Dapagliflozin prevents oxidative stress-induced endothelial dysfunction via sirtuin 1 activation", "doi": "10.1016/j.biopha.2023.115213", "year": 2023 }, { "pmid": "38017499", "title": "SIRT1 mediates the inhibitory effect of Dapagliflozin on EndMT by inhibiting the acetylation of endothelium Notch1", "doi": "10.1186/s12933-023-02040-x", "year": 2023 }, { "pmid": "37664712", "title": "Dapagliflozin impedes endothelial cell senescence by activating the SIRT1 signaling pathway in type 2 diabetes", "doi": "10.1016/j.heliyon.2023.e19152", "year": 2023 } ], "bc": [ { "pmid": "35448021", "title": "SIRT1 Interacts with Prepro-Orexin in the Hypothalamus in SOD1G93A Mice", "doi": "10.3390/brainsci12040490", "year": 2022 } ] } }, { "id": 39403, "drug": "dapagliflozin", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "upregulates", "mediator": "AMPK", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "amyotrophic lateral sclerosis", "outcome_type": "disease", "outcome_domain": "als", "score": 0.24849066497880004, "filtered_score": 0.24849066497880004, "filter_reason": null, "outreach_score": 0.24849066497880004, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "dapagliflozin", "mediator_canonical": "AMPK", "outcome_canonical": "amyotrophic lateral sclerosis", "ab_count": 5, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40264429", "title": "Dapagliflozin ameliorates kidney injury following limb ischemia-reperfusion via the AMPK/SIRT1/NLRP3 pathway", "doi": "10.1080/0886022x.2025.2495111", "year": 2025 }, { "pmid": "36809274", "title": "Mapping the metabolic reprogramming induced by sodium-glucose cotransporter 2 inhibition", "doi": "10.1172/jci.insight.164296", "year": 2023 }, { "pmid": "35274762", "title": "Dapagliflozin attenuates high glucose‐induced endothelial cell apoptosis and inflammation through AMPK/SIRT1 activation", "doi": "10.1111/1440-1681.13638", "year": 2022 } ], "bc": [ { "pmid": "34393724", "title": "Contribution of Energy Dysfunction to Impaired Protein Translation in Neurodegenerative Diseases", "doi": "10.3389/fncel.2021.668500", "year": 2021 } ] } }, { "id": 1360, "drug": "1A-116", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "inhibits", "mediator": "RAC1", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "Alzheimer's disease", "outcome_type": "disease", "outcome_domain": "alzheimer", "score": 0.24849066497880004, "filtered_score": 0.24849066497880004, "filter_reason": null, "outreach_score": 0.24849066497880004, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "1a-116", "mediator_canonical": "rac1", "outcome_canonical": "Alzheimer disease", "ab_count": 2, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "36230732", "title": "Preclinical Efficacy and Toxicology Evaluation of RAC1 Inhibitor 1A-116 in Human Glioblastoma Models", "doi": "10.3390/cancers14194810", "year": 2022 }, { "pmid": "34371781", "title": "Timing of Novel Drug 1A-116 to Circadian Rhythms Improves Therapeutic Effects against Glioblastoma", "doi": "10.3390/pharmaceutics13071091", "year": 2021 } ], "bc": [ { "pmid": "31321704", "title": "Inhibition of Rac1-dependent forgetting alleviates memory deficits in animal models of Alzheimer’s disease", "doi": "10.1007/s13238-019-0641-0", "year": 2019 }, { "pmid": "30005699", "title": "Rac1 activation links tau hyperphosphorylation and Aβ dysmetabolism in Alzheimer’s disease", "doi": "10.1186/s40478-018-0567-4", "year": 2018 } ] } }, { "id": 32913, "drug": "rhTM", "drug_type": "drug", "drug_domain": "inflammatory_bowel_disease", "predicate_ab": "inhibits", "mediator": "HMGB1", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "epilepsy", "outcome_type": "disease", "outcome_domain": "epilepsy", "score": 0.24849066497880004, "filtered_score": 0.24849066497880004, "filter_reason": null, "outreach_score": 0.24849066497880004, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "rhtm", "mediator_canonical": "HMGB1", "outcome_canonical": "epilepsy", "ab_count": 1, "bc_count": 5, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "26302768", "title": "Recombinant Thrombomodulin Modulates Murine Colitis Possibly via High-Mobility Group Box 1 Protein Inhibition", "doi": "10.1159/000438507", "year": 2015 } ], "bc": [ { "pmid": "39466324", "title": "Clinical and biochemical assessments of circulating High Mobility Group Box Protein1 in children with epilepsy: relation to cognitive function and drug responsiveness", "doi": "10.1007/s10072-024-07795-z", "year": 2024 }, { "pmid": "32538745", "title": "Correlation of MMP-9 and HMGB1 expression with the cognitive function in patients with epilepsy and factors affecting the prognosis", "doi": "10.14715/cmb/2020.66.3.6", "year": 2020 }, { "pmid": "33150666", "title": "Evaluation of serum high-mobility group box 1 concentration in dogs with epilepsy: A case-control study", "doi": "10.1111/jvim.15940", "year": 2020 } ] } }, { "id": 32912, "drug": "Melatonin", "drug_type": "drug", "drug_domain": "inflammatory_bowel_disease", "predicate_ab": "inhibits", "mediator": "HMGB1", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "epilepsy", "outcome_type": "disease", "outcome_domain": "epilepsy", "score": 0.24849066497880004, "filtered_score": 0.24849066497880004, "filter_reason": null, "outreach_score": 0.24849066497880004, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "completed", "clinical_trial_nct_ids": [ "NCT07221968", "NCT05439876", "NCT04665453" ], "literature_status": "reproduces_known", "drug_canonical": "melatonin", "mediator_canonical": "HMGB1", "outcome_canonical": "epilepsy", "ab_count": 1, "bc_count": 5, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "31082723", "title": "Melatonin alleviates circadian rhythm disruption exacerbating DSS-induced colitis by inhibiting the distribution of HMGB1 in intestinal tissues", "doi": "10.1016/j.intimp.2019.05.005", "year": 2019 } ], "bc": [ { "pmid": "39466324", "title": "Clinical and biochemical assessments of circulating High Mobility Group Box Protein1 in children with epilepsy: relation to cognitive function and drug responsiveness", "doi": "10.1007/s10072-024-07795-z", "year": 2024 }, { "pmid": "32538745", "title": "Correlation of MMP-9 and HMGB1 expression with the cognitive function in patients with epilepsy and factors affecting the prognosis", "doi": "10.14715/cmb/2020.66.3.6", "year": 2020 }, { "pmid": "33150666", "title": "Evaluation of serum high-mobility group box 1 concentration in dogs with epilepsy: A case-control study", "doi": "10.1111/jvim.15940", "year": 2020 } ] } }, { "id": 32911, "drug": "DPG", "drug_type": "drug", "drug_domain": "inflammatory_bowel_disease", "predicate_ab": "inhibits", "mediator": "HMGB1", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "epilepsy", "outcome_type": "disease", "outcome_domain": "epilepsy", "score": 0.24849066497880004, "filtered_score": 0.24849066497880004, "filter_reason": null, "outreach_score": 0.24849066497880004, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "dpg", "mediator_canonical": "HMGB1", "outcome_canonical": "epilepsy", "ab_count": 1, "bc_count": 5, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "31105713", "title": "Dipotassium Glycyrrhizate Improves Intestinal Mucosal Healing by Modulating Extracellular Matrix Remodeling Genes and Restoring Epithelial Barrier Functions", "doi": "10.3389/fimmu.2019.00939", "year": 2019 } ], "bc": [ { "pmid": "39466324", "title": "Clinical and biochemical assessments of circulating High Mobility Group Box Protein1 in children with epilepsy: relation to cognitive function and drug responsiveness", "doi": "10.1007/s10072-024-07795-z", "year": 2024 }, { "pmid": "32538745", "title": "Correlation of MMP-9 and HMGB1 expression with the cognitive function in patients with epilepsy and factors affecting the prognosis", "doi": "10.14715/cmb/2020.66.3.6", "year": 2020 }, { "pmid": "33150666", "title": "Evaluation of serum high-mobility group box 1 concentration in dogs with epilepsy: A case-control study", "doi": "10.1111/jvim.15940", "year": 2020 } ] } }, { "id": 37650, "drug": "bimekizumab", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "inhibits", "mediator": "IL-17A", "mediator_type": "protein", "predicate_bc": "decreases", "outcome": "motor neuron viability", "outcome_type": "phenotype", "outcome_domain": "als", "score": 0.24849066497880004, "filtered_score": 0.24849066497880004, "filter_reason": null, "outreach_score": 0.24849066497880004, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "bimekizumab", "mediator_canonical": "il-17a", "outcome_canonical": "motor neuron viability", "ab_count": 5, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "39215949", "title": "Safety and Efficacy of Bimekizumab in Patients with Psoriatic Arthritis: 2-Year Results from Two Phase 3 Studies", "doi": "10.1007/s40744-024-00708-8", "year": 2024 }, { "pmid": "39620046", "title": "Impact of bimekizumab and certolizumab pegol on efficacy, safety and osteoblastic activity in radiographic axial spondyloarthritis: results from a phase IIa, multicentre, randomised, double-blind, exploratory study with PET-CT imaging", "doi": "10.1177/1759720x241293944", "year": 2024 }, { "pmid": "37808274", "title": "Safe and Effective Subcutaneous Self-Injection of Bimekizumab with Safety Syringe and Auto-Injector Devices: Results from a Multicenter, Randomized, Open-Label Study in Patients with Psoriatic Arthritis", "doi": "10.2147/ppa.s427809", "year": 2023 } ], "bc": [ { "pmid": "34360808", "title": "Interleukin-17 and Th17 Lymphocytes Directly Impair Motoneuron Survival of Wildtype and FUS-ALS Mutant Human iPSCs", "doi": "10.3390/ijms22158042", "year": 2021 } ] } }, { "id": 560, "drug": "Bevacizumab", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "binds_to", "mediator": "VEGF", "mediator_type": "protein", "predicate_bc": "increases", "outcome": "BBB permeability", "outcome_type": "phenotype", "outcome_domain": "epilepsy", "score": 0.24849066497880004, "filtered_score": 0.24849066497880004, "filter_reason": null, "outreach_score": 0.24849066497880004, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "bevacizumab", "mediator_canonical": "VEGF", "outcome_canonical": "bbb permeability", "ab_count": 5, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41951573", "title": "L-RNA aptamer-based CXCL12 inhibition combined with radiotherapy and bevacizumab in newly-diagnosed glioblastoma: expansion of the phase I/II GLORIA trial", "doi": "10.1038/s41467-026-71362-7", "year": 2026 }, { "pmid": "40757003", "title": "Developing Immunoniosomes (INs): Antibody and Fab conjugations of niosomal nanoparticles via UV-NBS and EDC/NHS chemistry for treating glioblastoma cells", "doi": "10.1016/j.ijpx.2025.100367", "year": 2025 }, { "pmid": "41431343", "title": "Incidence of Bevacizumab‐Associated Toxicity in Children With Low‐Grade Glioma With and Without Neurofibromatosis Type 1", "doi": "10.1002/1545-5017.70059", "year": 2025 } ], "bc": [ { "pmid": "38049961", "title": "Cerebral vascular and blood brain–barrier abnormalities in a mouse model of epilepsy and tuberous sclerosis complex", "doi": "10.1111/epi.17848", "year": 2023 } ] } }, { "id": 32323, "drug": "LWE", "drug_type": "drug", "drug_domain": "inflammatory_bowel_disease", "predicate_ab": "upregulates", "mediator": "SOD1", "mediator_type": "gene", "predicate_bc": "associated_with", "outcome": "familial amyotrophic lateral sclerosis", "outcome_type": "disease", "outcome_domain": "als", "score": 0.24849066497880004, "filtered_score": 0.24849066497880004, "filter_reason": null, "outreach_score": 0.24849066497880004, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "lwe", "mediator_canonical": "SOD1", "outcome_canonical": "familial amyotrophic lateral sclerosis", "ab_count": 1, "bc_count": 5, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "39061864", "title": "Hydroethanolic Extract of Lepidium apetalum Willdenow Alleviates Dextran Sulfate Sodium-Induced Colitis by Enhancing Intestinal Barrier Integrity and Inhibiting Oxidative Stress and Inflammasome Activation", "doi": "10.3390/antiox13070795", "year": 2024 } ], "bc": [ { "pmid": "35576897", "title": "Genetic Epidemiology of Amyotrophic Lateral Sclerosis in Norway: A 2-Year Population-Based Study", "doi": "10.1159/000525091", "year": 2022 }, { "pmid": "31134679", "title": "SOD1 in amyotrophic lateral sclerosis development – in silico analysis and molecular dynamics of A4F and A4V variants", "doi": "10.1002/jcb.29048", "year": 2019 }, { "pmid": "29609497", "title": "A novel D90_K91insN mutation in exon 4 of the SOD1 gene caused familial amyotrophic lateral sclerosis in a Chinese pedigree", "doi": "10.1080/21678421.2018.1457057", "year": 2018 } ] } }, { "id": 7646, "drug": "glycyrrhizin", "drug_type": "drug", "drug_domain": "als", "predicate_ab": "binds_to", "mediator": "HMGB1", "mediator_type": "protein", "predicate_bc": "predicts", "outcome": "drug-resistant epilepsy", "outcome_type": "disease", "outcome_domain": "epilepsy", "score": 0.24849066497880004, "filtered_score": 0.24849066497880004, "filter_reason": null, "outreach_score": 0.24849066497880004, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "glycyrrhizin", "mediator_canonical": "HMGB1", "outcome_canonical": "drug-resistant epilepsy", "ab_count": 2, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41139682", "title": "Therapeutic potential of glycyrrhizin in nervous system diseases", "doi": "10.1097/cm9.0000000000003806", "year": 2025 } ], "bc": [ { "pmid": "34747496", "title": "High‐mobility group box 1 as a predictive biomarker for drug‐resistant epilepsy: A proof‐of‐concept study", "doi": "10.1111/epi.17116", "year": 2021 } ] } }, { "id": 564, "drug": "Bevacizumab", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "binds_to", "mediator": "VEGF", "mediator_type": "protein", "predicate_bc": "prevents", "outcome": "hippocampal neuron loss", "outcome_type": "phenotype", "outcome_domain": "epilepsy", "score": 0.24849066497880004, "filtered_score": 0.24849066497880004, "filter_reason": null, "outreach_score": 0.24849066497880004, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "bevacizumab", "mediator_canonical": "VEGF", "outcome_canonical": "hippocampal neuron loss", "ab_count": 5, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41951573", "title": "L-RNA aptamer-based CXCL12 inhibition combined with radiotherapy and bevacizumab in newly-diagnosed glioblastoma: expansion of the phase I/II GLORIA trial", "doi": "10.1038/s41467-026-71362-7", "year": 2026 }, { "pmid": "40757003", "title": "Developing Immunoniosomes (INs): Antibody and Fab conjugations of niosomal nanoparticles via UV-NBS and EDC/NHS chemistry for treating glioblastoma cells", "doi": "10.1016/j.ijpx.2025.100367", "year": 2025 }, { "pmid": "41431343", "title": "Incidence of Bevacizumab‐Associated Toxicity in Children With Low‐Grade Glioma With and Without Neurofibromatosis Type 1", "doi": "10.1002/1545-5017.70059", "year": 2025 } ], "bc": [ { "pmid": "35002944", "title": "VEGF Modulates Neurogenesis and Microvascular Remodeling in Epileptogenesis After Status Epilepticus in Immature Rats", "doi": "10.3389/fneur.2021.808568", "year": 2021 } ] } }, { "id": 8792, "drug": "CLR01", "drug_type": "drug", "drug_domain": "alzheimer", "predicate_ab": "binds_to", "mediator": "TAU", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "Alzheimer's disease", "outcome_type": "disease", "outcome_domain": "als", "score": 0.24849066497880004, "filtered_score": 0.24849066497880004, "filter_reason": null, "outreach_score": 0.24849066497880004, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "clr01", "mediator_canonical": "MAPT", "outcome_canonical": "Alzheimer disease", "ab_count": 3, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "31046227", "title": "Major Differences between the Self-Assembly and Seeding Behavior of Heparin-Induced and in Vitro Phosphorylated Tau and Their Modulation by Potential Inhibitors", "doi": "10.1021/acschembio.9b00325", "year": 2019 }, { "pmid": "30062477", "title": "Native Top-Down Mass Spectrometry and Ion Mobility Spectrometry of the Interaction of Tau Protein with a Molecular Tweezer Assembly Modulator", "doi": "10.1007/s13361-018-2027-6", "year": 2018 } ], "bc": [ { "pmid": "41532955", "title": "Unveiling the Proteomic Landscape of Extracellular Vesicles: Implications for Neurodegeneration and Neuroprotection", "doi": "10.1111/jnc.70350", "year": 2026 }, { "pmid": "26705184", "title": "[Histopathological and immunohistochemical study of spinal cord tissues in neurodegenerative diseases].", "doi": null, "year": 2015 } ] } }, { "id": 38819, "drug": "bimekizumab", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "inhibits", "mediator": "IL-17A", "mediator_type": "protein", "predicate_bc": "increases", "outcome": "EAE severity", "outcome_type": "phenotype", "outcome_domain": "multiple_sclerosis", "score": 0.24849066497880004, "filtered_score": 0.24849066497880004, "filter_reason": null, "outreach_score": 0.24849066497880004, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "bimekizumab", "mediator_canonical": "il-17a", "outcome_canonical": "eae severity", "ab_count": 5, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "39215949", "title": "Safety and Efficacy of Bimekizumab in Patients with Psoriatic Arthritis: 2-Year Results from Two Phase 3 Studies", "doi": "10.1007/s40744-024-00708-8", "year": 2024 }, { "pmid": "39620046", "title": "Impact of bimekizumab and certolizumab pegol on efficacy, safety and osteoblastic activity in radiographic axial spondyloarthritis: results from a phase IIa, multicentre, randomised, double-blind, exploratory study with PET-CT imaging", "doi": "10.1177/1759720x241293944", "year": 2024 }, { "pmid": "37808274", "title": "Safe and Effective Subcutaneous Self-Injection of Bimekizumab with Safety Syringe and Auto-Injector Devices: Results from a Multicenter, Randomized, Open-Label Study in Patients with Psoriatic Arthritis", "doi": "10.2147/ppa.s427809", "year": 2023 } ], "bc": [ { "pmid": "36857006", "title": "IL-17A Facilitates Entry of Autoreactive T-Cells and Granulocytes into the CNS During EAE", "doi": "10.1007/s12017-023-08739-0", "year": 2023 } ] } }, { "id": 23214, "drug": "recombinant thrombomodulin", "drug_type": "drug", "drug_domain": "multiple_sclerosis", "predicate_ab": "suppresses", "mediator": "HMGB1", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "epilepsy", "outcome_type": "disease", "outcome_domain": "epilepsy", "score": 0.24849066497880004, "filtered_score": 0.24849066497880004, "filter_reason": null, "outreach_score": 0.24849066497880004, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "recombinant thrombomodulin", "mediator_canonical": "HMGB1", "outcome_canonical": "epilepsy", "ab_count": 1, "bc_count": 5, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "29509323", "title": "Recombinant thrombomodulin ameliorates experimental autoimmune encephalomyelitis by suppressing high mobility group box 1 and inflammatory cytokines", "doi": "10.1111/cei.13123", "year": 2018 } ], "bc": [ { "pmid": "39466324", "title": "Clinical and biochemical assessments of circulating High Mobility Group Box Protein1 in children with epilepsy: relation to cognitive function and drug responsiveness", "doi": "10.1007/s10072-024-07795-z", "year": 2024 }, { "pmid": "32538745", "title": "Correlation of MMP-9 and HMGB1 expression with the cognitive function in patients with epilepsy and factors affecting the prognosis", "doi": "10.14715/cmb/2020.66.3.6", "year": 2020 }, { "pmid": "33150666", "title": "Evaluation of serum high-mobility group box 1 concentration in dogs with epilepsy: A case-control study", "doi": "10.1111/jvim.15940", "year": 2020 } ] } }, { "id": 51362, "drug": "sulforaphane", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "activates", "mediator": "Nrf2", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "disease progression", "outcome_type": "phenotype", "outcome_domain": "multiple_sclerosis", "score": 0.24849066497880004, "filtered_score": 0.24849066497880004, "filter_reason": null, "outreach_score": 0.24849066497880004, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 5, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "33067900", "title": "Sulforaphane prevents age‐associated cardiac and muscular dysfunction through Nrf2 signaling", "doi": "10.1111/acel.13261", "year": 2020 }, { "pmid": "31270951", "title": "Protection against diabetic cardiomyopathy is achieved using a combination of sulforaphane and zinc in type 1 diabetic OVE26 mice", "doi": "10.1111/jcmm.14520", "year": 2019 }, { "pmid": "29353218", "title": "Sulforaphane prevents angiotensin II-induced cardiomyopathy by activation of Nrf2 via stimulating the Akt/GSK-3ß/Fyn pathway", "doi": "10.1016/j.redox.2017.12.016", "year": 2018 } ], "bc": [ { "pmid": "33396641", "title": "Peripheral Blood NRF2 Expression as a Biomarker in Human Health and Disease", "doi": "10.3390/antiox10010028", "year": 2020 } ] } }, { "id": 3781, "drug": "sodium butyrate", "drug_type": "drug", "drug_domain": "alzheimer", "predicate_ab": "upregulates", "mediator": "Sod1", "mediator_type": "gene", "predicate_bc": "associated_with", "outcome": "familial amyotrophic lateral sclerosis", "outcome_type": "disease", "outcome_domain": "als", "score": 0.24849066497880004, "filtered_score": 0.24849066497880004, "filter_reason": null, "outreach_score": 0.24849066497880004, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "sodium butyrate", "mediator_canonical": "SOD1", "outcome_canonical": "familial amyotrophic lateral sclerosis", "ab_count": 1, "bc_count": 5, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "32555166", "title": "Sodium butyrate inhibits high cholesterol-induced neuronal amyloidogenesis by modulating NRF2 stabilization-mediated ROS levels: involvement of NOX2 and SOD1", "doi": "10.1038/s41419-020-2663-1", "year": 2020 } ], "bc": [ { "pmid": "35576897", "title": "Genetic Epidemiology of Amyotrophic Lateral Sclerosis in Norway: A 2-Year Population-Based Study", "doi": "10.1159/000525091", "year": 2022 }, { "pmid": "31134679", "title": "SOD1 in amyotrophic lateral sclerosis development – in silico analysis and molecular dynamics of A4F and A4V variants", "doi": "10.1002/jcb.29048", "year": 2019 }, { "pmid": "29609497", "title": "A novel D90_K91insN mutation in exon 4 of the SOD1 gene caused familial amyotrophic lateral sclerosis in a Chinese pedigree", "doi": "10.1080/21678421.2018.1457057", "year": 2018 } ] } }, { "id": 31922, "drug": "Bevacizumab", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "inhibits", "mediator": "VEGF", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "DAS28", "outcome_type": "phenotype", "outcome_domain": "rheumatoid_arthritis", "score": 0.24849066497880004, "filtered_score": 0.24849066497880004, "filter_reason": null, "outreach_score": 0.24849066497880004, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "bevacizumab", "mediator_canonical": "VEGF", "outcome_canonical": "das28", "ab_count": 5, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41951573", "title": "L-RNA aptamer-based CXCL12 inhibition combined with radiotherapy and bevacizumab in newly-diagnosed glioblastoma: expansion of the phase I/II GLORIA trial", "doi": "10.1038/s41467-026-71362-7", "year": 2026 }, { "pmid": "40757003", "title": "Developing Immunoniosomes (INs): Antibody and Fab conjugations of niosomal nanoparticles via UV-NBS and EDC/NHS chemistry for treating glioblastoma cells", "doi": "10.1016/j.ijpx.2025.100367", "year": 2025 }, { "pmid": "41431343", "title": "Incidence of Bevacizumab‐Associated Toxicity in Children With Low‐Grade Glioma With and Without Neurofibromatosis Type 1", "doi": "10.1002/1545-5017.70059", "year": 2025 } ], "bc": [ { "pmid": "29336711", "title": "Circulating serum interleukin-6, serum chitinase-3-like protein-1, and plasma vascular endothelial growth factor are not predictive for remission and radiographic progression in patients with early rheumatoid arthritis: post-hoc explorative and validation studies based on the CIMESTRA and OPERA trials", "doi": "10.1080/03009742.2017.1376107", "year": 2018 } ] } }, { "id": 51563, "drug": "digoxin", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "inhibits", "mediator": "PKM2", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "poor overall survival", "outcome_type": "phenotype", "outcome_domain": "pancreatic_cancer", "score": 0.24849066497880004, "filtered_score": 0.24849066497880004, "filter_reason": null, "outreach_score": 0.24849066497880004, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 5, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "31411894", "title": "Digoxin improves steatohepatitis with differential involvement of liver cell subsets in mice through inhibition of PKM2 transactivation", "doi": "10.1152/ajpgi.00054.2019", "year": 2019 } ], "bc": [ { "pmid": "27478385", "title": "Pyruvate kinase M2 overexpression and poor prognosis in solid tumors of digestive system: evidence from 16 cohort studies", "doi": "10.2147/ott.s106508", "year": 2016 } ] } }, { "id": 51564, "drug": "sulforaphane", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "activates", "mediator": "Nrf2", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "poor prognosis", "outcome_type": "phenotype", "outcome_domain": "pancreatic_cancer", "score": 0.24849066497880004, "filtered_score": 0.24849066497880004, "filter_reason": null, "outreach_score": 0.24849066497880004, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 5, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "33067900", "title": "Sulforaphane prevents age‐associated cardiac and muscular dysfunction through Nrf2 signaling", "doi": "10.1111/acel.13261", "year": 2020 }, { "pmid": "31270951", "title": "Protection against diabetic cardiomyopathy is achieved using a combination of sulforaphane and zinc in type 1 diabetic OVE26 mice", "doi": "10.1111/jcmm.14520", "year": 2019 }, { "pmid": "29353218", "title": "Sulforaphane prevents angiotensin II-induced cardiomyopathy by activation of Nrf2 via stimulating the Akt/GSK-3ß/Fyn pathway", "doi": "10.1016/j.redox.2017.12.016", "year": 2018 } ], "bc": [ { "pmid": "31911550", "title": "Undermining Glutaminolysis Bolsters Chemotherapy While NRF2 Promotes Chemoresistance in KRAS-Driven Pancreatic Cancers", "doi": "10.1158/0008-5472.can-19-1363", "year": 2020 } ] } }, { "id": 2885, "drug": "pridopidine", "drug_type": "drug", "drug_domain": "als", "predicate_ab": "activates", "mediator": "sigma-1 receptor", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "glioblastoma", "outcome_type": "disease", "outcome_domain": "glioblastoma", "score": 0.24849066497880004, "filtered_score": 0.24849066497880004, "filter_reason": null, "outreach_score": 0.24849066497880004, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "pridopidine", "mediator_canonical": "sigma-1 receptor", "outcome_canonical": "glioblastoma", "ab_count": 3, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41471389", "title": "Pridopidine, a Potent and Selective Therapeutic Sigma-1 Receptor (S1R) Agonist for Treating Neurodegenerative Diseases", "doi": "10.3390/ph18121900", "year": 2025 }, { "pmid": "35080077", "title": "Pridopidine modifies disease phenotype in a SOD1 mouse model of amyotrophic lateral sclerosis", "doi": "10.1111/ejn.15608", "year": 2022 }, { "pmid": "30824685", "title": "Targeting the Sigma-1 Receptor via Pridopidine Ameliorates Central Features of ALS Pathology in a SOD1G93A Model", "doi": "10.1038/s41419-019-1451-2", "year": 2019 } ], "bc": [ { "pmid": "32384802", "title": "Sigma-1 Receptor Positron Emission Tomography: A New Molecular Imaging Approach Using (S)-(−)-[18F]Fluspidine in Glioblastoma", "doi": "10.3390/molecules25092170", "year": 2020 } ] } }, { "id": 51565, "drug": "Shikonin", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "inhibits", "mediator": "PKM2", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "poor overall survival", "outcome_type": "phenotype", "outcome_domain": "pancreatic_cancer", "score": 0.24849066497880004, "filtered_score": 0.24849066497880004, "filter_reason": null, "outreach_score": 0.24849066497880004, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 5, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "34687136", "title": "PKM2 promotes angiotensin‐II‐induced cardiac remodelling by activating TGF‐β/Smad2/3 and Jak2/Stat3 pathways through oxidative stress", "doi": "10.1111/jcmm.17007", "year": 2021 } ], "bc": [ { "pmid": "27478385", "title": "Pyruvate kinase M2 overexpression and poor prognosis in solid tumors of digestive system: evidence from 16 cohort studies", "doi": "10.2147/ott.s106508", "year": 2016 } ] } }, { "id": 36851, "drug": "durvalumab", "drug_type": "drug", "drug_domain": "pancreatic_cancer", "predicate_ab": "inhibits", "mediator": "PD-L1", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "colitis", "outcome_type": "disease", "outcome_domain": "inflammatory_bowel_disease", "score": 0.24849066497880004, "filtered_score": 0.24849066497880004, "filter_reason": null, "outreach_score": 0.24849066497880004, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "durvalumab", "mediator_canonical": "PD-L1", "outcome_canonical": "colitis", "ab_count": 3, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37452505", "title": "Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: An early exploratory analysis of real‐world data", "doi": "10.1111/liv.15641", "year": 2023 }, { "pmid": "33688022", "title": "Safety and activity of the TGFβ receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer", "doi": "10.1136/jitc-2020-002068", "year": 2021 }, { "pmid": "31230047", "title": "A Phase 1b/2 Study of the Bruton Tyrosine Kinase Inhibitor Ibrutinib and the PD-L1 Inhibitor Durvalumab in Patients with Pretreated Solid Tumors", "doi": "10.1159/000500571", "year": 2019 } ], "bc": [ { "pmid": "40661950", "title": "PD-L1 deficiency exacerbates colitis severity by remodeling gut microbiota in inflammatory bowel disease", "doi": "10.3389/fimmu.2025.1622744", "year": 2025 }, { "pmid": "37435072", "title": "Case Report: A severe case of immunosuppressant-refractory immune checkpoint inhibitor-mediated colitis rescued by tofacitinib", "doi": "10.3389/fimmu.2023.1212432", "year": 2023 } ] } }, { "id": 57058, "drug": "olaparib", "drug_type": "drug", "drug_domain": "pancreatic_cancer", "predicate_ab": "inhibits", "mediator": "PARP", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "chronic heart failure", "outcome_type": "disease", "outcome_domain": "heart_failure", "score": 0.24849066497880004, "filtered_score": 0.24849066497880004, "filter_reason": null, "outreach_score": 0.24849066497880004, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 5, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "33662100", "title": "Olaparib Monotherapy for Previously Treated Pancreatic Cancer With DNA Damage Repair Genetic Alterations Other Than Germline BRCA Variants", "doi": "10.1001/jamaoncol.2021.0006", "year": 2021 }, { "pmid": "31157963", "title": "Maintenance Olaparib for Germline BRCA -Mutated Metastatic Pancreatic Cancer", "doi": "10.1056/nejmoa1903387", "year": 2019 }, { "pmid": "30407790", "title": "Epidermal Growth Factor Receptor-Targeting Peptide Nanoparticles Simultaneously Deliver Gemcitabine and Olaparib To Treat Pancreatic Cancer with Breast Cancer 2 (BRCA2) Mutation", "doi": "10.1021/acsnano.8b01573", "year": 2018 } ], "bc": [ { "pmid": "29250299", "title": "Oxidative Stress‐Related Parthanatos of Circulating Mononuclear Leukocytes in Heart Failure", "doi": "10.1155/2017/1249614", "year": 2017 } ] } }, { "id": 59064, "drug": "bimekizumab", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "inhibits", "mediator": "IL-17A", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "left atrial diameter", "outcome_type": "phenotype", "outcome_domain": "heart_failure", "score": 0.24849066497880004, "filtered_score": 0.24849066497880004, "filter_reason": null, "outreach_score": 0.24849066497880004, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 5, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "39215949", "title": "Safety and Efficacy of Bimekizumab in Patients with Psoriatic Arthritis: 2-Year Results from Two Phase 3 Studies", "doi": "10.1007/s40744-024-00708-8", "year": 2024 }, { "pmid": "39620046", "title": "Impact of bimekizumab and certolizumab pegol on efficacy, safety and osteoblastic activity in radiographic axial spondyloarthritis: results from a phase IIa, multicentre, randomised, double-blind, exploratory study with PET-CT imaging", "doi": "10.1177/1759720x241293944", "year": 2024 }, { "pmid": "37808274", "title": "Safe and Effective Subcutaneous Self-Injection of Bimekizumab with Safety Syringe and Auto-Injector Devices: Results from a Multicenter, Randomized, Open-Label Study in Patients with Psoriatic Arthritis", "doi": "10.2147/ppa.s427809", "year": 2023 } ], "bc": [ { "pmid": "27198976", "title": "Elevated plasma levels of Th17-related cytokines are associated with increased risk of atrial fibrillation", "doi": "10.1038/srep26543", "year": 2016 } ] } }, { "id": 10707, "drug": "etomidate", "drug_type": "drug", "drug_domain": "depression", "predicate_ab": "suppresses", "mediator": "cortisol", "mediator_type": "biomarker", "predicate_bc": "correlates_with", "outcome": "Alzheimer's disease", "outcome_type": "disease", "outcome_domain": "alzheimer", "score": 0.24849066497880004, "filtered_score": 0.24849066497880004, "filter_reason": null, "outreach_score": 0.24849066497880004, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "etomidate", "mediator_canonical": "cortisol", "outcome_canonical": "Alzheimer disease", "ab_count": 1, "bc_count": 5, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41855383", "title": "Role of Anesthesia in ECT for Major Depressive Disorder", "doi": "10.1097/yct.0000000000001259", "year": 2026 } ], "bc": [ { "pmid": "37251803", "title": "Serum cortisol is negatively related to hippocampal volume, brain structure, and memory performance in healthy aging and Alzheimer’s disease", "doi": "10.3389/fnagi.2023.1154112", "year": 2023 }, { "pmid": "37583892", "title": "The effect of plasma cortisol on hippocampal atrophy and clinical progression in mild cognitive impairment", "doi": "10.1002/dad2.12463", "year": 2023 }, { "pmid": "31256117", "title": "Cortisol, Amyloid-β, and Reserve Predicts Alzheimer’s Disease Progression for Cognitively Normal Older Adults", "doi": "10.3233/jad-181030", "year": 2019 } ] } }, { "id": 3576, "drug": "CLR01", "drug_type": "drug", "drug_domain": "alzheimer", "predicate_ab": "binds_to", "mediator": "TAU", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "memory performance", "outcome_type": "phenotype", "outcome_domain": "epilepsy", "score": 0.24849066497880004, "filtered_score": 0.24849066497880004, "filter_reason": null, "outreach_score": 0.24849066497880004, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "clr01", "mediator_canonical": "MAPT", "outcome_canonical": "memory performance", "ab_count": 3, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "31046227", "title": "Major Differences between the Self-Assembly and Seeding Behavior of Heparin-Induced and in Vitro Phosphorylated Tau and Their Modulation by Potential Inhibitors", "doi": "10.1021/acschembio.9b00325", "year": 2019 }, { "pmid": "30062477", "title": "Native Top-Down Mass Spectrometry and Ion Mobility Spectrometry of the Interaction of Tau Protein with a Molecular Tweezer Assembly Modulator", "doi": "10.1007/s13361-018-2027-6", "year": 2018 } ], "bc": [ { "pmid": "33725124", "title": "Early stages of tau pathology and its associations with functional connectivity, atrophy and memory", "doi": "10.1093/brain/awab114", "year": 2021 } ] } }, { "id": 59070, "drug": "bimekizumab", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "inhibits", "mediator": "IL-17F", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "left ventricle ejection fraction", "outcome_type": "phenotype", "outcome_domain": "heart_failure", "score": 0.24849066497880004, "filtered_score": 0.24849066497880004, "filter_reason": null, "outreach_score": 0.24849066497880004, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 5, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "39215949", "title": "Safety and Efficacy of Bimekizumab in Patients with Psoriatic Arthritis: 2-Year Results from Two Phase 3 Studies", "doi": "10.1007/s40744-024-00708-8", "year": 2024 }, { "pmid": "39620046", "title": "Impact of bimekizumab and certolizumab pegol on efficacy, safety and osteoblastic activity in radiographic axial spondyloarthritis: results from a phase IIa, multicentre, randomised, double-blind, exploratory study with PET-CT imaging", "doi": "10.1177/1759720x241293944", "year": 2024 }, { "pmid": "37808274", "title": "Safe and Effective Subcutaneous Self-Injection of Bimekizumab with Safety Syringe and Auto-Injector Devices: Results from a Multicenter, Randomized, Open-Label Study in Patients with Psoriatic Arthritis", "doi": "10.2147/ppa.s427809", "year": 2023 } ], "bc": [ { "pmid": "27198976", "title": "Elevated plasma levels of Th17-related cytokines are associated with increased risk of atrial fibrillation", "doi": "10.1038/srep26543", "year": 2016 } ] } }, { "id": 40791, "drug": "dapagliflozin", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "upregulates", "mediator": "SIRT1", "mediator_type": "protein", "predicate_bc": "increases", "outcome": "tumor-initiating capacity", "outcome_type": "phenotype", "outcome_domain": "pancreatic_cancer", "score": 0.24849066497880004, "filtered_score": 0.24849066497880004, "filter_reason": null, "outreach_score": 0.24849066497880004, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "dapagliflozin", "mediator_canonical": "SIRT1", "outcome_canonical": "tumor-initiating capacity", "ab_count": 5, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37517289", "title": "Dapagliflozin prevents oxidative stress-induced endothelial dysfunction via sirtuin 1 activation", "doi": "10.1016/j.biopha.2023.115213", "year": 2023 }, { "pmid": "38017499", "title": "SIRT1 mediates the inhibitory effect of Dapagliflozin on EndMT by inhibiting the acetylation of endothelium Notch1", "doi": "10.1186/s12933-023-02040-x", "year": 2023 }, { "pmid": "37664712", "title": "Dapagliflozin impedes endothelial cell senescence by activating the SIRT1 signaling pathway in type 2 diabetes", "doi": "10.1016/j.heliyon.2023.e19152", "year": 2023 } ], "bc": [ { "pmid": "34163012", "title": "SIRT1 coordinates with the CRL4B complex to regulate pancreatic cancer stem cells to promote tumorigenesis", "doi": "10.1038/s41418-021-00821-z", "year": 2021 } ] } }, { "id": 40790, "drug": "dapagliflozin", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "upregulates", "mediator": "AMPK", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "pancreatic cancer progression", "outcome_type": "disease", "outcome_domain": "pancreatic_cancer", "score": 0.24849066497880004, "filtered_score": 0.24849066497880004, "filter_reason": null, "outreach_score": 0.24849066497880004, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "dapagliflozin", "mediator_canonical": "AMPK", "outcome_canonical": "pancreatic cancer progression", "ab_count": 5, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40264429", "title": "Dapagliflozin ameliorates kidney injury following limb ischemia-reperfusion via the AMPK/SIRT1/NLRP3 pathway", "doi": "10.1080/0886022x.2025.2495111", "year": 2025 }, { "pmid": "36809274", "title": "Mapping the metabolic reprogramming induced by sodium-glucose cotransporter 2 inhibition", "doi": "10.1172/jci.insight.164296", "year": 2023 }, { "pmid": "35274762", "title": "Dapagliflozin attenuates high glucose‐induced endothelial cell apoptosis and inflammation through AMPK/SIRT1 activation", "doi": "10.1111/1440-1681.13638", "year": 2022 } ], "bc": [ { "pmid": "31205544", "title": "AMPK Inhibition Suppresses the Malignant Phenotype of Pancreatic Cancer Cells in Part by Attenuating Aerobic Glycolysis", "doi": "10.7150/jca.28299", "year": 2019 } ] } }, { "id": 38813, "drug": "bimekizumab", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "inhibits", "mediator": "IL-17A", "mediator_type": "protein", "predicate_bc": "causes", "outcome": "CNS autoimmunity", "outcome_type": "disease", "outcome_domain": "multiple_sclerosis", "score": 0.24849066497880004, "filtered_score": 0.24849066497880004, "filter_reason": null, "outreach_score": 0.24849066497880004, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "preclinical_only", "clinical_trial_nct_ids": [ "NCT07138898" ], "literature_status": "novel_signal", "drug_canonical": "bimekizumab", "mediator_canonical": "il-17a", "outcome_canonical": "cns autoimmunity", "ab_count": 5, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "39215949", "title": "Safety and Efficacy of Bimekizumab in Patients with Psoriatic Arthritis: 2-Year Results from Two Phase 3 Studies", "doi": "10.1007/s40744-024-00708-8", "year": 2024 }, { "pmid": "39620046", "title": "Impact of bimekizumab and certolizumab pegol on efficacy, safety and osteoblastic activity in radiographic axial spondyloarthritis: results from a phase IIa, multicentre, randomised, double-blind, exploratory study with PET-CT imaging", "doi": "10.1177/1759720x241293944", "year": 2024 }, { "pmid": "37808274", "title": "Safe and Effective Subcutaneous Self-Injection of Bimekizumab with Safety Syringe and Auto-Injector Devices: Results from a Multicenter, Randomized, Open-Label Study in Patients with Psoriatic Arthritis", "doi": "10.2147/ppa.s427809", "year": 2023 } ], "bc": [ { "pmid": "33547052", "title": "IL-17 controls central nervous system autoimmunity through the intestinal microbiome", "doi": "10.1126/sciimmunol.aaz6563", "year": 2021 } ] } }, { "id": 40796, "drug": "lobeglitazone", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "binds_to", "mediator": "PPARγ", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "pancreatic cancer", "outcome_type": "disease", "outcome_domain": "pancreatic_cancer", "score": 0.23025850929940456, "filtered_score": 0.23025850929940456, "filter_reason": null, "outreach_score": 0.23025850929940456, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "lobeglitazone", "mediator_canonical": "pparγ", "outcome_canonical": "pancreatic cancer", "ab_count": 4, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "29311579", "title": "Structural Basis for the Enhanced Anti-Diabetic Efficacy of Lobeglitazone on PPARγ", "doi": "10.1038/s41598-017-18274-1", "year": 2018 }, { "pmid": "29203903", "title": "Structures of PPARγ complexed with lobeglitazone and pioglitazone reveal key determinants for the recognition of antidiabetic drugs", "doi": "10.1038/s41598-017-17082-x", "year": 2017 } ], "bc": [ { "pmid": "32801648", "title": "<p>The PPARγ Agonist Rosiglitazone Enhances the Radiosensitivity of Human Pancreatic Cancer Cells</p>", "doi": "10.2147/dddt.s242557", "year": 2020 } ] } }, { "id": 32857, "drug": "bovine colostrum", "drug_type": "drug", "drug_domain": "inflammatory_bowel_disease", "predicate_ab": "downregulates", "mediator": "IL-8", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "major depressive disorder", "outcome_type": "disease", "outcome_domain": "depression", "score": 0.23025850929940456, "filtered_score": 0.23025850929940456, "filter_reason": null, "outreach_score": 0.23025850929940456, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "bovine colostrum", "mediator_canonical": "IL8", "outcome_canonical": "major depressive disorder", "ab_count": 1, "bc_count": 4, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "30138385", "title": "Preventive effects of bovine colostrum supplementation in TNBS-induced colitis in mice", "doi": "10.1371/journal.pone.0202929", "year": 2018 } ], "bc": [ { "pmid": "41876463", "title": "Prediction of depressive episodes based on clinical features, cognitive characteristics, inflammation-related proteins, and EEG data", "doi": "10.1038/s41398-026-03960-4", "year": 2026 }, { "pmid": "34294614", "title": "White Matter Alterations Associated with Pro-inflammatory Cytokines in Patients with Major Depressive Disorder", "doi": "10.9758/cpn.2021.19.3.449", "year": 2021 }, { "pmid": "32874955", "title": "Serum levels of chemokines in adolescents with major depression treated with fluoxetine", "doi": "10.5498/wjp.v10.i8.175", "year": 2020 } ] } }, { "id": 32856, "drug": "AJE", "drug_type": "drug", "drug_domain": "inflammatory_bowel_disease", "predicate_ab": "inhibits", "mediator": "IL-8", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "major depressive disorder", "outcome_type": "disease", "outcome_domain": "depression", "score": 0.23025850929940456, "filtered_score": 0.23025850929940456, "filter_reason": null, "outreach_score": 0.23025850929940456, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "aje", "mediator_canonical": "IL8", "outcome_canonical": "major depressive disorder", "ab_count": 1, "bc_count": 4, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "30372880", "title": "Ameliorative effect of Alnus japonica ethanol extract on colitis through the inhibition of inflammatory responses and attenuation of intestinal barrier disruption in vivo and in vitro", "doi": "10.1016/j.biopha.2018.10.050", "year": 2018 } ], "bc": [ { "pmid": "41876463", "title": "Prediction of depressive episodes based on clinical features, cognitive characteristics, inflammation-related proteins, and EEG data", "doi": "10.1038/s41398-026-03960-4", "year": 2026 }, { "pmid": "34294614", "title": "White Matter Alterations Associated with Pro-inflammatory Cytokines in Patients with Major Depressive Disorder", "doi": "10.9758/cpn.2021.19.3.449", "year": 2021 }, { "pmid": "32874955", "title": "Serum levels of chemokines in adolescents with major depression treated with fluoxetine", "doi": "10.5498/wjp.v10.i8.175", "year": 2020 } ] } }, { "id": 38217, "drug": "FK506", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "suppresses", "mediator": "IL-8", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "major depressive disorder", "outcome_type": "disease", "outcome_domain": "depression", "score": 0.23025850929940456, "filtered_score": 0.23025850929940456, "filter_reason": null, "outreach_score": 0.23025850929940456, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "tacrolimus", "mediator_canonical": "IL8", "outcome_canonical": "major depressive disorder", "ab_count": 1, "bc_count": 4, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "30753461", "title": "Anti-receptor activator of nuclear factor κB ligand antibody treatment increases osteoclastogenesis-promoting IL-8 in patients with rheumatoid arthritis", "doi": "10.1093/intimm/dxz009", "year": 2019 } ], "bc": [ { "pmid": "41876463", "title": "Prediction of depressive episodes based on clinical features, cognitive characteristics, inflammation-related proteins, and EEG data", "doi": "10.1038/s41398-026-03960-4", "year": 2026 }, { "pmid": "34294614", "title": "White Matter Alterations Associated with Pro-inflammatory Cytokines in Patients with Major Depressive Disorder", "doi": "10.9758/cpn.2021.19.3.449", "year": 2021 }, { "pmid": "32874955", "title": "Serum levels of chemokines in adolescents with major depression treated with fluoxetine", "doi": "10.5498/wjp.v10.i8.175", "year": 2020 } ] } }, { "id": 35482, "drug": "DMF", "drug_type": "drug", "drug_domain": "multiple_sclerosis", "predicate_ab": "activates", "mediator": "Nrf2", "mediator_type": "protein", "predicate_bc": "decreases", "outcome": "toxicity of conventional anti-rheumatic therapies", "outcome_type": "phenotype", "outcome_domain": "rheumatoid_arthritis", "score": 0.23025850929940456, "filtered_score": 0.23025850929940456, "filter_reason": null, "outreach_score": 0.23025850929940456, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "dmf", "mediator_canonical": "NRF2", "outcome_canonical": "toxicity of conventional anti-rheumatic therapies", "ab_count": 4, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "35743211", "title": "Mechanisms of Sensitivity and Resistance of Primary Effusion Lymphoma to Dimethyl Fumarate (DMF)", "doi": "10.3390/ijms23126773", "year": 2022 }, { "pmid": "32672401", "title": "Structural insights into the multiple binding modes of Dimethyl Fumarate (DMF) and its analogs to the Kelch domain of Keap1", "doi": "10.1111/febs.15485", "year": 2020 }, { "pmid": "32394330", "title": "Characterization of More Selective Central Nervous System Nrf2-Activating Novel Vinyl Sulfoximine Compounds Compared to Dimethyl Fumarate", "doi": "10.1007/s13311-020-00855-0", "year": 2020 } ], "bc": [ { "pmid": "35964840", "title": "Pros and cons of NRF2 activation as adjunctive therapy in rheumatoid arthritis", "doi": "10.1016/j.freeradbiomed.2022.08.012", "year": 2022 } ] } }, { "id": 23419, "drug": "pembrolizumab", "drug_type": "drug", "drug_domain": "multiple_sclerosis", "predicate_ab": "inhibits", "mediator": "PD-1", "mediator_type": "protein", "predicate_bc": "predicts", "outcome": "unfavorable prognosis", "outcome_type": "phenotype", "outcome_domain": "als", "score": 0.23025850929940456, "filtered_score": 0.23025850929940456, "filter_reason": null, "outreach_score": 0.23025850929940456, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "pembrolizumab", "mediator_canonical": "pd-1", "outcome_canonical": "unfavorable prognosis", "ab_count": 4, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41232216", "title": "Iatrogenic NORSE: Immune checkpoint inhibitor-related anti-GFAP autoimmune astrocytopathy", "doi": "10.1016/j.jneuroim.2025.578805", "year": 2025 }, { "pmid": "35637642", "title": "Pembrolizumab for the treatment of Progressive Multifocal Leukoencephalopathy (PML) in a patient with AIDS: A case report and literature review", "doi": "10.1016/j.idcr.2022.e01514", "year": 2022 }, { "pmid": "33995251", "title": "Case Report: Longitudinal Extensive Transverse Myelitis With Novel Autoantibodies Following Two Rounds of Pembrolizumab", "doi": "10.3389/fneur.2021.655283", "year": 2021 } ], "bc": [ { "pmid": "40755012", "title": "Immune checkpoint changes correlate with the progression and prognosis of amyotrophic lateral sclerosis", "doi": "10.1080/07853890.2025.2540023", "year": 2025 } ] } }, { "id": 50584, "drug": "tafamidis", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "binds_to", "mediator": "TTR", "mediator_type": "protein", "predicate_bc": "predicts", "outcome": "major depressive disorder", "outcome_type": "disease", "outcome_domain": "depression", "score": 0.23025850929940456, "filtered_score": 0.23025850929940456, "filter_reason": null, "outreach_score": 0.23025850929940456, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 4, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "28951660", "title": "Treatment With Tafamidis Slows Disease Progression in Early-Stage Transthyretin Cardiomyopathy", "doi": "10.1177/1179546817730322", "year": 2017 }, { "pmid": "25872787", "title": "Tafamidis in Transthyretin Amyloid Cardiomyopathy", "doi": "10.1161/circheartfailure.113.000890", "year": 2015 }, { "pmid": "26193961", "title": "Personalized medicine approach for optimizing the dose of tafamidis to potentially ameliorate wild-type transthyretin amyloidosis (cardiomyopathy)", "doi": "10.3109/13506129.2015.1063485", "year": 2015 } ], "bc": [ { "pmid": "34572310", "title": "Transthyretin as a Biomarker to Predict and Monitor Major Depressive Disorder Identified by Whole-Genome Transcriptomic Analysis in Mouse Models", "doi": "10.3390/biomedicines9091124", "year": 2021 } ] } }, { "id": 50583, "drug": "dapagliflozin", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "inhibits", "mediator": "IL-8", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "major depressive disorder", "outcome_type": "disease", "outcome_domain": "depression", "score": 0.23025850929940456, "filtered_score": 0.23025850929940456, "filter_reason": null, "outreach_score": 0.23025850929940456, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 4, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "36077544", "title": "Dapagliflozin Mitigates Doxorubicin-Caused Myocardium Damage by Regulating AKT-Mediated Oxidative Stress, Cardiac Remodeling, and Inflammation", "doi": "10.3390/ijms231710146", "year": 2022 } ], "bc": [ { "pmid": "41876463", "title": "Prediction of depressive episodes based on clinical features, cognitive characteristics, inflammation-related proteins, and EEG data", "doi": "10.1038/s41398-026-03960-4", "year": 2026 }, { "pmid": "34294614", "title": "White Matter Alterations Associated with Pro-inflammatory Cytokines in Patients with Major Depressive Disorder", "doi": "10.9758/cpn.2021.19.3.449", "year": 2021 }, { "pmid": "32874955", "title": "Serum levels of chemokines in adolescents with major depression treated with fluoxetine", "doi": "10.5498/wjp.v10.i8.175", "year": 2020 } ] } }, { "id": 37663, "drug": "E6011", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "inhibits", "mediator": "fractalkine", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "ALS", "outcome_type": "disease", "outcome_domain": "als", "score": 0.23025850929940456, "filtered_score": 0.23025850929940456, "filter_reason": null, "outreach_score": 0.23025850929940456, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "e6011", "mediator_canonical": "fractalkine", "outcome_canonical": "amyotrophic lateral sclerosis", "ab_count": 4, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "36680426", "title": "Long-term safety and efficacy of E6011, an anti-fractalkine monoclonal antibody, in patients with rheumatoid arthritis inadequately responding to methotrexate", "doi": "10.1093/mr/road004", "year": 2023 }, { "pmid": "33038062", "title": "Efficacy and Safety of E6011, an Anti‐Fractalkine Monoclonal Antibody, in Patients With Active Rheumatoid Arthritis With Inadequate Response to Methotrexate: Results of a Randomized, Double‐Blind, Placebo‐Controlled Phase II Study", "doi": "10.1002/art.41555", "year": 2020 }, { "pmid": "30575978", "title": "Pharmacokinetics, Pharmacodynamics, and Safety of E6011, a Novel Humanized Antifractalkine (CX3CL1) Monoclonal Antibody: A Randomized, Double‐Blind, Placebo‐Controlled Single‐Ascending‐Dose Study", "doi": "10.1002/jcph.1361", "year": 2018 } ], "bc": [ { "pmid": "38625841", "title": "Enhanced levels of fractalkine and HSP60 in cerebrospinal fluid of sporadic amyotrophic lateral sclerosis patients", "doi": "10.1080/00207454.2024.2344581", "year": 2024 } ] } }, { "id": 38837, "drug": "secukinumab", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "inhibits", "mediator": "IL-17A", "mediator_type": "protein", "predicate_bc": "causes", "outcome": "CNS autoimmunity", "outcome_type": "disease", "outcome_domain": "multiple_sclerosis", "score": 0.23025850929940456, "filtered_score": 0.23025850929940456, "filter_reason": null, "outreach_score": 0.23025850929940456, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "completed", "clinical_trial_nct_ids": [ "NCT01051817", "NCT07138898", "NCT06130540" ], "literature_status": "novel_signal", "drug_canonical": "secukinumab", "mediator_canonical": "il-17a", "outcome_canonical": "cns autoimmunity", "ab_count": 4, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "33913511", "title": "Efficacy of secukinumab and adalimumab in patients with psoriatic arthritis and concomitant moderate‐to‐severe plaque psoriasis: results from EXCEED, a randomized, double‐blind head‐to‐head monotherapy study", "doi": "10.1111/bjd.20413", "year": 2021 }, { "pmid": "34919658", "title": "Secukinumab-induced systemic lupus erythematosus occurring in a patient with ankylosing spondylitis", "doi": "10.1093/rheumatology/keab918", "year": 2021 }, { "pmid": "33120695", "title": "Role of secukinumab in ankylosing spondylitis with tubercular uveitis", "doi": "10.4103/ijo.ijo_1081_20", "year": 2020 } ], "bc": [ { "pmid": "33547052", "title": "IL-17 controls central nervous system autoimmunity through the intestinal microbiome", "doi": "10.1126/sciimmunol.aaz6563", "year": 2021 } ] } }, { "id": 51948, "drug": "dietary methionine restriction", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "induces", "mediator": "adiponectin", "mediator_type": "protein", "predicate_bc": "prevents", "outcome": "type 2 diabetes", "outcome_type": "disease", "outcome_domain": "type_2_diabetes", "score": 0.23025850929940456, "filtered_score": 0.23025850929940456, "filter_reason": null, "outreach_score": 0.23025850929940456, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 4, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "25744495", "title": "Dietary Methionine Restriction in Mice Elicits an Adaptive Cardiovascular Response to Hyperhomocysteinemia", "doi": "10.1038/srep08886", "year": 2015 } ], "bc": [ { "pmid": "38455654", "title": "The role of adiponectin in the association between abdominal obesity and type 2 diabetes: a mediation analysis among 232,438 Chinese participants", "doi": "10.3389/fendo.2024.1327716", "year": 2024 }, { "pmid": "30599058", "title": "Protein markers and risk of type 2 diabetes and prediabetes: a targeted proteomics approach in the KORA F4/FF4 study", "doi": "10.1007/s10654-018-0475-8", "year": 2018 }, { "pmid": "30069271", "title": "Clinical Applications of Adiponectin Measurements in Type 2 Diabetes Mellitus: Screening, Diagnosis, and Marker of Diabetes Control", "doi": "10.1155/2018/5187940", "year": 2018 } ] } }, { "id": 51365, "drug": "tafamidis", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "binds_to", "mediator": "TTR", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "diseases of the neuronal system", "outcome_type": "disease", "outcome_domain": "multiple_sclerosis", "score": 0.23025850929940456, "filtered_score": 0.23025850929940456, "filter_reason": null, "outreach_score": 0.23025850929940456, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 4, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "28951660", "title": "Treatment With Tafamidis Slows Disease Progression in Early-Stage Transthyretin Cardiomyopathy", "doi": "10.1177/1179546817730322", "year": 2017 }, { "pmid": "25872787", "title": "Tafamidis in Transthyretin Amyloid Cardiomyopathy", "doi": "10.1161/circheartfailure.113.000890", "year": 2015 }, { "pmid": "26193961", "title": "Personalized medicine approach for optimizing the dose of tafamidis to potentially ameliorate wild-type transthyretin amyloidosis (cardiomyopathy)", "doi": "10.3109/13506129.2015.1063485", "year": 2015 } ], "bc": [ { "pmid": "39901093", "title": "Exploring proteomic immunoprofiles: common neurological and immunological pathways in multiple sclerosis and type 1 diabetes mellitus", "doi": "10.1186/s10020-025-01084-x", "year": 2025 } ] } }, { "id": 32865, "drug": "D+Q", "drug_type": "drug", "drug_domain": "inflammatory_bowel_disease", "predicate_ab": "induces", "mediator": "IL-8", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "major depressive disorder", "outcome_type": "disease", "outcome_domain": "depression", "score": 0.23025850929940456, "filtered_score": 0.23025850929940456, "filter_reason": null, "outreach_score": 0.23025850929940456, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "unknown", "drug_canonical": "d+q", "mediator_canonical": "IL8", "outcome_canonical": "major depressive disorder", "ab_count": 1, "bc_count": 4, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "39986536", "title": "Effects of senotherapeutics on gut microbiome dysbiosis and intestinal inflammation in Crohn's disease: A pilot study", "doi": "10.1016/j.trsl.2025.02.004", "year": 2025 } ], "bc": [ { "pmid": "41876463", "title": "Prediction of depressive episodes based on clinical features, cognitive characteristics, inflammation-related proteins, and EEG data", "doi": "10.1038/s41398-026-03960-4", "year": 2026 }, { "pmid": "34294614", "title": "White Matter Alterations Associated with Pro-inflammatory Cytokines in Patients with Major Depressive Disorder", "doi": "10.9758/cpn.2021.19.3.449", "year": 2021 }, { "pmid": "32874955", "title": "Serum levels of chemokines in adolescents with major depression treated with fluoxetine", "doi": "10.5498/wjp.v10.i8.175", "year": 2020 } ] } }, { "id": 50395, "drug": "tafamidis", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "binds_to", "mediator": "TTR", "mediator_type": "protein", "predicate_bc": "prevents", "outcome": "Aβ aggregation", "outcome_type": "phenotype", "outcome_domain": "alzheimer", "score": 0.23025850929940456, "filtered_score": 0.23025850929940456, "filter_reason": null, "outreach_score": 0.23025850929940456, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 4, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "28951660", "title": "Treatment With Tafamidis Slows Disease Progression in Early-Stage Transthyretin Cardiomyopathy", "doi": "10.1177/1179546817730322", "year": 2017 }, { "pmid": "25872787", "title": "Tafamidis in Transthyretin Amyloid Cardiomyopathy", "doi": "10.1161/circheartfailure.113.000890", "year": 2015 }, { "pmid": "26193961", "title": "Personalized medicine approach for optimizing the dose of tafamidis to potentially ameliorate wild-type transthyretin amyloidosis (cardiomyopathy)", "doi": "10.3109/13506129.2015.1063485", "year": 2015 } ], "bc": [ { "pmid": "33433479", "title": "Application of PROTAC strategy to TTR-Aβ protein-protein interaction for the development of Alzheimer’s disease drugs", "doi": "10.4103/1673-5374.303017", "year": 2021 } ] } }, { "id": 50392, "drug": "tafamidis", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "binds_to", "mediator": "TTR", "mediator_type": "protein", "predicate_bc": "increases", "outcome": "Aβ clearance", "outcome_type": "phenotype", "outcome_domain": "alzheimer", "score": 0.23025850929940456, "filtered_score": 0.23025850929940456, "filter_reason": null, "outreach_score": 0.23025850929940456, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 4, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "28951660", "title": "Treatment With Tafamidis Slows Disease Progression in Early-Stage Transthyretin Cardiomyopathy", "doi": "10.1177/1179546817730322", "year": 2017 }, { "pmid": "25872787", "title": "Tafamidis in Transthyretin Amyloid Cardiomyopathy", "doi": "10.1161/circheartfailure.113.000890", "year": 2015 }, { "pmid": "26193961", "title": "Personalized medicine approach for optimizing the dose of tafamidis to potentially ameliorate wild-type transthyretin amyloidosis (cardiomyopathy)", "doi": "10.3109/13506129.2015.1063485", "year": 2015 } ], "bc": [ { "pmid": "33433479", "title": "Application of PROTAC strategy to TTR-Aβ protein-protein interaction for the development of Alzheimer’s disease drugs", "doi": "10.4103/1673-5374.303017", "year": 2021 } ] } }, { "id": 59093, "drug": "secukinumab", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "inhibits", "mediator": "IL-17A", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "atrial fibrillation", "outcome_type": "disease", "outcome_domain": "heart_failure", "score": 0.23025850929940456, "filtered_score": 0.23025850929940456, "filter_reason": null, "outreach_score": 0.23025850929940456, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 4, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "33913511", "title": "Efficacy of secukinumab and adalimumab in patients with psoriatic arthritis and concomitant moderate‐to‐severe plaque psoriasis: results from EXCEED, a randomized, double‐blind head‐to‐head monotherapy study", "doi": "10.1111/bjd.20413", "year": 2021 }, { "pmid": "34919658", "title": "Secukinumab-induced systemic lupus erythematosus occurring in a patient with ankylosing spondylitis", "doi": "10.1093/rheumatology/keab918", "year": 2021 }, { "pmid": "33120695", "title": "Role of secukinumab in ankylosing spondylitis with tubercular uveitis", "doi": "10.4103/ijo.ijo_1081_20", "year": 2020 } ], "bc": [ { "pmid": "27198976", "title": "Elevated plasma levels of Th17-related cytokines are associated with increased risk of atrial fibrillation", "doi": "10.1038/srep26543", "year": 2016 } ] } }, { "id": 18584, "drug": "Levetiracetam", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "binds_to", "mediator": "SV2A", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "synapse density", "outcome_type": "phenotype", "outcome_domain": "multiple_sclerosis", "score": 0.23025850929940456, "filtered_score": 0.23025850929940456, "filter_reason": null, "outreach_score": 0.23025850929940456, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "levetiracetam", "mediator_canonical": "sv2a", "outcome_canonical": "synapse density", "ab_count": 4, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "35848684", "title": "Levetiracetam-induced gingival hyperplasia", "doi": "10.4103/jpgm.jpgm_1059_21", "year": 2022 }, { "pmid": "33654068", "title": "Levetiracetam treatment leads to functional recovery after thoracic or cervical injuries of the spinal cord", "doi": "10.1038/s41536-021-00121-7", "year": 2021 }, { "pmid": "32908767", "title": "Levetiracetam Induced Behavioral Abnormalities in a Patient with Seizure Disorder: A Diagnostic Challenge", "doi": "10.1155/2020/8883802", "year": 2020 } ], "bc": [ { "pmid": "41032626", "title": "SV2A-PET imaging uncovers cortical synapse loss in multiple sclerosis", "doi": "10.1126/scitranslmed.adt5585", "year": 2025 } ] } }, { "id": 33508, "drug": "tACS", "drug_type": "drug", "drug_domain": "inflammatory_bowel_disease", "predicate_ab": "binds_to", "mediator": "CD44", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "poor prognosis", "outcome_type": "phenotype", "outcome_domain": "pancreatic_cancer", "score": 0.23025850929940456, "filtered_score": 0.23025850929940456, "filter_reason": null, "outreach_score": 0.23025850929940456, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "tacs", "mediator_canonical": "cd44", "outcome_canonical": null, "ab_count": 1, "bc_count": 4, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37224059", "title": "Efficient Therapy of Inflammatory Bowel Disease (IBD) with Highly Specific and Durable Targeted Ta2C Modified with Chondroitin Sulfate (TACS)", "doi": "10.1002/adma.202301585", "year": 2023 } ], "bc": [ { "pmid": "35931675", "title": "Gemcitabine resistance of pancreatic cancer cells is mediated by IGF1R dependent upregulation of CD44 expression and isoform switching", "doi": "10.1038/s41419-022-05103-1", "year": 2022 }, { "pmid": "28659655", "title": "Expression and Clinical Significance of Cancer Stem Cell Markers CD24, CD44, and CD133 in Pancreatic Ductal Adenocarcinoma and Chronic Pancreatitis", "doi": "10.1155/2017/3276806", "year": 2017 }, { "pmid": "26261555", "title": "Expression of CD44 in pancreatic cancer and its significance.", "doi": null, "year": 2015 } ] } }, { "id": 39033, "drug": "E6011", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "inhibits", "mediator": "fractalkine", "mediator_type": "protein", "predicate_bc": "increases", "outcome": "proliferation", "outcome_type": "phenotype", "outcome_domain": "pancreatic_cancer", "score": 0.23025850929940456, "filtered_score": 0.23025850929940456, "filter_reason": null, "outreach_score": 0.23025850929940456, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "e6011", "mediator_canonical": "fractalkine", "outcome_canonical": null, "ab_count": 4, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "36680426", "title": "Long-term safety and efficacy of E6011, an anti-fractalkine monoclonal antibody, in patients with rheumatoid arthritis inadequately responding to methotrexate", "doi": "10.1093/mr/road004", "year": 2023 }, { "pmid": "33038062", "title": "Efficacy and Safety of E6011, an Anti‐Fractalkine Monoclonal Antibody, in Patients With Active Rheumatoid Arthritis With Inadequate Response to Methotrexate: Results of a Randomized, Double‐Blind, Placebo‐Controlled Phase II Study", "doi": "10.1002/art.41555", "year": 2020 }, { "pmid": "30575978", "title": "Pharmacokinetics, Pharmacodynamics, and Safety of E6011, a Novel Humanized Antifractalkine (CX3CL1) Monoclonal Antibody: A Randomized, Double‐Blind, Placebo‐Controlled Single‐Ascending‐Dose Study", "doi": "10.1002/jcph.1361", "year": 2018 } ], "bc": [ { "pmid": "28845524", "title": "Fractalkine/CX3CR1 induces apoptosis resistance and proliferation through the activation of the AKT/NF‐κB cascade in pancreatic cancer cells", "doi": "10.1002/cbf.3278", "year": 2017 } ] } }, { "id": 40797, "drug": "Exendin-4", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "activates", "mediator": "GLP-1R", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "pancreatic ductal adenocarcinoma", "outcome_type": "disease", "outcome_domain": "pancreatic_cancer", "score": 0.23025850929940456, "filtered_score": 0.23025850929940456, "filter_reason": null, "outreach_score": 0.23025850929940456, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "exendin-4", "mediator_canonical": "glp-1r", "outcome_canonical": "pancreatic ductal adenocarcinoma", "ab_count": 4, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "29045658", "title": "Exendin-4, a Glucagonlike Peptide-1 Receptor Agonist, Attenuates Breast Cancer Growth by Inhibiting NF-κB Activation", "doi": "10.1210/en.2017-00461", "year": 2017 }, { "pmid": "28912645", "title": "Anti-inflammatory Effect of Glucagon Like Peptide-1 Receptor Agonist, Exendin-4, through Modulation of IB1/JIP1 Expression and JNK Signaling in Stroke", "doi": "10.5607/en.2017.26.4.227", "year": 2017 }, { "pmid": "27013681", "title": "Astrocytes Regulate GLP-1 Receptor-Mediated Effects on Energy Balance", "doi": "10.1523/jneurosci.3579-15.2016", "year": 2016 } ], "bc": [ { "pmid": "26495786", "title": "Glucagon-Like Peptide-1 Receptor Expression in Normal and Neoplastic Human Pancreatic Tissues", "doi": "10.1097/mpa.0000000000000521", "year": 2015 } ] } }, { "id": 5169, "drug": "xanthohumol", "drug_type": "drug", "drug_domain": "pancreatic_cancer", "predicate_ab": "suppresses", "mediator": "IL-8", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "major depressive disorder", "outcome_type": "disease", "outcome_domain": "depression", "score": 0.23025850929940456, "filtered_score": 0.23025850929940456, "filter_reason": null, "outreach_score": 0.23025850929940456, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "xanthohumol", "mediator_canonical": "IL8", "outcome_canonical": "major depressive disorder", "ab_count": 1, "bc_count": 4, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "29121426", "title": "Xanthohumol inhibits angiogenesis by suppressing nuclear factor‐κB activation in pancreatic cancer", "doi": "10.1111/cas.13441", "year": 2017 } ], "bc": [ { "pmid": "41876463", "title": "Prediction of depressive episodes based on clinical features, cognitive characteristics, inflammation-related proteins, and EEG data", "doi": "10.1038/s41398-026-03960-4", "year": 2026 }, { "pmid": "34294614", "title": "White Matter Alterations Associated with Pro-inflammatory Cytokines in Patients with Major Depressive Disorder", "doi": "10.9758/cpn.2021.19.3.449", "year": 2021 }, { "pmid": "32874955", "title": "Serum levels of chemokines in adolescents with major depression treated with fluoxetine", "doi": "10.5498/wjp.v10.i8.175", "year": 2020 } ] } }, { "id": 7257, "drug": "SVHRP", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "upregulates", "mediator": "NPY", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "appetite changes", "outcome_type": "phenotype", "outcome_domain": "depression", "score": 0.23025850929940456, "filtered_score": 0.23025850929940456, "filter_reason": null, "outreach_score": 0.23025850929940456, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "svhrp", "mediator_canonical": "npy", "outcome_canonical": "appetite changes", "ab_count": 1, "bc_count": 4, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "33825777", "title": "Effects of scorpion venom heat-resistant peptide on the hippocampal neurons of kainic acid-induced epileptic rats", "doi": "10.1590/1414-431x202010717", "year": 2021 } ], "bc": [ { "pmid": "41484969", "title": "Differences in serum neuropeptide Y levels and appetite changes in patients with major depressive disorder stratified by sex and reproductive aging", "doi": "10.1186/s12888-025-07753-9", "year": 2026 } ] } }, { "id": 38213, "drug": "secukinumab", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "inhibits", "mediator": "IL-17A", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "antidepressant treatment resistance", "outcome_type": "phenotype", "outcome_domain": "depression", "score": 0.23025850929940456, "filtered_score": 0.23025850929940456, "filter_reason": null, "outreach_score": 0.23025850929940456, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "secukinumab", "mediator_canonical": "il-17a", "outcome_canonical": "antidepressant treatment resistance", "ab_count": 4, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "33913511", "title": "Efficacy of secukinumab and adalimumab in patients with psoriatic arthritis and concomitant moderate‐to‐severe plaque psoriasis: results from EXCEED, a randomized, double‐blind head‐to‐head monotherapy study", "doi": "10.1111/bjd.20413", "year": 2021 }, { "pmid": "34919658", "title": "Secukinumab-induced systemic lupus erythematosus occurring in a patient with ankylosing spondylitis", "doi": "10.1093/rheumatology/keab918", "year": 2021 }, { "pmid": "33120695", "title": "Role of secukinumab in ankylosing spondylitis with tubercular uveitis", "doi": "10.4103/ijo.ijo_1081_20", "year": 2020 } ], "bc": [ { "pmid": "31793127", "title": "The cytokine IL‐17A as a marker of treatment resistance in major depressive disorder?", "doi": "10.1111/ejn.14636", "year": 2019 } ] } }, { "id": 38218, "drug": "tocilizumab", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "inhibits", "mediator": "IL-8", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "major depressive disorder", "outcome_type": "disease", "outcome_domain": "depression", "score": 0.23025850929940456, "filtered_score": 0.23025850929940456, "filter_reason": null, "outreach_score": 0.23025850929940456, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "active", "clinical_trial_nct_ids": [ "NCT07493317", "NCT07052058", "NCT02660528" ], "literature_status": "partial_evidence", "drug_canonical": "tocilizumab", "mediator_canonical": "IL8", "outcome_canonical": "major depressive disorder", "ab_count": 1, "bc_count": 4, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "33264466", "title": "Tocilizumab inhibits IL‐8 and the proangiogenic potential of triple negative breast cancer cells", "doi": "10.1002/mc.23270", "year": 2020 } ], "bc": [ { "pmid": "41876463", "title": "Prediction of depressive episodes based on clinical features, cognitive characteristics, inflammation-related proteins, and EEG data", "doi": "10.1038/s41398-026-03960-4", "year": 2026 }, { "pmid": "34294614", "title": "White Matter Alterations Associated with Pro-inflammatory Cytokines in Patients with Major Depressive Disorder", "doi": "10.9758/cpn.2021.19.3.449", "year": 2021 }, { "pmid": "32874955", "title": "Serum levels of chemokines in adolescents with major depression treated with fluoxetine", "doi": "10.5498/wjp.v10.i8.175", "year": 2020 } ] } }, { "id": 37660, "drug": "secukinumab", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "inhibits", "mediator": "IL-17A", "mediator_type": "protein", "predicate_bc": "decreases", "outcome": "motor neuron viability", "outcome_type": "phenotype", "outcome_domain": "als", "score": 0.23025850929940456, "filtered_score": 0.23025850929940456, "filter_reason": null, "outreach_score": 0.23025850929940456, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "secukinumab", "mediator_canonical": "il-17a", "outcome_canonical": "motor neuron viability", "ab_count": 4, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "33913511", "title": "Efficacy of secukinumab and adalimumab in patients with psoriatic arthritis and concomitant moderate‐to‐severe plaque psoriasis: results from EXCEED, a randomized, double‐blind head‐to‐head monotherapy study", "doi": "10.1111/bjd.20413", "year": 2021 }, { "pmid": "34919658", "title": "Secukinumab-induced systemic lupus erythematosus occurring in a patient with ankylosing spondylitis", "doi": "10.1093/rheumatology/keab918", "year": 2021 }, { "pmid": "33120695", "title": "Role of secukinumab in ankylosing spondylitis with tubercular uveitis", "doi": "10.4103/ijo.ijo_1081_20", "year": 2020 } ], "bc": [ { "pmid": "34360808", "title": "Interleukin-17 and Th17 Lymphocytes Directly Impair Motoneuron Survival of Wildtype and FUS-ALS Mutant Human iPSCs", "doi": "10.3390/ijms22158042", "year": 2021 } ] } }, { "id": 39035, "drug": "secukinumab", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "inhibits", "mediator": "IL-17A", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "acinar-ductal metaplasia", "outcome_type": "phenotype", "outcome_domain": "pancreatic_cancer", "score": 0.23025850929940456, "filtered_score": 0.23025850929940456, "filter_reason": null, "outreach_score": 0.23025850929940456, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "secukinumab", "mediator_canonical": "il-17a", "outcome_canonical": "acinar-ductal metaplasia", "ab_count": 4, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "33913511", "title": "Efficacy of secukinumab and adalimumab in patients with psoriatic arthritis and concomitant moderate‐to‐severe plaque psoriasis: results from EXCEED, a randomized, double‐blind head‐to‐head monotherapy study", "doi": "10.1111/bjd.20413", "year": 2021 }, { "pmid": "34919658", "title": "Secukinumab-induced systemic lupus erythematosus occurring in a patient with ankylosing spondylitis", "doi": "10.1093/rheumatology/keab918", "year": 2021 }, { "pmid": "33120695", "title": "Role of secukinumab in ankylosing spondylitis with tubercular uveitis", "doi": "10.4103/ijo.ijo_1081_20", "year": 2020 } ], "bc": [ { "pmid": "33294254", "title": "IL-17 in pancreatic disease: pathogenesis and pharmacotherapy.", "doi": null, "year": 2020 } ] } }, { "id": 6680, "drug": "Ketogenic diet", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "upregulates", "mediator": "Sod1", "mediator_type": "gene", "predicate_bc": "associated_with", "outcome": "familial ALS", "outcome_type": "disease", "outcome_domain": "als", "score": 0.23025850929940456, "filtered_score": 0.23025850929940456, "filter_reason": null, "outreach_score": 0.23025850929940456, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "ketogenic diet", "mediator_canonical": "SOD1", "outcome_canonical": "familial als", "ab_count": 1, "bc_count": 4, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "31873138", "title": "Ketogenic diet induces skeletal muscle atrophy via reducing muscle protein synthesis and possibly activating proteolysis in mice", "doi": "10.1038/s41598-019-56166-8", "year": 2019 } ], "bc": [ { "pmid": "41673790", "title": "Comprehensive clinical and genetic architecture of familial amyotrophic lateral sclerosis in China: A 15-year cohort study with 302 families", "doi": "10.4103/nrr.nrr-d-24-00701", "year": 2025 }, { "pmid": "32166880", "title": "Clinical and genetic features of patients with amyotrophic lateral sclerosis in southern China", "doi": "10.1111/ene.14213", "year": 2020 }, { "pmid": "29504729", "title": "Possible etiology and treatment of amyotrophic lateral sclerosis.", "doi": null, "year": 2018 } ] } }, { "id": 38267, "drug": "secukinumab", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "inhibits", "mediator": "IL-17A", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "LTP dysfunction", "outcome_type": "phenotype", "outcome_domain": "epilepsy", "score": 0.23025850929940456, "filtered_score": 0.23025850929940456, "filter_reason": null, "outreach_score": 0.23025850929940456, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "secukinumab", "mediator_canonical": "il-17a", "outcome_canonical": "ltp dysfunction", "ab_count": 4, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "33913511", "title": "Efficacy of secukinumab and adalimumab in patients with psoriatic arthritis and concomitant moderate‐to‐severe plaque psoriasis: results from EXCEED, a randomized, double‐blind head‐to‐head monotherapy study", "doi": "10.1111/bjd.20413", "year": 2021 }, { "pmid": "34919658", "title": "Secukinumab-induced systemic lupus erythematosus occurring in a patient with ankylosing spondylitis", "doi": "10.1093/rheumatology/keab918", "year": 2021 }, { "pmid": "33120695", "title": "Role of secukinumab in ankylosing spondylitis with tubercular uveitis", "doi": "10.4103/ijo.ijo_1081_20", "year": 2020 } ], "bc": [ { "pmid": "34879272", "title": "Interleukin-17 affects synaptic plasticity and cognition in an experimental model of multiple sclerosis", "doi": "10.1016/j.celrep.2021.110094", "year": 2021 } ] } }, { "id": 38268, "drug": "secukinumab", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "inhibits", "mediator": "IL-17A", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "anxiety", "outcome_type": "phenotype", "outcome_domain": "epilepsy", "score": 0.23025850929940456, "filtered_score": 0.23025850929940456, "filter_reason": null, "outreach_score": 0.23025850929940456, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "secukinumab", "mediator_canonical": "il-17a", "outcome_canonical": "anxiety", "ab_count": 4, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "33913511", "title": "Efficacy of secukinumab and adalimumab in patients with psoriatic arthritis and concomitant moderate‐to‐severe plaque psoriasis: results from EXCEED, a randomized, double‐blind head‐to‐head monotherapy study", "doi": "10.1111/bjd.20413", "year": 2021 }, { "pmid": "34919658", "title": "Secukinumab-induced systemic lupus erythematosus occurring in a patient with ankylosing spondylitis", "doi": "10.1093/rheumatology/keab918", "year": 2021 }, { "pmid": "33120695", "title": "Role of secukinumab in ankylosing spondylitis with tubercular uveitis", "doi": "10.4103/ijo.ijo_1081_20", "year": 2020 } ], "bc": [ { "pmid": "35875667", "title": "Interleukin-17A Mediates Hippocampal Damage and Aberrant Neurogenesis Contributing to Epilepsy-Associated Anxiety", "doi": "10.3389/fnmol.2022.917598", "year": 2022 } ] } }, { "id": 37865, "drug": "anti-TNF treatment", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "downregulates", "mediator": "YKL-40", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "Alzheimer's disease", "outcome_type": "disease", "outcome_domain": "alzheimer", "score": 0.23025850929940456, "filtered_score": 0.23025850929940456, "filter_reason": null, "outreach_score": 0.23025850929940456, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "completed", "clinical_trial_nct_ids": [ "NCT04571697", "NCT04529902" ], "literature_status": "partial_evidence", "drug_canonical": "anti-tnf treatment", "mediator_canonical": "ykl-40", "outcome_canonical": "Alzheimer disease", "ab_count": 1, "bc_count": 4, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "34175943", "title": "Early prediction of clinical response to anti-TNF treatment using multi-omics and machine learning in rheumatoid arthritis", "doi": "10.1093/rheumatology/keab521", "year": 2021 } ], "bc": [ { "pmid": "35879733", "title": "YKL-40 changes are not detected in post-mortem brain of patients with Alzheimer’s disease and frontotemporal lobar degeneration", "doi": "10.1186/s13195-022-01039-y", "year": 2022 }, { "pmid": "34572280", "title": "Increased YKL-40 but Not C-Reactive Protein Levels in Patients with Alzheimer’s Disease", "doi": "10.3390/biomedicines9091094", "year": 2021 }, { "pmid": "31127154", "title": "Different pattern of CSF glial markers between dementia with Lewy bodies and Alzheimer’s disease", "doi": "10.1038/s41598-019-44173-8", "year": 2019 } ] } }, { "id": 23416, "drug": "pembrolizumab", "drug_type": "drug", "drug_domain": "multiple_sclerosis", "predicate_ab": "inhibits", "mediator": "PD-1", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "ALS", "outcome_type": "disease", "outcome_domain": "als", "score": 0.23025850929940456, "filtered_score": 0.23025850929940456, "filter_reason": null, "outreach_score": 0.23025850929940456, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "pembrolizumab", "mediator_canonical": "pd-1", "outcome_canonical": "amyotrophic lateral sclerosis", "ab_count": 4, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41232216", "title": "Iatrogenic NORSE: Immune checkpoint inhibitor-related anti-GFAP autoimmune astrocytopathy", "doi": "10.1016/j.jneuroim.2025.578805", "year": 2025 }, { "pmid": "35637642", "title": "Pembrolizumab for the treatment of Progressive Multifocal Leukoencephalopathy (PML) in a patient with AIDS: A case report and literature review", "doi": "10.1016/j.idcr.2022.e01514", "year": 2022 }, { "pmid": "33995251", "title": "Case Report: Longitudinal Extensive Transverse Myelitis With Novel Autoantibodies Following Two Rounds of Pembrolizumab", "doi": "10.3389/fneur.2021.655283", "year": 2021 } ], "bc": [ { "pmid": "40755012", "title": "Immune checkpoint changes correlate with the progression and prognosis of amyotrophic lateral sclerosis", "doi": "10.1080/07853890.2025.2540023", "year": 2025 } ] } }, { "id": 23015, "drug": "pembrolizumab", "drug_type": "drug", "drug_domain": "multiple_sclerosis", "predicate_ab": "inhibits", "mediator": "PD-1", "mediator_type": "protein", "predicate_bc": "increases", "outcome": "glioblastoma growth", "outcome_type": "phenotype", "outcome_domain": "glioblastoma", "score": 0.23025850929940456, "filtered_score": 0.23025850929940456, "filter_reason": null, "outreach_score": 0.23025850929940456, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "completed", "clinical_trial_nct_ids": [ "NCT03797326" ], "literature_status": "novel_signal", "drug_canonical": "pembrolizumab", "mediator_canonical": "pd-1", "outcome_canonical": "glioblastoma growth", "ab_count": 4, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41232216", "title": "Iatrogenic NORSE: Immune checkpoint inhibitor-related anti-GFAP autoimmune astrocytopathy", "doi": "10.1016/j.jneuroim.2025.578805", "year": 2025 }, { "pmid": "35637642", "title": "Pembrolizumab for the treatment of Progressive Multifocal Leukoencephalopathy (PML) in a patient with AIDS: A case report and literature review", "doi": "10.1016/j.idcr.2022.e01514", "year": 2022 }, { "pmid": "33995251", "title": "Case Report: Longitudinal Extensive Transverse Myelitis With Novel Autoantibodies Following Two Rounds of Pembrolizumab", "doi": "10.3389/fneur.2021.655283", "year": 2021 } ], "bc": [ { "pmid": "34739319", "title": "PD-1 independent of PD-L1 ligation promotes glioblastoma growth through the NFκB pathway", "doi": "10.1126/sciadv.abh2148", "year": 2021 } ] } }, { "id": 59081, "drug": "secukinumab", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "inhibits", "mediator": "IL-17A", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "left ventricular function", "outcome_type": "phenotype", "outcome_domain": "heart_failure", "score": 0.23025850929940456, "filtered_score": 0.23025850929940456, "filter_reason": null, "outreach_score": 0.23025850929940456, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 4, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "33913511", "title": "Efficacy of secukinumab and adalimumab in patients with psoriatic arthritis and concomitant moderate‐to‐severe plaque psoriasis: results from EXCEED, a randomized, double‐blind head‐to‐head monotherapy study", "doi": "10.1111/bjd.20413", "year": 2021 }, { "pmid": "34919658", "title": "Secukinumab-induced systemic lupus erythematosus occurring in a patient with ankylosing spondylitis", "doi": "10.1093/rheumatology/keab918", "year": 2021 }, { "pmid": "33120695", "title": "Role of secukinumab in ankylosing spondylitis with tubercular uveitis", "doi": "10.4103/ijo.ijo_1081_20", "year": 2020 } ], "bc": [ { "pmid": "28278264", "title": "The role of interleukin 17-mediated immune response in Chagas disease: High level is correlated with better left ventricular function", "doi": "10.1371/journal.pone.0172833", "year": 2017 } ] } }, { "id": 2340, "drug": "Levetiracetam", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "binds_to", "mediator": "SV2A", "mediator_type": "protein", "predicate_bc": "decreases", "outcome": "tau hyperphosphorylation", "outcome_type": "phenotype", "outcome_domain": "alzheimer", "score": 0.23025850929940456, "filtered_score": 0.23025850929940456, "filter_reason": null, "outreach_score": 0.23025850929940456, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "levetiracetam", "mediator_canonical": "sv2a", "outcome_canonical": "tau hyperphosphorylation", "ab_count": 4, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "35848684", "title": "Levetiracetam-induced gingival hyperplasia", "doi": "10.4103/jpgm.jpgm_1059_21", "year": 2022 }, { "pmid": "33654068", "title": "Levetiracetam treatment leads to functional recovery after thoracic or cervical injuries of the spinal cord", "doi": "10.1038/s41536-021-00121-7", "year": 2021 }, { "pmid": "32908767", "title": "Levetiracetam Induced Behavioral Abnormalities in a Patient with Seizure Disorder: A Diagnostic Challenge", "doi": "10.1155/2020/8883802", "year": 2020 } ], "bc": [ { "pmid": "34277597", "title": "The Synaptic Vesicle Protein 2A Interacts With Key Pathogenic Factors in Alzheimer’s Disease: Implications for Treatment", "doi": "10.3389/fcell.2021.609908", "year": 2021 } ] } }, { "id": 35479, "drug": "DMF", "drug_type": "drug", "drug_domain": "multiple_sclerosis", "predicate_ab": "activates", "mediator": "Nrf2", "mediator_type": "protein", "predicate_bc": "increases", "outcome": "drug efflux", "outcome_type": "phenotype", "outcome_domain": "rheumatoid_arthritis", "score": 0.23025850929940456, "filtered_score": 0.23025850929940456, "filter_reason": null, "outreach_score": 0.23025850929940456, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "dmf", "mediator_canonical": "NRF2", "outcome_canonical": "drug efflux", "ab_count": 4, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "35743211", "title": "Mechanisms of Sensitivity and Resistance of Primary Effusion Lymphoma to Dimethyl Fumarate (DMF)", "doi": "10.3390/ijms23126773", "year": 2022 }, { "pmid": "32672401", "title": "Structural insights into the multiple binding modes of Dimethyl Fumarate (DMF) and its analogs to the Kelch domain of Keap1", "doi": "10.1111/febs.15485", "year": 2020 }, { "pmid": "32394330", "title": "Characterization of More Selective Central Nervous System Nrf2-Activating Novel Vinyl Sulfoximine Compounds Compared to Dimethyl Fumarate", "doi": "10.1007/s13311-020-00855-0", "year": 2020 } ], "bc": [ { "pmid": "35964840", "title": "Pros and cons of NRF2 activation as adjunctive therapy in rheumatoid arthritis", "doi": "10.1016/j.freeradbiomed.2022.08.012", "year": 2022 } ] } }, { "id": 23218, "drug": "mitoxantrone", "drug_type": "drug", "drug_domain": "multiple_sclerosis", "predicate_ab": "upregulates", "mediator": "BDNF", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "epilepsy", "outcome_type": "disease", "outcome_domain": "epilepsy", "score": 0.23025850929940456, "filtered_score": 0.23025850929940456, "filter_reason": null, "outreach_score": 0.23025850929940456, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "mitoxantrone", "mediator_canonical": "BDNF", "outcome_canonical": "epilepsy", "ab_count": 1, "bc_count": 4, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "35247984", "title": "Does physical exercise improve or deteriorate treatment of multiple sclerosis with mitoxantrone? Experimental autoimmune encephalomyelitis study in rats", "doi": "10.1186/s12868-022-00692-1", "year": 2022 } ], "bc": [ { "pmid": "39474368", "title": "Reduced serum neurotrophic factors and monoamine neurotransmitters in epilepsy patients with comorbid depression", "doi": "10.3389/fneur.2024.1480854", "year": 2024 }, { "pmid": "35557046", "title": "Overexpression of BDNF in the ventrolateral periaqueductal gray regulates the behavior of epilepsy–migraine comorbid rats", "doi": "10.1002/brb3.2594", "year": 2022 }, { "pmid": "34331458", "title": "Inflammatory and neurotrophic factor plasma levels are related to epilepsy independently of etiology", "doi": "10.1111/epi.17023", "year": 2021 } ] } }, { "id": 35071, "drug": "pembrolizumab", "drug_type": "drug", "drug_domain": "multiple_sclerosis", "predicate_ab": "inhibits", "mediator": "PD-1", "mediator_type": "protein", "predicate_bc": "decreases", "outcome": "PD-1 inhibitor-associated colitis", "outcome_type": "disease", "outcome_domain": "inflammatory_bowel_disease", "score": 0.23025850929940456, "filtered_score": 0.23025850929940456, "filter_reason": null, "outreach_score": 0.23025850929940456, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "pembrolizumab", "mediator_canonical": "pd-1", "outcome_canonical": "pd-1 inhibitor-associated colitis", "ab_count": 4, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41232216", "title": "Iatrogenic NORSE: Immune checkpoint inhibitor-related anti-GFAP autoimmune astrocytopathy", "doi": "10.1016/j.jneuroim.2025.578805", "year": 2025 }, { "pmid": "35637642", "title": "Pembrolizumab for the treatment of Progressive Multifocal Leukoencephalopathy (PML) in a patient with AIDS: A case report and literature review", "doi": "10.1016/j.idcr.2022.e01514", "year": 2022 }, { "pmid": "33995251", "title": "Case Report: Longitudinal Extensive Transverse Myelitis With Novel Autoantibodies Following Two Rounds of Pembrolizumab", "doi": "10.3389/fneur.2021.655283", "year": 2021 } ], "bc": [ { "pmid": "32298485", "title": "Programmed cell death‐1 (PD‐1) and programmed death‐ligand 1 (PD‐L1) expression in PD‐1 inhibitor‐associated colitis and its mimics", "doi": "10.1111/his.14115", "year": 2020 } ] } }, { "id": 6878, "drug": "Levetiracetam", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "binds_to", "mediator": "SV2A", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "cognitive performance", "outcome_type": "phenotype", "outcome_domain": "alzheimer", "score": 0.23025850929940456, "filtered_score": 0.23025850929940456, "filter_reason": null, "outreach_score": 0.23025850929940456, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "active", "clinical_trial_nct_ids": [ "NCT06224530" ], "literature_status": "reproduces_known", "drug_canonical": "levetiracetam", "mediator_canonical": "sv2a", "outcome_canonical": "cognitive performance", "ab_count": 4, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "35848684", "title": "Levetiracetam-induced gingival hyperplasia", "doi": "10.4103/jpgm.jpgm_1059_21", "year": 2022 }, { "pmid": "33654068", "title": "Levetiracetam treatment leads to functional recovery after thoracic or cervical injuries of the spinal cord", "doi": "10.1038/s41536-021-00121-7", "year": 2021 }, { "pmid": "32908767", "title": "Levetiracetam Induced Behavioral Abnormalities in a Patient with Seizure Disorder: A Diagnostic Challenge", "doi": "10.1155/2020/8883802", "year": 2020 } ], "bc": [ { "pmid": "35976998", "title": "Widespread cell stress and mitochondrial dysfunction occur in patients with early Alzheimer’s disease", "doi": "10.1126/scitranslmed.abk1051", "year": 2022 } ] } }, { "id": 10180, "drug": "PFD", "drug_type": "drug", "drug_domain": "pancreatic_cancer", "predicate_ab": "suppresses", "mediator": "IL-8", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "major depressive disorder", "outcome_type": "disease", "outcome_domain": "depression", "score": 0.23025850929940456, "filtered_score": 0.23025850929940456, "filter_reason": null, "outreach_score": 0.23025850929940456, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "pfd", "mediator_canonical": "IL8", "outcome_canonical": "major depressive disorder", "ab_count": 1, "bc_count": 4, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "39904796", "title": "Cancer-associated fibroblasts promote pro-tumor functions of neutrophils in pancreatic cancer via IL-8: potential suppression by pirfenidone", "doi": "10.1007/s00262-025-03946-z", "year": 2025 } ], "bc": [ { "pmid": "41876463", "title": "Prediction of depressive episodes based on clinical features, cognitive characteristics, inflammation-related proteins, and EEG data", "doi": "10.1038/s41398-026-03960-4", "year": 2026 }, { "pmid": "34294614", "title": "White Matter Alterations Associated with Pro-inflammatory Cytokines in Patients with Major Depressive Disorder", "doi": "10.9758/cpn.2021.19.3.449", "year": 2021 }, { "pmid": "32874955", "title": "Serum levels of chemokines in adolescents with major depression treated with fluoxetine", "doi": "10.5498/wjp.v10.i8.175", "year": 2020 } ] } }, { "id": 51363, "drug": "tafamidis", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "binds_to", "mediator": "TTR", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "multiple sclerosis", "outcome_type": "disease", "outcome_domain": "multiple_sclerosis", "score": 0.23025850929940456, "filtered_score": 0.23025850929940456, "filter_reason": null, "outreach_score": 0.23025850929940456, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 4, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "28951660", "title": "Treatment With Tafamidis Slows Disease Progression in Early-Stage Transthyretin Cardiomyopathy", "doi": "10.1177/1179546817730322", "year": 2017 }, { "pmid": "25872787", "title": "Tafamidis in Transthyretin Amyloid Cardiomyopathy", "doi": "10.1161/circheartfailure.113.000890", "year": 2015 }, { "pmid": "26193961", "title": "Personalized medicine approach for optimizing the dose of tafamidis to potentially ameliorate wild-type transthyretin amyloidosis (cardiomyopathy)", "doi": "10.3109/13506129.2015.1063485", "year": 2015 } ], "bc": [ { "pmid": "35135578", "title": "Posttranslational modifications of proteins are key features in the identification of CSF biomarkers of multiple sclerosis", "doi": "10.1186/s12974-022-02404-2", "year": 2022 } ] } }, { "id": 39029, "drug": "secukinumab", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "inhibits", "mediator": "IL-17A", "mediator_type": "protein", "predicate_bc": "causes", "outcome": "islet β-cell apoptosis", "outcome_type": "phenotype", "outcome_domain": "pancreatic_cancer", "score": 0.23025850929940456, "filtered_score": 0.23025850929940456, "filter_reason": null, "outreach_score": 0.23025850929940456, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "secukinumab", "mediator_canonical": "il-17a", "outcome_canonical": "islet β-cell apoptosis", "ab_count": 4, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "33913511", "title": "Efficacy of secukinumab and adalimumab in patients with psoriatic arthritis and concomitant moderate‐to‐severe plaque psoriasis: results from EXCEED, a randomized, double‐blind head‐to‐head monotherapy study", "doi": "10.1111/bjd.20413", "year": 2021 }, { "pmid": "34919658", "title": "Secukinumab-induced systemic lupus erythematosus occurring in a patient with ankylosing spondylitis", "doi": "10.1093/rheumatology/keab918", "year": 2021 }, { "pmid": "33120695", "title": "Role of secukinumab in ankylosing spondylitis with tubercular uveitis", "doi": "10.4103/ijo.ijo_1081_20", "year": 2020 } ], "bc": [ { "pmid": "33294254", "title": "IL-17 in pancreatic disease: pathogenesis and pharmacotherapy.", "doi": null, "year": 2020 } ] } }, { "id": 38825, "drug": "secukinumab", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "inhibits", "mediator": "IL-17A", "mediator_type": "protein", "predicate_bc": "increases", "outcome": "EAE susceptibility", "outcome_type": "disease", "outcome_domain": "multiple_sclerosis", "score": 0.23025850929940456, "filtered_score": 0.23025850929940456, "filter_reason": null, "outreach_score": 0.23025850929940456, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "secukinumab", "mediator_canonical": "il-17a", "outcome_canonical": "eae susceptibility", "ab_count": 4, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "33913511", "title": "Efficacy of secukinumab and adalimumab in patients with psoriatic arthritis and concomitant moderate‐to‐severe plaque psoriasis: results from EXCEED, a randomized, double‐blind head‐to‐head monotherapy study", "doi": "10.1111/bjd.20413", "year": 2021 }, { "pmid": "34919658", "title": "Secukinumab-induced systemic lupus erythematosus occurring in a patient with ankylosing spondylitis", "doi": "10.1093/rheumatology/keab918", "year": 2021 }, { "pmid": "33120695", "title": "Role of secukinumab in ankylosing spondylitis with tubercular uveitis", "doi": "10.4103/ijo.ijo_1081_20", "year": 2020 } ], "bc": [ { "pmid": "33547052", "title": "IL-17 controls central nervous system autoimmunity through the intestinal microbiome", "doi": "10.1126/sciimmunol.aaz6563", "year": 2021 } ] } }, { "id": 1585, "drug": "HA-CPNs", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "binds_to", "mediator": "CD44", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "poor prognosis", "outcome_type": "phenotype", "outcome_domain": "pancreatic_cancer", "score": 0.23025850929940456, "filtered_score": 0.23025850929940456, "filter_reason": null, "outreach_score": 0.23025850929940456, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "ha-cpns", "mediator_canonical": "cd44", "outcome_canonical": null, "ab_count": 1, "bc_count": 4, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "35840697", "title": "Impairing proliferation of glioblastoma multiforme with CD44+ selective conjugated polymer nanoparticles", "doi": "10.1038/s41598-022-15244-0", "year": 2022 } ], "bc": [ { "pmid": "35931675", "title": "Gemcitabine resistance of pancreatic cancer cells is mediated by IGF1R dependent upregulation of CD44 expression and isoform switching", "doi": "10.1038/s41419-022-05103-1", "year": 2022 }, { "pmid": "28659655", "title": "Expression and Clinical Significance of Cancer Stem Cell Markers CD24, CD44, and CD133 in Pancreatic Ductal Adenocarcinoma and Chronic Pancreatitis", "doi": "10.1155/2017/3276806", "year": 2017 }, { "pmid": "26261555", "title": "Expression of CD44 in pancreatic cancer and its significance.", "doi": null, "year": 2015 } ] } }, { "id": 55091, "drug": "DMF", "drug_type": "drug", "drug_domain": "multiple_sclerosis", "predicate_ab": "activates", "mediator": "Nrf2", "mediator_type": "protein", "predicate_bc": "prevents", "outcome": "myocardial necrosis", "outcome_type": "phenotype", "outcome_domain": "heart_failure", "score": 0.23025850929940456, "filtered_score": 0.23025850929940456, "filter_reason": null, "outreach_score": 0.23025850929940456, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 4, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "35743211", "title": "Mechanisms of Sensitivity and Resistance of Primary Effusion Lymphoma to Dimethyl Fumarate (DMF)", "doi": "10.3390/ijms23126773", "year": 2022 }, { "pmid": "32672401", "title": "Structural insights into the multiple binding modes of Dimethyl Fumarate (DMF) and its analogs to the Kelch domain of Keap1", "doi": "10.1111/febs.15485", "year": 2020 }, { "pmid": "32394330", "title": "Characterization of More Selective Central Nervous System Nrf2-Activating Novel Vinyl Sulfoximine Compounds Compared to Dimethyl Fumarate", "doi": "10.1007/s13311-020-00855-0", "year": 2020 } ], "bc": [ { "pmid": "26573705", "title": "Nrf2-Mediated Cardiac Maladaptive Remodeling and Dysfunction in a Setting of Autophagy Insufficiency", "doi": "10.1161/hypertensionaha.115.06062", "year": 2015 } ] } }, { "id": 10443, "drug": "AIGG", "drug_type": "drug", "drug_domain": "depression", "predicate_ab": "upregulates", "mediator": "BDNF", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "epilepsy", "outcome_type": "disease", "outcome_domain": "epilepsy", "score": 0.23025850929940456, "filtered_score": 0.23025850929940456, "filter_reason": null, "outreach_score": 0.23025850929940456, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "aigg", "mediator_canonical": "BDNF", "outcome_canonical": "epilepsy", "ab_count": 1, "bc_count": 4, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41417271", "title": "Antidepressant‐Like Mechanisms of Gekko gecko Active Compounds: Multi‐Omics Elucidation of the cAMP–PRKACA–BDNF Signaling Axis", "doi": "10.1002/cbdv.202502015", "year": 2025 } ], "bc": [ { "pmid": "39474368", "title": "Reduced serum neurotrophic factors and monoamine neurotransmitters in epilepsy patients with comorbid depression", "doi": "10.3389/fneur.2024.1480854", "year": 2024 }, { "pmid": "35557046", "title": "Overexpression of BDNF in the ventrolateral periaqueductal gray regulates the behavior of epilepsy–migraine comorbid rats", "doi": "10.1002/brb3.2594", "year": 2022 }, { "pmid": "34331458", "title": "Inflammatory and neurotrophic factor plasma levels are related to epilepsy independently of etiology", "doi": "10.1111/epi.17023", "year": 2021 } ] } }, { "id": 35483, "drug": "teriflunomide", "drug_type": "drug", "drug_domain": "multiple_sclerosis", "predicate_ab": "upregulates", "mediator": "STAT1", "mediator_type": "gene", "predicate_bc": "associated_with", "outcome": "rheumatoid arthritis", "outcome_type": "disease", "outcome_domain": "rheumatoid_arthritis", "score": 0.23025850929940456, "filtered_score": 0.23025850929940456, "filter_reason": null, "outreach_score": 0.23025850929940456, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "teriflunomide", "mediator_canonical": "stat1", "outcome_canonical": "rheumatoid arthritis", "ab_count": 1, "bc_count": 4, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "39545481", "title": "Expression of STAT‐ and T‐cell‐related genes in women with first‐line treatment of relapsing‐remitting multiple sclerosis", "doi": "10.1111/sji.13424", "year": 2024 } ], "bc": [ { "pmid": "41131607", "title": "Integrated analysis of single-cell RNA-seq and bulk RNA-seq reveal macrophage subpopulation characteristics and the role of STAT1 in rheumatoid arthritis", "doi": "10.1186/s12967-025-07015-y", "year": 2025 }, { "pmid": "40849565", "title": "Aging associated immunosenescence in rheumatoid arthritis identified by machine learning and single cell profiling", "doi": "10.1038/s41598-025-15370-5", "year": 2025 }, { "pmid": "36247278", "title": "Identification and validation of potential hub genes in rheumatoid arthritis by bioinformatics analysis.", "doi": null, "year": 2022 } ] } }, { "id": 59080, "drug": "secukinumab", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "inhibits", "mediator": "IL-17A", "mediator_type": "protein", "predicate_bc": "prevents", "outcome": "myocardial damage", "outcome_type": "phenotype", "outcome_domain": "heart_failure", "score": 0.23025850929940456, "filtered_score": 0.23025850929940456, "filter_reason": null, "outreach_score": 0.23025850929940456, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 4, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "33913511", "title": "Efficacy of secukinumab and adalimumab in patients with psoriatic arthritis and concomitant moderate‐to‐severe plaque psoriasis: results from EXCEED, a randomized, double‐blind head‐to‐head monotherapy study", "doi": "10.1111/bjd.20413", "year": 2021 }, { "pmid": "34919658", "title": "Secukinumab-induced systemic lupus erythematosus occurring in a patient with ankylosing spondylitis", "doi": "10.1093/rheumatology/keab918", "year": 2021 }, { "pmid": "33120695", "title": "Role of secukinumab in ankylosing spondylitis with tubercular uveitis", "doi": "10.4103/ijo.ijo_1081_20", "year": 2020 } ], "bc": [ { "pmid": "28278264", "title": "The role of interleukin 17-mediated immune response in Chagas disease: High level is correlated with better left ventricular function", "doi": "10.1371/journal.pone.0172833", "year": 2017 } ] } }, { "id": 37667, "drug": "secukinumab", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "inhibits", "mediator": "IL-17A", "mediator_type": "protein", "predicate_bc": "decreases", "outcome": "neurite length", "outcome_type": "phenotype", "outcome_domain": "als", "score": 0.23025850929940456, "filtered_score": 0.23025850929940456, "filter_reason": null, "outreach_score": 0.23025850929940456, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "secukinumab", "mediator_canonical": "il-17a", "outcome_canonical": "neurite length", "ab_count": 4, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "33913511", "title": "Efficacy of secukinumab and adalimumab in patients with psoriatic arthritis and concomitant moderate‐to‐severe plaque psoriasis: results from EXCEED, a randomized, double‐blind head‐to‐head monotherapy study", "doi": "10.1111/bjd.20413", "year": 2021 }, { "pmid": "34919658", "title": "Secukinumab-induced systemic lupus erythematosus occurring in a patient with ankylosing spondylitis", "doi": "10.1093/rheumatology/keab918", "year": 2021 }, { "pmid": "33120695", "title": "Role of secukinumab in ankylosing spondylitis with tubercular uveitis", "doi": "10.4103/ijo.ijo_1081_20", "year": 2020 } ], "bc": [ { "pmid": "34360808", "title": "Interleukin-17 and Th17 Lymphocytes Directly Impair Motoneuron Survival of Wildtype and FUS-ALS Mutant Human iPSCs", "doi": "10.3390/ijms22158042", "year": 2021 } ] } }, { "id": 38221, "drug": "anti-RANKL antibody", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "induces", "mediator": "IL-8", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "major depressive disorder", "outcome_type": "disease", "outcome_domain": "depression", "score": 0.23025850929940456, "filtered_score": 0.23025850929940456, "filter_reason": null, "outreach_score": 0.23025850929940456, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "anti-rankl antibody", "mediator_canonical": "IL8", "outcome_canonical": "major depressive disorder", "ab_count": 1, "bc_count": 4, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "30753461", "title": "Anti-receptor activator of nuclear factor κB ligand antibody treatment increases osteoclastogenesis-promoting IL-8 in patients with rheumatoid arthritis", "doi": "10.1093/intimm/dxz009", "year": 2019 } ], "bc": [ { "pmid": "41876463", "title": "Prediction of depressive episodes based on clinical features, cognitive characteristics, inflammation-related proteins, and EEG data", "doi": "10.1038/s41398-026-03960-4", "year": 2026 }, { "pmid": "34294614", "title": "White Matter Alterations Associated with Pro-inflammatory Cytokines in Patients with Major Depressive Disorder", "doi": "10.9758/cpn.2021.19.3.449", "year": 2021 }, { "pmid": "32874955", "title": "Serum levels of chemokines in adolescents with major depression treated with fluoxetine", "doi": "10.5498/wjp.v10.i8.175", "year": 2020 } ] } }, { "id": 23417, "drug": "DMF", "drug_type": "drug", "drug_domain": "multiple_sclerosis", "predicate_ab": "activates", "mediator": "NRF2", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "antioxidant defense", "outcome_type": "phenotype", "outcome_domain": "als", "score": 0.23025850929940456, "filtered_score": 0.23025850929940456, "filter_reason": null, "outreach_score": 0.23025850929940456, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "dmf", "mediator_canonical": "NRF2", "outcome_canonical": "antioxidant defense", "ab_count": 4, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "35743211", "title": "Mechanisms of Sensitivity and Resistance of Primary Effusion Lymphoma to Dimethyl Fumarate (DMF)", "doi": "10.3390/ijms23126773", "year": 2022 }, { "pmid": "32672401", "title": "Structural insights into the multiple binding modes of Dimethyl Fumarate (DMF) and its analogs to the Kelch domain of Keap1", "doi": "10.1111/febs.15485", "year": 2020 }, { "pmid": "32394330", "title": "Characterization of More Selective Central Nervous System Nrf2-Activating Novel Vinyl Sulfoximine Compounds Compared to Dimethyl Fumarate", "doi": "10.1007/s13311-020-00855-0", "year": 2020 } ], "bc": [ { "pmid": "37862202", "title": "NRF2 signaling cascade in amyotrophic lateral sclerosis: bridging the gap between promise and reality", "doi": "10.4103/1673-5374.385283", "year": 2023 } ] } }, { "id": 51761, "drug": "tafamidis", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "binds_to", "mediator": "TTR", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "rheumatoid arthritis", "outcome_type": "disease", "outcome_domain": "rheumatoid_arthritis", "score": 0.23025850929940456, "filtered_score": 0.23025850929940456, "filter_reason": null, "outreach_score": 0.23025850929940456, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 4, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "28951660", "title": "Treatment With Tafamidis Slows Disease Progression in Early-Stage Transthyretin Cardiomyopathy", "doi": "10.1177/1179546817730322", "year": 2017 }, { "pmid": "25872787", "title": "Tafamidis in Transthyretin Amyloid Cardiomyopathy", "doi": "10.1161/circheartfailure.113.000890", "year": 2015 }, { "pmid": "26193961", "title": "Personalized medicine approach for optimizing the dose of tafamidis to potentially ameliorate wild-type transthyretin amyloidosis (cardiomyopathy)", "doi": "10.3109/13506129.2015.1063485", "year": 2015 } ], "bc": [ { "pmid": "34737606", "title": "Transthyretin and Receptor for Advanced Glycation End Product’s Differential Levels Associated with the Pathogenesis of Rheumatoid Arthritis", "doi": "10.2147/jir.s327736", "year": 2021 } ] } }, { "id": 61003, "drug": "lobeglitazone", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "binds_to", "mediator": "PPARγ", "mediator_type": "protein", "predicate_bc": "decreases", "outcome": "interstitial fibrosis", "outcome_type": "disease", "outcome_domain": "heart_failure", "score": 0.23025850929940456, "filtered_score": 0.23025850929940456, "filter_reason": null, "outreach_score": 0.23025850929940456, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 4, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "29311579", "title": "Structural Basis for the Enhanced Anti-Diabetic Efficacy of Lobeglitazone on PPARγ", "doi": "10.1038/s41598-017-18274-1", "year": 2018 }, { "pmid": "29203903", "title": "Structures of PPARγ complexed with lobeglitazone and pioglitazone reveal key determinants for the recognition of antidiabetic drugs", "doi": "10.1038/s41598-017-17082-x", "year": 2017 } ], "bc": [ { "pmid": "25633415", "title": "Activation of Peroxisome Proliferator-Activated Receptor γ (PPARγ) Through NF-κB/Brg1 and TGF-ß1 Pathways Attenuates Cardiac Remodeling in Pressure-Overloaded Rat Hearts", "doi": "10.1159/000369747", "year": 2015 } ] } }, { "id": 23418, "drug": "pembrolizumab", "drug_type": "drug", "drug_domain": "multiple_sclerosis", "predicate_ab": "inhibits", "mediator": "PD-1", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "ALS disease progression", "outcome_type": "phenotype", "outcome_domain": "als", "score": 0.23025850929940456, "filtered_score": 0.23025850929940456, "filter_reason": null, "outreach_score": 0.23025850929940456, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "pembrolizumab", "mediator_canonical": "pd-1", "outcome_canonical": "als disease progression", "ab_count": 4, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41232216", "title": "Iatrogenic NORSE: Immune checkpoint inhibitor-related anti-GFAP autoimmune astrocytopathy", "doi": "10.1016/j.jneuroim.2025.578805", "year": 2025 }, { "pmid": "35637642", "title": "Pembrolizumab for the treatment of Progressive Multifocal Leukoencephalopathy (PML) in a patient with AIDS: A case report and literature review", "doi": "10.1016/j.idcr.2022.e01514", "year": 2022 }, { "pmid": "33995251", "title": "Case Report: Longitudinal Extensive Transverse Myelitis With Novel Autoantibodies Following Two Rounds of Pembrolizumab", "doi": "10.3389/fneur.2021.655283", "year": 2021 } ], "bc": [ { "pmid": "40755012", "title": "Immune checkpoint changes correlate with the progression and prognosis of amyotrophic lateral sclerosis", "doi": "10.1080/07853890.2025.2540023", "year": 2025 } ] } }, { "id": 23610, "drug": "DMF", "drug_type": "drug", "drug_domain": "multiple_sclerosis", "predicate_ab": "activates", "mediator": "NRF2", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "Alzheimer's disease", "outcome_type": "disease", "outcome_domain": "alzheimer", "score": 0.23025850929940456, "filtered_score": 0.23025850929940456, "filter_reason": null, "outreach_score": 0.23025850929940456, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "active", "clinical_trial_nct_ids": [ "NCT06850597" ], "literature_status": "reproduces_known", "drug_canonical": "dmf", "mediator_canonical": "NRF2", "outcome_canonical": "Alzheimer disease", "ab_count": 4, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "35743211", "title": "Mechanisms of Sensitivity and Resistance of Primary Effusion Lymphoma to Dimethyl Fumarate (DMF)", "doi": "10.3390/ijms23126773", "year": 2022 }, { "pmid": "32672401", "title": "Structural insights into the multiple binding modes of Dimethyl Fumarate (DMF) and its analogs to the Kelch domain of Keap1", "doi": "10.1111/febs.15485", "year": 2020 }, { "pmid": "32394330", "title": "Characterization of More Selective Central Nervous System Nrf2-Activating Novel Vinyl Sulfoximine Compounds Compared to Dimethyl Fumarate", "doi": "10.1007/s13311-020-00855-0", "year": 2020 } ], "bc": [ { "pmid": "40867848", "title": "Exploring the Impact of Bioactive Compounds Found in Extra Virgin Olive Oil on NRF2 Modulation in Alzheimer’s Disease", "doi": "10.3390/antiox14080952", "year": 2025 } ] } }, { "id": 32869, "drug": "LPS", "drug_type": "drug", "drug_domain": "inflammatory_bowel_disease", "predicate_ab": "upregulates", "mediator": "IL-8", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "major depressive disorder", "outcome_type": "disease", "outcome_domain": "depression", "score": 0.23025850929940456, "filtered_score": 0.23025850929940456, "filter_reason": null, "outreach_score": 0.23025850929940456, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "active", "clinical_trial_nct_ids": [ "NCT04751331", "NCT03142919" ], "literature_status": "reproduces_known", "drug_canonical": "lps", "mediator_canonical": "IL8", "outcome_canonical": "major depressive disorder", "ab_count": 1, "bc_count": 4, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "30590414", "title": "Transplantation of Human Intestine Into the Mouse: A Novel Platform for Study of Inflammatory Enterocutaneous Fistulas", "doi": "10.1093/ecco-jcc/jjy226", "year": 2018 } ], "bc": [ { "pmid": "41876463", "title": "Prediction of depressive episodes based on clinical features, cognitive characteristics, inflammation-related proteins, and EEG data", "doi": "10.1038/s41398-026-03960-4", "year": 2026 }, { "pmid": "34294614", "title": "White Matter Alterations Associated with Pro-inflammatory Cytokines in Patients with Major Depressive Disorder", "doi": "10.9758/cpn.2021.19.3.449", "year": 2021 }, { "pmid": "32874955", "title": "Serum levels of chemokines in adolescents with major depression treated with fluoxetine", "doi": "10.5498/wjp.v10.i8.175", "year": 2020 } ] } }, { "id": 3616, "drug": "Sinapic acid", "drug_type": "drug", "drug_domain": "alzheimer", "predicate_ab": "upregulates", "mediator": "BDNF", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "epilepsy", "outcome_type": "disease", "outcome_domain": "epilepsy", "score": 0.23025850929940456, "filtered_score": 0.23025850929940456, "filter_reason": null, "outreach_score": 0.23025850929940456, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "sinapic acid", "mediator_canonical": "BDNF", "outcome_canonical": "epilepsy", "ab_count": 1, "bc_count": 4, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "36979237", "title": "Effect of Sinapic Acid on Scopolamine-Induced Learning and Memory Impairment in SD Rats", "doi": "10.3390/brainsci13030427", "year": 2023 } ], "bc": [ { "pmid": "39474368", "title": "Reduced serum neurotrophic factors and monoamine neurotransmitters in epilepsy patients with comorbid depression", "doi": "10.3389/fneur.2024.1480854", "year": 2024 }, { "pmid": "35557046", "title": "Overexpression of BDNF in the ventrolateral periaqueductal gray regulates the behavior of epilepsy–migraine comorbid rats", "doi": "10.1002/brb3.2594", "year": 2022 }, { "pmid": "34331458", "title": "Inflammatory and neurotrophic factor plasma levels are related to epilepsy independently of etiology", "doi": "10.1111/epi.17023", "year": 2021 } ] } }, { "id": 39036, "drug": "tofacitinib", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "inhibits", "mediator": "JAK2", "mediator_type": "protein", "predicate_bc": "predicts", "outcome": "poor prognosis", "outcome_type": "phenotype", "outcome_domain": "pancreatic_cancer", "score": 0.23025850929940456, "filtered_score": 0.23025850929940456, "filter_reason": null, "outreach_score": 0.23025850929940456, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "tofacitinib", "mediator_canonical": "jak2", "outcome_canonical": null, "ab_count": 4, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37384596", "title": "Efficacy and Safety of Tofacitinib in Patients with Polymyalgia Rheumatica (EAST PMR): An open-label randomized controlled trial", "doi": "10.1371/journal.pmed.1004249", "year": 2023 }, { "pmid": "37906702", "title": "Machine Learning-Based Drug Repositioning of Novel Janus Kinase 2 Inhibitors Utilizing Molecular Docking and Molecular Dynamic Simulation", "doi": "10.1021/acs.jcim.3c01090", "year": 2023 }, { "pmid": "31956784", "title": "Insights into the Binding Recognition and Susceptibility of Tofacitinib toward Janus Kinases", "doi": "10.1021/acsomega.9b02800", "year": 2020 } ], "bc": [ { "pmid": "33029256", "title": "High JAK2 Protein Expression Predicts a Poor Prognosis in Patients with Resectable Pancreatic Ductal Adenocarcinoma", "doi": "10.1155/2020/7656031", "year": 2020 } ] } }, { "id": 60402, "drug": "Apabetalone", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "suppresses", "mediator": "IL-8", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "major depressive disorder", "outcome_type": "disease", "outcome_domain": "depression", "score": 0.23025850929940456, "filtered_score": 0.23025850929940456, "filter_reason": null, "outreach_score": 0.23025850929940456, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 4, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "33172487", "title": "BET protein inhibitor apabetalone (RVX-208) suppresses pro-inflammatory hyper-activation of monocytes from patients with cardiovascular disease and type 2 diabetes", "doi": "10.1186/s13148-020-00943-0", "year": 2020 } ], "bc": [ { "pmid": "41876463", "title": "Prediction of depressive episodes based on clinical features, cognitive characteristics, inflammation-related proteins, and EEG data", "doi": "10.1038/s41398-026-03960-4", "year": 2026 }, { "pmid": "34294614", "title": "White Matter Alterations Associated with Pro-inflammatory Cytokines in Patients with Major Depressive Disorder", "doi": "10.9758/cpn.2021.19.3.449", "year": 2021 }, { "pmid": "32874955", "title": "Serum levels of chemokines in adolescents with major depression treated with fluoxetine", "doi": "10.5498/wjp.v10.i8.175", "year": 2020 } ] } }, { "id": 39024, "drug": "BER-DEX hyalurosomes", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "binds_to", "mediator": "CD44", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "poor prognosis", "outcome_type": "phenotype", "outcome_domain": "pancreatic_cancer", "score": 0.23025850929940456, "filtered_score": 0.23025850929940456, "filter_reason": null, "outreach_score": 0.23025850929940456, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "ber-dex hyalurosomes", "mediator_canonical": "cd44", "outcome_canonical": null, "ab_count": 1, "bc_count": 4, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40358395", "title": "Unveiling the synergistic impact of cocktail nanohyalurosomes encapsulating berberine and dexamethasone in managing rheumatoid arthritis: in-vitro evaluation and biological studies", "doi": "10.1080/02652048.2025.2498963", "year": 2025 } ], "bc": [ { "pmid": "35931675", "title": "Gemcitabine resistance of pancreatic cancer cells is mediated by IGF1R dependent upregulation of CD44 expression and isoform switching", "doi": "10.1038/s41419-022-05103-1", "year": 2022 }, { "pmid": "28659655", "title": "Expression and Clinical Significance of Cancer Stem Cell Markers CD24, CD44, and CD133 in Pancreatic Ductal Adenocarcinoma and Chronic Pancreatitis", "doi": "10.1155/2017/3276806", "year": 2017 }, { "pmid": "26261555", "title": "Expression of CD44 in pancreatic cancer and its significance.", "doi": null, "year": 2015 } ] } }, { "id": 37664, "drug": "E6011", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "inhibits", "mediator": "fractalkine", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "ALSFRS score", "outcome_type": "phenotype", "outcome_domain": "als", "score": 0.23025850929940456, "filtered_score": 0.23025850929940456, "filter_reason": null, "outreach_score": 0.23025850929940456, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "e6011", "mediator_canonical": "fractalkine", "outcome_canonical": "alsfrs score", "ab_count": 4, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "36680426", "title": "Long-term safety and efficacy of E6011, an anti-fractalkine monoclonal antibody, in patients with rheumatoid arthritis inadequately responding to methotrexate", "doi": "10.1093/mr/road004", "year": 2023 }, { "pmid": "33038062", "title": "Efficacy and Safety of E6011, an Anti‐Fractalkine Monoclonal Antibody, in Patients With Active Rheumatoid Arthritis With Inadequate Response to Methotrexate: Results of a Randomized, Double‐Blind, Placebo‐Controlled Phase II Study", "doi": "10.1002/art.41555", "year": 2020 }, { "pmid": "30575978", "title": "Pharmacokinetics, Pharmacodynamics, and Safety of E6011, a Novel Humanized Antifractalkine (CX3CL1) Monoclonal Antibody: A Randomized, Double‐Blind, Placebo‐Controlled Single‐Ascending‐Dose Study", "doi": "10.1002/jcph.1361", "year": 2018 } ], "bc": [ { "pmid": "38625841", "title": "Enhanced levels of fractalkine and HSP60 in cerebrospinal fluid of sporadic amyotrophic lateral sclerosis patients", "doi": "10.1080/00207454.2024.2344581", "year": 2024 } ] } }, { "id": 3609, "drug": "GQ1b", "drug_type": "drug", "drug_domain": "alzheimer", "predicate_ab": "upregulates", "mediator": "BDNF", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "epilepsy", "outcome_type": "disease", "outcome_domain": "epilepsy", "score": 0.23025850929940456, "filtered_score": 0.23025850929940456, "filter_reason": null, "outreach_score": 0.23025850929940456, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "gq1b", "mediator_canonical": "BDNF", "outcome_canonical": "epilepsy", "ab_count": 1, "bc_count": 4, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "31186474", "title": "Ganglioside GQ1b ameliorates cognitive impairments in an Alzheimer’s disease mouse model, and causes reduction of amyloid precursor protein", "doi": "10.1038/s41598-019-44739-6", "year": 2019 } ], "bc": [ { "pmid": "39474368", "title": "Reduced serum neurotrophic factors and monoamine neurotransmitters in epilepsy patients with comorbid depression", "doi": "10.3389/fneur.2024.1480854", "year": 2024 }, { "pmid": "35557046", "title": "Overexpression of BDNF in the ventrolateral periaqueductal gray regulates the behavior of epilepsy–migraine comorbid rats", "doi": "10.1002/brb3.2594", "year": 2022 }, { "pmid": "34331458", "title": "Inflammatory and neurotrophic factor plasma levels are related to epilepsy independently of etiology", "doi": "10.1111/epi.17023", "year": 2021 } ] } }, { "id": 35657, "drug": "DMF", "drug_type": "drug", "drug_domain": "multiple_sclerosis", "predicate_ab": "activates", "mediator": "Nrf2", "mediator_type": "protein", "predicate_bc": "prevents", "outcome": "type 1 diabetes", "outcome_type": "disease", "outcome_domain": "type_2_diabetes", "score": 0.23025850929940456, "filtered_score": 0.23025850929940456, "filter_reason": null, "outreach_score": 0.23025850929940456, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "active", "clinical_trial_nct_ids": [ "NCT07258394", "NCT07548996" ], "literature_status": "reproduces_known", "drug_canonical": "dmf", "mediator_canonical": "NRF2", "outcome_canonical": "type 1 diabetes", "ab_count": 4, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "35743211", "title": "Mechanisms of Sensitivity and Resistance of Primary Effusion Lymphoma to Dimethyl Fumarate (DMF)", "doi": "10.3390/ijms23126773", "year": 2022 }, { "pmid": "32672401", "title": "Structural insights into the multiple binding modes of Dimethyl Fumarate (DMF) and its analogs to the Kelch domain of Keap1", "doi": "10.1111/febs.15485", "year": 2020 }, { "pmid": "32394330", "title": "Characterization of More Selective Central Nervous System Nrf2-Activating Novel Vinyl Sulfoximine Compounds Compared to Dimethyl Fumarate", "doi": "10.1007/s13311-020-00855-0", "year": 2020 } ], "bc": [ { "pmid": "30625116", "title": "Nrf2 represses the onset of type 1 diabetes in non-obese diabetic mice", "doi": "10.1530/joe-18-0355", "year": 2019 } ] } }, { "id": 10444, "drug": "Calycosin", "drug_type": "drug", "drug_domain": "depression", "predicate_ab": "upregulates", "mediator": "BDNF", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "epilepsy", "outcome_type": "disease", "outcome_domain": "epilepsy", "score": 0.23025850929940456, "filtered_score": 0.23025850929940456, "filter_reason": null, "outreach_score": 0.23025850929940456, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "calycosin", "mediator_canonical": "BDNF", "outcome_canonical": "epilepsy", "ab_count": 1, "bc_count": 4, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40260589", "title": "Therapeutic Targets and Molecular Mechanisms of Calycosin in the Treatment of Depression: Insights From Chronic Mild Stress Animal Models", "doi": "10.1111/cns.70353", "year": 2025 } ], "bc": [ { "pmid": "39474368", "title": "Reduced serum neurotrophic factors and monoamine neurotransmitters in epilepsy patients with comorbid depression", "doi": "10.3389/fneur.2024.1480854", "year": 2024 }, { "pmid": "35557046", "title": "Overexpression of BDNF in the ventrolateral periaqueductal gray regulates the behavior of epilepsy–migraine comorbid rats", "doi": "10.1002/brb3.2594", "year": 2022 }, { "pmid": "34331458", "title": "Inflammatory and neurotrophic factor plasma levels are related to epilepsy independently of etiology", "doi": "10.1111/epi.17023", "year": 2021 } ] } }, { "id": 39408, "drug": "saxagliptin", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "upregulates", "mediator": "SOD1", "mediator_type": "gene", "predicate_bc": "associated_with", "outcome": "familial ALS", "outcome_type": "disease", "outcome_domain": "als", "score": 0.23025850929940456, "filtered_score": 0.23025850929940456, "filter_reason": null, "outreach_score": 0.23025850929940456, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "saxagliptin", "mediator_canonical": "SOD1", "outcome_canonical": "familial als", "ab_count": 1, "bc_count": 4, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "29724198", "title": "The synergistic effects of saxagliptin and metformin on CD34+ endothelial progenitor cells in early type 2 diabetes patients: a randomized clinical trial", "doi": "10.1186/s12933-018-0709-9", "year": 2018 } ], "bc": [ { "pmid": "41673790", "title": "Comprehensive clinical and genetic architecture of familial amyotrophic lateral sclerosis in China: A 15-year cohort study with 302 families", "doi": "10.4103/nrr.nrr-d-24-00701", "year": 2025 }, { "pmid": "32166880", "title": "Clinical and genetic features of patients with amyotrophic lateral sclerosis in southern China", "doi": "10.1111/ene.14213", "year": 2020 }, { "pmid": "29504729", "title": "Possible etiology and treatment of amyotrophic lateral sclerosis.", "doi": null, "year": 2018 } ] } }, { "id": 55095, "drug": "DMF", "drug_type": "drug", "drug_domain": "multiple_sclerosis", "predicate_ab": "activates", "mediator": "Nrf2", "mediator_type": "protein", "predicate_bc": "prevents", "outcome": "DNA damage", "outcome_type": "phenotype", "outcome_domain": "heart_failure", "score": 0.23025850929940456, "filtered_score": 0.23025850929940456, "filter_reason": null, "outreach_score": 0.23025850929940456, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 4, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "35743211", "title": "Mechanisms of Sensitivity and Resistance of Primary Effusion Lymphoma to Dimethyl Fumarate (DMF)", "doi": "10.3390/ijms23126773", "year": 2022 }, { "pmid": "32672401", "title": "Structural insights into the multiple binding modes of Dimethyl Fumarate (DMF) and its analogs to the Kelch domain of Keap1", "doi": "10.1111/febs.15485", "year": 2020 }, { "pmid": "32394330", "title": "Characterization of More Selective Central Nervous System Nrf2-Activating Novel Vinyl Sulfoximine Compounds Compared to Dimethyl Fumarate", "doi": "10.1007/s13311-020-00855-0", "year": 2020 } ], "bc": [ { "pmid": "39657243", "title": "NRF2 activation in the heart induces glucose metabolic reprogramming and reduces cardiac dysfunction via upregulation of the pentose phosphate pathway", "doi": "10.1093/cvr/cvae250", "year": 2024 } ] } }, { "id": 55094, "drug": "DMF", "drug_type": "drug", "drug_domain": "multiple_sclerosis", "predicate_ab": "activates", "mediator": "Nrf2", "mediator_type": "protein", "predicate_bc": "prevents", "outcome": "angiotensin II-induced cardiomyopathy", "outcome_type": "disease", "outcome_domain": "heart_failure", "score": 0.23025850929940456, "filtered_score": 0.23025850929940456, "filter_reason": null, "outreach_score": 0.23025850929940456, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 4, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "35743211", "title": "Mechanisms of Sensitivity and Resistance of Primary Effusion Lymphoma to Dimethyl Fumarate (DMF)", "doi": "10.3390/ijms23126773", "year": 2022 }, { "pmid": "32672401", "title": "Structural insights into the multiple binding modes of Dimethyl Fumarate (DMF) and its analogs to the Kelch domain of Keap1", "doi": "10.1111/febs.15485", "year": 2020 }, { "pmid": "32394330", "title": "Characterization of More Selective Central Nervous System Nrf2-Activating Novel Vinyl Sulfoximine Compounds Compared to Dimethyl Fumarate", "doi": "10.1007/s13311-020-00855-0", "year": 2020 } ], "bc": [ { "pmid": "29353218", "title": "Sulforaphane prevents angiotensin II-induced cardiomyopathy by activation of Nrf2 via stimulating the Akt/GSK-3ß/Fyn pathway", "doi": "10.1016/j.redox.2017.12.016", "year": 2018 } ] } }, { "id": 38220, "drug": "TIM1", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "inhibits", "mediator": "IL-8", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "major depressive disorder", "outcome_type": "disease", "outcome_domain": "depression", "score": 0.23025850929940456, "filtered_score": 0.23025850929940456, "filter_reason": null, "outreach_score": 0.23025850929940456, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "tim1", "mediator_canonical": "IL8", "outcome_canonical": "major depressive disorder", "ab_count": 1, "bc_count": 4, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "36346838", "title": "An orally active, small-molecule TNF inhibitor that disrupts the homotrimerization interface improves inflammatory arthritis in mice", "doi": "10.1126/scisignal.abi8713", "year": 2022 } ], "bc": [ { "pmid": "41876463", "title": "Prediction of depressive episodes based on clinical features, cognitive characteristics, inflammation-related proteins, and EEG data", "doi": "10.1038/s41398-026-03960-4", "year": 2026 }, { "pmid": "34294614", "title": "White Matter Alterations Associated with Pro-inflammatory Cytokines in Patients with Major Depressive Disorder", "doi": "10.9758/cpn.2021.19.3.449", "year": 2021 }, { "pmid": "32874955", "title": "Serum levels of chemokines in adolescents with major depression treated with fluoxetine", "doi": "10.5498/wjp.v10.i8.175", "year": 2020 } ] } }, { "id": 38214, "drug": "tofacitinib", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "downregulates", "mediator": "IL-8", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "major depressive disorder", "outcome_type": "disease", "outcome_domain": "depression", "score": 0.23025850929940456, "filtered_score": 0.23025850929940456, "filter_reason": null, "outreach_score": 0.23025850929940456, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "tofacitinib", "mediator_canonical": "IL8", "outcome_canonical": "major depressive disorder", "ab_count": 1, "bc_count": 4, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "36537363", "title": "Synovitis, acne, pustulosis, hyperostosis and osteitis syndrome with mandibular involvement: Would surgical operation help?", "doi": "10.1111/1756-185x.14542", "year": 2022 } ], "bc": [ { "pmid": "41876463", "title": "Prediction of depressive episodes based on clinical features, cognitive characteristics, inflammation-related proteins, and EEG data", "doi": "10.1038/s41398-026-03960-4", "year": 2026 }, { "pmid": "34294614", "title": "White Matter Alterations Associated with Pro-inflammatory Cytokines in Patients with Major Depressive Disorder", "doi": "10.9758/cpn.2021.19.3.449", "year": 2021 }, { "pmid": "32874955", "title": "Serum levels of chemokines in adolescents with major depression treated with fluoxetine", "doi": "10.5498/wjp.v10.i8.175", "year": 2020 } ] } }, { "id": 55093, "drug": "DMF", "drug_type": "drug", "drug_domain": "multiple_sclerosis", "predicate_ab": "activates", "mediator": "Nrf2", "mediator_type": "protein", "predicate_bc": "increases", "outcome": "exercise capacity", "outcome_type": "phenotype", "outcome_domain": "heart_failure", "score": 0.23025850929940456, "filtered_score": 0.23025850929940456, "filter_reason": null, "outreach_score": 0.23025850929940456, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 4, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "35743211", "title": "Mechanisms of Sensitivity and Resistance of Primary Effusion Lymphoma to Dimethyl Fumarate (DMF)", "doi": "10.3390/ijms23126773", "year": 2022 }, { "pmid": "32672401", "title": "Structural insights into the multiple binding modes of Dimethyl Fumarate (DMF) and its analogs to the Kelch domain of Keap1", "doi": "10.1111/febs.15485", "year": 2020 }, { "pmid": "32394330", "title": "Characterization of More Selective Central Nervous System Nrf2-Activating Novel Vinyl Sulfoximine Compounds Compared to Dimethyl Fumarate", "doi": "10.1007/s13311-020-00855-0", "year": 2020 } ], "bc": [ { "pmid": "30589411", "title": "Myocardial NADPH oxidase-4 regulates the physiological response to acute exercise", "doi": "10.7554/elife.41044", "year": 2018 } ] } }, { "id": 23808, "drug": "DMF", "drug_type": "drug", "drug_domain": "multiple_sclerosis", "predicate_ab": "activates", "mediator": "NRF2", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "poor prognosis", "outcome_type": "phenotype", "outcome_domain": "pancreatic_cancer", "score": 0.23025850929940456, "filtered_score": 0.23025850929940456, "filter_reason": null, "outreach_score": 0.23025850929940456, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "dmf", "mediator_canonical": "NRF2", "outcome_canonical": null, "ab_count": 4, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "35743211", "title": "Mechanisms of Sensitivity and Resistance of Primary Effusion Lymphoma to Dimethyl Fumarate (DMF)", "doi": "10.3390/ijms23126773", "year": 2022 }, { "pmid": "32672401", "title": "Structural insights into the multiple binding modes of Dimethyl Fumarate (DMF) and its analogs to the Kelch domain of Keap1", "doi": "10.1111/febs.15485", "year": 2020 }, { "pmid": "32394330", "title": "Characterization of More Selective Central Nervous System Nrf2-Activating Novel Vinyl Sulfoximine Compounds Compared to Dimethyl Fumarate", "doi": "10.1007/s13311-020-00855-0", "year": 2020 } ], "bc": [ { "pmid": "31911550", "title": "Undermining Glutaminolysis Bolsters Chemotherapy While NRF2 Promotes Chemoresistance in KRAS-Driven Pancreatic Cancers", "doi": "10.1158/0008-5472.can-19-1363", "year": 2020 } ] } }, { "id": 23415, "drug": "DMF", "drug_type": "drug", "drug_domain": "multiple_sclerosis", "predicate_ab": "activates", "mediator": "NRF2", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "ALS", "outcome_type": "disease", "outcome_domain": "als", "score": 0.23025850929940456, "filtered_score": 0.23025850929940456, "filter_reason": null, "outreach_score": 0.23025850929940456, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "dmf", "mediator_canonical": "NRF2", "outcome_canonical": "amyotrophic lateral sclerosis", "ab_count": 4, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "35743211", "title": "Mechanisms of Sensitivity and Resistance of Primary Effusion Lymphoma to Dimethyl Fumarate (DMF)", "doi": "10.3390/ijms23126773", "year": 2022 }, { "pmid": "32672401", "title": "Structural insights into the multiple binding modes of Dimethyl Fumarate (DMF) and its analogs to the Kelch domain of Keap1", "doi": "10.1111/febs.15485", "year": 2020 }, { "pmid": "32394330", "title": "Characterization of More Selective Central Nervous System Nrf2-Activating Novel Vinyl Sulfoximine Compounds Compared to Dimethyl Fumarate", "doi": "10.1007/s13311-020-00855-0", "year": 2020 } ], "bc": [ { "pmid": "40581791", "title": "Identification of disease-associated molecular signatures in the Prp-TDP-43A315T mouse model of ALS: Toward preclinical biomarker development", "doi": "10.1093/jnen/nlaf071", "year": 2025 } ] } }, { "id": 38704, "drug": "secukinumab", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "inhibits", "mediator": "IL-17A", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "Behcet's uveitis", "outcome_type": "disease", "outcome_domain": "inflammatory_bowel_disease", "score": 0.23025850929940456, "filtered_score": 0.23025850929940456, "filter_reason": null, "outreach_score": 0.23025850929940456, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "completed", "clinical_trial_nct_ids": [ "NCT00685399", "NCT00995709" ], "literature_status": "reproduces_known", "drug_canonical": "secukinumab", "mediator_canonical": "il-17a", "outcome_canonical": "behcet's uveitis", "ab_count": 4, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "33913511", "title": "Efficacy of secukinumab and adalimumab in patients with psoriatic arthritis and concomitant moderate‐to‐severe plaque psoriasis: results from EXCEED, a randomized, double‐blind head‐to‐head monotherapy study", "doi": "10.1111/bjd.20413", "year": 2021 }, { "pmid": "34919658", "title": "Secukinumab-induced systemic lupus erythematosus occurring in a patient with ankylosing spondylitis", "doi": "10.1093/rheumatology/keab918", "year": 2021 }, { "pmid": "33120695", "title": "Role of secukinumab in ankylosing spondylitis with tubercular uveitis", "doi": "10.4103/ijo.ijo_1081_20", "year": 2020 } ], "bc": [ { "pmid": "37553722", "title": "Potential gastrointestinal Behcet’s disease flare after treatment with anti-interleukin 17a therapy", "doi": "10.1186/s41927-023-00344-9", "year": 2023 } ] } }, { "id": 38680, "drug": "secukinumab", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "inhibits", "mediator": "IL-17A", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "endoscopic severity", "outcome_type": "phenotype", "outcome_domain": "inflammatory_bowel_disease", "score": 0.23025850929940456, "filtered_score": 0.23025850929940456, "filter_reason": null, "outreach_score": 0.23025850929940456, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "secukinumab", "mediator_canonical": "il-17a", "outcome_canonical": "endoscopic severity", "ab_count": 4, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "33913511", "title": "Efficacy of secukinumab and adalimumab in patients with psoriatic arthritis and concomitant moderate‐to‐severe plaque psoriasis: results from EXCEED, a randomized, double‐blind head‐to‐head monotherapy study", "doi": "10.1111/bjd.20413", "year": 2021 }, { "pmid": "34919658", "title": "Secukinumab-induced systemic lupus erythematosus occurring in a patient with ankylosing spondylitis", "doi": "10.1093/rheumatology/keab918", "year": 2021 }, { "pmid": "33120695", "title": "Role of secukinumab in ankylosing spondylitis with tubercular uveitis", "doi": "10.4103/ijo.ijo_1081_20", "year": 2020 } ], "bc": [ { "pmid": "39412247", "title": "Mucosal Cytokine Expression Associated With Deep Endoscopic Mucosal Healing in Ulcerative Colitis", "doi": "10.1093/ecco-jcc/jjae158", "year": 2024 } ] } }, { "id": 39232, "drug": "tocilizumab", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "downregulates", "mediator": "C-reactive protein", "mediator_type": "biomarker", "predicate_bc": "correlates_with", "outcome": "type 2 diabetes", "outcome_type": "disease", "outcome_domain": "type_2_diabetes", "score": 0.23025850929940456, "filtered_score": 0.23025850929940456, "filter_reason": null, "outreach_score": 0.23025850929940456, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "completed", "clinical_trial_nct_ids": [ "NCT01073826" ], "literature_status": "reproduces_known", "drug_canonical": "tocilizumab", "mediator_canonical": "c-reactive protein", "outcome_canonical": "type 2 diabetes", "ab_count": 1, "bc_count": 4, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "39754984", "title": "Anti-IL-6R Ab tocilizumab to treat paraneoplastic inflammatory syndrome of solid cancers", "doi": "10.1016/j.esmoop.2024.104088", "year": 2025 } ], "bc": [ { "pmid": "30872696", "title": "Association of C-Reactive Protein with Risk of Developing Type 2 Diabetes Mellitus, and Role of Obesity and Hypertension: A Large Population-Based Korean Cohort Study", "doi": "10.1038/s41598-019-40987-8", "year": 2019 }, { "pmid": "27013319", "title": "Oxidative stress, inflammation, endothelial dysfunction and incidence of type 2 diabetes", "doi": "10.1186/s12933-016-0369-6", "year": 2016 } ] } }, { "id": 39235, "drug": "upadacitinib", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "downregulates", "mediator": "C-reactive protein", "mediator_type": "biomarker", "predicate_bc": "correlates_with", "outcome": "type 2 diabetes", "outcome_type": "disease", "outcome_domain": "type_2_diabetes", "score": 0.23025850929940456, "filtered_score": 0.23025850929940456, "filter_reason": null, "outreach_score": 0.23025850929940456, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "upadacitinib", "mediator_canonical": "c-reactive protein", "outcome_canonical": "type 2 diabetes", "ab_count": 1, "bc_count": 4, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "39909970", "title": "Real-world effectiveness and retention rate of upadacitinib in patients with rheumatoid arthritis: results from a multicentre study", "doi": "10.1007/s10238-025-01578-2", "year": 2025 } ], "bc": [ { "pmid": "30872696", "title": "Association of C-Reactive Protein with Risk of Developing Type 2 Diabetes Mellitus, and Role of Obesity and Hypertension: A Large Population-Based Korean Cohort Study", "doi": "10.1038/s41598-019-40987-8", "year": 2019 }, { "pmid": "27013319", "title": "Oxidative stress, inflammation, endothelial dysfunction and incidence of type 2 diabetes", "doi": "10.1186/s12933-016-0369-6", "year": 2016 } ] } }, { "id": 38824, "drug": "secukinumab", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "inhibits", "mediator": "IL-17A", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "response to interferon-beta therapy", "outcome_type": "phenotype", "outcome_domain": "multiple_sclerosis", "score": 0.23025850929940456, "filtered_score": 0.23025850929940456, "filter_reason": null, "outreach_score": 0.23025850929940456, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "secukinumab", "mediator_canonical": "il-17a", "outcome_canonical": "response to interferon-beta therapy", "ab_count": 4, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "33913511", "title": "Efficacy of secukinumab and adalimumab in patients with psoriatic arthritis and concomitant moderate‐to‐severe plaque psoriasis: results from EXCEED, a randomized, double‐blind head‐to‐head monotherapy study", "doi": "10.1111/bjd.20413", "year": 2021 }, { "pmid": "34919658", "title": "Secukinumab-induced systemic lupus erythematosus occurring in a patient with ankylosing spondylitis", "doi": "10.1093/rheumatology/keab918", "year": 2021 }, { "pmid": "33120695", "title": "Role of secukinumab in ankylosing spondylitis with tubercular uveitis", "doi": "10.4103/ijo.ijo_1081_20", "year": 2020 } ], "bc": [ { "pmid": "33463108", "title": "Comparison of Expression Levels of miR-29b-3p and miR-326 in T Helper-1 and T Helper-17 Cells Isolated from Responsive and Non-responsive Relapsing-remitting Multiple Sclerosis Patients Treated with Interferon-beta", "doi": "10.18502/ijaai.v19i4.4116", "year": 2020 } ] } }, { "id": 23809, "drug": "pembrolizumab", "drug_type": "drug", "drug_domain": "multiple_sclerosis", "predicate_ab": "inhibits", "mediator": "PD-1", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "advanced T stage", "outcome_type": "phenotype", "outcome_domain": "pancreatic_cancer", "score": 0.23025850929940456, "filtered_score": 0.23025850929940456, "filter_reason": null, "outreach_score": 0.23025850929940456, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "active", "clinical_trial_nct_ids": [ "NCT06989112", "NCT05956041", "NCT05727904" ], "literature_status": "novel_signal", "drug_canonical": "pembrolizumab", "mediator_canonical": "pd-1", "outcome_canonical": "advanced t stage", "ab_count": 4, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41232216", "title": "Iatrogenic NORSE: Immune checkpoint inhibitor-related anti-GFAP autoimmune astrocytopathy", "doi": "10.1016/j.jneuroim.2025.578805", "year": 2025 }, { "pmid": "35637642", "title": "Pembrolizumab for the treatment of Progressive Multifocal Leukoencephalopathy (PML) in a patient with AIDS: A case report and literature review", "doi": "10.1016/j.idcr.2022.e01514", "year": 2022 }, { "pmid": "33995251", "title": "Case Report: Longitudinal Extensive Transverse Myelitis With Novel Autoantibodies Following Two Rounds of Pembrolizumab", "doi": "10.3389/fneur.2021.655283", "year": 2021 } ], "bc": [ { "pmid": "28030840", "title": "Prognostic value and clinicopathological features of PD-1/PD-L1 expression with mismatch repair status and desmoplastic stroma in Chinese patients with pancreatic cancer", "doi": "10.18632/oncotarget.14069", "year": 2016 } ] } }, { "id": 38835, "drug": "secukinumab", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "inhibits", "mediator": "IL-17A", "mediator_type": "protein", "predicate_bc": "increases", "outcome": "EAE severity", "outcome_type": "phenotype", "outcome_domain": "multiple_sclerosis", "score": 0.23025850929940456, "filtered_score": 0.23025850929940456, "filter_reason": null, "outreach_score": 0.23025850929940456, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "secukinumab", "mediator_canonical": "il-17a", "outcome_canonical": "eae severity", "ab_count": 4, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "33913511", "title": "Efficacy of secukinumab and adalimumab in patients with psoriatic arthritis and concomitant moderate‐to‐severe plaque psoriasis: results from EXCEED, a randomized, double‐blind head‐to‐head monotherapy study", "doi": "10.1111/bjd.20413", "year": 2021 }, { "pmid": "34919658", "title": "Secukinumab-induced systemic lupus erythematosus occurring in a patient with ankylosing spondylitis", "doi": "10.1093/rheumatology/keab918", "year": 2021 }, { "pmid": "33120695", "title": "Role of secukinumab in ankylosing spondylitis with tubercular uveitis", "doi": "10.4103/ijo.ijo_1081_20", "year": 2020 } ], "bc": [ { "pmid": "36857006", "title": "IL-17A Facilitates Entry of Autoreactive T-Cells and Granulocytes into the CNS During EAE", "doi": "10.1007/s12017-023-08739-0", "year": 2023 } ] } }, { "id": 38261, "drug": "secukinumab", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "inhibits", "mediator": "IL-17A", "mediator_type": "protein", "predicate_bc": "increases", "outcome": "hippocampal neuronal death", "outcome_type": "phenotype", "outcome_domain": "epilepsy", "score": 0.23025850929940456, "filtered_score": 0.23025850929940456, "filter_reason": null, "outreach_score": 0.23025850929940456, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "secukinumab", "mediator_canonical": "il-17a", "outcome_canonical": "hippocampal neuronal death", "ab_count": 4, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "33913511", "title": "Efficacy of secukinumab and adalimumab in patients with psoriatic arthritis and concomitant moderate‐to‐severe plaque psoriasis: results from EXCEED, a randomized, double‐blind head‐to‐head monotherapy study", "doi": "10.1111/bjd.20413", "year": 2021 }, { "pmid": "34919658", "title": "Secukinumab-induced systemic lupus erythematosus occurring in a patient with ankylosing spondylitis", "doi": "10.1093/rheumatology/keab918", "year": 2021 }, { "pmid": "33120695", "title": "Role of secukinumab in ankylosing spondylitis with tubercular uveitis", "doi": "10.4103/ijo.ijo_1081_20", "year": 2020 } ], "bc": [ { "pmid": "35875667", "title": "Interleukin-17A Mediates Hippocampal Damage and Aberrant Neurogenesis Contributing to Epilepsy-Associated Anxiety", "doi": "10.3389/fnmol.2022.917598", "year": 2022 } ] } }, { "id": 23811, "drug": "pembrolizumab", "drug_type": "drug", "drug_domain": "multiple_sclerosis", "predicate_ab": "inhibits", "mediator": "PD-1", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "lymph node metastasis", "outcome_type": "disease", "outcome_domain": "pancreatic_cancer", "score": 0.23025850929940456, "filtered_score": 0.23025850929940456, "filter_reason": null, "outreach_score": 0.23025850929940456, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "completed", "clinical_trial_nct_ids": [ "NCT02509507", "NCT02423928", "NCT04725331" ], "literature_status": "reproduces_known", "drug_canonical": "pembrolizumab", "mediator_canonical": "pd-1", "outcome_canonical": "lymph node metastasis", "ab_count": 4, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41232216", "title": "Iatrogenic NORSE: Immune checkpoint inhibitor-related anti-GFAP autoimmune astrocytopathy", "doi": "10.1016/j.jneuroim.2025.578805", "year": 2025 }, { "pmid": "35637642", "title": "Pembrolizumab for the treatment of Progressive Multifocal Leukoencephalopathy (PML) in a patient with AIDS: A case report and literature review", "doi": "10.1016/j.idcr.2022.e01514", "year": 2022 }, { "pmid": "33995251", "title": "Case Report: Longitudinal Extensive Transverse Myelitis With Novel Autoantibodies Following Two Rounds of Pembrolizumab", "doi": "10.3389/fneur.2021.655283", "year": 2021 } ], "bc": [ { "pmid": "32987956", "title": "PD-1 Expression by Lymph Node and Intratumoral Regulatory T Cells Is Associated with Lymph Node Metastasis in Pancreatic Cancer", "doi": "10.3390/cancers12102756", "year": 2020 } ] } }, { "id": 38693, "drug": "E6011", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "inhibits", "mediator": "fractalkine", "mediator_type": "protein", "predicate_bc": "causes", "outcome": "periodontitis", "outcome_type": "disease", "outcome_domain": "inflammatory_bowel_disease", "score": 0.23025850929940456, "filtered_score": 0.23025850929940456, "filter_reason": null, "outreach_score": 0.23025850929940456, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "e6011", "mediator_canonical": "fractalkine", "outcome_canonical": "periodontitis", "ab_count": 4, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "36680426", "title": "Long-term safety and efficacy of E6011, an anti-fractalkine monoclonal antibody, in patients with rheumatoid arthritis inadequately responding to methotrexate", "doi": "10.1093/mr/road004", "year": 2023 }, { "pmid": "33038062", "title": "Efficacy and Safety of E6011, an Anti‐Fractalkine Monoclonal Antibody, in Patients With Active Rheumatoid Arthritis With Inadequate Response to Methotrexate: Results of a Randomized, Double‐Blind, Placebo‐Controlled Phase II Study", "doi": "10.1002/art.41555", "year": 2020 }, { "pmid": "30575978", "title": "Pharmacokinetics, Pharmacodynamics, and Safety of E6011, a Novel Humanized Antifractalkine (CX3CL1) Monoclonal Antibody: A Randomized, Double‐Blind, Placebo‐Controlled Single‐Ascending‐Dose Study", "doi": "10.1002/jcph.1361", "year": 2018 } ], "bc": [ { "pmid": "41443202", "title": "Unraveling the Gut-Oral Axis: A Mendelian Randomization Analysis of Gut Microbiota Impact on Periodontitis via Circulating Inflammatory Proteins", "doi": "10.12968/hmed.2025.0447", "year": 2025 } ] } }, { "id": 23810, "drug": "pembrolizumab", "drug_type": "drug", "drug_domain": "multiple_sclerosis", "predicate_ab": "inhibits", "mediator": "PD-1", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "prognosis", "outcome_type": "phenotype", "outcome_domain": "pancreatic_cancer", "score": 0.23025850929940456, "filtered_score": 0.23025850929940456, "filter_reason": null, "outreach_score": 0.23025850929940456, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "active", "clinical_trial_nct_ids": [ "NCT04994795", "NCT06702566", "NCT03391973" ], "literature_status": "reproduces_known", "drug_canonical": "pembrolizumab", "mediator_canonical": "pd-1", "outcome_canonical": null, "ab_count": 4, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41232216", "title": "Iatrogenic NORSE: Immune checkpoint inhibitor-related anti-GFAP autoimmune astrocytopathy", "doi": "10.1016/j.jneuroim.2025.578805", "year": 2025 }, { "pmid": "35637642", "title": "Pembrolizumab for the treatment of Progressive Multifocal Leukoencephalopathy (PML) in a patient with AIDS: A case report and literature review", "doi": "10.1016/j.idcr.2022.e01514", "year": 2022 }, { "pmid": "33995251", "title": "Case Report: Longitudinal Extensive Transverse Myelitis With Novel Autoantibodies Following Two Rounds of Pembrolizumab", "doi": "10.3389/fneur.2021.655283", "year": 2021 } ], "bc": [ { "pmid": "36359736", "title": "CXCR4-CXCL12-CXCR7 and PD-1/PD-L1 in Pancreatic Cancer: CXCL12 Predicts Survival of Radically Resected Patients", "doi": "10.3390/cells11213340", "year": 2022 } ] } }, { "id": 3644, "drug": "GJD", "drug_type": "drug", "drug_domain": "alzheimer", "predicate_ab": "upregulates", "mediator": "BDNF", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "epilepsy", "outcome_type": "disease", "outcome_domain": "epilepsy", "score": 0.23025850929940456, "filtered_score": 0.23025850929940456, "filter_reason": null, "outreach_score": 0.23025850929940456, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "gjd", "mediator_canonical": "BDNF", "outcome_canonical": "epilepsy", "ab_count": 1, "bc_count": 4, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41260522", "title": "Traditional herbal medicine Ga-Mi Gongjindan improves muscarinic cholinergic dysfunction through regulation of BDNF/CREB signaling pathway using a scopolamine-induced cognitive impairment of mouse model", "doi": "10.1016/j.brainresbull.2025.111644", "year": 2025 } ], "bc": [ { "pmid": "39474368", "title": "Reduced serum neurotrophic factors and monoamine neurotransmitters in epilepsy patients with comorbid depression", "doi": "10.3389/fneur.2024.1480854", "year": 2024 }, { "pmid": "35557046", "title": "Overexpression of BDNF in the ventrolateral periaqueductal gray regulates the behavior of epilepsy–migraine comorbid rats", "doi": "10.1002/brb3.2594", "year": 2022 }, { "pmid": "34331458", "title": "Inflammatory and neurotrophic factor plasma levels are related to epilepsy independently of etiology", "doi": "10.1111/epi.17023", "year": 2021 } ] } }, { "id": 32331, "drug": "LWE", "drug_type": "drug", "drug_domain": "inflammatory_bowel_disease", "predicate_ab": "upregulates", "mediator": "SOD1", "mediator_type": "gene", "predicate_bc": "associated_with", "outcome": "familial ALS", "outcome_type": "disease", "outcome_domain": "als", "score": 0.23025850929940456, "filtered_score": 0.23025850929940456, "filter_reason": null, "outreach_score": 0.23025850929940456, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "lwe", "mediator_canonical": "SOD1", "outcome_canonical": "familial als", "ab_count": 1, "bc_count": 4, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "39061864", "title": "Hydroethanolic Extract of Lepidium apetalum Willdenow Alleviates Dextran Sulfate Sodium-Induced Colitis by Enhancing Intestinal Barrier Integrity and Inhibiting Oxidative Stress and Inflammasome Activation", "doi": "10.3390/antiox13070795", "year": 2024 } ], "bc": [ { "pmid": "41673790", "title": "Comprehensive clinical and genetic architecture of familial amyotrophic lateral sclerosis in China: A 15-year cohort study with 302 families", "doi": "10.4103/nrr.nrr-d-24-00701", "year": 2025 }, { "pmid": "32166880", "title": "Clinical and genetic features of patients with amyotrophic lateral sclerosis in southern China", "doi": "10.1111/ene.14213", "year": 2020 }, { "pmid": "29504729", "title": "Possible etiology and treatment of amyotrophic lateral sclerosis.", "doi": null, "year": 2018 } ] } }, { "id": 35485, "drug": "DMF", "drug_type": "drug", "drug_domain": "multiple_sclerosis", "predicate_ab": "activates", "mediator": "Nrf2", "mediator_type": "protein", "predicate_bc": "decreases", "outcome": "efficacy of synthetic anti-rheumatic drugs", "outcome_type": "phenotype", "outcome_domain": "rheumatoid_arthritis", "score": 0.23025850929940456, "filtered_score": 0.23025850929940456, "filter_reason": null, "outreach_score": 0.23025850929940456, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "dmf", "mediator_canonical": "NRF2", "outcome_canonical": "efficacy of synthetic anti-rheumatic drugs", "ab_count": 4, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "35743211", "title": "Mechanisms of Sensitivity and Resistance of Primary Effusion Lymphoma to Dimethyl Fumarate (DMF)", "doi": "10.3390/ijms23126773", "year": 2022 }, { "pmid": "32672401", "title": "Structural insights into the multiple binding modes of Dimethyl Fumarate (DMF) and its analogs to the Kelch domain of Keap1", "doi": "10.1111/febs.15485", "year": 2020 }, { "pmid": "32394330", "title": "Characterization of More Selective Central Nervous System Nrf2-Activating Novel Vinyl Sulfoximine Compounds Compared to Dimethyl Fumarate", "doi": "10.1007/s13311-020-00855-0", "year": 2020 } ], "bc": [ { "pmid": "35964840", "title": "Pros and cons of NRF2 activation as adjunctive therapy in rheumatoid arthritis", "doi": "10.1016/j.freeradbiomed.2022.08.012", "year": 2022 } ] } }, { "id": 38263, "drug": "secukinumab", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "inhibits", "mediator": "IL-17A", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "neural progenitor proliferation", "outcome_type": "phenotype", "outcome_domain": "epilepsy", "score": 0.23025850929940456, "filtered_score": 0.23025850929940456, "filter_reason": null, "outreach_score": 0.23025850929940456, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "secukinumab", "mediator_canonical": "il-17a", "outcome_canonical": "neural progenitor proliferation", "ab_count": 4, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "33913511", "title": "Efficacy of secukinumab and adalimumab in patients with psoriatic arthritis and concomitant moderate‐to‐severe plaque psoriasis: results from EXCEED, a randomized, double‐blind head‐to‐head monotherapy study", "doi": "10.1111/bjd.20413", "year": 2021 }, { "pmid": "34919658", "title": "Secukinumab-induced systemic lupus erythematosus occurring in a patient with ankylosing spondylitis", "doi": "10.1093/rheumatology/keab918", "year": 2021 }, { "pmid": "33120695", "title": "Role of secukinumab in ankylosing spondylitis with tubercular uveitis", "doi": "10.4103/ijo.ijo_1081_20", "year": 2020 } ], "bc": [ { "pmid": "35875667", "title": "Interleukin-17A Mediates Hippocampal Damage and Aberrant Neurogenesis Contributing to Epilepsy-Associated Anxiety", "doi": "10.3389/fnmol.2022.917598", "year": 2022 } ] } }, { "id": 37866, "drug": "NBTL", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "suppresses", "mediator": "MAPT", "mediator_type": "gene", "predicate_bc": "associated_with", "outcome": "Alzheimer's disease", "outcome_type": "disease", "outcome_domain": "alzheimer", "score": 0.23025850929940456, "filtered_score": 0.23025850929940456, "filter_reason": null, "outreach_score": 0.23025850929940456, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "nbtl", "mediator_canonical": "MAPT", "outcome_canonical": "Alzheimer disease", "ab_count": 1, "bc_count": 4, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41234504", "title": "New Bitongling Ameliorates Joint Tissue Damage in Collagen-Induced Arthritis Mice by Suppressing Mapt Expression: A Genome-Wide Sequencing Study", "doi": "10.2147/jir.s557354", "year": 2025 } ], "bc": [ { "pmid": "41634510", "title": "The 3xTg-AD Mouse Model: A Comprehensive Tool for Understanding Alzheimer’s Disease", "doi": "10.1007/s10571-025-01655-w", "year": 2026 }, { "pmid": "33415685", "title": "Directly Reprogrammed Neurons Express MAPT and APP Splice Variants Pertinent to Ageing and Neurodegeneration", "doi": "10.1007/s12035-020-02258-w", "year": 2021 }, { "pmid": "31182772", "title": "Genetic analyses of early-onset Alzheimer’s disease using next generation sequencing", "doi": "10.1038/s41598-019-44848-2", "year": 2019 } ] } }, { "id": 35486, "drug": "DMF", "drug_type": "drug", "drug_domain": "multiple_sclerosis", "predicate_ab": "activates", "mediator": "Nrf2", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "interstitial lung disease", "outcome_type": "disease", "outcome_domain": "rheumatoid_arthritis", "score": 0.23025850929940456, "filtered_score": 0.23025850929940456, "filter_reason": null, "outreach_score": 0.23025850929940456, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "dmf", "mediator_canonical": "NRF2", "outcome_canonical": "interstitial lung disease", "ab_count": 4, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "35743211", "title": "Mechanisms of Sensitivity and Resistance of Primary Effusion Lymphoma to Dimethyl Fumarate (DMF)", "doi": "10.3390/ijms23126773", "year": 2022 }, { "pmid": "32672401", "title": "Structural insights into the multiple binding modes of Dimethyl Fumarate (DMF) and its analogs to the Kelch domain of Keap1", "doi": "10.1111/febs.15485", "year": 2020 }, { "pmid": "32394330", "title": "Characterization of More Selective Central Nervous System Nrf2-Activating Novel Vinyl Sulfoximine Compounds Compared to Dimethyl Fumarate", "doi": "10.1007/s13311-020-00855-0", "year": 2020 } ], "bc": [ { "pmid": "36574898", "title": "Expression of Nrf2 protein in serum of patients with rheumatoid arthritis: A novel indicator for disease activity and disease prognosis", "doi": "10.1016/j.clinbiochem.2022.12.011", "year": 2022 } ] } }, { "id": 38686, "drug": "secukinumab", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "inhibits", "mediator": "IL-17A", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "fibrosis", "outcome_type": "disease", "outcome_domain": "inflammatory_bowel_disease", "score": 0.23025850929940456, "filtered_score": 0.23025850929940456, "filter_reason": null, "outreach_score": 0.23025850929940456, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "secukinumab", "mediator_canonical": "il-17a", "outcome_canonical": "fibrosis", "ab_count": 4, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "33913511", "title": "Efficacy of secukinumab and adalimumab in patients with psoriatic arthritis and concomitant moderate‐to‐severe plaque psoriasis: results from EXCEED, a randomized, double‐blind head‐to‐head monotherapy study", "doi": "10.1111/bjd.20413", "year": 2021 }, { "pmid": "34919658", "title": "Secukinumab-induced systemic lupus erythematosus occurring in a patient with ankylosing spondylitis", "doi": "10.1093/rheumatology/keab918", "year": 2021 }, { "pmid": "33120695", "title": "Role of secukinumab in ankylosing spondylitis with tubercular uveitis", "doi": "10.4103/ijo.ijo_1081_20", "year": 2020 } ], "bc": [ { "pmid": "31296924", "title": "Fibrogenesis in Chronic DSS Colitis is Not Influenced by Neutralisation of Regulatory T Cells, of Major T Helper Cytokines or Absence of IL-13", "doi": "10.1038/s41598-019-46472-6", "year": 2019 } ] } }, { "id": 3592, "drug": "TFSeB", "drug_type": "drug", "drug_domain": "alzheimer", "predicate_ab": "upregulates", "mediator": "BDNF", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "epilepsy", "outcome_type": "disease", "outcome_domain": "epilepsy", "score": 0.23025850929940456, "filtered_score": 0.23025850929940456, "filter_reason": null, "outreach_score": 0.23025850929940456, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "tfseb", "mediator_canonical": "BDNF", "outcome_canonical": "epilepsy", "ab_count": 1, "bc_count": 4, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40523837", "title": "Neuroprotective Effects of a Benzofuran-Containing Selenium in a Mouse Alzheimer’s Disease Model: Molecular, Biochemical, and Behavioral Analyses", "doi": "10.1021/acschemneuro.5c00139", "year": 2025 } ], "bc": [ { "pmid": "39474368", "title": "Reduced serum neurotrophic factors and monoamine neurotransmitters in epilepsy patients with comorbid depression", "doi": "10.3389/fneur.2024.1480854", "year": 2024 }, { "pmid": "35557046", "title": "Overexpression of BDNF in the ventrolateral periaqueductal gray regulates the behavior of epilepsy–migraine comorbid rats", "doi": "10.1002/brb3.2594", "year": 2022 }, { "pmid": "34331458", "title": "Inflammatory and neurotrophic factor plasma levels are related to epilepsy independently of etiology", "doi": "10.1111/epi.17023", "year": 2021 } ] } }, { "id": 39795, "drug": "apabetalone", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "suppresses", "mediator": "IL-8", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "major depressive disorder", "outcome_type": "disease", "outcome_domain": "depression", "score": 0.23025850929940456, "filtered_score": 0.23025850929940456, "filter_reason": null, "outreach_score": 0.23025850929940456, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "apabetalone", "mediator_canonical": "IL8", "outcome_canonical": "major depressive disorder", "ab_count": 1, "bc_count": 4, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "33172487", "title": "BET protein inhibitor apabetalone (RVX-208) suppresses pro-inflammatory hyper-activation of monocytes from patients with cardiovascular disease and type 2 diabetes", "doi": "10.1186/s13148-020-00943-0", "year": 2020 } ], "bc": [ { "pmid": "41876463", "title": "Prediction of depressive episodes based on clinical features, cognitive characteristics, inflammation-related proteins, and EEG data", "doi": "10.1038/s41398-026-03960-4", "year": 2026 }, { "pmid": "34294614", "title": "White Matter Alterations Associated with Pro-inflammatory Cytokines in Patients with Major Depressive Disorder", "doi": "10.9758/cpn.2021.19.3.449", "year": 2021 }, { "pmid": "32874955", "title": "Serum levels of chemokines in adolescents with major depression treated with fluoxetine", "doi": "10.5498/wjp.v10.i8.175", "year": 2020 } ] } }, { "id": 35481, "drug": "M2000", "drug_type": "drug", "drug_domain": "multiple_sclerosis", "predicate_ab": "downregulates", "mediator": "STAT1", "mediator_type": "gene", "predicate_bc": "associated_with", "outcome": "rheumatoid arthritis", "outcome_type": "disease", "outcome_domain": "rheumatoid_arthritis", "score": 0.23025850929940456, "filtered_score": 0.23025850929940456, "filter_reason": null, "outreach_score": 0.23025850929940456, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "m2000", "mediator_canonical": "stat1", "outcome_canonical": "rheumatoid arthritis", "ab_count": 1, "bc_count": 4, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "34825387", "title": "The Effects of Mannuronic Acid on IL‐1β, IL‐17A, STAT1, and STAT3 Gene Expressions and TLR2 and TLR4 Molecules in Multiple Sclerosis", "doi": "10.1002/jcph.2008", "year": 2021 } ], "bc": [ { "pmid": "41131607", "title": "Integrated analysis of single-cell RNA-seq and bulk RNA-seq reveal macrophage subpopulation characteristics and the role of STAT1 in rheumatoid arthritis", "doi": "10.1186/s12967-025-07015-y", "year": 2025 }, { "pmid": "40849565", "title": "Aging associated immunosenescence in rheumatoid arthritis identified by machine learning and single cell profiling", "doi": "10.1038/s41598-025-15370-5", "year": 2025 }, { "pmid": "36247278", "title": "Identification and validation of potential hub genes in rheumatoid arthritis by bioinformatics analysis.", "doi": null, "year": 2022 } ] } }, { "id": 7648, "drug": "Palmitoylethanolamide", "drug_type": "drug", "drug_domain": "als", "predicate_ab": "upregulates", "mediator": "BDNF", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "epilepsy", "outcome_type": "disease", "outcome_domain": "epilepsy", "score": 0.23025850929940456, "filtered_score": 0.23025850929940456, "filter_reason": null, "outreach_score": 0.23025850929940456, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "palmitoylethanolamide", "mediator_canonical": "BDNF", "outcome_canonical": "epilepsy", "ab_count": 1, "bc_count": 4, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "42041537", "title": "Sustained Palmitoylethanolamide Infusion Restores Incentive Motivation and Synaptic Plasticity in the Tg2576 Mouse Model of Alzheimer’s Disease", "doi": "10.3390/cells15080669", "year": 2026 } ], "bc": [ { "pmid": "39474368", "title": "Reduced serum neurotrophic factors and monoamine neurotransmitters in epilepsy patients with comorbid depression", "doi": "10.3389/fneur.2024.1480854", "year": 2024 }, { "pmid": "35557046", "title": "Overexpression of BDNF in the ventrolateral periaqueductal gray regulates the behavior of epilepsy–migraine comorbid rats", "doi": "10.1002/brb3.2594", "year": 2022 }, { "pmid": "34331458", "title": "Inflammatory and neurotrophic factor plasma levels are related to epilepsy independently of etiology", "doi": "10.1111/epi.17023", "year": 2021 } ] } }, { "id": 38836, "drug": "secukinumab", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "inhibits", "mediator": "IL-17A", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "BBB dysfunction", "outcome_type": "phenotype", "outcome_domain": "multiple_sclerosis", "score": 0.23025850929940456, "filtered_score": 0.23025850929940456, "filter_reason": null, "outreach_score": 0.23025850929940456, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "secukinumab", "mediator_canonical": "il-17a", "outcome_canonical": "bbb dysfunction", "ab_count": 4, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "33913511", "title": "Efficacy of secukinumab and adalimumab in patients with psoriatic arthritis and concomitant moderate‐to‐severe plaque psoriasis: results from EXCEED, a randomized, double‐blind head‐to‐head monotherapy study", "doi": "10.1111/bjd.20413", "year": 2021 }, { "pmid": "34919658", "title": "Secukinumab-induced systemic lupus erythematosus occurring in a patient with ankylosing spondylitis", "doi": "10.1093/rheumatology/keab918", "year": 2021 }, { "pmid": "33120695", "title": "Role of secukinumab in ankylosing spondylitis with tubercular uveitis", "doi": "10.4103/ijo.ijo_1081_20", "year": 2020 } ], "bc": [ { "pmid": "31034962", "title": "IL-17A is associated with the breakdown of the blood-brain barrier in relapsing-remitting multiple sclerosis", "doi": "10.1016/j.jneuroim.2019.04.011", "year": 2019 } ] } }, { "id": 8793, "drug": "sodium butyrate", "drug_type": "drug", "drug_domain": "alzheimer", "predicate_ab": "upregulates", "mediator": "Sod1", "mediator_type": "gene", "predicate_bc": "associated_with", "outcome": "familial ALS", "outcome_type": "disease", "outcome_domain": "als", "score": 0.23025850929940456, "filtered_score": 0.23025850929940456, "filter_reason": null, "outreach_score": 0.23025850929940456, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "sodium butyrate", "mediator_canonical": "SOD1", "outcome_canonical": "familial als", "ab_count": 1, "bc_count": 4, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "32555166", "title": "Sodium butyrate inhibits high cholesterol-induced neuronal amyloidogenesis by modulating NRF2 stabilization-mediated ROS levels: involvement of NOX2 and SOD1", "doi": "10.1038/s41419-020-2663-1", "year": 2020 } ], "bc": [ { "pmid": "41673790", "title": "Comprehensive clinical and genetic architecture of familial amyotrophic lateral sclerosis in China: A 15-year cohort study with 302 families", "doi": "10.4103/nrr.nrr-d-24-00701", "year": 2025 }, { "pmid": "32166880", "title": "Clinical and genetic features of patients with amyotrophic lateral sclerosis in southern China", "doi": "10.1111/ene.14213", "year": 2020 }, { "pmid": "29504729", "title": "Possible etiology and treatment of amyotrophic lateral sclerosis.", "doi": null, "year": 2018 } ] } }, { "id": 35271, "drug": "DMF", "drug_type": "drug", "drug_domain": "multiple_sclerosis", "predicate_ab": "activates", "mediator": "Nrf2", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "poor prognosis", "outcome_type": "phenotype", "outcome_domain": "pancreatic_cancer", "score": 0.23025850929940456, "filtered_score": 0.23025850929940456, "filter_reason": null, "outreach_score": 0.23025850929940456, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "dmf", "mediator_canonical": "NRF2", "outcome_canonical": null, "ab_count": 4, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "35743211", "title": "Mechanisms of Sensitivity and Resistance of Primary Effusion Lymphoma to Dimethyl Fumarate (DMF)", "doi": "10.3390/ijms23126773", "year": 2022 }, { "pmid": "32672401", "title": "Structural insights into the multiple binding modes of Dimethyl Fumarate (DMF) and its analogs to the Kelch domain of Keap1", "doi": "10.1111/febs.15485", "year": 2020 }, { "pmid": "32394330", "title": "Characterization of More Selective Central Nervous System Nrf2-Activating Novel Vinyl Sulfoximine Compounds Compared to Dimethyl Fumarate", "doi": "10.1007/s13311-020-00855-0", "year": 2020 } ], "bc": [ { "pmid": "31911550", "title": "Undermining Glutaminolysis Bolsters Chemotherapy While NRF2 Promotes Chemoresistance in KRAS-Driven Pancreatic Cancers", "doi": "10.1158/0008-5472.can-19-1363", "year": 2020 } ] } }, { "id": 39030, "drug": "chondroitin sulfate", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "binds_to", "mediator": "CD44", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "poor prognosis", "outcome_type": "phenotype", "outcome_domain": "pancreatic_cancer", "score": 0.23025850929940456, "filtered_score": 0.23025850929940456, "filter_reason": null, "outreach_score": 0.23025850929940456, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "chondroitin sulfate", "mediator_canonical": "cd44", "outcome_canonical": null, "ab_count": 1, "bc_count": 4, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "38169139", "title": "pH and ROS Dual‐Sensitive Nanocarriers for the Targeted Co‐Delivery and On‐Demand Sequential Release of Tofacitinib and Glucosamine for Synergistic Rheumatoid Arthritis Treatment", "doi": "10.1002/smll.202308520", "year": 2024 } ], "bc": [ { "pmid": "35931675", "title": "Gemcitabine resistance of pancreatic cancer cells is mediated by IGF1R dependent upregulation of CD44 expression and isoform switching", "doi": "10.1038/s41419-022-05103-1", "year": 2022 }, { "pmid": "28659655", "title": "Expression and Clinical Significance of Cancer Stem Cell Markers CD24, CD44, and CD133 in Pancreatic Ductal Adenocarcinoma and Chronic Pancreatitis", "doi": "10.1155/2017/3276806", "year": 2017 }, { "pmid": "26261555", "title": "Expression of CD44 in pancreatic cancer and its significance.", "doi": null, "year": 2015 } ] } }, { "id": 38828, "drug": "secukinumab", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "inhibits", "mediator": "IL-17A", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "intestinal homeostasis", "outcome_type": "phenotype", "outcome_domain": "multiple_sclerosis", "score": 0.23025850929940456, "filtered_score": 0.23025850929940456, "filter_reason": null, "outreach_score": 0.23025850929940456, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "secukinumab", "mediator_canonical": "il-17a", "outcome_canonical": "intestinal homeostasis", "ab_count": 4, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "33913511", "title": "Efficacy of secukinumab and adalimumab in patients with psoriatic arthritis and concomitant moderate‐to‐severe plaque psoriasis: results from EXCEED, a randomized, double‐blind head‐to‐head monotherapy study", "doi": "10.1111/bjd.20413", "year": 2021 }, { "pmid": "34919658", "title": "Secukinumab-induced systemic lupus erythematosus occurring in a patient with ankylosing spondylitis", "doi": "10.1093/rheumatology/keab918", "year": 2021 }, { "pmid": "33120695", "title": "Role of secukinumab in ankylosing spondylitis with tubercular uveitis", "doi": "10.4103/ijo.ijo_1081_20", "year": 2020 } ], "bc": [ { "pmid": "33547052", "title": "IL-17 controls central nervous system autoimmunity through the intestinal microbiome", "doi": "10.1126/sciimmunol.aaz6563", "year": 2021 } ] } }, { "id": 39034, "drug": "Ruxolitinib", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "binds_to", "mediator": "JAK2", "mediator_type": "protein", "predicate_bc": "predicts", "outcome": "poor prognosis", "outcome_type": "phenotype", "outcome_domain": "pancreatic_cancer", "score": 0.23025850929940456, "filtered_score": 0.23025850929940456, "filter_reason": null, "outreach_score": 0.23025850929940456, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "ruxolitinib", "mediator_canonical": "jak2", "outcome_canonical": null, "ab_count": 4, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37521191", "title": "Ruxolitinib cream for the treatment of cutaneous sarcoidosis", "doi": "10.1016/j.jdcr.2023.05.032", "year": 2023 }, { "pmid": "36142375", "title": "Atomic Simulation of the Binding of JAK1 and JAK2 with the Selective Inhibitor Ruxolitinib", "doi": "10.3390/ijms231810466", "year": 2022 }, { "pmid": "33570945", "title": "Structural Insights into JAK2 Inhibition by Ruxolitinib, Fedratinib, and Derivatives Thereof", "doi": "10.1021/acs.jmedchem.0c01952", "year": 2021 } ], "bc": [ { "pmid": "33029256", "title": "High JAK2 Protein Expression Predicts a Poor Prognosis in Patients with Resectable Pancreatic Ductal Adenocarcinoma", "doi": "10.1155/2020/7656031", "year": 2020 } ] } }, { "id": 51947, "drug": "tafamidis", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "binds_to", "mediator": "TTR", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "hypertriglyceridemia", "outcome_type": "disease", "outcome_domain": "type_2_diabetes", "score": 0.23025850929940456, "filtered_score": 0.23025850929940456, "filter_reason": null, "outreach_score": 0.23025850929940456, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 4, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "28951660", "title": "Treatment With Tafamidis Slows Disease Progression in Early-Stage Transthyretin Cardiomyopathy", "doi": "10.1177/1179546817730322", "year": 2017 }, { "pmid": "25872787", "title": "Tafamidis in Transthyretin Amyloid Cardiomyopathy", "doi": "10.1161/circheartfailure.113.000890", "year": 2015 }, { "pmid": "26193961", "title": "Personalized medicine approach for optimizing the dose of tafamidis to potentially ameliorate wild-type transthyretin amyloidosis (cardiomyopathy)", "doi": "10.3109/13506129.2015.1063485", "year": 2015 } ], "bc": [ { "pmid": "29747616", "title": "Association of retinol binding protein 4 and transthyretin with triglyceride levels and insulin resistance in rural thais with high type 2 diabetes risk", "doi": "10.1186/s12902-018-0254-2", "year": 2018 } ] } }, { "id": 59087, "drug": "E6011", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "inhibits", "mediator": "fractalkine", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "left ventricular hypertrophy", "outcome_type": "phenotype", "outcome_domain": "heart_failure", "score": 0.23025850929940456, "filtered_score": 0.23025850929940456, "filter_reason": null, "outreach_score": 0.23025850929940456, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 4, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "36680426", "title": "Long-term safety and efficacy of E6011, an anti-fractalkine monoclonal antibody, in patients with rheumatoid arthritis inadequately responding to methotrexate", "doi": "10.1093/mr/road004", "year": 2023 }, { "pmid": "33038062", "title": "Efficacy and Safety of E6011, an Anti‐Fractalkine Monoclonal Antibody, in Patients With Active Rheumatoid Arthritis With Inadequate Response to Methotrexate: Results of a Randomized, Double‐Blind, Placebo‐Controlled Phase II Study", "doi": "10.1002/art.41555", "year": 2020 }, { "pmid": "30575978", "title": "Pharmacokinetics, Pharmacodynamics, and Safety of E6011, a Novel Humanized Antifractalkine (CX3CL1) Monoclonal Antibody: A Randomized, Double‐Blind, Placebo‐Controlled Single‐Ascending‐Dose Study", "doi": "10.1002/jcph.1361", "year": 2018 } ], "bc": [ { "pmid": "34019435", "title": "Multiomic Profiling in Black and White Populations Reveals Novel Candidate Pathways in Left Ventricular Hypertrophy and Incident Heart Failure Specific to Black Adults", "doi": "10.1161/circgen.120.003191", "year": 2021 } ] } }, { "id": 38826, "drug": "secukinumab", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "inhibits", "mediator": "IL-17A", "mediator_type": "protein", "predicate_bc": "increases", "outcome": "EAE", "outcome_type": "disease", "outcome_domain": "multiple_sclerosis", "score": 0.23025850929940456, "filtered_score": 0.23025850929940456, "filter_reason": null, "outreach_score": 0.23025850929940456, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "secukinumab", "mediator_canonical": "il-17a", "outcome_canonical": "eae", "ab_count": 4, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "33913511", "title": "Efficacy of secukinumab and adalimumab in patients with psoriatic arthritis and concomitant moderate‐to‐severe plaque psoriasis: results from EXCEED, a randomized, double‐blind head‐to‐head monotherapy study", "doi": "10.1111/bjd.20413", "year": 2021 }, { "pmid": "34919658", "title": "Secukinumab-induced systemic lupus erythematosus occurring in a patient with ankylosing spondylitis", "doi": "10.1093/rheumatology/keab918", "year": 2021 }, { "pmid": "33120695", "title": "Role of secukinumab in ankylosing spondylitis with tubercular uveitis", "doi": "10.4103/ijo.ijo_1081_20", "year": 2020 } ], "bc": [ { "pmid": "31034962", "title": "IL-17A is associated with the breakdown of the blood-brain barrier in relapsing-remitting multiple sclerosis", "doi": "10.1016/j.jneuroim.2019.04.011", "year": 2019 } ] } }, { "id": 39028, "drug": "E6011", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "inhibits", "mediator": "fractalkine", "mediator_type": "protein", "predicate_bc": "confers_resistance_to", "outcome": "apoptosis", "outcome_type": "phenotype", "outcome_domain": "pancreatic_cancer", "score": 0.23025850929940456, "filtered_score": 0.23025850929940456, "filter_reason": null, "outreach_score": 0.23025850929940456, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "e6011", "mediator_canonical": "fractalkine", "outcome_canonical": "apoptosis", "ab_count": 4, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "36680426", "title": "Long-term safety and efficacy of E6011, an anti-fractalkine monoclonal antibody, in patients with rheumatoid arthritis inadequately responding to methotrexate", "doi": "10.1093/mr/road004", "year": 2023 }, { "pmid": "33038062", "title": "Efficacy and Safety of E6011, an Anti‐Fractalkine Monoclonal Antibody, in Patients With Active Rheumatoid Arthritis With Inadequate Response to Methotrexate: Results of a Randomized, Double‐Blind, Placebo‐Controlled Phase II Study", "doi": "10.1002/art.41555", "year": 2020 }, { "pmid": "30575978", "title": "Pharmacokinetics, Pharmacodynamics, and Safety of E6011, a Novel Humanized Antifractalkine (CX3CL1) Monoclonal Antibody: A Randomized, Double‐Blind, Placebo‐Controlled Single‐Ascending‐Dose Study", "doi": "10.1002/jcph.1361", "year": 2018 } ], "bc": [ { "pmid": "28845524", "title": "Fractalkine/CX3CR1 induces apoptosis resistance and proliferation through the activation of the AKT/NF‐κB cascade in pancreatic cancer cells", "doi": "10.1002/cbf.3278", "year": 2017 } ] } }, { "id": 39230, "drug": "tofacitinib", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "downregulates", "mediator": "C-reactive protein", "mediator_type": "biomarker", "predicate_bc": "correlates_with", "outcome": "type 2 diabetes", "outcome_type": "disease", "outcome_domain": "type_2_diabetes", "score": 0.23025850929940456, "filtered_score": 0.23025850929940456, "filter_reason": null, "outreach_score": 0.23025850929940456, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "tofacitinib", "mediator_canonical": "c-reactive protein", "outcome_canonical": "type 2 diabetes", "ab_count": 1, "bc_count": 4, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40692219", "title": "Short‐Term Effectiveness of Sulfasalazine and Tofacitinib in NSAID ‐Refractory Reactive Arthritis: An Observational Study", "doi": "10.1111/1756-185x.70370", "year": 2025 } ], "bc": [ { "pmid": "30872696", "title": "Association of C-Reactive Protein with Risk of Developing Type 2 Diabetes Mellitus, and Role of Obesity and Hypertension: A Large Population-Based Korean Cohort Study", "doi": "10.1038/s41598-019-40987-8", "year": 2019 }, { "pmid": "27013319", "title": "Oxidative stress, inflammation, endothelial dysfunction and incidence of type 2 diabetes", "doi": "10.1186/s12933-016-0369-6", "year": 2016 } ] } }, { "id": 23812, "drug": "pembrolizumab", "drug_type": "drug", "drug_domain": "multiple_sclerosis", "predicate_ab": "inhibits", "mediator": "PD-1", "mediator_type": "protein", "predicate_bc": "increases", "outcome": "pancreatic cancer", "outcome_type": "disease", "outcome_domain": "pancreatic_cancer", "score": 0.23025850929940456, "filtered_score": 0.23025850929940456, "filter_reason": null, "outreach_score": 0.23025850929940456, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "active", "clinical_trial_nct_ids": [ "NCT01174121", "NCT05208762", "NCT07223047" ], "literature_status": "reproduces_known", "drug_canonical": "pembrolizumab", "mediator_canonical": "pd-1", "outcome_canonical": "pancreatic cancer", "ab_count": 4, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41232216", "title": "Iatrogenic NORSE: Immune checkpoint inhibitor-related anti-GFAP autoimmune astrocytopathy", "doi": "10.1016/j.jneuroim.2025.578805", "year": 2025 }, { "pmid": "35637642", "title": "Pembrolizumab for the treatment of Progressive Multifocal Leukoencephalopathy (PML) in a patient with AIDS: A case report and literature review", "doi": "10.1016/j.idcr.2022.e01514", "year": 2022 }, { "pmid": "33995251", "title": "Case Report: Longitudinal Extensive Transverse Myelitis With Novel Autoantibodies Following Two Rounds of Pembrolizumab", "doi": "10.3389/fneur.2021.655283", "year": 2021 } ], "bc": [ { "pmid": "30377341", "title": "Direct therapeutic targeting of immune checkpoint PD-1 in pancreatic cancer", "doi": "10.1038/s41416-018-0298-0", "year": 2018 } ] } }, { "id": 40392, "drug": "Sitagliptin", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "inhibits", "mediator": "DPP-4", "mediator_type": "protein", "predicate_bc": "predicts", "outcome": "treatment escalation", "outcome_type": "phenotype", "outcome_domain": "inflammatory_bowel_disease", "score": 0.23025850929940456, "filtered_score": 0.23025850929940456, "filter_reason": null, "outreach_score": 0.23025850929940456, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "completed", "clinical_trial_nct_ids": [ "NCT03813316" ], "literature_status": "partial_evidence", "drug_canonical": "sitagliptin", "mediator_canonical": "dpp-4", "outcome_canonical": "treatment escalation", "ab_count": 4, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "38556837", "title": "Selective targeting of dipeptidyl‐peptidase 4 (DPP‐4) positive senescent chondrocyte ameliorates osteoarthritis progression", "doi": "10.1111/acel.14161", "year": 2024 }, { "pmid": "33406328", "title": "Dipeptidyl Peptidase 4 Inhibition for Prophylaxis of Acute Graft-versus-Host Disease", "doi": "10.1056/nejmoa2027372", "year": 2021 }, { "pmid": "34779087", "title": "A randomized clinical trial of the efficacy and safety of sitagliptin as initial oral therapy in youth with type 2 diabetes", "doi": "10.1111/pedi.13279", "year": 2021 } ], "bc": [ { "pmid": "31912883", "title": "Serum Dipeptidyl Peptidase 4: A Predictor of Disease Activity and Prognosis in Inflammatory Bowel Disease", "doi": "10.1093/ibd/izz319", "year": 2020 } ] } }, { "id": 55092, "drug": "DMF", "drug_type": "drug", "drug_domain": "multiple_sclerosis", "predicate_ab": "activates", "mediator": "Nrf2", "mediator_type": "protein", "predicate_bc": "increases", "outcome": "antioxidant status", "outcome_type": "phenotype", "outcome_domain": "heart_failure", "score": 0.23025850929940456, "filtered_score": 0.23025850929940456, "filter_reason": null, "outreach_score": 0.23025850929940456, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 4, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "35743211", "title": "Mechanisms of Sensitivity and Resistance of Primary Effusion Lymphoma to Dimethyl Fumarate (DMF)", "doi": "10.3390/ijms23126773", "year": 2022 }, { "pmid": "32672401", "title": "Structural insights into the multiple binding modes of Dimethyl Fumarate (DMF) and its analogs to the Kelch domain of Keap1", "doi": "10.1111/febs.15485", "year": 2020 }, { "pmid": "32394330", "title": "Characterization of More Selective Central Nervous System Nrf2-Activating Novel Vinyl Sulfoximine Compounds Compared to Dimethyl Fumarate", "doi": "10.1007/s13311-020-00855-0", "year": 2020 } ], "bc": [ { "pmid": "31155513", "title": "Enhanced Keap1-Nrf2 signaling protects the myocardium from isoproterenol-induced pathological remodeling in mice", "doi": "10.1016/j.redox.2019.101212", "year": 2019 } ] } }, { "id": 7850, "drug": "thiophene derivatives", "drug_type": "drug", "drug_domain": "als", "predicate_ab": "inhibits", "mediator": "amyloid-β", "mediator_type": "protein", "predicate_bc": "causes", "outcome": "Alzheimer's disease", "outcome_type": "disease", "outcome_domain": "alzheimer", "score": 0.23025850929940456, "filtered_score": 0.23025850929940456, "filter_reason": null, "outreach_score": 0.23025850929940456, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "thiophene derivatives", "mediator_canonical": "amyloid-β", "outcome_canonical": "Alzheimer disease", "ab_count": 1, "bc_count": 4, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40916690", "title": "Exploring Thiophene-Based Pharmacophores as Emerging Therapeutics for Neurodegenerative Disorders", "doi": "10.1080/10408347.2025.2554239", "year": 2025 } ], "bc": [ { "pmid": "36606679", "title": "Functional Network Alterations Associated with Cognition in Pre-Clinical Alzheimer's Disease", "doi": "10.1089/brain.2022.0032", "year": 2023 }, { "pmid": "32403399", "title": "Predictive Potential of Circulating Ube2h mRNA as an E2 Ubiquitin-Conjugating Enzyme for Diagnosis or Treatment of Alzheimer’s Disease", "doi": "10.3390/ijms21093398", "year": 2020 }, { "pmid": "32244832", "title": "Combining Virtual Screening Protocol and In Vitro Evaluation towards the Discovery of BACE1 Inhibitors", "doi": "10.3390/biom10040535", "year": 2020 } ] } }, { "id": 40385, "drug": "Sitagliptin", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "inhibits", "mediator": "DPP-4", "mediator_type": "protein", "predicate_bc": "predicts", "outcome": "biological treatment response", "outcome_type": "phenotype", "outcome_domain": "inflammatory_bowel_disease", "score": 0.23025850929940456, "filtered_score": 0.23025850929940456, "filter_reason": null, "outreach_score": 0.23025850929940456, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "sitagliptin", "mediator_canonical": "dpp-4", "outcome_canonical": "biological treatment response", "ab_count": 4, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "38556837", "title": "Selective targeting of dipeptidyl‐peptidase 4 (DPP‐4) positive senescent chondrocyte ameliorates osteoarthritis progression", "doi": "10.1111/acel.14161", "year": 2024 }, { "pmid": "33406328", "title": "Dipeptidyl Peptidase 4 Inhibition for Prophylaxis of Acute Graft-versus-Host Disease", "doi": "10.1056/nejmoa2027372", "year": 2021 }, { "pmid": "34779087", "title": "A randomized clinical trial of the efficacy and safety of sitagliptin as initial oral therapy in youth with type 2 diabetes", "doi": "10.1111/pedi.13279", "year": 2021 } ], "bc": [ { "pmid": "31912883", "title": "Serum Dipeptidyl Peptidase 4: A Predictor of Disease Activity and Prognosis in Inflammatory Bowel Disease", "doi": "10.1093/ibd/izz319", "year": 2020 } ] } }, { "id": 59088, "drug": "secukinumab", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "inhibits", "mediator": "IL-17A", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "left atrial diameter", "outcome_type": "phenotype", "outcome_domain": "heart_failure", "score": 0.23025850929940456, "filtered_score": 0.23025850929940456, "filter_reason": null, "outreach_score": 0.23025850929940456, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 4, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "33913511", "title": "Efficacy of secukinumab and adalimumab in patients with psoriatic arthritis and concomitant moderate‐to‐severe plaque psoriasis: results from EXCEED, a randomized, double‐blind head‐to‐head monotherapy study", "doi": "10.1111/bjd.20413", "year": 2021 }, { "pmid": "34919658", "title": "Secukinumab-induced systemic lupus erythematosus occurring in a patient with ankylosing spondylitis", "doi": "10.1093/rheumatology/keab918", "year": 2021 }, { "pmid": "33120695", "title": "Role of secukinumab in ankylosing spondylitis with tubercular uveitis", "doi": "10.4103/ijo.ijo_1081_20", "year": 2020 } ], "bc": [ { "pmid": "27198976", "title": "Elevated plasma levels of Th17-related cytokines are associated with increased risk of atrial fibrillation", "doi": "10.1038/srep26543", "year": 2016 } ] } }, { "id": 37249, "drug": "polyinosine-polycytidylic acid", "drug_type": "drug", "drug_domain": "pancreatic_cancer", "predicate_ab": "activates", "mediator": "STAT1", "mediator_type": "gene", "predicate_bc": "associated_with", "outcome": "rheumatoid arthritis", "outcome_type": "disease", "outcome_domain": "rheumatoid_arthritis", "score": 0.23025850929940456, "filtered_score": 0.23025850929940456, "filter_reason": null, "outreach_score": 0.23025850929940456, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "polyinosine-polycytidylic acid", "mediator_canonical": "stat1", "outcome_canonical": "rheumatoid arthritis", "ab_count": 1, "bc_count": 4, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37935566", "title": "Cytoplasmic-delivery of polyinosine-polycytidylic acid inhibits pancreatic cancer progression increasing survival by activating Stat1-CCL2-mediated immunity", "doi": "10.1136/jitc-2023-007624", "year": 2023 } ], "bc": [ { "pmid": "41131607", "title": "Integrated analysis of single-cell RNA-seq and bulk RNA-seq reveal macrophage subpopulation characteristics and the role of STAT1 in rheumatoid arthritis", "doi": "10.1186/s12967-025-07015-y", "year": 2025 }, { "pmid": "40849565", "title": "Aging associated immunosenescence in rheumatoid arthritis identified by machine learning and single cell profiling", "doi": "10.1038/s41598-025-15370-5", "year": 2025 }, { "pmid": "36247278", "title": "Identification and validation of potential hub genes in rheumatoid arthritis by bioinformatics analysis.", "doi": null, "year": 2022 } ] } }, { "id": 53145, "drug": "2'-fucosyllactose", "drug_type": "drug", "drug_domain": "inflammatory_bowel_disease", "predicate_ab": "activates", "mediator": "ADAM17", "mediator_type": "protein", "predicate_bc": "predicts", "outcome": "post-MI heart failure", "outcome_type": "disease", "outcome_domain": "heart_failure", "score": 0.21972245773362195, "filtered_score": 0.21972245773362195, "filter_reason": null, "outreach_score": 0.21972245773362195, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 2, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41492469", "title": "2′-Fucosyllactose transactivates EGF receptor in intestinal epithelial cells for prevention of colitis in adulthood", "doi": "10.1016/j.isci.2025.114308", "year": 2025 } ], "bc": [ { "pmid": "37046278", "title": "P38 MAPK activated ADAM17 mediates ACE2 shedding and promotes cardiac remodeling and heart failure after myocardial infarction", "doi": "10.1186/s12964-023-01087-3", "year": 2023 } ] } }, { "id": 8802, "drug": "5-NBA", "drug_type": "drug", "drug_domain": "alzheimer", "predicate_ab": "inhibits", "mediator": "α-synuclein", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "multiple system atrophy", "outcome_type": "disease", "outcome_domain": "als", "score": 0.21972245773362195, "filtered_score": 0.21972245773362195, "filter_reason": null, "outreach_score": 0.21972245773362195, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "5-nba", "mediator_canonical": "SNCA", "outcome_canonical": "multiple system atrophy", "ab_count": 2, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37305264", "title": "5-Nitro-1,2-benzothiazol-3-amine and N-Ethyl-1-[(ethylcarbamoyl)(5-nitro-1,2-benzothiazol-3-yl)amino]formamide Modulate α-Synuclein and Tau Aggregation", "doi": "10.1021/acsomega.3c02668", "year": 2023 } ], "bc": [ { "pmid": "35746899", "title": "A pathologically confirmed case of combined amyotrophic lateral sclerosis with C9orf72 mutation and multiple system atrophy", "doi": "10.1111/neup.12808", "year": 2022 }, { "pmid": "26705184", "title": "[Histopathological and immunohistochemical study of spinal cord tissues in neurodegenerative diseases].", "doi": null, "year": 2015 } ] } }, { "id": 6107, "drug": "temozolomide", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "downregulates", "mediator": "PD-L1", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "type 2 autoimmune pancreatitis", "outcome_type": "disease", "outcome_domain": "pancreatic_cancer", "score": 0.21972245773362195, "filtered_score": 0.21972245773362195, "filter_reason": null, "outreach_score": 0.21972245773362195, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "temozolomide", "mediator_canonical": "PD-L1", "outcome_canonical": "type 2 autoimmune pancreatitis", "ab_count": 2, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "30709339", "title": "Crosslink between Temozolomide and PD-L1 immune-checkpoint inhibition in glioblastoma multiforme", "doi": "10.1186/s12885-019-5308-y", "year": 2019 } ], "bc": [ { "pmid": "31135488", "title": "Autoimmune Pancreatitis Type 2", "doi": "10.1097/pas.0000000000001282", "year": 2019 } ] } }, { "id": 1581, "drug": "temozolomide", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "downregulates", "mediator": "PD-L1", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "poor differentiation", "outcome_type": "phenotype", "outcome_domain": "pancreatic_cancer", "score": 0.21972245773362195, "filtered_score": 0.21972245773362195, "filter_reason": null, "outreach_score": 0.21972245773362195, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "temozolomide", "mediator_canonical": "PD-L1", "outcome_canonical": null, "ab_count": 2, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "30709339", "title": "Crosslink between Temozolomide and PD-L1 immune-checkpoint inhibition in glioblastoma multiforme", "doi": "10.1186/s12885-019-5308-y", "year": 2019 } ], "bc": [ { "pmid": "35624419", "title": "Clinical significance and correlation of PD-L1, B7-H3, B7-H4, and TILs in pancreatic cancer", "doi": "10.1186/s12885-022-09639-5", "year": 2022 }, { "pmid": "28030840", "title": "Prognostic value and clinicopathological features of PD-1/PD-L1 expression with mismatch repair status and desmoplastic stroma in Chinese patients with pancreatic cancer", "doi": "10.18632/oncotarget.14069", "year": 2016 } ] } }, { "id": 51170, "drug": "modified citrus pectin", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "inhibits", "mediator": "galectin-3", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "inflammatory bowel diseases", "outcome_type": "disease", "outcome_domain": "inflammatory_bowel_disease", "score": 0.21972245773362195, "filtered_score": 0.21972245773362195, "filter_reason": null, "outreach_score": 0.21972245773362195, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 2, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "33532663", "title": "Galectin-3 Inhibition With Modified Citrus Pectin in Hypertension", "doi": "10.1016/j.jacbts.2020.10.006", "year": 2021 }, { "pmid": "32172066", "title": "Modified citrus pectin ameliorates myocardial fibrosis and inflammation via suppressing galectin-3 and TLR4/MyD88/NF-κB signaling pathway", "doi": "10.1016/j.biopha.2020.110071", "year": 2020 } ], "bc": [ { "pmid": "31929564", "title": "Serum galectins as potential biomarkers of inflammatory bowel diseases", "doi": "10.1371/journal.pone.0227306", "year": 2020 } ] } }, { "id": 40804, "drug": "liraglutide", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "upregulates", "mediator": "SIRT1", "mediator_type": "gene", "predicate_bc": "increases", "outcome": "cell migration", "outcome_type": "phenotype", "outcome_domain": "pancreatic_cancer", "score": 0.21972245773362195, "filtered_score": 0.21972245773362195, "filter_reason": null, "outreach_score": 0.21972245773362195, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "liraglutide", "mediator_canonical": "SIRT1", "outcome_canonical": "cell migration", "ab_count": 2, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "30901315", "title": "Liraglutide exerts an anti-inflammatory action in obese patients with type 2 diabetes", "doi": "10.2478/rjim-2019-0003", "year": 2019 }, { "pmid": "26666995", "title": "Liraglutide ameliorates non‐alcoholic fatty liver disease by enhancing mitochondrial architecture and promoting autophagy through the SIRT1/SIRT3–FOXO3a pathway", "doi": "10.1111/hepr.12634", "year": 2015 } ], "bc": [ { "pmid": "27170223", "title": "SIRT 1 Overexpression is Associated with Metastasis of Pancreatic Ductal Adenocarcinoma (PDAC) and Promotes Migration and Growth of PDAC Cells", "doi": "10.12659/msm.896697", "year": 2016 } ] } }, { "id": 40805, "drug": "liraglutide", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "inhibits", "mediator": "SIRT1", "mediator_type": "protein", "predicate_bc": "increases", "outcome": "proliferation", "outcome_type": "phenotype", "outcome_domain": "pancreatic_cancer", "score": 0.21972245773362195, "filtered_score": 0.21972245773362195, "filter_reason": null, "outreach_score": 0.21972245773362195, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "liraglutide", "mediator_canonical": "SIRT1", "outcome_canonical": null, "ab_count": 2, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "29328405", "title": "Liraglutide repairs the infarcted heart: The role of the SIRT1/Parkin/mitophagy pathway", "doi": "10.3892/mmr.2018.8371", "year": 2018 }, { "pmid": "30575282", "title": "Effect of liraglutide on the Janus kinase/signal transducer and transcription activator (JAK/STAT) pathway in diabetic kidney disease in db/db mice and in cultured endothelial cells", "doi": "10.1111/1753-0407.12891", "year": 2018 } ], "bc": [ { "pmid": "34163012", "title": "SIRT1 coordinates with the CRL4B complex to regulate pancreatic cancer stem cells to promote tumorigenesis", "doi": "10.1038/s41418-021-00821-z", "year": 2021 }, { "pmid": "27494892", "title": "Sirtuin 1 stimulates the proliferation and the expression of glycolysis genes in pancreatic neoplastic lesions", "doi": "10.18632/oncotarget.11013", "year": 2016 } ] } }, { "id": 40801, "drug": "Canagliflozin", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "suppresses", "mediator": "PD-L1", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "poor differentiation", "outcome_type": "phenotype", "outcome_domain": "pancreatic_cancer", "score": 0.21972245773362195, "filtered_score": 0.21972245773362195, "filter_reason": null, "outreach_score": 0.21972245773362195, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "canagliflozin", "mediator_canonical": "PD-L1", "outcome_canonical": null, "ab_count": 2, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "38816549", "title": "SGLT2 inhibition eliminates senescent cells and alleviates pathological aging", "doi": "10.1038/s43587-024-00642-y", "year": 2024 }, { "pmid": "36594471", "title": "Canagliflozin primes antitumor immunity by triggering PD-L1 degradation in endocytic recycling", "doi": "10.1172/jci154754", "year": 2023 } ], "bc": [ { "pmid": "35624419", "title": "Clinical significance and correlation of PD-L1, B7-H3, B7-H4, and TILs in pancreatic cancer", "doi": "10.1186/s12885-022-09639-5", "year": 2022 }, { "pmid": "28030840", "title": "Prognostic value and clinicopathological features of PD-1/PD-L1 expression with mismatch repair status and desmoplastic stroma in Chinese patients with pancreatic cancer", "doi": "10.18632/oncotarget.14069", "year": 2016 } ] } }, { "id": 51949, "drug": "modified citrus pectin", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "inhibits", "mediator": "galectin-3", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "cardiovascular events", "outcome_type": "disease", "outcome_domain": "type_2_diabetes", "score": 0.21972245773362195, "filtered_score": 0.21972245773362195, "filter_reason": null, "outreach_score": 0.21972245773362195, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 2, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "33532663", "title": "Galectin-3 Inhibition With Modified Citrus Pectin in Hypertension", "doi": "10.1016/j.jacbts.2020.10.006", "year": 2021 }, { "pmid": "32172066", "title": "Modified citrus pectin ameliorates myocardial fibrosis and inflammation via suppressing galectin-3 and TLR4/MyD88/NF-κB signaling pathway", "doi": "10.1016/j.biopha.2020.110071", "year": 2020 } ], "bc": [ { "pmid": "30378236", "title": "Galectin‐3 and risk of cardiovascular events and all‐cause mortality in type 2 diabetes", "doi": "10.1002/dmrr.3093", "year": 2018 } ] } }, { "id": 33837, "drug": "secukinumab", "drug_type": "drug", "drug_domain": "inflammatory_bowel_disease", "predicate_ab": "inhibits", "mediator": "IL-17A", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "early rheumatoid arthritis", "outcome_type": "disease", "outcome_domain": "rheumatoid_arthritis", "score": 0.21972245773362195, "filtered_score": 0.21972245773362195, "filter_reason": null, "outreach_score": 0.21972245773362195, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "secukinumab", "mediator_canonical": "il-17a", "outcome_canonical": "early rheumatoid arthritis", "ab_count": 2, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37553722", "title": "Potential gastrointestinal Behcet’s disease flare after treatment with anti-interleukin 17a therapy", "doi": "10.1186/s41927-023-00344-9", "year": 2023 }, { "pmid": "32774388", "title": "Secukinumab-Induced Inflammatory Bowel Disease in a Patient Treated for Chronic Plaque Psoriasis and Psoriatic Arthritis: A Case Report and Review of the Role of Novel Biologic Agents Targeting the p19 Subunit of IL-23", "doi": "10.1155/2020/9404505", "year": 2020 } ], "bc": [ { "pmid": "33497394", "title": "Potential applicability of cytokines as biomarkers of disease activity in rheumatoid arthritis: Enzyme-linked immunosorbent spot assay-based evaluation of TNF-α, IL-1β, IL-10 and IL-17A", "doi": "10.1371/journal.pone.0246111", "year": 2021 }, { "pmid": "34321563", "title": "The role of IL-18 in addition to Th17 cytokines in rheumatoid arthritis development and treatment in women", "doi": "10.1038/s41598-021-94841-x", "year": 2021 } ] } }, { "id": 33829, "drug": "butyrate", "drug_type": "drug", "drug_domain": "inflammatory_bowel_disease", "predicate_ab": "upregulates", "mediator": "IL-10", "mediator_type": "protein", "predicate_bc": "increases", "outcome": "rheumatoid arthritis", "outcome_type": "disease", "outcome_domain": "rheumatoid_arthritis", "score": 0.21972245773362195, "filtered_score": 0.21972245773362195, "filter_reason": null, "outreach_score": 0.21972245773362195, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "completed", "clinical_trial_nct_ids": [ "NCT05718583", "NCT05576597", "NCT05152615" ], "literature_status": "reproduces_known", "drug_canonical": "butyrate", "mediator_canonical": "il-10", "outcome_canonical": "rheumatoid arthritis", "ab_count": 2, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "33363521", "title": "Butyrate Mitigates Weanling Piglets From Lipopolysaccharide-Induced Colitis by Regulating Microbiota and Energy Metabolism of the Gut–Liver Axis", "doi": "10.3389/fmicb.2020.588666", "year": 2020 }, { "pmid": "30918945", "title": "Microbiota Metabolite Butyrate Differentially Regulates Th1 and Th17 Cells’ Differentiation and Function in Induction of Colitis", "doi": "10.1093/ibd/izz046", "year": 2019 } ], "bc": [ { "pmid": "39475124", "title": "Inflammatory cytokines, metabolites, and rheumatoid arthritis", "doi": "10.1093/postmj/qgae146", "year": 2024 }, { "pmid": "30915732", "title": "Diagnostic values of serum IL-10 and IL-17 in rheumatoid arthritis and their correlation with serum 14-3-3η protein.", "doi": "10.26355/eurrev_201903_17227", "year": 2019 } ] } }, { "id": 8810, "drug": "Fe-TMPyP", "drug_type": "drug", "drug_domain": "alzheimer", "predicate_ab": "binds_to", "mediator": "α-synuclein", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "multiple system atrophy", "outcome_type": "disease", "outcome_domain": "als", "score": 0.21972245773362195, "filtered_score": 0.21972245773362195, "filter_reason": null, "outreach_score": 0.21972245773362195, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "fe-tmpyp", "mediator_canonical": "SNCA", "outcome_canonical": "multiple system atrophy", "ab_count": 2, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "31306510", "title": "Characterizing the inhibition of α‐synuclein oligomerization by a pharmacological chaperone that prevents prion formation by the protein PrP", "doi": "10.1002/pro.3684", "year": 2019 } ], "bc": [ { "pmid": "35746899", "title": "A pathologically confirmed case of combined amyotrophic lateral sclerosis with C9orf72 mutation and multiple system atrophy", "doi": "10.1111/neup.12808", "year": 2022 }, { "pmid": "26705184", "title": "[Histopathological and immunohistochemical study of spinal cord tissues in neurodegenerative diseases].", "doi": null, "year": 2015 } ] } }, { "id": 3423, "drug": "DMT", "drug_type": "drug", "drug_domain": "alzheimer", "predicate_ab": "activates", "mediator": "sigma-1 receptor", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "glioblastoma", "outcome_type": "disease", "outcome_domain": "glioblastoma", "score": 0.21972245773362195, "filtered_score": 0.21972245773362195, "filter_reason": null, "outreach_score": 0.21972245773362195, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "dmt", "mediator_canonical": "sigma-1 receptor", "outcome_canonical": "glioblastoma", "ab_count": 2, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "38693554", "title": "N, N-Dimethyltryptamine, a natural hallucinogen, ameliorates Alzheimer’s disease by restoring neuronal Sigma-1 receptor-mediated endoplasmic reticulum-mitochondria crosstalk", "doi": "10.1186/s13195-024-01462-3", "year": 2024 } ], "bc": [ { "pmid": "32384802", "title": "Sigma-1 Receptor Positron Emission Tomography: A New Molecular Imaging Approach Using (S)-(−)-[18F]Fluspidine in Glioblastoma", "doi": "10.3390/molecules25092170", "year": 2020 } ] } }, { "id": 23813, "drug": "L-ascorbic acid, N-acetylcysteine, and dimethyl fumarate", "drug_type": "drug", "drug_domain": "multiple_sclerosis", "predicate_ab": "activates", "mediator": "NRF2", "mediator_type": "protein", "predicate_bc": "causes", "outcome": "chemoresistance", "outcome_type": "phenotype", "outcome_domain": "pancreatic_cancer", "score": 0.21972245773362195, "filtered_score": 0.21972245773362195, "filter_reason": null, "outreach_score": 0.21972245773362195, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "unknown", "drug_canonical": "l-ascorbic acid, n-acetylcysteine, and dimethyl fumarate", "mediator_canonical": "NRF2", "outcome_canonical": null, "ab_count": 2, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40375363", "title": "Therapeutic combination of L-ascorbic acid, N-acetylcysteine, and dimethyl fumarate in Friedreich’s ataxia: insights from in vitro models", "doi": "10.1080/13510002.2025.2505303", "year": 2025 } ], "bc": [ { "pmid": "31911550", "title": "Undermining Glutaminolysis Bolsters Chemotherapy While NRF2 Promotes Chemoresistance in KRAS-Driven Pancreatic Cancers", "doi": "10.1158/0008-5472.can-19-1363", "year": 2020 }, { "pmid": "30735911", "title": "Digoxin sensitizes gemcitabine-resistant pancreatic cancer cells to gemcitabine via inhibiting Nrf2 signaling pathway", "doi": "10.1016/j.redox.2019.101131", "year": 2019 } ] } }, { "id": 31335, "drug": "temozolomide", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "downregulates", "mediator": "PD-L1", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "colitis", "outcome_type": "disease", "outcome_domain": "inflammatory_bowel_disease", "score": 0.21972245773362195, "filtered_score": 0.21972245773362195, "filter_reason": null, "outreach_score": 0.21972245773362195, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "temozolomide", "mediator_canonical": "PD-L1", "outcome_canonical": "colitis", "ab_count": 2, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "30709339", "title": "Crosslink between Temozolomide and PD-L1 immune-checkpoint inhibition in glioblastoma multiforme", "doi": "10.1186/s12885-019-5308-y", "year": 2019 } ], "bc": [ { "pmid": "40661950", "title": "PD-L1 deficiency exacerbates colitis severity by remodeling gut microbiota in inflammatory bowel disease", "doi": "10.3389/fimmu.2025.1622744", "year": 2025 }, { "pmid": "37435072", "title": "Case Report: A severe case of immunosuppressant-refractory immune checkpoint inhibitor-mediated colitis rescued by tofacitinib", "doi": "10.3389/fimmu.2023.1212432", "year": 2023 } ] } }, { "id": 9406, "drug": "anti-TF ADC", "drug_type": "drug", "drug_domain": "pancreatic_cancer", "predicate_ab": "binds_to", "mediator": "tissue factor", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "microvascular area", "outcome_type": "phenotype", "outcome_domain": "glioblastoma", "score": 0.21972245773362195, "filtered_score": 0.21972245773362195, "filter_reason": null, "outreach_score": 0.21972245773362195, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "anti-tf adc", "mediator_canonical": "tissue factor", "outcome_canonical": "microvascular area", "ab_count": 2, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "33200231", "title": "Antitumor effect of humanized anti‑tissue factor antibody‑drug conjugate in a model of peritoneal disseminated pancreatic cancer", "doi": "10.3892/or.2020.7850", "year": 2020 }, { "pmid": "31348600", "title": "Evaluation of the antitumor mechanism of antibody‐drug conjugates against tissue factor in stroma‐rich allograft models", "doi": "10.1111/cas.14146", "year": 2019 } ], "bc": [ { "pmid": "29333924", "title": "Dynamic MR imaging for functional vascularization depends on tissue factor signaling in glioblastoma", "doi": "10.1080/15384047.2018.1423924", "year": 2018 } ] } }, { "id": 53844, "drug": "p-Hydroxybenzaldehyde", "drug_type": "drug", "drug_domain": "inflammatory_bowel_disease", "predicate_ab": "upregulates", "mediator": "Nrf2", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "disease activity", "outcome_type": "phenotype", "outcome_domain": "rheumatoid_arthritis", "score": 0.21972245773362195, "filtered_score": 0.21972245773362195, "filter_reason": null, "outreach_score": 0.21972245773362195, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 2, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "39128305", "title": "p-Hydroxy benzaldehyde, a phenolic compound from Nostoc commune, ameliorates DSS-induced colitis against oxidative stress via the Nrf2/HO-1/NQO-1/NF-κB/AP-1 pathway", "doi": "10.1016/j.phymed.2024.155941", "year": 2024 } ], "bc": [ { "pmid": "36574898", "title": "Expression of Nrf2 protein in serum of patients with rheumatoid arthritis: A novel indicator for disease activity and disease prognosis", "doi": "10.1016/j.clinbiochem.2022.12.011", "year": 2022 } ] } }, { "id": 9407, "drug": "afatinib", "drug_type": "drug", "drug_domain": "pancreatic_cancer", "predicate_ab": "inhibits", "mediator": "EGFR", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "glioblastoma", "outcome_type": "disease", "outcome_domain": "glioblastoma", "score": 0.21972245773362195, "filtered_score": 0.21972245773362195, "filter_reason": null, "outreach_score": 0.21972245773362195, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "active", "clinical_trial_nct_ids": [ "NCT05432518", "NCT02423525", "NCT00977431" ], "literature_status": "reproduces_known", "drug_canonical": "afatinib", "mediator_canonical": "EGFR", "outcome_canonical": "glioblastoma", "ab_count": 2, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "39541736", "title": "A novel regimen for pancreatic ductal adenocarcinoma targeting MEK, BCL-xL, and EGFR", "doi": "10.1016/j.neo.2024.101070", "year": 2024 }, { "pmid": "33125153", "title": "Synergistic activity of agents targeting growth factor receptors, CDKs and downstream signaling molecules in a panel of pancreatic cancer cell lines and the identification of antagonistic combinations: Implications for future clinical trials in pancreatic cancer", "doi": "10.3892/or.2020.7822", "year": 2020 } ], "bc": [ { "pmid": "41473440", "title": "A PET-CT study of the uptake of labeled aptamers [18F]FB-Gol1 and [18F]FB-GR20 in rat 101.8 glioblastoma model", "doi": "10.3389/fonc.2025.1713181", "year": 2025 }, { "pmid": "38396993", "title": "Epidermal Growth Factor Receptor Inhibitors in Glioblastoma: Current Status and Future Possibilities", "doi": "10.3390/ijms25042316", "year": 2024 } ] } }, { "id": 8809, "drug": "DMSO", "drug_type": "drug", "drug_domain": "alzheimer", "predicate_ab": "induces", "mediator": "α-synuclein", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "multiple system atrophy", "outcome_type": "disease", "outcome_domain": "als", "score": 0.21972245773362195, "filtered_score": 0.21972245773362195, "filter_reason": null, "outreach_score": 0.21972245773362195, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "dmso", "mediator_canonical": "SNCA", "outcome_canonical": "multiple system atrophy", "ab_count": 2, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "35260646", "title": "Low dose DMSO treatment induces oligomerization and accelerates aggregation of α-synuclein", "doi": "10.1038/s41598-022-07706-2", "year": 2022 } ], "bc": [ { "pmid": "35746899", "title": "A pathologically confirmed case of combined amyotrophic lateral sclerosis with C9orf72 mutation and multiple system atrophy", "doi": "10.1111/neup.12808", "year": 2022 }, { "pmid": "26705184", "title": "[Histopathological and immunohistochemical study of spinal cord tissues in neurodegenerative diseases].", "doi": null, "year": 2015 } ] } }, { "id": 8795, "drug": "PFP nanosheets", "drug_type": "drug", "drug_domain": "alzheimer", "predicate_ab": "binds_to", "mediator": "α-synuclein", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "neurodegenerative diseases", "outcome_type": "disease", "outcome_domain": "als", "score": 0.21972245773362195, "filtered_score": 0.21972245773362195, "filter_reason": null, "outreach_score": 0.21972245773362195, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "pfp nanosheets", "mediator_canonical": "SNCA", "outcome_canonical": null, "ab_count": 2, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "36314062", "title": "Polyphenols-Based Nanosheets of Propolis Modulate Cytotoxic Amyloid Fibril Assembly of α-Synuclein", "doi": "10.1021/acschemneuro.2c00465", "year": 2022 } ], "bc": [ { "pmid": "40960157", "title": "Protein aggregation in neurodegenerative diseases", "doi": "10.1097/cm9.0000000000003802", "year": 2025 }, { "pmid": "38382884", "title": "The potential roles of salivary biomarkers in neurodegenerative diseases", "doi": "10.1016/j.nbd.2024.106442", "year": 2024 } ] } }, { "id": 8812, "drug": "Fe-TMPyP", "drug_type": "drug", "drug_domain": "alzheimer", "predicate_ab": "binds_to", "mediator": "α-synuclein", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "Parkinson's disease", "outcome_type": "disease", "outcome_domain": "als", "score": 0.21972245773362195, "filtered_score": 0.21972245773362195, "filter_reason": null, "outreach_score": 0.21972245773362195, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "fe-tmpyp", "mediator_canonical": "SNCA", "outcome_canonical": "Parkinson disease", "ab_count": 2, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "31306510", "title": "Characterizing the inhibition of α‐synuclein oligomerization by a pharmacological chaperone that prevents prion formation by the protein PrP", "doi": "10.1002/pro.3684", "year": 2019 } ], "bc": [ { "pmid": "41532955", "title": "Unveiling the Proteomic Landscape of Extracellular Vesicles: Implications for Neurodegeneration and Neuroprotection", "doi": "10.1111/jnc.70350", "year": 2026 }, { "pmid": "26705184", "title": "[Histopathological and immunohistochemical study of spinal cord tissues in neurodegenerative diseases].", "doi": null, "year": 2015 } ] } }, { "id": 31748, "drug": "procyanidin B1", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "downregulates", "mediator": "Nrf2", "mediator_type": "protein", "predicate_bc": "causes", "outcome": "chemoresistance", "outcome_type": "phenotype", "outcome_domain": "pancreatic_cancer", "score": 0.21972245773362195, "filtered_score": 0.21972245773362195, "filter_reason": null, "outreach_score": 0.21972245773362195, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "procyanidin b1", "mediator_canonical": "NRF2", "outcome_canonical": null, "ab_count": 2, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "39293861", "title": "Procyanidin B1 Promotes PSMC3‐NRF2 Ubiquitination to Induce Ferroptosis in Glioblastoma", "doi": "10.1002/ptr.8328", "year": 2024 } ], "bc": [ { "pmid": "31911550", "title": "Undermining Glutaminolysis Bolsters Chemotherapy While NRF2 Promotes Chemoresistance in KRAS-Driven Pancreatic Cancers", "doi": "10.1158/0008-5472.can-19-1363", "year": 2020 }, { "pmid": "30735911", "title": "Digoxin sensitizes gemcitabine-resistant pancreatic cancer cells to gemcitabine via inhibiting Nrf2 signaling pathway", "doi": "10.1016/j.redox.2019.101131", "year": 2019 } ] } }, { "id": 8806, "drug": "DMSO", "drug_type": "drug", "drug_domain": "alzheimer", "predicate_ab": "induces", "mediator": "α-synuclein", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "Parkinson's disease", "outcome_type": "disease", "outcome_domain": "als", "score": 0.21972245773362195, "filtered_score": 0.21972245773362195, "filter_reason": null, "outreach_score": 0.21972245773362195, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "dmso", "mediator_canonical": "SNCA", "outcome_canonical": "Parkinson disease", "ab_count": 2, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "35260646", "title": "Low dose DMSO treatment induces oligomerization and accelerates aggregation of α-synuclein", "doi": "10.1038/s41598-022-07706-2", "year": 2022 } ], "bc": [ { "pmid": "41532955", "title": "Unveiling the Proteomic Landscape of Extracellular Vesicles: Implications for Neurodegeneration and Neuroprotection", "doi": "10.1111/jnc.70350", "year": 2026 }, { "pmid": "26705184", "title": "[Histopathological and immunohistochemical study of spinal cord tissues in neurodegenerative diseases].", "doi": null, "year": 2015 } ] } }, { "id": 8811, "drug": "5-NBA", "drug_type": "drug", "drug_domain": "alzheimer", "predicate_ab": "inhibits", "mediator": "α-synuclein", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "neurodegenerative diseases", "outcome_type": "disease", "outcome_domain": "als", "score": 0.21972245773362195, "filtered_score": 0.21972245773362195, "filter_reason": null, "outreach_score": 0.21972245773362195, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "5-nba", "mediator_canonical": "SNCA", "outcome_canonical": null, "ab_count": 2, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37305264", "title": "5-Nitro-1,2-benzothiazol-3-amine and N-Ethyl-1-[(ethylcarbamoyl)(5-nitro-1,2-benzothiazol-3-yl)amino]formamide Modulate α-Synuclein and Tau Aggregation", "doi": "10.1021/acsomega.3c02668", "year": 2023 } ], "bc": [ { "pmid": "40960157", "title": "Protein aggregation in neurodegenerative diseases", "doi": "10.1097/cm9.0000000000003802", "year": 2025 }, { "pmid": "38382884", "title": "The potential roles of salivary biomarkers in neurodegenerative diseases", "doi": "10.1016/j.nbd.2024.106442", "year": 2024 } ] } }, { "id": 6885, "drug": "Sinapic Acid", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "binds_to", "mediator": "ASC", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "AD", "outcome_type": "disease", "outcome_domain": "alzheimer", "score": 0.21972245773362195, "filtered_score": 0.21972245773362195, "filter_reason": null, "outreach_score": 0.21972245773362195, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "sinapic acid", "mediator_canonical": "asc", "outcome_canonical": "ad", "ab_count": 2, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "38662166", "title": "Sinapic Acid Mitigates Pentylenetetrazol-induced Acute Seizures By Modulating the NLRP3 Inflammasome and Regulating Calcium/calcineurin Signaling: In Vivo and In Silico Approaches", "doi": "10.1007/s10753-024-02019-0", "year": 2024 } ], "bc": [ { "pmid": "32630059", "title": "The Inflammasome Adaptor Protein ASC in Mild Cognitive Impairment and Alzheimer’s Disease", "doi": "10.3390/ijms21134674", "year": 2020 } ] } }, { "id": 3776, "drug": "DMSO", "drug_type": "drug", "drug_domain": "alzheimer", "predicate_ab": "induces", "mediator": "α-synuclein", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "neurodegenerative diseases", "outcome_type": "disease", "outcome_domain": "als", "score": 0.21972245773362195, "filtered_score": 0.21972245773362195, "filter_reason": null, "outreach_score": 0.21972245773362195, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "dmso", "mediator_canonical": "SNCA", "outcome_canonical": null, "ab_count": 2, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "35260646", "title": "Low dose DMSO treatment induces oligomerization and accelerates aggregation of α-synuclein", "doi": "10.1038/s41598-022-07706-2", "year": 2022 } ], "bc": [ { "pmid": "40960157", "title": "Protein aggregation in neurodegenerative diseases", "doi": "10.1097/cm9.0000000000003802", "year": 2025 }, { "pmid": "38382884", "title": "The potential roles of salivary biomarkers in neurodegenerative diseases", "doi": "10.1016/j.nbd.2024.106442", "year": 2024 } ] } }, { "id": 53845, "drug": "p-Hydroxybenzaldehyde", "drug_type": "drug", "drug_domain": "inflammatory_bowel_disease", "predicate_ab": "upregulates", "mediator": "Nrf2", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "rheumatoid arthritis", "outcome_type": "disease", "outcome_domain": "rheumatoid_arthritis", "score": 0.21972245773362195, "filtered_score": 0.21972245773362195, "filter_reason": null, "outreach_score": 0.21972245773362195, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 2, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "39128305", "title": "p-Hydroxy benzaldehyde, a phenolic compound from Nostoc commune, ameliorates DSS-induced colitis against oxidative stress via the Nrf2/HO-1/NQO-1/NF-κB/AP-1 pathway", "doi": "10.1016/j.phymed.2024.155941", "year": 2024 } ], "bc": [ { "pmid": "40247798", "title": "Emerging Therapeutic Targets in Rheumatoid Arthritis: Focusing on HIF-1α, Nrf2, STATs, and RORγt", "doi": "10.2174/0113894501372670250408074908", "year": 2025 }, { "pmid": "36574898", "title": "Expression of Nrf2 protein in serum of patients with rheumatoid arthritis: A novel indicator for disease activity and disease prognosis", "doi": "10.1016/j.clinbiochem.2022.12.011", "year": 2022 } ] } }, { "id": 8800, "drug": "PFP nanosheets", "drug_type": "drug", "drug_domain": "alzheimer", "predicate_ab": "binds_to", "mediator": "α-synuclein", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "Parkinson's disease", "outcome_type": "disease", "outcome_domain": "als", "score": 0.21972245773362195, "filtered_score": 0.21972245773362195, "filter_reason": null, "outreach_score": 0.21972245773362195, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "pfp nanosheets", "mediator_canonical": "SNCA", "outcome_canonical": "Parkinson disease", "ab_count": 2, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "36314062", "title": "Polyphenols-Based Nanosheets of Propolis Modulate Cytotoxic Amyloid Fibril Assembly of α-Synuclein", "doi": "10.1021/acschemneuro.2c00465", "year": 2022 } ], "bc": [ { "pmid": "41532955", "title": "Unveiling the Proteomic Landscape of Extracellular Vesicles: Implications for Neurodegeneration and Neuroprotection", "doi": "10.1111/jnc.70350", "year": 2026 }, { "pmid": "26705184", "title": "[Histopathological and immunohistochemical study of spinal cord tissues in neurodegenerative diseases].", "doi": null, "year": 2015 } ] } }, { "id": 8808, "drug": "5-NBA", "drug_type": "drug", "drug_domain": "alzheimer", "predicate_ab": "inhibits", "mediator": "α-synuclein", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "Parkinson's disease", "outcome_type": "disease", "outcome_domain": "als", "score": 0.21972245773362195, "filtered_score": 0.21972245773362195, "filter_reason": null, "outreach_score": 0.21972245773362195, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "5-nba", "mediator_canonical": "SNCA", "outcome_canonical": "Parkinson disease", "ab_count": 2, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37305264", "title": "5-Nitro-1,2-benzothiazol-3-amine and N-Ethyl-1-[(ethylcarbamoyl)(5-nitro-1,2-benzothiazol-3-yl)amino]formamide Modulate α-Synuclein and Tau Aggregation", "doi": "10.1021/acsomega.3c02668", "year": 2023 } ], "bc": [ { "pmid": "41532955", "title": "Unveiling the Proteomic Landscape of Extracellular Vesicles: Implications for Neurodegeneration and Neuroprotection", "doi": "10.1111/jnc.70350", "year": 2026 }, { "pmid": "26705184", "title": "[Histopathological and immunohistochemical study of spinal cord tissues in neurodegenerative diseases].", "doi": null, "year": 2015 } ] } }, { "id": 35494, "drug": "IDMF", "drug_type": "drug", "drug_domain": "multiple_sclerosis", "predicate_ab": "activates", "mediator": "Nrf2", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "rheumatoid arthritis", "outcome_type": "disease", "outcome_domain": "rheumatoid_arthritis", "score": 0.21972245773362195, "filtered_score": 0.21972245773362195, "filter_reason": null, "outreach_score": 0.21972245773362195, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "idmf", "mediator_canonical": "NRF2", "outcome_canonical": "rheumatoid arthritis", "ab_count": 2, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "35455458", "title": "Transcriptomic Analysis of Fumarate Compounds Identifies Unique Effects of Isosorbide Di-(Methyl Fumarate) on NRF2, NF-kappaB and IRF1 Pathway Genes", "doi": "10.3390/ph15040461", "year": 2022 }, { "pmid": "34909741", "title": "A Sensitization-Free Dimethyl Fumarate Prodrug, Isosorbide Di-(Methyl Fumarate), Provides a Topical Treatment Candidate for Psoriasis", "doi": "10.1016/j.xjidi.2021.100040", "year": 2021 } ], "bc": [ { "pmid": "40247798", "title": "Emerging Therapeutic Targets in Rheumatoid Arthritis: Focusing on HIF-1α, Nrf2, STATs, and RORγt", "doi": "10.2174/0113894501372670250408074908", "year": 2025 }, { "pmid": "36574898", "title": "Expression of Nrf2 protein in serum of patients with rheumatoid arthritis: A novel indicator for disease activity and disease prognosis", "doi": "10.1016/j.clinbiochem.2022.12.011", "year": 2022 } ] } }, { "id": 3141, "drug": "Isoginkgetin", "drug_type": "drug", "drug_domain": "als", "predicate_ab": "inhibits", "mediator": "GSK-3β", "mediator_type": "protein", "predicate_bc": "increases", "outcome": "tau hyperphosphorylation", "outcome_type": "phenotype", "outcome_domain": "alzheimer", "score": 0.21972245773362195, "filtered_score": 0.21972245773362195, "filter_reason": null, "outreach_score": 0.21972245773362195, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "isoginkgetin", "mediator_canonical": "GSK3B", "outcome_canonical": "tau hyperphosphorylation", "ab_count": 2, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41912102", "title": "Isoginkgetin protects against degeneration of ALS motor neurons via regulating the GSK-3β–TFEB signaling axis", "doi": "10.1016/j.phrs.2026.108172", "year": 2026 } ], "bc": [ { "pmid": "41459736", "title": "Type 3 Diabetes: A Molecular Link Between Cerebral Insulin Resistance and Neurodegeneration via AGE–RAGE Signaling", "doi": "10.1111/ejn.70364", "year": 2025 }, { "pmid": "33554064", "title": "Isoform-selective decrease of glycogen synthase kinase-3-beta (GSK-3β) reduces synaptic tau phosphorylation, transcellular spreading, and aggregation", "doi": "10.1016/j.isci.2021.102058", "year": 2021 } ] } }, { "id": 24559, "drug": "Glycyrrhizin", "drug_type": "drug", "drug_domain": "als", "predicate_ab": "binds_to", "mediator": "HMGB1", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "drug resistance", "outcome_type": "phenotype", "outcome_domain": "epilepsy", "score": 0.21972245773362195, "filtered_score": 0.21972245773362195, "filter_reason": null, "outreach_score": 0.21972245773362195, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "glycyrrhizin", "mediator_canonical": "HMGB1", "outcome_canonical": null, "ab_count": 2, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41139682", "title": "Therapeutic potential of glycyrrhizin in nervous system diseases", "doi": "10.1097/cm9.0000000000003806", "year": 2025 } ], "bc": [ { "pmid": "39466324", "title": "Clinical and biochemical assessments of circulating High Mobility Group Box Protein1 in children with epilepsy: relation to cognitive function and drug responsiveness", "doi": "10.1007/s10072-024-07795-z", "year": 2024 }, { "pmid": "31241711", "title": "Circulating high mobility group box-1 and toll-like receptor 4 expressions increase the risk and severity of epilepsy", "doi": "10.1590/1414-431x20197374", "year": 2019 } ] } }, { "id": 53846, "drug": "Roseburia intestinalis", "drug_type": "drug", "drug_domain": "inflammatory_bowel_disease", "predicate_ab": "inhibits", "mediator": "interleukin-17", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "systemic lupus erythematosus disease activity", "outcome_type": "phenotype", "outcome_domain": "rheumatoid_arthritis", "score": 0.21972245773362195, "filtered_score": 0.21972245773362195, "filter_reason": null, "outreach_score": 0.21972245773362195, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 2, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "29620246", "title": "Roseburia intestinalis inhibits interleukin‑17 excretion and promotes regulatory T cells differentiation in colitis", "doi": "10.3892/mmr.2018.8833", "year": 2018 } ], "bc": [ { "pmid": "39351141", "title": "Role of Interleukin-17 in Predicting Activity of Rheumatoid Arthritis and Systemic Lupus Erythematosus", "doi": "10.1177/11795441241276880", "year": 2024 } ] } }, { "id": 53853, "drug": "butyrate", "drug_type": "drug", "drug_domain": "inflammatory_bowel_disease", "predicate_ab": "upregulates", "mediator": "IL-10", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "depressive symptoms", "outcome_type": "phenotype", "outcome_domain": "rheumatoid_arthritis", "score": 0.21972245773362195, "filtered_score": 0.21972245773362195, "filter_reason": null, "outreach_score": 0.21972245773362195, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 2, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "33363521", "title": "Butyrate Mitigates Weanling Piglets From Lipopolysaccharide-Induced Colitis by Regulating Microbiota and Energy Metabolism of the Gut–Liver Axis", "doi": "10.3389/fmicb.2020.588666", "year": 2020 }, { "pmid": "30918945", "title": "Microbiota Metabolite Butyrate Differentially Regulates Th1 and Th17 Cells’ Differentiation and Function in Induction of Colitis", "doi": "10.1093/ibd/izz046", "year": 2019 } ], "bc": [ { "pmid": "30148175", "title": "Influence of Biological Therapeutics, Cytokines, and Disease Activity on Depression in Rheumatoid Arthritis", "doi": "10.1155/2018/5954897", "year": 2018 } ] } }, { "id": 33833, "drug": "5-ASA", "drug_type": "drug", "drug_domain": "inflammatory_bowel_disease", "predicate_ab": "inhibits", "mediator": "miR-155", "mediator_type": "gene", "predicate_bc": "associated_with", "outcome": "rheumatoid arthritis", "outcome_type": "disease", "outcome_domain": "rheumatoid_arthritis", "score": 0.21972245773362195, "filtered_score": 0.21972245773362195, "filter_reason": null, "outreach_score": 0.21972245773362195, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "completed", "clinical_trial_nct_ids": [ "NCT01463189", "NCT02930343", "NCT02219191" ], "literature_status": "reproduces_known", "drug_canonical": "5-asa", "mediator_canonical": "mir-155", "outcome_canonical": "rheumatoid arthritis", "ab_count": 2, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "34987126", "title": "5-aminosalicylic acid inhibits the expression of oncomiRs and pro-inflammatory microRNAs: an in vitro study.", "doi": "10.26402/jpp.2021.4.04", "year": 2021 } ], "bc": [ { "pmid": "37527031", "title": "Liposomal AntagomiR‐155‐5p Restores Anti‐Inflammatory Macrophages and Improves Arthritis in Preclinical Models of Rheumatoid Arthritis", "doi": "10.1002/art.42665", "year": 2023 }, { "pmid": "38351964", "title": "Impact of miR-155 rs767649 Polymorphism on Rheumatoid Arthritis Activity in Egyptian Patients", "doi": "10.7759/cureus.49297", "year": 2023 } ] } }, { "id": 33836, "drug": "Lactobacillus acidophilus", "drug_type": "drug", "drug_domain": "inflammatory_bowel_disease", "predicate_ab": "suppresses", "mediator": "IL-17", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "depression", "outcome_type": "disease", "outcome_domain": "rheumatoid_arthritis", "score": 0.21972245773362195, "filtered_score": 0.21972245773362195, "filter_reason": null, "outreach_score": 0.21972245773362195, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "active", "clinical_trial_nct_ids": [ "NCT03277586", "NCT04093960", "NCT05568498" ], "literature_status": "reproduces_known", "drug_canonical": "lactobacillus acidophilus", "mediator_canonical": "il-17", "outcome_canonical": "depression", "ab_count": 2, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "29336663", "title": "Lactobacillus acidophilus Improves Intestinal Inflammation in an Acute Colitis Mouse Model by Regulation of Th17 and Treg Cell Balance and Fibrosis Development", "doi": "10.1089/jmf.2017.3990", "year": 2018 } ], "bc": [ { "pmid": "30848077", "title": "Interleukin‐6 and interleukin‐17 are related to depression in patients with rheumatoid arthritis", "doi": "10.1111/1756-185x.13529", "year": 2019 } ] } }, { "id": 37668, "drug": "baricitinib", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "inhibits", "mediator": "MCP-1", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "ALS", "outcome_type": "disease", "outcome_domain": "als", "score": 0.21972245773362195, "filtered_score": 0.21972245773362195, "filter_reason": null, "outreach_score": 0.21972245773362195, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "completed", "clinical_trial_nct_ids": [ "NCT05189106" ], "literature_status": "partial_evidence", "drug_canonical": "baricitinib", "mediator_canonical": "mcp-1", "outcome_canonical": "amyotrophic lateral sclerosis", "ab_count": 2, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "34665696", "title": "The JAK inhibitor baricitinib inhibits oncostatin M induction of proinflammatory mediators in ex-vivo synovial derived cells", "doi": "10.55563/clinexprheumatol/cfsajk", "year": 2020 } ], "bc": [ { "pmid": "41689476", "title": "Systemic immune-metabolic interactions in patients with amyotrophic lateral sclerosis: correlations of plasma cytokines with metabolic status", "doi": "10.1080/21678421.2026.2627902", "year": 2026 }, { "pmid": "32515902", "title": "Longitudinal biomarkers in amyotrophic lateral sclerosis", "doi": "10.1002/acn3.51078", "year": 2020 } ] } }, { "id": 38744, "drug": "FHD", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "suppresses", "mediator": "HIF-1α", "mediator_type": "protein", "predicate_bc": "prevents", "outcome": "ulcerative colitis", "outcome_type": "disease", "outcome_domain": "inflammatory_bowel_disease", "score": 0.21972245773362195, "filtered_score": 0.21972245773362195, "filter_reason": null, "outreach_score": 0.21972245773362195, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "fhd", "mediator_canonical": "hif-1α", "outcome_canonical": "ulcerative colitis", "ab_count": 2, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "38614265", "title": "Fangji Huangqi Decoction alleviates rheumatoid arthritis through regulating HIF-1α mediated the angiogenesis and the balance between autophagy and apoptosis", "doi": "10.1016/j.jep.2024.118061", "year": 2024 } ], "bc": [ { "pmid": "38137357", "title": "Interrelation of Hypoxia-Inducible Factor-1 Alpha (HIF-1 α) and the Ratio between the Mean Corpuscular Volume/Lymphocytes (MCVL) and the Cumulative Inflammatory Index (IIC) in Ulcerative Colitis", "doi": "10.3390/biomedicines11123137", "year": 2023 }, { "pmid": "31944416", "title": "Mucosal inflammation downregulates PHD1 expression promoting a barrier‐protective HIF‐1α response in ulcerative colitis patients", "doi": "10.1096/fj.201902103r", "year": 2020 } ] } }, { "id": 33831, "drug": "Lactobacillus acidophilus", "drug_type": "drug", "drug_domain": "inflammatory_bowel_disease", "predicate_ab": "suppresses", "mediator": "IL-17", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "rheumatoid arthritis", "outcome_type": "disease", "outcome_domain": "rheumatoid_arthritis", "score": 0.21972245773362195, "filtered_score": 0.21972245773362195, "filter_reason": null, "outreach_score": 0.21972245773362195, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "completed", "clinical_trial_nct_ids": [ "NCT00664820", "NCT04696718" ], "literature_status": "partial_evidence", "drug_canonical": "lactobacillus acidophilus", "mediator_canonical": "il-17", "outcome_canonical": "rheumatoid arthritis", "ab_count": 2, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "29336663", "title": "Lactobacillus acidophilus Improves Intestinal Inflammation in an Acute Colitis Mouse Model by Regulation of Th17 and Treg Cell Balance and Fibrosis Development", "doi": "10.1089/jmf.2017.3990", "year": 2018 } ], "bc": [ { "pmid": "30915732", "title": "Diagnostic values of serum IL-10 and IL-17 in rheumatoid arthritis and their correlation with serum 14-3-3η protein.", "doi": "10.26355/eurrev_201903_17227", "year": 2019 }, { "pmid": "29512371", "title": "Th1-Th17 Ratio as a New Insight in Rheumatoid Arthritis Disease.", "doi": null, "year": 2018 } ] } }, { "id": 33827, "drug": "secukinumab", "drug_type": "drug", "drug_domain": "inflammatory_bowel_disease", "predicate_ab": "inhibits", "mediator": "IL-17A", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "DAS28", "outcome_type": "phenotype", "outcome_domain": "rheumatoid_arthritis", "score": 0.21972245773362195, "filtered_score": 0.21972245773362195, "filter_reason": null, "outreach_score": 0.21972245773362195, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "secukinumab", "mediator_canonical": "il-17a", "outcome_canonical": "das28", "ab_count": 2, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37553722", "title": "Potential gastrointestinal Behcet’s disease flare after treatment with anti-interleukin 17a therapy", "doi": "10.1186/s41927-023-00344-9", "year": 2023 }, { "pmid": "32774388", "title": "Secukinumab-Induced Inflammatory Bowel Disease in a Patient Treated for Chronic Plaque Psoriasis and Psoriatic Arthritis: A Case Report and Review of the Role of Novel Biologic Agents Targeting the p19 Subunit of IL-23", "doi": "10.1155/2020/9404505", "year": 2020 } ], "bc": [ { "pmid": "33497394", "title": "Potential applicability of cytokines as biomarkers of disease activity in rheumatoid arthritis: Enzyme-linked immunosorbent spot assay-based evaluation of TNF-α, IL-1β, IL-10 and IL-17A", "doi": "10.1371/journal.pone.0246111", "year": 2021 } ] } }, { "id": 33828, "drug": "Roseburia intestinalis", "drug_type": "drug", "drug_domain": "inflammatory_bowel_disease", "predicate_ab": "inhibits", "mediator": "interleukin-17", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "rheumatoid arthritis disease activity", "outcome_type": "phenotype", "outcome_domain": "rheumatoid_arthritis", "score": 0.21972245773362195, "filtered_score": 0.21972245773362195, "filter_reason": null, "outreach_score": 0.21972245773362195, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "roseburia intestinalis", "mediator_canonical": "interleukin-17", "outcome_canonical": "rheumatoid arthritis disease activity", "ab_count": 2, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "29620246", "title": "Roseburia intestinalis inhibits interleukin‑17 excretion and promotes regulatory T cells differentiation in colitis", "doi": "10.3892/mmr.2018.8833", "year": 2018 } ], "bc": [ { "pmid": "39351141", "title": "Role of Interleukin-17 in Predicting Activity of Rheumatoid Arthritis and Systemic Lupus Erythematosus", "doi": "10.1177/11795441241276880", "year": 2024 } ] } }, { "id": 8799, "drug": "PFP nanosheets", "drug_type": "drug", "drug_domain": "alzheimer", "predicate_ab": "binds_to", "mediator": "α-synuclein", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "multiple system atrophy", "outcome_type": "disease", "outcome_domain": "als", "score": 0.21972245773362195, "filtered_score": 0.21972245773362195, "filter_reason": null, "outreach_score": 0.21972245773362195, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "pfp nanosheets", "mediator_canonical": "SNCA", "outcome_canonical": "multiple system atrophy", "ab_count": 2, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "36314062", "title": "Polyphenols-Based Nanosheets of Propolis Modulate Cytotoxic Amyloid Fibril Assembly of α-Synuclein", "doi": "10.1021/acschemneuro.2c00465", "year": 2022 } ], "bc": [ { "pmid": "35746899", "title": "A pathologically confirmed case of combined amyotrophic lateral sclerosis with C9orf72 mutation and multiple system atrophy", "doi": "10.1111/neup.12808", "year": 2022 }, { "pmid": "26705184", "title": "[Histopathological and immunohistochemical study of spinal cord tissues in neurodegenerative diseases].", "doi": null, "year": 2015 } ] } }, { "id": 8803, "drug": "E2814", "drug_type": "drug", "drug_domain": "alzheimer", "predicate_ab": "inhibits", "mediator": "TAU", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "Alzheimer's disease", "outcome_type": "disease", "outcome_domain": "als", "score": 0.21972245773362195, "filtered_score": 0.21972245773362195, "filter_reason": null, "outreach_score": 0.21972245773362195, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "active", "clinical_trial_nct_ids": [ "NCT01760005", "NCT05269394", "NCT06602258" ], "literature_status": "reproduces_known", "drug_canonical": "e2814", "mediator_canonical": "MAPT", "outcome_canonical": "Alzheimer disease", "ab_count": 2, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "32019610", "title": "Pre-clinical characterisation of E2814, a high-affinity antibody targeting the microtubule-binding repeat domain of tau for passive immunotherapy in Alzheimer’s disease", "doi": "10.1186/s40478-020-0884-2", "year": 2020 } ], "bc": [ { "pmid": "41532955", "title": "Unveiling the Proteomic Landscape of Extracellular Vesicles: Implications for Neurodegeneration and Neuroprotection", "doi": "10.1111/jnc.70350", "year": 2026 }, { "pmid": "26705184", "title": "[Histopathological and immunohistochemical study of spinal cord tissues in neurodegenerative diseases].", "doi": null, "year": 2015 } ] } }, { "id": 3572, "drug": "Uncaria rhynchophylla", "drug_type": "drug", "drug_domain": "alzheimer", "predicate_ab": "induces", "mediator": "TAU", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "memory performance", "outcome_type": "phenotype", "outcome_domain": "epilepsy", "score": 0.21972245773362195, "filtered_score": 0.21972245773362195, "filter_reason": null, "outreach_score": 0.21972245773362195, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "uncaria rhynchophylla", "mediator_canonical": "MAPT", "outcome_canonical": "memory performance", "ab_count": 2, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "36242849", "title": "Dual modulators of aggregation and dissociation of amyloid beta and tau: In vitro, in vivo, and in silico studies of Uncaria rhynchophylla and its bioactive components", "doi": "10.1016/j.biopha.2022.113865", "year": 2022 } ], "bc": [ { "pmid": "33725124", "title": "Early stages of tau pathology and its associations with functional connectivity, atrophy and memory", "doi": "10.1093/brain/awab114", "year": 2021 } ] } }, { "id": 8794, "drug": "Uncaria rhynchophylla", "drug_type": "drug", "drug_domain": "alzheimer", "predicate_ab": "induces", "mediator": "TAU", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "Alzheimer's disease", "outcome_type": "disease", "outcome_domain": "als", "score": 0.21972245773362195, "filtered_score": 0.21972245773362195, "filter_reason": null, "outreach_score": 0.21972245773362195, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "uncaria rhynchophylla", "mediator_canonical": "MAPT", "outcome_canonical": "Alzheimer disease", "ab_count": 2, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "36242849", "title": "Dual modulators of aggregation and dissociation of amyloid beta and tau: In vitro, in vivo, and in silico studies of Uncaria rhynchophylla and its bioactive components", "doi": "10.1016/j.biopha.2022.113865", "year": 2022 } ], "bc": [ { "pmid": "41532955", "title": "Unveiling the Proteomic Landscape of Extracellular Vesicles: Implications for Neurodegeneration and Neuroprotection", "doi": "10.1111/jnc.70350", "year": 2026 }, { "pmid": "26705184", "title": "[Histopathological and immunohistochemical study of spinal cord tissues in neurodegenerative diseases].", "doi": null, "year": 2015 } ] } }, { "id": 23815, "drug": "IDMF", "drug_type": "drug", "drug_domain": "multiple_sclerosis", "predicate_ab": "activates", "mediator": "NRF2", "mediator_type": "protein", "predicate_bc": "causes", "outcome": "chemoresistance", "outcome_type": "phenotype", "outcome_domain": "pancreatic_cancer", "score": 0.21972245773362195, "filtered_score": 0.21972245773362195, "filter_reason": null, "outreach_score": 0.21972245773362195, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "idmf", "mediator_canonical": "NRF2", "outcome_canonical": null, "ab_count": 2, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "35455458", "title": "Transcriptomic Analysis of Fumarate Compounds Identifies Unique Effects of Isosorbide Di-(Methyl Fumarate) on NRF2, NF-kappaB and IRF1 Pathway Genes", "doi": "10.3390/ph15040461", "year": 2022 }, { "pmid": "34909741", "title": "A Sensitization-Free Dimethyl Fumarate Prodrug, Isosorbide Di-(Methyl Fumarate), Provides a Topical Treatment Candidate for Psoriasis", "doi": "10.1016/j.xjidi.2021.100040", "year": 2021 } ], "bc": [ { "pmid": "31911550", "title": "Undermining Glutaminolysis Bolsters Chemotherapy While NRF2 Promotes Chemoresistance in KRAS-Driven Pancreatic Cancers", "doi": "10.1158/0008-5472.can-19-1363", "year": 2020 }, { "pmid": "30735911", "title": "Digoxin sensitizes gemcitabine-resistant pancreatic cancer cells to gemcitabine via inhibiting Nrf2 signaling pathway", "doi": "10.1016/j.redox.2019.101131", "year": 2019 } ] } }, { "id": 8807, "drug": "F-Florzolotau", "drug_type": "drug", "drug_domain": "alzheimer", "predicate_ab": "binds_to", "mediator": "TAU", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "Alzheimer's disease", "outcome_type": "disease", "outcome_domain": "als", "score": 0.21972245773362195, "filtered_score": 0.21972245773362195, "filter_reason": null, "outreach_score": 0.21972245773362195, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "f-florzolotau", "mediator_canonical": "MAPT", "outcome_canonical": "Alzheimer disease", "ab_count": 2, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "39555939", "title": "18F‐Florzolotau PET Imaging Unveils Tau Pathology in Dementia with Lewy Bodies", "doi": "10.1002/mds.30055", "year": 2024 }, { "pmid": "39850631", "title": "Clinical characteristics and biomarker profile in early- and late-onset Alzheimer’s disease: the Shanghai Memory Study", "doi": "10.1093/braincomms/fcaf015", "year": 2024 } ], "bc": [ { "pmid": "41532955", "title": "Unveiling the Proteomic Landscape of Extracellular Vesicles: Implications for Neurodegeneration and Neuroprotection", "doi": "10.1111/jnc.70350", "year": 2026 }, { "pmid": "26705184", "title": "[Histopathological and immunohistochemical study of spinal cord tissues in neurodegenerative diseases].", "doi": null, "year": 2015 } ] } }, { "id": 40398, "drug": "trelagliptin", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "binds_to", "mediator": "DPP-4", "mediator_type": "protein", "predicate_bc": "predicts", "outcome": "disease activity", "outcome_type": "phenotype", "outcome_domain": "inflammatory_bowel_disease", "score": 0.21972245773362195, "filtered_score": 0.21972245773362195, "filter_reason": null, "outreach_score": 0.21972245773362195, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "trelagliptin", "mediator_canonical": "dpp-4", "outcome_canonical": "disease activity", "ab_count": 2, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "27328054", "title": "Trelagliptin (SYR-472, Zafatek), Novel Once-Weekly Treatment for Type 2 Diabetes, Inhibits Dipeptidyl Peptidase-4 (DPP-4) via a Non-Covalent Mechanism", "doi": "10.1371/journal.pone.0157509", "year": 2016 } ], "bc": [ { "pmid": "31912883", "title": "Serum Dipeptidyl Peptidase 4: A Predictor of Disease Activity and Prognosis in Inflammatory Bowel Disease", "doi": "10.1093/ibd/izz319", "year": 2020 } ] } }, { "id": 3573, "drug": "E2814", "drug_type": "drug", "drug_domain": "alzheimer", "predicate_ab": "inhibits", "mediator": "TAU", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "memory performance", "outcome_type": "phenotype", "outcome_domain": "epilepsy", "score": 0.21972245773362195, "filtered_score": 0.21972245773362195, "filter_reason": null, "outreach_score": 0.21972245773362195, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "e2814", "mediator_canonical": "MAPT", "outcome_canonical": "memory performance", "ab_count": 2, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "32019610", "title": "Pre-clinical characterisation of E2814, a high-affinity antibody targeting the microtubule-binding repeat domain of tau for passive immunotherapy in Alzheimer’s disease", "doi": "10.1186/s40478-020-0884-2", "year": 2020 } ], "bc": [ { "pmid": "33725124", "title": "Early stages of tau pathology and its associations with functional connectivity, atrophy and memory", "doi": "10.1093/brain/awab114", "year": 2021 } ] } }, { "id": 9405, "drug": "anti-TF ADC", "drug_type": "drug", "drug_domain": "pancreatic_cancer", "predicate_ab": "binds_to", "mediator": "tissue factor", "mediator_type": "protein", "predicate_bc": "decreases", "outcome": "glomeruloid vascular proliferation", "outcome_type": "phenotype", "outcome_domain": "glioblastoma", "score": 0.21972245773362195, "filtered_score": 0.21972245773362195, "filter_reason": null, "outreach_score": 0.21972245773362195, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "anti-tf adc", "mediator_canonical": "tissue factor", "outcome_canonical": "glomeruloid vascular proliferation", "ab_count": 2, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "33200231", "title": "Antitumor effect of humanized anti‑tissue factor antibody‑drug conjugate in a model of peritoneal disseminated pancreatic cancer", "doi": "10.3892/or.2020.7850", "year": 2020 }, { "pmid": "31348600", "title": "Evaluation of the antitumor mechanism of antibody‐drug conjugates against tissue factor in stroma‐rich allograft models", "doi": "10.1111/cas.14146", "year": 2019 } ], "bc": [ { "pmid": "29333924", "title": "Dynamic MR imaging for functional vascularization depends on tissue factor signaling in glioblastoma", "doi": "10.1080/15384047.2018.1423924", "year": 2018 } ] } }, { "id": 40798, "drug": "exenatide", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "upregulates", "mediator": "SIRT1", "mediator_type": "protein", "predicate_bc": "increases", "outcome": "proliferation", "outcome_type": "phenotype", "outcome_domain": "pancreatic_cancer", "score": 0.21972245773362195, "filtered_score": 0.21972245773362195, "filter_reason": null, "outreach_score": 0.21972245773362195, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "exenatide", "mediator_canonical": "SIRT1", "outcome_canonical": null, "ab_count": 2, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "28439947", "title": "SIRT1/HSF1/HSP pathway is essential for exenatide‐alleviated, lipid‐induced hepatic endoplasmic reticulum stress", "doi": "10.1002/hep.29238", "year": 2017 }, { "pmid": "26339397", "title": "Expression of SIRT1 in the ovaries of rats with polycystic ovary syndrome before and after therapeutic intervention with exenatide.", "doi": null, "year": 2015 } ], "bc": [ { "pmid": "34163012", "title": "SIRT1 coordinates with the CRL4B complex to regulate pancreatic cancer stem cells to promote tumorigenesis", "doi": "10.1038/s41418-021-00821-z", "year": 2021 }, { "pmid": "27494892", "title": "Sirtuin 1 stimulates the proliferation and the expression of glycolysis genes in pancreatic neoplastic lesions", "doi": "10.18632/oncotarget.11013", "year": 2016 } ] } }, { "id": 40397, "drug": "vildagliptin", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "inhibits", "mediator": "DPP-4", "mediator_type": "protein", "predicate_bc": "predicts", "outcome": "disease activity", "outcome_type": "phenotype", "outcome_domain": "inflammatory_bowel_disease", "score": 0.21972245773362195, "filtered_score": 0.21972245773362195, "filter_reason": null, "outreach_score": 0.21972245773362195, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "completed", "clinical_trial_nct_ids": [ "NCT00382096", "NCT00616811", "NCT00770081" ], "literature_status": "partial_evidence", "drug_canonical": "vildagliptin", "mediator_canonical": "dpp-4", "outcome_canonical": "disease activity", "ab_count": 2, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "26786576", "title": "A Protein Preload Enhances the Glucose-Lowering Efficacy of Vildagliptin in Type 2 Diabetes", "doi": "10.2337/dc15-2298", "year": 2016 }, { "pmid": "27207543", "title": "Quantification of the Contribution of GLP-1 to Mediating Insulinotropic Effects of DPP-4 Inhibition With Vildagliptin in Healthy Subjects and Patients With Type 2 Diabetes Using Exendin [9-39] as a GLP-1 Receptor Antagonist", "doi": "10.2337/db16-0107", "year": 2016 } ], "bc": [ { "pmid": "31912883", "title": "Serum Dipeptidyl Peptidase 4: A Predictor of Disease Activity and Prognosis in Inflammatory Bowel Disease", "doi": "10.1093/ibd/izz319", "year": 2020 } ] } }, { "id": 40394, "drug": "Omarigliptin", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "inhibits", "mediator": "DPP-4", "mediator_type": "protein", "predicate_bc": "predicts", "outcome": "disease activity", "outcome_type": "phenotype", "outcome_domain": "inflammatory_bowel_disease", "score": 0.21972245773362195, "filtered_score": 0.21972245773362195, "filter_reason": null, "outreach_score": 0.21972245773362195, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "omarigliptin", "mediator_canonical": "dpp-4", "outcome_canonical": "disease activity", "ab_count": 2, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "27225334", "title": "Pharmacokinetics and Pharmacodynamics of Omarigliptin, a Once‐Weekly Dipeptidyl Peptidase‐4 (DPP‐4) Inhibitor, After Single and Multiple Doses in Healthy Subjects", "doi": "10.1002/jcph.773", "year": 2016 }, { "pmid": "26310692", "title": "Safety and Efficacy of Omarigliptin (MK-3102), a Novel Once-Weekly DPP-4 Inhibitor for the Treatment of Patients With Type 2 Diabetes", "doi": "10.2337/dc15-0109", "year": 2015 } ], "bc": [ { "pmid": "31912883", "title": "Serum Dipeptidyl Peptidase 4: A Predictor of Disease Activity and Prognosis in Inflammatory Bowel Disease", "doi": "10.1093/ibd/izz319", "year": 2020 } ] } }, { "id": 57062, "drug": "glucocorticoids", "drug_type": "drug", "drug_domain": "pancreatic_cancer", "predicate_ab": "activates", "mediator": "ROCK2", "mediator_type": "protein", "predicate_bc": "prevents", "outcome": "cardiac insulin resistance", "outcome_type": "disease", "outcome_domain": "heart_failure", "score": 0.21972245773362195, "filtered_score": 0.21972245773362195, "filter_reason": null, "outreach_score": 0.21972245773362195, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 2, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37164685", "title": "Glucocorticoids promote lung metastasis of pancreatic cancer cells through enhancing cell adhesion, migration and invasion", "doi": "10.1507/endocrj.ej21-0787", "year": 2023 } ], "bc": [ { "pmid": "25910808", "title": "Partial deletion of ROCK2 protects mice from high-fat diet-induced cardiac insulin resistance and contractile dysfunction", "doi": "10.1152/ajpheart.00664.2014", "year": 2015 } ] } }, { "id": 40399, "drug": "teneligliptin", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "binds_to", "mediator": "DPP-4", "mediator_type": "protein", "predicate_bc": "predicts", "outcome": "disease activity", "outcome_type": "phenotype", "outcome_domain": "inflammatory_bowel_disease", "score": 0.21972245773362195, "filtered_score": 0.21972245773362195, "filter_reason": null, "outreach_score": 0.21972245773362195, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "completed", "clinical_trial_nct_ids": [ "NCT02512523" ], "literature_status": "novel_signal", "drug_canonical": "teneligliptin", "mediator_canonical": "dpp-4", "outcome_canonical": "disease activity", "ab_count": 2, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "27832184", "title": "Comparative Binding Analysis of Dipeptidyl Peptidase IV (DPP-4) with Antidiabetic Drugs – An Ab Initio Fragment Molecular Orbital Study", "doi": "10.1371/journal.pone.0166275", "year": 2016 } ], "bc": [ { "pmid": "31912883", "title": "Serum Dipeptidyl Peptidase 4: A Predictor of Disease Activity and Prognosis in Inflammatory Bowel Disease", "doi": "10.1093/ibd/izz319", "year": 2020 } ] } }, { "id": 51567, "drug": "modified citrus pectin", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "inhibits", "mediator": "galectin-3", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "pancreatic cancer-associated diabetes", "outcome_type": "disease", "outcome_domain": "pancreatic_cancer", "score": 0.21972245773362195, "filtered_score": 0.21972245773362195, "filter_reason": null, "outreach_score": 0.21972245773362195, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 2, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "33532663", "title": "Galectin-3 Inhibition With Modified Citrus Pectin in Hypertension", "doi": "10.1016/j.jacbts.2020.10.006", "year": 2021 }, { "pmid": "32172066", "title": "Modified citrus pectin ameliorates myocardial fibrosis and inflammation via suppressing galectin-3 and TLR4/MyD88/NF-κB signaling pathway", "doi": "10.1016/j.biopha.2020.110071", "year": 2020 } ], "bc": [ { "pmid": "31262951", "title": "Galectin-3 and S100A9: Novel Diabetogenic Factors Mediating Pancreatic Cancer–Associated Diabetes", "doi": "10.2337/dc19-0217", "year": 2019 } ] } }, { "id": 51569, "drug": "Phloretin", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "upregulates", "mediator": "SIRT1", "mediator_type": "protein", "predicate_bc": "increases", "outcome": "proliferation", "outcome_type": "phenotype", "outcome_domain": "pancreatic_cancer", "score": 0.21972245773362195, "filtered_score": 0.21972245773362195, "filter_reason": null, "outreach_score": 0.21972245773362195, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 2, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "31076562", "title": "Phloretin protects against cardiac damage and remodeling via restoring SIRT1 and anti-inflammatory effects in the streptozotocin-induced diabetic mouse model", "doi": "10.18632/aging.101954", "year": 2019 } ], "bc": [ { "pmid": "34163012", "title": "SIRT1 coordinates with the CRL4B complex to regulate pancreatic cancer stem cells to promote tumorigenesis", "doi": "10.1038/s41418-021-00821-z", "year": 2021 }, { "pmid": "27494892", "title": "Sirtuin 1 stimulates the proliferation and the expression of glycolysis genes in pancreatic neoplastic lesions", "doi": "10.18632/oncotarget.11013", "year": 2016 } ] } }, { "id": 23814, "drug": "Bleomycin", "drug_type": "drug", "drug_domain": "multiple_sclerosis", "predicate_ab": "upregulates", "mediator": "MMP9", "mediator_type": "protein", "predicate_bc": "predicts", "outcome": "pancreatic cancer", "outcome_type": "disease", "outcome_domain": "pancreatic_cancer", "score": 0.21972245773362195, "filtered_score": 0.21972245773362195, "filter_reason": null, "outreach_score": 0.21972245773362195, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "active", "clinical_trial_nct_ids": [ "NCT06753136", "NCT04281290", "NCT03225781" ], "literature_status": "reproduces_known", "drug_canonical": "bleomycin", "mediator_canonical": "MMP9", "outcome_canonical": "pancreatic cancer", "ab_count": 2, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "31066254", "title": "Gelatinases Increase in Bleomycin-induced Systemic Sclerosis Mouse Model", "doi": "10.18502/ijaai.v18i2.921", "year": 2019 } ], "bc": [ { "pmid": "39487843", "title": "MMP9 and pancreatic cancer", "doi": "10.4149/bll_2024_110", "year": 2024 } ] } }, { "id": 51570, "drug": "Phloretin", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "upregulates", "mediator": "SIRT1", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "pancreatic cancer", "outcome_type": "disease", "outcome_domain": "pancreatic_cancer", "score": 0.21972245773362195, "filtered_score": 0.21972245773362195, "filter_reason": null, "outreach_score": 0.21972245773362195, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 2, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "31076562", "title": "Phloretin protects against cardiac damage and remodeling via restoring SIRT1 and anti-inflammatory effects in the streptozotocin-induced diabetic mouse model", "doi": "10.18632/aging.101954", "year": 2019 } ], "bc": [ { "pmid": "34163012", "title": "SIRT1 coordinates with the CRL4B complex to regulate pancreatic cancer stem cells to promote tumorigenesis", "doi": "10.1038/s41418-021-00821-z", "year": 2021 }, { "pmid": "28351313", "title": "SIRT1 promotes the proliferation and metastasis of human pancreatic cancer cells", "doi": "10.1177/1010428317691180", "year": 2017 } ] } }, { "id": 23421, "drug": "glycyrrhizin", "drug_type": "drug", "drug_domain": "multiple_sclerosis", "predicate_ab": "suppresses", "mediator": "HMGB1", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "ALS", "outcome_type": "disease", "outcome_domain": "als", "score": 0.21972245773362195, "filtered_score": 0.21972245773362195, "filter_reason": null, "outreach_score": 0.21972245773362195, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "glycyrrhizin", "mediator_canonical": "HMGB1", "outcome_canonical": "amyotrophic lateral sclerosis", "ab_count": 2, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "30013568", "title": "Glycyrrhizin Protects Mice Against Experimental Autoimmune Encephalomyelitis by Inhibiting High-Mobility Group Box 1 (HMGB1) Expression and Neuronal HMGB1 Release", "doi": "10.3389/fimmu.2018.01518", "year": 2018 } ], "bc": [ { "pmid": "35216298", "title": "The Involvement of RAGE and Its Ligands during Progression of ALS in SOD1 G93A Transgenic Mice", "doi": "10.3390/ijms23042184", "year": 2022 }, { "pmid": "26733811", "title": "Receptor for Advanced Glycation End Products and its Inflammatory Ligands are Upregulated in Amyotrophic Lateral Sclerosis", "doi": "10.3389/fncel.2015.00485", "year": 2015 } ] } }, { "id": 50401, "drug": "c-AUCB", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "inhibits", "mediator": "sEH", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "Alzheimer's disease", "outcome_type": "disease", "outcome_domain": "alzheimer", "score": 0.21972245773362195, "filtered_score": 0.21972245773362195, "filter_reason": null, "outreach_score": 0.21972245773362195, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 2, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "25969338", "title": "Inhibition of soluble epoxide hydrolase counteracts the development of renal dysfunction and progression of congestive heart failure in Ren‐2 transgenic hypertensive rats with aorto‐caval fistula", "doi": "10.1111/1440-1681.12419", "year": 2015 }, { "pmid": "26047375", "title": "Inhibition of Soluble Epoxide Hydrolase Does Not Improve the Course of Congestive Heart Failure and the Development of Renal Dysfunction in Rats With Volume Overload Induced by Aorto-Caval Fistula", "doi": "10.33549/physiolres.932977", "year": 2015 } ], "bc": [ { "pmid": "33298560", "title": "An epoxide hydrolase inhibitor reduces neuroinflammation in a mouse model of Alzheimer’s disease", "doi": "10.1126/scitranslmed.abb1206", "year": 2020 }, { "pmid": "31847859", "title": "Genetic deletion of soluble epoxide hydrolase delays the progression of Alzheimer’s disease", "doi": "10.1186/s12974-019-1635-9", "year": 2019 } ] } }, { "id": 3063, "drug": "Isoginkgetin", "drug_type": "drug", "drug_domain": "als", "predicate_ab": "inhibits", "mediator": "GSK-3β", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "Alzheimer's disease", "outcome_type": "disease", "outcome_domain": "alzheimer", "score": 0.21972245773362195, "filtered_score": 0.21972245773362195, "filter_reason": null, "outreach_score": 0.21972245773362195, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "isoginkgetin", "mediator_canonical": "GSK3B", "outcome_canonical": "Alzheimer disease", "ab_count": 2, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41912102", "title": "Isoginkgetin protects against degeneration of ALS motor neurons via regulating the GSK-3β–TFEB signaling axis", "doi": "10.1016/j.phrs.2026.108172", "year": 2026 } ], "bc": [ { "pmid": "40414897", "title": "Mapping the hippocampal spatial proteomic signature in male and female mice of an early Alzheimer’s disease model", "doi": "10.1186/s13293-025-00697-5", "year": 2025 }, { "pmid": "33945025", "title": "High-throughput screening of natural compounds and inhibition of a major therapeutic target HsGSK-3β for Alzheimer’s disease using computational approaches", "doi": "10.1186/s43141-021-00163-w", "year": 2021 } ] } }, { "id": 8796, "drug": "Fe-TMPyP", "drug_type": "drug", "drug_domain": "alzheimer", "predicate_ab": "binds_to", "mediator": "α-synuclein", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "neurodegenerative diseases", "outcome_type": "disease", "outcome_domain": "als", "score": 0.21972245773362195, "filtered_score": 0.21972245773362195, "filter_reason": null, "outreach_score": 0.21972245773362195, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "fe-tmpyp", "mediator_canonical": "SNCA", "outcome_canonical": null, "ab_count": 2, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "31306510", "title": "Characterizing the inhibition of α‐synuclein oligomerization by a pharmacological chaperone that prevents prion formation by the protein PrP", "doi": "10.1002/pro.3684", "year": 2019 } ], "bc": [ { "pmid": "40960157", "title": "Protein aggregation in neurodegenerative diseases", "doi": "10.1097/cm9.0000000000003802", "year": 2025 }, { "pmid": "38382884", "title": "The potential roles of salivary biomarkers in neurodegenerative diseases", "doi": "10.1016/j.nbd.2024.106442", "year": 2024 } ] } }, { "id": 6103, "drug": "THQPMP", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "inhibits", "mediator": "EGFR", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "pancreatic adenocarcinoma", "outcome_type": "disease", "outcome_domain": "pancreatic_cancer", "score": 0.21972245773362195, "filtered_score": 0.21972245773362195, "filter_reason": null, "outreach_score": 0.21972245773362195, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "thqpmp", "mediator_canonical": "EGFR", "outcome_canonical": "pancreatic adenocarcinoma", "ab_count": 2, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41839309", "title": "Preclinical validation of tetrahydroquinoline derivatives as EGFR inhibitor inducing glioblastoma cell death", "doi": "10.1016/j.ejps.2026.107503", "year": 2026 } ], "bc": [ { "pmid": "37370756", "title": "Anoikis-Related Gene Signature for Prognostication of Pancreatic Adenocarcinoma: A Multi-Omics Exploration and Verification Study", "doi": "10.3390/cancers15123146", "year": 2023 }, { "pmid": "27130234", "title": "Selecting Tumor-Specific Molecular Targets in Pancreatic Adenocarcinoma: Paving the Way for Image-Guided Pancreatic Surgery", "doi": "10.1007/s11307-016-0959-4", "year": 2016 } ] } }, { "id": 6105, "drug": "potential FAK inhibitors", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "inhibits", "mediator": "FAK", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "chemoresistance", "outcome_type": "phenotype", "outcome_domain": "pancreatic_cancer", "score": 0.21972245773362195, "filtered_score": 0.21972245773362195, "filter_reason": null, "outreach_score": 0.21972245773362195, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "potential fak inhibitors", "mediator_canonical": "fak", "outcome_canonical": null, "ab_count": 2, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "39425154", "title": "Combined machine learning models, docking analysis, ADMET studies and molecular dynamics simulations for the design of novel FAK inhibitors against glioblastoma", "doi": "10.1186/s13065-024-01316-x", "year": 2024 } ], "bc": [ { "pmid": "38269431", "title": "Exploring the Therapeutic Potential of Focal Adhesion Kinase Inhibition in Overcoming Chemoresistance in Pancreatic Ductal Adenocarcinoma", "doi": "10.4155/fmc-2023-0234", "year": 2024 }, { "pmid": "35929603", "title": "Focal adhesion kinase priming in pancreatic cancer, altering biomechanics to improve chemotherapy", "doi": "10.1042/bst20220162", "year": 2022 } ] } }, { "id": 5173, "drug": "gemcitabine", "drug_type": "drug", "drug_domain": "pancreatic_cancer", "predicate_ab": "upregulates", "mediator": "IL-8", "mediator_type": "protein", "predicate_bc": "decreases", "outcome": "depressed mood", "outcome_type": "phenotype", "outcome_domain": "depression", "score": 0.21972245773362195, "filtered_score": 0.21972245773362195, "filter_reason": null, "outreach_score": 0.21972245773362195, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "gemcitabine", "mediator_canonical": "IL8", "outcome_canonical": "depressed mood", "ab_count": 2, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "30097594", "title": "Gemcitabine treatment promotes immunosuppressive microenvironment in pancreatic tumors by supporting the infiltration, growth, and polarization of macrophages", "doi": "10.1038/s41598-018-30437-2", "year": 2018 }, { "pmid": "25970774", "title": "Gemcitabine triggers angiogenesis-promoting molecular signals in pancreatic cancer cells: Therapeutic implications", "doi": "10.18632/oncotarget.3784", "year": 2015 } ], "bc": [ { "pmid": "35871638", "title": "Interleukin-8 and depressive responses to an inflammatory challenge: secondary analysis of a randomized controlled trial", "doi": "10.1038/s41598-022-16364-3", "year": 2022 } ] } }, { "id": 39800, "drug": "Glp1R0017", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "binds_to", "mediator": "GLP1R", "mediator_type": "protein", "predicate_bc": "decreases", "outcome": "bipolar disorder", "outcome_type": "disease", "outcome_domain": "depression", "score": 0.21972245773362195, "filtered_score": 0.21972245773362195, "filter_reason": null, "outreach_score": 0.21972245773362195, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "glp1r0017", "mediator_canonical": "glp1r", "outcome_canonical": "bipolar disorder", "ab_count": 2, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "29119245", "title": "Development and characterisation of a novel glucagon like peptide-1 receptor antibody", "doi": "10.1007/s00125-017-4491-0", "year": 2017 } ], "bc": [ { "pmid": "40770700", "title": "Genetically proxied glucagon-like peptide-1 receptor perturbation and risk of mood disorders: a Mendelian randomization study", "doi": "10.1186/s12888-025-07152-0", "year": 2025 } ] } }, { "id": 1565, "drug": "procyanidin B1", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "downregulates", "mediator": "NRF2", "mediator_type": "protein", "predicate_bc": "causes", "outcome": "chemoresistance", "outcome_type": "phenotype", "outcome_domain": "pancreatic_cancer", "score": 0.21972245773362195, "filtered_score": 0.21972245773362195, "filter_reason": null, "outreach_score": 0.21972245773362195, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "procyanidin b1", "mediator_canonical": "NRF2", "outcome_canonical": null, "ab_count": 2, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "39293861", "title": "Procyanidin B1 Promotes PSMC3‐NRF2 Ubiquitination to Induce Ferroptosis in Glioblastoma", "doi": "10.1002/ptr.8328", "year": 2024 } ], "bc": [ { "pmid": "31911550", "title": "Undermining Glutaminolysis Bolsters Chemotherapy While NRF2 Promotes Chemoresistance in KRAS-Driven Pancreatic Cancers", "doi": "10.1158/0008-5472.can-19-1363", "year": 2020 }, { "pmid": "30735911", "title": "Digoxin sensitizes gemcitabine-resistant pancreatic cancer cells to gemcitabine via inhibiting Nrf2 signaling pathway", "doi": "10.1016/j.redox.2019.101131", "year": 2019 } ] } }, { "id": 40803, "drug": "Canagliflozin", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "suppresses", "mediator": "PD-L1", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "type 2 autoimmune pancreatitis", "outcome_type": "disease", "outcome_domain": "pancreatic_cancer", "score": 0.21972245773362195, "filtered_score": 0.21972245773362195, "filter_reason": null, "outreach_score": 0.21972245773362195, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "canagliflozin", "mediator_canonical": "PD-L1", "outcome_canonical": "type 2 autoimmune pancreatitis", "ab_count": 2, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "38816549", "title": "SGLT2 inhibition eliminates senescent cells and alleviates pathological aging", "doi": "10.1038/s43587-024-00642-y", "year": 2024 }, { "pmid": "36594471", "title": "Canagliflozin primes antitumor immunity by triggering PD-L1 degradation in endocytic recycling", "doi": "10.1172/jci154754", "year": 2023 } ], "bc": [ { "pmid": "31135488", "title": "Autoimmune Pancreatitis Type 2", "doi": "10.1097/pas.0000000000001282", "year": 2019 } ] } }, { "id": 34682, "drug": "Glycyrrhizin", "drug_type": "drug", "drug_domain": "multiple_sclerosis", "predicate_ab": "suppresses", "mediator": "HMGB1", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "drug resistance", "outcome_type": "phenotype", "outcome_domain": "epilepsy", "score": 0.21972245773362195, "filtered_score": 0.21972245773362195, "filter_reason": null, "outreach_score": 0.21972245773362195, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "glycyrrhizin", "mediator_canonical": "HMGB1", "outcome_canonical": null, "ab_count": 2, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "30013568", "title": "Glycyrrhizin Protects Mice Against Experimental Autoimmune Encephalomyelitis by Inhibiting High-Mobility Group Box 1 (HMGB1) Expression and Neuronal HMGB1 Release", "doi": "10.3389/fimmu.2018.01518", "year": 2018 } ], "bc": [ { "pmid": "39466324", "title": "Clinical and biochemical assessments of circulating High Mobility Group Box Protein1 in children with epilepsy: relation to cognitive function and drug responsiveness", "doi": "10.1007/s10072-024-07795-z", "year": 2024 }, { "pmid": "31241711", "title": "Circulating high mobility group box-1 and toll-like receptor 4 expressions increase the risk and severity of epilepsy", "doi": "10.1590/1414-431x20197374", "year": 2019 } ] } }, { "id": 5178, "drug": "gemcitabine", "drug_type": "drug", "drug_domain": "pancreatic_cancer", "predicate_ab": "upregulates", "mediator": "IL-8", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "response to ketamine", "outcome_type": "phenotype", "outcome_domain": "depression", "score": 0.21972245773362195, "filtered_score": 0.21972245773362195, "filter_reason": null, "outreach_score": 0.21972245773362195, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "gemcitabine", "mediator_canonical": "IL8", "outcome_canonical": "response to ketamine", "ab_count": 2, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "30097594", "title": "Gemcitabine treatment promotes immunosuppressive microenvironment in pancreatic tumors by supporting the infiltration, growth, and polarization of macrophages", "doi": "10.1038/s41598-018-30437-2", "year": 2018 }, { "pmid": "25970774", "title": "Gemcitabine triggers angiogenesis-promoting molecular signals in pancreatic cancer cells: Therapeutic implications", "doi": "10.18632/oncotarget.3784", "year": 2015 } ], "bc": [ { "pmid": "33723220", "title": "Depression treatment response to ketamine: sex-specific role of interleukin-8, but not other inflammatory markers", "doi": "10.1038/s41398-021-01268-z", "year": 2021 } ] } }, { "id": 5175, "drug": "gemcitabine", "drug_type": "drug", "drug_domain": "pancreatic_cancer", "predicate_ab": "upregulates", "mediator": "IL-8", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "depression severity", "outcome_type": "disease", "outcome_domain": "depression", "score": 0.21972245773362195, "filtered_score": 0.21972245773362195, "filter_reason": null, "outreach_score": 0.21972245773362195, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "gemcitabine", "mediator_canonical": "IL8", "outcome_canonical": "depression severity", "ab_count": 2, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "30097594", "title": "Gemcitabine treatment promotes immunosuppressive microenvironment in pancreatic tumors by supporting the infiltration, growth, and polarization of macrophages", "doi": "10.1038/s41598-018-30437-2", "year": 2018 }, { "pmid": "25970774", "title": "Gemcitabine triggers angiogenesis-promoting molecular signals in pancreatic cancer cells: Therapeutic implications", "doi": "10.18632/oncotarget.3784", "year": 2015 } ], "bc": [ { "pmid": "36600668", "title": "Structural brain plasticity and inflammation are independently related to changes in depressive symptoms six months after an index ECT course", "doi": "10.1017/s0033291722003555", "year": 2023 }, { "pmid": "29856741", "title": "Changes in the serum levels of inflammatory cytokines in antidepressant drug-naïve patients with major depression", "doi": "10.1371/journal.pone.0197267", "year": 2018 } ] } }, { "id": 18587, "drug": "Sinapic Acid", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "binds_to", "mediator": "ASC", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "Multiple Sclerosis", "outcome_type": "disease", "outcome_domain": "multiple_sclerosis", "score": 0.21972245773362195, "filtered_score": 0.21972245773362195, "filter_reason": null, "outreach_score": 0.21972245773362195, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "sinapic acid", "mediator_canonical": "asc", "outcome_canonical": "multiple sclerosis", "ab_count": 2, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "38662166", "title": "Sinapic Acid Mitigates Pentylenetetrazol-induced Acute Seizures By Modulating the NLRP3 Inflammasome and Regulating Calcium/calcineurin Signaling: In Vivo and In Silico Approaches", "doi": "10.1007/s10753-024-02019-0", "year": 2024 } ], "bc": [ { "pmid": "29615953", "title": "Inflammasome Proteins As Biomarkers of Multiple Sclerosis", "doi": "10.3389/fneur.2018.00135", "year": 2018 } ] } }, { "id": 8596, "drug": "F-Florzolotau", "drug_type": "drug", "drug_domain": "alzheimer", "predicate_ab": "binds_to", "mediator": "TAU", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "memory performance", "outcome_type": "phenotype", "outcome_domain": "epilepsy", "score": 0.21972245773362195, "filtered_score": 0.21972245773362195, "filter_reason": null, "outreach_score": 0.21972245773362195, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "f-florzolotau", "mediator_canonical": "MAPT", "outcome_canonical": "memory performance", "ab_count": 2, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "39555939", "title": "18F‐Florzolotau PET Imaging Unveils Tau Pathology in Dementia with Lewy Bodies", "doi": "10.1002/mds.30055", "year": 2024 }, { "pmid": "39850631", "title": "Clinical characteristics and biomarker profile in early- and late-onset Alzheimer’s disease: the Shanghai Memory Study", "doi": "10.1093/braincomms/fcaf015", "year": 2024 } ], "bc": [ { "pmid": "33725124", "title": "Early stages of tau pathology and its associations with functional connectivity, atrophy and memory", "doi": "10.1093/brain/awab114", "year": 2021 } ] } }, { "id": 2095, "drug": "Ketogenic diet", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "downregulates", "mediator": "Kynurenine", "mediator_type": "biomarker", "predicate_bc": "increases", "outcome": "ALS", "outcome_type": "disease", "outcome_domain": "als", "score": 0.21972245773362195, "filtered_score": 0.21972245773362195, "filter_reason": null, "outreach_score": 0.21972245773362195, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "active", "clinical_trial_nct_ids": [ "NCT07233148", "NCT04204889", "NCT01016522" ], "literature_status": "reproduces_known", "drug_canonical": "ketogenic diet", "mediator_canonical": "kynurenine", "outcome_canonical": "amyotrophic lateral sclerosis", "ab_count": 2, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "29605816", "title": "Regulation of kynurenine metabolism by a ketogenic diet", "doi": "10.1194/jlr.m079251", "year": 2018 } ], "bc": [ { "pmid": "35275534", "title": "Investigating Casual Associations Among Gut Microbiota, Metabolites, and Neurodegenerative Diseases: A Mendelian Randomization Study", "doi": "10.3233/jad-215411", "year": 2022 }, { "pmid": "34063031", "title": "Some CSF Kynurenine Pathway Intermediates Associated with Disease Evolution in Amyotrophic Lateral Sclerosis", "doi": "10.3390/biom11050691", "year": 2021 } ] } }, { "id": 51951, "drug": "bromocriptine", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "inhibits", "mediator": "Prolactin", "mediator_type": "protein", "predicate_bc": "decreases", "outcome": "type 2 diabetes", "outcome_type": "disease", "outcome_domain": "type_2_diabetes", "score": 0.21972245773362195, "filtered_score": 0.21972245773362195, "filter_reason": null, "outreach_score": 0.21972245773362195, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 2, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "29792513", "title": "Cardiogenic shock complicating peripartum cardiomyopathy: Importance of early left ventricular unloading and bromocriptine therapy", "doi": "10.1177/2048872618777876", "year": 2018 }, { "pmid": "30565890", "title": "The Effect of Bromocriptine on Left Ventricular Functional Recovery in Peripartum Cardiomyopathy: Insights from the BRO-HF Retrospective Cohort Study", "doi": "10.1002/ehf2.12376", "year": 2018 } ], "bc": [ { "pmid": "27466075", "title": "Circulating Prolactin and Risk of Type 2 Diabetes: A Prospective Study", "doi": "10.1093/aje/kwv326", "year": 2016 } ] } }, { "id": 61006, "drug": "Semaglutide", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "activates", "mediator": "AMPK", "mediator_type": "protein", "predicate_bc": "prevents", "outcome": "metabolic dysfunction", "outcome_type": "disease", "outcome_domain": "heart_failure", "score": 0.21972245773362195, "filtered_score": 0.21972245773362195, "filter_reason": null, "outreach_score": 0.21972245773362195, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 2, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40151913", "title": "Semaglutide improves cognitive function and neuroinflammation in APP/PS1 transgenic mice by activating AMPK and inhibiting TLR4/NF-κB pathway", "doi": "10.1177/13872877251329439", "year": 2025 }, { "pmid": "39665144", "title": "Semaglutide Improves Myocardial Perfusion and Performance in a Large Animal Model of Coronary Artery Disease", "doi": "10.1161/atvbaha.124.321850", "year": 2024 } ], "bc": [ { "pmid": "37194385", "title": "Adenosine monophosphate‐activated protein kinase is elevated in human cachectic muscle and prevents cancer‐induced metabolic dysfunction in mice", "doi": "10.1002/jcsm.13238", "year": 2023 } ] } }, { "id": 61005, "drug": "pioglitazone", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "activates", "mediator": "AMPK", "mediator_type": "protein", "predicate_bc": "prevents", "outcome": "metabolic dysfunction", "outcome_type": "disease", "outcome_domain": "heart_failure", "score": 0.21972245773362195, "filtered_score": 0.21972245773362195, "filter_reason": null, "outreach_score": 0.21972245773362195, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 2, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "30367397", "title": "Pioglitazone Reduces Hepatocellular Carcinoma Development in Two Rodent Models of Cirrhosis", "doi": "10.1007/s11605-018-4004-6", "year": 2018 }, { "pmid": "30127742", "title": "Pioglitazone Protects Against Renal Ischemia-Reperfusion Injury via the AMP-Activated Protein Kinase-Regulated Autophagy Pathway", "doi": "10.3389/fphar.2018.00851", "year": 2018 } ], "bc": [ { "pmid": "37194385", "title": "Adenosine monophosphate‐activated protein kinase is elevated in human cachectic muscle and prevents cancer‐induced metabolic dysfunction in mice", "doi": "10.1002/jcsm.13238", "year": 2023 } ] } }, { "id": 35490, "drug": "ocrelizumab", "drug_type": "drug", "drug_domain": "multiple_sclerosis", "predicate_ab": "induces", "mediator": "cytokines", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "rheumatoid arthritis", "outcome_type": "disease", "outcome_domain": "rheumatoid_arthritis", "score": 0.21972245773362195, "filtered_score": 0.21972245773362195, "filter_reason": null, "outreach_score": 0.21972245773362195, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "completed", "clinical_trial_nct_ids": [ "NCT00077870", "NCT00673920", "NCT00406419" ], "literature_status": "reproduces_known", "drug_canonical": "ocrelizumab", "mediator_canonical": "cytokines", "outcome_canonical": "rheumatoid arthritis", "ab_count": 2, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "36430240", "title": "Acute Effects of Ocrelizumab Infusion in Multiple Sclerosis Patients", "doi": "10.3390/ijms232213759", "year": 2022 } ], "bc": [ { "pmid": "37593880", "title": "Highly Biocompatible Smart Injectable Hydrogel for the Management of Rheumatoid Arthritis", "doi": "10.1021/acsbiomaterials.3c00514", "year": 2023 }, { "pmid": "29928007", "title": "A cytokine protein-protein interaction network for identifying key molecules in rheumatoid arthritis", "doi": "10.1371/journal.pone.0199530", "year": 2018 } ] } }, { "id": 38844, "drug": "compound 7c", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "inhibits", "mediator": "IL-33", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "relapsing-remitting multiple sclerosis", "outcome_type": "disease", "outcome_domain": "multiple_sclerosis", "score": 0.21972245773362195, "filtered_score": 0.21972245773362195, "filter_reason": null, "outreach_score": 0.21972245773362195, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "compound 7c", "mediator_canonical": "il-33", "outcome_canonical": "relapsing-remitting multiple sclerosis", "ab_count": 2, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "34553505", "title": "Rational Design, Synthesis and Evaluation of Oxazolo[4,5‐c]‐quinolinone Analogs as Novel Interleukin‐33 Inhibitors", "doi": "10.1002/asia.202100896", "year": 2021 } ], "bc": [ { "pmid": "34030079", "title": "Plasma Interleukin-33 level in relapsing-remitting multiple sclerosis. Is it negatively correlated with central nervous system lesions in patients with mild disability?", "doi": "10.1016/j.clineuro.2021.106700", "year": 2021 } ] } }, { "id": 40799, "drug": "formononetin", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "upregulates", "mediator": "SIRT1", "mediator_type": "gene", "predicate_bc": "increases", "outcome": "cell migration", "outcome_type": "phenotype", "outcome_domain": "pancreatic_cancer", "score": 0.21972245773362195, "filtered_score": 0.21972245773362195, "filter_reason": null, "outreach_score": 0.21972245773362195, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "formononetin", "mediator_canonical": "SIRT1", "outcome_canonical": "cell migration", "ab_count": 2, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "32459048", "title": "Formononetin Ameliorates Diabetic Neuropathy by Increasing Expression of SIRT1 and NGF", "doi": "10.1002/cbdv.202000162", "year": 2020 }, { "pmid": "30072892", "title": "Formononetin Treatment in Type 2 Diabetic Rats Reduces Insulin Resistance and Hyperglycemia", "doi": "10.3389/fphar.2018.00739", "year": 2018 } ], "bc": [ { "pmid": "27170223", "title": "SIRT 1 Overexpression is Associated with Metastasis of Pancreatic Ductal Adenocarcinoma (PDAC) and Promotes Migration and Growth of PDAC Cells", "doi": "10.12659/msm.896697", "year": 2016 } ] } }, { "id": 40176, "drug": "Canagliflozin", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "suppresses", "mediator": "PD-L1", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "overall survival", "outcome_type": "phenotype", "outcome_domain": "glioblastoma", "score": 0.21972245773362195, "filtered_score": 0.21972245773362195, "filter_reason": null, "outreach_score": 0.21972245773362195, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "canagliflozin", "mediator_canonical": "PD-L1", "outcome_canonical": null, "ab_count": 2, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "38816549", "title": "SGLT2 inhibition eliminates senescent cells and alleviates pathological aging", "doi": "10.1038/s43587-024-00642-y", "year": 2024 }, { "pmid": "36594471", "title": "Canagliflozin primes antitumor immunity by triggering PD-L1 degradation in endocytic recycling", "doi": "10.1172/jci154754", "year": 2023 } ], "bc": [ { "pmid": "40002543", "title": "Prognostic Biomarkers in Isocitrate Dehydrogenase Wild-Type Glioblastoma: A Focus on B7-H3", "doi": "10.3390/brainsci15020212", "year": 2025 }, { "pmid": "37529045", "title": "Plasma PD-L1 as a biomarker in the clinical management of glioblastoma multiforme—a retrospective cohort study", "doi": "10.3389/fimmu.2023.1202098", "year": 2023 } ] } }, { "id": 32918, "drug": "5-ASA", "drug_type": "drug", "drug_domain": "inflammatory_bowel_disease", "predicate_ab": "inhibits", "mediator": "miR-155", "mediator_type": "gene", "predicate_bc": "predicts", "outcome": "epilepsy", "outcome_type": "disease", "outcome_domain": "epilepsy", "score": 0.21972245773362195, "filtered_score": 0.21972245773362195, "filter_reason": null, "outreach_score": 0.21972245773362195, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "preclinical_only", "clinical_trial_nct_ids": [ "NCT07421661" ], "literature_status": "novel_signal", "drug_canonical": "5-asa", "mediator_canonical": "mir-155", "outcome_canonical": "epilepsy", "ab_count": 2, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "34987126", "title": "5-aminosalicylic acid inhibits the expression of oncomiRs and pro-inflammatory microRNAs: an in vitro study.", "doi": "10.26402/jpp.2021.4.04", "year": 2021 } ], "bc": [ { "pmid": "35928925", "title": "Expression of miR-155 in Serum Exosomes in Children with Epilepsy and Its Diagnostic Value", "doi": "10.1155/2022/7979500", "year": 2022 }, { "pmid": "30928987", "title": "Silencing MicroRNA-155 Attenuates Kainic Acid-Induced Seizure by Inhibiting Microglia Activation", "doi": "10.1159/000496344", "year": 2019 } ] } }, { "id": 55096, "drug": "Dimethyl fumarate", "drug_type": "drug", "drug_domain": "multiple_sclerosis", "predicate_ab": "upregulates", "mediator": "Nrf2", "mediator_type": "gene", "predicate_bc": "increases", "outcome": "diabetic cardiomyopathy", "outcome_type": "disease", "outcome_domain": "heart_failure", "score": 0.21972245773362195, "filtered_score": 0.21972245773362195, "filter_reason": null, "outreach_score": 0.21972245773362195, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 2, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "38383481", "title": "Dimethyl fumarate improves cognitive impairment and neuroinflammation in mice with Alzheimer’s disease", "doi": "10.1186/s12974-024-03046-2", "year": 2024 }, { "pmid": "35782648", "title": "Dimethyl fumarate ameliorates lipopolysaccharide-induced acute lung injury by inhibiting NLRP3 inflammasome-mediated pyroptosis through enhancing Nrf2 signaling", "doi": "10.1093/toxres/tfac020", "year": 2022 } ], "bc": [ { "pmid": "38308838", "title": "Nrf2 prevents diabetic cardiomyopathy via antioxidant effect and normalization of glucose and lipid metabolism in the heart", "doi": "10.1002/jcp.31149", "year": 2024 }, { "pmid": "32948607", "title": "Autophagy Inhibition Enables Nrf2 to Exaggerate the Progression of Diabetic Cardiomyopathy in Mice", "doi": "10.2337/db19-1176", "year": 2020 } ] } }, { "id": 31933, "drug": "procyanidin B1", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "downregulates", "mediator": "Nrf2", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "rheumatoid arthritis", "outcome_type": "disease", "outcome_domain": "rheumatoid_arthritis", "score": 0.21972245773362195, "filtered_score": 0.21972245773362195, "filter_reason": null, "outreach_score": 0.21972245773362195, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "procyanidin b1", "mediator_canonical": "NRF2", "outcome_canonical": "rheumatoid arthritis", "ab_count": 2, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "39293861", "title": "Procyanidin B1 Promotes PSMC3‐NRF2 Ubiquitination to Induce Ferroptosis in Glioblastoma", "doi": "10.1002/ptr.8328", "year": 2024 } ], "bc": [ { "pmid": "40247798", "title": "Emerging Therapeutic Targets in Rheumatoid Arthritis: Focusing on HIF-1α, Nrf2, STATs, and RORγt", "doi": "10.2174/0113894501372670250408074908", "year": 2025 }, { "pmid": "36574898", "title": "Expression of Nrf2 protein in serum of patients with rheumatoid arthritis: A novel indicator for disease activity and disease prognosis", "doi": "10.1016/j.clinbiochem.2022.12.011", "year": 2022 } ] } }, { "id": 31935, "drug": "procyanidin B1", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "downregulates", "mediator": "Nrf2", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "disease activity", "outcome_type": "phenotype", "outcome_domain": "rheumatoid_arthritis", "score": 0.21972245773362195, "filtered_score": 0.21972245773362195, "filter_reason": null, "outreach_score": 0.21972245773362195, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "procyanidin b1", "mediator_canonical": "NRF2", "outcome_canonical": "disease activity", "ab_count": 2, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "39293861", "title": "Procyanidin B1 Promotes PSMC3‐NRF2 Ubiquitination to Induce Ferroptosis in Glioblastoma", "doi": "10.1002/ptr.8328", "year": 2024 } ], "bc": [ { "pmid": "36574898", "title": "Expression of Nrf2 protein in serum of patients with rheumatoid arthritis: A novel indicator for disease activity and disease prognosis", "doi": "10.1016/j.clinbiochem.2022.12.011", "year": 2022 } ] } }, { "id": 23220, "drug": "glycyrrhizin", "drug_type": "drug", "drug_domain": "multiple_sclerosis", "predicate_ab": "suppresses", "mediator": "HMGB1", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "drug resistance", "outcome_type": "phenotype", "outcome_domain": "epilepsy", "score": 0.21972245773362195, "filtered_score": 0.21972245773362195, "filter_reason": null, "outreach_score": 0.21972245773362195, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "glycyrrhizin", "mediator_canonical": "HMGB1", "outcome_canonical": null, "ab_count": 2, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "30013568", "title": "Glycyrrhizin Protects Mice Against Experimental Autoimmune Encephalomyelitis by Inhibiting High-Mobility Group Box 1 (HMGB1) Expression and Neuronal HMGB1 Release", "doi": "10.3389/fimmu.2018.01518", "year": 2018 } ], "bc": [ { "pmid": "39466324", "title": "Clinical and biochemical assessments of circulating High Mobility Group Box Protein1 in children with epilepsy: relation to cognitive function and drug responsiveness", "doi": "10.1007/s10072-024-07795-z", "year": 2024 }, { "pmid": "31241711", "title": "Circulating high mobility group box-1 and toll-like receptor 4 expressions increase the risk and severity of epilepsy", "doi": "10.1590/1414-431x20197374", "year": 2019 } ] } }, { "id": 35489, "drug": "IDMF", "drug_type": "drug", "drug_domain": "multiple_sclerosis", "predicate_ab": "activates", "mediator": "Nrf2", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "disease activity", "outcome_type": "phenotype", "outcome_domain": "rheumatoid_arthritis", "score": 0.21972245773362195, "filtered_score": 0.21972245773362195, "filter_reason": null, "outreach_score": 0.21972245773362195, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "idmf", "mediator_canonical": "NRF2", "outcome_canonical": "disease activity", "ab_count": 2, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "35455458", "title": "Transcriptomic Analysis of Fumarate Compounds Identifies Unique Effects of Isosorbide Di-(Methyl Fumarate) on NRF2, NF-kappaB and IRF1 Pathway Genes", "doi": "10.3390/ph15040461", "year": 2022 }, { "pmid": "34909741", "title": "A Sensitization-Free Dimethyl Fumarate Prodrug, Isosorbide Di-(Methyl Fumarate), Provides a Topical Treatment Candidate for Psoriasis", "doi": "10.1016/j.xjidi.2021.100040", "year": 2021 } ], "bc": [ { "pmid": "36574898", "title": "Expression of Nrf2 protein in serum of patients with rheumatoid arthritis: A novel indicator for disease activity and disease prognosis", "doi": "10.1016/j.clinbiochem.2022.12.011", "year": 2022 } ] } }, { "id": 33514, "drug": "p-Hydroxybenzaldehyde", "drug_type": "drug", "drug_domain": "inflammatory_bowel_disease", "predicate_ab": "upregulates", "mediator": "Nrf2", "mediator_type": "protein", "predicate_bc": "causes", "outcome": "chemoresistance", "outcome_type": "phenotype", "outcome_domain": "pancreatic_cancer", "score": 0.21972245773362195, "filtered_score": 0.21972245773362195, "filter_reason": null, "outreach_score": 0.21972245773362195, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "p-hydroxybenzaldehyde", "mediator_canonical": "NRF2", "outcome_canonical": null, "ab_count": 2, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "39128305", "title": "p-Hydroxy benzaldehyde, a phenolic compound from Nostoc commune, ameliorates DSS-induced colitis against oxidative stress via the Nrf2/HO-1/NQO-1/NF-κB/AP-1 pathway", "doi": "10.1016/j.phymed.2024.155941", "year": 2024 } ], "bc": [ { "pmid": "31911550", "title": "Undermining Glutaminolysis Bolsters Chemotherapy While NRF2 Promotes Chemoresistance in KRAS-Driven Pancreatic Cancers", "doi": "10.1158/0008-5472.can-19-1363", "year": 2020 }, { "pmid": "30735911", "title": "Digoxin sensitizes gemcitabine-resistant pancreatic cancer cells to gemcitabine via inhibiting Nrf2 signaling pathway", "doi": "10.1016/j.redox.2019.101131", "year": 2019 } ] } }, { "id": 7653, "drug": "glycyrrhizin", "drug_type": "drug", "drug_domain": "als", "predicate_ab": "binds_to", "mediator": "HMGB1", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "cognitive function", "outcome_type": "phenotype", "outcome_domain": "epilepsy", "score": 0.21972245773362195, "filtered_score": 0.21972245773362195, "filter_reason": null, "outreach_score": 0.21972245773362195, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "glycyrrhizin", "mediator_canonical": "HMGB1", "outcome_canonical": "cognitive function", "ab_count": 2, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41139682", "title": "Therapeutic potential of glycyrrhizin in nervous system diseases", "doi": "10.1097/cm9.0000000000003806", "year": 2025 } ], "bc": [ { "pmid": "39466324", "title": "Clinical and biochemical assessments of circulating High Mobility Group Box Protein1 in children with epilepsy: relation to cognitive function and drug responsiveness", "doi": "10.1007/s10072-024-07795-z", "year": 2024 }, { "pmid": "32538745", "title": "Correlation of MMP-9 and HMGB1 expression with the cognitive function in patients with epilepsy and factors affecting the prognosis", "doi": "10.14715/cmb/2020.66.3.6", "year": 2020 } ] } }, { "id": 19718, "drug": "glycyrrhizin", "drug_type": "drug", "drug_domain": "als", "predicate_ab": "binds_to", "mediator": "HMGB1", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "Multiple Sclerosis", "outcome_type": "disease", "outcome_domain": "multiple_sclerosis", "score": 0.21972245773362195, "filtered_score": 0.21972245773362195, "filter_reason": null, "outreach_score": 0.21972245773362195, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "glycyrrhizin", "mediator_canonical": "HMGB1", "outcome_canonical": "multiple sclerosis", "ab_count": 2, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41139682", "title": "Therapeutic potential of glycyrrhizin in nervous system diseases", "doi": "10.1097/cm9.0000000000003806", "year": 2025 } ], "bc": [ { "pmid": "35263889", "title": "Does the Serum Expression Level of High-Mobility Group Box 1 (HMGB1) in Multiple Sclerosis Patients have a Relationship with Physical and Psychological Status? A 12-Month Follow-Up Study on Newly Diagnosed MS Patients", "doi": "10.4103/0028-3886.338707", "year": 2022 }, { "pmid": "31663345", "title": "Decreased plasma levels of 25(OH)D in multiple sclerosis patients. Correlation with disease severity expressed by EDSS, MSSS, progression index and Herbert´s scale severity grade", "doi": "10.4149/bll_2019_120", "year": 2019 } ] } }, { "id": 47021, "drug": "ketogenic diet", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "downregulates", "mediator": "Kynurenine", "mediator_type": "biomarker", "predicate_bc": "predicts", "outcome": "ventricular remodeling", "outcome_type": "disease", "outcome_domain": "heart_failure", "score": 0.21972245773362195, "filtered_score": 0.21972245773362195, "filter_reason": null, "outreach_score": 0.21972245773362195, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 2, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "29605816", "title": "Regulation of kynurenine metabolism by a ketogenic diet", "doi": "10.1194/jlr.m079251", "year": 2018 } ], "bc": [ { "pmid": "37450589", "title": "Targeting gut microbiota–derived kynurenine to predict and protect the remodeling of the pressure-overloaded young heart", "doi": "10.1126/sciadv.adg7417", "year": 2023 } ] } }, { "id": 51950, "drug": "modified citrus pectin", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "inhibits", "mediator": "galectin-3", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "all-cause mortality", "outcome_type": "phenotype", "outcome_domain": "type_2_diabetes", "score": 0.21972245773362195, "filtered_score": 0.21972245773362195, "filter_reason": null, "outreach_score": 0.21972245773362195, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 2, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "33532663", "title": "Galectin-3 Inhibition With Modified Citrus Pectin in Hypertension", "doi": "10.1016/j.jacbts.2020.10.006", "year": 2021 }, { "pmid": "32172066", "title": "Modified citrus pectin ameliorates myocardial fibrosis and inflammation via suppressing galectin-3 and TLR4/MyD88/NF-κB signaling pathway", "doi": "10.1016/j.biopha.2020.110071", "year": 2020 } ], "bc": [ { "pmid": "30378236", "title": "Galectin‐3 and risk of cardiovascular events and all‐cause mortality in type 2 diabetes", "doi": "10.1002/dmrr.3093", "year": 2018 } ] } }, { "id": 40800, "drug": "pioglitazone", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "activates", "mediator": "SIRT1", "mediator_type": "protein", "predicate_bc": "increases", "outcome": "proliferation", "outcome_type": "phenotype", "outcome_domain": "pancreatic_cancer", "score": 0.21972245773362195, "filtered_score": 0.21972245773362195, "filter_reason": null, "outreach_score": 0.21972245773362195, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "completed", "clinical_trial_nct_ids": [ "NCT00819325" ], "literature_status": "reproduces_known", "drug_canonical": "pioglitazone", "mediator_canonical": "SIRT1", "outcome_canonical": null, "ab_count": 2, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37934372", "title": "Pioglitazone attenuates tamoxifen-induced liver damage in rats via modulating Keap1/Nrf2/HO-1 and SIRT1/Notch1 signaling pathways: In-vivo investigations, and molecular docking analysis", "doi": "10.1007/s11033-023-08847-x", "year": 2023 }, { "pmid": "32881246", "title": "Pioglitazone alleviates cisplatin nephrotoxicity by suppressing mitochondria‐mediated apoptosis via SIRT1/p53 signalling", "doi": "10.1111/jcmm.15782", "year": 2020 } ], "bc": [ { "pmid": "34163012", "title": "SIRT1 coordinates with the CRL4B complex to regulate pancreatic cancer stem cells to promote tumorigenesis", "doi": "10.1038/s41418-021-00821-z", "year": 2021 }, { "pmid": "27494892", "title": "Sirtuin 1 stimulates the proliferation and the expression of glycolysis genes in pancreatic neoplastic lesions", "doi": "10.18632/oncotarget.11013", "year": 2016 } ] } }, { "id": 40802, "drug": "liraglutide", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "inhibits", "mediator": "SIRT1", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "pancreatic cancer", "outcome_type": "disease", "outcome_domain": "pancreatic_cancer", "score": 0.21972245773362195, "filtered_score": 0.21972245773362195, "filter_reason": null, "outreach_score": 0.21972245773362195, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "completed", "clinical_trial_nct_ids": [ "NCT02475499" ], "literature_status": "reproduces_known", "drug_canonical": "liraglutide", "mediator_canonical": "SIRT1", "outcome_canonical": "pancreatic cancer", "ab_count": 2, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "29328405", "title": "Liraglutide repairs the infarcted heart: The role of the SIRT1/Parkin/mitophagy pathway", "doi": "10.3892/mmr.2018.8371", "year": 2018 }, { "pmid": "30575282", "title": "Effect of liraglutide on the Janus kinase/signal transducer and transcription activator (JAK/STAT) pathway in diabetic kidney disease in db/db mice and in cultured endothelial cells", "doi": "10.1111/1753-0407.12891", "year": 2018 } ], "bc": [ { "pmid": "34163012", "title": "SIRT1 coordinates with the CRL4B complex to regulate pancreatic cancer stem cells to promote tumorigenesis", "doi": "10.1038/s41418-021-00821-z", "year": 2021 }, { "pmid": "28351313", "title": "SIRT1 promotes the proliferation and metastasis of human pancreatic cancer cells", "doi": "10.1177/1010428317691180", "year": 2017 } ] } }, { "id": 39603, "drug": "liraglutide", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "downregulates", "mediator": "PCSK9", "mediator_type": "protein", "predicate_bc": "increases", "outcome": "Aβ accumulation", "outcome_type": "phenotype", "outcome_domain": "alzheimer", "score": 0.21972245773362195, "filtered_score": 0.21972245773362195, "filter_reason": null, "outreach_score": 0.21972245773362195, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "liraglutide", "mediator_canonical": "pcsk9", "outcome_canonical": "aβ accumulation", "ab_count": 2, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "29618348", "title": "Liraglutide downregulates hepatic LDL receptor and PCSK9 expression in HepG2 cells and db/db mice through a HNF-1a dependent mechanism", "doi": "10.1186/s12933-018-0689-9", "year": 2018 } ], "bc": [ { "pmid": "41465790", "title": "The Roles of PCSK9 in Alzheimer’s Disease: A Systematic Review of Clinical, Genetic, and Preclinical Evidence", "doi": "10.3390/life15121851", "year": 2025 } ] } }, { "id": 51171, "drug": "Melatonin", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "inhibits", "mediator": "Mst1", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "IBD", "outcome_type": "disease", "outcome_domain": "inflammatory_bowel_disease", "score": 0.21972245773362195, "filtered_score": 0.21972245773362195, "filter_reason": null, "outreach_score": 0.21972245773362195, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 2, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "30063115", "title": "Melatonin activates Parkin translocation and rescues the impaired mitophagy activity of diabetic cardiomyopathy through Mst1 inhibition", "doi": "10.1111/jcmm.13802", "year": 2018 }, { "pmid": "27696525", "title": "Melatonin alleviates postinfarction cardiac remodeling and dysfunction by inhibiting Mst1", "doi": "10.1111/jpi.12368", "year": 2016 } ], "bc": [ { "pmid": "39414629", "title": "Identification of potential novel targets for treating inflammatory bowel disease using Mendelian randomization analysis", "doi": "10.1007/s00384-024-04744-2", "year": 2024 }, { "pmid": "36857861", "title": "Therapeutic targets for inflammatory bowel disease: proteome-wide Mendelian randomization and colocalization analyses", "doi": "10.1016/j.ebiom.2023.104494", "year": 2023 } ] } }, { "id": 35495, "drug": "L-ascorbic acid, N-acetylcysteine, and dimethyl fumarate", "drug_type": "drug", "drug_domain": "multiple_sclerosis", "predicate_ab": "activates", "mediator": "Nrf2", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "rheumatoid arthritis", "outcome_type": "disease", "outcome_domain": "rheumatoid_arthritis", "score": 0.21972245773362195, "filtered_score": 0.21972245773362195, "filter_reason": null, "outreach_score": 0.21972245773362195, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "unknown", "drug_canonical": "l-ascorbic acid, n-acetylcysteine, and dimethyl fumarate", "mediator_canonical": "NRF2", "outcome_canonical": "rheumatoid arthritis", "ab_count": 2, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40375363", "title": "Therapeutic combination of L-ascorbic acid, N-acetylcysteine, and dimethyl fumarate in Friedreich’s ataxia: insights from in vitro models", "doi": "10.1080/13510002.2025.2505303", "year": 2025 } ], "bc": [ { "pmid": "40247798", "title": "Emerging Therapeutic Targets in Rheumatoid Arthritis: Focusing on HIF-1α, Nrf2, STATs, and RORγt", "doi": "10.2174/0113894501372670250408074908", "year": 2025 }, { "pmid": "36574898", "title": "Expression of Nrf2 protein in serum of patients with rheumatoid arthritis: A novel indicator for disease activity and disease prognosis", "doi": "10.1016/j.clinbiochem.2022.12.011", "year": 2022 } ] } }, { "id": 33314, "drug": "5-ASA", "drug_type": "drug", "drug_domain": "inflammatory_bowel_disease", "predicate_ab": "inhibits", "mediator": "miR-155", "mediator_type": "gene", "predicate_bc": "correlates_with", "outcome": "multiple sclerosis", "outcome_type": "disease", "outcome_domain": "multiple_sclerosis", "score": 0.21972245773362195, "filtered_score": 0.21972245773362195, "filter_reason": null, "outreach_score": 0.21972245773362195, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "completed", "clinical_trial_nct_ids": [ "NCT02090413" ], "literature_status": "partial_evidence", "drug_canonical": "5-asa", "mediator_canonical": "mir-155", "outcome_canonical": "multiple sclerosis", "ab_count": 2, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "34987126", "title": "5-aminosalicylic acid inhibits the expression of oncomiRs and pro-inflammatory microRNAs: an in vitro study.", "doi": "10.26402/jpp.2021.4.04", "year": 2021 } ], "bc": [ { "pmid": "37032715", "title": "MicroRNA‑155 modulation of CD8+ T‑cell activity personalizes response to disease‑modifying therapies of patients with relapsing‑remitting multiple sclerosis", "doi": "10.3892/mi.2023.80", "year": 2023 }, { "pmid": "34503396", "title": "The expression and prognostic value of miR-146a and miR-155 in Turkish patients with multiple sclerosis", "doi": "10.1080/01616412.2021.1975221", "year": 2021 } ] } }, { "id": 35274, "drug": "IDMF", "drug_type": "drug", "drug_domain": "multiple_sclerosis", "predicate_ab": "activates", "mediator": "Nrf2", "mediator_type": "protein", "predicate_bc": "causes", "outcome": "chemoresistance", "outcome_type": "phenotype", "outcome_domain": "pancreatic_cancer", "score": 0.21972245773362195, "filtered_score": 0.21972245773362195, "filter_reason": null, "outreach_score": 0.21972245773362195, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "idmf", "mediator_canonical": "NRF2", "outcome_canonical": null, "ab_count": 2, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "35455458", "title": "Transcriptomic Analysis of Fumarate Compounds Identifies Unique Effects of Isosorbide Di-(Methyl Fumarate) on NRF2, NF-kappaB and IRF1 Pathway Genes", "doi": "10.3390/ph15040461", "year": 2022 }, { "pmid": "34909741", "title": "A Sensitization-Free Dimethyl Fumarate Prodrug, Isosorbide Di-(Methyl Fumarate), Provides a Topical Treatment Candidate for Psoriasis", "doi": "10.1016/j.xjidi.2021.100040", "year": 2021 } ], "bc": [ { "pmid": "31911550", "title": "Undermining Glutaminolysis Bolsters Chemotherapy While NRF2 Promotes Chemoresistance in KRAS-Driven Pancreatic Cancers", "doi": "10.1158/0008-5472.can-19-1363", "year": 2020 }, { "pmid": "30735911", "title": "Digoxin sensitizes gemcitabine-resistant pancreatic cancer cells to gemcitabine via inhibiting Nrf2 signaling pathway", "doi": "10.1016/j.redox.2019.101131", "year": 2019 } ] } }, { "id": 7650, "drug": "glycyrrhizin", "drug_type": "drug", "drug_domain": "als", "predicate_ab": "binds_to", "mediator": "HMGB1", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "suspected autoimmune epilepsy", "outcome_type": "disease", "outcome_domain": "epilepsy", "score": 0.21972245773362195, "filtered_score": 0.21972245773362195, "filter_reason": null, "outreach_score": 0.21972245773362195, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "glycyrrhizin", "mediator_canonical": "HMGB1", "outcome_canonical": "suspected autoimmune epilepsy", "ab_count": 2, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41139682", "title": "Therapeutic potential of glycyrrhizin in nervous system diseases", "doi": "10.1097/cm9.0000000000003806", "year": 2025 } ], "bc": [ { "pmid": "32547032", "title": "<p>HMGB1/CXCL12-Mediated Immunity and Th17 Cells Might Underlie Highly Suspected Autoimmune Epilepsy in Elderly Individuals</p>", "doi": "10.2147/ndt.s242766", "year": 2020 } ] } }, { "id": 7651, "drug": "AIM4", "drug_type": "drug", "drug_domain": "als", "predicate_ab": "inhibits", "mediator": "TDP-43", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "hippocampal sclerosis", "outcome_type": "disease", "outcome_domain": "epilepsy", "score": 0.21972245773362195, "filtered_score": 0.21972245773362195, "filter_reason": null, "outreach_score": 0.21972245773362195, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "aim4", "mediator_canonical": "TDP-43", "outcome_canonical": "hippocampal sclerosis", "ab_count": 2, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "28000730", "title": "An acridine derivative, [4,5-bis{(N-carboxy methyl imidazolium)methyl}acridine] dibromide, shows anti-TDP-43 aggregation effect in ALS disease models", "doi": "10.1038/srep39490", "year": 2016 } ], "bc": [ { "pmid": "30452409", "title": "TDP-43 Neuropathologic Associations in the Nun Study and the Honolulu-Asia Aging Study", "doi": "10.3233/jad-180162", "year": 2018 } ] } }, { "id": 35276, "drug": "L-ascorbic acid, N-acetylcysteine, and dimethyl fumarate", "drug_type": "drug", "drug_domain": "multiple_sclerosis", "predicate_ab": "activates", "mediator": "Nrf2", "mediator_type": "protein", "predicate_bc": "causes", "outcome": "chemoresistance", "outcome_type": "phenotype", "outcome_domain": "pancreatic_cancer", "score": 0.21972245773362195, "filtered_score": 0.21972245773362195, "filter_reason": null, "outreach_score": 0.21972245773362195, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "unknown", "drug_canonical": "l-ascorbic acid, n-acetylcysteine, and dimethyl fumarate", "mediator_canonical": "NRF2", "outcome_canonical": null, "ab_count": 2, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40375363", "title": "Therapeutic combination of L-ascorbic acid, N-acetylcysteine, and dimethyl fumarate in Friedreich’s ataxia: insights from in vitro models", "doi": "10.1080/13510002.2025.2505303", "year": 2025 } ], "bc": [ { "pmid": "31911550", "title": "Undermining Glutaminolysis Bolsters Chemotherapy While NRF2 Promotes Chemoresistance in KRAS-Driven Pancreatic Cancers", "doi": "10.1158/0008-5472.can-19-1363", "year": 2020 }, { "pmid": "30735911", "title": "Digoxin sensitizes gemcitabine-resistant pancreatic cancer cells to gemcitabine via inhibiting Nrf2 signaling pathway", "doi": "10.1016/j.redox.2019.101131", "year": 2019 } ] } }, { "id": 59105, "drug": "xanthohumol", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "binds_to", "mediator": "AMPK", "mediator_type": "protein", "predicate_bc": "prevents", "outcome": "metabolic dysfunction", "outcome_type": "disease", "outcome_domain": "heart_failure", "score": 0.21972245773362195, "filtered_score": 0.21972245773362195, "filter_reason": null, "outreach_score": 0.21972245773362195, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 2, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37699859", "title": "Xanthohumol relieves arthritis pain in mice by suppressing mitochondrial-mediated inflammation", "doi": "10.1177/17448069231204051", "year": 2023 } ], "bc": [ { "pmid": "37194385", "title": "Adenosine monophosphate‐activated protein kinase is elevated in human cachectic muscle and prevents cancer‐induced metabolic dysfunction in mice", "doi": "10.1002/jcsm.13238", "year": 2023 } ] } }, { "id": 59094, "drug": "HA-AKBA-LCNP", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "downregulates", "mediator": "CD44", "mediator_type": "protein", "predicate_bc": "increases", "outcome": "liver fibrosis", "outcome_type": "disease", "outcome_domain": "heart_failure", "score": 0.21972245773362195, "filtered_score": 0.21972245773362195, "filter_reason": null, "outreach_score": 0.21972245773362195, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 2, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41267073", "title": "Surface-engineered hyaluronic acid-coated lyotropic liquid crystalline nanoparticles for CD44-targeting of 3-Acetyl-11-keto-β-boswellic acid in rheumatoid arthritis treatment", "doi": "10.1186/s12951-025-03846-5", "year": 2025 } ], "bc": [ { "pmid": "34430787", "title": "Cluster of Differentiation 44 Promotes Liver Fibrosis and Serves as a Biomarker in Congestive Hepatopathy", "doi": "10.1002/hep4.1721", "year": 2021 } ] } }, { "id": 7652, "drug": "glycyrrhizin", "drug_type": "drug", "drug_domain": "als", "predicate_ab": "binds_to", "mediator": "HMGB1", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "drug resistance", "outcome_type": "phenotype", "outcome_domain": "epilepsy", "score": 0.21972245773362195, "filtered_score": 0.21972245773362195, "filter_reason": null, "outreach_score": 0.21972245773362195, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "glycyrrhizin", "mediator_canonical": "HMGB1", "outcome_canonical": null, "ab_count": 2, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41139682", "title": "Therapeutic potential of glycyrrhizin in nervous system diseases", "doi": "10.1097/cm9.0000000000003806", "year": 2025 } ], "bc": [ { "pmid": "39466324", "title": "Clinical and biochemical assessments of circulating High Mobility Group Box Protein1 in children with epilepsy: relation to cognitive function and drug responsiveness", "doi": "10.1007/s10072-024-07795-z", "year": 2024 }, { "pmid": "31241711", "title": "Circulating high mobility group box-1 and toll-like receptor 4 expressions increase the risk and severity of epilepsy", "doi": "10.1590/1414-431x20197374", "year": 2019 } ] } }, { "id": 35492, "drug": "L-ascorbic acid, N-acetylcysteine, and dimethyl fumarate", "drug_type": "drug", "drug_domain": "multiple_sclerosis", "predicate_ab": "activates", "mediator": "Nrf2", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "disease activity", "outcome_type": "phenotype", "outcome_domain": "rheumatoid_arthritis", "score": 0.21972245773362195, "filtered_score": 0.21972245773362195, "filter_reason": null, "outreach_score": 0.21972245773362195, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "unknown", "drug_canonical": "l-ascorbic acid, n-acetylcysteine, and dimethyl fumarate", "mediator_canonical": "NRF2", "outcome_canonical": "disease activity", "ab_count": 2, "bc_count": 2, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40375363", "title": "Therapeutic combination of L-ascorbic acid, N-acetylcysteine, and dimethyl fumarate in Friedreich’s ataxia: insights from in vitro models", "doi": "10.1080/13510002.2025.2505303", "year": 2025 } ], "bc": [ { "pmid": "36574898", "title": "Expression of Nrf2 protein in serum of patients with rheumatoid arthritis: A novel indicator for disease activity and disease prognosis", "doi": "10.1016/j.clinbiochem.2022.12.011", "year": 2022 } ] } }, { "id": 38756, "drug": "erianin", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "inhibits", "mediator": "IL-17A", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "inflammatory bowel disease", "outcome_type": "disease", "outcome_domain": "inflammatory_bowel_disease", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "erianin", "mediator_canonical": "il-17a", "outcome_canonical": "inflammatory bowel disease", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37711216", "title": "Erianin alleviates collagen-induced arthritis in mice by inhibiting Th17 cell differentiation", "doi": "10.1515/biol-2022-0703", "year": 2023 } ], "bc": [ { "pmid": "32724117", "title": "Serum interleukin 17A and interleukin 17F in children with inflammatory bowel disease", "doi": "10.1038/s41598-020-69567-x", "year": 2020 }, { "pmid": "27049090", "title": "Relationship between serum interleukin-17 level and inflammatory bowel disease.", "doi": null, "year": 2016 } ] } }, { "id": 23016, "drug": "Fingolimod", "drug_type": "drug", "drug_domain": "multiple_sclerosis", "predicate_ab": "downregulates", "mediator": "mTOR", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "glioblastoma", "outcome_type": "disease", "outcome_domain": "glioblastoma", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "completed", "clinical_trial_nct_ids": [ "NCT02490930" ], "literature_status": "reproduces_known", "drug_canonical": "fingolimod", "mediator_canonical": "mTOR", "outcome_canonical": "glioblastoma", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "30388910", "title": "Fingolimod augments Pemetrexed killing of non-small cell lung cancer and overcomes resistance to ERBB inhibition", "doi": "10.1080/15384047.2018.1538616", "year": 2018 } ], "bc": [ { "pmid": "39622049", "title": "A Dual-Target and Dual-Mechanism Design Strategy by Combining Inhibition and Degradation Together", "doi": "10.1021/jacs.4c11930", "year": 2024 }, { "pmid": "33162811", "title": "Mitochondrial dysfunction contributes to Rapamycin-induced apoptosis of Human Glioblastoma Cells - A synergistic effect with Temozolomide", "doi": "10.7150/ijms.40159", "year": 2020 }, { "pmid": "30793789", "title": "The effect of the mTOR inhibitor rapamycin on glucoCEST signal in a preclinical model of glioblastoma", "doi": "10.1002/mrm.27683", "year": 2019 } ] } }, { "id": 3064, "drug": "preconditioned secretome", "drug_type": "drug", "drug_domain": "als", "predicate_ab": "suppresses", "mediator": "GFAP", "mediator_type": "gene", "predicate_bc": "associated_with", "outcome": "Alzheimer's disease", "outcome_type": "disease", "outcome_domain": "alzheimer", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "preconditioned secretome", "mediator_canonical": "GFAP", "outcome_canonical": "Alzheimer disease", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "36140218", "title": "Intrathecal Injection of the Secretome from ALS Motor Neurons Regulated for miR-124 Expression Prevents Disease Outcomes in SOD1-G93A Mice", "doi": "10.3390/biomedicines10092120", "year": 2022 } ], "bc": [ { "pmid": "38236817", "title": "Large-scale gene expression changes in APP/PSEN1 and GFAP mutation models exhibit high congruence with Alzheimer’s disease", "doi": "10.1371/journal.pone.0291995", "year": 2024 }, { "pmid": "30400085", "title": "Changes in Expression Profiles Revealed by Transcriptomic Analysis in Peripheral Blood Mononuclear Cells of Alzheimer’s Disease Patients", "doi": "10.3233/jad-170205", "year": 2018 }, { "pmid": "30040709", "title": "A Selection of Important Genes and Their Correlated Behavior in Alzheimer’s Disease", "doi": "10.3233/jad-170799", "year": 2018 } ] } }, { "id": 27528, "drug": "exendin-3(9-39)amide", "drug_type": "drug", "drug_domain": "alzheimer", "predicate_ab": "inhibits", "mediator": "GLP-1R", "mediator_type": "protein", "predicate_bc": "decreases", "outcome": "food intake", "outcome_type": "phenotype", "outcome_domain": "type_2_diabetes", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "exendin-3(9-39)amide", "mediator_canonical": "glp-1r", "outcome_canonical": "food intake", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "34356351", "title": "Failure of the Brain Glucagon-Like Peptide-1-Mediated Control of Intestinal Redox Homeostasis in a Rat Model of Sporadic Alzheimer’s Disease", "doi": "10.3390/antiox10071118", "year": 2021 } ], "bc": [ { "pmid": "37729419", "title": "The locus coeruleus contributes to the anorectic, nausea, and autonomic physiological effects of glucagon-like peptide-1", "doi": "10.1126/sciadv.adh0980", "year": 2023 }, { "pmid": "28894301", "title": "Lateral hypothalamic GLP-1 receptors are critical for the control of food reinforcement, ingestive behavior and body weight", "doi": "10.1038/mp.2017.187", "year": 2017 }, { "pmid": "28811293", "title": "The glucagon-like peptide-1 receptor in the ventromedial hypothalamus reduces short-term food intake in male mice by regulating nutrient sensor activity", "doi": "10.1152/ajpendo.00113.2017", "year": 2017 } ] } }, { "id": 37913, "drug": "CEPT", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "downregulates", "mediator": "ASC", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "MCI", "outcome_type": "disease", "outcome_domain": "alzheimer", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "cept", "mediator_canonical": "asc", "outcome_canonical": "mci", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "34581056", "title": "[Therapeutic mechanism of Psammosilene tunicoides extract on rheumatoid arthritis based on NLRP3 inflammasome].", "doi": "10.19540/j.cnki.cjcmm.20210609.701", "year": 2021 } ], "bc": [ { "pmid": "32630059", "title": "The Inflammasome Adaptor Protein ASC in Mild Cognitive Impairment and Alzheimer’s Disease", "doi": "10.3390/ijms21134674", "year": 2020 } ] } }, { "id": 38762, "drug": "tocilizumab", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "downregulates", "mediator": "C-reactive protein", "mediator_type": "biomarker", "predicate_bc": "predicts", "outcome": "Crohn's disease", "outcome_type": "disease", "outcome_domain": "inflammatory_bowel_disease", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "tocilizumab", "mediator_canonical": "c-reactive protein", "outcome_canonical": "crohn's disease", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "39754984", "title": "Anti-IL-6R Ab tocilizumab to treat paraneoplastic inflammatory syndrome of solid cancers", "doi": "10.1016/j.esmoop.2024.104088", "year": 2025 } ], "bc": [ { "pmid": "39878038", "title": "The diagnostic accuracy of plasma and serum calprotectin is inferior to C-reactive protein in patients with suspected Crohn’s disease", "doi": "10.1080/00365521.2025.2459236", "year": 2025 }, { "pmid": "36294408", "title": "Evaluation of Fecal Calprotectin, Serum C-Reactive Protein, Erythrocyte Sedimentation Rate, Seromucoid and Procalcitonin in the Diagnostics and Monitoring of Crohn’s Disease in Children", "doi": "10.3390/jcm11206086", "year": 2022 }, { "pmid": "34682868", "title": "Machine Learning Prediction Model for Inflammatory Bowel Disease Based on Laboratory Markers. Working Model in a Discovery Cohort Study", "doi": "10.3390/jcm10204745", "year": 2021 } ] } }, { "id": 39647, "drug": "pioglitazone", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "suppresses", "mediator": "Rac1", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "Alzheimer's disease", "outcome_type": "disease", "outcome_domain": "alzheimer", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "completed", "clinical_trial_nct_ids": [ "NCT00982202", "NCT01931566", "NCT02284906" ], "literature_status": "reproduces_known", "drug_canonical": "pioglitazone", "mediator_canonical": "rac1", "outcome_canonical": "Alzheimer disease", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "29554649", "title": "Pioglitazone Confers Neuroprotection Against Ischemia-Induced Pyroptosis due to its Inhibitory Effects on HMGB-1/RAGE and Rac1/ROS Pathway by Activating PPAR-ɤ", "doi": "10.1159/000488183", "year": 2018 } ], "bc": [ { "pmid": "31321704", "title": "Inhibition of Rac1-dependent forgetting alleviates memory deficits in animal models of Alzheimer’s disease", "doi": "10.1007/s13238-019-0641-0", "year": 2019 }, { "pmid": "30005699", "title": "Rac1 activation links tau hyperphosphorylation and Aβ dysmetabolism in Alzheimer’s disease", "doi": "10.1186/s40478-018-0567-4", "year": 2018 } ] } }, { "id": 39802, "drug": "liraglutide", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "induces", "mediator": "FGF21", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "depression severity", "outcome_type": "phenotype", "outcome_domain": "depression", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "liraglutide", "mediator_canonical": "fgf21", "outcome_canonical": "depression severity", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37030441", "title": "Fibroblast growth factor-21 is required for weight loss induced by the glucagon-like peptide-1 receptor agonist liraglutide in male mice fed high carbohydrate diets", "doi": "10.1016/j.molmet.2023.101718", "year": 2023 }, { "pmid": "33851458", "title": "Hepatic Fibroblast Growth Factor 21 Is Involved in Mediating Functions of Liraglutide in Mice With Dietary Challenge", "doi": "10.1002/hep.31856", "year": 2021 }, { "pmid": "30827929", "title": "Liver-derived fibroblast growth factor 21 mediates effects of glucagon-like peptide-1 in attenuating hepatic glucose output", "doi": "10.1016/j.ebiom.2019.02.037", "year": 2019 } ], "bc": [ { "pmid": "35017468", "title": "Fibroblast growth factor 21 (FGF21) is increased in MDD and interacts with body mass index (BMI) to affect depression trajectory", "doi": "10.1038/s41398-021-01679-y", "year": 2022 } ] } }, { "id": 35502, "drug": "LLL12b", "drug_type": "drug", "drug_domain": "multiple_sclerosis", "predicate_ab": "inhibits", "mediator": "STAT3", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "prurigo nodularis", "outcome_type": "disease", "outcome_domain": "rheumatoid_arthritis", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "lll12b", "mediator_canonical": "STAT3", "outcome_canonical": "prurigo nodularis", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "33411696", "title": "A STAT3 inhibitor ameliorates CNS autoimmunity by restoring Teff:Treg Balance", "doi": "10.1172/jci.insight.142376", "year": 2021 } ], "bc": [ { "pmid": "39912139", "title": "Translating tissue expression of STAT 1, 3 and 6 in prurigo nodularis to clinical efficacy of oral tofacitinib – A prospective single-arm investigational study", "doi": "10.25259/ijdvl_1017_2024", "year": 2025 }, { "pmid": "40162359", "title": "Successful Use of Tofacitinib in Paediatric Prurigo Nodularis: A Report of Four Cases", "doi": "10.4103/ijd.ijd_842_24", "year": 2025 }, { "pmid": "37521237", "title": "A case of recalcitrant prurigo nodularis with heightened expression of STAT 3 and STAT 6 and its dramatic response to tofacitinib", "doi": "10.4103/idoj.idoj_508_22", "year": 2023 } ] } }, { "id": 36861, "drug": "Indox", "drug_type": "drug", "drug_domain": "pancreatic_cancer", "predicate_ab": "downregulates", "mediator": "MMP-9", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "ulcerative colitis", "outcome_type": "disease", "outcome_domain": "inflammatory_bowel_disease", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "indox", "mediator_canonical": "MMP9", "outcome_canonical": "ulcerative colitis", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "31671317", "title": "Indirubin 3′-Oxime Inhibits Migration, Invasion, and Metastasis in Mice Bearing Spontaneously Occurring Pancreatic Cancer via Blocking the RAF/ERK, AKT, and SAPK/JNK Pathways", "doi": "10.1016/j.tranon.2019.08.010", "year": 2019 } ], "bc": [ { "pmid": "35566780", "title": "Are Matrix Metalloproteinase-9 and Tissue Inhibitor of Metalloproteinase-1 Useful as Markers in Diagnostic Management of Children with Newly Diagnosed Ulcerative Colitis?", "doi": "10.3390/jcm11092655", "year": 2022 }, { "pmid": "27034654", "title": "Expressions of Matrix Metalloproteinases (MMP-2, MMP-7, and MMP-9) and Their Inhibitors (TIMP-1, TIMP-2) in Inflammatory Bowel Diseases", "doi": "10.1155/2016/2456179", "year": 2016 }, { "pmid": "26514773", "title": "Matrix metalloproteinase 9-induced increase in intestinal epithelial tight junction permeability contributes to the severity of experimental DSS colitis", "doi": "10.1152/ajpgi.00256.2015", "year": 2015 } ] } }, { "id": 37289, "drug": "Betulinic acid", "drug_type": "drug", "drug_domain": "pancreatic_cancer", "predicate_ab": "inhibits", "mediator": "STAT3", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "prurigo nodularis", "outcome_type": "disease", "outcome_domain": "rheumatoid_arthritis", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "betulinic acid", "mediator_canonical": "STAT3", "outcome_canonical": "prurigo nodularis", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37415745", "title": "Betulinic acid-mediating miRNA-365 inhibited the progression of pancreatic cancer", "doi": "10.32604/or.2023.026959", "year": 2023 } ], "bc": [ { "pmid": "39912139", "title": "Translating tissue expression of STAT 1, 3 and 6 in prurigo nodularis to clinical efficacy of oral tofacitinib – A prospective single-arm investigational study", "doi": "10.25259/ijdvl_1017_2024", "year": 2025 }, { "pmid": "40162359", "title": "Successful Use of Tofacitinib in Paediatric Prurigo Nodularis: A Report of Four Cases", "doi": "10.4103/ijd.ijd_842_24", "year": 2025 }, { "pmid": "37521237", "title": "A case of recalcitrant prurigo nodularis with heightened expression of STAT 3 and STAT 6 and its dramatic response to tofacitinib", "doi": "10.4103/idoj.idoj_508_22", "year": 2023 } ] } }, { "id": 38286, "drug": "tofacitinib", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "downregulates", "mediator": "IFN-γ", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "ketogenic diet adaptation", "outcome_type": "phenotype", "outcome_domain": "epilepsy", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "tofacitinib", "mediator_canonical": "ifn-γ", "outcome_canonical": "ketogenic diet adaptation", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "33899926", "title": "Lymphocyte modulation by tofacitinib in patients with rheumatoid arthritis", "doi": "10.1111/cei.13609", "year": 2021 }, { "pmid": "32616791", "title": "Tofacitinib treatment aggravates Staphylococcus aureus septic arthritis, but attenuates sepsis and enterotoxin induced shock in mice", "doi": "10.1038/s41598-020-67928-0", "year": 2020 }, { "pmid": "31638166", "title": "The JAK inhibitor tofacitinib ameliorates immune‑mediated liver injury in mice", "doi": "10.3892/mmr.2019.10750", "year": 2019 } ], "bc": [ { "pmid": "32969535", "title": "Adaptation to a ketogenic diet modulates adaptive and mucosal immune markers in trained male endurance athletes", "doi": "10.1111/sms.13833", "year": 2020 } ] } }, { "id": 38439, "drug": "Phlorizin", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "downregulates", "mediator": "mTOR", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "glioblastoma", "outcome_type": "disease", "outcome_domain": "glioblastoma", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "phlorizin", "mediator_canonical": "mTOR", "outcome_canonical": "glioblastoma", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "38688626", "title": "Phlorizin Regulates Synovial Hyperplasia and Inflammation in Rats With Rheumatoid Arthritis by Regulating the mTOR Pathway", "doi": "10.21873/invivo.13553", "year": 2024 } ], "bc": [ { "pmid": "39622049", "title": "A Dual-Target and Dual-Mechanism Design Strategy by Combining Inhibition and Degradation Together", "doi": "10.1021/jacs.4c11930", "year": 2024 }, { "pmid": "33162811", "title": "Mitochondrial dysfunction contributes to Rapamycin-induced apoptosis of Human Glioblastoma Cells - A synergistic effect with Temozolomide", "doi": "10.7150/ijms.40159", "year": 2020 }, { "pmid": "30793789", "title": "The effect of the mTOR inhibitor rapamycin on glucoCEST signal in a preclinical model of glioblastoma", "doi": "10.1002/mrm.27683", "year": 2019 } ] } }, { "id": 35514, "drug": "Bacoside-A", "drug_type": "drug", "drug_domain": "multiple_sclerosis", "predicate_ab": "downregulates", "mediator": "IL-17A", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "rheumatoid arthritis", "outcome_type": "disease", "outcome_domain": "rheumatoid_arthritis", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "bacoside-a", "mediator_canonical": "il-17a", "outcome_canonical": "rheumatoid arthritis", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "30551384", "title": "Bacoside-A inhibits inflammatory cytokines and chemokine in experimental autoimmune encephalomyelitis", "doi": "10.1016/j.biopha.2018.10.188", "year": 2018 } ], "bc": [ { "pmid": "37926850", "title": "Genetic association between interleukin-17 and susceptibility to rheumatoid arthritis", "doi": "10.1186/s12920-023-01713-6", "year": 2023 }, { "pmid": "34321563", "title": "The role of IL-18 in addition to Th17 cytokines in rheumatoid arthritis development and treatment in women", "doi": "10.1038/s41598-021-94841-x", "year": 2021 }, { "pmid": "32048307", "title": "The prostaglandin E2 increases the production of IL‐17 and the expression of costimulatory molecules on γδ T cells in rheumatoid arthritis", "doi": "10.1111/sji.12872", "year": 2020 } ] } }, { "id": 35505, "drug": "D11", "drug_type": "drug", "drug_domain": "multiple_sclerosis", "predicate_ab": "activates", "mediator": "STAT3", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "prurigo nodularis", "outcome_type": "disease", "outcome_domain": "rheumatoid_arthritis", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "d11", "mediator_canonical": "STAT3", "outcome_canonical": "prurigo nodularis", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "30856328", "title": "Phenotypic Screening-Based Identification of 3,4-Disubstituted Piperidine Derivatives as Macrophage M2 Polarization Modulators: An Opportunity for Treating Multiple Sclerosis", "doi": "10.1021/acs.jmedchem.8b01635", "year": 2019 } ], "bc": [ { "pmid": "39912139", "title": "Translating tissue expression of STAT 1, 3 and 6 in prurigo nodularis to clinical efficacy of oral tofacitinib – A prospective single-arm investigational study", "doi": "10.25259/ijdvl_1017_2024", "year": 2025 }, { "pmid": "40162359", "title": "Successful Use of Tofacitinib in Paediatric Prurigo Nodularis: A Report of Four Cases", "doi": "10.4103/ijd.ijd_842_24", "year": 2025 }, { "pmid": "37521237", "title": "A case of recalcitrant prurigo nodularis with heightened expression of STAT 3 and STAT 6 and its dramatic response to tofacitinib", "doi": "10.4103/idoj.idoj_508_22", "year": 2023 } ] } }, { "id": 35519, "drug": "Pien Tze Huang", "drug_type": "drug", "drug_domain": "multiple_sclerosis", "predicate_ab": "downregulates", "mediator": "IL-17A", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "rheumatoid arthritis", "outcome_type": "disease", "outcome_domain": "rheumatoid_arthritis", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "pien tze huang", "mediator_canonical": "il-17a", "outcome_canonical": "rheumatoid arthritis", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "30429789", "title": "Pien Tze Huang Alleviates Relapsing-Remitting Experimental Autoimmune Encephalomyelitis Mice by Regulating Th1 and Th17 Cells", "doi": "10.3389/fphar.2018.01237", "year": 2018 } ], "bc": [ { "pmid": "37926850", "title": "Genetic association between interleukin-17 and susceptibility to rheumatoid arthritis", "doi": "10.1186/s12920-023-01713-6", "year": 2023 }, { "pmid": "34321563", "title": "The role of IL-18 in addition to Th17 cytokines in rheumatoid arthritis development and treatment in women", "doi": "10.1038/s41598-021-94841-x", "year": 2021 }, { "pmid": "32048307", "title": "The prostaglandin E2 increases the production of IL‐17 and the expression of costimulatory molecules on γδ T cells in rheumatoid arthritis", "doi": "10.1111/sji.12872", "year": 2020 } ] } }, { "id": 35518, "drug": "fingolimod", "drug_type": "drug", "drug_domain": "multiple_sclerosis", "predicate_ab": "suppresses", "mediator": "IL-17A", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "rheumatoid arthritis", "outcome_type": "disease", "outcome_domain": "rheumatoid_arthritis", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "fingolimod", "mediator_canonical": "il-17a", "outcome_canonical": "rheumatoid arthritis", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "32655793", "title": "The immunosuppressant fingolimod ameliorates experimental autoimmune myasthenia gravis by regulating T-cell balance and cytokine secretion.", "doi": null, "year": 2020 } ], "bc": [ { "pmid": "37926850", "title": "Genetic association between interleukin-17 and susceptibility to rheumatoid arthritis", "doi": "10.1186/s12920-023-01713-6", "year": 2023 }, { "pmid": "34321563", "title": "The role of IL-18 in addition to Th17 cytokines in rheumatoid arthritis development and treatment in women", "doi": "10.1038/s41598-021-94841-x", "year": 2021 }, { "pmid": "32048307", "title": "The prostaglandin E2 increases the production of IL‐17 and the expression of costimulatory molecules on γδ T cells in rheumatoid arthritis", "doi": "10.1111/sji.12872", "year": 2020 } ] } }, { "id": 35504, "drug": "lenalidomide", "drug_type": "drug", "drug_domain": "multiple_sclerosis", "predicate_ab": "activates", "mediator": "STAT3", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "prurigo nodularis", "outcome_type": "disease", "outcome_domain": "rheumatoid_arthritis", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "lenalidomide", "mediator_canonical": "STAT3", "outcome_canonical": "prurigo nodularis", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "29445144", "title": "Lenalidomide regulates CNS autoimmunity by promoting M2 macrophages polarization", "doi": "10.1038/s41419-018-0290-x", "year": 2018 } ], "bc": [ { "pmid": "39912139", "title": "Translating tissue expression of STAT 1, 3 and 6 in prurigo nodularis to clinical efficacy of oral tofacitinib – A prospective single-arm investigational study", "doi": "10.25259/ijdvl_1017_2024", "year": 2025 }, { "pmid": "40162359", "title": "Successful Use of Tofacitinib in Paediatric Prurigo Nodularis: A Report of Four Cases", "doi": "10.4103/ijd.ijd_842_24", "year": 2025 }, { "pmid": "37521237", "title": "A case of recalcitrant prurigo nodularis with heightened expression of STAT 3 and STAT 6 and its dramatic response to tofacitinib", "doi": "10.4103/idoj.idoj_508_22", "year": 2023 } ] } }, { "id": 35498, "drug": "DMF", "drug_type": "drug", "drug_domain": "multiple_sclerosis", "predicate_ab": "inhibits", "mediator": "STAT3", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "prurigo nodularis", "outcome_type": "disease", "outcome_domain": "rheumatoid_arthritis", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "dmf", "mediator_canonical": "STAT3", "outcome_canonical": "prurigo nodularis", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "35743211", "title": "Mechanisms of Sensitivity and Resistance of Primary Effusion Lymphoma to Dimethyl Fumarate (DMF)", "doi": "10.3390/ijms23126773", "year": 2022 } ], "bc": [ { "pmid": "39912139", "title": "Translating tissue expression of STAT 1, 3 and 6 in prurigo nodularis to clinical efficacy of oral tofacitinib – A prospective single-arm investigational study", "doi": "10.25259/ijdvl_1017_2024", "year": 2025 }, { "pmid": "40162359", "title": "Successful Use of Tofacitinib in Paediatric Prurigo Nodularis: A Report of Four Cases", "doi": "10.4103/ijd.ijd_842_24", "year": 2025 }, { "pmid": "37521237", "title": "A case of recalcitrant prurigo nodularis with heightened expression of STAT 3 and STAT 6 and its dramatic response to tofacitinib", "doi": "10.4103/idoj.idoj_508_22", "year": 2023 } ] } }, { "id": 35500, "drug": "niraparib", "drug_type": "drug", "drug_domain": "multiple_sclerosis", "predicate_ab": "inhibits", "mediator": "IL-17A", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "rheumatoid arthritis", "outcome_type": "disease", "outcome_domain": "rheumatoid_arthritis", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "niraparib", "mediator_canonical": "il-17a", "outcome_canonical": "rheumatoid arthritis", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40924614", "title": "Niraparib Demonstrates Therapeutic Potential in Multiple Sclerosis through Inhibition of IL-17A Receptor Interaction and Promotion of Remyelination", "doi": "10.1021/acschemneuro.5c00519", "year": 2025 } ], "bc": [ { "pmid": "37926850", "title": "Genetic association between interleukin-17 and susceptibility to rheumatoid arthritis", "doi": "10.1186/s12920-023-01713-6", "year": 2023 }, { "pmid": "34321563", "title": "The role of IL-18 in addition to Th17 cytokines in rheumatoid arthritis development and treatment in women", "doi": "10.1038/s41598-021-94841-x", "year": 2021 }, { "pmid": "32048307", "title": "The prostaglandin E2 increases the production of IL‐17 and the expression of costimulatory molecules on γδ T cells in rheumatoid arthritis", "doi": "10.1111/sji.12872", "year": 2020 } ] } }, { "id": 35516, "drug": "Berberine and Fingolimod", "drug_type": "drug", "drug_domain": "multiple_sclerosis", "predicate_ab": "inhibits", "mediator": "STAT3", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "prurigo nodularis", "outcome_type": "disease", "outcome_domain": "rheumatoid_arthritis", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "berberine and fingolimod", "mediator_canonical": "STAT3", "outcome_canonical": "prurigo nodularis", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "32432470", "title": "Anti-inflammatory Efficacy of Combined Natural Alkaloid Berberine and S1PR Modulator Fingolimod at Low Doses in Ulcerative Colitis Preclinical Models", "doi": "10.1021/acs.jnatprod.0c00175", "year": 2020 } ], "bc": [ { "pmid": "39912139", "title": "Translating tissue expression of STAT 1, 3 and 6 in prurigo nodularis to clinical efficacy of oral tofacitinib – A prospective single-arm investigational study", "doi": "10.25259/ijdvl_1017_2024", "year": 2025 }, { "pmid": "40162359", "title": "Successful Use of Tofacitinib in Paediatric Prurigo Nodularis: A Report of Four Cases", "doi": "10.4103/ijd.ijd_842_24", "year": 2025 }, { "pmid": "37521237", "title": "A case of recalcitrant prurigo nodularis with heightened expression of STAT 3 and STAT 6 and its dramatic response to tofacitinib", "doi": "10.4103/idoj.idoj_508_22", "year": 2023 } ] } }, { "id": 35520, "drug": "interferon-beta", "drug_type": "drug", "drug_domain": "multiple_sclerosis", "predicate_ab": "downregulates", "mediator": "IL-17A", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "rheumatoid arthritis", "outcome_type": "disease", "outcome_domain": "rheumatoid_arthritis", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "interferon-beta", "mediator_canonical": "il-17a", "outcome_canonical": "rheumatoid arthritis", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "34808619", "title": "The Effect of Interferon-Beta Therapy on T-Helper 17/miR-326 and T-Helper 1/miR-29b-3p Axis in Relapsing-Remitting Multiple Sclerosis Patients", "doi": "10.1159/000519777", "year": 2021 } ], "bc": [ { "pmid": "37926850", "title": "Genetic association between interleukin-17 and susceptibility to rheumatoid arthritis", "doi": "10.1186/s12920-023-01713-6", "year": 2023 }, { "pmid": "34321563", "title": "The role of IL-18 in addition to Th17 cytokines in rheumatoid arthritis development and treatment in women", "doi": "10.1038/s41598-021-94841-x", "year": 2021 }, { "pmid": "32048307", "title": "The prostaglandin E2 increases the production of IL‐17 and the expression of costimulatory molecules on γδ T cells in rheumatoid arthritis", "doi": "10.1111/sji.12872", "year": 2020 } ] } }, { "id": 35507, "drug": "Stattic", "drug_type": "drug", "drug_domain": "multiple_sclerosis", "predicate_ab": "downregulates", "mediator": "IL-17A", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "rheumatoid arthritis", "outcome_type": "disease", "outcome_domain": "rheumatoid_arthritis", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "stattic", "mediator_canonical": "il-17a", "outcome_canonical": "rheumatoid arthritis", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "34206429", "title": "Pharmacological Inhibition of STAT3 by Stattic Ameliorates Clinical Symptoms and Reduces Autoinflammation in Myeloid, Lymphoid, and Neuronal Tissue Compartments in Relapsing–Remitting Model of Experimental Autoimmune Encephalomyelitis in SJL/J Mice", "doi": "10.3390/pharmaceutics13070925", "year": 2021 } ], "bc": [ { "pmid": "37926850", "title": "Genetic association between interleukin-17 and susceptibility to rheumatoid arthritis", "doi": "10.1186/s12920-023-01713-6", "year": 2023 }, { "pmid": "34321563", "title": "The role of IL-18 in addition to Th17 cytokines in rheumatoid arthritis development and treatment in women", "doi": "10.1038/s41598-021-94841-x", "year": 2021 }, { "pmid": "32048307", "title": "The prostaglandin E2 increases the production of IL‐17 and the expression of costimulatory molecules on γδ T cells in rheumatoid arthritis", "doi": "10.1111/sji.12872", "year": 2020 } ] } }, { "id": 35509, "drug": "kaempferol", "drug_type": "drug", "drug_domain": "multiple_sclerosis", "predicate_ab": "binds_to", "mediator": "MMP3", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "Sarcopenia", "outcome_type": "phenotype", "outcome_domain": "rheumatoid_arthritis", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "kaempferol", "mediator_canonical": "mmp3", "outcome_canonical": "sarcopenia", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41082138", "title": "Identification of Kaempferol as a Critical Component in Mahuang Fuzi Xixin Decoction for Protecting Against Demyelination in Multiple Sclerosis via Matrix Metalloproteinase‐3 Inhibition", "doi": "10.1096/fsb2.71088", "year": 2025 } ], "bc": [ { "pmid": "30187662", "title": "Matrix metalloprotease 3 is associated with sarcopenia in rheumatoid arthritis ‐ results from the CHIKARA study", "doi": "10.1111/1756-185x.13335", "year": 2018 } ] } }, { "id": 41883, "drug": "nicotinamide", "drug_type": "drug", "drug_domain": "als", "predicate_ab": "activates", "mediator": "SIRT3", "mediator_type": "protein", "predicate_bc": "decreases", "outcome": "oxidative stress", "outcome_type": "phenotype", "outcome_domain": "heart_failure", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "33184465", "title": "ALS motor neurons exhibit hallmark metabolic defects that are rescued by SIRT3 activation", "doi": "10.1038/s41418-020-00664-0", "year": 2020 } ], "bc": [ { "pmid": "37080445", "title": "Cardioprotective effect of ultrasound‐targeted destruction of Sirt3‐loaded cationic microbubbles in a large animal model of pathological cardiac hypertrophy", "doi": "10.1016/j.actbio.2023.04.020", "year": 2023 }, { "pmid": "33244875", "title": "Elabela may regulate SIRT3‐mediated inhibition of oxidative stress through Foxo3a deacetylation preventing diabetic‐induced myocardial injury", "doi": "10.1111/jcmm.16052", "year": 2020 }, { "pmid": "31318577", "title": "The nuclear and mitochondrial sirtuins, Sirt6 and Sirt3, regulate each other's activity and protect the heart from developing obesity‐mediated diabetic cardiomyopathy", "doi": "10.1096/fj.201900767r", "year": 2019 } ] } }, { "id": 41884, "drug": "pridopidine", "drug_type": "drug", "drug_domain": "als", "predicate_ab": "activates", "mediator": "Sigma-1 receptor", "mediator_type": "protein", "predicate_bc": "decreases", "outcome": "endoplasmic reticulum stress", "outcome_type": "phenotype", "outcome_domain": "heart_failure", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41471389", "title": "Pridopidine, a Potent and Selective Therapeutic Sigma-1 Receptor (S1R) Agonist for Treating Neurodegenerative Diseases", "doi": "10.3390/ph18121900", "year": 2025 }, { "pmid": "35080077", "title": "Pridopidine modifies disease phenotype in a SOD1 mouse model of amyotrophic lateral sclerosis", "doi": "10.1111/ejn.15608", "year": 2022 }, { "pmid": "30824685", "title": "Targeting the Sigma-1 Receptor via Pridopidine Ameliorates Central Features of ALS Pathology in a SOD1G93A Model", "doi": "10.1038/s41419-019-1451-2", "year": 2019 } ], "bc": [ { "pmid": "40001213", "title": "Sigma-1 receptor activation attenuates DOX-induced cardiotoxicity by alleviating endoplasmic reticulum stress and mitochondrial calcium overload via PERK and IP3R-VDAC1-MCU signaling pathways", "doi": "10.1186/s13062-025-00617-y", "year": 2025 } ] } }, { "id": 41886, "drug": "pridopidine", "drug_type": "drug", "drug_domain": "als", "predicate_ab": "activates", "mediator": "Sigma-1 receptor", "mediator_type": "protein", "predicate_bc": "decreases", "outcome": "mitochondrial calcium overload", "outcome_type": "phenotype", "outcome_domain": "heart_failure", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41471389", "title": "Pridopidine, a Potent and Selective Therapeutic Sigma-1 Receptor (S1R) Agonist for Treating Neurodegenerative Diseases", "doi": "10.3390/ph18121900", "year": 2025 }, { "pmid": "35080077", "title": "Pridopidine modifies disease phenotype in a SOD1 mouse model of amyotrophic lateral sclerosis", "doi": "10.1111/ejn.15608", "year": 2022 }, { "pmid": "30824685", "title": "Targeting the Sigma-1 Receptor via Pridopidine Ameliorates Central Features of ALS Pathology in a SOD1G93A Model", "doi": "10.1038/s41419-019-1451-2", "year": 2019 } ], "bc": [ { "pmid": "40001213", "title": "Sigma-1 receptor activation attenuates DOX-induced cardiotoxicity by alleviating endoplasmic reticulum stress and mitochondrial calcium overload via PERK and IP3R-VDAC1-MCU signaling pathways", "doi": "10.1186/s13062-025-00617-y", "year": 2025 } ] } }, { "id": 24954, "drug": "Insulin", "drug_type": "drug", "drug_domain": "als", "predicate_ab": "downregulates", "mediator": "ferritin", "mediator_type": "protein", "predicate_bc": "predicts", "outcome": "iron deficiency", "outcome_type": "disease", "outcome_domain": "inflammatory_bowel_disease", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "active", "clinical_trial_nct_ids": [ "NCT04008147", "NCT06879080" ], "literature_status": "reproduces_known", "drug_canonical": "insulin", "mediator_canonical": "ferritin", "outcome_canonical": "iron deficiency", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "29380557", "title": "hmSOD1 gene mutation‐induced disturbance in iron metabolism is mediated by impairment of Akt signalling pathway", "doi": "10.1002/jcsm.12283", "year": 2018 } ], "bc": [ { "pmid": "32323356", "title": "Comparative accuracy of ferritin, transferrin saturation and soluble transferrin receptor for the diagnosis of iron deficiency in inflammatory bowel disease", "doi": "10.1111/apt.15739", "year": 2020 } ] } }, { "id": 8814, "drug": "voluntary running", "drug_type": "drug", "drug_domain": "alzheimer", "predicate_ab": "inhibits", "mediator": "S100B", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "ALS", "outcome_type": "disease", "outcome_domain": "als", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "voluntary running", "mediator_canonical": "s100b", "outcome_canonical": "amyotrophic lateral sclerosis", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37146123", "title": "The effects of voluntary running exercise on the astrocytes of the medial prefrontal cortex in APP/PS1 mice", "doi": "10.1002/cne.25485", "year": 2023 } ], "bc": [ { "pmid": "35216298", "title": "The Involvement of RAGE and Its Ligands during Progression of ALS in SOD1 G93A Transgenic Mice", "doi": "10.3390/ijms23042184", "year": 2022 }, { "pmid": "28713206", "title": "The Astrocytic S100B Protein with Its Receptor RAGE Is Aberrantly Expressed in SOD1G93A Models, and Its Inhibition Decreases the Expression of Proinflammatory Genes", "doi": "10.1155/2017/1626204", "year": 2017 }, { "pmid": "26733811", "title": "Receptor for Advanced Glycation End Products and its Inflammatory Ligands are Upregulated in Amyotrophic Lateral Sclerosis", "doi": "10.3389/fncel.2015.00485", "year": 2015 } ] } }, { "id": 3777, "drug": "Hit-6 compound", "drug_type": "drug", "drug_domain": "alzheimer", "predicate_ab": "inhibits", "mediator": "RAGE", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "ALS", "outcome_type": "disease", "outcome_domain": "als", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "hit-6 compound", "mediator_canonical": "rage", "outcome_canonical": "amyotrophic lateral sclerosis", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40404684", "title": "Identifying RAGE inhibitors as potential therapeutics for Alzheimer’s disease via integrated in-silico approaches", "doi": "10.1038/s41598-025-01271-0", "year": 2025 } ], "bc": [ { "pmid": "35216298", "title": "The Involvement of RAGE and Its Ligands during Progression of ALS in SOD1 G93A Transgenic Mice", "doi": "10.3390/ijms23042184", "year": 2022 }, { "pmid": "27242430", "title": "Soluble RAGE Treatment Delays Progression of Amyotrophic Lateral Sclerosis in SOD1 Mice", "doi": "10.3389/fncel.2016.00117", "year": 2016 }, { "pmid": "26733811", "title": "Receptor for Advanced Glycation End Products and its Inflammatory Ligands are Upregulated in Amyotrophic Lateral Sclerosis", "doi": "10.3389/fncel.2015.00485", "year": 2015 } ] } }, { "id": 8821, "drug": "arsenic", "drug_type": "drug", "drug_domain": "alzheimer", "predicate_ab": "upregulates", "mediator": "RAGE", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "ALS", "outcome_type": "disease", "outcome_domain": "als", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "arsenic", "mediator_canonical": "rage", "outcome_canonical": "amyotrophic lateral sclerosis", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37921143", "title": "Arsenic Exposure and Amyloid Precursor Protein Processing: A Focus onAlzheimer's Disease", "doi": "10.2174/0118761429272806231020045840", "year": 2023 } ], "bc": [ { "pmid": "35216298", "title": "The Involvement of RAGE and Its Ligands during Progression of ALS in SOD1 G93A Transgenic Mice", "doi": "10.3390/ijms23042184", "year": 2022 }, { "pmid": "27242430", "title": "Soluble RAGE Treatment Delays Progression of Amyotrophic Lateral Sclerosis in SOD1 Mice", "doi": "10.3389/fncel.2016.00117", "year": 2016 }, { "pmid": "26733811", "title": "Receptor for Advanced Glycation End Products and its Inflammatory Ligands are Upregulated in Amyotrophic Lateral Sclerosis", "doi": "10.3389/fncel.2015.00485", "year": 2015 } ] } }, { "id": 4176, "drug": "Sinapic acid", "drug_type": "drug", "drug_domain": "alzheimer", "predicate_ab": "upregulates", "mediator": "BDNF", "mediator_type": "protein", "predicate_bc": "decreases", "outcome": "schizophrenia", "outcome_type": "disease", "outcome_domain": "depression", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "sinapic acid", "mediator_canonical": "BDNF", "outcome_canonical": "schizophrenia", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "36979237", "title": "Effect of Sinapic Acid on Scopolamine-Induced Learning and Memory Impairment in SD Rats", "doi": "10.3390/brainsci13030427", "year": 2023 } ], "bc": [ { "pmid": "34280516", "title": "Associations of immunological proteins/traits with schizophrenia, major depression and bipolar disorder: A bi-directional two-sample mendelian randomization study", "doi": "10.1016/j.bbi.2021.07.009", "year": 2021 }, { "pmid": "30794585", "title": "Accuracy of brain-derived neurotrophic factor levels for differentiating between Taiwanese patients with major depressive disorder or schizophrenia and healthy controls", "doi": "10.1371/journal.pone.0212373", "year": 2019 } ] } }, { "id": 193, "drug": "cannabidiol", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "inhibits", "mediator": "P-glycoprotein", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "multidrug resistance", "outcome_type": "phenotype", "outcome_domain": "glioblastoma", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "cannabidiol", "mediator_canonical": "ABCB1", "outcome_canonical": null, "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "33807975", "title": "Cannabidiol (CBD) Alters the Functionality of Neutrophils (PMN). Implications in the Refractory Epilepsy Treatment", "doi": "10.3390/ph14030220", "year": 2021 }, { "pmid": "32256321", "title": "Cannabidiol (CBD) Inhibited Rhodamine-123 Efflux in Cultured Vascular Endothelial Cells and Astrocytes Under Hypoxic Conditions", "doi": "10.3389/fnbeh.2020.00032", "year": 2020 } ], "bc": [ { "pmid": "35093870", "title": "Ko143 Reverses MDR in Glioblastoma via Deactivating P-Glycoprotein, Sensitizing a Resistant Phenotype to TMZ Treatment", "doi": "10.21873/anticanres.15530", "year": 2022 } ] } }, { "id": 32139, "drug": "Chlorotoxin", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "binds_to", "mediator": "MMP-2", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "brachial 24-h pulse pressure", "outcome_type": "phenotype", "outcome_domain": "type_2_diabetes", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "chlorotoxin", "mediator_canonical": "MMP2", "outcome_canonical": "brachial 24-h pulse pressure", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41955189", "title": "Chlorotoxin does not target matrix metalloproteinase-2 in glioblastoma", "doi": "10.1371/journal.pone.0328964", "year": 2026 } ], "bc": [ { "pmid": "29070037", "title": "Circulating matrix metalloproteinases are associated with arterial stiffness in patients with type 1 diabetes: pooled analysis of three cohort studies", "doi": "10.1186/s12933-017-0620-9", "year": 2017 } ] } }, { "id": 3066, "drug": "pridopidine", "drug_type": "drug", "drug_domain": "als", "predicate_ab": "activates", "mediator": "sigma-1 receptor", "mediator_type": "protein", "predicate_bc": "treats", "outcome": "Alzheimer's disease", "outcome_type": "disease", "outcome_domain": "alzheimer", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "pridopidine", "mediator_canonical": "sigma-1 receptor", "outcome_canonical": "Alzheimer disease", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41471389", "title": "Pridopidine, a Potent and Selective Therapeutic Sigma-1 Receptor (S1R) Agonist for Treating Neurodegenerative Diseases", "doi": "10.3390/ph18121900", "year": 2025 }, { "pmid": "35080077", "title": "Pridopidine modifies disease phenotype in a SOD1 mouse model of amyotrophic lateral sclerosis", "doi": "10.1111/ejn.15608", "year": 2022 }, { "pmid": "30824685", "title": "Targeting the Sigma-1 Receptor via Pridopidine Ameliorates Central Features of ALS Pathology in a SOD1G93A Model", "doi": "10.1038/s41419-019-1451-2", "year": 2019 } ], "bc": [ { "pmid": "41488323", "title": "Sigma receptors and mitochondria-associated ER membranes are converging therapeutic targets for Alzheimer’s disease", "doi": "10.3389/fnins.2025.1733659", "year": 2025 } ] } }, { "id": 4177, "drug": "GQ1b", "drug_type": "drug", "drug_domain": "alzheimer", "predicate_ab": "upregulates", "mediator": "BDNF", "mediator_type": "protein", "predicate_bc": "decreases", "outcome": "schizophrenia", "outcome_type": "disease", "outcome_domain": "depression", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "gq1b", "mediator_canonical": "BDNF", "outcome_canonical": "schizophrenia", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "31186474", "title": "Ganglioside GQ1b ameliorates cognitive impairments in an Alzheimer’s disease mouse model, and causes reduction of amyloid precursor protein", "doi": "10.1038/s41598-019-44739-6", "year": 2019 } ], "bc": [ { "pmid": "34280516", "title": "Associations of immunological proteins/traits with schizophrenia, major depression and bipolar disorder: A bi-directional two-sample mendelian randomization study", "doi": "10.1016/j.bbi.2021.07.009", "year": 2021 }, { "pmid": "30794585", "title": "Accuracy of brain-derived neurotrophic factor levels for differentiating between Taiwanese patients with major depressive disorder or schizophrenia and healthy controls", "doi": "10.1371/journal.pone.0212373", "year": 2019 } ] } }, { "id": 1631, "drug": "Serclutamab talirine", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "binds_to", "mediator": "EGFR", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "pancreatic ductal adenocarcinoma", "outcome_type": "disease", "outcome_domain": "pancreatic_cancer", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "serclutamab talirine", "mediator_canonical": "EGFR", "outcome_canonical": "pancreatic ductal adenocarcinoma", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "36814898", "title": "Phase I study of anti-epidermal growth factor receptor antibody-drug conjugate serclutamab talirine: Safety, pharmacokinetics, and antitumor activity in advanced glioblastoma", "doi": "10.1093/noajnl/vdac183", "year": 2022 } ], "bc": [ { "pmid": "40130819", "title": "Identification of Tumor‐Specific Surface Proteins Enables Quantification of Extracellular Vesicle Subtypes for Early Detection of Pancreatic Ductal Adenocarcinoma", "doi": "10.1002/advs.202414982", "year": 2025 }, { "pmid": "31584260", "title": "Design and Evaluation of PEGylated Liposomal Formulation of a Novel Multikinase Inhibitor for Enhanced Chemosensitivity and Inhibition of Metastatic Pancreatic Ductal Adenocarcinoma", "doi": "10.1021/acs.bioconjchem.9b00632", "year": 2019 }, { "pmid": "26339400", "title": "EGFR expression in pancreatic intraepithelial neoplasia and ductal adenocarcinoma.", "doi": null, "year": 2015 } ] } }, { "id": 27341, "drug": "Carnosol", "drug_type": "drug", "drug_domain": "alzheimer", "predicate_ab": "binds_to", "mediator": "STAT3", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "prurigo nodularis", "outcome_type": "disease", "outcome_domain": "rheumatoid_arthritis", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "carnosol", "mediator_canonical": "STAT3", "outcome_canonical": "prurigo nodularis", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40745201", "title": "Uncovering active ingredients and mechanisms of Pholiota adiposa in the treatment of Alzheimer’s disease based on network pharmacology and bioinformatics", "doi": "10.1038/s41598-025-94861-x", "year": 2025 } ], "bc": [ { "pmid": "39912139", "title": "Translating tissue expression of STAT 1, 3 and 6 in prurigo nodularis to clinical efficacy of oral tofacitinib – A prospective single-arm investigational study", "doi": "10.25259/ijdvl_1017_2024", "year": 2025 }, { "pmid": "40162359", "title": "Successful Use of Tofacitinib in Paediatric Prurigo Nodularis: A Report of Four Cases", "doi": "10.4103/ijd.ijd_842_24", "year": 2025 }, { "pmid": "37521237", "title": "A case of recalcitrant prurigo nodularis with heightened expression of STAT 3 and STAT 6 and its dramatic response to tofacitinib", "doi": "10.4103/idoj.idoj_508_22", "year": 2023 } ] } }, { "id": 10634, "drug": "dextromethorphan", "drug_type": "drug", "drug_domain": "depression", "predicate_ab": "inhibits", "mediator": "NMDA receptor", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "pain", "outcome_type": "phenotype", "outcome_domain": "als", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "active", "clinical_trial_nct_ids": [ "NCT00333242", "NCT05278494", "NCT05068791" ], "literature_status": "reproduces_known", "drug_canonical": "dextromethorphan", "mediator_canonical": "nmda receptor", "outcome_canonical": "pain", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41913380", "title": "Bupropion‐Memantine Combination in the Treatment of Major Depressive Disorder and Treatment‐Resistant Depression", "doi": "10.1002/hup.70039", "year": 2026 }, { "pmid": "27738380", "title": "Treatment Resistant Depression with Loss of Antidepressant Response: Rapid—Acting Antidepressant Action of Dextromethorphan, A Possible Treatment Bridging Molecule", "doi": "10.64719/pb.4347", "year": 2025 }, { "pmid": "38231578", "title": "Dextromethorphan/Bupropion: A Novel Treatment for Patients With Major Depressive Disorder", "doi": "10.1097/mjt.0000000000001699", "year": 2024 } ], "bc": [ { "pmid": "33467407", "title": "Delayed Onset Muscle Soreness (DOMS): The Repeated Bout Effect and Chemotherapy-Induced Axonopathy May Help Explain the Dying-Back Mechanism in Amyotrophic Lateral Sclerosis and Other Neurodegenerative Diseases", "doi": "10.3390/brainsci11010108", "year": 2021 } ] } }, { "id": 10636, "drug": "dextromethorphan", "drug_type": "drug", "drug_domain": "depression", "predicate_ab": "inhibits", "mediator": "NMDA receptor", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "cell-autonomous excitotoxicity", "outcome_type": "phenotype", "outcome_domain": "als", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "dextromethorphan", "mediator_canonical": "nmda receptor", "outcome_canonical": "cell-autonomous excitotoxicity", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41913380", "title": "Bupropion‐Memantine Combination in the Treatment of Major Depressive Disorder and Treatment‐Resistant Depression", "doi": "10.1002/hup.70039", "year": 2026 }, { "pmid": "27738380", "title": "Treatment Resistant Depression with Loss of Antidepressant Response: Rapid—Acting Antidepressant Action of Dextromethorphan, A Possible Treatment Bridging Molecule", "doi": "10.64719/pb.4347", "year": 2025 }, { "pmid": "38231578", "title": "Dextromethorphan/Bupropion: A Novel Treatment for Patients With Major Depressive Disorder", "doi": "10.1097/mjt.0000000000001699", "year": 2024 } ], "bc": [ { "pmid": "30037833", "title": "C9orf72 Dipeptide Repeats Cause Selective Neurodegeneration and Cell-Autonomous Excitotoxicity in Drosophila Glutamatergic Neurons", "doi": "10.1523/jneurosci.0908-18.2018", "year": 2018 } ] } }, { "id": 10635, "drug": "dantrolene", "drug_type": "drug", "drug_domain": "depression", "predicate_ab": "inhibits", "mediator": "IL-18", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "ALS", "outcome_type": "disease", "outcome_domain": "als", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "dantrolene", "mediator_canonical": "il-18", "outcome_canonical": "amyotrophic lateral sclerosis", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41633971", "title": "Intranasal dantrolene nanoparticles inhibit lipopolysaccharide-induced depression and anxiety behavior in mice", "doi": "10.1038/s41398-026-03816-x", "year": 2026 } ], "bc": [ { "pmid": "41789732", "title": "3D Artificial Skin Model As a Novel Strategy for the Detection of Pyroptosis-Cascade Activation in Amyotrophic Lateral Sclerosis", "doi": "10.1021/acsami.5c23366", "year": 2026 }, { "pmid": "32515902", "title": "Longitudinal biomarkers in amyotrophic lateral sclerosis", "doi": "10.1002/acn3.51078", "year": 2020 }, { "pmid": "29472887", "title": "A Possible Role for Platelet-Activating Factor Receptor in Amyotrophic Lateral Sclerosis Treatment", "doi": "10.3389/fneur.2018.00039", "year": 2018 } ] } }, { "id": 5318, "drug": "JNJ-54175446", "drug_type": "drug", "drug_domain": "depression", "predicate_ab": "inhibits", "mediator": "P2X7R", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "temporal lobe epilepsy", "outcome_type": "disease", "outcome_domain": "epilepsy", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "jnj-54175446", "mediator_canonical": "P2X7R", "outcome_canonical": "temporal lobe epilepsy", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37482560", "title": "Characterization of the central nervous system penetrant and selective purine P2X7 receptor antagonist JNJ-54175446 in patients with major depressive disorder", "doi": "10.1038/s41398-023-02557-5", "year": 2023 } ], "bc": [ { "pmid": "36507708", "title": "Increased uptake of the P2X7 receptor radiotracer 18F‐JNJ‐64413739 in the brain and peripheral organs according to the severity of status epilepticus in male mice", "doi": "10.1111/epi.17484", "year": 2022 }, { "pmid": "34572093", "title": "Circulating P2X7 Receptor Signaling Components as Diagnostic Biomarkers for Temporal Lobe Epilepsy", "doi": "10.3390/cells10092444", "year": 2021 }, { "pmid": "31059094", "title": "Increased expression of the P2X7 receptor in temporal lobe epilepsy: Animal models and clinical evidence", "doi": "10.3892/mmr.2019.10202", "year": 2019 } ] } }, { "id": 5317, "drug": "JNJ-54175446", "drug_type": "drug", "drug_domain": "depression", "predicate_ab": "inhibits", "mediator": "P2X7R", "mediator_type": "protein", "predicate_bc": "increases", "outcome": "seizure severity", "outcome_type": "phenotype", "outcome_domain": "epilepsy", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "jnj-54175446", "mediator_canonical": "P2X7R", "outcome_canonical": "seizure severity", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37482560", "title": "Characterization of the central nervous system penetrant and selective purine P2X7 receptor antagonist JNJ-54175446 in patients with major depressive disorder", "doi": "10.1038/s41398-023-02557-5", "year": 2023 } ], "bc": [ { "pmid": "36637008", "title": "The P2X7 receptor contributes to seizures and inflammation‐driven long‐lasting brain hyperexcitability following hypoxia in neonatal mice", "doi": "10.1111/bph.16033", "year": 2023 }, { "pmid": "36507708", "title": "Increased uptake of the P2X7 receptor radiotracer 18F‐JNJ‐64413739 in the brain and peripheral organs according to the severity of status epilepticus in male mice", "doi": "10.1111/epi.17484", "year": 2022 } ] } }, { "id": 45521, "drug": "dantrolene", "drug_type": "drug", "drug_domain": "depression", "predicate_ab": "inhibits", "mediator": "IL-18", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "adverse clinical events", "outcome_type": "disease", "outcome_domain": "heart_failure", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41633971", "title": "Intranasal dantrolene nanoparticles inhibit lipopolysaccharide-induced depression and anxiety behavior in mice", "doi": "10.1038/s41398-026-03816-x", "year": 2026 } ], "bc": [ { "pmid": "38402570", "title": "Prognostic significance of IL‐18 in acute coronary syndrome patients", "doi": "10.1002/clc.24229", "year": 2024 } ] } }, { "id": 22881, "drug": "dextromethorphan", "drug_type": "drug", "drug_domain": "depression", "predicate_ab": "inhibits", "mediator": "NMDA receptor", "mediator_type": "protein", "predicate_bc": "causes", "outcome": "calcium accumulation", "outcome_type": "phenotype", "outcome_domain": "multiple_sclerosis", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "dextromethorphan", "mediator_canonical": "nmda receptor", "outcome_canonical": "calcium accumulation", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41913380", "title": "Bupropion‐Memantine Combination in the Treatment of Major Depressive Disorder and Treatment‐Resistant Depression", "doi": "10.1002/hup.70039", "year": 2026 }, { "pmid": "27738380", "title": "Treatment Resistant Depression with Loss of Antidepressant Response: Rapid—Acting Antidepressant Action of Dextromethorphan, A Possible Treatment Bridging Molecule", "doi": "10.64719/pb.4347", "year": 2025 }, { "pmid": "38231578", "title": "Dextromethorphan/Bupropion: A Novel Treatment for Patients With Major Depressive Disorder", "doi": "10.1097/mjt.0000000000001699", "year": 2024 } ], "bc": [ { "pmid": "32031240", "title": "Influence of retinal NMDA receptor activity during autoimmune optic neuritis", "doi": "10.1111/jnc.14980", "year": 2020 } ] } }, { "id": 22879, "drug": "dextromethorphan", "drug_type": "drug", "drug_domain": "depression", "predicate_ab": "inhibits", "mediator": "NMDA receptor", "mediator_type": "protein", "predicate_bc": "causes", "outcome": "actin destabilization", "outcome_type": "phenotype", "outcome_domain": "multiple_sclerosis", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "dextromethorphan", "mediator_canonical": "nmda receptor", "outcome_canonical": "actin destabilization", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41913380", "title": "Bupropion‐Memantine Combination in the Treatment of Major Depressive Disorder and Treatment‐Resistant Depression", "doi": "10.1002/hup.70039", "year": 2026 }, { "pmid": "27738380", "title": "Treatment Resistant Depression with Loss of Antidepressant Response: Rapid—Acting Antidepressant Action of Dextromethorphan, A Possible Treatment Bridging Molecule", "doi": "10.64719/pb.4347", "year": 2025 }, { "pmid": "38231578", "title": "Dextromethorphan/Bupropion: A Novel Treatment for Patients With Major Depressive Disorder", "doi": "10.1097/mjt.0000000000001699", "year": 2024 } ], "bc": [ { "pmid": "32031240", "title": "Influence of retinal NMDA receptor activity during autoimmune optic neuritis", "doi": "10.1111/jnc.14980", "year": 2020 } ] } }, { "id": 22880, "drug": "dextromethorphan", "drug_type": "drug", "drug_domain": "depression", "predicate_ab": "inhibits", "mediator": "NMDA receptor", "mediator_type": "protein", "predicate_bc": "causes", "outcome": "deterioration of visual acuity", "outcome_type": "phenotype", "outcome_domain": "multiple_sclerosis", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "dextromethorphan", "mediator_canonical": "nmda receptor", "outcome_canonical": "deterioration of visual acuity", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41913380", "title": "Bupropion‐Memantine Combination in the Treatment of Major Depressive Disorder and Treatment‐Resistant Depression", "doi": "10.1002/hup.70039", "year": 2026 }, { "pmid": "27738380", "title": "Treatment Resistant Depression with Loss of Antidepressant Response: Rapid—Acting Antidepressant Action of Dextromethorphan, A Possible Treatment Bridging Molecule", "doi": "10.64719/pb.4347", "year": 2025 }, { "pmid": "38231578", "title": "Dextromethorphan/Bupropion: A Novel Treatment for Patients With Major Depressive Disorder", "doi": "10.1097/mjt.0000000000001699", "year": 2024 } ], "bc": [ { "pmid": "32031240", "title": "Influence of retinal NMDA receptor activity during autoimmune optic neuritis", "doi": "10.1111/jnc.14980", "year": 2020 } ] } }, { "id": 2101, "drug": "zonisamide", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "downregulates", "mediator": "Cx43", "mediator_type": "protein", "predicate_bc": "increases", "outcome": "hemichannel-mediated activity", "outcome_type": "phenotype", "outcome_domain": "als", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "zonisamide", "mediator_canonical": "GJA1", "outcome_canonical": "hemichannel-mediated activity", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "32516974", "title": "Effects of Carbamazepine, Lacosamide and Zonisamide on Gliotransmitter Release Associated with Activated Astroglial Hemichannels", "doi": "10.3390/ph13060117", "year": 2020 }, { "pmid": "32443400", "title": "Upregulated and Hyperactivated Thalamic Connexin 43 Plays Important Roles in Pathomechanisms of Cognitive Impairment and Seizure of Autosomal Dominant Sleep-Related Hypermotor Epilepsy with S284L-Mutant α4 Subunit of Nicotinic ACh Receptor", "doi": "10.3390/ph13050099", "year": 2020 } ], "bc": [ { "pmid": "27083773", "title": "Connexin 43 in astrocytes contributes to motor neuron toxicity in amyotrophic lateral sclerosis", "doi": "10.1002/glia.22989", "year": 2016 } ] } }, { "id": 2103, "drug": "scopadulcic acid", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "inhibits", "mediator": "S100B", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "ALS", "outcome_type": "disease", "outcome_domain": "als", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "scopadulcic acid", "mediator_canonical": "s100b", "outcome_canonical": "amyotrophic lateral sclerosis", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37965486", "title": "Integrated virtual screening, molecular modeling and machine learning approaches revealed potential natural inhibitors for epilepsy", "doi": "10.1016/j.jsps.2023.101835", "year": 2023 } ], "bc": [ { "pmid": "35216298", "title": "The Involvement of RAGE and Its Ligands during Progression of ALS in SOD1 G93A Transgenic Mice", "doi": "10.3390/ijms23042184", "year": 2022 }, { "pmid": "28713206", "title": "The Astrocytic S100B Protein with Its Receptor RAGE Is Aberrantly Expressed in SOD1G93A Models, and Its Inhibition Decreases the Expression of Proinflammatory Genes", "doi": "10.1155/2017/1626204", "year": 2017 }, { "pmid": "26733811", "title": "Receptor for Advanced Glycation End Products and its Inflammatory Ligands are Upregulated in Amyotrophic Lateral Sclerosis", "doi": "10.3389/fncel.2015.00485", "year": 2015 } ] } }, { "id": 6685, "drug": "brivaracetam", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "suppresses", "mediator": "Cx43", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "ALS", "outcome_type": "disease", "outcome_domain": "als", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "brivaracetam", "mediator_canonical": "GJA1", "outcome_canonical": "amyotrophic lateral sclerosis", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "35562864", "title": "Brivaracetam and Levetiracetam Suppress Astroglial L-Glutamate Release through Hemichannel via Inhibition of Synaptic Vesicle Protein", "doi": "10.3390/ijms23094473", "year": 2022 } ], "bc": [ { "pmid": "35312356", "title": "Cx43 hemichannels contribute to astrocyte-mediated toxicity in sporadic and familial ALS", "doi": "10.1073/pnas.2107391119", "year": 2022 }, { "pmid": "27083773", "title": "Connexin 43 in astrocytes contributes to motor neuron toxicity in amyotrophic lateral sclerosis", "doi": "10.1002/glia.22989", "year": 2016 } ] } }, { "id": 2102, "drug": "zonisamide", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "downregulates", "mediator": "Cx43", "mediator_type": "protein", "predicate_bc": "increases", "outcome": "gap junction coupling", "outcome_type": "phenotype", "outcome_domain": "als", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "zonisamide", "mediator_canonical": "GJA1", "outcome_canonical": "gap junction coupling", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "32516974", "title": "Effects of Carbamazepine, Lacosamide and Zonisamide on Gliotransmitter Release Associated with Activated Astroglial Hemichannels", "doi": "10.3390/ph13060117", "year": 2020 }, { "pmid": "32443400", "title": "Upregulated and Hyperactivated Thalamic Connexin 43 Plays Important Roles in Pathomechanisms of Cognitive Impairment and Seizure of Autosomal Dominant Sleep-Related Hypermotor Epilepsy with S284L-Mutant α4 Subunit of Nicotinic ACh Receptor", "doi": "10.3390/ph13050099", "year": 2020 } ], "bc": [ { "pmid": "27083773", "title": "Connexin 43 in astrocytes contributes to motor neuron toxicity in amyotrophic lateral sclerosis", "doi": "10.1002/glia.22989", "year": 2016 } ] } }, { "id": 2097, "drug": "rhinacanthin K", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "inhibits", "mediator": "S100B", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "ALS", "outcome_type": "disease", "outcome_domain": "als", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "rhinacanthin k", "mediator_canonical": "s100b", "outcome_canonical": "amyotrophic lateral sclerosis", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37965486", "title": "Integrated virtual screening, molecular modeling and machine learning approaches revealed potential natural inhibitors for epilepsy", "doi": "10.1016/j.jsps.2023.101835", "year": 2023 } ], "bc": [ { "pmid": "35216298", "title": "The Involvement of RAGE and Its Ligands during Progression of ALS in SOD1 G93A Transgenic Mice", "doi": "10.3390/ijms23042184", "year": 2022 }, { "pmid": "28713206", "title": "The Astrocytic S100B Protein with Its Receptor RAGE Is Aberrantly Expressed in SOD1G93A Models, and Its Inhibition Decreases the Expression of Proinflammatory Genes", "doi": "10.1155/2017/1626204", "year": 2017 }, { "pmid": "26733811", "title": "Receptor for Advanced Glycation End Products and its Inflammatory Ligands are Upregulated in Amyotrophic Lateral Sclerosis", "doi": "10.3389/fncel.2015.00485", "year": 2015 } ] } }, { "id": 2098, "drug": "thiobinupharidine", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "inhibits", "mediator": "S100B", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "ALS", "outcome_type": "disease", "outcome_domain": "als", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "thiobinupharidine", "mediator_canonical": "s100b", "outcome_canonical": "amyotrophic lateral sclerosis", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37965486", "title": "Integrated virtual screening, molecular modeling and machine learning approaches revealed potential natural inhibitors for epilepsy", "doi": "10.1016/j.jsps.2023.101835", "year": 2023 } ], "bc": [ { "pmid": "35216298", "title": "The Involvement of RAGE and Its Ligands during Progression of ALS in SOD1 G93A Transgenic Mice", "doi": "10.3390/ijms23042184", "year": 2022 }, { "pmid": "28713206", "title": "The Astrocytic S100B Protein with Its Receptor RAGE Is Aberrantly Expressed in SOD1G93A Models, and Its Inhibition Decreases the Expression of Proinflammatory Genes", "doi": "10.1155/2017/1626204", "year": 2017 }, { "pmid": "26733811", "title": "Receptor for Advanced Glycation End Products and its Inflammatory Ligands are Upregulated in Amyotrophic Lateral Sclerosis", "doi": "10.3389/fncel.2015.00485", "year": 2015 } ] } }, { "id": 2099, "drug": "maslinic acid", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "inhibits", "mediator": "S100B", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "ALS", "outcome_type": "disease", "outcome_domain": "als", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "maslinic acid", "mediator_canonical": "s100b", "outcome_canonical": "amyotrophic lateral sclerosis", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37965486", "title": "Integrated virtual screening, molecular modeling and machine learning approaches revealed potential natural inhibitors for epilepsy", "doi": "10.1016/j.jsps.2023.101835", "year": 2023 } ], "bc": [ { "pmid": "35216298", "title": "The Involvement of RAGE and Its Ligands during Progression of ALS in SOD1 G93A Transgenic Mice", "doi": "10.3390/ijms23042184", "year": 2022 }, { "pmid": "28713206", "title": "The Astrocytic S100B Protein with Its Receptor RAGE Is Aberrantly Expressed in SOD1G93A Models, and Its Inhibition Decreases the Expression of Proinflammatory Genes", "doi": "10.1155/2017/1626204", "year": 2017 }, { "pmid": "26733811", "title": "Receptor for Advanced Glycation End Products and its Inflammatory Ligands are Upregulated in Amyotrophic Lateral Sclerosis", "doi": "10.3389/fncel.2015.00485", "year": 2015 } ] } }, { "id": 6910, "drug": "compound 7b", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "downregulates", "mediator": "GFAP", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "cognitive impairment", "outcome_type": "phenotype", "outcome_domain": "alzheimer", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "compound 7b", "mediator_canonical": "GFAP", "outcome_canonical": "cognitive impairment", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41113602", "title": "Discovery and characterization of phenoxyacetic acid derivatives as potential antiepileptic agents", "doi": "10.1039/d5ra05596b", "year": 2025 } ], "bc": [ { "pmid": "36576155", "title": "Plasma glial fibrillary acidic protein in autosomal dominant Alzheimer's disease: Associations with Aβ‐PET, neurodegeneration, and cognition", "doi": "10.1002/alz.12879", "year": 2022 }, { "pmid": "32514860", "title": "Synaptic Loss, ER Stress and Neuro-Inflammation Emerge Late in the Lateral Temporal Cortex and Associate with Progressive Tau Pathology in Alzheimer’s Disease", "doi": "10.1007/s12035-020-01950-1", "year": 2020 }, { "pmid": "30594925", "title": "Glial Fibrillary Acidic Protein in Serum is Increased in Alzheimer’s Disease and Correlates with Cognitive Impairment", "doi": "10.3233/jad-180325", "year": 2018 } ] } }, { "id": 2301, "drug": "valproic acid and furosemide combination therapy", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "downregulates", "mediator": "ASC", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "MCI", "outcome_type": "disease", "outcome_domain": "alzheimer", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "unknown", "drug_canonical": "valproic acid and furosemide combination therapy", "mediator_canonical": "asc", "outcome_canonical": "mci", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "36209957", "title": "The effect of valproic acid and furosemide on the regulation of the inflammasome complex (NLRP1 and NLRP3 mRNA) in the brain of epileptic animal model", "doi": "10.1016/j.brainresbull.2022.10.002", "year": 2022 } ], "bc": [ { "pmid": "32630059", "title": "The Inflammasome Adaptor Protein ASC in Mild Cognitive Impairment and Alzheimer’s Disease", "doi": "10.3390/ijms21134674", "year": 2020 } ] } }, { "id": 2302, "drug": "EGCG-SeNPs", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "downregulates", "mediator": "GFAP", "mediator_type": "protein", "predicate_bc": "predicts", "outcome": "cognitive decline", "outcome_type": "phenotype", "outcome_domain": "alzheimer", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "egcg-senps", "mediator_canonical": "GFAP", "outcome_canonical": "cognitive decline", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37509594", "title": "Biosynthesized Selenium Nanoparticles Using Epigallocatechin Gallate Protect against Pentylenetetrazole-Induced Acute Epileptic Seizures in Mice via Antioxidative, Anti-Inflammatory, and Anti-Apoptotic Activities", "doi": "10.3390/biomedicines11071955", "year": 2023 } ], "bc": [ { "pmid": "40110647", "title": "Exploratory analysis of the proteomic profile in plasma in adults with Down syndrome in the context of Alzheimer's disease", "doi": "10.1002/alz.70040", "year": 2025 }, { "pmid": "37787146", "title": "Longitudinal associations of serum biomarkers with early cognitive, amyloid and grey matter changes", "doi": "10.1093/brain/awad330", "year": 2023 }, { "pmid": "36446595", "title": "Longitudinal Changes in Blood Biomarkers of Clinical Alzheimer Disease in a Biracial Population Sample", "doi": "10.1212/wnl.0000000000201289", "year": 2022 } ] } }, { "id": 6890, "drug": "topiramate", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "downregulates", "mediator": "GFAP", "mediator_type": "protein", "predicate_bc": "predicts", "outcome": "Alzheimer's disease", "outcome_type": "disease", "outcome_domain": "alzheimer", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "topiramate", "mediator_canonical": "GFAP", "outcome_canonical": "Alzheimer disease", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "36978280", "title": "Topiramate affords neuroprotection in diabetic neuropathy model via downregulating spinal GFAP/inflammatory burden and improving neurofilament production", "doi": "10.1080/15376516.2023.2196687", "year": 2023 } ], "bc": [ { "pmid": "39252463", "title": "Plasma proteomics for risk prediction of Alzheimer's disease in the general population", "doi": "10.1111/acel.14330", "year": 2024 }, { "pmid": "35890250", "title": "Glial Fibrillary Acidic Protein: A Biomarker and Drug Target for Alzheimer’s Disease", "doi": "10.3390/pharmaceutics14071354", "year": 2022 }, { "pmid": "34828359", "title": "Investigating Markers of the NLRP3 Inflammasome Pathway in Alzheimer’s Disease: A Human Post-Mortem Study", "doi": "10.3390/genes12111753", "year": 2021 } ] } }, { "id": 7264, "drug": "gastrodin", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "suppresses", "mediator": "BDNF", "mediator_type": "protein", "predicate_bc": "decreases", "outcome": "schizophrenia", "outcome_type": "disease", "outcome_domain": "depression", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "gastrodin", "mediator_canonical": "BDNF", "outcome_canonical": "schizophrenia", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "33704382", "title": "Gastrodin attenuates lithium-pilocarpine-induced epilepsy by activating AMPK-mediated PPARα in a juvenile rat model", "doi": "10.1093/bbb/zbab013", "year": 2021 } ], "bc": [ { "pmid": "34280516", "title": "Associations of immunological proteins/traits with schizophrenia, major depression and bipolar disorder: A bi-directional two-sample mendelian randomization study", "doi": "10.1016/j.bbi.2021.07.009", "year": 2021 }, { "pmid": "30794585", "title": "Accuracy of brain-derived neurotrophic factor levels for differentiating between Taiwanese patients with major depressive disorder or schizophrenia and healthy controls", "doi": "10.1371/journal.pone.0212373", "year": 2019 } ] } }, { "id": 7263, "drug": "SVHRP", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "upregulates", "mediator": "BDNF", "mediator_type": "protein", "predicate_bc": "decreases", "outcome": "schizophrenia", "outcome_type": "disease", "outcome_domain": "depression", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "svhrp", "mediator_canonical": "BDNF", "outcome_canonical": "schizophrenia", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "33825777", "title": "Effects of scorpion venom heat-resistant peptide on the hippocampal neurons of kainic acid-induced epileptic rats", "doi": "10.1590/1414-431x202010717", "year": 2021 } ], "bc": [ { "pmid": "34280516", "title": "Associations of immunological proteins/traits with schizophrenia, major depression and bipolar disorder: A bi-directional two-sample mendelian randomization study", "doi": "10.1016/j.bbi.2021.07.009", "year": 2021 }, { "pmid": "30794585", "title": "Accuracy of brain-derived neurotrophic factor levels for differentiating between Taiwanese patients with major depressive disorder or schizophrenia and healthy controls", "doi": "10.1371/journal.pone.0212373", "year": 2019 } ] } }, { "id": 7266, "drug": "sakuranetin", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "binds_to", "mediator": "BDNF", "mediator_type": "protein", "predicate_bc": "decreases", "outcome": "schizophrenia", "outcome_type": "disease", "outcome_domain": "depression", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "sakuranetin", "mediator_canonical": "BDNF", "outcome_canonical": "schizophrenia", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41462371", "title": "In vivo, in silico effects of sakuranetin as a multi-target nutraceutical against PTZ-induced seizures via GABA restoration and BDNF/TrkB activation", "doi": "10.1038/s41598-025-26746-y", "year": 2025 } ], "bc": [ { "pmid": "34280516", "title": "Associations of immunological proteins/traits with schizophrenia, major depression and bipolar disorder: A bi-directional two-sample mendelian randomization study", "doi": "10.1016/j.bbi.2021.07.009", "year": 2021 }, { "pmid": "30794585", "title": "Accuracy of brain-derived neurotrophic factor levels for differentiating between Taiwanese patients with major depressive disorder or schizophrenia and healthy controls", "doi": "10.1371/journal.pone.0212373", "year": 2019 } ] } }, { "id": 4186, "drug": "CLR01", "drug_type": "drug", "drug_domain": "alzheimer", "predicate_ab": "binds_to", "mediator": "TAU", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "late-life depression", "outcome_type": "disease", "outcome_domain": "depression", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "clr01", "mediator_canonical": "MAPT", "outcome_canonical": "late-life depression", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "31046227", "title": "Major Differences between the Self-Assembly and Seeding Behavior of Heparin-Induced and in Vitro Phosphorylated Tau and Their Modulation by Potential Inhibitors", "doi": "10.1021/acschembio.9b00325", "year": 2019 }, { "pmid": "30062477", "title": "Native Top-Down Mass Spectrometry and Ion Mobility Spectrometry of the Interaction of Tau Protein with a Molecular Tweezer Assembly Modulator", "doi": "10.1007/s13361-018-2027-6", "year": 2018 } ], "bc": [ { "pmid": "41922490", "title": "Trajectories of late-life depression: insights from molecular imaging", "doi": "10.1038/s41386-026-02340-2", "year": 2026 } ] } }, { "id": 6489, "drug": "MCT", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "downregulates", "mediator": "mTOR", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "glioblastoma", "outcome_type": "disease", "outcome_domain": "glioblastoma", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "active", "clinical_trial_nct_ids": [ "NCT04691960", "NCT03075514", "NCT02149459" ], "literature_status": "reproduces_known", "drug_canonical": "mct", "mediator_canonical": "mTOR", "outcome_canonical": "glioblastoma", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40114545", "title": "Medium‐Chain Triglycerides Supplementation Protects Epilepsy‐Associated Behavioral Impairments in a Mouse Model", "doi": "10.1002/jbt.70213", "year": 2025 } ], "bc": [ { "pmid": "39622049", "title": "A Dual-Target and Dual-Mechanism Design Strategy by Combining Inhibition and Degradation Together", "doi": "10.1021/jacs.4c11930", "year": 2024 }, { "pmid": "33162811", "title": "Mitochondrial dysfunction contributes to Rapamycin-induced apoptosis of Human Glioblastoma Cells - A synergistic effect with Temozolomide", "doi": "10.7150/ijms.40159", "year": 2020 }, { "pmid": "30793789", "title": "The effect of the mTOR inhibitor rapamycin on glucoCEST signal in a preclinical model of glioblastoma", "doi": "10.1002/mrm.27683", "year": 2019 } ] } }, { "id": 194, "drug": "zonisamide", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "downregulates", "mediator": "Cx43", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "therapy resistance", "outcome_type": "phenotype", "outcome_domain": "glioblastoma", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "preclinical_only", "clinical_trial_nct_ids": [ "NCT00552526" ], "literature_status": "partial_evidence", "drug_canonical": "zonisamide", "mediator_canonical": "GJA1", "outcome_canonical": "therapy resistance", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "32516974", "title": "Effects of Carbamazepine, Lacosamide and Zonisamide on Gliotransmitter Release Associated with Activated Astroglial Hemichannels", "doi": "10.3390/ph13060117", "year": 2020 }, { "pmid": "32443400", "title": "Upregulated and Hyperactivated Thalamic Connexin 43 Plays Important Roles in Pathomechanisms of Cognitive Impairment and Seizure of Autosomal Dominant Sleep-Related Hypermotor Epilepsy with S284L-Mutant α4 Subunit of Nicotinic ACh Receptor", "doi": "10.3390/ph13050099", "year": 2020 } ], "bc": [ { "pmid": "38489314", "title": "Integrating and optimizing tonabersat in standard glioblastoma therapy: A preclinical study", "doi": "10.1371/journal.pone.0300552", "year": 2024 } ] } }, { "id": 40971, "drug": "alirocumab", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "inhibits", "mediator": "PCSK9", "mediator_type": "protein", "predicate_bc": "causes", "outcome": "atrial structural remodeling", "outcome_type": "phenotype", "outcome_domain": "rheumatoid_arthritis", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "alirocumab", "mediator_canonical": "pcsk9", "outcome_canonical": "atrial structural remodeling", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "32035487", "title": "Effect of alirocumab on individuals with type 2 diabetes, high triglycerides, and low high-density lipoprotein cholesterol", "doi": "10.1186/s12933-020-0991-1", "year": 2020 }, { "pmid": "28799203", "title": "Efficacy and safety of alirocumab in people with prediabetes vs those with normoglycaemia at baseline: a pooled analysis of 10 phase III ODYSSEY clinical trials", "doi": "10.1111/dme.13450", "year": 2017 }, { "pmid": "28545518", "title": "Design and rationale of the ODYSSEY DM-DYSLIPIDEMIA trial: lipid-lowering efficacy and safety of alirocumab in individuals with type 2 diabetes and mixed dyslipidaemia at high cardiovascular risk", "doi": "10.1186/s12933-017-0552-4", "year": 2017 } ], "bc": [ { "pmid": "37709197", "title": "Evolocumab prevents atrial fibrillation in rheumatoid arthritis rats through restraint of PCSK9 induced atrial remodeling", "doi": "10.1016/j.jare.2023.09.007", "year": 2023 } ] } }, { "id": 195, "drug": "cannabidiol", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "inhibits", "mediator": "P-glycoprotein", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "temozolomide resistance", "outcome_type": "phenotype", "outcome_domain": "glioblastoma", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "cannabidiol", "mediator_canonical": "ABCB1", "outcome_canonical": "temozolomide resistance", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "33807975", "title": "Cannabidiol (CBD) Alters the Functionality of Neutrophils (PMN). Implications in the Refractory Epilepsy Treatment", "doi": "10.3390/ph14030220", "year": 2021 }, { "pmid": "32256321", "title": "Cannabidiol (CBD) Inhibited Rhodamine-123 Efflux in Cultured Vascular Endothelial Cells and Astrocytes Under Hypoxic Conditions", "doi": "10.3389/fnbeh.2020.00032", "year": 2020 } ], "bc": [ { "pmid": "35093870", "title": "Ko143 Reverses MDR in Glioblastoma via Deactivating P-Glycoprotein, Sensitizing a Resistant Phenotype to TMZ Treatment", "doi": "10.21873/anticanres.15530", "year": 2022 } ] } }, { "id": 563, "drug": "AZ10606120", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "inhibits", "mediator": "P2X7R", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "temporal lobe epilepsy", "outcome_type": "disease", "outcome_domain": "epilepsy", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "az10606120", "mediator_canonical": "P2X7R", "outcome_canonical": "temporal lobe epilepsy", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37225786", "title": "P2X7 receptor antagonism by AZ10606120 significantly reduced in vitro tumour growth in human glioblastoma", "doi": "10.1038/s41598-023-35712-5", "year": 2023 } ], "bc": [ { "pmid": "36507708", "title": "Increased uptake of the P2X7 receptor radiotracer 18F‐JNJ‐64413739 in the brain and peripheral organs according to the severity of status epilepticus in male mice", "doi": "10.1111/epi.17484", "year": 2022 }, { "pmid": "34572093", "title": "Circulating P2X7 Receptor Signaling Components as Diagnostic Biomarkers for Temporal Lobe Epilepsy", "doi": "10.3390/cells10092444", "year": 2021 }, { "pmid": "31059094", "title": "Increased expression of the P2X7 receptor in temporal lobe epilepsy: Animal models and clinical evidence", "doi": "10.3892/mmr.2019.10202", "year": 2019 } ] } }, { "id": 562, "drug": "AZ10606120", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "inhibits", "mediator": "P2X7R", "mediator_type": "protein", "predicate_bc": "increases", "outcome": "seizure severity", "outcome_type": "phenotype", "outcome_domain": "epilepsy", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "az10606120", "mediator_canonical": "P2X7R", "outcome_canonical": "seizure severity", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37225786", "title": "P2X7 receptor antagonism by AZ10606120 significantly reduced in vitro tumour growth in human glioblastoma", "doi": "10.1038/s41598-023-35712-5", "year": 2023 } ], "bc": [ { "pmid": "36637008", "title": "The P2X7 receptor contributes to seizures and inflammation‐driven long‐lasting brain hyperexcitability following hypoxia in neonatal mice", "doi": "10.1111/bph.16033", "year": 2023 }, { "pmid": "36507708", "title": "Increased uptake of the P2X7 receptor radiotracer 18F‐JNJ‐64413739 in the brain and peripheral organs according to the severity of status epilepticus in male mice", "doi": "10.1111/epi.17484", "year": 2022 } ] } }, { "id": 1377, "drug": "Si306", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "inhibits", "mediator": "Src", "mediator_type": "protein", "predicate_bc": "predicts", "outcome": "Vascular dementia", "outcome_type": "disease", "outcome_domain": "alzheimer", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "si306", "mediator_canonical": "src", "outcome_canonical": "Vascular dementia", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "32545852", "title": "Src Inhibitors Pyrazolo[3,4-d]pyrimidines, Si306 and Pro-Si306, Inhibit Focal Adhesion Kinase and Suppress Human Glioblastoma Invasion In Vitro and In Vivo", "doi": "10.3390/cancers12061570", "year": 2020 }, { "pmid": "31248184", "title": "A New Strategy for Glioblastoma Treatment: In Vitro and In Vivo Preclinical Characterization of Si306, a Pyrazolo[3,4-d]Pyrimidine Dual Src/P-Glycoprotein Inhibitor", "doi": "10.3390/cancers11060848", "year": 2019 }, { "pmid": "31554327", "title": "Proton Therapy and Src Family Kinase Inhibitor Combined Treatments on U87 Human Glioblastoma Multiforme Cell Line", "doi": "10.3390/ijms20194745", "year": 2019 } ], "bc": [ { "pmid": "36761180", "title": "Urinary protein biomarkers based on LC–MS/MS analysis to discriminate vascular dementia from Alzheimer’s disease in Han Chinese population", "doi": "10.3389/fnagi.2023.1070854", "year": 2023 } ] } }, { "id": 1881, "drug": "ibudilast", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "inhibits", "mediator": "MIF", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "major depressive disorder", "outcome_type": "disease", "outcome_domain": "depression", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "ibudilast", "mediator_canonical": "mif", "outcome_canonical": "major depressive disorder", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "30814573", "title": "Ibudilast sensitizes glioblastoma to temozolomide by targeting Macrophage Migration Inhibitory Factor (MIF)", "doi": "10.1038/s41598-019-39427-4", "year": 2019 } ], "bc": [ { "pmid": "38144435", "title": "Elevated Serum Macrophage Migration Inhibitory Factor Levels are Associated With Major Depressive Disorder", "doi": "10.1177/2632010x231220841", "year": 2023 }, { "pmid": "36555097", "title": "Macrophage Migration Inhibitory Factor in Major Depressive Disorder: A Multilevel Pilot Study", "doi": "10.3390/ijms232415460", "year": 2022 } ] } }, { "id": 2695, "drug": "chrysophanol", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "suppresses", "mediator": "cortisol", "mediator_type": "biomarker", "predicate_bc": "associated_with", "outcome": "major depressive disorder", "outcome_type": "disease", "outcome_domain": "depression", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "chrysophanol", "mediator_canonical": "cortisol", "outcome_canonical": "major depressive disorder", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "39650161", "title": "Chrysophanol attenuates cognitive impairment, neuroinflammation, and oxidative stress by TLR4/NFκB-Nrf2/HO-1 and BDNF/VEGF signaling in stress-intensified PTZ induced epilepsy in mice", "doi": "10.3389/fphar.2024.1446304", "year": 2024 } ], "bc": [ { "pmid": "30927011", "title": "Cortisol Stress Response and in Vivo PET Imaging of Human Brain Serotonin 1A Receptor Binding", "doi": "10.1093/ijnp/pyz009", "year": 2019 }, { "pmid": "29770218", "title": "Elevated serum levels of malondialdehyde and cortisol are associated with major depressive disorder: A case-control study", "doi": "10.1177/2050312118773953", "year": 2018 } ] } }, { "id": 2699, "drug": "chrysophanol", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "suppresses", "mediator": "cortisol", "mediator_type": "biomarker", "predicate_bc": "predicts", "outcome": "depression", "outcome_type": "disease", "outcome_domain": "depression", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "chrysophanol", "mediator_canonical": "cortisol", "outcome_canonical": "depression", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "39650161", "title": "Chrysophanol attenuates cognitive impairment, neuroinflammation, and oxidative stress by TLR4/NFκB-Nrf2/HO-1 and BDNF/VEGF signaling in stress-intensified PTZ induced epilepsy in mice", "doi": "10.3389/fphar.2024.1446304", "year": 2024 } ], "bc": [ { "pmid": "36090246", "title": "Combined serum IL-6, C-reactive protein, and cortisol may distinguish patients with anhedonia in major depressive disorder", "doi": "10.3389/fnmol.2022.935031", "year": 2022 }, { "pmid": "32038321", "title": "Cognitive Distortions in Relation to Plasma Cortisol and Oxytocin Levels in Major Depressive Disorder", "doi": "10.3389/fpsyt.2019.00971", "year": 2020 }, { "pmid": "29683396", "title": "Reduced peripheral availability of tryptophan and increased activation of the kynurenine pathway and cortisol correlate with major depression and suicide", "doi": "10.1080/15622975.2018.1468031", "year": 2018 } ] } }, { "id": 3424, "drug": "tFNAs", "drug_type": "drug", "drug_domain": "alzheimer", "predicate_ab": "upregulates", "mediator": "RRM2", "mediator_type": "gene", "predicate_bc": "associated_with", "outcome": "glioblastoma", "outcome_type": "disease", "outcome_domain": "glioblastoma", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "tfnas", "mediator_canonical": "RRM2", "outcome_canonical": "glioblastoma", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "39506721", "title": "Tetrahedral framework nucleic acids inhibit Aβ-mediated ferroptosis and ameliorate cognitive and synaptic impairments in Alzheimer’s disease", "doi": "10.1186/s12951-024-02963-x", "year": 2024 } ], "bc": [ { "pmid": "39248068", "title": "Bioinformatics Analysis Screening and Identification of Key Biomarkers and Drug Targets in Human Glioblastoma", "doi": "10.2174/0109298673316883240829073901", "year": 2024 }, { "pmid": "35651787", "title": "RRM2 Mediates the Anti-Tumor Effect of the Natural Product Pectolinarigenin on Glioblastoma Through Promoting CDK1 Protein Degradation by Increasing Autophagic Flux", "doi": "10.3389/fonc.2022.887294", "year": 2022 }, { "pmid": "31119182", "title": "Identification of Potential Biomarkers in Glioblastoma through Bioinformatic Analysis and Evaluating Their Prognostic Value", "doi": "10.1155/2019/6581576", "year": 2019 } ] } }, { "id": 3588, "drug": "CLR01", "drug_type": "drug", "drug_domain": "alzheimer", "predicate_ab": "binds_to", "mediator": "TAU", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "BA35 thickness", "outcome_type": "phenotype", "outcome_domain": "epilepsy", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "clr01", "mediator_canonical": "MAPT", "outcome_canonical": "ba35 thickness", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "31046227", "title": "Major Differences between the Self-Assembly and Seeding Behavior of Heparin-Induced and in Vitro Phosphorylated Tau and Their Modulation by Potential Inhibitors", "doi": "10.1021/acschembio.9b00325", "year": 2019 }, { "pmid": "30062477", "title": "Native Top-Down Mass Spectrometry and Ion Mobility Spectrometry of the Interaction of Tau Protein with a Molecular Tweezer Assembly Modulator", "doi": "10.1007/s13361-018-2027-6", "year": 2018 } ], "bc": [ { "pmid": "34289895", "title": "Downstream effects of polypathology on neurodegeneration of medial temporal lobe subregions", "doi": "10.1186/s40478-021-01225-3", "year": 2021 } ] } }, { "id": 3589, "drug": "CLR01", "drug_type": "drug", "drug_domain": "alzheimer", "predicate_ab": "binds_to", "mediator": "TAU", "mediator_type": "protein", "predicate_bc": "causes", "outcome": "excitation/inhibition imbalance", "outcome_type": "phenotype", "outcome_domain": "epilepsy", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "clr01", "mediator_canonical": "MAPT", "outcome_canonical": "excitation/inhibition imbalance", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "31046227", "title": "Major Differences between the Self-Assembly and Seeding Behavior of Heparin-Induced and in Vitro Phosphorylated Tau and Their Modulation by Potential Inhibitors", "doi": "10.1021/acschembio.9b00325", "year": 2019 }, { "pmid": "30062477", "title": "Native Top-Down Mass Spectrometry and Ion Mobility Spectrometry of the Interaction of Tau Protein with a Molecular Tweezer Assembly Modulator", "doi": "10.1007/s13361-018-2027-6", "year": 2018 } ], "bc": [ { "pmid": "37662693", "title": "Combining aperiodic 1/f slopes and brain simulation: An EEG/MEG proxy marker of excitation/inhibition imbalance in Alzheimer's disease", "doi": "10.1002/dad2.12477", "year": 2023 } ] } }, { "id": 3590, "drug": "CLR01", "drug_type": "drug", "drug_domain": "alzheimer", "predicate_ab": "binds_to", "mediator": "TAU", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "entorhinal cortex atrophy", "outcome_type": "phenotype", "outcome_domain": "epilepsy", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "clr01", "mediator_canonical": "MAPT", "outcome_canonical": "entorhinal cortex atrophy", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "31046227", "title": "Major Differences between the Self-Assembly and Seeding Behavior of Heparin-Induced and in Vitro Phosphorylated Tau and Their Modulation by Potential Inhibitors", "doi": "10.1021/acschembio.9b00325", "year": 2019 }, { "pmid": "30062477", "title": "Native Top-Down Mass Spectrometry and Ion Mobility Spectrometry of the Interaction of Tau Protein with a Molecular Tweezer Assembly Modulator", "doi": "10.1007/s13361-018-2027-6", "year": 2018 } ], "bc": [ { "pmid": "33725124", "title": "Early stages of tau pathology and its associations with functional connectivity, atrophy and memory", "doi": "10.1093/brain/awab114", "year": 2021 } ] } }, { "id": 3600, "drug": "CLR01", "drug_type": "drug", "drug_domain": "alzheimer", "predicate_ab": "binds_to", "mediator": "TAU", "mediator_type": "protein", "predicate_bc": "causes", "outcome": "seizures", "outcome_type": "phenotype", "outcome_domain": "epilepsy", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "clr01", "mediator_canonical": "MAPT", "outcome_canonical": "seizures", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "31046227", "title": "Major Differences between the Self-Assembly and Seeding Behavior of Heparin-Induced and in Vitro Phosphorylated Tau and Their Modulation by Potential Inhibitors", "doi": "10.1021/acschembio.9b00325", "year": 2019 }, { "pmid": "30062477", "title": "Native Top-Down Mass Spectrometry and Ion Mobility Spectrometry of the Interaction of Tau Protein with a Molecular Tweezer Assembly Modulator", "doi": "10.1007/s13361-018-2027-6", "year": 2018 } ], "bc": [ { "pmid": "36648207", "title": "Does Alzheimer's disease with mesial temporal lobe epilepsy represent a distinct disease subtype?", "doi": "10.1002/alz.12943", "year": 2023 } ] } }, { "id": 3627, "drug": "CLR01", "drug_type": "drug", "drug_domain": "alzheimer", "predicate_ab": "binds_to", "mediator": "TAU", "mediator_type": "protein", "predicate_bc": "increases", "outcome": "neuronal hyperexcitability", "outcome_type": "phenotype", "outcome_domain": "epilepsy", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "clr01", "mediator_canonical": "MAPT", "outcome_canonical": "neuronal hyperexcitability", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "31046227", "title": "Major Differences between the Self-Assembly and Seeding Behavior of Heparin-Induced and in Vitro Phosphorylated Tau and Their Modulation by Potential Inhibitors", "doi": "10.1021/acschembio.9b00325", "year": 2019 }, { "pmid": "30062477", "title": "Native Top-Down Mass Spectrometry and Ion Mobility Spectrometry of the Interaction of Tau Protein with a Molecular Tweezer Assembly Modulator", "doi": "10.1007/s13361-018-2027-6", "year": 2018 } ], "bc": [ { "pmid": "36648207", "title": "Does Alzheimer's disease with mesial temporal lobe epilepsy represent a distinct disease subtype?", "doi": "10.1002/alz.12943", "year": 2023 } ] } }, { "id": 3650, "drug": "CLR01", "drug_type": "drug", "drug_domain": "alzheimer", "predicate_ab": "binds_to", "mediator": "TAU", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "subiculum thickness", "outcome_type": "phenotype", "outcome_domain": "epilepsy", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "clr01", "mediator_canonical": "MAPT", "outcome_canonical": "subiculum thickness", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "31046227", "title": "Major Differences between the Self-Assembly and Seeding Behavior of Heparin-Induced and in Vitro Phosphorylated Tau and Their Modulation by Potential Inhibitors", "doi": "10.1021/acschembio.9b00325", "year": 2019 }, { "pmid": "30062477", "title": "Native Top-Down Mass Spectrometry and Ion Mobility Spectrometry of the Interaction of Tau Protein with a Molecular Tweezer Assembly Modulator", "doi": "10.1007/s13361-018-2027-6", "year": 2018 } ], "bc": [ { "pmid": "34289895", "title": "Downstream effects of polypathology on neurodegeneration of medial temporal lobe subregions", "doi": "10.1186/s40478-021-01225-3", "year": 2021 } ] } }, { "id": 3651, "drug": "CLR01", "drug_type": "drug", "drug_domain": "alzheimer", "predicate_ab": "binds_to", "mediator": "TAU", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "SRLM thickness", "outcome_type": "phenotype", "outcome_domain": "epilepsy", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "clr01", "mediator_canonical": "MAPT", "outcome_canonical": "srlm thickness", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "31046227", "title": "Major Differences between the Self-Assembly and Seeding Behavior of Heparin-Induced and in Vitro Phosphorylated Tau and Their Modulation by Potential Inhibitors", "doi": "10.1021/acschembio.9b00325", "year": 2019 }, { "pmid": "30062477", "title": "Native Top-Down Mass Spectrometry and Ion Mobility Spectrometry of the Interaction of Tau Protein with a Molecular Tweezer Assembly Modulator", "doi": "10.1007/s13361-018-2027-6", "year": 2018 } ], "bc": [ { "pmid": "34289895", "title": "Downstream effects of polypathology on neurodegeneration of medial temporal lobe subregions", "doi": "10.1186/s40478-021-01225-3", "year": 2021 } ] } }, { "id": 3665, "drug": "CLR01", "drug_type": "drug", "drug_domain": "alzheimer", "predicate_ab": "binds_to", "mediator": "TAU", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "entorhinal cortex volume", "outcome_type": "phenotype", "outcome_domain": "epilepsy", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "clr01", "mediator_canonical": "MAPT", "outcome_canonical": "entorhinal cortex volume", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "31046227", "title": "Major Differences between the Self-Assembly and Seeding Behavior of Heparin-Induced and in Vitro Phosphorylated Tau and Their Modulation by Potential Inhibitors", "doi": "10.1021/acschembio.9b00325", "year": 2019 }, { "pmid": "30062477", "title": "Native Top-Down Mass Spectrometry and Ion Mobility Spectrometry of the Interaction of Tau Protein with a Molecular Tweezer Assembly Modulator", "doi": "10.1007/s13361-018-2027-6", "year": 2018 } ], "bc": [ { "pmid": "33990226", "title": "Pathological drivers of neurodegeneration in suspected non-Alzheimer’s disease pathophysiology", "doi": "10.1186/s13195-021-00835-2", "year": 2021 } ] } }, { "id": 3666, "drug": "CLR01", "drug_type": "drug", "drug_domain": "alzheimer", "predicate_ab": "binds_to", "mediator": "TAU", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "ERC thickness", "outcome_type": "phenotype", "outcome_domain": "epilepsy", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "clr01", "mediator_canonical": "MAPT", "outcome_canonical": "erc thickness", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "31046227", "title": "Major Differences between the Self-Assembly and Seeding Behavior of Heparin-Induced and in Vitro Phosphorylated Tau and Their Modulation by Potential Inhibitors", "doi": "10.1021/acschembio.9b00325", "year": 2019 }, { "pmid": "30062477", "title": "Native Top-Down Mass Spectrometry and Ion Mobility Spectrometry of the Interaction of Tau Protein with a Molecular Tweezer Assembly Modulator", "doi": "10.1007/s13361-018-2027-6", "year": 2018 } ], "bc": [ { "pmid": "34289895", "title": "Downstream effects of polypathology on neurodegeneration of medial temporal lobe subregions", "doi": "10.1186/s40478-021-01225-3", "year": 2021 } ] } }, { "id": 3679, "drug": "CLR01", "drug_type": "drug", "drug_domain": "alzheimer", "predicate_ab": "binds_to", "mediator": "TAU", "mediator_type": "protein", "predicate_bc": "predicts", "outcome": "neuronal injury severity", "outcome_type": "phenotype", "outcome_domain": "epilepsy", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "clr01", "mediator_canonical": "MAPT", "outcome_canonical": "neuronal injury severity", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "31046227", "title": "Major Differences between the Self-Assembly and Seeding Behavior of Heparin-Induced and in Vitro Phosphorylated Tau and Their Modulation by Potential Inhibitors", "doi": "10.1021/acschembio.9b00325", "year": 2019 }, { "pmid": "30062477", "title": "Native Top-Down Mass Spectrometry and Ion Mobility Spectrometry of the Interaction of Tau Protein with a Molecular Tweezer Assembly Modulator", "doi": "10.1007/s13361-018-2027-6", "year": 2018 } ], "bc": [ { "pmid": "38249745", "title": "Proposed mechanisms of tau: relationships to traumatic brain injury, Alzheimer’s disease, and epilepsy", "doi": "10.3389/fneur.2023.1287545", "year": 2024 } ] } }, { "id": 3695, "drug": "CLR01", "drug_type": "drug", "drug_domain": "alzheimer", "predicate_ab": "binds_to", "mediator": "TAU", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "object memory impairment", "outcome_type": "phenotype", "outcome_domain": "epilepsy", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "clr01", "mediator_canonical": "MAPT", "outcome_canonical": "object memory impairment", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "31046227", "title": "Major Differences between the Self-Assembly and Seeding Behavior of Heparin-Induced and in Vitro Phosphorylated Tau and Their Modulation by Potential Inhibitors", "doi": "10.1021/acschembio.9b00325", "year": 2019 }, { "pmid": "30062477", "title": "Native Top-Down Mass Spectrometry and Ion Mobility Spectrometry of the Interaction of Tau Protein with a Molecular Tweezer Assembly Modulator", "doi": "10.1007/s13361-018-2027-6", "year": 2018 } ], "bc": [ { "pmid": "31199481", "title": "Alzheimer’s pathology targets distinct memory networks in the ageing brain", "doi": "10.1093/brain/awz154", "year": 2019 } ] } }, { "id": 3720, "drug": "CLR01", "drug_type": "drug", "drug_domain": "alzheimer", "predicate_ab": "binds_to", "mediator": "TAU", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "posterior hippocampal atrophy", "outcome_type": "phenotype", "outcome_domain": "epilepsy", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "clr01", "mediator_canonical": "MAPT", "outcome_canonical": "posterior hippocampal atrophy", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "31046227", "title": "Major Differences between the Self-Assembly and Seeding Behavior of Heparin-Induced and in Vitro Phosphorylated Tau and Their Modulation by Potential Inhibitors", "doi": "10.1021/acschembio.9b00325", "year": 2019 }, { "pmid": "30062477", "title": "Native Top-Down Mass Spectrometry and Ion Mobility Spectrometry of the Interaction of Tau Protein with a Molecular Tweezer Assembly Modulator", "doi": "10.1007/s13361-018-2027-6", "year": 2018 } ], "bc": [ { "pmid": "33725124", "title": "Early stages of tau pathology and its associations with functional connectivity, atrophy and memory", "doi": "10.1093/brain/awab114", "year": 2021 } ] } }, { "id": 3778, "drug": "CLR01", "drug_type": "drug", "drug_domain": "alzheimer", "predicate_ab": "binds_to", "mediator": "TAU", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "Kii ALS/PDC", "outcome_type": "disease", "outcome_domain": "als", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "clr01", "mediator_canonical": "MAPT", "outcome_canonical": "kii als/pdc", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "31046227", "title": "Major Differences between the Self-Assembly and Seeding Behavior of Heparin-Induced and in Vitro Phosphorylated Tau and Their Modulation by Potential Inhibitors", "doi": "10.1021/acschembio.9b00325", "year": 2019 }, { "pmid": "30062477", "title": "Native Top-Down Mass Spectrometry and Ion Mobility Spectrometry of the Interaction of Tau Protein with a Molecular Tweezer Assembly Modulator", "doi": "10.1007/s13361-018-2027-6", "year": 2018 } ], "bc": [ { "pmid": "29063640", "title": "Amyotrophic lateral sclerosis and parkinsonism‐dementia complex of the Hohara focus of the Kii Peninsula: A multiple proteinopathy?", "doi": "10.1111/neup.12434", "year": 2017 } ] } }, { "id": 4390, "drug": "AZ20", "drug_type": "drug", "drug_domain": "pancreatic_cancer", "predicate_ab": "downregulates", "mediator": "RRM2", "mediator_type": "gene", "predicate_bc": "associated_with", "outcome": "glioblastoma", "outcome_type": "disease", "outcome_domain": "glioblastoma", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "az20", "mediator_canonical": "RRM2", "outcome_canonical": "glioblastoma", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "28440428", "title": "Inhibition of ATR potentiates the cytotoxic effect of gemcitabine on pancreatic cancer cells through enhancement of DNA damage and abrogation of ribonucleotide reductase induction by gemcitabine", "doi": "10.3892/or.2017.5580", "year": 2017 } ], "bc": [ { "pmid": "39248068", "title": "Bioinformatics Analysis Screening and Identification of Key Biomarkers and Drug Targets in Human Glioblastoma", "doi": "10.2174/0109298673316883240829073901", "year": 2024 }, { "pmid": "35651787", "title": "RRM2 Mediates the Anti-Tumor Effect of the Natural Product Pectolinarigenin on Glioblastoma Through Promoting CDK1 Protein Degradation by Increasing Autophagic Flux", "doi": "10.3389/fonc.2022.887294", "year": 2022 }, { "pmid": "31119182", "title": "Identification of Potential Biomarkers in Glioblastoma through Bioinformatic Analysis and Evaluating Their Prognostic Value", "doi": "10.1155/2019/6581576", "year": 2019 } ] } }, { "id": 4391, "drug": "deferasirox", "drug_type": "drug", "drug_domain": "pancreatic_cancer", "predicate_ab": "inhibits", "mediator": "RRM2", "mediator_type": "gene", "predicate_bc": "associated_with", "outcome": "glioblastoma", "outcome_type": "disease", "outcome_domain": "glioblastoma", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "deferasirox", "mediator_canonical": "RRM2", "outcome_canonical": "glioblastoma", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "34575569", "title": "M1 Macrophage-Derived Exosomes Loaded with Gemcitabine and Deferasirox against Chemoresistant Pancreatic Cancer", "doi": "10.3390/pharmaceutics13091493", "year": 2021 } ], "bc": [ { "pmid": "39248068", "title": "Bioinformatics Analysis Screening and Identification of Key Biomarkers and Drug Targets in Human Glioblastoma", "doi": "10.2174/0109298673316883240829073901", "year": 2024 }, { "pmid": "35651787", "title": "RRM2 Mediates the Anti-Tumor Effect of the Natural Product Pectolinarigenin on Glioblastoma Through Promoting CDK1 Protein Degradation by Increasing Autophagic Flux", "doi": "10.3389/fonc.2022.887294", "year": 2022 }, { "pmid": "31119182", "title": "Identification of Potential Biomarkers in Glioblastoma through Bioinformatic Analysis and Evaluating Their Prognostic Value", "doi": "10.1155/2019/6581576", "year": 2019 } ] } }, { "id": 5288, "drug": "Glyphosate", "drug_type": "drug", "drug_domain": "depression", "predicate_ab": "binds_to", "mediator": "TP53", "mediator_type": "gene", "predicate_bc": "associated_with", "outcome": "glioblastoma", "outcome_type": "disease", "outcome_domain": "glioblastoma", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "glyphosate", "mediator_canonical": "TP53", "outcome_canonical": "glioblastoma", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "38297317", "title": "Clarification of the molecular mechanisms underlying glyphosate-induced major depressive disorder: a network toxicology approach", "doi": "10.1186/s12991-024-00491-4", "year": 2024 } ], "bc": [ { "pmid": "38473403", "title": "Haploinsufficiency of Adenomatous Polyposis Coli Coupled with Kirsten Rat Sarcoma Viral Oncogene Homologue Activation and P53 Loss Provokes High-Grade Glioblastoma Formation in Mice", "doi": "10.3390/cancers16051046", "year": 2024 }, { "pmid": "39611928", "title": "Bioinformatics Examination of Glioblastoma Identifies a Potential Panel of Therapeutic Biomarkers", "doi": "10.31557/apjcp.2024.25.11.4035", "year": 2024 }, { "pmid": "37140883", "title": "Genome-wide profiling of patient-derived glioblastoma stem-like cells reveals recurrent genetic and transcriptomic signatures associated with brain tumors", "doi": "10.1007/s11060-023-04287-6", "year": 2023 } ] } }, { "id": 5448, "drug": "mosapramine", "drug_type": "drug", "drug_domain": "depression", "predicate_ab": "binds_to", "mediator": "EGFR", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "pancreatic ductal adenocarcinoma", "outcome_type": "disease", "outcome_domain": "pancreatic_cancer", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "mosapramine", "mediator_canonical": "EGFR", "outcome_canonical": "pancreatic ductal adenocarcinoma", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41326335", "title": "Computational biological analysis reveals that HIF-1 and FoxO signaling pathways influence cognitive impairment in patients with depression", "doi": "10.1038/s41398-025-03775-9", "year": 2025 } ], "bc": [ { "pmid": "40130819", "title": "Identification of Tumor‐Specific Surface Proteins Enables Quantification of Extracellular Vesicle Subtypes for Early Detection of Pancreatic Ductal Adenocarcinoma", "doi": "10.1002/advs.202414982", "year": 2025 }, { "pmid": "31584260", "title": "Design and Evaluation of PEGylated Liposomal Formulation of a Novel Multikinase Inhibitor for Enhanced Chemosensitivity and Inhibition of Metastatic Pancreatic Ductal Adenocarcinoma", "doi": "10.1021/acs.bioconjchem.9b00632", "year": 2019 }, { "pmid": "26339400", "title": "EGFR expression in pancreatic intraepithelial neoplasia and ductal adenocarcinoma.", "doi": null, "year": 2015 } ] } }, { "id": 5473, "drug": "Glyphosate", "drug_type": "drug", "drug_domain": "depression", "predicate_ab": "binds_to", "mediator": "TP53", "mediator_type": "gene", "predicate_bc": "prevents", "outcome": "pancreatic cancer", "outcome_type": "disease", "outcome_domain": "pancreatic_cancer", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "glyphosate", "mediator_canonical": "TP53", "outcome_canonical": "pancreatic cancer", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "38297317", "title": "Clarification of the molecular mechanisms underlying glyphosate-induced major depressive disorder: a network toxicology approach", "doi": "10.1186/s12991-024-00491-4", "year": 2024 } ], "bc": [ { "pmid": "36853374", "title": "Precision Oncology in Pancreatic Cancer: Experiences and Challenges of the CCCMunichLMU Molecular Tumor Board", "doi": "10.1007/s11523-023-00950-0", "year": 2023 }, { "pmid": "33350171", "title": "Genetic aberrations in Chinese pancreatic cancer patients and their association with anatomic location and disease outcomes", "doi": "10.1002/cam4.3679", "year": 2020 }, { "pmid": "27991926", "title": "Chronic inflammation initiates multiple forms of K-Ras-independent mouse pancreatic cancer in the absence of TP53", "doi": "10.1038/onc.2016.461", "year": 2016 } ] } }, { "id": 5925, "drug": "Chlorotoxin", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "binds_to", "mediator": "MMP-2", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "brain amyloid deposition", "outcome_type": "phenotype", "outcome_domain": "alzheimer", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "chlorotoxin", "mediator_canonical": "MMP2", "outcome_canonical": "brain amyloid deposition", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41955189", "title": "Chlorotoxin does not target matrix metalloproteinase-2 in glioblastoma", "doi": "10.1371/journal.pone.0328964", "year": 2026 } ], "bc": [ { "pmid": "34680129", "title": "Relationship between Cerebrospinal Fluid Matrix Metalloproteinases Levels and Brain Amyloid Deposition in Mild Cognitive Impairment", "doi": "10.3390/biom11101496", "year": 2021 } ] } }, { "id": 5937, "drug": "CGF-Conditioned Medium", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "upregulates", "mediator": "GFAP", "mediator_type": "protein", "predicate_bc": "predicts", "outcome": "cognitive decline", "outcome_type": "phenotype", "outcome_domain": "alzheimer", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "cgf-conditioned medium", "mediator_canonical": "GFAP", "outcome_canonical": "cognitive decline", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41154863", "title": "CGF-Conditioned Medium Modulates Astrocytic Differentiation and Invasiveness in U87MG Glioblastoma Cells", "doi": "10.3390/biology14101461", "year": 2025 } ], "bc": [ { "pmid": "40110647", "title": "Exploratory analysis of the proteomic profile in plasma in adults with Down syndrome in the context of Alzheimer's disease", "doi": "10.1002/alz.70040", "year": 2025 }, { "pmid": "37787146", "title": "Longitudinal associations of serum biomarkers with early cognitive, amyloid and grey matter changes", "doi": "10.1093/brain/awad330", "year": 2023 }, { "pmid": "36446595", "title": "Longitudinal Changes in Blood Biomarkers of Clinical Alzheimer Disease in a Biracial Population Sample", "doi": "10.1212/wnl.0000000000201289", "year": 2022 } ] } }, { "id": 6160, "drug": "Chlorotoxin", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "binds_to", "mediator": "MMP-2", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "pancreatic cancer", "outcome_type": "disease", "outcome_domain": "pancreatic_cancer", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "completed", "clinical_trial_nct_ids": [ "NCT00379132" ], "literature_status": "novel_signal", "drug_canonical": "chlorotoxin", "mediator_canonical": "MMP2", "outcome_canonical": "pancreatic cancer", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41955189", "title": "Chlorotoxin does not target matrix metalloproteinase-2 in glioblastoma", "doi": "10.1371/journal.pone.0328964", "year": 2026 } ], "bc": [ { "pmid": "29355139", "title": "Prognostic significance of plasma matrix metalloprotease-2 in pancreatic cancer patients", "doi": "10.4103/ijmr.ijmr_1348_15", "year": 2017 } ] } }, { "id": 6138, "drug": "GR20hh'", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "binds_to", "mediator": "EGFR", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "pancreatic ductal adenocarcinoma", "outcome_type": "disease", "outcome_domain": "pancreatic_cancer", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "gr20hh'", "mediator_canonical": "EGFR", "outcome_canonical": "pancreatic ductal adenocarcinoma", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40943631", "title": "Real-Time Kinetics of Internalization of Anti-EGFR DNA Aptamers and Aptamer Constructs into Cells Derived from Glioblastoma Patients as Indicated by Doxorubicin", "doi": "10.3390/ijms26178712", "year": 2025 } ], "bc": [ { "pmid": "40130819", "title": "Identification of Tumor‐Specific Surface Proteins Enables Quantification of Extracellular Vesicle Subtypes for Early Detection of Pancreatic Ductal Adenocarcinoma", "doi": "10.1002/advs.202414982", "year": 2025 }, { "pmid": "31584260", "title": "Design and Evaluation of PEGylated Liposomal Formulation of a Novel Multikinase Inhibitor for Enhanced Chemosensitivity and Inhibition of Metastatic Pancreatic Ductal Adenocarcinoma", "doi": "10.1021/acs.bioconjchem.9b00632", "year": 2019 }, { "pmid": "26339400", "title": "EGFR expression in pancreatic intraepithelial neoplasia and ductal adenocarcinoma.", "doi": null, "year": 2015 } ] } }, { "id": 25967, "drug": "CLR01", "drug_type": "drug", "drug_domain": "alzheimer", "predicate_ab": "binds_to", "mediator": "tau", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "neurodegenerative diseases", "outcome_type": "disease", "outcome_domain": "als", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "clr01", "mediator_canonical": "MAPT", "outcome_canonical": null, "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "31046227", "title": "Major Differences between the Self-Assembly and Seeding Behavior of Heparin-Induced and in Vitro Phosphorylated Tau and Their Modulation by Potential Inhibitors", "doi": "10.1021/acschembio.9b00325", "year": 2019 }, { "pmid": "30062477", "title": "Native Top-Down Mass Spectrometry and Ion Mobility Spectrometry of the Interaction of Tau Protein with a Molecular Tweezer Assembly Modulator", "doi": "10.1007/s13361-018-2027-6", "year": 2018 } ], "bc": [ { "pmid": "40960157", "title": "Protein aggregation in neurodegenerative diseases", "doi": "10.1097/cm9.0000000000003802", "year": 2025 } ] } }, { "id": 6905, "drug": "Ketogenic diet", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "downregulates", "mediator": "GFAP", "mediator_type": "protein", "predicate_bc": "predicts", "outcome": "cognitive decline", "outcome_type": "phenotype", "outcome_domain": "alzheimer", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "active", "clinical_trial_nct_ids": [ "NCT03472664", "NCT05708716", "NCT06444568" ], "literature_status": "reproduces_known", "drug_canonical": "ketogenic diet", "mediator_canonical": "GFAP", "outcome_canonical": "cognitive decline", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "32539054", "title": "Amelioration of clinical course and demyelination in the cuprizone mouse model in relation to ketogenic diet", "doi": "10.1039/c9fo02944c", "year": 2020 } ], "bc": [ { "pmid": "40110647", "title": "Exploratory analysis of the proteomic profile in plasma in adults with Down syndrome in the context of Alzheimer's disease", "doi": "10.1002/alz.70040", "year": 2025 }, { "pmid": "37787146", "title": "Longitudinal associations of serum biomarkers with early cognitive, amyloid and grey matter changes", "doi": "10.1093/brain/awad330", "year": 2023 }, { "pmid": "36446595", "title": "Longitudinal Changes in Blood Biomarkers of Clinical Alzheimer Disease in a Biracial Population Sample", "doi": "10.1212/wnl.0000000000201289", "year": 2022 } ] } }, { "id": 6917, "drug": "Ketogenic diet", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "downregulates", "mediator": "GFAP", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "Alzheimer disease", "outcome_type": "disease", "outcome_domain": "alzheimer", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "active", "clinical_trial_nct_ids": [ "NCT04968041", "NCT03472664", "NCT04701957" ], "literature_status": "reproduces_known", "drug_canonical": "ketogenic diet", "mediator_canonical": "GFAP", "outcome_canonical": "Alzheimer disease", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "32539054", "title": "Amelioration of clinical course and demyelination in the cuprizone mouse model in relation to ketogenic diet", "doi": "10.1039/c9fo02944c", "year": 2020 } ], "bc": [ { "pmid": "41081630", "title": "Age-Specific Control and Alzheimer Disease Reference Curves and z -Scores for Glial Fibrillary Acidic Protein in Blood", "doi": "10.1093/clinchem/hvaf120", "year": 2025 }, { "pmid": "29755340", "title": "Glutamate Transporter GLT1 Expression in Alzheimer Disease and Dementia With Lewy Bodies", "doi": "10.3389/fnagi.2018.00122", "year": 2018 } ] } }, { "id": 6892, "drug": "FK506", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "downregulates", "mediator": "GFAP", "mediator_type": "protein", "predicate_bc": "predicts", "outcome": "cognitive decline", "outcome_type": "phenotype", "outcome_domain": "alzheimer", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "completed", "clinical_trial_nct_ids": [ "NCT04263519" ], "literature_status": "reproduces_known", "drug_canonical": "tacrolimus", "mediator_canonical": "GFAP", "outcome_canonical": "cognitive decline", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "29375315", "title": "The Calcineurin Inhibitor FK506 Prevents Cognitive Impairment by Inhibiting Reactive Astrogliosis in Pilocarpine-Induced Status Epilepticus Rats", "doi": "10.3389/fncel.2017.00428", "year": 2018 } ], "bc": [ { "pmid": "40110647", "title": "Exploratory analysis of the proteomic profile in plasma in adults with Down syndrome in the context of Alzheimer's disease", "doi": "10.1002/alz.70040", "year": 2025 }, { "pmid": "37787146", "title": "Longitudinal associations of serum biomarkers with early cognitive, amyloid and grey matter changes", "doi": "10.1093/brain/awad330", "year": 2023 }, { "pmid": "36446595", "title": "Longitudinal Changes in Blood Biomarkers of Clinical Alzheimer Disease in a Biracial Population Sample", "doi": "10.1212/wnl.0000000000201289", "year": 2022 } ] } }, { "id": 6889, "drug": "compound 7b", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "downregulates", "mediator": "GFAP", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "Alzheimer disease", "outcome_type": "disease", "outcome_domain": "alzheimer", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "compound 7b", "mediator_canonical": "GFAP", "outcome_canonical": "Alzheimer disease", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41113602", "title": "Discovery and characterization of phenoxyacetic acid derivatives as potential antiepileptic agents", "doi": "10.1039/d5ra05596b", "year": 2025 } ], "bc": [ { "pmid": "41081630", "title": "Age-Specific Control and Alzheimer Disease Reference Curves and z -Scores for Glial Fibrillary Acidic Protein in Blood", "doi": "10.1093/clinchem/hvaf120", "year": 2025 }, { "pmid": "29755340", "title": "Glutamate Transporter GLT1 Expression in Alzheimer Disease and Dementia With Lewy Bodies", "doi": "10.3389/fnagi.2018.00122", "year": 2018 } ] } }, { "id": 6909, "drug": "compound 7b", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "downregulates", "mediator": "GFAP", "mediator_type": "protein", "predicate_bc": "predicts", "outcome": "cognitive decline", "outcome_type": "phenotype", "outcome_domain": "alzheimer", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "compound 7b", "mediator_canonical": "GFAP", "outcome_canonical": "cognitive decline", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41113602", "title": "Discovery and characterization of phenoxyacetic acid derivatives as potential antiepileptic agents", "doi": "10.1039/d5ra05596b", "year": 2025 } ], "bc": [ { "pmid": "40110647", "title": "Exploratory analysis of the proteomic profile in plasma in adults with Down syndrome in the context of Alzheimer's disease", "doi": "10.1002/alz.70040", "year": 2025 }, { "pmid": "37787146", "title": "Longitudinal associations of serum biomarkers with early cognitive, amyloid and grey matter changes", "doi": "10.1093/brain/awad330", "year": 2023 }, { "pmid": "36446595", "title": "Longitudinal Changes in Blood Biomarkers of Clinical Alzheimer Disease in a Biracial Population Sample", "doi": "10.1212/wnl.0000000000201289", "year": 2022 } ] } }, { "id": 7654, "drug": "pridopidine", "drug_type": "drug", "drug_domain": "als", "predicate_ab": "activates", "mediator": "sigma-1 receptor", "mediator_type": "protein", "predicate_bc": "decreases", "outcome": "seizure susceptibility", "outcome_type": "phenotype", "outcome_domain": "epilepsy", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "pridopidine", "mediator_canonical": "sigma-1 receptor", "outcome_canonical": "seizure susceptibility", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41471389", "title": "Pridopidine, a Potent and Selective Therapeutic Sigma-1 Receptor (S1R) Agonist for Treating Neurodegenerative Diseases", "doi": "10.3390/ph18121900", "year": 2025 }, { "pmid": "35080077", "title": "Pridopidine modifies disease phenotype in a SOD1 mouse model of amyotrophic lateral sclerosis", "doi": "10.1111/ejn.15608", "year": 2022 }, { "pmid": "30824685", "title": "Targeting the Sigma-1 Receptor via Pridopidine Ameliorates Central Features of ALS Pathology in a SOD1G93A Model", "doi": "10.1038/s41419-019-1451-2", "year": 2019 } ], "bc": [ { "pmid": "33385516", "title": "Genetic inactivation of the sigma-1 chaperone protein results in decreased expression of the R2 subunit of the GABA-B receptor and increased susceptibility to seizures", "doi": "10.1016/j.nbd.2020.105244", "year": 2020 } ] } }, { "id": 8239, "drug": "Palmitoylethanolamide", "drug_type": "drug", "drug_domain": "als", "predicate_ab": "upregulates", "mediator": "BDNF", "mediator_type": "protein", "predicate_bc": "decreases", "outcome": "schizophrenia", "outcome_type": "disease", "outcome_domain": "depression", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "preclinical_only", "clinical_trial_nct_ids": [ "NCT06037993" ], "literature_status": "partial_evidence", "drug_canonical": "palmitoylethanolamide", "mediator_canonical": "BDNF", "outcome_canonical": "schizophrenia", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "42041537", "title": "Sustained Palmitoylethanolamide Infusion Restores Incentive Motivation and Synaptic Plasticity in the Tg2576 Mouse Model of Alzheimer’s Disease", "doi": "10.3390/cells15080669", "year": 2026 } ], "bc": [ { "pmid": "34280516", "title": "Associations of immunological proteins/traits with schizophrenia, major depression and bipolar disorder: A bi-directional two-sample mendelian randomization study", "doi": "10.1016/j.bbi.2021.07.009", "year": 2021 }, { "pmid": "30794585", "title": "Accuracy of brain-derived neurotrophic factor levels for differentiating between Taiwanese patients with major depressive disorder or schizophrenia and healthy controls", "doi": "10.1371/journal.pone.0212373", "year": 2019 } ] } }, { "id": 8603, "drug": "CLR01", "drug_type": "drug", "drug_domain": "alzheimer", "predicate_ab": "binds_to", "mediator": "TAU", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "increased glucose metabolism", "outcome_type": "phenotype", "outcome_domain": "epilepsy", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "clr01", "mediator_canonical": "MAPT", "outcome_canonical": "increased glucose metabolism", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "31046227", "title": "Major Differences between the Self-Assembly and Seeding Behavior of Heparin-Induced and in Vitro Phosphorylated Tau and Their Modulation by Potential Inhibitors", "doi": "10.1021/acschembio.9b00325", "year": 2019 }, { "pmid": "30062477", "title": "Native Top-Down Mass Spectrometry and Ion Mobility Spectrometry of the Interaction of Tau Protein with a Molecular Tweezer Assembly Modulator", "doi": "10.1007/s13361-018-2027-6", "year": 2018 } ], "bc": [ { "pmid": "29912295", "title": "Relationships Between Tau and Glucose Metabolism Reflect Alzheimer’s Disease Pathology in Cognitively Normal Older Adults", "doi": "10.1093/cercor/bhy078", "year": 2018 } ] } }, { "id": 8604, "drug": "CLR01", "drug_type": "drug", "drug_domain": "alzheimer", "predicate_ab": "binds_to", "mediator": "TAU", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "memory", "outcome_type": "phenotype", "outcome_domain": "epilepsy", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "clr01", "mediator_canonical": "MAPT", "outcome_canonical": "memory", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "31046227", "title": "Major Differences between the Self-Assembly and Seeding Behavior of Heparin-Induced and in Vitro Phosphorylated Tau and Their Modulation by Potential Inhibitors", "doi": "10.1021/acschembio.9b00325", "year": 2019 }, { "pmid": "30062477", "title": "Native Top-Down Mass Spectrometry and Ion Mobility Spectrometry of the Interaction of Tau Protein with a Molecular Tweezer Assembly Modulator", "doi": "10.1007/s13361-018-2027-6", "year": 2018 } ], "bc": [ { "pmid": "36353072", "title": "Cerebral blood flow, tau imaging, and memory associations in cognitively unimpaired older adults", "doi": "10.1016/j.cccb.2022.100153", "year": 2022 } ] } }, { "id": 8606, "drug": "CLR01", "drug_type": "drug", "drug_domain": "alzheimer", "predicate_ab": "binds_to", "mediator": "TAU", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "cognition", "outcome_type": "phenotype", "outcome_domain": "epilepsy", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "clr01", "mediator_canonical": "MAPT", "outcome_canonical": "cognition", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "31046227", "title": "Major Differences between the Self-Assembly and Seeding Behavior of Heparin-Induced and in Vitro Phosphorylated Tau and Their Modulation by Potential Inhibitors", "doi": "10.1021/acschembio.9b00325", "year": 2019 }, { "pmid": "30062477", "title": "Native Top-Down Mass Spectrometry and Ion Mobility Spectrometry of the Interaction of Tau Protein with a Molecular Tweezer Assembly Modulator", "doi": "10.1007/s13361-018-2027-6", "year": 2018 } ], "bc": [ { "pmid": "31584490", "title": "In Vivo Assessment of Tau Deposition in Alzheimer Disease and Assessing Its Relationship to Regional Brain Glucose Metabolism and Cognition", "doi": "10.1097/rlu.0000000000002791", "year": 2019 } ] } }, { "id": 8612, "drug": "CLR01", "drug_type": "drug", "drug_domain": "alzheimer", "predicate_ab": "binds_to", "mediator": "TAU", "mediator_type": "protein", "predicate_bc": "predicts", "outcome": "global neurodegeneration", "outcome_type": "phenotype", "outcome_domain": "epilepsy", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "clr01", "mediator_canonical": "MAPT", "outcome_canonical": "global neurodegeneration", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "31046227", "title": "Major Differences between the Self-Assembly and Seeding Behavior of Heparin-Induced and in Vitro Phosphorylated Tau and Their Modulation by Potential Inhibitors", "doi": "10.1021/acschembio.9b00325", "year": 2019 }, { "pmid": "30062477", "title": "Native Top-Down Mass Spectrometry and Ion Mobility Spectrometry of the Interaction of Tau Protein with a Molecular Tweezer Assembly Modulator", "doi": "10.1007/s13361-018-2027-6", "year": 2018 } ], "bc": [ { "pmid": "40665478", "title": "Alzheimer's disease and its co‐pathologies: Implications for hippocampal degeneration, cognitive decline, and the role of APOE ε4", "doi": "10.1002/alz.70483", "year": 2025 } ] } }, { "id": 8613, "drug": "CLR01", "drug_type": "drug", "drug_domain": "alzheimer", "predicate_ab": "binds_to", "mediator": "TAU", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "cognitive scores", "outcome_type": "phenotype", "outcome_domain": "epilepsy", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "clr01", "mediator_canonical": "MAPT", "outcome_canonical": "cognitive scores", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "31046227", "title": "Major Differences between the Self-Assembly and Seeding Behavior of Heparin-Induced and in Vitro Phosphorylated Tau and Their Modulation by Potential Inhibitors", "doi": "10.1021/acschembio.9b00325", "year": 2019 }, { "pmid": "30062477", "title": "Native Top-Down Mass Spectrometry and Ion Mobility Spectrometry of the Interaction of Tau Protein with a Molecular Tweezer Assembly Modulator", "doi": "10.1007/s13361-018-2027-6", "year": 2018 } ], "bc": [ { "pmid": "35226120", "title": "Image-level trajectory inference of tau pathology using variational autoencoder for Flortaucipir PET", "doi": "10.1007/s00259-021-05662-z", "year": 2022 } ] } }, { "id": 8621, "drug": "CLR01", "drug_type": "drug", "drug_domain": "alzheimer", "predicate_ab": "binds_to", "mediator": "TAU", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "hypometabolism", "outcome_type": "phenotype", "outcome_domain": "epilepsy", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "clr01", "mediator_canonical": "MAPT", "outcome_canonical": "hypometabolism", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "31046227", "title": "Major Differences between the Self-Assembly and Seeding Behavior of Heparin-Induced and in Vitro Phosphorylated Tau and Their Modulation by Potential Inhibitors", "doi": "10.1021/acschembio.9b00325", "year": 2019 }, { "pmid": "30062477", "title": "Native Top-Down Mass Spectrometry and Ion Mobility Spectrometry of the Interaction of Tau Protein with a Molecular Tweezer Assembly Modulator", "doi": "10.1007/s13361-018-2027-6", "year": 2018 } ], "bc": [ { "pmid": "29912295", "title": "Relationships Between Tau and Glucose Metabolism Reflect Alzheimer’s Disease Pathology in Cognitively Normal Older Adults", "doi": "10.1093/cercor/bhy078", "year": 2018 } ] } }, { "id": 8626, "drug": "CLR01", "drug_type": "drug", "drug_domain": "alzheimer", "predicate_ab": "binds_to", "mediator": "TAU", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "Braak staging", "outcome_type": "phenotype", "outcome_domain": "epilepsy", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "clr01", "mediator_canonical": "MAPT", "outcome_canonical": "braak staging", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "31046227", "title": "Major Differences between the Self-Assembly and Seeding Behavior of Heparin-Induced and in Vitro Phosphorylated Tau and Their Modulation by Potential Inhibitors", "doi": "10.1021/acschembio.9b00325", "year": 2019 }, { "pmid": "30062477", "title": "Native Top-Down Mass Spectrometry and Ion Mobility Spectrometry of the Interaction of Tau Protein with a Molecular Tweezer Assembly Modulator", "doi": "10.1007/s13361-018-2027-6", "year": 2018 } ], "bc": [ { "pmid": "35226120", "title": "Image-level trajectory inference of tau pathology using variational autoencoder for Flortaucipir PET", "doi": "10.1007/s00259-021-05662-z", "year": 2022 } ] } }, { "id": 8813, "drug": "CLR01", "drug_type": "drug", "drug_domain": "alzheimer", "predicate_ab": "binds_to", "mediator": "TAU", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "protein aggregation", "outcome_type": "phenotype", "outcome_domain": "als", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "clr01", "mediator_canonical": "MAPT", "outcome_canonical": "protein aggregation", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "31046227", "title": "Major Differences between the Self-Assembly and Seeding Behavior of Heparin-Induced and in Vitro Phosphorylated Tau and Their Modulation by Potential Inhibitors", "doi": "10.1021/acschembio.9b00325", "year": 2019 }, { "pmid": "30062477", "title": "Native Top-Down Mass Spectrometry and Ion Mobility Spectrometry of the Interaction of Tau Protein with a Molecular Tweezer Assembly Modulator", "doi": "10.1007/s13361-018-2027-6", "year": 2018 } ], "bc": [ { "pmid": "31722306", "title": "[The Propagation Hypothesis of Prion-like Protein Agregates in Neurodegenerative Diseases].", "doi": "10.11477/mf.1416201430", "year": 2019 } ] } }, { "id": 9201, "drug": "Polyphenols", "drug_type": "drug", "drug_domain": "alzheimer", "predicate_ab": "inhibits", "mediator": "homocysteine", "mediator_type": "biomarker", "predicate_bc": "associated_with", "outcome": "bipolar disorder", "outcome_type": "disease", "outcome_domain": "depression", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "polyphenols", "mediator_canonical": "homocysteine", "outcome_canonical": "bipolar disorder", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "34099562", "title": "Homocysteine fibrillar assemblies display cross-talk with Alzheimer’s disease β-amyloid polypeptide", "doi": "10.1073/pnas.2017575118", "year": 2021 } ], "bc": [ { "pmid": "36411779", "title": "Individuals with Bipolar Disorder Have a Higher Level of Homocysteine Than Major Depressive Disorder: A Retrospective Chart Review and Observational Study", "doi": "10.2147/ndt.s387063", "year": 2022 } ] } }, { "id": 8987, "drug": "Genistein", "drug_type": "drug", "drug_domain": "alzheimer", "predicate_ab": "inhibits", "mediator": "EGFR", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "pancreatic ductal adenocarcinoma", "outcome_type": "disease", "outcome_domain": "pancreatic_cancer", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "genistein", "mediator_canonical": "EGFR", "outcome_canonical": "pancreatic ductal adenocarcinoma", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "39610096", "title": "Genistein: a possible solution for the treatment of Alzheimer’s disease", "doi": "10.4103/nrr.nrr-d-24-00713", "year": 2024 } ], "bc": [ { "pmid": "40130819", "title": "Identification of Tumor‐Specific Surface Proteins Enables Quantification of Extracellular Vesicle Subtypes for Early Detection of Pancreatic Ductal Adenocarcinoma", "doi": "10.1002/advs.202414982", "year": 2025 }, { "pmid": "31584260", "title": "Design and Evaluation of PEGylated Liposomal Formulation of a Novel Multikinase Inhibitor for Enhanced Chemosensitivity and Inhibition of Metastatic Pancreatic Ductal Adenocarcinoma", "doi": "10.1021/acs.bioconjchem.9b00632", "year": 2019 }, { "pmid": "26339400", "title": "EGFR expression in pancreatic intraepithelial neoplasia and ductal adenocarcinoma.", "doi": null, "year": 2015 } ] } }, { "id": 9798, "drug": "ursolic acid", "drug_type": "drug", "drug_domain": "pancreatic_cancer", "predicate_ab": "downregulates", "mediator": "RAGE", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "ALS", "outcome_type": "disease", "outcome_domain": "als", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "ursolic acid", "mediator_canonical": "rage", "outcome_canonical": "amyotrophic lateral sclerosis", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "32185829", "title": "Ursolic acid promotes apoptosis, autophagy, and chemosensitivity in gemcitabine‐resistant human pancreatic cancer cells", "doi": "10.1002/ptr.6669", "year": 2020 } ], "bc": [ { "pmid": "35216298", "title": "The Involvement of RAGE and Its Ligands during Progression of ALS in SOD1 G93A Transgenic Mice", "doi": "10.3390/ijms23042184", "year": 2022 }, { "pmid": "27242430", "title": "Soluble RAGE Treatment Delays Progression of Amyotrophic Lateral Sclerosis in SOD1 Mice", "doi": "10.3389/fncel.2016.00117", "year": 2016 }, { "pmid": "26733811", "title": "Receptor for Advanced Glycation End Products and its Inflammatory Ligands are Upregulated in Amyotrophic Lateral Sclerosis", "doi": "10.3389/fncel.2015.00485", "year": 2015 } ] } }, { "id": 10448, "drug": "dextromethorphan", "drug_type": "drug", "drug_domain": "depression", "predicate_ab": "inhibits", "mediator": "NMDA receptor", "mediator_type": "protein", "predicate_bc": "causes", "outcome": "neuronal death", "outcome_type": "phenotype", "outcome_domain": "epilepsy", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "dextromethorphan", "mediator_canonical": "nmda receptor", "outcome_canonical": "neuronal death", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41913380", "title": "Bupropion‐Memantine Combination in the Treatment of Major Depressive Disorder and Treatment‐Resistant Depression", "doi": "10.1002/hup.70039", "year": 2026 }, { "pmid": "27738380", "title": "Treatment Resistant Depression with Loss of Antidepressant Response: Rapid—Acting Antidepressant Action of Dextromethorphan, A Possible Treatment Bridging Molecule", "doi": "10.64719/pb.4347", "year": 2025 }, { "pmid": "38231578", "title": "Dextromethorphan/Bupropion: A Novel Treatment for Patients With Major Depressive Disorder", "doi": "10.1097/mjt.0000000000001699", "year": 2024 } ], "bc": [ { "pmid": "36648377", "title": "Reactive oxygen species in status epilepticus", "doi": "10.1002/epi4.12691", "year": 2023 } ] } }, { "id": 10450, "drug": "dextromethorphan", "drug_type": "drug", "drug_domain": "depression", "predicate_ab": "inhibits", "mediator": "NMDA receptor", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "neurodevelopmental disorders", "outcome_type": "disease", "outcome_domain": "epilepsy", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "completed", "clinical_trial_nct_ids": [ "NCT01630811", "NCT02212275", "NCT01787136" ], "literature_status": "partial_evidence", "drug_canonical": "dextromethorphan", "mediator_canonical": "nmda receptor", "outcome_canonical": "neurodevelopmental disorders", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41913380", "title": "Bupropion‐Memantine Combination in the Treatment of Major Depressive Disorder and Treatment‐Resistant Depression", "doi": "10.1002/hup.70039", "year": 2026 }, { "pmid": "27738380", "title": "Treatment Resistant Depression with Loss of Antidepressant Response: Rapid—Acting Antidepressant Action of Dextromethorphan, A Possible Treatment Bridging Molecule", "doi": "10.64719/pb.4347", "year": 2025 }, { "pmid": "38231578", "title": "Dextromethorphan/Bupropion: A Novel Treatment for Patients With Major Depressive Disorder", "doi": "10.1097/mjt.0000000000001699", "year": 2024 } ], "bc": [ { "pmid": "30280376", "title": "GRIN2D variants in three cases of developmental and epileptic encephalopathy", "doi": "10.1111/cge.13454", "year": 2018 } ] } }, { "id": 17424, "drug": "Chlorotoxin", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "binds_to", "mediator": "MMP-2", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "Multiple Sclerosis", "outcome_type": "disease", "outcome_domain": "multiple_sclerosis", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "chlorotoxin", "mediator_canonical": "MMP2", "outcome_canonical": "multiple sclerosis", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41955189", "title": "Chlorotoxin does not target matrix metalloproteinase-2 in glioblastoma", "doi": "10.1371/journal.pone.0328964", "year": 2026 } ], "bc": [ { "pmid": "32243867", "title": "Serum levels of matrix metalloproteinase-2, -9, and vitamin D in patients with multiple sclerosis with or without herpesvirus-6 seropositivity", "doi": "10.1016/j.bjid.2020.02.001", "year": 2020 } ] } }, { "id": 20909, "drug": "CLR01", "drug_type": "drug", "drug_domain": "alzheimer", "predicate_ab": "binds_to", "mediator": "TAU", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "multiple sclerosis progression", "outcome_type": "phenotype", "outcome_domain": "multiple_sclerosis", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "clr01", "mediator_canonical": "MAPT", "outcome_canonical": "multiple sclerosis progression", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "31046227", "title": "Major Differences between the Self-Assembly and Seeding Behavior of Heparin-Induced and in Vitro Phosphorylated Tau and Their Modulation by Potential Inhibitors", "doi": "10.1021/acschembio.9b00325", "year": 2019 }, { "pmid": "30062477", "title": "Native Top-Down Mass Spectrometry and Ion Mobility Spectrometry of the Interaction of Tau Protein with a Molecular Tweezer Assembly Modulator", "doi": "10.1007/s13361-018-2027-6", "year": 2018 } ], "bc": [ { "pmid": "29865854", "title": "BDNF and Tau as Biomarkers of Severity in Multiple Sclerosis", "doi": "10.2217/bmm-2017-0374", "year": 2018 } ] } }, { "id": 23017, "drug": "DMF", "drug_type": "drug", "drug_domain": "multiple_sclerosis", "predicate_ab": "upregulates", "mediator": "NRF2", "mediator_type": "gene", "predicate_bc": "correlates_with", "outcome": "patient survival", "outcome_type": "phenotype", "outcome_domain": "glioblastoma", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "dmf", "mediator_canonical": "NRF2", "outcome_canonical": "patient survival", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "35326142", "title": "Lung-Targeted Delivery of Dimethyl Fumarate Promotes the Reversal of Age-Dependent Established Lung Fibrosis", "doi": "10.3390/antiox11030492", "year": 2022 }, { "pmid": "36670906", "title": "Dimethyl Fumarate Protects Retinal Pigment Epithelium from Blue Light-Induced Oxidative Damage via the Nrf2 Pathway", "doi": "10.3390/antiox12010045", "year": 2022 } ], "bc": [ { "pmid": "33271924", "title": "Revealing Temozolomide Resistance Mechanisms via Genome-Wide CRISPR Libraries", "doi": "10.3390/cells9122573", "year": 2020 } ] } }, { "id": 23225, "drug": "Fingolimod", "drug_type": "drug", "drug_domain": "multiple_sclerosis", "predicate_ab": "downregulates", "mediator": "HMGB1", "mediator_type": "protein", "predicate_bc": "predicts", "outcome": "drug-resistant epilepsy", "outcome_type": "disease", "outcome_domain": "epilepsy", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "fingolimod", "mediator_canonical": "HMGB1", "outcome_canonical": "drug-resistant epilepsy", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "39207074", "title": "Fingolimod Alleviates Inflammation after Cerebral Ischemia via HMGB1/TLR4/NF-κB Signaling Pathway", "doi": "10.31083/j.jin2308142", "year": 2024 } ], "bc": [ { "pmid": "34747496", "title": "High‐mobility group box 1 as a predictive biomarker for drug‐resistant epilepsy: A proof‐of‐concept study", "doi": "10.1111/epi.17116", "year": 2021 } ] } }, { "id": 22883, "drug": "dextromethorphan", "drug_type": "drug", "drug_domain": "depression", "predicate_ab": "inhibits", "mediator": "NMDA receptor", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "neuronal degeneration", "outcome_type": "phenotype", "outcome_domain": "multiple_sclerosis", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "dextromethorphan", "mediator_canonical": "nmda receptor", "outcome_canonical": "neuronal degeneration", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41913380", "title": "Bupropion‐Memantine Combination in the Treatment of Major Depressive Disorder and Treatment‐Resistant Depression", "doi": "10.1002/hup.70039", "year": 2026 }, { "pmid": "27738380", "title": "Treatment Resistant Depression with Loss of Antidepressant Response: Rapid—Acting Antidepressant Action of Dextromethorphan, A Possible Treatment Bridging Molecule", "doi": "10.64719/pb.4347", "year": 2025 }, { "pmid": "38231578", "title": "Dextromethorphan/Bupropion: A Novel Treatment for Patients With Major Depressive Disorder", "doi": "10.1097/mjt.0000000000001699", "year": 2024 } ], "bc": [ { "pmid": "31412103", "title": "MicroRNA-223 protects neurons from degeneration in experimental autoimmune encephalomyelitis", "doi": "10.1093/brain/awz245", "year": 2019 } ] } }, { "id": 23434, "drug": "DMF", "drug_type": "drug", "drug_domain": "multiple_sclerosis", "predicate_ab": "upregulates", "mediator": "NRF2", "mediator_type": "gene", "predicate_bc": "associated_with", "outcome": "neurodegenerative processes", "outcome_type": "disease", "outcome_domain": "als", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "dmf", "mediator_canonical": "NRF2", "outcome_canonical": "neurodegenerative processes", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "35326142", "title": "Lung-Targeted Delivery of Dimethyl Fumarate Promotes the Reversal of Age-Dependent Established Lung Fibrosis", "doi": "10.3390/antiox11030492", "year": 2022 }, { "pmid": "36670906", "title": "Dimethyl Fumarate Protects Retinal Pigment Epithelium from Blue Light-Induced Oxidative Damage via the Nrf2 Pathway", "doi": "10.3390/antiox12010045", "year": 2022 } ], "bc": [ { "pmid": "41684011", "title": "Nrf2-Activating Natural Compounds in Neurodegenerative Diseases: Targeting Oxidative Stress and Protein Aggregation", "doi": "10.3390/ijms27031592", "year": 2026 } ] } }, { "id": 23625, "drug": "TOL", "drug_type": "drug", "drug_domain": "multiple_sclerosis", "predicate_ab": "upregulates", "mediator": "SIRT1", "mediator_type": "protein", "predicate_bc": "predicts", "outcome": "Alzheimer's disease", "outcome_type": "disease", "outcome_domain": "alzheimer", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "tol", "mediator_canonical": "SIRT1", "outcome_canonical": "Alzheimer disease", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "32802267", "title": "Olive Leaf Polyphenols Attenuate the Clinical Course of Experimental Autoimmune Encephalomyelitis and Provide Neuroprotection by Reducing Oxidative Stress, Regulating Microglia and SIRT1, and Preserving Myelin Integrity", "doi": "10.1155/2020/6125638", "year": 2020 } ], "bc": [ { "pmid": "37742223", "title": "Serum sirtuin1: a potential blood biomarker for early diagnosis of Alzheimer’s disease", "doi": "10.18632/aging.205015", "year": 2023 }, { "pmid": "30243024", "title": "Sirt1 enhances tau exon 10 inclusion and improves spatial memory of Htau mice", "doi": "10.18632/aging.101564", "year": 2018 } ] } }, { "id": 23637, "drug": "pentamidine", "drug_type": "drug", "drug_domain": "multiple_sclerosis", "predicate_ab": "inhibits", "mediator": "S100B", "mediator_type": "protein", "predicate_bc": "prevents", "outcome": "tau seeding", "outcome_type": "phenotype", "outcome_domain": "alzheimer", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "pentamidine", "mediator_canonical": "s100b", "outcome_canonical": "tau seeding", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40649727", "title": "Effect on Different Glial Cell Types of S100B Modulation in Multiple Sclerosis Experimental Models", "doi": "10.3390/ijms26135948", "year": 2025 }, { "pmid": "35620168", "title": "S100B inhibition protects from chronic experimental autoimmune encephalomyelitis", "doi": "10.1093/braincomms/fcac076", "year": 2022 }, { "pmid": "32197530", "title": "The S100B Inhibitor Pentamidine Ameliorates Clinical Score and Neuropathology of Relapsing—Remitting Multiple Sclerosis Mouse Model", "doi": "10.3390/cells9030748", "year": 2020 } ], "bc": [ { "pmid": "34725360", "title": "Dynamic interactions and Ca2+-binding modulate the holdase-type chaperone activity of S100B preventing tau aggregation and seeding", "doi": "10.1038/s41467-021-26584-2", "year": 2021 } ] } }, { "id": 23817, "drug": "DMF", "drug_type": "drug", "drug_domain": "multiple_sclerosis", "predicate_ab": "upregulates", "mediator": "NRF2", "mediator_type": "gene", "predicate_bc": "correlates_with", "outcome": "poor survival", "outcome_type": "phenotype", "outcome_domain": "pancreatic_cancer", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "dmf", "mediator_canonical": "NRF2", "outcome_canonical": "poor survival", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "35326142", "title": "Lung-Targeted Delivery of Dimethyl Fumarate Promotes the Reversal of Age-Dependent Established Lung Fibrosis", "doi": "10.3390/antiox11030492", "year": 2022 }, { "pmid": "36670906", "title": "Dimethyl Fumarate Protects Retinal Pigment Epithelium from Blue Light-Induced Oxidative Damage via the Nrf2 Pathway", "doi": "10.3390/antiox12010045", "year": 2022 } ], "bc": [ { "pmid": "32629871", "title": "NRF2 Knockdown Resensitizes 5-Fluorouracil-Resistant Pancreatic Cancer Cells by Suppressing HO-1 and ABCG2 Expression", "doi": "10.3390/ijms21134646", "year": 2020 } ] } }, { "id": 23825, "drug": "DMF", "drug_type": "drug", "drug_domain": "multiple_sclerosis", "predicate_ab": "upregulates", "mediator": "NRF2", "mediator_type": "gene", "predicate_bc": "associated_with", "outcome": "5-FU resistance", "outcome_type": "phenotype", "outcome_domain": "pancreatic_cancer", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "dmf", "mediator_canonical": "NRF2", "outcome_canonical": "5-fu resistance", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "35326142", "title": "Lung-Targeted Delivery of Dimethyl Fumarate Promotes the Reversal of Age-Dependent Established Lung Fibrosis", "doi": "10.3390/antiox11030492", "year": 2022 }, { "pmid": "36670906", "title": "Dimethyl Fumarate Protects Retinal Pigment Epithelium from Blue Light-Induced Oxidative Damage via the Nrf2 Pathway", "doi": "10.3390/antiox12010045", "year": 2022 } ], "bc": [ { "pmid": "32629871", "title": "NRF2 Knockdown Resensitizes 5-Fluorouracil-Resistant Pancreatic Cancer Cells by Suppressing HO-1 and ABCG2 Expression", "doi": "10.3390/ijms21134646", "year": 2020 } ] } }, { "id": 23826, "drug": "DMF", "drug_type": "drug", "drug_domain": "multiple_sclerosis", "predicate_ab": "upregulates", "mediator": "NRF2", "mediator_type": "gene", "predicate_bc": "increases", "outcome": "cell proliferation", "outcome_type": "phenotype", "outcome_domain": "pancreatic_cancer", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "dmf", "mediator_canonical": "NRF2", "outcome_canonical": "cell proliferation", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "35326142", "title": "Lung-Targeted Delivery of Dimethyl Fumarate Promotes the Reversal of Age-Dependent Established Lung Fibrosis", "doi": "10.3390/antiox11030492", "year": 2022 }, { "pmid": "36670906", "title": "Dimethyl Fumarate Protects Retinal Pigment Epithelium from Blue Light-Induced Oxidative Damage via the Nrf2 Pathway", "doi": "10.3390/antiox12010045", "year": 2022 } ], "bc": [ { "pmid": "27167341", "title": "Soluble factors from stellate cells induce pancreatic cancer cell proliferation via Nrf2-activated metabolic reprogramming and ROS detoxification", "doi": "10.18632/oncotarget.9165", "year": 2016 } ] } }, { "id": 35658, "drug": "DMF", "drug_type": "drug", "drug_domain": "multiple_sclerosis", "predicate_ab": "upregulates", "mediator": "Nrf2", "mediator_type": "gene", "predicate_bc": "increases", "outcome": "lipid accumulation", "outcome_type": "phenotype", "outcome_domain": "type_2_diabetes", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "dmf", "mediator_canonical": "NRF2", "outcome_canonical": "lipid accumulation", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "35326142", "title": "Lung-Targeted Delivery of Dimethyl Fumarate Promotes the Reversal of Age-Dependent Established Lung Fibrosis", "doi": "10.3390/antiox11030492", "year": 2022 }, { "pmid": "36670906", "title": "Dimethyl Fumarate Protects Retinal Pigment Epithelium from Blue Light-Induced Oxidative Damage via the Nrf2 Pathway", "doi": "10.3390/antiox12010045", "year": 2022 } ], "bc": [ { "pmid": "37760019", "title": "NRF2 Deficiency Attenuates Diabetic Kidney Disease in Db/Db Mice via Down-Regulation of Angiotensinogen, SGLT2, CD36, and FABP4 Expression and Lipid Accumulation in Renal Proximal Tubular Cells", "doi": "10.3390/antiox12091715", "year": 2023 } ] } }, { "id": 35659, "drug": "DMF", "drug_type": "drug", "drug_domain": "multiple_sclerosis", "predicate_ab": "upregulates", "mediator": "Nrf2", "mediator_type": "gene", "predicate_bc": "prevents", "outcome": "diabetic cardiomyopathy", "outcome_type": "disease", "outcome_domain": "type_2_diabetes", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "dmf", "mediator_canonical": "NRF2", "outcome_canonical": "diabetic cardiomyopathy", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "35326142", "title": "Lung-Targeted Delivery of Dimethyl Fumarate Promotes the Reversal of Age-Dependent Established Lung Fibrosis", "doi": "10.3390/antiox11030492", "year": 2022 }, { "pmid": "36670906", "title": "Dimethyl Fumarate Protects Retinal Pigment Epithelium from Blue Light-Induced Oxidative Damage via the Nrf2 Pathway", "doi": "10.3390/antiox12010045", "year": 2022 } ], "bc": [ { "pmid": "27903744", "title": "Metallothionein Is Downstream of Nrf2 and Partially Mediates Sulforaphane Prevention of Diabetic Cardiomyopathy", "doi": "10.2337/db15-1274", "year": 2016 } ] } }, { "id": 24021, "drug": "mitoxantrone", "drug_type": "drug", "drug_domain": "multiple_sclerosis", "predicate_ab": "upregulates", "mediator": "BDNF", "mediator_type": "protein", "predicate_bc": "decreases", "outcome": "schizophrenia", "outcome_type": "disease", "outcome_domain": "depression", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "mitoxantrone", "mediator_canonical": "BDNF", "outcome_canonical": "schizophrenia", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "35247984", "title": "Does physical exercise improve or deteriorate treatment of multiple sclerosis with mitoxantrone? Experimental autoimmune encephalomyelitis study in rats", "doi": "10.1186/s12868-022-00692-1", "year": 2022 } ], "bc": [ { "pmid": "34280516", "title": "Associations of immunological proteins/traits with schizophrenia, major depression and bipolar disorder: A bi-directional two-sample mendelian randomization study", "doi": "10.1016/j.bbi.2021.07.009", "year": 2021 }, { "pmid": "30794585", "title": "Accuracy of brain-derived neurotrophic factor levels for differentiating between Taiwanese patients with major depressive disorder or schizophrenia and healthy controls", "doi": "10.1371/journal.pone.0212373", "year": 2019 } ] } }, { "id": 37256, "drug": "Isocorydine", "drug_type": "drug", "drug_domain": "pancreatic_cancer", "predicate_ab": "inhibits", "mediator": "STAT3", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "prurigo nodularis", "outcome_type": "disease", "outcome_domain": "rheumatoid_arthritis", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "isocorydine", "mediator_canonical": "STAT3", "outcome_canonical": "prurigo nodularis", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "32774728", "title": "Isocorydine decrease gemcitabine-resistance by inhibiting epithelial-mesenchymal transition via STAT3 in pancreatic cancer cells.", "doi": null, "year": 2020 } ], "bc": [ { "pmid": "39912139", "title": "Translating tissue expression of STAT 1, 3 and 6 in prurigo nodularis to clinical efficacy of oral tofacitinib – A prospective single-arm investigational study", "doi": "10.25259/ijdvl_1017_2024", "year": 2025 }, { "pmid": "40162359", "title": "Successful Use of Tofacitinib in Paediatric Prurigo Nodularis: A Report of Four Cases", "doi": "10.4103/ijd.ijd_842_24", "year": 2025 }, { "pmid": "37521237", "title": "A case of recalcitrant prurigo nodularis with heightened expression of STAT 3 and STAT 6 and its dramatic response to tofacitinib", "doi": "10.4103/idoj.idoj_508_22", "year": 2023 } ] } }, { "id": 37259, "drug": "DHA", "drug_type": "drug", "drug_domain": "pancreatic_cancer", "predicate_ab": "suppresses", "mediator": "STAT3", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "prurigo nodularis", "outcome_type": "disease", "outcome_domain": "rheumatoid_arthritis", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "dha", "mediator_canonical": "STAT3", "outcome_canonical": "prurigo nodularis", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "30400136", "title": "Docoxahexaenoic Acid Induces Apoptosis of Pancreatic Cancer Cells by Suppressing Activation of STAT3 and NF-κB", "doi": "10.3390/nu10111621", "year": 2018 } ], "bc": [ { "pmid": "39912139", "title": "Translating tissue expression of STAT 1, 3 and 6 in prurigo nodularis to clinical efficacy of oral tofacitinib – A prospective single-arm investigational study", "doi": "10.25259/ijdvl_1017_2024", "year": 2025 }, { "pmid": "40162359", "title": "Successful Use of Tofacitinib in Paediatric Prurigo Nodularis: A Report of Four Cases", "doi": "10.4103/ijd.ijd_842_24", "year": 2025 }, { "pmid": "37521237", "title": "A case of recalcitrant prurigo nodularis with heightened expression of STAT 3 and STAT 6 and its dramatic response to tofacitinib", "doi": "10.4103/idoj.idoj_508_22", "year": 2023 } ] } }, { "id": 37260, "drug": "CuB", "drug_type": "drug", "drug_domain": "pancreatic_cancer", "predicate_ab": "inhibits", "mediator": "STAT3", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "prurigo nodularis", "outcome_type": "disease", "outcome_domain": "rheumatoid_arthritis", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "cub", "mediator_canonical": "STAT3", "outcome_canonical": "prurigo nodularis", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "29262554", "title": "Cucurbitacin B and SCH772984 exhibit synergistic anti-pancreatic cancer activities by suppressing EGFR, PI3K/Akt/mTOR, STAT3 and ERK signaling", "doi": "10.18632/oncotarget.21704", "year": 2017 } ], "bc": [ { "pmid": "39912139", "title": "Translating tissue expression of STAT 1, 3 and 6 in prurigo nodularis to clinical efficacy of oral tofacitinib – A prospective single-arm investigational study", "doi": "10.25259/ijdvl_1017_2024", "year": 2025 }, { "pmid": "40162359", "title": "Successful Use of Tofacitinib in Paediatric Prurigo Nodularis: A Report of Four Cases", "doi": "10.4103/ijd.ijd_842_24", "year": 2025 }, { "pmid": "37521237", "title": "A case of recalcitrant prurigo nodularis with heightened expression of STAT 3 and STAT 6 and its dramatic response to tofacitinib", "doi": "10.4103/idoj.idoj_508_22", "year": 2023 } ] } }, { "id": 23818, "drug": "ACT-1004-1239", "drug_type": "drug", "drug_domain": "multiple_sclerosis", "predicate_ab": "inhibits", "mediator": "CXCR7", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "poor overall survival", "outcome_type": "phenotype", "outcome_domain": "pancreatic_cancer", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "act-1004-1239", "mediator_canonical": "cxcr7", "outcome_canonical": "poor overall survival", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "33595155", "title": "ACT‐1004‐1239, a first‐in‐class CXCR7 antagonist with both immunomodulatory and promyelinating effects for the treatment of inflammatory demyelinating diseases", "doi": "10.1096/fj.202002465r", "year": 2021 } ], "bc": [ { "pmid": "30574021", "title": "Prognostic significance of CXCR7 in cancer patients: a meta-analysis", "doi": "10.1186/s12935-018-0702-0", "year": 2018 } ] } }, { "id": 38749, "drug": "CT-P13", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "induces", "mediator": "anti-drug antibodies", "mediator_type": "biomarker", "predicate_bc": "associated_with", "outcome": "loss of response", "outcome_type": "phenotype", "outcome_domain": "inflammatory_bowel_disease", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "ct-p13", "mediator_canonical": "anti-drug antibodies", "outcome_canonical": "loss of response", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "31754088", "title": "Efficacy, immunogenicity and cost analysis of a systematic switch from originator infliximab to biosimilar CT-P13 of all patients with inflammatory arthritis from a single center.", "doi": null, "year": 2020 } ], "bc": [ { "pmid": "37961895", "title": "Anti-drug antibodies against anti-TNF in patients with inflammatory bowel disease: an evaluation of possible strategies", "doi": "10.1080/00365521.2023.2278424", "year": 2023 }, { "pmid": "34559428", "title": "Loss of response to anti‐TNFα agents depends on treatment duration in patients with inflammatory bowel disease", "doi": "10.1111/apt.16605", "year": 2021 }, { "pmid": "29383030", "title": "Immunogenicity of biologics in inflammatory bowel disease", "doi": "10.1177/1756283x17750355", "year": 2018 } ] } }, { "id": 38759, "drug": "izokibep", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "inhibits", "mediator": "IL-17A", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "inflammatory bowel disease", "outcome_type": "disease", "outcome_domain": "inflammatory_bowel_disease", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "izokibep", "mediator_canonical": "il-17a", "outcome_canonical": "inflammatory bowel disease", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37184136", "title": "Izokibep: Preclinical development and first-in-human study of a novel IL-17A neutralizing Affibody molecule in patients with plaque psoriasis", "doi": "10.1080/19420862.2023.2209920", "year": 2023 } ], "bc": [ { "pmid": "32724117", "title": "Serum interleukin 17A and interleukin 17F in children with inflammatory bowel disease", "doi": "10.1038/s41598-020-69567-x", "year": 2020 }, { "pmid": "27049090", "title": "Relationship between serum interleukin-17 level and inflammatory bowel disease.", "doi": null, "year": 2016 } ] } }, { "id": 38766, "drug": "CLHE", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "downregulates", "mediator": "MMP-9", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "ulcerative colitis", "outcome_type": "disease", "outcome_domain": "inflammatory_bowel_disease", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "clhe", "mediator_canonical": "MMP9", "outcome_canonical": "ulcerative colitis", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "39683414", "title": "Phytochemical, Cytoprotective Profiling, and Anti-Inflammatory Potential of Colchicum luteum in Rheumatoid Arthritis: An Experimental and Simulation Study", "doi": "10.3390/nu16234020", "year": 2024 } ], "bc": [ { "pmid": "35566780", "title": "Are Matrix Metalloproteinase-9 and Tissue Inhibitor of Metalloproteinase-1 Useful as Markers in Diagnostic Management of Children with Newly Diagnosed Ulcerative Colitis?", "doi": "10.3390/jcm11092655", "year": 2022 }, { "pmid": "27034654", "title": "Expressions of Matrix Metalloproteinases (MMP-2, MMP-7, and MMP-9) and Their Inhibitors (TIMP-1, TIMP-2) in Inflammatory Bowel Diseases", "doi": "10.1155/2016/2456179", "year": 2016 }, { "pmid": "26514773", "title": "Matrix metalloproteinase 9-induced increase in intestinal epithelial tight junction permeability contributes to the severity of experimental DSS colitis", "doi": "10.1152/ajpgi.00256.2015", "year": 2015 } ] } }, { "id": 27347, "drug": "Stattic", "drug_type": "drug", "drug_domain": "alzheimer", "predicate_ab": "inhibits", "mediator": "STAT3", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "prurigo nodularis", "outcome_type": "disease", "outcome_domain": "rheumatoid_arthritis", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "stattic", "mediator_canonical": "STAT3", "outcome_canonical": "prurigo nodularis", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "32507685", "title": "Inhibition of STAT3 phosphorylation attenuates impairments in learning and memory in 5XFAD mice, an animal model of Alzheimer's disease", "doi": "10.1016/j.jphs.2020.05.009", "year": 2020 } ], "bc": [ { "pmid": "39912139", "title": "Translating tissue expression of STAT 1, 3 and 6 in prurigo nodularis to clinical efficacy of oral tofacitinib – A prospective single-arm investigational study", "doi": "10.25259/ijdvl_1017_2024", "year": 2025 }, { "pmid": "40162359", "title": "Successful Use of Tofacitinib in Paediatric Prurigo Nodularis: A Report of Four Cases", "doi": "10.4103/ijd.ijd_842_24", "year": 2025 }, { "pmid": "37521237", "title": "A case of recalcitrant prurigo nodularis with heightened expression of STAT 3 and STAT 6 and its dramatic response to tofacitinib", "doi": "10.4103/idoj.idoj_508_22", "year": 2023 } ] } }, { "id": 39262, "drug": "glucocorticoids", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "suppresses", "mediator": "sclerostin", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "cardiovascular mortality", "outcome_type": "phenotype", "outcome_domain": "type_2_diabetes", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "completed", "clinical_trial_nct_ids": [ "NCT00953303" ], "literature_status": "reproduces_known", "drug_canonical": "glucocorticoids", "mediator_canonical": "sclerostin", "outcome_canonical": "cardiovascular mortality", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "31234141", "title": "Regulation of sclerostin in glucocorticoid-induced osteoporosis (GIO) in mice and humans", "doi": "10.1530/ec-19-0104", "year": 2019 } ], "bc": [ { "pmid": "29928063", "title": "Circulating levels of sclerostin are associated with cardiovascular mortality", "doi": "10.1371/journal.pone.0199504", "year": 2018 } ] } }, { "id": 29352, "drug": "Cannabidiol", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "inhibits", "mediator": "P-glycoprotein", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "multidrug resistance", "outcome_type": "phenotype", "outcome_domain": "glioblastoma", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "cannabidiol", "mediator_canonical": "ABCB1", "outcome_canonical": null, "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "33807975", "title": "Cannabidiol (CBD) Alters the Functionality of Neutrophils (PMN). Implications in the Refractory Epilepsy Treatment", "doi": "10.3390/ph14030220", "year": 2021 }, { "pmid": "32256321", "title": "Cannabidiol (CBD) Inhibited Rhodamine-123 Efflux in Cultured Vascular Endothelial Cells and Astrocytes Under Hypoxic Conditions", "doi": "10.3389/fnbeh.2020.00032", "year": 2020 } ], "bc": [ { "pmid": "35093870", "title": "Ko143 Reverses MDR in Glioblastoma via Deactivating P-Glycoprotein, Sensitizing a Resistant Phenotype to TMZ Treatment", "doi": "10.21873/anticanres.15530", "year": 2022 } ] } }, { "id": 29548, "drug": "BHB", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "downregulates", "mediator": "IL-17", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "Crohn's disease", "outcome_type": "disease", "outcome_domain": "inflammatory_bowel_disease", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "active", "clinical_trial_nct_ids": [ "NCT06351124" ], "literature_status": "novel_signal", "drug_canonical": "bhb", "mediator_canonical": "il-17", "outcome_canonical": "crohn's disease", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "36834515", "title": "The Ketogenic Diet and Neuroinflammation: The Action of Beta-Hydroxybutyrate in a Microglial Cell Line", "doi": "10.3390/ijms24043102", "year": 2023 } ], "bc": [ { "pmid": "39803916", "title": "Correlation between IL-17 and inflammatory bowel disease", "doi": "10.55133/eji.320106", "year": 2025 }, { "pmid": "38229938", "title": "Crohn's disease and clinical management today: How it does?", "doi": "10.5662/wjm.v13.i5.399", "year": 2023 }, { "pmid": "28533995", "title": "Crohn’s Disease and Ulcerative Colitis Show Unique Cytokine Profiles", "doi": "10.7759/cureus.1177", "year": 2017 } ] } }, { "id": 39806, "drug": "liraglutide", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "induces", "mediator": "FGF21", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "depression trajectory", "outcome_type": "phenotype", "outcome_domain": "depression", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "liraglutide", "mediator_canonical": "fgf21", "outcome_canonical": "depression trajectory", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37030441", "title": "Fibroblast growth factor-21 is required for weight loss induced by the glucagon-like peptide-1 receptor agonist liraglutide in male mice fed high carbohydrate diets", "doi": "10.1016/j.molmet.2023.101718", "year": 2023 }, { "pmid": "33851458", "title": "Hepatic Fibroblast Growth Factor 21 Is Involved in Mediating Functions of Liraglutide in Mice With Dietary Challenge", "doi": "10.1002/hep.31856", "year": 2021 }, { "pmid": "30827929", "title": "Liver-derived fibroblast growth factor 21 mediates effects of glucagon-like peptide-1 in attenuating hepatic glucose output", "doi": "10.1016/j.ebiom.2019.02.037", "year": 2019 } ], "bc": [ { "pmid": "35017468", "title": "Fibroblast growth factor 21 (FGF21) is increased in MDD and interacts with body mass index (BMI) to affect depression trajectory", "doi": "10.1038/s41398-021-01679-y", "year": 2022 } ] } }, { "id": 40180, "drug": "liraglutide", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "induces", "mediator": "FGF21", "mediator_type": "protein", "predicate_bc": "prevents", "outcome": "GBM", "outcome_type": "disease", "outcome_domain": "glioblastoma", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "liraglutide", "mediator_canonical": "fgf21", "outcome_canonical": "glioblastoma", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37030441", "title": "Fibroblast growth factor-21 is required for weight loss induced by the glucagon-like peptide-1 receptor agonist liraglutide in male mice fed high carbohydrate diets", "doi": "10.1016/j.molmet.2023.101718", "year": 2023 }, { "pmid": "33851458", "title": "Hepatic Fibroblast Growth Factor 21 Is Involved in Mediating Functions of Liraglutide in Mice With Dietary Challenge", "doi": "10.1002/hep.31856", "year": 2021 }, { "pmid": "30827929", "title": "Liver-derived fibroblast growth factor 21 mediates effects of glucagon-like peptide-1 in attenuating hepatic glucose output", "doi": "10.1016/j.ebiom.2019.02.037", "year": 2019 } ], "bc": [ { "pmid": "39744501", "title": "Genetically Predicted 3-Methoxytyrosine Mediates the Causal Association between Fibroblast Growth Factor 21 and Glioblastoma Multiforme", "doi": "10.7150/jca.98035", "year": 2024 } ] } }, { "id": 40182, "drug": "Empagliflozin", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "downregulates", "mediator": "mTOR", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "glioblastoma", "outcome_type": "disease", "outcome_domain": "glioblastoma", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "empagliflozin", "mediator_canonical": "mTOR", "outcome_canonical": "glioblastoma", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "35767208", "title": "Empagliflozin mitigates type 2 diabetes-associated peripheral neuropathy: a glucose-independent effect through AMPK signaling", "doi": "10.1007/s12272-022-01391-5", "year": 2022 } ], "bc": [ { "pmid": "39622049", "title": "A Dual-Target and Dual-Mechanism Design Strategy by Combining Inhibition and Degradation Together", "doi": "10.1021/jacs.4c11930", "year": 2024 }, { "pmid": "33162811", "title": "Mitochondrial dysfunction contributes to Rapamycin-induced apoptosis of Human Glioblastoma Cells - A synergistic effect with Temozolomide", "doi": "10.7150/ijms.40159", "year": 2020 }, { "pmid": "30793789", "title": "The effect of the mTOR inhibitor rapamycin on glucoCEST signal in a preclinical model of glioblastoma", "doi": "10.1002/mrm.27683", "year": 2019 } ] } }, { "id": 40183, "drug": "Canagliflozin", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "suppresses", "mediator": "HIF-1α", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "glioma grade", "outcome_type": "phenotype", "outcome_domain": "glioblastoma", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "canagliflozin", "mediator_canonical": "hif-1α", "outcome_canonical": "glioma grade", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37684337", "title": "The SGLT2 inhibitor canagliflozin suppresses growth and enhances prostate cancer response to radiotherapy", "doi": "10.1038/s42003-023-05289-w", "year": 2023 }, { "pmid": "37584455", "title": "Canagliflozin mediates tumor suppression alone and in combination with radiotherapy in non‐small cell lung cancer (NSCLC) through inhibition of HIF‐1α", "doi": "10.1002/1878-0261.13508", "year": 2023 }, { "pmid": "34142035", "title": "Canagliflozin attenuates lipotoxicity in cardiomyocytes and protects diabetic mouse hearts by inhibiting the mTOR/HIF-1α pathway", "doi": "10.1016/j.isci.2021.102521", "year": 2021 } ], "bc": [ { "pmid": "41806060", "title": "Spatial heterogeneity of malignant molecular markers in glioma revealed by stereotactic biopsy", "doi": "10.1007/s12672-026-04720-y", "year": 2026 } ] } }, { "id": 40185, "drug": "MPCi", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "activates", "mediator": "mTOR", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "glioblastoma", "outcome_type": "disease", "outcome_domain": "glioblastoma", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "mpci", "mediator_canonical": "mTOR", "outcome_canonical": "glioblastoma", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "36801448", "title": "Mitochondrial pyruvate carrier inhibition initiates metabolic crosstalk to stimulate branched chain amino acid catabolism", "doi": "10.1016/j.molmet.2023.101694", "year": 2023 } ], "bc": [ { "pmid": "39622049", "title": "A Dual-Target and Dual-Mechanism Design Strategy by Combining Inhibition and Degradation Together", "doi": "10.1021/jacs.4c11930", "year": 2024 }, { "pmid": "33162811", "title": "Mitochondrial dysfunction contributes to Rapamycin-induced apoptosis of Human Glioblastoma Cells - A synergistic effect with Temozolomide", "doi": "10.7150/ijms.40159", "year": 2020 }, { "pmid": "30793789", "title": "The effect of the mTOR inhibitor rapamycin on glucoCEST signal in a preclinical model of glioblastoma", "doi": "10.1002/mrm.27683", "year": 2019 } ] } }, { "id": 40186, "drug": "Canagliflozin", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "suppresses", "mediator": "HIF-1α", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "temozolomide sensitivity", "outcome_type": "phenotype", "outcome_domain": "glioblastoma", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "canagliflozin", "mediator_canonical": "hif-1α", "outcome_canonical": "temozolomide sensitivity", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37684337", "title": "The SGLT2 inhibitor canagliflozin suppresses growth and enhances prostate cancer response to radiotherapy", "doi": "10.1038/s42003-023-05289-w", "year": 2023 }, { "pmid": "37584455", "title": "Canagliflozin mediates tumor suppression alone and in combination with radiotherapy in non‐small cell lung cancer (NSCLC) through inhibition of HIF‐1α", "doi": "10.1002/1878-0261.13508", "year": 2023 }, { "pmid": "34142035", "title": "Canagliflozin attenuates lipotoxicity in cardiomyocytes and protects diabetic mouse hearts by inhibiting the mTOR/HIF-1α pathway", "doi": "10.1016/j.isci.2021.102521", "year": 2021 } ], "bc": [ { "pmid": "30013951", "title": "Hypoxia-Inducible Factor-1α Activity as a Switch for Glioblastoma Responsiveness to Temozolomide", "doi": "10.3389/fonc.2018.00249", "year": 2018 } ] } }, { "id": 40194, "drug": "EtOAc", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "downregulates", "mediator": "mTOR", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "glioblastoma", "outcome_type": "disease", "outcome_domain": "glioblastoma", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "etoac", "mediator_canonical": "mTOR", "outcome_canonical": "glioblastoma", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "34385108", "title": "Phenolics from Physalis peruviana fruits ameliorate streptozotocin-induced diabetes and diabetic nephropathy in rats via induction of autophagy and apoptosis regression", "doi": "10.1016/j.biopha.2021.111948", "year": 2021 } ], "bc": [ { "pmid": "39622049", "title": "A Dual-Target and Dual-Mechanism Design Strategy by Combining Inhibition and Degradation Together", "doi": "10.1021/jacs.4c11930", "year": 2024 }, { "pmid": "33162811", "title": "Mitochondrial dysfunction contributes to Rapamycin-induced apoptosis of Human Glioblastoma Cells - A synergistic effect with Temozolomide", "doi": "10.7150/ijms.40159", "year": 2020 }, { "pmid": "30793789", "title": "The effect of the mTOR inhibitor rapamycin on glucoCEST signal in a preclinical model of glioblastoma", "doi": "10.1002/mrm.27683", "year": 2019 } ] } }, { "id": 40196, "drug": "liraglutide", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "downregulates", "mediator": "mTOR", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "glioblastoma", "outcome_type": "disease", "outcome_domain": "glioblastoma", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "liraglutide", "mediator_canonical": "mTOR", "outcome_canonical": "glioblastoma", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "34357376", "title": "Glucagon-like peptide-1 attenuates cardiac hypertrophy via the AngII/AT1R/ACE2 and AMPK/mTOR/p70S6K pathways", "doi": "10.1093/abbs/gmab099", "year": 2021 } ], "bc": [ { "pmid": "39622049", "title": "A Dual-Target and Dual-Mechanism Design Strategy by Combining Inhibition and Degradation Together", "doi": "10.1021/jacs.4c11930", "year": 2024 }, { "pmid": "33162811", "title": "Mitochondrial dysfunction contributes to Rapamycin-induced apoptosis of Human Glioblastoma Cells - A synergistic effect with Temozolomide", "doi": "10.7150/ijms.40159", "year": 2020 }, { "pmid": "30793789", "title": "The effect of the mTOR inhibitor rapamycin on glucoCEST signal in a preclinical model of glioblastoma", "doi": "10.1002/mrm.27683", "year": 2019 } ] } }, { "id": 40408, "drug": "alirocumab", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "inhibits", "mediator": "PCSK9", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "endoscopic Mayo Score", "outcome_type": "phenotype", "outcome_domain": "inflammatory_bowel_disease", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "alirocumab", "mediator_canonical": "pcsk9", "outcome_canonical": "endoscopic mayo score", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "32035487", "title": "Effect of alirocumab on individuals with type 2 diabetes, high triglycerides, and low high-density lipoprotein cholesterol", "doi": "10.1186/s12933-020-0991-1", "year": 2020 }, { "pmid": "28799203", "title": "Efficacy and safety of alirocumab in people with prediabetes vs those with normoglycaemia at baseline: a pooled analysis of 10 phase III ODYSSEY clinical trials", "doi": "10.1111/dme.13450", "year": 2017 }, { "pmid": "28545518", "title": "Design and rationale of the ODYSSEY DM-DYSLIPIDEMIA trial: lipid-lowering efficacy and safety of alirocumab in individuals with type 2 diabetes and mixed dyslipidaemia at high cardiovascular risk", "doi": "10.1186/s12933-017-0552-4", "year": 2017 } ], "bc": [ { "pmid": "34560758", "title": "Serum Levels of PCSK9 Are Increased in Patients With Active Ulcerative Colitis Representing a Potential Biomarker of Disease Activity", "doi": "10.1097/mcg.0000000000001607", "year": 2021 } ] } }, { "id": 40417, "drug": "alirocumab", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "inhibits", "mediator": "PCSK9", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "UC-Riley Index", "outcome_type": "phenotype", "outcome_domain": "inflammatory_bowel_disease", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "alirocumab", "mediator_canonical": "pcsk9", "outcome_canonical": "uc-riley index", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "32035487", "title": "Effect of alirocumab on individuals with type 2 diabetes, high triglycerides, and low high-density lipoprotein cholesterol", "doi": "10.1186/s12933-020-0991-1", "year": 2020 }, { "pmid": "28799203", "title": "Efficacy and safety of alirocumab in people with prediabetes vs those with normoglycaemia at baseline: a pooled analysis of 10 phase III ODYSSEY clinical trials", "doi": "10.1111/dme.13450", "year": 2017 }, { "pmid": "28545518", "title": "Design and rationale of the ODYSSEY DM-DYSLIPIDEMIA trial: lipid-lowering efficacy and safety of alirocumab in individuals with type 2 diabetes and mixed dyslipidaemia at high cardiovascular risk", "doi": "10.1186/s12933-017-0552-4", "year": 2017 } ], "bc": [ { "pmid": "34560758", "title": "Serum Levels of PCSK9 Are Increased in Patients With Active Ulcerative Colitis Representing a Potential Biomarker of Disease Activity", "doi": "10.1097/mcg.0000000000001607", "year": 2021 } ] } }, { "id": 40426, "drug": "alirocumab", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "inhibits", "mediator": "PCSK9", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "disease severity", "outcome_type": "phenotype", "outcome_domain": "inflammatory_bowel_disease", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "preclinical_only", "clinical_trial_nct_ids": [ "NCT03355027" ], "literature_status": "novel_signal", "drug_canonical": "alirocumab", "mediator_canonical": "pcsk9", "outcome_canonical": "disease severity", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "32035487", "title": "Effect of alirocumab on individuals with type 2 diabetes, high triglycerides, and low high-density lipoprotein cholesterol", "doi": "10.1186/s12933-020-0991-1", "year": 2020 }, { "pmid": "28799203", "title": "Efficacy and safety of alirocumab in people with prediabetes vs those with normoglycaemia at baseline: a pooled analysis of 10 phase III ODYSSEY clinical trials", "doi": "10.1111/dme.13450", "year": 2017 }, { "pmid": "28545518", "title": "Design and rationale of the ODYSSEY DM-DYSLIPIDEMIA trial: lipid-lowering efficacy and safety of alirocumab in individuals with type 2 diabetes and mixed dyslipidaemia at high cardiovascular risk", "doi": "10.1186/s12933-017-0552-4", "year": 2017 } ], "bc": [ { "pmid": "40265438", "title": "Cholesteryl Ester Species but Not Serum Proprotein Convertase Subtilisin/Kexin Type 9 Levels Decline in Male Patients with Active Inflammatory Bowel Disease", "doi": "10.3390/pathophysiology32020013", "year": 2025 } ] } }, { "id": 31345, "drug": "Chlorotoxin", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "binds_to", "mediator": "MMP-2", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "Crohn's disease", "outcome_type": "disease", "outcome_domain": "inflammatory_bowel_disease", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "chlorotoxin", "mediator_canonical": "MMP2", "outcome_canonical": "crohn's disease", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41955189", "title": "Chlorotoxin does not target matrix metalloproteinase-2 in glioblastoma", "doi": "10.1371/journal.pone.0328964", "year": 2026 } ], "bc": [ { "pmid": "27034654", "title": "Expressions of Matrix Metalloproteinases (MMP-2, MMP-7, and MMP-9) and Their Inhibitors (TIMP-1, TIMP-2) in Inflammatory Bowel Diseases", "doi": "10.1155/2016/2456179", "year": 2016 } ] } }, { "id": 31338, "drug": "Astaxanthin", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "downregulates", "mediator": "MMP-9", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "ulcerative colitis", "outcome_type": "disease", "outcome_domain": "inflammatory_bowel_disease", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "astaxanthin", "mediator_canonical": "MMP9", "outcome_canonical": "ulcerative colitis", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "32711429", "title": "Anti-Migration and Invasion Effects of Astaxanthin against A172 Human Glioblastoma Cell Line", "doi": "10.31557/apjcp.2020.21.7.2029", "year": 2020 } ], "bc": [ { "pmid": "35566780", "title": "Are Matrix Metalloproteinase-9 and Tissue Inhibitor of Metalloproteinase-1 Useful as Markers in Diagnostic Management of Children with Newly Diagnosed Ulcerative Colitis?", "doi": "10.3390/jcm11092655", "year": 2022 }, { "pmid": "27034654", "title": "Expressions of Matrix Metalloproteinases (MMP-2, MMP-7, and MMP-9) and Their Inhibitors (TIMP-1, TIMP-2) in Inflammatory Bowel Diseases", "doi": "10.1155/2016/2456179", "year": 2016 }, { "pmid": "26514773", "title": "Matrix metalloproteinase 9-induced increase in intestinal epithelial tight junction permeability contributes to the severity of experimental DSS colitis", "doi": "10.1152/ajpgi.00256.2015", "year": 2015 } ] } }, { "id": 31339, "drug": "Hesperetin", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "downregulates", "mediator": "MMP-9", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "ulcerative colitis", "outcome_type": "disease", "outcome_domain": "inflammatory_bowel_disease", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "hesperetin", "mediator_canonical": "MMP9", "outcome_canonical": "ulcerative colitis", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "35836521", "title": "Hesperetin ameliorates glioblastoma by inhibiting proliferation, inducing apoptosis, and suppressing metastasis", "doi": "10.21037/tcr-22-1497", "year": 2022 } ], "bc": [ { "pmid": "35566780", "title": "Are Matrix Metalloproteinase-9 and Tissue Inhibitor of Metalloproteinase-1 Useful as Markers in Diagnostic Management of Children with Newly Diagnosed Ulcerative Colitis?", "doi": "10.3390/jcm11092655", "year": 2022 }, { "pmid": "27034654", "title": "Expressions of Matrix Metalloproteinases (MMP-2, MMP-7, and MMP-9) and Their Inhibitors (TIMP-1, TIMP-2) in Inflammatory Bowel Diseases", "doi": "10.1155/2016/2456179", "year": 2016 }, { "pmid": "26514773", "title": "Matrix metalloproteinase 9-induced increase in intestinal epithelial tight junction permeability contributes to the severity of experimental DSS colitis", "doi": "10.1152/ajpgi.00256.2015", "year": 2015 } ] } }, { "id": 40985, "drug": "pioglitazone", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "suppresses", "mediator": "STAT3", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "prurigo nodularis", "outcome_type": "disease", "outcome_domain": "rheumatoid_arthritis", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "pioglitazone", "mediator_canonical": "STAT3", "outcome_canonical": "prurigo nodularis", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "29030979", "title": "Pioglitazone inhibits cancer cell growth through STAT3 inhibition and enhanced AIF expression via a PPARγ‐independent pathway", "doi": "10.1002/jcp.26225", "year": 2017 } ], "bc": [ { "pmid": "39912139", "title": "Translating tissue expression of STAT 1, 3 and 6 in prurigo nodularis to clinical efficacy of oral tofacitinib – A prospective single-arm investigational study", "doi": "10.25259/ijdvl_1017_2024", "year": 2025 }, { "pmid": "40162359", "title": "Successful Use of Tofacitinib in Paediatric Prurigo Nodularis: A Report of Four Cases", "doi": "10.4103/ijd.ijd_842_24", "year": 2025 }, { "pmid": "37521237", "title": "A case of recalcitrant prurigo nodularis with heightened expression of STAT 3 and STAT 6 and its dramatic response to tofacitinib", "doi": "10.4103/idoj.idoj_508_22", "year": 2023 } ] } }, { "id": 40990, "drug": "Canagliflozin", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "suppresses", "mediator": "HIF-1α", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "rheumatoid arthritis", "outcome_type": "disease", "outcome_domain": "rheumatoid_arthritis", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "canagliflozin", "mediator_canonical": "hif-1α", "outcome_canonical": "rheumatoid arthritis", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37684337", "title": "The SGLT2 inhibitor canagliflozin suppresses growth and enhances prostate cancer response to radiotherapy", "doi": "10.1038/s42003-023-05289-w", "year": 2023 }, { "pmid": "37584455", "title": "Canagliflozin mediates tumor suppression alone and in combination with radiotherapy in non‐small cell lung cancer (NSCLC) through inhibition of HIF‐1α", "doi": "10.1002/1878-0261.13508", "year": 2023 }, { "pmid": "34142035", "title": "Canagliflozin attenuates lipotoxicity in cardiomyocytes and protects diabetic mouse hearts by inhibiting the mTOR/HIF-1α pathway", "doi": "10.1016/j.isci.2021.102521", "year": 2021 } ], "bc": [ { "pmid": "40247798", "title": "Emerging Therapeutic Targets in Rheumatoid Arthritis: Focusing on HIF-1α, Nrf2, STATs, and RORγt", "doi": "10.2174/0113894501372670250408074908", "year": 2025 } ] } }, { "id": 41001, "drug": "alirocumab", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "inhibits", "mediator": "PCSK9", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "atrial fibrillation", "outcome_type": "disease", "outcome_domain": "rheumatoid_arthritis", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "alirocumab", "mediator_canonical": "pcsk9", "outcome_canonical": "atrial fibrillation", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "32035487", "title": "Effect of alirocumab on individuals with type 2 diabetes, high triglycerides, and low high-density lipoprotein cholesterol", "doi": "10.1186/s12933-020-0991-1", "year": 2020 }, { "pmid": "28799203", "title": "Efficacy and safety of alirocumab in people with prediabetes vs those with normoglycaemia at baseline: a pooled analysis of 10 phase III ODYSSEY clinical trials", "doi": "10.1111/dme.13450", "year": 2017 }, { "pmid": "28545518", "title": "Design and rationale of the ODYSSEY DM-DYSLIPIDEMIA trial: lipid-lowering efficacy and safety of alirocumab in individuals with type 2 diabetes and mixed dyslipidaemia at high cardiovascular risk", "doi": "10.1186/s12933-017-0552-4", "year": 2017 } ], "bc": [ { "pmid": "37709197", "title": "Evolocumab prevents atrial fibrillation in rheumatoid arthritis rats through restraint of PCSK9 induced atrial remodeling", "doi": "10.1016/j.jare.2023.09.007", "year": 2023 } ] } }, { "id": 5195, "drug": "anti-oxMIF mAbs", "drug_type": "drug", "drug_domain": "pancreatic_cancer", "predicate_ab": "inhibits", "mediator": "MIF", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "major depressive disorder", "outcome_type": "disease", "outcome_domain": "depression", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "anti-oxmif mabs", "mediator_canonical": "mif", "outcome_canonical": "major depressive disorder", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "27636991", "title": "Oxidized macrophage migration inhibitory factor is a potential new tissue marker and drug target in cancer", "doi": "10.18632/oncotarget.11970", "year": 2016 } ], "bc": [ { "pmid": "38144435", "title": "Elevated Serum Macrophage Migration Inhibitory Factor Levels are Associated With Major Depressive Disorder", "doi": "10.1177/2632010x231220841", "year": 2023 }, { "pmid": "36555097", "title": "Macrophage Migration Inhibitory Factor in Major Depressive Disorder: A Multilevel Pilot Study", "doi": "10.3390/ijms232415460", "year": 2022 } ] } }, { "id": 32133, "drug": "Chlorotoxin", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "binds_to", "mediator": "MMP-2", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "all-cause mortality", "outcome_type": "phenotype", "outcome_domain": "type_2_diabetes", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "chlorotoxin", "mediator_canonical": "MMP2", "outcome_canonical": "all-cause mortality", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41955189", "title": "Chlorotoxin does not target matrix metalloproteinase-2 in glioblastoma", "doi": "10.1371/journal.pone.0328964", "year": 2026 } ], "bc": [ { "pmid": "28446168", "title": "Plasma matrix metalloproteinases are associated with incident cardiovascular disease and all-cause mortality in patients with type 1 diabetes: a 12-year follow-up study", "doi": "10.1186/s12933-017-0539-1", "year": 2017 } ] } }, { "id": 32135, "drug": "TTFields", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "downregulates", "mediator": "TXNIP", "mediator_type": "gene", "predicate_bc": "associated_with", "outcome": "type 2 diabetes", "outcome_type": "disease", "outcome_domain": "type_2_diabetes", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "ttfields", "mediator_canonical": "txnip", "outcome_canonical": "type 2 diabetes", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40885689", "title": "Tumor treating fields alter local coagulation dynamics in glioblastoma patients", "doi": "10.1016/j.neurot.2025.e00715", "year": 2025 } ], "bc": [ { "pmid": "34214161", "title": "DNA Methylation Changes Associated With Type 2 Diabetes and Diabetic Kidney Disease in an East Asian Population", "doi": "10.1210/clinem/dgab488", "year": 2021 }, { "pmid": "30107520", "title": "Epigenome-wide association study in whole blood on type 2 diabetes among sub-Saharan African individuals: findings from the RODAM study", "doi": "10.1093/ije/dyy171", "year": 2018 }, { "pmid": "26823690", "title": "Epigenetic associations of type 2 diabetes and BMI in an Arab population", "doi": "10.1186/s13148-016-0177-6", "year": 2016 } ] } }, { "id": 32641, "drug": "B-0N", "drug_type": "drug", "drug_domain": "inflammatory_bowel_disease", "predicate_ab": "inhibits", "mediator": "Rac1", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "Alzheimer's disease", "outcome_type": "disease", "outcome_domain": "alzheimer", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "b-0n", "mediator_canonical": "rac1", "outcome_canonical": "Alzheimer disease", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "27112707", "title": "Designer Thiopurine-analogues for Optimised Immunosuppression in Inflammatory Bowel Diseases", "doi": "10.1093/ecco-jcc/jjw091", "year": 2016 } ], "bc": [ { "pmid": "31321704", "title": "Inhibition of Rac1-dependent forgetting alleviates memory deficits in animal models of Alzheimer’s disease", "doi": "10.1007/s13238-019-0641-0", "year": 2019 }, { "pmid": "30005699", "title": "Rac1 activation links tau hyperphosphorylation and Aβ dysmetabolism in Alzheimer’s disease", "doi": "10.1186/s40478-018-0567-4", "year": 2018 } ] } }, { "id": 33110, "drug": "ajmalin", "drug_type": "drug", "drug_domain": "inflammatory_bowel_disease", "predicate_ab": "binds_to", "mediator": "mTOR", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "glioblastoma", "outcome_type": "disease", "outcome_domain": "glioblastoma", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "ajmalin", "mediator_canonical": "mTOR", "outcome_canonical": "glioblastoma", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40281051", "title": "Exploring the efficacy of Benincasa hispida extract on obesity linked inflammatory bowel disease by integrating computational analysis and experimental validations", "doi": "10.1038/s41598-025-99256-6", "year": 2025 } ], "bc": [ { "pmid": "39622049", "title": "A Dual-Target and Dual-Mechanism Design Strategy by Combining Inhibition and Degradation Together", "doi": "10.1021/jacs.4c11930", "year": 2024 }, { "pmid": "33162811", "title": "Mitochondrial dysfunction contributes to Rapamycin-induced apoptosis of Human Glioblastoma Cells - A synergistic effect with Temozolomide", "doi": "10.7150/ijms.40159", "year": 2020 }, { "pmid": "30793789", "title": "The effect of the mTOR inhibitor rapamycin on glucoCEST signal in a preclinical model of glioblastoma", "doi": "10.1002/mrm.27683", "year": 2019 } ] } }, { "id": 33525, "drug": "2'-fucosyllactose", "drug_type": "drug", "drug_domain": "inflammatory_bowel_disease", "predicate_ab": "activates", "mediator": "EGFR", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "pancreatic ductal adenocarcinoma", "outcome_type": "disease", "outcome_domain": "pancreatic_cancer", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "2'-fucosyllactose", "mediator_canonical": "EGFR", "outcome_canonical": "pancreatic ductal adenocarcinoma", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41492469", "title": "2′-Fucosyllactose transactivates EGF receptor in intestinal epithelial cells for prevention of colitis in adulthood", "doi": "10.1016/j.isci.2025.114308", "year": 2025 } ], "bc": [ { "pmid": "40130819", "title": "Identification of Tumor‐Specific Surface Proteins Enables Quantification of Extracellular Vesicle Subtypes for Early Detection of Pancreatic Ductal Adenocarcinoma", "doi": "10.1002/advs.202414982", "year": 2025 }, { "pmid": "31584260", "title": "Design and Evaluation of PEGylated Liposomal Formulation of a Novel Multikinase Inhibitor for Enhanced Chemosensitivity and Inhibition of Metastatic Pancreatic Ductal Adenocarcinoma", "doi": "10.1021/acs.bioconjchem.9b00632", "year": 2019 }, { "pmid": "26339400", "title": "EGFR expression in pancreatic intraepithelial neoplasia and ductal adenocarcinoma.", "doi": null, "year": 2015 } ] } }, { "id": 33858, "drug": "infliximab", "drug_type": "drug", "drug_domain": "inflammatory_bowel_disease", "predicate_ab": "downregulates", "mediator": "IL-34", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "bone erosion", "outcome_type": "phenotype", "outcome_domain": "rheumatoid_arthritis", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "completed", "clinical_trial_nct_ids": [ "NCT00006292" ], "literature_status": "reproduces_known", "drug_canonical": "infliximab", "mediator_canonical": "il-34", "outcome_canonical": "bone erosion", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "25800277", "title": "Interleukin-34 sustains inflammatory pathways in the gut", "doi": "10.1042/cs20150132", "year": 2015 } ], "bc": [ { "pmid": "37551285", "title": "Serum levels of interleukin-34 and RANKL as multivariable predictors of bone erosion seen by ultrasonography in patients with ankylosing spondylitis", "doi": "10.2478/abm-2022-0011", "year": 2022 }, { "pmid": "30880555", "title": "The correlation between interleukin-34 and bone erosion under ultrasound in rheumatoid arthritis", "doi": "10.1080/14397595.2019.1593576", "year": 2019 } ] } }, { "id": 33866, "drug": "Peimisine", "drug_type": "drug", "drug_domain": "inflammatory_bowel_disease", "predicate_ab": "downregulates", "mediator": "STAT3", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "prurigo nodularis", "outcome_type": "disease", "outcome_domain": "rheumatoid_arthritis", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "peimisine", "mediator_canonical": "STAT3", "outcome_canonical": "prurigo nodularis", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "38007392", "title": "Peimisine ameliorates DSS-induced colitis by suppressing Jak–Stat activation and alleviating gut microbiota dysbiosis in mice", "doi": "10.1093/jpp/rgad091", "year": 2023 } ], "bc": [ { "pmid": "39912139", "title": "Translating tissue expression of STAT 1, 3 and 6 in prurigo nodularis to clinical efficacy of oral tofacitinib – A prospective single-arm investigational study", "doi": "10.25259/ijdvl_1017_2024", "year": 2025 }, { "pmid": "40162359", "title": "Successful Use of Tofacitinib in Paediatric Prurigo Nodularis: A Report of Four Cases", "doi": "10.4103/ijd.ijd_842_24", "year": 2025 }, { "pmid": "37521237", "title": "A case of recalcitrant prurigo nodularis with heightened expression of STAT 3 and STAT 6 and its dramatic response to tofacitinib", "doi": "10.4103/idoj.idoj_508_22", "year": 2023 } ] } }, { "id": 35094, "drug": "alemtuzumab", "drug_type": "drug", "drug_domain": "multiple_sclerosis", "predicate_ab": "induces", "mediator": "anti-drug antibodies", "mediator_type": "biomarker", "predicate_bc": "associated_with", "outcome": "loss of response", "outcome_type": "phenotype", "outcome_domain": "inflammatory_bowel_disease", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "alemtuzumab", "mediator_canonical": "anti-drug antibodies", "outcome_canonical": "loss of response", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "32117274", "title": "The Irony of Humanization: Alemtuzumab, the First, But One of the Most Immunogenic, Humanized Monoclonal Antibodies", "doi": "10.3389/fimmu.2020.00124", "year": 2020 } ], "bc": [ { "pmid": "37961895", "title": "Anti-drug antibodies against anti-TNF in patients with inflammatory bowel disease: an evaluation of possible strategies", "doi": "10.1080/00365521.2023.2278424", "year": 2023 }, { "pmid": "34559428", "title": "Loss of response to anti‐TNFα agents depends on treatment duration in patients with inflammatory bowel disease", "doi": "10.1111/apt.16605", "year": 2021 }, { "pmid": "29383030", "title": "Immunogenicity of biologics in inflammatory bowel disease", "doi": "10.1177/1756283x17750355", "year": 2018 } ] } }, { "id": 40994, "drug": "exenatide", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "downregulates", "mediator": "MMP-3", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "rheumatoid arthritis", "outcome_type": "disease", "outcome_domain": "rheumatoid_arthritis", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "exenatide", "mediator_canonical": "mmp-3", "outcome_canonical": "rheumatoid arthritis", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "30897288", "title": "Exenatide ameliorates inflammatory response in human rheumatoid arthritis fibroblast‐like synoviocytes", "doi": "10.1002/iub.2031", "year": 2019 } ], "bc": [ { "pmid": "40140918", "title": "Predicting rheumatoid arthritis progression from seronegative undifferentiated arthritis using machine learning: a deep learning model trained on the KURAMA cohort and externally validated with the ANSWER cohort", "doi": "10.1186/s13075-025-03541-8", "year": 2025 }, { "pmid": "30740946", "title": "Matrix metalloproteinase-3 levels in relation to disease activityand radiological progression in rheumatoid arthritis", "doi": "10.17219/acem/94065", "year": 2019 }, { "pmid": "33405657", "title": "Fluorogenic Probe for Detecting Active Matrix Metalloproteinase-3 (MMP-3) in Plasma and Peripheral Blood Neutrophils to Indicate the Severity of Rheumatoid Arthritis", "doi": "10.1021/acsbiomaterials.9b00084", "year": 2019 } ] } }, { "id": 40976, "drug": "IL-6-blocking antibody", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "inhibits", "mediator": "STAT3", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "prurigo nodularis", "outcome_type": "disease", "outcome_domain": "rheumatoid_arthritis", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "il-6-blocking antibody", "mediator_canonical": "STAT3", "outcome_canonical": "prurigo nodularis", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "36384099", "title": "Anti-diabetic effects of GLP1 analogs are mediated by thermogenic interleukin-6 signaling in adipocytes", "doi": "10.1016/j.xcrm.2022.100813", "year": 2022 } ], "bc": [ { "pmid": "39912139", "title": "Translating tissue expression of STAT 1, 3 and 6 in prurigo nodularis to clinical efficacy of oral tofacitinib – A prospective single-arm investigational study", "doi": "10.25259/ijdvl_1017_2024", "year": 2025 }, { "pmid": "40162359", "title": "Successful Use of Tofacitinib in Paediatric Prurigo Nodularis: A Report of Four Cases", "doi": "10.4103/ijd.ijd_842_24", "year": 2025 }, { "pmid": "37521237", "title": "A case of recalcitrant prurigo nodularis with heightened expression of STAT 3 and STAT 6 and its dramatic response to tofacitinib", "doi": "10.4103/idoj.idoj_508_22", "year": 2023 } ] } }, { "id": 47025, "drug": "zonisamide", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "downregulates", "mediator": "Cx43", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "arrhythmogenesis", "outcome_type": "disease", "outcome_domain": "heart_failure", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "32516974", "title": "Effects of Carbamazepine, Lacosamide and Zonisamide on Gliotransmitter Release Associated with Activated Astroglial Hemichannels", "doi": "10.3390/ph13060117", "year": 2020 }, { "pmid": "32443400", "title": "Upregulated and Hyperactivated Thalamic Connexin 43 Plays Important Roles in Pathomechanisms of Cognitive Impairment and Seizure of Autosomal Dominant Sleep-Related Hypermotor Epilepsy with S284L-Mutant α4 Subunit of Nicotinic ACh Receptor", "doi": "10.3390/ph13050099", "year": 2020 } ], "bc": [ { "pmid": "32327677", "title": "Cardiac remodeling and arrhythmogenesis are ameliorated by administration of Cx43 mimetic peptide Gap27 in heart failure rats", "doi": "10.1038/s41598-020-63336-6", "year": 2020 } ] } }, { "id": 47026, "drug": "Adjudin", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "activates", "mediator": "SIRT3", "mediator_type": "protein", "predicate_bc": "decreases", "outcome": "oxidative stress", "outcome_type": "phenotype", "outcome_domain": "heart_failure", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "38406970", "title": "Sirtuin 3 regulates astrocyte activation by reducing Notch1 signaling after status epilepticus", "doi": "10.1002/glia.24520", "year": 2024 } ], "bc": [ { "pmid": "37080445", "title": "Cardioprotective effect of ultrasound‐targeted destruction of Sirt3‐loaded cationic microbubbles in a large animal model of pathological cardiac hypertrophy", "doi": "10.1016/j.actbio.2023.04.020", "year": 2023 }, { "pmid": "33244875", "title": "Elabela may regulate SIRT3‐mediated inhibition of oxidative stress through Foxo3a deacetylation preventing diabetic‐induced myocardial injury", "doi": "10.1111/jcmm.16052", "year": 2020 }, { "pmid": "31318577", "title": "The nuclear and mitochondrial sirtuins, Sirt6 and Sirt3, regulate each other's activity and protect the heart from developing obesity‐mediated diabetic cardiomyopathy", "doi": "10.1096/fj.201900767r", "year": 2019 } ] } }, { "id": 47027, "drug": "zonisamide", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "downregulates", "mediator": "Cx43", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "cardiac dysfunction", "outcome_type": "disease", "outcome_domain": "heart_failure", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "32516974", "title": "Effects of Carbamazepine, Lacosamide and Zonisamide on Gliotransmitter Release Associated with Activated Astroglial Hemichannels", "doi": "10.3390/ph13060117", "year": 2020 }, { "pmid": "32443400", "title": "Upregulated and Hyperactivated Thalamic Connexin 43 Plays Important Roles in Pathomechanisms of Cognitive Impairment and Seizure of Autosomal Dominant Sleep-Related Hypermotor Epilepsy with S284L-Mutant α4 Subunit of Nicotinic ACh Receptor", "doi": "10.3390/ph13050099", "year": 2020 } ], "bc": [ { "pmid": "32327677", "title": "Cardiac remodeling and arrhythmogenesis are ameliorated by administration of Cx43 mimetic peptide Gap27 in heart failure rats", "doi": "10.1038/s41598-020-63336-6", "year": 2020 } ] } }, { "id": 30141, "drug": "antagomiR-155", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "downregulates", "mediator": "MMP3", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "Sarcopenia", "outcome_type": "phenotype", "outcome_domain": "rheumatoid_arthritis", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "antagomir-155", "mediator_canonical": "mmp3", "outcome_canonical": "sarcopenia", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "30031401", "title": "Increased expression of matrix metalloproteinase 3 can be attenuated by inhibition of microRNA-155 in cultured human astrocytes", "doi": "10.1186/s12974-018-1245-y", "year": 2018 } ], "bc": [ { "pmid": "30187662", "title": "Matrix metalloprotease 3 is associated with sarcopenia in rheumatoid arthritis ‐ results from the CHIKARA study", "doi": "10.1111/1756-185x.13335", "year": 2018 } ] } }, { "id": 1163, "drug": "Azeliragon", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "inhibits", "mediator": "RAGE", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "ALS", "outcome_type": "disease", "outcome_domain": "als", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "azeliragon", "mediator_canonical": "rage", "outcome_canonical": "amyotrophic lateral sclerosis", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "39744679", "title": "S100A proteins show a spatial distribution of inflammation associated with the glioblastoma microenvironment architecture", "doi": "10.7150/thno.100638", "year": 2024 } ], "bc": [ { "pmid": "35216298", "title": "The Involvement of RAGE and Its Ligands during Progression of ALS in SOD1 G93A Transgenic Mice", "doi": "10.3390/ijms23042184", "year": 2022 }, { "pmid": "27242430", "title": "Soluble RAGE Treatment Delays Progression of Amyotrophic Lateral Sclerosis in SOD1 Mice", "doi": "10.3389/fncel.2016.00117", "year": 2016 }, { "pmid": "26733811", "title": "Receptor for Advanced Glycation End Products and its Inflammatory Ligands are Upregulated in Amyotrophic Lateral Sclerosis", "doi": "10.3389/fncel.2015.00485", "year": 2015 } ] } }, { "id": 1162, "drug": "tonabersat", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "inhibits", "mediator": "Cx43", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "ALS", "outcome_type": "disease", "outcome_domain": "als", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "tonabersat", "mediator_canonical": "GJA1", "outcome_canonical": "amyotrophic lateral sclerosis", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "38489314", "title": "Integrating and optimizing tonabersat in standard glioblastoma therapy: A preclinical study", "doi": "10.1371/journal.pone.0300552", "year": 2024 } ], "bc": [ { "pmid": "35312356", "title": "Cx43 hemichannels contribute to astrocyte-mediated toxicity in sporadic and familial ALS", "doi": "10.1073/pnas.2107391119", "year": 2022 }, { "pmid": "27083773", "title": "Connexin 43 in astrocytes contributes to motor neuron toxicity in amyotrophic lateral sclerosis", "doi": "10.1002/glia.22989", "year": 2016 } ] } }, { "id": 1164, "drug": "Si306", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "inhibits", "mediator": "Src", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "amyotrophic lateral sclerosis", "outcome_type": "disease", "outcome_domain": "als", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "si306", "mediator_canonical": "src", "outcome_canonical": "amyotrophic lateral sclerosis", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "32545852", "title": "Src Inhibitors Pyrazolo[3,4-d]pyrimidines, Si306 and Pro-Si306, Inhibit Focal Adhesion Kinase and Suppress Human Glioblastoma Invasion In Vitro and In Vivo", "doi": "10.3390/cancers12061570", "year": 2020 }, { "pmid": "31248184", "title": "A New Strategy for Glioblastoma Treatment: In Vitro and In Vivo Preclinical Characterization of Si306, a Pyrazolo[3,4-d]Pyrimidine Dual Src/P-Glycoprotein Inhibitor", "doi": "10.3390/cancers11060848", "year": 2019 }, { "pmid": "31554327", "title": "Proton Therapy and Src Family Kinase Inhibitor Combined Treatments on U87 Human Glioblastoma Multiforme Cell Line", "doi": "10.3390/ijms20194745", "year": 2019 } ], "bc": [ { "pmid": "37682161", "title": "Exploring the mechanism of Semen Strychni in treating amyotrophic lateral sclerosis based on network pharmacology", "doi": "10.1097/md.0000000000035101", "year": 2023 } ] } }, { "id": 5705, "drug": "Bo-Gas-LP", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "downregulates", "mediator": "Cx43", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "ALS", "outcome_type": "disease", "outcome_domain": "als", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "bo-gas-lp", "mediator_canonical": "GJA1", "outcome_canonical": "amyotrophic lateral sclerosis", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "39180545", "title": "Gastrodin Liposomes Block Crosstalk between Astrocytes and Glioma Cells via Downregulating Cx43 to Improve Antiglioblastoma Efficacy of Temozolomide", "doi": "10.1021/acs.bioconjchem.4c00300", "year": 2024 } ], "bc": [ { "pmid": "35312356", "title": "Cx43 hemichannels contribute to astrocyte-mediated toxicity in sporadic and familial ALS", "doi": "10.1073/pnas.2107391119", "year": 2022 }, { "pmid": "27083773", "title": "Connexin 43 in astrocytes contributes to motor neuron toxicity in amyotrophic lateral sclerosis", "doi": "10.1002/glia.22989", "year": 2016 } ] } }, { "id": 1388, "drug": "carbon dot probes", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "binds_to", "mediator": "GFAP", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "cognitive impairment", "outcome_type": "phenotype", "outcome_domain": "alzheimer", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "carbon dot probes", "mediator_canonical": "GFAP", "outcome_canonical": "cognitive impairment", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "35434521", "title": "Carbon dot-based fluorescent antibody nanoprobes as brain tumour glioblastoma diagnostics", "doi": "10.1039/d2na00060a", "year": 2022 } ], "bc": [ { "pmid": "36576155", "title": "Plasma glial fibrillary acidic protein in autosomal dominant Alzheimer's disease: Associations with Aβ‐PET, neurodegeneration, and cognition", "doi": "10.1002/alz.12879", "year": 2022 }, { "pmid": "32514860", "title": "Synaptic Loss, ER Stress and Neuro-Inflammation Emerge Late in the Lateral Temporal Cortex and Associate with Progressive Tau Pathology in Alzheimer’s Disease", "doi": "10.1007/s12035-020-01950-1", "year": 2020 }, { "pmid": "30594925", "title": "Glial Fibrillary Acidic Protein in Serum is Increased in Alzheimer’s Disease and Correlates with Cognitive Impairment", "doi": "10.3233/jad-180325", "year": 2018 } ] } }, { "id": 1583, "drug": "anti-EGFR-coated Raman tags", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "binds_to", "mediator": "EGFR", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "pancreatic ductal adenocarcinoma", "outcome_type": "disease", "outcome_domain": "pancreatic_cancer", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "anti-egfr-coated raman tags", "mediator_canonical": "EGFR", "outcome_canonical": "pancreatic ductal adenocarcinoma", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40100247", "title": "Selective Photothermal Eradication of Glioblastoma Cells Coexisting with Astrocytes by Anti-EGFR-Coated Raman Tags", "doi": "10.1021/acsabm.4c01986", "year": 2025 } ], "bc": [ { "pmid": "40130819", "title": "Identification of Tumor‐Specific Surface Proteins Enables Quantification of Extracellular Vesicle Subtypes for Early Detection of Pancreatic Ductal Adenocarcinoma", "doi": "10.1002/advs.202414982", "year": 2025 }, { "pmid": "31584260", "title": "Design and Evaluation of PEGylated Liposomal Formulation of a Novel Multikinase Inhibitor for Enhanced Chemosensitivity and Inhibition of Metastatic Pancreatic Ductal Adenocarcinoma", "doi": "10.1021/acs.bioconjchem.9b00632", "year": 2019 }, { "pmid": "26339400", "title": "EGFR expression in pancreatic intraepithelial neoplasia and ductal adenocarcinoma.", "doi": null, "year": 2015 } ] } }, { "id": 6136, "drug": "BaP", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "binds_to", "mediator": "EGFR", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "pancreatic ductal adenocarcinoma", "outcome_type": "disease", "outcome_domain": "pancreatic_cancer", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "bap", "mediator_canonical": "EGFR", "outcome_canonical": "pancreatic ductal adenocarcinoma", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41384939", "title": "Uncovering the toxicological impact of benzo[a]pyrene on Alzheimer's disease via network toxicology, machine learning, and single-cell transcriptomics", "doi": "10.1177/13872877251405468", "year": 2025 } ], "bc": [ { "pmid": "40130819", "title": "Identification of Tumor‐Specific Surface Proteins Enables Quantification of Extracellular Vesicle Subtypes for Early Detection of Pancreatic Ductal Adenocarcinoma", "doi": "10.1002/advs.202414982", "year": 2025 }, { "pmid": "31584260", "title": "Design and Evaluation of PEGylated Liposomal Formulation of a Novel Multikinase Inhibitor for Enhanced Chemosensitivity and Inhibition of Metastatic Pancreatic Ductal Adenocarcinoma", "doi": "10.1021/acs.bioconjchem.9b00632", "year": 2019 }, { "pmid": "26339400", "title": "EGFR expression in pancreatic intraepithelial neoplasia and ductal adenocarcinoma.", "doi": null, "year": 2015 } ] } }, { "id": 6157, "drug": "Chlorotoxin", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "binds_to", "mediator": "MMP-2", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "perineural invasion", "outcome_type": "phenotype", "outcome_domain": "pancreatic_cancer", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "chlorotoxin", "mediator_canonical": "MMP2", "outcome_canonical": "perineural invasion", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41955189", "title": "Chlorotoxin does not target matrix metalloproteinase-2 in glioblastoma", "doi": "10.1371/journal.pone.0328964", "year": 2026 } ], "bc": [ { "pmid": "26504399", "title": "Upregulated matrix metalloproteinase-2 and downregulated tissue factor pathway inhibitor-2 are risk factors for lymph node metastasis and perineural invasion in pancreatic carcinoma", "doi": "10.2147/ott.s90599", "year": 2015 } ] } }, { "id": 6137, "drug": "Panitumumab", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "binds_to", "mediator": "EGFR", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "pancreatic ductal adenocarcinoma", "outcome_type": "disease", "outcome_domain": "pancreatic_cancer", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "active", "clinical_trial_nct_ids": [ "NCT07094204", "NCT07094113" ], "literature_status": "partial_evidence", "drug_canonical": "panitumumab", "mediator_canonical": "EGFR", "outcome_canonical": "pancreatic ductal adenocarcinoma", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40862481", "title": "Targeted Therapy for Glioblastoma: Synergistic Effects of GO/C-TMZ,@, PmAb and Magnetic Hyperthermia", "doi": "10.1021/acsabm.5c00905", "year": 2025 } ], "bc": [ { "pmid": "40130819", "title": "Identification of Tumor‐Specific Surface Proteins Enables Quantification of Extracellular Vesicle Subtypes for Early Detection of Pancreatic Ductal Adenocarcinoma", "doi": "10.1002/advs.202414982", "year": 2025 }, { "pmid": "31584260", "title": "Design and Evaluation of PEGylated Liposomal Formulation of a Novel Multikinase Inhibitor for Enhanced Chemosensitivity and Inhibition of Metastatic Pancreatic Ductal Adenocarcinoma", "doi": "10.1021/acs.bioconjchem.9b00632", "year": 2019 }, { "pmid": "26339400", "title": "EGFR expression in pancreatic intraepithelial neoplasia and ductal adenocarcinoma.", "doi": null, "year": 2015 } ] } }, { "id": 1569, "drug": "Si306", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "inhibits", "mediator": "Src", "mediator_type": "protein", "predicate_bc": "increases", "outcome": "migration", "outcome_type": "phenotype", "outcome_domain": "pancreatic_cancer", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "si306", "mediator_canonical": "src", "outcome_canonical": "migration", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "32545852", "title": "Src Inhibitors Pyrazolo[3,4-d]pyrimidines, Si306 and Pro-Si306, Inhibit Focal Adhesion Kinase and Suppress Human Glioblastoma Invasion In Vitro and In Vivo", "doi": "10.3390/cancers12061570", "year": 2020 }, { "pmid": "31248184", "title": "A New Strategy for Glioblastoma Treatment: In Vitro and In Vivo Preclinical Characterization of Si306, a Pyrazolo[3,4-d]Pyrimidine Dual Src/P-Glycoprotein Inhibitor", "doi": "10.3390/cancers11060848", "year": 2019 }, { "pmid": "31554327", "title": "Proton Therapy and Src Family Kinase Inhibitor Combined Treatments on U87 Human Glioblastoma Multiforme Cell Line", "doi": "10.3390/ijms20194745", "year": 2019 } ], "bc": [ { "pmid": "26695438", "title": "A novel nuclear Src and p300 signaling axis controls migratory and invasive behavior in pancreatic cancer", "doi": "10.18632/oncotarget.6635", "year": 2015 } ] } }, { "id": 50206, "drug": "asiatic acid", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "downregulates", "mediator": "RAGE", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "ALS", "outcome_type": "disease", "outcome_domain": "als", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "26190771", "title": "Asiatic acid and maslinic acid protected heart via anti-glycative and anti-coagulatory activities in diabetic mice", "doi": "10.1039/c5fo00549c", "year": 2015 } ], "bc": [ { "pmid": "35216298", "title": "The Involvement of RAGE and Its Ligands during Progression of ALS in SOD1 G93A Transgenic Mice", "doi": "10.3390/ijms23042184", "year": 2022 }, { "pmid": "27242430", "title": "Soluble RAGE Treatment Delays Progression of Amyotrophic Lateral Sclerosis in SOD1 Mice", "doi": "10.3389/fncel.2016.00117", "year": 2016 }, { "pmid": "26733811", "title": "Receptor for Advanced Glycation End Products and its Inflammatory Ligands are Upregulated in Amyotrophic Lateral Sclerosis", "doi": "10.3389/fncel.2015.00485", "year": 2015 } ] } }, { "id": 5498, "drug": "DOX", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "suppresses", "mediator": "HMGB1", "mediator_type": "protein", "predicate_bc": "predicts", "outcome": "drug-resistant epilepsy", "outcome_type": "disease", "outcome_domain": "epilepsy", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "dox", "mediator_canonical": "HMGB1", "outcome_canonical": "drug-resistant epilepsy", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "30676239", "title": "Doxorubicin Conjugated With Nanodiamonds and in Free Form Commit Glioblastoma Cells to Heterodromous Fates", "doi": "10.2217/nnm-2018-0330", "year": 2019 } ], "bc": [ { "pmid": "34747496", "title": "High‐mobility group box 1 as a predictive biomarker for drug‐resistant epilepsy: A proof‐of‐concept study", "doi": "10.1111/epi.17116", "year": 2021 } ] } }, { "id": 50409, "drug": "kaempferol", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "upregulates", "mediator": "SIRT1", "mediator_type": "protein", "predicate_bc": "predicts", "outcome": "Alzheimer's disease", "outcome_type": "disease", "outcome_domain": "alzheimer", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "34810287", "title": "Kaempferol protects against streptozotocin-induced diabetic cardiomyopathy in rats by a hypoglycemic effect and upregulating SIRT1.", "doi": "10.26402/jpp.2021.3.04", "year": 2021 } ], "bc": [ { "pmid": "37742223", "title": "Serum sirtuin1: a potential blood biomarker for early diagnosis of Alzheimer’s disease", "doi": "10.18632/aging.205015", "year": 2023 }, { "pmid": "30243024", "title": "Sirt1 enhances tau exon 10 inclusion and improves spatial memory of Htau mice", "doi": "10.18632/aging.101564", "year": 2018 } ] } }, { "id": 50412, "drug": "ginsenoside Rc", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "upregulates", "mediator": "SIRT1", "mediator_type": "protein", "predicate_bc": "predicts", "outcome": "Alzheimer's disease", "outcome_type": "disease", "outcome_domain": "alzheimer", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "34146399", "title": "Protective effects of ginsenoside Rc against acute cold exposure‐induced myocardial injury in rats", "doi": "10.1111/1750-3841.15757", "year": 2021 } ], "bc": [ { "pmid": "37742223", "title": "Serum sirtuin1: a potential blood biomarker for early diagnosis of Alzheimer’s disease", "doi": "10.18632/aging.205015", "year": 2023 }, { "pmid": "30243024", "title": "Sirt1 enhances tau exon 10 inclusion and improves spatial memory of Htau mice", "doi": "10.18632/aging.101564", "year": 2018 } ] } }, { "id": 50414, "drug": "antimiR199a therapy", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "upregulates", "mediator": "SIRT1", "mediator_type": "protein", "predicate_bc": "predicts", "outcome": "Alzheimer's disease", "outcome_type": "disease", "outcome_domain": "alzheimer", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "33594087", "title": "The miRNA199a/SIRT1/P300/Yy1/sST2 signaling axis regulates adverse cardiac remodeling following MI", "doi": "10.1038/s41598-021-82745-9", "year": 2021 } ], "bc": [ { "pmid": "37742223", "title": "Serum sirtuin1: a potential blood biomarker for early diagnosis of Alzheimer’s disease", "doi": "10.18632/aging.205015", "year": 2023 }, { "pmid": "30243024", "title": "Sirt1 enhances tau exon 10 inclusion and improves spatial memory of Htau mice", "doi": "10.18632/aging.101564", "year": 2018 } ] } }, { "id": 50422, "drug": "EGCG", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "upregulates", "mediator": "SIRT1", "mediator_type": "protein", "predicate_bc": "predicts", "outcome": "Alzheimer's disease", "outcome_type": "disease", "outcome_domain": "alzheimer", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "28714516", "title": "(−)-Epigallocatechin-3-gallate attenuates myocardial injury induced by ischemia/reperfusion in diabetic rats and in H9c2 cells under hyperglycemic conditions", "doi": "10.3892/ijmm.2017.3014", "year": 2017 } ], "bc": [ { "pmid": "37742223", "title": "Serum sirtuin1: a potential blood biomarker for early diagnosis of Alzheimer’s disease", "doi": "10.18632/aging.205015", "year": 2023 }, { "pmid": "30243024", "title": "Sirt1 enhances tau exon 10 inclusion and improves spatial memory of Htau mice", "doi": "10.18632/aging.101564", "year": 2018 } ] } }, { "id": 50425, "drug": "Tan IIA", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "upregulates", "mediator": "SIRT1", "mediator_type": "protein", "predicate_bc": "predicts", "outcome": "Alzheimer's disease", "outcome_type": "disease", "outcome_domain": "alzheimer", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37128721", "title": "Tanshinone IIA ameliorates experimental diabetic cardiomyopathy by inhibiting endoplasmic reticulum stress in cardiomyocytes via SIRT1", "doi": "10.1002/ptr.7831", "year": 2023 } ], "bc": [ { "pmid": "37742223", "title": "Serum sirtuin1: a potential blood biomarker for early diagnosis of Alzheimer’s disease", "doi": "10.18632/aging.205015", "year": 2023 }, { "pmid": "30243024", "title": "Sirt1 enhances tau exon 10 inclusion and improves spatial memory of Htau mice", "doi": "10.18632/aging.101564", "year": 2018 } ] } }, { "id": 50429, "drug": "Shengmai San", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "upregulates", "mediator": "SIRT1", "mediator_type": "protein", "predicate_bc": "predicts", "outcome": "Alzheimer's disease", "outcome_type": "disease", "outcome_domain": "alzheimer", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "30384366", "title": "Shengmai San Alleviates Diabetic Cardiomyopathy Through Improvement of Mitochondrial Lipid Metabolic Disorder", "doi": "10.1159/000494791", "year": 2018 } ], "bc": [ { "pmid": "37742223", "title": "Serum sirtuin1: a potential blood biomarker for early diagnosis of Alzheimer’s disease", "doi": "10.18632/aging.205015", "year": 2023 }, { "pmid": "30243024", "title": "Sirt1 enhances tau exon 10 inclusion and improves spatial memory of Htau mice", "doi": "10.18632/aging.101564", "year": 2018 } ] } }, { "id": 50434, "drug": "acacetin", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "activates", "mediator": "SIRT1", "mediator_type": "protein", "predicate_bc": "predicts", "outcome": "Alzheimer's disease", "outcome_type": "disease", "outcome_domain": "alzheimer", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "32918384", "title": "Doxorubicin cardiomyopathy is ameliorated by acacetin via Sirt1‐mediated activation of AMPK/Nrf2 signal molecules", "doi": "10.1111/jcmm.15859", "year": 2020 } ], "bc": [ { "pmid": "37742223", "title": "Serum sirtuin1: a potential blood biomarker for early diagnosis of Alzheimer’s disease", "doi": "10.18632/aging.205015", "year": 2023 }, { "pmid": "30243024", "title": "Sirt1 enhances tau exon 10 inclusion and improves spatial memory of Htau mice", "doi": "10.18632/aging.101564", "year": 2018 } ] } }, { "id": 50436, "drug": "B-LAP", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "upregulates", "mediator": "SIRT1", "mediator_type": "protein", "predicate_bc": "predicts", "outcome": "Alzheimer's disease", "outcome_type": "disease", "outcome_domain": "alzheimer", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "31630478", "title": "β‐LAPachone ameliorates doxorubicin‐induced cardiotoxicity via regulating autophagy and Nrf2 signalling pathways in mice", "doi": "10.1111/bcpt.13340", "year": 2019 } ], "bc": [ { "pmid": "37742223", "title": "Serum sirtuin1: a potential blood biomarker for early diagnosis of Alzheimer’s disease", "doi": "10.18632/aging.205015", "year": 2023 }, { "pmid": "30243024", "title": "Sirt1 enhances tau exon 10 inclusion and improves spatial memory of Htau mice", "doi": "10.18632/aging.101564", "year": 2018 } ] } }, { "id": 51765, "drug": "cryptotanshinone", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "inhibits", "mediator": "STAT3", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "prurigo nodularis", "outcome_type": "disease", "outcome_domain": "rheumatoid_arthritis", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "28176375", "title": "Cryptotanshinone Inhibits STAT3 Signaling to Alleviate Cardiac Fibrosis in Type 1-like Diabetic Rats", "doi": "10.1002/ptr.5777", "year": 2017 } ], "bc": [ { "pmid": "39912139", "title": "Translating tissue expression of STAT 1, 3 and 6 in prurigo nodularis to clinical efficacy of oral tofacitinib – A prospective single-arm investigational study", "doi": "10.25259/ijdvl_1017_2024", "year": 2025 }, { "pmid": "40162359", "title": "Successful Use of Tofacitinib in Paediatric Prurigo Nodularis: A Report of Four Cases", "doi": "10.4103/ijd.ijd_842_24", "year": 2025 }, { "pmid": "37521237", "title": "A case of recalcitrant prurigo nodularis with heightened expression of STAT 3 and STAT 6 and its dramatic response to tofacitinib", "doi": "10.4103/idoj.idoj_508_22", "year": 2023 } ] } }, { "id": 51770, "drug": "digoxin", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "inhibits", "mediator": "STAT3", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "prurigo nodularis", "outcome_type": "disease", "outcome_domain": "rheumatoid_arthritis", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "25955608", "title": "Digoxin Suppresses Tumor Malignancy through Inhibiting Multiple Src-Related Signaling Pathways in Non-Small Cell Lung Cancer", "doi": "10.1371/journal.pone.0123305", "year": 2015 } ], "bc": [ { "pmid": "39912139", "title": "Translating tissue expression of STAT 1, 3 and 6 in prurigo nodularis to clinical efficacy of oral tofacitinib – A prospective single-arm investigational study", "doi": "10.25259/ijdvl_1017_2024", "year": 2025 }, { "pmid": "40162359", "title": "Successful Use of Tofacitinib in Paediatric Prurigo Nodularis: A Report of Four Cases", "doi": "10.4103/ijd.ijd_842_24", "year": 2025 }, { "pmid": "37521237", "title": "A case of recalcitrant prurigo nodularis with heightened expression of STAT 3 and STAT 6 and its dramatic response to tofacitinib", "doi": "10.4103/idoj.idoj_508_22", "year": 2023 } ] } }, { "id": 51774, "drug": "KN-93", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "downregulates", "mediator": "STAT3", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "prurigo nodularis", "outcome_type": "disease", "outcome_domain": "rheumatoid_arthritis", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "34845819", "title": "CaMKII inhibitor KN‐93 impaired angiogenesis and aggravated cardiac remodelling and heart failure via inhibiting NOX2/mtROS/p‐VEGFR2 and STAT3 pathways", "doi": "10.1111/jcmm.17081", "year": 2021 } ], "bc": [ { "pmid": "39912139", "title": "Translating tissue expression of STAT 1, 3 and 6 in prurigo nodularis to clinical efficacy of oral tofacitinib – A prospective single-arm investigational study", "doi": "10.25259/ijdvl_1017_2024", "year": 2025 }, { "pmid": "40162359", "title": "Successful Use of Tofacitinib in Paediatric Prurigo Nodularis: A Report of Four Cases", "doi": "10.4103/ijd.ijd_842_24", "year": 2025 }, { "pmid": "37521237", "title": "A case of recalcitrant prurigo nodularis with heightened expression of STAT 3 and STAT 6 and its dramatic response to tofacitinib", "doi": "10.4103/idoj.idoj_508_22", "year": 2023 } ] } }, { "id": 51957, "drug": "LHD", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "inhibits", "mediator": "FTO", "mediator_type": "gene", "predicate_bc": "associated_with", "outcome": "type 2 diabetes", "outcome_type": "disease", "outcome_domain": "type_2_diabetes", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "34881240", "title": "LuHui Derivative, A Novel Compound That Inhibits the Fat Mass and Obesity-Associated (FTO), Alleviates the Inflammatory Response and Injury in Hyperlipidemia-Induced Cardiomyopathy", "doi": "10.3389/fcell.2021.731365", "year": 2021 } ], "bc": [ { "pmid": "37433298", "title": "Genetic underpinning of the comorbidity between type 2 diabetes and osteoarthritis", "doi": "10.1016/j.ajhg.2023.06.010", "year": 2023 }, { "pmid": "28067832", "title": "Type 2 Diabetes Susceptibility in the Greek-Cypriot Population: Replication of Associations with TCF7L2, FTO, HHEX, SLC30A8 and IGF2BP2 Polymorphisms", "doi": "10.3390/genes8010016", "year": 2017 }, { "pmid": "27249024", "title": "Association of Metabolites with Obesity and Type 2 Diabetes Based on FTO Genotype", "doi": "10.1371/journal.pone.0156612", "year": 2016 } ] } }, { "id": 51959, "drug": "vildagliptin", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "induces", "mediator": "FGF21", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "brown adipose tissue activity", "outcome_type": "phenotype", "outcome_domain": "type_2_diabetes", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "33073318", "title": "DPP-4 inhibitor induces FGF21 expression via sirtuin 1 signaling and improves myocardial energy metabolism", "doi": "10.1007/s00380-020-01711-z", "year": 2020 } ], "bc": [ { "pmid": "25985218", "title": "Serum FGF21 levels are associated with brown adipose tissue activity in humans", "doi": "10.1038/srep10275", "year": 2015 } ] } }, { "id": 51964, "drug": "dietary methionine restriction", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "induces", "mediator": "FGF21", "mediator_type": "protein", "predicate_bc": "decreases", "outcome": "body weight", "outcome_type": "phenotype", "outcome_domain": "type_2_diabetes", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "25744495", "title": "Dietary Methionine Restriction in Mice Elicits an Adaptive Cardiovascular Response to Hyperhomocysteinemia", "doi": "10.1038/srep08886", "year": 2015 } ], "bc": [ { "pmid": "37030441", "title": "Fibroblast growth factor-21 is required for weight loss induced by the glucagon-like peptide-1 receptor agonist liraglutide in male mice fed high carbohydrate diets", "doi": "10.1016/j.molmet.2023.101718", "year": 2023 }, { "pmid": "31130574", "title": "Effects of sodium-glucose cotransporter 2 inhibitor (dapagliflozin) on food intake and plasma fibroblast growth factor 21 levels in type 2 diabetes patients", "doi": "10.1507/endocrj.ej19-0013", "year": 2019 }, { "pmid": "28515909", "title": "Metabolic role of fibroblast growth factor 21 in liver, adipose and nervous system tissues", "doi": "10.3892/br.2017.890", "year": 2017 } ] } }, { "id": 51966, "drug": "dietary methionine restriction", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "induces", "mediator": "FGF21", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "brown adipose tissue activity", "outcome_type": "phenotype", "outcome_domain": "type_2_diabetes", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "25744495", "title": "Dietary Methionine Restriction in Mice Elicits an Adaptive Cardiovascular Response to Hyperhomocysteinemia", "doi": "10.1038/srep08886", "year": 2015 } ], "bc": [ { "pmid": "25985218", "title": "Serum FGF21 levels are associated with brown adipose tissue activity in humans", "doi": "10.1038/srep10275", "year": 2015 } ] } }, { "id": 51970, "drug": "LHD", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "inhibits", "mediator": "FTO", "mediator_type": "gene", "predicate_bc": "associated_with", "outcome": "obesity", "outcome_type": "disease", "outcome_domain": "type_2_diabetes", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "34881240", "title": "LuHui Derivative, A Novel Compound That Inhibits the Fat Mass and Obesity-Associated (FTO), Alleviates the Inflammatory Response and Injury in Hyperlipidemia-Induced Cardiomyopathy", "doi": "10.3389/fcell.2021.731365", "year": 2021 } ], "bc": [ { "pmid": "28738793", "title": "Association between 28 single nucleotide polymorphisms and type 2 diabetes mellitus in the Kazakh population: a case-control study", "doi": "10.1186/s12881-017-0443-2", "year": 2017 }, { "pmid": "26961502", "title": "Variants in the FTO and CDKAL1 loci have recessive effects on risk of obesity and type 2 diabetes, respectively", "doi": "10.1007/s00125-016-3908-5", "year": 2016 }, { "pmid": "27249024", "title": "Association of Metabolites with Obesity and Type 2 Diabetes Based on FTO Genotype", "doi": "10.1371/journal.pone.0156612", "year": 2016 } ] } }, { "id": 51971, "drug": "DMB", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "inhibits", "mediator": "TMAO", "mediator_type": "biomarker", "predicate_bc": "associated_with", "outcome": "type 2 diabetes", "outcome_type": "disease", "outcome_domain": "type_2_diabetes", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "34721039", "title": "Attenuation of Circulating Trimethylamine N-Oxide Prevents the Progression of Cardiac and Renal Dysfunction in a Rat Model of Chronic Cardiorenal Syndrome", "doi": "10.3389/fphar.2021.751380", "year": 2021 } ], "bc": [ { "pmid": "35631234", "title": "Association between Plasma Trimethylamine N-Oxide Levels and Type 2 Diabetes: A Case Control Study", "doi": "10.3390/nu14102093", "year": 2022 }, { "pmid": "34448864", "title": "Association of TrimethylamineN-Oxide and Related Metabolites in Plasma and Incident Type 2 Diabetes", "doi": "10.1001/jamanetworkopen.2021.22844", "year": 2021 } ] } }, { "id": 32407, "drug": "Acanthoside B", "drug_type": "drug", "drug_domain": "inflammatory_bowel_disease", "predicate_ab": "downregulates", "mediator": "RAGE", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "ALS", "outcome_type": "disease", "outcome_domain": "als", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "acanthoside b", "mediator_canonical": "rage", "outcome_canonical": "amyotrophic lateral sclerosis", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "39786883", "title": "Acanthoside B attenuates NLRP3-mediated pyroptosis and ulcerative colitis through inhibition of tAGE/RAGE pathway", "doi": "10.15586/aei.v53i1.1224", "year": 2025 } ], "bc": [ { "pmid": "35216298", "title": "The Involvement of RAGE and Its Ligands during Progression of ALS in SOD1 G93A Transgenic Mice", "doi": "10.3390/ijms23042184", "year": 2022 }, { "pmid": "27242430", "title": "Soluble RAGE Treatment Delays Progression of Amyotrophic Lateral Sclerosis in SOD1 Mice", "doi": "10.3389/fncel.2016.00117", "year": 2016 }, { "pmid": "26733811", "title": "Receptor for Advanced Glycation End Products and its Inflammatory Ligands are Upregulated in Amyotrophic Lateral Sclerosis", "doi": "10.3389/fncel.2015.00485", "year": 2015 } ] } }, { "id": 52360, "drug": "camel milk exosomes", "drug_type": "drug", "drug_domain": "inflammatory_bowel_disease", "predicate_ab": "upregulates", "mediator": "SIRT1", "mediator_type": "protein", "predicate_bc": "predicts", "outcome": "Alzheimer's disease", "outcome_type": "disease", "outcome_domain": "alzheimer", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41451640", "title": "Therapeutic Effects of Camel Milk Exosomes and Their miR-148a-3p Cargo on DSS-Induced Colitis: Modulating Gut Inflammation through the SIRT1/NF-κB Pathway and Microbiota Alterations", "doi": "10.1021/acs.jafc.5c11226", "year": 2025 } ], "bc": [ { "pmid": "37742223", "title": "Serum sirtuin1: a potential blood biomarker for early diagnosis of Alzheimer’s disease", "doi": "10.18632/aging.205015", "year": 2023 }, { "pmid": "30243024", "title": "Sirt1 enhances tau exon 10 inclusion and improves spatial memory of Htau mice", "doi": "10.18632/aging.101564", "year": 2018 } ] } }, { "id": 52498, "drug": "Arctigenin", "drug_type": "drug", "drug_domain": "inflammatory_bowel_disease", "predicate_ab": "upregulates", "mediator": "ERβ", "mediator_type": "protein", "predicate_bc": "prevents", "outcome": "Alzheimer's disease pathology", "outcome_type": "disease", "outcome_domain": "alzheimer", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41205410", "title": "Estrogen receptor β deficiency increases the susceptibility to ulcerative colitis by inducing mitochondrial fission and consequently accelerating senescence of colonic epithelial cells", "doi": "10.1016/j.redox.2025.103919", "year": 2025 }, { "pmid": "31908053", "title": "Pharmacological activation of ERβ by arctigenin maintains the integrity of intestinal epithelial barrier in inflammatory bowel diseases", "doi": "10.1096/fj.201901638rr", "year": 2019 } ], "bc": [ { "pmid": "40302001", "title": "ERβ mediates sex-specific protection in the App-NL-G-F mouse model of Alzheimer’s disease", "doi": "10.1186/s13293-025-00711-w", "year": 2025 } ] } }, { "id": 38761, "drug": "GMSC-Exo", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "inhibits", "mediator": "IL-17A", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "inflammatory bowel disease", "outcome_type": "disease", "outcome_domain": "inflammatory_bowel_disease", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "gmsc-exo", "mediator_canonical": "il-17a", "outcome_canonical": "inflammatory bowel disease", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "34953015", "title": "Gingival mesenchymal stem cell‐derived exosomes are immunosuppressive in preventing collagen‐induced arthritis", "doi": "10.1111/jcmm.17086", "year": 2021 } ], "bc": [ { "pmid": "32724117", "title": "Serum interleukin 17A and interleukin 17F in children with inflammatory bowel disease", "doi": "10.1038/s41598-020-69567-x", "year": 2020 }, { "pmid": "27049090", "title": "Relationship between serum interleukin-17 level and inflammatory bowel disease.", "doi": null, "year": 2016 } ] } }, { "id": 32922, "drug": "Ethyl pyruvate", "drug_type": "drug", "drug_domain": "inflammatory_bowel_disease", "predicate_ab": "inhibits", "mediator": "HMGB1", "mediator_type": "protein", "predicate_bc": "predicts", "outcome": "drug-resistant epilepsy", "outcome_type": "disease", "outcome_domain": "epilepsy", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "ethyl pyruvate", "mediator_canonical": "HMGB1", "outcome_canonical": "drug-resistant epilepsy", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "31082723", "title": "Melatonin alleviates circadian rhythm disruption exacerbating DSS-induced colitis by inhibiting the distribution of HMGB1 in intestinal tissues", "doi": "10.1016/j.intimp.2019.05.005", "year": 2019 } ], "bc": [ { "pmid": "34747496", "title": "High‐mobility group box 1 as a predictive biomarker for drug‐resistant epilepsy: A proof‐of‐concept study", "doi": "10.1111/epi.17116", "year": 2021 } ] } }, { "id": 32921, "drug": "Melatonin", "drug_type": "drug", "drug_domain": "inflammatory_bowel_disease", "predicate_ab": "inhibits", "mediator": "HMGB1", "mediator_type": "protein", "predicate_bc": "predicts", "outcome": "drug-resistant epilepsy", "outcome_type": "disease", "outcome_domain": "epilepsy", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "completed", "clinical_trial_nct_ids": [ "NCT01161108" ], "literature_status": "partial_evidence", "drug_canonical": "melatonin", "mediator_canonical": "HMGB1", "outcome_canonical": "drug-resistant epilepsy", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "31082723", "title": "Melatonin alleviates circadian rhythm disruption exacerbating DSS-induced colitis by inhibiting the distribution of HMGB1 in intestinal tissues", "doi": "10.1016/j.intimp.2019.05.005", "year": 2019 } ], "bc": [ { "pmid": "34747496", "title": "High‐mobility group box 1 as a predictive biomarker for drug‐resistant epilepsy: A proof‐of‐concept study", "doi": "10.1111/epi.17116", "year": 2021 } ] } }, { "id": 53159, "drug": "Arctigenin", "drug_type": "drug", "drug_domain": "inflammatory_bowel_disease", "predicate_ab": "upregulates", "mediator": "ERβ", "mediator_type": "protein", "predicate_bc": "decreases", "outcome": "left ventricular contractility", "outcome_type": "phenotype", "outcome_domain": "heart_failure", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41205410", "title": "Estrogen receptor β deficiency increases the susceptibility to ulcerative colitis by inducing mitochondrial fission and consequently accelerating senescence of colonic epithelial cells", "doi": "10.1016/j.redox.2025.103919", "year": 2025 }, { "pmid": "31908053", "title": "Pharmacological activation of ERβ by arctigenin maintains the integrity of intestinal epithelial barrier in inflammatory bowel diseases", "doi": "10.1096/fj.201901638rr", "year": 2019 } ], "bc": [ { "pmid": "31050200", "title": "Cardiac changes during the peri‐menopausal period in a VCD‐induced murine model of ovarian failure", "doi": "10.1111/apha.13290", "year": 2019 } ] } }, { "id": 33517, "drug": "oxymatrine", "drug_type": "drug", "drug_domain": "inflammatory_bowel_disease", "predicate_ab": "binds_to", "mediator": "EGFR", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "pancreatic ductal adenocarcinoma", "outcome_type": "disease", "outcome_domain": "pancreatic_cancer", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "oxymatrine", "mediator_canonical": "EGFR", "outcome_canonical": "pancreatic ductal adenocarcinoma", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41394814", "title": "Evaluation of the safety and efficacy of Sophorae Flavescentis Radix extract in the treatment of inflammatory bowel disease based on zebrafish models", "doi": "10.3389/fimmu.2025.1722777", "year": 2025 } ], "bc": [ { "pmid": "40130819", "title": "Identification of Tumor‐Specific Surface Proteins Enables Quantification of Extracellular Vesicle Subtypes for Early Detection of Pancreatic Ductal Adenocarcinoma", "doi": "10.1002/advs.202414982", "year": 2025 }, { "pmid": "31584260", "title": "Design and Evaluation of PEGylated Liposomal Formulation of a Novel Multikinase Inhibitor for Enhanced Chemosensitivity and Inhibition of Metastatic Pancreatic Ductal Adenocarcinoma", "doi": "10.1021/acs.bioconjchem.9b00632", "year": 2019 }, { "pmid": "26339400", "title": "EGFR expression in pancreatic intraepithelial neoplasia and ductal adenocarcinoma.", "doi": null, "year": 2015 } ] } }, { "id": 38776, "drug": "tomatidine", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "downregulates", "mediator": "MMP-9", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "ulcerative colitis", "outcome_type": "disease", "outcome_domain": "inflammatory_bowel_disease", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "tomatidine", "mediator_canonical": "MMP9", "outcome_canonical": "ulcerative colitis", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "34512321", "title": "Tomatidine Suppresses the Destructive Behaviors of Fibroblast-Like Synoviocytes and Ameliorates Type II Collagen-Induced Arthritis in Rats", "doi": "10.3389/fphar.2021.670707", "year": 2021 } ], "bc": [ { "pmid": "35566780", "title": "Are Matrix Metalloproteinase-9 and Tissue Inhibitor of Metalloproteinase-1 Useful as Markers in Diagnostic Management of Children with Newly Diagnosed Ulcerative Colitis?", "doi": "10.3390/jcm11092655", "year": 2022 }, { "pmid": "27034654", "title": "Expressions of Matrix Metalloproteinases (MMP-2, MMP-7, and MMP-9) and Their Inhibitors (TIMP-1, TIMP-2) in Inflammatory Bowel Diseases", "doi": "10.1155/2016/2456179", "year": 2016 }, { "pmid": "26514773", "title": "Matrix metalloproteinase 9-induced increase in intestinal epithelial tight junction permeability contributes to the severity of experimental DSS colitis", "doi": "10.1152/ajpgi.00256.2015", "year": 2015 } ] } }, { "id": 36867, "drug": "Deguelin", "drug_type": "drug", "drug_domain": "pancreatic_cancer", "predicate_ab": "suppresses", "mediator": "MMP-9", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "ulcerative colitis", "outcome_type": "disease", "outcome_domain": "inflammatory_bowel_disease", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "deguelin", "mediator_canonical": "MMP9", "outcome_canonical": "ulcerative colitis", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "27698853", "title": "Deguelin inhibits proliferation and migration of human pancreatic cancer cells in vitro targeting hedgehog pathway", "doi": "10.3892/ol.2016.4928", "year": 2016 } ], "bc": [ { "pmid": "35566780", "title": "Are Matrix Metalloproteinase-9 and Tissue Inhibitor of Metalloproteinase-1 Useful as Markers in Diagnostic Management of Children with Newly Diagnosed Ulcerative Colitis?", "doi": "10.3390/jcm11092655", "year": 2022 }, { "pmid": "27034654", "title": "Expressions of Matrix Metalloproteinases (MMP-2, MMP-7, and MMP-9) and Their Inhibitors (TIMP-1, TIMP-2) in Inflammatory Bowel Diseases", "doi": "10.1155/2016/2456179", "year": 2016 }, { "pmid": "26514773", "title": "Matrix metalloproteinase 9-induced increase in intestinal epithelial tight junction permeability contributes to the severity of experimental DSS colitis", "doi": "10.1152/ajpgi.00256.2015", "year": 2015 } ] } }, { "id": 24020, "drug": "UV-phototherapy", "drug_type": "drug", "drug_domain": "multiple_sclerosis", "predicate_ab": "induces", "mediator": "vitamin D", "mediator_type": "biomarker", "predicate_bc": "associated_with", "outcome": "major depressive disorder", "outcome_type": "disease", "outcome_domain": "depression", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "active", "clinical_trial_nct_ids": [ "NCT07002554" ], "literature_status": "novel_signal", "drug_canonical": "uv-phototherapy", "mediator_canonical": "vitamin d", "outcome_canonical": "major depressive disorder", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "33376202", "title": "Sunlight exposure exerts immunomodulatory effects to reduce multiple sclerosis severity", "doi": "10.1073/pnas.2018457118", "year": 2020 } ], "bc": [ { "pmid": "40441192", "title": "Serum vitamin levels and major depressive disorder: Age-dependent associations in the US adult population", "doi": "10.1097/md.0000000000042514", "year": 2025 }, { "pmid": "35221997", "title": "The Relationship Between Vitamin D, Clinical Manifestations, and Functional Network Connectivity in Female Patients With Major Depressive Disorder", "doi": "10.3389/fnagi.2022.817607", "year": 2022 } ] } }, { "id": 24018, "drug": "IFN-beta", "drug_type": "drug", "drug_domain": "multiple_sclerosis", "predicate_ab": "upregulates", "mediator": "BDNF", "mediator_type": "biomarker", "predicate_bc": "predicts", "outcome": "MDD", "outcome_type": "disease", "outcome_domain": "depression", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "ifn-beta", "mediator_canonical": "BDNF", "outcome_canonical": "major depressive disorder", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "34182566", "title": "The Effect of IFN-β Treatment on Plasma Levels of BDNF and IL-6 in Relapsing-Remitting Multiple Sclerosis Patients", "doi": "10.1159/000515595", "year": 2021 } ], "bc": [ { "pmid": "41906159", "title": "Alterations in serum melatonin, IL-6 and BDNF levels and their clinical correlations in first-episode major depressive disorder", "doi": "10.1186/s12991-026-00657-2", "year": 2026 }, { "pmid": "36386998", "title": "Potential value of serum brain-derived neurotrophic factor, vascular endothelial growth factor, and S100B for identifying major depressive disorder in knee osteoarthritis patients", "doi": "10.3389/fpsyt.2022.1019367", "year": 2022 }, { "pmid": "32085720", "title": "Reduced serum BDNF levels are associated with the increased risk for developing MDD: a case–control study with or without antidepressant therapy", "doi": "10.1186/s13104-020-04952-3", "year": 2020 } ] } }, { "id": 55098, "drug": "fumaric acid esters", "drug_type": "drug", "drug_domain": "multiple_sclerosis", "predicate_ab": "inhibits", "mediator": "miR-21", "mediator_type": "gene", "predicate_bc": "increases", "outcome": "cardiac fibrosis", "outcome_type": "disease", "outcome_domain": "heart_failure", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "30698680", "title": "Fumarates target the metabolic-epigenetic interplay of brain-homing T cells in multiple sclerosis", "doi": "10.1093/brain/awy344", "year": 2018 } ], "bc": [ { "pmid": "33550817", "title": "MicroRNA-21–Dependent Macrophage-to-Fibroblast Signaling Determines the Cardiac Response to Pressure Overload", "doi": "10.1161/circulationaha.120.050682", "year": 2021 }, { "pmid": "33804922", "title": "Therapeutic miR-21 Silencing Reduces Cardiac Fibrosis and Modulates Inflammatory Response in Chronic Chagas Disease", "doi": "10.3390/ijms22073307", "year": 2021 }, { "pmid": "28335740", "title": "miR-21 enhances cardiac fibrotic remodeling and fibroblast proliferation via CADM1/STAT3 pathway", "doi": "10.1186/s12872-017-0520-7", "year": 2017 } ] } }, { "id": 35081, "drug": "interferon-beta", "drug_type": "drug", "drug_domain": "multiple_sclerosis", "predicate_ab": "downregulates", "mediator": "IL-17A", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "inflammatory bowel disease", "outcome_type": "disease", "outcome_domain": "inflammatory_bowel_disease", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "completed", "clinical_trial_nct_ids": [ "NCT00304252", "NCT00048347", "NCT00303381" ], "literature_status": "reproduces_known", "drug_canonical": "interferon-beta", "mediator_canonical": "il-17a", "outcome_canonical": "inflammatory bowel disease", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "34808619", "title": "The Effect of Interferon-Beta Therapy on T-Helper 17/miR-326 and T-Helper 1/miR-29b-3p Axis in Relapsing-Remitting Multiple Sclerosis Patients", "doi": "10.1159/000519777", "year": 2021 } ], "bc": [ { "pmid": "32724117", "title": "Serum interleukin 17A and interleukin 17F in children with inflammatory bowel disease", "doi": "10.1038/s41598-020-69567-x", "year": 2020 }, { "pmid": "27049090", "title": "Relationship between serum interleukin-17 level and inflammatory bowel disease.", "doi": null, "year": 2016 } ] } }, { "id": 35083, "drug": "CTX:SBA-15", "drug_type": "drug", "drug_domain": "multiple_sclerosis", "predicate_ab": "downregulates", "mediator": "IL-17", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "Crohn's disease", "outcome_type": "disease", "outcome_domain": "inflammatory_bowel_disease", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "ctx:sba-15", "mediator_canonical": "il-17", "outcome_canonical": "crohn's disease", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "33193433", "title": "The Crotoxin:SBA-15 Complex Down-Regulates the Incidence and Intensity of Experimental Autoimmune Encephalomyelitis Through Peripheral and Central Actions", "doi": "10.3389/fimmu.2020.591563", "year": 2020 } ], "bc": [ { "pmid": "39803916", "title": "Correlation between IL-17 and inflammatory bowel disease", "doi": "10.55133/eji.320106", "year": 2025 }, { "pmid": "38229938", "title": "Crohn's disease and clinical management today: How it does?", "doi": "10.5662/wjm.v13.i5.399", "year": 2023 }, { "pmid": "28533995", "title": "Crohn’s Disease and Ulcerative Colitis Show Unique Cytokine Profiles", "doi": "10.7759/cureus.1177", "year": 2017 } ] } }, { "id": 35084, "drug": "Forskolin", "drug_type": "drug", "drug_domain": "multiple_sclerosis", "predicate_ab": "downregulates", "mediator": "IL-17", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "Crohn's disease", "outcome_type": "disease", "outcome_domain": "inflammatory_bowel_disease", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "forskolin", "mediator_canonical": "il-17", "outcome_canonical": "crohn's disease", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "39229522", "title": "Forskolin improves experimental autoimmune encephalomyelitis in mice probably by inhibiting the calcium and the IL-17-STEAP4 signaling pathway", "doi": "10.1016/j.heliyon.2024.e36063", "year": 2024 } ], "bc": [ { "pmid": "39803916", "title": "Correlation between IL-17 and inflammatory bowel disease", "doi": "10.55133/eji.320106", "year": 2025 }, { "pmid": "38229938", "title": "Crohn's disease and clinical management today: How it does?", "doi": "10.5662/wjm.v13.i5.399", "year": 2023 }, { "pmid": "28533995", "title": "Crohn’s Disease and Ulcerative Colitis Show Unique Cytokine Profiles", "doi": "10.7759/cureus.1177", "year": 2017 } ] } }, { "id": 35087, "drug": "biosim-NTZ", "drug_type": "drug", "drug_domain": "multiple_sclerosis", "predicate_ab": "induces", "mediator": "anti-drug antibodies", "mediator_type": "biomarker", "predicate_bc": "associated_with", "outcome": "loss of response", "outcome_type": "phenotype", "outcome_domain": "inflammatory_bowel_disease", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "biosim-ntz", "mediator_canonical": "anti-drug antibodies", "outcome_canonical": "loss of response", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "39749348", "title": "Comparative immunogenicity assessment of biosimilar natalizumab to its reference medicine: a matching immunogenicity profile", "doi": "10.3389/fimmu.2024.1414304", "year": 2024 } ], "bc": [ { "pmid": "37961895", "title": "Anti-drug antibodies against anti-TNF in patients with inflammatory bowel disease: an evaluation of possible strategies", "doi": "10.1080/00365521.2023.2278424", "year": 2023 }, { "pmid": "34559428", "title": "Loss of response to anti‐TNFα agents depends on treatment duration in patients with inflammatory bowel disease", "doi": "10.1111/apt.16605", "year": 2021 }, { "pmid": "29383030", "title": "Immunogenicity of biologics in inflammatory bowel disease", "doi": "10.1177/1756283x17750355", "year": 2018 } ] } }, { "id": 35091, "drug": "Crotalphine", "drug_type": "drug", "drug_domain": "multiple_sclerosis", "predicate_ab": "downregulates", "mediator": "IL-17", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "Crohn's disease", "outcome_type": "disease", "outcome_domain": "inflammatory_bowel_disease", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "crotalphine", "mediator_canonical": "il-17", "outcome_canonical": "crohn's disease", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "34822611", "title": "Crotalphine Attenuates Pain and Neuroinflammation Induced by Experimental Autoimmune Encephalomyelitis in Mice", "doi": "10.3390/toxins13110827", "year": 2021 } ], "bc": [ { "pmid": "39803916", "title": "Correlation between IL-17 and inflammatory bowel disease", "doi": "10.55133/eji.320106", "year": 2025 }, { "pmid": "38229938", "title": "Crohn's disease and clinical management today: How it does?", "doi": "10.5662/wjm.v13.i5.399", "year": 2023 }, { "pmid": "28533995", "title": "Crohn’s Disease and Ulcerative Colitis Show Unique Cytokine Profiles", "doi": "10.7759/cureus.1177", "year": 2017 } ] } }, { "id": 35090, "drug": "niraparib", "drug_type": "drug", "drug_domain": "multiple_sclerosis", "predicate_ab": "inhibits", "mediator": "IL-17A", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "inflammatory bowel disease", "outcome_type": "disease", "outcome_domain": "inflammatory_bowel_disease", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "niraparib", "mediator_canonical": "il-17a", "outcome_canonical": "inflammatory bowel disease", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40924614", "title": "Niraparib Demonstrates Therapeutic Potential in Multiple Sclerosis through Inhibition of IL-17A Receptor Interaction and Promotion of Remyelination", "doi": "10.1021/acschemneuro.5c00519", "year": 2025 } ], "bc": [ { "pmid": "32724117", "title": "Serum interleukin 17A and interleukin 17F in children with inflammatory bowel disease", "doi": "10.1038/s41598-020-69567-x", "year": 2020 }, { "pmid": "27049090", "title": "Relationship between serum interleukin-17 level and inflammatory bowel disease.", "doi": null, "year": 2016 } ] } }, { "id": 35086, "drug": "Pien Tze Huang", "drug_type": "drug", "drug_domain": "multiple_sclerosis", "predicate_ab": "downregulates", "mediator": "IL-17A", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "inflammatory bowel disease", "outcome_type": "disease", "outcome_domain": "inflammatory_bowel_disease", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "pien tze huang", "mediator_canonical": "il-17a", "outcome_canonical": "inflammatory bowel disease", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "30429789", "title": "Pien Tze Huang Alleviates Relapsing-Remitting Experimental Autoimmune Encephalomyelitis Mice by Regulating Th1 and Th17 Cells", "doi": "10.3389/fphar.2018.01237", "year": 2018 } ], "bc": [ { "pmid": "32724117", "title": "Serum interleukin 17A and interleukin 17F in children with inflammatory bowel disease", "doi": "10.1038/s41598-020-69567-x", "year": 2020 }, { "pmid": "27049090", "title": "Relationship between serum interleukin-17 level and inflammatory bowel disease.", "doi": null, "year": 2016 } ] } }, { "id": 35097, "drug": "AHSCT", "drug_type": "drug", "drug_domain": "multiple_sclerosis", "predicate_ab": "suppresses", "mediator": "IL-17", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "Crohn's disease", "outcome_type": "disease", "outcome_domain": "inflammatory_bowel_disease", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "active", "clinical_trial_nct_ids": [ "NCT01915927", "NCT04224558", "NCT00692939" ], "literature_status": "reproduces_known", "drug_canonical": "ahsct", "mediator_canonical": "il-17", "outcome_canonical": "crohn's disease", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "35126353", "title": "Long-Term Suppression of Circulating Proinflammatory Cytokines in Multiple Sclerosis Patients Following Autologous Haematopoietic Stem Cell Transplantation", "doi": "10.3389/fimmu.2021.782935", "year": 2022 } ], "bc": [ { "pmid": "39803916", "title": "Correlation between IL-17 and inflammatory bowel disease", "doi": "10.55133/eji.320106", "year": 2025 }, { "pmid": "38229938", "title": "Crohn's disease and clinical management today: How it does?", "doi": "10.5662/wjm.v13.i5.399", "year": 2023 }, { "pmid": "28533995", "title": "Crohn’s Disease and Ulcerative Colitis Show Unique Cytokine Profiles", "doi": "10.7759/cureus.1177", "year": 2017 } ] } }, { "id": 35095, "drug": "fingolimod", "drug_type": "drug", "drug_domain": "multiple_sclerosis", "predicate_ab": "suppresses", "mediator": "IL-17A", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "inflammatory bowel disease", "outcome_type": "disease", "outcome_domain": "inflammatory_bowel_disease", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "fingolimod", "mediator_canonical": "il-17a", "outcome_canonical": "inflammatory bowel disease", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "32655793", "title": "The immunosuppressant fingolimod ameliorates experimental autoimmune myasthenia gravis by regulating T-cell balance and cytokine secretion.", "doi": null, "year": 2020 } ], "bc": [ { "pmid": "32724117", "title": "Serum interleukin 17A and interleukin 17F in children with inflammatory bowel disease", "doi": "10.1038/s41598-020-69567-x", "year": 2020 }, { "pmid": "27049090", "title": "Relationship between serum interleukin-17 level and inflammatory bowel disease.", "doi": null, "year": 2016 } ] } }, { "id": 35085, "drug": "nivolumab", "drug_type": "drug", "drug_domain": "multiple_sclerosis", "predicate_ab": "inhibits", "mediator": "PD-1", "mediator_type": "protein", "predicate_bc": "decreases", "outcome": "PD-1 inhibitor-associated colitis", "outcome_type": "disease", "outcome_domain": "inflammatory_bowel_disease", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "nivolumab", "mediator_canonical": "pd-1", "outcome_canonical": "pd-1 inhibitor-associated colitis", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41846303", "title": "Nivolumab‐Associated Autoimmune Encephalopathy in a Child With Multiply Relapsed Anaplastic Ependymoma", "doi": "10.1002/1545-5017.70262", "year": 2026 }, { "pmid": "31135622", "title": "Severe Relapse of Vaccine-Induced Guillain–Barré Syndrome After Treatment With Nivolumab", "doi": "10.1097/cnd.0000000000000230", "year": 2019 }, { "pmid": "30465016", "title": "Natalizumab may control immune checkpoint inhibitor–induced limbic encephalitis", "doi": "10.1212/nxi.0000000000000439", "year": 2018 } ], "bc": [ { "pmid": "32298485", "title": "Programmed cell death‐1 (PD‐1) and programmed death‐ligand 1 (PD‐L1) expression in PD‐1 inhibitor‐associated colitis and its mimics", "doi": "10.1111/his.14115", "year": 2020 } ] } }, { "id": 35089, "drug": "GlcNAc", "drug_type": "drug", "drug_domain": "multiple_sclerosis", "predicate_ab": "inhibits", "mediator": "IL-17", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "Crohn's disease", "outcome_type": "disease", "outcome_domain": "inflammatory_bowel_disease", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "preclinical_only", "clinical_trial_nct_ids": [ "NCT07225998" ], "literature_status": "partial_evidence", "drug_canonical": "glcnac", "mediator_canonical": "il-17", "outcome_canonical": "crohn's disease", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37705084", "title": "N-acetylglucosamine inhibits inflammation and neurodegeneration markers in multiple sclerosis: a mechanistic trial", "doi": "10.1186/s12974-023-02893-9", "year": 2023 } ], "bc": [ { "pmid": "39803916", "title": "Correlation between IL-17 and inflammatory bowel disease", "doi": "10.55133/eji.320106", "year": 2025 }, { "pmid": "38229938", "title": "Crohn's disease and clinical management today: How it does?", "doi": "10.5662/wjm.v13.i5.399", "year": 2023 }, { "pmid": "28533995", "title": "Crohn’s Disease and Ulcerative Colitis Show Unique Cytokine Profiles", "doi": "10.7759/cureus.1177", "year": 2017 } ] } }, { "id": 23822, "drug": "nivolumab", "drug_type": "drug", "drug_domain": "multiple_sclerosis", "predicate_ab": "inhibits", "mediator": "PD-1", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "lymph node metastasis", "outcome_type": "disease", "outcome_domain": "pancreatic_cancer", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "active", "clinical_trial_nct_ids": [ "NCT03793166", "NCT03518320", "NCT05504642" ], "literature_status": "reproduces_known", "drug_canonical": "nivolumab", "mediator_canonical": "pd-1", "outcome_canonical": "lymph node metastasis", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41846303", "title": "Nivolumab‐Associated Autoimmune Encephalopathy in a Child With Multiply Relapsed Anaplastic Ependymoma", "doi": "10.1002/1545-5017.70262", "year": 2026 }, { "pmid": "31135622", "title": "Severe Relapse of Vaccine-Induced Guillain–Barré Syndrome After Treatment With Nivolumab", "doi": "10.1097/cnd.0000000000000230", "year": 2019 }, { "pmid": "30465016", "title": "Natalizumab may control immune checkpoint inhibitor–induced limbic encephalitis", "doi": "10.1212/nxi.0000000000000439", "year": 2018 } ], "bc": [ { "pmid": "32987956", "title": "PD-1 Expression by Lymph Node and Intratumoral Regulatory T Cells Is Associated with Lymph Node Metastasis in Pancreatic Cancer", "doi": "10.3390/cancers12102756", "year": 2020 } ] } }, { "id": 37271, "drug": "miR-365 inhibitors", "drug_type": "drug", "drug_domain": "pancreatic_cancer", "predicate_ab": "inhibits", "mediator": "STAT3", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "prurigo nodularis", "outcome_type": "disease", "outcome_domain": "rheumatoid_arthritis", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "mir-365 inhibitors", "mediator_canonical": "STAT3", "outcome_canonical": "prurigo nodularis", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37415745", "title": "Betulinic acid-mediating miRNA-365 inhibited the progression of pancreatic cancer", "doi": "10.32604/or.2023.026959", "year": 2023 } ], "bc": [ { "pmid": "39912139", "title": "Translating tissue expression of STAT 1, 3 and 6 in prurigo nodularis to clinical efficacy of oral tofacitinib – A prospective single-arm investigational study", "doi": "10.25259/ijdvl_1017_2024", "year": 2025 }, { "pmid": "40162359", "title": "Successful Use of Tofacitinib in Paediatric Prurigo Nodularis: A Report of Four Cases", "doi": "10.4103/ijd.ijd_842_24", "year": 2025 }, { "pmid": "37521237", "title": "A case of recalcitrant prurigo nodularis with heightened expression of STAT 3 and STAT 6 and its dramatic response to tofacitinib", "doi": "10.4103/idoj.idoj_508_22", "year": 2023 } ] } }, { "id": 37295, "drug": "AMD3100", "drug_type": "drug", "drug_domain": "pancreatic_cancer", "predicate_ab": "inhibits", "mediator": "CXCR4", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "chondrocyte senescence", "outcome_type": "phenotype", "outcome_domain": "rheumatoid_arthritis", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "plerixafor", "mediator_canonical": "CXCR4", "outcome_canonical": "chondrocyte senescence", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "36145541", "title": "Development and Evaluation of a Peptide Heterodimeric Tracer Targeting CXCR4 and Integrin αvβ3 for Pancreatic Cancer Imaging", "doi": "10.3390/pharmaceutics14091791", "year": 2022 }, { "pmid": "35797269", "title": "Interaction of immune checkpoint PD-1 and chemokine receptor 4 (CXCR4) promotes a malignant phenotype in pancreatic cancer cells", "doi": "10.1371/journal.pone.0270832", "year": 2022 }, { "pmid": "33127761", "title": "CXCR4 inhibition in human pancreatic and colorectal cancers induces an integrated immune response", "doi": "10.1073/pnas.2013644117", "year": 2020 } ], "bc": [ { "pmid": "41331944", "title": "Targeting the CXCL12/CXCR4 pathway by an optimized derivative or EPI-X4 preserves chondrocyte function and offers a novel therapeutic approach in rheumatic diseases", "doi": "10.1186/s13075-025-03691-9", "year": 2025 } ] } }, { "id": 37267, "drug": "MEK inhibitors", "drug_type": "drug", "drug_domain": "pancreatic_cancer", "predicate_ab": "activates", "mediator": "STAT3", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "prurigo nodularis", "outcome_type": "disease", "outcome_domain": "rheumatoid_arthritis", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "mek inhibitors", "mediator_canonical": "STAT3", "outcome_canonical": "prurigo nodularis", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "25961376", "title": "Rational combination of MEK inhibitor and the STAT3 pathway modulator for the therapy in K-Ras mutated pancreatic and colon cancer cells", "doi": "10.18632/oncotarget.3991", "year": 2015 } ], "bc": [ { "pmid": "39912139", "title": "Translating tissue expression of STAT 1, 3 and 6 in prurigo nodularis to clinical efficacy of oral tofacitinib – A prospective single-arm investigational study", "doi": "10.25259/ijdvl_1017_2024", "year": 2025 }, { "pmid": "40162359", "title": "Successful Use of Tofacitinib in Paediatric Prurigo Nodularis: A Report of Four Cases", "doi": "10.4103/ijd.ijd_842_24", "year": 2025 }, { "pmid": "37521237", "title": "A case of recalcitrant prurigo nodularis with heightened expression of STAT 3 and STAT 6 and its dramatic response to tofacitinib", "doi": "10.4103/idoj.idoj_508_22", "year": 2023 } ] } }, { "id": 37284, "drug": "PG-S3-001", "drug_type": "drug", "drug_domain": "pancreatic_cancer", "predicate_ab": "binds_to", "mediator": "STAT3", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "prurigo nodularis", "outcome_type": "disease", "outcome_domain": "rheumatoid_arthritis", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "pg-s3-001", "mediator_canonical": "STAT3", "outcome_canonical": "prurigo nodularis", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "26873728", "title": "Applying Small Molecule Signal Transducer and Activator of Transcription-3 (STAT3) Protein Inhibitors as Pancreatic Cancer Therapeutics", "doi": "10.1158/1535-7163.mct-15-0003", "year": 2016 } ], "bc": [ { "pmid": "39912139", "title": "Translating tissue expression of STAT 1, 3 and 6 in prurigo nodularis to clinical efficacy of oral tofacitinib – A prospective single-arm investigational study", "doi": "10.25259/ijdvl_1017_2024", "year": 2025 }, { "pmid": "40162359", "title": "Successful Use of Tofacitinib in Paediatric Prurigo Nodularis: A Report of Four Cases", "doi": "10.4103/ijd.ijd_842_24", "year": 2025 }, { "pmid": "37521237", "title": "A case of recalcitrant prurigo nodularis with heightened expression of STAT 3 and STAT 6 and its dramatic response to tofacitinib", "doi": "10.4103/idoj.idoj_508_22", "year": 2023 } ] } }, { "id": 37279, "drug": "aripiprazole", "drug_type": "drug", "drug_domain": "pancreatic_cancer", "predicate_ab": "inhibits", "mediator": "STAT3", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "prurigo nodularis", "outcome_type": "disease", "outcome_domain": "rheumatoid_arthritis", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "aripiprazole", "mediator_canonical": "STAT3", "outcome_canonical": "prurigo nodularis", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "39540370", "title": "Repositioning of aripiprazole, an anti‑psychotic drug, to sensitize the chemotherapy of pancreatic cancer", "doi": "10.3892/ijmm.2024.5458", "year": 2024 } ], "bc": [ { "pmid": "39912139", "title": "Translating tissue expression of STAT 1, 3 and 6 in prurigo nodularis to clinical efficacy of oral tofacitinib – A prospective single-arm investigational study", "doi": "10.25259/ijdvl_1017_2024", "year": 2025 }, { "pmid": "40162359", "title": "Successful Use of Tofacitinib in Paediatric Prurigo Nodularis: A Report of Four Cases", "doi": "10.4103/ijd.ijd_842_24", "year": 2025 }, { "pmid": "37521237", "title": "A case of recalcitrant prurigo nodularis with heightened expression of STAT 3 and STAT 6 and its dramatic response to tofacitinib", "doi": "10.4103/idoj.idoj_508_22", "year": 2023 } ] } }, { "id": 37273, "drug": "Evodiamine", "drug_type": "drug", "drug_domain": "pancreatic_cancer", "predicate_ab": "inhibits", "mediator": "STAT3", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "prurigo nodularis", "outcome_type": "disease", "outcome_domain": "rheumatoid_arthritis", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "evodiamine", "mediator_canonical": "STAT3", "outcome_canonical": "prurigo nodularis", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "31922213", "title": "Effects of evodiamine on PI3K/Akt and MAPK/ERK signaling pathways in pancreatic cancer cells", "doi": "10.3892/ijo.2020.4956", "year": 2020 } ], "bc": [ { "pmid": "39912139", "title": "Translating tissue expression of STAT 1, 3 and 6 in prurigo nodularis to clinical efficacy of oral tofacitinib – A prospective single-arm investigational study", "doi": "10.25259/ijdvl_1017_2024", "year": 2025 }, { "pmid": "40162359", "title": "Successful Use of Tofacitinib in Paediatric Prurigo Nodularis: A Report of Four Cases", "doi": "10.4103/ijd.ijd_842_24", "year": 2025 }, { "pmid": "37521237", "title": "A case of recalcitrant prurigo nodularis with heightened expression of STAT 3 and STAT 6 and its dramatic response to tofacitinib", "doi": "10.4103/idoj.idoj_508_22", "year": 2023 } ] } }, { "id": 37269, "drug": "bazedoxifene", "drug_type": "drug", "drug_domain": "pancreatic_cancer", "predicate_ab": "inhibits", "mediator": "STAT3", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "prurigo nodularis", "outcome_type": "disease", "outcome_domain": "rheumatoid_arthritis", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "bazedoxifene", "mediator_canonical": "STAT3", "outcome_canonical": "prurigo nodularis", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "27535971", "title": "Bazedoxifene as a Novel GP130 Inhibitor for Pancreatic Cancer Therapy", "doi": "10.1158/1535-7163.mct-15-0921", "year": 2016 } ], "bc": [ { "pmid": "39912139", "title": "Translating tissue expression of STAT 1, 3 and 6 in prurigo nodularis to clinical efficacy of oral tofacitinib – A prospective single-arm investigational study", "doi": "10.25259/ijdvl_1017_2024", "year": 2025 }, { "pmid": "40162359", "title": "Successful Use of Tofacitinib in Paediatric Prurigo Nodularis: A Report of Four Cases", "doi": "10.4103/ijd.ijd_842_24", "year": 2025 }, { "pmid": "37521237", "title": "A case of recalcitrant prurigo nodularis with heightened expression of STAT 3 and STAT 6 and its dramatic response to tofacitinib", "doi": "10.4103/idoj.idoj_508_22", "year": 2023 } ] } }, { "id": 37277, "drug": "caryophyllane sesquiterpenes", "drug_type": "drug", "drug_domain": "pancreatic_cancer", "predicate_ab": "inhibits", "mediator": "STAT3", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "prurigo nodularis", "outcome_type": "disease", "outcome_domain": "rheumatoid_arthritis", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "caryophyllane sesquiterpenes", "mediator_canonical": "STAT3", "outcome_canonical": "prurigo nodularis", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "35745837", "title": "Sorafenib Chemosensitization by Caryophyllane Sesquiterpenes in Liver, Biliary, and Pancreatic Cancer Cells: The Role of STAT3/ABC Transporter Axis", "doi": "10.3390/pharmaceutics14061264", "year": 2022 } ], "bc": [ { "pmid": "39912139", "title": "Translating tissue expression of STAT 1, 3 and 6 in prurigo nodularis to clinical efficacy of oral tofacitinib – A prospective single-arm investigational study", "doi": "10.25259/ijdvl_1017_2024", "year": 2025 }, { "pmid": "40162359", "title": "Successful Use of Tofacitinib in Paediatric Prurigo Nodularis: A Report of Four Cases", "doi": "10.4103/ijd.ijd_842_24", "year": 2025 }, { "pmid": "37521237", "title": "A case of recalcitrant prurigo nodularis with heightened expression of STAT 3 and STAT 6 and its dramatic response to tofacitinib", "doi": "10.4103/idoj.idoj_508_22", "year": 2023 } ] } }, { "id": 37276, "drug": "combination treatment of biochanin A and atorvastatin", "drug_type": "drug", "drug_domain": "pancreatic_cancer", "predicate_ab": "downregulates", "mediator": "STAT3", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "prurigo nodularis", "outcome_type": "disease", "outcome_domain": "rheumatoid_arthritis", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "unknown", "drug_canonical": "combination treatment of biochanin a and atorvastatin", "mediator_canonical": "STAT3", "outcome_canonical": "prurigo nodularis", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "38821627", "title": "Combination Treatment of Biochanin A and Atorvastatin Alters Mitochondrial Bioenergetics, Modulating Cell Metabolism and Inducing Cell Cycle Arrest in Pancreatic Cancer Cells", "doi": "10.21873/anticanres.17038", "year": 2024 } ], "bc": [ { "pmid": "39912139", "title": "Translating tissue expression of STAT 1, 3 and 6 in prurigo nodularis to clinical efficacy of oral tofacitinib – A prospective single-arm investigational study", "doi": "10.25259/ijdvl_1017_2024", "year": 2025 }, { "pmid": "40162359", "title": "Successful Use of Tofacitinib in Paediatric Prurigo Nodularis: A Report of Four Cases", "doi": "10.4103/ijd.ijd_842_24", "year": 2025 }, { "pmid": "37521237", "title": "A case of recalcitrant prurigo nodularis with heightened expression of STAT 3 and STAT 6 and its dramatic response to tofacitinib", "doi": "10.4103/idoj.idoj_508_22", "year": 2023 } ] } }, { "id": 37300, "drug": "Nexrutine", "drug_type": "drug", "drug_domain": "pancreatic_cancer", "predicate_ab": "inhibits", "mediator": "STAT3", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "prurigo nodularis", "outcome_type": "disease", "outcome_domain": "rheumatoid_arthritis", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "nexrutine", "mediator_canonical": "STAT3", "outcome_canonical": "prurigo nodularis", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "27208550", "title": "Downregulation of STAT3/NF‐κB potentiates gemcitabine activity in pancreatic cancer cells", "doi": "10.1002/mc.22503", "year": 2016 } ], "bc": [ { "pmid": "39912139", "title": "Translating tissue expression of STAT 1, 3 and 6 in prurigo nodularis to clinical efficacy of oral tofacitinib – A prospective single-arm investigational study", "doi": "10.25259/ijdvl_1017_2024", "year": 2025 }, { "pmid": "40162359", "title": "Successful Use of Tofacitinib in Paediatric Prurigo Nodularis: A Report of Four Cases", "doi": "10.4103/ijd.ijd_842_24", "year": 2025 }, { "pmid": "37521237", "title": "A case of recalcitrant prurigo nodularis with heightened expression of STAT 3 and STAT 6 and its dramatic response to tofacitinib", "doi": "10.4103/idoj.idoj_508_22", "year": 2023 } ] } }, { "id": 37290, "drug": "6-bromomeisoindigo", "drug_type": "drug", "drug_domain": "pancreatic_cancer", "predicate_ab": "inhibits", "mediator": "STAT3", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "prurigo nodularis", "outcome_type": "disease", "outcome_domain": "rheumatoid_arthritis", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "6-bromomeisoindigo", "mediator_canonical": "STAT3", "outcome_canonical": "prurigo nodularis", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "32961646", "title": "Methylisoindigo and Its Bromo-Derivatives Are Selective Tyrosine Kinase Inhibitors, Repressing Cellular Stat3 Activity, and Target CD133+ Cancer Stem Cells in PDAC", "doi": "10.3390/molecules22091546", "year": 2017 } ], "bc": [ { "pmid": "39912139", "title": "Translating tissue expression of STAT 1, 3 and 6 in prurigo nodularis to clinical efficacy of oral tofacitinib – A prospective single-arm investigational study", "doi": "10.25259/ijdvl_1017_2024", "year": 2025 }, { "pmid": "40162359", "title": "Successful Use of Tofacitinib in Paediatric Prurigo Nodularis: A Report of Four Cases", "doi": "10.4103/ijd.ijd_842_24", "year": 2025 }, { "pmid": "37521237", "title": "A case of recalcitrant prurigo nodularis with heightened expression of STAT 3 and STAT 6 and its dramatic response to tofacitinib", "doi": "10.4103/idoj.idoj_508_22", "year": 2023 } ] } }, { "id": 37973, "drug": "pegcetacoplan", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "inhibits", "mediator": "complement C3", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "Alzheimer's disease", "outcome_type": "disease", "outcome_domain": "alzheimer", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "pegcetacoplan", "mediator_canonical": "complement c3", "outcome_canonical": "Alzheimer disease", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "38212259", "title": "Avacincaptad Pegol (Izervay) for Geographic Atrophy in Age-Related Macular Degeneration", "doi": "10.58347/tml.2024.1694d", "year": 2024 } ], "bc": [ { "pmid": "32831200", "title": "Dickkopf-1 Overexpression in vitro Nominates Candidate Blood Biomarkers Relating to Alzheimer’s Disease Pathology", "doi": "10.3233/jad-200208", "year": 2020 }, { "pmid": "30243924", "title": "An updated Alzheimer hypothesis: Complement C3 and risk of Alzheimer‘s disease—A cohort study of 95,442 individuals", "doi": "10.1016/j.jalz.2018.07.223", "year": 2018 } ] } }, { "id": 37272, "drug": "Trienomycin A", "drug_type": "drug", "drug_domain": "pancreatic_cancer", "predicate_ab": "binds_to", "mediator": "STAT3", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "prurigo nodularis", "outcome_type": "disease", "outcome_domain": "rheumatoid_arthritis", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "trienomycin a", "mediator_canonical": "STAT3", "outcome_canonical": "prurigo nodularis", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "33687738", "title": "The natural product trienomycin A is a STAT3 pathway inhibitor that exhibits potent in vitro and in vivo efficacy against pancreatic cancer", "doi": "10.1111/bph.15435", "year": 2021 } ], "bc": [ { "pmid": "39912139", "title": "Translating tissue expression of STAT 1, 3 and 6 in prurigo nodularis to clinical efficacy of oral tofacitinib – A prospective single-arm investigational study", "doi": "10.25259/ijdvl_1017_2024", "year": 2025 }, { "pmid": "40162359", "title": "Successful Use of Tofacitinib in Paediatric Prurigo Nodularis: A Report of Four Cases", "doi": "10.4103/ijd.ijd_842_24", "year": 2025 }, { "pmid": "37521237", "title": "A case of recalcitrant prurigo nodularis with heightened expression of STAT 3 and STAT 6 and its dramatic response to tofacitinib", "doi": "10.4103/idoj.idoj_508_22", "year": 2023 } ] } }, { "id": 59116, "drug": "tofacitinib", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "downregulates", "mediator": "C-reactive protein", "mediator_type": "biomarker", "predicate_bc": "predicts", "outcome": "in-hospital mortality", "outcome_type": "phenotype", "outcome_domain": "heart_failure", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40692219", "title": "Short‐Term Effectiveness of Sulfasalazine and Tofacitinib in NSAID ‐Refractory Reactive Arthritis: An Observational Study", "doi": "10.1111/1756-185x.70370", "year": 2025 } ], "bc": [ { "pmid": "32169690", "title": "Biomarkers for prediction of mortality in left-sided infective endocarditis", "doi": "10.1016/j.ijid.2020.03.009", "year": 2020 }, { "pmid": "29382606", "title": "Outcomes of infective endocarditis in the current era: Early predictors of a poor prognosis", "doi": "10.1016/j.ijid.2018.01.016", "year": 2018 }, { "pmid": "28357890", "title": "Pneumonia and inflammation in acute decompensated heart failure: a registry-based analysis of 1939 patients", "doi": "10.1177/2048872617700874", "year": 2017 } ] } }, { "id": 59141, "drug": "namilumab", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "binds_to", "mediator": "GM-CSF", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "cardiac complication", "outcome_type": "disease", "outcome_domain": "heart_failure", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "30999929", "title": "Efficacy and safety of namilumab, a human monoclonal antibody against granulocyte-macrophage colony-stimulating factor (GM-CSF) ligand in patients with rheumatoid arthritis (RA) with either an inadequate response to background methotrexate therapy or an inadequate response or intolerance to an anti-TNF (tumour necrosis factor) biologic therapy: a randomized, controlled trial", "doi": "10.1186/s13075-019-1879-x", "year": 2019 }, { "pmid": "30168415", "title": "Randomized, double-blind, placebo-controlled, phase I study of the safety and pharmacokinetics of namilumab in healthy Japanese and Caucasian men", "doi": "10.5414/cp203235", "year": 2018 } ], "bc": [ { "pmid": "32963156", "title": "The Cytokine Expression in Patients with Cardiac Complication after Immune Checkpoint Inhibitor Therapy", "doi": "10.2169/internalmedicine.5317-20", "year": 2020 } ] } }, { "id": 59144, "drug": "tofacitinib", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "downregulates", "mediator": "IFN-γ", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "Chagas disease cardiomyopathy", "outcome_type": "disease", "outcome_domain": "heart_failure", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "33899926", "title": "Lymphocyte modulation by tofacitinib in patients with rheumatoid arthritis", "doi": "10.1111/cei.13609", "year": 2021 }, { "pmid": "32616791", "title": "Tofacitinib treatment aggravates Staphylococcus aureus septic arthritis, but attenuates sepsis and enterotoxin induced shock in mice", "doi": "10.1038/s41598-020-67928-0", "year": 2020 }, { "pmid": "31638166", "title": "The JAK inhibitor tofacitinib ameliorates immune‑mediated liver injury in mice", "doi": "10.3892/mmr.2019.10750", "year": 2019 } ], "bc": [ { "pmid": "30559742", "title": "Disease Tolerance and Pathogen Resistance Genes May Underlie Trypanosoma cruzi Persistence and Differential Progression to Chagas Disease Cardiomyopathy", "doi": "10.3389/fimmu.2018.02791", "year": 2018 } ] } }, { "id": 38751, "drug": "deucravacitinib", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "inhibits", "mediator": "TYK2", "mediator_type": "protein", "predicate_bc": "prevents", "outcome": "colitis", "outcome_type": "disease", "outcome_domain": "inflammatory_bowel_disease", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "completed", "clinical_trial_nct_ids": [ "NCT04877990", "NCT04613518", "NCT03934216" ], "literature_status": "reproduces_known", "drug_canonical": "deucravacitinib", "mediator_canonical": "tyk2", "outcome_canonical": "colitis", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37132187", "title": "English version of Japanese guidance for the use of oral Janus kinase inhibitors (JAK1 and TYK2 inhibitors) in the treatments of psoriasis", "doi": "10.1111/1346-8138.16797", "year": 2023 }, { "pmid": "34471993", "title": "Selectivity Profile of the Tyrosine Kinase 2 Inhibitor Deucravacitinib Compared with Janus Kinase 1/2/3 Inhibitors", "doi": "10.1007/s13555-021-00596-8", "year": 2021 } ], "bc": [ { "pmid": "26432894", "title": "Intestinal Epithelial Cell Tyrosine Kinase 2 Transduces IL-22 Signals To Protect from Acute Colitis", "doi": "10.4049/jimmunol.1402565", "year": 2015 } ] } }, { "id": 59364, "drug": "kaempferol", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "binds_to", "mediator": "IL-17", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "Crohn's disease", "outcome_type": "disease", "outcome_domain": "inflammatory_bowel_disease", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "36424369", "title": "Revealing the Active Constituents and Mechanisms of Semiliquidambar cathayensis Chang Roots against Rheumatoid Arthritis through Network Pharmacology, Molecular Docking, and in Vivo Experiment", "doi": "10.1002/cbdv.202200916", "year": 2022 } ], "bc": [ { "pmid": "39803916", "title": "Correlation between IL-17 and inflammatory bowel disease", "doi": "10.55133/eji.320106", "year": 2025 }, { "pmid": "38229938", "title": "Crohn's disease and clinical management today: How it does?", "doi": "10.5662/wjm.v13.i5.399", "year": 2023 }, { "pmid": "28533995", "title": "Crohn’s Disease and Ulcerative Colitis Show Unique Cytokine Profiles", "doi": "10.7759/cureus.1177", "year": 2017 } ] } }, { "id": 59368, "drug": "CT-P47", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "induces", "mediator": "anti-drug antibodies", "mediator_type": "biomarker", "predicate_bc": "associated_with", "outcome": "loss of response", "outcome_type": "phenotype", "outcome_domain": "inflammatory_bowel_disease", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "39415551", "title": "Pharmacokinetics and Safety of Intravenous Candidate Biosimilar CT‐P47 and Reference Tocilizumab: A Randomized, Double‐Blind, Phase 1 Study", "doi": "10.1002/jcph.6139", "year": 2024 } ], "bc": [ { "pmid": "37961895", "title": "Anti-drug antibodies against anti-TNF in patients with inflammatory bowel disease: an evaluation of possible strategies", "doi": "10.1080/00365521.2023.2278424", "year": 2023 }, { "pmid": "34559428", "title": "Loss of response to anti‐TNFα agents depends on treatment duration in patients with inflammatory bowel disease", "doi": "10.1111/apt.16605", "year": 2021 }, { "pmid": "29383030", "title": "Immunogenicity of biologics in inflammatory bowel disease", "doi": "10.1177/1756283x17750355", "year": 2018 } ] } }, { "id": 59370, "drug": "namilumab", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "binds_to", "mediator": "GM-CSF", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "PCDAI", "outcome_type": "phenotype", "outcome_domain": "inflammatory_bowel_disease", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "30999929", "title": "Efficacy and safety of namilumab, a human monoclonal antibody against granulocyte-macrophage colony-stimulating factor (GM-CSF) ligand in patients with rheumatoid arthritis (RA) with either an inadequate response to background methotrexate therapy or an inadequate response or intolerance to an anti-TNF (tumour necrosis factor) biologic therapy: a randomized, controlled trial", "doi": "10.1186/s13075-019-1879-x", "year": 2019 }, { "pmid": "30168415", "title": "Randomized, double-blind, placebo-controlled, phase I study of the safety and pharmacokinetics of namilumab in healthy Japanese and Caucasian men", "doi": "10.5414/cp203235", "year": 2018 } ], "bc": [ { "pmid": "32884009", "title": "Serological cytokine signature in paediatric patients with inflammatory bowel disease impacts diagnosis", "doi": "10.1038/s41598-020-71503-y", "year": 2020 } ] } }, { "id": 38783, "drug": "doxycycline", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "inhibits", "mediator": "MMP-9", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "ulcerative colitis", "outcome_type": "disease", "outcome_domain": "inflammatory_bowel_disease", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "completed", "clinical_trial_nct_ids": [ "NCT06201793", "NCT02345733", "NCT02033408" ], "literature_status": "reproduces_known", "drug_canonical": "doxycycline", "mediator_canonical": "MMP9", "outcome_canonical": "ulcerative colitis", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "33185166", "title": "Predictors of Cardiovascular Affection in Patients with Active Rheumatoid Arthritis: Secondary Analysis of a Randomized Controlled Trial", "doi": "10.2174/1573397116666201113090145", "year": 2020 } ], "bc": [ { "pmid": "35566780", "title": "Are Matrix Metalloproteinase-9 and Tissue Inhibitor of Metalloproteinase-1 Useful as Markers in Diagnostic Management of Children with Newly Diagnosed Ulcerative Colitis?", "doi": "10.3390/jcm11092655", "year": 2022 }, { "pmid": "27034654", "title": "Expressions of Matrix Metalloproteinases (MMP-2, MMP-7, and MMP-9) and Their Inhibitors (TIMP-1, TIMP-2) in Inflammatory Bowel Diseases", "doi": "10.1155/2016/2456179", "year": 2016 }, { "pmid": "26514773", "title": "Matrix metalloproteinase 9-induced increase in intestinal epithelial tight junction permeability contributes to the severity of experimental DSS colitis", "doi": "10.1152/ajpgi.00256.2015", "year": 2015 } ] } }, { "id": 38765, "drug": "tofacitinib", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "inhibits", "mediator": "STAT3", "mediator_type": "protein", "predicate_bc": "prevents", "outcome": "DSS-induced colitis", "outcome_type": "disease", "outcome_domain": "inflammatory_bowel_disease", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "tofacitinib", "mediator_canonical": "STAT3", "outcome_canonical": "dss-induced colitis", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40373045", "title": "Rheumatoid arthritis synovial fluid induces JAK-dependent intracellular activation of human sensory neurons", "doi": "10.1172/jci.insight.186646", "year": 2025 }, { "pmid": "32927842", "title": "Tofacitinib and Baricitinib Are Taken up by Different Uptake Mechanisms Determining the Efficacy of Both Drugs in RA", "doi": "10.3390/ijms21186632", "year": 2020 }, { "pmid": "30357932", "title": "JAK1/3 inhibition preserves epidermal morphology in full‐thickness 3D skin models of atopic dermatitis and psoriasis", "doi": "10.1111/jdv.15301", "year": 2018 } ], "bc": [ { "pmid": "33673239", "title": "STAT3 Signalling via the IL-6ST/gp130 Cytokine Receptor Promotes Epithelial Integrity and Intestinal Barrier Function during DSS-Induced Colitis", "doi": "10.3390/biomedicines9020187", "year": 2021 } ] } }, { "id": 38779, "drug": "tofacitinib", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "downregulates", "mediator": "IFN-γ", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "recurrence", "outcome_type": "disease", "outcome_domain": "inflammatory_bowel_disease", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "active", "clinical_trial_nct_ids": [ "NCT05326464" ], "literature_status": "reproduces_known", "drug_canonical": "tofacitinib", "mediator_canonical": "ifn-γ", "outcome_canonical": null, "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "33899926", "title": "Lymphocyte modulation by tofacitinib in patients with rheumatoid arthritis", "doi": "10.1111/cei.13609", "year": 2021 }, { "pmid": "32616791", "title": "Tofacitinib treatment aggravates Staphylococcus aureus septic arthritis, but attenuates sepsis and enterotoxin induced shock in mice", "doi": "10.1038/s41598-020-67928-0", "year": 2020 }, { "pmid": "31638166", "title": "The JAK inhibitor tofacitinib ameliorates immune‑mediated liver injury in mice", "doi": "10.3892/mmr.2019.10750", "year": 2019 } ], "bc": [ { "pmid": "40920365", "title": "Blood proteomic signatures associated with disease activity in inflammatory bowel diseases", "doi": "10.1093/ecco-jcc/jjaf162", "year": 2025 } ] } }, { "id": 59389, "drug": "tofacitinib", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "downregulates", "mediator": "IFN-γ", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "disease activity", "outcome_type": "disease", "outcome_domain": "inflammatory_bowel_disease", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "33899926", "title": "Lymphocyte modulation by tofacitinib in patients with rheumatoid arthritis", "doi": "10.1111/cei.13609", "year": 2021 }, { "pmid": "32616791", "title": "Tofacitinib treatment aggravates Staphylococcus aureus septic arthritis, but attenuates sepsis and enterotoxin induced shock in mice", "doi": "10.1038/s41598-020-67928-0", "year": 2020 }, { "pmid": "31638166", "title": "The JAK inhibitor tofacitinib ameliorates immune‑mediated liver injury in mice", "doi": "10.3892/mmr.2019.10750", "year": 2019 } ], "bc": [ { "pmid": "40920365", "title": "Blood proteomic signatures associated with disease activity in inflammatory bowel diseases", "doi": "10.1093/ecco-jcc/jjaf162", "year": 2025 } ] } }, { "id": 38768, "drug": "Adalimumab", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "induces", "mediator": "anti-drug antibodies", "mediator_type": "biomarker", "predicate_bc": "associated_with", "outcome": "loss of response", "outcome_type": "phenotype", "outcome_domain": "inflammatory_bowel_disease", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "active", "clinical_trial_nct_ids": [ "NCT06180382", "NCT01338740", "NCT02896985" ], "literature_status": "reproduces_known", "drug_canonical": "adalimumab", "mediator_canonical": "anti-drug antibodies", "outcome_canonical": "loss of response", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37014287", "title": "Adalimumab combined with methotrexate versus adalimumab monotherapy in psoriasis: Three‐year follow‐up data of a single‐blind randomized controlled trial", "doi": "10.1111/jdv.19089", "year": 2023 } ], "bc": [ { "pmid": "37961895", "title": "Anti-drug antibodies against anti-TNF in patients with inflammatory bowel disease: an evaluation of possible strategies", "doi": "10.1080/00365521.2023.2278424", "year": 2023 }, { "pmid": "34559428", "title": "Loss of response to anti‐TNFα agents depends on treatment duration in patients with inflammatory bowel disease", "doi": "10.1111/apt.16605", "year": 2021 }, { "pmid": "29383030", "title": "Immunogenicity of biologics in inflammatory bowel disease", "doi": "10.1177/1756283x17750355", "year": 2018 } ] } }, { "id": 38846, "drug": "namilumab", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "binds_to", "mediator": "GM-CSF", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "autoimmune diseases", "outcome_type": "disease", "outcome_domain": "multiple_sclerosis", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "completed", "clinical_trial_nct_ids": [ "NCT02379091", "NCT02528786", "NCT01317797" ], "literature_status": "partial_evidence", "drug_canonical": "namilumab", "mediator_canonical": "gm-csf", "outcome_canonical": "autoimmune diseases", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "30999929", "title": "Efficacy and safety of namilumab, a human monoclonal antibody against granulocyte-macrophage colony-stimulating factor (GM-CSF) ligand in patients with rheumatoid arthritis (RA) with either an inadequate response to background methotrexate therapy or an inadequate response or intolerance to an anti-TNF (tumour necrosis factor) biologic therapy: a randomized, controlled trial", "doi": "10.1186/s13075-019-1879-x", "year": 2019 }, { "pmid": "30168415", "title": "Randomized, double-blind, placebo-controlled, phase I study of the safety and pharmacokinetics of namilumab in healthy Japanese and Caucasian men", "doi": "10.5414/cp203235", "year": 2018 } ], "bc": [ { "pmid": "34285924", "title": "Gene Regulatory Network of Human GM-CSF-Secreting T Helper Cells", "doi": "10.1155/2021/8880585", "year": 2021 } ] } }, { "id": 39064, "drug": "EMO", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "inhibits", "mediator": "EGFR", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "pancreatic ductal adenocarcinoma", "outcome_type": "disease", "outcome_domain": "pancreatic_cancer", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "emo", "mediator_canonical": "EGFR", "outcome_canonical": "pancreatic ductal adenocarcinoma", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37324499", "title": "The elucidation of the anti-inflammatory mechanism of EMO in rheumatoid arthritis through an integrative approach combining bioinformatics and experimental verification", "doi": "10.3389/fphar.2023.1195567", "year": 2023 } ], "bc": [ { "pmid": "40130819", "title": "Identification of Tumor‐Specific Surface Proteins Enables Quantification of Extracellular Vesicle Subtypes for Early Detection of Pancreatic Ductal Adenocarcinoma", "doi": "10.1002/advs.202414982", "year": 2025 }, { "pmid": "31584260", "title": "Design and Evaluation of PEGylated Liposomal Formulation of a Novel Multikinase Inhibitor for Enhanced Chemosensitivity and Inhibition of Metastatic Pancreatic Ductal Adenocarcinoma", "doi": "10.1021/acs.bioconjchem.9b00632", "year": 2019 }, { "pmid": "26339400", "title": "EGFR expression in pancreatic intraepithelial neoplasia and ductal adenocarcinoma.", "doi": null, "year": 2015 } ] } }, { "id": 39048, "drug": "fedratinib", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "inhibits", "mediator": "JAK2", "mediator_type": "protein", "predicate_bc": "predicts", "outcome": "poor prognosis", "outcome_type": "phenotype", "outcome_domain": "pancreatic_cancer", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "fedratinib", "mediator_canonical": "jak2", "outcome_canonical": null, "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "36001108", "title": "Effect of fluconazole on the pharmacokinetics of a single dose of fedratinib in healthy adults", "doi": "10.1007/s00280-022-04464-w", "year": 2022 }, { "pmid": "33570945", "title": "Structural Insights into JAK2 Inhibition by Ruxolitinib, Fedratinib, and Derivatives Thereof", "doi": "10.1021/acs.jmedchem.0c01952", "year": 2021 } ], "bc": [ { "pmid": "33029256", "title": "High JAK2 Protein Expression Predicts a Poor Prognosis in Patients with Resectable Pancreatic Ductal Adenocarcinoma", "doi": "10.1155/2020/7656031", "year": 2020 } ] } }, { "id": 39054, "drug": "tofacitinib", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "inhibits", "mediator": "STAT3", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "pancreatic ductal adenocarcinoma", "outcome_type": "disease", "outcome_domain": "pancreatic_cancer", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "tofacitinib", "mediator_canonical": "STAT3", "outcome_canonical": "pancreatic ductal adenocarcinoma", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40373045", "title": "Rheumatoid arthritis synovial fluid induces JAK-dependent intracellular activation of human sensory neurons", "doi": "10.1172/jci.insight.186646", "year": 2025 }, { "pmid": "32927842", "title": "Tofacitinib and Baricitinib Are Taken up by Different Uptake Mechanisms Determining the Efficacy of Both Drugs in RA", "doi": "10.3390/ijms21186632", "year": 2020 }, { "pmid": "30357932", "title": "JAK1/3 inhibition preserves epidermal morphology in full‐thickness 3D skin models of atopic dermatitis and psoriasis", "doi": "10.1111/jdv.15301", "year": 2018 } ], "bc": [ { "pmid": "38464736", "title": "Role of STAT3 in pancreatic cancer", "doi": "10.37349/etat.2024.00202", "year": 2024 } ] } }, { "id": 39432, "drug": "liraglutide", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "activates", "mediator": "AMPK", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "amyotrophic lateral sclerosis", "outcome_type": "disease", "outcome_domain": "als", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "active", "clinical_trial_nct_ids": [ "NCT06726577" ], "literature_status": "partial_evidence", "drug_canonical": "liraglutide", "mediator_canonical": "AMPK", "outcome_canonical": "amyotrophic lateral sclerosis", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "39779525", "title": "The protective effects of liraglutide in reducing lipid droplets accumulation and myocardial fibrosis in diabetic cardiomyopathy", "doi": "10.1007/s00018-024-05558-9", "year": 2025 }, { "pmid": "34357376", "title": "Glucagon-like peptide-1 attenuates cardiac hypertrophy via the AngII/AT1R/ACE2 and AMPK/mTOR/p70S6K pathways", "doi": "10.1093/abbs/gmab099", "year": 2021 }, { "pmid": "27473212", "title": "The GLP-1 receptor agonists exenatide and liraglutide activate Glucose transport by an AMPK-dependent mechanism", "doi": "10.1186/s12967-016-0985-7", "year": 2016 } ], "bc": [ { "pmid": "34393724", "title": "Contribution of Energy Dysfunction to Impaired Protein Translation in Neurodegenerative Diseases", "doi": "10.3389/fncel.2021.668500", "year": 2021 } ] } }, { "id": 39423, "drug": "LIRA", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "downregulates", "mediator": "RAGE", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "ALS", "outcome_type": "disease", "outcome_domain": "als", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "lira", "mediator_canonical": "rage", "outcome_canonical": "amyotrophic lateral sclerosis", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "39080620", "title": "Liraglutide, a glucagon-like peptide-1 receptor agonist, ameliorates inflammation and apoptosis via inhibition of receptor for advanced glycation end products signaling in AGEs induced chondrocytes", "doi": "10.1186/s12891-024-07640-6", "year": 2024 } ], "bc": [ { "pmid": "35216298", "title": "The Involvement of RAGE and Its Ligands during Progression of ALS in SOD1 G93A Transgenic Mice", "doi": "10.3390/ijms23042184", "year": 2022 }, { "pmid": "27242430", "title": "Soluble RAGE Treatment Delays Progression of Amyotrophic Lateral Sclerosis in SOD1 Mice", "doi": "10.3389/fncel.2016.00117", "year": 2016 }, { "pmid": "26733811", "title": "Receptor for Advanced Glycation End Products and its Inflammatory Ligands are Upregulated in Amyotrophic Lateral Sclerosis", "doi": "10.3389/fncel.2015.00485", "year": 2015 } ] } }, { "id": 39632, "drug": "Fucoxanthin", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "activates", "mediator": "SIRT1", "mediator_type": "protein", "predicate_bc": "predicts", "outcome": "Alzheimer's disease", "outcome_type": "disease", "outcome_domain": "alzheimer", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "fucoxanthin", "mediator_canonical": "SIRT1", "outcome_canonical": "Alzheimer disease", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41094589", "title": "Marine nutraceuticals as a source of SIRT1 and NRF2 activators for diabetes and aging-related metabolic disorders", "doi": "10.1186/s13098-025-01981-5", "year": 2025 } ], "bc": [ { "pmid": "37742223", "title": "Serum sirtuin1: a potential blood biomarker for early diagnosis of Alzheimer’s disease", "doi": "10.18632/aging.205015", "year": 2023 }, { "pmid": "30243024", "title": "Sirt1 enhances tau exon 10 inclusion and improves spatial memory of Htau mice", "doi": "10.18632/aging.101564", "year": 2018 } ] } }, { "id": 39646, "drug": "coral-derived steroids", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "activates", "mediator": "SIRT1", "mediator_type": "protein", "predicate_bc": "predicts", "outcome": "Alzheimer's disease", "outcome_type": "disease", "outcome_domain": "alzheimer", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "coral-derived steroids", "mediator_canonical": "SIRT1", "outcome_canonical": "Alzheimer disease", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41094589", "title": "Marine nutraceuticals as a source of SIRT1 and NRF2 activators for diabetes and aging-related metabolic disorders", "doi": "10.1186/s13098-025-01981-5", "year": 2025 } ], "bc": [ { "pmid": "37742223", "title": "Serum sirtuin1: a potential blood biomarker for early diagnosis of Alzheimer’s disease", "doi": "10.18632/aging.205015", "year": 2023 }, { "pmid": "30243024", "title": "Sirt1 enhances tau exon 10 inclusion and improves spatial memory of Htau mice", "doi": "10.18632/aging.101564", "year": 2018 } ] } }, { "id": 60234, "drug": "Alirocumab", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "inhibits", "mediator": "PCSK9", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "Alzheimer disease", "outcome_type": "disease", "outcome_domain": "alzheimer", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "32035487", "title": "Effect of alirocumab on individuals with type 2 diabetes, high triglycerides, and low high-density lipoprotein cholesterol", "doi": "10.1186/s12933-020-0991-1", "year": 2020 }, { "pmid": "28799203", "title": "Efficacy and safety of alirocumab in people with prediabetes vs those with normoglycaemia at baseline: a pooled analysis of 10 phase III ODYSSEY clinical trials", "doi": "10.1111/dme.13450", "year": 2017 }, { "pmid": "28545518", "title": "Design and rationale of the ODYSSEY DM-DYSLIPIDEMIA trial: lipid-lowering efficacy and safety of alirocumab in individuals with type 2 diabetes and mixed dyslipidaemia at high cardiovascular risk", "doi": "10.1186/s12933-017-0552-4", "year": 2017 } ], "bc": [ { "pmid": "31437157", "title": "Proprotein convertase subtilisin/kexin type 9 (PCSK9) in Alzheimer’s disease: A genetic and proteomic multi-cohort study", "doi": "10.1371/journal.pone.0220254", "year": 2019 } ] } }, { "id": 39804, "drug": "Sitagliptin", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "upregulates", "mediator": "BDNF", "mediator_type": "protein", "predicate_bc": "decreases", "outcome": "schizophrenia", "outcome_type": "disease", "outcome_domain": "depression", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "sitagliptin", "mediator_canonical": "BDNF", "outcome_canonical": "schizophrenia", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "29781786", "title": "Sitagliptin rescues memory deficits in Parkinsonian rats via upregulating BDNF to prevent neuron and dendritic spine loss", "doi": "10.1080/01616412.2018.1474840", "year": 2018 } ], "bc": [ { "pmid": "34280516", "title": "Associations of immunological proteins/traits with schizophrenia, major depression and bipolar disorder: A bi-directional two-sample mendelian randomization study", "doi": "10.1016/j.bbi.2021.07.009", "year": 2021 }, { "pmid": "30794585", "title": "Accuracy of brain-derived neurotrophic factor levels for differentiating between Taiwanese patients with major depressive disorder or schizophrenia and healthy controls", "doi": "10.1371/journal.pone.0212373", "year": 2019 } ] } }, { "id": 39994, "drug": "Canagliflozin", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "inhibits", "mediator": "mTOR", "mediator_type": "protein", "predicate_bc": "causes", "outcome": "mTOR-opathies", "outcome_type": "disease", "outcome_domain": "epilepsy", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "canagliflozin", "mediator_canonical": "mTOR", "outcome_canonical": "mtor-opathies", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37584455", "title": "Canagliflozin mediates tumor suppression alone and in combination with radiotherapy in non‐small cell lung cancer (NSCLC) through inhibition of HIF‐1α", "doi": "10.1002/1878-0261.13508", "year": 2023 }, { "pmid": "34142035", "title": "Canagliflozin attenuates lipotoxicity in cardiomyocytes and protects diabetic mouse hearts by inhibiting the mTOR/HIF-1α pathway", "doi": "10.1016/j.isci.2021.102521", "year": 2021 } ], "bc": [ { "pmid": "29447953", "title": "Dendrite growth and the effect of ectopic Rheb expression on cortical neurons", "doi": "10.1016/j.neulet.2018.02.021", "year": 2018 } ] } }, { "id": 39987, "drug": "exenatide", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "activates", "mediator": "AMPK", "mediator_type": "protein", "predicate_bc": "increases", "outcome": "spike-wave seizures", "outcome_type": "phenotype", "outcome_domain": "epilepsy", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "exenatide", "mediator_canonical": "AMPK", "outcome_canonical": "spike-wave seizures", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "33044023", "title": "Exenatide improves random‐pattern skin flap survival via TFE3 mediated autophagy augment", "doi": "10.1002/jcp.30102", "year": 2020 }, { "pmid": "27473212", "title": "The GLP-1 receptor agonists exenatide and liraglutide activate Glucose transport by an AMPK-dependent mechanism", "doi": "10.1186/s12967-016-0985-7", "year": 2016 }, { "pmid": "25720388", "title": "Exenatide Protects Against Glucose- and Lipid-Induced Endothelial Dysfunction: Evidence for Direct Vasodilation Effect of GLP-1 Receptor Agonists in Humans", "doi": "10.2337/db14-0976", "year": 2015 } ], "bc": [ { "pmid": "35134125", "title": "AMPK-mediated potentiation of GABAergic signalling drives hypoglycaemia-provoked spike-wave seizures", "doi": "10.1093/brain/awac037", "year": 2022 } ] } }, { "id": 39995, "drug": "Canagliflozin", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "suppresses", "mediator": "HIF-1α", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "epilepsy", "outcome_type": "disease", "outcome_domain": "epilepsy", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "canagliflozin", "mediator_canonical": "hif-1α", "outcome_canonical": "epilepsy", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37684337", "title": "The SGLT2 inhibitor canagliflozin suppresses growth and enhances prostate cancer response to radiotherapy", "doi": "10.1038/s42003-023-05289-w", "year": 2023 }, { "pmid": "37584455", "title": "Canagliflozin mediates tumor suppression alone and in combination with radiotherapy in non‐small cell lung cancer (NSCLC) through inhibition of HIF‐1α", "doi": "10.1002/1878-0261.13508", "year": 2023 }, { "pmid": "34142035", "title": "Canagliflozin attenuates lipotoxicity in cardiomyocytes and protects diabetic mouse hearts by inhibiting the mTOR/HIF-1α pathway", "doi": "10.1016/j.isci.2021.102521", "year": 2021 } ], "bc": [ { "pmid": "41324728", "title": "The Role of HIF-1α/BNIP3 Pathway in Hippocampal Neuronal Autophagy in Epilepsy", "doi": "10.1007/s12035-025-05406-2", "year": 2025 } ] } }, { "id": 39988, "drug": "exenatide", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "activates", "mediator": "AMPK", "mediator_type": "protein", "predicate_bc": "increases", "outcome": "epileptiform network activity", "outcome_type": "phenotype", "outcome_domain": "epilepsy", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "exenatide", "mediator_canonical": "AMPK", "outcome_canonical": "epileptiform network activity", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "33044023", "title": "Exenatide improves random‐pattern skin flap survival via TFE3 mediated autophagy augment", "doi": "10.1002/jcp.30102", "year": 2020 }, { "pmid": "27473212", "title": "The GLP-1 receptor agonists exenatide and liraglutide activate Glucose transport by an AMPK-dependent mechanism", "doi": "10.1186/s12967-016-0985-7", "year": 2016 }, { "pmid": "25720388", "title": "Exenatide Protects Against Glucose- and Lipid-Induced Endothelial Dysfunction: Evidence for Direct Vasodilation Effect of GLP-1 Receptor Agonists in Humans", "doi": "10.2337/db14-0976", "year": 2015 } ], "bc": [ { "pmid": "35134125", "title": "AMPK-mediated potentiation of GABAergic signalling drives hypoglycaemia-provoked spike-wave seizures", "doi": "10.1093/brain/awac037", "year": 2022 } ] } }, { "id": 39989, "drug": "liraglutide", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "activates", "mediator": "AMPK", "mediator_type": "protein", "predicate_bc": "increases", "outcome": "spike-wave seizures", "outcome_type": "phenotype", "outcome_domain": "epilepsy", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "liraglutide", "mediator_canonical": "AMPK", "outcome_canonical": "spike-wave seizures", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "39779525", "title": "The protective effects of liraglutide in reducing lipid droplets accumulation and myocardial fibrosis in diabetic cardiomyopathy", "doi": "10.1007/s00018-024-05558-9", "year": 2025 }, { "pmid": "34357376", "title": "Glucagon-like peptide-1 attenuates cardiac hypertrophy via the AngII/AT1R/ACE2 and AMPK/mTOR/p70S6K pathways", "doi": "10.1093/abbs/gmab099", "year": 2021 }, { "pmid": "27473212", "title": "The GLP-1 receptor agonists exenatide and liraglutide activate Glucose transport by an AMPK-dependent mechanism", "doi": "10.1186/s12967-016-0985-7", "year": 2016 } ], "bc": [ { "pmid": "35134125", "title": "AMPK-mediated potentiation of GABAergic signalling drives hypoglycaemia-provoked spike-wave seizures", "doi": "10.1093/brain/awac037", "year": 2022 } ] } }, { "id": 39990, "drug": "Canagliflozin", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "inhibits", "mediator": "mTOR", "mediator_type": "protein", "predicate_bc": "increases", "outcome": "neuronal spiking activity", "outcome_type": "phenotype", "outcome_domain": "epilepsy", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "canagliflozin", "mediator_canonical": "mTOR", "outcome_canonical": "neuronal spiking activity", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37584455", "title": "Canagliflozin mediates tumor suppression alone and in combination with radiotherapy in non‐small cell lung cancer (NSCLC) through inhibition of HIF‐1α", "doi": "10.1002/1878-0261.13508", "year": 2023 }, { "pmid": "34142035", "title": "Canagliflozin attenuates lipotoxicity in cardiomyocytes and protects diabetic mouse hearts by inhibiting the mTOR/HIF-1α pathway", "doi": "10.1016/j.isci.2021.102521", "year": 2021 } ], "bc": [ { "pmid": "34994387", "title": "IDH-mutated gliomas promote epileptogenesis through d-2-hydroxyglutarate-dependent mTOR hyperactivation", "doi": "10.1093/neuonc/noac003", "year": 2022 } ] } }, { "id": 39993, "drug": "Canagliflozin", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "suppresses", "mediator": "HIF-1α", "mediator_type": "protein", "predicate_bc": "increases", "outcome": "hippocampal neuron damage", "outcome_type": "phenotype", "outcome_domain": "epilepsy", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "canagliflozin", "mediator_canonical": "hif-1α", "outcome_canonical": "hippocampal neuron damage", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37684337", "title": "The SGLT2 inhibitor canagliflozin suppresses growth and enhances prostate cancer response to radiotherapy", "doi": "10.1038/s42003-023-05289-w", "year": 2023 }, { "pmid": "37584455", "title": "Canagliflozin mediates tumor suppression alone and in combination with radiotherapy in non‐small cell lung cancer (NSCLC) through inhibition of HIF‐1α", "doi": "10.1002/1878-0261.13508", "year": 2023 }, { "pmid": "34142035", "title": "Canagliflozin attenuates lipotoxicity in cardiomyocytes and protects diabetic mouse hearts by inhibiting the mTOR/HIF-1α pathway", "doi": "10.1016/j.isci.2021.102521", "year": 2021 } ], "bc": [ { "pmid": "41324728", "title": "The Role of HIF-1α/BNIP3 Pathway in Hippocampal Neuronal Autophagy in Epilepsy", "doi": "10.1007/s12035-025-05406-2", "year": 2025 } ] } }, { "id": 39992, "drug": "liraglutide", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "activates", "mediator": "AMPK", "mediator_type": "protein", "predicate_bc": "increases", "outcome": "epileptiform network activity", "outcome_type": "phenotype", "outcome_domain": "epilepsy", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "liraglutide", "mediator_canonical": "AMPK", "outcome_canonical": "epileptiform network activity", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "39779525", "title": "The protective effects of liraglutide in reducing lipid droplets accumulation and myocardial fibrosis in diabetic cardiomyopathy", "doi": "10.1007/s00018-024-05558-9", "year": 2025 }, { "pmid": "34357376", "title": "Glucagon-like peptide-1 attenuates cardiac hypertrophy via the AngII/AT1R/ACE2 and AMPK/mTOR/p70S6K pathways", "doi": "10.1093/abbs/gmab099", "year": 2021 }, { "pmid": "27473212", "title": "The GLP-1 receptor agonists exenatide and liraglutide activate Glucose transport by an AMPK-dependent mechanism", "doi": "10.1186/s12967-016-0985-7", "year": 2016 } ], "bc": [ { "pmid": "35134125", "title": "AMPK-mediated potentiation of GABAergic signalling drives hypoglycaemia-provoked spike-wave seizures", "doi": "10.1093/brain/awac037", "year": 2022 } ] } }, { "id": 61009, "drug": "EMPA", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "upregulates", "mediator": "SIRT3", "mediator_type": "protein", "predicate_bc": "decreases", "outcome": "oxidative stress", "outcome_type": "phenotype", "outcome_domain": "heart_failure", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "39334359", "title": "Empagliflozin alleviates obesity-related cardiac dysfunction via the activation of SIRT3-mediated autophagosome formation", "doi": "10.1186/s12944-024-02293-9", "year": 2024 } ], "bc": [ { "pmid": "37080445", "title": "Cardioprotective effect of ultrasound‐targeted destruction of Sirt3‐loaded cationic microbubbles in a large animal model of pathological cardiac hypertrophy", "doi": "10.1016/j.actbio.2023.04.020", "year": 2023 }, { "pmid": "33244875", "title": "Elabela may regulate SIRT3‐mediated inhibition of oxidative stress through Foxo3a deacetylation preventing diabetic‐induced myocardial injury", "doi": "10.1111/jcmm.16052", "year": 2020 }, { "pmid": "31318577", "title": "The nuclear and mitochondrial sirtuins, Sirt6 and Sirt3, regulate each other's activity and protect the heart from developing obesity‐mediated diabetic cardiomyopathy", "doi": "10.1096/fj.201900767r", "year": 2019 } ] } }, { "id": 61010, "drug": "exenatide", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "activates", "mediator": "AMPK", "mediator_type": "protein", "predicate_bc": "increases", "outcome": "ventricular cell shortening", "outcome_type": "phenotype", "outcome_domain": "heart_failure", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "33044023", "title": "Exenatide improves random‐pattern skin flap survival via TFE3 mediated autophagy augment", "doi": "10.1002/jcp.30102", "year": 2020 }, { "pmid": "27473212", "title": "The GLP-1 receptor agonists exenatide and liraglutide activate Glucose transport by an AMPK-dependent mechanism", "doi": "10.1186/s12967-016-0985-7", "year": 2016 }, { "pmid": "25720388", "title": "Exenatide Protects Against Glucose- and Lipid-Induced Endothelial Dysfunction: Evidence for Direct Vasodilation Effect of GLP-1 Receptor Agonists in Humans", "doi": "10.2337/db14-0976", "year": 2015 } ], "bc": [ { "pmid": "26023060", "title": "AMPK deficiency in cardiac muscle results in dilated cardiomyopathy in the absence of changes in energy metabolism", "doi": "10.1093/cvr/cvv166", "year": 2015 } ] } }, { "id": 61011, "drug": "liraglutide", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "activates", "mediator": "AMPK", "mediator_type": "protein", "predicate_bc": "prevents", "outcome": "myocardial ischemia-reperfusion injury", "outcome_type": "disease", "outcome_domain": "heart_failure", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "39779525", "title": "The protective effects of liraglutide in reducing lipid droplets accumulation and myocardial fibrosis in diabetic cardiomyopathy", "doi": "10.1007/s00018-024-05558-9", "year": 2025 }, { "pmid": "34357376", "title": "Glucagon-like peptide-1 attenuates cardiac hypertrophy via the AngII/AT1R/ACE2 and AMPK/mTOR/p70S6K pathways", "doi": "10.1093/abbs/gmab099", "year": 2021 }, { "pmid": "27473212", "title": "The GLP-1 receptor agonists exenatide and liraglutide activate Glucose transport by an AMPK-dependent mechanism", "doi": "10.1186/s12967-016-0985-7", "year": 2016 } ], "bc": [ { "pmid": "29689567", "title": "AMPK Contributes to Cardioprotective Effects of Pterostilbene Against Myocardial Ischemia- Reperfusion Injury in Diabetic Rats by Suppressing Cardiac Oxidative Stress and Apoptosis", "doi": "10.1159/000489154", "year": 2018 } ] } }, { "id": 61012, "drug": "sotagliflozin", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "inhibits", "mediator": "SGLT2", "mediator_type": "protein", "predicate_bc": "causes", "outcome": "eNOS-NO/ROS imbalance", "outcome_type": "phenotype", "outcome_domain": "heart_failure", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "34152828", "title": "Effect of Sotagliflozin on Total Hospitalizations in Patients With Type 2 Diabetes and Worsening Heart Failure", "doi": "10.7326/m21-0651", "year": 2021 }, { "pmid": "29916741", "title": "Combined SGLT1 and SGLT2 Inhibitors and Their Role in Diabetes Care", "doi": "10.1089/dia.2018.0081", "year": 2018 }, { "pmid": "26049551", "title": "Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Type 1 Diabetes", "doi": "10.2337/dc14-2806", "year": 2015 } ], "bc": [ { "pmid": "39739876", "title": "SGLT2 expression in human vasculature and heart correlates with low-grade inflammation and causes eNOS-NO/ROS imbalance", "doi": "10.1093/cvr/cvae257", "year": 2024 } ] } }, { "id": 61014, "drug": "Semaglutide", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "upregulates", "mediator": "SIRT3", "mediator_type": "protein", "predicate_bc": "decreases", "outcome": "oxidative stress", "outcome_type": "phenotype", "outcome_domain": "heart_failure", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "39710830", "title": "Semaglutide protects against diabetes‐associated cardiac inflammation via Sirt3‐dependent RKIP pathway", "doi": "10.1111/bph.17327", "year": 2024 } ], "bc": [ { "pmid": "37080445", "title": "Cardioprotective effect of ultrasound‐targeted destruction of Sirt3‐loaded cationic microbubbles in a large animal model of pathological cardiac hypertrophy", "doi": "10.1016/j.actbio.2023.04.020", "year": 2023 }, { "pmid": "33244875", "title": "Elabela may regulate SIRT3‐mediated inhibition of oxidative stress through Foxo3a deacetylation preventing diabetic‐induced myocardial injury", "doi": "10.1111/jcmm.16052", "year": 2020 }, { "pmid": "31318577", "title": "The nuclear and mitochondrial sirtuins, Sirt6 and Sirt3, regulate each other's activity and protect the heart from developing obesity‐mediated diabetic cardiomyopathy", "doi": "10.1096/fj.201900767r", "year": 2019 } ] } }, { "id": 61015, "drug": "Sitagliptin", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "downregulates", "mediator": "miR-21", "mediator_type": "gene", "predicate_bc": "increases", "outcome": "cardiac fibrosis", "outcome_type": "disease", "outcome_domain": "heart_failure", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "28652790", "title": "Sitagliptin ameliorates oxidative stress in experimental diabetic nephropathy by diminishing the miR-200a/Keap-1/Nrf2 antioxidant pathway", "doi": "10.2147/dmso.s132537", "year": 2017 } ], "bc": [ { "pmid": "33550817", "title": "MicroRNA-21–Dependent Macrophage-to-Fibroblast Signaling Determines the Cardiac Response to Pressure Overload", "doi": "10.1161/circulationaha.120.050682", "year": 2021 }, { "pmid": "33804922", "title": "Therapeutic miR-21 Silencing Reduces Cardiac Fibrosis and Modulates Inflammatory Response in Chronic Chagas Disease", "doi": "10.3390/ijms22073307", "year": 2021 }, { "pmid": "28335740", "title": "miR-21 enhances cardiac fibrotic remodeling and fibroblast proliferation via CADM1/STAT3 pathway", "doi": "10.1186/s12872-017-0520-7", "year": 2017 } ] } }, { "id": 61017, "drug": "exenatide", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "activates", "mediator": "AMPK", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "cardiovascular aging", "outcome_type": "phenotype", "outcome_domain": "heart_failure", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "33044023", "title": "Exenatide improves random‐pattern skin flap survival via TFE3 mediated autophagy augment", "doi": "10.1002/jcp.30102", "year": 2020 }, { "pmid": "27473212", "title": "The GLP-1 receptor agonists exenatide and liraglutide activate Glucose transport by an AMPK-dependent mechanism", "doi": "10.1186/s12967-016-0985-7", "year": 2016 }, { "pmid": "25720388", "title": "Exenatide Protects Against Glucose- and Lipid-Induced Endothelial Dysfunction: Evidence for Direct Vasodilation Effect of GLP-1 Receptor Agonists in Humans", "doi": "10.2337/db14-0976", "year": 2015 } ], "bc": [ { "pmid": "41194190", "title": "Cellular senescence and cell therapy in cardiovascular diseases", "doi": "10.1186/s13287-025-04731-6", "year": 2025 } ] } }, { "id": 61018, "drug": "liraglutide", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "activates", "mediator": "AMPK", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "cardiovascular aging", "outcome_type": "phenotype", "outcome_domain": "heart_failure", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "39779525", "title": "The protective effects of liraglutide in reducing lipid droplets accumulation and myocardial fibrosis in diabetic cardiomyopathy", "doi": "10.1007/s00018-024-05558-9", "year": 2025 }, { "pmid": "34357376", "title": "Glucagon-like peptide-1 attenuates cardiac hypertrophy via the AngII/AT1R/ACE2 and AMPK/mTOR/p70S6K pathways", "doi": "10.1093/abbs/gmab099", "year": 2021 }, { "pmid": "27473212", "title": "The GLP-1 receptor agonists exenatide and liraglutide activate Glucose transport by an AMPK-dependent mechanism", "doi": "10.1186/s12967-016-0985-7", "year": 2016 } ], "bc": [ { "pmid": "41194190", "title": "Cellular senescence and cell therapy in cardiovascular diseases", "doi": "10.1186/s13287-025-04731-6", "year": 2025 } ] } }, { "id": 61023, "drug": "Canagliflozin", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "upregulates", "mediator": "SIRT3", "mediator_type": "protein", "predicate_bc": "decreases", "outcome": "oxidative stress", "outcome_type": "phenotype", "outcome_domain": "heart_failure", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "38744404", "title": "Sodium-glucose exchanger 2 inhibitor canagliflozin promotes mitochondrial metabolism and alleviates salt-induced cardiac hypertrophy via preserving SIRT3 expression", "doi": "10.1016/j.jare.2024.04.030", "year": 2024 } ], "bc": [ { "pmid": "37080445", "title": "Cardioprotective effect of ultrasound‐targeted destruction of Sirt3‐loaded cationic microbubbles in a large animal model of pathological cardiac hypertrophy", "doi": "10.1016/j.actbio.2023.04.020", "year": 2023 }, { "pmid": "33244875", "title": "Elabela may regulate SIRT3‐mediated inhibition of oxidative stress through Foxo3a deacetylation preventing diabetic‐induced myocardial injury", "doi": "10.1111/jcmm.16052", "year": 2020 }, { "pmid": "31318577", "title": "The nuclear and mitochondrial sirtuins, Sirt6 and Sirt3, regulate each other's activity and protect the heart from developing obesity‐mediated diabetic cardiomyopathy", "doi": "10.1096/fj.201900767r", "year": 2019 } ] } }, { "id": 61027, "drug": "exenatide", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "activates", "mediator": "AMPK", "mediator_type": "protein", "predicate_bc": "prevents", "outcome": "myocardial ischemia-reperfusion injury", "outcome_type": "disease", "outcome_domain": "heart_failure", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "33044023", "title": "Exenatide improves random‐pattern skin flap survival via TFE3 mediated autophagy augment", "doi": "10.1002/jcp.30102", "year": 2020 }, { "pmid": "27473212", "title": "The GLP-1 receptor agonists exenatide and liraglutide activate Glucose transport by an AMPK-dependent mechanism", "doi": "10.1186/s12967-016-0985-7", "year": 2016 }, { "pmid": "25720388", "title": "Exenatide Protects Against Glucose- and Lipid-Induced Endothelial Dysfunction: Evidence for Direct Vasodilation Effect of GLP-1 Receptor Agonists in Humans", "doi": "10.2337/db14-0976", "year": 2015 } ], "bc": [ { "pmid": "29689567", "title": "AMPK Contributes to Cardioprotective Effects of Pterostilbene Against Myocardial Ischemia- Reperfusion Injury in Diabetic Rats by Suppressing Cardiac Oxidative Stress and Apoptosis", "doi": "10.1159/000489154", "year": 2018 } ] } }, { "id": 61028, "drug": "liraglutide", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "activates", "mediator": "AMPK", "mediator_type": "protein", "predicate_bc": "increases", "outcome": "ventricular cell shortening", "outcome_type": "phenotype", "outcome_domain": "heart_failure", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "39779525", "title": "The protective effects of liraglutide in reducing lipid droplets accumulation and myocardial fibrosis in diabetic cardiomyopathy", "doi": "10.1007/s00018-024-05558-9", "year": 2025 }, { "pmid": "34357376", "title": "Glucagon-like peptide-1 attenuates cardiac hypertrophy via the AngII/AT1R/ACE2 and AMPK/mTOR/p70S6K pathways", "doi": "10.1093/abbs/gmab099", "year": 2021 }, { "pmid": "27473212", "title": "The GLP-1 receptor agonists exenatide and liraglutide activate Glucose transport by an AMPK-dependent mechanism", "doi": "10.1186/s12967-016-0985-7", "year": 2016 } ], "bc": [ { "pmid": "26023060", "title": "AMPK deficiency in cardiac muscle results in dilated cardiomyopathy in the absence of changes in energy metabolism", "doi": "10.1093/cvr/cvv166", "year": 2015 } ] } }, { "id": 61029, "drug": "liraglutide", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "induces", "mediator": "FGF21", "mediator_type": "protein", "predicate_bc": "causes", "outcome": "cardiac remodeling", "outcome_type": "phenotype", "outcome_domain": "heart_failure", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37030441", "title": "Fibroblast growth factor-21 is required for weight loss induced by the glucagon-like peptide-1 receptor agonist liraglutide in male mice fed high carbohydrate diets", "doi": "10.1016/j.molmet.2023.101718", "year": 2023 }, { "pmid": "33851458", "title": "Hepatic Fibroblast Growth Factor 21 Is Involved in Mediating Functions of Liraglutide in Mice With Dietary Challenge", "doi": "10.1002/hep.31856", "year": 2021 }, { "pmid": "30827929", "title": "Liver-derived fibroblast growth factor 21 mediates effects of glucagon-like peptide-1 in attenuating hepatic glucose output", "doi": "10.1016/j.ebiom.2019.02.037", "year": 2019 } ], "bc": [ { "pmid": "28472473", "title": "Fgf21 is required for cardiac remodeling in pregnancy", "doi": "10.1093/cvr/cvx088", "year": 2017 } ] } }, { "id": 61030, "drug": "liraglutide", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "activates", "mediator": "AMPK", "mediator_type": "protein", "predicate_bc": "increases", "outcome": "glycogen storage", "outcome_type": "phenotype", "outcome_domain": "heart_failure", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "39779525", "title": "The protective effects of liraglutide in reducing lipid droplets accumulation and myocardial fibrosis in diabetic cardiomyopathy", "doi": "10.1007/s00018-024-05558-9", "year": 2025 }, { "pmid": "34357376", "title": "Glucagon-like peptide-1 attenuates cardiac hypertrophy via the AngII/AT1R/ACE2 and AMPK/mTOR/p70S6K pathways", "doi": "10.1093/abbs/gmab099", "year": 2021 }, { "pmid": "27473212", "title": "The GLP-1 receptor agonists exenatide and liraglutide activate Glucose transport by an AMPK-dependent mechanism", "doi": "10.1186/s12967-016-0985-7", "year": 2016 } ], "bc": [ { "pmid": "28009297", "title": "Integrative Analysis of PRKAG2 Cardiomyopathy iPS and Microtissue Models Identifies AMPK as a Regulator of Metabolism, Survival, and Fibrosis", "doi": "10.1016/j.celrep.2016.11.066", "year": 2016 } ] } }, { "id": 61031, "drug": "liraglutide", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "activates", "mediator": "AMPK", "mediator_type": "protein", "predicate_bc": "causes", "outcome": "dilated cardiomyopathy", "outcome_type": "disease", "outcome_domain": "heart_failure", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "39779525", "title": "The protective effects of liraglutide in reducing lipid droplets accumulation and myocardial fibrosis in diabetic cardiomyopathy", "doi": "10.1007/s00018-024-05558-9", "year": 2025 }, { "pmid": "34357376", "title": "Glucagon-like peptide-1 attenuates cardiac hypertrophy via the AngII/AT1R/ACE2 and AMPK/mTOR/p70S6K pathways", "doi": "10.1093/abbs/gmab099", "year": 2021 }, { "pmid": "27473212", "title": "The GLP-1 receptor agonists exenatide and liraglutide activate Glucose transport by an AMPK-dependent mechanism", "doi": "10.1186/s12967-016-0985-7", "year": 2016 } ], "bc": [ { "pmid": "26023060", "title": "AMPK deficiency in cardiac muscle results in dilated cardiomyopathy in the absence of changes in energy metabolism", "doi": "10.1093/cvr/cvv166", "year": 2015 } ] } }, { "id": 61034, "drug": "Alirocumab", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "inhibits", "mediator": "PCSK9", "mediator_type": "protein", "predicate_bc": "increases", "outcome": "infarct size", "outcome_type": "disease", "outcome_domain": "heart_failure", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "32035487", "title": "Effect of alirocumab on individuals with type 2 diabetes, high triglycerides, and low high-density lipoprotein cholesterol", "doi": "10.1186/s12933-020-0991-1", "year": 2020 }, { "pmid": "28799203", "title": "Efficacy and safety of alirocumab in people with prediabetes vs those with normoglycaemia at baseline: a pooled analysis of 10 phase III ODYSSEY clinical trials", "doi": "10.1111/dme.13450", "year": 2017 }, { "pmid": "28545518", "title": "Design and rationale of the ODYSSEY DM-DYSLIPIDEMIA trial: lipid-lowering efficacy and safety of alirocumab in individuals with type 2 diabetes and mixed dyslipidaemia at high cardiovascular risk", "doi": "10.1186/s12933-017-0552-4", "year": 2017 } ], "bc": [ { "pmid": "29800228", "title": "PCSK9 expression in the ischaemic heart and its relationship to infarct size, cardiac function, and development of autophagy", "doi": "10.1093/cvr/cvy128", "year": 2018 } ] } }, { "id": 61035, "drug": "liraglutide", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "induces", "mediator": "FGF21", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "left ventricular systolic dysfunction", "outcome_type": "disease", "outcome_domain": "heart_failure", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37030441", "title": "Fibroblast growth factor-21 is required for weight loss induced by the glucagon-like peptide-1 receptor agonist liraglutide in male mice fed high carbohydrate diets", "doi": "10.1016/j.molmet.2023.101718", "year": 2023 }, { "pmid": "33851458", "title": "Hepatic Fibroblast Growth Factor 21 Is Involved in Mediating Functions of Liraglutide in Mice With Dietary Challenge", "doi": "10.1002/hep.31856", "year": 2021 }, { "pmid": "30827929", "title": "Liver-derived fibroblast growth factor 21 mediates effects of glucagon-like peptide-1 in attenuating hepatic glucose output", "doi": "10.1016/j.ebiom.2019.02.037", "year": 2019 } ], "bc": [ { "pmid": "28821258", "title": "Contribution of serum FGF21 level to the identification of left ventricular systolic dysfunction and cardiac death", "doi": "10.1186/s12933-017-0588-5", "year": 2017 } ] } }, { "id": 61036, "drug": "liraglutide", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "induces", "mediator": "FGF21", "mediator_type": "protein", "predicate_bc": "predicts", "outcome": "cardiovascular diseases", "outcome_type": "disease", "outcome_domain": "heart_failure", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37030441", "title": "Fibroblast growth factor-21 is required for weight loss induced by the glucagon-like peptide-1 receptor agonist liraglutide in male mice fed high carbohydrate diets", "doi": "10.1016/j.molmet.2023.101718", "year": 2023 }, { "pmid": "33851458", "title": "Hepatic Fibroblast Growth Factor 21 Is Involved in Mediating Functions of Liraglutide in Mice With Dietary Challenge", "doi": "10.1002/hep.31856", "year": 2021 }, { "pmid": "30827929", "title": "Liver-derived fibroblast growth factor 21 mediates effects of glucagon-like peptide-1 in attenuating hepatic glucose output", "doi": "10.1016/j.ebiom.2019.02.037", "year": 2019 } ], "bc": [ { "pmid": "34939977", "title": "The role of FGF21 in the pathogenesis of cardiovascular disease", "doi": "10.1097/cm9.0000000000001890", "year": 2021 } ] } }, { "id": 61038, "drug": "exenatide", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "activates", "mediator": "AMPK", "mediator_type": "protein", "predicate_bc": "causes", "outcome": "dilated cardiomyopathy", "outcome_type": "disease", "outcome_domain": "heart_failure", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "33044023", "title": "Exenatide improves random‐pattern skin flap survival via TFE3 mediated autophagy augment", "doi": "10.1002/jcp.30102", "year": 2020 }, { "pmid": "27473212", "title": "The GLP-1 receptor agonists exenatide and liraglutide activate Glucose transport by an AMPK-dependent mechanism", "doi": "10.1186/s12967-016-0985-7", "year": 2016 }, { "pmid": "25720388", "title": "Exenatide Protects Against Glucose- and Lipid-Induced Endothelial Dysfunction: Evidence for Direct Vasodilation Effect of GLP-1 Receptor Agonists in Humans", "doi": "10.2337/db14-0976", "year": 2015 } ], "bc": [ { "pmid": "26023060", "title": "AMPK deficiency in cardiac muscle results in dilated cardiomyopathy in the absence of changes in energy metabolism", "doi": "10.1093/cvr/cvv166", "year": 2015 } ] } }, { "id": 61043, "drug": "GLP-1", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "downregulates", "mediator": "IL-18", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "adverse clinical events", "outcome_type": "disease", "outcome_domain": "heart_failure", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "33641439", "title": "GLP-1 alleviates NLRP3 inflammasome-dependent inflammation in perivascular adipose tissue by inhibiting the NF-κB signalling pathway", "doi": "10.1177/0300060521992981", "year": 2021 } ], "bc": [ { "pmid": "38402570", "title": "Prognostic significance of IL‐18 in acute coronary syndrome patients", "doi": "10.1002/clc.24229", "year": 2024 } ] } }, { "id": 61044, "drug": "exenatide", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "activates", "mediator": "AMPK", "mediator_type": "protein", "predicate_bc": "increases", "outcome": "glycogen storage", "outcome_type": "phenotype", "outcome_domain": "heart_failure", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "33044023", "title": "Exenatide improves random‐pattern skin flap survival via TFE3 mediated autophagy augment", "doi": "10.1002/jcp.30102", "year": 2020 }, { "pmid": "27473212", "title": "The GLP-1 receptor agonists exenatide and liraglutide activate Glucose transport by an AMPK-dependent mechanism", "doi": "10.1186/s12967-016-0985-7", "year": 2016 }, { "pmid": "25720388", "title": "Exenatide Protects Against Glucose- and Lipid-Induced Endothelial Dysfunction: Evidence for Direct Vasodilation Effect of GLP-1 Receptor Agonists in Humans", "doi": "10.2337/db14-0976", "year": 2015 } ], "bc": [ { "pmid": "28009297", "title": "Integrative Analysis of PRKAG2 Cardiomyopathy iPS and Microtissue Models Identifies AMPK as a Regulator of Metabolism, Survival, and Fibrosis", "doi": "10.1016/j.celrep.2016.11.066", "year": 2016 } ] } }, { "id": 61187, "drug": "Alirocumab", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "inhibits", "mediator": "PCSK9", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "endoscopic Mayo Score", "outcome_type": "phenotype", "outcome_domain": "inflammatory_bowel_disease", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "32035487", "title": "Effect of alirocumab on individuals with type 2 diabetes, high triglycerides, and low high-density lipoprotein cholesterol", "doi": "10.1186/s12933-020-0991-1", "year": 2020 }, { "pmid": "28799203", "title": "Efficacy and safety of alirocumab in people with prediabetes vs those with normoglycaemia at baseline: a pooled analysis of 10 phase III ODYSSEY clinical trials", "doi": "10.1111/dme.13450", "year": 2017 }, { "pmid": "28545518", "title": "Design and rationale of the ODYSSEY DM-DYSLIPIDEMIA trial: lipid-lowering efficacy and safety of alirocumab in individuals with type 2 diabetes and mixed dyslipidaemia at high cardiovascular risk", "doi": "10.1186/s12933-017-0552-4", "year": 2017 } ], "bc": [ { "pmid": "34560758", "title": "Serum Levels of PCSK9 Are Increased in Patients With Active Ulcerative Colitis Representing a Potential Biomarker of Disease Activity", "doi": "10.1097/mcg.0000000000001607", "year": 2021 } ] } }, { "id": 61195, "drug": "Alirocumab", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "inhibits", "mediator": "PCSK9", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "active ulcerative colitis", "outcome_type": "disease", "outcome_domain": "inflammatory_bowel_disease", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "32035487", "title": "Effect of alirocumab on individuals with type 2 diabetes, high triglycerides, and low high-density lipoprotein cholesterol", "doi": "10.1186/s12933-020-0991-1", "year": 2020 }, { "pmid": "28799203", "title": "Efficacy and safety of alirocumab in people with prediabetes vs those with normoglycaemia at baseline: a pooled analysis of 10 phase III ODYSSEY clinical trials", "doi": "10.1111/dme.13450", "year": 2017 }, { "pmid": "28545518", "title": "Design and rationale of the ODYSSEY DM-DYSLIPIDEMIA trial: lipid-lowering efficacy and safety of alirocumab in individuals with type 2 diabetes and mixed dyslipidaemia at high cardiovascular risk", "doi": "10.1186/s12933-017-0552-4", "year": 2017 } ], "bc": [ { "pmid": "34560758", "title": "Serum Levels of PCSK9 Are Increased in Patients With Active Ulcerative Colitis Representing a Potential Biomarker of Disease Activity", "doi": "10.1097/mcg.0000000000001607", "year": 2021 } ] } }, { "id": 61200, "drug": "Alirocumab", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "inhibits", "mediator": "PCSK9", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "UC-Riley Index", "outcome_type": "phenotype", "outcome_domain": "inflammatory_bowel_disease", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "32035487", "title": "Effect of alirocumab on individuals with type 2 diabetes, high triglycerides, and low high-density lipoprotein cholesterol", "doi": "10.1186/s12933-020-0991-1", "year": 2020 }, { "pmid": "28799203", "title": "Efficacy and safety of alirocumab in people with prediabetes vs those with normoglycaemia at baseline: a pooled analysis of 10 phase III ODYSSEY clinical trials", "doi": "10.1111/dme.13450", "year": 2017 }, { "pmid": "28545518", "title": "Design and rationale of the ODYSSEY DM-DYSLIPIDEMIA trial: lipid-lowering efficacy and safety of alirocumab in individuals with type 2 diabetes and mixed dyslipidaemia at high cardiovascular risk", "doi": "10.1186/s12933-017-0552-4", "year": 2017 } ], "bc": [ { "pmid": "34560758", "title": "Serum Levels of PCSK9 Are Increased in Patients With Active Ulcerative Colitis Representing a Potential Biomarker of Disease Activity", "doi": "10.1097/mcg.0000000000001607", "year": 2021 } ] } }, { "id": 61203, "drug": "Alirocumab", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "inhibits", "mediator": "PCSK9", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "disease severity", "outcome_type": "phenotype", "outcome_domain": "inflammatory_bowel_disease", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "32035487", "title": "Effect of alirocumab on individuals with type 2 diabetes, high triglycerides, and low high-density lipoprotein cholesterol", "doi": "10.1186/s12933-020-0991-1", "year": 2020 }, { "pmid": "28799203", "title": "Efficacy and safety of alirocumab in people with prediabetes vs those with normoglycaemia at baseline: a pooled analysis of 10 phase III ODYSSEY clinical trials", "doi": "10.1111/dme.13450", "year": 2017 }, { "pmid": "28545518", "title": "Design and rationale of the ODYSSEY DM-DYSLIPIDEMIA trial: lipid-lowering efficacy and safety of alirocumab in individuals with type 2 diabetes and mixed dyslipidaemia at high cardiovascular risk", "doi": "10.1186/s12933-017-0552-4", "year": 2017 } ], "bc": [ { "pmid": "40265438", "title": "Cholesteryl Ester Species but Not Serum Proprotein Convertase Subtilisin/Kexin Type 9 Levels Decline in Male Patients with Active Inflammatory Bowel Disease", "doi": "10.3390/pathophysiology32020013", "year": 2025 } ] } }, { "id": 40424, "drug": "Canagliflozin", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "suppresses", "mediator": "HIF-1α", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "inflammatory bowel disease", "outcome_type": "disease", "outcome_domain": "inflammatory_bowel_disease", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "canagliflozin", "mediator_canonical": "hif-1α", "outcome_canonical": "inflammatory bowel disease", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37684337", "title": "The SGLT2 inhibitor canagliflozin suppresses growth and enhances prostate cancer response to radiotherapy", "doi": "10.1038/s42003-023-05289-w", "year": 2023 }, { "pmid": "37584455", "title": "Canagliflozin mediates tumor suppression alone and in combination with radiotherapy in non‐small cell lung cancer (NSCLC) through inhibition of HIF‐1α", "doi": "10.1002/1878-0261.13508", "year": 2023 }, { "pmid": "34142035", "title": "Canagliflozin attenuates lipotoxicity in cardiomyocytes and protects diabetic mouse hearts by inhibiting the mTOR/HIF-1α pathway", "doi": "10.1016/j.isci.2021.102521", "year": 2021 } ], "bc": [ { "pmid": "38605960", "title": "Crosstalk between hypoxia-inducible factor-1α and short-chain fatty acids in inflammatory bowel disease: key clues toward unraveling the mystery", "doi": "10.3389/fimmu.2024.1385907", "year": 2024 } ] } }, { "id": 40428, "drug": "liraglutide", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "activates", "mediator": "AMPK", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "intestinal epithelial repair", "outcome_type": "phenotype", "outcome_domain": "inflammatory_bowel_disease", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "liraglutide", "mediator_canonical": "AMPK", "outcome_canonical": "intestinal epithelial repair", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "39779525", "title": "The protective effects of liraglutide in reducing lipid droplets accumulation and myocardial fibrosis in diabetic cardiomyopathy", "doi": "10.1007/s00018-024-05558-9", "year": 2025 }, { "pmid": "34357376", "title": "Glucagon-like peptide-1 attenuates cardiac hypertrophy via the AngII/AT1R/ACE2 and AMPK/mTOR/p70S6K pathways", "doi": "10.1093/abbs/gmab099", "year": 2021 }, { "pmid": "27473212", "title": "The GLP-1 receptor agonists exenatide and liraglutide activate Glucose transport by an AMPK-dependent mechanism", "doi": "10.1186/s12967-016-0985-7", "year": 2016 } ], "bc": [ { "pmid": "35203241", "title": "Intestinal Epithelial AMPK Deficiency Causes Delayed Colonic Epithelial Repair in DSS-Induced Colitis", "doi": "10.3390/cells11040590", "year": 2022 } ] } }, { "id": 40422, "drug": "exenatide", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "activates", "mediator": "AMPK", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "intestinal epithelial repair", "outcome_type": "phenotype", "outcome_domain": "inflammatory_bowel_disease", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "exenatide", "mediator_canonical": "AMPK", "outcome_canonical": "intestinal epithelial repair", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "33044023", "title": "Exenatide improves random‐pattern skin flap survival via TFE3 mediated autophagy augment", "doi": "10.1002/jcp.30102", "year": 2020 }, { "pmid": "27473212", "title": "The GLP-1 receptor agonists exenatide and liraglutide activate Glucose transport by an AMPK-dependent mechanism", "doi": "10.1186/s12967-016-0985-7", "year": 2016 }, { "pmid": "25720388", "title": "Exenatide Protects Against Glucose- and Lipid-Induced Endothelial Dysfunction: Evidence for Direct Vasodilation Effect of GLP-1 Receptor Agonists in Humans", "doi": "10.2337/db14-0976", "year": 2015 } ], "bc": [ { "pmid": "35203241", "title": "Intestinal Epithelial AMPK Deficiency Causes Delayed Colonic Epithelial Repair in DSS-Induced Colitis", "doi": "10.3390/cells11040590", "year": 2022 } ] } }, { "id": 40429, "drug": "Empagliflozin", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "downregulates", "mediator": "IL-17", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "Crohn's disease", "outcome_type": "disease", "outcome_domain": "inflammatory_bowel_disease", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "completed", "clinical_trial_nct_ids": [ "NCT05078879" ], "literature_status": "novel_signal", "drug_canonical": "empagliflozin", "mediator_canonical": "il-17", "outcome_canonical": "crohn's disease", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "31666643", "title": "Empagliflozin and Dulaglutide are Effective against Obesity-induced Airway Hyperresponsiveness and Fibrosis in A Murine Model", "doi": "10.1038/s41598-019-51648-1", "year": 2019 } ], "bc": [ { "pmid": "39803916", "title": "Correlation between IL-17 and inflammatory bowel disease", "doi": "10.55133/eji.320106", "year": 2025 }, { "pmid": "38229938", "title": "Crohn's disease and clinical management today: How it does?", "doi": "10.5662/wjm.v13.i5.399", "year": 2023 }, { "pmid": "28533995", "title": "Crohn’s Disease and Ulcerative Colitis Show Unique Cytokine Profiles", "doi": "10.7759/cureus.1177", "year": 2017 } ] } }, { "id": 40425, "drug": "exenatide", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "activates", "mediator": "AMPK", "mediator_type": "protein", "predicate_bc": "treats", "outcome": "intestinal inflammation", "outcome_type": "disease", "outcome_domain": "inflammatory_bowel_disease", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "exenatide", "mediator_canonical": "AMPK", "outcome_canonical": "intestinal inflammation", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "33044023", "title": "Exenatide improves random‐pattern skin flap survival via TFE3 mediated autophagy augment", "doi": "10.1002/jcp.30102", "year": 2020 }, { "pmid": "27473212", "title": "The GLP-1 receptor agonists exenatide and liraglutide activate Glucose transport by an AMPK-dependent mechanism", "doi": "10.1186/s12967-016-0985-7", "year": 2016 }, { "pmid": "25720388", "title": "Exenatide Protects Against Glucose- and Lipid-Induced Endothelial Dysfunction: Evidence for Direct Vasodilation Effect of GLP-1 Receptor Agonists in Humans", "doi": "10.2337/db14-0976", "year": 2015 } ], "bc": [ { "pmid": "33252129", "title": "Salicylates Ameliorate Intestinal Inflammation by Activating Macrophage AMPK", "doi": "10.1093/ibd/izaa305", "year": 2020 } ] } }, { "id": 40571, "drug": "liraglutide", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "induces", "mediator": "FGF21", "mediator_type": "protein", "predicate_bc": "decreases", "outcome": "microglial amoeboid morphology", "outcome_type": "phenotype", "outcome_domain": "multiple_sclerosis", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "liraglutide", "mediator_canonical": "fgf21", "outcome_canonical": "microglial amoeboid morphology", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37030441", "title": "Fibroblast growth factor-21 is required for weight loss induced by the glucagon-like peptide-1 receptor agonist liraglutide in male mice fed high carbohydrate diets", "doi": "10.1016/j.molmet.2023.101718", "year": 2023 }, { "pmid": "33851458", "title": "Hepatic Fibroblast Growth Factor 21 Is Involved in Mediating Functions of Liraglutide in Mice With Dietary Challenge", "doi": "10.1002/hep.31856", "year": 2021 }, { "pmid": "30827929", "title": "Liver-derived fibroblast growth factor 21 mediates effects of glucagon-like peptide-1 in attenuating hepatic glucose output", "doi": "10.1016/j.ebiom.2019.02.037", "year": 2019 } ], "bc": [ { "pmid": "40557530", "title": "Targeted Neuroimmune Modulation via FGF21‐Loaded Dual‐Layer Electrospun Nanofibrous Scaffold to Suppress Secondary Injury After Severe Traumatic Brain Injury", "doi": "10.1002/adhm.202500905", "year": 2025 } ] } }, { "id": 40403, "drug": "Canagliflozin", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "suppresses", "mediator": "HIF-1α", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "disease activity", "outcome_type": "phenotype", "outcome_domain": "inflammatory_bowel_disease", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "completed", "clinical_trial_nct_ids": [ "NCT02920918", "NCT01137812", "NCT01106677" ], "literature_status": "partial_evidence", "drug_canonical": "canagliflozin", "mediator_canonical": "hif-1α", "outcome_canonical": "disease activity", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37684337", "title": "The SGLT2 inhibitor canagliflozin suppresses growth and enhances prostate cancer response to radiotherapy", "doi": "10.1038/s42003-023-05289-w", "year": 2023 }, { "pmid": "37584455", "title": "Canagliflozin mediates tumor suppression alone and in combination with radiotherapy in non‐small cell lung cancer (NSCLC) through inhibition of HIF‐1α", "doi": "10.1002/1878-0261.13508", "year": 2023 }, { "pmid": "34142035", "title": "Canagliflozin attenuates lipotoxicity in cardiomyocytes and protects diabetic mouse hearts by inhibiting the mTOR/HIF-1α pathway", "doi": "10.1016/j.isci.2021.102521", "year": 2021 } ], "bc": [ { "pmid": "38137357", "title": "Interrelation of Hypoxia-Inducible Factor-1 Alpha (HIF-1 α) and the Ratio between the Mean Corpuscular Volume/Lymphocytes (MCVL) and the Cumulative Inflammatory Index (IIC) in Ulcerative Colitis", "doi": "10.3390/biomedicines11123137", "year": 2023 } ] } }, { "id": 40806, "drug": "Canagliflozin", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "suppresses", "mediator": "HIF-1α", "mediator_type": "protein", "predicate_bc": "increases", "outcome": "cell invasion", "outcome_type": "phenotype", "outcome_domain": "pancreatic_cancer", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "canagliflozin", "mediator_canonical": "hif-1α", "outcome_canonical": "cell invasion", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37684337", "title": "The SGLT2 inhibitor canagliflozin suppresses growth and enhances prostate cancer response to radiotherapy", "doi": "10.1038/s42003-023-05289-w", "year": 2023 }, { "pmid": "37584455", "title": "Canagliflozin mediates tumor suppression alone and in combination with radiotherapy in non‐small cell lung cancer (NSCLC) through inhibition of HIF‐1α", "doi": "10.1002/1878-0261.13508", "year": 2023 }, { "pmid": "34142035", "title": "Canagliflozin attenuates lipotoxicity in cardiomyocytes and protects diabetic mouse hearts by inhibiting the mTOR/HIF-1α pathway", "doi": "10.1016/j.isci.2021.102521", "year": 2021 } ], "bc": [ { "pmid": "28069592", "title": "MiR-142 modulates human pancreatic cancer proliferation and invasion by targeting hypoxia-inducible factor 1 (HIF-1α) in the tumor microenvironments", "doi": "10.1242/bio.021774", "year": 2017 } ] } }, { "id": 40828, "drug": "Canagliflozin", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "suppresses", "mediator": "HIF-1α", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "tumor cell migration", "outcome_type": "phenotype", "outcome_domain": "pancreatic_cancer", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "active", "clinical_trial_nct_ids": [ "NCT07188545" ], "literature_status": "novel_signal", "drug_canonical": "canagliflozin", "mediator_canonical": "hif-1α", "outcome_canonical": "tumor cell migration", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37684337", "title": "The SGLT2 inhibitor canagliflozin suppresses growth and enhances prostate cancer response to radiotherapy", "doi": "10.1038/s42003-023-05289-w", "year": 2023 }, { "pmid": "37584455", "title": "Canagliflozin mediates tumor suppression alone and in combination with radiotherapy in non‐small cell lung cancer (NSCLC) through inhibition of HIF‐1α", "doi": "10.1002/1878-0261.13508", "year": 2023 }, { "pmid": "34142035", "title": "Canagliflozin attenuates lipotoxicity in cardiomyocytes and protects diabetic mouse hearts by inhibiting the mTOR/HIF-1α pathway", "doi": "10.1016/j.isci.2021.102521", "year": 2021 } ], "bc": [ { "pmid": "27367674", "title": "CD133 Modulate HIF-1α Expression under Hypoxia in EMT Phenotype Pancreatic Cancer Stem-Like Cells", "doi": "10.3390/ijms17071025", "year": 2016 } ] } }, { "id": 40826, "drug": "liraglutide", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "activates", "mediator": "AMPK", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "pancreatic cancer progression", "outcome_type": "disease", "outcome_domain": "pancreatic_cancer", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "liraglutide", "mediator_canonical": "AMPK", "outcome_canonical": "pancreatic cancer progression", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "39779525", "title": "The protective effects of liraglutide in reducing lipid droplets accumulation and myocardial fibrosis in diabetic cardiomyopathy", "doi": "10.1007/s00018-024-05558-9", "year": 2025 }, { "pmid": "34357376", "title": "Glucagon-like peptide-1 attenuates cardiac hypertrophy via the AngII/AT1R/ACE2 and AMPK/mTOR/p70S6K pathways", "doi": "10.1093/abbs/gmab099", "year": 2021 }, { "pmid": "27473212", "title": "The GLP-1 receptor agonists exenatide and liraglutide activate Glucose transport by an AMPK-dependent mechanism", "doi": "10.1186/s12967-016-0985-7", "year": 2016 } ], "bc": [ { "pmid": "31205544", "title": "AMPK Inhibition Suppresses the Malignant Phenotype of Pancreatic Cancer Cells in Part by Attenuating Aerobic Glycolysis", "doi": "10.7150/jca.28299", "year": 2019 } ] } }, { "id": 40827, "drug": "liraglutide", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "activates", "mediator": "AMPK", "mediator_type": "protein", "predicate_bc": "decreases", "outcome": "invasion", "outcome_type": "phenotype", "outcome_domain": "pancreatic_cancer", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "liraglutide", "mediator_canonical": "AMPK", "outcome_canonical": "invasion", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "39779525", "title": "The protective effects of liraglutide in reducing lipid droplets accumulation and myocardial fibrosis in diabetic cardiomyopathy", "doi": "10.1007/s00018-024-05558-9", "year": 2025 }, { "pmid": "34357376", "title": "Glucagon-like peptide-1 attenuates cardiac hypertrophy via the AngII/AT1R/ACE2 and AMPK/mTOR/p70S6K pathways", "doi": "10.1093/abbs/gmab099", "year": 2021 }, { "pmid": "27473212", "title": "The GLP-1 receptor agonists exenatide and liraglutide activate Glucose transport by an AMPK-dependent mechanism", "doi": "10.1186/s12967-016-0985-7", "year": 2016 } ], "bc": [ { "pmid": "28783244", "title": "Loss of AMPK activation promotes the invasion and metastasis of pancreatic cancer through an HSF1‐dependent pathway", "doi": "10.1002/1878-0261.12116", "year": 2017 } ] } }, { "id": 40833, "drug": "Canagliflozin", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "suppresses", "mediator": "HIF-1α", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "pancreatic ductal adenocarcinoma", "outcome_type": "disease", "outcome_domain": "pancreatic_cancer", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "canagliflozin", "mediator_canonical": "hif-1α", "outcome_canonical": "pancreatic ductal adenocarcinoma", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37684337", "title": "The SGLT2 inhibitor canagliflozin suppresses growth and enhances prostate cancer response to radiotherapy", "doi": "10.1038/s42003-023-05289-w", "year": 2023 }, { "pmid": "37584455", "title": "Canagliflozin mediates tumor suppression alone and in combination with radiotherapy in non‐small cell lung cancer (NSCLC) through inhibition of HIF‐1α", "doi": "10.1002/1878-0261.13508", "year": 2023 }, { "pmid": "34142035", "title": "Canagliflozin attenuates lipotoxicity in cardiomyocytes and protects diabetic mouse hearts by inhibiting the mTOR/HIF-1α pathway", "doi": "10.1016/j.isci.2021.102521", "year": 2021 } ], "bc": [ { "pmid": "36237265", "title": "High expression of hypoxia-inducible factor 1-alpha predicts poor prognosis in pancreatic ductal adenocarcinoma: a meta-analysis and database validation protocol", "doi": "10.21037/tcr-22-787", "year": 2022 } ] } }, { "id": 40821, "drug": "danuglipron", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "activates", "mediator": "GLP-1R", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "pancreatic ductal adenocarcinoma", "outcome_type": "disease", "outcome_domain": "pancreatic_cancer", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "danuglipron", "mediator_canonical": "glp-1r", "outcome_canonical": "pancreatic ductal adenocarcinoma", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37213102", "title": "Efficacy and Safety of Oral Small Molecule Glucagon-Like Peptide 1 Receptor Agonist Danuglipron for Glycemic Control Among Patients With Type 2 Diabetes", "doi": "10.1001/jamanetworkopen.2023.14493", "year": 2023 }, { "pmid": "35647711", "title": "A Small-Molecule Oral Agonist of the Human Glucagon-like Peptide-1 Receptor", "doi": "10.1021/acs.jmedchem.1c01856", "year": 2022 } ], "bc": [ { "pmid": "26495786", "title": "Glucagon-Like Peptide-1 Receptor Expression in Normal and Neoplastic Human Pancreatic Tissues", "doi": "10.1097/mpa.0000000000000521", "year": 2015 } ] } }, { "id": 40845, "drug": "Canagliflozin", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "suppresses", "mediator": "HIF-1α", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "poor prognosis", "outcome_type": "phenotype", "outcome_domain": "pancreatic_cancer", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "canagliflozin", "mediator_canonical": "hif-1α", "outcome_canonical": null, "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37684337", "title": "The SGLT2 inhibitor canagliflozin suppresses growth and enhances prostate cancer response to radiotherapy", "doi": "10.1038/s42003-023-05289-w", "year": 2023 }, { "pmid": "37584455", "title": "Canagliflozin mediates tumor suppression alone and in combination with radiotherapy in non‐small cell lung cancer (NSCLC) through inhibition of HIF‐1α", "doi": "10.1002/1878-0261.13508", "year": 2023 }, { "pmid": "34142035", "title": "Canagliflozin attenuates lipotoxicity in cardiomyocytes and protects diabetic mouse hearts by inhibiting the mTOR/HIF-1α pathway", "doi": "10.1016/j.isci.2021.102521", "year": 2021 } ], "bc": [ { "pmid": "36237265", "title": "High expression of hypoxia-inducible factor 1-alpha predicts poor prognosis in pancreatic ductal adenocarcinoma: a meta-analysis and database validation protocol", "doi": "10.21037/tcr-22-787", "year": 2022 } ] } }, { "id": 40838, "drug": "Canagliflozin", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "inhibits", "mediator": "mTOR", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "pancreatic ductal adenocarcinoma", "outcome_type": "disease", "outcome_domain": "pancreatic_cancer", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "canagliflozin", "mediator_canonical": "mTOR", "outcome_canonical": "pancreatic ductal adenocarcinoma", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37584455", "title": "Canagliflozin mediates tumor suppression alone and in combination with radiotherapy in non‐small cell lung cancer (NSCLC) through inhibition of HIF‐1α", "doi": "10.1002/1878-0261.13508", "year": 2023 }, { "pmid": "34142035", "title": "Canagliflozin attenuates lipotoxicity in cardiomyocytes and protects diabetic mouse hearts by inhibiting the mTOR/HIF-1α pathway", "doi": "10.1016/j.isci.2021.102521", "year": 2021 } ], "bc": [ { "pmid": "29384525", "title": "MTOR inhibitor-based combination therapies for pancreatic cancer", "doi": "10.1038/bjc.2017.421", "year": 2018 } ] } }, { "id": 40832, "drug": "exenatide", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "activates", "mediator": "AMPK", "mediator_type": "protein", "predicate_bc": "decreases", "outcome": "invasion", "outcome_type": "phenotype", "outcome_domain": "pancreatic_cancer", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "exenatide", "mediator_canonical": "AMPK", "outcome_canonical": "invasion", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "33044023", "title": "Exenatide improves random‐pattern skin flap survival via TFE3 mediated autophagy augment", "doi": "10.1002/jcp.30102", "year": 2020 }, { "pmid": "27473212", "title": "The GLP-1 receptor agonists exenatide and liraglutide activate Glucose transport by an AMPK-dependent mechanism", "doi": "10.1186/s12967-016-0985-7", "year": 2016 }, { "pmid": "25720388", "title": "Exenatide Protects Against Glucose- and Lipid-Induced Endothelial Dysfunction: Evidence for Direct Vasodilation Effect of GLP-1 Receptor Agonists in Humans", "doi": "10.2337/db14-0976", "year": 2015 } ], "bc": [ { "pmid": "28783244", "title": "Loss of AMPK activation promotes the invasion and metastasis of pancreatic cancer through an HSF1‐dependent pathway", "doi": "10.1002/1878-0261.12116", "year": 2017 } ] } }, { "id": 40836, "drug": "sotagliflozin", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "inhibits", "mediator": "SGLT2", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "pancreatic adenocarcinoma", "outcome_type": "disease", "outcome_domain": "pancreatic_cancer", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "sotagliflozin", "mediator_canonical": "sglt2", "outcome_canonical": "pancreatic adenocarcinoma", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "34152828", "title": "Effect of Sotagliflozin on Total Hospitalizations in Patients With Type 2 Diabetes and Worsening Heart Failure", "doi": "10.7326/m21-0651", "year": 2021 }, { "pmid": "29916741", "title": "Combined SGLT1 and SGLT2 Inhibitors and Their Role in Diabetes Care", "doi": "10.1089/dia.2018.0081", "year": 2018 }, { "pmid": "26049551", "title": "Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Type 1 Diabetes", "doi": "10.2337/dc14-2806", "year": 2015 } ], "bc": [ { "pmid": "26170283", "title": "Functional expression of sodium-glucose transporters in cancer", "doi": "10.1073/pnas.1511698112", "year": 2015 } ] } }, { "id": 40837, "drug": "sotagliflozin", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "inhibits", "mediator": "SGLT2", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "prostate adenocarcinoma", "outcome_type": "disease", "outcome_domain": "pancreatic_cancer", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "sotagliflozin", "mediator_canonical": "sglt2", "outcome_canonical": "prostate adenocarcinoma", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "34152828", "title": "Effect of Sotagliflozin on Total Hospitalizations in Patients With Type 2 Diabetes and Worsening Heart Failure", "doi": "10.7326/m21-0651", "year": 2021 }, { "pmid": "29916741", "title": "Combined SGLT1 and SGLT2 Inhibitors and Their Role in Diabetes Care", "doi": "10.1089/dia.2018.0081", "year": 2018 }, { "pmid": "26049551", "title": "Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Type 1 Diabetes", "doi": "10.2337/dc14-2806", "year": 2015 } ], "bc": [ { "pmid": "26170283", "title": "Functional expression of sodium-glucose transporters in cancer", "doi": "10.1073/pnas.1511698112", "year": 2015 } ] } }, { "id": 40819, "drug": "liraglutide", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "activates", "mediator": "AMPK", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "pancreatic ductal adenocarcinoma", "outcome_type": "disease", "outcome_domain": "pancreatic_cancer", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "liraglutide", "mediator_canonical": "AMPK", "outcome_canonical": "pancreatic ductal adenocarcinoma", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "39779525", "title": "The protective effects of liraglutide in reducing lipid droplets accumulation and myocardial fibrosis in diabetic cardiomyopathy", "doi": "10.1007/s00018-024-05558-9", "year": 2025 }, { "pmid": "34357376", "title": "Glucagon-like peptide-1 attenuates cardiac hypertrophy via the AngII/AT1R/ACE2 and AMPK/mTOR/p70S6K pathways", "doi": "10.1093/abbs/gmab099", "year": 2021 }, { "pmid": "27473212", "title": "The GLP-1 receptor agonists exenatide and liraglutide activate Glucose transport by an AMPK-dependent mechanism", "doi": "10.1186/s12967-016-0985-7", "year": 2016 } ], "bc": [ { "pmid": "38885414", "title": "A Novel AMPK Inhibitor Sensitizes Pancreatic Cancer Cells to Ferroptosis Induction", "doi": "10.1002/advs.202307695", "year": 2024 } ] } }, { "id": 40817, "drug": "Canagliflozin", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "suppresses", "mediator": "HIF-1α", "mediator_type": "protein", "predicate_bc": "confers_resistance_to", "outcome": "radiation", "outcome_type": "phenotype", "outcome_domain": "pancreatic_cancer", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "canagliflozin", "mediator_canonical": "hif-1α", "outcome_canonical": "radiation", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37684337", "title": "The SGLT2 inhibitor canagliflozin suppresses growth and enhances prostate cancer response to radiotherapy", "doi": "10.1038/s42003-023-05289-w", "year": 2023 }, { "pmid": "37584455", "title": "Canagliflozin mediates tumor suppression alone and in combination with radiotherapy in non‐small cell lung cancer (NSCLC) through inhibition of HIF‐1α", "doi": "10.1002/1878-0261.13508", "year": 2023 }, { "pmid": "34142035", "title": "Canagliflozin attenuates lipotoxicity in cardiomyocytes and protects diabetic mouse hearts by inhibiting the mTOR/HIF-1α pathway", "doi": "10.1016/j.isci.2021.102521", "year": 2021 } ], "bc": [ { "pmid": "30801702", "title": "Inhibition of HSP90 overcomes resistance to chemotherapy and radiotherapy in pancreatic cancer", "doi": "10.1002/ijc.32227", "year": 2019 } ] } }, { "id": 40816, "drug": "exenatide", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "activates", "mediator": "AMPK", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "pancreatic ductal adenocarcinoma", "outcome_type": "disease", "outcome_domain": "pancreatic_cancer", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "exenatide", "mediator_canonical": "AMPK", "outcome_canonical": "pancreatic ductal adenocarcinoma", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "33044023", "title": "Exenatide improves random‐pattern skin flap survival via TFE3 mediated autophagy augment", "doi": "10.1002/jcp.30102", "year": 2020 }, { "pmid": "27473212", "title": "The GLP-1 receptor agonists exenatide and liraglutide activate Glucose transport by an AMPK-dependent mechanism", "doi": "10.1186/s12967-016-0985-7", "year": 2016 }, { "pmid": "25720388", "title": "Exenatide Protects Against Glucose- and Lipid-Induced Endothelial Dysfunction: Evidence for Direct Vasodilation Effect of GLP-1 Receptor Agonists in Humans", "doi": "10.2337/db14-0976", "year": 2015 } ], "bc": [ { "pmid": "38885414", "title": "A Novel AMPK Inhibitor Sensitizes Pancreatic Cancer Cells to Ferroptosis Induction", "doi": "10.1002/advs.202307695", "year": 2024 } ] } }, { "id": 61766, "drug": "Alirocumab", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "inhibits", "mediator": "PCSK9", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "atrial fibrillation", "outcome_type": "disease", "outcome_domain": "rheumatoid_arthritis", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "32035487", "title": "Effect of alirocumab on individuals with type 2 diabetes, high triglycerides, and low high-density lipoprotein cholesterol", "doi": "10.1186/s12933-020-0991-1", "year": 2020 }, { "pmid": "28799203", "title": "Efficacy and safety of alirocumab in people with prediabetes vs those with normoglycaemia at baseline: a pooled analysis of 10 phase III ODYSSEY clinical trials", "doi": "10.1111/dme.13450", "year": 2017 }, { "pmid": "28545518", "title": "Design and rationale of the ODYSSEY DM-DYSLIPIDEMIA trial: lipid-lowering efficacy and safety of alirocumab in individuals with type 2 diabetes and mixed dyslipidaemia at high cardiovascular risk", "doi": "10.1186/s12933-017-0552-4", "year": 2017 } ], "bc": [ { "pmid": "37709197", "title": "Evolocumab prevents atrial fibrillation in rheumatoid arthritis rats through restraint of PCSK9 induced atrial remodeling", "doi": "10.1016/j.jare.2023.09.007", "year": 2023 } ] } }, { "id": 40975, "drug": "Lycopene", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "inhibits", "mediator": "STAT3", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "prurigo nodularis", "outcome_type": "disease", "outcome_domain": "rheumatoid_arthritis", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "lycopene", "mediator_canonical": "STAT3", "outcome_canonical": "prurigo nodularis", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "28472825", "title": "Lycopene Improves Insulin Sensitivity through Inhibition of STAT3/Srebp-1c-Mediated Lipid Accumulation and Inflammation in Mice fed a High-Fat Diet", "doi": "10.1055/s-0043-101919", "year": 2017 } ], "bc": [ { "pmid": "39912139", "title": "Translating tissue expression of STAT 1, 3 and 6 in prurigo nodularis to clinical efficacy of oral tofacitinib – A prospective single-arm investigational study", "doi": "10.25259/ijdvl_1017_2024", "year": 2025 }, { "pmid": "40162359", "title": "Successful Use of Tofacitinib in Paediatric Prurigo Nodularis: A Report of Four Cases", "doi": "10.4103/ijd.ijd_842_24", "year": 2025 }, { "pmid": "37521237", "title": "A case of recalcitrant prurigo nodularis with heightened expression of STAT 3 and STAT 6 and its dramatic response to tofacitinib", "doi": "10.4103/idoj.idoj_508_22", "year": 2023 } ] } }, { "id": 40983, "drug": "C5aRA", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "suppresses", "mediator": "STAT3", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "prurigo nodularis", "outcome_type": "disease", "outcome_domain": "rheumatoid_arthritis", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "c5ara", "mediator_canonical": "STAT3", "outcome_canonical": "prurigo nodularis", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "33280239", "title": "Complement C5 activation promotes type 2 diabetic kidney disease via activating STAT3 pathway and disrupting the gut‐kidney axis", "doi": "10.1111/jcmm.16157", "year": 2020 } ], "bc": [ { "pmid": "39912139", "title": "Translating tissue expression of STAT 1, 3 and 6 in prurigo nodularis to clinical efficacy of oral tofacitinib – A prospective single-arm investigational study", "doi": "10.25259/ijdvl_1017_2024", "year": 2025 }, { "pmid": "40162359", "title": "Successful Use of Tofacitinib in Paediatric Prurigo Nodularis: A Report of Four Cases", "doi": "10.4103/ijd.ijd_842_24", "year": 2025 }, { "pmid": "37521237", "title": "A case of recalcitrant prurigo nodularis with heightened expression of STAT 3 and STAT 6 and its dramatic response to tofacitinib", "doi": "10.4103/idoj.idoj_508_22", "year": 2023 } ] } }, { "id": 61789, "drug": "Alirocumab", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "inhibits", "mediator": "PCSK9", "mediator_type": "protein", "predicate_bc": "causes", "outcome": "atrial structural remodeling", "outcome_type": "phenotype", "outcome_domain": "rheumatoid_arthritis", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "32035487", "title": "Effect of alirocumab on individuals with type 2 diabetes, high triglycerides, and low high-density lipoprotein cholesterol", "doi": "10.1186/s12933-020-0991-1", "year": 2020 }, { "pmid": "28799203", "title": "Efficacy and safety of alirocumab in people with prediabetes vs those with normoglycaemia at baseline: a pooled analysis of 10 phase III ODYSSEY clinical trials", "doi": "10.1111/dme.13450", "year": 2017 }, { "pmid": "28545518", "title": "Design and rationale of the ODYSSEY DM-DYSLIPIDEMIA trial: lipid-lowering efficacy and safety of alirocumab in individuals with type 2 diabetes and mixed dyslipidaemia at high cardiovascular risk", "doi": "10.1186/s12933-017-0552-4", "year": 2017 } ], "bc": [ { "pmid": "37709197", "title": "Evolocumab prevents atrial fibrillation in rheumatoid arthritis rats through restraint of PCSK9 induced atrial remodeling", "doi": "10.1016/j.jare.2023.09.007", "year": 2023 } ] } }, { "id": 5290, "drug": "cyanate", "drug_type": "drug", "drug_domain": "depression", "predicate_ab": "binds_to", "mediator": "mTOR", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "glioblastoma", "outcome_type": "disease", "outcome_domain": "glioblastoma", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "cyanate", "mediator_canonical": "mTOR", "outcome_canonical": "glioblastoma", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "31628020", "title": "High urea induces depression and LTP impairment through mTOR signalling suppression caused by carbamylation", "doi": "10.1016/j.ebiom.2019.09.049", "year": 2019 } ], "bc": [ { "pmid": "39622049", "title": "A Dual-Target and Dual-Mechanism Design Strategy by Combining Inhibition and Degradation Together", "doi": "10.1021/jacs.4c11930", "year": 2024 }, { "pmid": "33162811", "title": "Mitochondrial dysfunction contributes to Rapamycin-induced apoptosis of Human Glioblastoma Cells - A synergistic effect with Temozolomide", "doi": "10.7150/ijms.40159", "year": 2020 }, { "pmid": "30793789", "title": "The effect of the mTOR inhibitor rapamycin on glucoCEST signal in a preclinical model of glioblastoma", "doi": "10.1002/mrm.27683", "year": 2019 } ] } }, { "id": 8988, "drug": "HPTQC", "drug_type": "drug", "drug_domain": "alzheimer", "predicate_ab": "downregulates", "mediator": "EGFR", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "pancreatic ductal adenocarcinoma", "outcome_type": "disease", "outcome_domain": "pancreatic_cancer", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "hptqc", "mediator_canonical": "EGFR", "outcome_canonical": "pancreatic ductal adenocarcinoma", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "32495567", "title": "[Effects of Huangpu Tongqiao Capsules on EGFR-PLCγ signal pathway of hippocampus in rats with Alzheimer's disease].", "doi": "10.19540/j.cnki.cjcmm.20191219.401", "year": 2020 } ], "bc": [ { "pmid": "40130819", "title": "Identification of Tumor‐Specific Surface Proteins Enables Quantification of Extracellular Vesicle Subtypes for Early Detection of Pancreatic Ductal Adenocarcinoma", "doi": "10.1002/advs.202414982", "year": 2025 }, { "pmid": "31584260", "title": "Design and Evaluation of PEGylated Liposomal Formulation of a Novel Multikinase Inhibitor for Enhanced Chemosensitivity and Inhibition of Metastatic Pancreatic Ductal Adenocarcinoma", "doi": "10.1021/acs.bioconjchem.9b00632", "year": 2019 }, { "pmid": "26339400", "title": "EGFR expression in pancreatic intraepithelial neoplasia and ductal adenocarcinoma.", "doi": null, "year": 2015 } ] } }, { "id": 4172, "drug": "GJD", "drug_type": "drug", "drug_domain": "alzheimer", "predicate_ab": "upregulates", "mediator": "BDNF", "mediator_type": "protein", "predicate_bc": "decreases", "outcome": "schizophrenia", "outcome_type": "disease", "outcome_domain": "depression", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "gjd", "mediator_canonical": "BDNF", "outcome_canonical": "schizophrenia", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41260522", "title": "Traditional herbal medicine Ga-Mi Gongjindan improves muscarinic cholinergic dysfunction through regulation of BDNF/CREB signaling pathway using a scopolamine-induced cognitive impairment of mouse model", "doi": "10.1016/j.brainresbull.2025.111644", "year": 2025 } ], "bc": [ { "pmid": "34280516", "title": "Associations of immunological proteins/traits with schizophrenia, major depression and bipolar disorder: A bi-directional two-sample mendelian randomization study", "doi": "10.1016/j.bbi.2021.07.009", "year": 2021 }, { "pmid": "30794585", "title": "Accuracy of brain-derived neurotrophic factor levels for differentiating between Taiwanese patients with major depressive disorder or schizophrenia and healthy controls", "doi": "10.1371/journal.pone.0212373", "year": 2019 } ] } }, { "id": 20907, "drug": "CLR01", "drug_type": "drug", "drug_domain": "alzheimer", "predicate_ab": "binds_to", "mediator": "TAU", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "secondary-progressive multiple sclerosis", "outcome_type": "disease", "outcome_domain": "multiple_sclerosis", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "clr01", "mediator_canonical": "MAPT", "outcome_canonical": "secondary-progressive multiple sclerosis", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "31046227", "title": "Major Differences between the Self-Assembly and Seeding Behavior of Heparin-Induced and in Vitro Phosphorylated Tau and Their Modulation by Potential Inhibitors", "doi": "10.1021/acschembio.9b00325", "year": 2019 }, { "pmid": "30062477", "title": "Native Top-Down Mass Spectrometry and Ion Mobility Spectrometry of the Interaction of Tau Protein with a Molecular Tweezer Assembly Modulator", "doi": "10.1007/s13361-018-2027-6", "year": 2018 } ], "bc": [ { "pmid": "29865854", "title": "BDNF and Tau as Biomarkers of Severity in Multiple Sclerosis", "doi": "10.2217/bmm-2017-0374", "year": 2018 } ] } }, { "id": 20908, "drug": "Thiamet G", "drug_type": "drug", "drug_domain": "alzheimer", "predicate_ab": "inhibits", "mediator": "OGA", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "Multiple Sclerosis", "outcome_type": "disease", "outcome_domain": "multiple_sclerosis", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "thiamet g", "mediator_canonical": "oga", "outcome_canonical": "multiple sclerosis", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "39823370", "title": "Brain Transcriptome Changes Associated With an Acute Increase of Protein O‐ GlcNAcylation and Implications for Neurodegenerative Disease", "doi": "10.1111/jnc.16302", "year": 2025 }, { "pmid": "37735138", "title": "Increasing O-GlcNAcylation Attenuates tau Hyperphosphorylation and Behavioral Impairment in rTg4510 Tauopathy Mice", "doi": "10.31083/j.jin2205135", "year": 2023 }, { "pmid": "35248135", "title": "Acute inhibition of OGA sex-dependently alters the networks associated with bioenergetics, autophagy, and neurodegeneration", "doi": "10.1186/s13041-022-00906-x", "year": 2022 } ], "bc": [ { "pmid": "40108295", "title": "Multi-omic biomarkers associated with multiple sclerosis: from Mendelian randomization to drug prediction", "doi": "10.1038/s41598-025-94303-8", "year": 2025 } ] } }, { "id": 37705, "drug": "chelerythrine", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "inhibits", "mediator": "TDP-43", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "FTLD", "outcome_type": "disease", "outcome_domain": "als", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "chelerythrine", "mediator_canonical": "TDP-43", "outcome_canonical": "ftld", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "29396541", "title": "TDP-43 self-interaction is modulated by redox-active compounds Auranofin, Chelerythrine and Riluzole", "doi": "10.1038/s41598-018-20565-0", "year": 2018 } ], "bc": [ { "pmid": "40619651", "title": "TDP-43 Proteinopathies in ALS and FTLD: Mechanistic Insights andTherapeutic Approaches", "doi": "10.2174/0118715273374466250617085832", "year": 2025 }, { "pmid": "31529970", "title": "Using Tetracysteine-Tagged TDP-43 with a Biarsenical Dye To Monitor Real-Time Trafficking in a Cell Model of Amyotrophic Lateral Sclerosis", "doi": "10.1021/acs.biochem.9b00592", "year": 2019 }, { "pmid": "26689008", "title": "[RNA processing TDP-43 protein has a main pathological role in FTLD and ALS].", "doi": null, "year": 2015 } ] } }, { "id": 32549, "drug": "GHK-Cu", "drug_type": "drug", "drug_domain": "inflammatory_bowel_disease", "predicate_ab": "upregulates", "mediator": "SIRT1", "mediator_type": "protein", "predicate_bc": "predicts", "outcome": "Alzheimer's disease", "outcome_type": "disease", "outcome_domain": "alzheimer", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "ghk-cu", "mediator_canonical": "SIRT1", "outcome_canonical": "Alzheimer disease", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40672369", "title": "Exploring the beneficial effects of GHK-Cu on an experimental model of colitis and the underlying mechanisms", "doi": "10.3389/fphar.2025.1551843", "year": 2025 } ], "bc": [ { "pmid": "37742223", "title": "Serum sirtuin1: a potential blood biomarker for early diagnosis of Alzheimer’s disease", "doi": "10.18632/aging.205015", "year": 2023 }, { "pmid": "30243024", "title": "Sirt1 enhances tau exon 10 inclusion and improves spatial memory of Htau mice", "doi": "10.18632/aging.101564", "year": 2018 } ] } }, { "id": 4174, "drug": "TFSeB", "drug_type": "drug", "drug_domain": "alzheimer", "predicate_ab": "upregulates", "mediator": "BDNF", "mediator_type": "protein", "predicate_bc": "decreases", "outcome": "schizophrenia", "outcome_type": "disease", "outcome_domain": "depression", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "tfseb", "mediator_canonical": "BDNF", "outcome_canonical": "schizophrenia", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40523837", "title": "Neuroprotective Effects of a Benzofuran-Containing Selenium in a Mouse Alzheimer’s Disease Model: Molecular, Biochemical, and Behavioral Analyses", "doi": "10.1021/acschemneuro.5c00139", "year": 2025 } ], "bc": [ { "pmid": "34280516", "title": "Associations of immunological proteins/traits with schizophrenia, major depression and bipolar disorder: A bi-directional two-sample mendelian randomization study", "doi": "10.1016/j.bbi.2021.07.009", "year": 2021 }, { "pmid": "30794585", "title": "Accuracy of brain-derived neurotrophic factor levels for differentiating between Taiwanese patients with major depressive disorder or schizophrenia and healthy controls", "doi": "10.1371/journal.pone.0212373", "year": 2019 } ] } }, { "id": 4385, "drug": "ABC294640", "drug_type": "drug", "drug_domain": "pancreatic_cancer", "predicate_ab": "downregulates", "mediator": "RRM2", "mediator_type": "gene", "predicate_bc": "associated_with", "outcome": "glioblastoma", "outcome_type": "disease", "outcome_domain": "glioblastoma", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "abc294640", "mediator_canonical": "RRM2", "outcome_canonical": "glioblastoma", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "27517489", "title": "Suppression of c-Myc and RRM2 expression in pancreatic cancer cells by the sphingosine kinase-2 inhibitor ABC294640", "doi": "10.18632/oncotarget.11112", "year": 2016 } ], "bc": [ { "pmid": "39248068", "title": "Bioinformatics Analysis Screening and Identification of Key Biomarkers and Drug Targets in Human Glioblastoma", "doi": "10.2174/0109298673316883240829073901", "year": 2024 }, { "pmid": "35651787", "title": "RRM2 Mediates the Anti-Tumor Effect of the Natural Product Pectolinarigenin on Glioblastoma Through Promoting CDK1 Protein Degradation by Increasing Autophagic Flux", "doi": "10.3389/fonc.2022.887294", "year": 2022 }, { "pmid": "31119182", "title": "Identification of Potential Biomarkers in Glioblastoma through Bioinformatic Analysis and Evaluating Their Prognostic Value", "doi": "10.1155/2019/6581576", "year": 2019 } ] } }, { "id": 23633, "drug": "SVF+PRP", "drug_type": "drug", "drug_domain": "multiple_sclerosis", "predicate_ab": "downregulates", "mediator": "GFAP", "mediator_type": "gene", "predicate_bc": "associated_with", "outcome": "Alzheimer's disease", "outcome_type": "disease", "outcome_domain": "alzheimer", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "unknown", "drug_canonical": "svf+prp", "mediator_canonical": "GFAP", "outcome_canonical": "Alzheimer disease", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "38326395", "title": "RETRACTED ARTICLE: Combined laser-activated SVF and PRP remodeled spinal sclerosis via activation of Olig-2, MBP, and neurotrophic factors and inhibition of BAX and GFAP", "doi": "10.1038/s41598-024-52962-z", "year": 2024 } ], "bc": [ { "pmid": "38236817", "title": "Large-scale gene expression changes in APP/PSEN1 and GFAP mutation models exhibit high congruence with Alzheimer’s disease", "doi": "10.1371/journal.pone.0291995", "year": 2024 }, { "pmid": "30400085", "title": "Changes in Expression Profiles Revealed by Transcriptomic Analysis in Peripheral Blood Mononuclear Cells of Alzheimer’s Disease Patients", "doi": "10.3233/jad-170205", "year": 2018 }, { "pmid": "30040709", "title": "A Selection of Important Genes and Their Correlated Behavior in Alzheimer’s Disease", "doi": "10.3233/jad-170799", "year": 2018 } ] } }, { "id": 38008, "drug": "tofacitinib", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "inhibits", "mediator": "STAT3", "mediator_type": "protein", "predicate_bc": "treats", "outcome": "cognitive deficits", "outcome_type": "phenotype", "outcome_domain": "alzheimer", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "preclinical_only", "clinical_trial_nct_ids": [ "NCT04378621" ], "literature_status": "partial_evidence", "drug_canonical": "tofacitinib", "mediator_canonical": "STAT3", "outcome_canonical": "cognitive deficits", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40373045", "title": "Rheumatoid arthritis synovial fluid induces JAK-dependent intracellular activation of human sensory neurons", "doi": "10.1172/jci.insight.186646", "year": 2025 }, { "pmid": "32927842", "title": "Tofacitinib and Baricitinib Are Taken up by Different Uptake Mechanisms Determining the Efficacy of Both Drugs in RA", "doi": "10.3390/ijms21186632", "year": 2020 }, { "pmid": "30357932", "title": "JAK1/3 inhibition preserves epidermal morphology in full‐thickness 3D skin models of atopic dermatitis and psoriasis", "doi": "10.1111/jdv.15301", "year": 2018 } ], "bc": [ { "pmid": "33859760", "title": "STAT3 ameliorates cognitive deficits via regulation of NMDAR expression in an Alzheimer's disease animal model", "doi": "10.7150/thno.56541", "year": 2021 } ] } }, { "id": 3789, "drug": "CLR01", "drug_type": "drug", "drug_domain": "alzheimer", "predicate_ab": "binds_to", "mediator": "TAU", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "neurodegenerative diseases", "outcome_type": "disease", "outcome_domain": "als", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "clr01", "mediator_canonical": "MAPT", "outcome_canonical": null, "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "31046227", "title": "Major Differences between the Self-Assembly and Seeding Behavior of Heparin-Induced and in Vitro Phosphorylated Tau and Their Modulation by Potential Inhibitors", "doi": "10.1021/acschembio.9b00325", "year": 2019 }, { "pmid": "30062477", "title": "Native Top-Down Mass Spectrometry and Ion Mobility Spectrometry of the Interaction of Tau Protein with a Molecular Tweezer Assembly Modulator", "doi": "10.1007/s13361-018-2027-6", "year": 2018 } ], "bc": [ { "pmid": "40960157", "title": "Protein aggregation in neurodegenerative diseases", "doi": "10.1097/cm9.0000000000003802", "year": 2025 } ] } }, { "id": 3694, "drug": "CLR01", "drug_type": "drug", "drug_domain": "alzheimer", "predicate_ab": "binds_to", "mediator": "TAU", "mediator_type": "protein", "predicate_bc": "causes", "outcome": "seizure generation", "outcome_type": "phenotype", "outcome_domain": "epilepsy", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "clr01", "mediator_canonical": "MAPT", "outcome_canonical": "seizure generation", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "31046227", "title": "Major Differences between the Self-Assembly and Seeding Behavior of Heparin-Induced and in Vitro Phosphorylated Tau and Their Modulation by Potential Inhibitors", "doi": "10.1021/acschembio.9b00325", "year": 2019 }, { "pmid": "30062477", "title": "Native Top-Down Mass Spectrometry and Ion Mobility Spectrometry of the Interaction of Tau Protein with a Molecular Tweezer Assembly Modulator", "doi": "10.1007/s13361-018-2027-6", "year": 2018 } ], "bc": [ { "pmid": "31780921", "title": "Tau Phosphorylation in a Mouse Model of Temporal Lobe Epilepsy", "doi": "10.3389/fnagi.2019.00308", "year": 2019 } ] } }, { "id": 23427, "drug": "pentamidine", "drug_type": "drug", "drug_domain": "multiple_sclerosis", "predicate_ab": "inhibits", "mediator": "S100B", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "clinical improvement", "outcome_type": "phenotype", "outcome_domain": "als", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "pentamidine", "mediator_canonical": "s100b", "outcome_canonical": "clinical improvement", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40649727", "title": "Effect on Different Glial Cell Types of S100B Modulation in Multiple Sclerosis Experimental Models", "doi": "10.3390/ijms26135948", "year": 2025 }, { "pmid": "35620168", "title": "S100B inhibition protects from chronic experimental autoimmune encephalomyelitis", "doi": "10.1093/braincomms/fcac076", "year": 2022 }, { "pmid": "32197530", "title": "The S100B Inhibitor Pentamidine Ameliorates Clinical Score and Neuropathology of Relapsing—Remitting Multiple Sclerosis Mouse Model", "doi": "10.3390/cells9030748", "year": 2020 } ], "bc": [ { "pmid": "42066366", "title": "Characterizing immune involvement in degenerative cervical myelopathy: a systematic review.", "doi": "10.3171/2025.12.spine251122", "year": 2026 } ] } }, { "id": 38277, "drug": "tofacitinib", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "inhibits", "mediator": "STAT3", "mediator_type": "protein", "predicate_bc": "prevents", "outcome": "general cell loss", "outcome_type": "phenotype", "outcome_domain": "epilepsy", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "tofacitinib", "mediator_canonical": "STAT3", "outcome_canonical": "general cell loss", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40373045", "title": "Rheumatoid arthritis synovial fluid induces JAK-dependent intracellular activation of human sensory neurons", "doi": "10.1172/jci.insight.186646", "year": 2025 }, { "pmid": "32927842", "title": "Tofacitinib and Baricitinib Are Taken up by Different Uptake Mechanisms Determining the Efficacy of Both Drugs in RA", "doi": "10.3390/ijms21186632", "year": 2020 }, { "pmid": "30357932", "title": "JAK1/3 inhibition preserves epidermal morphology in full‐thickness 3D skin models of atopic dermatitis and psoriasis", "doi": "10.1111/jdv.15301", "year": 2018 } ], "bc": [ { "pmid": "36825472", "title": "Blockage of STAT3 during epileptogenesis prevents GABAergic loss and imprinting of the epileptic state", "doi": "10.1093/brain/awad055", "year": 2023 } ] } }, { "id": 23631, "drug": "Pirfenidone", "drug_type": "drug", "drug_domain": "multiple_sclerosis", "predicate_ab": "upregulates", "mediator": "SIRT1", "mediator_type": "protein", "predicate_bc": "predicts", "outcome": "Alzheimer's disease", "outcome_type": "disease", "outcome_domain": "alzheimer", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "pirfenidone", "mediator_canonical": "SIRT1", "outcome_canonical": "Alzheimer disease", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "39404841", "title": "Pirfenidone mitigates demyelination and electrophysiological alterations in multiple sclerosis: Targeting NF-κB, sirt1, and neurotrophic genes", "doi": "10.1007/s00210-024-03496-8", "year": 2024 } ], "bc": [ { "pmid": "37742223", "title": "Serum sirtuin1: a potential blood biomarker for early diagnosis of Alzheimer’s disease", "doi": "10.18632/aging.205015", "year": 2023 }, { "pmid": "30243024", "title": "Sirt1 enhances tau exon 10 inclusion and improves spatial memory of Htau mice", "doi": "10.18632/aging.101564", "year": 2018 } ] } }, { "id": 40409, "drug": "DPP-4 inhibitors", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "binds_to", "mediator": "DPP-4", "mediator_type": "protein", "predicate_bc": "predicts", "outcome": "biological treatment response", "outcome_type": "phenotype", "outcome_domain": "inflammatory_bowel_disease", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "dpp-4 inhibitors", "mediator_canonical": "dpp-4", "outcome_canonical": "biological treatment response", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "28794822", "title": "Overview of Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Patients with Type 2 Diabetes.", "doi": null, "year": 2017 }, { "pmid": "30815539", "title": "A comparative study of the binding properties, dipeptidyl peptidase‐4 (DPP‐4) inhibitory activity and glucose‐lowering efficacy of the DPP‐4 inhibitors alogliptin, linagliptin, saxagliptin, sitagliptin and vildagliptin in mice", "doi": "10.1002/edm2.2", "year": 2017 } ], "bc": [ { "pmid": "31912883", "title": "Serum Dipeptidyl Peptidase 4: A Predictor of Disease Activity and Prognosis in Inflammatory Bowel Disease", "doi": "10.1093/ibd/izz319", "year": 2020 } ] } }, { "id": 3800, "drug": "electroacupuncture", "drug_type": "drug", "drug_domain": "alzheimer", "predicate_ab": "downregulates", "mediator": "APP", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "MND", "outcome_type": "disease", "outcome_domain": "als", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "electroacupuncture", "mediator_canonical": "app", "outcome_canonical": "mnd", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "32116652", "title": "Electroacupuncture Ameliorates Cognitive Impairment by Inhibiting the JNK Signaling Pathway in a Mouse Model of Alzheimer’s Disease", "doi": "10.3389/fnagi.2020.00023", "year": 2020 }, { "pmid": "31223308", "title": "Electroacupuncture Mitigates Hippocampal Cognitive Impairments by Reducing BACE1 Deposition and Activating PKA in APP/PS1 Double Transgenic Mice", "doi": "10.1155/2019/2823679", "year": 2019 }, { "pmid": "29888573", "title": "[Kidney-reinforcing and Governor Vessel-regulating EA Intervention May Improve Learningmemory Possibly by Suppressing Formation of Senile Plaques in Hippocampus in APP/PS 1 Double Transgenic Alzheimer's Disease Mice].", "doi": "10.13702/j.1000-0607.170460", "year": 2018 } ], "bc": [ { "pmid": "27877154", "title": "Immununochemical Markers of the Amyloid Cascade in the Hippocampus in Motor Neuron Diseases", "doi": "10.3389/fneur.2016.00195", "year": 2016 } ] } }, { "id": 8822, "drug": "Cornuside", "drug_type": "drug", "drug_domain": "alzheimer", "predicate_ab": "downregulates", "mediator": "RAGE", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "ALS", "outcome_type": "disease", "outcome_domain": "als", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "cornuside", "mediator_canonical": "rage", "outcome_canonical": "amyotrophic lateral sclerosis", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "36781177", "title": "Cornuside, by regulating the AGEs‐RAGE‐IκBα‐ERK1/2 signaling pathway, ameliorates cognitive impairment associated with brain aging", "doi": "10.1002/ptr.7765", "year": 2023 } ], "bc": [ { "pmid": "35216298", "title": "The Involvement of RAGE and Its Ligands during Progression of ALS in SOD1 G93A Transgenic Mice", "doi": "10.3390/ijms23042184", "year": 2022 }, { "pmid": "27242430", "title": "Soluble RAGE Treatment Delays Progression of Amyotrophic Lateral Sclerosis in SOD1 Mice", "doi": "10.3389/fncel.2016.00117", "year": 2016 }, { "pmid": "26733811", "title": "Receptor for Advanced Glycation End Products and its Inflammatory Ligands are Upregulated in Amyotrophic Lateral Sclerosis", "doi": "10.3389/fncel.2015.00485", "year": 2015 } ] } }, { "id": 8825, "drug": "lead peptide", "drug_type": "drug", "drug_domain": "alzheimer", "predicate_ab": "binds_to", "mediator": "RAGE", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "ALS", "outcome_type": "disease", "outcome_domain": "als", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "lead peptide", "mediator_canonical": "rage", "outcome_canonical": "amyotrophic lateral sclerosis", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "36291595", "title": "Selecting Multitarget Peptides for Alzheimer’s Disease", "doi": "10.3390/biom12101386", "year": 2022 } ], "bc": [ { "pmid": "35216298", "title": "The Involvement of RAGE and Its Ligands during Progression of ALS in SOD1 G93A Transgenic Mice", "doi": "10.3390/ijms23042184", "year": 2022 }, { "pmid": "27242430", "title": "Soluble RAGE Treatment Delays Progression of Amyotrophic Lateral Sclerosis in SOD1 Mice", "doi": "10.3389/fncel.2016.00117", "year": 2016 }, { "pmid": "26733811", "title": "Receptor for Advanced Glycation End Products and its Inflammatory Ligands are Upregulated in Amyotrophic Lateral Sclerosis", "doi": "10.3389/fncel.2015.00485", "year": 2015 } ] } }, { "id": 6900, "drug": "FK506", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "downregulates", "mediator": "GFAP", "mediator_type": "protein", "predicate_bc": "predicts", "outcome": "Alzheimer's disease", "outcome_type": "disease", "outcome_domain": "alzheimer", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "completed", "clinical_trial_nct_ids": [ "NCT04263519" ], "literature_status": "reproduces_known", "drug_canonical": "tacrolimus", "mediator_canonical": "GFAP", "outcome_canonical": "Alzheimer disease", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "29375315", "title": "The Calcineurin Inhibitor FK506 Prevents Cognitive Impairment by Inhibiting Reactive Astrogliosis in Pilocarpine-Induced Status Epilepticus Rats", "doi": "10.3389/fncel.2017.00428", "year": 2018 } ], "bc": [ { "pmid": "39252463", "title": "Plasma proteomics for risk prediction of Alzheimer's disease in the general population", "doi": "10.1111/acel.14330", "year": 2024 }, { "pmid": "35890250", "title": "Glial Fibrillary Acidic Protein: A Biomarker and Drug Target for Alzheimer’s Disease", "doi": "10.3390/pharmaceutics14071354", "year": 2022 }, { "pmid": "34828359", "title": "Investigating Markers of the NLRP3 Inflammasome Pathway in Alzheimer’s Disease: A Human Post-Mortem Study", "doi": "10.3390/genes12111753", "year": 2021 } ] } }, { "id": 38757, "drug": "SDZ ETN", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "induces", "mediator": "anti-drug antibodies", "mediator_type": "biomarker", "predicate_bc": "associated_with", "outcome": "loss of response", "outcome_type": "phenotype", "outcome_domain": "inflammatory_bowel_disease", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "sdz etn", "mediator_canonical": "anti-drug antibodies", "outcome_canonical": "loss of response", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "31138316", "title": "Switch from reference etanercept to SDZ ETN, an etanercept biosimilar, does not impact efficacy, safety, and immunogenicity of etanercept in patients with moderate-to-severe rheumatoid arthritis: 48-week results from the phase III, randomized, double-blind EQUIRA study", "doi": "10.1186/s13075-019-1907-x", "year": 2019 } ], "bc": [ { "pmid": "37961895", "title": "Anti-drug antibodies against anti-TNF in patients with inflammatory bowel disease: an evaluation of possible strategies", "doi": "10.1080/00365521.2023.2278424", "year": 2023 }, { "pmid": "34559428", "title": "Loss of response to anti‐TNFα agents depends on treatment duration in patients with inflammatory bowel disease", "doi": "10.1111/apt.16605", "year": 2021 }, { "pmid": "29383030", "title": "Immunogenicity of biologics in inflammatory bowel disease", "doi": "10.1177/1756283x17750355", "year": 2018 } ] } }, { "id": 59366, "drug": "total flavonoids of Rhizoma Drynariae", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "downregulates", "mediator": "IL-17A", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "inflammatory bowel disease", "outcome_type": "disease", "outcome_domain": "inflammatory_bowel_disease", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "35702063", "title": "Network Pharmacology Analysis and Experimental Validation to Investigate the Mechanism of Total Flavonoids of Rhizoma Drynariae in Treating Rheumatoid Arthritis", "doi": "10.2147/dddt.s354946", "year": 2022 } ], "bc": [ { "pmid": "32724117", "title": "Serum interleukin 17A and interleukin 17F in children with inflammatory bowel disease", "doi": "10.1038/s41598-020-69567-x", "year": 2020 }, { "pmid": "27049090", "title": "Relationship between serum interleukin-17 level and inflammatory bowel disease.", "doi": null, "year": 2016 } ] } }, { "id": 8396, "drug": "rapalogs", "drug_type": "drug", "drug_domain": "alzheimer", "predicate_ab": "inhibits", "mediator": "mTOR", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "glioblastoma", "outcome_type": "disease", "outcome_domain": "glioblastoma", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "rapalogs", "mediator_canonical": "mTOR", "outcome_canonical": "glioblastoma", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "31169184", "title": "The local mammalian target of rapamycin (mTOR) modulation: a promising strategy to counteract neurodegeneration", "doi": "10.4103/1673-5374.257524", "year": 2019 } ], "bc": [ { "pmid": "39622049", "title": "A Dual-Target and Dual-Mechanism Design Strategy by Combining Inhibition and Degradation Together", "doi": "10.1021/jacs.4c11930", "year": 2024 }, { "pmid": "33162811", "title": "Mitochondrial dysfunction contributes to Rapamycin-induced apoptosis of Human Glioblastoma Cells - A synergistic effect with Temozolomide", "doi": "10.7150/ijms.40159", "year": 2020 }, { "pmid": "30793789", "title": "The effect of the mTOR inhibitor rapamycin on glucoCEST signal in a preclinical model of glioblastoma", "doi": "10.1002/mrm.27683", "year": 2019 } ] } }, { "id": 6688, "drug": "Levetiracetam", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "suppresses", "mediator": "Cx43", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "ALS", "outcome_type": "disease", "outcome_domain": "als", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "completed", "clinical_trial_nct_ids": [ "NCT00324454" ], "literature_status": "partial_evidence", "drug_canonical": "levetiracetam", "mediator_canonical": "GJA1", "outcome_canonical": "amyotrophic lateral sclerosis", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "35562864", "title": "Brivaracetam and Levetiracetam Suppress Astroglial L-Glutamate Release through Hemichannel via Inhibition of Synaptic Vesicle Protein", "doi": "10.3390/ijms23094473", "year": 2022 } ], "bc": [ { "pmid": "35312356", "title": "Cx43 hemichannels contribute to astrocyte-mediated toxicity in sporadic and familial ALS", "doi": "10.1073/pnas.2107391119", "year": 2022 }, { "pmid": "27083773", "title": "Connexin 43 in astrocytes contributes to motor neuron toxicity in amyotrophic lateral sclerosis", "doi": "10.1002/glia.22989", "year": 2016 } ] } }, { "id": 33534, "drug": "Ginkgetin", "drug_type": "drug", "drug_domain": "inflammatory_bowel_disease", "predicate_ab": "activates", "mediator": "EGFR", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "pancreatic ductal adenocarcinoma", "outcome_type": "disease", "outcome_domain": "pancreatic_cancer", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "ginkgetin", "mediator_canonical": "EGFR", "outcome_canonical": "pancreatic ductal adenocarcinoma", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "39003633", "title": "Ginkgetin improved experimental colitis by inhibiting intestinal epithelial cell apoptosis through EGFR/PI3K/AKT signaling", "doi": "10.1096/fj.202400211rr", "year": 2024 } ], "bc": [ { "pmid": "40130819", "title": "Identification of Tumor‐Specific Surface Proteins Enables Quantification of Extracellular Vesicle Subtypes for Early Detection of Pancreatic Ductal Adenocarcinoma", "doi": "10.1002/advs.202414982", "year": 2025 }, { "pmid": "31584260", "title": "Design and Evaluation of PEGylated Liposomal Formulation of a Novel Multikinase Inhibitor for Enhanced Chemosensitivity and Inhibition of Metastatic Pancreatic Ductal Adenocarcinoma", "doi": "10.1021/acs.bioconjchem.9b00632", "year": 2019 }, { "pmid": "26339400", "title": "EGFR expression in pancreatic intraepithelial neoplasia and ductal adenocarcinoma.", "doi": null, "year": 2015 } ] } }, { "id": 33528, "drug": "bergapten", "drug_type": "drug", "drug_domain": "inflammatory_bowel_disease", "predicate_ab": "binds_to", "mediator": "EGFR", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "pancreatic ductal adenocarcinoma", "outcome_type": "disease", "outcome_domain": "pancreatic_cancer", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "bergapten", "mediator_canonical": "EGFR", "outcome_canonical": "pancreatic ductal adenocarcinoma", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40092097", "title": "Exploring the bioactive properties and mechanism of Aegle marmelos in the treatment of inflammatory bowel disease through network pharmacology and a molecular docking approach", "doi": "10.62347/gccv5213", "year": 2025 } ], "bc": [ { "pmid": "40130819", "title": "Identification of Tumor‐Specific Surface Proteins Enables Quantification of Extracellular Vesicle Subtypes for Early Detection of Pancreatic Ductal Adenocarcinoma", "doi": "10.1002/advs.202414982", "year": 2025 }, { "pmid": "31584260", "title": "Design and Evaluation of PEGylated Liposomal Formulation of a Novel Multikinase Inhibitor for Enhanced Chemosensitivity and Inhibition of Metastatic Pancreatic Ductal Adenocarcinoma", "doi": "10.1021/acs.bioconjchem.9b00632", "year": 2019 }, { "pmid": "26339400", "title": "EGFR expression in pancreatic intraepithelial neoplasia and ductal adenocarcinoma.", "doi": null, "year": 2015 } ] } }, { "id": 1165, "drug": "G721-0282", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "inhibits", "mediator": "CHI3L1", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "ALS", "outcome_type": "disease", "outcome_domain": "als", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "g721-0282", "mediator_canonical": "chi3l1", "outcome_canonical": "amyotrophic lateral sclerosis", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "36921538", "title": "Multimodal study of CHI3L1 inhibition and its effect on angiogenesis, migration, immune response and refractive index of cellular structures in glioblastoma", "doi": "10.1016/j.biopha.2023.114520", "year": 2023 } ], "bc": [ { "pmid": "36983366", "title": "Plasma CHI3L1 in Amyotrophic Lateral Sclerosis: A Potential Differential Diagnostic Biomarker", "doi": "10.3390/jcm12062367", "year": 2023 }, { "pmid": "34054686", "title": "Monocyte-Derived Macrophages Contribute to Chitinase Dysregulation in Amyotrophic Lateral Sclerosis: A Pilot Study", "doi": "10.3389/fneur.2021.629332", "year": 2021 }, { "pmid": "31937582", "title": "Cross-sectional and longitudinal measures of chitinase proteins in amyotrophic lateral sclerosis and expression of CHI3L1 in activated astrocytes", "doi": "10.1136/jnnp-2019-321916", "year": 2020 } ] } }, { "id": 1376, "drug": "carbon dot probes", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "binds_to", "mediator": "GFAP", "mediator_type": "protein", "predicate_bc": "predicts", "outcome": "cognitive decline", "outcome_type": "phenotype", "outcome_domain": "alzheimer", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "carbon dot probes", "mediator_canonical": "GFAP", "outcome_canonical": "cognitive decline", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "35434521", "title": "Carbon dot-based fluorescent antibody nanoprobes as brain tumour glioblastoma diagnostics", "doi": "10.1039/d2na00060a", "year": 2022 } ], "bc": [ { "pmid": "40110647", "title": "Exploratory analysis of the proteomic profile in plasma in adults with Down syndrome in the context of Alzheimer's disease", "doi": "10.1002/alz.70040", "year": 2025 }, { "pmid": "37787146", "title": "Longitudinal associations of serum biomarkers with early cognitive, amyloid and grey matter changes", "doi": "10.1093/brain/awad330", "year": 2023 }, { "pmid": "36446595", "title": "Longitudinal Changes in Blood Biomarkers of Clinical Alzheimer Disease in a Biracial Population Sample", "doi": "10.1212/wnl.0000000000201289", "year": 2022 } ] } }, { "id": 1373, "drug": "carbon dot probes", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "binds_to", "mediator": "GFAP", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "Alzheimer disease", "outcome_type": "disease", "outcome_domain": "alzheimer", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "carbon dot probes", "mediator_canonical": "GFAP", "outcome_canonical": "Alzheimer disease", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "35434521", "title": "Carbon dot-based fluorescent antibody nanoprobes as brain tumour glioblastoma diagnostics", "doi": "10.1039/d2na00060a", "year": 2022 } ], "bc": [ { "pmid": "41081630", "title": "Age-Specific Control and Alzheimer Disease Reference Curves and z -Scores for Glial Fibrillary Acidic Protein in Blood", "doi": "10.1093/clinchem/hvaf120", "year": 2025 }, { "pmid": "29755340", "title": "Glutamate Transporter GLT1 Expression in Alzheimer Disease and Dementia With Lewy Bodies", "doi": "10.3389/fnagi.2018.00122", "year": 2018 } ] } }, { "id": 5929, "drug": "CGF-Conditioned Medium", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "upregulates", "mediator": "GFAP", "mediator_type": "protein", "predicate_bc": "predicts", "outcome": "Alzheimer's disease", "outcome_type": "disease", "outcome_domain": "alzheimer", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "cgf-conditioned medium", "mediator_canonical": "GFAP", "outcome_canonical": "Alzheimer disease", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41154863", "title": "CGF-Conditioned Medium Modulates Astrocytic Differentiation and Invasiveness in U87MG Glioblastoma Cells", "doi": "10.3390/biology14101461", "year": 2025 } ], "bc": [ { "pmid": "39252463", "title": "Plasma proteomics for risk prediction of Alzheimer's disease in the general population", "doi": "10.1111/acel.14330", "year": 2024 }, { "pmid": "35890250", "title": "Glial Fibrillary Acidic Protein: A Biomarker and Drug Target for Alzheimer’s Disease", "doi": "10.3390/pharmaceutics14071354", "year": 2022 }, { "pmid": "34828359", "title": "Investigating Markers of the NLRP3 Inflammasome Pathway in Alzheimer’s Disease: A Human Post-Mortem Study", "doi": "10.3390/genes12111753", "year": 2021 } ] } }, { "id": 6282, "drug": "PEITC", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "downregulates", "mediator": "MIF", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "major depressive disorder", "outcome_type": "disease", "outcome_domain": "depression", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "peitc", "mediator_canonical": "mif", "outcome_canonical": "major depressive disorder", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40528798", "title": "Phenethyl isothiocyanate modulates macrophage migration inhibitory factor and suppresses malignant phenotypes of glioblastoma cells", "doi": "10.1039/d5fo00415b", "year": 2025 } ], "bc": [ { "pmid": "38144435", "title": "Elevated Serum Macrophage Migration Inhibitory Factor Levels are Associated With Major Depressive Disorder", "doi": "10.1177/2632010x231220841", "year": 2023 }, { "pmid": "36555097", "title": "Macrophage Migration Inhibitory Factor in Major Depressive Disorder: A Multilevel Pilot Study", "doi": "10.3390/ijms232415460", "year": 2022 } ] } }, { "id": 5496, "drug": "Chlorotoxin", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "binds_to", "mediator": "MMP-2", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "epilepsy", "outcome_type": "disease", "outcome_domain": "epilepsy", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "chlorotoxin", "mediator_canonical": "MMP2", "outcome_canonical": "epilepsy", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41955189", "title": "Chlorotoxin does not target matrix metalloproteinase-2 in glioblastoma", "doi": "10.1371/journal.pone.0328964", "year": 2026 } ], "bc": [ { "pmid": "36766708", "title": "Blood-Brain Barrier-Associated Proteins Are Elevated in Serum of Epilepsy Patients", "doi": "10.3390/cells12030368", "year": 2023 } ] } }, { "id": 4398, "drug": "durvalumab", "drug_type": "drug", "drug_domain": "pancreatic_cancer", "predicate_ab": "inhibits", "mediator": "PD-L1", "mediator_type": "protein", "predicate_bc": "predicts", "outcome": "treatment resistance", "outcome_type": "phenotype", "outcome_domain": "glioblastoma", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "active", "clinical_trial_nct_ids": [ "NCT02966587", "NCT07288034", "NCT07174570" ], "literature_status": "reproduces_known", "drug_canonical": "durvalumab", "mediator_canonical": "PD-L1", "outcome_canonical": "treatment resistance", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37452505", "title": "Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: An early exploratory analysis of real‐world data", "doi": "10.1111/liv.15641", "year": 2023 }, { "pmid": "33688022", "title": "Safety and activity of the TGFβ receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer", "doi": "10.1136/jitc-2020-002068", "year": 2021 }, { "pmid": "31230047", "title": "A Phase 1b/2 Study of the Bruton Tyrosine Kinase Inhibitor Ibrutinib and the PD-L1 Inhibitor Durvalumab in Patients with Pretreated Solid Tumors", "doi": "10.1159/000500571", "year": 2019 } ], "bc": [ { "pmid": "31926117", "title": "Anti‐tumour immune response in GL261 glioblastoma generated by Temozolomide Immune‐Enhancing Metronomic Schedule monitored with MRSI‐based nosological images", "doi": "10.1002/nbm.4229", "year": 2020 } ] } }, { "id": 4389, "drug": "durvalumab", "drug_type": "drug", "drug_domain": "pancreatic_cancer", "predicate_ab": "inhibits", "mediator": "PD-L1", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "longer survival", "outcome_type": "phenotype", "outcome_domain": "glioblastoma", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "durvalumab", "mediator_canonical": "PD-L1", "outcome_canonical": "longer survival", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37452505", "title": "Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: An early exploratory analysis of real‐world data", "doi": "10.1111/liv.15641", "year": 2023 }, { "pmid": "33688022", "title": "Safety and activity of the TGFβ receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer", "doi": "10.1136/jitc-2020-002068", "year": 2021 }, { "pmid": "31230047", "title": "A Phase 1b/2 Study of the Bruton Tyrosine Kinase Inhibitor Ibrutinib and the PD-L1 Inhibitor Durvalumab in Patients with Pretreated Solid Tumors", "doi": "10.1159/000500571", "year": 2019 } ], "bc": [ { "pmid": "37605497", "title": "Epigenetic Regulation of the Expression of T Cell Stimulatory and Inhibitory Factors by Histone H3 Lysine Modification Enzymes and Its Prognostic Roles in Glioblastoma", "doi": "10.3346/jkms.2023.38.e258", "year": 2023 } ] } }, { "id": 4386, "drug": "durvalumab", "drug_type": "drug", "drug_domain": "pancreatic_cancer", "predicate_ab": "inhibits", "mediator": "PD-L1", "mediator_type": "protein", "predicate_bc": "predicts", "outcome": "prognosis", "outcome_type": "phenotype", "outcome_domain": "glioblastoma", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "active", "clinical_trial_nct_ids": [ "NCT06702566" ], "literature_status": "reproduces_known", "drug_canonical": "durvalumab", "mediator_canonical": "PD-L1", "outcome_canonical": null, "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37452505", "title": "Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: An early exploratory analysis of real‐world data", "doi": "10.1111/liv.15641", "year": 2023 }, { "pmid": "33688022", "title": "Safety and activity of the TGFβ receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer", "doi": "10.1136/jitc-2020-002068", "year": 2021 }, { "pmid": "31230047", "title": "A Phase 1b/2 Study of the Bruton Tyrosine Kinase Inhibitor Ibrutinib and the PD-L1 Inhibitor Durvalumab in Patients with Pretreated Solid Tumors", "doi": "10.1159/000500571", "year": 2019 } ], "bc": [ { "pmid": "34638219", "title": "Immunohistochemical expression of programmed death-ligand 1 and CD8 in glioblastomas", "doi": "10.4132/jptm.2021.08.04", "year": 2021 } ] } }, { "id": 4392, "drug": "durvalumab", "drug_type": "drug", "drug_domain": "pancreatic_cancer", "predicate_ab": "inhibits", "mediator": "PD-L1", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "clinical response", "outcome_type": "phenotype", "outcome_domain": "glioblastoma", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "completed", "clinical_trial_nct_ids": [ "NCT03871036" ], "literature_status": "reproduces_known", "drug_canonical": "durvalumab", "mediator_canonical": "PD-L1", "outcome_canonical": null, "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37452505", "title": "Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: An early exploratory analysis of real‐world data", "doi": "10.1111/liv.15641", "year": 2023 }, { "pmid": "33688022", "title": "Safety and activity of the TGFβ receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer", "doi": "10.1136/jitc-2020-002068", "year": 2021 }, { "pmid": "31230047", "title": "A Phase 1b/2 Study of the Bruton Tyrosine Kinase Inhibitor Ibrutinib and the PD-L1 Inhibitor Durvalumab in Patients with Pretreated Solid Tumors", "doi": "10.1159/000500571", "year": 2019 } ], "bc": [ { "pmid": "31929892", "title": "Impact of pre‐therapy glioblastoma multiforme microenvironment on clinical response to autologous CMV‐specific T‐cell therapy", "doi": "10.1002/cti2.1088", "year": 2019 } ] } }, { "id": 4458, "drug": "oleandrin", "drug_type": "drug", "drug_domain": "pancreatic_cancer", "predicate_ab": "downregulates", "mediator": "mTOR", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "glioblastoma", "outcome_type": "disease", "outcome_domain": "glioblastoma", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "oleandrin", "mediator_canonical": "mTOR", "outcome_canonical": "glioblastoma", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "32452588", "title": "A Phase II, Single-Arm, Open-Label, Bayesian Adaptive Efficacy and Safety Study of PBI-05204 in Patients with Stage IV Metastatic Pancreatic Adenocarcinoma", "doi": "10.1634/theoncologist.2020-0440", "year": 2020 } ], "bc": [ { "pmid": "39622049", "title": "A Dual-Target and Dual-Mechanism Design Strategy by Combining Inhibition and Degradation Together", "doi": "10.1021/jacs.4c11930", "year": 2024 }, { "pmid": "33162811", "title": "Mitochondrial dysfunction contributes to Rapamycin-induced apoptosis of Human Glioblastoma Cells - A synergistic effect with Temozolomide", "doi": "10.7150/ijms.40159", "year": 2020 }, { "pmid": "30793789", "title": "The effect of the mTOR inhibitor rapamycin on glucoCEST signal in a preclinical model of glioblastoma", "doi": "10.1002/mrm.27683", "year": 2019 } ] } }, { "id": 4401, "drug": "durvalumab", "drug_type": "drug", "drug_domain": "pancreatic_cancer", "predicate_ab": "inhibits", "mediator": "PD-L1", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "worse progression-free survival", "outcome_type": "phenotype", "outcome_domain": "glioblastoma", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "durvalumab", "mediator_canonical": "PD-L1", "outcome_canonical": "worse progression-free survival", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37452505", "title": "Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: An early exploratory analysis of real‐world data", "doi": "10.1111/liv.15641", "year": 2023 }, { "pmid": "33688022", "title": "Safety and activity of the TGFβ receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer", "doi": "10.1136/jitc-2020-002068", "year": 2021 }, { "pmid": "31230047", "title": "A Phase 1b/2 Study of the Bruton Tyrosine Kinase Inhibitor Ibrutinib and the PD-L1 Inhibitor Durvalumab in Patients with Pretreated Solid Tumors", "doi": "10.1159/000500571", "year": 2019 } ], "bc": [ { "pmid": "34638219", "title": "Immunohistochemical expression of programmed death-ligand 1 and CD8 in glioblastomas", "doi": "10.4132/jptm.2021.08.04", "year": 2021 } ] } }, { "id": 4400, "drug": "durvalumab", "drug_type": "drug", "drug_domain": "pancreatic_cancer", "predicate_ab": "inhibits", "mediator": "PD-L1", "mediator_type": "protein", "predicate_bc": "prevents", "outcome": "immune control", "outcome_type": "phenotype", "outcome_domain": "glioblastoma", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "completed", "clinical_trial_nct_ids": [ "NCT06274879", "NCT02125461", "NCT04447612" ], "literature_status": "partial_evidence", "drug_canonical": "durvalumab", "mediator_canonical": "PD-L1", "outcome_canonical": "immune control", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37452505", "title": "Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: An early exploratory analysis of real‐world data", "doi": "10.1111/liv.15641", "year": 2023 }, { "pmid": "33688022", "title": "Safety and activity of the TGFβ receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer", "doi": "10.1136/jitc-2020-002068", "year": 2021 }, { "pmid": "31230047", "title": "A Phase 1b/2 Study of the Bruton Tyrosine Kinase Inhibitor Ibrutinib and the PD-L1 Inhibitor Durvalumab in Patients with Pretreated Solid Tumors", "doi": "10.1159/000500571", "year": 2019 } ], "bc": [ { "pmid": "31929892", "title": "Impact of pre‐therapy glioblastoma multiforme microenvironment on clinical response to autologous CMV‐specific T‐cell therapy", "doi": "10.1002/cti2.1088", "year": 2019 } ] } }, { "id": 49008, "drug": "miR21ASO", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "inhibits", "mediator": "miR-21", "mediator_type": "gene", "predicate_bc": "increases", "outcome": "cardiac fibrosis", "outcome_type": "disease", "outcome_domain": "heart_failure", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "29340361", "title": "A curcumin-loaded polymeric micelle as a carrier of a microRNA-21 antisense-oligonucleotide for enhanced anti-tumor effects in a glioblastoma animal model", "doi": "10.1039/c7bm01088e", "year": 2018 } ], "bc": [ { "pmid": "33550817", "title": "MicroRNA-21–Dependent Macrophage-to-Fibroblast Signaling Determines the Cardiac Response to Pressure Overload", "doi": "10.1161/circulationaha.120.050682", "year": 2021 }, { "pmid": "33804922", "title": "Therapeutic miR-21 Silencing Reduces Cardiac Fibrosis and Modulates Inflammatory Response in Chronic Chagas Disease", "doi": "10.3390/ijms22073307", "year": 2021 }, { "pmid": "28335740", "title": "miR-21 enhances cardiac fibrotic remodeling and fibroblast proliferation via CADM1/STAT3 pathway", "doi": "10.1186/s12872-017-0520-7", "year": 2017 } ] } }, { "id": 49009, "drug": "antisense miR-21", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "inhibits", "mediator": "miR-21", "mediator_type": "gene", "predicate_bc": "increases", "outcome": "cardiac fibrosis", "outcome_type": "disease", "outcome_domain": "heart_failure", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "34641347", "title": "MicroRNA Delivery by Graphene-Based Complexes into Glioblastoma Cells", "doi": "10.3390/molecules26195804", "year": 2021 } ], "bc": [ { "pmid": "33550817", "title": "MicroRNA-21–Dependent Macrophage-to-Fibroblast Signaling Determines the Cardiac Response to Pressure Overload", "doi": "10.1161/circulationaha.120.050682", "year": 2021 }, { "pmid": "33804922", "title": "Therapeutic miR-21 Silencing Reduces Cardiac Fibrosis and Modulates Inflammatory Response in Chronic Chagas Disease", "doi": "10.3390/ijms22073307", "year": 2021 }, { "pmid": "28335740", "title": "miR-21 enhances cardiac fibrotic remodeling and fibroblast proliferation via CADM1/STAT3 pathway", "doi": "10.1186/s12872-017-0520-7", "year": 2017 } ] } }, { "id": 49010, "drug": "Chlorotoxin", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "binds_to", "mediator": "MMP-2", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "degree of kidney failure", "outcome_type": "phenotype", "outcome_domain": "heart_failure", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41955189", "title": "Chlorotoxin does not target matrix metalloproteinase-2 in glioblastoma", "doi": "10.1371/journal.pone.0328964", "year": 2026 } ], "bc": [ { "pmid": "29915813", "title": "MMP-2 and TIMP-2 in patients with heart failure and chronic kidney disease", "doi": "10.1515/med-2018-0037", "year": 2018 } ] } }, { "id": 49012, "drug": "AMO21", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "inhibits", "mediator": "miR-21", "mediator_type": "gene", "predicate_bc": "increases", "outcome": "cardiac fibrosis", "outcome_type": "disease", "outcome_domain": "heart_failure", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40838609", "title": "Targeted delivery of anti-microRNA-21 oligonucleotides using chlorotoxin-engineered extracellular vesicles for treatment of glioblastoma", "doi": "10.1080/1061186x.2025.2550594", "year": 2025 } ], "bc": [ { "pmid": "33550817", "title": "MicroRNA-21–Dependent Macrophage-to-Fibroblast Signaling Determines the Cardiac Response to Pressure Overload", "doi": "10.1161/circulationaha.120.050682", "year": 2021 }, { "pmid": "33804922", "title": "Therapeutic miR-21 Silencing Reduces Cardiac Fibrosis and Modulates Inflammatory Response in Chronic Chagas Disease", "doi": "10.3390/ijms22073307", "year": 2021 }, { "pmid": "28335740", "title": "miR-21 enhances cardiac fibrotic remodeling and fibroblast proliferation via CADM1/STAT3 pathway", "doi": "10.1186/s12872-017-0520-7", "year": 2017 } ] } }, { "id": 49013, "drug": "AMO21c", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "downregulates", "mediator": "miR-21", "mediator_type": "gene", "predicate_bc": "increases", "outcome": "cardiac fibrosis", "outcome_type": "disease", "outcome_domain": "heart_failure", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "36925699", "title": "Brain‐targeted exosome‐mimetic cell membrane nanovesicles with therapeutic oligonucleotides elicit anti‐tumor effects in glioblastoma animal models", "doi": "10.1002/btm2.10426", "year": 2022 } ], "bc": [ { "pmid": "33550817", "title": "MicroRNA-21–Dependent Macrophage-to-Fibroblast Signaling Determines the Cardiac Response to Pressure Overload", "doi": "10.1161/circulationaha.120.050682", "year": 2021 }, { "pmid": "33804922", "title": "Therapeutic miR-21 Silencing Reduces Cardiac Fibrosis and Modulates Inflammatory Response in Chronic Chagas Disease", "doi": "10.3390/ijms22073307", "year": 2021 }, { "pmid": "28335740", "title": "miR-21 enhances cardiac fibrotic remodeling and fibroblast proliferation via CADM1/STAT3 pathway", "doi": "10.1186/s12872-017-0520-7", "year": 2017 } ] } }, { "id": 49016, "drug": "Chlorotoxin", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "binds_to", "mediator": "MMP-2", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "ejection fraction", "outcome_type": "phenotype", "outcome_domain": "heart_failure", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41955189", "title": "Chlorotoxin does not target matrix metalloproteinase-2 in glioblastoma", "doi": "10.1371/journal.pone.0328964", "year": 2026 } ], "bc": [ { "pmid": "29915813", "title": "MMP-2 and TIMP-2 in patients with heart failure and chronic kidney disease", "doi": "10.1515/med-2018-0037", "year": 2018 } ] } }, { "id": 49017, "drug": "Chlorotoxin", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "binds_to", "mediator": "MMP-2", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "chronic kidney disease", "outcome_type": "disease", "outcome_domain": "heart_failure", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41955189", "title": "Chlorotoxin does not target matrix metalloproteinase-2 in glioblastoma", "doi": "10.1371/journal.pone.0328964", "year": 2026 } ], "bc": [ { "pmid": "29915813", "title": "MMP-2 and TIMP-2 in patients with heart failure and chronic kidney disease", "doi": "10.1515/med-2018-0037", "year": 2018 } ] } }, { "id": 49018, "drug": "Chlorotoxin", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "binds_to", "mediator": "MMP-2", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "global cardiac fibrosis", "outcome_type": "phenotype", "outcome_domain": "heart_failure", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41955189", "title": "Chlorotoxin does not target matrix metalloproteinase-2 in glioblastoma", "doi": "10.1371/journal.pone.0328964", "year": 2026 } ], "bc": [ { "pmid": "30413105", "title": "Combination of Plasma Biomarkers and Clinical Data for the Detection of Myocardial Fibrosis or Aggravation of Heart Failure Symptoms in Heart Failure with Preserved Ejection Fraction Patients", "doi": "10.3390/jcm7110427", "year": 2018 } ] } }, { "id": 49019, "drug": "Pt3glc", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "downregulates", "mediator": "SIRT3", "mediator_type": "protein", "predicate_bc": "decreases", "outcome": "oxidative stress", "outcome_type": "phenotype", "outcome_domain": "heart_failure", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "29336479", "title": "Inhibition of glycolytic metabolism in glioblastoma cells by Pt3glc combinated with PI3K inhibitor via SIRT3‐mediated mitochondrial and PI3K/Akt–MAPK pathway", "doi": "10.1002/jcp.26474", "year": 2018 } ], "bc": [ { "pmid": "37080445", "title": "Cardioprotective effect of ultrasound‐targeted destruction of Sirt3‐loaded cationic microbubbles in a large animal model of pathological cardiac hypertrophy", "doi": "10.1016/j.actbio.2023.04.020", "year": 2023 }, { "pmid": "33244875", "title": "Elabela may regulate SIRT3‐mediated inhibition of oxidative stress through Foxo3a deacetylation preventing diabetic‐induced myocardial injury", "doi": "10.1111/jcmm.16052", "year": 2020 }, { "pmid": "31318577", "title": "The nuclear and mitochondrial sirtuins, Sirt6 and Sirt3, regulate each other's activity and protect the heart from developing obesity‐mediated diabetic cardiomyopathy", "doi": "10.1096/fj.201900767r", "year": 2019 } ] } }, { "id": 4399, "drug": "durvalumab", "drug_type": "drug", "drug_domain": "pancreatic_cancer", "predicate_ab": "inhibits", "mediator": "PD-L1", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "Glioblastoma multiforme", "outcome_type": "disease", "outcome_domain": "glioblastoma", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "active", "clinical_trial_nct_ids": [ "NCT04521686", "NCT02866747", "NCT02336165" ], "literature_status": "novel_signal", "drug_canonical": "durvalumab", "mediator_canonical": "PD-L1", "outcome_canonical": "glioblastoma", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37452505", "title": "Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: An early exploratory analysis of real‐world data", "doi": "10.1111/liv.15641", "year": 2023 }, { "pmid": "33688022", "title": "Safety and activity of the TGFβ receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer", "doi": "10.1136/jitc-2020-002068", "year": 2021 }, { "pmid": "31230047", "title": "A Phase 1b/2 Study of the Bruton Tyrosine Kinase Inhibitor Ibrutinib and the PD-L1 Inhibitor Durvalumab in Patients with Pretreated Solid Tumors", "doi": "10.1159/000500571", "year": 2019 } ], "bc": [ { "pmid": "37529045", "title": "Plasma PD-L1 as a biomarker in the clinical management of glioblastoma multiforme—a retrospective cohort study", "doi": "10.3389/fimmu.2023.1202098", "year": 2023 } ] } }, { "id": 4393, "drug": "durvalumab", "drug_type": "drug", "drug_domain": "pancreatic_cancer", "predicate_ab": "inhibits", "mediator": "PD-L1", "mediator_type": "protein", "predicate_bc": "predicts", "outcome": "survival", "outcome_type": "phenotype", "outcome_domain": "glioblastoma", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "active", "clinical_trial_nct_ids": [ "NCT07235007", "NCT03164616", "NCT01993810" ], "literature_status": "reproduces_known", "drug_canonical": "durvalumab", "mediator_canonical": "PD-L1", "outcome_canonical": null, "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37452505", "title": "Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: An early exploratory analysis of real‐world data", "doi": "10.1111/liv.15641", "year": 2023 }, { "pmid": "33688022", "title": "Safety and activity of the TGFβ receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer", "doi": "10.1136/jitc-2020-002068", "year": 2021 }, { "pmid": "31230047", "title": "A Phase 1b/2 Study of the Bruton Tyrosine Kinase Inhibitor Ibrutinib and the PD-L1 Inhibitor Durvalumab in Patients with Pretreated Solid Tumors", "doi": "10.1159/000500571", "year": 2019 } ], "bc": [ { "pmid": "33990845", "title": "Expression and Prognostic Value of the Immune Checkpoints Galectin-9 and PD-L1 in Glioblastomas", "doi": "10.1093/jnen/nlab041", "year": 2021 } ] } }, { "id": 9423, "drug": "ZQJ29", "drug_type": "drug", "drug_domain": "pancreatic_cancer", "predicate_ab": "upregulates", "mediator": "TP53", "mediator_type": "gene", "predicate_bc": "associated_with", "outcome": "glioblastoma", "outcome_type": "disease", "outcome_domain": "glioblastoma", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "zqj29", "mediator_canonical": "TP53", "outcome_canonical": "glioblastoma", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40387570", "title": "Novel Cyano‐Artemisinin Dimer ZQJ29 Targets PARP1 to Induce Ferroptosis in Pancreatic Cancer Treatment", "doi": "10.1002/advs.202501935", "year": 2025 } ], "bc": [ { "pmid": "38473403", "title": "Haploinsufficiency of Adenomatous Polyposis Coli Coupled with Kirsten Rat Sarcoma Viral Oncogene Homologue Activation and P53 Loss Provokes High-Grade Glioblastoma Formation in Mice", "doi": "10.3390/cancers16051046", "year": 2024 }, { "pmid": "39611928", "title": "Bioinformatics Examination of Glioblastoma Identifies a Potential Panel of Therapeutic Biomarkers", "doi": "10.31557/apjcp.2024.25.11.4035", "year": 2024 }, { "pmid": "37140883", "title": "Genome-wide profiling of patient-derived glioblastoma stem-like cells reveals recurrent genetic and transcriptomic signatures associated with brain tumors", "doi": "10.1007/s11060-023-04287-6", "year": 2023 } ] } }, { "id": 31348, "drug": "paroxetine", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "downregulates", "mediator": "MMP-9", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "ulcerative colitis", "outcome_type": "disease", "outcome_domain": "inflammatory_bowel_disease", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "paroxetine", "mediator_canonical": "MMP9", "outcome_canonical": "ulcerative colitis", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41698807", "title": "Targeting of HSP27 and MMP-2/9 Crosstalk by High-Throughput Drug Repurposing Strategies Identifies Paroxetine as a Potential Candidate in Glioblastoma", "doi": "10.1021/acs.jmedchem.5c03278", "year": 2026 } ], "bc": [ { "pmid": "35566780", "title": "Are Matrix Metalloproteinase-9 and Tissue Inhibitor of Metalloproteinase-1 Useful as Markers in Diagnostic Management of Children with Newly Diagnosed Ulcerative Colitis?", "doi": "10.3390/jcm11092655", "year": 2022 }, { "pmid": "27034654", "title": "Expressions of Matrix Metalloproteinases (MMP-2, MMP-7, and MMP-9) and Their Inhibitors (TIMP-1, TIMP-2) in Inflammatory Bowel Diseases", "doi": "10.1155/2016/2456179", "year": 2016 }, { "pmid": "26514773", "title": "Matrix metalloproteinase 9-induced increase in intestinal epithelial tight junction permeability contributes to the severity of experimental DSS colitis", "doi": "10.1152/ajpgi.00256.2015", "year": 2015 } ] } }, { "id": 6124, "drug": "Chlorotoxin", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "binds_to", "mediator": "MMP-2", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "female gender", "outcome_type": "phenotype", "outcome_domain": "pancreatic_cancer", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "chlorotoxin", "mediator_canonical": "MMP2", "outcome_canonical": "female gender", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41955189", "title": "Chlorotoxin does not target matrix metalloproteinase-2 in glioblastoma", "doi": "10.1371/journal.pone.0328964", "year": 2026 } ], "bc": [ { "pmid": "27429508", "title": "Expressions of Matrix Metalloproteinases 2, 7, and 9 in Carcinogenesis of Pancreatic Ductal Adenocarcinoma", "doi": "10.1155/2016/9895721", "year": 2016 } ] } }, { "id": 1636, "drug": "LASSBio-1971", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "inhibits", "mediator": "EGFR", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "pancreatic ductal adenocarcinoma", "outcome_type": "disease", "outcome_domain": "pancreatic_cancer", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "lassbio-1971", "mediator_canonical": "EGFR", "outcome_canonical": "pancreatic ductal adenocarcinoma", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40650170", "title": "A Pharmacologic Approach Against Glioblastoma—A Synergistic Combination of a Quinoxaline-Based and a PI3K/mTOR Dual Inhibitor", "doi": "10.3390/ijms26136392", "year": 2025 } ], "bc": [ { "pmid": "40130819", "title": "Identification of Tumor‐Specific Surface Proteins Enables Quantification of Extracellular Vesicle Subtypes for Early Detection of Pancreatic Ductal Adenocarcinoma", "doi": "10.1002/advs.202414982", "year": 2025 }, { "pmid": "31584260", "title": "Design and Evaluation of PEGylated Liposomal Formulation of a Novel Multikinase Inhibitor for Enhanced Chemosensitivity and Inhibition of Metastatic Pancreatic Ductal Adenocarcinoma", "doi": "10.1021/acs.bioconjchem.9b00632", "year": 2019 }, { "pmid": "26339400", "title": "EGFR expression in pancreatic intraepithelial neoplasia and ductal adenocarcinoma.", "doi": null, "year": 2015 } ] } }, { "id": 6156, "drug": "HFn-conjugated mAbs", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "binds_to", "mediator": "EGFR", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "pancreatic ductal adenocarcinoma", "outcome_type": "disease", "outcome_domain": "pancreatic_cancer", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "hfn-conjugated mabs", "mediator_canonical": "EGFR", "outcome_canonical": "pancreatic ductal adenocarcinoma", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "33544109", "title": "H-Ferritin nanoparticle-mediated delivery of antibodies across a BBB in vitro model for treatment of brain malignancies", "doi": "10.1039/d0bm01726d", "year": 2021 } ], "bc": [ { "pmid": "40130819", "title": "Identification of Tumor‐Specific Surface Proteins Enables Quantification of Extracellular Vesicle Subtypes for Early Detection of Pancreatic Ductal Adenocarcinoma", "doi": "10.1002/advs.202414982", "year": 2025 }, { "pmid": "31584260", "title": "Design and Evaluation of PEGylated Liposomal Formulation of a Novel Multikinase Inhibitor for Enhanced Chemosensitivity and Inhibition of Metastatic Pancreatic Ductal Adenocarcinoma", "doi": "10.1021/acs.bioconjchem.9b00632", "year": 2019 }, { "pmid": "26339400", "title": "EGFR expression in pancreatic intraepithelial neoplasia and ductal adenocarcinoma.", "doi": null, "year": 2015 } ] } }, { "id": 1618, "drug": "dual inhibitors", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "downregulates", "mediator": "EGFR", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "pancreatic ductal adenocarcinoma", "outcome_type": "disease", "outcome_domain": "pancreatic_cancer", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "preclinical_only", "clinical_trial_nct_ids": [ "NCT06813079" ], "literature_status": "partial_evidence", "drug_canonical": "dual inhibitors", "mediator_canonical": "EGFR", "outcome_canonical": "pancreatic ductal adenocarcinoma", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "35884571", "title": "Multi-Targeting Approach in Glioblastoma Using Computer-Assisted Drug Discovery Tools to Overcome the Blood–Brain Barrier and Target EGFR/PI3Kp110β Signaling", "doi": "10.3390/cancers14143506", "year": 2022 } ], "bc": [ { "pmid": "40130819", "title": "Identification of Tumor‐Specific Surface Proteins Enables Quantification of Extracellular Vesicle Subtypes for Early Detection of Pancreatic Ductal Adenocarcinoma", "doi": "10.1002/advs.202414982", "year": 2025 }, { "pmid": "31584260", "title": "Design and Evaluation of PEGylated Liposomal Formulation of a Novel Multikinase Inhibitor for Enhanced Chemosensitivity and Inhibition of Metastatic Pancreatic Ductal Adenocarcinoma", "doi": "10.1021/acs.bioconjchem.9b00632", "year": 2019 }, { "pmid": "26339400", "title": "EGFR expression in pancreatic intraepithelial neoplasia and ductal adenocarcinoma.", "doi": null, "year": 2015 } ] } }, { "id": 1613, "drug": "panitumumab-IRDye800", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "binds_to", "mediator": "EGFR", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "pancreatic ductal adenocarcinoma", "outcome_type": "disease", "outcome_domain": "pancreatic_cancer", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "panitumumab-irdye800", "mediator_canonical": "EGFR", "outcome_canonical": "pancreatic ductal adenocarcinoma", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "36284595", "title": "Fluorescence-guided craniotomy of glioblastoma using panitumumab-IRDye800", "doi": "10.3171/2021.10.focvid21201", "year": 2022 } ], "bc": [ { "pmid": "40130819", "title": "Identification of Tumor‐Specific Surface Proteins Enables Quantification of Extracellular Vesicle Subtypes for Early Detection of Pancreatic Ductal Adenocarcinoma", "doi": "10.1002/advs.202414982", "year": 2025 }, { "pmid": "31584260", "title": "Design and Evaluation of PEGylated Liposomal Formulation of a Novel Multikinase Inhibitor for Enhanced Chemosensitivity and Inhibition of Metastatic Pancreatic Ductal Adenocarcinoma", "doi": "10.1021/acs.bioconjchem.9b00632", "year": 2019 }, { "pmid": "26339400", "title": "EGFR expression in pancreatic intraepithelial neoplasia and ductal adenocarcinoma.", "doi": null, "year": 2015 } ] } }, { "id": 1616, "drug": "Isochaihulactone", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "binds_to", "mediator": "EGFR", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "pancreatic ductal adenocarcinoma", "outcome_type": "disease", "outcome_domain": "pancreatic_cancer", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "isochaihulactone", "mediator_canonical": "EGFR", "outcome_canonical": "pancreatic ductal adenocarcinoma", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "39720087", "title": "Integrative bioinformatic analysis to identify potential phytochemical candidates for glioblastoma", "doi": "10.1016/j.heliyon.2024.e40744", "year": 2024 } ], "bc": [ { "pmid": "40130819", "title": "Identification of Tumor‐Specific Surface Proteins Enables Quantification of Extracellular Vesicle Subtypes for Early Detection of Pancreatic Ductal Adenocarcinoma", "doi": "10.1002/advs.202414982", "year": 2025 }, { "pmid": "31584260", "title": "Design and Evaluation of PEGylated Liposomal Formulation of a Novel Multikinase Inhibitor for Enhanced Chemosensitivity and Inhibition of Metastatic Pancreatic Ductal Adenocarcinoma", "doi": "10.1021/acs.bioconjchem.9b00632", "year": 2019 }, { "pmid": "26339400", "title": "EGFR expression in pancreatic intraepithelial neoplasia and ductal adenocarcinoma.", "doi": null, "year": 2015 } ] } }, { "id": 1628, "drug": "mAb806", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "binds_to", "mediator": "EGFR", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "pancreatic ductal adenocarcinoma", "outcome_type": "disease", "outcome_domain": "pancreatic_cancer", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "mab806", "mediator_canonical": "EGFR", "outcome_canonical": "pancreatic ductal adenocarcinoma", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "31528699", "title": "Convergence of EGFR glioblastoma mutations: evolution and allostery rationalizing targeted therapy", "doi": "10.1080/23723556.2019.1630798", "year": 2019 } ], "bc": [ { "pmid": "40130819", "title": "Identification of Tumor‐Specific Surface Proteins Enables Quantification of Extracellular Vesicle Subtypes for Early Detection of Pancreatic Ductal Adenocarcinoma", "doi": "10.1002/advs.202414982", "year": 2025 }, { "pmid": "31584260", "title": "Design and Evaluation of PEGylated Liposomal Formulation of a Novel Multikinase Inhibitor for Enhanced Chemosensitivity and Inhibition of Metastatic Pancreatic Ductal Adenocarcinoma", "doi": "10.1021/acs.bioconjchem.9b00632", "year": 2019 }, { "pmid": "26339400", "title": "EGFR expression in pancreatic intraepithelial neoplasia and ductal adenocarcinoma.", "doi": null, "year": 2015 } ] } }, { "id": 6123, "drug": "Chlorotoxin", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "binds_to", "mediator": "MMP-2", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "histopathological type of cancer", "outcome_type": "phenotype", "outcome_domain": "pancreatic_cancer", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "chlorotoxin", "mediator_canonical": "MMP2", "outcome_canonical": "histopathological type of cancer", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41955189", "title": "Chlorotoxin does not target matrix metalloproteinase-2 in glioblastoma", "doi": "10.1371/journal.pone.0328964", "year": 2026 } ], "bc": [ { "pmid": "27429508", "title": "Expressions of Matrix Metalloproteinases 2, 7, and 9 in Carcinogenesis of Pancreatic Ductal Adenocarcinoma", "doi": "10.1155/2016/9895721", "year": 2016 } ] } }, { "id": 1620, "drug": "modotuximab", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "binds_to", "mediator": "EGFR", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "pancreatic ductal adenocarcinoma", "outcome_type": "disease", "outcome_domain": "pancreatic_cancer", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "modotuximab", "mediator_canonical": "EGFR", "outcome_canonical": "pancreatic ductal adenocarcinoma", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "29564747", "title": "Sym004-induced EGFR elimination is associated with profound anti-tumor activity in EGFRvIII patient-derived glioblastoma models", "doi": "10.1007/s11060-018-2832-6", "year": 2018 } ], "bc": [ { "pmid": "40130819", "title": "Identification of Tumor‐Specific Surface Proteins Enables Quantification of Extracellular Vesicle Subtypes for Early Detection of Pancreatic Ductal Adenocarcinoma", "doi": "10.1002/advs.202414982", "year": 2025 }, { "pmid": "31584260", "title": "Design and Evaluation of PEGylated Liposomal Formulation of a Novel Multikinase Inhibitor for Enhanced Chemosensitivity and Inhibition of Metastatic Pancreatic Ductal Adenocarcinoma", "doi": "10.1021/acs.bioconjchem.9b00632", "year": 2019 }, { "pmid": "26339400", "title": "EGFR expression in pancreatic intraepithelial neoplasia and ductal adenocarcinoma.", "doi": null, "year": 2015 } ] } }, { "id": 1572, "drug": "dacomitinib", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "inhibits", "mediator": "EGFR", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "pancreatic ductal adenocarcinoma", "outcome_type": "disease", "outcome_domain": "pancreatic_cancer", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "dacomitinib", "mediator_canonical": "EGFR", "outcome_canonical": "pancreatic ductal adenocarcinoma", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37811539", "title": "Longitudinal analysis of serum-derived extracellular vesicle RNA to monitor dacomitinib treatment response in EGFR-amplified recurrent glioblastoma patients", "doi": "10.1093/noajnl/vdad104", "year": 2023 } ], "bc": [ { "pmid": "40130819", "title": "Identification of Tumor‐Specific Surface Proteins Enables Quantification of Extracellular Vesicle Subtypes for Early Detection of Pancreatic Ductal Adenocarcinoma", "doi": "10.1002/advs.202414982", "year": 2025 }, { "pmid": "31584260", "title": "Design and Evaluation of PEGylated Liposomal Formulation of a Novel Multikinase Inhibitor for Enhanced Chemosensitivity and Inhibition of Metastatic Pancreatic Ductal Adenocarcinoma", "doi": "10.1021/acs.bioconjchem.9b00632", "year": 2019 }, { "pmid": "26339400", "title": "EGFR expression in pancreatic intraepithelial neoplasia and ductal adenocarcinoma.", "doi": null, "year": 2015 } ] } }, { "id": 6108, "drug": "Chlorotoxin", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "binds_to", "mediator": "MMP-2", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "inflammation", "outcome_type": "phenotype", "outcome_domain": "pancreatic_cancer", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "chlorotoxin", "mediator_canonical": "MMP2", "outcome_canonical": null, "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41955189", "title": "Chlorotoxin does not target matrix metalloproteinase-2 in glioblastoma", "doi": "10.1371/journal.pone.0328964", "year": 2026 } ], "bc": [ { "pmid": "27429508", "title": "Expressions of Matrix Metalloproteinases 2, 7, and 9 in Carcinogenesis of Pancreatic Ductal Adenocarcinoma", "doi": "10.1155/2016/9895721", "year": 2016 } ] } }, { "id": 6132, "drug": "Cetuximab-Chlorin e6 conjugate", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "binds_to", "mediator": "EGFR", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "pancreatic ductal adenocarcinoma", "outcome_type": "disease", "outcome_domain": "pancreatic_cancer", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "cetuximab-chlorin e6 conjugate", "mediator_canonical": "EGFR", "outcome_canonical": "pancreatic ductal adenocarcinoma", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40052329", "title": "Multiprobe Photoproximity Labeling of the EGFR Interactome in Glioblastoma Using Red-Light", "doi": "10.1021/jacs.4c15537", "year": 2025 } ], "bc": [ { "pmid": "40130819", "title": "Identification of Tumor‐Specific Surface Proteins Enables Quantification of Extracellular Vesicle Subtypes for Early Detection of Pancreatic Ductal Adenocarcinoma", "doi": "10.1002/advs.202414982", "year": 2025 }, { "pmid": "31584260", "title": "Design and Evaluation of PEGylated Liposomal Formulation of a Novel Multikinase Inhibitor for Enhanced Chemosensitivity and Inhibition of Metastatic Pancreatic Ductal Adenocarcinoma", "doi": "10.1021/acs.bioconjchem.9b00632", "year": 2019 }, { "pmid": "26339400", "title": "EGFR expression in pancreatic intraepithelial neoplasia and ductal adenocarcinoma.", "doi": null, "year": 2015 } ] } }, { "id": 1602, "drug": "PU-H71", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "downregulates", "mediator": "EGFR", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "pancreatic ductal adenocarcinoma", "outcome_type": "disease", "outcome_domain": "pancreatic_cancer", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "pu-h71", "mediator_canonical": "EGFR", "outcome_canonical": "pancreatic ductal adenocarcinoma", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "39682123", "title": "Epichaperome Inhibition by PU-H71-Mediated Targeting of HSP90 Sensitizes Glioblastoma Cells to Alkylator-Induced DNA Damage", "doi": "10.3390/cancers16233934", "year": 2024 } ], "bc": [ { "pmid": "40130819", "title": "Identification of Tumor‐Specific Surface Proteins Enables Quantification of Extracellular Vesicle Subtypes for Early Detection of Pancreatic Ductal Adenocarcinoma", "doi": "10.1002/advs.202414982", "year": 2025 }, { "pmid": "31584260", "title": "Design and Evaluation of PEGylated Liposomal Formulation of a Novel Multikinase Inhibitor for Enhanced Chemosensitivity and Inhibition of Metastatic Pancreatic Ductal Adenocarcinoma", "doi": "10.1021/acs.bioconjchem.9b00632", "year": 2019 }, { "pmid": "26339400", "title": "EGFR expression in pancreatic intraepithelial neoplasia and ductal adenocarcinoma.", "doi": null, "year": 2015 } ] } }, { "id": 6110, "drug": "FB-GR20", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "binds_to", "mediator": "EGFR", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "pancreatic ductal adenocarcinoma", "outcome_type": "disease", "outcome_domain": "pancreatic_cancer", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "fb-gr20", "mediator_canonical": "EGFR", "outcome_canonical": "pancreatic ductal adenocarcinoma", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41473440", "title": "A PET-CT study of the uptake of labeled aptamers [18F]FB-Gol1 and [18F]FB-GR20 in rat 101.8 glioblastoma model", "doi": "10.3389/fonc.2025.1713181", "year": 2025 } ], "bc": [ { "pmid": "40130819", "title": "Identification of Tumor‐Specific Surface Proteins Enables Quantification of Extracellular Vesicle Subtypes for Early Detection of Pancreatic Ductal Adenocarcinoma", "doi": "10.1002/advs.202414982", "year": 2025 }, { "pmid": "31584260", "title": "Design and Evaluation of PEGylated Liposomal Formulation of a Novel Multikinase Inhibitor for Enhanced Chemosensitivity and Inhibition of Metastatic Pancreatic Ductal Adenocarcinoma", "doi": "10.1021/acs.bioconjchem.9b00632", "year": 2019 }, { "pmid": "26339400", "title": "EGFR expression in pancreatic intraepithelial neoplasia and ductal adenocarcinoma.", "doi": null, "year": 2015 } ] } }, { "id": 6147, "drug": "curcumin analogs", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "inhibits", "mediator": "EGFR", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "pancreatic ductal adenocarcinoma", "outcome_type": "disease", "outcome_domain": "pancreatic_cancer", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "curcumin analogs", "mediator_canonical": "EGFR", "outcome_canonical": "pancreatic ductal adenocarcinoma", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41918192", "title": "Curcumin Analogs in Glioblastoma Therapy: A Narrative Review", "doi": "10.2174/0109298673428440260303054650", "year": 2026 } ], "bc": [ { "pmid": "40130819", "title": "Identification of Tumor‐Specific Surface Proteins Enables Quantification of Extracellular Vesicle Subtypes for Early Detection of Pancreatic Ductal Adenocarcinoma", "doi": "10.1002/advs.202414982", "year": 2025 }, { "pmid": "31584260", "title": "Design and Evaluation of PEGylated Liposomal Formulation of a Novel Multikinase Inhibitor for Enhanced Chemosensitivity and Inhibition of Metastatic Pancreatic Ductal Adenocarcinoma", "doi": "10.1021/acs.bioconjchem.9b00632", "year": 2019 }, { "pmid": "26339400", "title": "EGFR expression in pancreatic intraepithelial neoplasia and ductal adenocarcinoma.", "doi": null, "year": 2015 } ] } }, { "id": 1575, "drug": "type-II kinase inhibitors", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "inhibits", "mediator": "EGFR", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "pancreatic ductal adenocarcinoma", "outcome_type": "disease", "outcome_domain": "pancreatic_cancer", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "preclinical_only", "clinical_trial_nct_ids": [ "NCT06813079" ], "literature_status": "novel_signal", "drug_canonical": "type-ii kinase inhibitors", "mediator_canonical": "EGFR", "outcome_canonical": "pancreatic ductal adenocarcinoma", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "31528699", "title": "Convergence of EGFR glioblastoma mutations: evolution and allostery rationalizing targeted therapy", "doi": "10.1080/23723556.2019.1630798", "year": 2019 } ], "bc": [ { "pmid": "40130819", "title": "Identification of Tumor‐Specific Surface Proteins Enables Quantification of Extracellular Vesicle Subtypes for Early Detection of Pancreatic Ductal Adenocarcinoma", "doi": "10.1002/advs.202414982", "year": 2025 }, { "pmid": "31584260", "title": "Design and Evaluation of PEGylated Liposomal Formulation of a Novel Multikinase Inhibitor for Enhanced Chemosensitivity and Inhibition of Metastatic Pancreatic Ductal Adenocarcinoma", "doi": "10.1021/acs.bioconjchem.9b00632", "year": 2019 }, { "pmid": "26339400", "title": "EGFR expression in pancreatic intraepithelial neoplasia and ductal adenocarcinoma.", "doi": null, "year": 2015 } ] } }, { "id": 1617, "drug": "futuximab", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "binds_to", "mediator": "EGFR", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "pancreatic ductal adenocarcinoma", "outcome_type": "disease", "outcome_domain": "pancreatic_cancer", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "futuximab", "mediator_canonical": "EGFR", "outcome_canonical": "pancreatic ductal adenocarcinoma", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "29564747", "title": "Sym004-induced EGFR elimination is associated with profound anti-tumor activity in EGFRvIII patient-derived glioblastoma models", "doi": "10.1007/s11060-018-2832-6", "year": 2018 } ], "bc": [ { "pmid": "40130819", "title": "Identification of Tumor‐Specific Surface Proteins Enables Quantification of Extracellular Vesicle Subtypes for Early Detection of Pancreatic Ductal Adenocarcinoma", "doi": "10.1002/advs.202414982", "year": 2025 }, { "pmid": "31584260", "title": "Design and Evaluation of PEGylated Liposomal Formulation of a Novel Multikinase Inhibitor for Enhanced Chemosensitivity and Inhibition of Metastatic Pancreatic Ductal Adenocarcinoma", "doi": "10.1021/acs.bioconjchem.9b00632", "year": 2019 }, { "pmid": "26339400", "title": "EGFR expression in pancreatic intraepithelial neoplasia and ductal adenocarcinoma.", "doi": null, "year": 2015 } ] } }, { "id": 1578, "drug": "Si306", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "downregulates", "mediator": "EGFR", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "pancreatic ductal adenocarcinoma", "outcome_type": "disease", "outcome_domain": "pancreatic_cancer", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "si306", "mediator_canonical": "EGFR", "outcome_canonical": "pancreatic ductal adenocarcinoma", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "32545852", "title": "Src Inhibitors Pyrazolo[3,4-d]pyrimidines, Si306 and Pro-Si306, Inhibit Focal Adhesion Kinase and Suppress Human Glioblastoma Invasion In Vitro and In Vivo", "doi": "10.3390/cancers12061570", "year": 2020 } ], "bc": [ { "pmid": "40130819", "title": "Identification of Tumor‐Specific Surface Proteins Enables Quantification of Extracellular Vesicle Subtypes for Early Detection of Pancreatic Ductal Adenocarcinoma", "doi": "10.1002/advs.202414982", "year": 2025 }, { "pmid": "31584260", "title": "Design and Evaluation of PEGylated Liposomal Formulation of a Novel Multikinase Inhibitor for Enhanced Chemosensitivity and Inhibition of Metastatic Pancreatic Ductal Adenocarcinoma", "doi": "10.1021/acs.bioconjchem.9b00632", "year": 2019 }, { "pmid": "26339400", "title": "EGFR expression in pancreatic intraepithelial neoplasia and ductal adenocarcinoma.", "doi": null, "year": 2015 } ] } }, { "id": 1580, "drug": "CCA-1.1", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "inhibits", "mediator": "EGFR", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "pancreatic ductal adenocarcinoma", "outcome_type": "disease", "outcome_domain": "pancreatic_cancer", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "cca-1.1", "mediator_canonical": "EGFR", "outcome_canonical": "pancreatic ductal adenocarcinoma", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "35977996", "title": "Identification of potential targets of the curcumin analog CCA-1.1 for glioblastoma treatment : integrated computational analysis and in vitro study", "doi": "10.1038/s41598-022-18348-9", "year": 2022 } ], "bc": [ { "pmid": "40130819", "title": "Identification of Tumor‐Specific Surface Proteins Enables Quantification of Extracellular Vesicle Subtypes for Early Detection of Pancreatic Ductal Adenocarcinoma", "doi": "10.1002/advs.202414982", "year": 2025 }, { "pmid": "31584260", "title": "Design and Evaluation of PEGylated Liposomal Formulation of a Novel Multikinase Inhibitor for Enhanced Chemosensitivity and Inhibition of Metastatic Pancreatic Ductal Adenocarcinoma", "doi": "10.1021/acs.bioconjchem.9b00632", "year": 2019 }, { "pmid": "26339400", "title": "EGFR expression in pancreatic intraepithelial neoplasia and ductal adenocarcinoma.", "doi": null, "year": 2015 } ] } }, { "id": 1586, "drug": "JIN-A02", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "inhibits", "mediator": "EGFR", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "pancreatic ductal adenocarcinoma", "outcome_type": "disease", "outcome_domain": "pancreatic_cancer", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "jin-a02", "mediator_canonical": "EGFR", "outcome_canonical": "pancreatic ductal adenocarcinoma", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41649868", "title": "JIN-A02, a Mutant-Selective Fourth-Generation EGFR Inhibitor, Overcomes C797S-Mediated Resistance and Demonstrates Intracranial Activity in NSCLC", "doi": "10.1158/1078-0432.ccr-25-3720", "year": 2026 } ], "bc": [ { "pmid": "40130819", "title": "Identification of Tumor‐Specific Surface Proteins Enables Quantification of Extracellular Vesicle Subtypes for Early Detection of Pancreatic Ductal Adenocarcinoma", "doi": "10.1002/advs.202414982", "year": 2025 }, { "pmid": "31584260", "title": "Design and Evaluation of PEGylated Liposomal Formulation of a Novel Multikinase Inhibitor for Enhanced Chemosensitivity and Inhibition of Metastatic Pancreatic Ductal Adenocarcinoma", "doi": "10.1021/acs.bioconjchem.9b00632", "year": 2019 }, { "pmid": "26339400", "title": "EGFR expression in pancreatic intraepithelial neoplasia and ductal adenocarcinoma.", "doi": null, "year": 2015 } ] } }, { "id": 6164, "drug": "AEV01", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "upregulates", "mediator": "TP53", "mediator_type": "gene", "predicate_bc": "prevents", "outcome": "pancreatic cancer", "outcome_type": "disease", "outcome_domain": "pancreatic_cancer", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "aev01", "mediator_canonical": "TP53", "outcome_canonical": "pancreatic cancer", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40011495", "title": "Anti-tumor efficacy and safety of AEV01 in preclinical glioblastoma and hepatocellular carcinoma models", "doi": "10.1038/s41598-025-89594-w", "year": 2025 } ], "bc": [ { "pmid": "36853374", "title": "Precision Oncology in Pancreatic Cancer: Experiences and Challenges of the CCCMunichLMU Molecular Tumor Board", "doi": "10.1007/s11523-023-00950-0", "year": 2023 }, { "pmid": "33350171", "title": "Genetic aberrations in Chinese pancreatic cancer patients and their association with anatomic location and disease outcomes", "doi": "10.1002/cam4.3679", "year": 2020 }, { "pmid": "27991926", "title": "Chronic inflammation initiates multiple forms of K-Ras-independent mouse pancreatic cancer in the absence of TP53", "doi": "10.1038/onc.2016.461", "year": 2016 } ] } }, { "id": 31937, "drug": "Siramesine", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "binds_to", "mediator": "STAT3", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "prurigo nodularis", "outcome_type": "disease", "outcome_domain": "rheumatoid_arthritis", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "siramesine", "mediator_canonical": "STAT3", "outcome_canonical": "prurigo nodularis", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40640878", "title": "Siramesine induced cell death of glioblastoma through inactivating the STAT3-MGMT signaling pathway", "doi": "10.1186/s12967-025-06693-y", "year": 2025 } ], "bc": [ { "pmid": "39912139", "title": "Translating tissue expression of STAT 1, 3 and 6 in prurigo nodularis to clinical efficacy of oral tofacitinib – A prospective single-arm investigational study", "doi": "10.25259/ijdvl_1017_2024", "year": 2025 }, { "pmid": "40162359", "title": "Successful Use of Tofacitinib in Paediatric Prurigo Nodularis: A Report of Four Cases", "doi": "10.4103/ijd.ijd_842_24", "year": 2025 }, { "pmid": "37521237", "title": "A case of recalcitrant prurigo nodularis with heightened expression of STAT 3 and STAT 6 and its dramatic response to tofacitinib", "doi": "10.4103/idoj.idoj_508_22", "year": 2023 } ] } }, { "id": 31959, "drug": "Chlorotoxin", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "binds_to", "mediator": "MMP-2", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "rheumatoid arthritis", "outcome_type": "disease", "outcome_domain": "rheumatoid_arthritis", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "chlorotoxin", "mediator_canonical": "MMP2", "outcome_canonical": "rheumatoid arthritis", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41955189", "title": "Chlorotoxin does not target matrix metalloproteinase-2 in glioblastoma", "doi": "10.1371/journal.pone.0328964", "year": 2026 } ], "bc": [ { "pmid": "35291607", "title": "HOTAIR and THRIL Long Non Coding RNAs and Their Target Genes in Rheumatoid Arthritis patients", "doi": "10.52547/rbmb.10.4.697", "year": 2022 } ] } }, { "id": 31939, "drug": "curcumin analogs", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "inhibits", "mediator": "STAT3", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "prurigo nodularis", "outcome_type": "disease", "outcome_domain": "rheumatoid_arthritis", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "curcumin analogs", "mediator_canonical": "STAT3", "outcome_canonical": "prurigo nodularis", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41918192", "title": "Curcumin Analogs in Glioblastoma Therapy: A Narrative Review", "doi": "10.2174/0109298673428440260303054650", "year": 2026 } ], "bc": [ { "pmid": "39912139", "title": "Translating tissue expression of STAT 1, 3 and 6 in prurigo nodularis to clinical efficacy of oral tofacitinib – A prospective single-arm investigational study", "doi": "10.25259/ijdvl_1017_2024", "year": 2025 }, { "pmid": "40162359", "title": "Successful Use of Tofacitinib in Paediatric Prurigo Nodularis: A Report of Four Cases", "doi": "10.4103/ijd.ijd_842_24", "year": 2025 }, { "pmid": "37521237", "title": "A case of recalcitrant prurigo nodularis with heightened expression of STAT 3 and STAT 6 and its dramatic response to tofacitinib", "doi": "10.4103/idoj.idoj_508_22", "year": 2023 } ] } }, { "id": 31957, "drug": "CHI3L1 inhibitor", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "inhibits", "mediator": "STAT3", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "prurigo nodularis", "outcome_type": "disease", "outcome_domain": "rheumatoid_arthritis", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "chi3l1 inhibitor", "mediator_canonical": "STAT3", "outcome_canonical": "prurigo nodularis", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41552549", "title": "Structure-Guided Discovery of CHI3L1 Inhibitors from Ultralarge Chemical Spaces for Glioblastoma Therapy", "doi": "10.1021/acsomega.5c08775", "year": 2025 } ], "bc": [ { "pmid": "39912139", "title": "Translating tissue expression of STAT 1, 3 and 6 in prurigo nodularis to clinical efficacy of oral tofacitinib – A prospective single-arm investigational study", "doi": "10.25259/ijdvl_1017_2024", "year": 2025 }, { "pmid": "40162359", "title": "Successful Use of Tofacitinib in Paediatric Prurigo Nodularis: A Report of Four Cases", "doi": "10.4103/ijd.ijd_842_24", "year": 2025 }, { "pmid": "37521237", "title": "A case of recalcitrant prurigo nodularis with heightened expression of STAT 3 and STAT 6 and its dramatic response to tofacitinib", "doi": "10.4103/idoj.idoj_508_22", "year": 2023 } ] } }, { "id": 31958, "drug": "Cucurbitacin B", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "suppresses", "mediator": "STAT3", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "prurigo nodularis", "outcome_type": "disease", "outcome_domain": "rheumatoid_arthritis", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "cucurbitacin b", "mediator_canonical": "STAT3", "outcome_canonical": "prurigo nodularis", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41145734", "title": "Cucurbitacin B suppresses glioblastoma via the STAT3/ROS/endoplasmic reticulum stress pathway", "doi": "10.1038/s41598-025-21526-0", "year": 2025 } ], "bc": [ { "pmid": "39912139", "title": "Translating tissue expression of STAT 1, 3 and 6 in prurigo nodularis to clinical efficacy of oral tofacitinib – A prospective single-arm investigational study", "doi": "10.25259/ijdvl_1017_2024", "year": 2025 }, { "pmid": "40162359", "title": "Successful Use of Tofacitinib in Paediatric Prurigo Nodularis: A Report of Four Cases", "doi": "10.4103/ijd.ijd_842_24", "year": 2025 }, { "pmid": "37521237", "title": "A case of recalcitrant prurigo nodularis with heightened expression of STAT 3 and STAT 6 and its dramatic response to tofacitinib", "doi": "10.4103/idoj.idoj_508_22", "year": 2023 } ] } }, { "id": 31960, "drug": "Gint4.T-STAT3", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "inhibits", "mediator": "STAT3", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "prurigo nodularis", "outcome_type": "disease", "outcome_domain": "rheumatoid_arthritis", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "gint4.t-stat3", "mediator_canonical": "STAT3", "outcome_canonical": "prurigo nodularis", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "32486489", "title": "Combined Targeting of Glioblastoma Stem-Like Cells by Neutralizing RNA-Bio-Drugs for STAT3", "doi": "10.3390/cancers12061434", "year": 2020 } ], "bc": [ { "pmid": "39912139", "title": "Translating tissue expression of STAT 1, 3 and 6 in prurigo nodularis to clinical efficacy of oral tofacitinib – A prospective single-arm investigational study", "doi": "10.25259/ijdvl_1017_2024", "year": 2025 }, { "pmid": "40162359", "title": "Successful Use of Tofacitinib in Paediatric Prurigo Nodularis: A Report of Four Cases", "doi": "10.4103/ijd.ijd_842_24", "year": 2025 }, { "pmid": "37521237", "title": "A case of recalcitrant prurigo nodularis with heightened expression of STAT 3 and STAT 6 and its dramatic response to tofacitinib", "doi": "10.4103/idoj.idoj_508_22", "year": 2023 } ] } }, { "id": 31950, "drug": "Vitexin", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "binds_to", "mediator": "STAT3", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "prurigo nodularis", "outcome_type": "disease", "outcome_domain": "rheumatoid_arthritis", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "vitexin", "mediator_canonical": "STAT3", "outcome_canonical": "prurigo nodularis", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "35281458", "title": "Effects of Vitexin, a Natural Flavonoid Glycoside, on the Proliferation, Invasion, and Apoptosis of Human U251 Glioblastoma Cells", "doi": "10.1155/2022/3129155", "year": 2022 } ], "bc": [ { "pmid": "39912139", "title": "Translating tissue expression of STAT 1, 3 and 6 in prurigo nodularis to clinical efficacy of oral tofacitinib – A prospective single-arm investigational study", "doi": "10.25259/ijdvl_1017_2024", "year": 2025 }, { "pmid": "40162359", "title": "Successful Use of Tofacitinib in Paediatric Prurigo Nodularis: A Report of Four Cases", "doi": "10.4103/ijd.ijd_842_24", "year": 2025 }, { "pmid": "37521237", "title": "A case of recalcitrant prurigo nodularis with heightened expression of STAT 3 and STAT 6 and its dramatic response to tofacitinib", "doi": "10.4103/idoj.idoj_508_22", "year": 2023 } ] } }, { "id": 31940, "drug": "5-AcTMF", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "downregulates", "mediator": "STAT3", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "prurigo nodularis", "outcome_type": "disease", "outcome_domain": "rheumatoid_arthritis", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "5-actmf", "mediator_canonical": "STAT3", "outcome_canonical": "prurigo nodularis", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "31323961", "title": "Blockade of STAT3 Signaling Contributes to Anticancer Effect of 5-Acetyloxy-6,7,8,4′-Tetra-Methoxyflavone, a Tangeretin Derivative, on Human Glioblastoma Multiforme Cells", "doi": "10.3390/ijms20133366", "year": 2019 } ], "bc": [ { "pmid": "39912139", "title": "Translating tissue expression of STAT 1, 3 and 6 in prurigo nodularis to clinical efficacy of oral tofacitinib – A prospective single-arm investigational study", "doi": "10.25259/ijdvl_1017_2024", "year": 2025 }, { "pmid": "40162359", "title": "Successful Use of Tofacitinib in Paediatric Prurigo Nodularis: A Report of Four Cases", "doi": "10.4103/ijd.ijd_842_24", "year": 2025 }, { "pmid": "37521237", "title": "A case of recalcitrant prurigo nodularis with heightened expression of STAT 3 and STAT 6 and its dramatic response to tofacitinib", "doi": "10.4103/idoj.idoj_508_22", "year": 2023 } ] } }, { "id": 31948, "drug": "sulfonamide inhibitors (AP-3, AP-6, AP-7)", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "inhibits", "mediator": "MMP3", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "Sarcopenia", "outcome_type": "phenotype", "outcome_domain": "rheumatoid_arthritis", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "unknown", "drug_canonical": "sulfonamide inhibitors (ap-3, ap-6, ap-7)", "mediator_canonical": "mmp3", "outcome_canonical": "sarcopenia", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "32156166", "title": "Examination of sulfonamide-based inhibitors of MMP3 using the conditioned media of invasive glioma cells", "doi": "10.1080/14756366.2020.1715387", "year": 2020 } ], "bc": [ { "pmid": "30187662", "title": "Matrix metalloprotease 3 is associated with sarcopenia in rheumatoid arthritis ‐ results from the CHIKARA study", "doi": "10.1111/1756-185x.13335", "year": 2018 } ] } }, { "id": 31942, "drug": "Pterostilbene", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "inhibits", "mediator": "STAT3", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "prurigo nodularis", "outcome_type": "disease", "outcome_domain": "rheumatoid_arthritis", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "pterostilbene", "mediator_canonical": "STAT3", "outcome_canonical": "prurigo nodularis", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40695147", "title": "Pterostilbene as a pyroptosis inducer and tumor microenvironment regulator inhibits glioblastoma and enhances the efficacy of immunotherapy", "doi": "10.1016/j.intimp.2025.115247", "year": 2025 } ], "bc": [ { "pmid": "39912139", "title": "Translating tissue expression of STAT 1, 3 and 6 in prurigo nodularis to clinical efficacy of oral tofacitinib – A prospective single-arm investigational study", "doi": "10.25259/ijdvl_1017_2024", "year": 2025 }, { "pmid": "40162359", "title": "Successful Use of Tofacitinib in Paediatric Prurigo Nodularis: A Report of Four Cases", "doi": "10.4103/ijd.ijd_842_24", "year": 2025 }, { "pmid": "37521237", "title": "A case of recalcitrant prurigo nodularis with heightened expression of STAT 3 and STAT 6 and its dramatic response to tofacitinib", "doi": "10.4103/idoj.idoj_508_22", "year": 2023 } ] } }, { "id": 8394, "drug": "STB-MP", "drug_type": "drug", "drug_domain": "alzheimer", "predicate_ab": "inhibits", "mediator": "mTOR", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "glioblastoma", "outcome_type": "disease", "outcome_domain": "glioblastoma", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "stb-mp", "mediator_canonical": "mTOR", "outcome_canonical": "glioblastoma", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "36903771", "title": "The Effect of a Novel Mica Nanoparticle, STB-MP, on an Alzheimer’s Disease Patient-Induced PSC-Derived Cortical Brain Organoid Model", "doi": "10.3390/nano13050893", "year": 2023 } ], "bc": [ { "pmid": "39622049", "title": "A Dual-Target and Dual-Mechanism Design Strategy by Combining Inhibition and Degradation Together", "doi": "10.1021/jacs.4c11930", "year": 2024 }, { "pmid": "33162811", "title": "Mitochondrial dysfunction contributes to Rapamycin-induced apoptosis of Human Glioblastoma Cells - A synergistic effect with Temozolomide", "doi": "10.7150/ijms.40159", "year": 2020 }, { "pmid": "30793789", "title": "The effect of the mTOR inhibitor rapamycin on glucoCEST signal in a preclinical model of glioblastoma", "doi": "10.1002/mrm.27683", "year": 2019 } ] } }, { "id": 32140, "drug": "Chlorotoxin", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "binds_to", "mediator": "MMP-2", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "central 24-h pulse pressure", "outcome_type": "phenotype", "outcome_domain": "type_2_diabetes", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "chlorotoxin", "mediator_canonical": "MMP2", "outcome_canonical": "central 24-h pulse pressure", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41955189", "title": "Chlorotoxin does not target matrix metalloproteinase-2 in glioblastoma", "doi": "10.1371/journal.pone.0328964", "year": 2026 } ], "bc": [ { "pmid": "29070037", "title": "Circulating matrix metalloproteinases are associated with arterial stiffness in patients with type 1 diabetes: pooled analysis of three cohort studies", "doi": "10.1186/s12933-017-0620-9", "year": 2017 } ] } }, { "id": 32136, "drug": "Chlorotoxin", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "binds_to", "mediator": "MMP-2", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "pre-hypertension", "outcome_type": "disease", "outcome_domain": "type_2_diabetes", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "chlorotoxin", "mediator_canonical": "MMP2", "outcome_canonical": "pre-hypertension", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41955189", "title": "Chlorotoxin does not target matrix metalloproteinase-2 in glioblastoma", "doi": "10.1371/journal.pone.0328964", "year": 2026 } ], "bc": [ { "pmid": "27490532", "title": "Serum Concentrations of Endothelin-1 and Matrix Metalloproteinases-2, -9 in Pre-Hypertensive and Hypertensive Patients with Type 2 Diabetes", "doi": "10.3390/ijms17081182", "year": 2016 } ] } }, { "id": 32141, "drug": "Chlorotoxin", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "binds_to", "mediator": "MMP-2", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "retinopathy", "outcome_type": "disease", "outcome_domain": "type_2_diabetes", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "chlorotoxin", "mediator_canonical": "MMP2", "outcome_canonical": "retinopathy", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41955189", "title": "Chlorotoxin does not target matrix metalloproteinase-2 in glioblastoma", "doi": "10.1371/journal.pone.0328964", "year": 2026 } ], "bc": [ { "pmid": "25848912", "title": "Plasma levels of matrix metalloproteinase-2, -3, -10, and tissue inhibitor of metalloproteinase-1 are associated with vascular complications in patients with type 1 diabetes: the EURODIAB Prospective Complications Study", "doi": "10.1186/s12933-015-0195-2", "year": 2015 } ] } }, { "id": 32127, "drug": "Chlorotoxin", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "binds_to", "mediator": "MMP-2", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "office pulse pressure", "outcome_type": "phenotype", "outcome_domain": "type_2_diabetes", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "chlorotoxin", "mediator_canonical": "MMP2", "outcome_canonical": "office pulse pressure", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41955189", "title": "Chlorotoxin does not target matrix metalloproteinase-2 in glioblastoma", "doi": "10.1371/journal.pone.0328964", "year": 2026 } ], "bc": [ { "pmid": "29070037", "title": "Circulating matrix metalloproteinases are associated with arterial stiffness in patients with type 1 diabetes: pooled analysis of three cohort studies", "doi": "10.1186/s12933-017-0620-9", "year": 2017 } ] } }, { "id": 8615, "drug": "CLR01", "drug_type": "drug", "drug_domain": "alzheimer", "predicate_ab": "binds_to", "mediator": "TAU", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "glucose metabolism", "outcome_type": "phenotype", "outcome_domain": "epilepsy", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "clr01", "mediator_canonical": "MAPT", "outcome_canonical": "glucose metabolism", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "31046227", "title": "Major Differences between the Self-Assembly and Seeding Behavior of Heparin-Induced and in Vitro Phosphorylated Tau and Their Modulation by Potential Inhibitors", "doi": "10.1021/acschembio.9b00325", "year": 2019 }, { "pmid": "30062477", "title": "Native Top-Down Mass Spectrometry and Ion Mobility Spectrometry of the Interaction of Tau Protein with a Molecular Tweezer Assembly Modulator", "doi": "10.1007/s13361-018-2027-6", "year": 2018 } ], "bc": [ { "pmid": "31584490", "title": "In Vivo Assessment of Tau Deposition in Alzheimer Disease and Assessing Its Relationship to Regional Brain Glucose Metabolism and Cognition", "doi": "10.1097/rlu.0000000000002791", "year": 2019 } ] } }, { "id": 4397, "drug": "durvalumab", "drug_type": "drug", "drug_domain": "pancreatic_cancer", "predicate_ab": "inhibits", "mediator": "PD-L1", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "worse overall survival", "outcome_type": "phenotype", "outcome_domain": "glioblastoma", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "durvalumab", "mediator_canonical": "PD-L1", "outcome_canonical": null, "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37452505", "title": "Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: An early exploratory analysis of real‐world data", "doi": "10.1111/liv.15641", "year": 2023 }, { "pmid": "33688022", "title": "Safety and activity of the TGFβ receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer", "doi": "10.1136/jitc-2020-002068", "year": 2021 }, { "pmid": "31230047", "title": "A Phase 1b/2 Study of the Bruton Tyrosine Kinase Inhibitor Ibrutinib and the PD-L1 Inhibitor Durvalumab in Patients with Pretreated Solid Tumors", "doi": "10.1159/000500571", "year": 2019 } ], "bc": [ { "pmid": "34638219", "title": "Immunohistochemical expression of programmed death-ligand 1 and CD8 in glioblastomas", "doi": "10.4132/jptm.2021.08.04", "year": 2021 } ] } }, { "id": 23628, "drug": "pentamidine", "drug_type": "drug", "drug_domain": "multiple_sclerosis", "predicate_ab": "inhibits", "mediator": "S100B", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "lower cognitive performance", "outcome_type": "phenotype", "outcome_domain": "alzheimer", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "pentamidine", "mediator_canonical": "s100b", "outcome_canonical": "lower cognitive performance", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40649727", "title": "Effect on Different Glial Cell Types of S100B Modulation in Multiple Sclerosis Experimental Models", "doi": "10.3390/ijms26135948", "year": 2025 }, { "pmid": "35620168", "title": "S100B inhibition protects from chronic experimental autoimmune encephalomyelitis", "doi": "10.1093/braincomms/fcac076", "year": 2022 }, { "pmid": "32197530", "title": "The S100B Inhibitor Pentamidine Ameliorates Clinical Score and Neuropathology of Relapsing—Remitting Multiple Sclerosis Mouse Model", "doi": "10.3390/cells9030748", "year": 2020 } ], "bc": [ { "pmid": "31683478", "title": "Association of Cerebrospinal Fluid S100B Protein with Core Biomarkers and Cognitive Deficits in Prodromal and Mild Alzheimer’s Disease", "doi": "10.3233/jad-190550", "year": 2019 } ] } }, { "id": 50199, "drug": "folic acid", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "downregulates", "mediator": "IL-18", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "ALS", "outcome_type": "disease", "outcome_domain": "als", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "34692767", "title": "Folic Acid Alleviates High Glucose and Fat-Induced Pyroptosis via Inhibition of the Hippo Signal Pathway on H9C2 Cells", "doi": "10.3389/fmolb.2021.698698", "year": 2021 } ], "bc": [ { "pmid": "41789732", "title": "3D Artificial Skin Model As a Novel Strategy for the Detection of Pyroptosis-Cascade Activation in Amyotrophic Lateral Sclerosis", "doi": "10.1021/acsami.5c23366", "year": 2026 }, { "pmid": "32515902", "title": "Longitudinal biomarkers in amyotrophic lateral sclerosis", "doi": "10.1002/acn3.51078", "year": 2020 }, { "pmid": "29472887", "title": "A Possible Role for Platelet-Activating Factor Receptor in Amyotrophic Lateral Sclerosis Treatment", "doi": "10.3389/fneur.2018.00039", "year": 2018 } ] } }, { "id": 50216, "drug": "mangiferin", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "downregulates", "mediator": "RAGE", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "ALS", "outcome_type": "disease", "outcome_domain": "als", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "26751764", "title": "Mangiferin suppressed advanced glycation end products (AGEs) through NF-κB deactivation and displayed anti-inflammatory effects in streptozotocin and high fat diet-diabetic cardiomyopathy rats", "doi": "10.1139/cjpp-2015-0073", "year": 2015 } ], "bc": [ { "pmid": "35216298", "title": "The Involvement of RAGE and Its Ligands during Progression of ALS in SOD1 G93A Transgenic Mice", "doi": "10.3390/ijms23042184", "year": 2022 }, { "pmid": "27242430", "title": "Soluble RAGE Treatment Delays Progression of Amyotrophic Lateral Sclerosis in SOD1 Mice", "doi": "10.3389/fncel.2016.00117", "year": 2016 }, { "pmid": "26733811", "title": "Receptor for Advanced Glycation End Products and its Inflammatory Ligands are Upregulated in Amyotrophic Lateral Sclerosis", "doi": "10.3389/fncel.2015.00485", "year": 2015 } ] } }, { "id": 7259, "drug": "DPN", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "upregulates", "mediator": "BDNF", "mediator_type": "protein", "predicate_bc": "decreases", "outcome": "schizophrenia", "outcome_type": "disease", "outcome_domain": "depression", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "preclinical_only", "clinical_trial_nct_ids": [ "NCT05416658" ], "literature_status": "partial_evidence", "drug_canonical": "dpn", "mediator_canonical": "BDNF", "outcome_canonical": "schizophrenia", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "31608530", "title": "Oestrogen receptor ERα and ERβ agonists ameliorate oxidative brain injury and improve memory dysfunction in rats with an epileptic seizure", "doi": "10.1113/ep087986", "year": 2019 } ], "bc": [ { "pmid": "34280516", "title": "Associations of immunological proteins/traits with schizophrenia, major depression and bipolar disorder: A bi-directional two-sample mendelian randomization study", "doi": "10.1016/j.bbi.2021.07.009", "year": 2021 }, { "pmid": "30794585", "title": "Accuracy of brain-derived neurotrophic factor levels for differentiating between Taiwanese patients with major depressive disorder or schizophrenia and healthy controls", "doi": "10.1371/journal.pone.0212373", "year": 2019 } ] } }, { "id": 5919, "drug": "CGF-Conditioned Medium", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "upregulates", "mediator": "GFAP", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "cognitive impairment", "outcome_type": "phenotype", "outcome_domain": "alzheimer", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "cgf-conditioned medium", "mediator_canonical": "GFAP", "outcome_canonical": "cognitive impairment", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41154863", "title": "CGF-Conditioned Medium Modulates Astrocytic Differentiation and Invasiveness in U87MG Glioblastoma Cells", "doi": "10.3390/biology14101461", "year": 2025 } ], "bc": [ { "pmid": "36576155", "title": "Plasma glial fibrillary acidic protein in autosomal dominant Alzheimer's disease: Associations with Aβ‐PET, neurodegeneration, and cognition", "doi": "10.1002/alz.12879", "year": 2022 }, { "pmid": "32514860", "title": "Synaptic Loss, ER Stress and Neuro-Inflammation Emerge Late in the Lateral Temporal Cortex and Associate with Progressive Tau Pathology in Alzheimer’s Disease", "doi": "10.1007/s12035-020-01950-1", "year": 2020 }, { "pmid": "30594925", "title": "Glial Fibrillary Acidic Protein in Serum is Increased in Alzheimer’s Disease and Correlates with Cognitive Impairment", "doi": "10.3233/jad-180325", "year": 2018 } ] } }, { "id": 50403, "drug": "Urolithin A", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "activates", "mediator": "SIRT1", "mediator_type": "protein", "predicate_bc": "predicts", "outcome": "Alzheimer's disease", "outcome_type": "disease", "outcome_domain": "alzheimer", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "35241966", "title": "Urolithin A prevents streptozotocin-induced diabetic cardiomyopathy in rats by activating SIRT1", "doi": "10.1016/j.sjbs.2021.09.045", "year": 2021 } ], "bc": [ { "pmid": "37742223", "title": "Serum sirtuin1: a potential blood biomarker for early diagnosis of Alzheimer’s disease", "doi": "10.18632/aging.205015", "year": 2023 }, { "pmid": "30243024", "title": "Sirt1 enhances tau exon 10 inclusion and improves spatial memory of Htau mice", "doi": "10.18632/aging.101564", "year": 2018 } ] } }, { "id": 50406, "drug": "2-DG", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "upregulates", "mediator": "SIRT1", "mediator_type": "protein", "predicate_bc": "predicts", "outcome": "Alzheimer's disease", "outcome_type": "disease", "outcome_domain": "alzheimer", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "28368517", "title": "Enhanced Glycolytic Metabolism Contributes to Cardiac Dysfunction in Polymicrobial Sepsis", "doi": "10.1093/infdis/jix138", "year": 2017 } ], "bc": [ { "pmid": "37742223", "title": "Serum sirtuin1: a potential blood biomarker for early diagnosis of Alzheimer’s disease", "doi": "10.18632/aging.205015", "year": 2023 }, { "pmid": "30243024", "title": "Sirt1 enhances tau exon 10 inclusion and improves spatial memory of Htau mice", "doi": "10.18632/aging.101564", "year": 2018 } ] } }, { "id": 33527, "drug": "Shogaol", "drug_type": "drug", "drug_domain": "inflammatory_bowel_disease", "predicate_ab": "downregulates", "mediator": "EGFR", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "pancreatic ductal adenocarcinoma", "outcome_type": "disease", "outcome_domain": "pancreatic_cancer", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "shogaol", "mediator_canonical": "EGFR", "outcome_canonical": "pancreatic ductal adenocarcinoma", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "30524695", "title": "The possibility of using shogaol for treatment of ulcerative colitis.", "doi": "10.22038/ijbms.2018.28616.6932", "year": 2018 } ], "bc": [ { "pmid": "40130819", "title": "Identification of Tumor‐Specific Surface Proteins Enables Quantification of Extracellular Vesicle Subtypes for Early Detection of Pancreatic Ductal Adenocarcinoma", "doi": "10.1002/advs.202414982", "year": 2025 }, { "pmid": "31584260", "title": "Design and Evaluation of PEGylated Liposomal Formulation of a Novel Multikinase Inhibitor for Enhanced Chemosensitivity and Inhibition of Metastatic Pancreatic Ductal Adenocarcinoma", "doi": "10.1021/acs.bioconjchem.9b00632", "year": 2019 }, { "pmid": "26339400", "title": "EGFR expression in pancreatic intraepithelial neoplasia and ductal adenocarcinoma.", "doi": null, "year": 2015 } ] } }, { "id": 33531, "drug": "mesalazine", "drug_type": "drug", "drug_domain": "inflammatory_bowel_disease", "predicate_ab": "binds_to", "mediator": "EGFR", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "pancreatic ductal adenocarcinoma", "outcome_type": "disease", "outcome_domain": "pancreatic_cancer", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "mesalazine", "mediator_canonical": "EGFR", "outcome_canonical": "pancreatic ductal adenocarcinoma", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "35662946", "title": "Integrated Analysis Reveals the Targets and Mechanisms in Immunosuppressive Effect of Mesalazine on Ulcerative Colitis", "doi": "10.3389/fnut.2022.867692", "year": 2022 } ], "bc": [ { "pmid": "40130819", "title": "Identification of Tumor‐Specific Surface Proteins Enables Quantification of Extracellular Vesicle Subtypes for Early Detection of Pancreatic Ductal Adenocarcinoma", "doi": "10.1002/advs.202414982", "year": 2025 }, { "pmid": "31584260", "title": "Design and Evaluation of PEGylated Liposomal Formulation of a Novel Multikinase Inhibitor for Enhanced Chemosensitivity and Inhibition of Metastatic Pancreatic Ductal Adenocarcinoma", "doi": "10.1021/acs.bioconjchem.9b00632", "year": 2019 }, { "pmid": "26339400", "title": "EGFR expression in pancreatic intraepithelial neoplasia and ductal adenocarcinoma.", "doi": null, "year": 2015 } ] } }, { "id": 33537, "drug": "diosgenin", "drug_type": "drug", "drug_domain": "inflammatory_bowel_disease", "predicate_ab": "binds_to", "mediator": "EGFR", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "pancreatic ductal adenocarcinoma", "outcome_type": "disease", "outcome_domain": "pancreatic_cancer", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "diosgenin", "mediator_canonical": "EGFR", "outcome_canonical": "pancreatic ductal adenocarcinoma", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "39323838", "title": "Insights into diosgenin against inflammatory bowel disease as functional food based on network pharmacology and molecular docking", "doi": "10.1016/j.heliyon.2024.e37937", "year": 2024 } ], "bc": [ { "pmid": "40130819", "title": "Identification of Tumor‐Specific Surface Proteins Enables Quantification of Extracellular Vesicle Subtypes for Early Detection of Pancreatic Ductal Adenocarcinoma", "doi": "10.1002/advs.202414982", "year": 2025 }, { "pmid": "31584260", "title": "Design and Evaluation of PEGylated Liposomal Formulation of a Novel Multikinase Inhibitor for Enhanced Chemosensitivity and Inhibition of Metastatic Pancreatic Ductal Adenocarcinoma", "doi": "10.1021/acs.bioconjchem.9b00632", "year": 2019 }, { "pmid": "26339400", "title": "EGFR expression in pancreatic intraepithelial neoplasia and ductal adenocarcinoma.", "doi": null, "year": 2015 } ] } }, { "id": 8397, "drug": "Artemether", "drug_type": "drug", "drug_domain": "alzheimer", "predicate_ab": "downregulates", "mediator": "mTOR", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "glioblastoma", "outcome_type": "disease", "outcome_domain": "glioblastoma", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "artemether", "mediator_canonical": "mTOR", "outcome_canonical": "glioblastoma", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "34655202", "title": "Artemether Attenuates Aβ25-35-Induced Cognitive Impairments by Downregulating Aβ, BACE1, mTOR and Tau Proteins", "doi": "10.7754/clin.lab.2021.201212", "year": 2021 } ], "bc": [ { "pmid": "39622049", "title": "A Dual-Target and Dual-Mechanism Design Strategy by Combining Inhibition and Degradation Together", "doi": "10.1021/jacs.4c11930", "year": 2024 }, { "pmid": "33162811", "title": "Mitochondrial dysfunction contributes to Rapamycin-induced apoptosis of Human Glioblastoma Cells - A synergistic effect with Temozolomide", "doi": "10.7150/ijms.40159", "year": 2020 }, { "pmid": "30793789", "title": "The effect of the mTOR inhibitor rapamycin on glucoCEST signal in a preclinical model of glioblastoma", "doi": "10.1002/mrm.27683", "year": 2019 } ] } }, { "id": 50782, "drug": "salvianolic acid B", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "inhibits", "mediator": "HMGB1", "mediator_type": "protein", "predicate_bc": "predicts", "outcome": "drug-resistant epilepsy", "outcome_type": "disease", "outcome_domain": "epilepsy", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "31853618", "title": "Salvianolic acid B protects against myocardial ischaemia-reperfusion injury in rats via inhibiting high mobility group box 1 protein expression through the PI3K/Akt signalling pathway", "doi": "10.1007/s00210-019-01755-7", "year": 2019 } ], "bc": [ { "pmid": "34747496", "title": "High‐mobility group box 1 as a predictive biomarker for drug‐resistant epilepsy: A proof‐of‐concept study", "doi": "10.1111/epi.17116", "year": 2021 } ] } }, { "id": 50784, "drug": "Empagliflozin", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "downregulates", "mediator": "HMGB1", "mediator_type": "protein", "predicate_bc": "predicts", "outcome": "drug-resistant epilepsy", "outcome_type": "disease", "outcome_domain": "epilepsy", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "35156391", "title": "HMGB1‐Promoted Neutrophil Extracellular Traps Contribute to Cardiac Diastolic Dysfunction in Mice", "doi": "10.1161/jaha.121.023800", "year": 2022 } ], "bc": [ { "pmid": "34747496", "title": "High‐mobility group box 1 as a predictive biomarker for drug‐resistant epilepsy: A proof‐of‐concept study", "doi": "10.1111/epi.17116", "year": 2021 } ] } }, { "id": 50786, "drug": "Ang II", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "binds_to", "mediator": "P2X7R", "mediator_type": "protein", "predicate_bc": "increases", "outcome": "seizure severity", "outcome_type": "phenotype", "outcome_domain": "epilepsy", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "38626575", "title": "Angiotension II directly bind P2X7 receptor to induce myocardial ferroptosis and remodeling by activating human antigen R", "doi": "10.1016/j.redox.2024.103154", "year": 2024 } ], "bc": [ { "pmid": "36637008", "title": "The P2X7 receptor contributes to seizures and inflammation‐driven long‐lasting brain hyperexcitability following hypoxia in neonatal mice", "doi": "10.1111/bph.16033", "year": 2023 }, { "pmid": "36507708", "title": "Increased uptake of the P2X7 receptor radiotracer 18F‐JNJ‐64413739 in the brain and peripheral organs according to the severity of status epilepticus in male mice", "doi": "10.1111/epi.17484", "year": 2022 } ] } }, { "id": 50788, "drug": "DEX", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "inhibits", "mediator": "HMGB1", "mediator_type": "protein", "predicate_bc": "predicts", "outcome": "drug-resistant epilepsy", "outcome_type": "disease", "outcome_domain": "epilepsy", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "31344138", "title": "Dexmedetomidine-induced cardioprotection is mediated by inhibition of high mobility group box-1 and the cholinergic anti-inflammatory pathway in myocardial ischemia-reperfusion injury", "doi": "10.1371/journal.pone.0218726", "year": 2019 } ], "bc": [ { "pmid": "34747496", "title": "High‐mobility group box 1 as a predictive biomarker for drug‐resistant epilepsy: A proof‐of‐concept study", "doi": "10.1111/epi.17116", "year": 2021 } ] } }, { "id": 50790, "drug": "Ang II", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "binds_to", "mediator": "P2X7R", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "temporal lobe epilepsy", "outcome_type": "disease", "outcome_domain": "epilepsy", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "38626575", "title": "Angiotension II directly bind P2X7 receptor to induce myocardial ferroptosis and remodeling by activating human antigen R", "doi": "10.1016/j.redox.2024.103154", "year": 2024 } ], "bc": [ { "pmid": "36507708", "title": "Increased uptake of the P2X7 receptor radiotracer 18F‐JNJ‐64413739 in the brain and peripheral organs according to the severity of status epilepticus in male mice", "doi": "10.1111/epi.17484", "year": 2022 }, { "pmid": "34572093", "title": "Circulating P2X7 Receptor Signaling Components as Diagnostic Biomarkers for Temporal Lobe Epilepsy", "doi": "10.3390/cells10092444", "year": 2021 }, { "pmid": "31059094", "title": "Increased expression of the P2X7 receptor in temporal lobe epilepsy: Animal models and clinical evidence", "doi": "10.3892/mmr.2019.10202", "year": 2019 } ] } }, { "id": 6695, "drug": "zonisamide", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "downregulates", "mediator": "Cx43", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "glutamate-mediated motor neuron toxicity", "outcome_type": "phenotype", "outcome_domain": "als", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "zonisamide", "mediator_canonical": "GJA1", "outcome_canonical": "glutamate-mediated motor neuron toxicity", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "32516974", "title": "Effects of Carbamazepine, Lacosamide and Zonisamide on Gliotransmitter Release Associated with Activated Astroglial Hemichannels", "doi": "10.3390/ph13060117", "year": 2020 }, { "pmid": "32443400", "title": "Upregulated and Hyperactivated Thalamic Connexin 43 Plays Important Roles in Pathomechanisms of Cognitive Impairment and Seizure of Autosomal Dominant Sleep-Related Hypermotor Epilepsy with S284L-Mutant α4 Subunit of Nicotinic ACh Receptor", "doi": "10.3390/ph13050099", "year": 2020 } ], "bc": [ { "pmid": "41369341", "title": "Targeting Astrocytic Connexin 43 Mitigates Glutamate-Driven Motor Neuron Stress in Late-Onset Spinal Muscular Atrophy", "doi": "10.3390/cells14231852", "year": 2025 } ] } }, { "id": 1589, "drug": "Sym004", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "downregulates", "mediator": "EGFR", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "pancreatic ductal adenocarcinoma", "outcome_type": "disease", "outcome_domain": "pancreatic_cancer", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "sym004", "mediator_canonical": "EGFR", "outcome_canonical": "pancreatic ductal adenocarcinoma", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "29564747", "title": "Sym004-induced EGFR elimination is associated with profound anti-tumor activity in EGFRvIII patient-derived glioblastoma models", "doi": "10.1007/s11060-018-2832-6", "year": 2018 } ], "bc": [ { "pmid": "40130819", "title": "Identification of Tumor‐Specific Surface Proteins Enables Quantification of Extracellular Vesicle Subtypes for Early Detection of Pancreatic Ductal Adenocarcinoma", "doi": "10.1002/advs.202414982", "year": 2025 }, { "pmid": "31584260", "title": "Design and Evaluation of PEGylated Liposomal Formulation of a Novel Multikinase Inhibitor for Enhanced Chemosensitivity and Inhibition of Metastatic Pancreatic Ductal Adenocarcinoma", "doi": "10.1021/acs.bioconjchem.9b00632", "year": 2019 }, { "pmid": "26339400", "title": "EGFR expression in pancreatic intraepithelial neoplasia and ductal adenocarcinoma.", "doi": null, "year": 2015 } ] } }, { "id": 38771, "drug": "crocin", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "inhibits", "mediator": "IL-17", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "Crohn's disease", "outcome_type": "disease", "outcome_domain": "inflammatory_bowel_disease", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "crocin", "mediator_canonical": "il-17", "outcome_canonical": "crohn's disease", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "29540097", "title": "Crocin exerts anti-inflammatory and anti-arthritic effects on type II collagen-induced arthritis in rats", "doi": "10.1080/13880209.2018.1448874", "year": 2018 } ], "bc": [ { "pmid": "39803916", "title": "Correlation between IL-17 and inflammatory bowel disease", "doi": "10.55133/eji.320106", "year": 2025 }, { "pmid": "38229938", "title": "Crohn's disease and clinical management today: How it does?", "doi": "10.5662/wjm.v13.i5.399", "year": 2023 }, { "pmid": "28533995", "title": "Crohn’s Disease and Ulcerative Colitis Show Unique Cytokine Profiles", "doi": "10.7759/cureus.1177", "year": 2017 } ] } }, { "id": 2114, "drug": "perampanel", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "inhibits", "mediator": "AMPA receptors", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "motor neuron excitability", "outcome_type": "phenotype", "outcome_domain": "als", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "perampanel", "mediator_canonical": "ampa receptors", "outcome_canonical": "motor neuron excitability", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "38226351", "title": "Perampanel increases seizure threshold in pentylenetetrazole-kindled mice and improves behavioral dysfunctions by modifying mRNA expression levels of BDNF/TrkB and inflammatory markers", "doi": "10.1016/j.jsps.2023.101930", "year": 2023 }, { "pmid": "31565443", "title": "Super-Refractory Status Epilepticus Treated with High Dose Perampanel: Case Series and Review of the Literature", "doi": "10.1155/2019/3218231", "year": 2019 }, { "pmid": "30324610", "title": "Perampanel and decanoic acid show synergistic action against AMPA receptors and seizures", "doi": "10.1111/epi.14578", "year": 2018 } ], "bc": [ { "pmid": "34107252", "title": "Human amyotrophic lateral sclerosis excitability phenotype screen: Target discovery and validation", "doi": "10.1016/j.celrep.2021.109224", "year": 2021 } ] } }, { "id": 6920, "drug": "topiramate", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "downregulates", "mediator": "GFAP", "mediator_type": "protein", "predicate_bc": "predicts", "outcome": "cognitive decline", "outcome_type": "phenotype", "outcome_domain": "alzheimer", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "active", "clinical_trial_nct_ids": [ "NCT02670161", "NCT01889602", "NCT00731900" ], "literature_status": "reproduces_known", "drug_canonical": "topiramate", "mediator_canonical": "GFAP", "outcome_canonical": "cognitive decline", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "36978280", "title": "Topiramate affords neuroprotection in diabetic neuropathy model via downregulating spinal GFAP/inflammatory burden and improving neurofilament production", "doi": "10.1080/15376516.2023.2196687", "year": 2023 } ], "bc": [ { "pmid": "40110647", "title": "Exploratory analysis of the proteomic profile in plasma in adults with Down syndrome in the context of Alzheimer's disease", "doi": "10.1002/alz.70040", "year": 2025 }, { "pmid": "37787146", "title": "Longitudinal associations of serum biomarkers with early cognitive, amyloid and grey matter changes", "doi": "10.1093/brain/awad330", "year": 2023 }, { "pmid": "36446595", "title": "Longitudinal Changes in Blood Biomarkers of Clinical Alzheimer Disease in a Biracial Population Sample", "doi": "10.1212/wnl.0000000000201289", "year": 2022 } ] } }, { "id": 2351, "drug": "EGCG-SeNPs", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "downregulates", "mediator": "GFAP", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "cognitive impairment", "outcome_type": "phenotype", "outcome_domain": "alzheimer", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "egcg-senps", "mediator_canonical": "GFAP", "outcome_canonical": "cognitive impairment", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37509594", "title": "Biosynthesized Selenium Nanoparticles Using Epigallocatechin Gallate Protect against Pentylenetetrazole-Induced Acute Epileptic Seizures in Mice via Antioxidative, Anti-Inflammatory, and Anti-Apoptotic Activities", "doi": "10.3390/biomedicines11071955", "year": 2023 } ], "bc": [ { "pmid": "36576155", "title": "Plasma glial fibrillary acidic protein in autosomal dominant Alzheimer's disease: Associations with Aβ‐PET, neurodegeneration, and cognition", "doi": "10.1002/alz.12879", "year": 2022 }, { "pmid": "32514860", "title": "Synaptic Loss, ER Stress and Neuro-Inflammation Emerge Late in the Lateral Temporal Cortex and Associate with Progressive Tau Pathology in Alzheimer’s Disease", "doi": "10.1007/s12035-020-01950-1", "year": 2020 }, { "pmid": "30594925", "title": "Glial Fibrillary Acidic Protein in Serum is Increased in Alzheimer’s Disease and Correlates with Cognitive Impairment", "doi": "10.3233/jad-180325", "year": 2018 } ] } }, { "id": 2304, "drug": "EGCG-SeNPs", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "downregulates", "mediator": "GFAP", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "Alzheimer disease", "outcome_type": "disease", "outcome_domain": "alzheimer", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "egcg-senps", "mediator_canonical": "GFAP", "outcome_canonical": "Alzheimer disease", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37509594", "title": "Biosynthesized Selenium Nanoparticles Using Epigallocatechin Gallate Protect against Pentylenetetrazole-Induced Acute Epileptic Seizures in Mice via Antioxidative, Anti-Inflammatory, and Anti-Apoptotic Activities", "doi": "10.3390/biomedicines11071955", "year": 2023 } ], "bc": [ { "pmid": "41081630", "title": "Age-Specific Control and Alzheimer Disease Reference Curves and z -Scores for Glial Fibrillary Acidic Protein in Blood", "doi": "10.1093/clinchem/hvaf120", "year": 2025 }, { "pmid": "29755340", "title": "Glutamate Transporter GLT1 Expression in Alzheimer Disease and Dementia With Lewy Bodies", "doi": "10.3389/fnagi.2018.00122", "year": 2018 } ] } }, { "id": 3134, "drug": "A-1", "drug_type": "drug", "drug_domain": "als", "predicate_ab": "activates", "mediator": "SIRT1", "mediator_type": "protein", "predicate_bc": "predicts", "outcome": "Alzheimer's disease", "outcome_type": "disease", "outcome_domain": "alzheimer", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "active", "clinical_trial_nct_ids": [ "NCT01300728", "NCT07332377", "NCT06112860" ], "literature_status": "reproduces_known", "drug_canonical": "a-1", "mediator_canonical": "SIRT1", "outcome_canonical": "Alzheimer disease", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "38872258", "title": "Arctigenin derivative A‐1 ameliorates motor dysfunction and pathological manifestations in SOD1G93A transgenic mice via the AMPK/SIRT1/PGC‐1α and AMPK/SIRT1/IL‐1β/NF‐κB pathways", "doi": "10.1111/cns.14692", "year": 2024 } ], "bc": [ { "pmid": "37742223", "title": "Serum sirtuin1: a potential blood biomarker for early diagnosis of Alzheimer’s disease", "doi": "10.18632/aging.205015", "year": 2023 }, { "pmid": "30243024", "title": "Sirt1 enhances tau exon 10 inclusion and improves spatial memory of Htau mice", "doi": "10.18632/aging.101564", "year": 2018 } ] } }, { "id": 2697, "drug": "irisin", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "upregulates", "mediator": "BDNF", "mediator_type": "protein", "predicate_bc": "decreases", "outcome": "schizophrenia", "outcome_type": "disease", "outcome_domain": "depression", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "irisin", "mediator_canonical": "BDNF", "outcome_canonical": "schizophrenia", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "34658794", "title": "Neuroprotective Effects of Exogenous Irisin in Kainic Acid-Induced Status Epilepticus", "doi": "10.3389/fncel.2021.738533", "year": 2021 } ], "bc": [ { "pmid": "34280516", "title": "Associations of immunological proteins/traits with schizophrenia, major depression and bipolar disorder: A bi-directional two-sample mendelian randomization study", "doi": "10.1016/j.bbi.2021.07.009", "year": 2021 }, { "pmid": "30794585", "title": "Accuracy of brain-derived neurotrophic factor levels for differentiating between Taiwanese patients with major depressive disorder or schizophrenia and healthy controls", "doi": "10.1371/journal.pone.0212373", "year": 2019 } ] } }, { "id": 38774, "drug": "gp130 monoclonal antibody", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "downregulates", "mediator": "MMP-9", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "ulcerative colitis", "outcome_type": "disease", "outcome_domain": "inflammatory_bowel_disease", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "gp130 monoclonal antibody", "mediator_canonical": "MMP9", "outcome_canonical": "ulcerative colitis", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "33604457", "title": "The study of gp130/the inflammatory factors regulating osteoclast differentiation in rheumatoid arthritis", "doi": "10.1016/j.bbrep.2021.100934", "year": 2021 } ], "bc": [ { "pmid": "35566780", "title": "Are Matrix Metalloproteinase-9 and Tissue Inhibitor of Metalloproteinase-1 Useful as Markers in Diagnostic Management of Children with Newly Diagnosed Ulcerative Colitis?", "doi": "10.3390/jcm11092655", "year": 2022 }, { "pmid": "27034654", "title": "Expressions of Matrix Metalloproteinases (MMP-2, MMP-7, and MMP-9) and Their Inhibitors (TIMP-1, TIMP-2) in Inflammatory Bowel Diseases", "doi": "10.1155/2016/2456179", "year": 2016 }, { "pmid": "26514773", "title": "Matrix metalloproteinase 9-induced increase in intestinal epithelial tight junction permeability contributes to the severity of experimental DSS colitis", "doi": "10.1152/ajpgi.00256.2015", "year": 2015 } ] } }, { "id": 196, "drug": "zonisamide", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "downregulates", "mediator": "Cx43", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "chemotherapy resistance", "outcome_type": "phenotype", "outcome_domain": "glioblastoma", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "zonisamide", "mediator_canonical": "GJA1", "outcome_canonical": "chemotherapy resistance", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "32516974", "title": "Effects of Carbamazepine, Lacosamide and Zonisamide on Gliotransmitter Release Associated with Activated Astroglial Hemichannels", "doi": "10.3390/ph13060117", "year": 2020 }, { "pmid": "32443400", "title": "Upregulated and Hyperactivated Thalamic Connexin 43 Plays Important Roles in Pathomechanisms of Cognitive Impairment and Seizure of Autosomal Dominant Sleep-Related Hypermotor Epilepsy with S284L-Mutant α4 Subunit of Nicotinic ACh Receptor", "doi": "10.3390/ph13050099", "year": 2020 } ], "bc": [ { "pmid": "40379630", "title": "Cytoplasmic connexin43-microtubule interactions promote glioblastoma stem-like cell maintenance and tumorigenicity", "doi": "10.1038/s41419-025-07514-2", "year": 2025 } ] } }, { "id": 192, "drug": "zonisamide", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "downregulates", "mediator": "Cx43", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "glioma progression", "outcome_type": "disease", "outcome_domain": "glioblastoma", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "zonisamide", "mediator_canonical": "GJA1", "outcome_canonical": "glioma progression", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "32516974", "title": "Effects of Carbamazepine, Lacosamide and Zonisamide on Gliotransmitter Release Associated with Activated Astroglial Hemichannels", "doi": "10.3390/ph13060117", "year": 2020 }, { "pmid": "32443400", "title": "Upregulated and Hyperactivated Thalamic Connexin 43 Plays Important Roles in Pathomechanisms of Cognitive Impairment and Seizure of Autosomal Dominant Sleep-Related Hypermotor Epilepsy with S284L-Mutant α4 Subunit of Nicotinic ACh Receptor", "doi": "10.3390/ph13050099", "year": 2020 } ], "bc": [ { "pmid": "38489314", "title": "Integrating and optimizing tonabersat in standard glioblastoma therapy: A preclinical study", "doi": "10.1371/journal.pone.0300552", "year": 2024 } ] } }, { "id": 50973, "drug": "Tanshinone IIA", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "downregulates", "mediator": "mTOR", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "glioblastoma", "outcome_type": "disease", "outcome_domain": "glioblastoma", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "30798134", "title": "Tanshinone IIA protects against heart failure post-myocardial infarction via AMPKs/mTOR-dependent autophagy pathway", "doi": "10.1016/j.biopha.2019.108599", "year": 2019 } ], "bc": [ { "pmid": "39622049", "title": "A Dual-Target and Dual-Mechanism Design Strategy by Combining Inhibition and Degradation Together", "doi": "10.1021/jacs.4c11930", "year": 2024 }, { "pmid": "33162811", "title": "Mitochondrial dysfunction contributes to Rapamycin-induced apoptosis of Human Glioblastoma Cells - A synergistic effect with Temozolomide", "doi": "10.7150/ijms.40159", "year": 2020 }, { "pmid": "30793789", "title": "The effect of the mTOR inhibitor rapamycin on glucoCEST signal in a preclinical model of glioblastoma", "doi": "10.1002/mrm.27683", "year": 2019 } ] } }, { "id": 50976, "drug": "Danshensu", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "activates", "mediator": "mTOR", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "glioblastoma", "outcome_type": "disease", "outcome_domain": "glioblastoma", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "27385290", "title": "Danshensu alleviates cardiac ischaemia/reperfusion injury by inhibiting autophagy and apoptosis via activation of mTOR signalling", "doi": "10.1111/jcmm.12883", "year": 2016 } ], "bc": [ { "pmid": "39622049", "title": "A Dual-Target and Dual-Mechanism Design Strategy by Combining Inhibition and Degradation Together", "doi": "10.1021/jacs.4c11930", "year": 2024 }, { "pmid": "33162811", "title": "Mitochondrial dysfunction contributes to Rapamycin-induced apoptosis of Human Glioblastoma Cells - A synergistic effect with Temozolomide", "doi": "10.7150/ijms.40159", "year": 2020 }, { "pmid": "30793789", "title": "The effect of the mTOR inhibitor rapamycin on glucoCEST signal in a preclinical model of glioblastoma", "doi": "10.1002/mrm.27683", "year": 2019 } ] } }, { "id": 50977, "drug": "rapamycin", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "inhibits", "mediator": "mTOR", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "glioblastoma", "outcome_type": "disease", "outcome_domain": "glioblastoma", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "27694325", "title": "Rapamycin Attenuates Cardiac Fibrosis in Experimental Uremic Cardiomyopathy by Reducing Marinobufagenin Levels and Inhibiting Downstream Pro‐Fibrotic Signaling", "doi": "10.1161/jaha.116.004106", "year": 2016 } ], "bc": [ { "pmid": "39622049", "title": "A Dual-Target and Dual-Mechanism Design Strategy by Combining Inhibition and Degradation Together", "doi": "10.1021/jacs.4c11930", "year": 2024 }, { "pmid": "33162811", "title": "Mitochondrial dysfunction contributes to Rapamycin-induced apoptosis of Human Glioblastoma Cells - A synergistic effect with Temozolomide", "doi": "10.7150/ijms.40159", "year": 2020 }, { "pmid": "30793789", "title": "The effect of the mTOR inhibitor rapamycin on glucoCEST signal in a preclinical model of glioblastoma", "doi": "10.1002/mrm.27683", "year": 2019 } ] } }, { "id": 50978, "drug": "MMP9 inhibitor", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "suppresses", "mediator": "mTOR", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "glioblastoma", "outcome_type": "disease", "outcome_domain": "glioblastoma", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "33064567", "title": "MMP9 inhibition increases autophagic flux in chronic heart failure", "doi": "10.1152/ajpheart.00032.2020", "year": 2020 } ], "bc": [ { "pmid": "39622049", "title": "A Dual-Target and Dual-Mechanism Design Strategy by Combining Inhibition and Degradation Together", "doi": "10.1021/jacs.4c11930", "year": 2024 }, { "pmid": "33162811", "title": "Mitochondrial dysfunction contributes to Rapamycin-induced apoptosis of Human Glioblastoma Cells - A synergistic effect with Temozolomide", "doi": "10.7150/ijms.40159", "year": 2020 }, { "pmid": "30793789", "title": "The effect of the mTOR inhibitor rapamycin on glucoCEST signal in a preclinical model of glioblastoma", "doi": "10.1002/mrm.27683", "year": 2019 } ] } }, { "id": 50987, "drug": "monocrotaline", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "suppresses", "mediator": "mTOR", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "glioblastoma", "outcome_type": "disease", "outcome_domain": "glioblastoma", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "28340591", "title": "Altered mTOR and Beclin-1 mediated autophagic activation during right ventricular remodeling in monocrotaline-induced pulmonary hypertension", "doi": "10.1186/s12931-017-0536-7", "year": 2017 } ], "bc": [ { "pmid": "39622049", "title": "A Dual-Target and Dual-Mechanism Design Strategy by Combining Inhibition and Degradation Together", "doi": "10.1021/jacs.4c11930", "year": 2024 }, { "pmid": "33162811", "title": "Mitochondrial dysfunction contributes to Rapamycin-induced apoptosis of Human Glioblastoma Cells - A synergistic effect with Temozolomide", "doi": "10.7150/ijms.40159", "year": 2020 }, { "pmid": "30793789", "title": "The effect of the mTOR inhibitor rapamycin on glucoCEST signal in a preclinical model of glioblastoma", "doi": "10.1002/mrm.27683", "year": 2019 } ] } }, { "id": 51179, "drug": "Anti-CCL21 antibody", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "suppresses", "mediator": "MMP-9", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "ulcerative colitis", "outcome_type": "disease", "outcome_domain": "inflammatory_bowel_disease", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "26393504", "title": "Anti-CCL21 Antibody Attenuates Infarct Size and Improves Cardiac Remodeling After Myocardial Infarction", "doi": "10.1159/000430224", "year": 2015 } ], "bc": [ { "pmid": "35566780", "title": "Are Matrix Metalloproteinase-9 and Tissue Inhibitor of Metalloproteinase-1 Useful as Markers in Diagnostic Management of Children with Newly Diagnosed Ulcerative Colitis?", "doi": "10.3390/jcm11092655", "year": 2022 }, { "pmid": "27034654", "title": "Expressions of Matrix Metalloproteinases (MMP-2, MMP-7, and MMP-9) and Their Inhibitors (TIMP-1, TIMP-2) in Inflammatory Bowel Diseases", "doi": "10.1155/2016/2456179", "year": 2016 }, { "pmid": "26514773", "title": "Matrix metalloproteinase 9-induced increase in intestinal epithelial tight junction permeability contributes to the severity of experimental DSS colitis", "doi": "10.1152/ajpgi.00256.2015", "year": 2015 } ] } }, { "id": 51184, "drug": "anthocyanin", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "downregulates", "mediator": "IL-17", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "Crohn's disease", "outcome_type": "disease", "outcome_domain": "inflammatory_bowel_disease", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "33603662", "title": "Anthocyanin Protects Cardiac Function and Cardiac Fibroblasts From High-Glucose Induced Inflammation and Myocardial Fibrosis by Inhibiting IL-17", "doi": "10.3389/fphar.2020.593633", "year": 2021 } ], "bc": [ { "pmid": "39803916", "title": "Correlation between IL-17 and inflammatory bowel disease", "doi": "10.55133/eji.320106", "year": 2025 }, { "pmid": "38229938", "title": "Crohn's disease and clinical management today: How it does?", "doi": "10.5662/wjm.v13.i5.399", "year": 2023 }, { "pmid": "28533995", "title": "Crohn’s Disease and Ulcerative Colitis Show Unique Cytokine Profiles", "doi": "10.7759/cureus.1177", "year": 2017 } ] } }, { "id": 38784, "drug": "tofacitinib", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "downregulates", "mediator": "IFN-γ", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "surgical relapse", "outcome_type": "phenotype", "outcome_domain": "inflammatory_bowel_disease", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "tofacitinib", "mediator_canonical": "ifn-γ", "outcome_canonical": "surgical relapse", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "33899926", "title": "Lymphocyte modulation by tofacitinib in patients with rheumatoid arthritis", "doi": "10.1111/cei.13609", "year": 2021 }, { "pmid": "32616791", "title": "Tofacitinib treatment aggravates Staphylococcus aureus septic arthritis, but attenuates sepsis and enterotoxin induced shock in mice", "doi": "10.1038/s41598-020-67928-0", "year": 2020 }, { "pmid": "31638166", "title": "The JAK inhibitor tofacitinib ameliorates immune‑mediated liver injury in mice", "doi": "10.3892/mmr.2019.10750", "year": 2019 } ], "bc": [ { "pmid": "33611347", "title": "Diving into Inflammation: A Pilot Study Exploring the Dynamics of the Immune–Microbiota Axis in Ileal Tissue Layers of Patients with Crohn’s Disease", "doi": "10.1093/ecco-jcc/jjab034", "year": 2021 } ] } }, { "id": 23432, "drug": "nivolumab", "drug_type": "drug", "drug_domain": "multiple_sclerosis", "predicate_ab": "inhibits", "mediator": "PD-1", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "ALS disease progression", "outcome_type": "phenotype", "outcome_domain": "als", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "nivolumab", "mediator_canonical": "pd-1", "outcome_canonical": "als disease progression", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41846303", "title": "Nivolumab‐Associated Autoimmune Encephalopathy in a Child With Multiply Relapsed Anaplastic Ependymoma", "doi": "10.1002/1545-5017.70262", "year": 2026 }, { "pmid": "31135622", "title": "Severe Relapse of Vaccine-Induced Guillain–Barré Syndrome After Treatment With Nivolumab", "doi": "10.1097/cnd.0000000000000230", "year": 2019 }, { "pmid": "30465016", "title": "Natalizumab may control immune checkpoint inhibitor–induced limbic encephalitis", "doi": "10.1212/nxi.0000000000000439", "year": 2018 } ], "bc": [ { "pmid": "40755012", "title": "Immune checkpoint changes correlate with the progression and prognosis of amyotrophic lateral sclerosis", "doi": "10.1080/07853890.2025.2540023", "year": 2025 } ] } }, { "id": 57073, "drug": "miR-21 antisense oligonucleotide", "drug_type": "drug", "drug_domain": "pancreatic_cancer", "predicate_ab": "inhibits", "mediator": "miR-21", "mediator_type": "gene", "predicate_bc": "increases", "outcome": "cardiac fibrosis", "outcome_type": "disease", "outcome_domain": "heart_failure", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "28444967", "title": "Co‐delivery of micro RNA ‐21 antisense oligonucleotides and gemcitabine using nanomedicine for pancreatic cancer therapy", "doi": "10.1111/cas.13267", "year": 2017 } ], "bc": [ { "pmid": "33550817", "title": "MicroRNA-21–Dependent Macrophage-to-Fibroblast Signaling Determines the Cardiac Response to Pressure Overload", "doi": "10.1161/circulationaha.120.050682", "year": 2021 }, { "pmid": "33804922", "title": "Therapeutic miR-21 Silencing Reduces Cardiac Fibrosis and Modulates Inflammatory Response in Chronic Chagas Disease", "doi": "10.3390/ijms22073307", "year": 2021 }, { "pmid": "28335740", "title": "miR-21 enhances cardiac fibrotic remodeling and fibroblast proliferation via CADM1/STAT3 pathway", "doi": "10.1186/s12872-017-0520-7", "year": 2017 } ] } }, { "id": 23018, "drug": "nivolumab", "drug_type": "drug", "drug_domain": "multiple_sclerosis", "predicate_ab": "inhibits", "mediator": "PD-1", "mediator_type": "protein", "predicate_bc": "increases", "outcome": "glioblastoma growth", "outcome_type": "phenotype", "outcome_domain": "glioblastoma", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "nivolumab", "mediator_canonical": "pd-1", "outcome_canonical": "glioblastoma growth", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41846303", "title": "Nivolumab‐Associated Autoimmune Encephalopathy in a Child With Multiply Relapsed Anaplastic Ependymoma", "doi": "10.1002/1545-5017.70262", "year": 2026 }, { "pmid": "31135622", "title": "Severe Relapse of Vaccine-Induced Guillain–Barré Syndrome After Treatment With Nivolumab", "doi": "10.1097/cnd.0000000000000230", "year": 2019 }, { "pmid": "30465016", "title": "Natalizumab may control immune checkpoint inhibitor–induced limbic encephalitis", "doi": "10.1212/nxi.0000000000000439", "year": 2018 } ], "bc": [ { "pmid": "34739319", "title": "PD-1 independent of PD-L1 ligation promotes glioblastoma growth through the NFκB pathway", "doi": "10.1126/sciadv.abh2148", "year": 2021 } ] } }, { "id": 35082, "drug": "Stattic", "drug_type": "drug", "drug_domain": "multiple_sclerosis", "predicate_ab": "downregulates", "mediator": "IL-17A", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "inflammatory bowel disease", "outcome_type": "disease", "outcome_domain": "inflammatory_bowel_disease", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "stattic", "mediator_canonical": "il-17a", "outcome_canonical": "inflammatory bowel disease", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "34206429", "title": "Pharmacological Inhibition of STAT3 by Stattic Ameliorates Clinical Symptoms and Reduces Autoinflammation in Myeloid, Lymphoid, and Neuronal Tissue Compartments in Relapsing–Remitting Model of Experimental Autoimmune Encephalomyelitis in SJL/J Mice", "doi": "10.3390/pharmaceutics13070925", "year": 2021 } ], "bc": [ { "pmid": "32724117", "title": "Serum interleukin 17A and interleukin 17F in children with inflammatory bowel disease", "doi": "10.1038/s41598-020-69567-x", "year": 2020 }, { "pmid": "27049090", "title": "Relationship between serum interleukin-17 level and inflammatory bowel disease.", "doi": null, "year": 2016 } ] } }, { "id": 23823, "drug": "anlotinib", "drug_type": "drug", "drug_domain": "multiple_sclerosis", "predicate_ab": "upregulates", "mediator": "CD73", "mediator_type": "protein", "predicate_bc": "predicts", "outcome": "poor prognosis", "outcome_type": "phenotype", "outcome_domain": "pancreatic_cancer", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "anlotinib", "mediator_canonical": "cd73", "outcome_canonical": null, "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "35638564", "title": "Anlotinib attenuates experimental autoimmune encephalomyelitis mice model of multiple sclerosis via modulating the differentiation of Th17 and Treg cells", "doi": "10.1080/08923973.2022.2071722", "year": 2022 } ], "bc": [ { "pmid": "37851808", "title": "CD73 controls Myosin II–driven invasion, metastasis, and immunosuppression in amoeboid pancreatic cancer cells", "doi": "10.1126/sciadv.adi0244", "year": 2023 }, { "pmid": "32643277", "title": "CD73 acts as a prognostic biomarker and promotes progression and immune escape in pancreatic cancer", "doi": "10.1111/jcmm.15500", "year": 2020 }, { "pmid": "30927045", "title": "The distinct role of CD73 in the progression of pancreatic cancer", "doi": "10.1007/s00109-018-01742-0", "year": 2019 } ] } }, { "id": 57075, "drug": "gemcitabine and crizotinib", "drug_type": "drug", "drug_domain": "pancreatic_cancer", "predicate_ab": "downregulates", "mediator": "miR-21", "mediator_type": "gene", "predicate_bc": "increases", "outcome": "cardiac fibrosis", "outcome_type": "disease", "outcome_domain": "heart_failure", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "28304379", "title": "Development of bioluminescent chick chorioallantoic membrane (CAM) models for primary pancreatic cancer cells: a platform for drug testing", "doi": "10.1038/srep44686", "year": 2017 } ], "bc": [ { "pmid": "33550817", "title": "MicroRNA-21–Dependent Macrophage-to-Fibroblast Signaling Determines the Cardiac Response to Pressure Overload", "doi": "10.1161/circulationaha.120.050682", "year": 2021 }, { "pmid": "33804922", "title": "Therapeutic miR-21 Silencing Reduces Cardiac Fibrosis and Modulates Inflammatory Response in Chronic Chagas Disease", "doi": "10.3390/ijms22073307", "year": 2021 }, { "pmid": "28335740", "title": "miR-21 enhances cardiac fibrotic remodeling and fibroblast proliferation via CADM1/STAT3 pathway", "doi": "10.1186/s12872-017-0520-7", "year": 2017 } ] } }, { "id": 57076, "drug": "multi-potent miRNA sponge", "drug_type": "drug", "drug_domain": "pancreatic_cancer", "predicate_ab": "inhibits", "mediator": "miR-21", "mediator_type": "gene", "predicate_bc": "increases", "outcome": "cardiac fibrosis", "outcome_type": "disease", "outcome_domain": "heart_failure", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "26284487", "title": "Simultaneous inhibition of multiple oncogenic miRNAs by a multi-potent microRNA sponge", "doi": "10.18632/oncotarget.4827", "year": 2015 } ], "bc": [ { "pmid": "33550817", "title": "MicroRNA-21–Dependent Macrophage-to-Fibroblast Signaling Determines the Cardiac Response to Pressure Overload", "doi": "10.1161/circulationaha.120.050682", "year": 2021 }, { "pmid": "33804922", "title": "Therapeutic miR-21 Silencing Reduces Cardiac Fibrosis and Modulates Inflammatory Response in Chronic Chagas Disease", "doi": "10.3390/ijms22073307", "year": 2021 }, { "pmid": "28335740", "title": "miR-21 enhances cardiac fibrotic remodeling and fibroblast proliferation via CADM1/STAT3 pathway", "doi": "10.1186/s12872-017-0520-7", "year": 2017 } ] } }, { "id": 4777, "drug": "RAP", "drug_type": "drug", "drug_domain": "pancreatic_cancer", "predicate_ab": "inhibits", "mediator": "RAGE", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "ALS", "outcome_type": "disease", "outcome_domain": "als", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "rap", "mediator_canonical": "rage", "outcome_canonical": "amyotrophic lateral sclerosis", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "29533466", "title": "The advanced glycation end‐product Nϵ‐carboxymethyllysine promotes progression of pancreatic cancer: implications for diabetes‐associated risk and its prevention", "doi": "10.1002/path.5072", "year": 2018 } ], "bc": [ { "pmid": "35216298", "title": "The Involvement of RAGE and Its Ligands during Progression of ALS in SOD1 G93A Transgenic Mice", "doi": "10.3390/ijms23042184", "year": 2022 }, { "pmid": "27242430", "title": "Soluble RAGE Treatment Delays Progression of Amyotrophic Lateral Sclerosis in SOD1 Mice", "doi": "10.3389/fncel.2016.00117", "year": 2016 }, { "pmid": "26733811", "title": "Receptor for Advanced Glycation End Products and its Inflammatory Ligands are Upregulated in Amyotrophic Lateral Sclerosis", "doi": "10.3389/fncel.2015.00485", "year": 2015 } ] } }, { "id": 51572, "drug": "digoxin", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "inhibits", "mediator": "EGFR", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "pancreatic ductal adenocarcinoma", "outcome_type": "disease", "outcome_domain": "pancreatic_cancer", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "25955608", "title": "Digoxin Suppresses Tumor Malignancy through Inhibiting Multiple Src-Related Signaling Pathways in Non-Small Cell Lung Cancer", "doi": "10.1371/journal.pone.0123305", "year": 2015 } ], "bc": [ { "pmid": "40130819", "title": "Identification of Tumor‐Specific Surface Proteins Enables Quantification of Extracellular Vesicle Subtypes for Early Detection of Pancreatic Ductal Adenocarcinoma", "doi": "10.1002/advs.202414982", "year": 2025 }, { "pmid": "31584260", "title": "Design and Evaluation of PEGylated Liposomal Formulation of a Novel Multikinase Inhibitor for Enhanced Chemosensitivity and Inhibition of Metastatic Pancreatic Ductal Adenocarcinoma", "doi": "10.1021/acs.bioconjchem.9b00632", "year": 2019 }, { "pmid": "26339400", "title": "EGFR expression in pancreatic intraepithelial neoplasia and ductal adenocarcinoma.", "doi": null, "year": 2015 } ] } }, { "id": 51586, "drug": "gallic acid", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "downregulates", "mediator": "EGFR", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "pancreatic ductal adenocarcinoma", "outcome_type": "disease", "outcome_domain": "pancreatic_cancer", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "30521107", "title": "Gallic Acid Suppresses Cardiac Hypertrophic Remodeling and Heart Failure", "doi": "10.1002/mnfr.201800807", "year": 2018 } ], "bc": [ { "pmid": "40130819", "title": "Identification of Tumor‐Specific Surface Proteins Enables Quantification of Extracellular Vesicle Subtypes for Early Detection of Pancreatic Ductal Adenocarcinoma", "doi": "10.1002/advs.202414982", "year": 2025 }, { "pmid": "31584260", "title": "Design and Evaluation of PEGylated Liposomal Formulation of a Novel Multikinase Inhibitor for Enhanced Chemosensitivity and Inhibition of Metastatic Pancreatic Ductal Adenocarcinoma", "doi": "10.1021/acs.bioconjchem.9b00632", "year": 2019 }, { "pmid": "26339400", "title": "EGFR expression in pancreatic intraepithelial neoplasia and ductal adenocarcinoma.", "doi": null, "year": 2015 } ] } }, { "id": 51783, "drug": "cabergoline", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "downregulates", "mediator": "miR-146a", "mediator_type": "biomarker", "predicate_bc": "associated_with", "outcome": "rheumatoid arthritis", "outcome_type": "disease", "outcome_domain": "rheumatoid_arthritis", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "36300679", "title": "Cabergoline Treatment Promotes Myocardial Recovery in Peripartum Cardiomyopathy", "doi": "10.1002/ehf2.14210", "year": 2022 } ], "bc": [ { "pmid": "40176861", "title": "Plasma Levels of miR-21b and miR-146a Can Discriminate Rheumatoid Arthritis Diagnosis and Severity.", "doi": "10.37796/2211-8039.1637", "year": 2025 }, { "pmid": "35128324", "title": "Plasma MicroRNAs (miR-146a, miR-103a, and miR-155) as Potential Biomarkers for Rheumatoid Arthritis (RA) and Disease Activity in Iranian Patients", "doi": "10.31138/mjr.32.4.324", "year": 2021 } ] } }, { "id": 51788, "drug": "paeonol", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "activates", "mediator": "STAT3", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "prurigo nodularis", "outcome_type": "disease", "outcome_domain": "rheumatoid_arthritis", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "34418601", "title": "Paeonol promotes Opa1-mediated mitochondrial fusion via activating the CK2α-Stat3 pathway in diabetic cardiomyopathy", "doi": "10.1016/j.redox.2021.102098", "year": 2021 } ], "bc": [ { "pmid": "39912139", "title": "Translating tissue expression of STAT 1, 3 and 6 in prurigo nodularis to clinical efficacy of oral tofacitinib – A prospective single-arm investigational study", "doi": "10.25259/ijdvl_1017_2024", "year": 2025 }, { "pmid": "40162359", "title": "Successful Use of Tofacitinib in Paediatric Prurigo Nodularis: A Report of Four Cases", "doi": "10.4103/ijd.ijd_842_24", "year": 2025 }, { "pmid": "37521237", "title": "A case of recalcitrant prurigo nodularis with heightened expression of STAT 3 and STAT 6 and its dramatic response to tofacitinib", "doi": "10.4103/idoj.idoj_508_22", "year": 2023 } ] } }, { "id": 51789, "drug": "angiotensin II", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "activates", "mediator": "STAT3", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "prurigo nodularis", "outcome_type": "disease", "outcome_domain": "rheumatoid_arthritis", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "30571233", "title": "Angiotensin II Causes Biphasic STAT3 Activation Through TLR4 to Initiate Cardiac Remodeling", "doi": "10.1161/hypertensionaha.118.11860", "year": 2018 } ], "bc": [ { "pmid": "39912139", "title": "Translating tissue expression of STAT 1, 3 and 6 in prurigo nodularis to clinical efficacy of oral tofacitinib – A prospective single-arm investigational study", "doi": "10.25259/ijdvl_1017_2024", "year": 2025 }, { "pmid": "40162359", "title": "Successful Use of Tofacitinib in Paediatric Prurigo Nodularis: A Report of Four Cases", "doi": "10.4103/ijd.ijd_842_24", "year": 2025 }, { "pmid": "37521237", "title": "A case of recalcitrant prurigo nodularis with heightened expression of STAT 3 and STAT 6 and its dramatic response to tofacitinib", "doi": "10.4103/idoj.idoj_508_22", "year": 2023 } ] } }, { "id": 51793, "drug": "S3I-201", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "inhibits", "mediator": "STAT3", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "prurigo nodularis", "outcome_type": "disease", "outcome_domain": "rheumatoid_arthritis", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "31277074", "title": "Inhibition of EGFR-STAT3 attenuates cardiomyopathy in streptozotocin-induced type 1 diabetes", "doi": "10.1530/joe-19-0058", "year": 2019 } ], "bc": [ { "pmid": "39912139", "title": "Translating tissue expression of STAT 1, 3 and 6 in prurigo nodularis to clinical efficacy of oral tofacitinib – A prospective single-arm investigational study", "doi": "10.25259/ijdvl_1017_2024", "year": 2025 }, { "pmid": "40162359", "title": "Successful Use of Tofacitinib in Paediatric Prurigo Nodularis: A Report of Four Cases", "doi": "10.4103/ijd.ijd_842_24", "year": 2025 }, { "pmid": "37521237", "title": "A case of recalcitrant prurigo nodularis with heightened expression of STAT 3 and STAT 6 and its dramatic response to tofacitinib", "doi": "10.4103/idoj.idoj_508_22", "year": 2023 } ] } }, { "id": 51797, "drug": "Astragaloside IV", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "phosphorylates", "mediator": "STAT3", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "prurigo nodularis", "outcome_type": "disease", "outcome_domain": "rheumatoid_arthritis", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "30905241", "title": "Astragaloside IV alleviates heart failure by promoting angiogenesis through the JAK-STAT3 pathway", "doi": "10.1080/13880209.2019.1569697", "year": 2019 } ], "bc": [ { "pmid": "39912139", "title": "Translating tissue expression of STAT 1, 3 and 6 in prurigo nodularis to clinical efficacy of oral tofacitinib – A prospective single-arm investigational study", "doi": "10.25259/ijdvl_1017_2024", "year": 2025 }, { "pmid": "40162359", "title": "Successful Use of Tofacitinib in Paediatric Prurigo Nodularis: A Report of Four Cases", "doi": "10.4103/ijd.ijd_842_24", "year": 2025 }, { "pmid": "37521237", "title": "A case of recalcitrant prurigo nodularis with heightened expression of STAT 3 and STAT 6 and its dramatic response to tofacitinib", "doi": "10.4103/idoj.idoj_508_22", "year": 2023 } ] } }, { "id": 51801, "drug": "corosolic acid", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "downregulates", "mediator": "STAT3", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "prurigo nodularis", "outcome_type": "disease", "outcome_domain": "rheumatoid_arthritis", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "36707177", "title": "Corosolic acid ameliorates vascular remodeling in pulmonary arterial hypertension via the downregulation of STAT3 signaling", "doi": "10.1016/j.jphs.2022.12.007", "year": 2022 } ], "bc": [ { "pmid": "39912139", "title": "Translating tissue expression of STAT 1, 3 and 6 in prurigo nodularis to clinical efficacy of oral tofacitinib – A prospective single-arm investigational study", "doi": "10.25259/ijdvl_1017_2024", "year": 2025 }, { "pmid": "40162359", "title": "Successful Use of Tofacitinib in Paediatric Prurigo Nodularis: A Report of Four Cases", "doi": "10.4103/ijd.ijd_842_24", "year": 2025 }, { "pmid": "37521237", "title": "A case of recalcitrant prurigo nodularis with heightened expression of STAT 3 and STAT 6 and its dramatic response to tofacitinib", "doi": "10.4103/idoj.idoj_508_22", "year": 2023 } ] } }, { "id": 51953, "drug": "vildagliptin", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "induces", "mediator": "FGF21", "mediator_type": "protein", "predicate_bc": "decreases", "outcome": "body weight", "outcome_type": "phenotype", "outcome_domain": "type_2_diabetes", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "33073318", "title": "DPP-4 inhibitor induces FGF21 expression via sirtuin 1 signaling and improves myocardial energy metabolism", "doi": "10.1007/s00380-020-01711-z", "year": 2020 } ], "bc": [ { "pmid": "37030441", "title": "Fibroblast growth factor-21 is required for weight loss induced by the glucagon-like peptide-1 receptor agonist liraglutide in male mice fed high carbohydrate diets", "doi": "10.1016/j.molmet.2023.101718", "year": 2023 }, { "pmid": "31130574", "title": "Effects of sodium-glucose cotransporter 2 inhibitor (dapagliflozin) on food intake and plasma fibroblast growth factor 21 levels in type 2 diabetes patients", "doi": "10.1507/endocrj.ej19-0013", "year": 2019 }, { "pmid": "28515909", "title": "Metabolic role of fibroblast growth factor 21 in liver, adipose and nervous system tissues", "doi": "10.3892/br.2017.890", "year": 2017 } ] } }, { "id": 51956, "drug": "doxorubicin", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "upregulates", "mediator": "NT-proBNP", "mediator_type": "biomarker", "predicate_bc": "predicts", "outcome": "death", "outcome_type": "phenotype", "outcome_domain": "type_2_diabetes", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37125336", "title": "Empagliflozin attenuates doxorubicin-induced cardiotoxicity by activating AMPK/SIRT-1/PGC-1α-mediated mitochondrial biogenesis", "doi": "10.1093/toxres/tfad007", "year": 2023 } ], "bc": [ { "pmid": "41166576", "title": "Screening Natriuretic Peptide Levels Predicts Heart Failure and Death in Individuals With Type 1 and Type 2 Diabetes Without Known Heart Failure", "doi": "10.2337/dc25-1260", "year": 2025 }, { "pmid": "28554908", "title": "Role of B‐Type Natriuretic Peptide and N‐Terminal Prohormone BNP as Predictors of Cardiovascular Morbidity and Mortality in Patients With a Recent Coronary Event and Type 2 Diabetes Mellitus", "doi": "10.1161/jaha.116.004743", "year": 2017 } ] } }, { "id": 32919, "drug": "DPG", "drug_type": "drug", "drug_domain": "inflammatory_bowel_disease", "predicate_ab": "inhibits", "mediator": "HMGB1", "mediator_type": "protein", "predicate_bc": "predicts", "outcome": "drug-resistant epilepsy", "outcome_type": "disease", "outcome_domain": "epilepsy", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "dpg", "mediator_canonical": "HMGB1", "outcome_canonical": "drug-resistant epilepsy", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "31105713", "title": "Dipotassium Glycyrrhizate Improves Intestinal Mucosal Healing by Modulating Extracellular Matrix Remodeling Genes and Restoring Epithelial Barrier Functions", "doi": "10.3389/fimmu.2019.00939", "year": 2019 } ], "bc": [ { "pmid": "34747496", "title": "High‐mobility group box 1 as a predictive biomarker for drug‐resistant epilepsy: A proof‐of‐concept study", "doi": "10.1111/epi.17116", "year": 2021 } ] } }, { "id": 32920, "drug": "rhTM", "drug_type": "drug", "drug_domain": "inflammatory_bowel_disease", "predicate_ab": "inhibits", "mediator": "HMGB1", "mediator_type": "protein", "predicate_bc": "predicts", "outcome": "drug-resistant epilepsy", "outcome_type": "disease", "outcome_domain": "epilepsy", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "rhtm", "mediator_canonical": "HMGB1", "outcome_canonical": "drug-resistant epilepsy", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "26302768", "title": "Recombinant Thrombomodulin Modulates Murine Colitis Possibly via High-Mobility Group Box 1 Protein Inhibition", "doi": "10.1159/000438507", "year": 2015 } ], "bc": [ { "pmid": "34747496", "title": "High‐mobility group box 1 as a predictive biomarker for drug‐resistant epilepsy: A proof‐of‐concept study", "doi": "10.1111/epi.17116", "year": 2021 } ] } }, { "id": 33535, "drug": "Clostridium butyricum", "drug_type": "drug", "drug_domain": "inflammatory_bowel_disease", "predicate_ab": "activates", "mediator": "EGFR", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "pancreatic ductal adenocarcinoma", "outcome_type": "disease", "outcome_domain": "pancreatic_cancer", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "clostridium butyricum", "mediator_canonical": "EGFR", "outcome_canonical": "pancreatic ductal adenocarcinoma", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "35678197", "title": "Clostridium butyricum, a butyrate-producing potential probiotic, alleviates experimental colitis through epidermal growth factor receptor activation", "doi": "10.1039/d2fo00478j", "year": 2022 } ], "bc": [ { "pmid": "40130819", "title": "Identification of Tumor‐Specific Surface Proteins Enables Quantification of Extracellular Vesicle Subtypes for Early Detection of Pancreatic Ductal Adenocarcinoma", "doi": "10.1002/advs.202414982", "year": 2025 }, { "pmid": "31584260", "title": "Design and Evaluation of PEGylated Liposomal Formulation of a Novel Multikinase Inhibitor for Enhanced Chemosensitivity and Inhibition of Metastatic Pancreatic Ductal Adenocarcinoma", "doi": "10.1021/acs.bioconjchem.9b00632", "year": 2019 }, { "pmid": "26339400", "title": "EGFR expression in pancreatic intraepithelial neoplasia and ductal adenocarcinoma.", "doi": null, "year": 2015 } ] } }, { "id": 23819, "drug": "tofacitinib", "drug_type": "drug", "drug_domain": "multiple_sclerosis", "predicate_ab": "inhibits", "mediator": "IFN signaling", "mediator_type": "pathway", "predicate_bc": "associated_with", "outcome": "pancreatic ductal adenocarcinoma", "outcome_type": "disease", "outcome_domain": "pancreatic_cancer", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "tofacitinib", "mediator_canonical": "ifn signaling", "outcome_canonical": "pancreatic ductal adenocarcinoma", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "35943798", "title": "Tofacitinib blocks IFN-regulated biomarker genes in skin fibroblasts and keratinocytes in a systemic sclerosis trial", "doi": "10.1172/jci.insight.159566", "year": 2022 } ], "bc": [ { "pmid": "32727774", "title": "Involvement of the Interferon Signaling Pathways in Pancreatic Cancer Cells", "doi": "10.21873/anticanres.14449", "year": 2020 } ] } }, { "id": 9418, "drug": "AMD3100", "drug_type": "drug", "drug_domain": "pancreatic_cancer", "predicate_ab": "inhibits", "mediator": "CXCR4", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "PCNSL", "outcome_type": "disease", "outcome_domain": "glioblastoma", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "plerixafor", "mediator_canonical": "CXCR4", "outcome_canonical": "pcnsl", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "36145541", "title": "Development and Evaluation of a Peptide Heterodimeric Tracer Targeting CXCR4 and Integrin αvβ3 for Pancreatic Cancer Imaging", "doi": "10.3390/pharmaceutics14091791", "year": 2022 }, { "pmid": "35797269", "title": "Interaction of immune checkpoint PD-1 and chemokine receptor 4 (CXCR4) promotes a malignant phenotype in pancreatic cancer cells", "doi": "10.1371/journal.pone.0270832", "year": 2022 }, { "pmid": "33127761", "title": "CXCR4 inhibition in human pancreatic and colorectal cancers induces an integrated immune response", "doi": "10.1073/pnas.2013644117", "year": 2020 } ], "bc": [ { "pmid": "39761437", "title": "68Ga-Pentixafor PET in Combination With MRI Improves the Differential Diagnosis of Glioblastoma and Primary Central Nervous System Lymphoma", "doi": "10.1097/rlu.0000000000005657", "year": 2025 } ] } }, { "id": 33879, "drug": "polydatin", "drug_type": "drug", "drug_domain": "inflammatory_bowel_disease", "predicate_ab": "binds_to", "mediator": "STAT3", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "prurigo nodularis", "outcome_type": "disease", "outcome_domain": "rheumatoid_arthritis", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "polydatin", "mediator_canonical": "STAT3", "outcome_canonical": "prurigo nodularis", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "35766233", "title": "Polydatin alleviates DSS‐ and TNBS‐induced colitis by suppressing Th17 cell differentiation via directly inhibiting STAT3", "doi": "10.1002/ptr.7533", "year": 2022 } ], "bc": [ { "pmid": "39912139", "title": "Translating tissue expression of STAT 1, 3 and 6 in prurigo nodularis to clinical efficacy of oral tofacitinib – A prospective single-arm investigational study", "doi": "10.25259/ijdvl_1017_2024", "year": 2025 }, { "pmid": "40162359", "title": "Successful Use of Tofacitinib in Paediatric Prurigo Nodularis: A Report of Four Cases", "doi": "10.4103/ijd.ijd_842_24", "year": 2025 }, { "pmid": "37521237", "title": "A case of recalcitrant prurigo nodularis with heightened expression of STAT 3 and STAT 6 and its dramatic response to tofacitinib", "doi": "10.4103/idoj.idoj_508_22", "year": 2023 } ] } }, { "id": 33850, "drug": "R. intestinalis supernatant", "drug_type": "drug", "drug_domain": "inflammatory_bowel_disease", "predicate_ab": "suppresses", "mediator": "STAT3", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "prurigo nodularis", "outcome_type": "disease", "outcome_domain": "rheumatoid_arthritis", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "r. intestinalis supernatant", "mediator_canonical": "STAT3", "outcome_canonical": "prurigo nodularis", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "31173202", "title": "Roseburia�intestinalis supernatant ameliorates colitis induced in mice by regulating the immune response", "doi": "10.3892/mmr.2019.10327", "year": 2019 } ], "bc": [ { "pmid": "39912139", "title": "Translating tissue expression of STAT 1, 3 and 6 in prurigo nodularis to clinical efficacy of oral tofacitinib – A prospective single-arm investigational study", "doi": "10.25259/ijdvl_1017_2024", "year": 2025 }, { "pmid": "40162359", "title": "Successful Use of Tofacitinib in Paediatric Prurigo Nodularis: A Report of Four Cases", "doi": "10.4103/ijd.ijd_842_24", "year": 2025 }, { "pmid": "37521237", "title": "A case of recalcitrant prurigo nodularis with heightened expression of STAT 3 and STAT 6 and its dramatic response to tofacitinib", "doi": "10.4103/idoj.idoj_508_22", "year": 2023 } ] } }, { "id": 33847, "drug": "HDC components", "drug_type": "drug", "drug_domain": "inflammatory_bowel_disease", "predicate_ab": "binds_to", "mediator": "STAT3", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "prurigo nodularis", "outcome_type": "disease", "outcome_domain": "rheumatoid_arthritis", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "hdc components", "mediator_canonical": "STAT3", "outcome_canonical": "prurigo nodularis", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "34675488", "title": "Investigation of the Active Ingredients and Mechanism of Hudi Enteric-Coated Capsules in DSS-Induced Ulcerative Colitis Mice Based on Network Pharmacology and Experimental Verification", "doi": "10.2147/dddt.s326029", "year": 2021 } ], "bc": [ { "pmid": "39912139", "title": "Translating tissue expression of STAT 1, 3 and 6 in prurigo nodularis to clinical efficacy of oral tofacitinib – A prospective single-arm investigational study", "doi": "10.25259/ijdvl_1017_2024", "year": 2025 }, { "pmid": "40162359", "title": "Successful Use of Tofacitinib in Paediatric Prurigo Nodularis: A Report of Four Cases", "doi": "10.4103/ijd.ijd_842_24", "year": 2025 }, { "pmid": "37521237", "title": "A case of recalcitrant prurigo nodularis with heightened expression of STAT 3 and STAT 6 and its dramatic response to tofacitinib", "doi": "10.4103/idoj.idoj_508_22", "year": 2023 } ] } }, { "id": 33873, "drug": "anemoside A3", "drug_type": "drug", "drug_domain": "inflammatory_bowel_disease", "predicate_ab": "binds_to", "mediator": "STAT3", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "prurigo nodularis", "outcome_type": "disease", "outcome_domain": "rheumatoid_arthritis", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "anemoside a3", "mediator_canonical": "STAT3", "outcome_canonical": "prurigo nodularis", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "36434688", "title": "Identification of potential immunomodulators from Pulsatilla decoction that act on therapeutic targets for ulcerative colitis based on pharmacological activity, absorbed ingredients, and in-silico molecular docking", "doi": "10.1186/s13020-022-00684-7", "year": 2022 } ], "bc": [ { "pmid": "39912139", "title": "Translating tissue expression of STAT 1, 3 and 6 in prurigo nodularis to clinical efficacy of oral tofacitinib – A prospective single-arm investigational study", "doi": "10.25259/ijdvl_1017_2024", "year": 2025 }, { "pmid": "40162359", "title": "Successful Use of Tofacitinib in Paediatric Prurigo Nodularis: A Report of Four Cases", "doi": "10.4103/ijd.ijd_842_24", "year": 2025 }, { "pmid": "37521237", "title": "A case of recalcitrant prurigo nodularis with heightened expression of STAT 3 and STAT 6 and its dramatic response to tofacitinib", "doi": "10.4103/idoj.idoj_508_22", "year": 2023 } ] } }, { "id": 33852, "drug": "Oleuropein", "drug_type": "drug", "drug_domain": "inflammatory_bowel_disease", "predicate_ab": "downregulates", "mediator": "STAT3", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "prurigo nodularis", "outcome_type": "disease", "outcome_domain": "rheumatoid_arthritis", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "oleuropein", "mediator_canonical": "STAT3", "outcome_canonical": "prurigo nodularis", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "26502315", "title": "Chemopreventive effect of oleuropein in colitis‐associated colorectal cancer in c57bl/6 mice", "doi": "10.1002/mnfr.201500605", "year": 2015 } ], "bc": [ { "pmid": "39912139", "title": "Translating tissue expression of STAT 1, 3 and 6 in prurigo nodularis to clinical efficacy of oral tofacitinib – A prospective single-arm investigational study", "doi": "10.25259/ijdvl_1017_2024", "year": 2025 }, { "pmid": "40162359", "title": "Successful Use of Tofacitinib in Paediatric Prurigo Nodularis: A Report of Four Cases", "doi": "10.4103/ijd.ijd_842_24", "year": 2025 }, { "pmid": "37521237", "title": "A case of recalcitrant prurigo nodularis with heightened expression of STAT 3 and STAT 6 and its dramatic response to tofacitinib", "doi": "10.4103/idoj.idoj_508_22", "year": 2023 } ] } }, { "id": 36868, "drug": "LXA4", "drug_type": "drug", "drug_domain": "pancreatic_cancer", "predicate_ab": "inhibits", "mediator": "MMP-9", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "ulcerative colitis", "outcome_type": "disease", "outcome_domain": "inflammatory_bowel_disease", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "lxa4", "mediator_canonical": "MMP9", "outcome_canonical": "ulcerative colitis", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "26649143", "title": "Lipoxin A4 Attenuates Cell Invasion by Inhibiting ROS/ERK/MMP Pathway in Pancreatic Cancer", "doi": "10.1155/2016/6815727", "year": 2015 } ], "bc": [ { "pmid": "35566780", "title": "Are Matrix Metalloproteinase-9 and Tissue Inhibitor of Metalloproteinase-1 Useful as Markers in Diagnostic Management of Children with Newly Diagnosed Ulcerative Colitis?", "doi": "10.3390/jcm11092655", "year": 2022 }, { "pmid": "27034654", "title": "Expressions of Matrix Metalloproteinases (MMP-2, MMP-7, and MMP-9) and Their Inhibitors (TIMP-1, TIMP-2) in Inflammatory Bowel Diseases", "doi": "10.1155/2016/2456179", "year": 2016 }, { "pmid": "26514773", "title": "Matrix metalloproteinase 9-induced increase in intestinal epithelial tight junction permeability contributes to the severity of experimental DSS colitis", "doi": "10.1152/ajpgi.00256.2015", "year": 2015 } ] } }, { "id": 36865, "drug": "durvalumab", "drug_type": "drug", "drug_domain": "pancreatic_cancer", "predicate_ab": "inhibits", "mediator": "PD-L1", "mediator_type": "protein", "predicate_bc": "prevents", "outcome": "inflammatory damage", "outcome_type": "phenotype", "outcome_domain": "inflammatory_bowel_disease", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "durvalumab", "mediator_canonical": "PD-L1", "outcome_canonical": "inflammatory damage", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37452505", "title": "Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: An early exploratory analysis of real‐world data", "doi": "10.1111/liv.15641", "year": 2023 }, { "pmid": "33688022", "title": "Safety and activity of the TGFβ receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer", "doi": "10.1136/jitc-2020-002068", "year": 2021 }, { "pmid": "31230047", "title": "A Phase 1b/2 Study of the Bruton Tyrosine Kinase Inhibitor Ibrutinib and the PD-L1 Inhibitor Durvalumab in Patients with Pretreated Solid Tumors", "doi": "10.1159/000500571", "year": 2019 } ], "bc": [ { "pmid": "32298485", "title": "Programmed cell death‐1 (PD‐1) and programmed death‐ligand 1 (PD‐L1) expression in PD‐1 inhibitor‐associated colitis and its mimics", "doi": "10.1111/his.14115", "year": 2020 } ] } }, { "id": 4396, "drug": "durvalumab", "drug_type": "drug", "drug_domain": "pancreatic_cancer", "predicate_ab": "inhibits", "mediator": "PD-L1", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "long-term survival", "outcome_type": "phenotype", "outcome_domain": "glioblastoma", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "completed", "clinical_trial_nct_ids": [ "NCT04078152" ], "literature_status": "reproduces_known", "drug_canonical": "durvalumab", "mediator_canonical": "PD-L1", "outcome_canonical": "long-term survival", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37452505", "title": "Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: An early exploratory analysis of real‐world data", "doi": "10.1111/liv.15641", "year": 2023 }, { "pmid": "33688022", "title": "Safety and activity of the TGFβ receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer", "doi": "10.1136/jitc-2020-002068", "year": 2021 }, { "pmid": "31230047", "title": "A Phase 1b/2 Study of the Bruton Tyrosine Kinase Inhibitor Ibrutinib and the PD-L1 Inhibitor Durvalumab in Patients with Pretreated Solid Tumors", "doi": "10.1159/000500571", "year": 2019 } ], "bc": [ { "pmid": "31929892", "title": "Impact of pre‐therapy glioblastoma multiforme microenvironment on clinical response to autologous CMV‐specific T‐cell therapy", "doi": "10.1002/cti2.1088", "year": 2019 } ] } }, { "id": 36866, "drug": "APS", "drug_type": "drug", "drug_domain": "pancreatic_cancer", "predicate_ab": "downregulates", "mediator": "MMP-9", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "ulcerative colitis", "outcome_type": "disease", "outcome_domain": "inflammatory_bowel_disease", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "aps", "mediator_canonical": "MMP9", "outcome_canonical": "ulcerative colitis", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "29785118", "title": "Traditional Chinese medicine <em>Astragalus </em>polysaccharide enhanced antitumor effects of the angiogenesis inhibitor apatinib in pancreatic cancer cells on proliferation, invasiveness, and apoptosis", "doi": "10.2147/ott.s157129", "year": 2018 } ], "bc": [ { "pmid": "35566780", "title": "Are Matrix Metalloproteinase-9 and Tissue Inhibitor of Metalloproteinase-1 Useful as Markers in Diagnostic Management of Children with Newly Diagnosed Ulcerative Colitis?", "doi": "10.3390/jcm11092655", "year": 2022 }, { "pmid": "27034654", "title": "Expressions of Matrix Metalloproteinases (MMP-2, MMP-7, and MMP-9) and Their Inhibitors (TIMP-1, TIMP-2) in Inflammatory Bowel Diseases", "doi": "10.1155/2016/2456179", "year": 2016 }, { "pmid": "26514773", "title": "Matrix metalloproteinase 9-induced increase in intestinal epithelial tight junction permeability contributes to the severity of experimental DSS colitis", "doi": "10.1152/ajpgi.00256.2015", "year": 2015 } ] } }, { "id": 39043, "drug": "tofacitinib", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "inhibits", "mediator": "STAT3", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "immune escape", "outcome_type": "phenotype", "outcome_domain": "pancreatic_cancer", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "tofacitinib", "mediator_canonical": "STAT3", "outcome_canonical": "immune escape", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40373045", "title": "Rheumatoid arthritis synovial fluid induces JAK-dependent intracellular activation of human sensory neurons", "doi": "10.1172/jci.insight.186646", "year": 2025 }, { "pmid": "32927842", "title": "Tofacitinib and Baricitinib Are Taken up by Different Uptake Mechanisms Determining the Efficacy of Both Drugs in RA", "doi": "10.3390/ijms21186632", "year": 2020 }, { "pmid": "30357932", "title": "JAK1/3 inhibition preserves epidermal morphology in full‐thickness 3D skin models of atopic dermatitis and psoriasis", "doi": "10.1111/jdv.15301", "year": 2018 } ], "bc": [ { "pmid": "38464736", "title": "Role of STAT3 in pancreatic cancer", "doi": "10.37349/etat.2024.00202", "year": 2024 } ] } }, { "id": 39050, "drug": "tofacitinib", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "inhibits", "mediator": "STAT3", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "pancreatic cancer", "outcome_type": "disease", "outcome_domain": "pancreatic_cancer", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "completed", "clinical_trial_nct_ids": [ "NCT04034238" ], "literature_status": "partial_evidence", "drug_canonical": "tofacitinib", "mediator_canonical": "STAT3", "outcome_canonical": "pancreatic cancer", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40373045", "title": "Rheumatoid arthritis synovial fluid induces JAK-dependent intracellular activation of human sensory neurons", "doi": "10.1172/jci.insight.186646", "year": 2025 }, { "pmid": "32927842", "title": "Tofacitinib and Baricitinib Are Taken up by Different Uptake Mechanisms Determining the Efficacy of Both Drugs in RA", "doi": "10.3390/ijms21186632", "year": 2020 }, { "pmid": "30357932", "title": "JAK1/3 inhibition preserves epidermal morphology in full‐thickness 3D skin models of atopic dermatitis and psoriasis", "doi": "10.1111/jdv.15301", "year": 2018 } ], "bc": [ { "pmid": "26873728", "title": "Applying Small Molecule Signal Transducer and Activator of Transcription-3 (STAT3) Protein Inhibitors as Pancreatic Cancer Therapeutics", "doi": "10.1158/1535-7163.mct-15-0003", "year": 2016 } ] } }, { "id": 36862, "drug": "durvalumab", "drug_type": "drug", "drug_domain": "pancreatic_cancer", "predicate_ab": "inhibits", "mediator": "PD-L1", "mediator_type": "protein", "predicate_bc": "increases", "outcome": "PD-1 inhibitor-associated colitis", "outcome_type": "disease", "outcome_domain": "inflammatory_bowel_disease", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "durvalumab", "mediator_canonical": "PD-L1", "outcome_canonical": "pd-1 inhibitor-associated colitis", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37452505", "title": "Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: An early exploratory analysis of real‐world data", "doi": "10.1111/liv.15641", "year": 2023 }, { "pmid": "33688022", "title": "Safety and activity of the TGFβ receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer", "doi": "10.1136/jitc-2020-002068", "year": 2021 }, { "pmid": "31230047", "title": "A Phase 1b/2 Study of the Bruton Tyrosine Kinase Inhibitor Ibrutinib and the PD-L1 Inhibitor Durvalumab in Patients with Pretreated Solid Tumors", "doi": "10.1159/000500571", "year": 2019 } ], "bc": [ { "pmid": "32298485", "title": "Programmed cell death‐1 (PD‐1) and programmed death‐ligand 1 (PD‐L1) expression in PD‐1 inhibitor‐associated colitis and its mimics", "doi": "10.1111/his.14115", "year": 2020 } ] } }, { "id": 36872, "drug": "paeoniflorin", "drug_type": "drug", "drug_domain": "pancreatic_cancer", "predicate_ab": "downregulates", "mediator": "MMP-9", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "ulcerative colitis", "outcome_type": "disease", "outcome_domain": "inflammatory_bowel_disease", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "paeoniflorin", "mediator_canonical": "MMP9", "outcome_canonical": "ulcerative colitis", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "27446455", "title": "Paeoniflorin inhibits human pancreatic cancer cell apoptosis via suppression of MMP-9 and ERK signaling", "doi": "10.3892/ol.2016.4761", "year": 2016 } ], "bc": [ { "pmid": "35566780", "title": "Are Matrix Metalloproteinase-9 and Tissue Inhibitor of Metalloproteinase-1 Useful as Markers in Diagnostic Management of Children with Newly Diagnosed Ulcerative Colitis?", "doi": "10.3390/jcm11092655", "year": 2022 }, { "pmid": "27034654", "title": "Expressions of Matrix Metalloproteinases (MMP-2, MMP-7, and MMP-9) and Their Inhibitors (TIMP-1, TIMP-2) in Inflammatory Bowel Diseases", "doi": "10.1155/2016/2456179", "year": 2016 }, { "pmid": "26514773", "title": "Matrix metalloproteinase 9-induced increase in intestinal epithelial tight junction permeability contributes to the severity of experimental DSS colitis", "doi": "10.1152/ajpgi.00256.2015", "year": 2015 } ] } }, { "id": 36871, "drug": "durvalumab", "drug_type": "drug", "drug_domain": "pancreatic_cancer", "predicate_ab": "inhibits", "mediator": "PD-L1", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "gut microbiota composition", "outcome_type": "phenotype", "outcome_domain": "inflammatory_bowel_disease", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "durvalumab", "mediator_canonical": "PD-L1", "outcome_canonical": "gut microbiota composition", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37452505", "title": "Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: An early exploratory analysis of real‐world data", "doi": "10.1111/liv.15641", "year": 2023 }, { "pmid": "33688022", "title": "Safety and activity of the TGFβ receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer", "doi": "10.1136/jitc-2020-002068", "year": 2021 }, { "pmid": "31230047", "title": "A Phase 1b/2 Study of the Bruton Tyrosine Kinase Inhibitor Ibrutinib and the PD-L1 Inhibitor Durvalumab in Patients with Pretreated Solid Tumors", "doi": "10.1159/000500571", "year": 2019 } ], "bc": [ { "pmid": "40661950", "title": "PD-L1 deficiency exacerbates colitis severity by remodeling gut microbiota in inflammatory bowel disease", "doi": "10.3389/fimmu.2025.1622744", "year": 2025 } ] } }, { "id": 39053, "drug": "namilumab", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "binds_to", "mediator": "GM-CSF", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "cachexia", "outcome_type": "disease", "outcome_domain": "pancreatic_cancer", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "namilumab", "mediator_canonical": "gm-csf", "outcome_canonical": "cachexia", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "30999929", "title": "Efficacy and safety of namilumab, a human monoclonal antibody against granulocyte-macrophage colony-stimulating factor (GM-CSF) ligand in patients with rheumatoid arthritis (RA) with either an inadequate response to background methotrexate therapy or an inadequate response or intolerance to an anti-TNF (tumour necrosis factor) biologic therapy: a randomized, controlled trial", "doi": "10.1186/s13075-019-1879-x", "year": 2019 }, { "pmid": "30168415", "title": "Randomized, double-blind, placebo-controlled, phase I study of the safety and pharmacokinetics of namilumab in healthy Japanese and Caucasian men", "doi": "10.5414/cp203235", "year": 2018 } ], "bc": [ { "pmid": "29316343", "title": "Circulating monocyte chemoattractant protein‐1 (MCP‐1) is associated with cachexia in treatment‐naïve pancreatic cancer patients", "doi": "10.1002/jcsm.12251", "year": 2018 } ] } }, { "id": 23424, "drug": "nivolumab", "drug_type": "drug", "drug_domain": "multiple_sclerosis", "predicate_ab": "inhibits", "mediator": "PD-1", "mediator_type": "protein", "predicate_bc": "predicts", "outcome": "unfavorable prognosis", "outcome_type": "phenotype", "outcome_domain": "als", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "nivolumab", "mediator_canonical": "pd-1", "outcome_canonical": "unfavorable prognosis", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41846303", "title": "Nivolumab‐Associated Autoimmune Encephalopathy in a Child With Multiply Relapsed Anaplastic Ependymoma", "doi": "10.1002/1545-5017.70262", "year": 2026 }, { "pmid": "31135622", "title": "Severe Relapse of Vaccine-Induced Guillain–Barré Syndrome After Treatment With Nivolumab", "doi": "10.1097/cnd.0000000000000230", "year": 2019 }, { "pmid": "30465016", "title": "Natalizumab may control immune checkpoint inhibitor–induced limbic encephalitis", "doi": "10.1212/nxi.0000000000000439", "year": 2018 } ], "bc": [ { "pmid": "40755012", "title": "Immune checkpoint changes correlate with the progression and prognosis of amyotrophic lateral sclerosis", "doi": "10.1080/07853890.2025.2540023", "year": 2025 } ] } }, { "id": 23426, "drug": "nivolumab", "drug_type": "drug", "drug_domain": "multiple_sclerosis", "predicate_ab": "inhibits", "mediator": "PD-1", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "ALS", "outcome_type": "disease", "outcome_domain": "als", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "nivolumab", "mediator_canonical": "pd-1", "outcome_canonical": "amyotrophic lateral sclerosis", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41846303", "title": "Nivolumab‐Associated Autoimmune Encephalopathy in a Child With Multiply Relapsed Anaplastic Ependymoma", "doi": "10.1002/1545-5017.70262", "year": 2026 }, { "pmid": "31135622", "title": "Severe Relapse of Vaccine-Induced Guillain–Barré Syndrome After Treatment With Nivolumab", "doi": "10.1097/cnd.0000000000000230", "year": 2019 }, { "pmid": "30465016", "title": "Natalizumab may control immune checkpoint inhibitor–induced limbic encephalitis", "doi": "10.1212/nxi.0000000000000439", "year": 2018 } ], "bc": [ { "pmid": "40755012", "title": "Immune checkpoint changes correlate with the progression and prognosis of amyotrophic lateral sclerosis", "doi": "10.1080/07853890.2025.2540023", "year": 2025 } ] } }, { "id": 23428, "drug": "arundic acid", "drug_type": "drug", "drug_domain": "multiple_sclerosis", "predicate_ab": "downregulates", "mediator": "S100B", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "ALS", "outcome_type": "disease", "outcome_domain": "als", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "arundic acid", "mediator_canonical": "s100b", "outcome_canonical": "amyotrophic lateral sclerosis", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40649727", "title": "Effect on Different Glial Cell Types of S100B Modulation in Multiple Sclerosis Experimental Models", "doi": "10.3390/ijms26135948", "year": 2025 } ], "bc": [ { "pmid": "35216298", "title": "The Involvement of RAGE and Its Ligands during Progression of ALS in SOD1 G93A Transgenic Mice", "doi": "10.3390/ijms23042184", "year": 2022 }, { "pmid": "28713206", "title": "The Astrocytic S100B Protein with Its Receptor RAGE Is Aberrantly Expressed in SOD1G93A Models, and Its Inhibition Decreases the Expression of Proinflammatory Genes", "doi": "10.1155/2017/1626204", "year": 2017 }, { "pmid": "26733811", "title": "Receptor for Advanced Glycation End Products and its Inflammatory Ligands are Upregulated in Amyotrophic Lateral Sclerosis", "doi": "10.3389/fncel.2015.00485", "year": 2015 } ] } }, { "id": 38778, "drug": "tofacitinib", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "downregulates", "mediator": "IFN-γ", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "fibrosis", "outcome_type": "disease", "outcome_domain": "inflammatory_bowel_disease", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "preclinical_only", "clinical_trial_nct_ids": [ "NCT05246293" ], "literature_status": "reproduces_known", "drug_canonical": "tofacitinib", "mediator_canonical": "ifn-γ", "outcome_canonical": "fibrosis", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "33899926", "title": "Lymphocyte modulation by tofacitinib in patients with rheumatoid arthritis", "doi": "10.1111/cei.13609", "year": 2021 }, { "pmid": "32616791", "title": "Tofacitinib treatment aggravates Staphylococcus aureus septic arthritis, but attenuates sepsis and enterotoxin induced shock in mice", "doi": "10.1038/s41598-020-67928-0", "year": 2020 }, { "pmid": "31638166", "title": "The JAK inhibitor tofacitinib ameliorates immune‑mediated liver injury in mice", "doi": "10.3892/mmr.2019.10750", "year": 2019 } ], "bc": [ { "pmid": "31296924", "title": "Fibrogenesis in Chronic DSS Colitis is Not Influenced by Neutralisation of Regulatory T Cells, of Major T Helper Cytokines or Absence of IL-13", "doi": "10.1038/s41598-019-46472-6", "year": 2019 } ] } }, { "id": 39062, "drug": "namilumab", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "binds_to", "mediator": "GM-CSF", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "poor prognosis", "outcome_type": "phenotype", "outcome_domain": "pancreatic_cancer", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "namilumab", "mediator_canonical": "gm-csf", "outcome_canonical": null, "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "30999929", "title": "Efficacy and safety of namilumab, a human monoclonal antibody against granulocyte-macrophage colony-stimulating factor (GM-CSF) ligand in patients with rheumatoid arthritis (RA) with either an inadequate response to background methotrexate therapy or an inadequate response or intolerance to an anti-TNF (tumour necrosis factor) biologic therapy: a randomized, controlled trial", "doi": "10.1186/s13075-019-1879-x", "year": 2019 }, { "pmid": "30168415", "title": "Randomized, double-blind, placebo-controlled, phase I study of the safety and pharmacokinetics of namilumab in healthy Japanese and Caucasian men", "doi": "10.5414/cp203235", "year": 2018 } ], "bc": [ { "pmid": "25952647", "title": "Chemotherapy-Derived Inflammatory Responses Accelerate the Formation of Immunosuppressive Myeloid Cells in the Tissue Microenvironment of Human Pancreatic Cancer", "doi": "10.1158/0008-5472.can-14-2921", "year": 2015 } ] } }, { "id": 39063, "drug": "YQCP", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "binds_to", "mediator": "EGFR", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "pancreatic ductal adenocarcinoma", "outcome_type": "disease", "outcome_domain": "pancreatic_cancer", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "yqcp", "mediator_canonical": "EGFR", "outcome_canonical": "pancreatic ductal adenocarcinoma", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "33992108", "title": "Network analysis indicating the pharmacological mechanism of Yunpi-Qufeng-Chushi-prescription in prophylactic treatment of rheumatoid arthritis", "doi": "10.1186/s12906-021-03311-4", "year": 2021 } ], "bc": [ { "pmid": "40130819", "title": "Identification of Tumor‐Specific Surface Proteins Enables Quantification of Extracellular Vesicle Subtypes for Early Detection of Pancreatic Ductal Adenocarcinoma", "doi": "10.1002/advs.202414982", "year": 2025 }, { "pmid": "31584260", "title": "Design and Evaluation of PEGylated Liposomal Formulation of a Novel Multikinase Inhibitor for Enhanced Chemosensitivity and Inhibition of Metastatic Pancreatic Ductal Adenocarcinoma", "doi": "10.1021/acs.bioconjchem.9b00632", "year": 2019 }, { "pmid": "26339400", "title": "EGFR expression in pancreatic intraepithelial neoplasia and ductal adenocarcinoma.", "doi": null, "year": 2015 } ] } }, { "id": 23226, "drug": "recombinant thrombomodulin", "drug_type": "drug", "drug_domain": "multiple_sclerosis", "predicate_ab": "suppresses", "mediator": "HMGB1", "mediator_type": "protein", "predicate_bc": "predicts", "outcome": "drug-resistant epilepsy", "outcome_type": "disease", "outcome_domain": "epilepsy", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "recombinant thrombomodulin", "mediator_canonical": "HMGB1", "outcome_canonical": "drug-resistant epilepsy", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "29509323", "title": "Recombinant thrombomodulin ameliorates experimental autoimmune encephalomyelitis by suppressing high mobility group box 1 and inflammatory cytokines", "doi": "10.1111/cei.13123", "year": 2018 } ], "bc": [ { "pmid": "34747496", "title": "High‐mobility group box 1 as a predictive biomarker for drug‐resistant epilepsy: A proof‐of‐concept study", "doi": "10.1111/epi.17116", "year": 2021 } ] } }, { "id": 23224, "drug": "Dimethyl fumarate", "drug_type": "drug", "drug_domain": "multiple_sclerosis", "predicate_ab": "upregulates", "mediator": "NQO1", "mediator_type": "gene", "predicate_bc": "associated_with", "outcome": "brain malignancy", "outcome_type": "disease", "outcome_domain": "epilepsy", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "completed", "clinical_trial_nct_ids": [ "NCT02337426" ], "literature_status": "novel_signal", "drug_canonical": "dimethyl fumarate", "mediator_canonical": "nqo1", "outcome_canonical": "brain malignancy", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "33572792", "title": "Prevention of Autoimmune Diabetes in NOD Mice by Dimethyl Fumarate", "doi": "10.3390/antiox10020193", "year": 2021 }, { "pmid": "32355819", "title": "Neuroprotective effect of dimethyl fumarate on cognitive impairment induced by ischemic stroke", "doi": "10.21037/atm.2020.02.10", "year": 2020 }, { "pmid": "31092974", "title": "Dimethyl fumarate ameliorates cisplatin-induced renal tubulointerstitial lesions", "doi": "10.1293/tox.2018-0049", "year": 2019 } ], "bc": [ { "pmid": "38167027", "title": "Impact of NQO1 dysregulation in CNS disorders", "doi": "10.1186/s12967-023-04802-3", "year": 2024 } ] } }, { "id": 23227, "drug": "Dimethyl fumarate", "drug_type": "drug", "drug_domain": "multiple_sclerosis", "predicate_ab": "upregulates", "mediator": "NQO1", "mediator_type": "gene", "predicate_bc": "causes", "outcome": "abnormal neurotransmitter release", "outcome_type": "phenotype", "outcome_domain": "epilepsy", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "dimethyl fumarate", "mediator_canonical": "nqo1", "outcome_canonical": "abnormal neurotransmitter release", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "33572792", "title": "Prevention of Autoimmune Diabetes in NOD Mice by Dimethyl Fumarate", "doi": "10.3390/antiox10020193", "year": 2021 }, { "pmid": "32355819", "title": "Neuroprotective effect of dimethyl fumarate on cognitive impairment induced by ischemic stroke", "doi": "10.21037/atm.2020.02.10", "year": 2020 }, { "pmid": "31092974", "title": "Dimethyl fumarate ameliorates cisplatin-induced renal tubulointerstitial lesions", "doi": "10.1293/tox.2018-0049", "year": 2019 } ], "bc": [ { "pmid": "38167027", "title": "Impact of NQO1 dysregulation in CNS disorders", "doi": "10.1186/s12967-023-04802-3", "year": 2024 } ] } }, { "id": 23223, "drug": "pentamidine", "drug_type": "drug", "drug_domain": "multiple_sclerosis", "predicate_ab": "inhibits", "mediator": "S100B", "mediator_type": "protein", "predicate_bc": "predicts", "outcome": "neuroscore recovery", "outcome_type": "phenotype", "outcome_domain": "epilepsy", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "pentamidine", "mediator_canonical": "s100b", "outcome_canonical": "neuroscore recovery", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40649727", "title": "Effect on Different Glial Cell Types of S100B Modulation in Multiple Sclerosis Experimental Models", "doi": "10.3390/ijms26135948", "year": 2025 }, { "pmid": "35620168", "title": "S100B inhibition protects from chronic experimental autoimmune encephalomyelitis", "doi": "10.1093/braincomms/fcac076", "year": 2022 }, { "pmid": "32197530", "title": "The S100B Inhibitor Pentamidine Ameliorates Clinical Score and Neuropathology of Relapsing—Remitting Multiple Sclerosis Mouse Model", "doi": "10.3390/cells9030748", "year": 2020 } ], "bc": [ { "pmid": "37026764", "title": "Early preclinical plasma protein biomarkers of brain trauma are influenced by early seizures and levetiracetam", "doi": "10.1002/epi4.12738", "year": 2023 } ] } }, { "id": 55101, "drug": "teriflunomide", "drug_type": "drug", "drug_domain": "multiple_sclerosis", "predicate_ab": "inhibits", "mediator": "DHODH", "mediator_type": "protein", "predicate_bc": "decreases", "outcome": "myocardial fibrosis", "outcome_type": "phenotype", "outcome_domain": "heart_failure", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "34721394", "title": "Teriflunomide Treatment of Multiple Sclerosis Selectively Modulates CD8 Memory T Cells", "doi": "10.3389/fimmu.2021.730342", "year": 2021 }, { "pmid": "34577124", "title": "The Mitochondria-Independent Cytotoxic Effect of Leflunomide on RPMI-8226 Multiple Myeloma Cell Line", "doi": "10.3390/molecules26185653", "year": 2021 }, { "pmid": "32339392", "title": "Precision Medicine With Leflunomide: Consideration of the DHODH Haplotype and Plasma Teriflunomide Concentration and Modification of Outcomes in Patients With Rheumatoid Arthritis", "doi": "10.1002/acr.24236", "year": 2020 } ], "bc": [ { "pmid": "39082362", "title": "DHODH Alleviates Heart Failure via the Modulation of CoQ-Related Ferroptotic Inhibition", "doi": "10.31083/j.fbl2907267", "year": 2024 } ] } }, { "id": 55102, "drug": "teriflunomide", "drug_type": "drug", "drug_domain": "multiple_sclerosis", "predicate_ab": "inhibits", "mediator": "DHODH", "mediator_type": "protein", "predicate_bc": "decreases", "outcome": "cardiac hypertrophy", "outcome_type": "phenotype", "outcome_domain": "heart_failure", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "34721394", "title": "Teriflunomide Treatment of Multiple Sclerosis Selectively Modulates CD8 Memory T Cells", "doi": "10.3389/fimmu.2021.730342", "year": 2021 }, { "pmid": "34577124", "title": "The Mitochondria-Independent Cytotoxic Effect of Leflunomide on RPMI-8226 Multiple Myeloma Cell Line", "doi": "10.3390/molecules26185653", "year": 2021 }, { "pmid": "32339392", "title": "Precision Medicine With Leflunomide: Consideration of the DHODH Haplotype and Plasma Teriflunomide Concentration and Modification of Outcomes in Patients With Rheumatoid Arthritis", "doi": "10.1002/acr.24236", "year": 2020 } ], "bc": [ { "pmid": "39082362", "title": "DHODH Alleviates Heart Failure via the Modulation of CoQ-Related Ferroptotic Inhibition", "doi": "10.31083/j.fbl2907267", "year": 2024 } ] } }, { "id": 55103, "drug": "DMF", "drug_type": "drug", "drug_domain": "multiple_sclerosis", "predicate_ab": "upregulates", "mediator": "Nrf2", "mediator_type": "gene", "predicate_bc": "decreases", "outcome": "myocardial fibrosis", "outcome_type": "phenotype", "outcome_domain": "heart_failure", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "35326142", "title": "Lung-Targeted Delivery of Dimethyl Fumarate Promotes the Reversal of Age-Dependent Established Lung Fibrosis", "doi": "10.3390/antiox11030492", "year": 2022 }, { "pmid": "36670906", "title": "Dimethyl Fumarate Protects Retinal Pigment Epithelium from Blue Light-Induced Oxidative Damage via the Nrf2 Pathway", "doi": "10.3390/antiox12010045", "year": 2022 } ], "bc": [ { "pmid": "38308838", "title": "Nrf2 prevents diabetic cardiomyopathy via antioxidant effect and normalization of glucose and lipid metabolism in the heart", "doi": "10.1002/jcp.31149", "year": 2024 } ] } }, { "id": 55106, "drug": "DMF", "drug_type": "drug", "drug_domain": "multiple_sclerosis", "predicate_ab": "upregulates", "mediator": "Nrf2", "mediator_type": "gene", "predicate_bc": "decreases", "outcome": "cardiac inflammation", "outcome_type": "phenotype", "outcome_domain": "heart_failure", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "35326142", "title": "Lung-Targeted Delivery of Dimethyl Fumarate Promotes the Reversal of Age-Dependent Established Lung Fibrosis", "doi": "10.3390/antiox11030492", "year": 2022 }, { "pmid": "36670906", "title": "Dimethyl Fumarate Protects Retinal Pigment Epithelium from Blue Light-Induced Oxidative Damage via the Nrf2 Pathway", "doi": "10.3390/antiox12010045", "year": 2022 } ], "bc": [ { "pmid": "38308838", "title": "Nrf2 prevents diabetic cardiomyopathy via antioxidant effect and normalization of glucose and lipid metabolism in the heart", "doi": "10.1002/jcp.31149", "year": 2024 } ] } }, { "id": 55108, "drug": "DMF", "drug_type": "drug", "drug_domain": "multiple_sclerosis", "predicate_ab": "upregulates", "mediator": "Nrf2", "mediator_type": "gene", "predicate_bc": "associated_with", "outcome": "sympathetic nerve activity", "outcome_type": "phenotype", "outcome_domain": "heart_failure", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "35326142", "title": "Lung-Targeted Delivery of Dimethyl Fumarate Promotes the Reversal of Age-Dependent Established Lung Fibrosis", "doi": "10.3390/antiox11030492", "year": 2022 }, { "pmid": "36670906", "title": "Dimethyl Fumarate Protects Retinal Pigment Epithelium from Blue Light-Induced Oxidative Damage via the Nrf2 Pathway", "doi": "10.3390/antiox12010045", "year": 2022 } ], "bc": [ { "pmid": "36098045", "title": "Extracellular Vesicles Regulate Sympatho-Excitation by Nrf2 in Heart Failure", "doi": "10.1161/circresaha.122.320916", "year": 2022 } ] } }, { "id": 37292, "drug": "EPA", "drug_type": "drug", "drug_domain": "pancreatic_cancer", "predicate_ab": "inhibits", "mediator": "STAT3", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "prurigo nodularis", "outcome_type": "disease", "outcome_domain": "rheumatoid_arthritis", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "epa", "mediator_canonical": "STAT3", "outcome_canonical": "prurigo nodularis", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "33801246", "title": "Eicosapentaenoic Acid Inhibits KRAS Mutant Pancreatic Cancer Cell Growth by Suppressing Hepassocin Expression and STAT3 Phosphorylation", "doi": "10.3390/biom11030370", "year": 2021 } ], "bc": [ { "pmid": "39912139", "title": "Translating tissue expression of STAT 1, 3 and 6 in prurigo nodularis to clinical efficacy of oral tofacitinib – A prospective single-arm investigational study", "doi": "10.25259/ijdvl_1017_2024", "year": 2025 }, { "pmid": "40162359", "title": "Successful Use of Tofacitinib in Paediatric Prurigo Nodularis: A Report of Four Cases", "doi": "10.4103/ijd.ijd_842_24", "year": 2025 }, { "pmid": "37521237", "title": "A case of recalcitrant prurigo nodularis with heightened expression of STAT 3 and STAT 6 and its dramatic response to tofacitinib", "doi": "10.4103/idoj.idoj_508_22", "year": 2023 } ] } }, { "id": 35096, "drug": "Bacoside-A", "drug_type": "drug", "drug_domain": "multiple_sclerosis", "predicate_ab": "downregulates", "mediator": "IL-17A", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "inflammatory bowel disease", "outcome_type": "disease", "outcome_domain": "inflammatory_bowel_disease", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "bacoside-a", "mediator_canonical": "il-17a", "outcome_canonical": "inflammatory bowel disease", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "30551384", "title": "Bacoside-A inhibits inflammatory cytokines and chemokine in experimental autoimmune encephalomyelitis", "doi": "10.1016/j.biopha.2018.10.188", "year": 2018 } ], "bc": [ { "pmid": "32724117", "title": "Serum interleukin 17A and interleukin 17F in children with inflammatory bowel disease", "doi": "10.1038/s41598-020-69567-x", "year": 2020 }, { "pmid": "27049090", "title": "Relationship between serum interleukin-17 level and inflammatory bowel disease.", "doi": null, "year": 2016 } ] } }, { "id": 38855, "drug": "tofacitinib", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "downregulates", "mediator": "IFN-γ", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "relapse rate", "outcome_type": "phenotype", "outcome_domain": "multiple_sclerosis", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "tofacitinib", "mediator_canonical": "ifn-γ", "outcome_canonical": "relapse rate", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "33899926", "title": "Lymphocyte modulation by tofacitinib in patients with rheumatoid arthritis", "doi": "10.1111/cei.13609", "year": 2021 }, { "pmid": "32616791", "title": "Tofacitinib treatment aggravates Staphylococcus aureus septic arthritis, but attenuates sepsis and enterotoxin induced shock in mice", "doi": "10.1038/s41598-020-67928-0", "year": 2020 }, { "pmid": "31638166", "title": "The JAK inhibitor tofacitinib ameliorates immune‑mediated liver injury in mice", "doi": "10.3892/mmr.2019.10750", "year": 2019 } ], "bc": [ { "pmid": "32071782", "title": "Long noncoding RNAs APOA1-AS, IFNG-AS1, RMRP and their related biomolecules in Egyptian patients with relapsing-remitting multiple sclerosis: Relation to disease activity and patient disability", "doi": "10.1016/j.jare.2019.10.012", "year": 2019 } ] } }, { "id": 23821, "drug": "Dimethyl fumarate", "drug_type": "drug", "drug_domain": "multiple_sclerosis", "predicate_ab": "upregulates", "mediator": "NQO1", "mediator_type": "gene", "predicate_bc": "associated_with", "outcome": "pancreatic cancer", "outcome_type": "disease", "outcome_domain": "pancreatic_cancer", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "dimethyl fumarate", "mediator_canonical": "nqo1", "outcome_canonical": "pancreatic cancer", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "33572792", "title": "Prevention of Autoimmune Diabetes in NOD Mice by Dimethyl Fumarate", "doi": "10.3390/antiox10020193", "year": 2021 }, { "pmid": "32355819", "title": "Neuroprotective effect of dimethyl fumarate on cognitive impairment induced by ischemic stroke", "doi": "10.21037/atm.2020.02.10", "year": 2020 }, { "pmid": "31092974", "title": "Dimethyl fumarate ameliorates cisplatin-induced renal tubulointerstitial lesions", "doi": "10.1293/tox.2018-0049", "year": 2019 } ], "bc": [ { "pmid": "28346693", "title": "Using a novel NQO1 bioactivatable drug, beta‐lapachone (ARQ761), to enhance chemotherapeutic effects by metabolic modulation in pancreatic cancer", "doi": "10.1002/jso.24624", "year": 2017 } ] } }, { "id": 23820, "drug": "nivolumab", "drug_type": "drug", "drug_domain": "multiple_sclerosis", "predicate_ab": "inhibits", "mediator": "PD-1", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "prognosis", "outcome_type": "phenotype", "outcome_domain": "pancreatic_cancer", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "active", "clinical_trial_nct_ids": [ "NCT04470440", "NCT06702566", "NCT04866654" ], "literature_status": "reproduces_known", "drug_canonical": "nivolumab", "mediator_canonical": "pd-1", "outcome_canonical": null, "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41846303", "title": "Nivolumab‐Associated Autoimmune Encephalopathy in a Child With Multiply Relapsed Anaplastic Ependymoma", "doi": "10.1002/1545-5017.70262", "year": 2026 }, { "pmid": "31135622", "title": "Severe Relapse of Vaccine-Induced Guillain–Barré Syndrome After Treatment With Nivolumab", "doi": "10.1097/cnd.0000000000000230", "year": 2019 }, { "pmid": "30465016", "title": "Natalizumab may control immune checkpoint inhibitor–induced limbic encephalitis", "doi": "10.1212/nxi.0000000000000439", "year": 2018 } ], "bc": [ { "pmid": "36359736", "title": "CXCR4-CXCL12-CXCR7 and PD-1/PD-L1 in Pancreatic Cancer: CXCL12 Predicts Survival of Radically Resected Patients", "doi": "10.3390/cells11213340", "year": 2022 } ] } }, { "id": 23816, "drug": "nivolumab", "drug_type": "drug", "drug_domain": "multiple_sclerosis", "predicate_ab": "inhibits", "mediator": "PD-1", "mediator_type": "protein", "predicate_bc": "increases", "outcome": "pancreatic cancer", "outcome_type": "disease", "outcome_domain": "pancreatic_cancer", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "active", "clinical_trial_nct_ids": [ "NCT06941857", "NCT07563738", "NCT04895709" ], "literature_status": "reproduces_known", "drug_canonical": "nivolumab", "mediator_canonical": "pd-1", "outcome_canonical": "pancreatic cancer", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41846303", "title": "Nivolumab‐Associated Autoimmune Encephalopathy in a Child With Multiply Relapsed Anaplastic Ependymoma", "doi": "10.1002/1545-5017.70262", "year": 2026 }, { "pmid": "31135622", "title": "Severe Relapse of Vaccine-Induced Guillain–Barré Syndrome After Treatment With Nivolumab", "doi": "10.1097/cnd.0000000000000230", "year": 2019 }, { "pmid": "30465016", "title": "Natalizumab may control immune checkpoint inhibitor–induced limbic encephalitis", "doi": "10.1212/nxi.0000000000000439", "year": 2018 } ], "bc": [ { "pmid": "30377341", "title": "Direct therapeutic targeting of immune checkpoint PD-1 in pancreatic cancer", "doi": "10.1038/s41416-018-0298-0", "year": 2018 } ] } }, { "id": 22105, "drug": "ibrutinib", "drug_type": "drug", "drug_domain": "pancreatic_cancer", "predicate_ab": "binds_to", "mediator": "BTK", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "chronic active lesions", "outcome_type": "disease", "outcome_domain": "multiple_sclerosis", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "ibrutinib", "mediator_canonical": "btk", "outcome_canonical": "chronic active lesions", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "31230047", "title": "A Phase 1b/2 Study of the Bruton Tyrosine Kinase Inhibitor Ibrutinib and the PD-L1 Inhibitor Durvalumab in Patients with Pretreated Solid Tumors", "doi": "10.1159/000500571", "year": 2019 }, { "pmid": "27489860", "title": "Ibrutinib repurposing: from B-cell malignancies to solid tumors", "doi": "10.18632/oncoscience.310", "year": 2016 } ], "bc": [ { "pmid": "38022591", "title": "Expression of Bruton´s tyrosine kinase in different type of brain lesions of multiple sclerosis patients and during experimental demyelination", "doi": "10.3389/fimmu.2023.1264128", "year": 2023 } ] } }, { "id": 22104, "drug": "ibrutinib", "drug_type": "drug", "drug_domain": "pancreatic_cancer", "predicate_ab": "binds_to", "mediator": "BTK", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "active lesions", "outcome_type": "disease", "outcome_domain": "multiple_sclerosis", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "ibrutinib", "mediator_canonical": "btk", "outcome_canonical": "active lesions", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "31230047", "title": "A Phase 1b/2 Study of the Bruton Tyrosine Kinase Inhibitor Ibrutinib and the PD-L1 Inhibitor Durvalumab in Patients with Pretreated Solid Tumors", "doi": "10.1159/000500571", "year": 2019 }, { "pmid": "27489860", "title": "Ibrutinib repurposing: from B-cell malignancies to solid tumors", "doi": "10.18632/oncoscience.310", "year": 2016 } ], "bc": [ { "pmid": "38022591", "title": "Expression of Bruton´s tyrosine kinase in different type of brain lesions of multiple sclerosis patients and during experimental demyelination", "doi": "10.3389/fimmu.2023.1264128", "year": 2023 } ] } }, { "id": 37294, "drug": "meisoindigo", "drug_type": "drug", "drug_domain": "pancreatic_cancer", "predicate_ab": "inhibits", "mediator": "STAT3", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "prurigo nodularis", "outcome_type": "disease", "outcome_domain": "rheumatoid_arthritis", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "meisoindigo", "mediator_canonical": "STAT3", "outcome_canonical": "prurigo nodularis", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "32961646", "title": "Methylisoindigo and Its Bromo-Derivatives Are Selective Tyrosine Kinase Inhibitors, Repressing Cellular Stat3 Activity, and Target CD133+ Cancer Stem Cells in PDAC", "doi": "10.3390/molecules22091546", "year": 2017 } ], "bc": [ { "pmid": "39912139", "title": "Translating tissue expression of STAT 1, 3 and 6 in prurigo nodularis to clinical efficacy of oral tofacitinib – A prospective single-arm investigational study", "doi": "10.25259/ijdvl_1017_2024", "year": 2025 }, { "pmid": "40162359", "title": "Successful Use of Tofacitinib in Paediatric Prurigo Nodularis: A Report of Four Cases", "doi": "10.4103/ijd.ijd_842_24", "year": 2025 }, { "pmid": "37521237", "title": "A case of recalcitrant prurigo nodularis with heightened expression of STAT 3 and STAT 6 and its dramatic response to tofacitinib", "doi": "10.4103/idoj.idoj_508_22", "year": 2023 } ] } }, { "id": 37263, "drug": "RoActemra", "drug_type": "drug", "drug_domain": "pancreatic_cancer", "predicate_ab": "inhibits", "mediator": "STAT3", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "prurigo nodularis", "outcome_type": "disease", "outcome_domain": "rheumatoid_arthritis", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "roactemra", "mediator_canonical": "STAT3", "outcome_canonical": "prurigo nodularis", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "29308316", "title": "Differential role of Interleukin-1 and Interleukin-6 in K-Ras-driven pancreatic carcinoma undergoing mesenchymal transition", "doi": "10.1080/2162402x.2017.1388485", "year": 2017 } ], "bc": [ { "pmid": "39912139", "title": "Translating tissue expression of STAT 1, 3 and 6 in prurigo nodularis to clinical efficacy of oral tofacitinib – A prospective single-arm investigational study", "doi": "10.25259/ijdvl_1017_2024", "year": 2025 }, { "pmid": "40162359", "title": "Successful Use of Tofacitinib in Paediatric Prurigo Nodularis: A Report of Four Cases", "doi": "10.4103/ijd.ijd_842_24", "year": 2025 }, { "pmid": "37521237", "title": "A case of recalcitrant prurigo nodularis with heightened expression of STAT 3 and STAT 6 and its dramatic response to tofacitinib", "doi": "10.4103/idoj.idoj_508_22", "year": 2023 } ] } }, { "id": 37281, "drug": "panaxadiol", "drug_type": "drug", "drug_domain": "pancreatic_cancer", "predicate_ab": "binds_to", "mediator": "STAT3", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "prurigo nodularis", "outcome_type": "disease", "outcome_domain": "rheumatoid_arthritis", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "panaxadiol", "mediator_canonical": "STAT3", "outcome_canonical": "prurigo nodularis", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "34623971", "title": "Inhibition of JAK2/STAT3 signaling pathway by panaxadiol limits the progression of pancreatic cancer", "doi": "10.18632/aging.203575", "year": 2021 } ], "bc": [ { "pmid": "39912139", "title": "Translating tissue expression of STAT 1, 3 and 6 in prurigo nodularis to clinical efficacy of oral tofacitinib – A prospective single-arm investigational study", "doi": "10.25259/ijdvl_1017_2024", "year": 2025 }, { "pmid": "40162359", "title": "Successful Use of Tofacitinib in Paediatric Prurigo Nodularis: A Report of Four Cases", "doi": "10.4103/ijd.ijd_842_24", "year": 2025 }, { "pmid": "37521237", "title": "A case of recalcitrant prurigo nodularis with heightened expression of STAT 3 and STAT 6 and its dramatic response to tofacitinib", "doi": "10.4103/idoj.idoj_508_22", "year": 2023 } ] } }, { "id": 37264, "drug": "LB-1", "drug_type": "drug", "drug_domain": "pancreatic_cancer", "predicate_ab": "inhibits", "mediator": "STAT3", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "prurigo nodularis", "outcome_type": "disease", "outcome_domain": "rheumatoid_arthritis", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "lb-1", "mediator_canonical": "STAT3", "outcome_canonical": "prurigo nodularis", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "25655308", "title": "LB‐1 Exerts Antitumor Activity in Pancreatic Cancer by Inhibiting HIF‐1α and Stat3 Signaling", "doi": "10.1002/jcp.24949", "year": 2015 } ], "bc": [ { "pmid": "39912139", "title": "Translating tissue expression of STAT 1, 3 and 6 in prurigo nodularis to clinical efficacy of oral tofacitinib – A prospective single-arm investigational study", "doi": "10.25259/ijdvl_1017_2024", "year": 2025 }, { "pmid": "40162359", "title": "Successful Use of Tofacitinib in Paediatric Prurigo Nodularis: A Report of Four Cases", "doi": "10.4103/ijd.ijd_842_24", "year": 2025 }, { "pmid": "37521237", "title": "A case of recalcitrant prurigo nodularis with heightened expression of STAT 3 and STAT 6 and its dramatic response to tofacitinib", "doi": "10.4103/idoj.idoj_508_22", "year": 2023 } ] } }, { "id": 37291, "drug": "Ref-1 inhibitors", "drug_type": "drug", "drug_domain": "pancreatic_cancer", "predicate_ab": "inhibits", "mediator": "STAT3", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "prurigo nodularis", "outcome_type": "disease", "outcome_domain": "rheumatoid_arthritis", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "ref-1 inhibitors", "mediator_canonical": "STAT3", "outcome_canonical": "prurigo nodularis", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "39635662", "title": "Combating PDAC Drug Resistance: The Role of Ref-1 Inhibitors in Accelerating Progress in Pancreatic Cancer Research", "doi": "10.33696/signaling.5.126", "year": 2024 } ], "bc": [ { "pmid": "39912139", "title": "Translating tissue expression of STAT 1, 3 and 6 in prurigo nodularis to clinical efficacy of oral tofacitinib – A prospective single-arm investigational study", "doi": "10.25259/ijdvl_1017_2024", "year": 2025 }, { "pmid": "40162359", "title": "Successful Use of Tofacitinib in Paediatric Prurigo Nodularis: A Report of Four Cases", "doi": "10.4103/ijd.ijd_842_24", "year": 2025 }, { "pmid": "37521237", "title": "A case of recalcitrant prurigo nodularis with heightened expression of STAT 3 and STAT 6 and its dramatic response to tofacitinib", "doi": "10.4103/idoj.idoj_508_22", "year": 2023 } ] } }, { "id": 37262, "drug": "durvalumab", "drug_type": "drug", "drug_domain": "pancreatic_cancer", "predicate_ab": "inhibits", "mediator": "PD-L1", "mediator_type": "protein", "predicate_bc": "decreases", "outcome": "T cell infiltration", "outcome_type": "phenotype", "outcome_domain": "rheumatoid_arthritis", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "completed", "clinical_trial_nct_ids": [ "NCT03426657", "NCT03853187", "NCT02997995" ], "literature_status": "reproduces_known", "drug_canonical": "durvalumab", "mediator_canonical": "PD-L1", "outcome_canonical": "t cell infiltration", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37452505", "title": "Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: An early exploratory analysis of real‐world data", "doi": "10.1111/liv.15641", "year": 2023 }, { "pmid": "33688022", "title": "Safety and activity of the TGFβ receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer", "doi": "10.1136/jitc-2020-002068", "year": 2021 }, { "pmid": "31230047", "title": "A Phase 1b/2 Study of the Bruton Tyrosine Kinase Inhibitor Ibrutinib and the PD-L1 Inhibitor Durvalumab in Patients with Pretreated Solid Tumors", "doi": "10.1159/000500571", "year": 2019 } ], "bc": [ { "pmid": "36936967", "title": "Intra-articular delivery of AAV vectors encoding PD-L1 attenuates joint inflammation and tissue damage in a mouse model of rheumatoid arthritis", "doi": "10.3389/fimmu.2023.1116084", "year": 2023 } ] } }, { "id": 37283, "drug": "tocilizumab", "drug_type": "drug", "drug_domain": "pancreatic_cancer", "predicate_ab": "inhibits", "mediator": "STAT3", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "prurigo nodularis", "outcome_type": "disease", "outcome_domain": "rheumatoid_arthritis", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "tocilizumab", "mediator_canonical": "STAT3", "outcome_canonical": "prurigo nodularis", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "34440697", "title": "The P2X7 Receptor Stimulates IL-6 Release from Pancreatic Stellate Cells and Tocilizumab Prevents Activation of STAT3 in Pancreatic Cancer Cells", "doi": "10.3390/cells10081928", "year": 2021 } ], "bc": [ { "pmid": "39912139", "title": "Translating tissue expression of STAT 1, 3 and 6 in prurigo nodularis to clinical efficacy of oral tofacitinib – A prospective single-arm investigational study", "doi": "10.25259/ijdvl_1017_2024", "year": 2025 }, { "pmid": "40162359", "title": "Successful Use of Tofacitinib in Paediatric Prurigo Nodularis: A Report of Four Cases", "doi": "10.4103/ijd.ijd_842_24", "year": 2025 }, { "pmid": "37521237", "title": "A case of recalcitrant prurigo nodularis with heightened expression of STAT 3 and STAT 6 and its dramatic response to tofacitinib", "doi": "10.4103/idoj.idoj_508_22", "year": 2023 } ] } }, { "id": 37278, "drug": "ursolic acid", "drug_type": "drug", "drug_domain": "pancreatic_cancer", "predicate_ab": "inhibits", "mediator": "STAT3", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "prurigo nodularis", "outcome_type": "disease", "outcome_domain": "rheumatoid_arthritis", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "ursolic acid", "mediator_canonical": "STAT3", "outcome_canonical": "prurigo nodularis", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "26909608", "title": "Ursolic acid inhibits the growth of human pancreatic cancer and enhances the antitumor potential of gemcitabine in an orthotopic mouse model through suppression of the inflammatory microenvironment", "doi": "10.18632/oncotarget.7537", "year": 2016 } ], "bc": [ { "pmid": "39912139", "title": "Translating tissue expression of STAT 1, 3 and 6 in prurigo nodularis to clinical efficacy of oral tofacitinib – A prospective single-arm investigational study", "doi": "10.25259/ijdvl_1017_2024", "year": 2025 }, { "pmid": "40162359", "title": "Successful Use of Tofacitinib in Paediatric Prurigo Nodularis: A Report of Four Cases", "doi": "10.4103/ijd.ijd_842_24", "year": 2025 }, { "pmid": "37521237", "title": "A case of recalcitrant prurigo nodularis with heightened expression of STAT 3 and STAT 6 and its dramatic response to tofacitinib", "doi": "10.4103/idoj.idoj_508_22", "year": 2023 } ] } }, { "id": 37285, "drug": "high-dose VPA", "drug_type": "drug", "drug_domain": "pancreatic_cancer", "predicate_ab": "suppresses", "mediator": "STAT3", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "prurigo nodularis", "outcome_type": "disease", "outcome_domain": "rheumatoid_arthritis", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "high-dose vpa", "mediator_canonical": "STAT3", "outcome_canonical": "prurigo nodularis", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "31244991", "title": "Combination chemotherapy of valproic acid (VPA) and gemcitabine regulates STAT3/Bmi1 pathway to differentially potentiate the motility of pancreatic cancer cells", "doi": "10.1186/s13578-019-0312-0", "year": 2019 } ], "bc": [ { "pmid": "39912139", "title": "Translating tissue expression of STAT 1, 3 and 6 in prurigo nodularis to clinical efficacy of oral tofacitinib – A prospective single-arm investigational study", "doi": "10.25259/ijdvl_1017_2024", "year": 2025 }, { "pmid": "40162359", "title": "Successful Use of Tofacitinib in Paediatric Prurigo Nodularis: A Report of Four Cases", "doi": "10.4103/ijd.ijd_842_24", "year": 2025 }, { "pmid": "37521237", "title": "A case of recalcitrant prurigo nodularis with heightened expression of STAT 3 and STAT 6 and its dramatic response to tofacitinib", "doi": "10.4103/idoj.idoj_508_22", "year": 2023 } ] } }, { "id": 37266, "drug": "STAT3 inhibitors", "drug_type": "drug", "drug_domain": "pancreatic_cancer", "predicate_ab": "inhibits", "mediator": "STAT3", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "prurigo nodularis", "outcome_type": "disease", "outcome_domain": "rheumatoid_arthritis", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "stat3 inhibitors", "mediator_canonical": "STAT3", "outcome_canonical": "prurigo nodularis", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "27748818", "title": "STAT3 as a potential therapeutic target in ALDH+ and CD44+/CD24+ stem cell-like pancreatic cancer cells", "doi": "10.3892/ijo.2016.3728", "year": 2016 } ], "bc": [ { "pmid": "39912139", "title": "Translating tissue expression of STAT 1, 3 and 6 in prurigo nodularis to clinical efficacy of oral tofacitinib – A prospective single-arm investigational study", "doi": "10.25259/ijdvl_1017_2024", "year": 2025 }, { "pmid": "40162359", "title": "Successful Use of Tofacitinib in Paediatric Prurigo Nodularis: A Report of Four Cases", "doi": "10.4103/ijd.ijd_842_24", "year": 2025 }, { "pmid": "37521237", "title": "A case of recalcitrant prurigo nodularis with heightened expression of STAT 3 and STAT 6 and its dramatic response to tofacitinib", "doi": "10.4103/idoj.idoj_508_22", "year": 2023 } ] } }, { "id": 37265, "drug": "durvalumab", "drug_type": "drug", "drug_domain": "pancreatic_cancer", "predicate_ab": "inhibits", "mediator": "PD-L1", "mediator_type": "protein", "predicate_bc": "decreases", "outcome": "joint swelling", "outcome_type": "phenotype", "outcome_domain": "rheumatoid_arthritis", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "durvalumab", "mediator_canonical": "PD-L1", "outcome_canonical": "joint swelling", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37452505", "title": "Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: An early exploratory analysis of real‐world data", "doi": "10.1111/liv.15641", "year": 2023 }, { "pmid": "33688022", "title": "Safety and activity of the TGFβ receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer", "doi": "10.1136/jitc-2020-002068", "year": 2021 }, { "pmid": "31230047", "title": "A Phase 1b/2 Study of the Bruton Tyrosine Kinase Inhibitor Ibrutinib and the PD-L1 Inhibitor Durvalumab in Patients with Pretreated Solid Tumors", "doi": "10.1159/000500571", "year": 2019 } ], "bc": [ { "pmid": "36936967", "title": "Intra-articular delivery of AAV vectors encoding PD-L1 attenuates joint inflammation and tissue damage in a mouse model of rheumatoid arthritis", "doi": "10.3389/fimmu.2023.1116084", "year": 2023 } ] } }, { "id": 37298, "drug": "Gemcitabine", "drug_type": "drug", "drug_domain": "pancreatic_cancer", "predicate_ab": "inhibits", "mediator": "STAT3", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "prurigo nodularis", "outcome_type": "disease", "outcome_domain": "rheumatoid_arthritis", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "gemcitabine", "mediator_canonical": "STAT3", "outcome_canonical": "prurigo nodularis", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "27687804", "title": "Gemcitabine reduces MDSCs, tregs and TGFβ-1 while restoring the teff/treg ratio in patients with pancreatic cancer", "doi": "10.1186/s12967-016-1037-z", "year": 2016 } ], "bc": [ { "pmid": "39912139", "title": "Translating tissue expression of STAT 1, 3 and 6 in prurigo nodularis to clinical efficacy of oral tofacitinib – A prospective single-arm investigational study", "doi": "10.25259/ijdvl_1017_2024", "year": 2025 }, { "pmid": "40162359", "title": "Successful Use of Tofacitinib in Paediatric Prurigo Nodularis: A Report of Four Cases", "doi": "10.4103/ijd.ijd_842_24", "year": 2025 }, { "pmid": "37521237", "title": "A case of recalcitrant prurigo nodularis with heightened expression of STAT 3 and STAT 6 and its dramatic response to tofacitinib", "doi": "10.4103/idoj.idoj_508_22", "year": 2023 } ] } }, { "id": 37297, "drug": "L61H46", "drug_type": "drug", "drug_domain": "pancreatic_cancer", "predicate_ab": "downregulates", "mediator": "STAT3", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "prurigo nodularis", "outcome_type": "disease", "outcome_domain": "rheumatoid_arthritis", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "l61h46", "mediator_canonical": "STAT3", "outcome_canonical": "prurigo nodularis", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "29606890", "title": "L61H46 shows potent efficacy against human pancreatic cancer through inhibiting STAT3 pathway", "doi": "10.2147/cmar.s159090", "year": 2018 } ], "bc": [ { "pmid": "39912139", "title": "Translating tissue expression of STAT 1, 3 and 6 in prurigo nodularis to clinical efficacy of oral tofacitinib – A prospective single-arm investigational study", "doi": "10.25259/ijdvl_1017_2024", "year": 2025 }, { "pmid": "40162359", "title": "Successful Use of Tofacitinib in Paediatric Prurigo Nodularis: A Report of Four Cases", "doi": "10.4103/ijd.ijd_842_24", "year": 2025 }, { "pmid": "37521237", "title": "A case of recalcitrant prurigo nodularis with heightened expression of STAT 3 and STAT 6 and its dramatic response to tofacitinib", "doi": "10.4103/idoj.idoj_508_22", "year": 2023 } ] } }, { "id": 37288, "drug": "silibinin", "drug_type": "drug", "drug_domain": "pancreatic_cancer", "predicate_ab": "inhibits", "mediator": "STAT3", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "prurigo nodularis", "outcome_type": "disease", "outcome_domain": "rheumatoid_arthritis", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "silibinin", "mediator_canonical": "STAT3", "outcome_canonical": "prurigo nodularis", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "26510913", "title": "Silibinin-mediated metabolic reprogramming attenuates pancreatic cancer-induced cachexia and tumor growth", "doi": "10.18632/oncotarget.5843", "year": 2015 } ], "bc": [ { "pmid": "39912139", "title": "Translating tissue expression of STAT 1, 3 and 6 in prurigo nodularis to clinical efficacy of oral tofacitinib – A prospective single-arm investigational study", "doi": "10.25259/ijdvl_1017_2024", "year": 2025 }, { "pmid": "40162359", "title": "Successful Use of Tofacitinib in Paediatric Prurigo Nodularis: A Report of Four Cases", "doi": "10.4103/ijd.ijd_842_24", "year": 2025 }, { "pmid": "37521237", "title": "A case of recalcitrant prurigo nodularis with heightened expression of STAT 3 and STAT 6 and its dramatic response to tofacitinib", "doi": "10.4103/idoj.idoj_508_22", "year": 2023 } ] } }, { "id": 37280, "drug": "Src/EGFR inhibition", "drug_type": "drug", "drug_domain": "pancreatic_cancer", "predicate_ab": "inhibits", "mediator": "STAT3", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "prurigo nodularis", "outcome_type": "disease", "outcome_domain": "rheumatoid_arthritis", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "unknown", "drug_canonical": "src/egfr inhibition", "mediator_canonical": "STAT3", "outcome_canonical": "prurigo nodularis", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "31949002", "title": "Combined Src/EGFR Inhibition Targets STAT3 Signaling and Induces Stromal Remodeling to Improve Survival in Pancreatic Cancer", "doi": "10.1158/1541-7786.mcr-19-0741", "year": 2020 } ], "bc": [ { "pmid": "39912139", "title": "Translating tissue expression of STAT 1, 3 and 6 in prurigo nodularis to clinical efficacy of oral tofacitinib – A prospective single-arm investigational study", "doi": "10.25259/ijdvl_1017_2024", "year": 2025 }, { "pmid": "40162359", "title": "Successful Use of Tofacitinib in Paediatric Prurigo Nodularis: A Report of Four Cases", "doi": "10.4103/ijd.ijd_842_24", "year": 2025 }, { "pmid": "37521237", "title": "A case of recalcitrant prurigo nodularis with heightened expression of STAT 3 and STAT 6 and its dramatic response to tofacitinib", "doi": "10.4103/idoj.idoj_508_22", "year": 2023 } ] } }, { "id": 37299, "drug": "Eckol", "drug_type": "drug", "drug_domain": "pancreatic_cancer", "predicate_ab": "downregulates", "mediator": "STAT3", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "prurigo nodularis", "outcome_type": "disease", "outcome_domain": "rheumatoid_arthritis", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "eckol", "mediator_canonical": "STAT3", "outcome_canonical": "prurigo nodularis", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "31572529", "title": "Eckol inhibits Reg3A‑induced proliferation of human SW1990 pancreatic cancer cells", "doi": "10.3892/etm.2019.7889", "year": 2019 } ], "bc": [ { "pmid": "39912139", "title": "Translating tissue expression of STAT 1, 3 and 6 in prurigo nodularis to clinical efficacy of oral tofacitinib – A prospective single-arm investigational study", "doi": "10.25259/ijdvl_1017_2024", "year": 2025 }, { "pmid": "40162359", "title": "Successful Use of Tofacitinib in Paediatric Prurigo Nodularis: A Report of Four Cases", "doi": "10.4103/ijd.ijd_842_24", "year": 2025 }, { "pmid": "37521237", "title": "A case of recalcitrant prurigo nodularis with heightened expression of STAT 3 and STAT 6 and its dramatic response to tofacitinib", "doi": "10.4103/idoj.idoj_508_22", "year": 2023 } ] } }, { "id": 37296, "drug": "AMD3100", "drug_type": "drug", "drug_domain": "pancreatic_cancer", "predicate_ab": "inhibits", "mediator": "CXCR4", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "Osteoarthritis", "outcome_type": "disease", "outcome_domain": "rheumatoid_arthritis", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "plerixafor", "mediator_canonical": "CXCR4", "outcome_canonical": "osteoarthritis", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "36145541", "title": "Development and Evaluation of a Peptide Heterodimeric Tracer Targeting CXCR4 and Integrin αvβ3 for Pancreatic Cancer Imaging", "doi": "10.3390/pharmaceutics14091791", "year": 2022 }, { "pmid": "35797269", "title": "Interaction of immune checkpoint PD-1 and chemokine receptor 4 (CXCR4) promotes a malignant phenotype in pancreatic cancer cells", "doi": "10.1371/journal.pone.0270832", "year": 2022 }, { "pmid": "33127761", "title": "CXCR4 inhibition in human pancreatic and colorectal cancers induces an integrated immune response", "doi": "10.1073/pnas.2013644117", "year": 2020 } ], "bc": [ { "pmid": "41331944", "title": "Targeting the CXCL12/CXCR4 pathway by an optimized derivative or EPI-X4 preserves chondrocyte function and offers a novel therapeutic approach in rheumatic diseases", "doi": "10.1186/s13075-025-03691-9", "year": 2025 } ] } }, { "id": 39433, "drug": "GLP-1", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "downregulates", "mediator": "IL-18", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "ALS", "outcome_type": "disease", "outcome_domain": "als", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "glp-1", "mediator_canonical": "il-18", "outcome_canonical": "amyotrophic lateral sclerosis", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "33641439", "title": "GLP-1 alleviates NLRP3 inflammasome-dependent inflammation in perivascular adipose tissue by inhibiting the NF-κB signalling pathway", "doi": "10.1177/0300060521992981", "year": 2021 } ], "bc": [ { "pmid": "41789732", "title": "3D Artificial Skin Model As a Novel Strategy for the Detection of Pyroptosis-Cascade Activation in Amyotrophic Lateral Sclerosis", "doi": "10.1021/acsami.5c23366", "year": 2026 }, { "pmid": "32515902", "title": "Longitudinal biomarkers in amyotrophic lateral sclerosis", "doi": "10.1002/acn3.51078", "year": 2020 }, { "pmid": "29472887", "title": "A Possible Role for Platelet-Activating Factor Receptor in Amyotrophic Lateral Sclerosis Treatment", "doi": "10.3389/fneur.2018.00039", "year": 2018 } ] } }, { "id": 37673, "drug": "tofacitinib", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "downregulates", "mediator": "IFN-γ", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "ALS", "outcome_type": "disease", "outcome_domain": "als", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "preclinical_only", "clinical_trial_nct_ids": [ "NCT06689982" ], "literature_status": "partial_evidence", "drug_canonical": "tofacitinib", "mediator_canonical": "ifn-γ", "outcome_canonical": "amyotrophic lateral sclerosis", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "33899926", "title": "Lymphocyte modulation by tofacitinib in patients with rheumatoid arthritis", "doi": "10.1111/cei.13609", "year": 2021 }, { "pmid": "32616791", "title": "Tofacitinib treatment aggravates Staphylococcus aureus septic arthritis, but attenuates sepsis and enterotoxin induced shock in mice", "doi": "10.1038/s41598-020-67928-0", "year": 2020 }, { "pmid": "31638166", "title": "The JAK inhibitor tofacitinib ameliorates immune‑mediated liver injury in mice", "doi": "10.3892/mmr.2019.10750", "year": 2019 } ], "bc": [ { "pmid": "26332465", "title": "Elevated Levels of IFN-γ in CSF and Serum of Patients with Amyotrophic Lateral Sclerosis", "doi": "10.1371/journal.pone.0136937", "year": 2015 } ] } }, { "id": 37733, "drug": "tofacitinib", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "inhibits", "mediator": "STAT3", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "muscle atrophy", "outcome_type": "phenotype", "outcome_domain": "als", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "tofacitinib", "mediator_canonical": "STAT3", "outcome_canonical": "muscle atrophy", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40373045", "title": "Rheumatoid arthritis synovial fluid induces JAK-dependent intracellular activation of human sensory neurons", "doi": "10.1172/jci.insight.186646", "year": 2025 }, { "pmid": "32927842", "title": "Tofacitinib and Baricitinib Are Taken up by Different Uptake Mechanisms Determining the Efficacy of Both Drugs in RA", "doi": "10.3390/ijms21186632", "year": 2020 }, { "pmid": "30357932", "title": "JAK1/3 inhibition preserves epidermal morphology in full‐thickness 3D skin models of atopic dermatitis and psoriasis", "doi": "10.1111/jdv.15301", "year": 2018 } ], "bc": [ { "pmid": "38914173", "title": "Sunitinib-mediated inhibition of STAT3 in skeletal muscle and spinal cord does not affect the disease in a mouse model of ALS", "doi": "10.1016/j.nbd.2024.106576", "year": 2024 } ] } }, { "id": 58327, "drug": "tofacitinib", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "inhibits", "mediator": "STAT3", "mediator_type": "protein", "predicate_bc": "treats", "outcome": "tau-N368-induced protein pathology", "outcome_type": "disease", "outcome_domain": "alzheimer", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40373045", "title": "Rheumatoid arthritis synovial fluid induces JAK-dependent intracellular activation of human sensory neurons", "doi": "10.1172/jci.insight.186646", "year": 2025 }, { "pmid": "32927842", "title": "Tofacitinib and Baricitinib Are Taken up by Different Uptake Mechanisms Determining the Efficacy of Both Drugs in RA", "doi": "10.3390/ijms21186632", "year": 2020 }, { "pmid": "30357932", "title": "JAK1/3 inhibition preserves epidermal morphology in full‐thickness 3D skin models of atopic dermatitis and psoriasis", "doi": "10.1111/jdv.15301", "year": 2018 } ], "bc": [ { "pmid": "37843229", "title": "STAT3 ameliorates truncated tau-induced cognitive deficits", "doi": "10.4103/1673-5374.382253", "year": 2023 } ] } }, { "id": 58328, "drug": "tofacitinib", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "downregulates", "mediator": "IFN-γ", "mediator_type": "protein", "predicate_bc": "increases", "outcome": "Alzheimer's disease", "outcome_type": "disease", "outcome_domain": "alzheimer", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "33899926", "title": "Lymphocyte modulation by tofacitinib in patients with rheumatoid arthritis", "doi": "10.1111/cei.13609", "year": 2021 }, { "pmid": "32616791", "title": "Tofacitinib treatment aggravates Staphylococcus aureus septic arthritis, but attenuates sepsis and enterotoxin induced shock in mice", "doi": "10.1038/s41598-020-67928-0", "year": 2020 }, { "pmid": "31638166", "title": "The JAK inhibitor tofacitinib ameliorates immune‑mediated liver injury in mice", "doi": "10.3892/mmr.2019.10750", "year": 2019 } ], "bc": [ { "pmid": "37158957", "title": "Inflammatory panel cytokines are elevated in the neocortex of late-stage Alzheimer’s disease but not Lewy body dementias", "doi": "10.1186/s12974-023-02789-8", "year": 2023 } ] } }, { "id": 37928, "drug": "tofacitinib", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "inhibits", "mediator": "STAT3", "mediator_type": "protein", "predicate_bc": "predicts", "outcome": "Alzheimer's disease", "outcome_type": "disease", "outcome_domain": "alzheimer", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "completed", "clinical_trial_nct_ids": [ "NCT04529876" ], "literature_status": "reproduces_known", "drug_canonical": "tofacitinib", "mediator_canonical": "STAT3", "outcome_canonical": "Alzheimer disease", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40373045", "title": "Rheumatoid arthritis synovial fluid induces JAK-dependent intracellular activation of human sensory neurons", "doi": "10.1172/jci.insight.186646", "year": 2025 }, { "pmid": "32927842", "title": "Tofacitinib and Baricitinib Are Taken up by Different Uptake Mechanisms Determining the Efficacy of Both Drugs in RA", "doi": "10.3390/ijms21186632", "year": 2020 }, { "pmid": "30357932", "title": "JAK1/3 inhibition preserves epidermal morphology in full‐thickness 3D skin models of atopic dermatitis and psoriasis", "doi": "10.1111/jdv.15301", "year": 2018 } ], "bc": [ { "pmid": "40745201", "title": "Uncovering active ingredients and mechanisms of Pholiota adiposa in the treatment of Alzheimer’s disease based on network pharmacology and bioinformatics", "doi": "10.1038/s41598-025-94861-x", "year": 2025 } ] } }, { "id": 37902, "drug": "Euphorbia factor L3", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "binds_to", "mediator": "Rac1", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "Alzheimer's disease", "outcome_type": "disease", "outcome_domain": "alzheimer", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "euphorbia factor l3", "mediator_canonical": "rac1", "outcome_canonical": "Alzheimer disease", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "35475473", "title": "Euphorbia factor L3 ameliorates rheumatoid arthritis by suppressing the inflammatory response by targeting Rac family small GTPase 1", "doi": "10.1080/21655979.2022.2066761", "year": 2022 } ], "bc": [ { "pmid": "31321704", "title": "Inhibition of Rac1-dependent forgetting alleviates memory deficits in animal models of Alzheimer’s disease", "doi": "10.1007/s13238-019-0641-0", "year": 2019 }, { "pmid": "30005699", "title": "Rac1 activation links tau hyperphosphorylation and Aβ dysmetabolism in Alzheimer’s disease", "doi": "10.1186/s40478-018-0567-4", "year": 2018 } ] } }, { "id": 37258, "drug": "low-dose VPA", "drug_type": "drug", "drug_domain": "pancreatic_cancer", "predicate_ab": "activates", "mediator": "STAT3", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "prurigo nodularis", "outcome_type": "disease", "outcome_domain": "rheumatoid_arthritis", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "low-dose vpa", "mediator_canonical": "STAT3", "outcome_canonical": "prurigo nodularis", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "31244991", "title": "Combination chemotherapy of valproic acid (VPA) and gemcitabine regulates STAT3/Bmi1 pathway to differentially potentiate the motility of pancreatic cancer cells", "doi": "10.1186/s13578-019-0312-0", "year": 2019 } ], "bc": [ { "pmid": "39912139", "title": "Translating tissue expression of STAT 1, 3 and 6 in prurigo nodularis to clinical efficacy of oral tofacitinib – A prospective single-arm investigational study", "doi": "10.25259/ijdvl_1017_2024", "year": 2025 }, { "pmid": "40162359", "title": "Successful Use of Tofacitinib in Paediatric Prurigo Nodularis: A Report of Four Cases", "doi": "10.4103/ijd.ijd_842_24", "year": 2025 }, { "pmid": "37521237", "title": "A case of recalcitrant prurigo nodularis with heightened expression of STAT 3 and STAT 6 and its dramatic response to tofacitinib", "doi": "10.4103/idoj.idoj_508_22", "year": 2023 } ] } }, { "id": 38280, "drug": "tofacitinib", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "inhibits", "mediator": "STAT3", "mediator_type": "protein", "predicate_bc": "prevents", "outcome": "GABAergic neuron loss", "outcome_type": "phenotype", "outcome_domain": "epilepsy", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "tofacitinib", "mediator_canonical": "STAT3", "outcome_canonical": "gabaergic neuron loss", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40373045", "title": "Rheumatoid arthritis synovial fluid induces JAK-dependent intracellular activation of human sensory neurons", "doi": "10.1172/jci.insight.186646", "year": 2025 }, { "pmid": "32927842", "title": "Tofacitinib and Baricitinib Are Taken up by Different Uptake Mechanisms Determining the Efficacy of Both Drugs in RA", "doi": "10.3390/ijms21186632", "year": 2020 }, { "pmid": "30357932", "title": "JAK1/3 inhibition preserves epidermal morphology in full‐thickness 3D skin models of atopic dermatitis and psoriasis", "doi": "10.1111/jdv.15301", "year": 2018 } ], "bc": [ { "pmid": "36825472", "title": "Blockage of STAT3 during epileptogenesis prevents GABAergic loss and imprinting of the epileptic state", "doi": "10.1093/brain/awad055", "year": 2023 } ] } }, { "id": 38284, "drug": "EMO", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "inhibits", "mediator": "HMGB1", "mediator_type": "protein", "predicate_bc": "predicts", "outcome": "drug-resistant epilepsy", "outcome_type": "disease", "outcome_domain": "epilepsy", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "emo", "mediator_canonical": "HMGB1", "outcome_canonical": "drug-resistant epilepsy", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37324499", "title": "The elucidation of the anti-inflammatory mechanism of EMO in rheumatoid arthritis through an integrative approach combining bioinformatics and experimental verification", "doi": "10.3389/fphar.2023.1195567", "year": 2023 } ], "bc": [ { "pmid": "34747496", "title": "High‐mobility group box 1 as a predictive biomarker for drug‐resistant epilepsy: A proof‐of‐concept study", "doi": "10.1111/epi.17116", "year": 2021 } ] } }, { "id": 38274, "drug": "tofacitinib", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "inhibits", "mediator": "STAT3", "mediator_type": "protein", "predicate_bc": "prevents", "outcome": "persistence of reactive glial states", "outcome_type": "phenotype", "outcome_domain": "epilepsy", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "tofacitinib", "mediator_canonical": "STAT3", "outcome_canonical": "persistence of reactive glial states", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40373045", "title": "Rheumatoid arthritis synovial fluid induces JAK-dependent intracellular activation of human sensory neurons", "doi": "10.1172/jci.insight.186646", "year": 2025 }, { "pmid": "32927842", "title": "Tofacitinib and Baricitinib Are Taken up by Different Uptake Mechanisms Determining the Efficacy of Both Drugs in RA", "doi": "10.3390/ijms21186632", "year": 2020 }, { "pmid": "30357932", "title": "JAK1/3 inhibition preserves epidermal morphology in full‐thickness 3D skin models of atopic dermatitis and psoriasis", "doi": "10.1111/jdv.15301", "year": 2018 } ], "bc": [ { "pmid": "36825472", "title": "Blockage of STAT3 during epileptogenesis prevents GABAergic loss and imprinting of the epileptic state", "doi": "10.1093/brain/awad055", "year": 2023 } ] } }, { "id": 38276, "drug": "P2-1", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "binds_to", "mediator": "HMGB1", "mediator_type": "protein", "predicate_bc": "predicts", "outcome": "drug-resistant epilepsy", "outcome_type": "disease", "outcome_domain": "epilepsy", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "p2-1", "mediator_canonical": "HMGB1", "outcome_canonical": "drug-resistant epilepsy", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41810149", "title": "Repurposing a detrimental antibody epitope as targeted therapeutics for sepsis and rheumatoid arthritis", "doi": "10.1186/s40779-026-00686-8", "year": 2026 } ], "bc": [ { "pmid": "34747496", "title": "High‐mobility group box 1 as a predictive biomarker for drug‐resistant epilepsy: A proof‐of‐concept study", "doi": "10.1111/epi.17116", "year": 2021 } ] } }, { "id": 38278, "drug": "tofacitinib", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "inhibits", "mediator": "STAT3", "mediator_type": "protein", "predicate_bc": "prevents", "outcome": "imprinting of epileptic activity patterns", "outcome_type": "phenotype", "outcome_domain": "epilepsy", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "tofacitinib", "mediator_canonical": "STAT3", "outcome_canonical": "imprinting of epileptic activity patterns", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40373045", "title": "Rheumatoid arthritis synovial fluid induces JAK-dependent intracellular activation of human sensory neurons", "doi": "10.1172/jci.insight.186646", "year": 2025 }, { "pmid": "32927842", "title": "Tofacitinib and Baricitinib Are Taken up by Different Uptake Mechanisms Determining the Efficacy of Both Drugs in RA", "doi": "10.3390/ijms21186632", "year": 2020 }, { "pmid": "30357932", "title": "JAK1/3 inhibition preserves epidermal morphology in full‐thickness 3D skin models of atopic dermatitis and psoriasis", "doi": "10.1111/jdv.15301", "year": 2018 } ], "bc": [ { "pmid": "36825472", "title": "Blockage of STAT3 during epileptogenesis prevents GABAergic loss and imprinting of the epileptic state", "doi": "10.1093/brain/awad055", "year": 2023 } ] } }, { "id": 38435, "drug": "tofacitinib", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "downregulates", "mediator": "IFN-γ", "mediator_type": "protein", "predicate_bc": "sensitizes_to", "outcome": "ferroptosis", "outcome_type": "phenotype", "outcome_domain": "glioblastoma", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "tofacitinib", "mediator_canonical": "ifn-γ", "outcome_canonical": "ferroptosis", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "33899926", "title": "Lymphocyte modulation by tofacitinib in patients with rheumatoid arthritis", "doi": "10.1111/cei.13609", "year": 2021 }, { "pmid": "32616791", "title": "Tofacitinib treatment aggravates Staphylococcus aureus septic arthritis, but attenuates sepsis and enterotoxin induced shock in mice", "doi": "10.1038/s41598-020-67928-0", "year": 2020 }, { "pmid": "31638166", "title": "The JAK inhibitor tofacitinib ameliorates immune‑mediated liver injury in mice", "doi": "10.3892/mmr.2019.10750", "year": 2019 } ], "bc": [ { "pmid": "41388541", "title": "Dual-targeted bacterial outer membrane vesicles enhance glioblastoma immunotherapy by regulating tumor microenvironment and inducing IFN-γ-mediated ferroptosis", "doi": "10.1186/s12951-025-03922-w", "year": 2025 } ] } }, { "id": 38436, "drug": "tofacitinib", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "inhibits", "mediator": "STAT3", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "glioblastoma progression", "outcome_type": "disease", "outcome_domain": "glioblastoma", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "tofacitinib", "mediator_canonical": "STAT3", "outcome_canonical": "glioblastoma progression", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40373045", "title": "Rheumatoid arthritis synovial fluid induces JAK-dependent intracellular activation of human sensory neurons", "doi": "10.1172/jci.insight.186646", "year": 2025 }, { "pmid": "32927842", "title": "Tofacitinib and Baricitinib Are Taken up by Different Uptake Mechanisms Determining the Efficacy of Both Drugs in RA", "doi": "10.3390/ijms21186632", "year": 2020 }, { "pmid": "30357932", "title": "JAK1/3 inhibition preserves epidermal morphology in full‐thickness 3D skin models of atopic dermatitis and psoriasis", "doi": "10.1111/jdv.15301", "year": 2018 } ], "bc": [ { "pmid": "41747967", "title": "STAT3 signaling as an adaptive hub in glioblastoma: Network rewiring, non-coding RNA circuits, and therapeutic vulnerabilities", "doi": "10.1016/j.nbd.2026.107330", "year": 2026 } ] } }, { "id": 20906, "drug": "CLR01", "drug_type": "drug", "drug_domain": "alzheimer", "predicate_ab": "binds_to", "mediator": "TAU", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "Multiple Sclerosis", "outcome_type": "disease", "outcome_domain": "multiple_sclerosis", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "clr01", "mediator_canonical": "MAPT", "outcome_canonical": "multiple sclerosis", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "31046227", "title": "Major Differences between the Self-Assembly and Seeding Behavior of Heparin-Induced and in Vitro Phosphorylated Tau and Their Modulation by Potential Inhibitors", "doi": "10.1021/acschembio.9b00325", "year": 2019 }, { "pmid": "30062477", "title": "Native Top-Down Mass Spectrometry and Ion Mobility Spectrometry of the Interaction of Tau Protein with a Molecular Tweezer Assembly Modulator", "doi": "10.1007/s13361-018-2027-6", "year": 2018 } ], "bc": [ { "pmid": "29865854", "title": "BDNF and Tau as Biomarkers of Severity in Multiple Sclerosis", "doi": "10.2217/bmm-2017-0374", "year": 2018 } ] } }, { "id": 59120, "drug": "upadacitinib", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "downregulates", "mediator": "C-reactive protein", "mediator_type": "biomarker", "predicate_bc": "predicts", "outcome": "heart failure", "outcome_type": "disease", "outcome_domain": "heart_failure", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "39909970", "title": "Real-world effectiveness and retention rate of upadacitinib in patients with rheumatoid arthritis: results from a multicentre study", "doi": "10.1007/s10238-025-01578-2", "year": 2025 } ], "bc": [ { "pmid": "33804661", "title": "C-Reactive Protein as a Risk Marker for Post-Infarct Heart Failure over a Multi-Year Period", "doi": "10.3390/ijms22063169", "year": 2021 }, { "pmid": "28883850", "title": "C-reactive protein levels predict systolic heart failure and outcome in patients with first ST-elevation myocardial infarction treated with coronary angioplasty", "doi": "10.5114/aoms.2017.69327", "year": 2017 } ] } }, { "id": 59123, "drug": "upadacitinib", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "downregulates", "mediator": "C-reactive protein", "mediator_type": "biomarker", "predicate_bc": "predicts", "outcome": "in-hospital mortality", "outcome_type": "phenotype", "outcome_domain": "heart_failure", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "39909970", "title": "Real-world effectiveness and retention rate of upadacitinib in patients with rheumatoid arthritis: results from a multicentre study", "doi": "10.1007/s10238-025-01578-2", "year": 2025 } ], "bc": [ { "pmid": "32169690", "title": "Biomarkers for prediction of mortality in left-sided infective endocarditis", "doi": "10.1016/j.ijid.2020.03.009", "year": 2020 }, { "pmid": "29382606", "title": "Outcomes of infective endocarditis in the current era: Early predictors of a poor prognosis", "doi": "10.1016/j.ijid.2018.01.016", "year": 2018 }, { "pmid": "28357890", "title": "Pneumonia and inflammation in acute decompensated heart failure: a registry-based analysis of 1939 patients", "doi": "10.1177/2048872617700874", "year": 2017 } ] } }, { "id": 59154, "drug": "poly(I:C)", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "upregulates", "mediator": "MIAT", "mediator_type": "gene", "predicate_bc": "correlates_with", "outcome": "chronic Chagas disease cardiomyopathy", "outcome_type": "disease", "outcome_domain": "heart_failure", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "34524081", "title": "Expression signature of inflammation-associated long non-coding RNAs in adult-onset Still's disease", "doi": "10.55563/clinexprheumatol/4jx6zy", "year": 2021 } ], "bc": [ { "pmid": "26951817", "title": "Myocardial Infarction–Associated Transcript, a Long Noncoding RNA, Is Overexpressed During Dilated Cardiomyopathy Due to Chronic Chagas Disease", "doi": "10.1093/infdis/jiw095", "year": 2016 } ] } }, { "id": 59156, "drug": "tofacitinib", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "downregulates", "mediator": "C-reactive protein", "mediator_type": "biomarker", "predicate_bc": "predicts", "outcome": "heart failure", "outcome_type": "disease", "outcome_domain": "heart_failure", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40692219", "title": "Short‐Term Effectiveness of Sulfasalazine and Tofacitinib in NSAID ‐Refractory Reactive Arthritis: An Observational Study", "doi": "10.1111/1756-185x.70370", "year": 2025 } ], "bc": [ { "pmid": "33804661", "title": "C-Reactive Protein as a Risk Marker for Post-Infarct Heart Failure over a Multi-Year Period", "doi": "10.3390/ijms22063169", "year": 2021 }, { "pmid": "28883850", "title": "C-reactive protein levels predict systolic heart failure and outcome in patients with first ST-elevation myocardial infarction treated with coronary angioplasty", "doi": "10.5114/aoms.2017.69327", "year": 2017 } ] } }, { "id": 1639, "drug": "STA", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "binds_to", "mediator": "EGFR", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "pancreatic ductal adenocarcinoma", "outcome_type": "disease", "outcome_domain": "pancreatic_cancer", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "sta", "mediator_canonical": "EGFR", "outcome_canonical": "pancreatic ductal adenocarcinoma", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37751870", "title": "Evaluation of the Antitumor Potential of Soloxolone Tryptamide against Glioblastoma Multiforme Using in silico, in vitro, and in vivo Approaches", "doi": "10.1134/s000629792307012x", "year": 2023 } ], "bc": [ { "pmid": "40130819", "title": "Identification of Tumor‐Specific Surface Proteins Enables Quantification of Extracellular Vesicle Subtypes for Early Detection of Pancreatic Ductal Adenocarcinoma", "doi": "10.1002/advs.202414982", "year": 2025 }, { "pmid": "31584260", "title": "Design and Evaluation of PEGylated Liposomal Formulation of a Novel Multikinase Inhibitor for Enhanced Chemosensitivity and Inhibition of Metastatic Pancreatic Ductal Adenocarcinoma", "doi": "10.1021/acs.bioconjchem.9b00632", "year": 2019 }, { "pmid": "26339400", "title": "EGFR expression in pancreatic intraepithelial neoplasia and ductal adenocarcinoma.", "doi": null, "year": 2015 } ] } }, { "id": 59175, "drug": "tocilizumab", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "downregulates", "mediator": "C-reactive protein", "mediator_type": "biomarker", "predicate_bc": "predicts", "outcome": "heart failure", "outcome_type": "disease", "outcome_domain": "heart_failure", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "39754984", "title": "Anti-IL-6R Ab tocilizumab to treat paraneoplastic inflammatory syndrome of solid cancers", "doi": "10.1016/j.esmoop.2024.104088", "year": 2025 } ], "bc": [ { "pmid": "33804661", "title": "C-Reactive Protein as a Risk Marker for Post-Infarct Heart Failure over a Multi-Year Period", "doi": "10.3390/ijms22063169", "year": 2021 }, { "pmid": "28883850", "title": "C-reactive protein levels predict systolic heart failure and outcome in patients with first ST-elevation myocardial infarction treated with coronary angioplasty", "doi": "10.5114/aoms.2017.69327", "year": 2017 } ] } }, { "id": 38755, "drug": "RMT1-10", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "suppresses", "mediator": "IL-17A", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "inflammatory bowel disease", "outcome_type": "disease", "outcome_domain": "inflammatory_bowel_disease", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "rmt1-10", "mediator_canonical": "il-17a", "outcome_canonical": "inflammatory bowel disease", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "38975703", "title": "Inhibition of the TIM-1 and -3 signaling pathway ameliorates disease in a murine model of rheumatoid arthritis", "doi": "10.1093/cei/uxae056", "year": 2024 } ], "bc": [ { "pmid": "32724117", "title": "Serum interleukin 17A and interleukin 17F in children with inflammatory bowel disease", "doi": "10.1038/s41598-020-69567-x", "year": 2020 }, { "pmid": "27049090", "title": "Relationship between serum interleukin-17 level and inflammatory bowel disease.", "doi": null, "year": 2016 } ] } }, { "id": 38782, "drug": "tofacitinib", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "inhibits", "mediator": "STAT3", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "UC", "outcome_type": "disease", "outcome_domain": "inflammatory_bowel_disease", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "active", "clinical_trial_nct_ids": [ "NCT07198113", "NCT06095128", "NCT06089590" ], "literature_status": "reproduces_known", "drug_canonical": "tofacitinib", "mediator_canonical": "STAT3", "outcome_canonical": "uc", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40373045", "title": "Rheumatoid arthritis synovial fluid induces JAK-dependent intracellular activation of human sensory neurons", "doi": "10.1172/jci.insight.186646", "year": 2025 }, { "pmid": "32927842", "title": "Tofacitinib and Baricitinib Are Taken up by Different Uptake Mechanisms Determining the Efficacy of Both Drugs in RA", "doi": "10.3390/ijms21186632", "year": 2020 }, { "pmid": "30357932", "title": "JAK1/3 inhibition preserves epidermal morphology in full‐thickness 3D skin models of atopic dermatitis and psoriasis", "doi": "10.1111/jdv.15301", "year": 2018 } ], "bc": [ { "pmid": "36857861", "title": "Therapeutic targets for inflammatory bowel disease: proteome-wide Mendelian randomization and colocalization analyses", "doi": "10.1016/j.ebiom.2023.104494", "year": 2023 } ] } }, { "id": 59386, "drug": "nimbolide", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "downregulates", "mediator": "IL-17", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "Crohn's disease", "outcome_type": "disease", "outcome_domain": "inflammatory_bowel_disease", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "36437579", "title": "Nimbolide attenuates complete Freund's adjuvant induced arthritis through expression regulation of toll‐like receptors signaling pathway", "doi": "10.1002/ptr.7672", "year": 2022 } ], "bc": [ { "pmid": "39803916", "title": "Correlation between IL-17 and inflammatory bowel disease", "doi": "10.55133/eji.320106", "year": 2025 }, { "pmid": "38229938", "title": "Crohn's disease and clinical management today: How it does?", "doi": "10.5662/wjm.v13.i5.399", "year": 2023 }, { "pmid": "28533995", "title": "Crohn’s Disease and Ulcerative Colitis Show Unique Cytokine Profiles", "doi": "10.7759/cureus.1177", "year": 2017 } ] } }, { "id": 38851, "drug": "tofacitinib", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "downregulates", "mediator": "IFN-γ", "mediator_type": "protein", "predicate_bc": "treats", "outcome": "experimental autoimmune encephalomyelitis", "outcome_type": "disease", "outcome_domain": "multiple_sclerosis", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "tofacitinib", "mediator_canonical": "ifn-γ", "outcome_canonical": "experimental autoimmune encephalomyelitis", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "33899926", "title": "Lymphocyte modulation by tofacitinib in patients with rheumatoid arthritis", "doi": "10.1111/cei.13609", "year": 2021 }, { "pmid": "32616791", "title": "Tofacitinib treatment aggravates Staphylococcus aureus septic arthritis, but attenuates sepsis and enterotoxin induced shock in mice", "doi": "10.1038/s41598-020-67928-0", "year": 2020 }, { "pmid": "31638166", "title": "The JAK inhibitor tofacitinib ameliorates immune‑mediated liver injury in mice", "doi": "10.3892/mmr.2019.10750", "year": 2019 } ], "bc": [ { "pmid": "29321652", "title": "Innate IFN-γ ameliorates experimental autoimmune encephalomyelitis and promotes myeloid expansion and PDL-1 expression", "doi": "10.1038/s41598-017-18543-z", "year": 2018 } ] } }, { "id": 38847, "drug": "namilumab", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "binds_to", "mediator": "GM-CSF", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "multiple sclerosis", "outcome_type": "disease", "outcome_domain": "multiple_sclerosis", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "namilumab", "mediator_canonical": "gm-csf", "outcome_canonical": "multiple sclerosis", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "30999929", "title": "Efficacy and safety of namilumab, a human monoclonal antibody against granulocyte-macrophage colony-stimulating factor (GM-CSF) ligand in patients with rheumatoid arthritis (RA) with either an inadequate response to background methotrexate therapy or an inadequate response or intolerance to an anti-TNF (tumour necrosis factor) biologic therapy: a randomized, controlled trial", "doi": "10.1186/s13075-019-1879-x", "year": 2019 }, { "pmid": "30168415", "title": "Randomized, double-blind, placebo-controlled, phase I study of the safety and pharmacokinetics of namilumab in healthy Japanese and Caucasian men", "doi": "10.5414/cp203235", "year": 2018 } ], "bc": [ { "pmid": "34285924", "title": "Gene Regulatory Network of Human GM-CSF-Secreting T Helper Cells", "doi": "10.1155/2021/8880585", "year": 2021 } ] } }, { "id": 38869, "drug": "namilumab", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "binds_to", "mediator": "GM-CSF", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "disability accumulation", "outcome_type": "phenotype", "outcome_domain": "multiple_sclerosis", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "namilumab", "mediator_canonical": "gm-csf", "outcome_canonical": "disability accumulation", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "30999929", "title": "Efficacy and safety of namilumab, a human monoclonal antibody against granulocyte-macrophage colony-stimulating factor (GM-CSF) ligand in patients with rheumatoid arthritis (RA) with either an inadequate response to background methotrexate therapy or an inadequate response or intolerance to an anti-TNF (tumour necrosis factor) biologic therapy: a randomized, controlled trial", "doi": "10.1186/s13075-019-1879-x", "year": 2019 }, { "pmid": "30168415", "title": "Randomized, double-blind, placebo-controlled, phase I study of the safety and pharmacokinetics of namilumab in healthy Japanese and Caucasian men", "doi": "10.5414/cp203235", "year": 2018 } ], "bc": [ { "pmid": "30079049", "title": "Intrathecal B Cells in MS Have Significantly Greater Lymphangiogenic Potential Compared to B Cells Derived From Non-MS Subjects", "doi": "10.3389/fneur.2018.00554", "year": 2018 } ] } }, { "id": 38866, "drug": "namilumab", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "binds_to", "mediator": "GM-CSF", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "relapsing-remitting multiple sclerosis", "outcome_type": "disease", "outcome_domain": "multiple_sclerosis", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "namilumab", "mediator_canonical": "gm-csf", "outcome_canonical": "relapsing-remitting multiple sclerosis", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "30999929", "title": "Efficacy and safety of namilumab, a human monoclonal antibody against granulocyte-macrophage colony-stimulating factor (GM-CSF) ligand in patients with rheumatoid arthritis (RA) with either an inadequate response to background methotrexate therapy or an inadequate response or intolerance to an anti-TNF (tumour necrosis factor) biologic therapy: a randomized, controlled trial", "doi": "10.1186/s13075-019-1879-x", "year": 2019 }, { "pmid": "30168415", "title": "Randomized, double-blind, placebo-controlled, phase I study of the safety and pharmacokinetics of namilumab in healthy Japanese and Caucasian men", "doi": "10.5414/cp203235", "year": 2018 } ], "bc": [ { "pmid": "31237799", "title": "T cells producing GM-CSF and IL-13 are enriched in the cerebrospinal fluid of relapsing MS patients", "doi": "10.1177/1352458519852092", "year": 2019 } ] } }, { "id": 38860, "drug": "tofacitinib", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "downregulates", "mediator": "IFN-γ", "mediator_type": "protein", "predicate_bc": "treats", "outcome": "NMOSD", "outcome_type": "disease", "outcome_domain": "multiple_sclerosis", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "tofacitinib", "mediator_canonical": "ifn-γ", "outcome_canonical": "nmosd", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "33899926", "title": "Lymphocyte modulation by tofacitinib in patients with rheumatoid arthritis", "doi": "10.1111/cei.13609", "year": 2021 }, { "pmid": "32616791", "title": "Tofacitinib treatment aggravates Staphylococcus aureus septic arthritis, but attenuates sepsis and enterotoxin induced shock in mice", "doi": "10.1038/s41598-020-67928-0", "year": 2020 }, { "pmid": "31638166", "title": "The JAK inhibitor tofacitinib ameliorates immune‑mediated liver injury in mice", "doi": "10.3892/mmr.2019.10750", "year": 2019 } ], "bc": [ { "pmid": "37931066", "title": "Interferon-γ controls aquaporin 4-specific Th17 and B cells in neuromyelitis optica spectrum disorder", "doi": "10.1093/brain/awad373", "year": 2023 } ] } }, { "id": 38859, "drug": "tofacitinib", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "downregulates", "mediator": "IFN-γ", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "oral microbiome dysbiosis", "outcome_type": "phenotype", "outcome_domain": "multiple_sclerosis", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "tofacitinib", "mediator_canonical": "ifn-γ", "outcome_canonical": "oral microbiome dysbiosis", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "33899926", "title": "Lymphocyte modulation by tofacitinib in patients with rheumatoid arthritis", "doi": "10.1111/cei.13609", "year": 2021 }, { "pmid": "32616791", "title": "Tofacitinib treatment aggravates Staphylococcus aureus septic arthritis, but attenuates sepsis and enterotoxin induced shock in mice", "doi": "10.1038/s41598-020-67928-0", "year": 2020 }, { "pmid": "31638166", "title": "The JAK inhibitor tofacitinib ameliorates immune‑mediated liver injury in mice", "doi": "10.3892/mmr.2019.10750", "year": 2019 } ], "bc": [ { "pmid": "41051180", "title": "Relapsing–Remitting Multiple Sclerosis Is Associated With a Dysbiotic Oral Microbiome", "doi": "10.1002/acn3.70212", "year": 2025 } ] } }, { "id": 1579, "drug": "Oxamate", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "downregulates", "mediator": "EGFR", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "pancreatic ductal adenocarcinoma", "outcome_type": "disease", "outcome_domain": "pancreatic_cancer", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "oxamate", "mediator_canonical": "EGFR", "outcome_canonical": "pancreatic ductal adenocarcinoma", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40565174", "title": "Oxamate, an LDHA Inhibitor, Inhibits Stemness, Including EMT and High DNA Repair Ability, Induces Senescence, and Exhibits Radiosensitizing Effects in Glioblastoma Cells", "doi": "10.3390/ijms26125710", "year": 2025 } ], "bc": [ { "pmid": "40130819", "title": "Identification of Tumor‐Specific Surface Proteins Enables Quantification of Extracellular Vesicle Subtypes for Early Detection of Pancreatic Ductal Adenocarcinoma", "doi": "10.1002/advs.202414982", "year": 2025 }, { "pmid": "31584260", "title": "Design and Evaluation of PEGylated Liposomal Formulation of a Novel Multikinase Inhibitor for Enhanced Chemosensitivity and Inhibition of Metastatic Pancreatic Ductal Adenocarcinoma", "doi": "10.1021/acs.bioconjchem.9b00632", "year": 2019 }, { "pmid": "26339400", "title": "EGFR expression in pancreatic intraepithelial neoplasia and ductal adenocarcinoma.", "doi": null, "year": 2015 } ] } }, { "id": 39049, "drug": "methotrexate", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "upregulates", "mediator": "CD73", "mediator_type": "protein", "predicate_bc": "predicts", "outcome": "poor prognosis", "outcome_type": "phenotype", "outcome_domain": "pancreatic_cancer", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "completed", "clinical_trial_nct_ids": [ "NCT01782339", "NCT00002835", "NCT00357084" ], "literature_status": "reproduces_known", "drug_canonical": "methotrexate", "mediator_canonical": "cd73", "outcome_canonical": null, "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "31684171", "title": "Methotrexate Restores CD73 Expression on Th1.17 in Rheumatoid Arthritis and Psoriatic Arthritis Patients and May Contribute to Its Anti-Inflammatory Effect through Ado Production", "doi": "10.3390/jcm8111859", "year": 2019 } ], "bc": [ { "pmid": "37851808", "title": "CD73 controls Myosin II–driven invasion, metastasis, and immunosuppression in amoeboid pancreatic cancer cells", "doi": "10.1126/sciadv.adi0244", "year": 2023 }, { "pmid": "32643277", "title": "CD73 acts as a prognostic biomarker and promotes progression and immune escape in pancreatic cancer", "doi": "10.1111/jcmm.15500", "year": 2020 }, { "pmid": "30927045", "title": "The distinct role of CD73 in the progression of pancreatic cancer", "doi": "10.1007/s00109-018-01742-0", "year": 2019 } ] } }, { "id": 39051, "drug": "tofacitinib", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "inhibits", "mediator": "STAT3", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "drug resistance", "outcome_type": "phenotype", "outcome_domain": "pancreatic_cancer", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "completed", "clinical_trial_nct_ids": [ "NCT04141904" ], "literature_status": "partial_evidence", "drug_canonical": "tofacitinib", "mediator_canonical": "STAT3", "outcome_canonical": null, "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40373045", "title": "Rheumatoid arthritis synovial fluid induces JAK-dependent intracellular activation of human sensory neurons", "doi": "10.1172/jci.insight.186646", "year": 2025 }, { "pmid": "32927842", "title": "Tofacitinib and Baricitinib Are Taken up by Different Uptake Mechanisms Determining the Efficacy of Both Drugs in RA", "doi": "10.3390/ijms21186632", "year": 2020 }, { "pmid": "30357932", "title": "JAK1/3 inhibition preserves epidermal morphology in full‐thickness 3D skin models of atopic dermatitis and psoriasis", "doi": "10.1111/jdv.15301", "year": 2018 } ], "bc": [ { "pmid": "38464736", "title": "Role of STAT3 in pancreatic cancer", "doi": "10.37349/etat.2024.00202", "year": 2024 } ] } }, { "id": 39058, "drug": "Tormentic acid", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "binds_to", "mediator": "EGFR", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "pancreatic ductal adenocarcinoma", "outcome_type": "disease", "outcome_domain": "pancreatic_cancer", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "tormentic acid", "mediator_canonical": "EGFR", "outcome_canonical": "pancreatic ductal adenocarcinoma", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "35813340", "title": "Network pharmacology and bioinformatics analysis identified essential genes of Jingulian in the treatment of rheumatoid arthritis and COVID-19", "doi": "10.21037/atm-22-1665", "year": 2022 } ], "bc": [ { "pmid": "40130819", "title": "Identification of Tumor‐Specific Surface Proteins Enables Quantification of Extracellular Vesicle Subtypes for Early Detection of Pancreatic Ductal Adenocarcinoma", "doi": "10.1002/advs.202414982", "year": 2025 }, { "pmid": "31584260", "title": "Design and Evaluation of PEGylated Liposomal Formulation of a Novel Multikinase Inhibitor for Enhanced Chemosensitivity and Inhibition of Metastatic Pancreatic Ductal Adenocarcinoma", "doi": "10.1021/acs.bioconjchem.9b00632", "year": 2019 }, { "pmid": "26339400", "title": "EGFR expression in pancreatic intraepithelial neoplasia and ductal adenocarcinoma.", "doi": null, "year": 2015 } ] } }, { "id": 39042, "drug": "namilumab", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "binds_to", "mediator": "GM-CSF", "mediator_type": "protein", "predicate_bc": "predicts", "outcome": "metastatic PDAC", "outcome_type": "disease", "outcome_domain": "pancreatic_cancer", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "namilumab", "mediator_canonical": "gm-csf", "outcome_canonical": "metastatic pdac", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "30999929", "title": "Efficacy and safety of namilumab, a human monoclonal antibody against granulocyte-macrophage colony-stimulating factor (GM-CSF) ligand in patients with rheumatoid arthritis (RA) with either an inadequate response to background methotrexate therapy or an inadequate response or intolerance to an anti-TNF (tumour necrosis factor) biologic therapy: a randomized, controlled trial", "doi": "10.1186/s13075-019-1879-x", "year": 2019 }, { "pmid": "30168415", "title": "Randomized, double-blind, placebo-controlled, phase I study of the safety and pharmacokinetics of namilumab in healthy Japanese and Caucasian men", "doi": "10.5414/cp203235", "year": 2018 } ], "bc": [ { "pmid": "35020761", "title": "Pancreatic ductal adenocarcinoma: Prognostic indicators of advanced disease", "doi": "10.1371/journal.pone.0262439", "year": 2022 } ] } }, { "id": 39044, "drug": "geniposide", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "binds_to", "mediator": "EGFR", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "pancreatic ductal adenocarcinoma", "outcome_type": "disease", "outcome_domain": "pancreatic_cancer", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "geniposide", "mediator_canonical": "EGFR", "outcome_canonical": "pancreatic ductal adenocarcinoma", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40640294", "title": "Exploring the anti-inflammatory mechanism of geniposide in rheumatoid arthritis via network pharmacology and experimental validation", "doi": "10.1038/s41598-025-10196-7", "year": 2025 } ], "bc": [ { "pmid": "40130819", "title": "Identification of Tumor‐Specific Surface Proteins Enables Quantification of Extracellular Vesicle Subtypes for Early Detection of Pancreatic Ductal Adenocarcinoma", "doi": "10.1002/advs.202414982", "year": 2025 }, { "pmid": "31584260", "title": "Design and Evaluation of PEGylated Liposomal Formulation of a Novel Multikinase Inhibitor for Enhanced Chemosensitivity and Inhibition of Metastatic Pancreatic Ductal Adenocarcinoma", "doi": "10.1021/acs.bioconjchem.9b00632", "year": 2019 }, { "pmid": "26339400", "title": "EGFR expression in pancreatic intraepithelial neoplasia and ductal adenocarcinoma.", "doi": null, "year": 2015 } ] } }, { "id": 39060, "drug": "Spinifoliumin A", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "binds_to", "mediator": "EGFR", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "pancreatic ductal adenocarcinoma", "outcome_type": "disease", "outcome_domain": "pancreatic_cancer", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "spinifoliumin a", "mediator_canonical": "EGFR", "outcome_canonical": "pancreatic ductal adenocarcinoma", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "39339390", "title": "Discovery of Coumarins from Zanthoxylum dimorphophyllum var. spinifoliumas and Their Potential against Rheumatoid Arthritis", "doi": "10.3390/molecules29184395", "year": 2024 } ], "bc": [ { "pmid": "40130819", "title": "Identification of Tumor‐Specific Surface Proteins Enables Quantification of Extracellular Vesicle Subtypes for Early Detection of Pancreatic Ductal Adenocarcinoma", "doi": "10.1002/advs.202414982", "year": 2025 }, { "pmid": "31584260", "title": "Design and Evaluation of PEGylated Liposomal Formulation of a Novel Multikinase Inhibitor for Enhanced Chemosensitivity and Inhibition of Metastatic Pancreatic Ductal Adenocarcinoma", "doi": "10.1021/acs.bioconjchem.9b00632", "year": 2019 }, { "pmid": "26339400", "title": "EGFR expression in pancreatic intraepithelial neoplasia and ductal adenocarcinoma.", "doi": null, "year": 2015 } ] } }, { "id": 31936, "drug": "Silybin", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "inhibits", "mediator": "STAT3", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "prurigo nodularis", "outcome_type": "disease", "outcome_domain": "rheumatoid_arthritis", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "silybin", "mediator_canonical": "STAT3", "outcome_canonical": "prurigo nodularis", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "35946547", "title": "Impressive response to dabrafenib and trametinib plus silybin in a heavily pretreated IDH wild-type glioblastoma patient with BRAFV600E-mutant and SOX2 amplification", "doi": "10.1097/cad.0000000000001376", "year": 2022 } ], "bc": [ { "pmid": "39912139", "title": "Translating tissue expression of STAT 1, 3 and 6 in prurigo nodularis to clinical efficacy of oral tofacitinib – A prospective single-arm investigational study", "doi": "10.25259/ijdvl_1017_2024", "year": 2025 }, { "pmid": "40162359", "title": "Successful Use of Tofacitinib in Paediatric Prurigo Nodularis: A Report of Four Cases", "doi": "10.4103/ijd.ijd_842_24", "year": 2025 }, { "pmid": "37521237", "title": "A case of recalcitrant prurigo nodularis with heightened expression of STAT 3 and STAT 6 and its dramatic response to tofacitinib", "doi": "10.4103/idoj.idoj_508_22", "year": 2023 } ] } }, { "id": 40420, "drug": "Genistein", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "downregulates", "mediator": "C-reactive protein", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "colonic inflammation", "outcome_type": "phenotype", "outcome_domain": "inflammatory_bowel_disease", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "genistein", "mediator_canonical": "c-reactive protein", "outcome_canonical": "colonic inflammation", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "30784939", "title": "Genistein enhances the secretion of glucagon-like peptide-1 (GLP-1) via downregulation of inflammatory responses", "doi": "10.1016/j.biopha.2019.108670", "year": 2019 } ], "bc": [ { "pmid": "34127687", "title": "C-reactive protein is superior to fecal biomarkers for evaluating colon-wide active inflammation in ulcerative colitis", "doi": "10.1038/s41598-021-90558-z", "year": 2021 } ] } }, { "id": 40419, "drug": "liraglutide", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "activates", "mediator": "AMPK", "mediator_type": "protein", "predicate_bc": "treats", "outcome": "intestinal inflammation", "outcome_type": "disease", "outcome_domain": "inflammatory_bowel_disease", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "liraglutide", "mediator_canonical": "AMPK", "outcome_canonical": "intestinal inflammation", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "39779525", "title": "The protective effects of liraglutide in reducing lipid droplets accumulation and myocardial fibrosis in diabetic cardiomyopathy", "doi": "10.1007/s00018-024-05558-9", "year": 2025 }, { "pmid": "34357376", "title": "Glucagon-like peptide-1 attenuates cardiac hypertrophy via the AngII/AT1R/ACE2 and AMPK/mTOR/p70S6K pathways", "doi": "10.1093/abbs/gmab099", "year": 2021 }, { "pmid": "27473212", "title": "The GLP-1 receptor agonists exenatide and liraglutide activate Glucose transport by an AMPK-dependent mechanism", "doi": "10.1186/s12967-016-0985-7", "year": 2016 } ], "bc": [ { "pmid": "33252129", "title": "Salicylates Ameliorate Intestinal Inflammation by Activating Macrophage AMPK", "doi": "10.1093/ibd/izaa305", "year": 2020 } ] } }, { "id": 40823, "drug": "exenatide", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "activates", "mediator": "AMPK", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "pancreatic cancer progression", "outcome_type": "disease", "outcome_domain": "pancreatic_cancer", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "exenatide", "mediator_canonical": "AMPK", "outcome_canonical": "pancreatic cancer progression", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "33044023", "title": "Exenatide improves random‐pattern skin flap survival via TFE3 mediated autophagy augment", "doi": "10.1002/jcp.30102", "year": 2020 }, { "pmid": "27473212", "title": "The GLP-1 receptor agonists exenatide and liraglutide activate Glucose transport by an AMPK-dependent mechanism", "doi": "10.1186/s12967-016-0985-7", "year": 2016 }, { "pmid": "25720388", "title": "Exenatide Protects Against Glucose- and Lipid-Induced Endothelial Dysfunction: Evidence for Direct Vasodilation Effect of GLP-1 Receptor Agonists in Humans", "doi": "10.2337/db14-0976", "year": 2015 } ], "bc": [ { "pmid": "31205544", "title": "AMPK Inhibition Suppresses the Malignant Phenotype of Pancreatic Cancer Cells in Part by Attenuating Aerobic Glycolysis", "doi": "10.7150/jca.28299", "year": 2019 } ] } }, { "id": 39415, "drug": "geraniol", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "suppresses", "mediator": "RAGE", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "ALS", "outcome_type": "disease", "outcome_domain": "als", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "geraniol", "mediator_canonical": "rage", "outcome_canonical": "amyotrophic lateral sclerosis", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "25679220", "title": "Geraniol, Alone and in Combination with Pioglitazone, Ameliorates Fructose-Induced Metabolic Syndrome in Rats via the Modulation of Both Inflammatory and Oxidative Stress Status", "doi": "10.1371/journal.pone.0117516", "year": 2015 } ], "bc": [ { "pmid": "35216298", "title": "The Involvement of RAGE and Its Ligands during Progression of ALS in SOD1 G93A Transgenic Mice", "doi": "10.3390/ijms23042184", "year": 2022 }, { "pmid": "27242430", "title": "Soluble RAGE Treatment Delays Progression of Amyotrophic Lateral Sclerosis in SOD1 Mice", "doi": "10.3389/fncel.2016.00117", "year": 2016 }, { "pmid": "26733811", "title": "Receptor for Advanced Glycation End Products and its Inflammatory Ligands are Upregulated in Amyotrophic Lateral Sclerosis", "doi": "10.3389/fncel.2015.00485", "year": 2015 } ] } }, { "id": 39450, "drug": "pioglitazone", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "downregulates", "mediator": "RAGE", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "ALS", "outcome_type": "disease", "outcome_domain": "als", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "completed", "clinical_trial_nct_ids": [ "NCT00919555", "NCT00690118" ], "literature_status": "reproduces_known", "drug_canonical": "pioglitazone", "mediator_canonical": "rage", "outcome_canonical": "amyotrophic lateral sclerosis", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "28708885", "title": "Pioglitazone ameliorates glomerular NLRP3 inflammasome activation in apolipoprotein E knockout mice with diabetes mellitus", "doi": "10.1371/journal.pone.0181248", "year": 2017 } ], "bc": [ { "pmid": "35216298", "title": "The Involvement of RAGE and Its Ligands during Progression of ALS in SOD1 G93A Transgenic Mice", "doi": "10.3390/ijms23042184", "year": 2022 }, { "pmid": "27242430", "title": "Soluble RAGE Treatment Delays Progression of Amyotrophic Lateral Sclerosis in SOD1 Mice", "doi": "10.3389/fncel.2016.00117", "year": 2016 }, { "pmid": "26733811", "title": "Receptor for Advanced Glycation End Products and its Inflammatory Ligands are Upregulated in Amyotrophic Lateral Sclerosis", "doi": "10.3389/fncel.2015.00485", "year": 2015 } ] } }, { "id": 39427, "drug": "Spatholobus suberectus", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "downregulates", "mediator": "RAGE", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "ALS", "outcome_type": "disease", "outcome_domain": "als", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "spatholobus suberectus", "mediator_canonical": "rage", "outcome_canonical": "amyotrophic lateral sclerosis", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "30223524", "title": "Spatholobus suberectus Ameliorates Diabetes-Induced Renal Damage by Suppressing Advanced Glycation End Products in db/db Mice", "doi": "10.3390/ijms19092774", "year": 2018 } ], "bc": [ { "pmid": "35216298", "title": "The Involvement of RAGE and Its Ligands during Progression of ALS in SOD1 G93A Transgenic Mice", "doi": "10.3390/ijms23042184", "year": 2022 }, { "pmid": "27242430", "title": "Soluble RAGE Treatment Delays Progression of Amyotrophic Lateral Sclerosis in SOD1 Mice", "doi": "10.3389/fncel.2016.00117", "year": 2016 }, { "pmid": "26733811", "title": "Receptor for Advanced Glycation End Products and its Inflammatory Ligands are Upregulated in Amyotrophic Lateral Sclerosis", "doi": "10.3389/fncel.2015.00485", "year": 2015 } ] } }, { "id": 39460, "drug": "amlexanox", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "inhibits", "mediator": "TBK1", "mediator_type": "gene", "predicate_bc": "causes", "outcome": "frontotemporal dementia", "outcome_type": "disease", "outcome_domain": "als", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "amlexanox", "mediator_canonical": "tbk1", "outcome_canonical": "frontotemporal dementia", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "29935921", "title": "Loss of Tbk1 kinase activity protects mice from diet-induced metabolic dysfunction", "doi": "10.1016/j.molmet.2018.06.007", "year": 2018 } ], "bc": [ { "pmid": "41645024", "title": " TBK 1 ‐Associated Primary Lateral Sclerosis Followed by Right Temporal Variant Frontotemporal Dementia", "doi": "10.1002/acn3.70329", "year": 2026 }, { "pmid": "34800171", "title": "TBK1 haploinsufficiency results in changes in the K63-ubiquitination profiles in brain and fibroblasts from affected and presymptomatic mutation carriers", "doi": "10.1007/s00415-021-10887-x", "year": 2021 }, { "pmid": "29146049", "title": "Common and rare TBK1 variants in early-onset Alzheimer disease in a European cohort", "doi": "10.1016/j.neurobiolaging.2017.10.012", "year": 2017 } ] } }, { "id": 39466, "drug": "liraglutide", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "induces", "mediator": "FGF21", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "tau phosphorylation", "outcome_type": "phenotype", "outcome_domain": "als", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "liraglutide", "mediator_canonical": "fgf21", "outcome_canonical": "tau phosphorylation", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37030441", "title": "Fibroblast growth factor-21 is required for weight loss induced by the glucagon-like peptide-1 receptor agonist liraglutide in male mice fed high carbohydrate diets", "doi": "10.1016/j.molmet.2023.101718", "year": 2023 }, { "pmid": "33851458", "title": "Hepatic Fibroblast Growth Factor 21 Is Involved in Mediating Functions of Liraglutide in Mice With Dietary Challenge", "doi": "10.1002/hep.31856", "year": 2021 }, { "pmid": "30827929", "title": "Liver-derived fibroblast growth factor 21 mediates effects of glucagon-like peptide-1 in attenuating hepatic glucose output", "doi": "10.1016/j.ebiom.2019.02.037", "year": 2019 } ], "bc": [ { "pmid": "30770297", "title": "Repeated cold exposures protect a mouse model of Alzheimer's disease against cold-induced tau phosphorylation", "doi": "10.1016/j.molmet.2019.01.008", "year": 2019 } ] } }, { "id": 39419, "drug": "GLP-1", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "downregulates", "mediator": "RAGE", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "ALS", "outcome_type": "disease", "outcome_domain": "als", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "glp-1", "mediator_canonical": "rage", "outcome_canonical": "amyotrophic lateral sclerosis", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "30852419", "title": "Glucagon-like peptide-1 attenuates endothelial barrier injury in diabetes via cAMP/PKA mediated down-regulation of MLC phosphorylation", "doi": "10.1016/j.biopha.2019.108667", "year": 2019 } ], "bc": [ { "pmid": "35216298", "title": "The Involvement of RAGE and Its Ligands during Progression of ALS in SOD1 G93A Transgenic Mice", "doi": "10.3390/ijms23042184", "year": 2022 }, { "pmid": "27242430", "title": "Soluble RAGE Treatment Delays Progression of Amyotrophic Lateral Sclerosis in SOD1 Mice", "doi": "10.3389/fncel.2016.00117", "year": 2016 }, { "pmid": "26733811", "title": "Receptor for Advanced Glycation End Products and its Inflammatory Ligands are Upregulated in Amyotrophic Lateral Sclerosis", "doi": "10.3389/fncel.2015.00485", "year": 2015 } ] } }, { "id": 39461, "drug": "Eucommia ulmoides", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "downregulates", "mediator": "RAGE", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "ALS", "outcome_type": "disease", "outcome_domain": "als", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "eucommia ulmoides", "mediator_canonical": "rage", "outcome_canonical": "amyotrophic lateral sclerosis", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "29495397", "title": "Eucommia ulmoides Ameliorates Glucotoxicity by Suppressing Advanced Glycation End-Products in Diabetic Mice Kidney", "doi": "10.3390/nu10030265", "year": 2018 } ], "bc": [ { "pmid": "35216298", "title": "The Involvement of RAGE and Its Ligands during Progression of ALS in SOD1 G93A Transgenic Mice", "doi": "10.3390/ijms23042184", "year": 2022 }, { "pmid": "27242430", "title": "Soluble RAGE Treatment Delays Progression of Amyotrophic Lateral Sclerosis in SOD1 Mice", "doi": "10.3389/fncel.2016.00117", "year": 2016 }, { "pmid": "26733811", "title": "Receptor for Advanced Glycation End Products and its Inflammatory Ligands are Upregulated in Amyotrophic Lateral Sclerosis", "doi": "10.3389/fncel.2015.00485", "year": 2015 } ] } }, { "id": 39420, "drug": "exenatide", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "activates", "mediator": "AMPK", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "amyotrophic lateral sclerosis", "outcome_type": "disease", "outcome_domain": "als", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "exenatide", "mediator_canonical": "AMPK", "outcome_canonical": "amyotrophic lateral sclerosis", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "33044023", "title": "Exenatide improves random‐pattern skin flap survival via TFE3 mediated autophagy augment", "doi": "10.1002/jcp.30102", "year": 2020 }, { "pmid": "27473212", "title": "The GLP-1 receptor agonists exenatide and liraglutide activate Glucose transport by an AMPK-dependent mechanism", "doi": "10.1186/s12967-016-0985-7", "year": 2016 }, { "pmid": "25720388", "title": "Exenatide Protects Against Glucose- and Lipid-Induced Endothelial Dysfunction: Evidence for Direct Vasodilation Effect of GLP-1 Receptor Agonists in Humans", "doi": "10.2337/db14-0976", "year": 2015 } ], "bc": [ { "pmid": "34393724", "title": "Contribution of Energy Dysfunction to Impaired Protein Translation in Neurodegenerative Diseases", "doi": "10.3389/fncel.2021.668500", "year": 2021 } ] } }, { "id": 39616, "drug": "exercise training", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "upregulates", "mediator": "SIRT1", "mediator_type": "protein", "predicate_bc": "predicts", "outcome": "Alzheimer's disease", "outcome_type": "disease", "outcome_domain": "alzheimer", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "active", "clinical_trial_nct_ids": [ "NCT03981159", "NCT05573490", "NCT06496425" ], "literature_status": "reproduces_known", "drug_canonical": "exercise training", "mediator_canonical": "SIRT1", "outcome_canonical": "Alzheimer disease", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "30988688", "title": "Exercise training upregulates SIRT1 to attenuate inflammation and metabolic dysfunction in kidney and liver of diabetic db/db mice", "doi": "10.1186/s12986-019-0349-4", "year": 2019 } ], "bc": [ { "pmid": "37742223", "title": "Serum sirtuin1: a potential blood biomarker for early diagnosis of Alzheimer’s disease", "doi": "10.18632/aging.205015", "year": 2023 }, { "pmid": "30243024", "title": "Sirt1 enhances tau exon 10 inclusion and improves spatial memory of Htau mice", "doi": "10.18632/aging.101564", "year": 2018 } ] } }, { "id": 39615, "drug": "l-Met-S", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "activates", "mediator": "SIRT1", "mediator_type": "protein", "predicate_bc": "predicts", "outcome": "Alzheimer's disease", "outcome_type": "disease", "outcome_domain": "alzheimer", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "l-met-s", "mediator_canonical": "SIRT1", "outcome_canonical": "Alzheimer disease", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "31532875", "title": "Dietary Supplementation of Methyl Donor l‐Methionine Alters Epigenetic Modification in Type 2 Diabetes", "doi": "10.1002/mnfr.201801401", "year": 2019 } ], "bc": [ { "pmid": "37742223", "title": "Serum sirtuin1: a potential blood biomarker for early diagnosis of Alzheimer’s disease", "doi": "10.18632/aging.205015", "year": 2023 }, { "pmid": "30243024", "title": "Sirt1 enhances tau exon 10 inclusion and improves spatial memory of Htau mice", "doi": "10.18632/aging.101564", "year": 2018 } ] } }, { "id": 39634, "drug": "bromophenols", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "activates", "mediator": "SIRT1", "mediator_type": "protein", "predicate_bc": "predicts", "outcome": "Alzheimer's disease", "outcome_type": "disease", "outcome_domain": "alzheimer", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "bromophenols", "mediator_canonical": "SIRT1", "outcome_canonical": "Alzheimer disease", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41094589", "title": "Marine nutraceuticals as a source of SIRT1 and NRF2 activators for diabetes and aging-related metabolic disorders", "doi": "10.1186/s13098-025-01981-5", "year": 2025 } ], "bc": [ { "pmid": "37742223", "title": "Serum sirtuin1: a potential blood biomarker for early diagnosis of Alzheimer’s disease", "doi": "10.18632/aging.205015", "year": 2023 }, { "pmid": "30243024", "title": "Sirt1 enhances tau exon 10 inclusion and improves spatial memory of Htau mice", "doi": "10.18632/aging.101564", "year": 2018 } ] } }, { "id": 39617, "drug": "Leucettinib-92", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "inhibits", "mediator": "DYRK1A", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "Alzheimer's disease", "outcome_type": "disease", "outcome_domain": "alzheimer", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "leucettinib-92", "mediator_canonical": "dyrk1a", "outcome_canonical": "Alzheimer disease", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40885332", "title": "DYRK1A inhibition restores pancreatic functions and improves glucose metabolism in a preclinical model of type 2 diabetes", "doi": "10.1016/j.molmet.2025.102242", "year": 2025 } ], "bc": [ { "pmid": "41189746", "title": "DYRK1A in the physiology and pathology of the neuron-astrocyte axis", "doi": "10.3389/fnins.2025.1626062", "year": 2025 }, { "pmid": "37015911", "title": "Increased plasma DYRK1A with aging may protect against neurodegenerative diseases", "doi": "10.1038/s41398-023-02419-0", "year": 2023 }, { "pmid": "35803734", "title": "DYRK1A Regulates the Bidirectional Axonal Transport of APP in Human-Derived Neurons", "doi": "10.1523/jneurosci.2551-21.2022", "year": 2022 } ] } }, { "id": 39623, "drug": "linagliptin", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "upregulates", "mediator": "SIRT1", "mediator_type": "protein", "predicate_bc": "predicts", "outcome": "Alzheimer's disease", "outcome_type": "disease", "outcome_domain": "alzheimer", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "completed", "clinical_trial_nct_ids": [ "NCT05768945" ], "literature_status": "reproduces_known", "drug_canonical": "linagliptin", "mediator_canonical": "SIRT1", "outcome_canonical": "Alzheimer disease", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "26010513", "title": "DPP‐4 Inhibitor Linagliptin Attenuates Aβ‐induced Cytotoxicity through Activation of AMPK in Neuronal Cells", "doi": "10.1111/cns.12404", "year": 2015 } ], "bc": [ { "pmid": "37742223", "title": "Serum sirtuin1: a potential blood biomarker for early diagnosis of Alzheimer’s disease", "doi": "10.18632/aging.205015", "year": 2023 }, { "pmid": "30243024", "title": "Sirt1 enhances tau exon 10 inclusion and improves spatial memory of Htau mice", "doi": "10.18632/aging.101564", "year": 2018 } ] } }, { "id": 39642, "drug": "pioglitazone", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "downregulates", "mediator": "GFAP", "mediator_type": "gene", "predicate_bc": "associated_with", "outcome": "Alzheimer's disease", "outcome_type": "disease", "outcome_domain": "alzheimer", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "completed", "clinical_trial_nct_ids": [ "NCT00982202", "NCT01931566", "NCT02284906" ], "literature_status": "reproduces_known", "drug_canonical": "pioglitazone", "mediator_canonical": "GFAP", "outcome_canonical": "Alzheimer disease", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "25599238", "title": "Pioglitazone rapidly reduces neuropathic pain through astrocyte and nongenomic PPARγ mechanisms", "doi": "10.1097/01.j.pain.0000460333.79127.be", "year": 2015 } ], "bc": [ { "pmid": "38236817", "title": "Large-scale gene expression changes in APP/PSEN1 and GFAP mutation models exhibit high congruence with Alzheimer’s disease", "doi": "10.1371/journal.pone.0291995", "year": 2024 }, { "pmid": "30400085", "title": "Changes in Expression Profiles Revealed by Transcriptomic Analysis in Peripheral Blood Mononuclear Cells of Alzheimer’s Disease Patients", "doi": "10.3233/jad-170205", "year": 2018 }, { "pmid": "30040709", "title": "A Selection of Important Genes and Their Correlated Behavior in Alzheimer’s Disease", "doi": "10.3233/jad-170799", "year": 2018 } ] } }, { "id": 5926, "drug": "Chlorotoxin", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "binds_to", "mediator": "MMP-2", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "Alzheimer's disease", "outcome_type": "disease", "outcome_domain": "alzheimer", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "chlorotoxin", "mediator_canonical": "MMP2", "outcome_canonical": "Alzheimer disease", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41955189", "title": "Chlorotoxin does not target matrix metalloproteinase-2 in glioblastoma", "doi": "10.1371/journal.pone.0328964", "year": 2026 } ], "bc": [ { "pmid": "37483327", "title": "Urinary Cytokines as Potential Biomarkers of Mild Cognitive Impairment and Alzheimer’s Disease: A Pilot Study", "doi": "10.3233/adr-220081", "year": 2023 } ] } }, { "id": 1623, "drug": "erlotinib+MLN0128", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "inhibits", "mediator": "EGFR", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "pancreatic ductal adenocarcinoma", "outcome_type": "disease", "outcome_domain": "pancreatic_cancer", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "unknown", "drug_canonical": "erlotinib+mln0128", "mediator_canonical": "EGFR", "outcome_canonical": "pancreatic ductal adenocarcinoma", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "36831214", "title": "Dual Targeting of EGFR and MTOR Pathways Inhibits Glioblastoma Growth by Modulating the Tumor Microenvironment", "doi": "10.3390/cells12040547", "year": 2023 } ], "bc": [ { "pmid": "40130819", "title": "Identification of Tumor‐Specific Surface Proteins Enables Quantification of Extracellular Vesicle Subtypes for Early Detection of Pancreatic Ductal Adenocarcinoma", "doi": "10.1002/advs.202414982", "year": 2025 }, { "pmid": "31584260", "title": "Design and Evaluation of PEGylated Liposomal Formulation of a Novel Multikinase Inhibitor for Enhanced Chemosensitivity and Inhibition of Metastatic Pancreatic Ductal Adenocarcinoma", "doi": "10.1021/acs.bioconjchem.9b00632", "year": 2019 }, { "pmid": "26339400", "title": "EGFR expression in pancreatic intraepithelial neoplasia and ductal adenocarcinoma.", "doi": null, "year": 2015 } ] } }, { "id": 1608, "drug": "carborane-containing bioisostere of erlotinib", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "inhibits", "mediator": "EGFR", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "pancreatic ductal adenocarcinoma", "outcome_type": "disease", "outcome_domain": "pancreatic_cancer", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "unknown", "drug_canonical": "carborane-containing bioisostere of erlotinib", "mediator_canonical": "EGFR", "outcome_canonical": "pancreatic ductal adenocarcinoma", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41179166", "title": "Escaping from Flatland: 3D Carborane-Based Bioisosteres of Erlotinib as Potential Anticancer Agents", "doi": "10.1021/acsomega.5c07982", "year": 2025 } ], "bc": [ { "pmid": "40130819", "title": "Identification of Tumor‐Specific Surface Proteins Enables Quantification of Extracellular Vesicle Subtypes for Early Detection of Pancreatic Ductal Adenocarcinoma", "doi": "10.1002/advs.202414982", "year": 2025 }, { "pmid": "31584260", "title": "Design and Evaluation of PEGylated Liposomal Formulation of a Novel Multikinase Inhibitor for Enhanced Chemosensitivity and Inhibition of Metastatic Pancreatic Ductal Adenocarcinoma", "doi": "10.1021/acs.bioconjchem.9b00632", "year": 2019 }, { "pmid": "26339400", "title": "EGFR expression in pancreatic intraepithelial neoplasia and ductal adenocarcinoma.", "doi": null, "year": 2015 } ] } }, { "id": 2307, "drug": "beta-hydroxybutyrate and decanoic acid", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "activates", "mediator": "SIRT1", "mediator_type": "protein", "predicate_bc": "predicts", "outcome": "Alzheimer's disease", "outcome_type": "disease", "outcome_domain": "alzheimer", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "unknown", "drug_canonical": "beta-hydroxybutyrate and decanoic acid", "mediator_canonical": "SIRT1", "outcome_canonical": "Alzheimer disease", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "32784510", "title": "Mechanism of Action of Ketogenic Diet Treatment: Impact of Decanoic Acid and Beta—Hydroxybutyrate on Sirtuins and Energy Metabolism in Hippocampal Murine Neurons", "doi": "10.3390/nu12082379", "year": 2020 } ], "bc": [ { "pmid": "37742223", "title": "Serum sirtuin1: a potential blood biomarker for early diagnosis of Alzheimer’s disease", "doi": "10.18632/aging.205015", "year": 2023 }, { "pmid": "30243024", "title": "Sirt1 enhances tau exon 10 inclusion and improves spatial memory of Htau mice", "doi": "10.18632/aging.101564", "year": 2018 } ] } }, { "id": 40181, "drug": "isorhamnetin", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "downregulates", "mediator": "mTOR", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "glioblastoma", "outcome_type": "disease", "outcome_domain": "glioblastoma", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "isorhamnetin", "mediator_canonical": "mTOR", "outcome_canonical": "glioblastoma", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "33401224", "title": "New insight into the role of isorhamnetin as a regulator of insulin signaling pathway in type 2 diabetes mellitus rat model: Molecular and computational approach", "doi": "10.1016/j.biopha.2020.111176", "year": 2021 } ], "bc": [ { "pmid": "39622049", "title": "A Dual-Target and Dual-Mechanism Design Strategy by Combining Inhibition and Degradation Together", "doi": "10.1021/jacs.4c11930", "year": 2024 }, { "pmid": "33162811", "title": "Mitochondrial dysfunction contributes to Rapamycin-induced apoptosis of Human Glioblastoma Cells - A synergistic effect with Temozolomide", "doi": "10.7150/ijms.40159", "year": 2020 }, { "pmid": "30793789", "title": "The effect of the mTOR inhibitor rapamycin on glucoCEST signal in a preclinical model of glioblastoma", "doi": "10.1002/mrm.27683", "year": 2019 } ] } }, { "id": 40188, "drug": "SGLT2i", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "suppresses", "mediator": "mTOR", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "glioblastoma", "outcome_type": "disease", "outcome_domain": "glioblastoma", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "sglt2i", "mediator_canonical": "mTOR", "outcome_canonical": "glioblastoma", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "32517059", "title": "Sodium Glucose Co-Transporter 2 Inhibitor Ameliorates Autophagic Flux Impairment on Renal Proximal Tubular Cells in Obesity Mice", "doi": "10.3390/ijms21114054", "year": 2020 } ], "bc": [ { "pmid": "39622049", "title": "A Dual-Target and Dual-Mechanism Design Strategy by Combining Inhibition and Degradation Together", "doi": "10.1021/jacs.4c11930", "year": 2024 }, { "pmid": "33162811", "title": "Mitochondrial dysfunction contributes to Rapamycin-induced apoptosis of Human Glioblastoma Cells - A synergistic effect with Temozolomide", "doi": "10.7150/ijms.40159", "year": 2020 }, { "pmid": "30793789", "title": "The effect of the mTOR inhibitor rapamycin on glucoCEST signal in a preclinical model of glioblastoma", "doi": "10.1002/mrm.27683", "year": 2019 } ] } }, { "id": 40193, "drug": "LIPUS", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "upregulates", "mediator": "mTOR", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "glioblastoma", "outcome_type": "disease", "outcome_domain": "glioblastoma", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "active", "clinical_trial_nct_ids": [ "NCT05902169", "NCT03744026", "NCT02253212" ], "literature_status": "partial_evidence", "drug_canonical": "lipus", "mediator_canonical": "mTOR", "outcome_canonical": "glioblastoma", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "29273088", "title": "Low-intensity pulsed ultrasound prevents muscle atrophy induced by type 1 diabetes in rats", "doi": "10.1186/s13395-017-0145-7", "year": 2017 } ], "bc": [ { "pmid": "39622049", "title": "A Dual-Target and Dual-Mechanism Design Strategy by Combining Inhibition and Degradation Together", "doi": "10.1021/jacs.4c11930", "year": 2024 }, { "pmid": "33162811", "title": "Mitochondrial dysfunction contributes to Rapamycin-induced apoptosis of Human Glioblastoma Cells - A synergistic effect with Temozolomide", "doi": "10.7150/ijms.40159", "year": 2020 }, { "pmid": "30793789", "title": "The effect of the mTOR inhibitor rapamycin on glucoCEST signal in a preclinical model of glioblastoma", "doi": "10.1002/mrm.27683", "year": 2019 } ] } }, { "id": 40404, "drug": "DPP-4 inhibitors", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "binds_to", "mediator": "DPP-4", "mediator_type": "protein", "predicate_bc": "predicts", "outcome": "treatment escalation", "outcome_type": "phenotype", "outcome_domain": "inflammatory_bowel_disease", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "completed", "clinical_trial_nct_ids": [ "NCT03813316" ], "literature_status": "novel_signal", "drug_canonical": "dpp-4 inhibitors", "mediator_canonical": "dpp-4", "outcome_canonical": "treatment escalation", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "28794822", "title": "Overview of Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Patients with Type 2 Diabetes.", "doi": null, "year": 2017 }, { "pmid": "30815539", "title": "A comparative study of the binding properties, dipeptidyl peptidase‐4 (DPP‐4) inhibitory activity and glucose‐lowering efficacy of the DPP‐4 inhibitors alogliptin, linagliptin, saxagliptin, sitagliptin and vildagliptin in mice", "doi": "10.1002/edm2.2", "year": 2017 } ], "bc": [ { "pmid": "31912883", "title": "Serum Dipeptidyl Peptidase 4: A Predictor of Disease Activity and Prognosis in Inflammatory Bowel Disease", "doi": "10.1093/ibd/izz319", "year": 2020 } ] } }, { "id": 23824, "drug": "nivolumab", "drug_type": "drug", "drug_domain": "multiple_sclerosis", "predicate_ab": "inhibits", "mediator": "PD-1", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "advanced T stage", "outcome_type": "phenotype", "outcome_domain": "pancreatic_cancer", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "active", "clinical_trial_nct_ids": [ "NCT06697197", "NCT04995003", "NCT05968690" ], "literature_status": "novel_signal", "drug_canonical": "nivolumab", "mediator_canonical": "pd-1", "outcome_canonical": "advanced t stage", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41846303", "title": "Nivolumab‐Associated Autoimmune Encephalopathy in a Child With Multiply Relapsed Anaplastic Ependymoma", "doi": "10.1002/1545-5017.70262", "year": 2026 }, { "pmid": "31135622", "title": "Severe Relapse of Vaccine-Induced Guillain–Barré Syndrome After Treatment With Nivolumab", "doi": "10.1097/cnd.0000000000000230", "year": 2019 }, { "pmid": "30465016", "title": "Natalizumab may control immune checkpoint inhibitor–induced limbic encephalitis", "doi": "10.1212/nxi.0000000000000439", "year": 2018 } ], "bc": [ { "pmid": "28030840", "title": "Prognostic value and clinicopathological features of PD-1/PD-L1 expression with mismatch repair status and desmoplastic stroma in Chinese patients with pancreatic cancer", "doi": "10.18632/oncotarget.14069", "year": 2016 } ] } }, { "id": 32646, "drug": "thiopurines", "drug_type": "drug", "drug_domain": "inflammatory_bowel_disease", "predicate_ab": "inhibits", "mediator": "Rac1", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "Alzheimer's disease", "outcome_type": "disease", "outcome_domain": "alzheimer", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "thiopurines", "mediator_canonical": "rac1", "outcome_canonical": "Alzheimer disease", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "34320903", "title": "Targeting Rac1 for the prevention of atherosclerosis among U.S. Veterans with inflammatory bowel disease", "doi": "10.1080/21541248.2021.1954863", "year": 2021 } ], "bc": [ { "pmid": "31321704", "title": "Inhibition of Rac1-dependent forgetting alleviates memory deficits in animal models of Alzheimer’s disease", "doi": "10.1007/s13238-019-0641-0", "year": 2019 }, { "pmid": "30005699", "title": "Rac1 activation links tau hyperphosphorylation and Aβ dysmetabolism in Alzheimer’s disease", "doi": "10.1186/s40478-018-0567-4", "year": 2018 } ] } }, { "id": 40407, "drug": "alirocumab", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "inhibits", "mediator": "PCSK9", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "active ulcerative colitis", "outcome_type": "disease", "outcome_domain": "inflammatory_bowel_disease", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "alirocumab", "mediator_canonical": "pcsk9", "outcome_canonical": "active ulcerative colitis", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "32035487", "title": "Effect of alirocumab on individuals with type 2 diabetes, high triglycerides, and low high-density lipoprotein cholesterol", "doi": "10.1186/s12933-020-0991-1", "year": 2020 }, { "pmid": "28799203", "title": "Efficacy and safety of alirocumab in people with prediabetes vs those with normoglycaemia at baseline: a pooled analysis of 10 phase III ODYSSEY clinical trials", "doi": "10.1111/dme.13450", "year": 2017 }, { "pmid": "28545518", "title": "Design and rationale of the ODYSSEY DM-DYSLIPIDEMIA trial: lipid-lowering efficacy and safety of alirocumab in individuals with type 2 diabetes and mixed dyslipidaemia at high cardiovascular risk", "doi": "10.1186/s12933-017-0552-4", "year": 2017 } ], "bc": [ { "pmid": "34560758", "title": "Serum Levels of PCSK9 Are Increased in Patients With Active Ulcerative Colitis Representing a Potential Biomarker of Disease Activity", "doi": "10.1097/mcg.0000000000001607", "year": 2021 } ] } }, { "id": 6139, "drug": "Chlorotoxin", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "binds_to", "mediator": "MMP-2", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "lymph node metastasis", "outcome_type": "phenotype", "outcome_domain": "pancreatic_cancer", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "chlorotoxin", "mediator_canonical": "MMP2", "outcome_canonical": "lymph node metastasis", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41955189", "title": "Chlorotoxin does not target matrix metalloproteinase-2 in glioblastoma", "doi": "10.1371/journal.pone.0328964", "year": 2026 } ], "bc": [ { "pmid": "26504399", "title": "Upregulated matrix metalloproteinase-2 and downregulated tissue factor pathway inhibitor-2 are risk factors for lymph node metastasis and perineural invasion in pancreatic carcinoma", "doi": "10.2147/ott.s90599", "year": 2015 } ] } }, { "id": 6127, "drug": "Chlorotoxin", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "binds_to", "mediator": "MMP-2", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "survival", "outcome_type": "phenotype", "outcome_domain": "pancreatic_cancer", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "chlorotoxin", "mediator_canonical": "MMP2", "outcome_canonical": null, "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41955189", "title": "Chlorotoxin does not target matrix metalloproteinase-2 in glioblastoma", "doi": "10.1371/journal.pone.0328964", "year": 2026 } ], "bc": [ { "pmid": "29355139", "title": "Prognostic significance of plasma matrix metalloprotease-2 in pancreatic cancer patients", "doi": "10.4103/ijmr.ijmr_1348_15", "year": 2017 } ] } }, { "id": 3633, "drug": "CLR01", "drug_type": "drug", "drug_domain": "alzheimer", "predicate_ab": "binds_to", "mediator": "TAU", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "hippocampal volume", "outcome_type": "phenotype", "outcome_domain": "epilepsy", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "clr01", "mediator_canonical": "MAPT", "outcome_canonical": "hippocampal volume", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "31046227", "title": "Major Differences between the Self-Assembly and Seeding Behavior of Heparin-Induced and in Vitro Phosphorylated Tau and Their Modulation by Potential Inhibitors", "doi": "10.1021/acschembio.9b00325", "year": 2019 }, { "pmid": "30062477", "title": "Native Top-Down Mass Spectrometry and Ion Mobility Spectrometry of the Interaction of Tau Protein with a Molecular Tweezer Assembly Modulator", "doi": "10.1007/s13361-018-2027-6", "year": 2018 } ], "bc": [ { "pmid": "33990226", "title": "Pathological drivers of neurodegeneration in suspected non-Alzheimer’s disease pathophysiology", "doi": "10.1186/s13195-021-00835-2", "year": 2021 } ] } }, { "id": 3704, "drug": "CLR01", "drug_type": "drug", "drug_domain": "alzheimer", "predicate_ab": "binds_to", "mediator": "TAU", "mediator_type": "protein", "predicate_bc": "causes", "outcome": "MTL neurodegeneration", "outcome_type": "disease", "outcome_domain": "epilepsy", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "clr01", "mediator_canonical": "MAPT", "outcome_canonical": "mtl neurodegeneration", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "31046227", "title": "Major Differences between the Self-Assembly and Seeding Behavior of Heparin-Induced and in Vitro Phosphorylated Tau and Their Modulation by Potential Inhibitors", "doi": "10.1021/acschembio.9b00325", "year": 2019 }, { "pmid": "30062477", "title": "Native Top-Down Mass Spectrometry and Ion Mobility Spectrometry of the Interaction of Tau Protein with a Molecular Tweezer Assembly Modulator", "doi": "10.1007/s13361-018-2027-6", "year": 2018 } ], "bc": [ { "pmid": "33990226", "title": "Pathological drivers of neurodegeneration in suspected non-Alzheimer’s disease pathophysiology", "doi": "10.1186/s13195-021-00835-2", "year": 2021 } ] } }, { "id": 6146, "drug": "nanobody-displaying AAV9 vectors", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "binds_to", "mediator": "CD73", "mediator_type": "protein", "predicate_bc": "predicts", "outcome": "poor prognosis", "outcome_type": "phenotype", "outcome_domain": "pancreatic_cancer", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "unknown", "drug_canonical": "nanobody-displaying aav9 vectors", "mediator_canonical": "cd73", "outcome_canonical": null, "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41933830", "title": "Targeting purinergic receptors in glioblastoma with nanobody-displaying AAV vectors", "doi": "10.1016/j.neuropharm.2026.110955", "year": 2026 } ], "bc": [ { "pmid": "37851808", "title": "CD73 controls Myosin II–driven invasion, metastasis, and immunosuppression in amoeboid pancreatic cancer cells", "doi": "10.1126/sciadv.adi0244", "year": 2023 }, { "pmid": "32643277", "title": "CD73 acts as a prognostic biomarker and promotes progression and immune escape in pancreatic cancer", "doi": "10.1111/jcmm.15500", "year": 2020 }, { "pmid": "30927045", "title": "The distinct role of CD73 in the progression of pancreatic cancer", "doi": "10.1007/s00109-018-01742-0", "year": 2019 } ] } }, { "id": 32671, "drug": "Brusatol", "drug_type": "drug", "drug_domain": "inflammatory_bowel_disease", "predicate_ab": "downregulates", "mediator": "LCN2", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "Alzheimer's disease", "outcome_type": "disease", "outcome_domain": "alzheimer", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "brusatol", "mediator_canonical": "lcn2", "outcome_canonical": "Alzheimer disease", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41358509", "title": "Brusatol Exerts Therapeutic Effects in Ulcerative Colitis by Regulating the UBE 3 A ‐ LCN 2‐Mediated Ferroptosis and Inflammation Axis", "doi": "10.1111/cbdd.70201", "year": 2025 } ], "bc": [ { "pmid": "40576449", "title": "LCN2 of cerebrospinal fluid: A potential biomarker for diagnosis and disease progression in Alzheimer's disease", "doi": "10.1177/13872877251352411", "year": 2025 }, { "pmid": "34829528", "title": "Role of Lipocalin-2 in Amyloid-Beta Oligomer-Induced Mouse Model of Alzheimer’s Disease", "doi": "10.3390/antiox10111657", "year": 2021 } ] } }, { "id": 31947, "drug": "PDR3", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "inhibits", "mediator": "STAT3", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "prurigo nodularis", "outcome_type": "disease", "outcome_domain": "rheumatoid_arthritis", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "pdr3", "mediator_canonical": "STAT3", "outcome_canonical": "prurigo nodularis", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "30594071", "title": "An RNA Aptamer Targeting the Receptor Tyrosine Kinase PDGFRα Induces Anti-tumor Effects through STAT3 and p53 in Glioblastoma", "doi": "10.1016/j.omtn.2018.11.012", "year": 2018 } ], "bc": [ { "pmid": "39912139", "title": "Translating tissue expression of STAT 1, 3 and 6 in prurigo nodularis to clinical efficacy of oral tofacitinib – A prospective single-arm investigational study", "doi": "10.25259/ijdvl_1017_2024", "year": 2025 }, { "pmid": "40162359", "title": "Successful Use of Tofacitinib in Paediatric Prurigo Nodularis: A Report of Four Cases", "doi": "10.4103/ijd.ijd_842_24", "year": 2025 }, { "pmid": "37521237", "title": "A case of recalcitrant prurigo nodularis with heightened expression of STAT 3 and STAT 6 and its dramatic response to tofacitinib", "doi": "10.4103/idoj.idoj_508_22", "year": 2023 } ] } }, { "id": 6896, "drug": "Ketogenic diet", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "downregulates", "mediator": "GFAP", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "cognitive impairment", "outcome_type": "phenotype", "outcome_domain": "alzheimer", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "active", "clinical_trial_nct_ids": [ "NCT04396015", "NCT03319173", "NCT03472664" ], "literature_status": "reproduces_known", "drug_canonical": "ketogenic diet", "mediator_canonical": "GFAP", "outcome_canonical": "cognitive impairment", "ab_count": 1, "bc_count": 3, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "32539054", "title": "Amelioration of clinical course and demyelination in the cuprizone mouse model in relation to ketogenic diet", "doi": "10.1039/c9fo02944c", "year": 2020 } ], "bc": [ { "pmid": "36576155", "title": "Plasma glial fibrillary acidic protein in autosomal dominant Alzheimer's disease: Associations with Aβ‐PET, neurodegeneration, and cognition", "doi": "10.1002/alz.12879", "year": 2022 }, { "pmid": "32514860", "title": "Synaptic Loss, ER Stress and Neuro-Inflammation Emerge Late in the Lateral Temporal Cortex and Associate with Progressive Tau Pathology in Alzheimer’s Disease", "doi": "10.1007/s12035-020-01950-1", "year": 2020 }, { "pmid": "30594925", "title": "Glial Fibrillary Acidic Protein in Serum is Increased in Alzheimer’s Disease and Correlates with Cognitive Impairment", "doi": "10.3233/jad-180325", "year": 2018 } ] } }, { "id": 32130, "drug": "Chlorotoxin", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "binds_to", "mediator": "MMP-2", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "albuminuria", "outcome_type": "disease", "outcome_domain": "type_2_diabetes", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "chlorotoxin", "mediator_canonical": "MMP2", "outcome_canonical": "albuminuria", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41955189", "title": "Chlorotoxin does not target matrix metalloproteinase-2 in glioblastoma", "doi": "10.1371/journal.pone.0328964", "year": 2026 } ], "bc": [ { "pmid": "25848912", "title": "Plasma levels of matrix metalloproteinase-2, -3, -10, and tissue inhibitor of metalloproteinase-1 are associated with vascular complications in patients with type 1 diabetes: the EURODIAB Prospective Complications Study", "doi": "10.1186/s12933-015-0195-2", "year": 2015 } ] } }, { "id": 32132, "drug": "Chlorotoxin", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "binds_to", "mediator": "MMP-2", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "cardiovascular events", "outcome_type": "disease", "outcome_domain": "type_2_diabetes", "score": 0.20794415416798356, "filtered_score": 0.20794415416798356, "filter_reason": null, "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "chlorotoxin", "mediator_canonical": "MMP2", "outcome_canonical": "cardiovascular events", "ab_count": 3, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41955189", "title": "Chlorotoxin does not target matrix metalloproteinase-2 in glioblastoma", "doi": "10.1371/journal.pone.0328964", "year": 2026 } ], "bc": [ { "pmid": "28446168", "title": "Plasma matrix metalloproteinases are associated with incident cardiovascular disease and all-cause mortality in patients with type 1 diabetes: a 12-year follow-up study", "doi": "10.1186/s12933-017-0539-1", "year": 2017 } ] } }, { "id": 27620, "drug": "resveratrol", "drug_type": "drug", "drug_domain": "alzheimer", "predicate_ab": "downregulates", "mediator": "amyloid precursor protein", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "CKD protection", "outcome_type": "phenotype", "outcome_domain": "type_2_diabetes", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "resveratrol", "mediator_canonical": "amyloid precursor protein", "outcome_canonical": "ckd protection", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "30864708", "title": "Resveratrol improves cognition and decreases amyloid plaque formation in Tg6799 mice", "doi": "10.3892/mmr.2019.10010", "year": 2019 } ], "bc": [ { "pmid": "31076418", "title": "Characterization of Glycolytic Enzymes and Pyruvate Kinase M2 in Type 1 and 2 Diabetic Nephropathy", "doi": "10.2337/dc18-2585", "year": 2019 } ] } }, { "id": 27489, "drug": "hydroxychloroquine", "drug_type": "drug", "drug_domain": "alzheimer", "predicate_ab": "inhibits", "mediator": "STAT3", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "arthritis", "outcome_type": "disease", "outcome_domain": "rheumatoid_arthritis", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "active", "clinical_trial_nct_ids": [ "NCT05678335", "NCT03414502", "NCT04354649" ], "literature_status": "reproduces_known", "drug_canonical": "hydroxychloroquine", "mediator_canonical": "STAT3", "outcome_canonical": "arthritis", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "36577843", "title": "Hydroxychloroquine lowers Alzheimer’s disease and related dementias risk and rescues molecular phenotypes related to Alzheimer’s disease", "doi": "10.1038/s41380-022-01912-0", "year": 2022 } ], "bc": [ { "pmid": "36368156", "title": "The Stat3 inhibitor F0648-0027 is a potential therapeutic against rheumatoid arthritis", "doi": "10.1016/j.bbrc.2022.10.106", "year": 2022 } ] } }, { "id": 4237, "drug": "curcumin", "drug_type": "drug", "drug_domain": "alzheimer", "predicate_ab": "upregulates", "mediator": "BDNF", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "depression severity (HAMD-17 score)", "outcome_type": "phenotype", "outcome_domain": "depression", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "curcumin", "mediator_canonical": "BDNF", "outcome_canonical": "depression severity (hamd-17 score)", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "38791161", "title": "Curcumin Improves Neurogenesis in Alzheimer’s Disease Mice via the Upregulation of Wnt/β-Catenin and BDNF", "doi": "10.3390/ijms25105123", "year": 2024 } ], "bc": [ { "pmid": "36860860", "title": "Association between inflammatory cytokines and symptoms of major depressive disorder in adults", "doi": "10.3389/fimmu.2023.1110775", "year": 2023 } ] } }, { "id": 341, "drug": "valproic acid", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "upregulates", "mediator": "CXCR4", "mediator_type": "gene", "predicate_bc": "correlates_with", "outcome": "immune infiltration", "outcome_type": "phenotype", "outcome_domain": "glioblastoma", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "valproic acid", "mediator_canonical": "CXCR4", "outcome_canonical": "immune infiltration", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40164048", "title": "Valproic acid preconditioning of bone marrow mesenchymal stem cells promotes remyelination of the corpus callosum in a cuprizone-induced demyelination model", "doi": "10.1016/j.biopha.2025.118027", "year": 2025 } ], "bc": [ { "pmid": "37626511", "title": "Development and Validation of CXCR4 Nomogram-Based Immune Infiltration/Tumor Inflammation in Primary Glioblastoma", "doi": "10.3390/brainsci13081152", "year": 2023 } ] } }, { "id": 26887, "drug": "resveratrol", "drug_type": "drug", "drug_domain": "alzheimer", "predicate_ab": "upregulates", "mediator": "Sod2", "mediator_type": "gene", "predicate_bc": "associated_with", "outcome": "Reactive arthritis", "outcome_type": "disease", "outcome_domain": "inflammatory_bowel_disease", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "active", "clinical_trial_nct_ids": [ "NCT07089381" ], "literature_status": "novel_signal", "drug_canonical": "resveratrol", "mediator_canonical": "sod2", "outcome_canonical": "reactive arthritis", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "30301188", "title": "Effect of Resveratrol on Reactive Oxygen Species-Induced Cognitive Impairment in Rats with Angiotensin II-Induced Early Alzheimer’s Disease †", "doi": "10.3390/jcm7100329", "year": 2018 } ], "bc": [ { "pmid": "32934294", "title": "Elucidating potential molecular signatures through host-microbe interactions for reactive arthritis and inflammatory bowel disease using combinatorial approach", "doi": "10.1038/s41598-020-71674-8", "year": 2020 } ] } }, { "id": 4213, "drug": "curcumin", "drug_type": "drug", "drug_domain": "alzheimer", "predicate_ab": "upregulates", "mediator": "BDNF", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "suicide risk", "outcome_type": "phenotype", "outcome_domain": "depression", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "curcumin", "mediator_canonical": "BDNF", "outcome_canonical": "suicide risk", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "38791161", "title": "Curcumin Improves Neurogenesis in Alzheimer’s Disease Mice via the Upregulation of Wnt/β-Catenin and BDNF", "doi": "10.3390/ijms25105123", "year": 2024 } ], "bc": [ { "pmid": "32209966", "title": "Understanding the Complex of Suicide in Depression: from Research to Clinics", "doi": "10.30773/pi.2019.0171", "year": 2020 } ] } }, { "id": 27586, "drug": "Curcumin", "drug_type": "drug", "drug_domain": "alzheimer", "predicate_ab": "binds_to", "mediator": "NFKB1", "mediator_type": "gene", "predicate_bc": "associated_with", "outcome": "diabetes progression", "outcome_type": "disease", "outcome_domain": "type_2_diabetes", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "curcumin", "mediator_canonical": "nfkb1", "outcome_canonical": "diabetes progression", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "36042609", "title": "A network pharmacology approach to identify the mechanisms and molecular targets of curcumin against Alzheimer disease", "doi": "10.1097/md.0000000000030194", "year": 2022 } ], "bc": [ { "pmid": "40533788", "title": "Machine learning-based stratification of prediabetes and type 2 diabetes progression", "doi": "10.1186/s13098-025-01786-6", "year": 2025 } ] } }, { "id": 26681, "drug": "hydroxychloroquine", "drug_type": "drug", "drug_domain": "alzheimer", "predicate_ab": "inhibits", "mediator": "STAT3", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "glioblastoma progression", "outcome_type": "disease", "outcome_domain": "glioblastoma", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "active", "clinical_trial_nct_ids": [ "NCT04678648" ], "literature_status": "novel_signal", "drug_canonical": "hydroxychloroquine", "mediator_canonical": "STAT3", "outcome_canonical": "glioblastoma progression", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "36577843", "title": "Hydroxychloroquine lowers Alzheimer’s disease and related dementias risk and rescues molecular phenotypes related to Alzheimer’s disease", "doi": "10.1038/s41380-022-01912-0", "year": 2022 } ], "bc": [ { "pmid": "41747967", "title": "STAT3 signaling as an adaptive hub in glioblastoma: Network rewiring, non-coding RNA circuits, and therapeutic vulnerabilities", "doi": "10.1016/j.nbd.2026.107330", "year": 2026 } ] } }, { "id": 25775, "drug": "resveratrol", "drug_type": "drug", "drug_domain": "als", "predicate_ab": "activates", "mediator": "SIRT1", "mediator_type": "protein", "predicate_bc": "decreases", "outcome": "inflammation", "outcome_type": "disease", "outcome_domain": "type_2_diabetes", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "active", "clinical_trial_nct_ids": [ "NCT07501377", "NCT07182370", "NCT07395921" ], "literature_status": "reproduces_known", "drug_canonical": "resveratrol", "mediator_canonical": "SIRT1", "outcome_canonical": null, "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "26981091", "title": "How does resveratrol influence the genesis of some neurodegenerative diseases?", "doi": "10.4103/1673-5374.175047", "year": 2016 } ], "bc": [ { "pmid": "30988688", "title": "Exercise training upregulates SIRT1 to attenuate inflammation and metabolic dysfunction in kidney and liver of diabetic db/db mice", "doi": "10.1186/s12986-019-0349-4", "year": 2019 } ] } }, { "id": 27207, "drug": "simvastatin", "drug_type": "drug", "drug_domain": "alzheimer", "predicate_ab": "inhibits", "mediator": "mevalonate pathway", "mediator_type": "pathway", "predicate_bc": "prevents", "outcome": "ferroptosis", "outcome_type": "phenotype", "outcome_domain": "pancreatic_cancer", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "simvastatin", "mediator_canonical": "mevalonate pathway", "outcome_canonical": "ferroptosis", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "38930515", "title": "Simvastatin, Its Antimicrobial Activity and Its Prevention of Alzheimer’s Disease", "doi": "10.3390/microorganisms12061133", "year": 2024 } ], "bc": [ { "pmid": "38029455", "title": "Organic Selenium induces ferroptosis in pancreatic cancer cells", "doi": "10.1016/j.redox.2023.102962", "year": 2023 } ] } }, { "id": 50345, "drug": "resveratrol", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "inhibits", "mediator": "mitophagy", "mediator_type": "pathway", "predicate_bc": "associated_with", "outcome": "neurodegenerative disease pathogenesis", "outcome_type": "disease", "outcome_domain": "als", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "29578301", "title": "Resveratrol Improves Muscle Atrophy by Modulating Mitochondrial Quality Control in STZ‐Induced Diabetic Mice", "doi": "10.1002/mnfr.201700941", "year": 2018 } ], "bc": [ { "pmid": "37862201", "title": "Mitophagy in neurodegenerative disease pathogenesis", "doi": "10.4103/1673-5374.385281", "year": 2023 } ] } }, { "id": 1545, "drug": "apigenin", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "upregulates", "mediator": "GFAP", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "neuropsychological test performance", "outcome_type": "phenotype", "outcome_domain": "alzheimer", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "apigenin", "mediator_canonical": "GFAP", "outcome_canonical": "neuropsychological test performance", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41090780", "title": "Apigenin Induces Autophagy and Apoptosis in Chemoresistant Glioblastoma Cells and Inhibits Tumorigenicity Associated with Regulation of Immunomodulatory Proteins and Glial Cells Response", "doi": "10.3390/cells14191552", "year": 2025 } ], "bc": [ { "pmid": "37885919", "title": "Cross‐sectional and longitudinal evaluation of plasma glial fibrillary acidic protein to detect and predict clinical syndromes of Alzheimer's disease", "doi": "10.1002/dad2.12492", "year": 2023 } ] } }, { "id": 26925, "drug": "metformin", "drug_type": "drug", "drug_domain": "alzheimer", "predicate_ab": "downregulates", "mediator": "c-myc", "mediator_type": "gene", "predicate_bc": "associated_with", "outcome": "IBD-associated intestinal adenocarcinoma", "outcome_type": "disease", "outcome_domain": "inflammatory_bowel_disease", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "metformin", "mediator_canonical": "c-myc", "outcome_canonical": "ibd-associated intestinal adenocarcinoma", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "32382652", "title": "If ineffective levels of transforming growth factors and their receptor account for old age being a risk factor for Alzheimer's disease, then increasing TGFBR2 might be therapeutic", "doi": "10.1002/trc2.12019", "year": 2020 } ], "bc": [ { "pmid": "29788391", "title": "Distinct Histopathologic and Molecular Alterations in Inflammatory Bowel Disease-Associated Intestinal Adenocarcinoma: c-MYC Amplification is Common and Associated with Mucinous/Signet Ring Cell Differentiation", "doi": "10.1093/ibd/izy057", "year": 2018 } ] } }, { "id": 3033, "drug": "niclosamide", "drug_type": "drug", "drug_domain": "als", "predicate_ab": "inhibits", "mediator": "STAT3", "mediator_type": "protein", "predicate_bc": "prevents", "outcome": "general cell loss", "outcome_type": "phenotype", "outcome_domain": "epilepsy", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "niclosamide", "mediator_canonical": "STAT3", "outcome_canonical": "general cell loss", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "38493058", "title": "Neuroprotective effects of niclosamide on disease progression via inflammatory pathways modulation in SOD1-G93A and FUS-associated amyotrophic lateral sclerosis models", "doi": "10.1016/j.neurot.2024.e00346", "year": 2024 } ], "bc": [ { "pmid": "36825472", "title": "Blockage of STAT3 during epileptogenesis prevents GABAergic loss and imprinting of the epileptic state", "doi": "10.1093/brain/awad055", "year": 2023 } ] } }, { "id": 25904, "drug": "riluzole", "drug_type": "drug", "drug_domain": "als", "predicate_ab": "downregulates", "mediator": "MMP-2", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "albuminuria", "outcome_type": "disease", "outcome_domain": "type_2_diabetes", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "riluzole", "mediator_canonical": "MMP2", "outcome_canonical": "albuminuria", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40012807", "title": "Investigation of the Neuroprotective Effect of Riluzole on Matrix Metalloproteinases in an Experimental Model of Glaucoma", "doi": "10.4103/joco.joco_290_23", "year": 2024 } ], "bc": [ { "pmid": "25848912", "title": "Plasma levels of matrix metalloproteinase-2, -3, -10, and tissue inhibitor of metalloproteinase-1 are associated with vascular complications in patients with type 1 diabetes: the EURODIAB Prospective Complications Study", "doi": "10.1186/s12933-015-0195-2", "year": 2015 } ] } }, { "id": 38542, "drug": "Auranofin", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "upregulates", "mediator": "PD-L1", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "longer survival", "outcome_type": "phenotype", "outcome_domain": "glioblastoma", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "auranofin", "mediator_canonical": "PD-L1", "outcome_canonical": "longer survival", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "31090219", "title": "Therapeutic cooperation between auranofin, a thioredoxin reductase inhibitor and anti‐PD‐L1 antibody for treatment of triple‐negative breast cancer", "doi": "10.1002/ijc.32410", "year": 2019 } ], "bc": [ { "pmid": "37605497", "title": "Epigenetic Regulation of the Expression of T Cell Stimulatory and Inhibitory Factors by Histone H3 Lysine Modification Enzymes and Its Prognostic Roles in Glioblastoma", "doi": "10.3346/jkms.2023.38.e258", "year": 2023 } ] } }, { "id": 38541, "drug": "Auranofin", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "upregulates", "mediator": "PD-L1", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "glioblastoma multiforme", "outcome_type": "disease", "outcome_domain": "glioblastoma", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "completed", "clinical_trial_nct_ids": [ "NCT02770378" ], "literature_status": "partial_evidence", "drug_canonical": "auranofin", "mediator_canonical": "PD-L1", "outcome_canonical": "glioblastoma", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "31090219", "title": "Therapeutic cooperation between auranofin, a thioredoxin reductase inhibitor and anti‐PD‐L1 antibody for treatment of triple‐negative breast cancer", "doi": "10.1002/ijc.32410", "year": 2019 } ], "bc": [ { "pmid": "37529045", "title": "Plasma PD-L1 as a biomarker in the clinical management of glioblastoma multiforme—a retrospective cohort study", "doi": "10.3389/fimmu.2023.1202098", "year": 2023 } ] } }, { "id": 25818, "drug": "riluzole", "drug_type": "drug", "drug_domain": "als", "predicate_ab": "downregulates", "mediator": "MMP-2", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "pre-hypertension", "outcome_type": "disease", "outcome_domain": "type_2_diabetes", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "riluzole", "mediator_canonical": "MMP2", "outcome_canonical": "pre-hypertension", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40012807", "title": "Investigation of the Neuroprotective Effect of Riluzole on Matrix Metalloproteinases in an Experimental Model of Glaucoma", "doi": "10.4103/joco.joco_290_23", "year": 2024 } ], "bc": [ { "pmid": "27490532", "title": "Serum Concentrations of Endothelin-1 and Matrix Metalloproteinases-2, -9 in Pre-Hypertensive and Hypertensive Patients with Type 2 Diabetes", "doi": "10.3390/ijms17081182", "year": 2016 } ] } }, { "id": 25773, "drug": "riluzole", "drug_type": "drug", "drug_domain": "als", "predicate_ab": "downregulates", "mediator": "MMP-2", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "cardiovascular events", "outcome_type": "disease", "outcome_domain": "type_2_diabetes", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "riluzole", "mediator_canonical": "MMP2", "outcome_canonical": "cardiovascular events", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40012807", "title": "Investigation of the Neuroprotective Effect of Riluzole on Matrix Metalloproteinases in an Experimental Model of Glaucoma", "doi": "10.4103/joco.joco_290_23", "year": 2024 } ], "bc": [ { "pmid": "28446168", "title": "Plasma matrix metalloproteinases are associated with incident cardiovascular disease and all-cause mortality in patients with type 1 diabetes: a 12-year follow-up study", "doi": "10.1186/s12933-017-0539-1", "year": 2017 } ] } }, { "id": 25708, "drug": "simvastatin", "drug_type": "drug", "drug_domain": "als", "predicate_ab": "upregulates", "mediator": "Alb", "mediator_type": "gene", "predicate_bc": "associated_with", "outcome": "rheumatoid arthritis", "outcome_type": "disease", "outcome_domain": "rheumatoid_arthritis", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "completed", "clinical_trial_nct_ids": [ "NCT04177173", "NCT02017639", "NCT01725230" ], "literature_status": "reproduces_known", "drug_canonical": "simvastatin", "mediator_canonical": "alb", "outcome_canonical": "rheumatoid arthritis", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "39569650", "title": "Therapeutic potential of simvastatin in ALS: Enhanced axonal integrity and motor neuron survival through Apoa4 and Alb modulation", "doi": "10.17305/bb.2024.11218", "year": 2024 } ], "bc": [ { "pmid": "36532774", "title": "Detecting potential mechanism of vitamin D in treating rheumatoid arthritis based on network pharmacology and molecular docking", "doi": "10.3389/fphar.2022.1047061", "year": 2022 } ] } }, { "id": 25690, "drug": "niclosamide", "drug_type": "drug", "drug_domain": "als", "predicate_ab": "inhibits", "mediator": "STAT3", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "arthritis", "outcome_type": "disease", "outcome_domain": "rheumatoid_arthritis", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "completed", "clinical_trial_nct_ids": [ "NCT03160001" ], "literature_status": "reproduces_known", "drug_canonical": "niclosamide", "mediator_canonical": "STAT3", "outcome_canonical": "arthritis", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "38493058", "title": "Neuroprotective effects of niclosamide on disease progression via inflammatory pathways modulation in SOD1-G93A and FUS-associated amyotrophic lateral sclerosis models", "doi": "10.1016/j.neurot.2024.e00346", "year": 2024 } ], "bc": [ { "pmid": "36368156", "title": "The Stat3 inhibitor F0648-0027 is a potential therapeutic against rheumatoid arthritis", "doi": "10.1016/j.bbrc.2022.10.106", "year": 2022 } ] } }, { "id": 25723, "drug": "riluzole", "drug_type": "drug", "drug_domain": "als", "predicate_ab": "downregulates", "mediator": "MMP-9", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "prevalent ILD", "outcome_type": "disease", "outcome_domain": "rheumatoid_arthritis", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "riluzole", "mediator_canonical": "MMP9", "outcome_canonical": "prevalent ild", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40012807", "title": "Investigation of the Neuroprotective Effect of Riluzole on Matrix Metalloproteinases in an Experimental Model of Glaucoma", "doi": "10.4103/joco.joco_290_23", "year": 2024 } ], "bc": [ { "pmid": "38268499", "title": "Plasma Matrix Metalloproteinase Concentrations and Risk of Interstitial Lung Disease in a Prospective Rheumatoid Arthritis Cohort", "doi": "10.1002/art.42812", "year": 2024 } ] } }, { "id": 42799, "drug": "sunitinib", "drug_type": "drug", "drug_domain": "als", "predicate_ab": "inhibits", "mediator": "STAT3", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "arthritis", "outcome_type": "disease", "outcome_domain": "rheumatoid_arthritis", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "38914173", "title": "Sunitinib-mediated inhibition of STAT3 in skeletal muscle and spinal cord does not affect the disease in a mouse model of ALS", "doi": "10.1016/j.nbd.2024.106576", "year": 2024 } ], "bc": [ { "pmid": "36368156", "title": "The Stat3 inhibitor F0648-0027 is a potential therapeutic against rheumatoid arthritis", "doi": "10.1016/j.bbrc.2022.10.106", "year": 2022 } ] } }, { "id": 25389, "drug": "riluzole", "drug_type": "drug", "drug_domain": "als", "predicate_ab": "downregulates", "mediator": "MMP-2", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "female gender", "outcome_type": "phenotype", "outcome_domain": "pancreatic_cancer", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "active", "clinical_trial_nct_ids": [ "NCT07447050", "NCT06580002", "NCT07013773" ], "literature_status": "partial_evidence", "drug_canonical": "riluzole", "mediator_canonical": "MMP2", "outcome_canonical": "female gender", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40012807", "title": "Investigation of the Neuroprotective Effect of Riluzole on Matrix Metalloproteinases in an Experimental Model of Glaucoma", "doi": "10.4103/joco.joco_290_23", "year": 2024 } ], "bc": [ { "pmid": "27429508", "title": "Expressions of Matrix Metalloproteinases 2, 7, and 9 in Carcinogenesis of Pancreatic Ductal Adenocarcinoma", "doi": "10.1155/2016/9895721", "year": 2016 } ] } }, { "id": 25086, "drug": "niclosamide", "drug_type": "drug", "drug_domain": "als", "predicate_ab": "inhibits", "mediator": "STAT3", "mediator_type": "protein", "predicate_bc": "prevents", "outcome": "DSS-induced colitis", "outcome_type": "disease", "outcome_domain": "inflammatory_bowel_disease", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "niclosamide", "mediator_canonical": "STAT3", "outcome_canonical": "dss-induced colitis", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "38493058", "title": "Neuroprotective effects of niclosamide on disease progression via inflammatory pathways modulation in SOD1-G93A and FUS-associated amyotrophic lateral sclerosis models", "doi": "10.1016/j.neurot.2024.e00346", "year": 2024 } ], "bc": [ { "pmid": "33673239", "title": "STAT3 Signalling via the IL-6ST/gp130 Cytokine Receptor Promotes Epithelial Integrity and Intestinal Barrier Function during DSS-Induced Colitis", "doi": "10.3390/biomedicines9020187", "year": 2021 } ] } }, { "id": 42779, "drug": "riluzole", "drug_type": "drug", "drug_domain": "als", "predicate_ab": "downregulates", "mediator": "MMP-2", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "rheumatoid arthritis", "outcome_type": "disease", "outcome_domain": "rheumatoid_arthritis", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40012807", "title": "Investigation of the Neuroprotective Effect of Riluzole on Matrix Metalloproteinases in an Experimental Model of Glaucoma", "doi": "10.4103/joco.joco_290_23", "year": 2024 } ], "bc": [ { "pmid": "35291607", "title": "HOTAIR and THRIL Long Non Coding RNAs and Their Target Genes in Rheumatoid Arthritis patients", "doi": "10.52547/rbmb.10.4.697", "year": 2022 } ] } }, { "id": 25663, "drug": "riluzole", "drug_type": "drug", "drug_domain": "als", "predicate_ab": "downregulates", "mediator": "MMP-9", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "forced vital capacity", "outcome_type": "phenotype", "outcome_domain": "rheumatoid_arthritis", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "riluzole", "mediator_canonical": "MMP9", "outcome_canonical": "forced vital capacity", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40012807", "title": "Investigation of the Neuroprotective Effect of Riluzole on Matrix Metalloproteinases in an Experimental Model of Glaucoma", "doi": "10.4103/joco.joco_290_23", "year": 2024 } ], "bc": [ { "pmid": "38268499", "title": "Plasma Matrix Metalloproteinase Concentrations and Risk of Interstitial Lung Disease in a Prospective Rheumatoid Arthritis Cohort", "doi": "10.1002/art.42812", "year": 2024 } ] } }, { "id": 25050, "drug": "riluzole", "drug_type": "drug", "drug_domain": "als", "predicate_ab": "activates", "mediator": "p53", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "architectural distortion", "outcome_type": "phenotype", "outcome_domain": "inflammatory_bowel_disease", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "riluzole", "mediator_canonical": "TP53", "outcome_canonical": "architectural distortion", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "32231713", "title": "Riluzole Enhances the Response of Human Nasopharyngeal Carcinoma Cells to Ionizing Radiation via ATM/P53 Signalling Pathway", "doi": "10.7150/jca.41217", "year": 2020 } ], "bc": [ { "pmid": "27578918", "title": "Expression Profile of p53 and p21 in Large Bowel Mucosa as Biomarkers of Inflammatory-Related Carcinogenesis in Ulcerative Colitis", "doi": "10.1155/2016/3625279", "year": 2016 } ] } }, { "id": 25026, "drug": "riluzole", "drug_type": "drug", "drug_domain": "als", "predicate_ab": "downregulates", "mediator": "MMP-9", "mediator_type": "protein", "predicate_bc": "increases", "outcome": "colonic epithelial permeability", "outcome_type": "phenotype", "outcome_domain": "inflammatory_bowel_disease", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "riluzole", "mediator_canonical": "MMP9", "outcome_canonical": "colonic epithelial permeability", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40012807", "title": "Investigation of the Neuroprotective Effect of Riluzole on Matrix Metalloproteinases in an Experimental Model of Glaucoma", "doi": "10.4103/joco.joco_290_23", "year": 2024 } ], "bc": [ { "pmid": "26514773", "title": "Matrix metalloproteinase 9-induced increase in intestinal epithelial tight junction permeability contributes to the severity of experimental DSS colitis", "doi": "10.1152/ajpgi.00256.2015", "year": 2015 } ] } }, { "id": 18304, "drug": "valproic acid", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "upregulates", "mediator": "CXCR4", "mediator_type": "gene", "predicate_bc": "associated_with", "outcome": "differentiated phenotype", "outcome_type": "phenotype", "outcome_domain": "pancreatic_cancer", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "valproic acid", "mediator_canonical": "CXCR4", "outcome_canonical": "differentiated phenotype", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40164048", "title": "Valproic acid preconditioning of bone marrow mesenchymal stem cells promotes remyelination of the corpus callosum in a cuprizone-induced demyelination model", "doi": "10.1016/j.biopha.2025.118027", "year": 2025 } ], "bc": [ { "pmid": "32606001", "title": "CXCR4 in Tumor Epithelial Cells Mediates Desmoplastic Reaction in Pancreatic Ductal Adenocarcinoma", "doi": "10.1158/0008-5472.can-19-2745", "year": 2020 } ] } }, { "id": 20678, "drug": "metformin", "drug_type": "drug", "drug_domain": "alzheimer", "predicate_ab": "downregulates", "mediator": "c-Myc", "mediator_type": "gene", "predicate_bc": "associated_with", "outcome": "gemcitabine resistance", "outcome_type": "phenotype", "outcome_domain": "pancreatic_cancer", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "metformin", "mediator_canonical": "c-myc", "outcome_canonical": "gemcitabine resistance", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "32382652", "title": "If ineffective levels of transforming growth factors and their receptor account for old age being a risk factor for Alzheimer's disease, then increasing TGFBR2 might be therapeutic", "doi": "10.1002/trc2.12019", "year": 2020 } ], "bc": [ { "pmid": "35586061", "title": "c-Myc-PD-L1 Axis Sustained Gemcitabine-Resistance in Pancreatic Cancer", "doi": "10.3389/fphar.2022.851512", "year": 2022 } ] } }, { "id": 25007, "drug": "resveratrol", "drug_type": "drug", "drug_domain": "als", "predicate_ab": "induces", "mediator": "PGC1α", "mediator_type": "protein", "predicate_bc": "decreases", "outcome": "inflammation", "outcome_type": "disease", "outcome_domain": "inflammatory_bowel_disease", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "active", "clinical_trial_nct_ids": [ "NCT07501377", "NCT07182370", "NCT07395921" ], "literature_status": "reproduces_known", "drug_canonical": "resveratrol", "mediator_canonical": "pgc1α", "outcome_canonical": null, "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "26981091", "title": "How does resveratrol influence the genesis of some neurodegenerative diseases?", "doi": "10.4103/1673-5374.175047", "year": 2016 } ], "bc": [ { "pmid": "26969166", "title": "Peroxisome Proliferator-activated Receptor-γ Coactivator 1-α (PGC1α) Protects against Experimental Murine Colitis", "doi": "10.1074/jbc.m115.688812", "year": 2016 } ] } }, { "id": 24711, "drug": "riluzole", "drug_type": "drug", "drug_domain": "als", "predicate_ab": "downregulates", "mediator": "MMP-9", "mediator_type": "protein", "predicate_bc": "predicts", "outcome": "poor prognosis", "outcome_type": "phenotype", "outcome_domain": "epilepsy", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "riluzole", "mediator_canonical": "MMP9", "outcome_canonical": null, "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40012807", "title": "Investigation of the Neuroprotective Effect of Riluzole on Matrix Metalloproteinases in an Experimental Model of Glaucoma", "doi": "10.4103/joco.joco_290_23", "year": 2024 } ], "bc": [ { "pmid": "32538745", "title": "Correlation of MMP-9 and HMGB1 expression with the cognitive function in patients with epilepsy and factors affecting the prognosis", "doi": "10.14715/cmb/2020.66.3.6", "year": 2020 } ] } }, { "id": 24710, "drug": "riluzole", "drug_type": "drug", "drug_domain": "als", "predicate_ab": "downregulates", "mediator": "MMP-9", "mediator_type": "protein", "predicate_bc": "increases", "outcome": "synaptic connectivity", "outcome_type": "phenotype", "outcome_domain": "epilepsy", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "riluzole", "mediator_canonical": "MMP9", "outcome_canonical": "synaptic connectivity", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40012807", "title": "Investigation of the Neuroprotective Effect of Riluzole on Matrix Metalloproteinases in an Experimental Model of Glaucoma", "doi": "10.4103/joco.joco_290_23", "year": 2024 } ], "bc": [ { "pmid": "34282726", "title": "Role of matrix metalloproteinase-9 in neurodevelopmental deficits and experience-dependent plasticity in Xenopus laevis", "doi": "10.7554/elife.62147", "year": 2021 } ] } }, { "id": 37098, "drug": "valproic acid", "drug_type": "drug", "drug_domain": "pancreatic_cancer", "predicate_ab": "downregulates", "mediator": "ERBB3", "mediator_type": "gene", "predicate_bc": "associated_with", "outcome": "multiple sclerosis", "outcome_type": "disease", "outcome_domain": "multiple_sclerosis", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "active", "clinical_trial_nct_ids": [ "NCT02670161" ], "literature_status": "reproduces_known", "drug_canonical": "valproic acid", "mediator_canonical": "erbb3", "outcome_canonical": "multiple sclerosis", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "30961642", "title": "Valproic acid exhibits anti-tumor activity selectively against EGFR/ErbB2/ErbB3-coexpressing pancreatic cancer via induction of ErbB family members-targeting microRNAs", "doi": "10.1186/s13046-019-1160-9", "year": 2019 } ], "bc": [ { "pmid": "29503661", "title": "Identification of Shared Molecular Signatures Indicate the Susceptibility of Endometriosis to Multiple Sclerosis", "doi": "10.3389/fgene.2018.00042", "year": 2018 } ] } }, { "id": 2738, "drug": "valproic acid", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "downregulates", "mediator": "BDNF", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "depressive disorder", "outcome_type": "disease", "outcome_domain": "depression", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "active", "clinical_trial_nct_ids": [ "NCT05603104", "NCT05973786", "NCT06729541" ], "literature_status": "reproduces_known", "drug_canonical": "valproic acid", "mediator_canonical": "BDNF", "outcome_canonical": "depressive disorder", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "35465089", "title": "Excitatory and Inhibitory Synaptic Imbalance Caused by Brain-Derived Neurotrophic Factor Deficits During Development in a Valproic Acid Mouse Model of Autism", "doi": "10.3389/fnmol.2022.860275", "year": 2022 } ], "bc": [ { "pmid": "34979889", "title": "The Role of Natural Products in Treatment of Depressive Disorder", "doi": "10.2174/1570159x20666220103140834", "year": 2022 } ] } }, { "id": 50653, "drug": "losartan", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "upregulates", "mediator": "AT1R", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "bipolar depression", "outcome_type": "disease", "outcome_domain": "depression", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "26168042", "title": "Chronic Losartan Treatment Up-Regulates AT1R and Increases the Heart Vulnerability to Acute Onset of Ischemia and Reperfusion Injury in Male Rats", "doi": "10.1371/journal.pone.0132712", "year": 2015 } ], "bc": [ { "pmid": "41823081", "title": "The Candesartan Adjunctive Depression Trials—CADET", "doi": "10.1097/jcp.0000000000002156", "year": 2026 } ] } }, { "id": 2804, "drug": "valproic acid", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "downregulates", "mediator": "BDNF", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "improvement in depressive symptoms", "outcome_type": "phenotype", "outcome_domain": "depression", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "valproic acid", "mediator_canonical": "BDNF", "outcome_canonical": "improvement in depressive symptoms", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "35465089", "title": "Excitatory and Inhibitory Synaptic Imbalance Caused by Brain-Derived Neurotrophic Factor Deficits During Development in a Valproic Acid Mouse Model of Autism", "doi": "10.3389/fnmol.2022.860275", "year": 2022 } ], "bc": [ { "pmid": "37891727", "title": "Changes in Adipokine, Resitin, and BDNF Concentrations in Treatment-Resistant Depression after Electroconvulsive Therapy", "doi": "10.3390/brainsci13101358", "year": 2023 } ] } }, { "id": 8200, "drug": "sunitinib", "drug_type": "drug", "drug_domain": "als", "predicate_ab": "inhibits", "mediator": "STAT3", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "drug resistance", "outcome_type": "phenotype", "outcome_domain": "pancreatic_cancer", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "sunitinib", "mediator_canonical": "STAT3", "outcome_canonical": null, "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "38914173", "title": "Sunitinib-mediated inhibition of STAT3 in skeletal muscle and spinal cord does not affect the disease in a mouse model of ALS", "doi": "10.1016/j.nbd.2024.106576", "year": 2024 } ], "bc": [ { "pmid": "38464736", "title": "Role of STAT3 in pancreatic cancer", "doi": "10.37349/etat.2024.00202", "year": 2024 } ] } }, { "id": 37097, "drug": "valproic acid", "drug_type": "drug", "drug_domain": "pancreatic_cancer", "predicate_ab": "downregulates", "mediator": "ERBB3", "mediator_type": "gene", "predicate_bc": "associated_with", "outcome": "endometriosis", "outcome_type": "disease", "outcome_domain": "multiple_sclerosis", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "valproic acid", "mediator_canonical": "erbb3", "outcome_canonical": "endometriosis", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "30961642", "title": "Valproic acid exhibits anti-tumor activity selectively against EGFR/ErbB2/ErbB3-coexpressing pancreatic cancer via induction of ErbB family members-targeting microRNAs", "doi": "10.1186/s13046-019-1160-9", "year": 2019 } ], "bc": [ { "pmid": "29503661", "title": "Identification of Shared Molecular Signatures Indicate the Susceptibility of Endometriosis to Multiple Sclerosis", "doi": "10.3389/fgene.2018.00042", "year": 2018 } ] } }, { "id": 50672, "drug": "losartan", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "downregulates", "mediator": "TGF-β1", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "depression severity", "outcome_type": "phenotype", "outcome_domain": "depression", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "25755735", "title": "Losartan reduces myocardial interstitial fibrosis in diabetic cardiomyopathy rats by inhibiting JAK/STAT signaling pathway.", "doi": null, "year": 2015 } ], "bc": [ { "pmid": "40958792", "title": "Transforming growth factor-β superfamily members as potential biomarkers for adolescent major depressive disorder", "doi": "10.3389/fpsyt.2025.1655332", "year": 2025 } ] } }, { "id": 42581, "drug": "riluzole", "drug_type": "drug", "drug_domain": "als", "predicate_ab": "downregulates", "mediator": "MMP-9", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "vascular invasion", "outcome_type": "phenotype", "outcome_domain": "pancreatic_cancer", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40012807", "title": "Investigation of the Neuroprotective Effect of Riluzole on Matrix Metalloproteinases in an Experimental Model of Glaucoma", "doi": "10.4103/joco.joco_290_23", "year": 2024 } ], "bc": [ { "pmid": "26652622", "title": "The co-expression of MMP-9 and Tenascin-C is significantly associated with the progression and prognosis of pancreatic cancer", "doi": "10.1186/s13000-015-0445-3", "year": 2015 } ] } }, { "id": 50726, "drug": "atorvastatin", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "downregulates", "mediator": "TGF-β1", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "depression severity", "outcome_type": "phenotype", "outcome_domain": "depression", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "26579943", "title": "Atorvastatin Ameliorates Radiation-Induced Cardiac Fibrosis in Rats", "doi": "10.1667/rr14075.1", "year": 2015 } ], "bc": [ { "pmid": "40958792", "title": "Transforming growth factor-β superfamily members as potential biomarkers for adolescent major depressive disorder", "doi": "10.3389/fpsyt.2025.1655332", "year": 2025 } ] } }, { "id": 50759, "drug": "resveratrol", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "upregulates", "mediator": "VEGF", "mediator_type": "protein", "predicate_bc": "predicts", "outcome": "antidepressant response to ketamine", "outcome_type": "phenotype", "outcome_domain": "depression", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "28138705", "title": "Resveratrol activates endogenous cardiac stem cells and improves myocardial regeneration following acute myocardial infarction", "doi": "10.3892/mmr.2017.6143", "year": 2017 } ], "bc": [ { "pmid": "34035893", "title": "Association of plasma VEGF levels and the antidepressant effects of ketamine in patients with depression", "doi": "10.1177/20451253211014320", "year": 2021 } ] } }, { "id": 37035, "drug": "Auranofin", "drug_type": "drug", "drug_domain": "pancreatic_cancer", "predicate_ab": "inhibits", "mediator": "HIF-1α", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "inflammatory bowel disease", "outcome_type": "disease", "outcome_domain": "inflammatory_bowel_disease", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "auranofin", "mediator_canonical": "hif-1α", "outcome_canonical": "inflammatory bowel disease", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "33981979", "title": "Antineoplastic effects of auranofin in human pancreatic adenocarcinoma preclinical models", "doi": "10.1016/j.sopen.2019.05.004", "year": 2019 } ], "bc": [ { "pmid": "38605960", "title": "Crosstalk between hypoxia-inducible factor-1α and short-chain fatty acids in inflammatory bowel disease: key clues toward unraveling the mystery", "doi": "10.3389/fimmu.2024.1385907", "year": 2024 } ] } }, { "id": 24680, "drug": "riluzole", "drug_type": "drug", "drug_domain": "als", "predicate_ab": "downregulates", "mediator": "MMP-2", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "epilepsy", "outcome_type": "disease", "outcome_domain": "epilepsy", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "riluzole", "mediator_canonical": "MMP2", "outcome_canonical": "epilepsy", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40012807", "title": "Investigation of the Neuroprotective Effect of Riluzole on Matrix Metalloproteinases in an Experimental Model of Glaucoma", "doi": "10.4103/joco.joco_290_23", "year": 2024 } ], "bc": [ { "pmid": "36766708", "title": "Blood-Brain Barrier-Associated Proteins Are Elevated in Serum of Epilepsy Patients", "doi": "10.3390/cells12030368", "year": 2023 } ] } }, { "id": 35812, "drug": "chloroquine", "drug_type": "drug", "drug_domain": "multiple_sclerosis", "predicate_ab": "upregulates", "mediator": "IL-10", "mediator_type": "protein", "predicate_bc": "treats", "outcome": "pain behavior", "outcome_type": "phenotype", "outcome_domain": "type_2_diabetes", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "chloroquine", "mediator_canonical": "il-10", "outcome_canonical": "pain behavior", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "32516999", "title": "Comprehensive Analysis of the Immune and Stromal Compartments of the CNS in EAE Mice Reveal Pathways by Which Chloroquine Suppresses Neuroinflammation", "doi": "10.3390/brainsci10060348", "year": 2020 } ], "bc": [ { "pmid": "33402846", "title": "Interleukin-10 Reduces Neurogenic Inflammation and Pain Behavior in a Mouse Model of Type 2 Diabetes", "doi": "10.2147/jpr.s264136", "year": 2020 } ] } }, { "id": 35766, "drug": "chloroquine", "drug_type": "drug", "drug_domain": "multiple_sclerosis", "predicate_ab": "upregulates", "mediator": "IL-10", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "Type 2 Diabetes Mellitus", "outcome_type": "disease", "outcome_domain": "type_2_diabetes", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "active", "clinical_trial_nct_ids": [ "NCT01326533", "NCT06319560", "NCT02026232" ], "literature_status": "reproduces_known", "drug_canonical": "chloroquine", "mediator_canonical": "il-10", "outcome_canonical": "type 2 diabetes mellitus", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "32516999", "title": "Comprehensive Analysis of the Immune and Stromal Compartments of the CNS in EAE Mice Reveal Pathways by Which Chloroquine Suppresses Neuroinflammation", "doi": "10.3390/brainsci10060348", "year": 2020 } ], "bc": [ { "pmid": "27684566", "title": "Adiponectin and pro‐inflammatory cytokines are modulated in Vietnamese patients with type 2 diabetes mellitus", "doi": "10.1111/jdi.12579", "year": 2016 } ] } }, { "id": 24175, "drug": "chloroquine", "drug_type": "drug", "drug_domain": "multiple_sclerosis", "predicate_ab": "upregulates", "mediator": "IL-10", "mediator_type": "protein", "predicate_bc": "increases", "outcome": "hippocampal dendritic spine density", "outcome_type": "phenotype", "outcome_domain": "depression", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "chloroquine", "mediator_canonical": "il-10", "outcome_canonical": "hippocampal dendritic spine density", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "32516999", "title": "Comprehensive Analysis of the Immune and Stromal Compartments of the CNS in EAE Mice Reveal Pathways by Which Chloroquine Suppresses Neuroinflammation", "doi": "10.3390/brainsci10060348", "year": 2020 } ], "bc": [ { "pmid": "32828124", "title": "Anti-inflammatory IL-10 administration rescues depression-associated learning and memory deficits in mice", "doi": "10.1186/s12974-020-01922-1", "year": 2020 } ] } }, { "id": 24079, "drug": "chloroquine", "drug_type": "drug", "drug_domain": "multiple_sclerosis", "predicate_ab": "upregulates", "mediator": "IL-10", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "therapeutic efficacy", "outcome_type": "phenotype", "outcome_domain": "depression", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "active", "clinical_trial_nct_ids": [ "NCT06862284", "NCT04481633", "NCT07533136" ], "literature_status": "reproduces_known", "drug_canonical": "chloroquine", "mediator_canonical": "il-10", "outcome_canonical": "therapeutic efficacy", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "32516999", "title": "Comprehensive Analysis of the Immune and Stromal Compartments of the CNS in EAE Mice Reveal Pathways by Which Chloroquine Suppresses Neuroinflammation", "doi": "10.3390/brainsci10060348", "year": 2020 } ], "bc": [ { "pmid": "41654910", "title": "Analysis of the correlation between the expression levels of caspase-1/IL-1β in the peripheral blood and clinical efficacy in patients with first-episode MDD", "doi": "10.1186/s12991-026-00632-x", "year": 2026 } ] } }, { "id": 23982, "drug": "acriflavine", "drug_type": "drug", "drug_domain": "multiple_sclerosis", "predicate_ab": "inhibits", "mediator": "HIF-1", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "poor prognosis", "outcome_type": "phenotype", "outcome_domain": "pancreatic_cancer", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "acriflavine", "mediator_canonical": "hif-1", "outcome_canonical": null, "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37942317", "title": "Acriflavine, a HIF-1 inhibitor, preserves vision in an experimental autoimmune encephalomyelitis model of optic neuritis", "doi": "10.3389/fimmu.2023.1271118", "year": 2023 } ], "bc": [ { "pmid": "26405594", "title": "HIF-1 is a critical target of pancreatic cancer", "doi": "10.1080/2162402x.2015.1026535", "year": 2015 } ] } }, { "id": 23936, "drug": "valproic acid", "drug_type": "drug", "drug_domain": "multiple_sclerosis", "predicate_ab": "upregulates", "mediator": "β-catenin", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "gemcitabine sensitivity", "outcome_type": "phenotype", "outcome_domain": "pancreatic_cancer", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "valproic acid", "mediator_canonical": "β-catenin", "outcome_canonical": "gemcitabine sensitivity", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37937413", "title": "Valproic acid effects on human adipose-derived stem cell differentiation into oligodendrocytes and improved remyelination in a mouse model of Multiple Sclerosis", "doi": "10.1387/ijdb.230154ng", "year": 2023 } ], "bc": [ { "pmid": "27830034", "title": "The Wnt/β-catenin signaling pathway mechanism for pancreatic cancer chemoresistance in a three-dimensional cancer microenvironment.", "doi": null, "year": 2016 } ] } }, { "id": 23512, "drug": "chloroquine", "drug_type": "drug", "drug_domain": "multiple_sclerosis", "predicate_ab": "upregulates", "mediator": "IL-10", "mediator_type": "protein", "predicate_bc": "increases", "outcome": "lifespan", "outcome_type": "phenotype", "outcome_domain": "als", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "chloroquine", "mediator_canonical": "il-10", "outcome_canonical": "lifespan", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "32516999", "title": "Comprehensive Analysis of the Immune and Stromal Compartments of the CNS in EAE Mice Reveal Pathways by Which Chloroquine Suppresses Neuroinflammation", "doi": "10.3390/brainsci10060348", "year": 2020 } ], "bc": [ { "pmid": "33257786", "title": "IL-10 based immunomodulation initiated at birth extends lifespan in a familial mouse model of amyotrophic lateral sclerosis", "doi": "10.1038/s41598-020-77564-3", "year": 2020 } ] } }, { "id": 7340, "drug": "valproic acid", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "downregulates", "mediator": "DNA methylation", "mediator_type": "biomarker", "predicate_bc": "associated_with", "outcome": "treatment response", "outcome_type": "phenotype", "outcome_domain": "depression", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "completed", "clinical_trial_nct_ids": [ "NCT02473250", "NCT01284517", "NCT03039842" ], "literature_status": "reproduces_known", "drug_canonical": "valproic acid", "mediator_canonical": "dna methylation", "outcome_canonical": "treatment response", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "35312054", "title": "Developmental administration of valproic acid alters DNA methylation and maternal behavior", "doi": "10.1002/dev.22231", "year": 2022 } ], "bc": [ { "pmid": "37664245", "title": "Longitudinal early epigenomic signatures inform molecular paths of therapy response and remission in depressed patients", "doi": "10.3389/fnmol.2023.1223216", "year": 2023 } ] } }, { "id": 23159, "drug": "chloroquine", "drug_type": "drug", "drug_domain": "multiple_sclerosis", "predicate_ab": "upregulates", "mediator": "IL-10", "mediator_type": "protein", "predicate_bc": "causes", "outcome": "tumor immune escape", "outcome_type": "phenotype", "outcome_domain": "glioblastoma", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "chloroquine", "mediator_canonical": "il-10", "outcome_canonical": "tumor immune escape", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "32516999", "title": "Comprehensive Analysis of the Immune and Stromal Compartments of the CNS in EAE Mice Reveal Pathways by Which Chloroquine Suppresses Neuroinflammation", "doi": "10.3390/brainsci10060348", "year": 2020 } ], "bc": [ { "pmid": "35177622", "title": "T-cell dysfunction in the glioblastoma microenvironment is mediated by myeloid cells releasing interleukin-10", "doi": "10.1038/s41467-022-28523-1", "year": 2022 } ] } }, { "id": 12829, "drug": "valproic acid", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "downregulates", "mediator": "DNA methylation", "mediator_type": "biomarker", "predicate_bc": "associated_with", "outcome": "suicidal behavior", "outcome_type": "phenotype", "outcome_domain": "depression", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "completed", "clinical_trial_nct_ids": [ "NCT02593643" ], "literature_status": "partial_evidence", "drug_canonical": "valproic acid", "mediator_canonical": "dna methylation", "outcome_canonical": "suicidal behavior", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "35312054", "title": "Developmental administration of valproic acid alters DNA methylation and maternal behavior", "doi": "10.1002/dev.22231", "year": 2022 } ], "bc": [ { "pmid": "39645539", "title": "Genome-wide methylome-based molecular pathologies associated with depression and suicide", "doi": "10.1038/s41386-024-02040-9", "year": 2024 } ] } }, { "id": 23145, "drug": "curcumin", "drug_type": "drug", "drug_domain": "multiple_sclerosis", "predicate_ab": "upregulates", "mediator": "Foxp3", "mediator_type": "gene", "predicate_bc": "associated_with", "outcome": "poor prognosis", "outcome_type": "phenotype", "outcome_domain": "glioblastoma", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "curcumin", "mediator_canonical": "foxp3", "outcome_canonical": null, "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "38566376", "title": "Immunoregulatory Effects of the Active Form of Vitamin D (Calcitriol),Individually and in Combination with Curcumin, on Peripheral BloodMononuclear Cells (PBMCs) of Multiple Sclerosis (MS) Patients", "doi": "10.2174/0118715230293847240314073359", "year": 2024 } ], "bc": [ { "pmid": "38561331", "title": "FOXP3 promote the progression of glioblastoma via inhibiting ferroptosis mediated by linc00857/miR-1290/GPX4 axis", "doi": "10.1038/s41419-024-06619-4", "year": 2024 } ] } }, { "id": 2867, "drug": "valproic acid", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "downregulates", "mediator": "BDNF", "mediator_type": "gene", "predicate_bc": "associated_with", "outcome": "antidepressant treatment response", "outcome_type": "phenotype", "outcome_domain": "depression", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "valproic acid", "mediator_canonical": "BDNF", "outcome_canonical": "antidepressant treatment response", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "30404997", "title": "Social behavior, neuroimmune markers and glutamic acid decarboxylase levels in a rat model of valproic acid-induced autism", "doi": "10.2131/jts.43.631", "year": 2018 } ], "bc": [ { "pmid": "29725086", "title": "Gene-based analysis of genes related to neurotrophic pathway suggests association of BDNF and VEGFA with antidepressant treatment-response in depressed patients", "doi": "10.1038/s41598-018-25529-y", "year": 2018 } ] } }, { "id": 23128, "drug": "acriflavine", "drug_type": "drug", "drug_domain": "multiple_sclerosis", "predicate_ab": "inhibits", "mediator": "HIF-1", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "glioblastoma progression", "outcome_type": "disease", "outcome_domain": "glioblastoma", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "acriflavine", "mediator_canonical": "hif-1", "outcome_canonical": "glioblastoma progression", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37942317", "title": "Acriflavine, a HIF-1 inhibitor, preserves vision in an experimental autoimmune encephalomyelitis model of optic neuritis", "doi": "10.3389/fimmu.2023.1271118", "year": 2023 } ], "bc": [ { "pmid": "40277699", "title": "Alginate–Gelatin Hydrogel Scaffold Model for Hypoxia Induction in Glioblastoma Embedded Spheroids", "doi": "10.3390/gels11040263", "year": 2025 } ] } }, { "id": 19539, "drug": "lithium", "drug_type": "drug", "drug_domain": "als", "predicate_ab": "inhibits", "mediator": "GSK-3β", "mediator_type": "protein", "predicate_bc": "increases", "outcome": "acinar-to-ductal metaplasia", "outcome_type": "disease", "outcome_domain": "pancreatic_cancer", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "lithium", "mediator_canonical": "GSK3B", "outcome_canonical": "acinar-to-ductal metaplasia", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "39363657", "title": "Lithium alleviates paralysis in experimental autoimmune neuritis in Lewis rats by modulating glycogen synthase kinase-3β activity", "doi": "10.4142/jvs.24212", "year": 2024 } ], "bc": [ { "pmid": "28639695", "title": "Glycogen synthase kinase‐3β ablation limits pancreatitis‐induced acinar‐to‐ductal metaplasia", "doi": "10.1002/path.4928", "year": 2017 } ] } }, { "id": 23069, "drug": "Luteolin", "drug_type": "drug", "drug_domain": "multiple_sclerosis", "predicate_ab": "activates", "mediator": "NRF2 pathway", "mediator_type": "pathway", "predicate_bc": "confers_resistance_to", "outcome": "ferroptosis", "outcome_type": "phenotype", "outcome_domain": "glioblastoma", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "luteolin", "mediator_canonical": "nrf2 pathway", "outcome_canonical": "ferroptosis", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41362005", "title": "Luteolin rescues myelin integrity and cognitive-motor function via Nrf2 pathway activation: a natural candidate vs. dimethyl fumarate in cuprizone-induced multiple sclerosis", "doi": "10.1080/1028415x.2025.2599459", "year": 2025 } ], "bc": [ { "pmid": "37879937", "title": "NRF2 connects Src tyrosine kinase to ferroptosis resistance in glioblastoma", "doi": "10.26508/lsa.202302205", "year": 2023 } ] } }, { "id": 17590, "drug": "epirubicin", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "inhibits", "mediator": "Foxp3", "mediator_type": "gene", "predicate_bc": "associated_with", "outcome": "Multiple Sclerosis", "outcome_type": "disease", "outcome_domain": "multiple_sclerosis", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "epirubicin", "mediator_canonical": "foxp3", "outcome_canonical": "multiple sclerosis", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "38561331", "title": "FOXP3 promote the progression of glioblastoma via inhibiting ferroptosis mediated by linc00857/miR-1290/GPX4 axis", "doi": "10.1038/s41419-024-06619-4", "year": 2024 } ], "bc": [ { "pmid": "33719347", "title": "Differential Gene Expression Patterns in Blood and Cerebrospinal Fluid of Multiple Sclerosis and Neuro-Behçet Disease", "doi": "10.3389/fgene.2021.638236", "year": 2021 } ] } }, { "id": 21399, "drug": "resveratrol", "drug_type": "drug", "drug_domain": "pancreatic_cancer", "predicate_ab": "upregulates", "mediator": "PTEN", "mediator_type": "gene", "predicate_bc": "decreases", "outcome": "neuroinflammation", "outcome_type": "disease", "outcome_domain": "epilepsy", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "active", "clinical_trial_nct_ids": [ "NCT07501377" ], "literature_status": "reproduces_known", "drug_canonical": "resveratrol", "mediator_canonical": "PTEN", "outcome_canonical": "neuroinflammation", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "29854071", "title": "Resveratrol Inhibits ROS‐Promoted Activation and Glycolysis of Pancreatic Stellate Cells via Suppression of miR‐21", "doi": "10.1155/2018/1346958", "year": 2018 } ], "bc": [ { "pmid": "31658159", "title": "Effect of adenovirus-mediated overexpression of PTEN on brain oxidative damage and neuroinflammation in a rat kindling model of epilepsy [RETRACTED]", "doi": "10.1097/cm9.0000000000000496", "year": 2019 } ] } }, { "id": 21346, "drug": "Auranofin", "drug_type": "drug", "drug_domain": "pancreatic_cancer", "predicate_ab": "inhibits", "mediator": "HIF-1α", "mediator_type": "protein", "predicate_bc": "increases", "outcome": "hippocampal neuron damage", "outcome_type": "phenotype", "outcome_domain": "epilepsy", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "auranofin", "mediator_canonical": "hif-1α", "outcome_canonical": "hippocampal neuron damage", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "33981979", "title": "Antineoplastic effects of auranofin in human pancreatic adenocarcinoma preclinical models", "doi": "10.1016/j.sopen.2019.05.004", "year": 2019 } ], "bc": [ { "pmid": "41324728", "title": "The Role of HIF-1α/BNIP3 Pathway in Hippocampal Neuronal Autophagy in Epilepsy", "doi": "10.1007/s12035-025-05406-2", "year": 2025 } ] } }, { "id": 20859, "drug": "curcumin", "drug_type": "drug", "drug_domain": "alzheimer", "predicate_ab": "upregulates", "mediator": "BDNF", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "depressive symptoms", "outcome_type": "phenotype", "outcome_domain": "depression", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "completed", "clinical_trial_nct_ids": [ "NCT01750359", "NCT01022632" ], "literature_status": "reproduces_known", "drug_canonical": "curcumin", "mediator_canonical": "BDNF", "outcome_canonical": "depressive symptoms", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "38791161", "title": "Curcumin Improves Neurogenesis in Alzheimer’s Disease Mice via the Upregulation of Wnt/β-Catenin and BDNF", "doi": "10.3390/ijms25105123", "year": 2024 } ], "bc": [ { "pmid": "29898192", "title": "Effects of cognitive-behavioral therapy on neurotrophic factors in patients with major depressive disorder", "doi": "10.1590/1516-4446-2017-2357", "year": 2018 } ] } }, { "id": 19835, "drug": "Riluzole", "drug_type": "drug", "drug_domain": "als", "predicate_ab": "upregulates", "mediator": "EAAT2", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "EDSS score", "outcome_type": "phenotype", "outcome_domain": "multiple_sclerosis", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "riluzole", "mediator_canonical": "eaat2", "outcome_canonical": "edss score", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "39806490", "title": "CEST imaging combined with 1H-MRS reveal the neuroprotective effects of riluzole by improving neurotransmitter imbalances in Alzheimer’s disease mice", "doi": "10.1186/s13195-025-01672-3", "year": 2025 } ], "bc": [ { "pmid": "39223661", "title": "Proteomic profile of extracellular vesicles from plasma and CSF of multiple sclerosis patients reveals disease activity-associated EAAT2", "doi": "10.1186/s12974-024-03148-x", "year": 2024 } ] } }, { "id": 19815, "drug": "Riluzole", "drug_type": "drug", "drug_domain": "als", "predicate_ab": "downregulates", "mediator": "MMP-2", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "Multiple Sclerosis", "outcome_type": "disease", "outcome_domain": "multiple_sclerosis", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "active", "clinical_trial_nct_ids": [ "NCT00403104", "NCT07142291", "NCT00202397" ], "literature_status": "reproduces_known", "drug_canonical": "riluzole", "mediator_canonical": "MMP2", "outcome_canonical": "multiple sclerosis", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40012807", "title": "Investigation of the Neuroprotective Effect of Riluzole on Matrix Metalloproteinases in an Experimental Model of Glaucoma", "doi": "10.4103/joco.joco_290_23", "year": 2024 } ], "bc": [ { "pmid": "32243867", "title": "Serum levels of matrix metalloproteinase-2, -9, and vitamin D in patients with multiple sclerosis with or without herpesvirus-6 seropositivity", "doi": "10.1016/j.bjid.2020.02.001", "year": 2020 } ] } }, { "id": 19787, "drug": "Riluzole", "drug_type": "drug", "drug_domain": "als", "predicate_ab": "downregulates", "mediator": "MMP-9", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "HHV-6 seropositivity", "outcome_type": "phenotype", "outcome_domain": "multiple_sclerosis", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "riluzole", "mediator_canonical": "MMP9", "outcome_canonical": "hhv-6 seropositivity", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40012807", "title": "Investigation of the Neuroprotective Effect of Riluzole on Matrix Metalloproteinases in an Experimental Model of Glaucoma", "doi": "10.4103/joco.joco_290_23", "year": 2024 } ], "bc": [ { "pmid": "32243867", "title": "Serum levels of matrix metalloproteinase-2, -9, and vitamin D in patients with multiple sclerosis with or without herpesvirus-6 seropositivity", "doi": "10.1016/j.bjid.2020.02.001", "year": 2020 } ] } }, { "id": 19772, "drug": "Riluzole", "drug_type": "drug", "drug_domain": "als", "predicate_ab": "downregulates", "mediator": "MMP-9", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "Multiple Sclerosis", "outcome_type": "disease", "outcome_domain": "multiple_sclerosis", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "active", "clinical_trial_nct_ids": [ "NCT00403104", "NCT07142291", "NCT00202397" ], "literature_status": "reproduces_known", "drug_canonical": "riluzole", "mediator_canonical": "MMP9", "outcome_canonical": "multiple sclerosis", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40012807", "title": "Investigation of the Neuroprotective Effect of Riluzole on Matrix Metalloproteinases in an Experimental Model of Glaucoma", "doi": "10.4103/joco.joco_290_23", "year": 2024 } ], "bc": [ { "pmid": "32243867", "title": "Serum levels of matrix metalloproteinase-2, -9, and vitamin D in patients with multiple sclerosis with or without herpesvirus-6 seropositivity", "doi": "10.1016/j.bjid.2020.02.001", "year": 2020 } ] } }, { "id": 19763, "drug": "Riluzole", "drug_type": "drug", "drug_domain": "als", "predicate_ab": "suppresses", "mediator": "MMP2", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "relapse-remitting multiple sclerosis", "outcome_type": "disease", "outcome_domain": "multiple_sclerosis", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "riluzole", "mediator_canonical": "MMP2", "outcome_canonical": "relapse-remitting multiple sclerosis", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40391158", "title": "Repurposing riluzole as an anti-osteosarcoma agent", "doi": "10.3389/fonc.2025.1508819", "year": 2025 } ], "bc": [ { "pmid": "35571066", "title": "Label-free Quantitative Proteomic Analysis of Cerebrospinal Fluid and Serum in Patients With Relapse-Remitting Multiple Sclerosis", "doi": "10.3389/fgene.2022.892491", "year": 2022 } ] } }, { "id": 18724, "drug": "Baicalin", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "upregulates", "mediator": "BDNF", "mediator_type": "protein", "predicate_bc": "predicts", "outcome": "Multiple Sclerosis", "outcome_type": "disease", "outcome_domain": "multiple_sclerosis", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "baicalin", "mediator_canonical": "BDNF", "outcome_canonical": "multiple sclerosis", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "38778616", "title": "Exploring the Therapeutic Potential of Baicalin: Mitigating Anxiety and Depression in Epileptic Rats", "doi": "10.2174/0113862073316021240520110301", "year": 2024 } ], "bc": [ { "pmid": "29865854", "title": "BDNF and Tau as Biomarkers of Severity in Multiple Sclerosis", "doi": "10.2217/bmm-2017-0374", "year": 2018 } ] } }, { "id": 18538, "drug": "Baicalin", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "upregulates", "mediator": "BDNF", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "visuospatial ability", "outcome_type": "phenotype", "outcome_domain": "depression", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "baicalin", "mediator_canonical": "BDNF", "outcome_canonical": "visuospatial ability", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "38778616", "title": "Exploring the Therapeutic Potential of Baicalin: Mitigating Anxiety and Depression in Epileptic Rats", "doi": "10.2174/0113862073316021240520110301", "year": 2024 } ], "bc": [ { "pmid": "39911552", "title": "Association of inflammation cytokines with cognitive function in first-episode major depressive disorder", "doi": "10.3389/fpsyt.2024.1473418", "year": 2025 } ] } }, { "id": 18363, "drug": "valproic acid", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "downregulates", "mediator": "FASN", "mediator_type": "gene", "predicate_bc": "associated_with", "outcome": "prognosis", "outcome_type": "phenotype", "outcome_domain": "pancreatic_cancer", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "valproic acid", "mediator_canonical": "fasn", "outcome_canonical": null, "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "36544904", "title": "Metabolomic profiling of triple negative breast cancer cells suggests that valproic acid can enhance the anticancer effect of cisplatin", "doi": "10.3389/fcell.2022.1014798", "year": 2022 } ], "bc": [ { "pmid": "36650542", "title": "FASN multi-omic characterization reveals metabolic heterogeneity in pancreatic and prostate adenocarcinoma", "doi": "10.1186/s12967-023-03874-5", "year": 2023 } ] } }, { "id": 8344, "drug": "Riluzole", "drug_type": "drug", "drug_domain": "als", "predicate_ab": "downregulates", "mediator": "MMP-9", "mediator_type": "protein", "predicate_bc": "increases", "outcome": "branching of excitatory neurons", "outcome_type": "phenotype", "outcome_domain": "depression", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "riluzole", "mediator_canonical": "MMP9", "outcome_canonical": "branching of excitatory neurons", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40012807", "title": "Investigation of the Neuroprotective Effect of Riluzole on Matrix Metalloproteinases in an Experimental Model of Glaucoma", "doi": "10.4103/joco.joco_290_23", "year": 2024 } ], "bc": [ { "pmid": "32269106", "title": "Venlafaxine Stimulates an MMP-9-Dependent Increase in Excitatory/Inhibitory Balance in a Stress Model of Depression", "doi": "10.1523/jneurosci.2387-19.2020", "year": 2020 } ] } }, { "id": 18158, "drug": "metformin", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "upregulates", "mediator": "α-synuclein", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "cognitive symptom onset", "outcome_type": "phenotype", "outcome_domain": "alzheimer", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "metformin", "mediator_canonical": "SNCA", "outcome_canonical": "cognitive symptom onset", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "30308130", "title": "Effects of metformin on apoptosis and α-synuclein in a rat model of pentylenetetrazole-induced epilepsy", "doi": "10.1139/cjpp-2018-0266", "year": 2018 } ], "bc": [ { "pmid": "30477568", "title": "The relevance of cerebrospinal fluid α-synuclein levels to sporadic and familial Alzheimer’s disease", "doi": "10.1186/s40478-018-0624-z", "year": 2018 } ] } }, { "id": 29252, "drug": "baicalin", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "upregulates", "mediator": "BDNF", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "improvement in depressive symptoms", "outcome_type": "phenotype", "outcome_domain": "depression", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "baicalin", "mediator_canonical": "BDNF", "outcome_canonical": "improvement in depressive symptoms", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "38778616", "title": "Exploring the Therapeutic Potential of Baicalin: Mitigating Anxiety and Depression in Epileptic Rats", "doi": "10.2174/0113862073316021240520110301", "year": 2024 } ], "bc": [ { "pmid": "37891727", "title": "Changes in Adipokine, Resitin, and BDNF Concentrations in Treatment-Resistant Depression after Electroconvulsive Therapy", "doi": "10.3390/brainsci13101358", "year": 2023 } ] } }, { "id": 46722, "drug": "valproic acid", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "downregulates", "mediator": "BDNF", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "major depression", "outcome_type": "disease", "outcome_domain": "depression", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "35465089", "title": "Excitatory and Inhibitory Synaptic Imbalance Caused by Brain-Derived Neurotrophic Factor Deficits During Development in a Valproic Acid Mouse Model of Autism", "doi": "10.3389/fnmol.2022.860275", "year": 2022 } ], "bc": [ { "pmid": "36831119", "title": "The Serum Brain-Derived Neurotrophic Factor Increases in Serotonin Reuptake Inhibitor Responders Patients with First-Episode, Drug-Naïve Major Depression", "doi": "10.3390/biomedicines11020584", "year": 2023 } ] } }, { "id": 18157, "drug": "metformin", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "upregulates", "mediator": "α-synuclein", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "clinical impairment exceeding biological stage", "outcome_type": "phenotype", "outcome_domain": "alzheimer", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "metformin", "mediator_canonical": "SNCA", "outcome_canonical": "clinical impairment exceeding biological stage", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "30308130", "title": "Effects of metformin on apoptosis and α-synuclein in a rat model of pentylenetetrazole-induced epilepsy", "doi": "10.1139/cjpp-2018-0266", "year": 2018 } ], "bc": [ { "pmid": "40388185", "title": "Evaluation of the Revised Criteria for Biological and Clinical Staging of Alzheimer Disease", "doi": "10.1001/jamaneurol.2025.1100", "year": 2025 } ] } }, { "id": 17981, "drug": "valproic acid", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "downregulates", "mediator": "VEGF", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "susceptibility to neurodegeneration", "outcome_type": "phenotype", "outcome_domain": "als", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "valproic acid", "mediator_canonical": "VEGF", "outcome_canonical": "susceptibility to neurodegeneration", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "32149283", "title": "l-Cysteine decorated nanoscale metal–organic frameworks delivering valproic acid/cisplatin for drug-resistant lung cancer therapy", "doi": "10.1039/c9cc09712k", "year": 2020 } ], "bc": [ { "pmid": "28570669", "title": "Extraocular motoneurons of the adult rat show higher levels of vascular endothelial growth factor and its receptor Flk-1 than other cranial motoneurons", "doi": "10.1371/journal.pone.0178616", "year": 2017 } ] } }, { "id": 17553, "drug": "apigenin", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "upregulates", "mediator": "GFAP", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "neuropathic pain", "outcome_type": "disease", "outcome_domain": "multiple_sclerosis", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "apigenin", "mediator_canonical": "GFAP", "outcome_canonical": "neuropathic pain", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41090780", "title": "Apigenin Induces Autophagy and Apoptosis in Chemoresistant Glioblastoma Cells and Inhibits Tumorigenicity Associated with Regulation of Immunomodulatory Proteins and Glial Cells Response", "doi": "10.3390/cells14191552", "year": 2025 } ], "bc": [ { "pmid": "41677653", "title": "Integrative Proteomics Reveal Neuroimmune and Dopaminergic Alterations Across the Nociceptive Neuraxis in Neuropathic Pain", "doi": "10.3390/cells15030290", "year": 2026 } ] } }, { "id": 56116, "drug": "propranolol", "drug_type": "drug", "drug_domain": "pancreatic_cancer", "predicate_ab": "suppresses", "mediator": "CREB", "mediator_type": "protein", "predicate_bc": "increases", "outcome": "dendritic health", "outcome_type": "phenotype", "outcome_domain": "als", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "39642318", "title": "Stress and Obesity Signaling Converge on CREB Phosphorylation to Promote Pancreatic Cancer", "doi": "10.1158/1541-7786.mcr-24-0785", "year": 2024 } ], "bc": [ { "pmid": "39589881", "title": "Early disruption of the CREB pathway drives dendritic morphological alterations in FTD/ALS cortical neurons", "doi": "10.1073/pnas.2406998121", "year": 2024 } ] } }, { "id": 1853, "drug": "auraptene", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "downregulates", "mediator": "MMP-9", "mediator_type": "protein", "predicate_bc": "increases", "outcome": "branching of excitatory neurons", "outcome_type": "phenotype", "outcome_domain": "depression", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "auraptene", "mediator_canonical": "MMP9", "outcome_canonical": "branching of excitatory neurons", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "39086858", "title": "Auraptene inhibits migration, invasion and metastatic behavior of human malignant glioblastoma cells: An in vitro and in silico study.", "doi": "10.22038/ajp.2023.23586", "year": 2024 } ], "bc": [ { "pmid": "32269106", "title": "Venlafaxine Stimulates an MMP-9-Dependent Increase in Excitatory/Inhibitory Balance in a Stress Model of Depression", "doi": "10.1523/jneurosci.2387-19.2020", "year": 2020 } ] } }, { "id": 46616, "drug": "valproic acid", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "downregulates", "mediator": "BDNF", "mediator_type": "gene", "predicate_bc": "associated_with", "outcome": "brain amyloid-beta deposition", "outcome_type": "phenotype", "outcome_domain": "alzheimer", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "30404997", "title": "Social behavior, neuroimmune markers and glutamic acid decarboxylase levels in a rat model of valproic acid-induced autism", "doi": "10.2131/jts.43.631", "year": 2018 } ], "bc": [ { "pmid": "31745181", "title": "Validation of a priori candidate Alzheimer’s disease SNPs with brain amyloid-beta deposition", "doi": "10.1038/s41598-019-53604-5", "year": 2019 } ] } }, { "id": 38540, "drug": "Auranofin", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "upregulates", "mediator": "PD-L1", "mediator_type": "protein", "predicate_bc": "predicts", "outcome": "treatment resistance", "outcome_type": "phenotype", "outcome_domain": "glioblastoma", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "auranofin", "mediator_canonical": "PD-L1", "outcome_canonical": "treatment resistance", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "31090219", "title": "Therapeutic cooperation between auranofin, a thioredoxin reductase inhibitor and anti‐PD‐L1 antibody for treatment of triple‐negative breast cancer", "doi": "10.1002/ijc.32410", "year": 2019 } ], "bc": [ { "pmid": "31926117", "title": "Anti‐tumour immune response in GL261 glioblastoma generated by Temozolomide Immune‐Enhancing Metronomic Schedule monitored with MRSI‐based nosological images", "doi": "10.1002/nbm.4229", "year": 2020 } ] } }, { "id": 17491, "drug": "auraptene", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "downregulates", "mediator": "MMP-9", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "Multiple Sclerosis", "outcome_type": "disease", "outcome_domain": "multiple_sclerosis", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "auraptene", "mediator_canonical": "MMP9", "outcome_canonical": "multiple sclerosis", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "39086858", "title": "Auraptene inhibits migration, invasion and metastatic behavior of human malignant glioblastoma cells: An in vitro and in silico study.", "doi": "10.22038/ajp.2023.23586", "year": 2024 } ], "bc": [ { "pmid": "32243867", "title": "Serum levels of matrix metalloproteinase-2, -9, and vitamin D in patients with multiple sclerosis with or without herpesvirus-6 seropositivity", "doi": "10.1016/j.bjid.2020.02.001", "year": 2020 } ] } }, { "id": 18156, "drug": "metformin", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "upregulates", "mediator": "α-synuclein", "mediator_type": "protein", "predicate_bc": "predicts", "outcome": "progression from MCI to AD", "outcome_type": "disease", "outcome_domain": "alzheimer", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "metformin", "mediator_canonical": "SNCA", "outcome_canonical": "progression from mci to ad", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "30308130", "title": "Effects of metformin on apoptosis and α-synuclein in a rat model of pentylenetetrazole-induced epilepsy", "doi": "10.1139/cjpp-2018-0266", "year": 2018 } ], "bc": [ { "pmid": "29376878", "title": "A Longitudinal Study of Total and Phosphorylated α-Synuclein with Other Biomarkers in Cerebrospinal Fluid of Alzheimer’s Disease and Mild Cognitive Impairment", "doi": "10.3233/jad-171013", "year": 2018 } ] } }, { "id": 2197, "drug": "valproic acid", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "suppresses", "mediator": "galectin-3", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "disease duration", "outcome_type": "phenotype", "outcome_domain": "als", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "active", "clinical_trial_nct_ids": [ "NCT05603104", "NCT05973786", "NCT01900730" ], "literature_status": "reproduces_known", "drug_canonical": "valproic acid", "mediator_canonical": "LGALS3", "outcome_canonical": "disease duration", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "34122007", "title": "Post-stroke Delivery of Valproic Acid Promotes Functional Recovery and Differentially Modifies Responses of Peri-Infarct Microglia", "doi": "10.3389/fnmol.2021.639145", "year": 2021 } ], "bc": [ { "pmid": "27900991", "title": "Increased Expressions of Plasma Galectin-3 in Patients with Amyotrophic Lateral Sclerosis", "doi": "10.4103/0366-6999.194656", "year": 2016 } ] } }, { "id": 29128, "drug": "metformin", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "inhibits", "mediator": "Caspase-3", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "dendritic spine loss", "outcome_type": "phenotype", "outcome_domain": "alzheimer", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "metformin", "mediator_canonical": "CASP3", "outcome_canonical": "dendritic spine loss", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "30308130", "title": "Effects of metformin on apoptosis and α-synuclein in a rat model of pentylenetetrazole-induced epilepsy", "doi": "10.1139/cjpp-2018-0266", "year": 2018 } ], "bc": [ { "pmid": "32610140", "title": "Caspase Activation and Caspase-Mediated Cleavage of APP Is Associated with Amyloid β-Protein-Induced Synapse Loss in Alzheimer’s Disease", "doi": "10.1016/j.celrep.2020.107839", "year": 2020 } ] } }, { "id": 17490, "drug": "auraptene", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "downregulates", "mediator": "MMP-9", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "HHV-6 seropositivity", "outcome_type": "phenotype", "outcome_domain": "multiple_sclerosis", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "auraptene", "mediator_canonical": "MMP9", "outcome_canonical": "hhv-6 seropositivity", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "39086858", "title": "Auraptene inhibits migration, invasion and metastatic behavior of human malignant glioblastoma cells: An in vitro and in silico study.", "doi": "10.22038/ajp.2023.23586", "year": 2024 } ], "bc": [ { "pmid": "32243867", "title": "Serum levels of matrix metalloproteinase-2, -9, and vitamin D in patients with multiple sclerosis with or without herpesvirus-6 seropositivity", "doi": "10.1016/j.bjid.2020.02.001", "year": 2020 } ] } }, { "id": 2273, "drug": "valproic acid", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "suppresses", "mediator": "galectin-3", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "female gender in ALS", "outcome_type": "phenotype", "outcome_domain": "als", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "valproic acid", "mediator_canonical": "LGALS3", "outcome_canonical": "female gender in als", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "34122007", "title": "Post-stroke Delivery of Valproic Acid Promotes Functional Recovery and Differentially Modifies Responses of Peri-Infarct Microglia", "doi": "10.3389/fnmol.2021.639145", "year": 2021 } ], "bc": [ { "pmid": "27900991", "title": "Increased Expressions of Plasma Galectin-3 in Patients with Amyotrophic Lateral Sclerosis", "doi": "10.4103/0366-6999.194656", "year": 2016 } ] } }, { "id": 2188, "drug": "valproic acid", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "downregulates", "mediator": "Progranulin", "mediator_type": "protein", "predicate_bc": "prevents", "outcome": "loss of large axon fibers", "outcome_type": "phenotype", "outcome_domain": "als", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "valproic acid", "mediator_canonical": "GRN", "outcome_canonical": "loss of large axon fibers", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "35318322", "title": "Progranulin improves neural development via the PI3K/Akt/GSK-3β pathway in the cerebellum of a VPA-induced rat model of ASD", "doi": "10.1038/s41398-022-01875-4", "year": 2022 } ], "bc": [ { "pmid": "30326935", "title": "Progranulin reduces insoluble TDP-43 levels, slows down axonal degeneration and prolongs survival in mutant TDP-43 mice", "doi": "10.1186/s13024-018-0288-y", "year": 2018 } ] } }, { "id": 50917, "drug": "resveratrol", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "inhibits", "mediator": "immunoproteasome", "mediator_type": "protein", "predicate_bc": "prevents", "outcome": "Purkinje cell degeneration", "outcome_type": "phenotype", "outcome_domain": "epilepsy", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "30412827", "title": "Resveratrol as a new inhibitor of immunoproteasome prevents PTEN degradation and attenuates cardiac hypertrophy after pressure overload", "doi": "10.1016/j.redox.2018.10.021", "year": 2018 } ], "bc": [ { "pmid": "38317856", "title": "Immunoproteasome deficiency results in age-dependent development of epilepsy", "doi": "10.1093/braincomms/fcae017", "year": 2023 } ] } }, { "id": 17461, "drug": "apigenin", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "upregulates", "mediator": "GFAP", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "paramagnetic rim lesions", "outcome_type": "phenotype", "outcome_domain": "multiple_sclerosis", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "apigenin", "mediator_canonical": "GFAP", "outcome_canonical": "paramagnetic rim lesions", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41090780", "title": "Apigenin Induces Autophagy and Apoptosis in Chemoresistant Glioblastoma Cells and Inhibits Tumorigenicity Associated with Regulation of Immunomodulatory Proteins and Glial Cells Response", "doi": "10.3390/cells14191552", "year": 2025 } ], "bc": [ { "pmid": "38145319", "title": "Plasma glial fibrillary acidic protein levels correlate with paramagnetic rim lesions in people with radiologically isolated syndrome", "doi": "10.1177/13524585231219131", "year": 2023 } ] } }, { "id": 5451, "drug": "fluoxetine", "drug_type": "drug", "drug_domain": "depression", "predicate_ab": "downregulates", "mediator": "TLR7", "mediator_type": "gene", "predicate_bc": "increases", "outcome": "cell proliferation", "outcome_type": "phenotype", "outcome_domain": "pancreatic_cancer", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "fluoxetine", "mediator_canonical": "tlr7", "outcome_canonical": "cell proliferation", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "31647818", "title": "Assessing the role of toll-like receptor in isolated, standard and enriched housing conditions", "doi": "10.1371/journal.pone.0222818", "year": 2019 } ], "bc": [ { "pmid": "26134824", "title": "TLR7 and TLR8 expression increases tumor cell proliferation and promotes chemoresistance in human pancreatic cancer", "doi": "10.3892/ijo.2015.3069", "year": 2015 } ] } }, { "id": 50952, "drug": "metformin", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "inhibits", "mediator": "mTOR pathway", "mediator_type": "pathway", "predicate_bc": "causes", "outcome": "FCDII", "outcome_type": "disease", "outcome_domain": "epilepsy", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "31182921", "title": "Metformin Inhibits the NLRP3 Inflammasome via AMPK/mTOR-dependent Effects in Diabetic Cardiomyopathy", "doi": "10.7150/ijbs.29680", "year": 2019 } ], "bc": [ { "pmid": "40526095", "title": "Dysmorphic neurons with ultralow intrinsic excitability are paradoxically hyperexcitable in neural network in a mouse model of focal cortical dysplasia type II", "doi": "10.1111/epi.18498", "year": 2025 } ] } }, { "id": 50953, "drug": "metformin", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "inhibits", "mediator": "mTOR pathway", "mediator_type": "pathway", "predicate_bc": "causes", "outcome": "mMCD/FCD1", "outcome_type": "disease", "outcome_domain": "epilepsy", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "31182921", "title": "Metformin Inhibits the NLRP3 Inflammasome via AMPK/mTOR-dependent Effects in Diabetic Cardiomyopathy", "doi": "10.7150/ijbs.29680", "year": 2019 } ], "bc": [ { "pmid": "31444548", "title": "Dissecting the genetic basis of focal cortical dysplasia: a large cohort study", "doi": "10.1007/s00401-019-02061-5", "year": 2019 } ] } }, { "id": 28283, "drug": "fluoxetine", "drug_type": "drug", "drug_domain": "depression", "predicate_ab": "downregulates", "mediator": "TLR7", "mediator_type": "gene", "predicate_bc": "prevents", "outcome": "intestinal inflammation", "outcome_type": "disease", "outcome_domain": "inflammatory_bowel_disease", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "fluoxetine", "mediator_canonical": "tlr7", "outcome_canonical": "intestinal inflammation", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "31647818", "title": "Assessing the role of toll-like receptor in isolated, standard and enriched housing conditions", "doi": "10.1371/journal.pone.0222818", "year": 2019 } ], "bc": [ { "pmid": "39464882", "title": "Toll-like receptor 7 protects against intestinal inflammation and restricts the development of colonic tissue-resident memory CD8+ T cells", "doi": "10.3389/fimmu.2024.1465175", "year": 2024 } ] } }, { "id": 16970, "drug": "apigenin", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "upregulates", "mediator": "GFAP", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "reactive astrogliosis", "outcome_type": "phenotype", "outcome_domain": "alzheimer", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "apigenin", "mediator_canonical": "GFAP", "outcome_canonical": "reactive astrogliosis", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41090780", "title": "Apigenin Induces Autophagy and Apoptosis in Chemoresistant Glioblastoma Cells and Inhibits Tumorigenicity Associated with Regulation of Immunomodulatory Proteins and Glial Cells Response", "doi": "10.3390/cells14191552", "year": 2025 } ], "bc": [ { "pmid": "31802051", "title": "Glial and neuroaxonal biomarkers in a multiple sclerosis (MS) cohort.", "doi": null, "year": 2020 } ] } }, { "id": 16968, "drug": "apigenin", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "upregulates", "mediator": "GFAP", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "impaired white matter microstructure", "outcome_type": "phenotype", "outcome_domain": "alzheimer", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "apigenin", "mediator_canonical": "GFAP", "outcome_canonical": "impaired white matter microstructure", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41090780", "title": "Apigenin Induces Autophagy and Apoptosis in Chemoresistant Glioblastoma Cells and Inhibits Tumorigenicity Associated with Regulation of Immunomodulatory Proteins and Glial Cells Response", "doi": "10.3390/cells14191552", "year": 2025 } ], "bc": [ { "pmid": "40877465", "title": "Associations between trajectories of plasma biomarkers for Alzheimer’s disease, brain structures, and cognitive function: a prospective cohort study in the UK Biobank", "doi": "10.1038/s41380-025-03166-y", "year": 2025 } ] } }, { "id": 6431, "drug": "erlotinib", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "inhibits", "mediator": "EGFR", "mediator_type": "gene", "predicate_bc": "prevents", "outcome": "MDD", "outcome_type": "disease", "outcome_domain": "depression", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "erlotinib", "mediator_canonical": "EGFR", "outcome_canonical": "major depressive disorder", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "30240496", "title": "Design of a Multicompartment Hydrogel that Facilitates Time‐Resolved Delivery of Combination Therapy and Synergized Killing of Glioblastoma", "doi": "10.1002/anie.201806483", "year": 2018 } ], "bc": [ { "pmid": "41912493", "title": "Bisphenol a exposure and major depressive disorder: an integrative analysis combining network toxicology, molecular docking, genetic epidemiology, and transcriptomic validation", "doi": "10.1038/s41398-026-03862-5", "year": 2026 } ] } }, { "id": 55975, "drug": "chloroquine", "drug_type": "drug", "drug_domain": "multiple_sclerosis", "predicate_ab": "upregulates", "mediator": "IL-10", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "prediabetes", "outcome_type": "disease", "outcome_domain": "type_2_diabetes", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "32516999", "title": "Comprehensive Analysis of the Immune and Stromal Compartments of the CNS in EAE Mice Reveal Pathways by Which Chloroquine Suppresses Neuroinflammation", "doi": "10.3390/brainsci10060348", "year": 2020 } ], "bc": [ { "pmid": "26346888", "title": "Role of inflammation in sensory neuropathy in prediabetes or diabetes", "doi": "10.1111/ane.12474", "year": 2015 } ] } }, { "id": 344, "drug": "verapamil", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "inhibits", "mediator": "P-glycoprotein", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "temozolomide resistance", "outcome_type": "phenotype", "outcome_domain": "glioblastoma", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "verapamil", "mediator_canonical": "ABCB1", "outcome_canonical": "temozolomide resistance", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "35953704", "title": "Efflux dynamics of the antiseizure drug, levetiracetam, through the P-glycoprotein channel revealed by advanced comparative molecular simulations", "doi": "10.1038/s41598-022-17994-3", "year": 2022 } ], "bc": [ { "pmid": "35093870", "title": "Ko143 Reverses MDR in Glioblastoma via Deactivating P-Glycoprotein, Sensitizing a Resistant Phenotype to TMZ Treatment", "doi": "10.21873/anticanres.15530", "year": 2022 } ] } }, { "id": 45022, "drug": "resveratrol", "drug_type": "drug", "drug_domain": "alzheimer", "predicate_ab": "activates", "mediator": "SIRT1", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "T2D onset", "outcome_type": "disease", "outcome_domain": "type_2_diabetes", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "30243024", "title": "Sirt1 enhances tau exon 10 inclusion and improves spatial memory of Htau mice", "doi": "10.18632/aging.101564", "year": 2018 } ], "bc": [ { "pmid": "35879296", "title": "Phenylalanine impairs insulin signaling and inhibits glucose uptake through modification of IRβ", "doi": "10.1038/s41467-022-32000-0", "year": 2022 } ] } }, { "id": 27657, "drug": "Curcumin", "drug_type": "drug", "drug_domain": "alzheimer", "predicate_ab": "upregulates", "mediator": "BDNF", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "diabetes risk factors", "outcome_type": "disease", "outcome_domain": "type_2_diabetes", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "curcumin", "mediator_canonical": "BDNF", "outcome_canonical": "diabetes risk factors", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "38791161", "title": "Curcumin Improves Neurogenesis in Alzheimer’s Disease Mice via the Upregulation of Wnt/β-Catenin and BDNF", "doi": "10.3390/ijms25105123", "year": 2024 } ], "bc": [ { "pmid": "30363954", "title": "Changes in the Brain-Derived Neurotrophic Factor Are Associated with Improvements in Diabetes Risk Factors after Exercise Training in Adolescents with Obesity: The HEARTY Randomized Controlled Trial", "doi": "10.1155/2018/7169583", "year": 2018 } ] } }, { "id": 16549, "drug": "Selinexor", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "induces", "mediator": "MGMT", "mediator_type": "gene", "predicate_bc": "correlates_with", "outcome": "progression-free survival", "outcome_type": "phenotype", "outcome_domain": "epilepsy", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "selinexor", "mediator_canonical": "mgmt", "outcome_canonical": null, "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41064076", "title": "XPO1-inhibitor Selinexor induces MGMT expression by activating PKA-CREB signaling in IDH wildtype glioblastoma", "doi": "10.3389/fonc.2025.1633580", "year": 2025 } ], "bc": [ { "pmid": "34621499", "title": "https://researchopenworld.com/the-addition-of-valproic-acid-to-concurrent-radiation-therapy-and-temozolomide-improves-patient-outcome-a-correlative-analysis-of-rtog-0525-seer-and-a-phase-ii-nci-trial/#", "doi": "10.31038/cst.2020511", "year": 2020 } ] } }, { "id": 12601, "drug": "valproic acid", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "downregulates", "mediator": "HDAC2", "mediator_type": "gene", "predicate_bc": "increases", "outcome": "metastasis", "outcome_type": "phenotype", "outcome_domain": "pancreatic_cancer", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "active", "clinical_trial_nct_ids": [ "NCT00159588", "NCT05821556", "NCT06714357" ], "literature_status": "reproduces_known", "drug_canonical": "valproic acid", "mediator_canonical": "hdac2", "outcome_canonical": "metastasis", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "38105511", "title": "Valproic acid ameliorates cauda equina injury by suppressing HDAC2‐mediated ferroptosis", "doi": "10.1111/cns.14524", "year": 2023 } ], "bc": [ { "pmid": "34903606", "title": "HDAC2 Facilitates Pancreatic Cancer Metastasis", "doi": "10.1158/0008-5472.can-20-3209", "year": 2021 } ] } }, { "id": 5603, "drug": "temsirolimus", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "inhibits", "mediator": "mTOR", "mediator_type": "protein", "predicate_bc": "causes", "outcome": "mTOR-opathies", "outcome_type": "disease", "outcome_domain": "epilepsy", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "temsirolimus", "mediator_canonical": "mTOR", "outcome_canonical": "mtor-opathies", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "29313954", "title": "Phase 1/2 trial of temsirolimus and sorafenib in the treatment of patients with recurrent glioblastoma: North Central Cancer Treatment Group Study/Alliance N0572", "doi": "10.1002/cncr.31219", "year": 2018 } ], "bc": [ { "pmid": "29447953", "title": "Dendrite growth and the effect of ectopic Rheb expression on cortical neurons", "doi": "10.1016/j.neulet.2018.02.021", "year": 2018 } ] } }, { "id": 16755, "drug": "apigenin", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "upregulates", "mediator": "GFAP", "mediator_type": "protein", "predicate_bc": "causes", "outcome": "Alexander disease", "outcome_type": "disease", "outcome_domain": "als", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "apigenin", "mediator_canonical": "GFAP", "outcome_canonical": "alexander disease", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41090780", "title": "Apigenin Induces Autophagy and Apoptosis in Chemoresistant Glioblastoma Cells and Inhibits Tumorigenicity Associated with Regulation of Immunomodulatory Proteins and Glial Cells Response", "doi": "10.3390/cells14191552", "year": 2025 } ], "bc": [ { "pmid": "41775321", "title": "From scaffold to effector: reframing GFAP in neurodegeneration", "doi": "10.1016/j.jare.2026.02.051", "year": 2026 } ] } }, { "id": 16547, "drug": "Riluzole", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "suppresses", "mediator": "MGMT", "mediator_type": "gene", "predicate_bc": "correlates_with", "outcome": "progression-free survival", "outcome_type": "phenotype", "outcome_domain": "epilepsy", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "riluzole", "mediator_canonical": "mgmt", "outcome_canonical": null, "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "32168477", "title": "Riluzole enhances the antitumor effects of temozolomide via suppression of MGMT expression in glioblastoma", "doi": "10.3171/2019.12.jns192682", "year": 2020 } ], "bc": [ { "pmid": "34621499", "title": "https://researchopenworld.com/the-addition-of-valproic-acid-to-concurrent-radiation-therapy-and-temozolomide-improves-patient-outcome-a-correlative-analysis-of-rtog-0525-seer-and-a-phase-ii-nci-trial/#", "doi": "10.31038/cst.2020511", "year": 2020 } ] } }, { "id": 14779, "drug": "curcumin", "drug_type": "drug", "drug_domain": "alzheimer", "predicate_ab": "upregulates", "mediator": "BDNF", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "visuospatial ability", "outcome_type": "phenotype", "outcome_domain": "depression", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "curcumin", "mediator_canonical": "BDNF", "outcome_canonical": "visuospatial ability", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "38791161", "title": "Curcumin Improves Neurogenesis in Alzheimer’s Disease Mice via the Upregulation of Wnt/β-Catenin and BDNF", "doi": "10.3390/ijms25105123", "year": 2024 } ], "bc": [ { "pmid": "39911552", "title": "Association of inflammation cytokines with cognitive function in first-episode major depressive disorder", "doi": "10.3389/fpsyt.2024.1473418", "year": 2025 } ] } }, { "id": 14558, "drug": "hydroxychloroquine", "drug_type": "drug", "drug_domain": "alzheimer", "predicate_ab": "inhibits", "mediator": "STAT3", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "pancreatic ductal adenocarcinoma", "outcome_type": "disease", "outcome_domain": "pancreatic_cancer", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "active", "clinical_trial_nct_ids": [ "NCT05630989", "NCT06828328", "NCT05365893" ], "literature_status": "reproduces_known", "drug_canonical": "hydroxychloroquine", "mediator_canonical": "STAT3", "outcome_canonical": "pancreatic ductal adenocarcinoma", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "36577843", "title": "Hydroxychloroquine lowers Alzheimer’s disease and related dementias risk and rescues molecular phenotypes related to Alzheimer’s disease", "doi": "10.1038/s41380-022-01912-0", "year": 2022 } ], "bc": [ { "pmid": "38464736", "title": "Role of STAT3 in pancreatic cancer", "doi": "10.37349/etat.2024.00202", "year": 2024 } ] } }, { "id": 13481, "drug": "sunitinib", "drug_type": "drug", "drug_domain": "als", "predicate_ab": "inhibits", "mediator": "STAT3", "mediator_type": "protein", "predicate_bc": "treats", "outcome": "cognitive deficits", "outcome_type": "phenotype", "outcome_domain": "alzheimer", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "sunitinib", "mediator_canonical": "STAT3", "outcome_canonical": "cognitive deficits", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "38914173", "title": "Sunitinib-mediated inhibition of STAT3 in skeletal muscle and spinal cord does not affect the disease in a mouse model of ALS", "doi": "10.1016/j.nbd.2024.106576", "year": 2024 } ], "bc": [ { "pmid": "33859760", "title": "STAT3 ameliorates cognitive deficits via regulation of NMDAR expression in an Alzheimer's disease animal model", "doi": "10.7150/thno.56541", "year": 2021 } ] } }, { "id": 51062, "drug": "erlotinib", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "inhibits", "mediator": "EGFR", "mediator_type": "protein", "predicate_bc": "predicts", "outcome": "Alzheimer's disease", "outcome_type": "disease", "outcome_domain": "glioblastoma", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "31277074", "title": "Inhibition of EGFR-STAT3 attenuates cardiomyopathy in streptozotocin-induced type 1 diabetes", "doi": "10.1530/joe-19-0058", "year": 2019 } ], "bc": [ { "pmid": "41384939", "title": "Uncovering the toxicological impact of benzo[a]pyrene on Alzheimer's disease via network toxicology, machine learning, and single-cell transcriptomics", "doi": "10.1177/13872877251405468", "year": 2025 } ] } }, { "id": 51069, "drug": "metformin", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "inhibits", "mediator": "mTOR pathway", "mediator_type": "pathway", "predicate_bc": "associated_with", "outcome": "GBM", "outcome_type": "disease", "outcome_domain": "glioblastoma", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "31182921", "title": "Metformin Inhibits the NLRP3 Inflammasome via AMPK/mTOR-dependent Effects in Diabetic Cardiomyopathy", "doi": "10.7150/ijbs.29680", "year": 2019 } ], "bc": [ { "pmid": "34944625", "title": "The Bumpy Road towards mTOR Inhibition in Glioblastoma: Quo Vadis?", "doi": "10.3390/biomedicines9121809", "year": 2021 } ] } }, { "id": 51073, "drug": "losartan", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "downregulates", "mediator": "Piezo1", "mediator_type": "protein", "predicate_bc": "increases", "outcome": "cell_motility", "outcome_type": "phenotype", "outcome_domain": "glioblastoma", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "28670382", "title": "Stretch-activated channel Piezo1 is up-regulated in failure heart and cardiomyocyte stimulated by AngII.", "doi": null, "year": 2017 } ], "bc": [ { "pmid": "39513613", "title": "Compression force promotes glioblastoma progression through the Piezo1‑GDF15‑CTLA4 axis", "doi": "10.3892/or.2024.8835", "year": 2024 } ] } }, { "id": 13463, "drug": "lithium", "drug_type": "drug", "drug_domain": "als", "predicate_ab": "inhibits", "mediator": "GSK-3β", "mediator_type": "protein", "predicate_bc": "increases", "outcome": "tau spreading", "outcome_type": "phenotype", "outcome_domain": "alzheimer", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "lithium", "mediator_canonical": "GSK3B", "outcome_canonical": "tau spreading", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "39363657", "title": "Lithium alleviates paralysis in experimental autoimmune neuritis in Lewis rats by modulating glycogen synthase kinase-3β activity", "doi": "10.4142/jvs.24212", "year": 2024 } ], "bc": [ { "pmid": "33554064", "title": "Isoform-selective decrease of glycogen synthase kinase-3-beta (GSK-3β) reduces synaptic tau phosphorylation, transcellular spreading, and aggregation", "doi": "10.1016/j.isci.2021.102058", "year": 2021 } ] } }, { "id": 51087, "drug": "resveratrol", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "inhibits", "mediator": "NF-κB signaling", "mediator_type": "pathway", "predicate_bc": "associated_with", "outcome": "typical responders", "outcome_type": "phenotype", "outcome_domain": "glioblastoma", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37541173", "title": "Resveratrol prevents Ang II-induced cardiac hypertrophy by inhibition of NF-κB signaling", "doi": "10.1016/j.biopha.2023.115275", "year": 2023 } ], "bc": [ { "pmid": "29983870", "title": "Comparative molecular characterization of typical and exceptional responders in glioblastoma", "doi": "10.18632/oncotarget.25420", "year": 2018 } ] } }, { "id": 51088, "drug": "resveratrol", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "inhibits", "mediator": "NF-κB signaling", "mediator_type": "pathway", "predicate_bc": "correlates_with", "outcome": "shorter survival", "outcome_type": "phenotype", "outcome_domain": "glioblastoma", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37541173", "title": "Resveratrol prevents Ang II-induced cardiac hypertrophy by inhibition of NF-κB signaling", "doi": "10.1016/j.biopha.2023.115275", "year": 2023 } ], "bc": [ { "pmid": "41716996", "title": "NF-κB and STAT3 signaling uniquely stratify survival in female glioblastoma patients", "doi": "10.1016/j.isci.2026.114761", "year": 2026 } ] } }, { "id": 13095, "drug": "Riluzole", "drug_type": "drug", "drug_domain": "als", "predicate_ab": "upregulates", "mediator": "EAAT2", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "glioma-associated epilepsy", "outcome_type": "disease", "outcome_domain": "glioblastoma", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "riluzole", "mediator_canonical": "eaat2", "outcome_canonical": "glioma-associated epilepsy", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "39806490", "title": "CEST imaging combined with 1H-MRS reveal the neuroprotective effects of riluzole by improving neurotransmitter imbalances in Alzheimer’s disease mice", "doi": "10.1186/s13195-025-01672-3", "year": 2025 } ], "bc": [ { "pmid": "41881974", "title": "Tumor-associated epilepsy and high expression of xCT shape the proteome of IDH-wildtype glioblastoma", "doi": "10.1038/s41420-026-03029-7", "year": 2026 } ] } }, { "id": 51095, "drug": "resveratrol", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "upregulates", "mediator": "VEGF", "mediator_type": "protein", "predicate_bc": "predicts", "outcome": "poor prognosis", "outcome_type": "phenotype", "outcome_domain": "glioblastoma", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "28138705", "title": "Resveratrol activates endogenous cardiac stem cells and improves myocardial regeneration following acute myocardial infarction", "doi": "10.3892/mmr.2017.6143", "year": 2017 } ], "bc": [ { "pmid": "41268261", "title": "Correlation between EGF and VEGF expression levels and the efficacy of radiosurgery in recurrent glioma", "doi": "10.62347/sqpz5153", "year": 2025 } ] } }, { "id": 12831, "drug": "Baicalin", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "upregulates", "mediator": "BDNF", "mediator_type": "protein", "predicate_bc": "increases", "outcome": "neurogenesis", "outcome_type": "phenotype", "outcome_domain": "depression", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "baicalin", "mediator_canonical": "BDNF", "outcome_canonical": "neurogenesis", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "38778616", "title": "Exploring the Therapeutic Potential of Baicalin: Mitigating Anxiety and Depression in Epileptic Rats", "doi": "10.2174/0113862073316021240520110301", "year": 2024 } ], "bc": [ { "pmid": "36062024", "title": "Intranasal Administration of Brain-Derived Neurotrophic Factor Rescues Depressive-Like Phenotypes in Chronic Unpredictable Mild Stress Mice", "doi": "10.2147/ndt.s369412", "year": 2022 } ] } }, { "id": 51106, "drug": "spironolactone", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "downregulates", "mediator": "vimentin", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "lower survival rate", "outcome_type": "phenotype", "outcome_domain": "glioblastoma", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "25967959", "title": "Protective Effect of Spironolactone on Endothelial-to-Mesenchymal Transition in HUVECs via Notch Pathway", "doi": "10.1159/000374063", "year": 2015 } ], "bc": [ { "pmid": "41241939", "title": "Intermediate filaments promote glioblastoma cell invasion by controlling nuclear deformations and mechanosensitive expression of MMP14", "doi": "10.1016/j.celrep.2025.116553", "year": 2025 } ] } }, { "id": 51109, "drug": "resveratrol", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "downregulates", "mediator": "FOXO1", "mediator_type": "gene", "predicate_bc": "increases", "outcome": "TMZ sensitivity", "outcome_type": "phenotype", "outcome_domain": "glioblastoma", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "26638758", "title": "Iron-overload injury and cardiomyopathy in acquired and genetic models is attenuated by resveratrol therapy", "doi": "10.1038/srep18132", "year": 2015 } ], "bc": [ { "pmid": "37551556", "title": "FOXO1-miR-506 axis promotes chemosensitivity to temozolomide and suppresses invasiveness in glioblastoma through a feedback loop of FOXO1/miR-506/ETS1/FOXO1", "doi": "10.1631/jzus.b2200503", "year": 2023 } ] } }, { "id": 2595, "drug": "valproic acid", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "downregulates", "mediator": "FASN", "mediator_type": "gene", "predicate_bc": "correlates_with", "outcome": "proliferation", "outcome_type": "phenotype", "outcome_domain": "pancreatic_cancer", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "valproic acid", "mediator_canonical": "fasn", "outcome_canonical": null, "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "36544904", "title": "Metabolomic profiling of triple negative breast cancer cells suggests that valproic acid can enhance the anticancer effect of cisplatin", "doi": "10.3389/fcell.2022.1014798", "year": 2022 } ], "bc": [ { "pmid": "29061815", "title": "Orlistat Reduces Proliferation and Enhances Apoptosis in Human Pancreatic Cancer Cells (PANC-1)", "doi": "10.21873/anticanres.12083", "year": 2017 } ] } }, { "id": 51123, "drug": "losartan", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "downregulates", "mediator": "TGF-β1", "mediator_type": "protein", "predicate_bc": "increases", "outcome": "cancer cell stemness", "outcome_type": "phenotype", "outcome_domain": "glioblastoma", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "25755735", "title": "Losartan reduces myocardial interstitial fibrosis in diabetic cardiomyopathy rats by inhibiting JAK/STAT signaling pathway.", "doi": null, "year": 2015 } ], "bc": [ { "pmid": "32368136", "title": "<p>LncRNA RPSAP52 Upregulates TGF-β1 to Increase Cancer Cell Stemness and Predict Postoperative Survival in Glioblastoma</p>", "doi": "10.2147/cmar.s227496", "year": 2020 } ] } }, { "id": 51138, "drug": "spironolactone", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "downregulates", "mediator": "TGF-β1", "mediator_type": "protein", "predicate_bc": "increases", "outcome": "cancer cell stemness", "outcome_type": "phenotype", "outcome_domain": "glioblastoma", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "27097055", "title": "Spironolactone Attenuates Doxorubicin‐induced Cardiotoxicity in Rats", "doi": "10.1111/1755-5922.12189", "year": 2016 } ], "bc": [ { "pmid": "32368136", "title": "<p>LncRNA RPSAP52 Upregulates TGF-β1 to Increase Cancer Cell Stemness and Predict Postoperative Survival in Glioblastoma</p>", "doi": "10.2147/cmar.s227496", "year": 2020 } ] } }, { "id": 2502, "drug": "valproic acid", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "downregulates", "mediator": "GLI1", "mediator_type": "gene", "predicate_bc": "correlates_with", "outcome": "nerve plexus density", "outcome_type": "phenotype", "outcome_domain": "pancreatic_cancer", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "valproic acid", "mediator_canonical": "gli1", "outcome_canonical": "nerve plexus density", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "32054823", "title": "GANT61 and Valproic Acid Synergistically Inhibited Multiple Myeloma Cell Proliferation via Hedgehog Signaling Pathway", "doi": "10.12659/msm.920541", "year": 2020 } ], "bc": [ { "pmid": "38041128", "title": "Hedgehog-Gli1-derived exosomal circ-0011536 mediates peripheral neural remodeling in pancreatic cancer by modulating the miR-451a/VGF axis", "doi": "10.1186/s13046-023-02894-9", "year": 2023 } ] } }, { "id": 12830, "drug": "valproic acid", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "downregulates", "mediator": "DNA methylation", "mediator_type": "biomarker", "predicate_bc": "associated_with", "outcome": "major depressive disorder", "outcome_type": "disease", "outcome_domain": "depression", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "active", "clinical_trial_nct_ids": [ "NCT05603104", "NCT06729541", "NCT00581009" ], "literature_status": "reproduces_known", "drug_canonical": "valproic acid", "mediator_canonical": "dna methylation", "outcome_canonical": "major depressive disorder", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "35312054", "title": "Developmental administration of valproic acid alters DNA methylation and maternal behavior", "doi": "10.1002/dev.22231", "year": 2022 } ], "bc": [ { "pmid": "31477685", "title": "Genome-wide profiling of DNA methylome and transcriptome in peripheral blood monocytes for major depression: A Monozygotic Discordant Twin Study", "doi": "10.1038/s41398-019-0550-2", "year": 2019 } ] } }, { "id": 12687, "drug": "valproic acid", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "suppresses", "mediator": "galectin-3", "mediator_type": "protein", "predicate_bc": "decreases", "outcome": "insulin-stimulated glucose uptake", "outcome_type": "phenotype", "outcome_domain": "pancreatic_cancer", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "valproic acid", "mediator_canonical": "LGALS3", "outcome_canonical": "insulin-stimulated glucose uptake", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "34122007", "title": "Post-stroke Delivery of Valproic Acid Promotes Functional Recovery and Differentially Modifies Responses of Peri-Infarct Microglia", "doi": "10.3389/fnmol.2021.639145", "year": 2021 } ], "bc": [ { "pmid": "31262951", "title": "Galectin-3 and S100A9: Novel Diabetogenic Factors Mediating Pancreatic Cancer–Associated Diabetes", "doi": "10.2337/dc19-0217", "year": 2019 } ] } }, { "id": 12686, "drug": "valproic acid", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "suppresses", "mediator": "galectin-3", "mediator_type": "protein", "predicate_bc": "predicts", "outcome": "pancreatobiliary cancer prognosis", "outcome_type": "phenotype", "outcome_domain": "pancreatic_cancer", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "valproic acid", "mediator_canonical": "LGALS3", "outcome_canonical": "pancreatobiliary cancer prognosis", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "34122007", "title": "Post-stroke Delivery of Valproic Acid Promotes Functional Recovery and Differentially Modifies Responses of Peri-Infarct Microglia", "doi": "10.3389/fnmol.2021.639145", "year": 2021 } ], "bc": [ { "pmid": "28870921", "title": "Significance of Circulating Galectin-3 in Patients with Pancreatobiliary Cancer", "doi": "10.21873/anticanres.11909", "year": 2017 } ] } }, { "id": 12478, "drug": "valproic acid", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "downregulates", "mediator": "DNA methylation", "mediator_type": "biomarker", "predicate_bc": "correlates_with", "outcome": "behavioral performance", "outcome_type": "phenotype", "outcome_domain": "alzheimer", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "valproic acid", "mediator_canonical": "dna methylation", "outcome_canonical": "behavioral performance", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "35312054", "title": "Developmental administration of valproic acid alters DNA methylation and maternal behavior", "doi": "10.1002/dev.22231", "year": 2022 } ], "bc": [ { "pmid": "31453788", "title": "Active Amyloid-β Vaccination Results in Epigenetic Changes in the Hippocampus of an Alzheimer’s Disease-Like Mouse Model", "doi": "10.2174/1567205016666190827122009", "year": 2019 } ] } }, { "id": 12046, "drug": "valproic acid", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "downregulates", "mediator": "VEGF", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "shorter overall survival", "outcome_type": "phenotype", "outcome_domain": "glioblastoma", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "valproic acid", "mediator_canonical": "VEGF", "outcome_canonical": "shorter overall survival", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "32149283", "title": "l-Cysteine decorated nanoscale metal–organic frameworks delivering valproic acid/cisplatin for drug-resistant lung cancer therapy", "doi": "10.1039/c9cc09712k", "year": 2020 } ], "bc": [ { "pmid": "41268261", "title": "Correlation between EGF and VEGF expression levels and the efficacy of radiosurgery in recurrent glioma", "doi": "10.62347/sqpz5153", "year": 2025 } ] } }, { "id": 40233, "drug": "metformin", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "upregulates", "mediator": "Stat3", "mediator_type": "gene", "predicate_bc": "associated_with", "outcome": "GBM progression", "outcome_type": "disease", "outcome_domain": "glioblastoma", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "metformin", "mediator_canonical": "STAT3", "outcome_canonical": "gbm progression", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37573301", "title": "STAT3/LKB1 controls metastatic prostate cancer by regulating mTORC1/CREB pathway", "doi": "10.1186/s12943-023-01825-8", "year": 2023 } ], "bc": [ { "pmid": "33173024", "title": "Systemic brain tumor delivery of synthetic protein nanoparticles for glioblastoma therapy", "doi": "10.1038/s41467-020-19225-7", "year": 2020 } ] } }, { "id": 12045, "drug": "valproic acid", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "downregulates", "mediator": "VEGF", "mediator_type": "protein", "predicate_bc": "causes", "outcome": "dural arteriovenous fistula", "outcome_type": "disease", "outcome_domain": "glioblastoma", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "valproic acid", "mediator_canonical": "VEGF", "outcome_canonical": "dural arteriovenous fistula", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "32149283", "title": "l-Cysteine decorated nanoscale metal–organic frameworks delivering valproic acid/cisplatin for drug-resistant lung cancer therapy", "doi": "10.1039/c9cc09712k", "year": 2020 } ], "bc": [ { "pmid": "39308833", "title": "Comparative Volumetric Analyses Following Bevacizumab Therapy for a Patient With Concomitant Glioblastoma, Meningioma, and Dural Arteriovenous Fistula: A Case Report and Review of Literature", "doi": "10.7759/cureus.69794", "year": 2024 } ] } }, { "id": 8129, "drug": "Riluzole", "drug_type": "drug", "drug_domain": "als", "predicate_ab": "suppresses", "mediator": "MMP2", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "pancreatic adenocarcinoma", "outcome_type": "disease", "outcome_domain": "pancreatic_cancer", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "riluzole", "mediator_canonical": "MMP2", "outcome_canonical": "pancreatic adenocarcinoma", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40391158", "title": "Repurposing riluzole as an anti-osteosarcoma agent", "doi": "10.3389/fonc.2025.1508819", "year": 2025 } ], "bc": [ { "pmid": "37370756", "title": "Anoikis-Related Gene Signature for Prognostication of Pancreatic Adenocarcinoma: A Multi-Omics Exploration and Verification Study", "doi": "10.3390/cancers15123146", "year": 2023 } ] } }, { "id": 12032, "drug": "metformin", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "upregulates", "mediator": "Hsp70", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "GBM", "outcome_type": "disease", "outcome_domain": "glioblastoma", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "active", "clinical_trial_nct_ids": [ "NCT04945148", "NCT05929495", "NCT04691960" ], "literature_status": "reproduces_known", "drug_canonical": "metformin", "mediator_canonical": "hsp70", "outcome_canonical": "glioblastoma", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "30308130", "title": "Effects of metformin on apoptosis and α-synuclein in a rat model of pentylenetetrazole-induced epilepsy", "doi": "10.1139/cjpp-2018-0266", "year": 2018 } ], "bc": [ { "pmid": "38542389", "title": "Hsp70 and Calcitonin Receptor Protein in Extracellular Vesicles from Glioblastoma Multiforme: Biomarkers with Putative Roles in Carcinogenesis and Potential for Differentiating Tumor Types", "doi": "10.3390/ijms25063415", "year": 2024 } ] } }, { "id": 30288, "drug": "valproic acid", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "downregulates", "mediator": "VEGF", "mediator_type": "protein", "predicate_bc": "predicts", "outcome": "rheumatoid arthritis", "outcome_type": "disease", "outcome_domain": "rheumatoid_arthritis", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "valproic acid", "mediator_canonical": "VEGF", "outcome_canonical": "rheumatoid arthritis", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "32149283", "title": "l-Cysteine decorated nanoscale metal–organic frameworks delivering valproic acid/cisplatin for drug-resistant lung cancer therapy", "doi": "10.1039/c9cc09712k", "year": 2020 } ], "bc": [ { "pmid": "35744097", "title": "VEGF Profile in Early Undifferentiated Arthritis Cohort", "doi": "10.3390/medicina58060833", "year": 2022 } ] } }, { "id": 12031, "drug": "metformin", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "upregulates", "mediator": "Hsp70", "mediator_type": "protein", "predicate_bc": "prevents", "outcome": "necrosis", "outcome_type": "phenotype", "outcome_domain": "glioblastoma", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "active", "clinical_trial_nct_ids": [ "NCT05182970", "NCT01217307", "NCT01700075" ], "literature_status": "reproduces_known", "drug_canonical": "metformin", "mediator_canonical": "hsp70", "outcome_canonical": "necrosis", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "30308130", "title": "Effects of metformin on apoptosis and α-synuclein in a rat model of pentylenetetrazole-induced epilepsy", "doi": "10.1139/cjpp-2018-0266", "year": 2018 } ], "bc": [ { "pmid": "39667305", "title": "Radiosensitizing capacity of fenofibrate in glioblastoma cells depends on lipid metabolism", "doi": "10.1016/j.redox.2024.103452", "year": 2024 } ] } }, { "id": 11313, "drug": "cisplatin", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "activates", "mediator": "caspase-3", "mediator_type": "protein", "predicate_bc": "causes", "outcome": "neuronal apoptosis", "outcome_type": "phenotype", "outcome_domain": "als", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "cisplatin", "mediator_canonical": "CASP3", "outcome_canonical": "neuronal apoptosis", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "39810130", "title": "Engineered biomimetic cisplatin-polyphenol nanocomplex for chemo-immunotherapy of glioblastoma by inducing pyroptosis", "doi": "10.1186/s12951-025-03091-w", "year": 2025 } ], "bc": [ { "pmid": "26064904", "title": "Implication of Caspase-3 as a Common Therapeutic Target for Multineurodegenerative Disorders and Its Inhibition Using Nonpeptidyl Natural Compounds", "doi": "10.1155/2015/379817", "year": 2015 } ] } }, { "id": 11299, "drug": "curcumin", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "upregulates", "mediator": "NRF2", "mediator_type": "gene", "predicate_bc": "associated_with", "outcome": "neurodegenerative processes", "outcome_type": "disease", "outcome_domain": "als", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "curcumin", "mediator_canonical": "NRF2", "outcome_canonical": "neurodegenerative processes", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40081725", "title": "Matrix metallopeptidase 2-responsive curcumin-loaded nanoparticles-induced signal transducer and activator of transcription 3 inhibition suppresses glioblastoma multiforme growth via enhancing nuclear factor erythroid 2-related factor 2 activity", "doi": "10.1016/j.ijbiomac.2025.141998", "year": 2025 } ], "bc": [ { "pmid": "41684011", "title": "Nrf2-Activating Natural Compounds in Neurodegenerative Diseases: Targeting Oxidative Stress and Protein Aggregation", "doi": "10.3390/ijms27031592", "year": 2026 } ] } }, { "id": 30411, "drug": "valproic acid", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "downregulates", "mediator": "BDNF", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "diabetes risk factors", "outcome_type": "disease", "outcome_domain": "type_2_diabetes", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "valproic acid", "mediator_canonical": "BDNF", "outcome_canonical": "diabetes risk factors", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "35465089", "title": "Excitatory and Inhibitory Synaptic Imbalance Caused by Brain-Derived Neurotrophic Factor Deficits During Development in a Valproic Acid Mouse Model of Autism", "doi": "10.3389/fnmol.2022.860275", "year": 2022 } ], "bc": [ { "pmid": "30363954", "title": "Changes in the Brain-Derived Neurotrophic Factor Are Associated with Improvements in Diabetes Risk Factors after Exercise Training in Adolescents with Obesity: The HEARTY Randomized Controlled Trial", "doi": "10.1155/2018/7169583", "year": 2018 } ] } }, { "id": 41322, "drug": "lithium", "drug_type": "drug", "drug_domain": "als", "predicate_ab": "inhibits", "mediator": "GSK-3β", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "neurogenesis", "outcome_type": "phenotype", "outcome_domain": "alzheimer", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "39363657", "title": "Lithium alleviates paralysis in experimental autoimmune neuritis in Lewis rats by modulating glycogen synthase kinase-3β activity", "doi": "10.4142/jvs.24212", "year": 2024 } ], "bc": [ { "pmid": "36178363", "title": "Therapeutic implications of glycogen synthase kinase-3β in Alzheimer’s disease: a novel therapeutic target", "doi": "10.1080/00207454.2022.2130297", "year": 2022 } ] } }, { "id": 11287, "drug": "resveratrol", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "downregulates", "mediator": "NRF2", "mediator_type": "gene", "predicate_bc": "associated_with", "outcome": "neurodegenerative processes", "outcome_type": "disease", "outcome_domain": "als", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "completed", "clinical_trial_nct_ids": [ "NCT05982860" ], "literature_status": "reproduces_known", "drug_canonical": "resveratrol", "mediator_canonical": "NRF2", "outcome_canonical": "neurodegenerative processes", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41841014", "title": "Concurrent Ferroptosis and Apoptosis in Resveratrol‐Treated Glioblastoma Cells: Relevance With NRF2 Downregulation and Oxidative Stress", "doi": "10.1002/cbin.70153", "year": 2026 } ], "bc": [ { "pmid": "41684011", "title": "Nrf2-Activating Natural Compounds in Neurodegenerative Diseases: Targeting Oxidative Stress and Protein Aggregation", "doi": "10.3390/ijms27031592", "year": 2026 } ] } }, { "id": 11129, "drug": "acriflavine", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "inhibits", "mediator": "HIF-1α", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "epilepsy", "outcome_type": "disease", "outcome_domain": "epilepsy", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "acriflavine", "mediator_canonical": "hif-1α", "outcome_canonical": "epilepsy", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40405165", "title": "Photo-controlled co-delivery of verteporfin and acriflavine via platelets achieves potentiated glioblastoma-targeted photodynamic therapy", "doi": "10.1186/s12951-025-03395-x", "year": 2025 } ], "bc": [ { "pmid": "41324728", "title": "The Role of HIF-1α/BNIP3 Pathway in Hippocampal Neuronal Autophagy in Epilepsy", "doi": "10.1007/s12035-025-05406-2", "year": 2025 } ] } }, { "id": 11109, "drug": "erlotinib", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "inhibits", "mediator": "EGFR", "mediator_type": "gene", "predicate_bc": "associated_with", "outcome": "lesional focal epilepsy", "outcome_type": "disease", "outcome_domain": "epilepsy", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "erlotinib", "mediator_canonical": "EGFR", "outcome_canonical": "lesional focal epilepsy", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "30240496", "title": "Design of a Multicompartment Hydrogel that Facilitates Time‐Resolved Delivery of Combination Therapy and Synergized Killing of Glioblastoma", "doi": "10.1002/anie.201806483", "year": 2018 } ], "bc": [ { "pmid": "39616148", "title": "Analysis of 1386 epileptogenic brain lesions reveals association with DYRK1A and EGFR", "doi": "10.1038/s41467-024-54911-w", "year": 2024 } ] } }, { "id": 30883, "drug": "auraptene", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "downregulates", "mediator": "MMP-9", "mediator_type": "protein", "predicate_bc": "predicts", "outcome": "DSAD", "outcome_type": "disease", "outcome_domain": "alzheimer", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "auraptene", "mediator_canonical": "MMP9", "outcome_canonical": "dsad", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "39086858", "title": "Auraptene inhibits migration, invasion and metastatic behavior of human malignant glioblastoma cells: An in vitro and in silico study.", "doi": "10.22038/ajp.2023.23586", "year": 2024 } ], "bc": [ { "pmid": "33226181", "title": "Nerve growth factor (NGF) pathway biomarkers in Down syndrome prior to and after the onset of clinical Alzheimer's disease: A paired CSF and plasma study", "doi": "10.1002/alz.12229", "year": 2020 } ] } }, { "id": 51293, "drug": "spironolactone", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "suppresses", "mediator": "hepcidin", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "iron deficiency anemia", "outcome_type": "disease", "outcome_domain": "inflammatory_bowel_disease", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "28385785", "title": "Imatinib and spironolactone suppress hepcidin expression", "doi": "10.3324/haematol.2016.162917", "year": 2017 } ], "bc": [ { "pmid": "33354248", "title": "Hepcidin Is a Reliable Marker of Iron Deficiency Anemia in Newly Diagnosed Patients with Inflammatory Bowel Disease", "doi": "10.1155/2020/8523205", "year": 2020 } ] } }, { "id": 11094, "drug": "resveratrol", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "downregulates", "mediator": "P-glycoprotein", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "drug-resistant epilepsy", "outcome_type": "disease", "outcome_domain": "epilepsy", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "resveratrol", "mediator_canonical": "ABCB1", "outcome_canonical": "drug-resistant epilepsy", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41253172", "title": "Resveratrol Sensitizes Temozolomide-Resistant Glioblastoma Cells Through Mitogen-Activated Protein Kinase Pathway Inhibition and P-Glycoprotein Modulation", "doi": "10.1055/a-2698-0203", "year": 2025 } ], "bc": [ { "pmid": "32627849", "title": "P‐glycoprotein overactivity in epileptogenic developmental lesions measured in vivo using (R)‐[11C]verapamil PET", "doi": "10.1111/epi.16581", "year": 2020 } ] } }, { "id": 9826, "drug": "Propranolol", "drug_type": "drug", "drug_domain": "pancreatic_cancer", "predicate_ab": "suppresses", "mediator": "CREB", "mediator_type": "protein", "predicate_bc": "increases", "outcome": "dendritic health", "outcome_type": "phenotype", "outcome_domain": "als", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "propranolol", "mediator_canonical": "creb", "outcome_canonical": "dendritic health", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "39642318", "title": "Stress and Obesity Signaling Converge on CREB Phosphorylation to Promote Pancreatic Cancer", "doi": "10.1158/1541-7786.mcr-24-0785", "year": 2024 } ], "bc": [ { "pmid": "39589881", "title": "Early disruption of the CREB pathway drives dendritic morphological alterations in FTD/ALS cortical neurons", "doi": "10.1073/pnas.2406998121", "year": 2024 } ] } }, { "id": 42533, "drug": "riluzole", "drug_type": "drug", "drug_domain": "als", "predicate_ab": "downregulates", "mediator": "MMP-2", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "histopathological type of cancer", "outcome_type": "phenotype", "outcome_domain": "pancreatic_cancer", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40012807", "title": "Investigation of the Neuroprotective Effect of Riluzole on Matrix Metalloproteinases in an Experimental Model of Glaucoma", "doi": "10.4103/joco.joco_290_23", "year": 2024 } ], "bc": [ { "pmid": "27429508", "title": "Expressions of Matrix Metalloproteinases 2, 7, and 9 in Carcinogenesis of Pancreatic Ductal Adenocarcinoma", "doi": "10.1155/2016/9895721", "year": 2016 } ] } }, { "id": 9730, "drug": "resveratrol", "drug_type": "drug", "drug_domain": "pancreatic_cancer", "predicate_ab": "upregulates", "mediator": "PTEN", "mediator_type": "gene", "predicate_bc": "associated_with", "outcome": "polymicrogyria", "outcome_type": "disease", "outcome_domain": "epilepsy", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "resveratrol", "mediator_canonical": "PTEN", "outcome_canonical": "polymicrogyria", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "29854071", "title": "Resveratrol Inhibits ROS‐Promoted Activation and Glycolysis of Pancreatic Stellate Cells via Suppression of miR‐21", "doi": "10.1155/2018/1346958", "year": 2018 } ], "bc": [ { "pmid": "32959437", "title": "Polymicrogyria is Associated With Pathogenic Variants in PTEN", "doi": "10.1002/ana.25904", "year": 2020 } ] } }, { "id": 9710, "drug": "curcumin", "drug_type": "drug", "drug_domain": "pancreatic_cancer", "predicate_ab": "inhibits", "mediator": "EZH2", "mediator_type": "gene", "predicate_bc": "prevents", "outcome": "epileptogenesis", "outcome_type": "disease", "outcome_domain": "epilepsy", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "curcumin", "mediator_canonical": "ezh2", "outcome_canonical": "epileptogenesis", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "29048549", "title": "Curcumin sensitizes pancreatic cancer cells to gemcitabine by attenuating PRC2 subunit EZH2, and the lncRNA PVT1 expression", "doi": "10.1093/carcin/bgx065", "year": 2017 } ], "bc": [ { "pmid": "31891591", "title": "A systems approach identifies Enhancer of Zeste Homolog 2 (EZH2) as a protective factor in epilepsy", "doi": "10.1371/journal.pone.0226733", "year": 2019 } ] } }, { "id": 9709, "drug": "fluoxetine", "drug_type": "drug", "drug_domain": "pancreatic_cancer", "predicate_ab": "inhibits", "mediator": "SERT", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "high SUDEP risk", "outcome_type": "disease", "outcome_domain": "epilepsy", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "fluoxetine", "mediator_canonical": "sert", "outcome_canonical": "high sudep risk", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "30058725", "title": "Serotonin uptake is required for Rac1 activation in Kras‐induced acinar‐to‐ductal metaplasia in the pancreas", "doi": "10.1002/path.5147", "year": 2018 } ], "bc": [ { "pmid": "35478467", "title": "Serotonin transporter in the temporal lobe, hippocampus and amygdala in SUDEP", "doi": "10.1111/bpa.13074", "year": 2022 } ] } }, { "id": 9639, "drug": "curcumin", "drug_type": "drug", "drug_domain": "pancreatic_cancer", "predicate_ab": "inhibits", "mediator": "EZH2", "mediator_type": "gene", "predicate_bc": "decreases", "outcome": "seizure burden", "outcome_type": "phenotype", "outcome_domain": "epilepsy", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "curcumin", "mediator_canonical": "ezh2", "outcome_canonical": "seizure burden", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "29048549", "title": "Curcumin sensitizes pancreatic cancer cells to gemcitabine by attenuating PRC2 subunit EZH2, and the lncRNA PVT1 expression", "doi": "10.1093/carcin/bgx065", "year": 2017 } ], "bc": [ { "pmid": "31891591", "title": "A systems approach identifies Enhancer of Zeste Homolog 2 (EZH2) as a protective factor in epilepsy", "doi": "10.1371/journal.pone.0226733", "year": 2019 } ] } }, { "id": 9307, "drug": "curcumin", "drug_type": "drug", "drug_domain": "alzheimer", "predicate_ab": "upregulates", "mediator": "BDNF", "mediator_type": "protein", "predicate_bc": "increases", "outcome": "remission", "outcome_type": "phenotype", "outcome_domain": "depression", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "completed", "clinical_trial_nct_ids": [ "NCT03795792", "NCT03122613", "NCT02683733" ], "literature_status": "reproduces_known", "drug_canonical": "curcumin", "mediator_canonical": "BDNF", "outcome_canonical": null, "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "38791161", "title": "Curcumin Improves Neurogenesis in Alzheimer’s Disease Mice via the Upregulation of Wnt/β-Catenin and BDNF", "doi": "10.3390/ijms25105123", "year": 2024 } ], "bc": [ { "pmid": "41584756", "title": "Employment-dependent associations of serum biomarkers with short- and long-term antidepressant treatment outcomes", "doi": "10.3389/fpsyt.2025.1662993", "year": 2026 } ] } }, { "id": 9144, "drug": "metformin", "drug_type": "drug", "drug_domain": "alzheimer", "predicate_ab": "activates", "mediator": "GSK-3β", "mediator_type": "protein", "predicate_bc": "increases", "outcome": "PanIN progression", "outcome_type": "disease", "outcome_domain": "pancreatic_cancer", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "metformin", "mediator_canonical": "GSK3B", "outcome_canonical": "panin progression", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "34432352", "title": "Pretreatment with metformin prevents microcystin‐LR‐induced tau hyperphosphorylation via mTOR‐dependent PP2A and GSK‐3β activation", "doi": "10.1002/tox.23354", "year": 2021 } ], "bc": [ { "pmid": "28639695", "title": "Glycogen synthase kinase‐3β ablation limits pancreatitis‐induced acinar‐to‐ductal metaplasia", "doi": "10.1002/path.4928", "year": 2017 } ] } }, { "id": 8462, "drug": "resveratrol", "drug_type": "drug", "drug_domain": "alzheimer", "predicate_ab": "upregulates", "mediator": "SOD2", "mediator_type": "gene", "predicate_bc": "confers_resistance_to", "outcome": "radiation resistance", "outcome_type": "phenotype", "outcome_domain": "glioblastoma", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "resveratrol", "mediator_canonical": "sod2", "outcome_canonical": "radiation resistance", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "30301188", "title": "Effect of Resveratrol on Reactive Oxygen Species-Induced Cognitive Impairment in Rats with Angiotensin II-Induced Early Alzheimer’s Disease †", "doi": "10.3390/jcm7100329", "year": 2018 } ], "bc": [ { "pmid": "40877007", "title": "SOD2-mediated TMZ-resistant Glioblastoma Cells Exhibit Cross-resistance to Irradiation", "doi": "10.21873/anticanres.17722", "year": 2025 } ] } }, { "id": 8361, "drug": "Riluzole", "drug_type": "drug", "drug_domain": "als", "predicate_ab": "downregulates", "mediator": "MMP-9", "mediator_type": "protein", "predicate_bc": "decreases", "outcome": "perineuronal net", "outcome_type": "phenotype", "outcome_domain": "depression", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "riluzole", "mediator_canonical": "MMP9", "outcome_canonical": "perineuronal net", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40012807", "title": "Investigation of the Neuroprotective Effect of Riluzole on Matrix Metalloproteinases in an Experimental Model of Glaucoma", "doi": "10.4103/joco.joco_290_23", "year": 2024 } ], "bc": [ { "pmid": "32269106", "title": "Venlafaxine Stimulates an MMP-9-Dependent Increase in Excitatory/Inhibitory Balance in a Stress Model of Depression", "doi": "10.1523/jneurosci.2387-19.2020", "year": 2020 } ] } }, { "id": 8345, "drug": "Riluzole", "drug_type": "drug", "drug_domain": "als", "predicate_ab": "downregulates", "mediator": "MMP-9", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "recent suicide attempt", "outcome_type": "phenotype", "outcome_domain": "depression", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "riluzole", "mediator_canonical": "MMP9", "outcome_canonical": "recent suicide attempt", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40012807", "title": "Investigation of the Neuroprotective Effect of Riluzole on Matrix Metalloproteinases in an Experimental Model of Glaucoma", "doi": "10.4103/joco.joco_290_23", "year": 2024 } ], "bc": [ { "pmid": "41561479", "title": "Levels of matrix metalloproteinase 9 (MMP-9) are elevated in persons with major depressive disorder who have had a recent suicide attempt", "doi": "10.1016/j.bbih.2025.101163", "year": 2025 } ] } }, { "id": 32067, "drug": "auraptene", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "downregulates", "mediator": "MMP-9", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "RA", "outcome_type": "disease", "outcome_domain": "rheumatoid_arthritis", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "auraptene", "mediator_canonical": "MMP9", "outcome_canonical": "ra", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "39086858", "title": "Auraptene inhibits migration, invasion and metastatic behavior of human malignant glioblastoma cells: An in vitro and in silico study.", "doi": "10.22038/ajp.2023.23586", "year": 2024 } ], "bc": [ { "pmid": "30668267", "title": "Expression Profile of Long Noncoding RNAs, lnc-Cox2, and HOTAIR in Rheumatoid Arthritis Patients", "doi": "10.1089/jir.2018.0117", "year": 2019 } ] } }, { "id": 8259, "drug": "Riluzole", "drug_type": "drug", "drug_domain": "als", "predicate_ab": "downregulates", "mediator": "MMP-9", "mediator_type": "protein", "predicate_bc": "decreases", "outcome": "inhibitory input to excitatory neurons", "outcome_type": "phenotype", "outcome_domain": "depression", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "riluzole", "mediator_canonical": "MMP9", "outcome_canonical": "inhibitory input to excitatory neurons", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40012807", "title": "Investigation of the Neuroprotective Effect of Riluzole on Matrix Metalloproteinases in an Experimental Model of Glaucoma", "doi": "10.4103/joco.joco_290_23", "year": 2024 } ], "bc": [ { "pmid": "32269106", "title": "Venlafaxine Stimulates an MMP-9-Dependent Increase in Excitatory/Inhibitory Balance in a Stress Model of Depression", "doi": "10.1523/jneurosci.2387-19.2020", "year": 2020 } ] } }, { "id": 8258, "drug": "Riluzole", "drug_type": "drug", "drug_domain": "als", "predicate_ab": "downregulates", "mediator": "MMP-9", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "major depressive disorder without recent suicide attempt", "outcome_type": "disease", "outcome_domain": "depression", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "riluzole", "mediator_canonical": "MMP9", "outcome_canonical": "major depressive disorder without recent suicide attempt", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40012807", "title": "Investigation of the Neuroprotective Effect of Riluzole on Matrix Metalloproteinases in an Experimental Model of Glaucoma", "doi": "10.4103/joco.joco_290_23", "year": 2024 } ], "bc": [ { "pmid": "41561479", "title": "Levels of matrix metalloproteinase 9 (MMP-9) are elevated in persons with major depressive disorder who have had a recent suicide attempt", "doi": "10.1016/j.bbih.2025.101163", "year": 2025 } ] } }, { "id": 8161, "drug": "Riluzole", "drug_type": "drug", "drug_domain": "als", "predicate_ab": "activates", "mediator": "p53", "mediator_type": "protein", "predicate_bc": "predicts", "outcome": "early recurrence", "outcome_type": "phenotype", "outcome_domain": "pancreatic_cancer", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "riluzole", "mediator_canonical": "TP53", "outcome_canonical": "early recurrence", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "32231713", "title": "Riluzole Enhances the Response of Human Nasopharyngeal Carcinoma Cells to Ionizing Radiation via ATM/P53 Signalling Pathway", "doi": "10.7150/jca.41217", "year": 2020 } ], "bc": [ { "pmid": "29771771", "title": "A Therapeutic Strategy for Resectable Pancreatic Cancer Based on Risk Factors of Early Recurrence", "doi": "10.1097/mpa.0000000000001066", "year": 2018 } ] } }, { "id": 8148, "drug": "Riluzole", "drug_type": "drug", "drug_domain": "als", "predicate_ab": "downregulates", "mediator": "MMP-2", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "inflammation", "outcome_type": "phenotype", "outcome_domain": "pancreatic_cancer", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "completed", "clinical_trial_nct_ids": [ "NCT03039673", "NCT02796755" ], "literature_status": "reproduces_known", "drug_canonical": "riluzole", "mediator_canonical": "MMP2", "outcome_canonical": null, "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40012807", "title": "Investigation of the Neuroprotective Effect of Riluzole on Matrix Metalloproteinases in an Experimental Model of Glaucoma", "doi": "10.4103/joco.joco_290_23", "year": 2024 } ], "bc": [ { "pmid": "27429508", "title": "Expressions of Matrix Metalloproteinases 2, 7, and 9 in Carcinogenesis of Pancreatic Ductal Adenocarcinoma", "doi": "10.1155/2016/9895721", "year": 2016 } ] } }, { "id": 8087, "drug": "lithium", "drug_type": "drug", "drug_domain": "als", "predicate_ab": "inhibits", "mediator": "GSK-3β", "mediator_type": "protein", "predicate_bc": "increases", "outcome": "PanIN progression", "outcome_type": "disease", "outcome_domain": "pancreatic_cancer", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "lithium", "mediator_canonical": "GSK3B", "outcome_canonical": "panin progression", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "39363657", "title": "Lithium alleviates paralysis in experimental autoimmune neuritis in Lewis rats by modulating glycogen synthase kinase-3β activity", "doi": "10.4142/jvs.24212", "year": 2024 } ], "bc": [ { "pmid": "28639695", "title": "Glycogen synthase kinase‐3β ablation limits pancreatitis‐induced acinar‐to‐ductal metaplasia", "doi": "10.1002/path.4928", "year": 2017 } ] } }, { "id": 8009, "drug": "resveratrol", "drug_type": "drug", "drug_domain": "als", "predicate_ab": "downregulates", "mediator": "GSK-3β", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "memory function", "outcome_type": "phenotype", "outcome_domain": "alzheimer", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "completed", "clinical_trial_nct_ids": [ "NCT01219244", "NCT02621554", "NCT01504854" ], "literature_status": "reproduces_known", "drug_canonical": "resveratrol", "mediator_canonical": "GSK3B", "outcome_canonical": "memory function", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "26981091", "title": "How does resveratrol influence the genesis of some neurodegenerative diseases?", "doi": "10.4103/1673-5374.175047", "year": 2016 } ], "bc": [ { "pmid": "36178363", "title": "Therapeutic implications of glycogen synthase kinase-3β in Alzheimer’s disease: a novel therapeutic target", "doi": "10.1080/00207454.2022.2130297", "year": 2022 } ] } }, { "id": 23785, "drug": "chloroquine", "drug_type": "drug", "drug_domain": "multiple_sclerosis", "predicate_ab": "upregulates", "mediator": "IL-10", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "cognitive decline", "outcome_type": "phenotype", "outcome_domain": "alzheimer", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "chloroquine", "mediator_canonical": "il-10", "outcome_canonical": "cognitive decline", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "32516999", "title": "Comprehensive Analysis of the Immune and Stromal Compartments of the CNS in EAE Mice Reveal Pathways by Which Chloroquine Suppresses Neuroinflammation", "doi": "10.3390/brainsci10060348", "year": 2020 } ], "bc": [ { "pmid": "32557792", "title": "Prospective longitudinal evaluation of cytokines in mild cognitive impairment due to AD and Lewy body disease", "doi": "10.1002/gps.5365", "year": 2020 } ] } }, { "id": 1726, "drug": "Auranofin", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "upregulates", "mediator": "p53", "mediator_type": "protein", "predicate_bc": "increases", "outcome": "lysophospholipid levels", "outcome_type": "phenotype", "outcome_domain": "pancreatic_cancer", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "auranofin", "mediator_canonical": "TP53", "outcome_canonical": "lysophospholipid levels", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "39456455", "title": "Synergistic Dual Targeting of Thioredoxin and Glutathione Systems Irrespective of p53 in Glioblastoma Stem Cells", "doi": "10.3390/antiox13101201", "year": 2024 } ], "bc": [ { "pmid": "35255936", "title": "p53-driven lipidome influences non-cell-autonomous lysophospholipids in pancreatic cancer", "doi": "10.1186/s13062-022-00319-9", "year": 2022 } ] } }, { "id": 7400, "drug": "valproic acid", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "downregulates", "mediator": "BDNF", "mediator_type": "protein", "predicate_bc": "increases", "outcome": "remission", "outcome_type": "phenotype", "outcome_domain": "depression", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "completed", "clinical_trial_nct_ids": [ "NCT02497443", "NCT03885947" ], "literature_status": "reproduces_known", "drug_canonical": "valproic acid", "mediator_canonical": "BDNF", "outcome_canonical": null, "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "35465089", "title": "Excitatory and Inhibitory Synaptic Imbalance Caused by Brain-Derived Neurotrophic Factor Deficits During Development in a Valproic Acid Mouse Model of Autism", "doi": "10.3389/fnmol.2022.860275", "year": 2022 } ], "bc": [ { "pmid": "41584756", "title": "Employment-dependent associations of serum biomarkers with short- and long-term antidepressant treatment outcomes", "doi": "10.3389/fpsyt.2025.1662993", "year": 2026 } ] } }, { "id": 7493, "drug": "niclosamide", "drug_type": "drug", "drug_domain": "als", "predicate_ab": "inhibits", "mediator": "STAT3", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "glioblastoma progression", "outcome_type": "disease", "outcome_domain": "glioblastoma", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "niclosamide", "mediator_canonical": "STAT3", "outcome_canonical": "glioblastoma progression", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "38493058", "title": "Neuroprotective effects of niclosamide on disease progression via inflammatory pathways modulation in SOD1-G93A and FUS-associated amyotrophic lateral sclerosis models", "doi": "10.1016/j.neurot.2024.e00346", "year": 2024 } ], "bc": [ { "pmid": "41747967", "title": "STAT3 signaling as an adaptive hub in glioblastoma: Network rewiring, non-coding RNA circuits, and therapeutic vulnerabilities", "doi": "10.1016/j.nbd.2026.107330", "year": 2026 } ] } }, { "id": 7566, "drug": "sunitinib", "drug_type": "drug", "drug_domain": "als", "predicate_ab": "inhibits", "mediator": "STAT3", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "glioblastoma progression", "outcome_type": "disease", "outcome_domain": "glioblastoma", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "sunitinib", "mediator_canonical": "STAT3", "outcome_canonical": "glioblastoma progression", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "38914173", "title": "Sunitinib-mediated inhibition of STAT3 in skeletal muscle and spinal cord does not affect the disease in a mouse model of ALS", "doi": "10.1016/j.nbd.2024.106576", "year": 2024 } ], "bc": [ { "pmid": "41747967", "title": "STAT3 signaling as an adaptive hub in glioblastoma: Network rewiring, non-coding RNA circuits, and therapeutic vulnerabilities", "doi": "10.1016/j.nbd.2026.107330", "year": 2026 } ] } }, { "id": 7810, "drug": "resveratrol", "drug_type": "drug", "drug_domain": "als", "predicate_ab": "downregulates", "mediator": "GSK-3β", "mediator_type": "protein", "predicate_bc": "increases", "outcome": "neurodegeneration", "outcome_type": "phenotype", "outcome_domain": "epilepsy", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "completed", "clinical_trial_nct_ids": [ "NCT05982860" ], "literature_status": "reproduces_known", "drug_canonical": "resveratrol", "mediator_canonical": "GSK3B", "outcome_canonical": null, "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "26981091", "title": "How does resveratrol influence the genesis of some neurodegenerative diseases?", "doi": "10.4103/1673-5374.175047", "year": 2016 } ], "bc": [ { "pmid": "30237424", "title": "Bi-directional genetic modulation of GSK-3β exacerbates hippocampal neuropathology in experimental status epilepticus", "doi": "10.1038/s41419-018-0963-5", "year": 2018 } ] } }, { "id": 7817, "drug": "lithium", "drug_type": "drug", "drug_domain": "als", "predicate_ab": "inhibits", "mediator": "GSK-3β", "mediator_type": "protein", "predicate_bc": "increases", "outcome": "hippocampal damage", "outcome_type": "phenotype", "outcome_domain": "epilepsy", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "lithium", "mediator_canonical": "GSK3B", "outcome_canonical": "hippocampal damage", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "39363657", "title": "Lithium alleviates paralysis in experimental autoimmune neuritis in Lewis rats by modulating glycogen synthase kinase-3β activity", "doi": "10.4142/jvs.24212", "year": 2024 } ], "bc": [ { "pmid": "30237424", "title": "Bi-directional genetic modulation of GSK-3β exacerbates hippocampal neuropathology in experimental status epilepticus", "doi": "10.1038/s41419-018-0963-5", "year": 2018 } ] } }, { "id": 7772, "drug": "sunitinib", "drug_type": "drug", "drug_domain": "als", "predicate_ab": "inhibits", "mediator": "STAT3", "mediator_type": "protein", "predicate_bc": "prevents", "outcome": "GABAergic neuron loss", "outcome_type": "phenotype", "outcome_domain": "epilepsy", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "sunitinib", "mediator_canonical": "STAT3", "outcome_canonical": "gabaergic neuron loss", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "38914173", "title": "Sunitinib-mediated inhibition of STAT3 in skeletal muscle and spinal cord does not affect the disease in a mouse model of ALS", "doi": "10.1016/j.nbd.2024.106576", "year": 2024 } ], "bc": [ { "pmid": "36825472", "title": "Blockage of STAT3 during epileptogenesis prevents GABAergic loss and imprinting of the epileptic state", "doi": "10.1093/brain/awad055", "year": 2023 } ] } }, { "id": 7707, "drug": "sunitinib", "drug_type": "drug", "drug_domain": "als", "predicate_ab": "inhibits", "mediator": "STAT3", "mediator_type": "protein", "predicate_bc": "prevents", "outcome": "general cell loss", "outcome_type": "phenotype", "outcome_domain": "epilepsy", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "sunitinib", "mediator_canonical": "STAT3", "outcome_canonical": "general cell loss", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "38914173", "title": "Sunitinib-mediated inhibition of STAT3 in skeletal muscle and spinal cord does not affect the disease in a mouse model of ALS", "doi": "10.1016/j.nbd.2024.106576", "year": 2024 } ], "bc": [ { "pmid": "36825472", "title": "Blockage of STAT3 during epileptogenesis prevents GABAergic loss and imprinting of the epileptic state", "doi": "10.1093/brain/awad055", "year": 2023 } ] } }, { "id": 7590, "drug": "Riluzole", "drug_type": "drug", "drug_domain": "als", "predicate_ab": "downregulates", "mediator": "MMP-9", "mediator_type": "protein", "predicate_bc": "predicts", "outcome": "recurrence or progression", "outcome_type": "phenotype", "outcome_domain": "glioblastoma", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "riluzole", "mediator_canonical": "MMP9", "outcome_canonical": "recurrence or progression", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40012807", "title": "Investigation of the Neuroprotective Effect of Riluzole on Matrix Metalloproteinases in an Experimental Model of Glaucoma", "doi": "10.4103/joco.joco_290_23", "year": 2024 } ], "bc": [ { "pmid": "41573658", "title": "High intra-tumoral and serum matrix metalloproteinase 9 levels are associated with reduced survival of patients with glioblastoma and brain metastases", "doi": "10.3389/fonc.2025.1577492", "year": 2026 } ] } }, { "id": 7389, "drug": "valproate", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "downregulates", "mediator": "COX-2", "mediator_type": "protein", "predicate_bc": "predicts", "outcome": "early treatment efficacy", "outcome_type": "phenotype", "outcome_domain": "depression", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "valproic acid", "mediator_canonical": "cox-2", "outcome_canonical": "early treatment efficacy", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "32054883", "title": "Downregulation of peripheral PTGS2/COX-2 in response to valproate treatment in patients with epilepsy", "doi": "10.1038/s41598-020-59259-x", "year": 2020 } ], "bc": [ { "pmid": "41749161", "title": "The predictive value of niacin skin flushing response and inflammatory factors for the antidepressant efficacy", "doi": "10.1186/s12888-026-07921-5", "year": 2026 } ] } }, { "id": 7790, "drug": "sunitinib", "drug_type": "drug", "drug_domain": "als", "predicate_ab": "inhibits", "mediator": "STAT3", "mediator_type": "protein", "predicate_bc": "prevents", "outcome": "persistence of reactive glial states", "outcome_type": "phenotype", "outcome_domain": "epilepsy", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "sunitinib", "mediator_canonical": "STAT3", "outcome_canonical": "persistence of reactive glial states", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "38914173", "title": "Sunitinib-mediated inhibition of STAT3 in skeletal muscle and spinal cord does not affect the disease in a mouse model of ALS", "doi": "10.1016/j.nbd.2024.106576", "year": 2024 } ], "bc": [ { "pmid": "36825472", "title": "Blockage of STAT3 during epileptogenesis prevents GABAergic loss and imprinting of the epileptic state", "doi": "10.1093/brain/awad055", "year": 2023 } ] } }, { "id": 7384, "drug": "Baicalin", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "upregulates", "mediator": "BDNF", "mediator_type": "protein", "predicate_bc": "decreases", "outcome": "oxidative stress", "outcome_type": "phenotype", "outcome_domain": "depression", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "baicalin", "mediator_canonical": "BDNF", "outcome_canonical": "oxidative stress", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "38778616", "title": "Exploring the Therapeutic Potential of Baicalin: Mitigating Anxiety and Depression in Epileptic Rats", "doi": "10.2174/0113862073316021240520110301", "year": 2024 } ], "bc": [ { "pmid": "36062024", "title": "Intranasal Administration of Brain-Derived Neurotrophic Factor Rescues Depressive-Like Phenotypes in Chronic Unpredictable Mild Stress Mice", "doi": "10.2147/ndt.s369412", "year": 2022 } ] } }, { "id": 51425, "drug": "colchicine", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "suppresses", "mediator": "NLRP3 inflammasome activation", "mediator_type": "pathway", "predicate_bc": "associated_with", "outcome": "acute lung injury", "outcome_type": "disease", "outcome_domain": "multiple_sclerosis", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "35766262", "title": "Colchicine Ameliorates Dilated Cardiomyopathy Via SIRT2‐Mediated Suppression of NLRP3 Inflammasome Activation", "doi": "10.1161/jaha.122.025266", "year": 2022 } ], "bc": [ { "pmid": "39974815", "title": "Fingolimod Suppresses NLRP3 Inflammasome Activation and Alleviates Oxidative Stress in Traumatic Brain Injury-Induced Acute Lung Injury", "doi": "10.2147/jir.s503428", "year": 2025 } ] } }, { "id": 1337, "drug": "Selinexor", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "inhibits", "mediator": "XPO1", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "TDP-43 nuclear export", "outcome_type": "phenotype", "outcome_domain": "als", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "selinexor", "mediator_canonical": "xpo1", "outcome_canonical": "tdp-43 nuclear export", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "34728525", "title": "A Phase II Study of the Efficacy and Safety of Oral Selinexor in Recurrent Glioblastoma", "doi": "10.1158/1078-0432.ccr-21-2225", "year": 2021 } ], "bc": [ { "pmid": "29728608", "title": "Active nuclear import and passive nuclear export are the primary determinants of TDP-43 localization", "doi": "10.1038/s41598-018-25008-4", "year": 2018 } ] } }, { "id": 27180, "drug": "Curcumin", "drug_type": "drug", "drug_domain": "alzheimer", "predicate_ab": "upregulates", "mediator": "Hes1", "mediator_type": "gene", "predicate_bc": "associated_with", "outcome": "poor prognosis", "outcome_type": "phenotype", "outcome_domain": "pancreatic_cancer", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "curcumin", "mediator_canonical": "hes1", "outcome_canonical": null, "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "31145652", "title": "Curcumin Promotes Proliferation of Adult Neural Stem Cells and the Birth of Neurons in Alzheimer's Disease Mice via Notch Signaling Pathway", "doi": "10.1089/cell.2018.0027", "year": 2019 } ], "bc": [ { "pmid": "25672829", "title": "HES 1 is essential for chemoresistance induced by stellate cells and is associated with poor prognosis in pancreatic cancer", "doi": "10.3892/or.2015.3789", "year": 2015 } ] } }, { "id": 7343, "drug": "metformin", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "upregulates", "mediator": "α-synuclein", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "major depressive disorder", "outcome_type": "disease", "outcome_domain": "depression", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "completed", "clinical_trial_nct_ids": [ "NCT04088448", "NCT00834652" ], "literature_status": "reproduces_known", "drug_canonical": "metformin", "mediator_canonical": "SNCA", "outcome_canonical": "major depressive disorder", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "30308130", "title": "Effects of metformin on apoptosis and α-synuclein in a rat model of pentylenetetrazole-induced epilepsy", "doi": "10.1139/cjpp-2018-0266", "year": 2018 } ], "bc": [ { "pmid": "40015617", "title": "Impaired unfolded protein response, BDNF and synuclein markers in postmortem dorsolateral prefrontal cortex and caudate nucleus of patients with depression and Parkinson's disease", "doi": "10.1016/j.pnpbp.2025.111299", "year": 2025 } ] } }, { "id": 7339, "drug": "valproic acid", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "downregulates", "mediator": "DNA methylation", "mediator_type": "biomarker", "predicate_bc": "associated_with", "outcome": "remission", "outcome_type": "phenotype", "outcome_domain": "depression", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "completed", "clinical_trial_nct_ids": [ "NCT02497443", "NCT03885947" ], "literature_status": "reproduces_known", "drug_canonical": "valproic acid", "mediator_canonical": "dna methylation", "outcome_canonical": null, "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "35312054", "title": "Developmental administration of valproic acid alters DNA methylation and maternal behavior", "doi": "10.1002/dev.22231", "year": 2022 } ], "bc": [ { "pmid": "37664245", "title": "Longitudinal early epigenomic signatures inform molecular paths of therapy response and remission in depressed patients", "doi": "10.3389/fnmol.2023.1223216", "year": 2023 } ] } }, { "id": 1748, "drug": "Flubendazole", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "inhibits", "mediator": "STAT3", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "drug resistance", "outcome_type": "phenotype", "outcome_domain": "pancreatic_cancer", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "flubendazole", "mediator_canonical": "STAT3", "outcome_canonical": null, "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37045903", "title": "Flubendazole exhibits anti-glioblastoma effect by inhibiting STAT3 and promoting cell cycle arrest", "doi": "10.1038/s41598-023-33047-9", "year": 2023 } ], "bc": [ { "pmid": "38464736", "title": "Role of STAT3 in pancreatic cancer", "doi": "10.37349/etat.2024.00202", "year": 2024 } ] } }, { "id": 7338, "drug": "Baicalin", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "upregulates", "mediator": "BDNF", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "major depression", "outcome_type": "disease", "outcome_domain": "depression", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "baicalin", "mediator_canonical": "BDNF", "outcome_canonical": "major depression", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "38778616", "title": "Exploring the Therapeutic Potential of Baicalin: Mitigating Anxiety and Depression in Epileptic Rats", "doi": "10.2174/0113862073316021240520110301", "year": 2024 } ], "bc": [ { "pmid": "36831119", "title": "The Serum Brain-Derived Neurotrophic Factor Increases in Serotonin Reuptake Inhibitor Responders Patients with First-Episode, Drug-Naïve Major Depression", "doi": "10.3390/biomedicines11020584", "year": 2023 } ] } }, { "id": 51522, "drug": "resveratrol", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "upregulates", "mediator": "VEGF", "mediator_type": "protein", "predicate_bc": "causes", "outcome": "multiple sclerosis", "outcome_type": "disease", "outcome_domain": "multiple_sclerosis", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "28138705", "title": "Resveratrol activates endogenous cardiac stem cells and improves myocardial regeneration following acute myocardial infarction", "doi": "10.3892/mmr.2017.6143", "year": 2017 } ], "bc": [ { "pmid": "34745143", "title": "Growth Factors and Their Roles in Multiple Sclerosis Risk", "doi": "10.3389/fimmu.2021.768682", "year": 2021 } ] } }, { "id": 51525, "drug": "resveratrol", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "inhibits", "mediator": "NF-κB signaling", "mediator_type": "pathway", "predicate_bc": "causes", "outcome": "demyelination", "outcome_type": "phenotype", "outcome_domain": "multiple_sclerosis", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37541173", "title": "Resveratrol prevents Ang II-induced cardiac hypertrophy by inhibition of NF-κB signaling", "doi": "10.1016/j.biopha.2023.115275", "year": 2023 } ], "bc": [ { "pmid": "41480772", "title": "Astrocyte-intrinsic signaling of chitinase-like protein CHI3L1 drives inflammation and amplifies demyelination in neuromyelitis optica", "doi": "10.1172/jci195506", "year": 2026 } ] } }, { "id": 7337, "drug": "Baicalin", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "upregulates", "mediator": "BDNF", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "anhedonia", "outcome_type": "phenotype", "outcome_domain": "depression", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "baicalin", "mediator_canonical": "BDNF", "outcome_canonical": "anhedonia", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "38778616", "title": "Exploring the Therapeutic Potential of Baicalin: Mitigating Anxiety and Depression in Epileptic Rats", "doi": "10.2174/0113862073316021240520110301", "year": 2024 } ], "bc": [ { "pmid": "32372985", "title": "Exploring Brain Derived Neurotrophic Factor and Cell Adhesion Molecules as Biomarkers for the Transdiagnostic Symptom Anhedonia in Alcohol Use Disorder and Comorbid Depression", "doi": "10.3389/fpsyt.2020.00296", "year": 2020 } ] } }, { "id": 51539, "drug": "Curcumin", "drug_type": "drug", "drug_domain": "heart_failure", "predicate_ab": "activates", "mediator": "SIRT1", "mediator_type": "protein", "predicate_bc": "increases", "outcome": "optokinetic response", "outcome_type": "phenotype", "outcome_domain": "multiple_sclerosis", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "38586339", "title": "Curcumin simultaneously improves mitochondrial dynamics and myocardial cell bioenergy after sepsis via the SIRT1-DRP1/PGC-1α pathway", "doi": "10.1016/j.heliyon.2024.e28501", "year": 2024 } ], "bc": [ { "pmid": "35740955", "title": "Selective Upregulation of SIRT1 Expression in Retinal Ganglion Cells by AAV-Mediated Gene Delivery Increases Neuronal Cell Survival and Alleviates Axon Demyelination Associated with Optic Neuritis", "doi": "10.3390/biom12060830", "year": 2022 } ] } }, { "id": 44572, "drug": "resveratrol", "drug_type": "drug", "drug_domain": "alzheimer", "predicate_ab": "activates", "mediator": "SIRT1", "mediator_type": "protein", "predicate_bc": "increases", "outcome": "stemness marker expression", "outcome_type": "phenotype", "outcome_domain": "pancreatic_cancer", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "30243024", "title": "Sirt1 enhances tau exon 10 inclusion and improves spatial memory of Htau mice", "doi": "10.18632/aging.101564", "year": 2018 } ], "bc": [ { "pmid": "34163012", "title": "SIRT1 coordinates with the CRL4B complex to regulate pancreatic cancer stem cells to promote tumorigenesis", "doi": "10.1038/s41418-021-00821-z", "year": 2021 } ] } }, { "id": 42255, "drug": "riluzole", "drug_type": "drug", "drug_domain": "als", "predicate_ab": "activates", "mediator": "cGAS/STING pathway", "mediator_type": "pathway", "predicate_bc": "causes", "outcome": "inflammation", "outcome_type": "disease", "outcome_domain": "inflammatory_bowel_disease", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "39382075", "title": "Riluzole Enhancing Anti-PD-1 Efficacy by Activating cGAS/STING Signaling in Colorectal Cancer", "doi": "10.1158/1535-7163.mct-24-0289", "year": 2024 } ], "bc": [ { "pmid": "37108510", "title": "HP1γ Prevents Activation of the cGAS/STING Pathway by Preserving Nuclear Envelope and Genomic Integrity in Colon Adenocarcinoma Cells", "doi": "10.3390/ijms24087347", "year": 2023 } ] } }, { "id": 7227, "drug": "valproic acid", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "upregulates", "mediator": "CXCR4", "mediator_type": "gene", "predicate_bc": "sensitizes_to", "outcome": "myofibroblast-induced invasion", "outcome_type": "phenotype", "outcome_domain": "pancreatic_cancer", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "valproic acid", "mediator_canonical": "CXCR4", "outcome_canonical": "myofibroblast-induced invasion", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40164048", "title": "Valproic acid preconditioning of bone marrow mesenchymal stem cells promotes remyelination of the corpus callosum in a cuprizone-induced demyelination model", "doi": "10.1016/j.biopha.2025.118027", "year": 2025 } ], "bc": [ { "pmid": "32606001", "title": "CXCR4 in Tumor Epithelial Cells Mediates Desmoplastic Reaction in Pancreatic Ductal Adenocarcinoma", "doi": "10.1158/0008-5472.can-19-2745", "year": 2020 } ] } }, { "id": 25061, "drug": "niclosamide", "drug_type": "drug", "drug_domain": "als", "predicate_ab": "inhibits", "mediator": "STAT3", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "UC", "outcome_type": "disease", "outcome_domain": "inflammatory_bowel_disease", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "niclosamide", "mediator_canonical": "STAT3", "outcome_canonical": "uc", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "38493058", "title": "Neuroprotective effects of niclosamide on disease progression via inflammatory pathways modulation in SOD1-G93A and FUS-associated amyotrophic lateral sclerosis models", "doi": "10.1016/j.neurot.2024.e00346", "year": 2024 } ], "bc": [ { "pmid": "36857861", "title": "Therapeutic targets for inflammatory bowel disease: proteome-wide Mendelian randomization and colocalization analyses", "doi": "10.1016/j.ebiom.2023.104494", "year": 2023 } ] } }, { "id": 7185, "drug": "metformin", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "upregulates", "mediator": "Hsp70", "mediator_type": "protein", "predicate_bc": "increases", "outcome": "pancreatic cancer growth", "outcome_type": "phenotype", "outcome_domain": "pancreatic_cancer", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "completed", "clinical_trial_nct_ids": [ "NCT02431676" ], "literature_status": "partial_evidence", "drug_canonical": "metformin", "mediator_canonical": "hsp70", "outcome_canonical": "pancreatic cancer growth", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "30308130", "title": "Effects of metformin on apoptosis and α-synuclein in a rat model of pentylenetetrazole-induced epilepsy", "doi": "10.1139/cjpp-2018-0266", "year": 2018 } ], "bc": [ { "pmid": "32973929", "title": "Radiofrequency ablation in combination with an mTOR inhibitor restrains pancreatic cancer growth induced by intrinsic HSP70", "doi": "10.1177/1758835920953728", "year": 2020 } ] } }, { "id": 7039, "drug": "valproic acid", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "downregulates", "mediator": "BDNF", "mediator_type": "protein", "predicate_bc": "prevents", "outcome": "neurodegenerative changes", "outcome_type": "phenotype", "outcome_domain": "alzheimer", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "valproic acid", "mediator_canonical": "BDNF", "outcome_canonical": "neurodegenerative changes", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "35465089", "title": "Excitatory and Inhibitory Synaptic Imbalance Caused by Brain-Derived Neurotrophic Factor Deficits During Development in a Valproic Acid Mouse Model of Autism", "doi": "10.3389/fnmol.2022.860275", "year": 2022 } ], "bc": [ { "pmid": "32733889", "title": "Brain-Derived Neurotrophic Factor (BDNF) Preserves the Functional Integrity of Neural Networks in the β-Amyloidopathy Model in vitro", "doi": "10.3389/fcell.2020.00582", "year": 2020 } ] } }, { "id": 7028, "drug": "valproic acid", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "downregulates", "mediator": "Progranulin", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "neurofibrillary tangle development", "outcome_type": "phenotype", "outcome_domain": "alzheimer", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "valproic acid", "mediator_canonical": "GRN", "outcome_canonical": "neurofibrillary tangle development", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "35318322", "title": "Progranulin improves neural development via the PI3K/Akt/GSK-3β pathway in the cerebellum of a VPA-induced rat model of ASD", "doi": "10.1038/s41398-022-01875-4", "year": 2022 } ], "bc": [ { "pmid": "34374777", "title": "Loss of Lysosomal Proteins Progranulin and Prosaposin Associated with Increased Neurofibrillary Tangle Development in Alzheimer Disease", "doi": "10.1093/jnen/nlab056", "year": 2021 } ] } }, { "id": 6637, "drug": "valproic acid", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "downregulates", "mediator": "PDYN", "mediator_type": "gene", "predicate_bc": "associated_with", "outcome": "GBM prognosis", "outcome_type": "phenotype", "outcome_domain": "glioblastoma", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "valproic acid", "mediator_canonical": "pdyn", "outcome_canonical": "gbm prognosis", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "31978376", "title": "Prenatal exposure to valproic acid reduces social responses and alters mRNA levels of opioid receptor and pre-pro-peptide in discrete brain regions of adolescent and adult male rats", "doi": "10.1016/j.brainres.2020.146675", "year": 2020 } ], "bc": [ { "pmid": "41815811", "title": "A novel mucosa-associated lymphoid tissue translocation gene 1-related immune prognostic signature and targeted drug screening for glioblastoma", "doi": "10.4103/bc.bc_65_24", "year": 2025 } ] } }, { "id": 6843, "drug": "metformin", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "inhibits", "mediator": "caspase-3", "mediator_type": "protein", "predicate_bc": "causes", "outcome": "neuronal apoptosis", "outcome_type": "phenotype", "outcome_domain": "als", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "metformin", "mediator_canonical": "CASP3", "outcome_canonical": "neuronal apoptosis", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "30308130", "title": "Effects of metformin on apoptosis and α-synuclein in a rat model of pentylenetetrazole-induced epilepsy", "doi": "10.1139/cjpp-2018-0266", "year": 2018 } ], "bc": [ { "pmid": "26064904", "title": "Implication of Caspase-3 as a Common Therapeutic Target for Multineurodegenerative Disorders and Its Inhibition Using Nonpeptidyl Natural Compounds", "doi": "10.1155/2015/379817", "year": 2015 } ] } }, { "id": 6789, "drug": "valproic acid", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "downregulates", "mediator": "Progranulin", "mediator_type": "protein", "predicate_bc": "prevents", "outcome": "dopaminergic neuron degeneration", "outcome_type": "phenotype", "outcome_domain": "als", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "valproic acid", "mediator_canonical": "GRN", "outcome_canonical": "dopaminergic neuron degeneration", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "35318322", "title": "Progranulin improves neural development via the PI3K/Akt/GSK-3β pathway in the cerebellum of a VPA-induced rat model of ASD", "doi": "10.1038/s41398-022-01875-4", "year": 2022 } ], "bc": [ { "pmid": "40992611", "title": "Gene therapy device-based delivery of progranulin, prosaposin, and GDNF as a combined precision and neurorestorative therapy in the rat 6-OHDA model of parkinsonism", "doi": "10.1016/j.expneurol.2025.115474", "year": 2025 } ] } }, { "id": 6422, "drug": "auraptene", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "inhibits", "mediator": "JNK", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "social cognition performance", "outcome_type": "phenotype", "outcome_domain": "depression", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "auraptene", "mediator_canonical": "jnk", "outcome_canonical": "social cognition performance", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "39086858", "title": "Auraptene inhibits migration, invasion and metastatic behavior of human malignant glioblastoma cells: An in vitro and in silico study.", "doi": "10.22038/ajp.2023.23586", "year": 2024 } ], "bc": [ { "pmid": "41786038", "title": "Associations between social cognition and inflammatory markers in eating disorders and borderline personality disorder", "doi": "10.1016/j.sjpmh.2026.02.003", "year": 2026 } ] } }, { "id": 5679, "drug": "resveratrol", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "downregulates", "mediator": "P-glycoprotein", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "SUDEP", "outcome_type": "disease", "outcome_domain": "epilepsy", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "resveratrol", "mediator_canonical": "ABCB1", "outcome_canonical": "sudep", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41253172", "title": "Resveratrol Sensitizes Temozolomide-Resistant Glioblastoma Cells Through Mitogen-Activated Protein Kinase Pathway Inhibition and P-Glycoprotein Modulation", "doi": "10.1055/a-2698-0203", "year": 2025 } ], "bc": [ { "pmid": "29462915", "title": "Pilocarpine-Induced Status Epilepticus Is Associated with P-Glycoprotein Induction in Cardiomyocytes, Electrocardiographic Changes, and Sudden Death", "doi": "10.3390/ph11010021", "year": 2018 } ] } }, { "id": 6076, "drug": "apigenin", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "upregulates", "mediator": "GFAP", "mediator_type": "protein", "predicate_bc": "predicts", "outcome": "disease progression", "outcome_type": "phenotype", "outcome_domain": "alzheimer", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "apigenin", "mediator_canonical": "GFAP", "outcome_canonical": "disease progression", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41090780", "title": "Apigenin Induces Autophagy and Apoptosis in Chemoresistant Glioblastoma Cells and Inhibits Tumorigenicity Associated with Regulation of Immunomodulatory Proteins and Glial Cells Response", "doi": "10.3390/cells14191552", "year": 2025 } ], "bc": [ { "pmid": "36576155", "title": "Plasma glial fibrillary acidic protein in autosomal dominant Alzheimer's disease: Associations with Aβ‐PET, neurodegeneration, and cognition", "doi": "10.1002/alz.12879", "year": 2022 } ] } }, { "id": 6027, "drug": "apigenin", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "upregulates", "mediator": "GFAP", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "astrogliosis", "outcome_type": "phenotype", "outcome_domain": "alzheimer", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "apigenin", "mediator_canonical": "GFAP", "outcome_canonical": "astrogliosis", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41090780", "title": "Apigenin Induces Autophagy and Apoptosis in Chemoresistant Glioblastoma Cells and Inhibits Tumorigenicity Associated with Regulation of Immunomodulatory Proteins and Glial Cells Response", "doi": "10.3390/cells14191552", "year": 2025 } ], "bc": [ { "pmid": "41081630", "title": "Age-Specific Control and Alzheimer Disease Reference Curves and z -Scores for Glial Fibrillary Acidic Protein in Blood", "doi": "10.1093/clinchem/hvaf120", "year": 2025 } ] } }, { "id": 6026, "drug": "apigenin", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "upregulates", "mediator": "GFAP", "mediator_type": "protein", "predicate_bc": "predicts", "outcome": "clinical Alzheimer's disease diagnosis", "outcome_type": "disease", "outcome_domain": "alzheimer", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "apigenin", "mediator_canonical": "GFAP", "outcome_canonical": "clinical alzheimer's disease diagnosis", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41090780", "title": "Apigenin Induces Autophagy and Apoptosis in Chemoresistant Glioblastoma Cells and Inhibits Tumorigenicity Associated with Regulation of Immunomodulatory Proteins and Glial Cells Response", "doi": "10.3390/cells14191552", "year": 2025 } ], "bc": [ { "pmid": "35852967", "title": "Amyloid‐beta misfolding and GFAP predict risk of clinical Alzheimer's disease diagnosis within 17 years", "doi": "10.1002/alz.12745", "year": 2022 } ] } }, { "id": 6025, "drug": "apigenin", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "upregulates", "mediator": "GFAP", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "dementia severity", "outcome_type": "phenotype", "outcome_domain": "alzheimer", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "apigenin", "mediator_canonical": "GFAP", "outcome_canonical": "dementia severity", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41090780", "title": "Apigenin Induces Autophagy and Apoptosis in Chemoresistant Glioblastoma Cells and Inhibits Tumorigenicity Associated with Regulation of Immunomodulatory Proteins and Glial Cells Response", "doi": "10.3390/cells14191552", "year": 2025 } ], "bc": [ { "pmid": "37885919", "title": "Cross‐sectional and longitudinal evaluation of plasma glial fibrillary acidic protein to detect and predict clinical syndromes of Alzheimer's disease", "doi": "10.1002/dad2.12492", "year": 2023 } ] } }, { "id": 5621, "drug": "curcumin", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "downregulates", "mediator": "MGMT", "mediator_type": "gene", "predicate_bc": "correlates_with", "outcome": "progression-free survival", "outcome_type": "phenotype", "outcome_domain": "epilepsy", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "curcumin", "mediator_canonical": "mgmt", "outcome_canonical": null, "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41844218", "title": "Synergistic Effects of Curcumin and Temozolomide in Overcoming Glioblastoma Drug Resistance through Regulation of O6-Methylguanine-DNA Methyltransferase, Mismatch Repair, and Poly(Adenosine Diphosphate Ribose) Polymerase 1", "doi": "10.1055/a-2800-2050", "year": 2026 } ], "bc": [ { "pmid": "34621499", "title": "https://researchopenworld.com/the-addition-of-valproic-acid-to-concurrent-radiation-therapy-and-temozolomide-improves-patient-outcome-a-correlative-analysis-of-rtog-0525-seer-and-a-phase-ii-nci-trial/#", "doi": "10.31038/cst.2020511", "year": 2020 } ] } }, { "id": 5620, "drug": "curcumin", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "downregulates", "mediator": "MGMT", "mediator_type": "gene", "predicate_bc": "correlates_with", "outcome": "seizure reduction", "outcome_type": "phenotype", "outcome_domain": "epilepsy", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "curcumin", "mediator_canonical": "mgmt", "outcome_canonical": "seizure reduction", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41844218", "title": "Synergistic Effects of Curcumin and Temozolomide in Overcoming Glioblastoma Drug Resistance through Regulation of O6-Methylguanine-DNA Methyltransferase, Mismatch Repair, and Poly(Adenosine Diphosphate Ribose) Polymerase 1", "doi": "10.1055/a-2800-2050", "year": 2026 } ], "bc": [ { "pmid": "30507318", "title": "Perampanel in patients with brain tumor-related epilepsy in real-life clinical practice: a retrospective analysis", "doi": "10.1080/00207454.2018.1555160", "year": 2018 } ] } }, { "id": 25126, "drug": "riluzole", "drug_type": "drug", "drug_domain": "als", "predicate_ab": "downregulates", "mediator": "MMP-9", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "colitis severity", "outcome_type": "disease", "outcome_domain": "inflammatory_bowel_disease", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "riluzole", "mediator_canonical": "MMP9", "outcome_canonical": "colitis severity", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40012807", "title": "Investigation of the Neuroprotective Effect of Riluzole on Matrix Metalloproteinases in an Experimental Model of Glaucoma", "doi": "10.4103/joco.joco_290_23", "year": 2024 } ], "bc": [ { "pmid": "33748570", "title": "Toward Point-of-Care Diagnostics to Monitor MMP-9 and TNF-α Levels in Inflammatory Bowel Disease", "doi": "10.1021/acsomega.0c05115", "year": 2021 } ] } }, { "id": 5465, "drug": "fluoxetine", "drug_type": "drug", "drug_domain": "depression", "predicate_ab": "downregulates", "mediator": "TLR7", "mediator_type": "gene", "predicate_bc": "decreases", "outcome": "chemosensitivity", "outcome_type": "phenotype", "outcome_domain": "pancreatic_cancer", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "fluoxetine", "mediator_canonical": "tlr7", "outcome_canonical": "chemosensitivity", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "31647818", "title": "Assessing the role of toll-like receptor in isolated, standard and enriched housing conditions", "doi": "10.1371/journal.pone.0222818", "year": 2019 } ], "bc": [ { "pmid": "26134824", "title": "TLR7 and TLR8 expression increases tumor cell proliferation and promotes chemoresistance in human pancreatic cancer", "doi": "10.3892/ijo.2015.3069", "year": 2015 } ] } }, { "id": 4865, "drug": "apigenin", "drug_type": "drug", "drug_domain": "pancreatic_cancer", "predicate_ab": "downregulates", "mediator": "HSP90", "mediator_type": "protein", "predicate_bc": "increases", "outcome": "TDP-43 proteinopathy", "outcome_type": "disease", "outcome_domain": "als", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "apigenin", "mediator_canonical": "hsp90", "outcome_canonical": "tdp-43 proteinopathy", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "31121848", "title": "Mutant p53, Stabilized by Its Interplay with HSP90, Activates a Positive Feed-Back Loop Between NRF2 and p62 that Induces Chemo-Resistance to Apigenin in Pancreatic Cancer Cells", "doi": "10.3390/cancers11050703", "year": 2019 } ], "bc": [ { "pmid": "39724103", "title": "Decreased Hsp90 activity protects against TDP-43 neurotoxicity in a C. elegans model of amyotrophic lateral sclerosis", "doi": "10.1371/journal.pgen.1011518", "year": 2024 } ] } }, { "id": 44505, "drug": "resveratrol", "drug_type": "drug", "drug_domain": "alzheimer", "predicate_ab": "upregulates", "mediator": "Sod2", "mediator_type": "gene", "predicate_bc": "increases", "outcome": "proliferation", "outcome_type": "phenotype", "outcome_domain": "pancreatic_cancer", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "30301188", "title": "Effect of Resveratrol on Reactive Oxygen Species-Induced Cognitive Impairment in Rats with Angiotensin II-Induced Early Alzheimer’s Disease †", "doi": "10.3390/jcm7100329", "year": 2018 } ], "bc": [ { "pmid": "41353397", "title": "Mitochondrial superoxide dismutase controls metabolic plasticity in pancreatic cancer", "doi": "10.1186/s12964-025-02555-8", "year": 2025 } ] } }, { "id": 4852, "drug": "apigenin", "drug_type": "drug", "drug_domain": "pancreatic_cancer", "predicate_ab": "downregulates", "mediator": "HSP90", "mediator_type": "protein", "predicate_bc": "prevents", "outcome": "TDP-43 toxicity", "outcome_type": "phenotype", "outcome_domain": "als", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "apigenin", "mediator_canonical": "hsp90", "outcome_canonical": "tdp-43 toxicity", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "31121848", "title": "Mutant p53, Stabilized by Its Interplay with HSP90, Activates a Positive Feed-Back Loop Between NRF2 and p62 that Induces Chemo-Resistance to Apigenin in Pancreatic Cancer Cells", "doi": "10.3390/cancers11050703", "year": 2019 } ], "bc": [ { "pmid": "33908654", "title": "Hsp90 and its co‐chaperone Sti1 control TDP‐43 misfolding and toxicity", "doi": "10.1096/fj.202002645r", "year": 2021 } ] } }, { "id": 4840, "drug": "resveratrol", "drug_type": "drug", "drug_domain": "pancreatic_cancer", "predicate_ab": "activates", "mediator": "AMPK", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "amyotrophic lateral sclerosis", "outcome_type": "disease", "outcome_domain": "als", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "completed", "clinical_trial_nct_ids": [ "NCT04654689" ], "literature_status": "reproduces_known", "drug_canonical": "resveratrol", "mediator_canonical": "AMPK", "outcome_canonical": "amyotrophic lateral sclerosis", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "27669292", "title": "YAP Inhibition by Resveratrol via Activation of AMPK Enhances the Sensitivity of Pancreatic Cancer Cells to Gemcitabine", "doi": "10.3390/nu8100546", "year": 2016 } ], "bc": [ { "pmid": "34393724", "title": "Contribution of Energy Dysfunction to Impaired Protein Translation in Neurodegenerative Diseases", "doi": "10.3389/fncel.2021.668500", "year": 2021 } ] } }, { "id": 4765, "drug": "resveratrol", "drug_type": "drug", "drug_domain": "pancreatic_cancer", "predicate_ab": "upregulates", "mediator": "PTEN", "mediator_type": "gene", "predicate_bc": "causes", "outcome": "cortical malformation", "outcome_type": "phenotype", "outcome_domain": "epilepsy", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "resveratrol", "mediator_canonical": "PTEN", "outcome_canonical": "cortical malformation", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "29854071", "title": "Resveratrol Inhibits ROS‐Promoted Activation and Glycolysis of Pancreatic Stellate Cells via Suppression of miR‐21", "doi": "10.1155/2018/1346958", "year": 2018 } ], "bc": [ { "pmid": "34048549", "title": "PTEN somatic mutations contribute to spectrum of cerebral overgrowth", "doi": "10.1093/brain/awab173", "year": 2021 } ] } }, { "id": 4710, "drug": "resveratrol", "drug_type": "drug", "drug_domain": "pancreatic_cancer", "predicate_ab": "upregulates", "mediator": "PTEN", "mediator_type": "gene", "predicate_bc": "causes", "outcome": "hemimegalencephaly", "outcome_type": "disease", "outcome_domain": "epilepsy", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "resveratrol", "mediator_canonical": "PTEN", "outcome_canonical": "hemimegalencephaly", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "29854071", "title": "Resveratrol Inhibits ROS‐Promoted Activation and Glycolysis of Pancreatic Stellate Cells via Suppression of miR‐21", "doi": "10.1155/2018/1346958", "year": 2018 } ], "bc": [ { "pmid": "34048549", "title": "PTEN somatic mutations contribute to spectrum of cerebral overgrowth", "doi": "10.1093/brain/awab173", "year": 2021 } ] } }, { "id": 4363, "drug": "curcumin", "drug_type": "drug", "drug_domain": "alzheimer", "predicate_ab": "downregulates", "mediator": "GSK3β", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "mood disorders", "outcome_type": "disease", "outcome_domain": "depression", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "completed", "clinical_trial_nct_ids": [ "NCT06763809", "NCT05518019", "NCT01750359" ], "literature_status": "reproduces_known", "drug_canonical": "curcumin", "mediator_canonical": "GSK3B", "outcome_canonical": "mood disorders", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "31754658", "title": "Curcumin Downregulates GSK3 and Cdk5 in Scopolamine-Induced Alzheimer’s Disease Rats Abrogating Aβ 40/42 and Tau Hyperphosphorylation", "doi": "10.3233/adr-190135", "year": 2019 } ], "bc": [ { "pmid": "30080747", "title": "Unravelling the GSK3β-related genotypic interaction network influencing hippocampal volume in recurrent major depressive disorder", "doi": "10.1097/ypg.0000000000000203", "year": 2018 } ] } }, { "id": 4346, "drug": "curcumin", "drug_type": "drug", "drug_domain": "alzheimer", "predicate_ab": "upregulates", "mediator": "BDNF", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "language function", "outcome_type": "phenotype", "outcome_domain": "depression", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "curcumin", "mediator_canonical": "BDNF", "outcome_canonical": "language function", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "38791161", "title": "Curcumin Improves Neurogenesis in Alzheimer’s Disease Mice via the Upregulation of Wnt/β-Catenin and BDNF", "doi": "10.3390/ijms25105123", "year": 2024 } ], "bc": [ { "pmid": "39911552", "title": "Association of inflammation cytokines with cognitive function in first-episode major depressive disorder", "doi": "10.3389/fpsyt.2024.1473418", "year": 2025 } ] } }, { "id": 4334, "drug": "curcumin", "drug_type": "drug", "drug_domain": "alzheimer", "predicate_ab": "upregulates", "mediator": "BDNF", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "anhedonia", "outcome_type": "phenotype", "outcome_domain": "depression", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "curcumin", "mediator_canonical": "BDNF", "outcome_canonical": "anhedonia", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "38791161", "title": "Curcumin Improves Neurogenesis in Alzheimer’s Disease Mice via the Upregulation of Wnt/β-Catenin and BDNF", "doi": "10.3390/ijms25105123", "year": 2024 } ], "bc": [ { "pmid": "32372985", "title": "Exploring Brain Derived Neurotrophic Factor and Cell Adhesion Molecules as Biomarkers for the Transdiagnostic Symptom Anhedonia in Alcohol Use Disorder and Comorbid Depression", "doi": "10.3389/fpsyt.2020.00296", "year": 2020 } ] } }, { "id": 23459, "drug": "chloroquine", "drug_type": "drug", "drug_domain": "multiple_sclerosis", "predicate_ab": "upregulates", "mediator": "IL-10", "mediator_type": "protein", "predicate_bc": "increases", "outcome": "microglial burden", "outcome_type": "phenotype", "outcome_domain": "als", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "chloroquine", "mediator_canonical": "il-10", "outcome_canonical": "microglial burden", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "32516999", "title": "Comprehensive Analysis of the Immune and Stromal Compartments of the CNS in EAE Mice Reveal Pathways by Which Chloroquine Suppresses Neuroinflammation", "doi": "10.3390/brainsci10060348", "year": 2020 } ], "bc": [ { "pmid": "33257786", "title": "IL-10 based immunomodulation initiated at birth extends lifespan in a familial mouse model of amyotrophic lateral sclerosis", "doi": "10.1038/s41598-020-77564-3", "year": 2020 } ] } }, { "id": 4319, "drug": "curcumin", "drug_type": "drug", "drug_domain": "alzheimer", "predicate_ab": "upregulates", "mediator": "BDNF", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "improvement in depressive symptoms", "outcome_type": "phenotype", "outcome_domain": "depression", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "curcumin", "mediator_canonical": "BDNF", "outcome_canonical": "improvement in depressive symptoms", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "38791161", "title": "Curcumin Improves Neurogenesis in Alzheimer’s Disease Mice via the Upregulation of Wnt/β-Catenin and BDNF", "doi": "10.3390/ijms25105123", "year": 2024 } ], "bc": [ { "pmid": "37891727", "title": "Changes in Adipokine, Resitin, and BDNF Concentrations in Treatment-Resistant Depression after Electroconvulsive Therapy", "doi": "10.3390/brainsci13101358", "year": 2023 } ] } }, { "id": 4157, "drug": "hydroxychloroquine", "drug_type": "drug", "drug_domain": "alzheimer", "predicate_ab": "inhibits", "mediator": "STAT3", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "pancreatic cancer", "outcome_type": "disease", "outcome_domain": "pancreatic_cancer", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "active", "clinical_trial_nct_ids": [ "NCT05083780", "NCT04678648", "NCT06828328" ], "literature_status": "reproduces_known", "drug_canonical": "hydroxychloroquine", "mediator_canonical": "STAT3", "outcome_canonical": "pancreatic cancer", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "36577843", "title": "Hydroxychloroquine lowers Alzheimer’s disease and related dementias risk and rescues molecular phenotypes related to Alzheimer’s disease", "doi": "10.1038/s41380-022-01912-0", "year": 2022 } ], "bc": [ { "pmid": "26873728", "title": "Applying Small Molecule Signal Transducer and Activator of Transcription-3 (STAT3) Protein Inhibitors as Pancreatic Cancer Therapeutics", "doi": "10.1158/1535-7163.mct-15-0003", "year": 2016 } ] } }, { "id": 4117, "drug": "hydroxychloroquine", "drug_type": "drug", "drug_domain": "alzheimer", "predicate_ab": "inhibits", "mediator": "STAT3", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "drug resistance", "outcome_type": "phenotype", "outcome_domain": "pancreatic_cancer", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "hydroxychloroquine", "mediator_canonical": "STAT3", "outcome_canonical": null, "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "36577843", "title": "Hydroxychloroquine lowers Alzheimer’s disease and related dementias risk and rescues molecular phenotypes related to Alzheimer’s disease", "doi": "10.1038/s41380-022-01912-0", "year": 2022 } ], "bc": [ { "pmid": "38464736", "title": "Role of STAT3 in pancreatic cancer", "doi": "10.37349/etat.2024.00202", "year": 2024 } ] } }, { "id": 44503, "drug": "Curcumin", "drug_type": "drug", "drug_domain": "alzheimer", "predicate_ab": "upregulates", "mediator": "Hes1", "mediator_type": "gene", "predicate_bc": "associated_with", "outcome": "pancreatic regeneration", "outcome_type": "phenotype", "outcome_domain": "pancreatic_cancer", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "31145652", "title": "Curcumin Promotes Proliferation of Adult Neural Stem Cells and the Birth of Neurons in Alzheimer's Disease Mice via Notch Signaling Pathway", "doi": "10.1089/cell.2018.0027", "year": 2019 } ], "bc": [ { "pmid": "36075324", "title": "Context-Dependent Roles of Hes1 in the Adult Pancreas and Pancreatic Tumor Formation", "doi": "10.1053/j.gastro.2022.08.048", "year": 2022 } ] } }, { "id": 25124, "drug": "niclosamide", "drug_type": "drug", "drug_domain": "als", "predicate_ab": "inhibits", "mediator": "STAT3", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "Crohn's disease", "outcome_type": "disease", "outcome_domain": "inflammatory_bowel_disease", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "niclosamide", "mediator_canonical": "STAT3", "outcome_canonical": "crohn's disease", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "38493058", "title": "Neuroprotective effects of niclosamide on disease progression via inflammatory pathways modulation in SOD1-G93A and FUS-associated amyotrophic lateral sclerosis models", "doi": "10.1016/j.neurot.2024.e00346", "year": 2024 } ], "bc": [ { "pmid": "36498596", "title": "Genetic and Small-Molecule Modulation of Stat3 in a Mouse Model of Crohn’s Disease", "doi": "10.3390/jcm11237020", "year": 2022 } ] } }, { "id": 42222, "drug": "riluzole", "drug_type": "drug", "drug_domain": "als", "predicate_ab": "activates", "mediator": "p53", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "colorectal neoplasia progression", "outcome_type": "disease", "outcome_domain": "inflammatory_bowel_disease", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "32231713", "title": "Riluzole Enhances the Response of Human Nasopharyngeal Carcinoma Cells to Ionizing Radiation via ATM/P53 Signalling Pathway", "doi": "10.7150/jca.41217", "year": 2020 } ], "bc": [ { "pmid": "26063242", "title": "Overexpression of p53 predicts colorectal neoplasia risk in patients with inflammatory bowel disease and mucosa changes indefinite for dysplasia", "doi": "10.1093/gastro/gov022", "year": 2015 } ] } }, { "id": 37826, "drug": "resveratrol", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "suppresses", "mediator": "TGF-β1", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "ALS", "outcome_type": "disease", "outcome_domain": "als", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "completed", "clinical_trial_nct_ids": [ "NCT04654689" ], "literature_status": "reproduces_known", "drug_canonical": "resveratrol", "mediator_canonical": "tgf-β1", "outcome_canonical": "amyotrophic lateral sclerosis", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "38745204", "title": "Resveratrol attenuates inflammation and fibrosis in rheumatoid arthritis-associated interstitial lung disease via the AKT/TMEM175 pathway", "doi": "10.1186/s12967-024-05228-1", "year": 2024 } ], "bc": [ { "pmid": "29326641", "title": "The TGF-β System As a Potential Pathogenic Player in Disease Modulation of Amyotrophic Lateral Sclerosis", "doi": "10.3389/fneur.2017.00669", "year": 2017 } ] } }, { "id": 4115, "drug": "curcumin", "drug_type": "drug", "drug_domain": "alzheimer", "predicate_ab": "upregulates", "mediator": "Hes1", "mediator_type": "gene", "predicate_bc": "associated_with", "outcome": "pancreatic regeneration", "outcome_type": "phenotype", "outcome_domain": "pancreatic_cancer", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "curcumin", "mediator_canonical": "hes1", "outcome_canonical": "pancreatic regeneration", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "31145652", "title": "Curcumin Promotes Proliferation of Adult Neural Stem Cells and the Birth of Neurons in Alzheimer's Disease Mice via Notch Signaling Pathway", "doi": "10.1089/cell.2018.0027", "year": 2019 } ], "bc": [ { "pmid": "36075324", "title": "Context-Dependent Roles of Hes1 in the Adult Pancreas and Pancreatic Tumor Formation", "doi": "10.1053/j.gastro.2022.08.048", "year": 2022 } ] } }, { "id": 1548, "drug": "apigenin", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "upregulates", "mediator": "GFAP", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "MMSE", "outcome_type": "phenotype", "outcome_domain": "alzheimer", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "apigenin", "mediator_canonical": "GFAP", "outcome_canonical": "mmse", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41090780", "title": "Apigenin Induces Autophagy and Apoptosis in Chemoresistant Glioblastoma Cells and Inhibits Tumorigenicity Associated with Regulation of Immunomodulatory Proteins and Glial Cells Response", "doi": "10.3390/cells14191552", "year": 2025 } ], "bc": [ { "pmid": "40830505", "title": "Optimizing timing and cost-effective use of plasma biomarkers in Alzheimer’s disease", "doi": "10.1186/s13195-025-01851-2", "year": 2025 } ] } }, { "id": 4094, "drug": "curcumin", "drug_type": "drug", "drug_domain": "alzheimer", "predicate_ab": "activates", "mediator": "NOTCH signaling pathway", "mediator_type": "pathway", "predicate_bc": "associated_with", "outcome": "pancreatic cancer", "outcome_type": "disease", "outcome_domain": "pancreatic_cancer", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "completed", "clinical_trial_nct_ids": [ "NCT00094445", "NCT00192842", "NCT00486460" ], "literature_status": "reproduces_known", "drug_canonical": "curcumin", "mediator_canonical": "notch signaling pathway", "outcome_canonical": "pancreatic cancer", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "31145652", "title": "Curcumin Promotes Proliferation of Adult Neural Stem Cells and the Birth of Neurons in Alzheimer's Disease Mice via Notch Signaling Pathway", "doi": "10.1089/cell.2018.0027", "year": 2019 } ], "bc": [ { "pmid": "28337369", "title": "Role of Notch signaling pathway in pancreatic cancer.", "doi": null, "year": 2017 } ] } }, { "id": 4093, "drug": "valproic acid", "drug_type": "drug", "drug_domain": "alzheimer", "predicate_ab": "activates", "mediator": "Wnt/β-catenin signaling pathway", "mediator_type": "pathway", "predicate_bc": "associated_with", "outcome": "pancreatic ductal adenocarcinoma", "outcome_type": "disease", "outcome_domain": "pancreatic_cancer", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "valproic acid", "mediator_canonical": "wnt/β-catenin signaling pathway", "outcome_canonical": "pancreatic ductal adenocarcinoma", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "30971911", "title": "Valproic Acid Stimulates Hippocampal Neurogenesis via Activating the Wnt/β-Catenin Signaling Pathway in the APP/PS1/Nestin-GFP Triple Transgenic Mouse Model of Alzheimer’s Disease", "doi": "10.3389/fnagi.2019.00062", "year": 2019 } ], "bc": [ { "pmid": "31452773", "title": "Circular RNA expression in pancreatic ductal adenocarcinoma", "doi": "10.3892/ol.2019.10624", "year": 2019 } ] } }, { "id": 4077, "drug": "hydroxychloroquine", "drug_type": "drug", "drug_domain": "alzheimer", "predicate_ab": "inhibits", "mediator": "STAT3", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "immune escape", "outcome_type": "phenotype", "outcome_domain": "pancreatic_cancer", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "hydroxychloroquine", "mediator_canonical": "STAT3", "outcome_canonical": "immune escape", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "36577843", "title": "Hydroxychloroquine lowers Alzheimer’s disease and related dementias risk and rescues molecular phenotypes related to Alzheimer’s disease", "doi": "10.1038/s41380-022-01912-0", "year": 2022 } ], "bc": [ { "pmid": "38464736", "title": "Role of STAT3 in pancreatic cancer", "doi": "10.37349/etat.2024.00202", "year": 2024 } ] } }, { "id": 3964, "drug": "curcumin", "drug_type": "drug", "drug_domain": "alzheimer", "predicate_ab": "binds_to", "mediator": "TDP-43", "mediator_type": "protein", "predicate_bc": "causes", "outcome": "organelle defects", "outcome_type": "phenotype", "outcome_domain": "als", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "curcumin", "mediator_canonical": "TDP-43", "outcome_canonical": "organelle defects", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "30092839", "title": "Different curcumin forms selectively bind fibrillar amyloid beta in post mortem Alzheimer’s disease brains: Implications for in-vivo diagnostics", "doi": "10.1186/s40478-018-0577-2", "year": 2018 } ], "bc": [ { "pmid": "31527135", "title": "Pleiotropic requirements for human TDP-43 in the regulation of cell and organelle homeostasis", "doi": "10.26508/lsa.201900358", "year": 2019 } ] } }, { "id": 25077, "drug": "sunitinib", "drug_type": "drug", "drug_domain": "als", "predicate_ab": "inhibits", "mediator": "STAT3", "mediator_type": "protein", "predicate_bc": "increases", "outcome": "ulcerative colitis carcinogenesis", "outcome_type": "disease", "outcome_domain": "inflammatory_bowel_disease", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "sunitinib", "mediator_canonical": "STAT3", "outcome_canonical": "ulcerative colitis carcinogenesis", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "38914173", "title": "Sunitinib-mediated inhibition of STAT3 in skeletal muscle and spinal cord does not affect the disease in a mouse model of ALS", "doi": "10.1016/j.nbd.2024.106576", "year": 2024 } ], "bc": [ { "pmid": "26550113", "title": "IL-6/STAT3/SOCS3 signaling pathway playing a regulatory role in ulcerative colitis carcinogenesis.", "doi": null, "year": 2015 } ] } }, { "id": 44336, "drug": "resveratrol", "drug_type": "drug", "drug_domain": "alzheimer", "predicate_ab": "activates", "mediator": "SIRT1", "mediator_type": "protein", "predicate_bc": "decreases", "outcome": "axon demyelination", "outcome_type": "phenotype", "outcome_domain": "multiple_sclerosis", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "30243024", "title": "Sirt1 enhances tau exon 10 inclusion and improves spatial memory of Htau mice", "doi": "10.18632/aging.101564", "year": 2018 } ], "bc": [ { "pmid": "35740955", "title": "Selective Upregulation of SIRT1 Expression in Retinal Ganglion Cells by AAV-Mediated Gene Delivery Increases Neuronal Cell Survival and Alleviates Axon Demyelination Associated with Optic Neuritis", "doi": "10.3390/biom12060830", "year": 2022 } ] } }, { "id": 3963, "drug": "curcumin", "drug_type": "drug", "drug_domain": "alzheimer", "predicate_ab": "binds_to", "mediator": "TDP-43", "mediator_type": "protein", "predicate_bc": "increases", "outcome": "pathological phenotypes", "outcome_type": "phenotype", "outcome_domain": "als", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "curcumin", "mediator_canonical": "TDP-43", "outcome_canonical": "pathological phenotypes", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "30092839", "title": "Different curcumin forms selectively bind fibrillar amyloid beta in post mortem Alzheimer’s disease brains: Implications for in-vivo diagnostics", "doi": "10.1186/s40478-018-0577-2", "year": 2018 } ], "bc": [ { "pmid": "27368346", "title": "Mislocated FUS is sufficient for gain-of-toxic-function amyotrophic lateral sclerosis phenotypes in mice", "doi": "10.1093/brain/aww161", "year": 2016 } ] } }, { "id": 3962, "drug": "curcumin", "drug_type": "drug", "drug_domain": "alzheimer", "predicate_ab": "binds_to", "mediator": "TDP-43", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "skeletal muscle atrophy", "outcome_type": "phenotype", "outcome_domain": "als", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "preclinical_only", "clinical_trial_nct_ids": [ "NCT05848830" ], "literature_status": "partial_evidence", "drug_canonical": "curcumin", "mediator_canonical": "TDP-43", "outcome_canonical": "skeletal muscle atrophy", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "30092839", "title": "Different curcumin forms selectively bind fibrillar amyloid beta in post mortem Alzheimer’s disease brains: Implications for in-vivo diagnostics", "doi": "10.1186/s40478-018-0577-2", "year": 2018 } ], "bc": [ { "pmid": "34774794", "title": "miR-23a suppression accelerates functional decline in the rNLS8 mouse model of TDP-43 proteinopathy", "doi": "10.1016/j.nbd.2021.105559", "year": 2021 } ] } }, { "id": 3932, "drug": "curcumin", "drug_type": "drug", "drug_domain": "alzheimer", "predicate_ab": "binds_to", "mediator": "TDP-43", "mediator_type": "protein", "predicate_bc": "increases", "outcome": "DNA damage", "outcome_type": "phenotype", "outcome_domain": "als", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "completed", "clinical_trial_nct_ids": [ "NCT05306002" ], "literature_status": "reproduces_known", "drug_canonical": "curcumin", "mediator_canonical": "TDP-43", "outcome_canonical": "dna damage", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "30092839", "title": "Different curcumin forms selectively bind fibrillar amyloid beta in post mortem Alzheimer’s disease brains: Implications for in-vivo diagnostics", "doi": "10.1186/s40478-018-0577-2", "year": 2018 } ], "bc": [ { "pmid": "37849894", "title": "Loss of TDP-43 function contributes to genomic instability in amyotrophic lateral sclerosis", "doi": "10.3389/fnins.2023.1251228", "year": 2023 } ] } }, { "id": 3931, "drug": "curcumin", "drug_type": "drug", "drug_domain": "alzheimer", "predicate_ab": "binds_to", "mediator": "TDP-43", "mediator_type": "protein", "predicate_bc": "predicts", "outcome": "behavioural variant frontotemporal dementia", "outcome_type": "disease", "outcome_domain": "als", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "curcumin", "mediator_canonical": "TDP-43", "outcome_canonical": "behavioural variant frontotemporal dementia", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "30092839", "title": "Different curcumin forms selectively bind fibrillar amyloid beta in post mortem Alzheimer’s disease brains: Implications for in-vivo diagnostics", "doi": "10.1186/s40478-018-0577-2", "year": 2018 } ], "bc": [ { "pmid": "26231953", "title": "TDP-43 proteinopathies: pathological identification of brain regions differentiating clinical phenotypes", "doi": "10.1093/brain/awv220", "year": 2015 } ] } }, { "id": 3930, "drug": "curcumin", "drug_type": "drug", "drug_domain": "alzheimer", "predicate_ab": "binds_to", "mediator": "TDP-43", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "sporadic amyotrophic lateral sclerosis", "outcome_type": "disease", "outcome_domain": "als", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "curcumin", "mediator_canonical": "TDP-43", "outcome_canonical": "sporadic amyotrophic lateral sclerosis", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "30092839", "title": "Different curcumin forms selectively bind fibrillar amyloid beta in post mortem Alzheimer’s disease brains: Implications for in-vivo diagnostics", "doi": "10.1186/s40478-018-0577-2", "year": 2018 } ], "bc": [ { "pmid": "29186496", "title": "Anterior Cingulate Cortex TDP-43 Pathology in Sporadic Amyotrophic Lateral Sclerosis", "doi": "10.1093/jnen/nlx104", "year": 2017 } ] } }, { "id": 3928, "drug": "curcumin", "drug_type": "drug", "drug_domain": "alzheimer", "predicate_ab": "binds_to", "mediator": "TDP-43", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "axon wrapping", "outcome_type": "phenotype", "outcome_domain": "als", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "curcumin", "mediator_canonical": "TDP-43", "outcome_canonical": "axon wrapping", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "30092839", "title": "Different curcumin forms selectively bind fibrillar amyloid beta in post mortem Alzheimer’s disease brains: Implications for in-vivo diagnostics", "doi": "10.1186/s40478-018-0577-2", "year": 2018 } ], "bc": [ { "pmid": "26276811", "title": "Glial TDP-43 regulates axon wrapping, GluRIIA clustering and fly motility by autonomous and non-autonomous mechanisms", "doi": "10.1093/hmg/ddv330", "year": 2015 } ] } }, { "id": 3927, "drug": "curcumin", "drug_type": "drug", "drug_domain": "alzheimer", "predicate_ab": "binds_to", "mediator": "TDP-43", "mediator_type": "protein", "predicate_bc": "decreases", "outcome": "axonal translation", "outcome_type": "phenotype", "outcome_domain": "als", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "curcumin", "mediator_canonical": "TDP-43", "outcome_canonical": "axonal translation", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "30092839", "title": "Different curcumin forms selectively bind fibrillar amyloid beta in post mortem Alzheimer’s disease brains: Implications for in-vivo diagnostics", "doi": "10.1186/s40478-018-0577-2", "year": 2018 } ], "bc": [ { "pmid": "38026702", "title": "Neuronal models of TDP-43 proteinopathy display reduced axonal translation, increased oxidative stress, and defective exocytosis", "doi": "10.3389/fncel.2023.1253543", "year": 2023 } ] } }, { "id": 3916, "drug": "curcumin", "drug_type": "drug", "drug_domain": "alzheimer", "predicate_ab": "downregulates", "mediator": "amyloid-beta", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "metabolic dyshomeostasis", "outcome_type": "phenotype", "outcome_domain": "als", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "curcumin", "mediator_canonical": "amyloid-beta", "outcome_canonical": "metabolic dyshomeostasis", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "31089060", "title": "miR-15b-5p targeting amyloid precursor protein is involved in the anti-amyloid eflect of curcumin in swAPP695-HEK293 cells", "doi": "10.4103/1673-5374.255979", "year": 2019 } ], "bc": [ { "pmid": "37248899", "title": "Prodromal Glutamatergic Modulation with Riluzole Impacts Glucose Homeostasis and Spatial Cognition in Alzheimer’s Disease Mice", "doi": "10.3233/jad-221245", "year": 2023 } ] } }, { "id": 3911, "drug": "curcumin", "drug_type": "drug", "drug_domain": "alzheimer", "predicate_ab": "downregulates", "mediator": "GSK3β", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "CTE-ALS", "outcome_type": "disease", "outcome_domain": "als", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "curcumin", "mediator_canonical": "GSK3B", "outcome_canonical": "cte-als", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "31754658", "title": "Curcumin Downregulates GSK3 and Cdk5 in Scopolamine-Induced Alzheimer’s Disease Rats Abrogating Aβ 40/42 and Tau Hyperphosphorylation", "doi": "10.3233/adr-190135", "year": 2019 } ], "bc": [ { "pmid": "29298849", "title": "Pathologic Thr 175 tau phosphorylation in CTE and CTE with ALS", "doi": "10.1212/wnl.0000000000004899", "year": 2018 } ] } }, { "id": 3891, "drug": "curcumin", "drug_type": "drug", "drug_domain": "alzheimer", "predicate_ab": "binds_to", "mediator": "TDP-43", "mediator_type": "protein", "predicate_bc": "decreases", "outcome": "cell viability", "outcome_type": "phenotype", "outcome_domain": "als", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "curcumin", "mediator_canonical": "TDP-43", "outcome_canonical": "cell viability", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "30092839", "title": "Different curcumin forms selectively bind fibrillar amyloid beta in post mortem Alzheimer’s disease brains: Implications for in-vivo diagnostics", "doi": "10.1186/s40478-018-0577-2", "year": 2018 } ], "bc": [ { "pmid": "31888078", "title": "TDP-43-Mediated Toxicity in HEK293T Cells: A Fast and Reproducible Protocol To Be Employed in the Search of New Therapeutic Options against Amyotrophic Lateral Sclerosis", "doi": "10.3390/cells9010068", "year": 2019 } ] } }, { "id": 3887, "drug": "curcumin", "drug_type": "drug", "drug_domain": "alzheimer", "predicate_ab": "binds_to", "mediator": "TDP-43", "mediator_type": "protein", "predicate_bc": "causes", "outcome": "memory loss", "outcome_type": "phenotype", "outcome_domain": "als", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "completed", "clinical_trial_nct_ids": [ "NCT01716637" ], "literature_status": "reproduces_known", "drug_canonical": "curcumin", "mediator_canonical": "TDP-43", "outcome_canonical": "memory loss", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "30092839", "title": "Different curcumin forms selectively bind fibrillar amyloid beta in post mortem Alzheimer’s disease brains: Implications for in-vivo diagnostics", "doi": "10.1186/s40478-018-0577-2", "year": 2018 } ], "bc": [ { "pmid": "30922385", "title": "Transcriptomopathies of pre- and post-symptomatic frontotemporal dementia-like mice with TDP-43 depletion in forebrain neurons", "doi": "10.1186/s40478-019-0674-x", "year": 2019 } ] } }, { "id": 44227, "drug": "hydroxychloroquine", "drug_type": "drug", "drug_domain": "alzheimer", "predicate_ab": "inhibits", "mediator": "STAT3", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "Crohn's disease", "outcome_type": "disease", "outcome_domain": "inflammatory_bowel_disease", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "36577843", "title": "Hydroxychloroquine lowers Alzheimer’s disease and related dementias risk and rescues molecular phenotypes related to Alzheimer’s disease", "doi": "10.1038/s41380-022-01912-0", "year": 2022 } ], "bc": [ { "pmid": "36498596", "title": "Genetic and Small-Molecule Modulation of Stat3 in a Mouse Model of Crohn’s Disease", "doi": "10.3390/jcm11237020", "year": 2022 } ] } }, { "id": 17967, "drug": "valproic acid", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "upregulates", "mediator": "NF-κB signaling pathway", "mediator_type": "pathway", "predicate_bc": "associated_with", "outcome": "ALS pathogenesis", "outcome_type": "disease", "outcome_domain": "als", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "valproic acid", "mediator_canonical": "nf-κb signaling pathway", "outcome_canonical": "als pathogenesis", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "39622390", "title": "Lipopolysaccharide induces neuroinflammation in a valproic acid male model of autism", "doi": "10.1016/j.brainresbull.2024.111154", "year": 2024 } ], "bc": [ { "pmid": "41199372", "title": "Multi-omics-based decoding of circulating biomarkers in amyotrophic lateral sclerosis and risks in environmental toxins", "doi": "10.1186/s40360-025-01024-9", "year": 2025 } ] } }, { "id": 3885, "drug": "curcumin", "drug_type": "drug", "drug_domain": "alzheimer", "predicate_ab": "binds_to", "mediator": "TDP-43", "mediator_type": "protein", "predicate_bc": "causes", "outcome": "RNA instability", "outcome_type": "phenotype", "outcome_domain": "als", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "curcumin", "mediator_canonical": "TDP-43", "outcome_canonical": "rna instability", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "30092839", "title": "Different curcumin forms selectively bind fibrillar amyloid beta in post mortem Alzheimer’s disease brains: Implications for in-vivo diagnostics", "doi": "10.1186/s40478-018-0577-2", "year": 2018 } ], "bc": [ { "pmid": "30030424", "title": "Abnormal RNA stability in amyotrophic lateral sclerosis", "doi": "10.1038/s41467-018-05049-z", "year": 2018 } ] } }, { "id": 57224, "drug": "Curcumin", "drug_type": "drug", "drug_domain": "pancreatic_cancer", "predicate_ab": "inhibits", "mediator": "Akt", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "cardiovascular aging", "outcome_type": "phenotype", "outcome_domain": "heart_failure", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "30542713", "title": "Curcumin attenuates hyperglycemia-driven EGF-induced invasive and migratory abilities of pancreatic cancer via suppression of the ERK and AKT pathways", "doi": "10.3892/or.2018.6833", "year": 2018 } ], "bc": [ { "pmid": "41194190", "title": "Cellular senescence and cell therapy in cardiovascular diseases", "doi": "10.1186/s13287-025-04731-6", "year": 2025 } ] } }, { "id": 3883, "drug": "curcumin", "drug_type": "drug", "drug_domain": "alzheimer", "predicate_ab": "binds_to", "mediator": "TDP-43", "mediator_type": "protein", "predicate_bc": "causes", "outcome": "presynaptic dysfunction", "outcome_type": "phenotype", "outcome_domain": "als", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "curcumin", "mediator_canonical": "TDP-43", "outcome_canonical": "presynaptic dysfunction", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "30092839", "title": "Different curcumin forms selectively bind fibrillar amyloid beta in post mortem Alzheimer’s disease brains: Implications for in-vivo diagnostics", "doi": "10.1186/s40478-018-0577-2", "year": 2018 } ], "bc": [ { "pmid": "38026702", "title": "Neuronal models of TDP-43 proteinopathy display reduced axonal translation, increased oxidative stress, and defective exocytosis", "doi": "10.3389/fncel.2023.1253543", "year": 2023 } ] } }, { "id": 3882, "drug": "curcumin", "drug_type": "drug", "drug_domain": "alzheimer", "predicate_ab": "binds_to", "mediator": "TDP-43", "mediator_type": "protein", "predicate_bc": "increases", "outcome": "cell cycle arrest at G2/M phase", "outcome_type": "phenotype", "outcome_domain": "als", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "curcumin", "mediator_canonical": "TDP-43", "outcome_canonical": "cell cycle arrest at g2/m phase", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "30092839", "title": "Different curcumin forms selectively bind fibrillar amyloid beta in post mortem Alzheimer’s disease brains: Implications for in-vivo diagnostics", "doi": "10.1186/s40478-018-0577-2", "year": 2018 } ], "bc": [ { "pmid": "31888078", "title": "TDP-43-Mediated Toxicity in HEK293T Cells: A Fast and Reproducible Protocol To Be Employed in the Search of New Therapeutic Options against Amyotrophic Lateral Sclerosis", "doi": "10.3390/cells9010068", "year": 2019 } ] } }, { "id": 3869, "drug": "curcumin", "drug_type": "drug", "drug_domain": "alzheimer", "predicate_ab": "downregulates", "mediator": "amyloid-beta", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "Parkinson's disease", "outcome_type": "disease", "outcome_domain": "als", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "completed", "clinical_trial_nct_ids": [ "NCT02445651" ], "literature_status": "reproduces_known", "drug_canonical": "curcumin", "mediator_canonical": "amyloid-beta", "outcome_canonical": "Parkinson disease", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "31089060", "title": "miR-15b-5p targeting amyloid precursor protein is involved in the anti-amyloid eflect of curcumin in swAPP695-HEK293 cells", "doi": "10.4103/1673-5374.255979", "year": 2019 } ], "bc": [ { "pmid": "37905874", "title": "Amyloid-beta and tau protein beyond Alzheimer’s disease", "doi": "10.4103/1673-5374.386406", "year": 2023 } ] } }, { "id": 3868, "drug": "curcumin", "drug_type": "drug", "drug_domain": "alzheimer", "predicate_ab": "downregulates", "mediator": "amyloid-beta", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "cardiovascular disease", "outcome_type": "disease", "outcome_domain": "als", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "active", "clinical_trial_nct_ids": [ "NCT06055894", "NCT06595355", "NCT04731844" ], "literature_status": "reproduces_known", "drug_canonical": "curcumin", "mediator_canonical": "amyloid-beta", "outcome_canonical": "cardiovascular disease", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "31089060", "title": "miR-15b-5p targeting amyloid precursor protein is involved in the anti-amyloid eflect of curcumin in swAPP695-HEK293 cells", "doi": "10.4103/1673-5374.255979", "year": 2019 } ], "bc": [ { "pmid": "37905874", "title": "Amyloid-beta and tau protein beyond Alzheimer’s disease", "doi": "10.4103/1673-5374.386406", "year": 2023 } ] } }, { "id": 3845, "drug": "resveratrol", "drug_type": "drug", "drug_domain": "alzheimer", "predicate_ab": "upregulates", "mediator": "Sod2", "mediator_type": "gene", "predicate_bc": "causes", "outcome": "demyelination", "outcome_type": "phenotype", "outcome_domain": "als", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "resveratrol", "mediator_canonical": "sod2", "outcome_canonical": "demyelination", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "30301188", "title": "Effect of Resveratrol on Reactive Oxygen Species-Induced Cognitive Impairment in Rats with Angiotensin II-Induced Early Alzheimer’s Disease †", "doi": "10.3390/jcm7100329", "year": 2018 } ], "bc": [ { "pmid": "36470129", "title": "Neuronal deletion of MnSOD in mice leads to demyelination, inflammation and progressive paralysis that mimics phenotypes associated with progressive multiple sclerosis", "doi": "10.1016/j.redox.2022.102550", "year": 2022 } ] } }, { "id": 3837, "drug": "curcumin", "drug_type": "drug", "drug_domain": "alzheimer", "predicate_ab": "binds_to", "mediator": "TDP-43", "mediator_type": "protein", "predicate_bc": "causes", "outcome": "motor neuron degeneration", "outcome_type": "phenotype", "outcome_domain": "als", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "curcumin", "mediator_canonical": "TDP-43", "outcome_canonical": "motor neuron degeneration", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "30092839", "title": "Different curcumin forms selectively bind fibrillar amyloid beta in post mortem Alzheimer’s disease brains: Implications for in-vivo diagnostics", "doi": "10.1186/s40478-018-0577-2", "year": 2018 } ], "bc": [ { "pmid": "27570488", "title": "The Overexpression of TDP-43 Protein in the Neuron and Oligodendrocyte Cells Causes the Progressive Motor Neuron Degeneration in the SOD1 G93A Transgenic Mouse Model of Amyotrophic Lateral Sclerosis", "doi": "10.7150/ijbs.15938", "year": 2016 } ] } }, { "id": 3836, "drug": "curcumin", "drug_type": "drug", "drug_domain": "alzheimer", "predicate_ab": "binds_to", "mediator": "TDP-43", "mediator_type": "protein", "predicate_bc": "decreases", "outcome": "growth cone size", "outcome_type": "phenotype", "outcome_domain": "als", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "curcumin", "mediator_canonical": "TDP-43", "outcome_canonical": "growth cone size", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "30092839", "title": "Different curcumin forms selectively bind fibrillar amyloid beta in post mortem Alzheimer’s disease brains: Implications for in-vivo diagnostics", "doi": "10.1186/s40478-018-0577-2", "year": 2018 } ], "bc": [ { "pmid": "29787572", "title": "TDP-43 causes neurotoxicity and cytoskeletal dysfunction in primary cortical neurons", "doi": "10.1371/journal.pone.0196528", "year": 2018 } ] } }, { "id": 44185, "drug": "resveratrol", "drug_type": "drug", "drug_domain": "alzheimer", "predicate_ab": "upregulates", "mediator": "Sod2", "mediator_type": "gene", "predicate_bc": "associated_with", "outcome": "clinical course", "outcome_type": "phenotype", "outcome_domain": "inflammatory_bowel_disease", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "30301188", "title": "Effect of Resveratrol on Reactive Oxygen Species-Induced Cognitive Impairment in Rats with Angiotensin II-Induced Early Alzheimer’s Disease †", "doi": "10.3390/jcm7100329", "year": 2018 } ], "bc": [ { "pmid": "32410873", "title": "Gene Expression Profiling of Mediators Associated with the Inflammatory Pathways in the Intestinal Tissue from Patients with Ulcerative Colitis", "doi": "10.1155/2020/9238970", "year": 2020 } ] } }, { "id": 3835, "drug": "curcumin", "drug_type": "drug", "drug_domain": "alzheimer", "predicate_ab": "binds_to", "mediator": "TDP-43", "mediator_type": "protein", "predicate_bc": "decreases", "outcome": "axonal transport", "outcome_type": "phenotype", "outcome_domain": "als", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "curcumin", "mediator_canonical": "TDP-43", "outcome_canonical": "axonal transport", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "30092839", "title": "Different curcumin forms selectively bind fibrillar amyloid beta in post mortem Alzheimer’s disease brains: Implications for in-vivo diagnostics", "doi": "10.1186/s40478-018-0577-2", "year": 2018 } ], "bc": [ { "pmid": "29787572", "title": "TDP-43 causes neurotoxicity and cytoskeletal dysfunction in primary cortical neurons", "doi": "10.1371/journal.pone.0196528", "year": 2018 } ] } }, { "id": 3815, "drug": "resveratrol", "drug_type": "drug", "drug_domain": "alzheimer", "predicate_ab": "upregulates", "mediator": "Sod2", "mediator_type": "gene", "predicate_bc": "increases", "outcome": "blood brain barrier permeability", "outcome_type": "phenotype", "outcome_domain": "als", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "resveratrol", "mediator_canonical": "sod2", "outcome_canonical": "blood brain barrier permeability", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "30301188", "title": "Effect of Resveratrol on Reactive Oxygen Species-Induced Cognitive Impairment in Rats with Angiotensin II-Induced Early Alzheimer’s Disease †", "doi": "10.3390/jcm7100329", "year": 2018 } ], "bc": [ { "pmid": "36470129", "title": "Neuronal deletion of MnSOD in mice leads to demyelination, inflammation and progressive paralysis that mimics phenotypes associated with progressive multiple sclerosis", "doi": "10.1016/j.redox.2022.102550", "year": 2022 } ] } }, { "id": 3763, "drug": "hydroxychloroquine", "drug_type": "drug", "drug_domain": "alzheimer", "predicate_ab": "inhibits", "mediator": "STAT3", "mediator_type": "protein", "predicate_bc": "prevents", "outcome": "general cell loss", "outcome_type": "phenotype", "outcome_domain": "epilepsy", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "hydroxychloroquine", "mediator_canonical": "STAT3", "outcome_canonical": "general cell loss", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "36577843", "title": "Hydroxychloroquine lowers Alzheimer’s disease and related dementias risk and rescues molecular phenotypes related to Alzheimer’s disease", "doi": "10.1038/s41380-022-01912-0", "year": 2022 } ], "bc": [ { "pmid": "36825472", "title": "Blockage of STAT3 during epileptogenesis prevents GABAergic loss and imprinting of the epileptic state", "doi": "10.1093/brain/awad055", "year": 2023 } ] } }, { "id": 3736, "drug": "resveratrol", "drug_type": "drug", "drug_domain": "alzheimer", "predicate_ab": "downregulates", "mediator": "NOX2", "mediator_type": "gene", "predicate_bc": "associated_with", "outcome": "seizure susceptibility", "outcome_type": "phenotype", "outcome_domain": "epilepsy", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "resveratrol", "mediator_canonical": "nox2", "outcome_canonical": "seizure susceptibility", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "30301188", "title": "Effect of Resveratrol on Reactive Oxygen Species-Induced Cognitive Impairment in Rats with Angiotensin II-Induced Early Alzheimer’s Disease †", "doi": "10.3390/jcm7100329", "year": 2018 } ], "bc": [ { "pmid": "40345502", "title": "Targeting NOX2 mitigates seizure susceptibility, oxidative stress, and neuroinflammation in the pentylenetetrazol seizure model", "doi": "10.1016/j.freeradbiomed.2025.05.386", "year": 2025 } ] } }, { "id": 3336, "drug": "curcumin", "drug_type": "drug", "drug_domain": "als", "predicate_ab": "inhibits", "mediator": "caspase-3", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "inflammatory peritumoral infiltration", "outcome_type": "phenotype", "outcome_domain": "pancreatic_cancer", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "curcumin", "mediator_canonical": "CASP3", "outcome_canonical": "inflammatory peritumoral infiltration", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "26064904", "title": "Implication of Caspase-3 as a Common Therapeutic Target for Multineurodegenerative Disorders and Its Inhibition Using Nonpeptidyl Natural Compounds", "doi": "10.1155/2015/379817", "year": 2015 } ], "bc": [ { "pmid": "26998093", "title": "Reduced expression of caspase-8 and cleaved caspase-3 in pancreatic ductal adenocarcinoma cells", "doi": "10.3892/ol.2016.4125", "year": 2016 } ] } }, { "id": 44176, "drug": "hydroxychloroquine", "drug_type": "drug", "drug_domain": "alzheimer", "predicate_ab": "inhibits", "mediator": "STAT3", "mediator_type": "protein", "predicate_bc": "prevents", "outcome": "DSS-induced colitis", "outcome_type": "disease", "outcome_domain": "inflammatory_bowel_disease", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "36577843", "title": "Hydroxychloroquine lowers Alzheimer’s disease and related dementias risk and rescues molecular phenotypes related to Alzheimer’s disease", "doi": "10.1038/s41380-022-01912-0", "year": 2022 } ], "bc": [ { "pmid": "33673239", "title": "STAT3 Signalling via the IL-6ST/gp130 Cytokine Receptor Promotes Epithelial Integrity and Intestinal Barrier Function during DSS-Induced Colitis", "doi": "10.3390/biomedicines9020187", "year": 2021 } ] } }, { "id": 3327, "drug": "niclosamide", "drug_type": "drug", "drug_domain": "als", "predicate_ab": "inhibits", "mediator": "STAT3", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "immune escape", "outcome_type": "phenotype", "outcome_domain": "pancreatic_cancer", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "niclosamide", "mediator_canonical": "STAT3", "outcome_canonical": "immune escape", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "38493058", "title": "Neuroprotective effects of niclosamide on disease progression via inflammatory pathways modulation in SOD1-G93A and FUS-associated amyotrophic lateral sclerosis models", "doi": "10.1016/j.neurot.2024.e00346", "year": 2024 } ], "bc": [ { "pmid": "38464736", "title": "Role of STAT3 in pancreatic cancer", "doi": "10.37349/etat.2024.00202", "year": 2024 } ] } }, { "id": 3304, "drug": "niclosamide", "drug_type": "drug", "drug_domain": "als", "predicate_ab": "downregulates", "mediator": "α-SMA", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "grade I pancreatic cancer", "outcome_type": "disease", "outcome_domain": "pancreatic_cancer", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "niclosamide", "mediator_canonical": "α-sma", "outcome_canonical": "grade i pancreatic cancer", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "34118929", "title": "Targeting S100A4 with niclosamide attenuates inflammatory and profibrotic pathways in models of amyotrophic lateral sclerosis", "doi": "10.1186/s12974-021-02184-1", "year": 2021 } ], "bc": [ { "pmid": "32143178", "title": "Uncovering Differently Expressed Markers and Heterogeneity on Human Pancreatic Cancer", "doi": "10.1016/j.tranon.2020.100749", "year": 2020 } ] } }, { "id": 3272, "drug": "Riluzole", "drug_type": "drug", "drug_domain": "als", "predicate_ab": "activates", "mediator": "p53", "mediator_type": "protein", "predicate_bc": "increases", "outcome": "lysophospholipid levels", "outcome_type": "phenotype", "outcome_domain": "pancreatic_cancer", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "riluzole", "mediator_canonical": "TP53", "outcome_canonical": "lysophospholipid levels", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "32231713", "title": "Riluzole Enhances the Response of Human Nasopharyngeal Carcinoma Cells to Ionizing Radiation via ATM/P53 Signalling Pathway", "doi": "10.7150/jca.41217", "year": 2020 } ], "bc": [ { "pmid": "35255936", "title": "p53-driven lipidome influences non-cell-autonomous lysophospholipids in pancreatic cancer", "doi": "10.1186/s13062-022-00319-9", "year": 2022 } ] } }, { "id": 3254, "drug": "niclosamide", "drug_type": "drug", "drug_domain": "als", "predicate_ab": "inhibits", "mediator": "STAT3", "mediator_type": "protein", "predicate_bc": "treats", "outcome": "cognitive deficits", "outcome_type": "phenotype", "outcome_domain": "alzheimer", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "niclosamide", "mediator_canonical": "STAT3", "outcome_canonical": "cognitive deficits", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "38493058", "title": "Neuroprotective effects of niclosamide on disease progression via inflammatory pathways modulation in SOD1-G93A and FUS-associated amyotrophic lateral sclerosis models", "doi": "10.1016/j.neurot.2024.e00346", "year": 2024 } ], "bc": [ { "pmid": "33859760", "title": "STAT3 ameliorates cognitive deficits via regulation of NMDAR expression in an Alzheimer's disease animal model", "doi": "10.7150/thno.56541", "year": 2021 } ] } }, { "id": 3055, "drug": "Riluzole", "drug_type": "drug", "drug_domain": "als", "predicate_ab": "downregulates", "mediator": "PI3K/AKT", "mediator_type": "pathway", "predicate_bc": "associated_with", "outcome": "PNES", "outcome_type": "disease", "outcome_domain": "epilepsy", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "riluzole", "mediator_canonical": "pi3k/akt", "outcome_canonical": "pnes", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "29453787", "title": "A phase II trial of riluzole, an antagonist of metabotropic glutamate receptor 1 (GRM1) signaling, in patients with advanced melanoma", "doi": "10.1111/pcmr.12694", "year": 2018 } ], "bc": [ { "pmid": "37252132", "title": "A systems biology approach for discovering the cellular and molecular aspects of psychogenic non-epileptic seizure", "doi": "10.3389/fpsyt.2023.1116892", "year": 2023 } ] } }, { "id": 44116, "drug": "hydroxychloroquine", "drug_type": "drug", "drug_domain": "alzheimer", "predicate_ab": "inhibits", "mediator": "STAT3", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "UC", "outcome_type": "disease", "outcome_domain": "inflammatory_bowel_disease", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "36577843", "title": "Hydroxychloroquine lowers Alzheimer’s disease and related dementias risk and rescues molecular phenotypes related to Alzheimer’s disease", "doi": "10.1038/s41380-022-01912-0", "year": 2022 } ], "bc": [ { "pmid": "36857861", "title": "Therapeutic targets for inflammatory bowel disease: proteome-wide Mendelian randomization and colocalization analyses", "doi": "10.1016/j.ebiom.2023.104494", "year": 2023 } ] } }, { "id": 3040, "drug": "niclosamide", "drug_type": "drug", "drug_domain": "als", "predicate_ab": "inhibits", "mediator": "STAT3", "mediator_type": "protein", "predicate_bc": "prevents", "outcome": "persistence of reactive glial states", "outcome_type": "phenotype", "outcome_domain": "epilepsy", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "niclosamide", "mediator_canonical": "STAT3", "outcome_canonical": "persistence of reactive glial states", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "38493058", "title": "Neuroprotective effects of niclosamide on disease progression via inflammatory pathways modulation in SOD1-G93A and FUS-associated amyotrophic lateral sclerosis models", "doi": "10.1016/j.neurot.2024.e00346", "year": 2024 } ], "bc": [ { "pmid": "36825472", "title": "Blockage of STAT3 during epileptogenesis prevents GABAergic loss and imprinting of the epileptic state", "doi": "10.1093/brain/awad055", "year": 2023 } ] } }, { "id": 3028, "drug": "niclosamide", "drug_type": "drug", "drug_domain": "als", "predicate_ab": "inhibits", "mediator": "STAT3", "mediator_type": "protein", "predicate_bc": "prevents", "outcome": "GABAergic neuron loss", "outcome_type": "phenotype", "outcome_domain": "epilepsy", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "niclosamide", "mediator_canonical": "STAT3", "outcome_canonical": "gabaergic neuron loss", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "38493058", "title": "Neuroprotective effects of niclosamide on disease progression via inflammatory pathways modulation in SOD1-G93A and FUS-associated amyotrophic lateral sclerosis models", "doi": "10.1016/j.neurot.2024.e00346", "year": 2024 } ], "bc": [ { "pmid": "36825472", "title": "Blockage of STAT3 during epileptogenesis prevents GABAergic loss and imprinting of the epileptic state", "doi": "10.1093/brain/awad055", "year": 2023 } ] } }, { "id": 2739, "drug": "valproic acid", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "downregulates", "mediator": "BDNF", "mediator_type": "protein", "predicate_bc": "increases", "outcome": "neurogenesis", "outcome_type": "phenotype", "outcome_domain": "depression", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "valproic acid", "mediator_canonical": "BDNF", "outcome_canonical": "neurogenesis", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "35465089", "title": "Excitatory and Inhibitory Synaptic Imbalance Caused by Brain-Derived Neurotrophic Factor Deficits During Development in a Valproic Acid Mouse Model of Autism", "doi": "10.3389/fnmol.2022.860275", "year": 2022 } ], "bc": [ { "pmid": "36062024", "title": "Intranasal Administration of Brain-Derived Neurotrophic Factor Rescues Depressive-Like Phenotypes in Chronic Unpredictable Mild Stress Mice", "doi": "10.2147/ndt.s369412", "year": 2022 } ] } }, { "id": 2971, "drug": "Riluzole", "drug_type": "drug", "drug_domain": "als", "predicate_ab": "activates", "mediator": "ATM", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "autism", "outcome_type": "disease", "outcome_domain": "epilepsy", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "completed", "clinical_trial_nct_ids": [ "NCT02081027", "NCT01661855", "NCT00251303" ], "literature_status": "reproduces_known", "drug_canonical": "riluzole", "mediator_canonical": "atm", "outcome_canonical": "autism", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "32231713", "title": "Riluzole Enhances the Response of Human Nasopharyngeal Carcinoma Cells to Ionizing Radiation via ATM/P53 Signalling Pathway", "doi": "10.7150/jca.41217", "year": 2020 } ], "bc": [ { "pmid": "33373327", "title": "The DNA repair protein ATM as a target in autism spectrum disorder", "doi": "10.1172/jci.insight.133654", "year": 2020 } ] } }, { "id": 44044, "drug": "Curcumin", "drug_type": "drug", "drug_domain": "alzheimer", "predicate_ab": "upregulates", "mediator": "BDNF", "mediator_type": "protein", "predicate_bc": "treats", "outcome": "septic myocardial dysfunction", "outcome_type": "disease", "outcome_domain": "heart_failure", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "38791161", "title": "Curcumin Improves Neurogenesis in Alzheimer’s Disease Mice via the Upregulation of Wnt/β-Catenin and BDNF", "doi": "10.3390/ijms25105123", "year": 2024 } ], "bc": [ { "pmid": "28770018", "title": "Brain‐Derived Neurotrophic Factor Attenuates Septic Myocardial Dysfunction via eNOS/NO Pathway in Rats", "doi": "10.1155/2017/1721434", "year": 2017 } ] } }, { "id": 43999, "drug": "resveratrol", "drug_type": "drug", "drug_domain": "alzheimer", "predicate_ab": "downregulates", "mediator": "NOX2", "mediator_type": "gene", "predicate_bc": "causes", "outcome": "telomere shortening", "outcome_type": "phenotype", "outcome_domain": "heart_failure", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "30301188", "title": "Effect of Resveratrol on Reactive Oxygen Species-Induced Cognitive Impairment in Rats with Angiotensin II-Induced Early Alzheimer’s Disease †", "doi": "10.3390/jcm7100329", "year": 2018 } ], "bc": [ { "pmid": "35862118", "title": "Telomere Shortening in Hypertensive Heart Disease Depends on Oxidative DNA Damage and Predicts Impaired Recovery of Cardiac Function in Heart Failure", "doi": "10.1161/hypertensionaha.121.18935", "year": 2022 } ] } }, { "id": 43998, "drug": "resveratrol", "drug_type": "drug", "drug_domain": "alzheimer", "predicate_ab": "downregulates", "mediator": "NOX2", "mediator_type": "gene", "predicate_bc": "associated_with", "outcome": "alcoholic cardiomyopathy", "outcome_type": "disease", "outcome_domain": "heart_failure", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "30301188", "title": "Effect of Resveratrol on Reactive Oxygen Species-Induced Cognitive Impairment in Rats with Angiotensin II-Induced Early Alzheimer’s Disease †", "doi": "10.3390/jcm7100329", "year": 2018 } ], "bc": [ { "pmid": "27624556", "title": "NOX2 amplifies acetaldehyde-mediated cardiomyocyte mitochondrial dysfunction in alcoholic cardiomyopathy", "doi": "10.1038/srep32554", "year": 2016 } ] } }, { "id": 16754, "drug": "apigenin", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "upregulates", "mediator": "GFAP", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "cold pain threshold", "outcome_type": "phenotype", "outcome_domain": "als", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "apigenin", "mediator_canonical": "GFAP", "outcome_canonical": "cold pain threshold", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41090780", "title": "Apigenin Induces Autophagy and Apoptosis in Chemoresistant Glioblastoma Cells and Inhibits Tumorigenicity Associated with Regulation of Immunomodulatory Proteins and Glial Cells Response", "doi": "10.3390/cells14191552", "year": 2025 } ], "bc": [ { "pmid": "40192786", "title": "Glial fibrillary acidic protein: a potential biomarker for small fiber neuropathy?", "doi": "10.1007/s00592-025-02500-8", "year": 2025 } ] } }, { "id": 43995, "drug": "resveratrol", "drug_type": "drug", "drug_domain": "alzheimer", "predicate_ab": "upregulates", "mediator": "SIRT1", "mediator_type": "gene", "predicate_bc": "decreases", "outcome": "oxidative stress injury", "outcome_type": "phenotype", "outcome_domain": "heart_failure", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "33381265", "title": "Resveratrol Mitigates Hippocampal Tau Acetylation and Cognitive Deficit by Activation SIRT1 in Aged Rats following Anesthesia and Surgery", "doi": "10.1155/2020/4635163", "year": 2020 } ], "bc": [ { "pmid": "29288528", "title": "Overexpression of miR‐22 attenuates oxidative stress injury in diabetic cardiomyopathy via Sirt 1", "doi": "10.1111/1755-5922.12318", "year": 2017 } ] } }, { "id": 2868, "drug": "valproic acid", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "downregulates", "mediator": "BDNF", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "depressive symptoms", "outcome_type": "phenotype", "outcome_domain": "depression", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "completed", "clinical_trial_nct_ids": [ "NCT00581009", "NCT00183443", "NCT02593643" ], "literature_status": "reproduces_known", "drug_canonical": "valproic acid", "mediator_canonical": "BDNF", "outcome_canonical": "depressive symptoms", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "35465089", "title": "Excitatory and Inhibitory Synaptic Imbalance Caused by Brain-Derived Neurotrophic Factor Deficits During Development in a Valproic Acid Mouse Model of Autism", "doi": "10.3389/fnmol.2022.860275", "year": 2022 } ], "bc": [ { "pmid": "29898192", "title": "Effects of cognitive-behavioral therapy on neurotrophic factors in patients with major depressive disorder", "doi": "10.1590/1516-4446-2017-2357", "year": 2018 } ] } }, { "id": 9675, "drug": "resveratrol", "drug_type": "drug", "drug_domain": "pancreatic_cancer", "predicate_ab": "upregulates", "mediator": "PTEN", "mediator_type": "gene", "predicate_bc": "associated_with", "outcome": "cerebral overgrowth", "outcome_type": "phenotype", "outcome_domain": "epilepsy", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "resveratrol", "mediator_canonical": "PTEN", "outcome_canonical": "cerebral overgrowth", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "29854071", "title": "Resveratrol Inhibits ROS‐Promoted Activation and Glycolysis of Pancreatic Stellate Cells via Suppression of miR‐21", "doi": "10.1155/2018/1346958", "year": 2018 } ], "bc": [ { "pmid": "34048549", "title": "PTEN somatic mutations contribute to spectrum of cerebral overgrowth", "doi": "10.1093/brain/awab173", "year": 2021 } ] } }, { "id": 2813, "drug": "valproate", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "downregulates", "mediator": "COX-2", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "poor antidepressant efficacy", "outcome_type": "phenotype", "outcome_domain": "depression", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "valproic acid", "mediator_canonical": "cox-2", "outcome_canonical": "poor antidepressant efficacy", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "32054883", "title": "Downregulation of peripheral PTGS2/COX-2 in response to valproate treatment in patients with epilepsy", "doi": "10.1038/s41598-020-59259-x", "year": 2020 } ], "bc": [ { "pmid": "40258421", "title": "Dysregulation of peripheral oxidative stress and the Nrf2 antioxidant system in Major Depressive Disorder", "doi": "10.1016/j.jad.2025.04.066", "year": 2025 } ] } }, { "id": 2805, "drug": "valproic acid", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "downregulates", "mediator": "BDNF", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "language function", "outcome_type": "phenotype", "outcome_domain": "depression", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "valproic acid", "mediator_canonical": "BDNF", "outcome_canonical": "language function", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "35465089", "title": "Excitatory and Inhibitory Synaptic Imbalance Caused by Brain-Derived Neurotrophic Factor Deficits During Development in a Valproic Acid Mouse Model of Autism", "doi": "10.3389/fnmol.2022.860275", "year": 2022 } ], "bc": [ { "pmid": "39911552", "title": "Association of inflammation cytokines with cognitive function in first-episode major depressive disorder", "doi": "10.3389/fpsyt.2024.1473418", "year": 2025 } ] } }, { "id": 24999, "drug": "riluzole", "drug_type": "drug", "drug_domain": "als", "predicate_ab": "activates", "mediator": "p53", "mediator_type": "protein", "predicate_bc": "predicts", "outcome": "colorectal neoplasia risk", "outcome_type": "disease", "outcome_domain": "inflammatory_bowel_disease", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "riluzole", "mediator_canonical": "TP53", "outcome_canonical": "colorectal neoplasia risk", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "32231713", "title": "Riluzole Enhances the Response of Human Nasopharyngeal Carcinoma Cells to Ionizing Radiation via ATM/P53 Signalling Pathway", "doi": "10.7150/jca.41217", "year": 2020 } ], "bc": [ { "pmid": "26063242", "title": "Overexpression of p53 predicts colorectal neoplasia risk in patients with inflammatory bowel disease and mucosa changes indefinite for dysplasia", "doi": "10.1093/gastro/gov022", "year": 2015 } ] } }, { "id": 24988, "drug": "riluzole", "drug_type": "drug", "drug_domain": "als", "predicate_ab": "downregulates", "mediator": "MMP-2", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "Crohn's disease", "outcome_type": "disease", "outcome_domain": "inflammatory_bowel_disease", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "riluzole", "mediator_canonical": "MMP2", "outcome_canonical": "crohn's disease", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40012807", "title": "Investigation of the Neuroprotective Effect of Riluzole on Matrix Metalloproteinases in an Experimental Model of Glaucoma", "doi": "10.4103/joco.joco_290_23", "year": 2024 } ], "bc": [ { "pmid": "27034654", "title": "Expressions of Matrix Metalloproteinases (MMP-2, MMP-7, and MMP-9) and Their Inhibitors (TIMP-1, TIMP-2) in Inflammatory Bowel Diseases", "doi": "10.1155/2016/2456179", "year": 2016 } ] } }, { "id": 25097, "drug": "sunitinib", "drug_type": "drug", "drug_domain": "als", "predicate_ab": "inhibits", "mediator": "STAT3", "mediator_type": "protein", "predicate_bc": "prevents", "outcome": "DSS-induced colitis", "outcome_type": "disease", "outcome_domain": "inflammatory_bowel_disease", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "sunitinib", "mediator_canonical": "STAT3", "outcome_canonical": "dss-induced colitis", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "38914173", "title": "Sunitinib-mediated inhibition of STAT3 in skeletal muscle and spinal cord does not affect the disease in a mouse model of ALS", "doi": "10.1016/j.nbd.2024.106576", "year": 2024 } ], "bc": [ { "pmid": "33673239", "title": "STAT3 Signalling via the IL-6ST/gp130 Cytokine Receptor Promotes Epithelial Integrity and Intestinal Barrier Function during DSS-Induced Colitis", "doi": "10.3390/biomedicines9020187", "year": 2021 } ] } }, { "id": 25025, "drug": "riluzole", "drug_type": "drug", "drug_domain": "als", "predicate_ab": "downregulates", "mediator": "MMP-9", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "Paris Classification", "outcome_type": "phenotype", "outcome_domain": "inflammatory_bowel_disease", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "riluzole", "mediator_canonical": "MMP9", "outcome_canonical": "paris classification", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40012807", "title": "Investigation of the Neuroprotective Effect of Riluzole on Matrix Metalloproteinases in an Experimental Model of Glaucoma", "doi": "10.4103/joco.joco_290_23", "year": 2024 } ], "bc": [ { "pmid": "35566780", "title": "Are Matrix Metalloproteinase-9 and Tissue Inhibitor of Metalloproteinase-1 Useful as Markers in Diagnostic Management of Children with Newly Diagnosed Ulcerative Colitis?", "doi": "10.3390/jcm11092655", "year": 2022 } ] } }, { "id": 2979, "drug": "curcumin", "drug_type": "drug", "drug_domain": "als", "predicate_ab": "inhibits", "mediator": "caspase-3", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "drug-resistant epilepsy", "outcome_type": "disease", "outcome_domain": "epilepsy", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "curcumin", "mediator_canonical": "CASP3", "outcome_canonical": "drug-resistant epilepsy", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "26064904", "title": "Implication of Caspase-3 as a Common Therapeutic Target for Multineurodegenerative Disorders and Its Inhibition Using Nonpeptidyl Natural Compounds", "doi": "10.1155/2015/379817", "year": 2015 } ], "bc": [ { "pmid": "37833937", "title": "Expression of Cytoskeletal Proteins (GFAP, Vimentin), Proapoptotic Protein (Caspase-3) and Protective Protein (S100) in the Epileptic Focus in Adults and Children with Drug-Resistant Temporal Lobe Epilepsy Associated with Focal Cortical Dysplasia", "doi": "10.3390/ijms241914490", "year": 2023 } ] } }, { "id": 41305, "drug": "riluzole", "drug_type": "drug", "drug_domain": "als", "predicate_ab": "upregulates", "mediator": "EAAT2", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "dementia", "outcome_type": "disease", "outcome_domain": "alzheimer", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "39806490", "title": "CEST imaging combined with 1H-MRS reveal the neuroprotective effects of riluzole by improving neurotransmitter imbalances in Alzheimer’s disease mice", "doi": "10.1186/s13195-025-01672-3", "year": 2025 } ], "bc": [ { "pmid": "29343737", "title": "Moderate decline in select synaptic markers in the prefrontal cortex (BA9) of patients with Alzheimer’s disease at various cognitive stages", "doi": "10.1038/s41598-018-19154-y", "year": 2018 } ] } }, { "id": 23947, "drug": "curcumin", "drug_type": "drug", "drug_domain": "multiple_sclerosis", "predicate_ab": "upregulates", "mediator": "Foxp3", "mediator_type": "gene", "predicate_bc": "associated_with", "outcome": "good prognosis", "outcome_type": "phenotype", "outcome_domain": "pancreatic_cancer", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "curcumin", "mediator_canonical": "foxp3", "outcome_canonical": "good prognosis", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "38566376", "title": "Immunoregulatory Effects of the Active Form of Vitamin D (Calcitriol),Individually and in Combination with Curcumin, on Peripheral BloodMononuclear Cells (PBMCs) of Multiple Sclerosis (MS) Patients", "doi": "10.2174/0118715230293847240314073359", "year": 2024 } ], "bc": [ { "pmid": "31381571", "title": "Tumour infiltrating lymphocytes and immune-related genes as predictors of outcome in pancreatic adenocarcinoma", "doi": "10.1371/journal.pone.0219566", "year": 2019 } ] } }, { "id": 1789, "drug": "auraptene", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "downregulates", "mediator": "MMP-9", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "recent suicide attempt", "outcome_type": "phenotype", "outcome_domain": "depression", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "auraptene", "mediator_canonical": "MMP9", "outcome_canonical": "recent suicide attempt", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "39086858", "title": "Auraptene inhibits migration, invasion and metastatic behavior of human malignant glioblastoma cells: An in vitro and in silico study.", "doi": "10.22038/ajp.2023.23586", "year": 2024 } ], "bc": [ { "pmid": "41561479", "title": "Levels of matrix metalloproteinase 9 (MMP-9) are elevated in persons with major depressive disorder who have had a recent suicide attempt", "doi": "10.1016/j.bbih.2025.101163", "year": 2025 } ] } }, { "id": 17552, "drug": "apigenin", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "upregulates", "mediator": "GFAP", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "multiple sclerosis progression", "outcome_type": "disease", "outcome_domain": "multiple_sclerosis", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "apigenin", "mediator_canonical": "GFAP", "outcome_canonical": "multiple sclerosis progression", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41090780", "title": "Apigenin Induces Autophagy and Apoptosis in Chemoresistant Glioblastoma Cells and Inhibits Tumorigenicity Associated with Regulation of Immunomodulatory Proteins and Glial Cells Response", "doi": "10.3390/cells14191552", "year": 2025 } ], "bc": [ { "pmid": "39575964", "title": "Glial fibrillary acidic protein: is there a relationship with the course of multiple sclerosis and traumatic brain injury before the onset of multiple sclerosis?", "doi": "10.17116/jnevro202412410180", "year": 2024 } ] } }, { "id": 2794, "drug": "valproic acid", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "downregulates", "mediator": "pdyn", "mediator_type": "gene", "predicate_bc": "associated_with", "outcome": "depressive symptoms", "outcome_type": "phenotype", "outcome_domain": "depression", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "completed", "clinical_trial_nct_ids": [ "NCT00581009", "NCT00183443", "NCT02593643" ], "literature_status": "reproduces_known", "drug_canonical": "valproic acid", "mediator_canonical": "pdyn", "outcome_canonical": "depressive symptoms", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "31978376", "title": "Prenatal exposure to valproic acid reduces social responses and alters mRNA levels of opioid receptor and pre-pro-peptide in discrete brain regions of adolescent and adult male rats", "doi": "10.1016/j.brainres.2020.146675", "year": 2020 } ], "bc": [ { "pmid": "37177778", "title": "Effect of PDYN and OPRK1 polymorphisms on the risk of alcohol use disorder and the intensity of depressive symptoms", "doi": "10.1093/alcalc/agad036", "year": 2023 } ] } }, { "id": 2790, "drug": "valproic acid", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "downregulates", "mediator": "BDNF", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "visuospatial ability", "outcome_type": "phenotype", "outcome_domain": "depression", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "valproic acid", "mediator_canonical": "BDNF", "outcome_canonical": "visuospatial ability", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "35465089", "title": "Excitatory and Inhibitory Synaptic Imbalance Caused by Brain-Derived Neurotrophic Factor Deficits During Development in a Valproic Acid Mouse Model of Autism", "doi": "10.3389/fnmol.2022.860275", "year": 2022 } ], "bc": [ { "pmid": "39911552", "title": "Association of inflammation cytokines with cognitive function in first-episode major depressive disorder", "doi": "10.3389/fpsyt.2024.1473418", "year": 2025 } ] } }, { "id": 55862, "drug": "chloroquine", "drug_type": "drug", "drug_domain": "multiple_sclerosis", "predicate_ab": "upregulates", "mediator": "IL-10", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "chikungunya infection", "outcome_type": "disease", "outcome_domain": "rheumatoid_arthritis", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "32516999", "title": "Comprehensive Analysis of the Immune and Stromal Compartments of the CNS in EAE Mice Reveal Pathways by Which Chloroquine Suppresses Neuroinflammation", "doi": "10.3390/brainsci10060348", "year": 2020 } ], "bc": [ { "pmid": "35874468", "title": "Role of cytokines, chemokines, C3a, and mannose-binding lectin in the evolution of the chikungunya infection.", "doi": null, "year": 2022 } ] } }, { "id": 589, "drug": "osimertinib", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "inhibits", "mediator": "EGFR", "mediator_type": "gene", "predicate_bc": "associated_with", "outcome": "lesional focal epilepsy", "outcome_type": "disease", "outcome_domain": "epilepsy", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "osimertinib", "mediator_canonical": "EGFR", "outcome_canonical": "lesional focal epilepsy", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "31678994", "title": "Betacellulin drives therapy resistance in glioblastoma", "doi": "10.1093/neuonc/noz206", "year": 2019 } ], "bc": [ { "pmid": "39616148", "title": "Analysis of 1386 epileptogenic brain lesions reveals association with DYRK1A and EGFR", "doi": "10.1038/s41467-024-54911-w", "year": 2024 } ] } }, { "id": 2789, "drug": "valproic acid", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "downregulates", "mediator": "BDNF", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "suicide risk", "outcome_type": "phenotype", "outcome_domain": "depression", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "valproic acid", "mediator_canonical": "BDNF", "outcome_canonical": "suicide risk", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "35465089", "title": "Excitatory and Inhibitory Synaptic Imbalance Caused by Brain-Derived Neurotrophic Factor Deficits During Development in a Valproic Acid Mouse Model of Autism", "doi": "10.3389/fnmol.2022.860275", "year": 2022 } ], "bc": [ { "pmid": "32209966", "title": "Understanding the Complex of Suicide in Depression: from Research to Clinics", "doi": "10.30773/pi.2019.0171", "year": 2020 } ] } }, { "id": 2774, "drug": "valproic acid", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "downregulates", "mediator": "BDNF", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "anhedonia", "outcome_type": "phenotype", "outcome_domain": "depression", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "valproic acid", "mediator_canonical": "BDNF", "outcome_canonical": "anhedonia", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "35465089", "title": "Excitatory and Inhibitory Synaptic Imbalance Caused by Brain-Derived Neurotrophic Factor Deficits During Development in a Valproic Acid Mouse Model of Autism", "doi": "10.3389/fnmol.2022.860275", "year": 2022 } ], "bc": [ { "pmid": "32372985", "title": "Exploring Brain Derived Neurotrophic Factor and Cell Adhesion Molecules as Biomarkers for the Transdiagnostic Symptom Anhedonia in Alcohol Use Disorder and Comorbid Depression", "doi": "10.3389/fpsyt.2020.00296", "year": 2020 } ] } }, { "id": 2737, "drug": "valproic acid", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "downregulates", "mediator": "BDNF", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "depression severity (HAMD-17 score)", "outcome_type": "phenotype", "outcome_domain": "depression", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "valproic acid", "mediator_canonical": "BDNF", "outcome_canonical": "depression severity (hamd-17 score)", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "35465089", "title": "Excitatory and Inhibitory Synaptic Imbalance Caused by Brain-Derived Neurotrophic Factor Deficits During Development in a Valproic Acid Mouse Model of Autism", "doi": "10.3389/fnmol.2022.860275", "year": 2022 } ], "bc": [ { "pmid": "36860860", "title": "Association between inflammatory cytokines and symptoms of major depressive disorder in adults", "doi": "10.3389/fimmu.2023.1110775", "year": 2023 } ] } }, { "id": 8201, "drug": "resveratrol", "drug_type": "drug", "drug_domain": "als", "predicate_ab": "induces", "mediator": "PGC1α", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "cachexia", "outcome_type": "disease", "outcome_domain": "pancreatic_cancer", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "resveratrol", "mediator_canonical": "pgc1α", "outcome_canonical": "cachexia", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "26981091", "title": "How does resveratrol influence the genesis of some neurodegenerative diseases?", "doi": "10.4103/1673-5374.175047", "year": 2016 } ], "bc": [ { "pmid": "35454855", "title": "Evaluation of Browning Markers in Subcutaneous Adipose Tissue of Newly Diagnosed Gastrointestinal Cancer Patients with and without Cachexia", "doi": "10.3390/cancers14081948", "year": 2022 } ] } }, { "id": 2675, "drug": "valproic acid", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "activates", "mediator": "TGFβ signaling", "mediator_type": "pathway", "predicate_bc": "increases", "outcome": "proliferation", "outcome_type": "phenotype", "outcome_domain": "pancreatic_cancer", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "valproic acid", "mediator_canonical": "tgfβ signaling", "outcome_canonical": null, "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "30050438", "title": "Valproic Acid Induces Endothelial-to-Mesenchymal Transition-Like Phenotypic Switching", "doi": "10.3389/fphar.2018.00737", "year": 2018 } ], "bc": [ { "pmid": "32457840", "title": "TGFβ Signaling Increases Net Acid Extrusion, Proliferation and Invasion in Panc-1 Pancreatic Cancer Cells: SMAD4 Dependence and Link to Merlin/NF2 Signaling", "doi": "10.3389/fonc.2020.00687", "year": 2020 } ] } }, { "id": 7708, "drug": "sunitinib", "drug_type": "drug", "drug_domain": "als", "predicate_ab": "inhibits", "mediator": "STAT3", "mediator_type": "protein", "predicate_bc": "prevents", "outcome": "imprinting of epileptic activity patterns", "outcome_type": "phenotype", "outcome_domain": "epilepsy", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "sunitinib", "mediator_canonical": "STAT3", "outcome_canonical": "imprinting of epileptic activity patterns", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "38914173", "title": "Sunitinib-mediated inhibition of STAT3 in skeletal muscle and spinal cord does not affect the disease in a mouse model of ALS", "doi": "10.1016/j.nbd.2024.106576", "year": 2024 } ], "bc": [ { "pmid": "36825472", "title": "Blockage of STAT3 during epileptogenesis prevents GABAergic loss and imprinting of the epileptic state", "doi": "10.1093/brain/awad055", "year": 2023 } ] } }, { "id": 2736, "drug": "valproic acid", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "downregulates", "mediator": "BDNF", "mediator_type": "gene", "predicate_bc": "associated_with", "outcome": "schizophrenia spectrum disorders", "outcome_type": "disease", "outcome_domain": "depression", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "active", "clinical_trial_nct_ids": [ "NCT05603104", "NCT06729541", "NCT06993662" ], "literature_status": "partial_evidence", "drug_canonical": "valproic acid", "mediator_canonical": "BDNF", "outcome_canonical": "schizophrenia spectrum disorders", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "30404997", "title": "Social behavior, neuroimmune markers and glutamic acid decarboxylase levels in a rat model of valproic acid-induced autism", "doi": "10.2131/jts.43.631", "year": 2018 } ], "bc": [ { "pmid": "37109044", "title": "Association Study of BDNF, SLC6A4, and FTO Genetic Variants with Schizophrenia Spectrum Disorders", "doi": "10.3390/jpm13040658", "year": 2023 } ] } }, { "id": 1747, "drug": "Flubendazole", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "inhibits", "mediator": "STAT3", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "pancreatic cancer", "outcome_type": "disease", "outcome_domain": "pancreatic_cancer", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "flubendazole", "mediator_canonical": "STAT3", "outcome_canonical": "pancreatic cancer", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37045903", "title": "Flubendazole exhibits anti-glioblastoma effect by inhibiting STAT3 and promoting cell cycle arrest", "doi": "10.1038/s41598-023-33047-9", "year": 2023 } ], "bc": [ { "pmid": "26873728", "title": "Applying Small Molecule Signal Transducer and Activator of Transcription-3 (STAT3) Protein Inhibitors as Pancreatic Cancer Therapeutics", "doi": "10.1158/1535-7163.mct-15-0003", "year": 2016 } ] } }, { "id": 5666, "drug": "resveratrol", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "upregulates", "mediator": "p53", "mediator_type": "gene", "predicate_bc": "increases", "outcome": "inflammatory marker activation", "outcome_type": "phenotype", "outcome_domain": "epilepsy", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "resveratrol", "mediator_canonical": "TP53", "outcome_canonical": "inflammatory marker activation", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40802352", "title": "Resveratrol and temozolomide induce apoptosis and suppress proliferation in glioblastoma cells via the apoptotic signaling pathway", "doi": "10.1590/acb405525", "year": 2025 } ], "bc": [ { "pmid": "30546381", "title": "p53-Sensitive Epileptic Behavior and Inflammation in Ft1 Hypomorphic Mice", "doi": "10.3389/fgene.2018.00581", "year": 2018 } ] } }, { "id": 54215, "drug": "chloroquine", "drug_type": "drug", "drug_domain": "multiple_sclerosis", "predicate_ab": "upregulates", "mediator": "IL-10", "mediator_type": "protein", "predicate_bc": "prevents", "outcome": "disease onset", "outcome_type": "disease", "outcome_domain": "als", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "32516999", "title": "Comprehensive Analysis of the Immune and Stromal Compartments of the CNS in EAE Mice Reveal Pathways by Which Chloroquine Suppresses Neuroinflammation", "doi": "10.3390/brainsci10060348", "year": 2020 } ], "bc": [ { "pmid": "26791230", "title": "IL-10 Controls Early Microglial Phenotypes and Disease Onset in ALS Caused by Misfolded Superoxide Dismutase 1", "doi": "10.1523/jneurosci.0854-15.2016", "year": 2016 } ] } }, { "id": 3180, "drug": "curcumin", "drug_type": "drug", "drug_domain": "als", "predicate_ab": "inhibits", "mediator": "caspase-3", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "dendritic spine loss", "outcome_type": "phenotype", "outcome_domain": "alzheimer", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "curcumin", "mediator_canonical": "CASP3", "outcome_canonical": "dendritic spine loss", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "26064904", "title": "Implication of Caspase-3 as a Common Therapeutic Target for Multineurodegenerative Disorders and Its Inhibition Using Nonpeptidyl Natural Compounds", "doi": "10.1155/2015/379817", "year": 2015 } ], "bc": [ { "pmid": "32610140", "title": "Caspase Activation and Caspase-Mediated Cleavage of APP Is Associated with Amyloid β-Protein-Induced Synapse Loss in Alzheimer’s Disease", "doi": "10.1016/j.celrep.2020.107839", "year": 2020 } ] } }, { "id": 1730, "drug": "acriflavine", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "inhibits", "mediator": "HIF-1α", "mediator_type": "protein", "predicate_bc": "confers_resistance_to", "outcome": "radiation", "outcome_type": "phenotype", "outcome_domain": "pancreatic_cancer", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "acriflavine", "mediator_canonical": "hif-1α", "outcome_canonical": "radiation", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40405165", "title": "Photo-controlled co-delivery of verteporfin and acriflavine via platelets achieves potentiated glioblastoma-targeted photodynamic therapy", "doi": "10.1186/s12951-025-03395-x", "year": 2025 } ], "bc": [ { "pmid": "30801702", "title": "Inhibition of HSP90 overcomes resistance to chemotherapy and radiotherapy in pancreatic cancer", "doi": "10.1002/ijc.32227", "year": 2019 } ] } }, { "id": 2244, "drug": "valproic acid", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "suppresses", "mediator": "galectin-3", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "disease duration >12 months", "outcome_type": "phenotype", "outcome_domain": "als", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "valproic acid", "mediator_canonical": "LGALS3", "outcome_canonical": "disease duration >12 months", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "34122007", "title": "Post-stroke Delivery of Valproic Acid Promotes Functional Recovery and Differentially Modifies Responses of Peri-Infarct Microglia", "doi": "10.3389/fnmol.2021.639145", "year": 2021 } ], "bc": [ { "pmid": "27900991", "title": "Increased Expressions of Plasma Galectin-3 in Patients with Amyotrophic Lateral Sclerosis", "doi": "10.4103/0366-6999.194656", "year": 2016 } ] } }, { "id": 2674, "drug": "valproic acid", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "activates", "mediator": "TGFβ signaling", "mediator_type": "pathway", "predicate_bc": "increases", "outcome": "invasion", "outcome_type": "phenotype", "outcome_domain": "pancreatic_cancer", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "valproic acid", "mediator_canonical": "tgfβ signaling", "outcome_canonical": "invasion", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "30050438", "title": "Valproic Acid Induces Endothelial-to-Mesenchymal Transition-Like Phenotypic Switching", "doi": "10.3389/fphar.2018.00737", "year": 2018 } ], "bc": [ { "pmid": "32457840", "title": "TGFβ Signaling Increases Net Acid Extrusion, Proliferation and Invasion in Panc-1 Pancreatic Cancer Cells: SMAD4 Dependence and Link to Merlin/NF2 Signaling", "doi": "10.3389/fonc.2020.00687", "year": 2020 } ] } }, { "id": 26323, "drug": "Curcumin", "drug_type": "drug", "drug_domain": "alzheimer", "predicate_ab": "upregulates", "mediator": "BDNF", "mediator_type": "protein", "predicate_bc": "increases", "outcome": "remission", "outcome_type": "phenotype", "outcome_domain": "depression", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "completed", "clinical_trial_nct_ids": [ "NCT03795792", "NCT03122613", "NCT02683733" ], "literature_status": "reproduces_known", "drug_canonical": "curcumin", "mediator_canonical": "BDNF", "outcome_canonical": null, "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "38791161", "title": "Curcumin Improves Neurogenesis in Alzheimer’s Disease Mice via the Upregulation of Wnt/β-Catenin and BDNF", "doi": "10.3390/ijms25105123", "year": 2024 } ], "bc": [ { "pmid": "41584756", "title": "Employment-dependent associations of serum biomarkers with short- and long-term antidepressant treatment outcomes", "doi": "10.3389/fpsyt.2025.1662993", "year": 2026 } ] } }, { "id": 3929, "drug": "curcumin", "drug_type": "drug", "drug_domain": "alzheimer", "predicate_ab": "binds_to", "mediator": "TDP-43", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "Perry syndrome", "outcome_type": "disease", "outcome_domain": "als", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "curcumin", "mediator_canonical": "TDP-43", "outcome_canonical": "perry syndrome", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "30092839", "title": "Different curcumin forms selectively bind fibrillar amyloid beta in post mortem Alzheimer’s disease brains: Implications for in-vivo diagnostics", "doi": "10.1186/s40478-018-0577-2", "year": 2018 } ], "bc": [ { "pmid": "28789478", "title": "Perry Syndrome: A Distinctive Type of TDP-43 Proteinopathy", "doi": "10.1093/jnen/nlx049", "year": 2017 } ] } }, { "id": 3219, "drug": "niclosamide", "drug_type": "drug", "drug_domain": "als", "predicate_ab": "inhibits", "mediator": "STAT3", "mediator_type": "protein", "predicate_bc": "predicts", "outcome": "Alzheimer's disease", "outcome_type": "disease", "outcome_domain": "alzheimer", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "niclosamide", "mediator_canonical": "STAT3", "outcome_canonical": "Alzheimer disease", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "38493058", "title": "Neuroprotective effects of niclosamide on disease progression via inflammatory pathways modulation in SOD1-G93A and FUS-associated amyotrophic lateral sclerosis models", "doi": "10.1016/j.neurot.2024.e00346", "year": 2024 } ], "bc": [ { "pmid": "40745201", "title": "Uncovering active ingredients and mechanisms of Pholiota adiposa in the treatment of Alzheimer’s disease based on network pharmacology and bioinformatics", "doi": "10.1038/s41598-025-94861-x", "year": 2025 } ] } }, { "id": 42034, "drug": "riluzole", "drug_type": "drug", "drug_domain": "als", "predicate_ab": "activates", "mediator": "p53", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "coronary microvascular dysfunction", "outcome_type": "disease", "outcome_domain": "heart_failure", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "32231713", "title": "Riluzole Enhances the Response of Human Nasopharyngeal Carcinoma Cells to Ionizing Radiation via ATM/P53 Signalling Pathway", "doi": "10.7150/jca.41217", "year": 2020 } ], "bc": [ { "pmid": "38328937", "title": "p53 Acetylation Exerts Critical Roles in Pressure Overload–Induced Coronary Microvascular Dysfunction and Heart Failure in Mice", "doi": "10.1161/atvbaha.123.319601", "year": 2024 } ] } }, { "id": 2651, "drug": "valproic acid", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "downregulates", "mediator": "PKM2", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "unfavorable outcome", "outcome_type": "phenotype", "outcome_domain": "pancreatic_cancer", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "valproic acid", "mediator_canonical": "PKM", "outcome_canonical": "unfavorable outcome", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "34263655", "title": "Valproic acid Suppresses Breast Cancer Cell Growth Through Triggering Pyruvate Kinase M2 Isoform Mediated Warburg Effect", "doi": "10.1177/09636897211027524", "year": 2021 } ], "bc": [ { "pmid": "32950968", "title": "Identification of genomic alterations and associated transcriptomic profiling reveal the prognostic significance of MMP14 and PKM2 in patients with pancreatic cancer", "doi": "10.18632/aging.103958", "year": 2020 } ] } }, { "id": 54995, "drug": "luteolin", "drug_type": "drug", "drug_domain": "multiple_sclerosis", "predicate_ab": "activates", "mediator": "Nrf2 pathway", "mediator_type": "pathway", "predicate_bc": "confers_resistance_to", "outcome": "ferroptosis", "outcome_type": "phenotype", "outcome_domain": "glioblastoma", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41362005", "title": "Luteolin rescues myelin integrity and cognitive-motor function via Nrf2 pathway activation: a natural candidate vs. dimethyl fumarate in cuprizone-induced multiple sclerosis", "doi": "10.1080/1028415x.2025.2599459", "year": 2025 } ], "bc": [ { "pmid": "37879937", "title": "NRF2 connects Src tyrosine kinase to ferroptosis resistance in glioblastoma", "doi": "10.26508/lsa.202302205", "year": 2023 } ] } }, { "id": 2623, "drug": "valproic acid", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "suppresses", "mediator": "galectin-3", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "weight loss", "outcome_type": "phenotype", "outcome_domain": "pancreatic_cancer", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "valproic acid", "mediator_canonical": "LGALS3", "outcome_canonical": "weight loss", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "34122007", "title": "Post-stroke Delivery of Valproic Acid Promotes Functional Recovery and Differentially Modifies Responses of Peri-Infarct Microglia", "doi": "10.3389/fnmol.2021.639145", "year": 2021 } ], "bc": [ { "pmid": "32100478", "title": "Relationship between pancreatic cancer‐associated diabetes and cachexia", "doi": "10.1002/jcsm.12553", "year": 2020 } ] } }, { "id": 2597, "drug": "valproic acid", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "downregulates", "mediator": "PKM2", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "PDAC", "outcome_type": "disease", "outcome_domain": "pancreatic_cancer", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "valproic acid", "mediator_canonical": "PKM", "outcome_canonical": "pancreatic ductal adenocarcinoma", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "34263655", "title": "Valproic acid Suppresses Breast Cancer Cell Growth Through Triggering Pyruvate Kinase M2 Isoform Mediated Warburg Effect", "doi": "10.1177/09636897211027524", "year": 2021 } ], "bc": [ { "pmid": "32127930", "title": "The combination of PKM2 overexpression and M2 macrophages infiltration confers a poor prognosis for PDAC patients", "doi": "10.7150/jca.38981", "year": 2020 } ] } }, { "id": 2577, "drug": "valproic acid", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "downregulates", "mediator": "GLI1", "mediator_type": "gene", "predicate_bc": "decreases", "outcome": "liver cancer stem cell function", "outcome_type": "phenotype", "outcome_domain": "pancreatic_cancer", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "valproic acid", "mediator_canonical": "gli1", "outcome_canonical": "liver cancer stem cell function", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "32054823", "title": "GANT61 and Valproic Acid Synergistically Inhibited Multiple Myeloma Cell Proliferation via Hedgehog Signaling Pathway", "doi": "10.12659/msm.920541", "year": 2020 } ], "bc": [ { "pmid": "29722127", "title": "The SHH/Gli axis regulates CD90‐mediated liver cancer stem cell function by activating the IL6/JAK2 pathway", "doi": "10.1111/jcmm.13651", "year": 2018 } ] } }, { "id": 2534, "drug": "valproic acid", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "downregulates", "mediator": "PKM2", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "poor prognosis", "outcome_type": "phenotype", "outcome_domain": "pancreatic_cancer", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "valproic acid", "mediator_canonical": "PKM", "outcome_canonical": null, "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "34263655", "title": "Valproic acid Suppresses Breast Cancer Cell Growth Through Triggering Pyruvate Kinase M2 Isoform Mediated Warburg Effect", "doi": "10.1177/09636897211027524", "year": 2021 } ], "bc": [ { "pmid": "26137268", "title": "The combination of the expression of hexokinase 2 and pyruvate kinase M2 is a prognostic marker in patients with pancreatic cancer", "doi": "10.3892/mco.2015.490", "year": 2015 } ] } }, { "id": 2353, "drug": "valproate", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "downregulates", "mediator": "COX-2", "mediator_type": "protein", "predicate_bc": "increases", "outcome": "Alzheimer's disease", "outcome_type": "disease", "outcome_domain": "alzheimer", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "completed", "clinical_trial_nct_ids": [ "NCT01729598", "NCT00071721", "NCT00208819" ], "literature_status": "reproduces_known", "drug_canonical": "valproic acid", "mediator_canonical": "cox-2", "outcome_canonical": "Alzheimer disease", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "32054883", "title": "Downregulation of peripheral PTGS2/COX-2 in response to valproate treatment in patients with epilepsy", "doi": "10.1038/s41598-020-59259-x", "year": 2020 } ], "bc": [ { "pmid": "38644825", "title": "Network pharmacology-based approach to elucidate the pharmacologic mechanisms of natural compounds from Dictyostelium discoideum for Alzheimer's disease treatment", "doi": "10.1016/j.heliyon.2024.e28852", "year": 2024 } ] } }, { "id": 2274, "drug": "valproic acid", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "suppresses", "mediator": "galectin-3", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "limb onset ALS", "outcome_type": "disease", "outcome_domain": "als", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "valproic acid", "mediator_canonical": "LGALS3", "outcome_canonical": "limb onset als", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "34122007", "title": "Post-stroke Delivery of Valproic Acid Promotes Functional Recovery and Differentially Modifies Responses of Peri-Infarct Microglia", "doi": "10.3389/fnmol.2021.639145", "year": 2021 } ], "bc": [ { "pmid": "27900991", "title": "Increased Expressions of Plasma Galectin-3 in Patients with Amyotrophic Lateral Sclerosis", "doi": "10.4103/0366-6999.194656", "year": 2016 } ] } }, { "id": 3150, "drug": "Riluzole", "drug_type": "drug", "drug_domain": "als", "predicate_ab": "upregulates", "mediator": "EAAT2", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "dementia", "outcome_type": "disease", "outcome_domain": "alzheimer", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "completed", "clinical_trial_nct_ids": [ "NCT01703117", "NCT00277602" ], "literature_status": "reproduces_known", "drug_canonical": "riluzole", "mediator_canonical": "eaat2", "outcome_canonical": "dementia", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "39806490", "title": "CEST imaging combined with 1H-MRS reveal the neuroprotective effects of riluzole by improving neurotransmitter imbalances in Alzheimer’s disease mice", "doi": "10.1186/s13195-025-01672-3", "year": 2025 } ], "bc": [ { "pmid": "29343737", "title": "Moderate decline in select synaptic markers in the prefrontal cortex (BA9) of patients with Alzheimer’s disease at various cognitive stages", "doi": "10.1038/s41598-018-19154-y", "year": 2018 } ] } }, { "id": 19522, "drug": "sunitinib", "drug_type": "drug", "drug_domain": "als", "predicate_ab": "inhibits", "mediator": "STAT3", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "immune escape", "outcome_type": "phenotype", "outcome_domain": "pancreatic_cancer", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "sunitinib", "mediator_canonical": "STAT3", "outcome_canonical": "immune escape", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "38914173", "title": "Sunitinib-mediated inhibition of STAT3 in skeletal muscle and spinal cord does not affect the disease in a mouse model of ALS", "doi": "10.1016/j.nbd.2024.106576", "year": 2024 } ], "bc": [ { "pmid": "38464736", "title": "Role of STAT3 in pancreatic cancer", "doi": "10.37349/etat.2024.00202", "year": 2024 } ] } }, { "id": 19525, "drug": "resveratrol", "drug_type": "drug", "drug_domain": "als", "predicate_ab": "downregulates", "mediator": "GSK-3β", "mediator_type": "protein", "predicate_bc": "increases", "outcome": "PanIN progression", "outcome_type": "disease", "outcome_domain": "pancreatic_cancer", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "resveratrol", "mediator_canonical": "GSK3B", "outcome_canonical": "panin progression", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "26981091", "title": "How does resveratrol influence the genesis of some neurodegenerative diseases?", "doi": "10.4103/1673-5374.175047", "year": 2016 } ], "bc": [ { "pmid": "28639695", "title": "Glycogen synthase kinase‐3β ablation limits pancreatitis‐induced acinar‐to‐ductal metaplasia", "doi": "10.1002/path.4928", "year": 2017 } ] } }, { "id": 12007, "drug": "valproate", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "downregulates", "mediator": "SLC44A2", "mediator_type": "gene", "predicate_bc": "correlates_with", "outcome": "GBM progression", "outcome_type": "phenotype", "outcome_domain": "glioblastoma", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "valproic acid", "mediator_canonical": "slc44a2", "outcome_canonical": "gbm progression", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "33890297", "title": "Antiseizure medications and fetal nutrients: Effects on choline transporters in a human placental cell line", "doi": "10.1111/epi.16905", "year": 2021 } ], "bc": [ { "pmid": "37482563", "title": "Gene co-expression network construction and analysis for identification of genetic biomarkers associated with glioblastoma multiforme using topological findings", "doi": "10.1186/s43046-023-00181-4", "year": 2023 } ] } }, { "id": 19548, "drug": "Riluzole", "drug_type": "drug", "drug_domain": "als", "predicate_ab": "activates", "mediator": "p53", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "high-grade PanIN", "outcome_type": "disease", "outcome_domain": "pancreatic_cancer", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "riluzole", "mediator_canonical": "TP53", "outcome_canonical": "high-grade panin", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "32231713", "title": "Riluzole Enhances the Response of Human Nasopharyngeal Carcinoma Cells to Ionizing Radiation via ATM/P53 Signalling Pathway", "doi": "10.7150/jca.41217", "year": 2020 } ], "bc": [ { "pmid": "29660164", "title": "High‐grade PanIN presenting with localised stricture of the main pancreatic duct: A clinicopathological and molecular study of 10 cases suggests a clue for the early detection of pancreatic cancer", "doi": "10.1111/his.13629", "year": 2018 } ] } }, { "id": 8231, "drug": "Riluzole", "drug_type": "drug", "drug_domain": "als", "predicate_ab": "downregulates", "mediator": "MMP-9", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "pancreatic cancer", "outcome_type": "disease", "outcome_domain": "pancreatic_cancer", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "riluzole", "mediator_canonical": "MMP9", "outcome_canonical": "pancreatic cancer", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40012807", "title": "Investigation of the Neuroprotective Effect of Riluzole on Matrix Metalloproteinases in an Experimental Model of Glaucoma", "doi": "10.4103/joco.joco_290_23", "year": 2024 } ], "bc": [ { "pmid": "26652622", "title": "The co-expression of MMP-9 and Tenascin-C is significantly associated with the progression and prognosis of pancreatic cancer", "doi": "10.1186/s13000-015-0445-3", "year": 2015 } ] } }, { "id": 1149, "drug": "apigenin", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "upregulates", "mediator": "GFAP", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "drug-resistant epilepsy", "outcome_type": "disease", "outcome_domain": "epilepsy", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "apigenin", "mediator_canonical": "GFAP", "outcome_canonical": "drug-resistant epilepsy", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41090780", "title": "Apigenin Induces Autophagy and Apoptosis in Chemoresistant Glioblastoma Cells and Inhibits Tumorigenicity Associated with Regulation of Immunomodulatory Proteins and Glial Cells Response", "doi": "10.3390/cells14191552", "year": 2025 } ], "bc": [ { "pmid": "37833937", "title": "Expression of Cytoskeletal Proteins (GFAP, Vimentin), Proapoptotic Protein (Caspase-3) and Protective Protein (S100) in the Epileptic Focus in Adults and Children with Drug-Resistant Temporal Lobe Epilepsy Associated with Focal Cortical Dysplasia", "doi": "10.3390/ijms241914490", "year": 2023 } ] } }, { "id": 60958, "drug": "Curcumin", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "phosphorylates", "mediator": "Akt", "mediator_type": "protein", "predicate_bc": "causes", "outcome": "subclonal progression", "outcome_type": "phenotype", "outcome_domain": "glioblastoma", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "36348361", "title": "Curcumin improves insulin sensitivity in high-fat diet-fed mice through gut microbiota", "doi": "10.1186/s12986-022-00712-1", "year": 2022 } ], "bc": [ { "pmid": "36239995", "title": "A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma", "doi": "10.1158/1078-0432.ccr-22-0611", "year": 2022 } ] } }, { "id": 60936, "drug": "metformin", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "upregulates", "mediator": "Stat3", "mediator_type": "gene", "predicate_bc": "correlates_with", "outcome": "drug sensitivity", "outcome_type": "phenotype", "outcome_domain": "glioblastoma", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37573301", "title": "STAT3/LKB1 controls metastatic prostate cancer by regulating mTORC1/CREB pathway", "doi": "10.1186/s12943-023-01825-8", "year": 2023 } ], "bc": [ { "pmid": "40813603", "title": "A novel neutrophil extracellular trap-related gene signature for predicting glioblastoma prognosis", "doi": "10.1038/s41598-025-15050-4", "year": 2025 } ] } }, { "id": 60913, "drug": "metformin", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "upregulates", "mediator": "Stat3", "mediator_type": "gene", "predicate_bc": "associated_with", "outcome": "glioma invasion", "outcome_type": "phenotype", "outcome_domain": "glioblastoma", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37573301", "title": "STAT3/LKB1 controls metastatic prostate cancer by regulating mTORC1/CREB pathway", "doi": "10.1186/s12943-023-01825-8", "year": 2023 } ], "bc": [ { "pmid": "37938214", "title": "Combining organotypic tissue culture with light‐sheet microscopy ( OTCxLSFM ) to study glioma invasion", "doi": "10.15252/embr.202356964", "year": 2023 } ] } }, { "id": 60547, "drug": "Curcumin", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "downregulates", "mediator": "total cholesterol", "mediator_type": "biomarker", "predicate_bc": "associated_with", "outcome": "bipolar disorder", "outcome_type": "disease", "outcome_domain": "depression", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "31645652", "title": "Histological evidence of chitosan-encapsulated curcumin suppresses heart and kidney damages on streptozotocin-induced type-1 diabetes in mice model", "doi": "10.1038/s41598-019-51821-6", "year": 2019 } ], "bc": [ { "pmid": "37845658", "title": "A preliminary composite of blood-based biomarkers to distinguish major depressive disorder and bipolar disorder in adolescents and adults", "doi": "10.1186/s12888-023-05204-x", "year": 2023 } ] } }, { "id": 60546, "drug": "Curcumin", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "downregulates", "mediator": "total cholesterol", "mediator_type": "biomarker", "predicate_bc": "correlates_with", "outcome": "suicide attempts", "outcome_type": "phenotype", "outcome_domain": "depression", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "31645652", "title": "Histological evidence of chitosan-encapsulated curcumin suppresses heart and kidney damages on streptozotocin-induced type-1 diabetes in mice model", "doi": "10.1038/s41598-019-51821-6", "year": 2019 } ], "bc": [ { "pmid": "30844329", "title": "Estimation of IL-6, INFγ, and Lipid Profile in Suicidal and Nonsuicidal Adults with Major Depressive Disorder", "doi": "10.1089/jir.2018.0134", "year": 2019 } ] } }, { "id": 25099, "drug": "riluzole", "drug_type": "drug", "drug_domain": "als", "predicate_ab": "activates", "mediator": "p53", "mediator_type": "protein", "predicate_bc": "predicts", "outcome": "dysplasia", "outcome_type": "disease", "outcome_domain": "inflammatory_bowel_disease", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "riluzole", "mediator_canonical": "TP53", "outcome_canonical": "dysplasia", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "32231713", "title": "Riluzole Enhances the Response of Human Nasopharyngeal Carcinoma Cells to Ionizing Radiation via ATM/P53 Signalling Pathway", "doi": "10.7150/jca.41217", "year": 2020 } ], "bc": [ { "pmid": "27578918", "title": "Expression Profile of p53 and p21 in Large Bowel Mucosa as Biomarkers of Inflammatory-Related Carcinogenesis in Ulcerative Colitis", "doi": "10.1155/2016/3625279", "year": 2016 } ] } }, { "id": 60525, "drug": "Curcumin", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "downregulates", "mediator": "blood glucose", "mediator_type": "biomarker", "predicate_bc": "associated_with", "outcome": "abnormal thyroid function", "outcome_type": "disease", "outcome_domain": "depression", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "31645652", "title": "Histological evidence of chitosan-encapsulated curcumin suppresses heart and kidney damages on streptozotocin-induced type-1 diabetes in mice model", "doi": "10.1038/s41598-019-51821-6", "year": 2019 } ], "bc": [ { "pmid": "41601507", "title": "Thyroid dysfunction in elderly first-episode drug-naïve major depressive disorder patients with comorbid dyslipidemia: prevalence, clinical profile and associated factors", "doi": "10.3389/fpsyt.2025.1742901", "year": 2026 } ] } }, { "id": 5474, "drug": "fluoxetine", "drug_type": "drug", "drug_domain": "depression", "predicate_ab": "downregulates", "mediator": "TLR7", "mediator_type": "gene", "predicate_bc": "associated_with", "outcome": "good prognosis", "outcome_type": "phenotype", "outcome_domain": "pancreatic_cancer", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "fluoxetine", "mediator_canonical": "tlr7", "outcome_canonical": "good prognosis", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "31647818", "title": "Assessing the role of toll-like receptor in isolated, standard and enriched housing conditions", "doi": "10.1371/journal.pone.0222818", "year": 2019 } ], "bc": [ { "pmid": "31381571", "title": "Tumour infiltrating lymphocytes and immune-related genes as predictors of outcome in pancreatic adenocarcinoma", "doi": "10.1371/journal.pone.0219566", "year": 2019 } ] } }, { "id": 20679, "drug": "metformin", "drug_type": "drug", "drug_domain": "alzheimer", "predicate_ab": "downregulates", "mediator": "c-Myc", "mediator_type": "gene", "predicate_bc": "decreases", "outcome": "DNA damage", "outcome_type": "phenotype", "outcome_domain": "pancreatic_cancer", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "metformin", "mediator_canonical": "c-myc", "outcome_canonical": "dna damage", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "32382652", "title": "If ineffective levels of transforming growth factors and their receptor account for old age being a risk factor for Alzheimer's disease, then increasing TGFBR2 might be therapeutic", "doi": "10.1002/trc2.12019", "year": 2020 } ], "bc": [ { "pmid": "36289751", "title": "c-Myc Sustains Pancreatic Cancer Cell Survival and mutp53 Stability through the Mevalonate Pathway", "doi": "10.3390/biomedicines10102489", "year": 2022 } ] } }, { "id": 1083, "drug": "resveratrol", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "upregulates", "mediator": "p53", "mediator_type": "gene", "predicate_bc": "increases", "outcome": "seizure", "outcome_type": "disease", "outcome_domain": "epilepsy", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "resveratrol", "mediator_canonical": "TP53", "outcome_canonical": "seizure", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40802352", "title": "Resveratrol and temozolomide induce apoptosis and suppress proliferation in glioblastoma cells via the apoptotic signaling pathway", "doi": "10.1590/acb405525", "year": 2025 } ], "bc": [ { "pmid": "30546381", "title": "p53-Sensitive Epileptic Behavior and Inflammation in Ft1 Hypomorphic Mice", "doi": "10.3389/fgene.2018.00581", "year": 2018 } ] } }, { "id": 60515, "drug": "luteolin", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "downregulates", "mediator": "pro-inflammatory cytokines", "mediator_type": "biomarker", "predicate_bc": "associated_with", "outcome": "frontal theta power", "outcome_type": "phenotype", "outcome_domain": "depression", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "35778706", "title": "Luteolin alleviates inflammation and autophagy of hippocampus induced by cerebral ischemia/reperfusion by activating PPAR gamma in rats", "doi": "10.1186/s12906-022-03652-8", "year": 2022 } ], "bc": [ { "pmid": "32174860", "title": "Exploratory Analysis of Behavioral Impulsivity, Pro-inflammatory Cytokines, and Resting-State Frontal EEG Activity Associated With Non-suicidal Self-Injury in Patients With Mood Disorder", "doi": "10.3389/fpsyt.2020.00124", "year": 2020 } ] } }, { "id": 58971, "drug": "resveratrol", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "suppresses", "mediator": "TGF-β1", "mediator_type": "protein", "predicate_bc": "increases", "outcome": "cancer cell stemness", "outcome_type": "phenotype", "outcome_domain": "glioblastoma", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "38745204", "title": "Resveratrol attenuates inflammation and fibrosis in rheumatoid arthritis-associated interstitial lung disease via the AKT/TMEM175 pathway", "doi": "10.1186/s12967-024-05228-1", "year": 2024 } ], "bc": [ { "pmid": "32368136", "title": "<p>LncRNA RPSAP52 Upregulates TGF-β1 to Increase Cancer Cell Stemness and Predict Postoperative Survival in Glioblastoma</p>", "doi": "10.2147/cmar.s227496", "year": 2020 } ] } }, { "id": 8097, "drug": "Riluzole", "drug_type": "drug", "drug_domain": "als", "predicate_ab": "downregulates", "mediator": "MMP-2", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "perineural invasion", "outcome_type": "phenotype", "outcome_domain": "pancreatic_cancer", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "riluzole", "mediator_canonical": "MMP2", "outcome_canonical": "perineural invasion", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40012807", "title": "Investigation of the Neuroprotective Effect of Riluzole on Matrix Metalloproteinases in an Experimental Model of Glaucoma", "doi": "10.4103/joco.joco_290_23", "year": 2024 } ], "bc": [ { "pmid": "26504399", "title": "Upregulated matrix metalloproteinase-2 and downregulated tissue factor pathway inhibitor-2 are risk factors for lymph node metastasis and perineural invasion in pancreatic carcinoma", "doi": "10.2147/ott.s90599", "year": 2015 } ] } }, { "id": 57808, "drug": "Apigenin", "drug_type": "drug", "drug_domain": "pancreatic_cancer", "predicate_ab": "inhibits", "mediator": "CK2", "mediator_type": "protein", "predicate_bc": "increases", "outcome": "Th1 and Th17 cell inflammatory responses", "outcome_type": "phenotype", "outcome_domain": "rheumatoid_arthritis", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "28152014", "title": "Apigenin: Selective CK2 inhibitor increases Ikaros expression and improves T cell homeostasis and function in murine pancreatic cancer", "doi": "10.1371/journal.pone.0170197", "year": 2017 } ], "bc": [ { "pmid": "34806506", "title": "Casein Kinase II exacerbates rheumatoid arthritis via promoting Th1 and Th17 cell inflammatory responses", "doi": "10.1080/14728222.2021.2010190", "year": 2021 } ] } }, { "id": 4212, "drug": "curcumin", "drug_type": "drug", "drug_domain": "alzheimer", "predicate_ab": "upregulates", "mediator": "BDNF", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "depressive disorder", "outcome_type": "disease", "outcome_domain": "depression", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "completed", "clinical_trial_nct_ids": [ "NCT01875822", "NCT07416747", "NCT04744545" ], "literature_status": "reproduces_known", "drug_canonical": "curcumin", "mediator_canonical": "BDNF", "outcome_canonical": "depressive disorder", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "38791161", "title": "Curcumin Improves Neurogenesis in Alzheimer’s Disease Mice via the Upregulation of Wnt/β-Catenin and BDNF", "doi": "10.3390/ijms25105123", "year": 2024 } ], "bc": [ { "pmid": "34979889", "title": "The Role of Natural Products in Treatment of Depressive Disorder", "doi": "10.2174/1570159x20666220103140834", "year": 2022 } ] } }, { "id": 4815, "drug": "niclosamide", "drug_type": "drug", "drug_domain": "pancreatic_cancer", "predicate_ab": "downregulates", "mediator": "β-catenin", "mediator_type": "protein", "predicate_bc": "causes", "outcome": "motor neuron degeneration", "outcome_type": "phenotype", "outcome_domain": "als", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "niclosamide", "mediator_canonical": "β-catenin", "outcome_canonical": "motor neuron degeneration", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "35115509", "title": "The anthelmintic drug niclosamide induces GSK-β-mediated β-catenin degradation to potentiate gemcitabine activity, reduce immune evasion ability and suppress pancreatic cancer progression", "doi": "10.1038/s41419-022-04573-7", "year": 2022 } ], "bc": [ { "pmid": "35750046", "title": "Upregulation of β-catenin due to loss of miR-139 contributes to motor neuron death in amyotrophic lateral sclerosis", "doi": "10.1016/j.stemcr.2022.05.019", "year": 2022 } ] } }, { "id": 25922, "drug": "riluzole", "drug_type": "drug", "drug_domain": "als", "predicate_ab": "activates", "mediator": "p53", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "T2DM", "outcome_type": "disease", "outcome_domain": "type_2_diabetes", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "riluzole", "mediator_canonical": "TP53", "outcome_canonical": "t2dm", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "32231713", "title": "Riluzole Enhances the Response of Human Nasopharyngeal Carcinoma Cells to Ionizing Radiation via ATM/P53 Signalling Pathway", "doi": "10.7150/jca.41217", "year": 2020 } ], "bc": [ { "pmid": "37512131", "title": "High-Intensity Interval Training Improves Glycemic Control, Cellular Apoptosis, and Oxidative Stress of Type 2 Diabetic Patients", "doi": "10.3390/medicina59071320", "year": 2023 } ] } }, { "id": 57613, "drug": "resveratrol", "drug_type": "drug", "drug_domain": "pancreatic_cancer", "predicate_ab": "downregulates", "mediator": "miR-21", "mediator_type": "gene", "predicate_bc": "associated_with", "outcome": "active multiple sclerosis lesions", "outcome_type": "disease", "outcome_domain": "multiple_sclerosis", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "29854071", "title": "Resveratrol Inhibits ROS‐Promoted Activation and Glycolysis of Pancreatic Stellate Cells via Suppression of miR‐21", "doi": "10.1155/2018/1346958", "year": 2018 } ], "bc": [ { "pmid": "31727077", "title": "Analysis of miRNA signatures in CSF identifies upregulation of miR-21 and miR-146a/b in patients with multiple sclerosis and active lesions", "doi": "10.1186/s12974-019-1590-5", "year": 2019 } ] } }, { "id": 2195, "drug": "valproic acid", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "downregulates", "mediator": "Progranulin", "mediator_type": "protein", "predicate_bc": "increases", "outcome": "survival", "outcome_type": "phenotype", "outcome_domain": "als", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "completed", "clinical_trial_nct_ids": [ "NCT00995332", "NCT02446652", "NCT01369368" ], "literature_status": "reproduces_known", "drug_canonical": "valproic acid", "mediator_canonical": "GRN", "outcome_canonical": null, "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "35318322", "title": "Progranulin improves neural development via the PI3K/Akt/GSK-3β pathway in the cerebellum of a VPA-induced rat model of ASD", "doi": "10.1038/s41398-022-01875-4", "year": 2022 } ], "bc": [ { "pmid": "30326935", "title": "Progranulin reduces insoluble TDP-43 levels, slows down axonal degeneration and prolongs survival in mutant TDP-43 mice", "doi": "10.1186/s13024-018-0288-y", "year": 2018 } ] } }, { "id": 57494, "drug": "Curcumin", "drug_type": "drug", "drug_domain": "pancreatic_cancer", "predicate_ab": "downregulates", "mediator": "MMP2", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "relapse-remitting multiple sclerosis", "outcome_type": "disease", "outcome_domain": "multiple_sclerosis", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "32945513", "title": "Curcumin enhances anti‑cancer efficacy of either gemcitabine or docetaxel on pancreatic cancer cells", "doi": "10.3892/or.2020.7713", "year": 2020 } ], "bc": [ { "pmid": "35571066", "title": "Label-free Quantitative Proteomic Analysis of Cerebrospinal Fluid and Serum in Patients With Relapse-Remitting Multiple Sclerosis", "doi": "10.3389/fgene.2022.892491", "year": 2022 } ] } }, { "id": 55590, "drug": "valproic acid", "drug_type": "drug", "drug_domain": "multiple_sclerosis", "predicate_ab": "upregulates", "mediator": "β-catenin", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "lower tumor grade", "outcome_type": "phenotype", "outcome_domain": "pancreatic_cancer", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37937413", "title": "Valproic acid effects on human adipose-derived stem cell differentiation into oligodendrocytes and improved remyelination in a mouse model of Multiple Sclerosis", "doi": "10.1387/ijdb.230154ng", "year": 2023 } ], "bc": [ { "pmid": "27411302", "title": "PROX1 and β-catenin are prognostic markers in pancreatic ductal adenocarcinoma", "doi": "10.1186/s12885-016-2497-5", "year": 2016 } ] } }, { "id": 1870, "drug": "auraptene", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "downregulates", "mediator": "MMP-9", "mediator_type": "protein", "predicate_bc": "decreases", "outcome": "perineuronal net", "outcome_type": "phenotype", "outcome_domain": "depression", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "auraptene", "mediator_canonical": "MMP9", "outcome_canonical": "perineuronal net", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "39086858", "title": "Auraptene inhibits migration, invasion and metastatic behavior of human malignant glioblastoma cells: An in vitro and in silico study.", "doi": "10.22038/ajp.2023.23586", "year": 2024 } ], "bc": [ { "pmid": "32269106", "title": "Venlafaxine Stimulates an MMP-9-Dependent Increase in Excitatory/Inhibitory Balance in a Stress Model of Depression", "doi": "10.1523/jneurosci.2387-19.2020", "year": 2020 } ] } }, { "id": 41282, "drug": "resveratrol", "drug_type": "drug", "drug_domain": "als", "predicate_ab": "downregulates", "mediator": "GSK-3β", "mediator_type": "protein", "predicate_bc": "increases", "outcome": "tau spread", "outcome_type": "phenotype", "outcome_domain": "alzheimer", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "26981091", "title": "How does resveratrol influence the genesis of some neurodegenerative diseases?", "doi": "10.4103/1673-5374.175047", "year": 2016 } ], "bc": [ { "pmid": "39350752", "title": "A Drosophila model for mechanistic investigation of tau protein spread", "doi": "10.1242/dmm.050858", "year": 2024 } ] } }, { "id": 2213, "drug": "valproic acid", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "downregulates", "mediator": "BDNF", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "disease progression", "outcome_type": "phenotype", "outcome_domain": "als", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "active", "clinical_trial_nct_ids": [ "NCT03919292", "NCT00071721", "NCT00670046" ], "literature_status": "reproduces_known", "drug_canonical": "valproic acid", "mediator_canonical": "BDNF", "outcome_canonical": "disease progression", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "35465089", "title": "Excitatory and Inhibitory Synaptic Imbalance Caused by Brain-Derived Neurotrophic Factor Deficits During Development in a Valproic Acid Mouse Model of Autism", "doi": "10.3389/fnmol.2022.860275", "year": 2022 } ], "bc": [ { "pmid": "35625004", "title": "BDNF and Pro-BDNF in Amyotrophic Lateral Sclerosis: A New Perspective for Biomarkers of Neurodegeneration", "doi": "10.3390/brainsci12050617", "year": 2022 } ] } }, { "id": 55241, "drug": "metformin", "drug_type": "drug", "drug_domain": "multiple_sclerosis", "predicate_ab": "activates", "mediator": "AMPK", "mediator_type": "protein", "predicate_bc": "increases", "outcome": "glycogen storage", "outcome_type": "phenotype", "outcome_domain": "heart_failure", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37904733", "title": "The AMPK activator metformin improves recovery from demyelination by shifting oligodendrocyte bioenergetics and accelerating OPC differentiation", "doi": "10.3389/fncel.2023.1254303", "year": 2023 } ], "bc": [ { "pmid": "28009297", "title": "Integrative Analysis of PRKAG2 Cardiomyopathy iPS and Microtissue Models Identifies AMPK as a Regulator of Metabolism, Survival, and Fibrosis", "doi": "10.1016/j.celrep.2016.11.066", "year": 2016 } ] } }, { "id": 25392, "drug": "riluzole", "drug_type": "drug", "drug_domain": "als", "predicate_ab": "activates", "mediator": "p53", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "recurrence distance to celiac axis", "outcome_type": "phenotype", "outcome_domain": "pancreatic_cancer", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "riluzole", "mediator_canonical": "TP53", "outcome_canonical": "recurrence distance to celiac axis", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "32231713", "title": "Riluzole Enhances the Response of Human Nasopharyngeal Carcinoma Cells to Ionizing Radiation via ATM/P53 Signalling Pathway", "doi": "10.7150/jca.41217", "year": 2020 } ], "bc": [ { "pmid": "32418280", "title": "Personalized designs of adjuvant radiotherapy for pancreatic cancer based on molecular profiles", "doi": "10.1111/cas.14486", "year": 2020 } ] } }, { "id": 4672, "drug": "valproic acid", "drug_type": "drug", "drug_domain": "pancreatic_cancer", "predicate_ab": "downregulates", "mediator": "EGFR", "mediator_type": "gene", "predicate_bc": "associated_with", "outcome": "juvenile focal epilepsies", "outcome_type": "disease", "outcome_domain": "epilepsy", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "valproic acid", "mediator_canonical": "EGFR", "outcome_canonical": "juvenile focal epilepsies", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "30961642", "title": "Valproic acid exhibits anti-tumor activity selectively against EGFR/ErbB2/ErbB3-coexpressing pancreatic cancer via induction of ErbB family members-targeting microRNAs", "doi": "10.1186/s13046-019-1160-9", "year": 2019 } ], "bc": [ { "pmid": "37181029", "title": "Identification of epidermal growth factor receptor as an immune-related biomarker in epilepsy using multi-transcriptome data", "doi": "10.21037/tp-23-196", "year": 2023 } ] } }, { "id": 25430, "drug": "riluzole", "drug_type": "drug", "drug_domain": "als", "predicate_ab": "downregulates", "mediator": "MMP-2", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "inflammation", "outcome_type": "phenotype", "outcome_domain": "pancreatic_cancer", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "completed", "clinical_trial_nct_ids": [ "NCT03039673", "NCT02796755" ], "literature_status": "reproduces_known", "drug_canonical": "riluzole", "mediator_canonical": "MMP2", "outcome_canonical": null, "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40012807", "title": "Investigation of the Neuroprotective Effect of Riluzole on Matrix Metalloproteinases in an Experimental Model of Glaucoma", "doi": "10.4103/joco.joco_290_23", "year": 2024 } ], "bc": [ { "pmid": "27429508", "title": "Expressions of Matrix Metalloproteinases 2, 7, and 9 in Carcinogenesis of Pancreatic Ductal Adenocarcinoma", "doi": "10.1155/2016/9895721", "year": 2016 } ] } }, { "id": 54797, "drug": "chloroquine", "drug_type": "drug", "drug_domain": "multiple_sclerosis", "predicate_ab": "upregulates", "mediator": "IL-10", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "seizures", "outcome_type": "phenotype", "outcome_domain": "epilepsy", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "32516999", "title": "Comprehensive Analysis of the Immune and Stromal Compartments of the CNS in EAE Mice Reveal Pathways by Which Chloroquine Suppresses Neuroinflammation", "doi": "10.3390/brainsci10060348", "year": 2020 } ], "bc": [ { "pmid": "32532251", "title": "Chronically reduced IL-10 plasma levels are associated with hippocampal sclerosis in temporal lobe epilepsy patients", "doi": "10.1186/s12883-020-01825-x", "year": 2020 } ] } }, { "id": 24121, "drug": "chloroquine", "drug_type": "drug", "drug_domain": "multiple_sclerosis", "predicate_ab": "upregulates", "mediator": "IL-10", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "bipolar disorder", "outcome_type": "disease", "outcome_domain": "depression", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "chloroquine", "mediator_canonical": "il-10", "outcome_canonical": "bipolar disorder", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "32516999", "title": "Comprehensive Analysis of the Immune and Stromal Compartments of the CNS in EAE Mice Reveal Pathways by Which Chloroquine Suppresses Neuroinflammation", "doi": "10.3390/brainsci10060348", "year": 2020 } ], "bc": [ { "pmid": "34589747", "title": "Blood cytokines differentiate bipolar disorder and major depressive disorder during a major depressive episode: Initial discovery and independent sample replication", "doi": "10.1016/j.bbih.2021.100232", "year": 2021 } ] } }, { "id": 34584, "drug": "chloroquine", "drug_type": "drug", "drug_domain": "multiple_sclerosis", "predicate_ab": "upregulates", "mediator": "IL-10", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "depression severity", "outcome_type": "phenotype", "outcome_domain": "depression", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "chloroquine", "mediator_canonical": "il-10", "outcome_canonical": "depression severity", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "32516999", "title": "Comprehensive Analysis of the Immune and Stromal Compartments of the CNS in EAE Mice Reveal Pathways by Which Chloroquine Suppresses Neuroinflammation", "doi": "10.3390/brainsci10060348", "year": 2020 } ], "bc": [ { "pmid": "32435448", "title": "Altered serum interleukin-7 and interleukin-10 are associated with drug-free major depressive disorder", "doi": "10.1177/2045125320916655", "year": 2020 } ] } }, { "id": 54192, "drug": "chloroquine", "drug_type": "drug", "drug_domain": "multiple_sclerosis", "predicate_ab": "upregulates", "mediator": "IL-10", "mediator_type": "protein", "predicate_bc": "treats", "outcome": "ALS", "outcome_type": "disease", "outcome_domain": "als", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "32516999", "title": "Comprehensive Analysis of the Immune and Stromal Compartments of the CNS in EAE Mice Reveal Pathways by Which Chloroquine Suppresses Neuroinflammation", "doi": "10.3390/brainsci10060348", "year": 2020 } ], "bc": [ { "pmid": "38129120", "title": "ALS iPSC-derived microglia and motor neurons respond to astrocyte-targeted IL-10 and CCL2 modulation", "doi": "10.1093/hmg/ddad209", "year": 2023 } ] } }, { "id": 57204, "drug": "resveratrol", "drug_type": "drug", "drug_domain": "pancreatic_cancer", "predicate_ab": "activates", "mediator": "AMPK", "mediator_type": "protein", "predicate_bc": "prevents", "outcome": "myocardial ischemia-reperfusion injury", "outcome_type": "disease", "outcome_domain": "heart_failure", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "27669292", "title": "YAP Inhibition by Resveratrol via Activation of AMPK Enhances the Sensitivity of Pancreatic Cancer Cells to Gemcitabine", "doi": "10.3390/nu8100546", "year": 2016 } ], "bc": [ { "pmid": "29689567", "title": "AMPK Contributes to Cardioprotective Effects of Pterostilbene Against Myocardial Ischemia- Reperfusion Injury in Diabetic Rats by Suppressing Cardiac Oxidative Stress and Apoptosis", "doi": "10.1159/000489154", "year": 2018 } ] } }, { "id": 2174, "drug": "valproate", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "upregulates", "mediator": "Kir4.1", "mediator_type": "protein", "predicate_bc": "increases", "outcome": "peak strength", "outcome_type": "phenotype", "outcome_domain": "als", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "valproic acid", "mediator_canonical": "kir4.1", "outcome_canonical": "peak strength", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "30127740", "title": "Antiepileptic Drugs Elevate Astrocytic Kir4.1 Expression in the Rat Limbic Region", "doi": "10.3389/fphar.2018.00845", "year": 2018 } ], "bc": [ { "pmid": "29606582", "title": "Kir4.1-Dependent Astrocyte-Fast Motor Neuron Interactions Are Required for Peak Strength", "doi": "10.1016/j.neuron.2018.03.010", "year": 2018 } ] } }, { "id": 19524, "drug": "resveratrol", "drug_type": "drug", "drug_domain": "als", "predicate_ab": "downregulates", "mediator": "GSK-3β", "mediator_type": "protein", "predicate_bc": "increases", "outcome": "acinar-to-ductal metaplasia", "outcome_type": "disease", "outcome_domain": "pancreatic_cancer", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "resveratrol", "mediator_canonical": "GSK3B", "outcome_canonical": "acinar-to-ductal metaplasia", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "26981091", "title": "How does resveratrol influence the genesis of some neurodegenerative diseases?", "doi": "10.4103/1673-5374.175047", "year": 2016 } ], "bc": [ { "pmid": "28639695", "title": "Glycogen synthase kinase‐3β ablation limits pancreatitis‐induced acinar‐to‐ductal metaplasia", "doi": "10.1002/path.4928", "year": 2017 } ] } }, { "id": 25499, "drug": "riluzole", "drug_type": "drug", "drug_domain": "als", "predicate_ab": "activates", "mediator": "p53", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "pancreatic intraepithelial neoplasia", "outcome_type": "disease", "outcome_domain": "pancreatic_cancer", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "riluzole", "mediator_canonical": "TP53", "outcome_canonical": "pancreatic intraepithelial neoplasia", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "32231713", "title": "Riluzole Enhances the Response of Human Nasopharyngeal Carcinoma Cells to Ionizing Radiation via ATM/P53 Signalling Pathway", "doi": "10.7150/jca.41217", "year": 2020 } ], "bc": [ { "pmid": "29388054", "title": "p16, p21, and p53 proteins play an important role in development of pancreatic intraepithelial neoplastic", "doi": "10.1007/s11845-018-1751-z", "year": 2018 } ] } }, { "id": 25916, "drug": "riluzole", "drug_type": "drug", "drug_domain": "als", "predicate_ab": "downregulates", "mediator": "MMP-2", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "all-cause mortality", "outcome_type": "phenotype", "outcome_domain": "type_2_diabetes", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "riluzole", "mediator_canonical": "MMP2", "outcome_canonical": "all-cause mortality", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40012807", "title": "Investigation of the Neuroprotective Effect of Riluzole on Matrix Metalloproteinases in an Experimental Model of Glaucoma", "doi": "10.4103/joco.joco_290_23", "year": 2024 } ], "bc": [ { "pmid": "28446168", "title": "Plasma matrix metalloproteinases are associated with incident cardiovascular disease and all-cause mortality in patients with type 1 diabetes: a 12-year follow-up study", "doi": "10.1186/s12933-017-0539-1", "year": 2017 } ] } }, { "id": 57200, "drug": "Curcumin", "drug_type": "drug", "drug_domain": "pancreatic_cancer", "predicate_ab": "downregulates", "mediator": "YAP", "mediator_type": "protein", "predicate_bc": "increases", "outcome": "heart failure", "outcome_type": "disease", "outcome_domain": "heart_failure", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "27738325", "title": "Antitumor activity of curcumin is involved in down-regulation of YAP/TAZ expression in pancreatic cancer cells", "doi": "10.18632/oncotarget.12596", "year": 2016 } ], "bc": [ { "pmid": "31768477", "title": "Yes-Associated Protein (YAP) Facilitates Pressure Overload–Induced Dysfunction in the Diabetic Heart", "doi": "10.1016/j.jacbts.2019.05.006", "year": 2019 } ] } }, { "id": 2158, "drug": "valproic acid", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "downregulates", "mediator": "Progranulin", "mediator_type": "protein", "predicate_bc": "decreases", "outcome": "axonal degeneration", "outcome_type": "phenotype", "outcome_domain": "als", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "valproic acid", "mediator_canonical": "GRN", "outcome_canonical": "axonal degeneration", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "35318322", "title": "Progranulin improves neural development via the PI3K/Akt/GSK-3β pathway in the cerebellum of a VPA-induced rat model of ASD", "doi": "10.1038/s41398-022-01875-4", "year": 2022 } ], "bc": [ { "pmid": "30326935", "title": "Progranulin reduces insoluble TDP-43 levels, slows down axonal degeneration and prolongs survival in mutant TDP-43 mice", "doi": "10.1186/s13024-018-0288-y", "year": 2018 } ] } }, { "id": 597, "drug": "Flubendazole", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "inhibits", "mediator": "STAT3", "mediator_type": "protein", "predicate_bc": "prevents", "outcome": "general cell loss", "outcome_type": "phenotype", "outcome_domain": "epilepsy", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "flubendazole", "mediator_canonical": "STAT3", "outcome_canonical": "general cell loss", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37045903", "title": "Flubendazole exhibits anti-glioblastoma effect by inhibiting STAT3 and promoting cell cycle arrest", "doi": "10.1038/s41598-023-33047-9", "year": 2023 } ], "bc": [ { "pmid": "36825472", "title": "Blockage of STAT3 during epileptogenesis prevents GABAergic loss and imprinting of the epileptic state", "doi": "10.1093/brain/awad055", "year": 2023 } ] } }, { "id": 50171, "drug": "Curcumin", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "upregulates", "mediator": "Nrf2", "mediator_type": "gene", "predicate_bc": "prevents", "outcome": "diabetic cardiomyopathy", "outcome_type": "disease", "outcome_domain": "type_2_diabetes", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40081725", "title": "Matrix metallopeptidase 2-responsive curcumin-loaded nanoparticles-induced signal transducer and activator of transcription 3 inhibition suppresses glioblastoma multiforme growth via enhancing nuclear factor erythroid 2-related factor 2 activity", "doi": "10.1016/j.ijbiomac.2025.141998", "year": 2025 } ], "bc": [ { "pmid": "27903744", "title": "Metallothionein Is Downstream of Nrf2 and Partially Mediates Sulforaphane Prevention of Diabetic Cardiomyopathy", "doi": "10.2337/db15-1274", "year": 2016 } ] } }, { "id": 49130, "drug": "Curcumin", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "upregulates", "mediator": "Nrf2", "mediator_type": "gene", "predicate_bc": "decreases", "outcome": "myocardial fibrosis", "outcome_type": "phenotype", "outcome_domain": "heart_failure", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40081725", "title": "Matrix metallopeptidase 2-responsive curcumin-loaded nanoparticles-induced signal transducer and activator of transcription 3 inhibition suppresses glioblastoma multiforme growth via enhancing nuclear factor erythroid 2-related factor 2 activity", "doi": "10.1016/j.ijbiomac.2025.141998", "year": 2025 } ], "bc": [ { "pmid": "38308838", "title": "Nrf2 prevents diabetic cardiomyopathy via antioxidant effect and normalization of glucose and lipid metabolism in the heart", "doi": "10.1002/jcp.31149", "year": 2024 } ] } }, { "id": 25772, "drug": "riluzole", "drug_type": "drug", "drug_domain": "als", "predicate_ab": "downregulates", "mediator": "MMP-2", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "retinopathy", "outcome_type": "disease", "outcome_domain": "type_2_diabetes", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "riluzole", "mediator_canonical": "MMP2", "outcome_canonical": "retinopathy", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40012807", "title": "Investigation of the Neuroprotective Effect of Riluzole on Matrix Metalloproteinases in an Experimental Model of Glaucoma", "doi": "10.4103/joco.joco_290_23", "year": 2024 } ], "bc": [ { "pmid": "25848912", "title": "Plasma levels of matrix metalloproteinase-2, -3, -10, and tissue inhibitor of metalloproteinase-1 are associated with vascular complications in patients with type 1 diabetes: the EURODIAB Prospective Complications Study", "doi": "10.1186/s12933-015-0195-2", "year": 2015 } ] } }, { "id": 25774, "drug": "riluzole", "drug_type": "drug", "drug_domain": "als", "predicate_ab": "downregulates", "mediator": "MMP-2", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "office pulse pressure", "outcome_type": "phenotype", "outcome_domain": "type_2_diabetes", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "riluzole", "mediator_canonical": "MMP2", "outcome_canonical": "office pulse pressure", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40012807", "title": "Investigation of the Neuroprotective Effect of Riluzole on Matrix Metalloproteinases in an Experimental Model of Glaucoma", "doi": "10.4103/joco.joco_290_23", "year": 2024 } ], "bc": [ { "pmid": "29070037", "title": "Circulating matrix metalloproteinases are associated with arterial stiffness in patients with type 1 diabetes: pooled analysis of three cohort studies", "doi": "10.1186/s12933-017-0620-9", "year": 2017 } ] } }, { "id": 5625, "drug": "Flubendazole", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "inhibits", "mediator": "STAT3", "mediator_type": "protein", "predicate_bc": "prevents", "outcome": "GABAergic neuron loss", "outcome_type": "phenotype", "outcome_domain": "epilepsy", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "flubendazole", "mediator_canonical": "STAT3", "outcome_canonical": "gabaergic neuron loss", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37045903", "title": "Flubendazole exhibits anti-glioblastoma effect by inhibiting STAT3 and promoting cell cycle arrest", "doi": "10.1038/s41598-023-33047-9", "year": 2023 } ], "bc": [ { "pmid": "36825472", "title": "Blockage of STAT3 during epileptogenesis prevents GABAergic loss and imprinting of the epileptic state", "doi": "10.1093/brain/awad055", "year": 2023 } ] } }, { "id": 31179, "drug": "auraptene", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "downregulates", "mediator": "MMP-9", "mediator_type": "protein", "predicate_bc": "increases", "outcome": "synaptic connectivity", "outcome_type": "phenotype", "outcome_domain": "epilepsy", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "auraptene", "mediator_canonical": "MMP9", "outcome_canonical": "synaptic connectivity", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "39086858", "title": "Auraptene inhibits migration, invasion and metastatic behavior of human malignant glioblastoma cells: An in vitro and in silico study.", "doi": "10.22038/ajp.2023.23586", "year": 2024 } ], "bc": [ { "pmid": "34282726", "title": "Role of matrix metalloproteinase-9 in neurodevelopmental deficits and experience-dependent plasticity in Xenopus laevis", "doi": "10.7554/elife.62147", "year": 2021 } ] } }, { "id": 30896, "drug": "Apigenin", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "upregulates", "mediator": "GFAP", "mediator_type": "protein", "predicate_bc": "predicts", "outcome": "Alzheimer's disease progression", "outcome_type": "disease", "outcome_domain": "alzheimer", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "apigenin", "mediator_canonical": "GFAP", "outcome_canonical": "alzheimer's disease progression", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41090780", "title": "Apigenin Induces Autophagy and Apoptosis in Chemoresistant Glioblastoma Cells and Inhibits Tumorigenicity Associated with Regulation of Immunomodulatory Proteins and Glial Cells Response", "doi": "10.3390/cells14191552", "year": 2025 } ], "bc": [ { "pmid": "32514860", "title": "Synaptic Loss, ER Stress and Neuro-Inflammation Emerge Late in the Lateral Temporal Cortex and Associate with Progressive Tau Pathology in Alzheimer’s Disease", "doi": "10.1007/s12035-020-01950-1", "year": 2020 } ] } }, { "id": 30895, "drug": "Apigenin", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "upregulates", "mediator": "GFAP", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "amyloid-β pathology", "outcome_type": "phenotype", "outcome_domain": "alzheimer", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "apigenin", "mediator_canonical": "GFAP", "outcome_canonical": "amyloid-β pathology", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41090780", "title": "Apigenin Induces Autophagy and Apoptosis in Chemoresistant Glioblastoma Cells and Inhibits Tumorigenicity Associated with Regulation of Immunomodulatory Proteins and Glial Cells Response", "doi": "10.3390/cells14191552", "year": 2025 } ], "bc": [ { "pmid": "33773595", "title": "Plasma glial fibrillary acidic protein detects Alzheimer pathology and predicts future conversion to Alzheimer dementia in patients with mild cognitive impairment", "doi": "10.1186/s13195-021-00804-9", "year": 2021 } ] } }, { "id": 30894, "drug": "Apigenin", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "upregulates", "mediator": "GFAP", "mediator_type": "protein", "predicate_bc": "predicts", "outcome": "Alzheimer dementia", "outcome_type": "disease", "outcome_domain": "alzheimer", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "apigenin", "mediator_canonical": "GFAP", "outcome_canonical": "alzheimer dementia", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41090780", "title": "Apigenin Induces Autophagy and Apoptosis in Chemoresistant Glioblastoma Cells and Inhibits Tumorigenicity Associated with Regulation of Immunomodulatory Proteins and Glial Cells Response", "doi": "10.3390/cells14191552", "year": 2025 } ], "bc": [ { "pmid": "33773595", "title": "Plasma glial fibrillary acidic protein detects Alzheimer pathology and predicts future conversion to Alzheimer dementia in patients with mild cognitive impairment", "doi": "10.1186/s13195-021-00804-9", "year": 2021 } ] } }, { "id": 30893, "drug": "Apigenin", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "upregulates", "mediator": "GFAP", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "Aβ positivity", "outcome_type": "phenotype", "outcome_domain": "alzheimer", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "apigenin", "mediator_canonical": "GFAP", "outcome_canonical": "aβ positivity", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41090780", "title": "Apigenin Induces Autophagy and Apoptosis in Chemoresistant Glioblastoma Cells and Inhibits Tumorigenicity Associated with Regulation of Immunomodulatory Proteins and Glial Cells Response", "doi": "10.3390/cells14191552", "year": 2025 } ], "bc": [ { "pmid": "33773595", "title": "Plasma glial fibrillary acidic protein detects Alzheimer pathology and predicts future conversion to Alzheimer dementia in patients with mild cognitive impairment", "doi": "10.1186/s13195-021-00804-9", "year": 2021 } ] } }, { "id": 5750, "drug": "Flubendazole", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "inhibits", "mediator": "STAT3", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "muscle atrophy", "outcome_type": "phenotype", "outcome_domain": "als", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "flubendazole", "mediator_canonical": "STAT3", "outcome_canonical": "muscle atrophy", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37045903", "title": "Flubendazole exhibits anti-glioblastoma effect by inhibiting STAT3 and promoting cell cycle arrest", "doi": "10.1038/s41598-023-33047-9", "year": 2023 } ], "bc": [ { "pmid": "38914173", "title": "Sunitinib-mediated inhibition of STAT3 in skeletal muscle and spinal cord does not affect the disease in a mouse model of ALS", "doi": "10.1016/j.nbd.2024.106576", "year": 2024 } ] } }, { "id": 48197, "drug": "valproic acid", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "downregulates", "mediator": "FASN", "mediator_type": "gene", "predicate_bc": "treats", "outcome": "hepatic steatosis", "outcome_type": "disease", "outcome_domain": "type_2_diabetes", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "36544904", "title": "Metabolomic profiling of triple negative breast cancer cells suggests that valproic acid can enhance the anticancer effect of cisplatin", "doi": "10.3389/fcell.2022.1014798", "year": 2022 } ], "bc": [ { "pmid": "37681411", "title": "Hepatic FASN deficiency differentially affects nonalcoholic fatty liver disease and diabetes in mouse obesity models", "doi": "10.1172/jci.insight.161282", "year": 2023 } ] } }, { "id": 1706, "drug": "cisplatin", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "upregulates", "mediator": "PD-L1", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "cancer-specific survival", "outcome_type": "phenotype", "outcome_domain": "pancreatic_cancer", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "completed", "clinical_trial_nct_ids": [ "NCT00765011" ], "literature_status": "reproduces_known", "drug_canonical": "cisplatin", "mediator_canonical": "PD-L1", "outcome_canonical": "cancer-specific survival", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "39810130", "title": "Engineered biomimetic cisplatin-polyphenol nanocomplex for chemo-immunotherapy of glioblastoma by inducing pyroptosis", "doi": "10.1186/s12951-025-03091-w", "year": 2025 } ], "bc": [ { "pmid": "28470686", "title": "Tumor cell expression of immune inhibitory molecules and tumor-infiltrating lymphocyte count predict cancer-specific survival in pancreatic and ampullary cancer", "doi": "10.1002/ijc.30760", "year": 2017 } ] } }, { "id": 1692, "drug": "sapanisertib", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "inhibits", "mediator": "mTOR", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "pancreatic ductal adenocarcinoma", "outcome_type": "disease", "outcome_domain": "pancreatic_cancer", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "sapanisertib", "mediator_canonical": "mTOR", "outcome_canonical": "pancreatic ductal adenocarcinoma", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37372982", "title": "mTOR Inhibition Is Effective against Growth, Survival and Migration, but Not against Microglia Activation in Preclinical Glioma Models", "doi": "10.3390/ijms24129834", "year": 2023 } ], "bc": [ { "pmid": "29384525", "title": "MTOR inhibitor-based combination therapies for pancreatic cancer", "doi": "10.1038/bjc.2017.421", "year": 2018 } ] } }, { "id": 48181, "drug": "valproate", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "activates", "mediator": "PPARγ", "mediator_type": "protein", "predicate_bc": "prevents", "outcome": "nicotine withdrawal symptoms", "outcome_type": "phenotype", "outcome_domain": "type_2_diabetes", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37334286", "title": "Association of epilepsy, anti-epileptic drugs (AEDs), and type 2 diabetes mellitus (T2DM): a population-based cohort retrospective study, impact of AEDs on T2DM-related molecular pathway, and via peroxisome proliferator-activated receptor γ transactivation", "doi": "10.3389/fendo.2023.1156952", "year": 2023 } ], "bc": [ { "pmid": "31685649", "title": "Activation of PPARγ Attenuates the Expression of Physical and Affective Nicotine Withdrawal Symptoms through Mechanisms Involving Amygdala and Hippocampus Neurotransmission", "doi": "10.1523/jneurosci.1922-19.2019", "year": 2019 } ] } }, { "id": 48136, "drug": "valproic acid", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "downregulates", "mediator": "PKM2", "mediator_type": "protein", "predicate_bc": "prevents", "outcome": "hyperglycemia-induced glomerular pathology", "outcome_type": "disease", "outcome_domain": "type_2_diabetes", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "34263655", "title": "Valproic acid Suppresses Breast Cancer Cell Growth Through Triggering Pyruvate Kinase M2 Isoform Mediated Warburg Effect", "doi": "10.1177/09636897211027524", "year": 2021 } ], "bc": [ { "pmid": "31076418", "title": "Characterization of Glycolytic Enzymes and Pyruvate Kinase M2 in Type 1 and 2 Diabetic Nephropathy", "doi": "10.2337/dc18-2585", "year": 2019 } ] } }, { "id": 30522, "drug": "valproic acid", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "downregulates", "mediator": "VEGF", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "diabetic retinopathy", "outcome_type": "disease", "outcome_domain": "type_2_diabetes", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "valproic acid", "mediator_canonical": "VEGF", "outcome_canonical": "diabetic retinopathy", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "32149283", "title": "l-Cysteine decorated nanoscale metal–organic frameworks delivering valproic acid/cisplatin for drug-resistant lung cancer therapy", "doi": "10.1039/c9cc09712k", "year": 2020 } ], "bc": [ { "pmid": "29582815", "title": "Biochemical scenario behind initiation of diabetic retinopathy in type 2 diabetes mellitus", "doi": "10.4103/ijo.ijo_1121_17", "year": 2018 } ] } }, { "id": 1657, "drug": "linalool", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "downregulates", "mediator": "PD-L1", "mediator_type": "protein", "predicate_bc": "increases", "outcome": "immunosuppression", "outcome_type": "phenotype", "outcome_domain": "pancreatic_cancer", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "linalool", "mediator_canonical": "PD-L1", "outcome_canonical": "immunosuppression", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40504869", "title": "Linalool-based silver nanoconjugates as potential therapeutics for glioblastoma: in silico and in vitro insights", "doi": "10.1371/journal.pone.0325281", "year": 2025 } ], "bc": [ { "pmid": "38474199", "title": "A Comparison of Spatial and Phenotypic Immune Profiles of Pancreatic Ductal Adenocarcinoma and Its Precursor Lesions", "doi": "10.3390/ijms25052953", "year": 2024 } ] } }, { "id": 1656, "drug": "linalool", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "downregulates", "mediator": "PD-L1", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "lymph node metastasis", "outcome_type": "phenotype", "outcome_domain": "pancreatic_cancer", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "linalool", "mediator_canonical": "PD-L1", "outcome_canonical": "lymph node metastasis", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40504869", "title": "Linalool-based silver nanoconjugates as potential therapeutics for glioblastoma: in silico and in vitro insights", "doi": "10.1371/journal.pone.0325281", "year": 2025 } ], "bc": [ { "pmid": "28030840", "title": "Prognostic value and clinicopathological features of PD-1/PD-L1 expression with mismatch repair status and desmoplastic stroma in Chinese patients with pancreatic cancer", "doi": "10.18632/oncotarget.14069", "year": 2016 } ] } }, { "id": 25872, "drug": "riluzole", "drug_type": "drug", "drug_domain": "als", "predicate_ab": "downregulates", "mediator": "MMP-2", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "central 24-h pulse pressure", "outcome_type": "phenotype", "outcome_domain": "type_2_diabetes", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "riluzole", "mediator_canonical": "MMP2", "outcome_canonical": "central 24-h pulse pressure", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40012807", "title": "Investigation of the Neuroprotective Effect of Riluzole on Matrix Metalloproteinases in an Experimental Model of Glaucoma", "doi": "10.4103/joco.joco_290_23", "year": 2024 } ], "bc": [ { "pmid": "29070037", "title": "Circulating matrix metalloproteinases are associated with arterial stiffness in patients with type 1 diabetes: pooled analysis of three cohort studies", "doi": "10.1186/s12933-017-0620-9", "year": 2017 } ] } }, { "id": 30521, "drug": "valproic acid", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "suppresses", "mediator": "galectin-3", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "hypertension", "outcome_type": "disease", "outcome_domain": "type_2_diabetes", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "completed", "clinical_trial_nct_ids": [ "NCT05224531" ], "literature_status": "reproduces_known", "drug_canonical": "valproic acid", "mediator_canonical": "LGALS3", "outcome_canonical": "hypertension", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "34122007", "title": "Post-stroke Delivery of Valproic Acid Promotes Functional Recovery and Differentially Modifies Responses of Peri-Infarct Microglia", "doi": "10.3389/fnmol.2021.639145", "year": 2021 } ], "bc": [ { "pmid": "26722123", "title": "Circulating Galectin‐3 Is Associated With Cardiometabolic Disease in the Community", "doi": "10.1161/jaha.115.002347", "year": 2016 } ] } }, { "id": 1549, "drug": "apigenin", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "upregulates", "mediator": "GFAP", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "neurodegeneration", "outcome_type": "phenotype", "outcome_domain": "alzheimer", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "apigenin", "mediator_canonical": "GFAP", "outcome_canonical": null, "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41090780", "title": "Apigenin Induces Autophagy and Apoptosis in Chemoresistant Glioblastoma Cells and Inhibits Tumorigenicity Associated with Regulation of Immunomodulatory Proteins and Glial Cells Response", "doi": "10.3390/cells14191552", "year": 2025 } ], "bc": [ { "pmid": "36576155", "title": "Plasma glial fibrillary acidic protein in autosomal dominant Alzheimer's disease: Associations with Aβ‐PET, neurodegeneration, and cognition", "doi": "10.1002/alz.12879", "year": 2022 } ] } }, { "id": 48101, "drug": "valproic acid", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "downregulates", "mediator": "DNA methylation", "mediator_type": "biomarker", "predicate_bc": "correlates_with", "outcome": "diabetic peripheral neuropathy", "outcome_type": "disease", "outcome_domain": "type_2_diabetes", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "35312054", "title": "Developmental administration of valproic acid alters DNA methylation and maternal behavior", "doi": "10.1002/dev.22231", "year": 2022 } ], "bc": [ { "pmid": "31132961", "title": "Genome-wide DNA methylation profiling of human diabetic peripheral neuropathy in subjects with type 2 diabetes mellitus", "doi": "10.1080/15592294.2019.1615352", "year": 2019 } ] } }, { "id": 4486, "drug": "niclosamide", "drug_type": "drug", "drug_domain": "pancreatic_cancer", "predicate_ab": "downregulates", "mediator": "PD-L1", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "clinical response", "outcome_type": "phenotype", "outcome_domain": "glioblastoma", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "niclosamide", "mediator_canonical": "PD-L1", "outcome_canonical": null, "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "35115509", "title": "The anthelmintic drug niclosamide induces GSK-β-mediated β-catenin degradation to potentiate gemcitabine activity, reduce immune evasion ability and suppress pancreatic cancer progression", "doi": "10.1038/s41419-022-04573-7", "year": 2022 } ], "bc": [ { "pmid": "31929892", "title": "Impact of pre‐therapy glioblastoma multiforme microenvironment on clinical response to autologous CMV‐specific T‐cell therapy", "doi": "10.1002/cti2.1088", "year": 2019 } ] } }, { "id": 4487, "drug": "niclosamide", "drug_type": "drug", "drug_domain": "pancreatic_cancer", "predicate_ab": "downregulates", "mediator": "PD-L1", "mediator_type": "protein", "predicate_bc": "predicts", "outcome": "prognosis", "outcome_type": "phenotype", "outcome_domain": "glioblastoma", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "niclosamide", "mediator_canonical": "PD-L1", "outcome_canonical": null, "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "35115509", "title": "The anthelmintic drug niclosamide induces GSK-β-mediated β-catenin degradation to potentiate gemcitabine activity, reduce immune evasion ability and suppress pancreatic cancer progression", "doi": "10.1038/s41419-022-04573-7", "year": 2022 } ], "bc": [ { "pmid": "34638219", "title": "Immunohistochemical expression of programmed death-ligand 1 and CD8 in glioblastomas", "doi": "10.4132/jptm.2021.08.04", "year": 2021 } ] } }, { "id": 48088, "drug": "valproic acid", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "suppresses", "mediator": "galectin-3", "mediator_type": "protein", "predicate_bc": "predicts", "outcome": "cardiometabolic disease", "outcome_type": "disease", "outcome_domain": "type_2_diabetes", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "34122007", "title": "Post-stroke Delivery of Valproic Acid Promotes Functional Recovery and Differentially Modifies Responses of Peri-Infarct Microglia", "doi": "10.3389/fnmol.2021.639145", "year": 2021 } ], "bc": [ { "pmid": "26722123", "title": "Circulating Galectin‐3 Is Associated With Cardiometabolic Disease in the Community", "doi": "10.1161/jaha.115.002347", "year": 2016 } ] } }, { "id": 48072, "drug": "valproic acid", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "downregulates", "mediator": "CREB", "mediator_type": "gene", "predicate_bc": "associated_with", "outcome": "PCa relapse", "outcome_type": "disease", "outcome_domain": "type_2_diabetes", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "29958461", "title": "Differential Gene Expression Profile Induced by Valproic Acid (VPA) in Pediatric Epileptic Patients", "doi": "10.3390/genes9070328", "year": 2018 } ], "bc": [ { "pmid": "37573301", "title": "STAT3/LKB1 controls metastatic prostate cancer by regulating mTORC1/CREB pathway", "doi": "10.1186/s12943-023-01825-8", "year": 2023 } ] } }, { "id": 4750, "drug": "valproic acid", "drug_type": "drug", "drug_domain": "pancreatic_cancer", "predicate_ab": "downregulates", "mediator": "EGFR", "mediator_type": "gene", "predicate_bc": "associated_with", "outcome": "lesional focal epilepsy", "outcome_type": "disease", "outcome_domain": "epilepsy", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "valproic acid", "mediator_canonical": "EGFR", "outcome_canonical": "lesional focal epilepsy", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "30961642", "title": "Valproic acid exhibits anti-tumor activity selectively against EGFR/ErbB2/ErbB3-coexpressing pancreatic cancer via induction of ErbB family members-targeting microRNAs", "doi": "10.1186/s13046-019-1160-9", "year": 2019 } ], "bc": [ { "pmid": "39616148", "title": "Analysis of 1386 epileptogenic brain lesions reveals association with DYRK1A and EGFR", "doi": "10.1038/s41467-024-54911-w", "year": 2024 } ] } }, { "id": 30309, "drug": "valproic acid", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "downregulates", "mediator": "VEGF", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "active infection", "outcome_type": "disease", "outcome_domain": "rheumatoid_arthritis", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "valproic acid", "mediator_canonical": "VEGF", "outcome_canonical": "active infection", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "32149283", "title": "l-Cysteine decorated nanoscale metal–organic frameworks delivering valproic acid/cisplatin for drug-resistant lung cancer therapy", "doi": "10.1039/c9cc09712k", "year": 2020 } ], "bc": [ { "pmid": "35744097", "title": "VEGF Profile in Early Undifferentiated Arthritis Cohort", "doi": "10.3390/medicina58060833", "year": 2022 } ] } }, { "id": 47988, "drug": "valproic acid", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "downregulates", "mediator": "VEGF", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "DAS28", "outcome_type": "phenotype", "outcome_domain": "rheumatoid_arthritis", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "32149283", "title": "l-Cysteine decorated nanoscale metal–organic frameworks delivering valproic acid/cisplatin for drug-resistant lung cancer therapy", "doi": "10.1039/c9cc09712k", "year": 2020 } ], "bc": [ { "pmid": "29336711", "title": "Circulating serum interleukin-6, serum chitinase-3-like protein-1, and plasma vascular endothelial growth factor are not predictive for remission and radiographic progression in patients with early rheumatoid arthritis: post-hoc explorative and validation studies based on the CIMESTRA and OPERA trials", "doi": "10.1080/03009742.2017.1376107", "year": 2018 } ] } }, { "id": 25905, "drug": "riluzole", "drug_type": "drug", "drug_domain": "als", "predicate_ab": "downregulates", "mediator": "MMP-2", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "brachial 24-h pulse pressure", "outcome_type": "phenotype", "outcome_domain": "type_2_diabetes", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "riluzole", "mediator_canonical": "MMP2", "outcome_canonical": "brachial 24-h pulse pressure", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40012807", "title": "Investigation of the Neuroprotective Effect of Riluzole on Matrix Metalloproteinases in an Experimental Model of Glaucoma", "doi": "10.4103/joco.joco_290_23", "year": 2024 } ], "bc": [ { "pmid": "29070037", "title": "Circulating matrix metalloproteinases are associated with arterial stiffness in patients with type 1 diabetes: pooled analysis of three cohort studies", "doi": "10.1186/s12933-017-0620-9", "year": 2017 } ] } }, { "id": 43036, "drug": "riluzole", "drug_type": "drug", "drug_domain": "als", "predicate_ab": "downregulates", "mediator": "MMP-9", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "pre-hypertension", "outcome_type": "disease", "outcome_domain": "type_2_diabetes", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40012807", "title": "Investigation of the Neuroprotective Effect of Riluzole on Matrix Metalloproteinases in an Experimental Model of Glaucoma", "doi": "10.4103/joco.joco_290_23", "year": 2024 } ], "bc": [ { "pmid": "27490532", "title": "Serum Concentrations of Endothelin-1 and Matrix Metalloproteinases-2, -9 in Pre-Hypertensive and Hypertensive Patients with Type 2 Diabetes", "doi": "10.3390/ijms17081182", "year": 2016 } ] } }, { "id": 42014, "drug": "riluzole", "drug_type": "drug", "drug_domain": "als", "predicate_ab": "downregulates", "mediator": "MMP-2", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "chronic kidney disease", "outcome_type": "disease", "outcome_domain": "heart_failure", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40012807", "title": "Investigation of the Neuroprotective Effect of Riluzole on Matrix Metalloproteinases in an Experimental Model of Glaucoma", "doi": "10.4103/joco.joco_290_23", "year": 2024 } ], "bc": [ { "pmid": "29915813", "title": "MMP-2 and TIMP-2 in patients with heart failure and chronic kidney disease", "doi": "10.1515/med-2018-0037", "year": 2018 } ] } }, { "id": 7420, "drug": "Baicalin", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "upregulates", "mediator": "BDNF", "mediator_type": "protein", "predicate_bc": "increases", "outcome": "remission", "outcome_type": "phenotype", "outcome_domain": "depression", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "baicalin", "mediator_canonical": "BDNF", "outcome_canonical": null, "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "38778616", "title": "Exploring the Therapeutic Potential of Baicalin: Mitigating Anxiety and Depression in Epileptic Rats", "doi": "10.2174/0113862073316021240520110301", "year": 2024 } ], "bc": [ { "pmid": "41584756", "title": "Employment-dependent associations of serum biomarkers with short- and long-term antidepressant treatment outcomes", "doi": "10.3389/fpsyt.2025.1662993", "year": 2026 } ] } }, { "id": 1877, "drug": "auraptene", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "downregulates", "mediator": "MMP-9", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "major depressive disorder without recent suicide attempt", "outcome_type": "disease", "outcome_domain": "depression", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "auraptene", "mediator_canonical": "MMP9", "outcome_canonical": "major depressive disorder without recent suicide attempt", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "39086858", "title": "Auraptene inhibits migration, invasion and metastatic behavior of human malignant glioblastoma cells: An in vitro and in silico study.", "doi": "10.22038/ajp.2023.23586", "year": 2024 } ], "bc": [ { "pmid": "41561479", "title": "Levels of matrix metalloproteinase 9 (MMP-9) are elevated in persons with major depressive disorder who have had a recent suicide attempt", "doi": "10.1016/j.bbih.2025.101163", "year": 2025 } ] } }, { "id": 4653, "drug": "resveratrol", "drug_type": "drug", "drug_domain": "pancreatic_cancer", "predicate_ab": "activates", "mediator": "AMPK", "mediator_type": "protein", "predicate_bc": "increases", "outcome": "spike-wave seizures", "outcome_type": "phenotype", "outcome_domain": "epilepsy", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "resveratrol", "mediator_canonical": "AMPK", "outcome_canonical": "spike-wave seizures", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "27669292", "title": "YAP Inhibition by Resveratrol via Activation of AMPK Enhances the Sensitivity of Pancreatic Cancer Cells to Gemcitabine", "doi": "10.3390/nu8100546", "year": 2016 } ], "bc": [ { "pmid": "35134125", "title": "AMPK-mediated potentiation of GABAergic signalling drives hypoglycaemia-provoked spike-wave seizures", "doi": "10.1093/brain/awac037", "year": 2022 } ] } }, { "id": 6024, "drug": "apigenin", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "upregulates", "mediator": "GFAP", "mediator_type": "protein", "predicate_bc": "predicts", "outcome": "Alzheimer's disease versus behavioral-variant frontotemporal dementia", "outcome_type": "disease", "outcome_domain": "alzheimer", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "apigenin", "mediator_canonical": "GFAP", "outcome_canonical": "alzheimer's disease versus behavioral-variant frontotemporal dementia", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41090780", "title": "Apigenin Induces Autophagy and Apoptosis in Chemoresistant Glioblastoma Cells and Inhibits Tumorigenicity Associated with Regulation of Immunomodulatory Proteins and Glial Cells Response", "doi": "10.3390/cells14191552", "year": 2025 } ], "bc": [ { "pmid": "39736793", "title": "Blood-based biomarkers and plasma Aβ assays in the differential diagnosis of Alzheimer’s disease and behavioral-variant frontotemporal dementia", "doi": "10.1186/s13195-024-01647-w", "year": 2024 } ] } }, { "id": 30266, "drug": "baicalin", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "upregulates", "mediator": "sirtuin-1", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "rheumatoid arthritis", "outcome_type": "disease", "outcome_domain": "rheumatoid_arthritis", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "baicalin", "mediator_canonical": "sirtuin-1", "outcome_canonical": "rheumatoid arthritis", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "35447549", "title": "Postnatal baicalin ameliorates behavioral and neurochemical alterations in valproic acid-induced rodent model of autism: The possible implication of sirtuin-1/mitofusin-2/ Bcl-2 pathway", "doi": "10.1016/j.biopha.2022.112960", "year": 2022 } ], "bc": [ { "pmid": "33507129", "title": "The clinical value of serum sirtuin-1 in the diagnosis of rheumatoid arthritis: a pilot study", "doi": "10.1080/09674845.2021.1880085", "year": 2021 } ] } }, { "id": 59017, "drug": "Curcumin", "drug_type": "drug", "drug_domain": "rheumatoid_arthritis", "predicate_ab": "inhibits", "mediator": "mTOR pathway", "mediator_type": "pathway", "predicate_bc": "associated_with", "outcome": "GBM", "outcome_type": "disease", "outcome_domain": "glioblastoma", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "30584274", "title": "Curcumin alleviates rheumatoid arthritis-induced inflammation and synovial hyperplasia by targeting mTOR pathway in rats", "doi": "10.2147/dddt.s175763", "year": 2018 } ], "bc": [ { "pmid": "34944625", "title": "The Bumpy Road towards mTOR Inhibition in Glioblastoma: Quo Vadis?", "doi": "10.3390/biomedicines9121809", "year": 2021 } ] } }, { "id": 30253, "drug": "valproate", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "downregulates", "mediator": "COX-2", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "rheumatoid arthritis", "outcome_type": "disease", "outcome_domain": "rheumatoid_arthritis", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "valproic acid", "mediator_canonical": "cox-2", "outcome_canonical": "rheumatoid arthritis", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "32054883", "title": "Downregulation of peripheral PTGS2/COX-2 in response to valproate treatment in patients with epilepsy", "doi": "10.1038/s41598-020-59259-x", "year": 2020 } ], "bc": [ { "pmid": "32742333", "title": "Serum COX‑2 and FOXO3a in patients with rheumatoid arthritis and correlation with disease activity", "doi": "10.3892/etm.2020.8779", "year": 2020 } ] } }, { "id": 30264, "drug": "valproic acid", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "inhibits", "mediator": "interferon-γ", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "Alopecia areata", "outcome_type": "disease", "outcome_domain": "rheumatoid_arthritis", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "completed", "clinical_trial_nct_ids": [ "NCT05017454", "NCT01548066" ], "literature_status": "novel_signal", "drug_canonical": "valproic acid", "mediator_canonical": "interferon-γ", "outcome_canonical": "alopecia areata", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "33082490", "title": "Valproic acid inhibits interferon-γ production by NK cells and increases susceptibility to Listeria monocytogenes infection", "doi": "10.1038/s41598-020-74836-w", "year": 2020 } ], "bc": [ { "pmid": "32258291", "title": "Successful treatment of alopecia totalis with ruxolitinib in a preadolescent patient", "doi": "10.1016/j.jdcr.2020.02.007", "year": 2020 } ] } }, { "id": 42013, "drug": "riluzole", "drug_type": "drug", "drug_domain": "als", "predicate_ab": "downregulates", "mediator": "MMP-2", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "degree of kidney failure", "outcome_type": "phenotype", "outcome_domain": "heart_failure", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40012807", "title": "Investigation of the Neuroprotective Effect of Riluzole on Matrix Metalloproteinases in an Experimental Model of Glaucoma", "doi": "10.4103/joco.joco_290_23", "year": 2024 } ], "bc": [ { "pmid": "29915813", "title": "MMP-2 and TIMP-2 in patients with heart failure and chronic kidney disease", "doi": "10.1515/med-2018-0037", "year": 2018 } ] } }, { "id": 4238, "drug": "curcumin", "drug_type": "drug", "drug_domain": "alzheimer", "predicate_ab": "upregulates", "mediator": "BDNF", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "major depression", "outcome_type": "disease", "outcome_domain": "depression", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "completed", "clinical_trial_nct_ids": [ "NCT01750359", "NCT01022632" ], "literature_status": "reproduces_known", "drug_canonical": "curcumin", "mediator_canonical": "BDNF", "outcome_canonical": "major depression", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "38791161", "title": "Curcumin Improves Neurogenesis in Alzheimer’s Disease Mice via the Upregulation of Wnt/β-Catenin and BDNF", "doi": "10.3390/ijms25105123", "year": 2024 } ], "bc": [ { "pmid": "36831119", "title": "The Serum Brain-Derived Neurotrophic Factor Increases in Serotonin Reuptake Inhibitor Responders Patients with First-Episode, Drug-Naïve Major Depression", "doi": "10.3390/biomedicines11020584", "year": 2023 } ] } }, { "id": 30216, "drug": "valproic acid", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "downregulates", "mediator": "LAIR1", "mediator_type": "gene", "predicate_bc": "associated_with", "outcome": "rheumatoid arthritis", "outcome_type": "disease", "outcome_domain": "rheumatoid_arthritis", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "valproic acid", "mediator_canonical": "lair1", "outcome_canonical": "rheumatoid arthritis", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "29958461", "title": "Differential Gene Expression Profile Induced by Valproic Acid (VPA) in Pediatric Epileptic Patients", "doi": "10.3390/genes9070328", "year": 2018 } ], "bc": [ { "pmid": "39887658", "title": "Genome‐Wide Aggregated Trans Effects Analysis Identifies Genes Encoding Immune Checkpoints as Core Genes for Rheumatoid Arthritis", "doi": "10.1002/art.43125", "year": 2025 } ] } }, { "id": 3884, "drug": "curcumin", "drug_type": "drug", "drug_domain": "alzheimer", "predicate_ab": "binds_to", "mediator": "TDP-43", "mediator_type": "protein", "predicate_bc": "prevents", "outcome": "harmful R-loop accumulation", "outcome_type": "phenotype", "outcome_domain": "als", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "curcumin", "mediator_canonical": "TDP-43", "outcome_canonical": "harmful r-loop accumulation", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "30092839", "title": "Different curcumin forms selectively bind fibrillar amyloid beta in post mortem Alzheimer’s disease brains: Implications for in-vivo diagnostics", "doi": "10.1186/s40478-018-0577-2", "year": 2018 } ], "bc": [ { "pmid": "33301444", "title": "TDP-43 mutations link Amyotrophic Lateral Sclerosis with R-loop homeostasis and R loop-mediated DNA damage", "doi": "10.1371/journal.pgen.1009260", "year": 2020 } ] } }, { "id": 47893, "drug": "valproic acid", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "downregulates", "mediator": "VEGF", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "SDAI", "outcome_type": "phenotype", "outcome_domain": "rheumatoid_arthritis", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "32149283", "title": "l-Cysteine decorated nanoscale metal–organic frameworks delivering valproic acid/cisplatin for drug-resistant lung cancer therapy", "doi": "10.1039/c9cc09712k", "year": 2020 } ], "bc": [ { "pmid": "31820713", "title": "Expression of Galectin-9 and correlation with disease activity and vascular endothelial growth factor in rheumatoid arthritis.", "doi": null, "year": 2020 } ] } }, { "id": 30103, "drug": "valproic acid", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "suppresses", "mediator": "galectin-3", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "malnutrition", "outcome_type": "phenotype", "outcome_domain": "pancreatic_cancer", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "valproic acid", "mediator_canonical": "LGALS3", "outcome_canonical": "malnutrition", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "34122007", "title": "Post-stroke Delivery of Valproic Acid Promotes Functional Recovery and Differentially Modifies Responses of Peri-Infarct Microglia", "doi": "10.3389/fnmol.2021.639145", "year": 2021 } ], "bc": [ { "pmid": "28870921", "title": "Significance of Circulating Galectin-3 in Patients with Pancreatobiliary Cancer", "doi": "10.21873/anticanres.11909", "year": 2017 } ] } }, { "id": 7183, "drug": "valproic acid", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "suppresses", "mediator": "galectin-3", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "high hypoxia status", "outcome_type": "phenotype", "outcome_domain": "pancreatic_cancer", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "valproic acid", "mediator_canonical": "LGALS3", "outcome_canonical": "high hypoxia status", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "34122007", "title": "Post-stroke Delivery of Valproic Acid Promotes Functional Recovery and Differentially Modifies Responses of Peri-Infarct Microglia", "doi": "10.3389/fnmol.2021.639145", "year": 2021 } ], "bc": [ { "pmid": "38510243", "title": "High hypoxia status in pancreatic cancer is associated with multiple hallmarks of an immunosuppressive tumor microenvironment", "doi": "10.3389/fimmu.2024.1360629", "year": 2024 } ] } }, { "id": 2557, "drug": "valproic acid", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "activates", "mediator": "TGFβ signaling", "mediator_type": "pathway", "predicate_bc": "increases", "outcome": "net acid extrusion", "outcome_type": "phenotype", "outcome_domain": "pancreatic_cancer", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "valproic acid", "mediator_canonical": "tgfβ signaling", "outcome_canonical": "net acid extrusion", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "30050438", "title": "Valproic Acid Induces Endothelial-to-Mesenchymal Transition-Like Phenotypic Switching", "doi": "10.3389/fphar.2018.00737", "year": 2018 } ], "bc": [ { "pmid": "32457840", "title": "TGFβ Signaling Increases Net Acid Extrusion, Proliferation and Invasion in Panc-1 Pancreatic Cancer Cells: SMAD4 Dependence and Link to Merlin/NF2 Signaling", "doi": "10.3389/fonc.2020.00687", "year": 2020 } ] } }, { "id": 29882, "drug": "valproate", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "downregulates", "mediator": "SLC44A2", "mediator_type": "gene", "predicate_bc": "associated_with", "outcome": "multiple sclerosis", "outcome_type": "disease", "outcome_domain": "multiple_sclerosis", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "active", "clinical_trial_nct_ids": [ "NCT02670161" ], "literature_status": "reproduces_known", "drug_canonical": "valproic acid", "mediator_canonical": "slc44a2", "outcome_canonical": "multiple sclerosis", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "33890297", "title": "Antiseizure medications and fetal nutrients: Effects on choline transporters in a human placental cell line", "doi": "10.1111/epi.16905", "year": 2021 } ], "bc": [ { "pmid": "30479356", "title": "Genome-wide DNA methylation changes in CD19+ B cells from relapsing-remitting multiple sclerosis patients", "doi": "10.1038/s41598-018-35603-0", "year": 2018 } ] } }, { "id": 9644, "drug": "Auranofin", "drug_type": "drug", "drug_domain": "pancreatic_cancer", "predicate_ab": "inhibits", "mediator": "HIF-1α", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "epilepsy", "outcome_type": "disease", "outcome_domain": "epilepsy", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "auranofin", "mediator_canonical": "hif-1α", "outcome_canonical": "epilepsy", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "33981979", "title": "Antineoplastic effects of auranofin in human pancreatic adenocarcinoma preclinical models", "doi": "10.1016/j.sopen.2019.05.004", "year": 2019 } ], "bc": [ { "pmid": "41324728", "title": "The Role of HIF-1α/BNIP3 Pathway in Hippocampal Neuronal Autophagy in Epilepsy", "doi": "10.1007/s12035-025-05406-2", "year": 2025 } ] } }, { "id": 643, "drug": "osimertinib", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "inhibits", "mediator": "EGFR", "mediator_type": "gene", "predicate_bc": "associated_with", "outcome": "juvenile focal epilepsies", "outcome_type": "disease", "outcome_domain": "epilepsy", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "osimertinib", "mediator_canonical": "EGFR", "outcome_canonical": "juvenile focal epilepsies", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "31678994", "title": "Betacellulin drives therapy resistance in glioblastoma", "doi": "10.1093/neuonc/noz206", "year": 2019 } ], "bc": [ { "pmid": "37181029", "title": "Identification of epidermal growth factor receptor as an immune-related biomarker in epilepsy using multi-transcriptome data", "doi": "10.21037/tp-23-196", "year": 2023 } ] } }, { "id": 29844, "drug": "valproic acid", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "downregulates", "mediator": "BDNF", "mediator_type": "gene", "predicate_bc": "associated_with", "outcome": "Multiple Sclerosis pathogenesis", "outcome_type": "disease", "outcome_domain": "multiple_sclerosis", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "valproic acid", "mediator_canonical": "BDNF", "outcome_canonical": "multiple sclerosis pathogenesis", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "30404997", "title": "Social behavior, neuroimmune markers and glutamic acid decarboxylase levels in a rat model of valproic acid-induced autism", "doi": "10.2131/jts.43.631", "year": 2018 } ], "bc": [ { "pmid": "30352103", "title": "BDNF rs6265 polymorphism methylation in Multiple Sclerosis: A possible marker of disease progression", "doi": "10.1371/journal.pone.0206140", "year": 2018 } ] } }, { "id": 47202, "drug": "valproic acid", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "downregulates", "mediator": "VEGF", "mediator_type": "protein", "predicate_bc": "causes", "outcome": "atrial arrhythmias", "outcome_type": "disease", "outcome_domain": "heart_failure", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "32149283", "title": "l-Cysteine decorated nanoscale metal–organic frameworks delivering valproic acid/cisplatin for drug-resistant lung cancer therapy", "doi": "10.1039/c9cc09712k", "year": 2020 } ], "bc": [ { "pmid": "33235263", "title": "Vascular endothelial growth factor promotes atrial arrhythmias by inducing acute intercalated disk remodeling", "doi": "10.1038/s41598-020-77562-5", "year": 2020 } ] } }, { "id": 47201, "drug": "valproic acid", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "suppresses", "mediator": "galectin-3", "mediator_type": "protein", "predicate_bc": "predicts", "outcome": "HFpEF", "outcome_type": "disease", "outcome_domain": "heart_failure", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "34122007", "title": "Post-stroke Delivery of Valproic Acid Promotes Functional Recovery and Differentially Modifies Responses of Peri-Infarct Microglia", "doi": "10.3389/fnmol.2021.639145", "year": 2021 } ], "bc": [ { "pmid": "26981573", "title": "Pattern of endothelial progenitor cells and apoptotic endothelial cell-derived microparticles in chronic heart failure patients with preserved and reduced left ventricular ejection fraction", "doi": "10.1016/j.ebiom.2016.01.018", "year": 2016 } ] } }, { "id": 47200, "drug": "valproic acid", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "suppresses", "mediator": "galectin-3", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "myocardial damage", "outcome_type": "disease", "outcome_domain": "heart_failure", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "34122007", "title": "Post-stroke Delivery of Valproic Acid Promotes Functional Recovery and Differentially Modifies Responses of Peri-Infarct Microglia", "doi": "10.3389/fnmol.2021.639145", "year": 2021 } ], "bc": [ { "pmid": "26781273", "title": "Inhibition of Galectin-3 Pathway Prevents Isoproterenol-Induced Left Ventricular Dysfunction and Fibrosis in Mice", "doi": "10.1161/hypertensionaha.115.06161", "year": 2016 } ] } }, { "id": 724, "drug": "Flubendazole", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "inhibits", "mediator": "STAT3", "mediator_type": "protein", "predicate_bc": "prevents", "outcome": "imprinting of epileptic activity patterns", "outcome_type": "phenotype", "outcome_domain": "epilepsy", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "flubendazole", "mediator_canonical": "STAT3", "outcome_canonical": "imprinting of epileptic activity patterns", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37045903", "title": "Flubendazole exhibits anti-glioblastoma effect by inhibiting STAT3 and promoting cell cycle arrest", "doi": "10.1038/s41598-023-33047-9", "year": 2023 } ], "bc": [ { "pmid": "36825472", "title": "Blockage of STAT3 during epileptogenesis prevents GABAergic loss and imprinting of the epileptic state", "doi": "10.1093/brain/awad055", "year": 2023 } ] } }, { "id": 4547, "drug": "resveratrol", "drug_type": "drug", "drug_domain": "pancreatic_cancer", "predicate_ab": "downregulates", "mediator": "miR-21", "mediator_type": "gene", "predicate_bc": "associated_with", "outcome": "overall survival", "outcome_type": "phenotype", "outcome_domain": "glioblastoma", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "resveratrol", "mediator_canonical": "mir-21", "outcome_canonical": null, "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "29854071", "title": "Resveratrol Inhibits ROS‐Promoted Activation and Glycolysis of Pancreatic Stellate Cells via Suppression of miR‐21", "doi": "10.1155/2018/1346958", "year": 2018 } ], "bc": [ { "pmid": "36902848", "title": "Identification of MGMT Downregulation Induced by miRNA in Glioblastoma and Possible Effect on Temozolomide Sensitivity", "doi": "10.3390/jcm12052061", "year": 2023 } ] } }, { "id": 47199, "drug": "valproic acid", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "suppresses", "mediator": "galectin-3", "mediator_type": "protein", "predicate_bc": "increases", "outcome": "AF inducibility", "outcome_type": "phenotype", "outcome_domain": "heart_failure", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "34122007", "title": "Post-stroke Delivery of Valproic Acid Promotes Functional Recovery and Differentially Modifies Responses of Peri-Infarct Microglia", "doi": "10.3389/fnmol.2021.639145", "year": 2021 } ], "bc": [ { "pmid": "27525318", "title": "Galectin-3 Regulates Atrial Fibrillation Remodeling and Predicts Catheter Ablation Outcomes", "doi": "10.1016/j.jacbts.2016.03.003", "year": 2016 } ] } }, { "id": 3360, "drug": "niclosamide", "drug_type": "drug", "drug_domain": "als", "predicate_ab": "inhibits", "mediator": "STAT3", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "drug resistance", "outcome_type": "phenotype", "outcome_domain": "pancreatic_cancer", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "niclosamide", "mediator_canonical": "STAT3", "outcome_canonical": null, "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "38493058", "title": "Neuroprotective effects of niclosamide on disease progression via inflammatory pathways modulation in SOD1-G93A and FUS-associated amyotrophic lateral sclerosis models", "doi": "10.1016/j.neurot.2024.e00346", "year": 2024 } ], "bc": [ { "pmid": "38464736", "title": "Role of STAT3 in pancreatic cancer", "doi": "10.37349/etat.2024.00202", "year": 2024 } ] } }, { "id": 2788, "drug": "valproic acid", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "downregulates", "mediator": "BDNF", "mediator_type": "gene", "predicate_bc": "causes", "outcome": "depressive phenotype", "outcome_type": "phenotype", "outcome_domain": "depression", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "valproic acid", "mediator_canonical": "BDNF", "outcome_canonical": "depressive phenotype", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "30404997", "title": "Social behavior, neuroimmune markers and glutamic acid decarboxylase levels in a rat model of valproic acid-induced autism", "doi": "10.2131/jts.43.631", "year": 2018 } ], "bc": [ { "pmid": "30548775", "title": "BDNF+/− rats exhibit depressive phenotype and altered expression of genes relevant in mood disorders", "doi": "10.1111/gbb.12546", "year": 2018 } ] } }, { "id": 47189, "drug": "valproic acid", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "activates", "mediator": "TGFβ signaling", "mediator_type": "pathway", "predicate_bc": "associated_with", "outcome": "heart failure", "outcome_type": "disease", "outcome_domain": "heart_failure", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "30050438", "title": "Valproic Acid Induces Endothelial-to-Mesenchymal Transition-Like Phenotypic Switching", "doi": "10.3389/fphar.2018.00737", "year": 2018 } ], "bc": [ { "pmid": "28509980", "title": "The role of TGFβ1 and LRG1 in cardiac remodelling and heart failure", "doi": "10.1007/s12551-014-0158-y", "year": 2015 } ] } }, { "id": 1505, "drug": "apigenin", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "upregulates", "mediator": "GFAP", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "hippocampal volume", "outcome_type": "phenotype", "outcome_domain": "alzheimer", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "apigenin", "mediator_canonical": "GFAP", "outcome_canonical": "hippocampal volume", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41090780", "title": "Apigenin Induces Autophagy and Apoptosis in Chemoresistant Glioblastoma Cells and Inhibits Tumorigenicity Associated with Regulation of Immunomodulatory Proteins and Glial Cells Response", "doi": "10.3390/cells14191552", "year": 2025 } ], "bc": [ { "pmid": "34494715", "title": "Diagnostic and prognostic plasma biomarkers for preclinical Alzheimer's disease", "doi": "10.1002/alz.12447", "year": 2021 } ] } }, { "id": 7517, "drug": "Riluzole", "drug_type": "drug", "drug_domain": "als", "predicate_ab": "downregulates", "mediator": "MMP-9", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "glioblastoma invasiveness", "outcome_type": "phenotype", "outcome_domain": "glioblastoma", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "riluzole", "mediator_canonical": "MMP9", "outcome_canonical": "glioblastoma invasiveness", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40012807", "title": "Investigation of the Neuroprotective Effect of Riluzole on Matrix Metalloproteinases in an Experimental Model of Glaucoma", "doi": "10.4103/joco.joco_290_23", "year": 2024 } ], "bc": [ { "pmid": "41154699", "title": "Engineered N-TIMP2 Variant Specifically Targeting MMP-9 Exhibits Potent Anti-Glioblastoma Activity", "doi": "10.3390/biom15101470", "year": 2025 } ] } }, { "id": 1089, "drug": "verteporfin", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "downregulates", "mediator": "EGFR", "mediator_type": "gene", "predicate_bc": "associated_with", "outcome": "juvenile focal epilepsies", "outcome_type": "disease", "outcome_domain": "epilepsy", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "verteporfin", "mediator_canonical": "EGFR", "outcome_canonical": "juvenile focal epilepsies", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "33172899", "title": "YAP/TAZ Transcriptional Coactivators Create Therapeutic Vulnerability to Verteporfin in EGFR-mutant Glioblastoma", "doi": "10.1158/1078-0432.ccr-20-0018", "year": 2020 } ], "bc": [ { "pmid": "37181029", "title": "Identification of epidermal growth factor receptor as an immune-related biomarker in epilepsy using multi-transcriptome data", "doi": "10.21037/tp-23-196", "year": 2023 } ] } }, { "id": 47147, "drug": "baicalin", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "upregulates", "mediator": "BDNF", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "adverse cardiac remodeling", "outcome_type": "phenotype", "outcome_domain": "heart_failure", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "38778616", "title": "Exploring the Therapeutic Potential of Baicalin: Mitigating Anxiety and Depression in Epileptic Rats", "doi": "10.2174/0113862073316021240520110301", "year": 2024 } ], "bc": [ { "pmid": "31659205", "title": "Brain-derived neurotrophic factor is related with adverse cardiac remodeling and high NTproBNP", "doi": "10.1038/s41598-019-51776-8", "year": 2019 } ] } }, { "id": 5764, "drug": "apigenin", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "upregulates", "mediator": "GFAP", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "nerve amplitude", "outcome_type": "phenotype", "outcome_domain": "als", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "apigenin", "mediator_canonical": "GFAP", "outcome_canonical": "nerve amplitude", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41090780", "title": "Apigenin Induces Autophagy and Apoptosis in Chemoresistant Glioblastoma Cells and Inhibits Tumorigenicity Associated with Regulation of Immunomodulatory Proteins and Glial Cells Response", "doi": "10.3390/cells14191552", "year": 2025 } ], "bc": [ { "pmid": "40192786", "title": "Glial fibrillary acidic protein: a potential biomarker for small fiber neuropathy?", "doi": "10.1007/s00592-025-02500-8", "year": 2025 } ] } }, { "id": 1431, "drug": "apigenin", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "upregulates", "mediator": "GFAP", "mediator_type": "protein", "predicate_bc": "predicts", "outcome": "conversion to mild cognitive impairment or dementia", "outcome_type": "disease", "outcome_domain": "alzheimer", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "apigenin", "mediator_canonical": "GFAP", "outcome_canonical": "conversion to mild cognitive impairment or dementia", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41090780", "title": "Apigenin Induces Autophagy and Apoptosis in Chemoresistant Glioblastoma Cells and Inhibits Tumorigenicity Associated with Regulation of Immunomodulatory Proteins and Glial Cells Response", "doi": "10.3390/cells14191552", "year": 2025 } ], "bc": [ { "pmid": "37885919", "title": "Cross‐sectional and longitudinal evaluation of plasma glial fibrillary acidic protein to detect and predict clinical syndromes of Alzheimer's disease", "doi": "10.1002/dad2.12492", "year": 2023 } ] } }, { "id": 1433, "drug": "apigenin", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "upregulates", "mediator": "GFAP", "mediator_type": "protein", "predicate_bc": "predicts", "outcome": "brain amyloidosis", "outcome_type": "disease", "outcome_domain": "alzheimer", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "apigenin", "mediator_canonical": "GFAP", "outcome_canonical": "brain amyloidosis", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41090780", "title": "Apigenin Induces Autophagy and Apoptosis in Chemoresistant Glioblastoma Cells and Inhibits Tumorigenicity Associated with Regulation of Immunomodulatory Proteins and Glial Cells Response", "doi": "10.3390/cells14191552", "year": 2025 } ], "bc": [ { "pmid": "34494715", "title": "Diagnostic and prognostic plasma biomarkers for preclinical Alzheimer's disease", "doi": "10.1002/alz.12447", "year": 2021 } ] } }, { "id": 6075, "drug": "apigenin", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "upregulates", "mediator": "GFAP", "mediator_type": "protein", "predicate_bc": "predicts", "outcome": "brain amyloid positivity", "outcome_type": "phenotype", "outcome_domain": "alzheimer", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "apigenin", "mediator_canonical": "GFAP", "outcome_canonical": "brain amyloid positivity", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41090780", "title": "Apigenin Induces Autophagy and Apoptosis in Chemoresistant Glioblastoma Cells and Inhibits Tumorigenicity Associated with Regulation of Immunomodulatory Proteins and Glial Cells Response", "doi": "10.3390/cells14191552", "year": 2025 } ], "bc": [ { "pmid": "38605996", "title": "Association of plasma GFAP with elevated brain amyloid is dependent on severity of white matter lesions in an Asian cognitively impaired cohort", "doi": "10.1002/dad2.12576", "year": 2024 } ] } }, { "id": 1697, "drug": "auraptene", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "downregulates", "mediator": "MMP-9", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "vascular invasion", "outcome_type": "phenotype", "outcome_domain": "pancreatic_cancer", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "auraptene", "mediator_canonical": "MMP9", "outcome_canonical": "vascular invasion", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "39086858", "title": "Auraptene inhibits migration, invasion and metastatic behavior of human malignant glioblastoma cells: An in vitro and in silico study.", "doi": "10.22038/ajp.2023.23586", "year": 2024 } ], "bc": [ { "pmid": "26652622", "title": "The co-expression of MMP-9 and Tenascin-C is significantly associated with the progression and prognosis of pancreatic cancer", "doi": "10.1186/s13000-015-0445-3", "year": 2015 } ] } }, { "id": 2146, "drug": "valproic acid", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "downregulates", "mediator": "BDNF", "mediator_type": "gene", "predicate_bc": "correlates_with", "outcome": "disease duration", "outcome_type": "phenotype", "outcome_domain": "als", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "active", "clinical_trial_nct_ids": [ "NCT05603104", "NCT05973786", "NCT01900730" ], "literature_status": "reproduces_known", "drug_canonical": "valproic acid", "mediator_canonical": "BDNF", "outcome_canonical": "disease duration", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "30404997", "title": "Social behavior, neuroimmune markers and glutamic acid decarboxylase levels in a rat model of valproic acid-induced autism", "doi": "10.2131/jts.43.631", "year": 2018 } ], "bc": [ { "pmid": "37450566", "title": "Distinct neuroinflammatory signatures exist across genetic and sporadic amyotrophic lateral sclerosis cohorts", "doi": "10.1093/brain/awad243", "year": 2023 } ] } }, { "id": 47146, "drug": "baicalin", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "upregulates", "mediator": "BDNF", "mediator_type": "protein", "predicate_bc": "treats", "outcome": "septic myocardial dysfunction", "outcome_type": "disease", "outcome_domain": "heart_failure", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "38778616", "title": "Exploring the Therapeutic Potential of Baicalin: Mitigating Anxiety and Depression in Epileptic Rats", "doi": "10.2174/0113862073316021240520110301", "year": 2024 } ], "bc": [ { "pmid": "28770018", "title": "Brain‐Derived Neurotrophic Factor Attenuates Septic Myocardial Dysfunction via eNOS/NO Pathway in Rats", "doi": "10.1155/2017/1721434", "year": 2017 } ] } }, { "id": 47141, "drug": "valproic acid", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "downregulates", "mediator": "BDNF", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "depressive symptoms", "outcome_type": "disease", "outcome_domain": "heart_failure", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "35465089", "title": "Excitatory and Inhibitory Synaptic Imbalance Caused by Brain-Derived Neurotrophic Factor Deficits During Development in a Valproic Acid Mouse Model of Autism", "doi": "10.3389/fnmol.2022.860275", "year": 2022 } ], "bc": [ { "pmid": "32967752", "title": "Brain-derived neurotrophic factor, depressive symptoms and somatic comorbidity in patients with coronary heart disease", "doi": "10.1017/neu.2020.31", "year": 2020 } ] } }, { "id": 47112, "drug": "valproic acid", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "suppresses", "mediator": "galectin-3", "mediator_type": "protein", "predicate_bc": "decreases", "outcome": "fibrosis", "outcome_type": "phenotype", "outcome_domain": "heart_failure", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "34122007", "title": "Post-stroke Delivery of Valproic Acid Promotes Functional Recovery and Differentially Modifies Responses of Peri-Infarct Microglia", "doi": "10.3389/fnmol.2021.639145", "year": 2021 } ], "bc": [ { "pmid": "38170009", "title": "Unraveling the role of galectin-3 in cardiac pathology and physiology", "doi": "10.3389/fphys.2023.1304735", "year": 2023 } ] } }, { "id": 1531, "drug": "dasatinib", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "inhibits", "mediator": "Src", "mediator_type": "protein", "predicate_bc": "predicts", "outcome": "Vascular dementia", "outcome_type": "disease", "outcome_domain": "alzheimer", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "dasatinib", "mediator_canonical": "src", "outcome_canonical": "Vascular dementia", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "34232320", "title": "A novel patient stratification strategy to enhance the therapeutic efficacy of dasatinib in glioblastoma", "doi": "10.1093/neuonc/noab158", "year": 2021 } ], "bc": [ { "pmid": "36761180", "title": "Urinary protein biomarkers based on LC–MS/MS analysis to discriminate vascular dementia from Alzheimer’s disease in Han Chinese population", "doi": "10.3389/fnagi.2023.1070854", "year": 2023 } ] } }, { "id": 47111, "drug": "valproic acid", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "suppresses", "mediator": "galectin-3", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "myocardial fibrosis", "outcome_type": "disease", "outcome_domain": "heart_failure", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "34122007", "title": "Post-stroke Delivery of Valproic Acid Promotes Functional Recovery and Differentially Modifies Responses of Peri-Infarct Microglia", "doi": "10.3389/fnmol.2021.639145", "year": 2021 } ], "bc": [ { "pmid": "26217237", "title": "Serum PINP, PIIINP, galectin-3, and ST2 as surrogates of myocardial fibrosis and echocardiographic left venticular diastolic filling properties", "doi": "10.3389/fphys.2015.00200", "year": 2015 } ] } }, { "id": 23072, "drug": "chloroquine", "drug_type": "drug", "drug_domain": "multiple_sclerosis", "predicate_ab": "upregulates", "mediator": "IL-10", "mediator_type": "protein", "predicate_bc": "predicts", "outcome": "glioblastoma", "outcome_type": "disease", "outcome_domain": "glioblastoma", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "completed", "clinical_trial_nct_ids": [ "NCT02378532", "NCT00486603", "NCT01602588" ], "literature_status": "reproduces_known", "drug_canonical": "chloroquine", "mediator_canonical": "il-10", "outcome_canonical": "glioblastoma", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "32516999", "title": "Comprehensive Analysis of the Immune and Stromal Compartments of the CNS in EAE Mice Reveal Pathways by Which Chloroquine Suppresses Neuroinflammation", "doi": "10.3390/brainsci10060348", "year": 2020 } ], "bc": [ { "pmid": "38003396", "title": "Cytokine Profile in Development of Glioblastoma in Relation to Healthy Individuals", "doi": "10.3390/ijms242216206", "year": 2023 } ] } }, { "id": 47110, "drug": "valproic acid", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "suppresses", "mediator": "galectin-3", "mediator_type": "protein", "predicate_bc": "predicts", "outcome": "left ventricular remodeling", "outcome_type": "phenotype", "outcome_domain": "heart_failure", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "34122007", "title": "Post-stroke Delivery of Valproic Acid Promotes Functional Recovery and Differentially Modifies Responses of Peri-Infarct Microglia", "doi": "10.3389/fnmol.2021.639145", "year": 2021 } ], "bc": [ { "pmid": "26693954", "title": "Galectin‐3 Predicts Left Ventricular Remodeling of Hypertension", "doi": "10.1111/jch.12757", "year": 2015 } ] } }, { "id": 47109, "drug": "valproic acid", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "suppresses", "mediator": "galectin-3", "mediator_type": "protein", "predicate_bc": "predicts", "outcome": "catheter ablation outcomes", "outcome_type": "phenotype", "outcome_domain": "heart_failure", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "34122007", "title": "Post-stroke Delivery of Valproic Acid Promotes Functional Recovery and Differentially Modifies Responses of Peri-Infarct Microglia", "doi": "10.3389/fnmol.2021.639145", "year": 2021 } ], "bc": [ { "pmid": "27525318", "title": "Galectin-3 Regulates Atrial Fibrillation Remodeling and Predicts Catheter Ablation Outcomes", "doi": "10.1016/j.jacbts.2016.03.003", "year": 2016 } ] } }, { "id": 1518, "drug": "auraptene", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "downregulates", "mediator": "MMP-2", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "brain amyloid deposition", "outcome_type": "phenotype", "outcome_domain": "alzheimer", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "auraptene", "mediator_canonical": "MMP2", "outcome_canonical": "brain amyloid deposition", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "39086858", "title": "Auraptene inhibits migration, invasion and metastatic behavior of human malignant glioblastoma cells: An in vitro and in silico study.", "doi": "10.22038/ajp.2023.23586", "year": 2024 } ], "bc": [ { "pmid": "34680129", "title": "Relationship between Cerebrospinal Fluid Matrix Metalloproteinases Levels and Brain Amyloid Deposition in Mild Cognitive Impairment", "doi": "10.3390/biom11101496", "year": 2021 } ] } }, { "id": 356, "drug": "valproic acid", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "downregulates", "mediator": "Twist1", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "astrocytoma grade", "outcome_type": "phenotype", "outcome_domain": "glioblastoma", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "completed", "clinical_trial_nct_ids": [ "NCT01817751", "NCT00879437", "NCT00404248" ], "literature_status": "novel_signal", "drug_canonical": "valproic acid", "mediator_canonical": "twist1", "outcome_canonical": "astrocytoma grade", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "30373123", "title": "Valproic Acid Inhibits Proliferation and Reduces Invasiveness in Glioma Stem Cells Through Wnt/β Catenin Signalling Activation", "doi": "10.3390/genes9110522", "year": 2018 } ], "bc": [ { "pmid": "31289562", "title": "Twist1 promotes astrocytoma development by stimulating vasculogenic mimicry", "doi": "10.3892/ol.2019.10380", "year": 2019 } ] } }, { "id": 7336, "drug": "Baicalin", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "upregulates", "mediator": "BDNF", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "suicide risk", "outcome_type": "phenotype", "outcome_domain": "depression", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "baicalin", "mediator_canonical": "BDNF", "outcome_canonical": "suicide risk", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "38778616", "title": "Exploring the Therapeutic Potential of Baicalin: Mitigating Anxiety and Depression in Epileptic Rats", "doi": "10.2174/0113862073316021240520110301", "year": 2024 } ], "bc": [ { "pmid": "32209966", "title": "Understanding the Complex of Suicide in Depression: from Research to Clinics", "doi": "10.30773/pi.2019.0171", "year": 2020 } ] } }, { "id": 41983, "drug": "riluzole", "drug_type": "drug", "drug_domain": "als", "predicate_ab": "downregulates", "mediator": "MMP-2", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "global cardiac fibrosis", "outcome_type": "phenotype", "outcome_domain": "heart_failure", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40012807", "title": "Investigation of the Neuroprotective Effect of Riluzole on Matrix Metalloproteinases in an Experimental Model of Glaucoma", "doi": "10.4103/joco.joco_290_23", "year": 2024 } ], "bc": [ { "pmid": "30413105", "title": "Combination of Plasma Biomarkers and Clinical Data for the Detection of Myocardial Fibrosis or Aggravation of Heart Failure Symptoms in Heart Failure with Preserved Ejection Fraction Patients", "doi": "10.3390/jcm7110427", "year": 2018 } ] } }, { "id": 19523, "drug": "Riluzole", "drug_type": "drug", "drug_domain": "als", "predicate_ab": "activates", "mediator": "p53", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "successful PDX engraftment", "outcome_type": "phenotype", "outcome_domain": "pancreatic_cancer", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "riluzole", "mediator_canonical": "TP53", "outcome_canonical": "successful pdx engraftment", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "32231713", "title": "Riluzole Enhances the Response of Human Nasopharyngeal Carcinoma Cells to Ionizing Radiation via ATM/P53 Signalling Pathway", "doi": "10.7150/jca.41217", "year": 2020 } ], "bc": [ { "pmid": "26851005", "title": "Surgical and Oncological Factors Affecting the Successful Engraftment of Patient-derived Xenografts in Pancreatic Ductal Adenocarcinoma.", "doi": null, "year": 2016 } ] } }, { "id": 48378, "drug": "Apigenin", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "upregulates", "mediator": "GFAP", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "nerve conductivity", "outcome_type": "phenotype", "outcome_domain": "als", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41090780", "title": "Apigenin Induces Autophagy and Apoptosis in Chemoresistant Glioblastoma Cells and Inhibits Tumorigenicity Associated with Regulation of Immunomodulatory Proteins and Glial Cells Response", "doi": "10.3390/cells14191552", "year": 2025 } ], "bc": [ { "pmid": "40192786", "title": "Glial fibrillary acidic protein: a potential biomarker for small fiber neuropathy?", "doi": "10.1007/s00592-025-02500-8", "year": 2025 } ] } }, { "id": 266, "drug": "valproic acid", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "activates", "mediator": "TGFβ signaling", "mediator_type": "pathway", "predicate_bc": "associated_with", "outcome": "recurrence", "outcome_type": "disease", "outcome_domain": "glioblastoma", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "active", "clinical_trial_nct_ids": [ "NCT00075777", "NCT02446431", "NCT01552434" ], "literature_status": "reproduces_known", "drug_canonical": "valproic acid", "mediator_canonical": "tgfβ signaling", "outcome_canonical": null, "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "30050438", "title": "Valproic Acid Induces Endothelial-to-Mesenchymal Transition-Like Phenotypic Switching", "doi": "10.3389/fphar.2018.00737", "year": 2018 } ], "bc": [ { "pmid": "36621024", "title": "Subclonal evolution and expansion of spatially distinct THY1-positive cells is associated with recurrence in glioblastoma", "doi": "10.1016/j.neo.2022.100872", "year": 2023 } ] } }, { "id": 25873, "drug": "resveratrol", "drug_type": "drug", "drug_domain": "als", "predicate_ab": "activates", "mediator": "SIRT1", "mediator_type": "protein", "predicate_bc": "treats", "outcome": "Type 2 Diabetes Mellitus", "outcome_type": "disease", "outcome_domain": "type_2_diabetes", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "active", "clinical_trial_nct_ids": [ "NCT07195994", "NCT03762096", "NCT07569744" ], "literature_status": "reproduces_known", "drug_canonical": "resveratrol", "mediator_canonical": "SIRT1", "outcome_canonical": "type 2 diabetes mellitus", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "26981091", "title": "How does resveratrol influence the genesis of some neurodegenerative diseases?", "doi": "10.4103/1673-5374.175047", "year": 2016 } ], "bc": [ { "pmid": "34379994", "title": "SIRT1: a promising therapeutic target in type 2 diabetes mellitus", "doi": "10.1080/13813455.2021.1956976", "year": 2021 } ] } }, { "id": 313, "drug": "valproic acid", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "upregulates", "mediator": "CXCR4", "mediator_type": "gene", "predicate_bc": "correlates_with", "outcome": "tumor inflammation", "outcome_type": "phenotype", "outcome_domain": "glioblastoma", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "valproic acid", "mediator_canonical": "CXCR4", "outcome_canonical": "tumor inflammation", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40164048", "title": "Valproic acid preconditioning of bone marrow mesenchymal stem cells promotes remyelination of the corpus callosum in a cuprizone-induced demyelination model", "doi": "10.1016/j.biopha.2025.118027", "year": 2025 } ], "bc": [ { "pmid": "37626511", "title": "Development and Validation of CXCR4 Nomogram-Based Immune Infiltration/Tumor Inflammation in Primary Glioblastoma", "doi": "10.3390/brainsci13081152", "year": 2023 } ] } }, { "id": 24658, "drug": "niclosamide", "drug_type": "drug", "drug_domain": "als", "predicate_ab": "inhibits", "mediator": "mTOR", "mediator_type": "protein", "predicate_bc": "causes", "outcome": "mTOR-opathies", "outcome_type": "disease", "outcome_domain": "epilepsy", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "niclosamide", "mediator_canonical": "mTOR", "outcome_canonical": "mtor-opathies", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "38493058", "title": "Neuroprotective effects of niclosamide on disease progression via inflammatory pathways modulation in SOD1-G93A and FUS-associated amyotrophic lateral sclerosis models", "doi": "10.1016/j.neurot.2024.e00346", "year": 2024 } ], "bc": [ { "pmid": "29447953", "title": "Dendrite growth and the effect of ectopic Rheb expression on cortical neurons", "doi": "10.1016/j.neulet.2018.02.021", "year": 2018 } ] } }, { "id": 620, "drug": "cisplatin", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "activates", "mediator": "caspase-3", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "drug-resistant epilepsy", "outcome_type": "disease", "outcome_domain": "epilepsy", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "cisplatin", "mediator_canonical": "CASP3", "outcome_canonical": "drug-resistant epilepsy", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "39810130", "title": "Engineered biomimetic cisplatin-polyphenol nanocomplex for chemo-immunotherapy of glioblastoma by inducing pyroptosis", "doi": "10.1186/s12951-025-03091-w", "year": 2025 } ], "bc": [ { "pmid": "37833937", "title": "Expression of Cytoskeletal Proteins (GFAP, Vimentin), Proapoptotic Protein (Caspase-3) and Protective Protein (S100) in the Epileptic Focus in Adults and Children with Drug-Resistant Temporal Lobe Epilepsy Associated with Focal Cortical Dysplasia", "doi": "10.3390/ijms241914490", "year": 2023 } ] } }, { "id": 34965, "drug": "Curcumin", "drug_type": "drug", "drug_domain": "multiple_sclerosis", "predicate_ab": "upregulates", "mediator": "FOXP3", "mediator_type": "gene", "predicate_bc": "associated_with", "outcome": "poor prognosis", "outcome_type": "phenotype", "outcome_domain": "glioblastoma", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "curcumin", "mediator_canonical": "foxp3", "outcome_canonical": null, "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "38566376", "title": "Immunoregulatory Effects of the Active Form of Vitamin D (Calcitriol),Individually and in Combination with Curcumin, on Peripheral BloodMononuclear Cells (PBMCs) of Multiple Sclerosis (MS) Patients", "doi": "10.2174/0118715230293847240314073359", "year": 2024 } ], "bc": [ { "pmid": "38561331", "title": "FOXP3 promote the progression of glioblastoma via inhibiting ferroptosis mediated by linc00857/miR-1290/GPX4 axis", "doi": "10.1038/s41419-024-06619-4", "year": 2024 } ] } }, { "id": 30889, "drug": "Apigenin", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "upregulates", "mediator": "GFAP", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "somatomotor network connectivity", "outcome_type": "phenotype", "outcome_domain": "alzheimer", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "apigenin", "mediator_canonical": "GFAP", "outcome_canonical": "somatomotor network connectivity", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41090780", "title": "Apigenin Induces Autophagy and Apoptosis in Chemoresistant Glioblastoma Cells and Inhibits Tumorigenicity Associated with Regulation of Immunomodulatory Proteins and Glial Cells Response", "doi": "10.3390/cells14191552", "year": 2025 } ], "bc": [ { "pmid": "39889254", "title": "Association of Plasma Biomarkers of Alzheimer Disease and Neurodegeneration With Longitudinal Intra-Network Functional Brain Connectivity", "doi": "10.1212/wnl.0000000000210271", "year": 2025 } ] } }, { "id": 56821, "drug": "resveratrol", "drug_type": "drug", "drug_domain": "pancreatic_cancer", "predicate_ab": "upregulates", "mediator": "Pten", "mediator_type": "gene", "predicate_bc": "decreases", "outcome": "neuroinflammation", "outcome_type": "disease", "outcome_domain": "epilepsy", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "29854071", "title": "Resveratrol Inhibits ROS‐Promoted Activation and Glycolysis of Pancreatic Stellate Cells via Suppression of miR‐21", "doi": "10.1155/2018/1346958", "year": 2018 } ], "bc": [ { "pmid": "31658159", "title": "Effect of adenovirus-mediated overexpression of PTEN on brain oxidative damage and neuroinflammation in a rat kindling model of epilepsy [RETRACTED]", "doi": "10.1097/cm9.0000000000000496", "year": 2019 } ] } }, { "id": 34804, "drug": "chloroquine", "drug_type": "drug", "drug_domain": "multiple_sclerosis", "predicate_ab": "upregulates", "mediator": "IL-10", "mediator_type": "protein", "predicate_bc": "increases", "outcome": "epileptogenesis", "outcome_type": "disease", "outcome_domain": "epilepsy", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "chloroquine", "mediator_canonical": "il-10", "outcome_canonical": "epileptogenesis", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "32516999", "title": "Comprehensive Analysis of the Immune and Stromal Compartments of the CNS in EAE Mice Reveal Pathways by Which Chloroquine Suppresses Neuroinflammation", "doi": "10.3390/brainsci10060348", "year": 2020 } ], "bc": [ { "pmid": "35625063", "title": "Hippocampal Cytokine Release in Experimental Epileptogenesis—A Longitudinal In Vivo Microdialysis Study", "doi": "10.3390/brainsci12050677", "year": 2022 } ] } }, { "id": 34653, "drug": "chloroquine", "drug_type": "drug", "drug_domain": "multiple_sclerosis", "predicate_ab": "upregulates", "mediator": "IL-10", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "suicidality", "outcome_type": "phenotype", "outcome_domain": "depression", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "chloroquine", "mediator_canonical": "il-10", "outcome_canonical": "suicidality", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "32516999", "title": "Comprehensive Analysis of the Immune and Stromal Compartments of the CNS in EAE Mice Reveal Pathways by Which Chloroquine Suppresses Neuroinflammation", "doi": "10.3390/brainsci10060348", "year": 2020 } ], "bc": [ { "pmid": "38549611", "title": "Association between cytokines and suicidality in patients with psychosis: A multicentre longitudinal analysis", "doi": "10.1016/j.bbih.2024.100756", "year": 2024 } ] } }, { "id": 32189, "drug": "auraptene", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "downregulates", "mediator": "MMP-2", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "brachial 24-h pulse pressure", "outcome_type": "phenotype", "outcome_domain": "type_2_diabetes", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "auraptene", "mediator_canonical": "MMP2", "outcome_canonical": "brachial 24-h pulse pressure", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "39086858", "title": "Auraptene inhibits migration, invasion and metastatic behavior of human malignant glioblastoma cells: An in vitro and in silico study.", "doi": "10.22038/ajp.2023.23586", "year": 2024 } ], "bc": [ { "pmid": "29070037", "title": "Circulating matrix metalloproteinases are associated with arterial stiffness in patients with type 1 diabetes: pooled analysis of three cohort studies", "doi": "10.1186/s12933-017-0620-9", "year": 2017 } ] } }, { "id": 48690, "drug": "Verteporfin", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "downregulates", "mediator": "EGFR", "mediator_type": "gene", "predicate_bc": "prevents", "outcome": "MDD", "outcome_type": "disease", "outcome_domain": "depression", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "33172899", "title": "YAP/TAZ Transcriptional Coactivators Create Therapeutic Vulnerability to Verteporfin in EGFR-mutant Glioblastoma", "doi": "10.1158/1078-0432.ccr-20-0018", "year": 2020 } ], "bc": [ { "pmid": "41912493", "title": "Bisphenol a exposure and major depressive disorder: an integrative analysis combining network toxicology, molecular docking, genetic epidemiology, and transcriptomic validation", "doi": "10.1038/s41398-026-03862-5", "year": 2026 } ] } }, { "id": 30962, "drug": "osimertinib", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "inhibits", "mediator": "EGFR", "mediator_type": "gene", "predicate_bc": "prevents", "outcome": "MDD", "outcome_type": "disease", "outcome_domain": "depression", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "osimertinib", "mediator_canonical": "EGFR", "outcome_canonical": "major depressive disorder", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "31678994", "title": "Betacellulin drives therapy resistance in glioblastoma", "doi": "10.1093/neuonc/noz206", "year": 2019 } ], "bc": [ { "pmid": "41912493", "title": "Bisphenol a exposure and major depressive disorder: an integrative analysis combining network toxicology, molecular docking, genetic epidemiology, and transcriptomic validation", "doi": "10.1038/s41398-026-03862-5", "year": 2026 } ] } }, { "id": 7803, "drug": "lithium", "drug_type": "drug", "drug_domain": "als", "predicate_ab": "inhibits", "mediator": "GSK-3β", "mediator_type": "protein", "predicate_bc": "increases", "outcome": "neurodegeneration", "outcome_type": "phenotype", "outcome_domain": "epilepsy", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "completed", "clinical_trial_nct_ids": [ "NCT00818389" ], "literature_status": "reproduces_known", "drug_canonical": "lithium", "mediator_canonical": "GSK3B", "outcome_canonical": null, "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "39363657", "title": "Lithium alleviates paralysis in experimental autoimmune neuritis in Lewis rats by modulating glycogen synthase kinase-3β activity", "doi": "10.4142/jvs.24212", "year": 2024 } ], "bc": [ { "pmid": "30237424", "title": "Bi-directional genetic modulation of GSK-3β exacerbates hippocampal neuropathology in experimental status epilepticus", "doi": "10.1038/s41419-018-0963-5", "year": 2018 } ] } }, { "id": 26882, "drug": "Curcumin", "drug_type": "drug", "drug_domain": "alzheimer", "predicate_ab": "upregulates", "mediator": "BDNF", "mediator_type": "protein", "predicate_bc": "increases", "outcome": "cell viability", "outcome_type": "phenotype", "outcome_domain": "inflammatory_bowel_disease", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "curcumin", "mediator_canonical": "BDNF", "outcome_canonical": "cell viability", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "38791161", "title": "Curcumin Improves Neurogenesis in Alzheimer’s Disease Mice via the Upregulation of Wnt/β-Catenin and BDNF", "doi": "10.3390/ijms25105123", "year": 2024 } ], "bc": [ { "pmid": "34543287", "title": "Chronic colitis upregulates microRNAs suppressing brain-derived neurotrophic factor in the adult heart", "doi": "10.1371/journal.pone.0257280", "year": 2021 } ] } }, { "id": 34397, "drug": "methylprednisolone", "drug_type": "drug", "drug_domain": "multiple_sclerosis", "predicate_ab": "downregulates", "mediator": "Iba1", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "Alzheimer's disease", "outcome_type": "disease", "outcome_domain": "alzheimer", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "methylprednisolone", "mediator_canonical": "iba1", "outcome_canonical": "Alzheimer disease", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "31886871", "title": "Intranasal Methylprednisolone Effectively Reduces Neuroinflammation in Mice With Experimental Autoimmune Encephalitis", "doi": "10.1093/jnen/nlz128", "year": 2019 } ], "bc": [ { "pmid": "32514860", "title": "Synaptic Loss, ER Stress and Neuro-Inflammation Emerge Late in the Lateral Temporal Cortex and Associate with Progressive Tau Pathology in Alzheimer’s Disease", "doi": "10.1007/s12035-020-01950-1", "year": 2020 } ] } }, { "id": 16967, "drug": "apigenin", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "upregulates", "mediator": "GFAP", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "FLR Aβ deposition", "outcome_type": "phenotype", "outcome_domain": "alzheimer", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "apigenin", "mediator_canonical": "GFAP", "outcome_canonical": "flr aβ deposition", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41090780", "title": "Apigenin Induces Autophagy and Apoptosis in Chemoresistant Glioblastoma Cells and Inhibits Tumorigenicity Associated with Regulation of Immunomodulatory Proteins and Glial Cells Response", "doi": "10.3390/cells14191552", "year": 2025 } ], "bc": [ { "pmid": "35491781", "title": "Blood Phosphorylated Tau 181 as a Biomarker for Amyloid Burden on Brain PET in Cognitively Healthy Adults", "doi": "10.3233/jad-215639", "year": 2022 } ] } }, { "id": 5601, "drug": "erlotinib", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "inhibits", "mediator": "EGFR", "mediator_type": "gene", "predicate_bc": "associated_with", "outcome": "juvenile focal epilepsies", "outcome_type": "disease", "outcome_domain": "epilepsy", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "erlotinib", "mediator_canonical": "EGFR", "outcome_canonical": "juvenile focal epilepsies", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "30240496", "title": "Design of a Multicompartment Hydrogel that Facilitates Time‐Resolved Delivery of Combination Therapy and Synergized Killing of Glioblastoma", "doi": "10.1002/anie.201806483", "year": 2018 } ], "bc": [ { "pmid": "37181029", "title": "Identification of epidermal growth factor receptor as an immune-related biomarker in epilepsy using multi-transcriptome data", "doi": "10.21037/tp-23-196", "year": 2023 } ] } }, { "id": 48955, "drug": "riluzole", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "suppresses", "mediator": "MGMT", "mediator_type": "gene", "predicate_bc": "correlates_with", "outcome": "seizure reduction", "outcome_type": "phenotype", "outcome_domain": "epilepsy", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "32168477", "title": "Riluzole enhances the antitumor effects of temozolomide via suppression of MGMT expression in glioblastoma", "doi": "10.3171/2019.12.jns192682", "year": 2020 } ], "bc": [ { "pmid": "30507318", "title": "Perampanel in patients with brain tumor-related epilepsy in real-life clinical practice: a retrospective analysis", "doi": "10.1080/00207454.2018.1555160", "year": 2018 } ] } }, { "id": 5546, "drug": "acriflavine", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "inhibits", "mediator": "HIF-1α", "mediator_type": "protein", "predicate_bc": "increases", "outcome": "hippocampal neuron damage", "outcome_type": "phenotype", "outcome_domain": "epilepsy", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "acriflavine", "mediator_canonical": "hif-1α", "outcome_canonical": "hippocampal neuron damage", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40405165", "title": "Photo-controlled co-delivery of verteporfin and acriflavine via platelets achieves potentiated glioblastoma-targeted photodynamic therapy", "doi": "10.1186/s12951-025-03395-x", "year": 2025 } ], "bc": [ { "pmid": "41324728", "title": "The Role of HIF-1α/BNIP3 Pathway in Hippocampal Neuronal Autophagy in Epilepsy", "doi": "10.1007/s12035-025-05406-2", "year": 2025 } ] } }, { "id": 5577, "drug": "resveratrol", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "downregulates", "mediator": "P-glycoprotein", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "QT interval prolongation", "outcome_type": "phenotype", "outcome_domain": "epilepsy", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "resveratrol", "mediator_canonical": "ABCB1", "outcome_canonical": "qt interval prolongation", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41253172", "title": "Resveratrol Sensitizes Temozolomide-Resistant Glioblastoma Cells Through Mitogen-Activated Protein Kinase Pathway Inhibition and P-Glycoprotein Modulation", "doi": "10.1055/a-2698-0203", "year": 2025 } ], "bc": [ { "pmid": "29462915", "title": "Pilocarpine-Induced Status Epilepticus Is Associated with P-Glycoprotein Induction in Cardiomyocytes, Electrocardiographic Changes, and Sudden Death", "doi": "10.3390/ph11010021", "year": 2018 } ] } }, { "id": 34223, "drug": "chloroquine", "drug_type": "drug", "drug_domain": "multiple_sclerosis", "predicate_ab": "upregulates", "mediator": "IL-10", "mediator_type": "protein", "predicate_bc": "increases", "outcome": "survival", "outcome_type": "phenotype", "outcome_domain": "als", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "completed", "clinical_trial_nct_ids": [ "NCT01727531", "NCT04566133", "NCT04359953" ], "literature_status": "reproduces_known", "drug_canonical": "chloroquine", "mediator_canonical": "il-10", "outcome_canonical": null, "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "32516999", "title": "Comprehensive Analysis of the Immune and Stromal Compartments of the CNS in EAE Mice Reveal Pathways by Which Chloroquine Suppresses Neuroinflammation", "doi": "10.3390/brainsci10060348", "year": 2020 } ], "bc": [ { "pmid": "26791230", "title": "IL-10 Controls Early Microglial Phenotypes and Disease Onset in ALS Caused by Misfolded Superoxide Dismutase 1", "doi": "10.1523/jneurosci.0854-15.2016", "year": 2016 } ] } }, { "id": 34209, "drug": "valproic acid", "drug_type": "drug", "drug_domain": "multiple_sclerosis", "predicate_ab": "upregulates", "mediator": "β-catenin", "mediator_type": "protein", "predicate_bc": "causes", "outcome": "motor neuron degeneration", "outcome_type": "phenotype", "outcome_domain": "als", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "valproic acid", "mediator_canonical": "β-catenin", "outcome_canonical": "motor neuron degeneration", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37937413", "title": "Valproic acid effects on human adipose-derived stem cell differentiation into oligodendrocytes and improved remyelination in a mouse model of Multiple Sclerosis", "doi": "10.1387/ijdb.230154ng", "year": 2023 } ], "bc": [ { "pmid": "35750046", "title": "Upregulation of β-catenin due to loss of miR-139 contributes to motor neuron death in amyotrophic lateral sclerosis", "doi": "10.1016/j.stemcr.2022.05.019", "year": 2022 } ] } }, { "id": 33292, "drug": "Mebendazole", "drug_type": "drug", "drug_domain": "inflammatory_bowel_disease", "predicate_ab": "downregulates", "mediator": "COL1A1", "mediator_type": "gene", "predicate_bc": "associated_with", "outcome": "glioma malignant behavior", "outcome_type": "phenotype", "outcome_domain": "glioblastoma", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "mebendazole", "mediator_canonical": "col1a1", "outcome_canonical": "glioma malignant behavior", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "35715495", "title": "Mebendazole, an anti-helminth drug, suppresses inflammation, oxidative stress and injury in a mouse model of ulcerative colitis", "doi": "10.1038/s41598-022-14420-6", "year": 2022 } ], "bc": [ { "pmid": "35750880", "title": "Spatiotemporal analysis of glioma heterogeneity reveals COL1A1 as an actionable target to disrupt tumor progression", "doi": "10.1038/s41467-022-31340-1", "year": 2022 } ] } }, { "id": 32049, "drug": "cabozantinib", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "inhibits", "mediator": "AXL", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "pro-inflammatory gene expression", "outcome_type": "phenotype", "outcome_domain": "rheumatoid_arthritis", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "cabozantinib", "mediator_canonical": "axl", "outcome_canonical": "pro-inflammatory gene expression", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "29660005", "title": "Volumetric response quantified using T1 subtraction predicts long-term survival benefit from cabozantinib monotherapy in recurrent glioblastoma", "doi": "10.1093/neuonc/noy054", "year": 2018 } ], "bc": [ { "pmid": "38493215", "title": "Axl and MerTK regulate synovial inflammation and are modulated by IL-6 inhibition in rheumatoid arthritis", "doi": "10.1038/s41467-024-46564-6", "year": 2024 } ] } }, { "id": 283, "drug": "verapamil", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "inhibits", "mediator": "P-glycoprotein", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "multidrug resistance", "outcome_type": "phenotype", "outcome_domain": "glioblastoma", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "verapamil", "mediator_canonical": "ABCB1", "outcome_canonical": null, "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "35953704", "title": "Efflux dynamics of the antiseizure drug, levetiracetam, through the P-glycoprotein channel revealed by advanced comparative molecular simulations", "doi": "10.1038/s41598-022-17994-3", "year": 2022 } ], "bc": [ { "pmid": "35093870", "title": "Ko143 Reverses MDR in Glioblastoma via Deactivating P-Glycoprotein, Sensitizing a Resistant Phenotype to TMZ Treatment", "doi": "10.21873/anticanres.15530", "year": 2022 } ] } }, { "id": 18512, "drug": "Baicalin", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "upregulates", "mediator": "BDNF", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "depressive disorder", "outcome_type": "disease", "outcome_domain": "depression", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "baicalin", "mediator_canonical": "BDNF", "outcome_canonical": "depressive disorder", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "38778616", "title": "Exploring the Therapeutic Potential of Baicalin: Mitigating Anxiety and Depression in Epileptic Rats", "doi": "10.2174/0113862073316021240520110301", "year": 2024 } ], "bc": [ { "pmid": "34979889", "title": "The Role of Natural Products in Treatment of Depressive Disorder", "doi": "10.2174/1570159x20666220103140834", "year": 2022 } ] } }, { "id": 25874, "drug": "resveratrol", "drug_type": "drug", "drug_domain": "als", "predicate_ab": "activates", "mediator": "SIRT1", "mediator_type": "protein", "predicate_bc": "treats", "outcome": "diabetic nephropathy", "outcome_type": "disease", "outcome_domain": "type_2_diabetes", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "completed", "clinical_trial_nct_ids": [ "NCT02704494" ], "literature_status": "reproduces_known", "drug_canonical": "resveratrol", "mediator_canonical": "SIRT1", "outcome_canonical": "diabetic nephropathy", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "26981091", "title": "How does resveratrol influence the genesis of some neurodegenerative diseases?", "doi": "10.4103/1673-5374.175047", "year": 2016 } ], "bc": [ { "pmid": "30988688", "title": "Exercise training upregulates SIRT1 to attenuate inflammation and metabolic dysfunction in kidney and liver of diabetic db/db mice", "doi": "10.1186/s12986-019-0349-4", "year": 2019 } ] } }, { "id": 25804, "drug": "niclosamide", "drug_type": "drug", "drug_domain": "als", "predicate_ab": "inhibits", "mediator": "mTOR", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "microvascular complications", "outcome_type": "disease", "outcome_domain": "type_2_diabetes", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "niclosamide", "mediator_canonical": "mTOR", "outcome_canonical": "microvascular complications", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "38493058", "title": "Neuroprotective effects of niclosamide on disease progression via inflammatory pathways modulation in SOD1-G93A and FUS-associated amyotrophic lateral sclerosis models", "doi": "10.1016/j.neurot.2024.e00346", "year": 2024 } ], "bc": [ { "pmid": "39261960", "title": "The relation of mTOR with diabetic complications and insulin resistance in patients with type 2 diabetes mellitus", "doi": "10.1186/s13098-024-01450-5", "year": 2024 } ] } }, { "id": 2990, "drug": "niclosamide", "drug_type": "drug", "drug_domain": "als", "predicate_ab": "inhibits", "mediator": "STAT3", "mediator_type": "protein", "predicate_bc": "prevents", "outcome": "imprinting of epileptic activity patterns", "outcome_type": "phenotype", "outcome_domain": "epilepsy", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "niclosamide", "mediator_canonical": "STAT3", "outcome_canonical": "imprinting of epileptic activity patterns", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "38493058", "title": "Neuroprotective effects of niclosamide on disease progression via inflammatory pathways modulation in SOD1-G93A and FUS-associated amyotrophic lateral sclerosis models", "doi": "10.1016/j.neurot.2024.e00346", "year": 2024 } ], "bc": [ { "pmid": "36825472", "title": "Blockage of STAT3 during epileptogenesis prevents GABAergic loss and imprinting of the epileptic state", "doi": "10.1093/brain/awad055", "year": 2023 } ] } }, { "id": 41611, "drug": "Curcumin", "drug_type": "drug", "drug_domain": "als", "predicate_ab": "inhibits", "mediator": "Caspase-3", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "drug-resistant epilepsy", "outcome_type": "disease", "outcome_domain": "epilepsy", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "26064904", "title": "Implication of Caspase-3 as a Common Therapeutic Target for Multineurodegenerative Disorders and Its Inhibition Using Nonpeptidyl Natural Compounds", "doi": "10.1155/2015/379817", "year": 2015 } ], "bc": [ { "pmid": "37833937", "title": "Expression of Cytoskeletal Proteins (GFAP, Vimentin), Proapoptotic Protein (Caspase-3) and Protective Protein (S100) in the Epileptic Focus in Adults and Children with Drug-Resistant Temporal Lobe Epilepsy Associated with Focal Cortical Dysplasia", "doi": "10.3390/ijms241914490", "year": 2023 } ] } }, { "id": 39545, "drug": "Curcumin", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "downregulates", "mediator": "total cholesterol", "mediator_type": "biomarker", "predicate_bc": "associated_with", "outcome": "earlier age at onset of ALS", "outcome_type": "phenotype", "outcome_domain": "als", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "curcumin", "mediator_canonical": "total cholesterol", "outcome_canonical": "earlier age at onset of als", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "31645652", "title": "Histological evidence of chitosan-encapsulated curcumin suppresses heart and kidney damages on streptozotocin-induced type-1 diabetes in mice model", "doi": "10.1038/s41598-019-51821-6", "year": 2019 } ], "bc": [ { "pmid": "37872557", "title": "Genome-wide analyses identify NEAT1 as genetic modifier of age at onset of amyotrophic lateral sclerosis", "doi": "10.1186/s13024-023-00669-6", "year": 2023 } ] } }, { "id": 25841, "drug": "resveratrol", "drug_type": "drug", "drug_domain": "als", "predicate_ab": "activates", "mediator": "SIRT1", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "T2D onset", "outcome_type": "disease", "outcome_domain": "type_2_diabetes", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "resveratrol", "mediator_canonical": "SIRT1", "outcome_canonical": "t2d onset", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "26981091", "title": "How does resveratrol influence the genesis of some neurodegenerative diseases?", "doi": "10.4103/1673-5374.175047", "year": 2016 } ], "bc": [ { "pmid": "35879296", "title": "Phenylalanine impairs insulin signaling and inhibits glucose uptake through modification of IRβ", "doi": "10.1038/s41467-022-32000-0", "year": 2022 } ] } }, { "id": 31654, "drug": "resveratrol", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "upregulates", "mediator": "p53", "mediator_type": "gene", "predicate_bc": "decreases", "outcome": "white matter damage", "outcome_type": "phenotype", "outcome_domain": "multiple_sclerosis", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "resveratrol", "mediator_canonical": "TP53", "outcome_canonical": "white matter damage", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40802352", "title": "Resveratrol and temozolomide induce apoptosis and suppress proliferation in glioblastoma cells via the apoptotic signaling pathway", "doi": "10.1590/acb405525", "year": 2025 } ], "bc": [ { "pmid": "34884611", "title": "Differential Role of p53 in Oligodendrocyte Survival in Response to Various Stresses: Experimental Autoimmune Encephalomyelitis, Cuprizone Intoxication or White Matter Stroke", "doi": "10.3390/ijms222312811", "year": 2021 } ] } }, { "id": 31594, "drug": "auraptene", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "downregulates", "mediator": "MMP-2", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "multiple sclerosis", "outcome_type": "disease", "outcome_domain": "multiple_sclerosis", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "auraptene", "mediator_canonical": "MMP2", "outcome_canonical": "multiple sclerosis", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "39086858", "title": "Auraptene inhibits migration, invasion and metastatic behavior of human malignant glioblastoma cells: An in vitro and in silico study.", "doi": "10.22038/ajp.2023.23586", "year": 2024 } ], "bc": [ { "pmid": "32243867", "title": "Serum levels of matrix metalloproteinase-2, -9, and vitamin D in patients with multiple sclerosis with or without herpesvirus-6 seropositivity", "doi": "10.1016/j.bjid.2020.02.001", "year": 2020 } ] } }, { "id": 30892, "drug": "Apigenin", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "upregulates", "mediator": "GFAP", "mediator_type": "protein", "predicate_bc": "increases", "outcome": "dementia risk", "outcome_type": "disease", "outcome_domain": "alzheimer", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "apigenin", "mediator_canonical": "GFAP", "outcome_canonical": "dementia risk", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41090780", "title": "Apigenin Induces Autophagy and Apoptosis in Chemoresistant Glioblastoma Cells and Inhibits Tumorigenicity Associated with Regulation of Immunomodulatory Proteins and Glial Cells Response", "doi": "10.3390/cells14191552", "year": 2025 } ], "bc": [ { "pmid": "39586964", "title": "Alzheimer’s Disease polygenic risk, the plasma proteome, and dementia incidence among UK older adults", "doi": "10.1007/s11357-024-01413-8", "year": 2024 } ] } }, { "id": 31716, "drug": "Curcumin", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "upregulates", "mediator": "Nrf2", "mediator_type": "gene", "predicate_bc": "increases", "outcome": "retinal ganglion cell survival", "outcome_type": "phenotype", "outcome_domain": "multiple_sclerosis", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "curcumin", "mediator_canonical": "NRF2", "outcome_canonical": "retinal ganglion cell survival", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40081725", "title": "Matrix metallopeptidase 2-responsive curcumin-loaded nanoparticles-induced signal transducer and activator of transcription 3 inhibition suppresses glioblastoma multiforme growth via enhancing nuclear factor erythroid 2-related factor 2 activity", "doi": "10.1016/j.ijbiomac.2025.141998", "year": 2025 } ], "bc": [ { "pmid": "29494741", "title": "SIRT1 and NRF2 Gene Transfer Mediate Distinct Neuroprotective Effects Upon Retinal Ganglion Cell Survival and Function in Experimental Optic Neuritis", "doi": "10.1167/iovs.17-22972", "year": 2018 } ] } }, { "id": 25819, "drug": "resveratrol", "drug_type": "drug", "drug_domain": "als", "predicate_ab": "activates", "mediator": "SIRT1", "mediator_type": "protein", "predicate_bc": "decreases", "outcome": "metabolic dysfunction", "outcome_type": "disease", "outcome_domain": "type_2_diabetes", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "active", "clinical_trial_nct_ids": [ "NCT02766803", "NCT07501377", "NCT04449198" ], "literature_status": "reproduces_known", "drug_canonical": "resveratrol", "mediator_canonical": "SIRT1", "outcome_canonical": "metabolic dysfunction", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "26981091", "title": "How does resveratrol influence the genesis of some neurodegenerative diseases?", "doi": "10.4103/1673-5374.175047", "year": 2016 } ], "bc": [ { "pmid": "30988688", "title": "Exercise training upregulates SIRT1 to attenuate inflammation and metabolic dysfunction in kidney and liver of diabetic db/db mice", "doi": "10.1186/s12986-019-0349-4", "year": 2019 } ] } }, { "id": 32204, "drug": "resveratrol", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "downregulates", "mediator": "Nrf2", "mediator_type": "gene", "predicate_bc": "prevents", "outcome": "diabetic cardiomyopathy", "outcome_type": "disease", "outcome_domain": "type_2_diabetes", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "resveratrol", "mediator_canonical": "NRF2", "outcome_canonical": "diabetic cardiomyopathy", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41841014", "title": "Concurrent Ferroptosis and Apoptosis in Resveratrol‐Treated Glioblastoma Cells: Relevance With NRF2 Downregulation and Oxidative Stress", "doi": "10.1002/cbin.70153", "year": 2026 } ], "bc": [ { "pmid": "27903744", "title": "Metallothionein Is Downstream of Nrf2 and Partially Mediates Sulforaphane Prevention of Diabetic Cardiomyopathy", "doi": "10.2337/db15-1274", "year": 2016 } ] } }, { "id": 1852, "drug": "auraptene", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "downregulates", "mediator": "MMP-9", "mediator_type": "protein", "predicate_bc": "decreases", "outcome": "inhibitory input to excitatory neurons", "outcome_type": "phenotype", "outcome_domain": "depression", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "auraptene", "mediator_canonical": "MMP9", "outcome_canonical": "inhibitory input to excitatory neurons", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "39086858", "title": "Auraptene inhibits migration, invasion and metastatic behavior of human malignant glioblastoma cells: An in vitro and in silico study.", "doi": "10.22038/ajp.2023.23586", "year": 2024 } ], "bc": [ { "pmid": "32269106", "title": "Venlafaxine Stimulates an MMP-9-Dependent Increase in Excitatory/Inhibitory Balance in a Stress Model of Depression", "doi": "10.1523/jneurosci.2387-19.2020", "year": 2020 } ] } }, { "id": 1502, "drug": "apigenin", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "upregulates", "mediator": "GFAP", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "AD dementia", "outcome_type": "disease", "outcome_domain": "alzheimer", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "apigenin", "mediator_canonical": "GFAP", "outcome_canonical": "ad dementia", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41090780", "title": "Apigenin Induces Autophagy and Apoptosis in Chemoresistant Glioblastoma Cells and Inhibits Tumorigenicity Associated with Regulation of Immunomodulatory Proteins and Glial Cells Response", "doi": "10.3390/cells14191552", "year": 2025 } ], "bc": [ { "pmid": "37885919", "title": "Cross‐sectional and longitudinal evaluation of plasma glial fibrillary acidic protein to detect and predict clinical syndromes of Alzheimer's disease", "doi": "10.1002/dad2.12492", "year": 2023 } ] } }, { "id": 1498, "drug": "cisplatin", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "activates", "mediator": "caspase-3", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "dendritic spine loss", "outcome_type": "phenotype", "outcome_domain": "alzheimer", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "cisplatin", "mediator_canonical": "CASP3", "outcome_canonical": "dendritic spine loss", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "39810130", "title": "Engineered biomimetic cisplatin-polyphenol nanocomplex for chemo-immunotherapy of glioblastoma by inducing pyroptosis", "doi": "10.1186/s12951-025-03091-w", "year": 2025 } ], "bc": [ { "pmid": "32610140", "title": "Caspase Activation and Caspase-Mediated Cleavage of APP Is Associated with Amyloid β-Protein-Induced Synapse Loss in Alzheimer’s Disease", "doi": "10.1016/j.celrep.2020.107839", "year": 2020 } ] } }, { "id": 31494, "drug": "cabozantinib", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "inhibits", "mediator": "AXL", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "IBD", "outcome_type": "disease", "outcome_domain": "inflammatory_bowel_disease", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "active", "clinical_trial_nct_ids": [ "NCT03816345" ], "literature_status": "novel_signal", "drug_canonical": "cabozantinib", "mediator_canonical": "axl", "outcome_canonical": "ibd", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "29660005", "title": "Volumetric response quantified using T1 subtraction predicts long-term survival benefit from cabozantinib monotherapy in recurrent glioblastoma", "doi": "10.1093/neuonc/noy054", "year": 2018 } ], "bc": [ { "pmid": "37005456", "title": "Axl alleviates DSS-induced colitis by preventing dysbiosis of gut microbiota", "doi": "10.1038/s41598-023-32527-2", "year": 2023 } ] } }, { "id": 1484, "drug": "Flubendazole", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "inhibits", "mediator": "STAT3", "mediator_type": "protein", "predicate_bc": "predicts", "outcome": "Alzheimer's disease", "outcome_type": "disease", "outcome_domain": "alzheimer", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "flubendazole", "mediator_canonical": "STAT3", "outcome_canonical": "Alzheimer disease", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37045903", "title": "Flubendazole exhibits anti-glioblastoma effect by inhibiting STAT3 and promoting cell cycle arrest", "doi": "10.1038/s41598-023-33047-9", "year": 2023 } ], "bc": [ { "pmid": "40745201", "title": "Uncovering active ingredients and mechanisms of Pholiota adiposa in the treatment of Alzheimer’s disease based on network pharmacology and bioinformatics", "doi": "10.1038/s41598-025-94861-x", "year": 2025 } ] } }, { "id": 12490, "drug": "valproic acid", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "inhibits", "mediator": "SOD2", "mediator_type": "protein", "predicate_bc": "increases", "outcome": "MCI", "outcome_type": "disease", "outcome_domain": "alzheimer", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "active", "clinical_trial_nct_ids": [ "NCT02670161" ], "literature_status": "partial_evidence", "drug_canonical": "valproic acid", "mediator_canonical": "sod2", "outcome_canonical": "mci", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "34895005", "title": "Valproic acid promotes SOD2 acetylation: a potential mechanism of valproic acid-induced oxidative stress in developing systems", "doi": "10.1080/10715762.2021.2017913", "year": 2021 } ], "bc": [ { "pmid": "40869114", "title": "Reliable New Biomarkers of Mitochondrial Oxidative Stress and Neuroinflammation in Cerebrospinal Fluid and Plasma from Alzheimer’s Disease Patients: A Pilot Study", "doi": "10.3390/ijms26167792", "year": 2025 } ] } }, { "id": 32188, "drug": "auraptene", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "downregulates", "mediator": "MMP-2", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "retinopathy", "outcome_type": "disease", "outcome_domain": "type_2_diabetes", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "auraptene", "mediator_canonical": "MMP2", "outcome_canonical": "retinopathy", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "39086858", "title": "Auraptene inhibits migration, invasion and metastatic behavior of human malignant glioblastoma cells: An in vitro and in silico study.", "doi": "10.22038/ajp.2023.23586", "year": 2024 } ], "bc": [ { "pmid": "25848912", "title": "Plasma levels of matrix metalloproteinase-2, -3, -10, and tissue inhibitor of metalloproteinase-1 are associated with vascular complications in patients with type 1 diabetes: the EURODIAB Prospective Complications Study", "doi": "10.1186/s12933-015-0195-2", "year": 2015 } ] } }, { "id": 1474, "drug": "apigenin", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "upregulates", "mediator": "GFAP", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "tau-PET abnormality", "outcome_type": "phenotype", "outcome_domain": "alzheimer", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "apigenin", "mediator_canonical": "GFAP", "outcome_canonical": "tau-pet abnormality", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41090780", "title": "Apigenin Induces Autophagy and Apoptosis in Chemoresistant Glioblastoma Cells and Inhibits Tumorigenicity Associated with Regulation of Immunomodulatory Proteins and Glial Cells Response", "doi": "10.3390/cells14191552", "year": 2025 } ], "bc": [ { "pmid": "35789365", "title": "Detection of Brain Tau Pathology in Down Syndrome Using Plasma Biomarkers", "doi": "10.1001/jamaneurol.2022.1740", "year": 2022 } ] } }, { "id": 31456, "drug": "metformin", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "upregulates", "mediator": "Per2", "mediator_type": "gene", "predicate_bc": "decreases", "outcome": "intestinal inflammation", "outcome_type": "disease", "outcome_domain": "inflammatory_bowel_disease", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "completed", "clinical_trial_nct_ids": [ "NCT04979130", "NCT01827280", "NCT04502303" ], "literature_status": "reproduces_known", "drug_canonical": "metformin", "mediator_canonical": "per2", "outcome_canonical": "intestinal inflammation", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40166471", "title": "Metformin upregulates circadian gene PER2 to inhibit growth and enhance the sensitivity of glioblastoma cell lines to radiotherapy via SIRT2/G6PD pathway", "doi": "10.3389/fphar.2025.1563865", "year": 2025 } ], "bc": [ { "pmid": "37660913", "title": "PER2/P65-driven glycogen synthase 1 transcription in macrophages modulates gut inflammation and pathogenesis of rectal prolapse", "doi": "10.1016/j.jbc.2023.105219", "year": 2023 } ] } }, { "id": 11016, "drug": "auraptene", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "inhibits", "mediator": "mTOR", "mediator_type": "protein", "predicate_bc": "causes", "outcome": "mTOR-opathies", "outcome_type": "disease", "outcome_domain": "epilepsy", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "auraptene", "mediator_canonical": "mTOR", "outcome_canonical": "mtor-opathies", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "39086858", "title": "Auraptene inhibits migration, invasion and metastatic behavior of human malignant glioblastoma cells: An in vitro and in silico study.", "doi": "10.22038/ajp.2023.23586", "year": 2024 } ], "bc": [ { "pmid": "29447953", "title": "Dendrite growth and the effect of ectopic Rheb expression on cortical neurons", "doi": "10.1016/j.neulet.2018.02.021", "year": 2018 } ] } }, { "id": 8103, "drug": "sunitinib", "drug_type": "drug", "drug_domain": "als", "predicate_ab": "inhibits", "mediator": "STAT3", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "pancreatic ductal adenocarcinoma", "outcome_type": "disease", "outcome_domain": "pancreatic_cancer", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "sunitinib", "mediator_canonical": "STAT3", "outcome_canonical": "pancreatic ductal adenocarcinoma", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "38914173", "title": "Sunitinib-mediated inhibition of STAT3 in skeletal muscle and spinal cord does not affect the disease in a mouse model of ALS", "doi": "10.1016/j.nbd.2024.106576", "year": 2024 } ], "bc": [ { "pmid": "38464736", "title": "Role of STAT3 in pancreatic cancer", "doi": "10.37349/etat.2024.00202", "year": 2024 } ] } }, { "id": 49113, "drug": "Verteporfin", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "inhibits", "mediator": "YAP", "mediator_type": "protein", "predicate_bc": "causes", "outcome": "cardiomyopathy", "outcome_type": "disease", "outcome_domain": "heart_failure", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40405165", "title": "Photo-controlled co-delivery of verteporfin and acriflavine via platelets achieves potentiated glioblastoma-targeted photodynamic therapy", "doi": "10.1186/s12951-025-03395-x", "year": 2025 } ], "bc": [ { "pmid": "33373332", "title": "YAP plays a crucial role in the development of cardiomyopathy in lysosomal storage diseases", "doi": "10.1172/jci143173", "year": 2020 } ] } }, { "id": 39553, "drug": "metformin", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "upregulates", "mediator": "nitric oxide", "mediator_type": "biomarker", "predicate_bc": "increases", "outcome": "sporadic amyotrophic lateral sclerosis", "outcome_type": "disease", "outcome_domain": "als", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "metformin", "mediator_canonical": "nitric oxide", "outcome_canonical": "sporadic amyotrophic lateral sclerosis", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "28887562", "title": "Metformin Improves Endothelial Function and Reduces Blood Pressure in Diabetic Spontaneously Hypertensive Rats Independent from Glycemia Control: Comparison to Vildagliptin", "doi": "10.1038/s41598-017-11430-7", "year": 2017 } ], "bc": [ { "pmid": "37635508", "title": "Values of Nitric Oxide and Superoxide Dismutase in Cerebrospinal Fluid of Patients with Sporadic Amyotrophic Lateral Sclerosis", "doi": "10.4103/0028-3886.383853", "year": 2023 } ] } }, { "id": 1440, "drug": "apigenin", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "upregulates", "mediator": "GFAP", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "processing speed", "outcome_type": "phenotype", "outcome_domain": "alzheimer", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "apigenin", "mediator_canonical": "GFAP", "outcome_canonical": "processing speed", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41090780", "title": "Apigenin Induces Autophagy and Apoptosis in Chemoresistant Glioblastoma Cells and Inhibits Tumorigenicity Associated with Regulation of Immunomodulatory Proteins and Glial Cells Response", "doi": "10.3390/cells14191552", "year": 2025 } ], "bc": [ { "pmid": "32753068", "title": "Association of glial and neuronal degeneration markers with Alzheimer’s disease cerebrospinal fluid profile and cognitive functions", "doi": "10.1186/s13195-020-00657-8", "year": 2020 } ] } }, { "id": 57908, "drug": "resveratrol", "drug_type": "drug", "drug_domain": "pancreatic_cancer", "predicate_ab": "inhibits", "mediator": "NAF-1", "mediator_type": "gene", "predicate_bc": "increases", "outcome": "mitochondrial labile iron accumulation", "outcome_type": "phenotype", "outcome_domain": "type_2_diabetes", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "32766132", "title": "NAF-1 Inhibition by Resveratrol Suppresses Cancer Stem Cell-Like Properties and the Invasion of Pancreatic Cancer", "doi": "10.3389/fonc.2020.01038", "year": 2020 } ], "bc": [ { "pmid": "27459537", "title": "GLP-1-RA Corrects Mitochondrial Labile Iron Accumulation and Improves β-Cell Function in Type 2 Wolfram Syndrome", "doi": "10.1210/jc.2016-2240", "year": 2016 } ] } }, { "id": 31444, "drug": "auraptene", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "downregulates", "mediator": "MMP-9", "mediator_type": "protein", "predicate_bc": "increases", "outcome": "colonic epithelial permeability", "outcome_type": "phenotype", "outcome_domain": "inflammatory_bowel_disease", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "auraptene", "mediator_canonical": "MMP9", "outcome_canonical": "colonic epithelial permeability", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "39086858", "title": "Auraptene inhibits migration, invasion and metastatic behavior of human malignant glioblastoma cells: An in vitro and in silico study.", "doi": "10.22038/ajp.2023.23586", "year": 2024 } ], "bc": [ { "pmid": "26514773", "title": "Matrix metalloproteinase 9-induced increase in intestinal epithelial tight junction permeability contributes to the severity of experimental DSS colitis", "doi": "10.1152/ajpgi.00256.2015", "year": 2015 } ] } }, { "id": 1437, "drug": "apigenin", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "upregulates", "mediator": "GFAP", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "executive functions", "outcome_type": "phenotype", "outcome_domain": "alzheimer", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "apigenin", "mediator_canonical": "GFAP", "outcome_canonical": "executive functions", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41090780", "title": "Apigenin Induces Autophagy and Apoptosis in Chemoresistant Glioblastoma Cells and Inhibits Tumorigenicity Associated with Regulation of Immunomodulatory Proteins and Glial Cells Response", "doi": "10.3390/cells14191552", "year": 2025 } ], "bc": [ { "pmid": "32753068", "title": "Association of glial and neuronal degeneration markers with Alzheimer’s disease cerebrospinal fluid profile and cognitive functions", "doi": "10.1186/s13195-020-00657-8", "year": 2020 } ] } }, { "id": 31282, "drug": "sapanisertib", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "inhibits", "mediator": "mTOR", "mediator_type": "protein", "predicate_bc": "causes", "outcome": "mTOR-opathies", "outcome_type": "disease", "outcome_domain": "epilepsy", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "sapanisertib", "mediator_canonical": "mTOR", "outcome_canonical": "mtor-opathies", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37372982", "title": "mTOR Inhibition Is Effective against Growth, Survival and Migration, but Not against Microglia Activation in Preclinical Glioma Models", "doi": "10.3390/ijms24129834", "year": 2023 } ], "bc": [ { "pmid": "29447953", "title": "Dendrite growth and the effect of ectopic Rheb expression on cortical neurons", "doi": "10.1016/j.neulet.2018.02.021", "year": 2018 } ] } }, { "id": 30471, "drug": "valproate", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "downregulates", "mediator": "SLC19A3", "mediator_type": "gene", "predicate_bc": "associated_with", "outcome": "severe retinopathy", "outcome_type": "disease", "outcome_domain": "type_2_diabetes", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "valproic acid", "mediator_canonical": "slc19a3", "outcome_canonical": "severe retinopathy", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "36056753", "title": "Lacosamide effects on placental carriers of essential compounds in comparison with valproate: Studies in perfused human placentas", "doi": "10.1111/epi.17395", "year": 2022 } ], "bc": [ { "pmid": "26718501", "title": "Variation in SLC19A3 and Protection From Microvascular Damage in Type 1 Diabetes", "doi": "10.2337/db15-1247", "year": 2015 } ] } }, { "id": 49294, "drug": "auraptene", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "downregulates", "mediator": "MMP-9", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "colitis severity", "outcome_type": "disease", "outcome_domain": "inflammatory_bowel_disease", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "39086858", "title": "Auraptene inhibits migration, invasion and metastatic behavior of human malignant glioblastoma cells: An in vitro and in silico study.", "doi": "10.22038/ajp.2023.23586", "year": 2024 } ], "bc": [ { "pmid": "33748570", "title": "Toward Point-of-Care Diagnostics to Monitor MMP-9 and TNF-α Levels in Inflammatory Bowel Disease", "doi": "10.1021/acsomega.0c05115", "year": 2021 } ] } }, { "id": 40731, "drug": "resveratrol", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "upregulates", "mediator": "adiponectin", "mediator_type": "protein", "predicate_bc": "predicts", "outcome": "Multiple Sclerosis Severity Score", "outcome_type": "phenotype", "outcome_domain": "multiple_sclerosis", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "resveratrol", "mediator_canonical": "adiponectin", "outcome_canonical": "multiple sclerosis severity score", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "36991247", "title": "Resveratrol and Dulaglutide ameliorate adiposity and liver dysfunction in rats with diet-induced metabolic syndrome: Role of SIRT-1 / adipokines / PPARγ and IGF-1", "doi": "10.1007/s40199-023-00458-y", "year": 2023 } ], "bc": [ { "pmid": "30300462", "title": "Adiponectin profile at baseline is correlated to progression and severity of multiple sclerosis", "doi": "10.1111/ene.13822", "year": 2018 } ] } }, { "id": 49307, "drug": "linalool", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "downregulates", "mediator": "PD-L1", "mediator_type": "protein", "predicate_bc": "prevents", "outcome": "inflammatory damage", "outcome_type": "phenotype", "outcome_domain": "inflammatory_bowel_disease", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40504869", "title": "Linalool-based silver nanoconjugates as potential therapeutics for glioblastoma: in silico and in vitro insights", "doi": "10.1371/journal.pone.0325281", "year": 2025 } ], "bc": [ { "pmid": "32298485", "title": "Programmed cell death‐1 (PD‐1) and programmed death‐ligand 1 (PD‐L1) expression in PD‐1 inhibitor‐associated colitis and its mimics", "doi": "10.1111/his.14115", "year": 2020 } ] } }, { "id": 49308, "drug": "linalool", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "downregulates", "mediator": "PD-L1", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "gut microbiota composition", "outcome_type": "phenotype", "outcome_domain": "inflammatory_bowel_disease", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40504869", "title": "Linalool-based silver nanoconjugates as potential therapeutics for glioblastoma: in silico and in vitro insights", "doi": "10.1371/journal.pone.0325281", "year": 2025 } ], "bc": [ { "pmid": "40661950", "title": "PD-L1 deficiency exacerbates colitis severity by remodeling gut microbiota in inflammatory bowel disease", "doi": "10.3389/fimmu.2025.1622744", "year": 2025 } ] } }, { "id": 49312, "drug": "Curcumin", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "inhibits", "mediator": "STAT3", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "Crohn's disease", "outcome_type": "disease", "outcome_domain": "inflammatory_bowel_disease", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40081725", "title": "Matrix metallopeptidase 2-responsive curcumin-loaded nanoparticles-induced signal transducer and activator of transcription 3 inhibition suppresses glioblastoma multiforme growth via enhancing nuclear factor erythroid 2-related factor 2 activity", "doi": "10.1016/j.ijbiomac.2025.141998", "year": 2025 } ], "bc": [ { "pmid": "36498596", "title": "Genetic and Small-Molecule Modulation of Stat3 in a Mouse Model of Crohn’s Disease", "doi": "10.3390/jcm11237020", "year": 2022 } ] } }, { "id": 25599, "drug": "riluzole", "drug_type": "drug", "drug_domain": "als", "predicate_ab": "downregulates", "mediator": "MMP-9", "mediator_type": "protein", "predicate_bc": "causes", "outcome": "cartilage matrix destruction", "outcome_type": "phenotype", "outcome_domain": "rheumatoid_arthritis", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "riluzole", "mediator_canonical": "MMP9", "outcome_canonical": "cartilage matrix destruction", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40012807", "title": "Investigation of the Neuroprotective Effect of Riluzole on Matrix Metalloproteinases in an Experimental Model of Glaucoma", "doi": "10.4103/joco.joco_290_23", "year": 2024 } ], "bc": [ { "pmid": "40343163", "title": "Inhibiting synovial inflammation and promoting cartilage repair in rheumatoid arthritis using a matrix metalloproteinase-binding hydrogel", "doi": "10.1016/j.mtbio.2025.101792", "year": 2025 } ] } }, { "id": 49350, "drug": "acriflavine", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "inhibits", "mediator": "HIF-1α", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "disease activity", "outcome_type": "phenotype", "outcome_domain": "inflammatory_bowel_disease", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40405165", "title": "Photo-controlled co-delivery of verteporfin and acriflavine via platelets achieves potentiated glioblastoma-targeted photodynamic therapy", "doi": "10.1186/s12951-025-03395-x", "year": 2025 } ], "bc": [ { "pmid": "38137357", "title": "Interrelation of Hypoxia-Inducible Factor-1 Alpha (HIF-1 α) and the Ratio between the Mean Corpuscular Volume/Lymphocytes (MCVL) and the Cumulative Inflammatory Index (IIC) in Ulcerative Colitis", "doi": "10.3390/biomedicines11123137", "year": 2023 } ] } }, { "id": 30520, "drug": "valproic acid", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "suppresses", "mediator": "galectin-3", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "obesity", "outcome_type": "disease", "outcome_domain": "type_2_diabetes", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "completed", "clinical_trial_nct_ids": [ "NCT02993861", "NCT03903302", "NCT00298857" ], "literature_status": "reproduces_known", "drug_canonical": "valproic acid", "mediator_canonical": "LGALS3", "outcome_canonical": "obesity", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "34122007", "title": "Post-stroke Delivery of Valproic Acid Promotes Functional Recovery and Differentially Modifies Responses of Peri-Infarct Microglia", "doi": "10.3389/fnmol.2021.639145", "year": 2021 } ], "bc": [ { "pmid": "26722123", "title": "Circulating Galectin‐3 Is Associated With Cardiometabolic Disease in the Community", "doi": "10.1161/jaha.115.002347", "year": 2016 } ] } }, { "id": 49366, "drug": "Flubendazole", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "inhibits", "mediator": "STAT3", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "UC", "outcome_type": "disease", "outcome_domain": "inflammatory_bowel_disease", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37045903", "title": "Flubendazole exhibits anti-glioblastoma effect by inhibiting STAT3 and promoting cell cycle arrest", "doi": "10.1038/s41598-023-33047-9", "year": 2023 } ], "bc": [ { "pmid": "36857861", "title": "Therapeutic targets for inflammatory bowel disease: proteome-wide Mendelian randomization and colocalization analyses", "doi": "10.1016/j.ebiom.2023.104494", "year": 2023 } ] } }, { "id": 25619, "drug": "riluzole", "drug_type": "drug", "drug_domain": "als", "predicate_ab": "downregulates", "mediator": "MMP-9", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "incident ILD", "outcome_type": "disease", "outcome_domain": "rheumatoid_arthritis", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "riluzole", "mediator_canonical": "MMP9", "outcome_canonical": "incident ild", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40012807", "title": "Investigation of the Neuroprotective Effect of Riluzole on Matrix Metalloproteinases in an Experimental Model of Glaucoma", "doi": "10.4103/joco.joco_290_23", "year": 2024 } ], "bc": [ { "pmid": "38268499", "title": "Plasma Matrix Metalloproteinase Concentrations and Risk of Interstitial Lung Disease in a Prospective Rheumatoid Arthritis Cohort", "doi": "10.1002/art.42812", "year": 2024 } ] } }, { "id": 49367, "drug": "Flubendazole", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "inhibits", "mediator": "STAT3", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "Crohn's disease", "outcome_type": "disease", "outcome_domain": "inflammatory_bowel_disease", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37045903", "title": "Flubendazole exhibits anti-glioblastoma effect by inhibiting STAT3 and promoting cell cycle arrest", "doi": "10.1038/s41598-023-33047-9", "year": 2023 } ], "bc": [ { "pmid": "36498596", "title": "Genetic and Small-Molecule Modulation of Stat3 in a Mouse Model of Crohn’s Disease", "doi": "10.3390/jcm11237020", "year": 2022 } ] } }, { "id": 2779, "drug": "valproic acid", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "downregulates", "mediator": "pdyn", "mediator_type": "gene", "predicate_bc": "associated_with", "outcome": "alcohol use disorder", "outcome_type": "disease", "outcome_domain": "depression", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "completed", "clinical_trial_nct_ids": [ "NCT01760785", "NCT01342549", "NCT03235531" ], "literature_status": "reproduces_known", "drug_canonical": "valproic acid", "mediator_canonical": "pdyn", "outcome_canonical": "alcohol use disorder", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "31978376", "title": "Prenatal exposure to valproic acid reduces social responses and alters mRNA levels of opioid receptor and pre-pro-peptide in discrete brain regions of adolescent and adult male rats", "doi": "10.1016/j.brainres.2020.146675", "year": 2020 } ], "bc": [ { "pmid": "37177778", "title": "Effect of PDYN and OPRK1 polymorphisms on the risk of alcohol use disorder and the intensity of depressive symptoms", "doi": "10.1093/alcalc/agad036", "year": 2023 } ] } }, { "id": 49381, "drug": "cabozantinib", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "inhibits", "mediator": "AXL", "mediator_type": "protein", "predicate_bc": "prevents", "outcome": "dysbiosis", "outcome_type": "phenotype", "outcome_domain": "inflammatory_bowel_disease", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "29660005", "title": "Volumetric response quantified using T1 subtraction predicts long-term survival benefit from cabozantinib monotherapy in recurrent glioblastoma", "doi": "10.1093/neuonc/noy054", "year": 2018 } ], "bc": [ { "pmid": "37005456", "title": "Axl alleviates DSS-induced colitis by preventing dysbiosis of gut microbiota", "doi": "10.1038/s41598-023-32527-2", "year": 2023 } ] } }, { "id": 49387, "drug": "Auranofin", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "upregulates", "mediator": "p53", "mediator_type": "protein", "predicate_bc": "predicts", "outcome": "dysplasia", "outcome_type": "disease", "outcome_domain": "inflammatory_bowel_disease", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "39456455", "title": "Synergistic Dual Targeting of Thioredoxin and Glutathione Systems Irrespective of p53 in Glioblastoma Stem Cells", "doi": "10.3390/antiox13101201", "year": 2024 } ], "bc": [ { "pmid": "27578918", "title": "Expression Profile of p53 and p21 in Large Bowel Mucosa as Biomarkers of Inflammatory-Related Carcinogenesis in Ulcerative Colitis", "doi": "10.1155/2016/3625279", "year": 2016 } ] } }, { "id": 49388, "drug": "Auranofin", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "upregulates", "mediator": "p53", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "colorectal neoplasia progression", "outcome_type": "disease", "outcome_domain": "inflammatory_bowel_disease", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "39456455", "title": "Synergistic Dual Targeting of Thioredoxin and Glutathione Systems Irrespective of p53 in Glioblastoma Stem Cells", "doi": "10.3390/antiox13101201", "year": 2024 } ], "bc": [ { "pmid": "26063242", "title": "Overexpression of p53 predicts colorectal neoplasia risk in patients with inflammatory bowel disease and mucosa changes indefinite for dysplasia", "doi": "10.1093/gastro/gov022", "year": 2015 } ] } }, { "id": 49389, "drug": "Auranofin", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "upregulates", "mediator": "p53", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "adenocarcinoma", "outcome_type": "disease", "outcome_domain": "inflammatory_bowel_disease", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "39456455", "title": "Synergistic Dual Targeting of Thioredoxin and Glutathione Systems Irrespective of p53 in Glioblastoma Stem Cells", "doi": "10.3390/antiox13101201", "year": 2024 } ], "bc": [ { "pmid": "31782007", "title": "Filiform polyposis with sigmoid colon adenocarcinoma: a case report", "doi": "10.1186/s40792-019-0747-x", "year": 2019 } ] } }, { "id": 49454, "drug": "resveratrol", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "downregulates", "mediator": "Nrf2", "mediator_type": "gene", "predicate_bc": "associated_with", "outcome": "Hashimoto's thyroiditis", "outcome_type": "disease", "outcome_domain": "multiple_sclerosis", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41841014", "title": "Concurrent Ferroptosis and Apoptosis in Resveratrol‐Treated Glioblastoma Cells: Relevance With NRF2 Downregulation and Oxidative Stress", "doi": "10.1002/cbin.70153", "year": 2026 } ], "bc": [ { "pmid": "35624879", "title": "Thyroid Disorders in Patients Treated with Dimethyl Fumarate for Multiple Sclerosis: A Retrospective Observational Study", "doi": "10.3390/antiox11051015", "year": 2022 } ] } }, { "id": 31589, "drug": "Curcumin", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "upregulates", "mediator": "Nrf2", "mediator_type": "gene", "predicate_bc": "increases", "outcome": "visual function", "outcome_type": "phenotype", "outcome_domain": "multiple_sclerosis", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "completed", "clinical_trial_nct_ids": [ "NCT01646047", "NCT04784234", "NCT02984813" ], "literature_status": "reproduces_known", "drug_canonical": "curcumin", "mediator_canonical": "NRF2", "outcome_canonical": "visual function", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40081725", "title": "Matrix metallopeptidase 2-responsive curcumin-loaded nanoparticles-induced signal transducer and activator of transcription 3 inhibition suppresses glioblastoma multiforme growth via enhancing nuclear factor erythroid 2-related factor 2 activity", "doi": "10.1016/j.ijbiomac.2025.141998", "year": 2025 } ], "bc": [ { "pmid": "29494741", "title": "SIRT1 and NRF2 Gene Transfer Mediate Distinct Neuroprotective Effects Upon Retinal Ganglion Cell Survival and Function in Experimental Optic Neuritis", "doi": "10.1167/iovs.17-22972", "year": 2018 } ] } }, { "id": 49526, "drug": "epirubicin", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "inhibits", "mediator": "FOXP3", "mediator_type": "gene", "predicate_bc": "associated_with", "outcome": "sex differences in autoimmunity", "outcome_type": "phenotype", "outcome_domain": "multiple_sclerosis", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "38561331", "title": "FOXP3 promote the progression of glioblastoma via inhibiting ferroptosis mediated by linc00857/miR-1290/GPX4 axis", "doi": "10.1038/s41419-024-06619-4", "year": 2024 } ], "bc": [ { "pmid": "29307297", "title": "Sex chromosome contributions to sex differences in multiple sclerosis susceptibility and progression", "doi": "10.1177/1352458517737394", "year": 2018 } ] } }, { "id": 49546, "drug": "Apigenin", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "upregulates", "mediator": "GFAP", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "intrathecal inflammation", "outcome_type": "phenotype", "outcome_domain": "multiple_sclerosis", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41090780", "title": "Apigenin Induces Autophagy and Apoptosis in Chemoresistant Glioblastoma Cells and Inhibits Tumorigenicity Associated with Regulation of Immunomodulatory Proteins and Glial Cells Response", "doi": "10.3390/cells14191552", "year": 2025 } ], "bc": [ { "pmid": "40407316", "title": "Glial Fibrillary Acid Protein Reflects Disease Activity in Autoimmune Encephalitis", "doi": "10.1111/ene.70207", "year": 2025 } ] } }, { "id": 31718, "drug": "resveratrol", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "upregulates", "mediator": "p53", "mediator_type": "gene", "predicate_bc": "associated_with", "outcome": "oligodendrocyte differentiation", "outcome_type": "phenotype", "outcome_domain": "multiple_sclerosis", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "resveratrol", "mediator_canonical": "TP53", "outcome_canonical": "oligodendrocyte differentiation", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40802352", "title": "Resveratrol and temozolomide induce apoptosis and suppress proliferation in glioblastoma cells via the apoptotic signaling pathway", "doi": "10.1590/acb405525", "year": 2025 } ], "bc": [ { "pmid": "34884611", "title": "Differential Role of p53 in Oligodendrocyte Survival in Response to Various Stresses: Experimental Autoimmune Encephalomyelitis, Cuprizone Intoxication or White Matter Stroke", "doi": "10.3390/ijms222312811", "year": 2021 } ] } }, { "id": 31691, "drug": "resveratrol", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "upregulates", "mediator": "p53", "mediator_type": "gene", "predicate_bc": "decreases", "outcome": "demyelination", "outcome_type": "phenotype", "outcome_domain": "multiple_sclerosis", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "resveratrol", "mediator_canonical": "TP53", "outcome_canonical": "demyelination", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40802352", "title": "Resveratrol and temozolomide induce apoptosis and suppress proliferation in glioblastoma cells via the apoptotic signaling pathway", "doi": "10.1590/acb405525", "year": 2025 } ], "bc": [ { "pmid": "34884611", "title": "Differential Role of p53 in Oligodendrocyte Survival in Response to Various Stresses: Experimental Autoimmune Encephalomyelitis, Cuprizone Intoxication or White Matter Stroke", "doi": "10.3390/ijms222312811", "year": 2021 } ] } }, { "id": 49570, "drug": "resveratrol", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "downregulates", "mediator": "Nrf2", "mediator_type": "gene", "predicate_bc": "increases", "outcome": "visual function", "outcome_type": "phenotype", "outcome_domain": "multiple_sclerosis", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41841014", "title": "Concurrent Ferroptosis and Apoptosis in Resveratrol‐Treated Glioblastoma Cells: Relevance With NRF2 Downregulation and Oxidative Stress", "doi": "10.1002/cbin.70153", "year": 2026 } ], "bc": [ { "pmid": "29494741", "title": "SIRT1 and NRF2 Gene Transfer Mediate Distinct Neuroprotective Effects Upon Retinal Ganglion Cell Survival and Function in Experimental Optic Neuritis", "doi": "10.1167/iovs.17-22972", "year": 2018 } ] } }, { "id": 31719, "drug": "resveratrol", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "upregulates", "mediator": "p53", "mediator_type": "gene", "predicate_bc": "correlates_with", "outcome": "EAE severity", "outcome_type": "phenotype", "outcome_domain": "multiple_sclerosis", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "resveratrol", "mediator_canonical": "TP53", "outcome_canonical": "eae severity", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40802352", "title": "Resveratrol and temozolomide induce apoptosis and suppress proliferation in glioblastoma cells via the apoptotic signaling pathway", "doi": "10.1590/acb405525", "year": 2025 } ], "bc": [ { "pmid": "34884611", "title": "Differential Role of p53 in Oligodendrocyte Survival in Response to Various Stresses: Experimental Autoimmune Encephalomyelitis, Cuprizone Intoxication or White Matter Stroke", "doi": "10.3390/ijms222312811", "year": 2021 } ] } }, { "id": 30022, "drug": "valproic acid", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "suppresses", "mediator": "galectin-3", "mediator_type": "protein", "predicate_bc": "predicts", "outcome": "pancreatobiliary cancer", "outcome_type": "disease", "outcome_domain": "pancreatic_cancer", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "valproic acid", "mediator_canonical": "LGALS3", "outcome_canonical": "pancreatobiliary cancer", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "34122007", "title": "Post-stroke Delivery of Valproic Acid Promotes Functional Recovery and Differentially Modifies Responses of Peri-Infarct Microglia", "doi": "10.3389/fnmol.2021.639145", "year": 2021 } ], "bc": [ { "pmid": "28870921", "title": "Significance of Circulating Galectin-3 in Patients with Pancreatobiliary Cancer", "doi": "10.21873/anticanres.11909", "year": 2017 } ] } }, { "id": 30287, "drug": "Curcumin", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "inhibits", "mediator": "NLRP3 inflammasome activation", "mediator_type": "pathway", "predicate_bc": "causes", "outcome": "inflammatory arthritis", "outcome_type": "disease", "outcome_domain": "rheumatoid_arthritis", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "active", "clinical_trial_nct_ids": [ "NCT07324746", "NCT03017118", "NCT06478290" ], "literature_status": "partial_evidence", "drug_canonical": "curcumin", "mediator_canonical": "nlrp3 inflammasome activation", "outcome_canonical": "inflammatory arthritis", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "30062967", "title": "Curcumin Reduces Neuronal Loss and Inhibits the NLRP3 Inflammasome Activation in an Epileptic Rat Model", "doi": "10.2174/1567202615666180731100224", "year": 2018 } ], "bc": [ { "pmid": "32843625", "title": "Calcium-sensing receptor-mediated NLRP3 inflammasome response to calciprotein particles drives inflammation in rheumatoid arthritis", "doi": "10.1038/s41467-020-17749-6", "year": 2020 } ] } }, { "id": 30210, "drug": "valproic acid", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "downregulates", "mediator": "VEGF", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "swollen joint count", "outcome_type": "phenotype", "outcome_domain": "rheumatoid_arthritis", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "valproic acid", "mediator_canonical": "VEGF", "outcome_canonical": "swollen joint count", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "32149283", "title": "l-Cysteine decorated nanoscale metal–organic frameworks delivering valproic acid/cisplatin for drug-resistant lung cancer therapy", "doi": "10.1039/c9cc09712k", "year": 2020 } ], "bc": [ { "pmid": "35744097", "title": "VEGF Profile in Early Undifferentiated Arthritis Cohort", "doi": "10.3390/medicina58060833", "year": 2022 } ] } }, { "id": 30110, "drug": "valproic acid", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "downregulates", "mediator": "CREB", "mediator_type": "gene", "predicate_bc": "increases", "outcome": "profibrotic inflammation", "outcome_type": "disease", "outcome_domain": "pancreatic_cancer", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "valproic acid", "mediator_canonical": "creb", "outcome_canonical": "profibrotic inflammation", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "29958461", "title": "Differential Gene Expression Profile Induced by Valproic Acid (VPA) in Pediatric Epileptic Patients", "doi": "10.3390/genes9070328", "year": 2018 } ], "bc": [ { "pmid": "40812683", "title": "CREB Drives Acinar to Ductal Cells Reprogramming and Promotes Pancreatic Cancer Progression in Preclinical Models of Alcoholic Pancreatitis", "doi": "10.1016/j.jcmgh.2025.101606", "year": 2025 } ] } }, { "id": 29904, "drug": "Curcumin", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "inhibits", "mediator": "NLRP3 inflammasome activation", "mediator_type": "pathway", "predicate_bc": "associated_with", "outcome": "acute lung injury", "outcome_type": "disease", "outcome_domain": "multiple_sclerosis", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "curcumin", "mediator_canonical": "nlrp3 inflammasome activation", "outcome_canonical": "acute lung injury", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "30062967", "title": "Curcumin Reduces Neuronal Loss and Inhibits the NLRP3 Inflammasome Activation in an Epileptic Rat Model", "doi": "10.2174/1567202615666180731100224", "year": 2018 } ], "bc": [ { "pmid": "39974815", "title": "Fingolimod Suppresses NLRP3 Inflammasome Activation and Alleviates Oxidative Stress in Traumatic Brain Injury-Induced Acute Lung Injury", "doi": "10.2147/jir.s503428", "year": 2025 } ] } }, { "id": 37628, "drug": "resveratrol", "drug_type": "drug", "drug_domain": "pancreatic_cancer", "predicate_ab": "downregulates", "mediator": "miR-21", "mediator_type": "gene", "predicate_bc": "associated_with", "outcome": "Type 2 Diabetes Mellitus", "outcome_type": "disease", "outcome_domain": "type_2_diabetes", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "active", "clinical_trial_nct_ids": [ "NCT07195994", "NCT03762096", "NCT07569744" ], "literature_status": "reproduces_known", "drug_canonical": "resveratrol", "mediator_canonical": "mir-21", "outcome_canonical": "type 2 diabetes mellitus", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "29854071", "title": "Resveratrol Inhibits ROS‐Promoted Activation and Glycolysis of Pancreatic Stellate Cells via Suppression of miR‐21", "doi": "10.1155/2018/1346958", "year": 2018 } ], "bc": [ { "pmid": "33155514", "title": "Non-coding RNAs and type 2 diabetes mellitus", "doi": "10.1080/13813455.2020.1843498", "year": 2020 } ] } }, { "id": 1430, "drug": "apigenin", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "upregulates", "mediator": "GFAP", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "elevated brain amyloid", "outcome_type": "phenotype", "outcome_domain": "alzheimer", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "apigenin", "mediator_canonical": "GFAP", "outcome_canonical": "elevated brain amyloid", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41090780", "title": "Apigenin Induces Autophagy and Apoptosis in Chemoresistant Glioblastoma Cells and Inhibits Tumorigenicity Associated with Regulation of Immunomodulatory Proteins and Glial Cells Response", "doi": "10.3390/cells14191552", "year": 2025 } ], "bc": [ { "pmid": "38605996", "title": "Association of plasma GFAP with elevated brain amyloid is dependent on severity of white matter lesions in an Asian cognitively impaired cohort", "doi": "10.1002/dad2.12576", "year": 2024 } ] } }, { "id": 1127, "drug": "temsirolimus", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "inhibits", "mediator": "mTOR", "mediator_type": "protein", "predicate_bc": "increases", "outcome": "neuronal spiking activity", "outcome_type": "phenotype", "outcome_domain": "epilepsy", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "temsirolimus", "mediator_canonical": "mTOR", "outcome_canonical": "neuronal spiking activity", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "29313954", "title": "Phase 1/2 trial of temsirolimus and sorafenib in the treatment of patients with recurrent glioblastoma: North Central Cancer Treatment Group Study/Alliance N0572", "doi": "10.1002/cncr.31219", "year": 2018 } ], "bc": [ { "pmid": "34994387", "title": "IDH-mutated gliomas promote epileptogenesis through d-2-hydroxyglutarate-dependent mTOR hyperactivation", "doi": "10.1093/neuonc/noac003", "year": 2022 } ] } }, { "id": 40302, "drug": "metformin", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "downregulates", "mediator": "mTORC1 signaling", "mediator_type": "pathway", "predicate_bc": "associated_with", "outcome": "therapy resistance", "outcome_type": "phenotype", "outcome_domain": "glioblastoma", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "active", "clinical_trial_nct_ids": [ "NCT06015594", "NCT06763328", "NCT06445946" ], "literature_status": "reproduces_known", "drug_canonical": "metformin", "mediator_canonical": "mtorc1 signaling", "outcome_canonical": "therapy resistance", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "31557380", "title": "Metformin blunts muscle hypertrophy in response to progressive resistance exercise training in older adults: A randomized, double‐blind, placebo‐controlled, multicenter trial: The MASTERS trial", "doi": "10.1111/acel.13039", "year": 2019 } ], "bc": [ { "pmid": "36906590", "title": "Systematic in vitro analysis of therapy resistance in glioblastoma cell lines by integration of clonogenic survival data with multi-level molecular data", "doi": "10.1186/s13014-023-02241-4", "year": 2023 } ] } }, { "id": 1351, "drug": "staurosporine", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "binds_to", "mediator": "FLNC", "mediator_type": "gene", "predicate_bc": "associated_with", "outcome": "FTD", "outcome_type": "disease", "outcome_domain": "als", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "staurosporine", "mediator_canonical": "flnc", "outcome_canonical": "ftd", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "39946771", "title": "Identification of therapeutic targets and immune landscape in glioblastoma through crosstalk with glioma-associated mesenchymal stem cells", "doi": "10.1016/j.intimp.2025.114228", "year": 2025 } ], "bc": [ { "pmid": "26555887", "title": "Investigating the role of filamin C in Belgian patients with frontotemporal dementia linked to GRN deficiency in FTLD-TDP brains", "doi": "10.1186/s40478-015-0246-7", "year": 2015 } ] } }, { "id": 1342, "drug": "apigenin", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "upregulates", "mediator": "GFAP", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "diabetic polyneuropathy", "outcome_type": "disease", "outcome_domain": "als", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "apigenin", "mediator_canonical": "GFAP", "outcome_canonical": "diabetic polyneuropathy", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41090780", "title": "Apigenin Induces Autophagy and Apoptosis in Chemoresistant Glioblastoma Cells and Inhibits Tumorigenicity Associated with Regulation of Immunomodulatory Proteins and Glial Cells Response", "doi": "10.3390/cells14191552", "year": 2025 } ], "bc": [ { "pmid": "40192786", "title": "Glial fibrillary acidic protein: a potential biomarker for small fiber neuropathy?", "doi": "10.1007/s00592-025-02500-8", "year": 2025 } ] } }, { "id": 3003, "drug": "niclosamide", "drug_type": "drug", "drug_domain": "als", "predicate_ab": "inhibits", "mediator": "mTOR", "mediator_type": "protein", "predicate_bc": "increases", "outcome": "neuronal spiking activity", "outcome_type": "phenotype", "outcome_domain": "epilepsy", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "niclosamide", "mediator_canonical": "mTOR", "outcome_canonical": "neuronal spiking activity", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "38493058", "title": "Neuroprotective effects of niclosamide on disease progression via inflammatory pathways modulation in SOD1-G93A and FUS-associated amyotrophic lateral sclerosis models", "doi": "10.1016/j.neurot.2024.e00346", "year": 2024 } ], "bc": [ { "pmid": "34994387", "title": "IDH-mutated gliomas promote epileptogenesis through d-2-hydroxyglutarate-dependent mTOR hyperactivation", "doi": "10.1093/neuonc/noac003", "year": 2022 } ] } }, { "id": 8195, "drug": "Riluzole", "drug_type": "drug", "drug_domain": "als", "predicate_ab": "downregulates", "mediator": "MMP-2", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "histopathological type of cancer", "outcome_type": "phenotype", "outcome_domain": "pancreatic_cancer", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "riluzole", "mediator_canonical": "MMP2", "outcome_canonical": "histopathological type of cancer", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40012807", "title": "Investigation of the Neuroprotective Effect of Riluzole on Matrix Metalloproteinases in an Experimental Model of Glaucoma", "doi": "10.4103/joco.joco_290_23", "year": 2024 } ], "bc": [ { "pmid": "27429508", "title": "Expressions of Matrix Metalloproteinases 2, 7, and 9 in Carcinogenesis of Pancreatic Ductal Adenocarcinoma", "doi": "10.1155/2016/9895721", "year": 2016 } ] } }, { "id": 12872, "drug": "valproate", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "downregulates", "mediator": "COX-2", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "social cognition performance", "outcome_type": "phenotype", "outcome_domain": "depression", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "valproic acid", "mediator_canonical": "cox-2", "outcome_canonical": "social cognition performance", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "32054883", "title": "Downregulation of peripheral PTGS2/COX-2 in response to valproate treatment in patients with epilepsy", "doi": "10.1038/s41598-020-59259-x", "year": 2020 } ], "bc": [ { "pmid": "41786038", "title": "Associations between social cognition and inflammatory markers in eating disorders and borderline personality disorder", "doi": "10.1016/j.sjpmh.2026.02.003", "year": 2026 } ] } }, { "id": 1341, "drug": "cisplatin", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "activates", "mediator": "caspase-3", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "Alzheimer's disease", "outcome_type": "disease", "outcome_domain": "als", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "cisplatin", "mediator_canonical": "CASP3", "outcome_canonical": "Alzheimer disease", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "39810130", "title": "Engineered biomimetic cisplatin-polyphenol nanocomplex for chemo-immunotherapy of glioblastoma by inducing pyroptosis", "doi": "10.1186/s12951-025-03091-w", "year": 2025 } ], "bc": [ { "pmid": "26064904", "title": "Implication of Caspase-3 as a Common Therapeutic Target for Multineurodegenerative Disorders and Its Inhibition Using Nonpeptidyl Natural Compounds", "doi": "10.1155/2015/379817", "year": 2015 } ] } }, { "id": 1269, "drug": "apigenin", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "upregulates", "mediator": "GFAP", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "nerve conductivity", "outcome_type": "phenotype", "outcome_domain": "als", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "apigenin", "mediator_canonical": "GFAP", "outcome_canonical": "nerve conductivity", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41090780", "title": "Apigenin Induces Autophagy and Apoptosis in Chemoresistant Glioblastoma Cells and Inhibits Tumorigenicity Associated with Regulation of Immunomodulatory Proteins and Glial Cells Response", "doi": "10.3390/cells14191552", "year": 2025 } ], "bc": [ { "pmid": "40192786", "title": "Glial fibrillary acidic protein: a potential biomarker for small fiber neuropathy?", "doi": "10.1007/s00592-025-02500-8", "year": 2025 } ] } }, { "id": 1195, "drug": "dasatinib", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "inhibits", "mediator": "Src", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "amyotrophic lateral sclerosis", "outcome_type": "disease", "outcome_domain": "als", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "dasatinib", "mediator_canonical": "src", "outcome_canonical": "amyotrophic lateral sclerosis", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "34232320", "title": "A novel patient stratification strategy to enhance the therapeutic efficacy of dasatinib in glioblastoma", "doi": "10.1093/neuonc/noab158", "year": 2021 } ], "bc": [ { "pmid": "37682161", "title": "Exploring the mechanism of Semen Strychni in treating amyotrophic lateral sclerosis based on network pharmacology", "doi": "10.1097/md.0000000000035101", "year": 2023 } ] } }, { "id": 1105, "drug": "sapanisertib", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "inhibits", "mediator": "mTOR", "mediator_type": "protein", "predicate_bc": "increases", "outcome": "neuronal spiking activity", "outcome_type": "phenotype", "outcome_domain": "epilepsy", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "sapanisertib", "mediator_canonical": "mTOR", "outcome_canonical": "neuronal spiking activity", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37372982", "title": "mTOR Inhibition Is Effective against Growth, Survival and Migration, but Not against Microglia Activation in Preclinical Glioma Models", "doi": "10.3390/ijms24129834", "year": 2023 } ], "bc": [ { "pmid": "34994387", "title": "IDH-mutated gliomas promote epileptogenesis through d-2-hydroxyglutarate-dependent mTOR hyperactivation", "doi": "10.1093/neuonc/noac003", "year": 2022 } ] } }, { "id": 1079, "drug": "auraptene", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "downregulates", "mediator": "MMP-9", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "cognitive function", "outcome_type": "phenotype", "outcome_domain": "epilepsy", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "auraptene", "mediator_canonical": "MMP9", "outcome_canonical": "cognitive function", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "39086858", "title": "Auraptene inhibits migration, invasion and metastatic behavior of human malignant glioblastoma cells: An in vitro and in silico study.", "doi": "10.22038/ajp.2023.23586", "year": 2024 } ], "bc": [ { "pmid": "32538745", "title": "Correlation of MMP-9 and HMGB1 expression with the cognitive function in patients with epilepsy and factors affecting the prognosis", "doi": "10.14715/cmb/2020.66.3.6", "year": 2020 } ] } }, { "id": 752, "drug": "verteporfin", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "downregulates", "mediator": "EGFR", "mediator_type": "gene", "predicate_bc": "associated_with", "outcome": "lesional focal epilepsy", "outcome_type": "disease", "outcome_domain": "epilepsy", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "verteporfin", "mediator_canonical": "EGFR", "outcome_canonical": "lesional focal epilepsy", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "33172899", "title": "YAP/TAZ Transcriptional Coactivators Create Therapeutic Vulnerability to Verteporfin in EGFR-mutant Glioblastoma", "doi": "10.1158/1078-0432.ccr-20-0018", "year": 2020 } ], "bc": [ { "pmid": "39616148", "title": "Analysis of 1386 epileptogenic brain lesions reveals association with DYRK1A and EGFR", "doi": "10.1038/s41467-024-54911-w", "year": 2024 } ] } }, { "id": 717, "drug": "auraptene", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "downregulates", "mediator": "MMP-2", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "epilepsy", "outcome_type": "disease", "outcome_domain": "epilepsy", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "auraptene", "mediator_canonical": "MMP2", "outcome_canonical": "epilepsy", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "39086858", "title": "Auraptene inhibits migration, invasion and metastatic behavior of human malignant glioblastoma cells: An in vitro and in silico study.", "doi": "10.22038/ajp.2023.23586", "year": 2024 } ], "bc": [ { "pmid": "36766708", "title": "Blood-Brain Barrier-Associated Proteins Are Elevated in Serum of Epilepsy Patients", "doi": "10.3390/cells12030368", "year": 2023 } ] } }, { "id": 705, "drug": "Flubendazole", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "inhibits", "mediator": "STAT3", "mediator_type": "protein", "predicate_bc": "prevents", "outcome": "persistence of reactive glial states", "outcome_type": "phenotype", "outcome_domain": "epilepsy", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "flubendazole", "mediator_canonical": "STAT3", "outcome_canonical": "persistence of reactive glial states", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37045903", "title": "Flubendazole exhibits anti-glioblastoma effect by inhibiting STAT3 and promoting cell cycle arrest", "doi": "10.1038/s41598-023-33047-9", "year": 2023 } ], "bc": [ { "pmid": "36825472", "title": "Blockage of STAT3 during epileptogenesis prevents GABAergic loss and imprinting of the epileptic state", "doi": "10.1093/brain/awad055", "year": 2023 } ] } }, { "id": 365, "drug": "valproic acid", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "upregulates", "mediator": "CXCR4", "mediator_type": "gene", "predicate_bc": "associated_with", "outcome": "poor prognosis", "outcome_type": "phenotype", "outcome_domain": "glioblastoma", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "valproic acid", "mediator_canonical": "CXCR4", "outcome_canonical": null, "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40164048", "title": "Valproic acid preconditioning of bone marrow mesenchymal stem cells promotes remyelination of the corpus callosum in a cuprizone-induced demyelination model", "doi": "10.1016/j.biopha.2025.118027", "year": 2025 } ], "bc": [ { "pmid": "37626511", "title": "Development and Validation of CXCR4 Nomogram-Based Immune Infiltration/Tumor Inflammation in Primary Glioblastoma", "doi": "10.3390/brainsci13081152", "year": 2023 } ] } }, { "id": 40274, "drug": "resveratrol", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "downregulates", "mediator": "Akt", "mediator_type": "protein", "predicate_bc": "causes", "outcome": "subclonal progression", "outcome_type": "phenotype", "outcome_domain": "glioblastoma", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "resveratrol", "mediator_canonical": "akt", "outcome_canonical": "subclonal progression", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "31623226", "title": "Effects of Resveratrol in Goto-Kakizaki Rat, a Model of Type 2 Diabetes", "doi": "10.3390/nu11102488", "year": 2019 } ], "bc": [ { "pmid": "36239995", "title": "A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma", "doi": "10.1158/1078-0432.ccr-22-0611", "year": 2022 } ] } }, { "id": 665, "drug": "apigenin", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "upregulates", "mediator": "GFAP", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "spike frequency", "outcome_type": "phenotype", "outcome_domain": "epilepsy", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "apigenin", "mediator_canonical": "GFAP", "outcome_canonical": "spike frequency", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41090780", "title": "Apigenin Induces Autophagy and Apoptosis in Chemoresistant Glioblastoma Cells and Inhibits Tumorigenicity Associated with Regulation of Immunomodulatory Proteins and Glial Cells Response", "doi": "10.3390/cells14191552", "year": 2025 } ], "bc": [ { "pmid": "29634780", "title": "Proteomic analysis of human epileptic neocortex predicts vascular and glial changes in epileptic regions", "doi": "10.1371/journal.pone.0195639", "year": 2018 } ] } }, { "id": 664, "drug": "apigenin", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "upregulates", "mediator": "GFAP", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "injury severity", "outcome_type": "phenotype", "outcome_domain": "epilepsy", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "apigenin", "mediator_canonical": "GFAP", "outcome_canonical": "injury severity", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "41090780", "title": "Apigenin Induces Autophagy and Apoptosis in Chemoresistant Glioblastoma Cells and Inhibits Tumorigenicity Associated with Regulation of Immunomodulatory Proteins and Glial Cells Response", "doi": "10.3390/cells14191552", "year": 2025 } ], "bc": [ { "pmid": "37026764", "title": "Early preclinical plasma protein biomarkers of brain trauma are influenced by early seizures and levetiracetam", "doi": "10.1002/epi4.12738", "year": 2023 } ] } }, { "id": 623, "drug": "auraptene", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "downregulates", "mediator": "MMP-9", "mediator_type": "protein", "predicate_bc": "predicts", "outcome": "poor prognosis", "outcome_type": "phenotype", "outcome_domain": "epilepsy", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "auraptene", "mediator_canonical": "MMP9", "outcome_canonical": null, "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "39086858", "title": "Auraptene inhibits migration, invasion and metastatic behavior of human malignant glioblastoma cells: An in vitro and in silico study.", "doi": "10.22038/ajp.2023.23586", "year": 2024 } ], "bc": [ { "pmid": "32538745", "title": "Correlation of MMP-9 and HMGB1 expression with the cognitive function in patients with epilepsy and factors affecting the prognosis", "doi": "10.14715/cmb/2020.66.3.6", "year": 2020 } ] } }, { "id": 590, "drug": "auraptene", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "inhibits", "mediator": "mTOR", "mediator_type": "protein", "predicate_bc": "increases", "outcome": "neuronal spiking activity", "outcome_type": "phenotype", "outcome_domain": "epilepsy", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "auraptene", "mediator_canonical": "mTOR", "outcome_canonical": "neuronal spiking activity", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "39086858", "title": "Auraptene inhibits migration, invasion and metastatic behavior of human malignant glioblastoma cells: An in vitro and in silico study.", "doi": "10.22038/ajp.2023.23586", "year": 2024 } ], "bc": [ { "pmid": "34994387", "title": "IDH-mutated gliomas promote epileptogenesis through d-2-hydroxyglutarate-dependent mTOR hyperactivation", "doi": "10.1093/neuonc/noac003", "year": 2022 } ] } }, { "id": 326, "drug": "valproic acid", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "downregulates", "mediator": "GLI1", "mediator_type": "gene", "predicate_bc": "associated_with", "outcome": "venous thromboembolism", "outcome_type": "disease", "outcome_domain": "glioblastoma", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "valproic acid", "mediator_canonical": "gli1", "outcome_canonical": "venous thromboembolism", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "32054823", "title": "GANT61 and Valproic Acid Synergistically Inhibited Multiple Myeloma Cell Proliferation via Hedgehog Signaling Pathway", "doi": "10.12659/msm.920541", "year": 2020 } ], "bc": [ { "pmid": "37918288", "title": "RNA-sequencing to discover genes and signaling pathways associated with venous thromboembolism in glioblastoma patients: A case-control study", "doi": "10.1016/j.thromres.2023.10.018", "year": 2023 } ] } }, { "id": 29267, "drug": "valproic acid", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "downregulates", "mediator": "VEGF", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "depressive symptom severity", "outcome_type": "phenotype", "outcome_domain": "depression", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "valproic acid", "mediator_canonical": "VEGF", "outcome_canonical": "depressive symptom severity", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "32149283", "title": "l-Cysteine decorated nanoscale metal–organic frameworks delivering valproic acid/cisplatin for drug-resistant lung cancer therapy", "doi": "10.1039/c9cc09712k", "year": 2020 } ], "bc": [ { "pmid": "32956213", "title": "Peripheral vascular endothelial growth factor changes after transcranial magnetic stimulation in treatment-resistant depression", "doi": "10.1097/wnr.0000000000001523", "year": 2020 } ] } }, { "id": 29253, "drug": "baicalin", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "upregulates", "mediator": "BDNF", "mediator_type": "protein", "predicate_bc": "increases", "outcome": "remission", "outcome_type": "phenotype", "outcome_domain": "depression", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "baicalin", "mediator_canonical": "BDNF", "outcome_canonical": null, "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "38778616", "title": "Exploring the Therapeutic Potential of Baicalin: Mitigating Anxiety and Depression in Epileptic Rats", "doi": "10.2174/0113862073316021240520110301", "year": 2024 } ], "bc": [ { "pmid": "41584756", "title": "Employment-dependent associations of serum biomarkers with short- and long-term antidepressant treatment outcomes", "doi": "10.3389/fpsyt.2025.1662993", "year": 2026 } ] } }, { "id": 28872, "drug": "valproic acid", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "suppresses", "mediator": "galectin-3", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "neurological distemper", "outcome_type": "disease", "outcome_domain": "als", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "valproic acid", "mediator_canonical": "LGALS3", "outcome_canonical": "neurological distemper", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "34122007", "title": "Post-stroke Delivery of Valproic Acid Promotes Functional Recovery and Differentially Modifies Responses of Peri-Infarct Microglia", "doi": "10.3389/fnmol.2021.639145", "year": 2021 } ], "bc": [ { "pmid": "40431592", "title": "Investigation of Galectin-3 and Cardiotrophin-1 Concentrations as Biomarkers in Dogs with Neurological Distemper", "doi": "10.3390/vetsci12050499", "year": 2025 } ] } }, { "id": 321, "drug": "valproic acid", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "suppresses", "mediator": "galectin-3", "mediator_type": "protein", "predicate_bc": "predicts", "outcome": "progression to glioblastoma", "outcome_type": "phenotype", "outcome_domain": "glioblastoma", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "valproic acid", "mediator_canonical": "LGALS3", "outcome_canonical": "progression to glioblastoma", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "34122007", "title": "Post-stroke Delivery of Valproic Acid Promotes Functional Recovery and Differentially Modifies Responses of Peri-Infarct Microglia", "doi": "10.3389/fnmol.2021.639145", "year": 2021 } ], "bc": [ { "pmid": "31435963", "title": "Clinical relevance of molecular subgrouping of gliomatosis cerebri per 2016 WHO classification: a clinicopathological study of 89 cases", "doi": "10.1111/bpa.12782", "year": 2019 } ] } }, { "id": 30399, "drug": "valproic acid", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "downregulates", "mediator": "FASN", "mediator_type": "gene", "predicate_bc": "treats", "outcome": "diabetes", "outcome_type": "disease", "outcome_domain": "type_2_diabetes", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "completed", "clinical_trial_nct_ids": [ "NCT03717909", "NCT00167934", "NCT04940572" ], "literature_status": "reproduces_known", "drug_canonical": "valproic acid", "mediator_canonical": "fasn", "outcome_canonical": "diabetes", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "36544904", "title": "Metabolomic profiling of triple negative breast cancer cells suggests that valproic acid can enhance the anticancer effect of cisplatin", "doi": "10.3389/fcell.2022.1014798", "year": 2022 } ], "bc": [ { "pmid": "37681411", "title": "Hepatic FASN deficiency differentially affects nonalcoholic fatty liver disease and diabetes in mouse obesity models", "doi": "10.1172/jci.insight.161282", "year": 2023 } ] } }, { "id": 25578, "drug": "riluzole", "drug_type": "drug", "drug_domain": "als", "predicate_ab": "downregulates", "mediator": "MMP-9", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "RA", "outcome_type": "disease", "outcome_domain": "rheumatoid_arthritis", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "riluzole", "mediator_canonical": "MMP9", "outcome_canonical": "ra", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40012807", "title": "Investigation of the Neuroprotective Effect of Riluzole on Matrix Metalloproteinases in an Experimental Model of Glaucoma", "doi": "10.4103/joco.joco_290_23", "year": 2024 } ], "bc": [ { "pmid": "30668267", "title": "Expression Profile of Long Noncoding RNAs, lnc-Cox2, and HOTAIR in Rheumatoid Arthritis Patients", "doi": "10.1089/jir.2018.0117", "year": 2019 } ] } }, { "id": 40096, "drug": "metformin", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "upregulates", "mediator": "Stat3", "mediator_type": "gene", "predicate_bc": "decreases", "outcome": "seizure progression", "outcome_type": "phenotype", "outcome_domain": "epilepsy", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "metformin", "mediator_canonical": "STAT3", "outcome_canonical": "seizure progression", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37573301", "title": "STAT3/LKB1 controls metastatic prostate cancer by regulating mTORC1/CREB pathway", "doi": "10.1186/s12943-023-01825-8", "year": 2023 } ], "bc": [ { "pmid": "36935347", "title": "Selective Neuronal Knockout of STAT3 Function Inhibits Epilepsy Progression, Improves Cognition, and Restores Dysregulated Gene Networks in a Temporal Lobe Epilepsy Model", "doi": "10.1002/ana.26644", "year": 2023 } ] } }, { "id": 40097, "drug": "metformin", "drug_type": "drug", "drug_domain": "type_2_diabetes", "predicate_ab": "upregulates", "mediator": "Stat3", "mediator_type": "gene", "predicate_bc": "correlates_with", "outcome": "seizure frequency", "outcome_type": "phenotype", "outcome_domain": "epilepsy", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "metformin", "mediator_canonical": "STAT3", "outcome_canonical": "seizure frequency", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37573301", "title": "STAT3/LKB1 controls metastatic prostate cancer by regulating mTORC1/CREB pathway", "doi": "10.1186/s12943-023-01825-8", "year": 2023 } ], "bc": [ { "pmid": "33225612", "title": "Bioinformatic analysis identifies key transcriptome signatures in temporal lobe epilepsy", "doi": "10.1111/cns.13470", "year": 2020 } ] } }, { "id": 3889, "drug": "curcumin", "drug_type": "drug", "drug_domain": "alzheimer", "predicate_ab": "binds_to", "mediator": "TDP-43", "mediator_type": "protein", "predicate_bc": "causes", "outcome": "neurotoxicity", "outcome_type": "phenotype", "outcome_domain": "als", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "curcumin", "mediator_canonical": "TDP-43", "outcome_canonical": "neurotoxicity", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "30092839", "title": "Different curcumin forms selectively bind fibrillar amyloid beta in post mortem Alzheimer’s disease brains: Implications for in-vivo diagnostics", "doi": "10.1186/s40478-018-0577-2", "year": 2018 } ], "bc": [ { "pmid": "29787572", "title": "TDP-43 causes neurotoxicity and cytoskeletal dysfunction in primary cortical neurons", "doi": "10.1371/journal.pone.0196528", "year": 2018 } ] } }, { "id": 292, "drug": "valproic acid", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "downregulates", "mediator": "Twist1", "mediator_type": "protein", "predicate_bc": "causes", "outcome": "astrocytoma development", "outcome_type": "disease", "outcome_domain": "glioblastoma", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "valproic acid", "mediator_canonical": "twist1", "outcome_canonical": "astrocytoma development", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "30373123", "title": "Valproic Acid Inhibits Proliferation and Reduces Invasiveness in Glioma Stem Cells Through Wnt/β Catenin Signalling Activation", "doi": "10.3390/genes9110522", "year": 2018 } ], "bc": [ { "pmid": "31289562", "title": "Twist1 promotes astrocytoma development by stimulating vasculogenic mimicry", "doi": "10.3892/ol.2019.10380", "year": 2019 } ] } }, { "id": 5162, "drug": "metformin", "drug_type": "drug", "drug_domain": "pancreatic_cancer", "predicate_ab": "inhibits", "mediator": "mTORC1", "mediator_type": "protein", "predicate_bc": "increases", "outcome": "early endosomal enlargement", "outcome_type": "phenotype", "outcome_domain": "alzheimer", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "metformin", "mediator_canonical": "mtorc1", "outcome_canonical": "early endosomal enlargement", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "29651002", "title": "Metformin Decreases the Incidence of Pancreatic Ductal Adenocarcinoma Promoted by Diet-induced Obesity in the Conditional KrasG12D Mouse Model", "doi": "10.1038/s41598-018-24337-8", "year": 2018 } ], "bc": [ { "pmid": "32436237", "title": "High glucose‐mediated PICALM and mTORC1 modulate processing of amyloid precursor protein via endosomal abnormalities", "doi": "10.1111/bph.15131", "year": 2020 } ] } }, { "id": 4688, "drug": "resveratrol", "drug_type": "drug", "drug_domain": "pancreatic_cancer", "predicate_ab": "activates", "mediator": "AMPK", "mediator_type": "protein", "predicate_bc": "increases", "outcome": "epileptiform network activity", "outcome_type": "phenotype", "outcome_domain": "epilepsy", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "resveratrol", "mediator_canonical": "AMPK", "outcome_canonical": "epileptiform network activity", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "27669292", "title": "YAP Inhibition by Resveratrol via Activation of AMPK Enhances the Sensitivity of Pancreatic Cancer Cells to Gemcitabine", "doi": "10.3390/nu8100546", "year": 2016 } ], "bc": [ { "pmid": "35134125", "title": "AMPK-mediated potentiation of GABAergic signalling drives hypoglycaemia-provoked spike-wave seizures", "doi": "10.1093/brain/awac037", "year": 2022 } ] } }, { "id": 17524, "drug": "curcumin", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "upregulates", "mediator": "NRF2", "mediator_type": "gene", "predicate_bc": "associated_with", "outcome": "Hashimoto's thyroiditis", "outcome_type": "disease", "outcome_domain": "multiple_sclerosis", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "preclinical_only", "clinical_trial_nct_ids": [ "NCT05975866" ], "literature_status": "partial_evidence", "drug_canonical": "curcumin", "mediator_canonical": "NRF2", "outcome_canonical": "hashimoto's thyroiditis", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40081725", "title": "Matrix metallopeptidase 2-responsive curcumin-loaded nanoparticles-induced signal transducer and activator of transcription 3 inhibition suppresses glioblastoma multiforme growth via enhancing nuclear factor erythroid 2-related factor 2 activity", "doi": "10.1016/j.ijbiomac.2025.141998", "year": 2025 } ], "bc": [ { "pmid": "35624879", "title": "Thyroid Disorders in Patients Treated with Dimethyl Fumarate for Multiple Sclerosis: A Retrospective Observational Study", "doi": "10.3390/antiox11051015", "year": 2022 } ] } }, { "id": 28755, "drug": "fluoxetine", "drug_type": "drug", "drug_domain": "depression", "predicate_ab": "downregulates", "mediator": "TLR7", "mediator_type": "gene", "predicate_bc": "associated_with", "outcome": "type 1 diabetes", "outcome_type": "disease", "outcome_domain": "type_2_diabetes", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "active", "clinical_trial_nct_ids": [ "NCT03228732", "NCT01672255", "NCT03893266" ], "literature_status": "reproduces_known", "drug_canonical": "fluoxetine", "mediator_canonical": "tlr7", "outcome_canonical": "type 1 diabetes", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "31647818", "title": "Assessing the role of toll-like receptor in isolated, standard and enriched housing conditions", "doi": "10.1371/journal.pone.0222818", "year": 2019 } ], "bc": [ { "pmid": "33432061", "title": "Toll-like receptor 7 deficiency suppresses type 1 diabetes development by modulating B-cell differentiation and function", "doi": "10.1038/s41423-020-00590-8", "year": 2021 } ] } }, { "id": 28274, "drug": "fluoxetine", "drug_type": "drug", "drug_domain": "depression", "predicate_ab": "downregulates", "mediator": "TLR7", "mediator_type": "gene", "predicate_bc": "prevents", "outcome": "colitis", "outcome_type": "disease", "outcome_domain": "inflammatory_bowel_disease", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "fluoxetine", "mediator_canonical": "tlr7", "outcome_canonical": "colitis", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "31647818", "title": "Assessing the role of toll-like receptor in isolated, standard and enriched housing conditions", "doi": "10.1371/journal.pone.0222818", "year": 2019 } ], "bc": [ { "pmid": "39464882", "title": "Toll-like receptor 7 protects against intestinal inflammation and restricts the development of colonic tissue-resident memory CD8+ T cells", "doi": "10.3389/fimmu.2024.1465175", "year": 2024 } ] } }, { "id": 29728, "drug": "baicalin", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "upregulates", "mediator": "BDNF", "mediator_type": "protein", "predicate_bc": "increases", "outcome": "cell viability", "outcome_type": "phenotype", "outcome_domain": "inflammatory_bowel_disease", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "baicalin", "mediator_canonical": "BDNF", "outcome_canonical": "cell viability", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "38778616", "title": "Exploring the Therapeutic Potential of Baicalin: Mitigating Anxiety and Depression in Epileptic Rats", "doi": "10.2174/0113862073316021240520110301", "year": 2024 } ], "bc": [ { "pmid": "34543287", "title": "Chronic colitis upregulates microRNAs suppressing brain-derived neurotrophic factor in the adult heart", "doi": "10.1371/journal.pone.0257280", "year": 2021 } ] } }, { "id": 29645, "drug": "valproate", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "downregulates", "mediator": "COX-2", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "FCEAI and histological alterations", "outcome_type": "phenotype", "outcome_domain": "inflammatory_bowel_disease", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "valproic acid", "mediator_canonical": "cox-2", "outcome_canonical": "fceai and histological alterations", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "32054883", "title": "Downregulation of peripheral PTGS2/COX-2 in response to valproate treatment in patients with epilepsy", "doi": "10.1038/s41598-020-59259-x", "year": 2020 } ], "bc": [ { "pmid": "29764431", "title": "Cyclooxygenase-2 immunoexpression in intestinal epithelium and lamina propria of cats with inflammatory bowel disease and low grade alimentary lymphoma", "doi": "10.1186/s12917-018-1486-0", "year": 2018 } ] } }, { "id": 4597, "drug": "resveratrol", "drug_type": "drug", "drug_domain": "pancreatic_cancer", "predicate_ab": "upregulates", "mediator": "PTEN", "mediator_type": "gene", "predicate_bc": "causes", "outcome": "hyperexcitable circuitry", "outcome_type": "phenotype", "outcome_domain": "epilepsy", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "resveratrol", "mediator_canonical": "PTEN", "outcome_canonical": "hyperexcitable circuitry", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "29854071", "title": "Resveratrol Inhibits ROS‐Promoted Activation and Glycolysis of Pancreatic Stellate Cells via Suppression of miR‐21", "doi": "10.1155/2018/1346958", "year": 2018 } ], "bc": [ { "pmid": "39547478", "title": "PTEN deletion in the adult dentate gyrus induces epilepsy", "doi": "10.1016/j.nbd.2024.106736", "year": 2024 } ] } }, { "id": 29130, "drug": "valproic acid", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "downregulates", "mediator": "VEGF", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "vascular dementia", "outcome_type": "disease", "outcome_domain": "alzheimer", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "partial_evidence", "drug_canonical": "valproic acid", "mediator_canonical": "VEGF", "outcome_canonical": "Vascular dementia", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "32149283", "title": "l-Cysteine decorated nanoscale metal–organic frameworks delivering valproic acid/cisplatin for drug-resistant lung cancer therapy", "doi": "10.1039/c9cc09712k", "year": 2020 } ], "bc": [ { "pmid": "29933741", "title": "Vascular Endothelial Growth Factor remains unchanged in cerebrospinal fluid of patients with Alzheimer’s disease and vascular dementia", "doi": "10.1186/s13195-018-0385-8", "year": 2018 } ] } }, { "id": 49890, "drug": "cisplatin", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "upregulates", "mediator": "PD-L1", "mediator_type": "protein", "predicate_bc": "decreases", "outcome": "joint swelling", "outcome_type": "phenotype", "outcome_domain": "rheumatoid_arthritis", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "39810130", "title": "Engineered biomimetic cisplatin-polyphenol nanocomplex for chemo-immunotherapy of glioblastoma by inducing pyroptosis", "doi": "10.1186/s12951-025-03091-w", "year": 2025 } ], "bc": [ { "pmid": "36936967", "title": "Intra-articular delivery of AAV vectors encoding PD-L1 attenuates joint inflammation and tissue damage in a mouse model of rheumatoid arthritis", "doi": "10.3389/fimmu.2023.1116084", "year": 2023 } ] } }, { "id": 2624, "drug": "valproate", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "activates", "mediator": "PPARγ", "mediator_type": "protein", "predicate_bc": "correlates_with", "outcome": "pancreatic cancer", "outcome_type": "disease", "outcome_domain": "pancreatic_cancer", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "active", "clinical_trial_nct_ids": [ "NCT03919292", "NCT05821556", "NCT01333631" ], "literature_status": "novel_signal", "drug_canonical": "valproic acid", "mediator_canonical": "pparγ", "outcome_canonical": "pancreatic cancer", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37334286", "title": "Association of epilepsy, anti-epileptic drugs (AEDs), and type 2 diabetes mellitus (T2DM): a population-based cohort retrospective study, impact of AEDs on T2DM-related molecular pathway, and via peroxisome proliferator-activated receptor γ transactivation", "doi": "10.3389/fendo.2023.1156952", "year": 2023 } ], "bc": [ { "pmid": "32801648", "title": "<p>The PPARγ Agonist Rosiglitazone Enhances the Radiosensitivity of Human Pancreatic Cancer Cells</p>", "doi": "10.2147/dddt.s242557", "year": 2020 } ] } }, { "id": 32063, "drug": "erlotinib", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "inhibits", "mediator": "EGFR", "mediator_type": "gene", "predicate_bc": "associated_with", "outcome": "cardiovascular disease", "outcome_type": "disease", "outcome_domain": "rheumatoid_arthritis", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "active", "clinical_trial_nct_ids": [ "NCT03297606", "NCT07267247", "NCT00725634" ], "literature_status": "partial_evidence", "drug_canonical": "erlotinib", "mediator_canonical": "EGFR", "outcome_canonical": "cardiovascular disease", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "30240496", "title": "Design of a Multicompartment Hydrogel that Facilitates Time‐Resolved Delivery of Combination Therapy and Synergized Killing of Glioblastoma", "doi": "10.1002/anie.201806483", "year": 2018 } ], "bc": [ { "pmid": "40964982", "title": "Selection of Common Genes Associated with Rheumatoid Arthritis and Cardiovascular Disease via a Network- and Pathway-Based Approach", "doi": "10.14744/anatoljcardiol.2025.5375", "year": 2025 } ] } }, { "id": 32078, "drug": "acriflavine", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "inhibits", "mediator": "HIF-1α", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "rheumatoid arthritis", "outcome_type": "disease", "outcome_domain": "rheumatoid_arthritis", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "acriflavine", "mediator_canonical": "hif-1α", "outcome_canonical": "rheumatoid arthritis", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40405165", "title": "Photo-controlled co-delivery of verteporfin and acriflavine via platelets achieves potentiated glioblastoma-targeted photodynamic therapy", "doi": "10.1186/s12951-025-03395-x", "year": 2025 } ], "bc": [ { "pmid": "40247798", "title": "Emerging Therapeutic Targets in Rheumatoid Arthritis: Focusing on HIF-1α, Nrf2, STATs, and RORγt", "doi": "10.2174/0113894501372670250408074908", "year": 2025 } ] } }, { "id": 32102, "drug": "cabozantinib", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "inhibits", "mediator": "AXL", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "low disease activity", "outcome_type": "phenotype", "outcome_domain": "rheumatoid_arthritis", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "cabozantinib", "mediator_canonical": "axl", "outcome_canonical": "low disease activity", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "29660005", "title": "Volumetric response quantified using T1 subtraction predicts long-term survival benefit from cabozantinib monotherapy in recurrent glioblastoma", "doi": "10.1093/neuonc/noy054", "year": 2018 } ], "bc": [ { "pmid": "38493215", "title": "Axl and MerTK regulate synovial inflammation and are modulated by IL-6 inhibition in rheumatoid arthritis", "doi": "10.1038/s41467-024-46564-6", "year": 2024 } ] } }, { "id": 49962, "drug": "auraptene", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "downregulates", "mediator": "MMP-9", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "incident ILD", "outcome_type": "disease", "outcome_domain": "rheumatoid_arthritis", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "39086858", "title": "Auraptene inhibits migration, invasion and metastatic behavior of human malignant glioblastoma cells: An in vitro and in silico study.", "doi": "10.22038/ajp.2023.23586", "year": 2024 } ], "bc": [ { "pmid": "38268499", "title": "Plasma Matrix Metalloproteinase Concentrations and Risk of Interstitial Lung Disease in a Prospective Rheumatoid Arthritis Cohort", "doi": "10.1002/art.42812", "year": 2024 } ] } }, { "id": 4548, "drug": "niclosamide", "drug_type": "drug", "drug_domain": "pancreatic_cancer", "predicate_ab": "downregulates", "mediator": "PD-L1", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "worse overall survival", "outcome_type": "phenotype", "outcome_domain": "glioblastoma", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "niclosamide", "mediator_canonical": "PD-L1", "outcome_canonical": null, "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "35115509", "title": "The anthelmintic drug niclosamide induces GSK-β-mediated β-catenin degradation to potentiate gemcitabine activity, reduce immune evasion ability and suppress pancreatic cancer progression", "doi": "10.1038/s41419-022-04573-7", "year": 2022 } ], "bc": [ { "pmid": "34638219", "title": "Immunohistochemical expression of programmed death-ligand 1 and CD8 in glioblastomas", "doi": "10.4132/jptm.2021.08.04", "year": 2021 } ] } }, { "id": 4480, "drug": "valproic acid", "drug_type": "drug", "drug_domain": "pancreatic_cancer", "predicate_ab": "downregulates", "mediator": "EGFR", "mediator_type": "gene", "predicate_bc": "correlates_with", "outcome": "progression-free survival", "outcome_type": "phenotype", "outcome_domain": "glioblastoma", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "valproic acid", "mediator_canonical": "EGFR", "outcome_canonical": null, "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "30961642", "title": "Valproic acid exhibits anti-tumor activity selectively against EGFR/ErbB2/ErbB3-coexpressing pancreatic cancer via induction of ErbB family members-targeting microRNAs", "doi": "10.1186/s13046-019-1160-9", "year": 2019 } ], "bc": [ { "pmid": "40042315", "title": "Dynamic Tumor in Situ Fluid Circulating Tumor DNA Postsurgery Effectively Predicts Recurrence and Clinical Benefits for Glioblastomas", "doi": "10.1227/neu.0000000000003384", "year": 2025 } ] } }, { "id": 4459, "drug": "metformin", "drug_type": "drug", "drug_domain": "pancreatic_cancer", "predicate_ab": "induces", "mediator": "DR5", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "apoptosis", "outcome_type": "phenotype", "outcome_domain": "glioblastoma", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "metformin", "mediator_canonical": "dr5", "outcome_canonical": "apoptosis", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "25955843", "title": "Metformin Causes G1-Phase Arrest via Down-Regulation of MiR-221 and Enhances TRAIL Sensitivity through DR5 Up-Regulation in Pancreatic Cancer Cells", "doi": "10.1371/journal.pone.0125779", "year": 2015 } ], "bc": [ { "pmid": "40377008", "title": "Chaetocin enhances tumor necrosis factor‑related apoptosis‑inducing ligand‑mediated apoptosis by enhancing DR5 stabilization and reactive oxygen species generation in human glioblastoma cells", "doi": "10.3892/ijo.2025.5753", "year": 2025 } ] } }, { "id": 4308, "drug": "resveratrol", "drug_type": "drug", "drug_domain": "alzheimer", "predicate_ab": "upregulates", "mediator": "Sirt1", "mediator_type": "gene", "predicate_bc": "increases", "outcome": "depressive symptoms", "outcome_type": "phenotype", "outcome_domain": "depression", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "resveratrol", "mediator_canonical": "SIRT1", "outcome_canonical": "depressive symptoms", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "33381265", "title": "Resveratrol Mitigates Hippocampal Tau Acetylation and Cognitive Deficit by Activation SIRT1 in Aged Rats following Anesthesia and Surgery", "doi": "10.1155/2020/4635163", "year": 2020 } ], "bc": [ { "pmid": "32849821", "title": "A Comprehensive Analysis of the Effect of SIRT1 Variation on the Risk of Schizophrenia and Depressive Symptoms", "doi": "10.3389/fgene.2020.00832", "year": 2020 } ] } }, { "id": 41283, "drug": "riluzole", "drug_type": "drug", "drug_domain": "als", "predicate_ab": "downregulates", "mediator": "MMP-2", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "Alzheimer's disease", "outcome_type": "disease", "outcome_domain": "alzheimer", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "40012807", "title": "Investigation of the Neuroprotective Effect of Riluzole on Matrix Metalloproteinases in an Experimental Model of Glaucoma", "doi": "10.4103/joco.joco_290_23", "year": 2024 } ], "bc": [ { "pmid": "37483327", "title": "Urinary Cytokines as Potential Biomarkers of Mild Cognitive Impairment and Alzheimer’s Disease: A Pilot Study", "doi": "10.3233/adr-220081", "year": 2023 } ] } }, { "id": 29129, "drug": "valproic acid", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "downregulates", "mediator": "VEGF", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "amyloid-β burden", "outcome_type": "phenotype", "outcome_domain": "alzheimer", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "novel_signal", "drug_canonical": "valproic acid", "mediator_canonical": "VEGF", "outcome_canonical": "amyloid-β burden", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "32149283", "title": "l-Cysteine decorated nanoscale metal–organic frameworks delivering valproic acid/cisplatin for drug-resistant lung cancer therapy", "doi": "10.1039/c9cc09712k", "year": 2020 } ], "bc": [ { "pmid": "38471064", "title": "Association of Neurotrophic Factors at Midlife With In Vivo Measures of β-Amyloid and Tau Burden 15 Years Later in Dementia-Free Adults", "doi": "10.1212/wnl.0000000000209198", "year": 2024 } ] } }, { "id": 4303, "drug": "curcumin", "drug_type": "drug", "drug_domain": "alzheimer", "predicate_ab": "upregulates", "mediator": "BDNF", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "MDD", "outcome_type": "disease", "outcome_domain": "depression", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "completed", "clinical_trial_nct_ids": [ "NCT01750359", "NCT01022632" ], "literature_status": "reproduces_known", "drug_canonical": "curcumin", "mediator_canonical": "BDNF", "outcome_canonical": "major depressive disorder", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "38791161", "title": "Curcumin Improves Neurogenesis in Alzheimer’s Disease Mice via the Upregulation of Wnt/β-Catenin and BDNF", "doi": "10.3390/ijms25105123", "year": 2024 } ], "bc": [ { "pmid": "29559928", "title": "Exercise Leads to Better Clinical Outcomes in Those Receiving Medication Plus Cognitive Behavioral Therapy for Major Depressive Disorder", "doi": "10.3389/fpsyt.2018.00037", "year": 2018 } ] } }, { "id": 50088, "drug": "Auranofin", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "upregulates", "mediator": "p53", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "T2DM", "outcome_type": "disease", "outcome_domain": "type_2_diabetes", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "39456455", "title": "Synergistic Dual Targeting of Thioredoxin and Glutathione Systems Irrespective of p53 in Glioblastoma Stem Cells", "doi": "10.3390/antiox13101201", "year": 2024 } ], "bc": [ { "pmid": "37512131", "title": "High-Intensity Interval Training Improves Glycemic Control, Cellular Apoptosis, and Oxidative Stress of Type 2 Diabetic Patients", "doi": "10.3390/medicina59071320", "year": 2023 } ] } }, { "id": 50092, "drug": "sapanisertib", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "inhibits", "mediator": "mTOR", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "microvascular complications", "outcome_type": "disease", "outcome_domain": "type_2_diabetes", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "37372982", "title": "mTOR Inhibition Is Effective against Growth, Survival and Migration, but Not against Microglia Activation in Preclinical Glioma Models", "doi": "10.3390/ijms24129834", "year": 2023 } ], "bc": [ { "pmid": "39261960", "title": "The relation of mTOR with diabetic complications and insulin resistance in patients with type 2 diabetes mellitus", "doi": "10.1186/s13098-024-01450-5", "year": 2024 } ] } }, { "id": 50111, "drug": "auraptene", "drug_type": "drug", "drug_domain": "glioblastoma", "predicate_ab": "downregulates", "mediator": "MMP-2", "mediator_type": "protein", "predicate_bc": "associated_with", "outcome": "central 24-h pulse pressure", "outcome_type": "phenotype", "outcome_domain": "type_2_diabetes", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "39086858", "title": "Auraptene inhibits migration, invasion and metastatic behavior of human malignant glioblastoma cells: An in vitro and in silico study.", "doi": "10.22038/ajp.2023.23586", "year": 2024 } ], "bc": [ { "pmid": "29070037", "title": "Circulating matrix metalloproteinases are associated with arterial stiffness in patients with type 1 diabetes: pooled analysis of three cohort studies", "doi": "10.1186/s12933-017-0620-9", "year": 2017 } ] } }, { "id": 29123, "drug": "valproic acid", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "downregulates", "mediator": "BDNF", "mediator_type": "gene", "predicate_bc": "associated_with", "outcome": "neuritic plaque pathology", "outcome_type": "phenotype", "outcome_domain": "alzheimer", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "completed", "clinical_trial_nct_ids": [ "NCT00088387" ], "literature_status": "novel_signal", "drug_canonical": "valproic acid", "mediator_canonical": "BDNF", "outcome_canonical": "neuritic plaque pathology", "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "30404997", "title": "Social behavior, neuroimmune markers and glutamic acid decarboxylase levels in a rat model of valproic acid-induced autism", "doi": "10.2131/jts.43.631", "year": 2018 } ], "bc": [ { "pmid": "31349032", "title": "Brain-derived neurotrophic factor (BDNF) and TrkB hippocampal gene expression are putative predictors of neuritic plaque and neurofibrillary tangle pathology", "doi": "10.1016/j.nbd.2019.104540", "year": 2019 } ] } }, { "id": 6572, "drug": "valproic acid", "drug_type": "drug", "drug_domain": "epilepsy", "predicate_ab": "downregulates", "mediator": "VEGF", "mediator_type": "protein", "predicate_bc": "predicts", "outcome": "poor prognosis", "outcome_type": "phenotype", "outcome_domain": "glioblastoma", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": "none", "clinical_trial_nct_ids": [], "literature_status": "reproduces_known", "drug_canonical": "valproic acid", "mediator_canonical": "VEGF", "outcome_canonical": null, "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "32149283", "title": "l-Cysteine decorated nanoscale metal–organic frameworks delivering valproic acid/cisplatin for drug-resistant lung cancer therapy", "doi": "10.1039/c9cc09712k", "year": 2020 } ], "bc": [ { "pmid": "41268261", "title": "Correlation between EGF and VEGF expression levels and the efficacy of radiosurgery in recurrent glioma", "doi": "10.62347/sqpz5153", "year": 2025 } ] } }, { "id": 56395, "drug": "metformin", "drug_type": "drug", "drug_domain": "pancreatic_cancer", "predicate_ab": "inhibits", "mediator": "Akt signaling", "mediator_type": "pathway", "predicate_bc": "correlates_with", "outcome": "Alzheimer disease", "outcome_type": "disease", "outcome_domain": "alzheimer", "score": 0.13862943611198905, "filtered_score": 0.20794415416798356, "filter_reason": "boosted_repurposing", "outreach_score": 0.20794415416798356, "outreach_quality": "mid", "outreach_reason": null, "clinical_trial_status": null, "clinical_trial_nct_ids": [], "literature_status": null, "drug_canonical": null, "mediator_canonical": null, "outcome_canonical": null, "ab_count": 1, "bc_count": 1, "direct_count": 0, "hypothesis_type": "cross_domain", "evidence": { "ab": [ { "pmid": "33042621", "title": "Metformin activates the STING/IRF3/IFN-β pathway by inhibiting AKT phosphorylation in pancreatic cancer.", "doi": null, "year": 2020 } ], "bc": [ { "pmid": "29358916", "title": "Reducing the Levels of Akt Activation by PDK1 Knock-in Mutation Protects Neuronal Cultures against Synthetic Amyloid-Beta Peptides", "doi": "10.3389/fnagi.2017.00435", "year": 2018 } ] } } ] }